PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	An, JB; Nagaki, Y; Motoyama, S; Kuze, Y; Hoshizaki, M; Kemuriyama, K; Yamaguchi, T; Ebihara, T; Minamiya, Y; Suzuki, Y; Imai, Y; Kuba, K				An, Jianbo; Nagaki, Yushi; Motoyama, Satoru; Kuze, Yuta; Hoshizaki, Midori; Kemuriyama, Kohei; Yamaguchi, Tomokazu; Ebihara, Takashi; Minamiya, Yoshihiro; Suzuki, Yutaka; Imai, Yumiko; Kuba, Keiji			Identification of Galectin-7 as a crucial metastatic enhancer of squamous cell carcinoma associated with immunosuppression	ONCOGENE			English	Article; Early Access							TUMOR PROGRESSION; CANCER; PATTERNS; MARKER; CHEMORADIOTHERAPY; LYMPHANGIOGENESIS; EXPRESSION; ESOPHAGEAL; PROMOTES; SURVIVAL	Metastasis predicts poor prognosis in cancer patients. It has been recognized that specific tumor microenvironment defines cancer cell metastasis, whereas the underlying mechanisms remain elusive. Here we show that Galectin-7 is a crucial mediator of metastasis associated with immunosuppression. In a syngeneic mouse squamous cell carcinoma (SCC) model of NR-S1M cells, we isolated metastasized NR-S1M cells from lymph nodes in tumor-bearing mice and established metastatic NR-S1M cells in in vitro culture. RNA-seq analysis revealed that interferon gene signature was markedly downregulated in metastatic NR-S1M cells compared with parental cells, and in vivo NR-S1M tumors heterogeneously developed focal immunosuppressive areas featured by deficiency of anti-tumor immune cells. Spatial transcriptome analysis (Visium) for the NR-S1M tumors revealed that various pro-metastatic genes were significantly upregulated in immunosuppressive areas when compared to immunocompetent areas. Notably, Galectin-7 was identified as a novel metastasis-driving factor. Galectin-7 expression was induced during tumorigenesis particularly in the microenvironment of immunosuppression, and extracellularly released at later stage of tumor progression. Deletion of Galectin-7 in NR-S1M cells significantly suppressed lymph node and lung metastasis without affecting primary tumor growth. Therefore, Galectin-7 is a crucial mediator of tumor metastasis of SCC, which is educated in the immune-suppressed tumor areas, and may be a potential target of cancer immunotherapy.	[An, Jianbo; Nagaki, Yushi; Hoshizaki, Midori; Kemuriyama, Kohei; Yamaguchi, Tomokazu; Kuba, Keiji] Akita Univ, Dept Biochem & Metab Sci, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan; [Nagaki, Yushi; Motoyama, Satoru; Kemuriyama, Kohei; Minamiya, Yoshihiro] Akita Univ, Dept Surg, Grad Sch Med, Akita, Japan; [Kuze, Yuta; Suzuki, Yutaka] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Chiba 2778562, Japan; [Hoshizaki, Midori; Ebihara, Takashi] Akita Univ, Dept Med Biol, Grad Sch Med, Akita, Japan; [Imai, Yumiko] Natl Inst Biomed Innovat Hlth & Nutr, Lab Regulat Intractable Infect Dis, Osaka 5670085, Japan; [Kuba, Keiji] Kyushu Univ, Dept Pharmacol, Grad Sch Med Sci, Fukuoka 8128582, Japan	Akita University; Akita University; University of Tokyo; Akita University; Kyushu University	Kuba, K (corresponding author), Akita Univ, Dept Biochem & Metab Sci, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan.; Kuba, K (corresponding author), Kyushu Univ, Dept Pharmacol, Grad Sch Med Sci, Fukuoka 8128582, Japan.	kuba.keiji.815@m.kyushu-u.ac.jp		Ebihara, Takashi/0000-0002-6056-3230	Kaken from Japanese Ministry of Science [20H03426, 20K21566, 22K19551, 20K07285, 20K09048, 17H06179]; Naito Foundation; AMED [JP 21lm0203079]	Kaken from Japanese Ministry of Science; Naito Foundation(Naito Memorial Foundation); AMED	KKuba is supported by the Kaken [20H03426, 20K21566, 22K19551] from Japanese Ministry of Science and the Naito Foundation. JA is supported by the Kaken [20K16153, 22K06907], SM is supported by the Kaken [20K09048], YI is supported by the Kaken [17H06179], and TY is supported by the Kaken [20K07285] from Japanese Ministry of Science. This research was also supported by AMED under Grant Number JP 21lm0203079.	Advedissian T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122760; Albini A, 2008, CANCER METAST REV, V27, P75, DOI 10.1007/s10555-007-9111-x; Alves PM, 2011, PATHOL RES PRACT, V207, P236, DOI 10.1016/j.prp.2011.02.004; Arnold M, 2020, GUT, V69, P1564, DOI 10.1136/gutjnl-2020-321600; Bogucka K, 2020, ELIFE, V9, DOI 10.7554/eLife.52511; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Chen YS, 2018, THERANOSTICS, V8, P3841, DOI 10.7150/thno.25784; Cramer JD, 2019, NAT REV CLIN ONCOL, V16, P669, DOI 10.1038/s41571-019-0227-z; Demers M, 2010, AM J PATHOL, V176, P3023, DOI 10.2353/ajpath.2010.090876; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Gozgit JM, 2021, CANCER CELL, V39, P1214, DOI 10.1016/j.ccell.2021.06.018; Guo JP, 2017, ONCOL LETT, V13, P1919, DOI 10.3892/ol.2017.5649; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Huang WC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1091-5; Janssen LME, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0283-9; Johannes L, 2018, J CELL SCI, V131, DOI 10.1242/jcs.208884; Kaur Manpreet, 2016, Asian Pac J Cancer Prev, V17, P455; Labrie M, 2014, ONCOTARGET, V5, P7705, DOI 10.18632/oncotarget.2299; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lawson DA, 2018, NAT CELL BIOL, V20, P1349, DOI 10.1038/s41556-018-0236-7; Li HJ, 2021, CANCER RES, V81, P4094, DOI 10.1158/0008-5472.CAN-20-3543; Liu XL, 2018, ONCOL RES, V26, P1123, DOI 10.3727/096504018X15166223632406; Liu Y, 2016, J MOL MED, V94, P509, DOI 10.1007/s00109-015-1376-x; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; Matsumoto G, 2010, CLIN EXP METASTAS, V27, P539, DOI 10.1007/s10585-010-9343-y; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mesquita JA, 2016, EUR ARCH OTO-RHINO-L, V273, P237, DOI 10.1007/s00405-014-3439-y; Mody MD, 2021, LANCET, V398, P2289, DOI 10.1016/S0140-6736(21)01550-6; Nagasawa S, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01959-9; Nguyen B, 2022, CELL, V185, P563, DOI 10.1016/j.cell.2022.01.003; Owen KL, 2020, EMBO REP, V21, DOI 10.15252/embr.202050162; Pape M, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.186; Pham NTH, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101308; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rahma OE, 2019, CLIN CANCER RES, V25, P5449, DOI 10.1158/1078-0432.CCR-18-1543; Richardson AM, 2018, CLIN CANCER RES, V24, P420, DOI 10.1158/1078-0432.CCR-17-1776; Saussez S, 2006, CELL MOL LIFE SCI, V63, P686, DOI 10.1007/s00018-005-5458-8; Saussez S, 2008, ORAL ONCOL, V44, P86, DOI 10.1016/j.oraloncology.2006.12.014; Saussez S, 2006, ANN SURG ONCOL, V13, P999, DOI 10.1245/ASO.2006.08.033; Saussez S, 2009, INT J ONCOL, V34, P433, DOI 10.3892/ijo_00000167; Sewgobind NV, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111720; Si YL, 2021, BBA-GEN SUBJECTS, V1865, DOI 10.1016/j.bbagen.2020.129755; St-Pierre Y, 2012, FRONT BIOSCI-LANDMRK, V17, P438, DOI 10.2741/3937; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Terry S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01625; Tsai CJ, 2013, GYNECOL ONCOL, V131, P645, DOI 10.1016/j.ygyno.2013.04.056; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Wang JW, 2018, CANCER LETT, V418, P176, DOI 10.1016/j.canlet.2018.01.040; Wenig BM, 2017, MODERN PATHOL, V30, pS112, DOI 10.1038/modpathol.2016.207; Yang Ri-Yao, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000719; Zhu H, 2013, INT J CANCER, V132, P1051, DOI 10.1002/ijc.27764; Zhu H, 2009, J PROTEOME RES, V8, P3969, DOI 10.1021/pr900287a; Zhu X, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-290	57	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02525-1	http://dx.doi.org/10.1038/s41388-022-02525-1		NOV 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5Y2QR	36335283	Bronze			2022-12-28	WOS:000879132500001
J	SHEETZ, MP				SHEETZ, MP			CAN INDIRECT COST FUNDING BE IMPROVED	FASEB JOURNAL			English	Editorial Material											SHEETZ, MP (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,468 SANDS BLDG RES DR,BOX 3011,DURHAM,NC 27710, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1992	6	14					3234	3235		10.1096/fasebj.6.14.1426760	http://dx.doi.org/10.1096/fasebj.6.14.1426760			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426760				2022-12-28	WOS:A1992JZ73400002
J	EHRETSMANN, CP; CARPOUSIS, AJ; KRISCH, HM				EHRETSMANN, CP; CARPOUSIS, AJ; KRISCH, HM			MESSENGER-RNA DEGRADATION IN PROKARYOTES	FASEB JOURNAL			English	Review						MESSENGER RNA DEGRADATION; MESSENGER RNA DECAY; RNA PROCESSING; RIBONUCLEASE; MESSENGER RNA STABILITY	ESCHERICHIA-COLI K-12; STABILITY AMS GENE; RIBONUCLEASE-III; PROCESSING ENZYME; POLYNUCLEOTIDE PHOSPHORYLASE; ENDONUCLEOLYTIC CLEAVAGE; RIBOSOMAL-PROTEIN; DECAY; SEQUENCE; EXPRESSION	The fast turnover of mRNA permits rapid changes in the pattern of gene expression. In procaryotes, many enzymes involved in mRNA degradation have been identified and some of these endo- and exo-ribonucleases are now being intensively studied. Some of the structural features of mRNA that influence decay rates have also recently been defined. Although important components of the decay pathway are still elusive, a coherent and simple model for mRNA decay has emerged in the last few years.	CNRS,CTR RECH BIOCHIM & GENET CELLULAIRE,118 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE; UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); University of Geneva			Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BARDWELL JCA, 1989, EMBO J, V8, P3401, DOI 10.1002/j.1460-2075.1989.tb08504.x; BECHHOFER DH, 1987, P NATL ACAD SCI USA, V84, P498, DOI 10.1073/pnas.84.2.498; BELASCO JG, 1986, CELL, V46, P245, DOI 10.1016/0092-8674(86)90741-5; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; CANNISTRARO VJ, 1986, J MOL BIOL, V192, P257, DOI 10.1016/0022-2836(86)90363-3; CANNISTRARO VJ, 1991, J BACTERIOL, V173, P4653, DOI 10.1128/jb.173.15.4653-4659.1991; CANNISTRARO VJ, 1989, EUR J BIOCHEM, V181, P3063; CHAUHAN AK, 1991, NUCLEIC ACIDS RES, V19, P125, DOI 10.1093/nar/19.1.125; CHELLADURAI BS, 1991, NUCLEIC ACIDS RES, V19, P1759, DOI 10.1093/nar/19.8.1759; CHEN CYA, 1990, J BACTERIOL, V172, P4578, DOI 10.1128/jb.172.8.4578-4586.1990; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLAVERIEMARTIN F, 1989, J BACTERIOL, V171, P5479, DOI 10.1128/jb.171.10.5479-5486.1989; COLE JR, 1986, J MOL BIOL, V188, P383, DOI 10.1016/0022-2836(86)90162-2; CREMER KJ, 1974, J BACTERIOL, V118, P582, DOI 10.1128/JB.118.2.582-589.1974; DATTA AK, 1975, J BIOL CHEM, V250, P7313; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; DONOVAN WP, 1983, NUCLEIC ACIDS RES, V2, P265; DUNN JJ, 1976, J BIOL CHEM, V251, P3807; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3296, DOI 10.1073/pnas.70.12.3296; EHRETSMANN C, 1990, NATO ADV SCI I H, V49, P21; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GESTELAND RF, 1966, J MOL BIOL, V16, P67, DOI 10.1016/S0022-2836(66)80263-2; GITELMAN DR, 1980, BIOCHEM BIOPH RES CO, V96, P1063, DOI 10.1016/0006-291X(80)90060-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GORSKI K, 1985, CELL, V43, P461, DOI 10.1016/0092-8674(85)90176-X; GUARNEROS G, 1982, P NATL ACAD SCI-BIOL, V79, P238, DOI 10.1073/pnas.79.2.238; GUREVITZ M, 1982, EUR J BIOCHEM, V124, P2553; KRINKE L, 1990, GENE DEV, V4, P2223, DOI 10.1101/gad.4.12a.2223; KRISCH HM, 1982, P NATL ACAD SCI-BIOL, V79, P4937, DOI 10.1073/pnas.79.16.4937; KRISCH HM, 1977, VIROLOGY, V78, P87, DOI 10.1016/0042-6822(77)90080-0; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; MEADOR J, 1990, GENE, V95, P1, DOI 10.1016/0378-1119(90)90406-H; MISRA TK, 1978, J BIOL CHEM, V253, P5594; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NASHIMOTO H, 1985, MOL GEN GENET, V201, P25, DOI 10.1007/BF00397981; NEWBURY SF, 1987, CELL, V48, P297, DOI 10.1016/0092-8674(87)90433-8; NILSSON G, 1984, NATURE, V312, P75, DOI 10.1038/312075a0; NILSSON G, 1987, P NATL ACAD SCI USA, V84, P4890, DOI 10.1073/pnas.84.14.4890; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PEDERSEN S, 1978, MOL GEN GENET, V166, P329, DOI 10.1007/BF00267626; PETERSEN C, 1987, MOL GEN GENET, V209, P179, DOI 10.1007/BF00329856; PLAMANN MD, 1990, MOL GEN GENET, V220, P301; PORTIER C, 1975, EUR J BIOCHEM, V55, P573, DOI 10.1111/j.1432-1033.1975.tb02194.x; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; REGNIER P, 1989, J MOL BIOL, V210, P293, DOI 10.1016/0022-2836(89)90331-8; REGNIER P, 1991, J MOL BIOL, V217, P2832; SPAHR PF, 1968, P NATL ACAD SCI USA, V59, P876, DOI 10.1073/pnas.59.3.876; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8895, DOI 10.1073/pnas.85.23.8895	60	85	89	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1992	6	13					3186	3192		10.1096/fasebj.6.13.1397840	http://dx.doi.org/10.1096/fasebj.6.13.1397840			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397840	Bronze			2022-12-28	WOS:A1992JU51200011
J	WEINER, S; TRAUB, W				WEINER, S; TRAUB, W			BONE-STRUCTURE - FROM ANGSTROMS TO MICRONS	FASEB JOURNAL			English	Article						CRYSTALS; COLLAGEN; MINERALIZED BONE; LAMELLAE	COLLAGEN FIBRILS; HYDROXYAPATITE CRYSTALS; ORIENTATION; MINERALIZATION; ORGANIZATION; DIFFRACTION; OSTEONS; TENDON; FIBERS	Bone has a complex hierarchical structure, which despite much investigation, is still not well understood. Here we bring together pieces of this complicated puzzle, albeit from different sources, to present a tentative overview of bone structure. The basic building blocks are the extremely small plate-shaped crystals of carbonate apatite, just hundreds of angstroms long and wide and some 20-30 angstrom thick. They are arranged in parallel layers within the collagenous framework. At the next hierarchical level these mineral-filled collagen fibrils are ordered into arrays in which the fibril axes and the crystal layers are all organized into a 3-dimensional structure that makes up a single layer or lamella of bone a few microns thick. The orientations of the collagen fibrils and the crystal layers in alternating lamellae of rat bone differ such that in the thinner lamellae, the fibrils and the crystal layers are parallel to the lamellar boundaries. In the thicker lamellae the fibrils are parallel to the boundary, but the crystal layers are rotated out of the plane of the boundary. In many bones these alternating lamellae are organized into even larger ordered structures to produce what is truly a remarkably ordered material, all the way from the molecular scale to the macroscopic product.			WEINER, S (corresponding author), WEIZMANN INST SCI, DEPT STRUCT BIOL, IL-76100 REHOVOT, ISRAEL.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006954] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-06954] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARSENAULT AL, 1991, CALCIFIED TISSUE INT, V48, P56, DOI 10.1007/BF02555796; ASCENZI A, 1986, J BIOMECH, V19, P455, DOI 10.1016/0021-9290(86)90022-9; BOYDE A, 1990, BONE, V11, P35, DOI 10.1016/8756-3282(90)90069-B; BROWN WE, 1976, ANNU REV MATER SCI, V6, P213, DOI 10.1146/annurev.ms.06.080176.001241; CURREY JD, 1984, PHILOS T ROY SOC B, V304, P509, DOI 10.1098/rstb.1984.0042; CURREY JD, 1984, MECH ADAPTATIONS BON, P24; EANES ED, 1970, CALC TISS RES, V6, P239, DOI 10.1007/BF02196204; ENLOW DH, 1962, AM J ANAT, V110, P79, DOI 10.1002/aja.1001100202; EVANS FG, 1969, J BIOMECH, V2, P63, DOI 10.1016/0021-9290(69)90042-6; FRASCA P, 1978, J DENT RES, V57, P526, DOI 10.1177/00220345780570032201; GIRAUDGUILLE MM, 1988, CALCIFIED TISSUE INT, V42, P167, DOI 10.1007/BF02556330; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; GRYNPAS MD, 1989, CONNECT TISSUE RES, V21, P557, DOI 10.3109/03008208909050012; Guinier A., 1963, XRAY DIFFRACTION CRY; Havers C., 1691, OSTEOLOGIA NOVA; HEYWOOD BR, 1990, CONNECT TISSUE RES, V25, P103, DOI 10.3109/03008209009006985; Hodge A, 1963, ASPECTS PROTEIN STRU, P289; HODGE AJ, 1989, CONNECT TISSUE RES, V21, P467, DOI 10.3109/03008208909050004; JACKSON SF, 1957, PROC R SOC SER B-BIO, V146, P270, DOI 10.1098/rspb.1957.0010; Katz E P, 1989, Connect Tissue Res, V21, P149, DOI 10.3109/03008208909050005; KATZ EP, 1973, J MOL BIOL, V80, P1, DOI 10.1016/0022-2836(73)90230-1; LANDIS WJ, 1991, CONNECT TISSUE RES, V25, P181, DOI 10.3109/03008209109029155; LEES S, 1984, INT J BIOL MACROMOL, V6, P321, DOI 10.1016/0141-8130(84)90017-5; LEES S, 1988, CONNECT TISSUE RES, V18, P41, DOI 10.3109/03008208809019071; MORADIANOLDAK J, 1991, CONNECT TISSUE RES, V25, P219, DOI 10.3109/03008209109029158; NELSON DGA, 1986, ULTRAMICROSCOPY, V19, P253, DOI 10.1016/0304-3991(86)90213-5; REID SA, 1986, ANAT EMBRYOL, V174, P329, DOI 10.1007/BF00698783; ROBINSON RA, 1952, J BONE JOINT SURG AM, V34-A, P389, DOI 10.2106/00004623-195234020-00013; ROBINSON RA, 1952, ANAT REC, V114, P383, DOI 10.1002/ar.1091140302; Schmidt W. J., 1936, NATURWISSENSCHAFTEN, V24, P361, DOI DOI 10.1007/BF01473678; SELVIG KA, 1970, CALC TISS RES, V6, P227, DOI 10.1007/BF02196203; TRAUB W, 1989, P NATL ACAD SCI USA, V86, P9822, DOI 10.1073/pnas.86.24.9822; VANLEEUWENHOECK A, 1693, PHIL T R SOC LONDON, V17, P838; WEINER S, 1989, CONNECT TISSUE RES, V21, P589, DOI 10.3109/03008208909050015; WEINER S, 1991, FEBS LETT, V285, P49, DOI 10.1016/0014-5793(91)80722-F; WEINER S, 1986, FEBS LETT, V206, P262, DOI 10.1016/0014-5793(86)80993-0; Weiner S., 1991, MECH PHYLOGENY MINER, P247; Weiner S., 1989, BIOMINERALIZATION, P144; Yamauchi M, 1989, Connect Tissue Res, V21, P159, DOI 10.3109/03008208909050006	39	409	420	7	84	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1992	6	3					879	885		10.1096/fasebj.6.3.1740237	http://dx.doi.org/10.1096/fasebj.6.3.1740237			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740237	Bronze			2022-12-28	WOS:A1992HE39000011
J	HIROYA, K; ISHIGOOKA, M; SHIMIZU, T; HATANO, M				HIROYA, K; ISHIGOOKA, M; SHIMIZU, T; HATANO, M			ROLE OF GLU318 AND THR319 IN THE CATALYTIC FUNCTION OF CYTOCHROME-P450D (P4501A2) - EFFECTS OF MUTATIONS ON THE METHANOL HYDROXYLATION	FASEB JOURNAL			English	Note						CYTOCHROME-P450; SITE-DIRECTED MUTAGENESIS; METHANOL; DISTAL SITE	MICROSOMAL CYTOCHROME-P-450; OXIDATION; ETHANOL; SYSTEM; FORMS; RATS; PURIFICATION; ACTIVATION; RADICALS; OXIDASE	Polar amino acids in the (putative) distal site are well conserved in P450s. For example, Glu318 for P450d is well conserved as either Glu or Asp for P450s, and Thr319 for P450d is also conserved for P450s. We have studied how mutations at Glu318 and Thr319 of P450d influence the catalytic activity toward methanol associated with the activation of O2. Catalytic activities of Glu318Asp, Glu318Ala, and Thr319Ala mutants toward methanol were 60, 25, and 38%, respectively, compared with that of the wild type. O2 consumption and NADPH oxidation rates of each mutants varied corresponding to the catalytic activities. However, surprisingly, efficiency (16-40%) of incorporated O to the substrate vs. consumed O2 for the Glu318Ala and Thr319Ala mutants were higher than that (9%) of the wild type. In addition, H2O2, which is produced from uncoupling for the wild-type P450d, was not observed for reaction of the Glu318Ala and Thr319Ala mutants. It seemed that consumed O2 was partially reduced to 2 mol of H2O by 4-electron transfer from NADPH for the wild-type and Thr319Ala mutant. However, for the two Glu318 mutants, it appeared that the consumed O2 was not reduced in the same way. It was thus suggested that the conserved Glu318 and Thr319 of P450d are not essential for the activation Of O2 in the methanol oxidation. Role of the water molecule or the methanol molecule in the catalytic function was implied.	TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 980,JAPAN	Tohoku University								CEDERBAUM AI, 1979, BIOCHEM BIOPH RES CO, V91, P747, DOI 10.1016/0006-291X(79)91943-0; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUENGERICH FP, 1978, J BIOL CHEM, V253, P7931; HIROYA K, 1991, CHEM LETT, P973, DOI 10.1246/cl.1991.973; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; INGELMANSUNDBERG M, 1984, J BIOL CHEM, V259, P6447; KRAINEV AG, 1991, BIOCHEMISTRY-US, V30, P11206, DOI 10.1021/bi00111a003; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MIWA GT, 1978, ARCH BIOCHEM BIOPHYS, V187, P464, DOI 10.1016/0003-9861(78)90058-9; MORGAN ET, 1982, J BIOL CHEM, V257, P3951; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1988, J BIOL CHEM, V263, P6038; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; RAAG R, IN PRESS BIOCHEMISTR; RYAN DE, 1980, J BIOL CHEM, V255, P7941; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P4659, DOI 10.1021/bi00233a004; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P1490, DOI 10.1021/bi00220a007; WINSTON GW, 1983, J BIOL CHEM, V258, P1514	24	26	26	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					749	751		10.1096/fasebj.6.2.1347023	http://dx.doi.org/10.1096/fasebj.6.2.1347023			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1347023				2022-12-28	WOS:A1992GZ44000017
J	POULOS, TL; RAAG, R				POULOS, TL; RAAG, R			CYTOCHROME-P450CAM - CRYSTALLOGRAPHY, OXYGEN ACTIVATION, AND ELECTRON-TRANSFER	FASEB JOURNAL			English	Article						P450CAM; OXYGEN ACTIVATION; ACID CATALYSIS; MUTAGENESIS; ELECTRON TRANSFER	PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; CRYSTAL-STRUCTURE; PUTIDAREDOXIN; MONOXYGENASE; STABILITY; COMPLEXES; REDUCTION; P450CAM; MODEL	Several crystal structures of various substrate and inhibited complexes of the camphor monoxygenase, cytochrome P450cam from Pseudomonas putida, are now available. These structures, together with mutagenesis, biochemical, and biophysical studies, have allowed for a detailed penetration into the problem of how P450s activate molecular oxygen, control stereoselectivity, and transfer electrons. This review will provide a of the crystallographic work in light of what these structures have taught us about P450 function.	MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; UNIV MARYLAND,DEPT CHEM BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park								ATKINS WM, 1987, J AM CHEM SOC, V109, P3754, DOI 10.1021/ja00246a038; ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; BRINIGAR WS, 1974, J AM CHEM SOC, V96, P5597, DOI 10.1021/ja00824a061; Collman J.P., 1980, METAL ION ACTIVATION, P1; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; GELB MH, 1982, BIOCHEMISTRY-US, V21, P370, DOI 10.1021/bi00531a026; GEREN L, 1986, J BIOL CHEM, V261, P5491; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; POULOS TL, 1987, ADV INORG BIOCHEM, V7, P1; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; SHIMADA H, 1991, INT S OXYGENASES OXY, P133; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1974, P NATL ACAD SCI USA, V71, P3906, DOI 10.1073/pnas.71.10.3906; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; [No title captured]	31	150	158	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					674	679		10.1096/fasebj.6.2.1537455	http://dx.doi.org/10.1096/fasebj.6.2.1537455			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537455				2022-12-28	WOS:A1992GZ44000005
J	KUMBLA, L; BHADRA, S; SUBBIAH, MTR				KUMBLA, L; BHADRA, S; SUBBIAH, MTR			MULTIFUNCTIONAL ROLE FOR FETUIN (FETAL PROTEIN) IN LIPID TRANSPORT	FASEB JOURNAL			English	Article						LIPID METABOLISM; CHOLESTEROL; FATTY ACID INCORPORATION	CHOLESTEROL	Recent studies from this laboratory have shown that fetuin 1) is nearly 50-fold more efficient than albumin in incorporating exogenous fatty acids into cultured cells, (JBC, 265: 5883, 1990), and 2) is associated with a lipoprotein-like particle (FASEB J. 3: 2075-2080, 1989). In the present study, this lipid-containing fraction (FLP) was isolated by ultracentrifugation, and its effect on cholesterol efflux from cultured human skin fibroblasts and Hep-G2 cells prelabeled with [C-14]cholesterol was investigated. FLP fraction caused a significant efflux of [C-14]cholesterol from cells, the same in magnitude as HDL. This effect of fetuin supranatant fraction increased proportionately with concentration and time. Similar results were observed with Hep-G2 cells. This ability to induce efflux of cholesterol was confirmed by a decrease in cholesterol mass of cells after 24 h incubation with FLP. The ultracentrifugal bottom (infranatant) fraction of fetuin (FI) was ineffective in this regard. However, FI was more effective in the incorporation of exogenous fatty acids into cellular triglycerides. These studies suggest that the fetuin molecule is a multifunctional protein (delivery of fatty acids to cells and cholesterol efflux from cells) which may play a role in lipid transport during fetal life.	UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,LIPID RES LAB,CINCINNATI,OH 45267	University of Cincinnati					NHLBI NIH HHS [HL-07460] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007460] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1989, ARTERIOSCLEROSIS, V9, P67, DOI 10.1161/01.ATV.9.1.67; CARDIN AD, 1984, METHODS PHARM, V6; CAYATTE AJ, 1990, J BIOL CHEM, V265, P5883; DZIEGIELEWSKA KM, 1983, COMP BIOCHEM PHYS A, V76, P241, DOI 10.1016/0300-9629(83)90321-3; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRIEDMAN M, 1957, P SOC EXP BIOL MED, V95, P586; GLICK JM, 1983, J BIOL CHEM, V258, P3425; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KUMBLA L, 1989, FASEB J, V3, P2075, DOI 10.1096/fasebj.3.9.2472993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEDERSEN KO, 1947, J PHYS COLLOID CHEM, V51, P164, DOI 10.1021/j150451a012; PUCK TT, 1968, P NATL ACAD SCI USA, V59, P192, DOI 10.1073/pnas.59.1.192; SPIRO RG, 1960, J BIOL CHEM, V235, P2860; SUBBIAH MTR, 1983, J CLIN INVEST, V71, P1509, DOI 10.1172/JCI110906; SUBBIAH MTR, 1991, P SOC EXP BIOL MED, V198, P495	16	20	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2971	2975		10.1096/fasebj.5.14.1721594	http://dx.doi.org/10.1096/fasebj.5.14.1721594			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1721594				2022-12-28	WOS:A1991GP26900013
J	RAPOPORT, TA				RAPOPORT, TA			PROTEIN-TRANSPORT ACROSS THE ENDOPLASMIC-RETICULUM MEMBRANE - FACTS, MODELS, MYSTERIES	FASEB JOURNAL			English	Review						TRANSLOCATION; ENDOPLASMIC RETICULUM; MEMBRANE; SIGNAL SEQUENCE	SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; NASCENT PREPROLACTIN; HYDROPHOBIC SEGMENT; SEQUENCE RECEPTOR; BINDING-PROTEINS; DOCKING PROTEIN; PLASMA-MEMBRANE; ER MEMBRANE	The first step in the biosynthesis of secretory proteins, plasma membrane proteins, and many other proteins in a eukaryotic cell involves the transport of at least portions of the polypeptides across the endoplasmic reticulum (ER) membrane. Parts of the polypeptide chains serve as signals that direct the translocation across and the integration into the ER membrane and also determine the orientation of membrane proteins. The transport process itself may be divided into two phases: an initiation or targeting cycle, which is fairly well understood, and the actual transfer of the polypeptide chain through the membrane, the mechanism of which is still mysterious. The initiation cycle generally involves the function of the signal recognition particle (SRP) which binds to signal sequences through its 54-kDa polypeptide component, and of the SRP-receptor (docking protein) in the ER membrane whose function is dependent on GTP. The membrane transfer of the polypeptide chain appears to involve a translocation complex consisting of several membrane proteins, one of which is the signal sequence receptor protein (SSR).			RAPOPORT, TA (corresponding author), ZENT INST MOLEK BIOL, ROBERT ROSSLE STR 10, W-1115 BERLIN, GERMANY.							BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BIRD P, 1990, J BIOL CHEM, V265, P8420; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DESHAIES RJ, 1990, NATO ADV SCI I H-CEL, V40, P327; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FINKELSTEIN AV, 1983, FEBS LETT, V161, P176, DOI 10.1016/0014-5793(83)81002-3; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; INNER MA, 1984, P NATL ACAD SCI USA, V81, P3708; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KREIBICH G, 1978, J SUPRAMOL STR CELL, V8, P279, DOI 10.1002/jss.400080307; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; RAPOPORT TA, 1991, NATURE, V349, P107, DOI 10.1038/349107a0; RAPOPORT TA, 1987, J MOL BIOL, V195, P621, DOI 10.1016/0022-2836(87)90186-0; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROBINSON A, 1987, BIOCHEM J, V242, P767, DOI 10.1042/bj2420767; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; THRIFT RN, 1991, IN PRESS J CELL BIOL; VOGEL F, 1990, IN PRESS EUR J CELL; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; YAMAMOTO Y, 1987, BIOCHEM BIOPH RES CO, V149, P431, DOI 10.1016/0006-291X(87)90385-8; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; ZIMMERMANN R, 1986, TRENDS BIOCHEM SCI, V11, P512, DOI 10.1016/0968-0004(86)90085-X; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x; [No title captured]	60	53	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1991	5	13					2792	2798		10.1096/fasebj.5.13.1916103	http://dx.doi.org/10.1096/fasebj.5.13.1916103			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916103				2022-12-28	WOS:A1991GJ47100007
J	FRIDMAN, WH				FRIDMAN, WH			FC-RECEPTORS AND IMMUNOGLOBULIN BINDING-FACTORS	FASEB JOURNAL			English	Article						FC RECEPTORS; EFFECTOR FUNCTIONS OF ANTIBODIES; IMMUNOREGULATION	NATURAL-KILLER CELLS; SINGLE AMINO-ACID; IGG FC; GAMMA-RECEPTOR; T-CELLS; SURFACE EXPRESSION; SOLUBLE CD23; EPSILON-RII; CD16; LYMPHOCYTES	Receptors for the Fc portion of Ig (Fc receptors, FcR) are found on all cell types of the immune system. Three types of FcR react with IgG: Fc-gamma-RI is a high-affinity receptor binding IgG monomers whereas Fc-gamma-RII and Fc-gamma-RIII are low-affinity receptors binding IgG immune complexes; the three types of Fc-gamma-R are members of the Ig superfamily. Two FcR react with IgE: Fc-epsilon-RI is a multichain receptor binding IgE with high affinity; it is composed of an IgE-binding alpha-chain, homologous to Fc-gamma-RIII, and of gamma and beta-chains that are necessary for receptor expression and signal transduction. The low-affinity Fc-epsilon-RII is the only FcR described so far that is not a member of the Ig superfamily but resembles animal lectins; it is composed of a transmembrane chain with an intracytoplasmic NH2 terminus. Fc-alpha-R has homology with Fc-gamma-R and is a member of the Ig superfamily. Receptors for IgM and IgD are not characterized yet. Finally, Ig transport is made by FcR-like molecules such as the poly-Ig receptor or an MHC-like receptor found on neonatal intestine. A remarkable property of most FcR is the fact that they are released in cell supernatants and circulate in biological fluids as immunoglobulin binding factors (IBF) generated either by cleavage at the cell membrane or by splicing of FcR transmembrane exon. Immunoglobulin binding factors may interfere with Ig-mediated functions and have direct immunoregulatory activities. Involvement of FcR or IBF has been postulated in several diseases, and monoclonal antibodies to FcR are beginning to be used in therapeutics, particularly to target cytotoxic effector lymphocytes and monocytes to tumor cells.			FRIDMAN, WH (corresponding author), INST CURIE, INSERM, U255, IMMUNOL CELLULAIRE & CLIN LAB, 26 RUE ULM, F-75231 PARIS 05, FRANCE.			fridman, wolf herman/0000-0002-1332-0973				AMIGORENA S, 1989, EUR J IMMUNOL, V19, P1379, DOI 10.1002/eji.1830190805; ANDERSON CL, 1986, IMMUNOL TODAY, V7, P264, DOI 10.1016/0167-5699(86)90007-1; ANEGON I, 1988, J EXP MED, V167, P452, DOI 10.1084/jem.167.2.452; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BRUNATI S, 1990, EUR J IMMUNOL, V20, P55, DOI 10.1002/eji.1830200109; CAPRON M, 1989, CHEM IMMUNOL, V47, P128; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; CLARKSON SB, 1988, J EXP MED, V167, P408, DOI 10.1084/jem.167.2.408; DAERON M, 1990, MOL IMMUNOL, V27, P1181, DOI 10.1016/0161-5890(90)90020-Z; DAERON M, 1991, IN PRESS IMMUNOL LET; DAERON M, 1989, CHEM IMMUNOL, V47, P21; DELESPESSE G, 1989, CHEM IMMUNOL, V47, P79; DESSAINT JP, 1990, FC RECEPTORS ACTION, P260; FANGER MW, 1989, CHEM IMMUNOL, V47, P214; Fridman W. H., 1989, CHEM IMMUNOL, V47, P1; FRIDMAN WH, 1986, MOL IMMUNOL, V23, P1141, DOI 10.1016/0161-5890(86)90144-6; FRIDMAN WH, 1974, CELL IMMUNOL, V11, P442, DOI 10.1016/0008-8749(74)90042-2; FRIDMAN WH, 1990, FC RECEPTORS ACTION, P335; GISLER RH, 1975, J EXP MED, V142, P507, DOI 10.1084/jem.142.2.507; HOOVER RG, 1981, IMMUNOL REV, V56, P115, DOI 10.1111/j.1600-065X.1981.tb01049.x; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; HUIZINGA TWJ, 1990, BLOOD, V76, P1927; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; ISHIZAKA K, 1985, J IMMUNOL, V135, pR1; KEHRY MR, 1990, RES IMMUNOL, V141, P77, DOI 10.1016/0923-2494(90)90106-9; KHAYAT D, 1984, J IMMUNOL, V132, P2496; KHAYAT D, 1987, J IMMUNOL METHODS, V100, P235, DOI 10.1016/0022-1759(87)90194-3; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KINET JP, 1990, FC RECEPTORS ACTION, P239; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LANIER LL, 1989, SCIENCE, V246, P1611, DOI 10.1126/science.2531919; LANIER LL, 1988, J IMMUNOL, V141, P3478; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LAWLEY TJ, 1980, J INVEST DERMATOL, V74, P339, DOI 10.1111/1523-1747.ep12543598; LETELLIER M, 1990, J EXP MED, V172, P693, DOI 10.1084/jem.172.3.693; LITWIN V, 1990, VIROLOGY, V178, P263, DOI 10.1016/0042-6822(90)90402-D; LYNCH RG, 1990, FC RECEPTORS ACTION, P305; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MOSSALAYI MD, 1990, J EXP MED, V171, P959, DOI 10.1084/jem.171.3.959; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NEAUPORTSAUTES C, 1975, EUR J IMMUNOL, V5, P849, DOI 10.1002/eji.1830051210; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RAN M, 1991, CANCER RES, V51, P612; Ravetch J.V., 1990, FC RECEPTORS ACTION, P211; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SARFATI M, 1988, BLOOD, V71, P94; SAUTES C, 1990, MOL IMMUNOL, V27, P1201, DOI 10.1016/0161-5890(90)90023-S; SAUTES C, 1991, EUR J IMMUNOL, V21, P231, DOI 10.1002/eji.1830210135; SEGAL DM, 1989, CHEM IMMUNOL, V47, P179; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; TEILLAUD JL, 1990, MOL IMMUNOL, V27, P1209, DOI 10.1016/0161-5890(90)90024-T; TORPIER G, 1979, NATURE, V278, P447, DOI 10.1038/278447a0; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VARIN N, 1989, EUR J IMMUNOL, V19, P2263, DOI 10.1002/eji.1830191213; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; VINCENDEAU P, 1989, J IMMUNOL, V142, P1702; WALDSCHMIDT TJ, 1989, J IMMUNOL, V143, P2820; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; YODOI J, 1989, CHEM IMMUNOL, V47, P106; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	66	105	134	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1991	5	12					2684	2690		10.1096/fasebj.5.12.1916092	http://dx.doi.org/10.1096/fasebj.5.12.1916092			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916092				2022-12-28	WOS:A1991GE81100009
J	HAGEN, TM; BAI, CL; JONES, DP				HAGEN, TM; BAI, CL; JONES, DP			STIMULATION OF GLUTATHIONE ABSORPTION IN RAT SMALL-INTESTINE BY ALPHA-ADRENERGIC AGONISTS	FASEB JOURNAL			English	Article						GLUTATHIONE; PHENYLEPHRINE; INTESTINAL ABSORPTION; ANTIOXIDANTS; DIETARY	BRUSH-BORDER MEMBRANES; DIETARY GLUTATHIONE; EXOGENOUS GLUTATHIONE; CELLULAR GLUTATHIONE; REDUCED GLUTATHIONE; OXIDATIVE INJURY; TRANSPORT; CELLS; BINDING; METABOLISM	The alpha-adrenergic agonist, phenylephrine (1.6-mu-M), caused a threefold stimulation of glutathione (GSH) transport from the lumen into the vasculature in isolated, vascularly perfused rat small intestine. Stimulation of GSH transport by phenylephrine was blocked by the alpha-adrenergic antagonists, prazosin or phentolamine. Norepinephrine and epinephrine (both alpha and beta-agonists) also stimulated GSH absorption but not to the same extent as phenylephrine. Isoproterenol, a strict beta-adrenergic agonist, had no effect on the rate of GSH absorption. Under physiological luminal GSH concentrations, phenylephrine stimulated GSH efflux from the lumen, accumulation in the intestinal mucosa, and transport into the mesenteric vasculature. Phenylephrine did not stimulate the transport of polyethylene glycol, a high molecular weight molecule, and stimulated uptake of cysteine and glycine by 30%. This suggests that the effect of phenylephrine on GSH transport is not due to enhanced bulk flow through paracellular pathways. Studies with isolated small intestinal epithelial cells showed that phenylephrine also stimulated the release of GSH from the cells. Oral administration of phenylephrine with GSH caused a two- to fivefold transient increase in plasma GSH concentrations in rats. Phenylephrine alone or with the amino acid constituents of GSH caused no increase in plasma GSH concentration. Thus, absorption of dietary GSH is under hormonal regulation. The physiological importance of this regulation is not known, although such regulation may function to control utilization of dietary GSH for detoxication and may have therapeutic benefits for individuals with deficient GSH or increased risk of oxidative or chemically induced injury.	EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, WINSHIP CANC CTR, ATLANTA, GA 30322 USA	Emory University; Emory University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039968] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39968] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BAI C, 1991, FASEB J, V5, pA1489; BASTIDAS JA, 1989, J SURG RES, V46, P484, DOI 10.1016/0022-4804(89)90165-0; BEUTLER E, 1985, J LAB CLIN MED, V105, P581; BUHL R, 1989, LANCET, V2, P1294; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANG EB, 1983, AM J PHYSIOL, V244, pG76, DOI 10.1152/ajpgi.1983.244.1.G76; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COMPORTI M, 1985, LAB INVEST, V53, P599; CORNELL JS, 1976, P NATL ACAD SCI USA, V73, P420, DOI 10.1073/pnas.73.2.420; COTGREAVE IA, 1987, BIOCHEM PHARMACOL, V36, P2899, DOI 10.1016/0006-2952(87)90200-0; COTTERELL DJ, 1984, BIOCHEM PHARMACOL, V33, P751, DOI 10.1016/0006-2952(84)90458-1; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; DYKE RMV, 1989, GASTROINTESTINAL DIS, P1062; FURUKAWA T, 1987, MECH AGEING DEV, V38, P107, DOI 10.1016/0047-6374(87)90071-6; GRAFSTROM R, 1979, MED BIOL, V57, P287; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; HAGEN TM, 1990, AM J PHYSIOL, V259, pG524; HAGEN TM, 1988, KIDNEY INT, V34, P74, DOI 10.1038/ki.1988.147; HAGEN TM, 1986, BIOCHEM PHARMACOL, V35, P4537, DOI 10.1016/0006-2952(86)90776-8; HAGEN TM, 1987, AM J PHYSIOL, V252, pG607, DOI 10.1152/ajpgi.1987.252.5.G607; HAGEN TM, 1990, AM J PHYSIOL, V259, pG530, DOI 10.1152/ajpgi.1990.259.4.G530; HAGEN TM, 1987, ADV BIOSCI, V65, P107; HAUSSINGER D, 1987, EUR J BIOCHEM, V163, P197, DOI 10.1111/j.1432-1033.1987.tb10755.x; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; JERNSTROM B, 1982, CARCINOGENESIS, V3, P861, DOI 10.1093/carcin/3.8.861; KOWALSKI DP, 1990, J NUTR, V120, P1115, DOI 10.1093/jn/120.9.1115; LASH LH, 1986, P NATL ACAD SCI USA, V83, P4641, DOI 10.1073/pnas.83.13.4641; LASH LH, 1984, AM J PHYSIOL, V247, pG394, DOI 10.1152/ajpgi.1984.247.4.G394; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; NAGANUMA A, 1990, BIOCHEM PHARMACOL, V40, P693; NOBILE MT, 1989, TUMORI, V75, P257, DOI 10.1177/030089168907500313; ORIANA S, 1987, TUMORI, V73, P337, DOI 10.1177/030089168707300403; ORRENIUS S, 1984, TRENDS PHARMACOL SCI, V5, P432, DOI 10.1016/0165-6147(84)90495-4; PALLER MS, 1986, KIDNEY INT, V29, P1162, DOI 10.1038/ki.1986.122; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; REVESZ L, 1983, FUNCTIONS GLUTATHION, P163; SCHASTEEN CS, 1983, BIOCHEM BIOPH RES CO, V112, P564, DOI 10.1016/0006-291X(83)91501-2; SIES H, 1985, BIOCHEM J, V226, P545, DOI 10.1042/bj2260545; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; TIMMERMANS PBMWM, 1983, N-S ARCH PHARMACOL, V324, P239, DOI 10.1007/BF00502618; VINCENZINI MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P29, DOI 10.1016/0005-2736(89)90451-3; VINCENZINI MT, 1988, BIOCHIM BIOPHYS ACTA, V942, P107, DOI 10.1016/0005-2736(88)90279-9; WEINER N, 1980, PHARMACOL BASIS THER, P138; YANG JG, 1987, J BIOL CHEM, V262, P13372	45	18	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1991	5	12					2721	2727		10.1096/fasebj.5.12.1680764	http://dx.doi.org/10.1096/fasebj.5.12.1680764			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1680764				2022-12-28	WOS:A1991GE81100014
J	MECHAM, RP				MECHAM, RP			RECEPTORS FOR LAMININ ON MAMMALIAN-CELLS	FASEB JOURNAL			English	Article						LAMININ; 67-KDA RECEPTOR; INTEGRINS; ELASTIN; LECTIN	AMINO-ACID-SEQUENCE; GALACTOSIDE-BINDING LECTIN; EXTRACELLULAR-MATRIX; MESSENGER-RNA; ALPHA-2-BETA-1 INTEGRINS; MONOCLONAL-ANTIBODIES; MULTIPLE RECEPTORS; MEMBRANE-PROTEIN; ELASTIN RECEPTOR; CARCINOMA-CELLS	Early in development, cells produce an extracellular matrix that provides important cues that regulate gene expression, cell division, and morphogenesis. Interactions with the extracellular matrix are mediated by cell-surface receptors providing a transmembrane link between extracellular and intracellular compartments. Laminin, a large, multichain glycoprotein found in basement membranes, is involved in various biological activities, including promotion of cell adhesion, growth, migration, differentiation, neurite outgrowth, and tumor metastases. To date, several classes of binding proteins have been found to interact with laminin, including a high-affinity 67-kDa receptor, galactoside-binding lectins, galactosyltransferase, sulfatides, and integrins. This review will summarize our current understanding of some of these laminin-binding proteins, and where possible, integrate the biochemistry and cell biology of ligand and receptor expression.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV RESP & CRIT CARE,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL)	MECHAM, RP (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT CELL BIOL,DIV RESP & CRIT CARE,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026499, R01HL041926] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41926, HL26499] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BLUM JL, 1989, ENVIRON HEALTH PERSP, V80, P71, DOI 10.2307/3430733; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; CLEGG DO, 1988, J CELL BIOL, V107, P699, DOI 10.1083/jcb.107.2.699; CLEMENT B, 1990, J CELL BIOL, V110, P185, DOI 10.1083/jcb.110.1.185; CODOGNO P, 1988, EXP CELL RES, V174, P344, DOI 10.1016/0014-4827(88)90305-9; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DEAN JW, 1990, J BIOL CHEM, V265, P12553; DOUVILLE PJ, 1988, J BIOL CHEM, V263, P14964; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FORSBERG E, 1990, J BIOL CHEM, V265, P6376; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HORWITZ A, 1985, J CELL BIOL, V101, P2134, DOI 10.1083/jcb.101.6.2134; HUARD TK, 1986, AM J PATHOL, V123, P365; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLEINMAN HK, 1985, J CELL BIOCHEM, V27, P317, DOI 10.1002/jcb.240270402; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LESOT H, 1983, EMBO J, V2, P861, DOI 10.1002/j.1460-2075.1983.tb01514.x; LOTAN R, 1991, IN PRESS HDB GLYCOPR; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MAKRIDES S, 1988, NUCLEIC ACIDS RES, V16, P2349, DOI 10.1093/nar/16.5.2349; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAO CN, 1983, BIOCHEM BIOPH RES CO, V111, P804; RAZ A, 1989, CANCER RES, V49, P3489; RISSE G, 1989, BIOCHIM BIOPHYS ACTA, V994, P258, DOI 10.1016/0167-4838(89)90302-6; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; SAMBROOK J, 1989, NATURE, V342, P224, DOI 10.1038/342224a0; Shur BD, 1989, CURR OPIN CELL BIOL, V1, P905, DOI 10.1016/0955-0674(89)90057-4; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; VONDERMARK K, 1985, BIOCHIM BIOPHYS ACTA, V823, P147; VONDERMARK K, 1987, METHOD ENZYMOL, V144, P490; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YANNARIELLOBROWN J, 1988, J CELL BIOL, V106, P1773, DOI 10.1083/jcb.106.5.1773; YAZAKI PJ, 1990, BIOCHEM BIOPH RES CO, V170, P1089, DOI 10.1016/0006-291X(90)90504-G; YOON PS, 1987, J IMMUNOL, V138, P259; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	71	230	238	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2538	2546		10.1096/fasebj.5.11.1651264	http://dx.doi.org/10.1096/fasebj.5.11.1651264			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1651264				2022-12-28	WOS:A1991GB09400006
J	ROSENBERG, ZF; FAUCI, AS				ROSENBERG, ZF; FAUCI, AS			IMMUNOPATHOGENESIS OF HIV-INFECTION	FASEB JOURNAL			English	Review						CD4+ LYMPHOCYTE-T; HIV PATHOGENESIS; VIRAL ACTIVATION	HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; LONG TERMINAL REPEAT; HUMAN CELL-LINES; MEMORY T-CELLS; PERIPHERAL-BLOOD; CD4+ LYMPHOCYTES; MONONUCLEAR PHAGOCYTES; TYPE-1 INFECTION; PROGENITOR CELLS	The ultimate consequence of infection with HIV is profound immunosuppression that is the result of both quantitative and qualitative abnormalities of the helper/inducer subset of T lymphocytes. The initial pathogenic event in HIV infection is binding of the envelope glycoprotein of HIV to the CD4 receptor molecule present on the surface of CD4+ T lymphocytes and monocyte/macrophages. In vivo the reservoir for HIV infection in the peripheral blood is the CD4+ T cell, whereas in other tissues the monocyte/macrophage may play a substantial role. As disease progresses in HIV-infected individuals, the viral burden in the peripheral blood CD4+ T cells increases. An understanding of the mechanisms involved in the transition from an initially low viral burden during the asymptomatic phase of HIV infection to the higher levels of virus expression detected iii late stage disease is being investigated intensively. A number of potential agents that may influence regulation of HIV expression have been identified including mitogens, antigens, heterologous viruses, cytokines, and physical factors. The pathogenic mechanisms of HIV-induced neurologic abnormalities and the potential role of HIV in a number of other clinical manifestations of HIV infection are also discussed.			ROSENBERG, ZF (corresponding author), NIAID, BETHESDA, MD 20892 USA.							ALBRECHT MA, 1989, J VIROL, V63, P1861, DOI 10.1128/JVI.63.5.1861-1868.1989; BARRESINOUSSI F, 1985, JAMA-J AM MED ASSOC, V253, P1737, DOI 10.1001/jama.253.12.1737; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BOHNLEIN E, 1989, J VIROL, V63, P1578; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; CANIVET M, 1990, VIROLOGY, V178, P543, DOI 10.1016/0042-6822(90)90352-R; CAO YZ, 1990, J VIROL, V64, P2553, DOI 10.1128/JVI.64.6.2553-2559.1990; CARRIGAN DR, 1990, J INFECT DIS, V162, P844, DOI 10.1093/infdis/162.4.844; CASAREALE D, 1989, INT J CANCER, V44, P124, DOI 10.1002/ijc.2910440122; CAVARD C, 1990, J CLIN INVEST, V86, P1369, DOI 10.1172/JCI114849; CEFAI D, 1990, J CLIN INVEST, V86, P2117, DOI 10.1172/JCI114950; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLOUSE KA, 1989, J IMMUNOL, V143, P470; COHEN AH, 1989, MODERN PATHOL, V2, P125; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; FAUCI AS, 1987, CLIN RES, V35, P503; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1988, SCIENCE, V242, P919, DOI 10.1126/science.2460922; GAY D, 1988, P NATL ACAD SCI USA, V85, P5629, DOI 10.1073/pnas.85.15.5629; GEELEN JLMC, 1988, J GEN VIROL, V69, P2913, DOI 10.1099/0022-1317-69-11-2913; GENESCA J, 1990, J INFECT DIS, V162, P1025, DOI 10.1093/infdis/162.5.1025; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOFMANN B, 1990, J IMMUNOL, V145, P3699; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HOXIE JA, 1985, SCIENCE, V229, P1400, DOI 10.1126/science.2994222; HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925; IKEUCHI K, 1990, J VIROL, V64, P4226, DOI 10.1128/JVI.64.9.4226-4231.1990; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOGA Y, 1990, J VIROL, V64, P4661, DOI 10.1128/JVI.64.10.4661-4671.1990; KUCERA LS, 1990, AIDS RES HUM RETROV, V6, P641, DOI 10.1089/aid.1990.6.641; KUNSCH C, 1989, J VIROL, V63, P5054, DOI 10.1128/JVI.63.12.5054-5061.1989; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LANE HC, 1985, ANNU REV IMMUNOL, V3, P477, DOI 10.1146/annurev.iy.03.040185.002401; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; LEE MR, 1987, SCIENCE, V237, P1047, DOI 10.1126/science.3039662; LEVY JA, 1989, AM J GASTROENTEROL, V84, P787; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MACATONIA SE, 1990, IMMUNOLOGY, V71, P38; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCELRATH MJ, 1991, J CLIN INVEST, V87, P27, DOI 10.1172/JCI114981; MCELRATH MJ, 1989, P NATL ACAD SCI USA, V86, P675, DOI 10.1073/pnas.86.2.675; MELLORS JW, 1991, J INFECT DIS, V163, P78, DOI 10.1093/infdis/163.1.78; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; MIKOVITS JA, 1990, J EXP MED, V171, P1705, DOI 10.1084/jem.171.5.1705; MOLINA JM, 1990, J VIROL, V64, P2901, DOI 10.1128/JVI.64.6.2901-2906.1990; MUNIS JR, 1990, J CLIN INVEST, V85, P591, DOI 10.1172/JCI114478; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NONG Y, 1991, CELL IMMUNOL, V132, P10, DOI 10.1016/0008-8749(91)90002-S; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; POLI G, 1991, J EXP MED, V173, P589, DOI 10.1084/jem.173.3.589; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024; RIECKMANN P, 1991, J EXP MED, V173, P1, DOI 10.1084/jem.173.1.1; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; ROSENBERG ZF, 1989, AIDS RES HUM RETROV, V5, P1, DOI 10.1089/aid.1989.5.1; ROSENBERG ZF, 1990, PEDIATRIC AIDS; ROSENBERG ZF, 1990, J NIH RES, V2, P41; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; RUEGG CL, 1990, J IMMUNOL, V144, P3928; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STANLEY SK, 1989, AIDS RES HUM RETROV, V5, P375, DOI 10.1089/aid.1989.5.375; STANLEY SK, 1990, J IMMUNOL, V145, P1120; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; STEVENSON M, 1990, J VIROL, V64, P2421, DOI 10.1128/JVI.64.5.2421-2425.1990; TEEUWSEN VJP, 1990, AIDS, V4, P77, DOI 10.1097/00002030-199001000-00011; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; VONLAER D, 1990, BLOOD, V76, P1281; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; WERNER A, 1990, AIDS, V4, P537, DOI 10.1097/00002030-199006000-00007; WILLARDGALLO KE, 1990, P NATL ACAD SCI USA, V87, P6713, DOI 10.1073/pnas.87.17.6713; WILLERFORD DM, 1990, J IMMUNOL, V144, P3779; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502; ZARLING JM, 1990, J IMMUNOL, V144, P2992	101	200	205	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2382	2390		10.1096/fasebj.5.10.1676689	http://dx.doi.org/10.1096/fasebj.5.10.1676689			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	1676689				2022-12-28	WOS:A1991FW08700008
J	MORIMOTO, BH; KOSHLAND, DE				MORIMOTO, BH; KOSHLAND, DE			SHORT-TERM AND LONG-TERM-MEMORY IN SINGLE CELLS	FASEB JOURNAL			English	Article						MEMORY; CHEMOTAXIS; NEURAL CELL LINES; LONG-TERM POTENTIATION; HABITUATION	NMDA RECEPTORS; PROTEIN-PHOSPHORYLATION; SYNAPTIC PLASTICITY; POTENTIATION; SYSTEM; ADAPTATION; CHEMOTAXIS; TRANSDUCTION; MODULATION; EXCITEMENT	Many approaches have been used to study short- and long-term memory. Bacteria detect chemical gradients using a memory obtained by the combination of a fast excitation process and a slow adaptation process. This model system, which has the advantages of extensive genetic and biochemical information, shows no features of long-term memory. To study long-term memory, neural cell line systems have been developed that exhibit two phenomena associated with learning and memory, habituation and potentiation. The expression of these phenomena in clonal cell lines, devoid of synaptic connections, makes it possible to study the biochemical and molecular mechanisms that contribute to short-term and long-term memory.			MORIMOTO, BH (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009765, R01DK009765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alkon D.L., 1983, Scientific American, V249, P64; BARINAGA M, 1990, SCIENCE, V248, P1603, DOI 10.1126/science.1973002; BARNES DM, 1988, SCIENCE, V239, P254, DOI 10.1126/science.2447649; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; BREAKEFIELD XO, 1974, P NATL ACAD SCI USA, V71, P2530, DOI 10.1073/pnas.71.6.2530; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; COLLINGRIDGE G, 1987, NATURE, V330, P604, DOI 10.1038/330604a0; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; CROW TJ, 1980, SCIENCE, V209, P412, DOI 10.1126/science.209.4454.412; Dudai Y., 1989, NEUROBIOLOGY MEMORY; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GORDON WC, 1989, LEARNING MEMORY; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HOSEY MM, 1990, ANN NY ACAD SCI, V558, P155; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KOSHLAND DE, 1977, SCIENCE, V196, P1055, DOI 10.1126/science.870969; KOSHLAND DE, 1981, ANNU REV BIOCHEM, V50, P765, DOI 10.1146/annurev.bi.50.070181.004001; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; KUHN H, 1977, BIOPHYS STRUCT MECH, V3, P175, DOI 10.1007/BF00535815; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCFADDEN PN, 1990, NEURON, V4, P615, DOI 10.1016/0896-6273(90)90119-Z; MCFADDEN PN, 1990, P NATL ACAD SCI USA, V87, P2031, DOI 10.1073/pnas.87.5.2031; MILLER JA, 1977, BIOCHEMISTRY-US, V16, P2633, DOI 10.1021/bi00631a009; MORIMOTO BH, 1990, P NATL ACAD SCI USA, V87, P3518, DOI 10.1073/pnas.87.9.3518; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; POCHEDLY C, 1976, NEUROBLASTOMA, P181; RESCORLA RA, 1967, PSYCHOL REV, V74, P71, DOI 10.1037/h0024109; SPRINGER MS, 1977, P NATL ACAD SCI USA, V74, P183, DOI 10.1073/pnas.74.1.183; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; THOMPSON RF, 1986, LEARNING MEMORY BIOL, P3; WROBLEWSKI JT, 1989, ANNU REV PHARMACOL, V29, P441, DOI 10.1146/annurev.pa.29.040189.002301; [No title captured]	41	36	37	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2061	2067		10.1096/fasebj.5.7.2010059	http://dx.doi.org/10.1096/fasebj.5.7.2010059			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010059				2022-12-28	WOS:A1991FF44200008
J	BERNOFSKY, C				BERNOFSKY, C			NUCLEOTIDE CHLORAMINES AND NEUTROPHIL-MEDIATED CYTOTOXICITY	FASEB JOURNAL			English	Review						HYPOCHLOROUS ACID; CYTOTOXICITY; CHLORAMINES; ADENINE NUCLEOTIDES; NUCLEOTIDE RADICALS; NEUTROPHILS; BACTERIAL KILLING; INFLAMMATION INJURY	HYPOCHLORITE-MODIFIED ADENOSINE; PIG POLYMORPHONUCLEAR LEUKOCYTES; CHRONIC GRANULOMATOUS-DISEASE; ACID-INSOLUBLE PRODUCTS; ENDOTHELIAL CELL-DAMAGE; 5'-MONOPHOSPHATE AMP; SODIUM-HYPOCHLORITE; ESCHERICHIA-COLI; NUCLEIC-ACIDS; BACILLUS-SUBTILIS	Hypochlorite is a reactive oxidant formed as an end product of the respiratory burst in activated neutrophils. It is responsible for killing bacteria and has been implicated in neutrophil-mediated tissue injury associated with the inflammatory process. Although hypochlorite is a potent cytotoxic agent, the primary mechanism by which it exerts its effect is unclear. This review examines evidence that the primary event in hypochlorite cytotoxicity is the loss of adenine nucleotides from the target cell. This loss appears to be mediated by the formation of adenine nucleotide chloramines which are reactive intermediates with a free radical character and are capable of forming stable ligands with proteins and nucleic acids.	TULANE UNIV,SCH MED,CTR BIOENVIRONM RES,NEW ORLEANS,LA 70112	Tulane University	BERNOFSKY, C (corresponding author), TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024003] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24003] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agner K., 1972, STRUCTURE FUNCTION O, P329; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ALBRICH JM, 1982, FEBS LETT, V144, P157, DOI 10.1016/0014-5793(82)80591-7; ALBRICH JM, 1986, J CLIN INVEST, V78, P177, DOI 10.1172/JCI112548; ALLISON RC, 1988, J APPL PHYSIOL, V64, P2175, DOI 10.1152/jappl.1988.64.5.2175; Atkinson DE, 1977, CELLULAR ENERGY META, DOI DOI 10.1016/C2009-0-03136-5; BABIOR B M, 1984, P190; BABIOR BM, 1983, ADV HOST DEFENSE MEC, V3, P91; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BARRETTE WC, 1987, INFECT IMMUN, V55, P2518, DOI 10.1128/IAI.55.10.2518-2525.1987; BARRETTE WC, 1989, BIOCHEMISTRY-US, V28, P9172, DOI 10.1021/bi00449a032; BEAMAN L, 1984, ANNU REV MICROBIOL, V38, P27; BEARMAN SI, 1980, J LAB CLIN MED, V96, P893; BERNOFSKY C, 1989, BIOCHEM ARCH, V5, P105; BERNOFSKY C, 1989, BIOCHEM ARCH, V5, P11; BERNOFSKY C, 1988, BIOCHEM ARCH, V4, P349; BERNOFSKY C, 1987, BIOCHEM ARCH, V3, P431; BERNOFSKY C, 1987, BIOCHEM ARCH, V3, P147; BERNOFSKY C, 1987, BIOCHEM ARCH, V3, P95; BERNOFSKY C, 1989, BIOCHEM ARCH, V5, P223; BERNOFSKY C, 1990, FREE RADICAL RES COM, V9, P303, DOI 10.3109/10715769009145689; BERNOFSKY C, 1990, FREE RADICAL BIO MED, V8, P231, DOI 10.1016/0891-5849(90)90068-T; BERNOFSKY C, 1988, BIOCHEM ARCH, V4, P103; BERNOFSKY C, 1987, 4TH INT C OXYG RAD L; BORREGAARD N, 1982, J CLIN INVEST, V70, P550, DOI 10.1172/JCI110647; CAMPER AK, 1979, APPL ENVIRON MICROB, V37, P633, DOI 10.1128/AEM.37.3.633-641.1979; CRONSTEIN BN, 1986, J CLIN INVEST, V78, P760, DOI 10.1172/JCI112638; CRONSTEIN BN, 1987, TOPICS PERSPECTIVES, P299; Dakin HD, 1916, P R SOC LOND B-CONTA, V89, P232, DOI 10.1098/rspb.1916.0008; DALLEGRI F, 1988, J LAB CLIN MED, V112, P765; DECHATELET LR, 1983, HOST DEFENSES INTRAC, P19; DENNIS WH, 1978, BIOCHEM BIOPH RES CO, V83, P168, DOI 10.1016/0006-291X(78)90412-6; DENNIS WH, 1979, WATER RES, V13, P357, DOI 10.1016/0043-1354(79)90023-X; FRIBERG L, 1956, ACTA PATHOL MIC SC, V38, P137; GOULD JP, 1984, WATER RES, V18, P205, DOI 10.1016/0043-1354(84)90070-8; GOULD JP, 1984, WATER RES, V18, P991, DOI 10.1016/0043-1354(84)90250-1; Green D. E., 1946, JOUR AMER WATER WORKS ASSOC, V38, P1301; HALLETT FR, 1970, BIOPHYS J, V10, P305, DOI 10.1016/S0006-3495(70)86303-2; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAYATSU H, 1971, CHEM PHARM BULL, V19, P2189; HOYANO Y, 1973, BIOCHEM BIOPH RES CO, V53, P1195, DOI 10.1016/0006-291X(73)90591-3; HSU YC, 1964, NATURE, V203, P152, DOI 10.1038/203152a0; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; ITOH N, 1987, BIOCHEMISTRY-US, V26, P282, DOI 10.1021/bi00375a039; JACKSON JH, 1988, HEMATOL ONCOL CLIN N, V2, P317, DOI 10.1016/S0889-8588(18)30624-5; JOHNSON RJ, 1987, J CLIN INVEST, V79, P1379, DOI 10.1172/JCI112965; KAR L, 1983, RADIAT RES, V93, P232, DOI 10.2307/3575980; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KLEBANOFF SJ, 1968, J BACTERIOL, V95, P2131, DOI 10.1128/JB.95.6.2131-2138.1968; KLEBANOFF SJ, 1970, SCIENCE, V169, P1095, DOI 10.1126/science.169.3950.1095; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KLEBANOFF SJ, 1976, CANCER ENZYMOLOGY, P267; MARTIN WJ, 1984, AM REV RESPIR DIS, V130, P290; MCKENNA SM, 1988, BIOCHEM J, V254, P685, DOI 10.1042/bj2540685; Morris J.C., 1966, J AM WATER WORKS ASS, V58, P1475, DOI [10.1002/j.1551-8833.1966.tb01719.x, DOI 10.1002/J.1551-8833.1966.TB01719.X]; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NIWA Y, 1982, CLIN EXP IMMUNOL, V49, P247; ODAJIMA T, 1980, JPN J ORAL BIOL, V22, P502; OLIVIERI VP, 1980, WATER CHLORINATION E, V3, P651; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; PRAT R, 1968, ANN I PASTEUR PARIS, V114, P595; Rall TW, 1983, REGULATORY FUNCTION, P347; RAPAPORT E, 1976, P NATL ACAD SCI USA, V73, P3122, DOI 10.1073/pnas.73.9.3122; ROOS D, 1980, ADV EXP MED BIOL, V121, P29; ROSENKRANZ HS, 1973, MUTAT RES, V21, P171, DOI 10.1016/0165-1218(73)90240-1; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; SBARRA AJ, 1988, RESPIRATORY BURST IT; SCHRAUFSTATTER IU, 1990, J CLIN INVEST, V85, P554, DOI 10.1172/JCI114472; SEGAL AW, 1989, BIOCHEM SOC T, V17, P427, DOI 10.1042/bst0170427; SHASBY DM, 1982, AM REV RESPIR DIS, V125, P1016; SHIH KL, 1976, SCIENCE, V192, P1141, DOI 10.1126/science.818709; SHIH KL, 1976, J BACTERIOL, V125, P934, DOI 10.1128/JB.125.3.934-945.1976; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; TAUBER AI, 1981, FEBS LETT, V129, P105, DOI 10.1016/0014-5793(81)80766-1; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; Thomas E L, 1986, Methods Enzymol, V132, P569; Thomas E L, 1986, Methods Enzymol, V132, P585; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; WARREN JS, 1988, RESPIRATORY BURST IT, P299; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEITZMAN SA, 1981, SCIENCE, V212, P546, DOI 10.1126/science.6259738; WETIZMAN SA, 1990, BLOOD, V76, P655; WHIE GC, 1972, HDB CHLORINATION, P182; Williams R.B., 1986, HDB PUBLIC WATER SYS, P379; Winterbourn C.C., 1990, OXYGEN RADICALS SYST, P31; WLODKOWSKI TJ, 1975, MUTAT RES, V31, P39, DOI 10.1016/0165-1161(75)90061-8; ZACHARA B, 1977, TRANSFUSION, V17, P628, DOI 10.1046/j.1537-2995.1977.17678075663.x	90	69	69	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					295	300		10.1096/fasebj.5.3.1848195	http://dx.doi.org/10.1096/fasebj.5.3.1848195			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	1848195				2022-12-28	WOS:A1991FC55600006
J	CROUCH, MF				CROUCH, MF			GROWTH FACTOR-INDUCED CELL-DIVISION IS PARALLELED BY TRANSLOCATION OF GI-ALPHA TO THE NUCLEUS	FASEB JOURNAL			English	Article						G PROTEIN; MYRISTOYLATION; ALPHA-SUBUNIT; GTP-BINDING PROTEIN; PERTUSSIS; MITOSIS	NUCLEOTIDE-BINDING-PROTEINS; RECEPTOR	Induction of mitosis by certain growth factors is inhibited by pertussis toxin, indicating that the GTP-binding protein, G(i), is involved in receptor signal transduction to initiate cell division. However, the substrates of receptor-activated G(i) that are involved in mitosis have not been determined. The present study has examined whether G(i) may directly modulate cell division by receptor-induced subcellular translocation of the alpha subunit of G(i) (G(i-alpha)). Insulin and EGF, particularly when added together or in combination with phorbol dibutyrate (PdBu), induced a rapid (1-4 h) redistribution of G(i-alpha) from the plasma membrane to perinuclear sites in the cell. After 2 days of stimulation, G(i-alpha) had translocated into the nucleus of dividing cells and bound specifically to the separating chromatin of dividing nuclei. Unstimulated cells did not display translocation of G(i-alpha). This demonstrates a direct involvement of G(i-alpha) in cell division, which provides an apparently uninterrupted link from growth factor receptor to nucleus.			CROUCH, MF (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV NEUROSCI,CANBERRA,ACT 2601,AUSTRALIA.							BENDITT JO, 1989, J BIOL CHEM, V86, P9327; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CROUCH MF, 1989, P NATL ACAD SCI USA, V86, P1776, DOI 10.1073/pnas.86.6.1776; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; CROUCH MF, 1990, BIOCHEM BIOPH RES CO, V167, P1369, DOI 10.1016/0006-291X(90)90674-C; FRANZE-FERNANDEZ M T, 1971, Proceedings of the National Academy of Sciences of the United States of America, V68, P3040, DOI 10.1073/pnas.68.12.3040; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; PETERS R, 1983, J BIOL CHEM, V258, P1427; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X	15	80	80	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					200	206		10.1096/fasebj.5.2.1900794	http://dx.doi.org/10.1096/fasebj.5.2.1900794			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	1900794				2022-12-28	WOS:A1991EZ00200009
J	GOTTSCHALL, PE; TATSUNO, I; ARIMURA, A				GOTTSCHALL, PE; TATSUNO, I; ARIMURA, A			HYPOTHALAMIC BINDING-SITES FOR PITUITARY ADENYLATE-CYCLASE ACTIVATING POLYPEPTIDE - CHARACTERIZATION AND MOLECULAR-IDENTIFICATION	FASEB JOURNAL			English	Article						PACAP; HYPOTHALAMUS; BINDING SITE; RECEPTOR; CROSS-LINKING	VASOACTIVE INTESTINAL POLYPEPTIDE; PEPTIDE RECEPTORS; VIP RECEPTORS; LUNG; MEMBRANES; CELLS; LIVER	The goal of these experiments was to identify and characterize binding sites in the rat hypothalamus for the peptide, pituitary adenylate cyclase activating polypeptide (PACAP). The 27 amino acid form of PACAP (PACAP27) was used as the radiolabeled ligand in these experiments. Binding of [I-125]PACAP27 to hypothalamic membrane preparations was rapid, reversible on addition of unlabeled peptide, and at least partially regulated by GTP. Nonhydrolyzable GTP analogs, guanosine-5'-O-(3-thiotriphosphate) (GTP-gamma-S), guanosine-5'-(2-thiodiphosphate) (GDP-beta-S), and guanylylimidophosphate (GppNHp) also displaced [I-125]PACAP27 binding to hypothalamic membrane preparations in a dose-dependent manner. The order of potency for the three analogs was GTP-gamma-S > GDP-beta-S > GppNHp. Both forms of the peptide, PACAP27 and PACAP38, were highly potent in displacing bound [I-125]PACAP27, whereas VIP or PACAP(1-23) were unable to displace binding at concentrations of up to 500 nM. Scatchard analysis of the PACAP27 and PACAP38 displacement curves revealed that the fit of both curves was consistent with a single class of high-affinity binding sites, although the site exhibited a greater affinity for PACAP38 compared with PACAP27 (PACAP27 K(d) = 1452 +/- 59 pM; PACAP38 K(d) = 175 +/- 13 pM; B(max) 23.2 +/- 1.1 pmol/mg protein). The possibility of the existence of a class of binding sites with extremely low affinity cannot be discounted. After covalent cross-linking of [I-125]PACAP27 with its receptor, the molecular weights of the complexes were estimated by electrophoresis and autoradiography. A major band of 60 K(d) was evident when membranes were incubated with VIP or PACAP(1-23). Previous incubation with unlabeled PACAP27 or PACAP38 eliminated visualization of this band. These results suggest that a specific, high-affinity binding site for PACAP27 is present in rat hypothalamus, and that this site shows a greater affinity for PACAP38 compared with PACAP27. The molecular weight of the peptide-receptor complex is 60,000 kDa, and therefore the receptor itself has an apparent molecular weight 57,000.	TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT ANAT,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT PHYSIOL,NEW ORLEANS,LA 70112	Tulane University; Tulane University; Tulane University	GOTTSCHALL, PE (corresponding author), TULANE UNIV,US JAPAN BIOMED RES LABS,HEBERT CTR,BELLE CHASSE,LA 70037, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009094] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09094] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIMURA A, 1989, 71ST ANN M END SOC S, P263; ARIMURA A, 1990, 72ND ANN M END SOC A, P340; BESSON J, 1987, ANN NY ACAD SCI, V527, P204; CLAYTON RN, 1979, ENDOCRINOLOGY, V105, P1369, DOI 10.1210/endo-105-6-1369; COUVINEAU A, 1985, BIOCHEM J, V225, P473, DOI 10.1042/bj2250473; COUVINEAU A, 1986, J NEUROCHEM, V47, P1469, DOI 10.1111/j.1471-4159.1986.tb00780.x; DICKINSON KEJ, 1986, PEPTIDES, V7, P791, DOI 10.1016/0196-9781(86)90097-5; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; KOVES K, 1990, ENDOCRINOLOGY, V127, P264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLEOD KR, 1989, ENDOCRINOLOGY, V125, P2258, DOI 10.1210/endo-125-5-2258; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1989, ANN M SOC NEUROSCIEN; OGAWA M, 1985, BIOMED RES-TOKYO, V6, P103; PATTHI S, 1988, J BIOL CHEM, V263, P19363; ROBBERECHT P, 1988, PEPTIDES, V9, P339, DOI 10.1016/0196-9781(88)90270-7; STAUNOLSEN P, 1985, BRAIN RES, V330, P317, DOI 10.1016/0006-8993(85)90691-2; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; TAYLOR DP, 1979, P NATL ACAD SCI USA, V76, P660, DOI 10.1073/pnas.76.2.660; VASILOFF J, 1986, Canadian Journal of Physiology and Pharmacology, P172; WOOD CL, 1985, REGUL PEPTIDES, V12, P237, DOI 10.1016/0167-0115(85)90065-5	22	84	84	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					194	199		10.1096/fasebj.5.2.1848519	http://dx.doi.org/10.1096/fasebj.5.2.1848519			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	1848519				2022-12-28	WOS:A1991EZ00200008
J	STREET, NE; MOSMANN, TR				STREET, NE; MOSMANN, TR			FUNCTIONAL DIVERSITY OF LYMPHOCYTE-T DUE TO SECRETION OF DIFFERENT CYTOKINE PATTERNS	FASEB JOURNAL			English	Article						T HELPER CELLS; CYTOKINES; CROSS-REGULATION; IMMUNE BALANCE; T CELL SUBSETS	DELAYED-TYPE HYPERSENSITIVITY; CONTACT SENSITIVITY RESPONSES; HUMORAL IMMUNE-RESPONSES; STIMULATORY FACTOR-I; CELL CLONE; IFN-GAMMA; INTERFERON-GAMMA; TH1 CLONES; B-CELLS; LYMPHOKINE ACTIVITIES	Different helper T cell subsets secrete different patterns of cytokines when stimulated by antigen. The TH1 and TH2 subsets differ in the secretion of at least eight cytokines, and three or more other cytokine secretion patterns also exist among both mouse and human T cell clones. Several properties of strong immune responses suggest that at least the TH1 and TH2 pheno-types can be present in vivo. As cytokines are major determinants of the functions of the T cells that produce them, these patterns lead to different properties of the T cell subsets. TH1 cells mediate several functions connected with cytotoxicity and local inflammatory reactions, and so these T cells are particularly effective at combating viruses and intracellular bacteria and parasites. TH2 cells are much more effective at stimulating B cells to produce antibody, and so should be more effective against free-living bacteria, and in inducing protective humoral immunity. Antibody and delayed inflammatory reactions are often mutually exclusive during immune responses, and this can be at least partially explained by cross-inhibition of TH1 and TH2 cells. A newly discovered cytokine, IL10, has been implicated as one of the cross-regulatory cytokines, as this TH2 product inhibits cytokine synthesis by TH1 cells.	DNAX RES INST MOLEC & CELLULAR BIOL INC, DEPT IMMUNOL, PALO ALTO, CA 94304 USA; UNIV ALBERTA, DEPT IMMUNOL, EDMONTON T6G 2H7, ALBERTA, CANADA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Alberta								BACCHETTA R, 1990, J IMMUNOL, V144, P902; BARTLETT WC, 1989, J IMMUNOL, V143, P1745; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; BOTTOMLY K, 1989, PROG IMMUNOL, V7, P593; BROWN KD, 1989, J IMMUNOL, V142, P679; BUDD RC, 1987, J IMMUNOL, V138, P3120; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Crowle A J, 1966, Clin Exp Immunol, V1, P323; FERNANDEZBOTRAN R, 1988, J EXP MED, V168, P543, DOI 10.1084/jem.168.2.543; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; FONG TAT, 1990, J IMMUNOL, V144, P1744; FONG TAT, 1989, J IMMUNOL, V143, P2887; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; GREENBAUM LA, 1988, J IMMUNOL, V140, P1555; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HAYAKAWA K, 1989, J EXP MED, V169, P2245, DOI 10.1084/jem.169.6.2245; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; JABARA HH, 1988, J CLIN IMMUNOL, V8, P437, DOI 10.1007/BF00916948; KATSURA Y, 1977, IMMUNOLOGY, V32, P227; KELLY JD, 1972, INT ARCH ALLER A IMM, V43, P497, DOI 10.1159/000230865; KELSO A, 1988, P NATL ACAD SCI USA, V85, P9189, DOI 10.1073/pnas.85.23.9189; LEE SH, 1984, J IMMUNOL, V133, P1083; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MAGILAVY DB, 1989, J EXP MED, V170, P985, DOI 10.1084/jem.170.3.985; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1990, J IMMUNOL, V145, P2938; NOELLE RJ, 1989, J MOL CELL IMMUNOL, V4, P161; PALIARD X, 1988, J IMMUNOL, V141, P849; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; POWRIE F, 1988, IMMUNOL TODAY, V9, P274, DOI 10.1016/0167-5699(88)91309-6; PTAK W, 1988, J IMMUNOL, V141, P756; PTAK W, 1988, J IMMUNOL, V141, P765; SALMON M, 1989, J IMMUNOL, V143, P907; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; STREET NE, 1990, J IMMUNOL, V144, P1629; SWAIN SL, 1990, J IMMUNOL, V144, P1788; SWAIN SL, 1988, J IMMUNOL, V141, P3445; UMETSU DT, 1988, J IMMUNOL, V140, P4211; WARREN MK, 1985, J IMMUNOL, V134, P2462; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; ZURAWSKI G, 1986, SCIENCE, V232, P772, DOI 10.1126/science.2938259	55	557	567	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1991	5	2					171	177		10.1096/fasebj.5.2.1825981	http://dx.doi.org/10.1096/fasebj.5.2.1825981			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	1825981				2022-12-28	WOS:A1991EZ00200005
J	MILLER, LG; LUMPKIN, M; GREENBLATT, DJ; SHADER, RI				MILLER, LG; LUMPKIN, M; GREENBLATT, DJ; SHADER, RI			ACCELERATED BENZODIAZEPINE RECEPTOR RECOVERY AFTER LORAZEPAM DISCONTINUATION	FASEB JOURNAL			English	Note						LORAZEPAM; DISCONTINUATION; EEDQ; BENZODIAZEPINE; GABA	N-ETHOXYCARBONYL-2-ETHOXY-1,2-DIHYDROQUINOLINE EEDQ; DOWN-REGULATION; RAT-BRAIN; TOLERANCE; DEPENDENCE; BINDING; INVIVO	Benzodiazepine discontinuation can lead to a behavioral syndrome in animals and humans. In a mouse model, this syndrome is associated with benzodiazepine receptor up-regulation. The protein-modifying reagent, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), has been used to irreversibly inactivate a number of neurotransmitter receptors including benzodiazepine receptors, and thus allows estimation of receptor recovery in vivo. To assess benzodiazepine receptor recovery after benzodiazepine discontinuation, we treated mice with lorazepam (LRZ), 2 mg.kg-1.day-1 for 1 wk. After 24 h, EEDQ (12.5 mg/kg) was administered, and benzodiazepine binding in the cortex and cerebellum was determined after 4-144 h. EEDQ treatment decreased receptor density in the cortex in both LRZ- and vehicle-treated groups by approximately 50%, with no change in apparent affinity as previously reported. Binding in both groups returned to control values after 96 h. Kinetic analysis indicated a more rapid increase in binding in LRZ-compared with vehicle-treated animals, with t1/2 for LRZ 19.1 h, and for vehicle, 30.8 h (P < 0.05). Receptor density was decreased in the cerebellum after EEDQ by approximately 40% in both treatment groups, with no change in apparent affinity. Receptor density returned to control values at 96 h, with no difference in kinetics in LRZ- compared with vehicle-treated mice. The decrease in receptor t1/2 associated with lorazepam discontinuation is consistent with the observed increase in benzodiazepine receptors in this setting.	TUFTS UNIV, SCH MED, DEPT PHARMACOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02111 USA; NEW ENGLAND MED CTR HOSP, BOSTON, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center	MILLER, LG (corresponding author), TUFTS UNIV, SCH MED, DIV CLIN PHARMACOL, BOSTON, MA 02111 USA.			Shader, Richard/0000-0002-1888-7565	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH034223, R01MH034223] Funding Source: NIH RePORTER; NIA NIH HHS [AG-01006] Funding Source: Medline; NIDA NIH HHS [DA-05258] Funding Source: Medline; NIMH NIH HHS [MH-34223] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BATTAGLIA G, 1987, J PHARMACOL EXP THER, V243, P69; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; GALLAGER DW, 1984, NATURE, V308, P74, DOI 10.1038/308074a0; GALPERN WR, 1990, IN PRESS BR J PHARM; GREENBLATT DJ, 1978, DRUG METAB REV, V8, P13, DOI 10.3109/03602537808993775; HESS EJ, 1988, J NEUROSCI, V8, P2361; LOPEZ F, 1990, NEUROPHARMACOLOGY, V29, P237, DOI 10.1016/0028-3908(90)90007-E; MARLEY RJ, 1989, EUR J PHARMACOL, V159, P217, DOI 10.1016/0014-2999(89)90151-9; MILLER LG, 1989, BIOCHEM PHARMACOL, V38, P3773, DOI 10.1016/0006-2952(89)90584-4; MILLER LG, 1988, J PHARMACOL EXP THER, V246, P170; MILLER LG, 1988, J PHARMACOL EXP THER, V246, P177; MILLER LG, 1990, ADV BIOCHEM PSYCHOPH, V46, P167; MILLER LG, 1990, IN PRESS J NEUROCHEM; NORMAN AB, 1989, LIFE SCI, V44, P831, DOI 10.1016/0024-3205(89)90583-3; PETURSSON H, 1981, BRIT J ADDICT, V76, P133; PILC A, 1989, BRAIN RES, V493, P8, DOI 10.1016/0006-8993(89)90994-3; SALLER CF, 1989, LIFE SCI, V45, P917, DOI 10.1016/0024-3205(89)90206-3; SIEGHART W, 1989, TRENDS PHARMACOL SCI, V10, P407, DOI 10.1016/0165-6147(89)90189-2; TIETZ EI, 1986, J PHARMACOL EXP THER, V236, P284	19	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1991	5	1					93	97		10.1096/fasebj.5.1.1846834	http://dx.doi.org/10.1096/fasebj.5.1.1846834			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1846834				2022-12-28	WOS:A1991ET60900020
J	MALTESE, WA				MALTESE, WA			POSTTRANSLATIONAL MODIFICATION OF PROTEINS BY ISOPRENOIDS IN MAMMALIAN-CELLS	FASEB JOURNAL			English	Review						ISOPRENYLATION; MEVALONATE; RAS; GUANINE NUCLEOTIDE BINDING PROTEINS; LAMINS	NEURO-BLASTOMA CELLS; GTP-BINDING PROTEINS; SWISS 3T3 CELLS; MEVALONIC ACID; NUCLEAR-ENVELOPE; COMPETITIVE INHIBITOR; CYSTEINE RESIDUE; GROWTH-FACTOR; RAS PROTEINS; BOVINE BRAIN	Isoprenylation is a posttranslational modification that involves the formation of thioether bonds between cysteine and isoprenyl groups derived from pyrophosphate intermediates of the cholesterol biosynthetic pathway. Numerous isoprenylated proteins have been detected in mammalian cells. Those identified include K-, N-, and H-p21ras, ras-related GTP-binding proteins such as G25K (G(p)), nuclear lamin B and prelamin A, and the gamma subunits of heterotrimeric G proteins. The modified cysteine is located in the fourth position from the carboxyl terminus in every protein where this has been studied. For p21ras, the last three amino acids are subsequently removed and the exposed cysteine is carboxylmethylated. Similar processing events may occur in lamin B and G protein gamma subunits, but the proteolytic cleavage in prelamin A occurs upstream from the modified cysteine. Lamin B and p21ras are modified by C-15 farnesyl groups, whereas other proteins such as the G protein gamma subunits are modified by C20 geranylgeranyl chains. Separate enzymes may catalyze these modifications. The structural features that govern the ability of particular proteins to serve as substrates for isoprenylation by C-15 or C20 groups are not completely defined, but studies of the p21ras modification using purified farnesyl:protein transferase suggest that the sequence of the carboxyl-terminal tetrapeptide is important. Isoprenylation plays a critical role in promoting the association of p21ras and the lamins with the cell membrane and nuclear envelope, respectively. Future studies of the role of isoprenylation in the localization and function of ras-related GTP-binding proteins and signal-transducing G proteins should provide valuable new insight into the link between isoprenoid biosynthesis and cell growth.			MALTESE, WA (corresponding author), GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822, USA.				NCI NIH HHS [R01 CA34569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BRAKE AJ, 1985, CURRENT COMMUNICATIO, P103; BRUENGER E, 1986, BIOCHEM BIOPH RES CO, V139, P209, DOI 10.1016/S0006-291X(86)80100-0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; EVANS T, 1986, J BIOL CHEM, V261, P7052; FAIRBANKS KP, 1984, J BIOL CHEM, V259, P1546; FARNSWORTH C, 1990, FASEB J, V4, pA1842; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FEINGOLD AA, 1990, SCIENCE, V249, P165; FREISSMUTH M, 1989, FASEB J, V3, P125; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HABENICHT AJR, 1980, J BIOL CHEM, V255, P5134; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HART MJ, 1990, J BIOL CHEM, V265, P5990; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P1049, DOI 10.1080/00021369.1979.10863559; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; LEONARD S, 1990, J BIOL CHEM, V265, P5157; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MALTESE WA, 1985, J CELL PHYSIOL, V125, P540, DOI 10.1002/jcp.1041250326; MALTESE WA, 1985, J BIOL CHEM, V260, P1524; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MALTESE WA, 1990, FASEB J, V4, pA1842; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REPKO EM, 1989, J BIOL CHEM, V264, P9945; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SAITO A, 1979, J BIOL CHEM, V254, P8511; SAKAGAMI Y, 1979, AGR BIOL CHEM TOKYO, V43, P2643, DOI 10.1080/00021369.1979.10863880; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1982, J CELL BIOL, V95, P144, DOI 10.1083/jcb.95.1.144; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEPPLORENZINO L, 1989, FEBS LETT, V245, P110, DOI 10.1016/0014-5793(89)80202-9; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WALDO GL, 1987, BIOCHEM J, V246, P431, DOI 10.1042/bj2460431; WEST RE, 1985, J BIOL CHEM, V260, P4428; WOLDA SL, 1988, J BIOL CHEM, V263, P5977; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	66	509	526	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1990	4	15					3319	3328		10.1096/fasebj.4.15.2123808	http://dx.doi.org/10.1096/fasebj.4.15.2123808			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EN696	2123808				2022-12-28	WOS:A1990EN69600007
J	Spina, R; Mills, I; Ahmad, F; Chen, CX; Ames, HM; Winkles, JA; Woodworth, GF; Bar, EE				Spina, Raffaella; Mills, Ian; Ahmad, Fahim; Chen, Chixiang; Ames, Heather M.; Winkles, Jeffrey A.; Woodworth, Graeme F.; Bar, Eli E.			DHODH inhibition impedes glioma stem cell proliferation, induces DNA damage, and prolongs survival in orthotopic glioblastoma xenografts	ONCOGENE			English	Article; Early Access							CENTRAL-NERVOUS-SYSTEM; PROMOTES RADIORESISTANCE; HYPOXIC MICROENVIRONMENT; THERAPEUTIC RESISTANCE; URIDINE LEVELS; CDP-CHOLINE; TUMORS; GROWTH; CLASSIFICATION; ACTIVATION	Glioma stem cells (GSCs) promote tumor progression and therapeutic resistance and exhibit remarkable bioenergetic and metabolic plasticity, a phenomenon that has been linked to their ability to escape standard and targeted therapies. However, specific mechanisms that promote therapeutic resistance have been somewhat elusive. We hypothesized that because GSCs proliferate continuously, they may require the salvage and de novo nucleotide synthesis pathways to satisfy their bioenergetic needs. Here, we demonstrate that GSCs lacking EGFR (or EGFRvIII) amplification are exquisitely sensitive to de novo pyrimidine synthesis perturbations, while GSCs that amplify EGFR are utterly resistant. Furthermore, we show that EGFRvIII promotes BAY2402234 resistance in otherwise BAY2402234 responsive GSCs. Remarkably, a novel, orally bioavailable, blood-brain-barrier penetrating, dihydroorotate dehydrogenase (DHODH) inhibitor BAY2402234 was found to abrogate GSC proliferation, block cell-cycle progression, and induce DNA damage and apoptosis. When dosed daily by oral gavage, BAY2402234 significantly impaired the growth of two different intracranial human glioblastoma xenograft models in mice. Given this observed efficacy and the previously established safety profiles in preclinical animal models and human clinical trials, the clinical testing of BAY2402234 in patients with primary glioblastoma that lacks EGFR amplification is warranted.	[Spina, Raffaella; Mills, Ian; Ahmad, Fahim; Ames, Heather M.; Bar, Eli E.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Chen, Chixiang; Winkles, Jeffrey A.; Woodworth, Graeme F.; Bar, Eli E.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Chen, Chixiang] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Ames, Heather M.; Winkles, Jeffrey A.; Woodworth, Graeme F.; Bar, Eli E.] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Winkles, Jeffrey A.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Winkles, Jeffrey A.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Bar, EE (corresponding author), Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA.; Bar, EE (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA.; Bar, EE (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.	ebar@som.umaryland.edu		Mills, Ian/0000-0003-1334-2686; Winkles, Jeffrey/0000-0002-3305-1424; Ahmad, Fahim/0000-0002-7216-5539; Chen, Chixiang/0000-0001-5474-2833	National Institutes of Health [R21NS106553, R01CA187780]; National Cancer Institute Cancer Center Support Grant (CCSG) [P30CA134274]; Maryland Department of Health's Cigarette Restitution Fund Program	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute Cancer Center Support Grant (CCSG); Maryland Department of Health's Cigarette Restitution Fund Program	This study is funded by National Institutes of Health grant R01CA187780 (EEB), National Institutes of Health grant R21NS106553 (EEB), National Cancer Institute Cancer Center Support Grant (CCSG) - P30CA134274, and Maryland Department of Health's Cigarette Restitution Fund Program.	Ashour OM, 2000, CANCER CHEMOTH PHARM, V45, P351, DOI 10.1007/s002800051002; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021; Cansev M, 2005, BRAIN RES, V1058, P101, DOI 10.1016/j.brainres.2005.07.054; Carruthers RD, 2018, CANCER RES, V78, P5060, DOI 10.1158/0008-5472.CAN-18-0569; Christian S, 2019, LEUKEMIA, V33, P2403, DOI 10.1038/s41375-019-0461-5; Chu Q, 2013, CLIN CANCER RES, V19, P3224, DOI 10.1158/1078-0432.CCR-12-2119; Dahan P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.509; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Fuller GN, 2008, ARCH PATHOL LAB MED, V132, P906, DOI 10.1043/1543-2165(2008)132[906:TWCOTO]2.0.CO;2; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Grant GD, 2018, CELL CYCLE, V17, P2496, DOI 10.1080/15384101.2018.1547001; Hardee ME, 2012, CANCER RES, V72, P4119, DOI 10.1158/0008-5472.CAN-12-0546; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Henricks LM, 2018, BRIT J CLIN PHARMACO, V84, P2761, DOI 10.1111/bcp.13719; Hess KR, 2004, CANCER, V101, P2293, DOI 10.1002/cncr.20621; Honoki K, 2010, ONCOL REP, V24, P501, DOI 10.3892/or_00000885; Jialiang W, 2009, NOTCH PROMOTES RADIO, V28, P17; Kahlert UD, 2015, BRAIN PATHOL, V25, P724, DOI 10.1111/bpa.12240; Kahlert UD, 2012, FOLIA NEUROPATHOL, V50, P357, DOI 10.5114/fn.2012.32365; Kim Y, 2012, LAB INVEST, V92, P466, DOI 10.1038/labinvest.2011.161; Lal B, 2009, MOL CANCER THER, V8, P1751, DOI 10.1158/1535-7163.MCT-09-0188; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lim KS, 2014, ONCOGENE, V33, P4433, DOI 10.1038/onc.2013.390; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Mashimo M, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.014479; Nakano RMAI, 2011, J CARCINOGENE MUTAGE, P1; Osuka S, 2017, J CLIN INVEST, V127, P415, DOI 10.1172/JCI89587; Pistollato F, 2009, STEM CELLS, V27, P7, DOI 10.1634/stemcells.2008-0402; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Quemeneur L, 2003, J IMMUNOL, V170, P4986, DOI 10.4049/jimmunol.170.10.4986; Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895; Robinson AD, 2020, CANCER LETT, V470, P134, DOI 10.1016/j.canlet.2019.11.013; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Singh SK, 2003, CANCER RES, V63, P5821; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Spina R., 2020, NEUROONCOL ADV, V2; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-401; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Szeto MD, 2009, CANCER RES, V69, P4502, DOI 10.1158/0008-5472.CAN-08-3884; Tilghman J, 2014, CANCER RES, V74, P3168, DOI 10.1158/0008-5472.CAN-13-2103; Uribe D, 2017, MOL ASPECTS MED, V55, P140, DOI 10.1016/j.mam.2017.01.009; van Wijk Nick, 2017, Alzheimers Dement (Amst), V8, P139, DOI 10.1016/j.dadm.2017.04.005; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Wang MX, 2013, INT J ONCOL, V43, P131, DOI 10.3892/ijo.2013.1929; Wang SD, 2012, ONCOGENE, V31, P5132, DOI 10.1038/onc.2012.16; Wang XX, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau4972; Williams MG, 2003, BIOMED CHROMATOGR, V17, P215, DOI 10.1002/bmc.210; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Wu YJ, 2012, CANCER SCI, V103, P1028, DOI 10.1111/j.1349-7006.2012.02260.x; Wurtman RJ, 2000, BIOCHEM PHARMACOL, V60, P989, DOI 10.1016/S0006-2952(00)00436-6; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Ying MY, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.588988; Ying MY, 2011, STEM CELLS, V29, P20, DOI 10.1002/stem.561	65	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02517-1	http://dx.doi.org/10.1038/s41388-022-02517-1		NOV 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5Z0JJ	36344676				2022-12-28	WOS:000879664600003
J	KIM, S; CHAO, PY; ALLEN, KGD				KIM, S; CHAO, PY; ALLEN, KGD			INHIBITION OF ELEVATED HEPATIC GLUTATHIONE ABOLISHES COPPER DEFICIENCY CHOLESTEROLEMIA	FASEB JOURNAL			English	Article						GLUTATHIONE; CHOLESTEROL; 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A; REGULATION; COPPER	THIOL DISULFIDE EXCHANGE; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; RAT-LIVER; REDUCTASE; METABOLISM; OXIDATION; ASSAY; ZINC; HYPERCHOLESTEROLEMIA	Dietary copper deficiency causes hypercholesterolemia and increased hepatic 3-hydroxy-3-methylglutaryl coenzyme A (MHG-CoA) reductase activity and increased hepatic glutathione (GSH) in rats. We hypothesized that inhibition of GSH production by L-buthionine sulfoximine (BSO), a specific GSH synthesis inhibitor, would abolish the cholesterolemia and increased HMG-CoA reductase activity of copper deficiency. In two experiments, two groups of 20 weanling male rats were fed diets providing 0.4 and 5.8-mu-g Cu/g, copper-deficient (Cu-D) and copper-adequate (Cu-A), respectively. At 35 days plasma cholesterol was significantly elevated by 30 to 43% in Cu-D and 10 animals in each of the Cu-D and Cu-A groups were randomly assigned to receive 10 mm BSO solution in place of drinking water and continued on the same diets for another 2 wk. At necropsy Cu-D animals had a significant 52 to 58% increase in plasma cholesterol. BSO administration abolished the cholesterolemia in Cu-D rats, but had no influence on plasma cholesterol of Cu-A rats. Hepatic GSH was increased 39 to 82% in Cu-D rats and BSO abolished this increase. BSO was without effect on cardiac hypertrophy, plasma and liver copper, and hematocrit indices of copper status. Liver microsome HMG-CoA reductase activity was significantly increased 85 to 288% in Cu-D rats and BSO administration abolished this increase in activity in Cu-D rats. The results suggest that copper deficiency cholesterolemia and elevated HMG-CoA reductase activity are a consequence of elevated hepatic GSH, and provide evidence for GSH regulation of cholesterol metabolism in intact animals.	COLORADO STATE UNIV,DEPT FOOD SCI & HUMAN NUTR,FT COLLINS,CO 80523	Colorado State University					NHLBI NIH HHS [HL 39759] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039759] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALLEN KGD, 1978, ATHEROSCLEROSIS, V29, P81, DOI 10.1016/0021-9150(78)90096-5; ALLEN KGD, 1987, CLIN CHIM ACTA, V162, P237, DOI 10.1016/0009-8981(87)90456-6; ALLEN KGD, 1988, P SOC EXP BIOL MED, V187, P38; ALLEN KGD, 1978, ATHEROSCLEROSIS, V31, P259, DOI 10.1016/0021-9150(78)90062-X; BIERI JG, 1977, J NUTR, V107, P1340; Bieri JG., 1980, J NUTR, V110, P1726, DOI [10.1093/jn/110.8.1726, DOI 10.1093/JN/110.8.1726]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CARR TP, 1990, ROLE COPPER LIPID ME, P89; CHAO PY, 1992, FREE RADICAL BIO MED, V12, P145, DOI 10.1016/0891-5849(92)90008-5; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; HASSEL CA, 1990, ROLE COPPER LIPID ME, P103; KLEVAY LM, 1973, AM J CLIN NUTR, V26, P1060, DOI 10.1093/ajcn/26.10.1060; LEI KY, 1978, J NUTR, V108, P232, DOI 10.1093/jn/108.2.232; LEI KY, 1977, NUTR REP INT, V15, P597; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MURTHY L, 1976, J AGR FOOD CHEM, V24, P808, DOI 10.1021/jf60206a048; NORUSIS MJ, 1984, STATISTICAL PACKAGE; PETERING HG, 1977, J AGR FOOD CHEM, V25, P1105, DOI 10.1021/jf60213a051; ROITELMAN J, 1984, J BIOL CHEM, V259, P870; SACCHETTA P, 1986, ANAL BIOCHEM, V154, P205, DOI 10.1016/0003-2697(86)90516-6; SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9; SHO MSJ, 1980, J NUTR, V110, P859; VALSALA P, 1987, J BIOSCIENCES, V12, P137, DOI 10.1007/BF02702965; YOUNT NY, 1990, J NUTR BIOCHEM, V1, P21, DOI 10.1016/0955-2863(90)90094-2; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	27	100	112	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2467	2471		10.1096/fasebj.6.7.1563598	http://dx.doi.org/10.1096/fasebj.6.7.1563598			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563598				2022-12-28	WOS:A1992HP03000013
J	PAUL, SM; PURDY, RH				PAUL, SM; PURDY, RH			NEUROACTIVE STEROIDS	FASEB JOURNAL			English	Review						NEUROACTIVE STEROIDS; GABA-A RECEPTORS; ANESTHETIC STEROIDS AND BARBITURATES; NONGENOMIC ACTIONS; MEMBRANE RECEPTORS; RAPID MODULATION OF INHIBITORY AND EXCITATORY NEUROTRANSMITTERS; NEUROSTEROIDS	GABAA RECEPTOR SUBUNIT; CHLORIDE-ION FLUX; BENZODIAZEPINE RECEPTORS; RAT-BRAIN; PREGNENOLONE-SULFATE; HORMONE METABOLITES; PHYSICAL SEPARATION; CENTRAL NEURONS; A RECEPTORS; GLIAL-CELLS	Neuroactive steroids are natural or synthetic steroids that rapidly alter the excitability of neurons by binding to membrane-bound receptors such as those for inhibitory and (or) excitatory neurotransmitters. The best-studied neuroactive steroids are a series of sedative-hypnotic 3-alpha-hydroxy ring A-reduced pregnane steroids that include the major metabolites of progesterone and deoxycorticosterone, 3-alpha-hydroxy-5-alpha-pregnan-20-one (allopregnanolone) and 3-alpha,21-dihydroxy-5-alpha-pregnan-20-one (allotetrahydroDOC), respectively. These 3-alpha-hydroxysteroids do not interact with classical intracellular steroid receptors but bind stereoselectively and with high affinity to receptors for the major inhibitory neurotransmitter in brain, gamma-aminobutyric acid (GABA). Biochemical and electrophysiological studies have shown that these steroids markedly augment GABA-activated chloride ion currents in a manner similar (but not identical) to that of anesthetic barbiturates. Several steroids have also been observed to have convulsant or proconvulsant properties, including the synthetic amidine 3-alpha-hydroxy-16-imino-5-beta-17-azaandrostan-11-one (RU5135) and the natural sulfate esters of pregnenolone and dehydroepiandrosterone. Several of these have been shown to be bicuculline or picrotoxin-like GABA(A) receptor antagonists. Examples of steroids that alter neuronal excitability rapidly by augmenting or inhibiting excitatory amino acid receptor-mediated responses have also been reported. Recently, allopregnanolone and allotetrahydroDOC have also been measured in brain and plasma where their levels have been shown to fluctuate in response to stress and during the estrous and menstrual cycles of rats and humans, respectively. Although the major fraction of allopregnanolone in tissue, including brain, is of adrenal and/or ovarian origin, appreciable levels of allopregnanolone can still be measured in the brains of adrenalectomized and/or oophorectomized animals. Receptor-active neurosteroids may represent an important class of neuromodulators that can rapidly alter central nervous system excitability via novel nongenomic mechanisms.	SW FDN BIOMED RES,DEPT ORGAN CHEM,SAN ANTONIO,TX 78228	Texas Biomedical Research Institute	PAUL, SM (corresponding author), NIMH,CLIN NEUROSCI BRANCH,MOLEC PHARMACOL SECT,BLDG 10,ROOM 4N224,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Paul, Steve/ABE-5400-2020; Porcu, Patrizia/B-8400-2015	Porcu, Patrizia/0000-0003-0848-7258				ATKINSON RM, 1965, J MED CHEM, V8, P426, DOI 10.1021/jm00328a004; BACKSTROM T, 1985, ACTA OBSTET GYNECO S, V130, P9; BARKER JL, 1978, J PHYSIOL-LONDON, V280, P355, DOI 10.1113/jphysiol.1978.sp012388; BARNEA A, 1990, ENDOCRINOLOGY, V127, P500, DOI 10.1210/endo-127-1-500; BAULIEU EE, 1990, J STEROID BIOCHEM, V37, P395, DOI 10.1016/0960-0760(90)90490-C; BAULIEU EE, 1981, WENNER GREN CTR INT, V34, P3; BECKER JB, 1990, NEUROSCI LETT, V118, P169, DOI 10.1016/0304-3940(90)90618-J; BELELLI D, 1989, EUR J PHARMACOL, V166, P325, DOI 10.1016/0014-2999(89)90077-0; BOWERY N, 1989, TRENDS PHARMACOL SCI, V10, P401, DOI 10.1016/0165-6147(89)90188-0; CARETTE B, 1984, NEUROSCI LETT, V45, P205, DOI 10.1016/0304-3940(84)90100-9; Cashin MF, 1927, AM J PHYSIOL, V82, P294, DOI 10.1152/ajplegacy.1927.82.2.294; CORPECHOT C, 1983, BRAIN RES, V270, P119, DOI 10.1016/0006-8993(83)90797-7; COTTRELL GA, 1987, BRIT J PHARMACOL, V90, P491, DOI 10.1111/j.1476-5381.1987.tb11198.x; CRAWLEY JN, 1986, BRAIN RES, V398, P382, DOI 10.1016/0006-8993(86)91500-3; FRIEDL W, 1988, NEUROPHARMACOLOGY, V27, P163, DOI 10.1016/0028-3908(88)90166-9; GEE KW, 1988, J PHARMACOL EXP THER, V246, P803; GEE KW, 1987, EUR J PHARMACOL, V136, P419, DOI 10.1016/0014-2999(87)90317-7; GEE KW, 1991, IN PRESS MOL PHARM; GYERMEK L, 1975, ANESTHESIOLOGY, V42, P331, DOI 10.1097/00000542-197503000-00017; HARRISON NL, 1984, BRAIN RES, V323, P287, DOI 10.1016/0006-8993(84)90299-3; HEUSER G, 1965, ARCH NEUROL-CHICAGO, V13, P195, DOI 10.1001/archneur.1965.00470020085012; HOLZBAUER M, 1976, MED BIOL, V54, P227; HOLZBAUER M, 1985, J STEROID BIOCHEM, V22, P97, DOI 10.1016/0022-4731(85)90147-5; HONOUR JW, 1978, J STEROID BIOCHEM, V9, P495, DOI 10.1016/0022-4731(78)90115-2; HU ZY, 1987, P NATL ACAD SCI USA, V84, P8215, DOI 10.1073/pnas.84.23.8215; HUNT P, 1981, NEUROPHARMACOLOGY, V20, P357, DOI 10.1016/0028-3908(81)90009-5; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; JUNGTESTAS I, 1989, J STEROID BIOCHEM, V34, P511, DOI 10.1016/0022-4731(89)90136-2; KARAVOLAS HJ, 1984, METABOLISM HORMONAL, V13, P149; KRAULIS I, 1975, BRAIN RES, V88, P1, DOI 10.1016/0006-8993(75)90942-7; KRIEGER NR, 1989, J NEUROCHEM, V52, P1866, DOI 10.1111/j.1471-4159.1989.tb07269.x; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; LAKSHMI V, 1991, ENDOCRINOLOGY, V128, P1741, DOI 10.1210/endo-128-4-1741; LAMBERT JJ, 1987, TRENDS PHARMACOL SCI, V8, P224, DOI 10.1016/0165-6147(87)90067-8; LAMBERT JJ, 1991, FIDIA RF S SERIES, V6, P219; LAN NC, 1991, J NEUROCHEM, V57, P1818, DOI 10.1111/j.1471-4159.1991.tb06388.x; LAWRENCE DK, 1975, MOL PHARMACOL, V11, P280; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LO MMS, 1982, P NATL ACAD SCI-BIOL, V79, P680, DOI 10.1073/pnas.79.2.680; LODGE D, 1984, BRIT J ANAESTH, V56, P1143, DOI 10.1093/bja/56.10.1143; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MAJEWSKA MD, 1987, BRAIN RES, V418, P377, DOI 10.1016/0006-8993(87)90107-7; MAJEWSKA MD, 1987, BRAIN RES, V404, P355; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MAJEWSKA MD, 1990, BRAIN RES, V526, P143, DOI 10.1016/0006-8993(90)90261-9; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; McEwen BS, 1989, BASIC NEUROCHEMISTRY, P893; MCNEIL RG, IN PRESS DRUG NEWS P; MELCANGI RC, 1990, BRAIN RES, V516, P229, DOI 10.1016/0006-8993(90)90923-Y; MENDELSON WB, 1987, PSYCHOPHARMACOLOGY, V93, P226; MIENVILLE JM, 1989, BRAIN RES, V489, P190, DOI 10.1016/0006-8993(89)90024-3; MOISAN MP, 1990, ENDOCRINOLOGY, V127, P1450, DOI 10.1210/endo-127-3-1450; MOK WM, 1990, BRAIN RES, V533, P42, DOI 10.1016/0006-8993(90)91792-F; MORGAN M, 1985, ANAESTHESIA, V40, P121; MORROW AL, 1990, MOL PHARMACOL, V37, P263; MORROW AL, 1987, EUR J PHARMACOL, V142, P483, DOI 10.1016/0014-2999(87)90094-X; MORROW AL, 1988, J NEUROCHEM, V50, P302, DOI 10.1111/j.1471-4159.1988.tb13264.x; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; MYSLOBODSKY MS, 1983, NEUROPHARMACOLOGY, V22, P157, DOI 10.1016/0028-3908(83)90003-5; NINAN PT, 1982, SCIENCE, V218, P1332, DOI 10.1126/science.6293059; OLIVER AE, 1991, BRAIN RES, V557, P298, DOI 10.1016/0006-8993(91)90148-O; OLSEN RW, 1984, EUR J PHARMACOL, V103, P333, DOI 10.1016/0014-2999(84)90495-3; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1981, J NEUROCHEM, V37, P1, DOI 10.1111/j.1471-4159.1981.tb05284.x; ONG J, 1987, NEUROSCI LETT, V82, P101, DOI 10.1016/0304-3940(87)90178-9; ORCHINIK M, 1991, SCIENCE, V252, P1848, DOI 10.1126/science.2063198; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; PURDY RH, 1990, STEROIDS, V55, P290, DOI 10.1016/0039-128X(90)90031-6; SCHILDKNECHT H, 1970, Angewandte Chemie International Edition in English, V9, P1, DOI 10.1002/anie.197000011; SCHILDKNECHT H, 1971, ENDEAVOUR, V30, P136, DOI 10.1016/0160-9327(71)90040-8; SCHILDKNECHT H, 1966, MEM I BUTANTAN S INT, V33, P121; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHOLFIELD CN, 1980, PFLUG ARCH EUR J PHY, V383, P249, DOI 10.1007/BF00587527; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; SHINGAI R, 1991, EUR J PHARM-MOLEC PH, V206, P77, DOI 10.1016/0922-4106(91)90149-C; SIMMONDS MA, 1985, BRIT J PHARMACOL, V84, P631, DOI 10.1111/j.1476-5381.1985.tb16143.x; SKOLNICK P, 1981, SCIENCE, V211, P1448, DOI 10.1126/science.6258230; SKOLNICK P, 1988, ISI ATLAS-PHARMACOL, V2, P19; SMITH SS, 1988, BRAIN RES, V475, P272, DOI 10.1016/0006-8993(88)90615-4; SMITH SS, 1987, BRAIN RES, V422, P40, DOI 10.1016/0006-8993(87)90538-5; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; STARNES WR, 1965, ANAL BIOCHEM, V12, P157, DOI 10.1016/0003-2697(65)90154-5; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; SUZDAK PD, 1986, SCIENCE, V234, P1243, DOI 10.1126/science.3022383; TALLMAN JF, 1980, SCIENCE, V207, P274, DOI 10.1126/science.6101294; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; WEIDENFELD J, 1980, J STEROID BIOCHEM, V13, P961, DOI 10.1016/0022-4731(80)90171-5; WEIZMAN A, 1990, BRAIN RES, V519, P347, DOI 10.1016/0006-8993(90)90100-P; WONG M, 1991, BRAIN RES, V543, P148, DOI 10.1016/0006-8993(91)91057-8; WOODBURY DM, 1952, J PHARMACOL EXP THER, V105, P27; WU FS, 1991, MOL PHARMACOL, V40, P333; WU FS, 1990, MOL PHARMACOL, V37, P597; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	97	1402	1437	2	69	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2311	2322		10.1096/fasebj.6.6.1347506	http://dx.doi.org/10.1096/fasebj.6.6.1347506			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1347506	Bronze			2022-12-28	WOS:A1992HJ25200008
J	COON, MJ; DING, XX; PERNECKY, SJ; VAZ, ADN				COON, MJ; DING, XX; PERNECKY, SJ; VAZ, ADN			CYTOCHROME-P450 - PROGRESS AND PREDICTIONS	FASEB JOURNAL			English	Review						CYTOCHROME-P450 ISOZYMES; OXYGEN ACTIVATION; REGULATION OF EXPRESSION; LIPID PEROXIDATION; OLEFIN FORMATION FROM ALDEHYDES	SITE-DIRECTED MUTAGENESIS; MICROSOMAL CYTOCHROME-P-450; INDUCIBLE CYTOCHROME-P-450; MECHANISM; RAT; P450; HYDROPEROXIDES; AROMATIZATION; DEMETHYLATION; PURIFICATION	The cytochrome P450 gene superfamily encodes many isoforms that are unusual in the variety of chemical reactions catalyzed and the number of substrates attacked. The latter include physiologically important substances such as steroids, eicosanoids, fatty acids, lipid hydroperoxides, retinoids, and other lipid metabolites, and xenobiotics such as drugs, alcohols, procarcinogens, antioxidants, organic solvents, anesthetics, dyes, pesticides, odorants, and flavorants. Accordingly, it is not surprising that these catalysts have come under intensive study in recent years in fields as diverse as biochemistry and molecular biology, endocrinology, pharmacology, toxicology, anesthesiology, nutrition, pathology, and oncology. In this review, recent advances in our knowledge of the catalytic properties, reaction mechanisms, and regulation of expression and activity of the P450 enzymes are briefly summarized. In addition, the prospects for research in this field are considered, and advances are predicted in four broad areas: improved basic knowledge of enzyme catalysis and regulation; synthesis of fine chemicals, including drug design and screening; removal of undesirable environmental chemicals; and biomedical applications related to steroid, drug, carcinogen, and alcohol metabolism.			COON, MJ (corresponding author), UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK010339, R01DK010339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006221] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-06221] Funding Source: Medline; NIDDK NIH HHS [DK-10339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKHTAR M, 1982, BIOCHEM J, V201, P569, DOI 10.1042/bj2010569; ALEXANDE.K, 1972, J CHEM SOC CHEM COMM, P383, DOI 10.1039/c39720000383; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; BLAKE RC, 1989, J BIOL CHEM, V264, P3694; BONDON A, 1989, J BIOL CHEM, V264, P1988; COLE PA, 1990, P NATL ACAD SCI USA, V87, P2999, DOI 10.1073/pnas.87.8.2999; COON MJ, 1991, IN PRESS OXIDATIVE D; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEMONTELLANO PRO, 1986, CYTOCHROME P450 STRU, P273; DEMONTELLANO PRO, 1989, TRENDS PHARMACOL SCI, V10, P3254; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; ELIASSON E, 1990, P NATL ACAD SCI USA, V87, P3225, DOI 10.1073/pnas.87.8.3225; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; FISHMAN J, 1982, CANCER RES, V42, P3277; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUSTAFSSON JA, 1976, SCIENCE, V191, P203, DOI 10.1126/science.1246611; HAUGEN DA, 1975, J BIOL CHEM, V250, P3567; HECKER M, 1989, J BIOL CHEM, V264, P141; JOHANSSON I, 1990, BIOCHEM BIOPH RES CO, V173, P331, DOI 10.1016/S0006-291X(05)81061-7; LARROQUE C, 1990, ARCH BIOCHEM BIOPHYS, V282, P198, DOI 10.1016/0003-9861(90)90104-7; LU AYH, 1980, PHARMACOL REV, V31, P277; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEF P, 1989, J BIOL CHEM, V264, P6780, DOI 10.1016/S0021-9258(18)83497-4; NEW MI, 1986, ANN NY ACAD SCI, V458, P216; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OMURA T., 1965, FEDERATION PROC, V24, P1181; OMURA T, 1964, J BIOL CHEM, V239, P2370; PANDEY RN, 1987, DRUG METAB DISPOS, V15, P518; PINEAU T, 1991, EUR J BIOCHEM, V197, P145, DOI 10.1111/j.1432-1033.1991.tb15893.x; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1985, J BIOL CHEM, V260, P6122; ROBERTS ES, 1991, P NATL ACAD SCI USA, V88, P8963, DOI 10.1073/pnas.88.20.8963; RYAN DE, 1990, PHARMACOL THERAPEUT, V45, P153, DOI 10.1016/0163-7258(90)90029-2; SCHWAB GE, 1987, MAMMALIAN CYTOCHROME, P55; SIMPSON ER, 1990, MOL CELL ENDOCRINOL, V70, pC25, DOI 10.1016/0303-7207(90)90151-W; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STEVENSON DE, 1988, J CHEM SOC P1, V1, P2043; TIERNEY D, 1990, FASEB J, V4, pA2240; UMENO M, 1988, J BIOL CHEM, V263, P4956; VAZ ADN, 1990, P NATL ACAD SCI USA, V87, P5499, DOI 10.1073/pnas.87.14.5499; VAZ ADN, 1987, P NATL ACAD SCI USA, V84, P1172, DOI 10.1073/pnas.84.5.1172; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066; WATANABE Y, 1989, J AM CHEM SOC, V111, P410, DOI 10.1021/ja00183a083; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; WHITE RE, 1991, PHARMACOL THERAPEUT, V49, P21, DOI 10.1016/0163-7258(91)90020-M; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WILLIAMS DE, 1984, J BIOL CHEM, V259, P4600; YOSHIDA Y, 1990, 8TH P INT S MICR DRU, P118	54	180	191	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					669	673		10.1096/fasebj.6.2.1537454	http://dx.doi.org/10.1096/fasebj.6.2.1537454			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537454				2022-12-28	WOS:A1992GZ44000004
J	GUENGERICH, FP				GUENGERICH, FP			CHARACTERIZATION OF HUMAN CYTOCHROME-P450 ENZYMES	FASEB JOURNAL			English	Article						CYTOCHROME-P450; DRUGS; CARCINOGENS; STEROIDS; HUMAN STUDIES	HUMAN-LIVER CYTOCHROME-P-450; OXIDATIVE DRUG-METABOLISM; HUMAN-FETAL LIVERS; GENETIC-POLYMORPHISM; PARTIAL-PURIFICATION; SPECIFICITY; EXPRESSION; RABBIT; RAT; MICROSOMES	Many biochemical approaches have been applied to the human cytochrome P450 enzymes, and more than 20 different gene products have been characterized with regard to their properties and catalytic specificities. The complement of the various cytochrome P450 enzymes in a given individual varies markedly, and dramatic differences may be seen in drug metabolism, pharmacological response, and susceptibility to toxic effects. An understanding of the nature of the individual cytochrome P450 enzymes and their regulation should be useful in determining the most suitable animal models, ascertaining risk from chemicals, and in avoiding undesirable drug interactions.	VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University	GUENGERICH, FP (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.				NCI NIH HHS [CA 44353] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAUNE P, 1979, BIOCHEM BIOPH RES CO, V88, P826, DOI 10.1016/0006-291X(79)91482-7; BOLT HM, 1977, ACTA ENDOCRINOL-COP, V85, P189; BRIAN WR, 1989, BIOCHEMISTRY-US, V28, P4993, DOI 10.1021/bi00438a014; COLE PA, 1990, J MED CHEM, V33, P2933, DOI 10.1021/jm00173a001; CONNEY AH, 1982, CANCER RES, V42, P4875; Distlerath L. M., 1987, MAMMALIAN CYTOCHROME, V1, P133; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; GUENGERICH FP, 1990, LIFE SCI, V47, P1981; GUENGERICH FP, 1989, ANNU REV PHARMACOL, V29, P241; GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1992, IN PRESS ENV HLTH PR; HIGASHI Y, 1991, J BIOCHEM-TOKYO, V109, P638, DOI 10.1093/oxfordjournals.jbchem.a123433; HUANG MT, 1981, J BIOL CHEM, V256, P897; JOHNSON EF, 1988, J BIOL CHEM, V263, P17672; KASCHNITZ RM, 1975, BIOCHEM PHARMACOL, V24, P259; KITADA M, 1987, BIOCHEM PHARMACOL, V36, P453, DOI 10.1016/0006-2952(87)90350-9; KITADA M, 1979, BIOCHEM PHARMACOL, V28, P793; KLEHR H, 1987, BIOL CHEM H-S, V368, P895, DOI 10.1515/bchm3.1987.368.2.895; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; KUNTZMAN R, 1966, J PHARMACOL EXP THER, V152, P151; LEVIN W, 1987, ARCH BIOCHEM BIOPHYS, V258, P630, DOI 10.1016/0003-9861(87)90386-9; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MOREL F, 1990, EUR J BIOCHEM, V191, P437, DOI 10.1111/j.1432-1033.1990.tb19140.x; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; REITZ RH, 1989, TOXICOL APPL PHARM, V97, P230, DOI 10.1016/0041-008X(89)90328-1; REMMER H, 1957, N-S ARCH PHARMACOL, V237, P296; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; SHAYIQ RM, 1989, BIOCHEMISTRY-US, V28, P7546, DOI 10.1021/bi00445a008; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SLOAN TP, 1978, BRIT MED J, V2, P655, DOI 10.1136/bmj.2.6138.655; SRIVASTAVA PK, 1991, MOL PHARMACOL, V40, P69; WANG P, 1980, ARCH BIOCHEM BIOPHYS, V199, P206, DOI 10.1016/0003-9861(80)90274-X; WATKINS PB, 1985, P NATL ACAD SCI USA, V82, P6310, DOI 10.1073/pnas.82.18.6310; WATKINS PB, 1990, CLIN PHARMACOL THER, V48, P120, DOI 10.1038/clpt.1990.126; WRIGHTON SA, 1990, MOL PHARMACOL, V38, P207; YUN CH, 1991, MOL PHARMACOL, V40, P679	40	229	234	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					745	748		10.1096/fasebj.6.2.1537465	http://dx.doi.org/10.1096/fasebj.6.2.1537465			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537465				2022-12-28	WOS:A1992GZ44000016
J	MERLINO, GT				MERLINO, GT			TRANSGENIC ANIMALS IN BIOMEDICAL-RESEARCH	FASEB JOURNAL			English	Article						GENE REGULATION; GENE THERAPY; CANCER; MUTATION; BIOTECHNOLOGY; TARGETED GENE INACTIVATION	TGF-ALPHA; INT-1 PROTOONCOGENE; LIVER NEOPLASIA; GERM LINE; T-CELLS; MICE; GENE; MOUSE; EXPRESSION; DEFICIENT	The advent of transgenic technology, in which foreign genetic information is stably introduced into the mammalian germ line, has dramatically enhanced our basic knowledge of physiologic and pathologic processes. Transgenic animals created by these genetic manipulations are being used to provide insights into gene regulation, development, pathogenesis, and the treatment of disease. Furthermore, transgenic biotechnology holds great promise for the creation of genetically superior livestock and the industrial production of precious pharmaceuticals. It is evident now that the study and use of transgenic animals will significantly improve the human condition.			MERLINO, GT (corresponding author), NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							BABINET C, 1989, GENOME, V31, P938, DOI 10.1139/g89-165; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONNELLY CS, 1989, EXP CELL RES, V183, P257, DOI 10.1016/0014-4827(89)90387-X; COSTANTINI F, 1986, SCIENCE, V233, P1192, DOI 10.1126/science.3461564; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; EDWARDS RH, 1989, CELL, V58, P161, DOI 10.1016/0092-8674(89)90412-1; EVANS GA, 1989, GENE DEV, V3, P259, DOI 10.1101/gad.3.3.259; FROHMAN MA, 1989, CELL, V56, P145, DOI 10.1016/0092-8674(89)90887-8; GALSKI H, 1989, MOL CELL BIOL, V9, P4357, DOI 10.1128/MCB.9.10.4357; GORDON JW, 1990, DEV BIOL, V137, P349, DOI 10.1016/0012-1606(90)90259-L; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1990, ANNU REV CELL BIOL, V6, P493, DOI 10.1146/annurev.cellbio.6.1.493; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENNIGHAUSEN L, 1990, Protein Expression and Purification, V1, P3, DOI 10.1016/1046-5928(90)90037-Y; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ISOLA LM, 1989, DEV GENET, V10, P349, DOI 10.1002/dvg.1020100502; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; MASON AJ, 1986, SCIENCE, V234, P1372, DOI 10.1126/science.3097822; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MICKISCH GH, 1991, P NATL ACAD SCI USA, V88, P547, DOI 10.1073/pnas.88.2.547; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PURSEL VG, 1989, SCIENCE, V244, P1281, DOI 10.1126/science.2499927; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; ROSSANT J, 1989, TRENDS GENET, V5, P277, DOI 10.1016/0168-9525(89)90102-9; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1989, ONCOGENE, V4, P715; SHAWLOT W, 1989, MOL BIOL MED, V6, P299; SILVERSIDES DW, 1991, IN PRESS DEVELOPMENT; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WESTPHAL H, 1989, FASEB J, V3, P117, DOI 10.1096/fasebj.3.2.2492478; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	58	29	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1991	5	14					2996	3001		10.1096/fasebj.5.14.1752364	http://dx.doi.org/10.1096/fasebj.5.14.1752364			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752364				2022-12-28	WOS:A1991GP26900017
J	Stubbs, FE; Flynn, BP; Rivers, CA; Birnie, MT; Herman, A; Swinstead, EE; Baek, S; Fang, H; Temple, J; Carroll, JS; Hager, GL; Lightman, SL; Conway-Campbell, BL				Stubbs, Felicity E.; Flynn, Benjamin P.; Rivers, Caroline A.; Birnie, Matthew T.; Herman, Andrew; Swinstead, Erin E.; Baek, Songjoon; Fang, Hai; Temple, Jillian; Carroll, Jason S.; Hager, Gordon L.; Lightman, Stafford L.; Conway-Campbell, Becky L.			Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation	ONCOGENE			English	Article; Early Access							CHROMATIN-REMODELING COMPLEX; GLUCOCORTICOID-RECEPTOR; TUMOR-SUPPRESSOR; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; SOLID TUMORS; 53BP1; BINDING; ARREST	ARID1a (BAF250), a component of human SWI/SNF chromatin remodeling complexes, is frequently mutated across numerous cancers, and its loss of function has been putatively linked to glucocorticoid resistance. Here, we interrogate the impact of siRNA knockdown of ARID1a compared to a functional interference approach in the HeLa human cervical cancer cell line. We report that ARID1a knockdown resulted in a significant global decrease in chromatin accessibility in ATAC-Seq analysis, as well as affecting a subset of genome-wide GR binding sites determined by analyzing GR ChIP-Seq data. Interestingly, the specific effects on gene expression were limited to a relatively small subset of glucocorticoid-regulated genes, notably those involved in cell cycle regulation and DNA repair. The vast majority of glucocorticoid-regulated genes were largely unaffected by ARID1a knockdown or functional interference, consistent with a more specific role for ARID1a in glucocorticoid function than previously speculated. Using liquid chromatography-mass spectrometry, we have identified a chromatin-associated protein complex comprising GR, ARID1a, and several DNA damage repair proteins including P53 binding protein 1 (P53BP1), Poly(ADP-Ribose) Polymerase 1 (PARP1), DNA damage-binding protein 1 (DDB1), DNA mismatch repair protein MSH6 and splicing factor proline and glutamine-rich protein (SFPQ), as well as the histone acetyltransferase KAT7, an epigenetic regulator of steroid-dependent transcription, DNA damage repair and cell cycle regulation. Not only was this protein complex ablated with both ARID1a knockdown and functional interference, but spontaneously arising DNA damage was also found to accumulate in a manner consistent with impaired DNA damage repair mechanisms. Recovery from dexamethasone-dependent cell cycle arrest was also significantly impaired. Taken together, our data demonstrate that although glucocorticoids can still promote cell cycle arrest in the absence of ARID1a, the purpose of this arrest to allow time for DNA damage repair is hindered.	[Stubbs, Felicity E.; Flynn, Benjamin P.; Rivers, Caroline A.; Birnie, Matthew T.; Lightman, Stafford L.; Conway-Campbell, Becky L.] Univ Bristol, Fac Hlth Sci, Henry Wellcome Labs Integrat Neurosci & Endocrino, Translat Hlth Sci, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England; [Stubbs, Felicity E.; Swinstead, Erin E.; Baek, Songjoon; Hager, Gordon L.] NCI, Lab Receptor Biol & Gene Express, US Natl Inst Hlth, 41 Medlars Dr, Bethesda, MD 20892 USA; [Herman, Andrew] Univ Bristol, Fac Life Sci, Sch Cellular & Mol Med, Flow Cytometry Facil, Biomed Sci Bldg, Bristol, Avon, England; [Fang, Hai] Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai,Sch Med, Thanghai Inst Hematol,State Key Lab Med Genom, Shanghai 200025, Peoples R China; [Temple, Jillian; Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Bristol; Chinese Academy of Sciences; Shanghai Jiao Tong University; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Conway-Campbell, BL (corresponding author), Univ Bristol, Fac Hlth Sci, Henry Wellcome Labs Integrat Neurosci & Endocrino, Translat Hlth Sci, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England.	b.conway-campbell@bristol.ac.uk		Flynn, Benjamin/0000-0002-1871-3039; Rivers, Caroline/0000-0002-2993-3723	Wellcome Trust [089647/Z/09/Z]; MRC [MR/R010919/1]; Needham Cooper Charitable Trust; Neuroendocrinology Charitable Trust; Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program [W81XWH-17-1-0067]	Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Needham Cooper Charitable Trust; Neuroendocrinology Charitable Trust; Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program	Majority of materials and consumables were provided by funding from Wellcome Trust Grant 089647/Z/09/Z and MRC Grant MR/R010919/1 to BLC-C and SLL FES was awarded an early career grant by The Society for Endocrinology for the costs of the proteomics and FACS studies. FES was supported by a Ph.D. scholarship provided by the Needham Cooper Charitable Trust and a research fellowship awarded by the Neuroendocrinology Charitable Trust. BLC-C was supported by Wellcome Trust Grant 089647/Z/09/Z and MRC Grant MR/R010919/1. EES was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Programunder Award No. W81XWH-17-1-0067. Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. Finally, we would like to thank The University of Bristol Genomics Facility (Dr. Christy Waterfall and Ms. Jane Coghill), Proteomics Facility (Dr. Kate Heesom), and FACS facility (Helen Rice and Lorena Sueiro Ballesteros) for their excellent technical support and invaluable advice throughout the course of the project.	Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; Baell JB, 2018, NATURE, V560, P253, DOI 10.1038/s41586-018-0387-5; Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Chapman JR, 2012, J CELL SCI, V125, P3529, DOI 10.1242/jcs.105353; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Conway-Campbell BL, 2011, MOL ENDOCRINOL, V25, P944, DOI 10.1210/me.2010-0073; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Cuella-Martin R, 2016, MOL CELL, V64, P51, DOI 10.1016/j.molcel.2016.08.002; de Silva HC, 2019, CELL MOL LIFE SCI, V76, P2015, DOI 10.1007/s00018-019-03033-4; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Drane P, 2017, NATURE, V543, P211, DOI 10.1038/nature21358; Du F, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0315-y; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Fang H, 2014, BIOCHEM BIOPH RES CO, V443, P285, DOI 10.1016/j.bbrc.2013.11.103; Flores-Alcantar A, 2011, CELL TISSUE RES, V345, P137, DOI 10.1007/s00441-011-1182-x; Fragkos M, 2009, MOL CELL BIOL, V29, P2828, DOI 10.1128/MCB.01830-08; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; George CL, 2017, MOL CELL ENDOCRINOL, V439, P46, DOI 10.1016/j.mce.2016.10.019; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; Grontved L, 2013, EMBO J, V32, P1568, DOI 10.1038/emboj.2013.106; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Han N, 2019, ONCOTARGETS THER, V12, P7591, DOI 10.2147/OTT.S222223; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; He B, 2016, J CELL PHYSIOL, V231, P233, DOI 10.1002/jcp.25076; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Herr I, 2006, LANCET ONCOL, V7, P425, DOI 10.1016/S1470-2045(06)70694-5; Hoffmann JA, 2018, ELIFE, V7, DOI 10.7554/eLife.35073; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Hu ZL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134299; Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759; Johnson TA, 2018, NUCLEIC ACIDS RES, V46, P203, DOI 10.1093/nar/gkx1044; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kang Y, 2011, BIOCHEM BIOPH RES CO, V404, P476, DOI 10.1016/j.bbrc.2010.12.005; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lovejoy CA, 2006, MOL CELL BIOL, V26, P7977, DOI 10.1128/MCB.00819-06; MacPherson L, 2020, NATURE, V577, P266, DOI 10.1038/s41586-019-1835-6; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; Mattern J, 2007, CANCER BIOL THER, V6, P1345, DOI 10.4161/cbt.6.9.4765; Mirza-Aghazadeh-Attari M, 2019, DNA REPAIR, V73, P110, DOI 10.1016/j.dnarep.2018.11.008; Mittica G, 2018, RECENT PAT ANTI-CANC, V13, P392, DOI 10.2174/1574892813666180305165256; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nagl NG, 2005, CANCER RES, V65, P9236, DOI 10.1158/0008-5472.CAN-05-1225; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Niida H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16102; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; Pardo M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08456-2; Petrucco S, 2003, NUCLEIC ACIDS RES, V31, P6689, DOI 10.1093/nar/gkg890; Planey SL, 2000, BIOCHEM BIOPH RES CO, V279, P307, DOI 10.1006/bbrc.2000.3922; Pommier Y, 2022, NAT REV MOL CELL BIO, V23, P407, DOI 10.1038/s41580-022-00452-3; Pooley JR, 2017, ENDOCRINOLOGY, V158, P1486, DOI 10.1210/en.2016-1929; Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416; Prekovic S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24537-3; Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; Senga T, 2006, J BIOL CHEM, V281, P6246, DOI 10.1074/jbc.M512705200; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; Sharma A, 2012, HISTONE H2AX PHOSPHO, V920; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Shen PL, 2021, BIOCHEM BIOPHYS REP, V28, DOI 10.1016/j.bbrep.2021.101151; Sossey-Alaoui K, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1774-z; Soussi T, 2017, TRENDS CELL BIOL, V27, P311, DOI 10.1016/j.tcb.2016.10.004; Stubbs FE, 2018, MOL CELL ENDOCRINOL, V461, P226, DOI 10.1016/j.mce.2017.09.018; Sun JB, 2014, CANCER LETT, V355, P25, DOI 10.1016/j.canlet.2014.09.022; Swinstead EE, 2016, CELL, V165, P593, DOI 10.1016/j.cell.2016.02.067; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trizzino M, 2018, CELL REP, V23, P3933, DOI 10.1016/j.celrep.2018.05.097; Trotter KW, 2008, MOL CELL BIOL, V28, P1413, DOI 10.1128/MCB.01301-07; Trotter KW, 2015, MOL CELL BIOL, V35, P2799, DOI 10.1128/MCB.00230-15; Visconti R, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0433-9; Vyas S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3240; Wacker DA, 2007, MOL CELL BIOL, V27, P7475, DOI 10.1128/MCB.01314-07; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Yoon CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042006; Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang XM, 2019, J RADIAT RES, V60, P318, DOI 10.1093/jrr/rrz003; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	99	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02516-2	http://dx.doi.org/10.1038/s41388-022-02516-2		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5Z0JJ	36344675	Green Published, hybrid			2022-12-28	WOS:000879664600001
J	Chen, H; Chen, XH; Zhang, ZJ; Bao, WH; Gao, ZQ; Li, DF; Xie, XY; Zhou, P; Yang, CX; Zhou, ZQ; Pan, JY; Kuang, XQ; Tang, RM; Feng, ZF; Zhou, LH; Zhu, DC; Yang, JA; Wang, L; Huang, HB; Tang, DL; Liu, JB; Jiang, LL				Chen, Han; Chen, Xuhong; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Zhou, Zhongqiu; Pan, Jinyuan; Kuang, Xiangqin; Tang, Ruiming; Feng, Zhengfu; Zhou, Lihuan; Zhu, Dachun; Yang, Jianan; Wang, Lan; Huang, Hongbiao; Tang, Daolin; Liu, Jinbao; Jiang, Lili			Extracellular vesicles-transferred SBSN drives glioma aggressiveness by activating NF-kappa B via ANXA1-dependent ubiquitination of NEMO	ONCOGENE			English	Article							GLIOBLASTOMA; COMPLEX; CANCER; EXOSOMES; RIP1; IKK	Glioma is the most common malignant primary brain tumor with aggressiveness and poor prognosis. Although extracellular vesicles (EVs)-based cell-to-cell communication mediates glioma progression, the key molecular mediators of this process are still not fully understood. Herein, we elucidated an EVs-mediated transfer of suprabasin (SBSN), leading to the aggressiveness and progression of glioma. High levels of SBSN were positively correlated with clinical grade, predicting poor clinical prognosis of patients. Upregulation of SBSN promoted, while silencing of SBSN suppressed tumorigenesis and aggressiveness of glioma cells in vivo. EVs-mediated transfer of SBSN resulted in an increase in SBSN levels, which promoted the aggressiveness of glioma cells by enhancing migration, invasion, and angiogenesis of recipient glioma cells. Mechanistically, SBSN activated NF-kappa B signaling by interacting with annexin A1, which further induced Lys63-linked and Met1-linear polyubiquitination of NF-kappa B essential modulator (NEMO). In conclusion, the communication of SBSN-containing EVs within glioma cells drives the formation and development of tumors by activating NF-kappa B pathway, which may provide potential therapeutic target for clinical intervention in glioma.	[Chen, Han; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Kuang, Xiangqin; Yang, Jianan; Huang, Hongbiao; Liu, Jinbao; Jiang, Lili] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China; [Chen, Han; Chen, Xuhong; Zhang, Zhuojun; Bao, Wenhao; Gao, Zhiqing; Li, Difeng; Xie, Xiaoyi; Zhou, Ping; Yang, Chunxiao; Kuang, Xiangqin; Huang, Hongbiao; Liu, Jinbao; Jiang, Lili] Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou 511436, Peoples R China; [Chen, Xuhong] Southern Univ Sci & Technol Hosp, Med Res Ctr, Shenzhen 518055, Peoples R China; [Zhou, Zhongqiu] Sichuan Univ, Alliance Hosp West China Univ Hosp 2, Meishan Women & Childrens Hosp, Meishan 620000, Peoples R China; [Pan, Jinyuan] Yangtze Univ, Dept Oncol, Huanggang Cent Hosp, Huanggang 438000, Peoples R China; [Tang, Ruiming; Feng, Zhengfu; Zhou, Lihuan] Guangzhou Med Univ, Qingyuan Peoples Hosp, Affiliated Hosp 6, Guangzhou 511518, Peoples R China; [Zhu, Dachun] Shenzhen Baoan Womens & Childirens Hosp, Dept Operating Room, Shenzhen 518000, Peoples R China; [Yang, Jianan] Guangzhou Med Univ, Dept Urol Oncosurg, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China; [Wang, Lan] Guangdong Pharmaceut Univ, Sch Basic Courses, Dept Pathogen Biol & Immunol, Guangzhou 510006, Peoples R China; [Tang, Daolin] UT Southwestern Med Ctr, Dept Surg, Dallas, TX 75390 USA	Guangzhou Medical University; Guangzhou Medical University; Southern University of Science & Technology; Sichuan University; Yangtze University; Guangzhou Medical University; Guangzhou Medical University; Guangdong Pharmaceutical University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Liu, JB; Jiang, LL (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China.; Liu, JB; Jiang, LL (corresponding author), Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou 511436, Peoples R China.	jliu@gzhmu.edu.cn; jianglili@gzhmu.edu.cn			Basic and Applied Research Projects of Guangzhou Science and Technology Bureau [202002030067]; Natural Science Foundation of China [82273464, 81972619, 81672874, 81972399]; Natural Science Foundation of Guangdong Province [2021A1515012477, 2022A1515012260]; Key Discipline of Guangzhou Education Bureau (Basic Medicine) [201851839]; Natural Science Foundation research team of Guangdong Province [2018B030312001]; Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital [202011-202]; Innovative Academic Team of Guangzhou Education System [1201610014]; Guangzhou key medical discipline construction project fun	Basic and Applied Research Projects of Guangzhou Science and Technology Bureau; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Key Discipline of Guangzhou Education Bureau (Basic Medicine); Natural Science Foundation research team of Guangdong Province; Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital; Innovative Academic Team of Guangzhou Education System; Guangzhou key medical discipline construction project fun	This work was supported by the Basic and Applied Research Projects of Guangzhou Science and Technology Bureau (202002030067), the Natural Science Foundation of China (82273464, 81972619, 81672874, and 81972399), the Natural Science Foundation of Guangdong Province (2021A1515012477 and 2022A1515012260), the Key Discipline of Guangzhou Education Bureau (Basic Medicine) (201851839), the Natural Science Foundation research team of Guangdong Province (2018B030312001), the open research funds from the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital (202011-202), the Innovative Academic Team of Guangzhou Education System (1201610014), and the Guangzhou key medical discipline construction project fun.	Abels ER, 2019, TRENDS CANCER, V5, P393, DOI 10.1016/j.trecan.2019.05.006; Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Aoshima M, 2019, J DERMATOL SCI, V95, P107, DOI 10.1016/j.jdermsci.2019.07.009; Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009; Bist P, 2011, ONCOGENE, V30, P3174, DOI 10.1038/onc.2011.28; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Cahill KE, 2016, NEURO-ONCOLOGY, V18, P329, DOI 10.1093/neuonc/nov265; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Cheng J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01189-3; de Vrij J, 2015, INT J CANCER, V137, P1630, DOI 10.1002/ijc.29521; Delgado-Lopez PD, 2016, CLIN TRANSL ONCOL, V18, P1062, DOI 10.1007/s12094-016-1497-x; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Gao XF, 2020, CELL REP, V30, P2489, DOI 10.1016/j.celrep.2020.01.089; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Ji JX, 2021, CELL DEATH DIFFER, V28, P367, DOI 10.1038/s41418-020-00606-w; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lauko A, 2022, SEMIN CANCER BIOL, V82, P162, DOI 10.1016/j.semcancer.2021.02.014; Lee IY, 2019, MOL CELL, V73, P1138, DOI 10.1016/j.molcel.2019.01.022; Liu YF, 2020, AGING-US, V12, P21559, DOI 10.18632/aging.103945; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; Matsui T, 2004, GENOMICS, V84, P384, DOI 10.1016/j.ygeno.2004.03.010; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Niu JX, 2011, EMBO J, V30, P3741, DOI 10.1038/emboj.2011.264; Oushy S, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0477; Park GT, 2002, J BIOL CHEM, V277, P45195, DOI 10.1074/jbc.M205380200; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Pribyl M, 2021, GENES-BASEL, V12, DOI 10.3390/genes12010108; Pribyl M, 2020, MOL ONCOL, V14, P2403, DOI 10.1002/1878-0261.12768; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Raychaudhuri B, 2007, J NEURO-ONCOL, V85, P39, DOI 10.1007/s11060-007-9390-7; Sarkar S, 2009, J NEURO-ONCOL, V91, P157, DOI 10.1007/s11060-008-9695-1; Song K, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI129374; Srivastava C, 2020, BMC CANCER, V20, DOI 10.1186/s12885-019-6435-1; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Wang SS, 2017, MOL THER-NUCL ACIDS, V8, P482, DOI 10.1016/j.omtn.2017.07.015; Wei S, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13090; Wertz IE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003350; Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011; Wu YB, 2018, AM J TRANSL RES, V10, P881; Yamamoto M, 2006, NAT IMMUNOL, V7, P962, DOI 10.1038/ni1367; Yang YB, 2014, CANCER DISCOV, V4, P480, DOI 10.1158/2159-8290.CD-13-0915; Yanovich-Arad G, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108787; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	52	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5253	5265		10.1038/s41388-022-02520-6	http://dx.doi.org/10.1038/s41388-022-02520-6		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316443				2022-12-28	WOS:000876857500001
J	Song, YL; Yang, MH; Zhang, S; Wang, H; Kai, KL; Yao, CX; Dai, FF; Zhou, MJ; Li, JB; Wei, ZR; Yin, ZN; Zhu, WG; Xue, LX; Zang, MX				Song, Yang-Liu; Yang, Ming-Hui; Zhang, Si; Wang, Hao; Kai, Kun-Lun; Yao, Chun-Xia; Dai, Fei-Fei; Zhou, Meng-Jiao; Li, Jin-Biao; Wei, Zhi-Ru; Yin, Zhongnan; Zhu, Wei-Guo; Xue, Lixiang; Zang, Ming-Xi			A GRIP-1-EZH2 switch binding to GATA-4 is linked to the genesis of rhabdomyosarcoma through miR-29a	ONCOGENE			English	Article							CYCLIN D1; DIFFERENTIATION; EXPRESSION; POLYCOMB; PROLIFERATION; PATHOGENESIS; PAX3-FOXO1; REPRESSES; GROWTH; CELLS	Terminal differentiation failure is an important cause of rhabdomyosarcoma genesis, however, little is known about the epigenetic regulation of aberrant myogenic differentiation. Here, we show that GATA-4 recruits polycomb group proteins such as EZH2 to negatively regulate miR-29a in undifferentiated C2C12 myoblast cells, whereas recruitment of GRIP-1 to GATA-4 proteins displaces EZH2, resulting in the activation of miR-29a during myogenic differentiation of C2C12 cells. Moreover, in poorly differentiated rhabdomyosarcoma cells, EZH2 still binds to the miR-29a promoter with GATA-4 to mediate transcriptional repression of miR-29a. Interestingly, once re-differentiation of rhabdomyosarcoma cells toward skeletal muscle, EZH2 was dispelled from miR-29a promoter which is similar to that in myogenic differentiation of C2C12 cells. Eventually, this expression of miR-29a results in limited rhabdomyosarcoma cell proliferation and promotes myogenic differentiation. We thus establish that GATA-4 can function as a molecular switch in the up- and downregulation of miR-29a expression. We also demonstrate that GATA-4 acts as a tumor suppressor in rhabdomyosarcoma partly via miR-29a, which thus provides a potential therapeutic target for rhabdomyosarcoma.	[Song, Yang-Liu; Yang, Ming-Hui; Zhang, Si; Kai, Kun-Lun; Yao, Chun-Xia; Dai, Fei-Fei; Zhou, Meng-Jiao; Li, Jin-Biao; Zang, Ming-Xi] Zhengzhou Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Zhengzhou, Peoples R China; [Wang, Hao; Yin, Zhongnan; Xue, Lixiang] Peking Univ Third Hosp, Ctr Basic Med Res, Inst Med Innovat & Res, 49 North Garden Rd, Beijing 100191, Peoples R China; [Wei, Zhi-Ru] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Zhu, Wei-Guo] Shenzhen Univ, Dept Biochem & Mol Biol, Sch Med, Shenzhen 518055, Peoples R China; [Xue, Lixiang] Peking Univ Third Hosp, Canc Ctr Peking Univ Third Hosp, Beijing 100191, Peoples R China	Zhengzhou University; Zhengzhou University; Shenzhen University	Zang, MX (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Zhengzhou, Peoples R China.; Xue, LX (corresponding author), Peking Univ Third Hosp, Ctr Basic Med Res, Inst Med Innovat & Res, 49 North Garden Rd, Beijing 100191, Peoples R China.; Xue, LX (corresponding author), Peking Univ Third Hosp, Canc Ctr Peking Univ Third Hosp, Beijing 100191, Peoples R China.	lixiangxue@hsc.pku.edu.cn; mzang@zzu.edu.cn			National Natural Science Foundation of China [82072975, 81771631, 81672091, 91749107]; High-Level Talents of Henan Province; Central Plains Basic Research [ZYQR201810120]; 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines); key project of discipline construction of Zhengzhou University in 2020 [XKZDQY202002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); High-Level Talents of Henan Province; Central Plains Basic Research; 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines); key project of discipline construction of Zhengzhou University in 2020	This study was supported by the National Natural Science Foundation of China (No. 82072975, 81771631, 81672091, and 91749107), the High-Level Talents of Henan Province, particularly the support for the Central Plains Thousand Talents Program, which are the leading talents of Central Plains Basic Research (ZYQR201810120), 2022 Henan Province Science and Technology R&D Program Joint Fund (Cultivation of Superior Disciplines), and the key project of discipline construction of Zhengzhou University in 2020 (XKZDQY202002).	Achour C, 2018, FRONT BIOSCI-LANDMRK, V23, P2106, DOI 10.2741/4693; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Ballarino M, 2016, J CLIN INVEST, V126, P2021, DOI 10.1172/JCI84419; Bersani F, 2016, CANCER RES, V76, P6095, DOI 10.1158/0008-5472.CAN-16-0709; Bevilacqua A, 2014, CARDIOVASC PATHOL, V23, P85, DOI 10.1016/j.carpath.2013.09.003; Cai R, 2018, J BIOL CHEM, V293, P19177, DOI 10.1074/jbc.RA118.003198; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01458; Chen SL, 2000, GENE DEV, V14, P1209; Chikenji A, 2016, J ORAL SCI, V58, P219, DOI 10.2334/josnusd.15-0684; Chinenov Y, 2012, P NATL ACAD SCI USA, V109, P11776, DOI 10.1073/pnas.1206059109; Ciesla M, 2014, INT J BIOCHEM CELL B, V53, P482, DOI 10.1016/j.biocel.2014.05.003; Dai XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0485-1; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; DiPiazza ARC, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100699118; Hanna JA, 2018, ONCOGENE, V37, P1991, DOI 10.1038/s41388-017-0081-3; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Healy E, 2019, MOL CELL, V76, P437, DOI 10.1016/j.molcel.2019.08.012; Hinson ARP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00183; Irrcher I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003614; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kouznetsova VL, 2019, PROTEIN SCI, V28, P1387, DOI 10.1002/pro.3647; Ma CX, 2015, CELL MOL LIFE SCI, V72, P2005, DOI 10.1007/s00018-014-1795-9; Megiorni F, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102673; Mikhailov AT, 2016, HEART FAIL REV, V21, P783, DOI 10.1007/s10741-016-9569-0; Missiaglia E, 2017, CANCER LETT, V385, P251, DOI 10.1016/j.canlet.2016.10.011; Pandey PR, 2017, J PATHOL, V241, P626, DOI 10.1002/path.4867; Qiu H, 2016, CELL DEATH DIFFER, V23, P1658, DOI 10.1038/cdd.2016.56; Qu Y, 2016, NUCLEIC ACIDS RES, V44, P7659, DOI 10.1093/nar/gkw463; Schwartz YB, 2014, CELL REP, V8, P321, DOI 10.1016/j.celrep.2014.07.001; Sun M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.225; Vella S, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0107-z; Vu LP, 2013, INT J HEMATOL, V97, P198, DOI 10.1007/s12185-012-1247-y; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Wannenes F, 2008, MOL CELL ENDOCRINOL, V292, P11, DOI 10.1016/j.mce.2008.05.018; Wei W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.184; Whitcomb J, 2020, IUBMB LIFE, V72, P53, DOI 10.1002/iub.2163; Xiong CJ, 2013, J CELL BIOCHEM, V114, P2708, DOI 10.1002/jcb.24619; Yao CX, 2015, J CELL BIOCHEM, V116, P1755, DOI 10.1002/jcb.25134; Yao CX, 2013, RNA BIOL, V10, P465, DOI 10.4161/rna.24370; Yao CX, 2012, J MOL BIOL, V415, P143, DOI 10.1016/j.jmb.2011.11.011; Zhang S, 2019, J CELL PHYSIOL, V234, P13252, DOI 10.1002/jcp.27997	43	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5223	5237		10.1038/s41388-022-02521-5	http://dx.doi.org/10.1038/s41388-022-02521-5		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36309571				2022-12-28	WOS:000875805200001
J	ROSENZWEIG, RM				ROSENZWEIG, RM			RESOLUTION OF THE INDIRECT COST ISSUE	FASEB JOURNAL			English	Editorial Material											ROSENZWEIG, RM (corresponding author), ASSOC AMER UNIV,1 DUPONT CIRCLE NW,SUITE 730,WASHINGTON,DC 20036, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1992	6	14					3236	3237		10.1096/fasebj.6.14.1426761	http://dx.doi.org/10.1096/fasebj.6.14.1426761			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426761				2022-12-28	WOS:A1992JZ73400003
J	ARZATE, H; OLSON, SW; PAGE, RC; GOWN, AM; NARAYANAN, AS				ARZATE, H; OLSON, SW; PAGE, RC; GOWN, AM; NARAYANAN, AS			PRODUCTION OF A MONOCLONAL-ANTIBODY TO AN ATTACHMENT PROTEIN DERIVED FROM HUMAN CEMENTUM	FASEB JOURNAL			English	Article						CEMENTUM; ATTACHMENT PROTEIN; ANTIBODY TO ATTACHMENT PROTEIN; FIBROBLASTS	HUMAN GINGIVAL FIBROBLASTS; PERIODONTAL-LIGAMENT; BONE SIALOPROTEIN; MINERALIZED TISSUES; INVITRO; CELLS; OSTEOPONTIN; EXTRACTS; DENTIN	Cementum is the mineralized structure that covers the surface of the roots of teeth; it serves as the attachment site for collagen fibers of adjacent soft connective tissues. Very little is known about how cementum formation is regulated or how it affects other periodontal structures. We have raised a monoclonal antibody that may aid in studies to determine the biology and function of cementum. Mice were immunized with a 55-kDa attachment protein partially purified from human cementum and a monoclonal antibody, H166, was produced. Incubation of tissue sections with this antibody and fluorescein isothiocyanate-conjugated secondary antibody revealed that it immunostains cementum but not dentin, gingiva, or periodontal ligament. Alveolar bone did not bind the antibody, although a few paravascular cells were positive. Long bones, kidney, liver, skin, and several other tissues were negative. Protein fractions separated from cementum extracts by binding to immobilized H166 column contained 55-, 49-, 39-, 29- to-31-, and 23- to 26-kDa components that cross-reacted with the antibody in Western blots; these components were previously shown to be derived from a common precursor. We conclude that the antibody recognizes a group of proteins related to 55-kDa attachment protein in cementum. Our data show that the antibody could serve as a marker for cementum.	UNIV WASHINGTON,SCH MED,DEPT PATHOL,SM-30,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,ORAL BIOL RES CTR,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Arzate, Higinio/K-1934-2019		NCI NIH HHS [CA-36250] Funding Source: Medline; NIDCR NIH HHS [DE-08229] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARZATE H, 1991, IN PRESS BONE MINER; BARTOLD PM, 1990, MATRIX, V10, P10, DOI 10.1016/S0934-8832(11)80132-0; BARTOLD PM, 1988, J PERIODONTAL RES, V23, P13, DOI 10.1111/j.1600-0765.1988.tb01020.x; BIRKEDALHANSEN H, 1977, CALC TISS RES, V23, P39, DOI 10.1007/BF02012764; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHO MI, 1989, ANAT REC, V223, P209, DOI 10.1002/ar.1092230214; CHRISTNER P, 1977, CALC TISS RES, V23, P147, DOI 10.1007/BF02012780; FISHER LW, 1987, J BIOL CHEM, V262, P9702; GLIMCHER MJ, 1989, CALCIFIED TISSUE INT, V45, P165, DOI 10.1007/BF02556060; KAZUGAI S, 1991, BONE MINER, V13, P235; MCALLISTER B, 1990, J PERIODONTAL RES, V25, P99, DOI 10.1111/j.1600-0765.1990.tb00899.x; MCCULLOCH CAG, 1987, ANAT RECORD, V219, P233, DOI 10.1002/ar.1092190304; MCCURDY SP, 1990, ARCH ORAL BIOL, V35, P347, DOI 10.1016/0003-9969(90)90181-9; MELCHER AH, 1986, J PERIODONTAL RES, V21, P592, DOI 10.1111/j.1600-0765.1986.tb01497.x; Melcher AH, 1988, PERIODONTOLOGY TODAY, P6; MIKI Y, 1987, J DENT RES, V66, P1399, DOI 10.1177/00220345870660082301; NAGATA T, 1991, BIOCHEM J, V274, P513, DOI 10.1042/bj2740513; NARAYANAN AS, 1985, J DENT RES, V64, P1111, DOI 10.1177/00220345850640090201; NISHIMURA K, 1989, J PERIODONTAL RES, V24, P146, DOI 10.1111/j.1600-0765.1989.tb00869.x; OLSON S, 1991, J DENT RES, V70, P1272, DOI 10.1177/00220345910700090801; POLSON AM, 1986, J CLIN PERIODONTOL, V13, P995; Slavkin HC, 1988, J PERIODONTAL RES, V23, P28; SOMERMAN MJ, 1987, ARCH ORAL BIOL, V32, P879, DOI 10.1016/0003-9969(87)90101-4; SOMERMAN MJ, 1991, J PERIODONTAL RES, V26, P10, DOI 10.1111/j.1600-0765.1991.tb01620.x; SOMERMAN MJ, 1987, J PERIODONTOL, V58, P349, DOI 10.1902/jop.1987.58.5.349; TSUKADA T, 1987, AM J PATHOL, V126, P51	27	68	75	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2990	2995		10.1096/fasebj.6.11.1644261	http://dx.doi.org/10.1096/fasebj.6.11.1644261			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644261				2022-12-28	WOS:A1992JJ66500013
J	PETERSON, TV; BENJAMIN, BA				PETERSON, TV; BENJAMIN, BA			THE HEART AND CONTROL OF RENAL EXCRETION - NEURAL AND ENDOCRINE MECHANISMS	FASEB JOURNAL			English	Article						CARDIAC RECEPTORS; ATRIAL PEPTIDES; BLOOD VOLUME CONTROL; RENAL FUNCTION	ATRIAL-NATRIURETIC-FACTOR; ANF PROHORMONE NH2-TERMINUS; COLLECTING DUCT CELLS; CONSCIOUS DOGS; VOLUME EXPANSION; SODIUM-EXCRETION; BLOOD-VOLUME; TRANSPLANT RECIPIENTS; OXYGEN-CONSUMPTION; NORMAL HUMANS	There has been a great deal of research concerning the heart being an important regulator of renal fluid and electrolyte excretion. This cardiac-renal connection involves two different types of major mechanisms, both of which are covered in this review. The first of these to bc discovered was neural reflex regulation. This type of control is due to the fact that the heart possesses nerve receptors whose activity is altered by changes in the degree of cardiac stretch that occur as a result of changes in blood volume. These receptors affect various humoral, neural, and perhaps hemodynamic mechanisms that modify renal excretion. A second, more recently discovered type of regulation is based on the concept that the heart is also an endocrine gland. Similar to neural receptor activity, cardiac hormone secretion is also linked to the degree of cardiac stretch or filling. These cardiac peptides have been shown to have a variety of physiologic effects, most of which directly or indirectly affect renal excretion. Both of the above cardiorenal control mechanisms, one neural and one humoral, may be important not only in maintaining normal fluid-electrolyte balance but may also have pathophysiologic relevance.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DIV PHYSIOL,DURHAM,NC 27710	Duke University	PETERSON, TV (corresponding author), TEXAS A&M UNIV SYST,HLTH SCI CTR,DEPT MED PHYSIOL,REYNOLDS MED BLDG,COLL STN,TX 77843, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031987, R29HL041028, K04HL001383] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL01383, HL41028, HL31987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNAULD E, 1977, PFLUG ARCH EUR J PHY, V371, P193, DOI 10.1007/BF00586258; BALLERMANN BJ, 1991, KIDNEY, P510; BENJAMIN BA, 1988, AM J PHYSIOL, V254, pR699, DOI 10.1152/ajpregu.1988.254.4.R699; BENJAMIN BA, 1988, FASEB J, V2, pA306; BENJAMIN BA, 1991, FASEB J, V5, pA672; BLAINE EH, 1990, HYPERTENSION, V15, P2, DOI 10.1161/01.HYP.15.1.2; BLAINE EH, 1986, J HYPERTENS, V4, pS17; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CORNISH KG, 1982, AM J PHYSIOL, V243, pR119, DOI 10.1152/ajpregu.1982.243.1.R119; COWLEY AW, 1988, AM J PHYSIOL, V255, pH144, DOI 10.1152/ajpheart.1988.255.1.H144; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DIETZ JR, 1991, AM J PHYSIOL, V260, pH1774, DOI 10.1152/ajpheart.1991.260.6.H1774; DING JF, 1987, ENDOCRINOLOGY, V121, P248, DOI 10.1210/endo-121-1-248; EGAN B, 1984, HYPERTENSION, V6, P832, DOI 10.1161/01.HYP.6.6.832; FATER DC, 1982, AM J PHYSIOL, V242, P1056; FERGUSON DW, 1984, CIRCULATION, V69, P451, DOI 10.1161/01.CIR.69.3.451; FRANCIS GS, 1985, AM J CARDIOL, V55, pA15, DOI 10.1016/0002-9149(85)90791-X; FUKUDA Y, 1988, BIOCHEM BIOPH RES CO, V155, P167, DOI 10.1016/S0006-291X(88)81064-7; GAGELMANN M, 1988, FEBS LETT, V233, P249, DOI 10.1016/0014-5793(88)80436-8; GARDNER DG, 1986, BIOCHEM BIOPH RES CO, V139, P1047, DOI 10.1016/S0006-291X(86)80283-2; GARDNER DG, 1987, MOL ENDOCRINOL, V1, P260, DOI 10.1210/mend-1-3-260; GENOVESI S, 1990, J HYPERTENS, V8, P703, DOI 10.1097/00004872-199008000-00003; Goetz K, 1991, REFLEX CONTROL CIRCU, P291; GOETZ KL, 1990, HYPERTENSION, V15, P9, DOI 10.1161/01.HYP.15.1.9; GOETZ KL, 1986, AM J PHYSIOL, V250, pR946, DOI 10.1152/ajpregu.1986.250.5.R946; GOLDSMITH SR, 1982, AM J PHYSIOL, V243, pH970, DOI 10.1152/ajpheart.1982.243.6.H970; Grassi G, 1988, Am J Med, V84, P97, DOI 10.1016/0002-9343(88)90212-4; GREENWALD JE, 1988, J CLIN INVEST, V81, P1036, DOI 10.1172/JCI113414; HAINSWORTH R, 1991, PHYSIOL REV, V71, P617, DOI 10.1152/physrev.1991.71.3.617; HAJDUCZOK G, 1987, AM J PHYSIOL, V253, pR242, DOI 10.1152/ajpregu.1987.253.2.R242; HARTSHORNE H, 1847, WATER VERSUS HYDROTH, P28; HENRY JP, 1956, J PHYSIOL-LONDON, V131, P572, DOI 10.1113/jphysiol.1956.sp005483; HENRY JP, 1956, CIRC RES, V4, P85, DOI 10.1161/01.RES.4.1.85; HIRTH C, 1986, J CARDIOVASC PHARM, V8, P268, DOI 10.1097/00005344-198603000-00008; INAGAMI T, 1989, CONTEMP ISS NEPHROL, V21, P25; KACZMARCZYK G, 1981, PFLUG ARCH EUR J PHY, V390, P125, DOI 10.1007/BF00590194; KARIM F, 1972, J PHYSIOL-LONDON, V227, P243, DOI 10.1113/jphysiol.1972.sp010030; KOPP VC, 1991, REFLEX CONTROL CIRCU, P493; LEDSOME JR, 1985, LIFE SCI, V36, P1315, DOI 10.1016/0024-3205(85)90036-0; LINDEN RJ, 1987, CARDIOGENIC REFLEXES, P18; LOTSHAW DP, 1989, CONTEMP ISS NEPHROL, V21, P137; MARTIN DR, 1990, AM J PHYSIOL, V258, pF1401, DOI 10.1152/ajprenal.1990.258.5.F1401; MARTIN ER, 1989, CONTEMP ISS NEPHROL, V21, P105; MARY DAS, 1987, CARDIOGENIC REFLEXES, P3; MENDEZ RE, 1987, AM J PHYSIOL, V253, pH1449, DOI 10.1152/ajpheart.1987.253.6.H1449; Minisi A. J., 1991, REFLEX CONTROL CIRCU, P359; Niijima A., 1991, REFLEX CONTROL CIRCU, P529; NISHIDA Y, 1987, AM J PHYSIOL, V253, pF1164; NORTHRIDGE DB, 1989, LANCET, V2, P591; PAINTAL AS, 1979, CARDIAC RECEPTORS, P73; PETERSON TV, 1983, CIRC RES, V53, P24, DOI 10.1161/01.RES.53.1.24; PETERSON TV, 1991, REFLEX CONTROL CIRCU, P313; PICHET R, 1988, AM J PHYSIOL, V254, pF780, DOI 10.1152/ajprenal.1988.254.6.F780; PRUSZCZYNSKI W, 1987, CLIN NEPHROL, V28, P65; REINECK HJ, 1985, KIDNEY PHYSL PATHOPH, P1137; REINHARDT HW, 1987, CARDIOGENIC REFLEXES, P140; RICHARDS AM, 1990, J CARDIOVASC PHARM, V16, pS39; SAKATA M, 1988, BIOCHEM BIOPH RES CO, V155, P990, DOI 10.1016/S0006-291X(88)80594-1; SCHULZKNAPPE P, 1988, KLIN WOCHENSCHR, V66, P752, DOI 10.1007/BF01726570; SCHWARTZ JC, 1990, LIFE SCI, V47, P1279, DOI 10.1016/0024-3205(90)90192-T; SONNENBERG H, 1984, BIOCHEM BIOPH RES CO, V124, P443, DOI 10.1016/0006-291X(84)91573-0; SREEHARAN N, 1981, Q J EXP PHYSIOL CMS, V66, P163, DOI 10.1113/expphysiol.1981.sp002543; STRIBLEY J, 1987, FASEB J, V46, P797; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; VATNER SF, 1986, AM J PHYSIOL, V250, pH546, DOI 10.1152/ajpheart.1986.250.4.H546; VERBURG KM, 1986, AM J PHYSIOL, V251, pR947, DOI 10.1152/ajpregu.1986.251.5.R947; VESELY DL, 1989, P SOC EXP BIOL MED, V192, P230; WILKINS MR, 1988, CARDIOVASC RES, V22, P231, DOI 10.1093/cvr/22.4.231; WINTERS CJ, 1989, CIRCULATION, V80, P438, DOI 10.1161/01.CIR.80.3.438; WONG NLM, 1988, AM J PHYSIOL, V255, pE260, DOI 10.1152/ajpendo.1988.255.3.E260; ZEIDEL ML, 1986, AM J PHYSIOL, V251, pF379, DOI 10.1152/ajprenal.1986.251.2.F379; ZEIDEL ML, 1989, CONTEMP ISS NEPHROL, V21, P191; ZUCKER IH, 1975, BRAIN RES, V95, P159, DOI 10.1016/0006-8993(75)90217-6; ZUCKER IH, 1980, J PHARMACOL EXP THER, V212, P320; ZUCKER IH, 1977, J CLIN INVEST, V60, P323, DOI 10.1172/JCI108780; Zucker IH, 1991, REFLEX CONTROL CIRCU	76	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2923	2932		10.1096/fasebj.6.11.1386584	http://dx.doi.org/10.1096/fasebj.6.11.1386584			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1386584				2022-12-28	WOS:A1992JJ66500006
J	SCHUT, HAJ; SHIVERICK, KT				SCHUT, HAJ; SHIVERICK, KT			DNA ADDUCTS IN HUMANS AS DOSIMETERS OF EXPOSURE TO ENVIRONMENTAL, OCCUPATIONAL, OR DIETARY GENOTOXINS	FASEB JOURNAL			English	Article						SMOKING-RELATED DNA ADDUCTS; WHITE BLOOD CELL DNA ADDUCTS; HUMAN TISSUE ADDUCTS; DIET-RELATED DNA ADDUCTS; MOLECULAR EPIDEMIOLOGY; CANCER EPIDEMIOLOGY; P-32-POSTLABELING; IMMUNOASSAYS; DNA ADDUCT-RELATED CANCER RISK	WHITE BLOOD-CELLS; P-32 POSTLABELING ANALYSIS; COKE-OVEN WORKERS; POLYCYCLIC AROMATIC-HYDROCARBONS; SISTER CHROMATID EXCHANGE; NUCLEIC-ACID ADDUCTS; HUMAN PLACENTAL DNA; P-32-POSTLABELING ANALYSIS; URINARY 3-METHYLADENINE; FOUNDRY WORKERS	The quantitation of adducts of genotoxins with DNA is probably one of the best indicators of genetic damage due to exposure to toxins or carcinogens. It is generally believed that such adducts can lead to mutations, which in turn can trigger the initiation of the carcinogenic process. DNA adducts have been quantitated in white blood cells and in various tissues of smokers, persons in certain high-exposure occupations, and persons consuming foods contaminated with certain carcinogens. The feasibility of this approach for biochemical epidemiologic studies has been demonstrated using methods such as P-32-postlabeling, enzyme-linked immunosorbent assay, and synchronous fluorescence spectrophotometry. Relatively large interindividual differences in DNA adducts have been observed in both exposed and nonexposed persons. As a result, there are only a few studies in which clear quantitative and qualitative differences between these two groups have been observed. In addition, it appears that in some studies the P-32-postlabeling method does not detect the presence of the polycyclic aromatic hydrocarbon DNA adducts that are detectable by immunoassays. More extensive studies in additional populations at risk should shed further light on the utility of DNA adduct analysis in biochemical monitoring, especially if further refinements in methodology would result in increased sensitivity and specificity.	UNIV FLORIDA,COLL MED,DEPT PHARMACOL & THERAPEUT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida	SCHUT, HAJ (corresponding author), MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43699, USA.							CHACKO M, 1988, CARCINOGENESIS, V9, P2309, DOI 10.1093/carcin/9.12.2309; CUZICK J, 1990, INT J CANCER, V45, P673, DOI 10.1002/ijc.2910450417; Doll R, 1981, J NATL CANCER I, V66, P1192; DUNN BP, 1991, INT J CANCER, V48, P485, DOI 10.1002/ijc.2910480403; DUNN BP, 1986, CARCINOGENESIS, V7, P1115, DOI 10.1093/carcin/7.7.1115; EBERLE G, 1990, CARCINOGENESIS, V11, P1753, DOI 10.1093/carcin/11.10.1753; EVERSON RB, 1988, J NATL CANCER I, V80, P567, DOI 10.1093/jnci/80.8.567; EVERSON RB, 1986, SCIENCE, V231, P54, DOI 10.1126/science.3941892; FOILES PG, 1989, CARCINOGENESIS, V10, P1429, DOI 10.1093/carcin/10.8.1429; FOILES PG, 1988, CANCER RES, V48, P4184; FRIESEN MD, 1991, CHEM RES TOXICOL, V4, P102, DOI 10.1021/tx00019a014; GARNER RC, 1988, INT ARCH OCC ENV HEA, V60, P145, DOI 10.1007/BF00378689; GENESTE O, 1991, CARCINOGENESIS, V12, P1301, DOI 10.1093/carcin/12.7.1301; GROOPMAN JD, 1985, P NATL ACAD SCI USA, V82, P6492, DOI 10.1073/pnas.82.19.6492; GUPTA RC, 1985, CANCER RES, V45, P5656; HARRIS CC, 1985, P NATL ACAD SCI USA, V82, P6672, DOI 10.1073/pnas.82.19.6672; HATCH MC, 1990, CARCINOGENESIS, V11, P1673, DOI 10.1093/carcin/11.9.1673; HAUGEN A, 1986, CANCER RES, V46, P4178; HEMMINKI K, 1990, CARCINOGENESIS, V11, P1229, DOI 10.1093/carcin/11.7.1229; HEMMINKI K, 1983, ARCH TOXICOL, V52, P249, DOI 10.1007/BF00316495; HEMMINKI K, 1990, SCAND J WORK ENV HEA, V16, P158, DOI 10.5271/sjweh.1798; HOLZ O, 1990, INT ARCH OCC ENV HEA, V62, P299, DOI 10.1007/BF00640837; HSIEH LL, 1988, CANCER RES, V48, P6328; HUH NH, 1989, CANCER RES, V49, P93; IZZOTTI A, 1991, CARCINOGENESIS, V12, P1281, DOI 10.1093/carcin/12.7.1281; JAHNKE GD, 1990, CARCINOGENESIS, V11, P205, DOI 10.1093/carcin/11.2.205; LEE HS, 1989, GASTROENTEROLOGY, V97, P1281, DOI 10.1016/0016-5085(89)91700-9; LIOU SH, 1989, CANCER RES, V49, P4929; MANCHESTER DK, 1988, P NATL ACAD SCI USA, V85, P9243, DOI 10.1073/pnas.85.23.9243; MANCHESTER DK, 1990, CARCINOGENESIS, V11, P553, DOI 10.1093/carcin/11.4.553; MUSTONEN R, 1991, CARCINOGENESIS, V12, P1413; PERERA FP, 1987, J NATL CANCER I, V79, P449; PERERA FP, 1988, CANCER RES, V48, P2288; PERERA FP, 1988, MUTAT RES, V205, P225; PHILLIPS DH, 1990, LANCET, V335, P417, DOI 10.1016/0140-6736(90)90257-6; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; PHILLIPS DH, 1988, MUTAT RES, V204, P531, DOI 10.1016/0165-1218(88)90047-X; PHILLIPS DH, 1986, CARCINOGENESIS, V7, P2071, DOI 10.1093/carcin/7.12.2071; PREVOST V, 1990, CARCINOGENESIS, V11, P1747, DOI 10.1093/carcin/11.10.1747; RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341; RANDERATH E, 1988, CARCINOGENESIS, V9, P75, DOI 10.1093/carcin/9.1.75; RANDERATH E, 1986, CANCER RES, V46, P5869; RANDERATH K, 1985, ENVIRON HEALTH PERSP, V62, P57, DOI 10.2307/3430093; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; ROTHMAN N, 1990, CARCINOGENESIS, V11, P1241, DOI 10.1093/carcin/11.7.1241; SANTELLA RM, 1991, J ENVIRON SCI HEAL C, V9, P57; SAVELA K, 1991, CARCINOGENESIS, V12, P503, DOI 10.1093/carcin/12.3.503; SCHOKET B, 1991, MUTAT RES, V260, P89, DOI 10.1016/0165-1218(91)90084-Y; SEIDMAN LA, 1988, CARCINOGENESIS, V9, P1071, DOI 10.1093/carcin/9.6.1071; SHAMSUDDIN AKM, 1985, CANCER RES, V45, P66; SHUKER DEG, 1987, CARCINOGENESIS, V8, P959, DOI 10.1093/carcin/8.7.959; SPIGELMAN AD, 1991, CARCINOGENESIS, V12, P1727, DOI 10.1093/carcin/12.9.1727; TALASKA G, 1991, CANCER EPIDEM BIOMAR, V1, P61; UMBENHAUER D, 1985, INT J CANCER, V36, P661, DOI 10.1002/ijc.2910360607; VANSCHOOTEN FJ, 1990, J NATL CANCER I, V82, P927, DOI 10.1093/jnci/82.11.927; VANSCHOOTEN FJ, 1990, CARCINOGENESIS, V11, P1677, DOI 10.1093/carcin/11.9.1677; WESTON A, 1991, CARCINOGENESIS, V12, P1445, DOI 10.1093/carcin/12.8.1445; WILSON VL, 1989, CARCINOGENESIS, V10, P2149, DOI 10.1093/carcin/10.11.2149	58	38	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2942	2951		10.1096/fasebj.6.11.1644258	http://dx.doi.org/10.1096/fasebj.6.11.1644258			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644258				2022-12-28	WOS:A1992JJ66500008
J	HOLTZMAN, NA				HOLTZMAN, NA			THE DIFFUSION OF NEW GENETIC TESTS FOR PREDICTING DISEASE	FASEB JOURNAL			English	Review						GENETIC DISORDER; FAMILY-CENTERED TESTING; GENETIC SCREENING; PHENYLKETONURIA; GENETIC TEST KIT; NONGENETIC PHYSICIAN SPECIALIST; POPULATION-ORIENTED SCREENING; POTENTIAL TESTEE; GENETICS SPECIALIST; ASYMPTOMATIC RELATIVE; ALLELE; DNA TECHNOLOGY; CARRIER SCREENING	SICKLE-CELL-ANEMIA; SCREENING PROGRAMS; CHILDREN	This paper examines the pathways by which new genetic tests will become available to the public. In view of the scarcity of genetic specialists, the pathway is likely to involve primary care physicians. Other pathways entail state-mandated testing, community-based programs, or testing by laboratories without much involvement of primary care physicians. When testing does become available the "destination" will be either family-centered testing or population-oriented screening. The deterrent to screening will not be the inability to detect disease-causing mutations but the costs and attitudes of providers and the public. When tests are provided primarily to provide information about risks to future children, some people will oppose screening on religious or moral grounds. When there are no inexpensive treatments, some will fear that insurance companies and employers will use tests to deny them health care coverage. Some may not want to know their risks for disorders about which little can be done. For common, multifactorial disorders, genetic tests will have low predictive value. Because of these problems, the decision to be tested, regardless of the destination, requires that "testees" be fully informed and consent to testing. When acceptance rates are low, screening is less likely to be cost-effective; family-centered testing becomes the default destination.			HOLTZMAN, NA (corresponding author), JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA.				NHGRI NIH HHS [R01-HG00026] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000026] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BLUMENTHAL D, INT J TECHNOL ASSESS, V5, P579; BOTKIN JR, 1988, JAMA-J AM MED ASSOC, V259, P1541, DOI 10.1001/jama.259.10.1541; BOWMAN JE, 1977, PHYLON, V38, P117, DOI 10.2307/274676; CHILDS B, 1976, AM J HUM GENET, V28, P537; CLEMENS PR, 1991, AM J HUM GENET, V49, P951; CUTTING GR, 1992, MOL DIAGNOSTICS RES; DIXON AS, 1990, MED CARE, V28, P201, DOI 10.1097/00005650-199003000-00002; FADEN R, 1982, AM J PUBLIC HEALTH, V72, P1347, DOI 10.2105/AJPH.72.12.1347; FOST N, 1973, PEDIATRICS, V51, P742; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GOLDSTEIN MS, 1977, SOC SCI MED, V11, P515, DOI 10.1016/0037-7856(77)90030-0; HAMPTON ML, 1974, AM J DIS CHILD, V128, P58, DOI 10.1001/archpedi.1974.02110260060010; HOLTZMAN NA, 1992, AM J HUM GENET, V50, P457; HOLTZMAN NA, 1977, PEDIATRICS, V59, P131; HOLTZMAN NA, 1977, PEDIATRICS, V60, P932; HOLTZMAN NA, 1986, NEW ENGL J MED, V314, P593, DOI 10.1056/NEJM198603063141001; HOLTZMAN NA, 1970, ANNU REV MED, V21, P335, DOI 10.1146/annurev.me.21.020170.002003; HOLTZMAN NA, 1991, NEW ENGL J MED, V325, P802, DOI 10.1056/NEJM199109123251109; HOLTZMAN NA, 1989, PROCEED CAUTION; HOLTZMAN NA, 1992, J CLIN ETHIC, V2, P241; Holtzman Neil A., 1980, GENETICS LAW, p[247, 253]; KABACK MM, 1974, PROG MED GENET, V10, P103; KAN YW, 1978, LANCET, V2, P910; KESSLER S, 1989, AM J MED GENET, V34, P340, DOI 10.1002/ajmg.1320340310; Kessler Seymour, 1992, J Genet Couns, V1, P9, DOI 10.1007/BF00960080; LANGFELDER EJ, 1992, HUM GENOME NEWS, V3, P1; LIPPMANHAND A, 1979, AM J MED GENET, V4, P51, DOI 10.1002/ajmg.1320040108; LUSTIG L, 1988, AM J MED GENET, V31, P211, DOI 10.1002/ajmg.1320310128; MACCREADY RA, 1974, J PEDIATR-US, V85, P383, DOI 10.1016/S0022-3476(74)80124-1; MASSARIK F, 1981, GENETIC DISEASE CONT; MCQUEEN DV, 1975, SOC BIOL, V22, P125, DOI 10.1080/19485565.1975.9988157; NATOWICZ MR, 1992, AM J HUM GENET, V50, P465; NELKIN D, 1989, ANNU REV PUBL HEALTH, V10, P95, DOI 10.1146/annurev.pu.10.050189.000523; PRITCHARD C, 1991, AM J HUM GENET, V49, P1; Reilly P., 1977, GENETICS LAW SOCIAL; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VERLINSKY Y, 1991, AM J HUM GENET, V49, P22; 1990, NEW ENGL J MED, V323, P70; 1975, GENETIC SCREENING PR; 1983, SCREENING COUNSELING	41	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2806	2812		10.1096/fasebj.6.10.1634043	http://dx.doi.org/10.1096/fasebj.6.10.1634043			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634043				2022-12-28	WOS:A1992JD95400007
J	VILLALOBOS, C; FONTERIZ, R; LOPEZ, MG; GARCIA, AG; GARCIASANCHO, J				VILLALOBOS, C; FONTERIZ, R; LOPEZ, MG; GARCIA, AG; GARCIASANCHO, J			INHIBITION OF VOLTAGE-GATED CA2+ ENTRY INTO GH3 AND CHROMAFFIN CELLS BY IMIDAZOLE ANTIMYCOTICS AND OTHER CYTOCHROME-P450 BLOCKERS	FASEB JOURNAL			English	Note						CA2+ CHANNELS; CYTOCHROME-P-450; GH3 PITUITARY CELLS; ADRENAL CHROMAFFIN CELLS	OPERATED CALCIUM CHANNELS; ARACHIDONIC-ACID; HUMAN-PLATELETS; REDUCED GLUTATHIONE; ANTIFUNGAL AGENTS; MICROSOMES; CYTOCHROMES-P-450; MOBILIZATION; MODULATION; METABOLISM	We have studied the effects of cytochrome P450 inhibitors on the entry of Ca2+ and Mn2+, used here as a Ca2+ surrogate for Ca2+ channels, in fura-2-loaded GH3 pituitary cells and bovine chromaffin cells depolarized with high-K+ solutions. Imidazole antimycotics were potent inhibitors (econazole > miconazole > clotrimazole > ketoconazole). Alpha-naphtoflavone and isosafrole, but not metyrapone, also inhibited the entry of Ca2+ and Mn2+ induced by depolarization. This inhibitory profile most resembles that reported for IA-type cytochrome P450. However, carbon monoxide (CO), a well-known cytochrome P450 antagonist, had no effect on Ca2+ (Mn2+) entry. Given the high selectivity of the imidazole antimycotics for the heme moiety, our results suggest that a hemoprotein closely related to cytochrome P450 (but insensitive to CO) might be involved in the regulation of voltage-gated Ca2+ channels. The inhibitory pattern was also similar to that previously reported for agonist-induced Ca2+ (Mn2+) influx in neutrophils and platelets, although CO was an efficient inhibitor in this case. These results pose the question of whether similarities in the sensitivity to cytochrome P450 inhibitors exhibited by receptor-operated and voltage-gated channels reflect unknown similarities either in structural features or regulation mechanisms.	UNIV VALLADOLID,FAC MED,DEPT BIOQUIM & BIOL MOLEC & FISIOL,VALLADOLID,SPAIN; UNIV AUTONOMA MADRID,FAC MED,DEPT FARMACOL & TERAPEUT,MADRID 34,SPAIN	Universidad de Valladolid; Autonomous University of Madrid			Villalobos, Carlos/M-9839-2017; Fonteriz, Rosalba/ABE-3175-2021; Fonteriz, Rosalba I/L-1212-2014; GARCIA, ANTONIO G/E-9961-2018; Lopez, Manuela G/D-2164-2015; Garcia-Sancho, Javier/K-2975-2014	Villalobos, Carlos/0000-0002-0429-3846; Fonteriz, Rosalba/0000-0001-8349-6264; Fonteriz, Rosalba I/0000-0001-8349-6264; GARCIA, ANTONIO G/0000-0002-6517-3565; Lopez, Manuela G/0000-0003-4461-8788; Garcia-Sancho, Javier/0000-0003-4573-7930				AHOKAS JT, 1987, PHARMACOL TOXICOL, V61, P184, DOI 10.1111/j.1600-0773.1987.tb01800.x; ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ALONSO MT, 1989, BIOCHEM BIOPH RES CO, V162, P24, DOI 10.1016/0006-291X(89)91956-6; ALONSO MT, 1990, BIOCHEM J, V272, P435, DOI 10.1042/bj2720435; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V432, P681, DOI 10.1113/jphysiol.1991.sp018406; BALLARD SA, 1988, BIOCHEM PHARMACOL, V37, P4643, DOI 10.1016/0006-2952(88)90333-4; BOSSU JL, 1991, J PHYSIOL-LONDON, V437, P621, DOI 10.1113/jphysiol.1991.sp018615; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CIARDO A, 1990, EUR J PHARM-MOLEC PH, V188, P417, DOI 10.1016/0922-4106(90)90204-B; CROUCH MF, 1988, BIOCHEM BIOPH RES CO, V153, P21, DOI 10.1016/S0006-291X(88)81184-7; ERICKSON RR, 1987, J PHARMACOL EXP THER, V242, P472; Gandia L, 1990, Neuroreport, V1, P119, DOI 10.1097/00001756-199010000-00009; GARCIA AG, 1984, NATURE, V309, P69, DOI 10.1038/309069a0; GARCIASANCHO J, 1989, BIOCHEM SOC T, V17, P980, DOI 10.1042/bst0170980; GARCIASANCHO J, 1992, TRENDS PHARMACOL SCI, V13, P12, DOI 10.1016/0165-6147(92)90007-S; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KALMAN D, 1988, J GEN PHYSIOL, V92, P531, DOI 10.1085/jgp.92.4.531; KORN SJ, 1990, MOL PHARMACOL, V38, P524; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; MURRAY M, 1990, PHARMACOL REV, V42, P85; MURRAY M, 1988, BIOCHEM PHARMACOL, V37, P415, DOI 10.1016/0006-2952(88)90208-0; NEGISHI M, 1979, J BIOL CHEM, V254, P1015; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PRASAD JS, 1986, ARCH BIOCHEM BIOPHYS, V248, P639, DOI 10.1016/0003-9861(86)90518-7; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0	35	89	93	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2742	2747		10.1096/fasebj.6.9.1319362	http://dx.doi.org/10.1096/fasebj.6.9.1319362			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1319362				2022-12-28	WOS:A1992HZ48100017
J	GRONEMEYER, H				GRONEMEYER, H			CONTROL OF TRANSCRIPTION ACTIVATION BY STEROID-HORMONE RECEPTORS	FASEB JOURNAL			English	Review						TRANSCRIPTION ACTIVATION; STEROID RECEPTOR ACTION; REGULATORY MECHANISMS; SIGNAL TRANSDUCTION	HUMAN ESTROGEN-RECEPTOR; DNA-BINDING DOMAIN; GLUCOCORTICOID-RESPONSIVE ELEMENT; CHICKEN PROGESTERONE-RECEPTOR; THYROID-HORMONE; NUCLEAR-LOCALIZATION; AMINO-ACIDS; C-JUN; ENHANCER; SEQUENCE	Multiple regulatory mechanisms assure that signal transduction, involving the nuclear receptor interface, results in an accurate regulation of the respective gene networks. These mechanisms involve selective expression of the cognate receptor and its binding to specific hormone response elements of target genes. However, superimposed onto this "simple" control of activity is interpretation of the signal by the multiple functional modules of a given receptor, based on a specific interplay with 1) various factors binding to complex target gene promoters, 2) cell-specific transcription factors that mediate its enhancer function, and 3) other signaling pathways. This interpretation can be further modulated by the differential target gene specificities of receptor isoforms and, according to in vitro evidence, by factors that increase the efficiency of the receptor to interact with its response element. Thus, steroid hormone-regulated gene transcription involves a multitude of interactive elements, as is expected from the central role of nuclear receptors in homeostasis, embryonic development, and differentiation.			GRONEMEYER, H (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,F-67085 STRASBOURG,FRANCE.		Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/G-6240-2011	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAULIEU EE, 1990, ANN NY ACAD SCI, V595, P300, DOI 10.1111/j.1749-6632.1990.tb34304.x; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HAGER GL, 1991, NUCLEAR HORMONE RECE, P217; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; NAAR AM, 1991, CELL, V65, P1276; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PEKKI AK, 1991, J HISTOCHEM CYTOCHEM, V39, P1095, DOI 10.1177/39.8.1856457; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	68	217	218	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2524	2529		10.1096/fasebj.6.8.1592204	http://dx.doi.org/10.1096/fasebj.6.8.1592204			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592204				2022-12-28	WOS:A1992HU42300004
J	SWOPE, SL; MOSS, SJ; BLACKSTONE, CD; HUGANIR, RL				SWOPE, SL; MOSS, SJ; BLACKSTONE, CD; HUGANIR, RL			PHOSPHORYLATION OF LIGAND-GATED ION CHANNELS - A POSSIBLE MODE OF SYNAPTIC PLASTICITY	FASEB JOURNAL			English	Review						PROTEIN KINASES; SIGNAL TRANSDUCTION; NEUROTRANSMITTER RECEPTORS; ION CHANNELS	NICOTINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-KINASE-C; LONG-TERM POTENTIATION; RETINAL HORIZONTAL CELLS; GENE-RELATED PEPTIDE; CILIARY GANGLION NEURONS; CHICK MUSCLE-CELLS; GABAA-RECEPTOR; CYCLIC-AMP; SUBSTANCE-P	Most neurotransmitter receptors examined to date have been shown either to be regulated by protein phosphorylation or to contain consensus sequences for phosphorylation by protein kinases. Neurotransmitter receptors that mediate rapid synaptic transmission in the nervous system are the ligand-gated ion channels and include the nicotinic acetylcholine receptors of muscle and nerve and the excitatory and inhibitory amino acid receptors: the glutamate, GABA(A), and glycine receptors. These receptors are multimeric proteins composed of homologous subunits which each span the membrane several times and contain a large intracellular loop that is a mosaic of consensus sites for protein phosphorylation. Recent evidence has suggested that extracellular signals released from the presynaptic neuron, such as neurotransmitters and neuropeptides as well as an extracellular matrix protein, regulate the phosphorylation of ligand-gated ion channels. The functional effects of phosphorylation are varied and include the regulation of receptor desensitization rate, subunit assembly, and receptor aggregation at the synapse. These results suggest that phosphorylation of neurotransmitter receptors represents a major mechanism in the regulation of their function and may play an important role in synaptic plasticity.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,725 N WOLFE ST,900 PCTB,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								ALBUQUERQUE EX, 1986, FEBS LETT, V199, P113, DOI 10.1016/0014-5793(86)81235-2; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; CALPHAM DE, 1983, J PHYSIOL-LONDON, V347, P255; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; CREPEL F, 1988, BRAIN RES, V458, P397, DOI 10.1016/0006-8993(88)90486-6; DOWNING JEG, 1987, P NATL ACAD SCI USA, V84, P7739, DOI 10.1073/pnas.84.21.7739; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; EUSEBI F, 1987, J PHYSIOL-LONDON, V393, P635, DOI 10.1113/jphysiol.1987.sp016845; EUSEBI F, 1985, J CELL BIOL, V100, P1339, DOI 10.1083/jcb.100.4.1339; Gasic G P, 1991, Curr Opin Neurobiol, V1, P20, DOI 10.1016/0959-4388(91)90006-S; GREEN WN, 1991, P NATL ACAD SCI USA, V88, P854, DOI 10.1073/pnas.88.3.854; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GURANTZ D, 1991, Society for Neuroscience Abstracts, V17, P959; GYENES M, 1988, MOL PHARMACOL, V34, P719; HALVORSEN SW, 1990, J NEUROSCI, V10, P1711; HANLEY MR, 1980, MOL PHARMACOL, V18, P78; HARRISON NL, 1989, NEUROSCI LETT, V105, P137, DOI 10.1016/0304-3940(89)90025-6; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; HUGANIR RL, 1987, NEUROMODULATION BIOC, P86; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KANO M, 1987, NATURE, V325, P276, DOI 10.1038/325276a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KIRKNESS EF, 1989, BIOCHEM J, V259, P613, DOI 10.1042/bj2590613; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; KNAPP AG, 1990, P NATL ACAD SCI USA, V87, P767, DOI 10.1073/pnas.87.2.767; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; LEIDENHEIMER NJ, 1991, J NEUROCHEM, V57, P722, DOI 10.1111/j.1471-4159.1991.tb03806.x; LIMAN ER, 1989, BRAIN RES, V481, P399, DOI 10.1016/0006-8993(89)90822-6; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LINDSTROM J, 1987, MOL NEUROBIOL, V1, P281, DOI 10.1007/BF02935740; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MARGIOTTA JF, 1987, P NATL ACAD SCI USA, V84, P8155, DOI 10.1073/pnas.84.22.8155; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MCMAHAN UJ, 1989, DEV NEUROSCI-BASEL, V11, P227, DOI 10.1159/000111903; MIDDLETON P, 1988, J NEUROSCI, V8, P3405; MIDDLETON P, 1986, P NATL ACAD SCI USA, V83, P4967, DOI 10.1073/pnas.83.13.4967; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; MILES K, 1987, P NATL ACAD SCI USA, V84, P6591, DOI 10.1073/pnas.84.18.6591; MILES K, 1989, CRIT REV BIOCH MOL B, V24, P183; MORAN O, 1989, MOL BRAIN RES, V5, P193, DOI 10.1016/0169-328X(89)90035-1; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; ORTEGA A, 1990, J BIOL CHEM, V265, P21404; PENG HB, 1991, NEURON, V6, P237; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; ROLE LW, 1984, P NATL ACAD SCI-BIOL, V81, P2924, DOI 10.1073/pnas.81.9.2924; ROSS A, 1988, J CELL BIOL, V107, P1139, DOI 10.1083/jcb.107.3.1139; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; ROSS AF, 1987, J BIOL CHEM, V262, P14640; RUIZGOMEZ A, 1991, J BIOL CHEM, V266, P559; SAFRAN A, 1987, J BIOL CHEM, V262, P10506; SCHROEDER W, 1990, FEBS LETT, V273, P31, DOI 10.1016/0014-5793(90)81044-O; SCHROEDER W, 1991, BIOCHEMISTRY-US, V30, P3583, DOI 10.1021/bi00228a032; SESSLER FM, 1989, BRAIN RES, V499, P27, DOI 10.1016/0006-8993(89)91132-3; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SIMMONS LK, 1990, NEURON, V4, P393, DOI 10.1016/0896-6273(90)90051-G; SMITH MM, 1987, P NATL ACAD SCI USA, V84, P6601, DOI 10.1073/pnas.84.18.6601; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; STALLCUP WB, 1980, P NATL ACAD SCI-BIOL, V77, P634, DOI 10.1073/pnas.77.1.634; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; STEPHENSON FA, 1988, BIOCHEM J, V249, P21, DOI 10.1042/bj2490021; SWEETNAM PM, 1988, J NEUROCHEM, V51, P1274, DOI 10.1111/j.1471-4159.1988.tb03097.x; TEHRANI MHJ, 1989, SYNAPSE, V4, P126, DOI 10.1002/syn.890040206; TICKU MK, 1990, MOL PHARMACOL, V38, P719; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIJAYARAGHAVAN S, 1990, J NEUROSCI, V10, P3255; WADA K, 1989, NATURE, V342, P687; WAGNER K, 1991, J BIOL CHEM, V266, P23784; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WHITE MM, 1988, MOL PHARMACOL, V34, P427; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WROBLEWSKI JT, 1989, ANNU REV PHARMACOL, V29, P441, DOI 10.1146/annurev.pa.29.040189.002301; YEE GH, 1987, J BIOL CHEM, V262, P16748	99	228	232	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2514	2523		10.1096/fasebj.6.8.1375568	http://dx.doi.org/10.1096/fasebj.6.8.1375568			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1375568				2022-12-28	WOS:A1992HU42300003
J	JOHNSON, JE; HAINES, WJ				JOHNSON, JE; HAINES, WJ			ROLE OF AMINO-ACIDS IN HUMAN-NUTRITION .12.	FASEB JOURNAL			English	Article																		McCoy RH, 1935, J BIOL CHEM, V112, P283; ROSE W C, 1957, Nutr Abstr Rev, V27, P631; ROSE WC, 1954, J BIOL CHEM, V210, P331; ROSE WC, 1950, J BIOL CHEM, V182, P541; ROSE WC, 1942, J BIOL CHEM, V146, P683; ROSE WC, 1979, ANN NY ACAD SCI, V325, P229	6	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2361	2362		10.1096/fasebj.6.6.1544546	http://dx.doi.org/10.1096/fasebj.6.6.1544546			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544546				2022-12-28	WOS:A1992HJ25200015
J	PUGA, A; RAYCHAUDHURI, B; NEBERT, DW				PUGA, A; RAYCHAUDHURI, B; NEBERT, DW			TRANSCRIPTIONAL DEREPRESSION OF THE MURINE CYP1A-1-GENE BY MEVINOLIN	FASEB JOURNAL			English	Note						CYTOCHROME-P450; HMG COA REDUCTASE; QUINONE REDUCTASE; AH LOCUS; AH-RECEPTOR	HYDROCARBON HYDROXYLASE INDUCTION; PROTEIN-DNA INTERACTIONS; DIOXIN-RESPONSIVE ENHANCER; CYTOCHROME P-450C GENE; POLYCYCLIC AROMATIC-HYDROCARBONS; MOUSE HEPATOMA-CELLS; COENZYME-A REDUCTASE; CIS-ACTING ELEMENTS; ENZYME-ACTIVITY; 3-HYDROXY-3-METHYLGLUTARYL COENZYME	In mouse hepatoma Hepa-1c1c7 cultures, polycyclic aromatic compounds such as benzol[a]pyrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; dioxin) activate the Cyp1a-1 (cytochrome P(1)450) and Nmo-1[NAD(P)H:menadione oxidoreductase] genes, two members of the aromatic hydrocarbon (Ah)-responsive gene battery. Mevinolin is known to inhibit 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase (EC 1.1.1.34), the rate-limiting step in cholesterol biosynthesis. We show here that in the absence of TCDD, mevinolin markedly increases Cyp1a-1 transcription, CYP1A1 mRNA and protein levels and enzyme activity, and NMO1 mRNA concentrations. Addition of mevalonate, the product of HMG-CoA reductase activity, fails to reverse the effects of mevinolin. In fact, when used at high concentrations, mevalonate activates Cyp1a-1 transcription. Mevinolin-induced Cyp1a-1 gene activation: (1) occurs independently of the lipid content of the growth medium, (2) is not suppressed by adding 25-hydroxycholesterol, which blocks MHG-CoA reductase activity, and (3) requires a functional Ah receptor and unimpaired nuclear translocation of the receptor. It is possible that an unknown metabolite (or metabolites) of mevinolin activates Cyp1a-1 expression and that high concentrations of mevalonate act via the same mechanism. Using chimaeric plasmids that contain different lengths of Cyp1a-1 5' flanking regions fused to the bacterial neomycin (neo) gene, we find that the mevinolin effect on Cyp1a-1 induction requires the 5' flanking sequences between -1647 and -824, which are also needed for TCDD induction. Mevinolin, however, is not a ligand for the Ah receptor. Gel mobility shift assays revealed that Cyp1a-1 activation caused by mevinolin does not involve the ligand-dependent formation of a functional Ah receptor-dependent DNA-binding complex, but instead appears to be correlated with release of a putative repressor from its cognate DNA site. Our results suggest that the basel level of Cyp1a-1 transcription is maintained by an unknown negative regulatory factor. We propose that Cyp1a-1 transcriptional activation can result not only from induction by polycyclic aromatic compounds but also from derepression by mevinolin, independent of HMG-CoA reductase inhibition.	NICHHD,DEV PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	PUGA, A (corresponding author), UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,3223 EDEN AVE,CINCINNATI,OH 45267, USA.		Puga, Alvaro/B-7676-2008					BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CHEN YT, 1987, BIOCHEM BIOPH RES CO, V143, P863, DOI 10.1016/0006-291X(87)90329-9; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CONNEY AH, 1982, CANCER RES, V42, P4875; CUTHILL S, 1989, J STEROID BIOCHEM, V34, P375, DOI 10.1016/0022-4731(89)90111-8; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURRIN LK, 1987, MOL CELL BIOL, V7, P3008, DOI 10.1128/MCB.7.8.3008; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; ENDO A, 1985, REGULATION HMG COA R, P49; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GASIEWICZ TA, 1991, BIOCHEMISTRY-US, V30, P2905; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; GIELEN JE, 1972, J BIOL CHEM, V247, P7591; GIL G, 1986, J BIOL CHEM, V261, P3710; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P5040; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HANNAH RR, 1981, J BIOL CHEM, V256, P4584; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KIMURA S, 1987, EMBO J, V6, P1929, DOI 10.1002/j.1460-2075.1987.tb02453.x; KIMURA S, 1984, J BIOL CHEM, V259, P705; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NEBERT DW, 1990, ENVIRON HEALTH PERSP, V88, P13, DOI 10.2307/3431045; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1970, J BIOL CHEM, V245, P160; NEBERT DW, 1968, J BIOL CHEM, V243, P6242; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; NEUHOLD LA, 1986, DNA-J MOLEC CELL BIO, V5, P403, DOI 10.1089/dna.1986.5.403; OKEY AB, 1980, J BIOL CHEM, V255, P1415; OWENS IS, 1975, MOL PHARMACOL, V11, P94; OWENS IS, 1976, BIOCHEM PHARMACOL, V25, P805, DOI 10.1016/0006-2952(76)90151-9; PAINE AJ, 1980, CHEM-BIOL INTERACT, V30, P343, DOI 10.1016/0009-2797(80)90057-5; PANINI SR, 1986, J LIPID RES, V27, P1190; PELKONEN O, 1982, PHARMACOL REV, V34, P189; PUGA A, 1990, DNA CELL BIOL, V9, P425, DOI 10.1089/dna.1990.9.425; RAYCHAUDHURI B, 1990, MOL ENDOCRINOL, V4, P1773, DOI 10.1210/mend-4-12-1773; REPKO EM, 1989, J BIOL CHEM, V264, P9945; ROBERTSON JA, 1987, CHEM SCRIPTA, V27A, P83; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TUKEY RH, 1982, CELL, V31, P275, DOI 10.1016/0092-8674(82)90427-5; VYAS KP, 1990, DRUG METAB DISPOS, V18, P218; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1460	68	24	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					777	785		10.1096/fasebj.6.2.1311272	http://dx.doi.org/10.1096/fasebj.6.2.1311272			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1311272				2022-12-28	WOS:A1992GZ44000022
J	MONDER, C				MONDER, C			CORTICOSTEROIDS, RECEPTORS, AND THE ORGAN-SPECIFIC FUNCTIONS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE	FASEB JOURNAL			English	Article						11-BETA-HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; KIDNEY; BRAIN FUNCTION; TESTIS; HYPERTENSION	HUMAN MINERALOCORTICOID RECEPTOR; HUMAN-FETAL LUNG; RAT-KIDNEY; GLUCOCORTICOID RECEPTOR; NERVOUS-SYSTEM; 11-BETA-DEHYDROGENASE; CORTISOL; LOCALIZATION; ALDOSTERONE; BINDING	Reversible oxidation of the biologically active corticosteroids to the inactive 11-dehydrocorticosteroids is catalyzed by 11-beta-hydroxysteroid dehydrogenase (11-beta-HSD). The properties of the enzyme based on clinical observations of individuals with defective 11-beta-HSD expression, and laboratory studies of the properties and behavior of the enzyme, are consistent with separate 11-beta-dehydrogenase and 11-oxoreductase species. However, recombinant enzyme expressed in mammalian cells retain both activities, leading to the conclusion that 11-beta-HSD is a unique, reversible enzyme. 11-beta-HSD is present in most tissues, but its specific functions in most tissues are unknown. How the enzyme may mediate corticosteroid-receptor interaction is illustrated by studies using kidney, testis, and brain. In kidney, 11-beta-HSD prevents glucocorticoids from competing inappropriately with aldosterone for mineralocorticoid receptor (MR). Lack of enzyme in humans due to natural causes or inhibition by pharmacological agents results in maximum activation of MR by glucocorticoids, leading to the clinical symptoms of apparent mineralocorticoid excess. Leydig cells of the testes synthesize testosterone, a process that is suppressed by events initiated by the binding of corticosteroid to glucocorticoid receptors (GR). Depletion of active steroid mediated by 11-beta-HSD may initiate testosterone production at puberty and affect testosterone production during adult life, as for example during periods of stress. The heterogeneous distribution of MR and GR in the brain reflects the specific regional effects of glucocorticoids and mineralocorticoids on neural function. Colocalization of 11-beta-HSD and corticosteroid receptors in brain may be important in controlling the specificity of corticosteroid interaction with GR and MR. The patterns of 11-beta-HSD-steroid-receptor interaction illustrated with these three tissues may provide models applicable to other tissues in which corticosteroid receptors and 11-beta-HSD coexist.			MONDER, C (corresponding author), POPULAT COUNCIL, CTR BIOMED RES, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ABAYASEKARA DRE, 1990, J ENDOCRINOL, V124; ABRAMOVITZ M, 1982, J CLIN ENDOCR METAB, V54, P563, DOI 10.1210/jcem-54-3-563; AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAGGIA S, 1990, ENDOCRINOLOGY, V127, P1735, DOI 10.1210/endo-127-4-1735; BAGGIA S, 1990, ENDOCRINOLOGY, V126, P2742, DOI 10.1210/endo-126-5-2742; BERNAL AL, 1982, J ENDOCRINOL, V93, P141, DOI 10.1677/joe.0.0930141; BONVALET JP, 1990, J CLIN INVEST, V86, P832, DOI 10.1172/JCI114781; BUSH IE, 1959, BIOCHEM J, V71, P718, DOI 10.1042/bj0710718; BUSH IE, 1959, BIOCHEM J, V71, P705, DOI 10.1042/bj0710705; BUSH IE, 1969, ADV BIOSCI, V3, P23; CASTELLO R, 1989, RENAL PHYSIOL BIOCH, V12, P320; DEKLOET ER, 1991, VOLUME TRANSMISSION; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; EDWARDS CRW, 1989, J STEROID BIOCHEM, V32, P213, DOI 10.1016/0022-4731(89)90167-2; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; FUNDER JW, 1973, ENDOCRINOLOGY, V92, P994, DOI 10.1210/endo-92-4-994; FUNDER JW, 1989, ENDOCRINOLOGY, V125, P2224, DOI 10.1210/endo-125-4-2224; FUNDER JW, 1990, TRENDS ENDOCRIN MET, V1, P145, DOI 10.1016/1043-2760(90)90026-Y; GOMEZSANCHEZ EP, 1990, AM J PHYSIOL, V258, pE649, DOI 10.1152/ajpendo.1990.258.4.E649; HUBENER HJ, 1956, J BIOL CHEM, V220, P499; KORNEL L, 1982, J STEROID BIOCHEM, V16, P245, DOI 10.1016/0022-4731(82)90173-X; KROZOWSKI Z, 1990, ENDOCRINOLOGY, V127, P3009, DOI 10.1210/endo-127-6-3009; LAKSHMI V, 1991, ENDOCRINOLOGY, V128, P1741, DOI 10.1210/endo-128-4-1741; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; LAKSHMI V, 1985, ENDOCRINOLOGY, V116, P552, DOI 10.1210/endo-116-2-552; LEWICKA S, 1990, ANN NY ACAD SCI, V595, P435, DOI 10.1111/j.1749-6632.1990.tb34329.x; MCEWEN BS, 1986, PHYSIOL REV, V66, P1121, DOI 10.1152/physrev.1986.66.4.1121; MENDELSON CR, 1989, TRENDS ENDOCRIN MET, V1, P20, DOI 10.1016/1043-2760(89)90025-8; MOISAN MP, 1990, J NEUROENDOCRINOL, V2, P853, DOI 10.1111/j.1365-2826.1990.tb00651.x; MONDER C, 1990, ENDOCRINOLOGY, V126, P2435, DOI 10.1210/endo-126-5-2435; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; MONDER C, 1989, J STEROID BIOCHEM, V32, P77, DOI 10.1016/0022-4731(89)90017-4; MONDER C, 1984, STEROIDS, V44, P383, DOI 10.1016/S0039-128X(84)80001-X; NARAYFEJESTOTH A, 1990, 72ND ANN M END SOC; New MI, 1982, SERONO S, P85; PACKAN DR, 1990, NEUROENDOCRINOLOGY, V51, P613, DOI 10.1159/000125400; PHILLIPOU G, 1985, J STEROID BIOCHEM, V22, P435, DOI 10.1016/0022-4731(85)90451-0; PHILLIPS DM, 1989, ENDOCRINOLOGY, V125, P209, DOI 10.1210/endo-125-1-209; QUIRK SJ, 1990, J STEROID BIOCHEM, V35, P623, DOI 10.1016/0022-4731(90)90208-A; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; RUNDLE SE, 1989, ENDOCRINOLOGY, V125, P1700, DOI 10.1210/endo-125-3-1700; SAKAI R R, 1990, Society for Neuroscience Abstracts, V16, P1309; SANCHEZ EPG, 1991, AM J HYPERTENS, V4, P374; SHACKLETON CHL, 1990, ENDOCRINE HYPERTENSI, P155; SLOVITER RS, 1989, SCIENCE, V243, P535, DOI 10.1126/science.2911756; SMITH BT, 1973, STEROIDS, V22, P515, DOI 10.1016/0039-128X(73)90007-X; STEWART PM, 1990, TRENDS ENDOCRIN MET, V1, P225; STEWART PM, 1991, ENDOCRINOLOGY, V128, P2129, DOI 10.1210/endo-128-4-2129; TAYLOR NF, 1984, J ENDOCRINOLOGY S, V102, P90, DOI DOI 10.1677/JOE.0.102S00NP; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; VANDENBERG DTWM, 1990, ENDOCRINOLOGY, V126, P118, DOI 10.1210/endo-126-1-118; VANEEKELEN JAM, 1988, J NEUROSCI RES, V21, P88, DOI 10.1002/jnr.490210113	54	124	124	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1991	5	15					3047	3054		10.1096/fasebj.5.15.1743437	http://dx.doi.org/10.1096/fasebj.5.15.1743437			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1743437				2022-12-28	WOS:A1991GU84200007
J	MASONGARCIA, M; BECKMAN, BS				MASONGARCIA, M; BECKMAN, BS			SIGNAL TRANSDUCTION IN ERYTHROPOIESIS	FASEB JOURNAL			English	Article						SIGNAL TRANSDUCTION; ERYTHROPOIETIN; PHOSPHOLIPASES	PROTEIN KINASE-C; INTRACELLULAR FREE CALCIUM; FETAL LIVER-CELLS; LIPOXYGENASE METABOLITES; RAPID ACTIVATION; PHOSPHOLIPASE-C; PROLIFERATION; INHIBITORS; RECEPTOR; LINES	The polypeptide hormone erythropoietin (Ep) is a growth factor whose actions on the erythroid progenitor cell induce proliferation and differentiation. The signal transduction system activated by Ep to mediate these cellular processes remains largely uncharacterized despite many years of research devoted to its elucidation. It is clear that an Ep receptor-mediated activation of adenylate cyclase or guanylate cyclase does not occur, although cAMP and cGMP may play modulatory roles. The role of calcium in the action of Ep is less clear. Although the presence of extracellular calcium seems to be an absolute requirement for Ep-induced proliferation, the positive changes induced by Ep in intracellular calcium occur with a time course suggestive of influx through ion channels opening within the cell membrane rather than release of intracellular stores by inositol trisphosphate. There is good evidence for the involvement of phospholipases A2 and C in the actions of Ep, including an early rise in lipoxygenase metabolites of arachidonic acid. Activation of phospholipase C can also result in the activation of protein kinase C in response to Ep. We present a model for the signal transduction pathway of Ep that is consistent with current knowledge and provides a framework for the coordinate actions of several intracellular mechanisms in the mediation of Ep-induced proliferation.	TULANE UNIV,DEPT PHARMACOL,1430 TULANE AVE,NEW ORLEANS,LA 70112	Tulane University								BECKMAN B, 1988, PROSTAG LEUKOTR ESS, V31, P23, DOI 10.1016/0952-3278(88)90160-3; BECKMAN BS, 1987, BIOCHEM BIOPH RES CO, V147, P392, DOI 10.1016/S0006-291X(87)80134-1; BECKMAN BS, 1989, EXP HEMATOL, V17, P309; BECKMAN BS, 1990, ADV PROSTAG THROMB L, V21, P831; BONANOUTZEDAKI SA, 1987, EXP CELL RES, V170, P276, DOI 10.1016/0014-4827(87)90306-5; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHANG J, 1987, BIOCHEM PHARMACOL, V36, P2429, DOI 10.1016/0006-2952(87)90512-0; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CLAESSON HE, 1985, BIOCHEM BIOPH RES CO, V131, P579, DOI 10.1016/0006-291X(85)91276-8; CLARK RB, 1987, BIOCHEM BIOPH RES CO, V145, P666, DOI 10.1016/0006-291X(87)91016-3; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; Hirth P, 1988, Contrib Nephrol, V66, P38; JENIS DM, 1989, INT J CELL CLONING, V7, P190, DOI 10.1002/stem.5530070306; JONES SS, 1990, BLOOD, V76, P31; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; MARTIN TW, 1987, BIOCHIM BIOPHYS ACTA, V917, P296, DOI 10.1016/0005-2760(87)90134-2; MASONGARCIA M, 1990, BIOCHEM BIOPH RES CO, V168, P490, DOI 10.1016/0006-291X(90)92348-4; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; MUNOZ E, 1991, FEBS LETT, V279, P319, DOI 10.1016/0014-5793(91)80178-6; NISHIJIMA J, 1989, BIOCHEMISTRY-US, V28, P2902, DOI 10.1021/bi00433a023; NOGUCHI T, 1988, MOL CELL BIOL, V8, P2604, DOI 10.1128/MCB.8.6.2604; OFFENSTEIN JP, 1987, P SOC EXP BIOL ME, V85, P147; RICHTER C, 1987, BIOCHEM BIOPH RES CO, V143, P609, DOI 10.1016/0006-291X(87)91397-0; SAWADA K, 1989, J CLIN INVEST, V83, P1701, DOI 10.1172/JCI114070; SHAAFI RI, 1981, J CELL PHYSIOL, V108, P401, DOI 10.1002/jcp.1041080314; SNYDER DS, 1986, BLOOD, V67, P1675; SNYDER DS, 1989, EXP HEMATOL, V17, P6; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SPIVAK JL, 1986, INT J CELL CLONING, V4, P139, DOI 10.1002/stem.5530040302; THOMPSON LP, 1988, FASEB J, V2, pA813; TSUKADA T, 1986, BIOCHEM BIOPH RES CO, V140, P832, DOI 10.1016/0006-291X(86)90709-6; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; UMEMURA T, 1988, LEUKEMIA RES, V12, P187, DOI 10.1016/0145-2126(88)90135-X; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; WHITE L, 1980, EXP HEMATOL, V8, P168	42	22	26	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2958	2964		10.1096/fasebj.5.14.1752362	http://dx.doi.org/10.1096/fasebj.5.14.1752362			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752362				2022-12-28	WOS:A1991GP26900011
J	SIEGALL, CB; EPSTEIN, S; SPEIR, E; HLA, T; FOROUGH, R; MACIAG, T; FITZGERALD, DJ; PASTAN, I				SIEGALL, CB; EPSTEIN, S; SPEIR, E; HLA, T; FOROUGH, R; MACIAG, T; FITZGERALD, DJ; PASTAN, I			CYTOTOXIC ACTIVITY OF CHIMERIC PROTEINS COMPOSED OF ACIDIC FIBROBLAST GROWTH-FACTOR AND PSEUDOMONAS EXOTOXIN ON A VARIETY OF CELL-TYPES	FASEB JOURNAL			English	Note						AFGF; TOXIN; CYTOTOXICITY; CHIMERIC; ANTIANGIOGENIC	RECOMBINANT FUSION PROTEIN; CYTO-TOXIC ACTIVITY; ENDOTHELIAL-CELLS; RECEPTOR-BINDING; ANIMAL TOXICITY; DOMAIN-I; SEQUENCE; FAMILY; ALPHA; GENE	Chimeric proteins composed of acidic fibroblast growth factor (acidic FGF) and several forms of Pseudomonas exotoxin (PE) that cannot bind to the PE receptor have been produced in Escherichia coli by expressing chimeric genes in which DNA encoding acidic FGF is fused to various mutant forms of PE. These acidic FGF-PE fusion proteins were found to be cytotoxic to a variety of tumor cell lines including hepatocellular (PLC/PRF/5 and HEPG2), prostatic (LNCaP), colon (HT29), and breast (MCF-7) carcinomas at concentrations of 1-70 ng/ml. The cytotoxic effects of acidic FGF-PE were FGF-receptor specific as demonstrated by competition with excess acidic FGF and by showing that acidic FGF-PE bound to the FGF receptor with the same affinity as acidic FGF. Furthermore, the cell-killing activity of acidic FGF-PE was toxin-mediated, as an acidic FGF-PE mutant, which does not possess ADP-ribosylation activity, failed to kill cells. These findings demonstrate that acidic FGF-PE is a potent cytotoxic molecule that can be targeted to FGF receptor-bearing cells. Because acidic FGF is a potent angiogenic molecule, cytotoxic acidic FGF-PE chimeras may have utility as anti-angiogenic agents. These molecules could be helpful in determining the functional role of FGF receptors in cellular processes.	NCI,DIV CANC BIOL,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BLDG 37,ROOM 4E16,BETHESDA,MD 20892; NHLBI,CARDIOL BRANCH,BETHESDA,MD 20892; AMER RED CROSS,JEROME H HOLLAND LABS BIOMED SCI,MOLEC BIOL LAB,ROCKVILLE,MD 20855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); American Red Cross			Hla, Timothy/G-5873-2012; pastan, ira/P-9319-2019	Hla, Timothy/0000-0001-8355-4065; pastan, ira/0000-0002-9223-0270	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, R01HL035627] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35627, HL-32348] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1990, J BIOL CHEM, V265, P16306; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; CHAUDRY GJ, 1989, J BIOL CHEM, V264, P15151; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; EDWARDS GM, 1989, MOL CELL BIOL, V9, P2860, DOI 10.1128/MCB.9.7.2860; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1988, BIOCHEM BIOPH RES CO, V151, P957, DOI 10.1016/S0006-291X(88)80459-5; Gospodarowicz Denis, 1989, Critical Reviews in Oncogenesis, V1, P1; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JINNO Y, 1988, J BIOL CHEM, V263, P13203; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KONDO T, 1988, J BIOL CHEM, V263, P9470; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LORBERBOUMGALSKI H, 1988, J BIOL CHEM, V263, P18650; LORBERBOUMGALSKI H, 1990, J BIOL CHEM, V265, P16311; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; MARICS I, 1989, ONCOGENE, V4, P335; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1989, J BIOL CHEM, V264, P15157; PRIOR TI, 1991, CANCER RES, V51, P174; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SEETHARAM S, 1991, IN PRESS J BIOL CHEM; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1990, J BIOL CHEM, V265, P16318; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SIEGALL CB, 1991, BIOCHEMISTRY-US, V30, P7154, DOI 10.1021/bi00243a016; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	43	33	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2843	2849		10.1096/fasebj.5.13.1717336	http://dx.doi.org/10.1096/fasebj.5.13.1717336			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1717336				2022-12-28	WOS:A1991GJ47100013
J	BRANN, DW; MAHESH, VB				BRANN, DW; MAHESH, VB			ROLE OF CORTICOSTEROIDS IN FEMALE REPRODUCTION	FASEB JOURNAL			English	Article						CORTICOSTEROID RECEPTORS; LUTEINIZING HORMONE; PROGESTERONE; OVULATION; FOLLICLE-STIMULATING HORMONE	FOLLICLE-STIMULATING-HORMONE; GLUCOCORTICOID RECEPTOR IMMUNOREACTIVITY; RAT GRANULOSA-CELLS; LUTEINIZING-HORMONE; GONADOTROPIN-SECRETION; CHRONIC STRESS; ESTROUS-CYCLE; PITUITARY; RELEASE; INVITRO	Corticosteroids, ACTH, and stress can exert inhibitory and facilitory effects on reproduction. The purpose of this review is to reconcile the divergent effects of corticosteroids on gonadotropin secretion based on recent work in the area. Whether stimulation or inhibition of gonadotropin secretion is observed appears to depend on two important variables: 1) length of exposure, and 2) background of estrogen priming. The acute administration of ACTH and certain corticosteroids to estrogen-primed animals brings about the release of LH and FSH. Corticosteroids have also been shown by some investigators to cause selective release of follicle-stimulating hormone (FSH) both in vitro and in vivo. This selective facilitation of FSH release by corticosteroids may explain many deleterious effects on reproduction observed after adrenalectomy, and it may have relevance in explaining the beneficial effects of corticosteroids in inducing ovulation in anovulatory patients suffering from polycystic ovarian syndrome. Finally, evidence is presented which suggests that adrenal steroids may participate in initiation and synchronization of the preovulatory LH and FSH surge, as well as the secondary FSH surge seen on estrus in the rat.	MED COLL GEORGIA,DEPT PHYSIOL & ENDOCRINOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University					NICHD NIH HHS [HD-16688] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016688] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMARIO A, 1987, J ENDOCRINOL, V112, P9, DOI 10.1677/joe.0.1120009; BALDWIN D, 1990, BIOL REPROD S1, V42, P150; BALDWIN DM, 1979, ENDOCRINOLOGY, V105, P120, DOI 10.1210/endo-105-1-120; BALDWIN DM, 1974, BRAIN RES, V80, P291, DOI 10.1016/0006-8993(74)90692-1; BAMBINO TH, 1981, ENDOCRINOLOGY, V108, P2142, DOI 10.1210/endo-108-6-2142; BARRACLOUGH CA, 1982, ENDOCR REV, V3, P91, DOI 10.1210/edrv-3-1-91; BELHADJ H, 1989, J ENDOCRINOL, V122, P451, DOI 10.1677/joe.0.1220451; BRANN DW, 1991, FRONT NEUROENDOCRIN, V12, P165; BRANN DW, 1990, ENDOCRINOLOGY, V126, P159, DOI 10.1210/endo-126-1-159; BRANN DW, 1991, BIOL REPROD, V44, P1005, DOI 10.1095/biolreprod44.6.1005; BRANN DW, 1991, STEROIDS, V56, P103, DOI 10.1016/0039-128X(91)90132-F; BRANN DW, 1991, IN PRESS REGULATION; BRANN DW, 1991, IN PRESS NEUROENDOCR; BRANN DW, 1990, P SOC EXP BIOL MED, V190, P176; BRISKI KP, 1988, NEUROENDOCRINOLOGY, V47, P194, DOI 10.1159/000124913; BUCKINGHAM JC, 1978, J ENDOCRINOL, V78, P359, DOI 10.1677/joe.0.0780359; CHEIFETZ P, 1968, ENDOCRINOLOGY, V82, P1117, DOI 10.1210/endo-82-6-1117; CHRISTIAN JJ, 1958, ENDOCRINOLOGY, V63, P517, DOI 10.1210/endo-63-5-517; CHRISTIAN JJ, 1971, BIOL REPROD, V4, P248, DOI 10.1093/biolreprod/4.3.248; CHRISTIAN JJ, 1964, ENDOCRINOLOGY, V75, P653, DOI 10.1210/endo-75-5-653; DAGOSTINO J, 1990, ENDOCRINOLOGY, V127, P891, DOI 10.1210/endo-127-2-891; DALLMAN MF, 1989, ACTA PHYSL SCAND S, V583, P27; DEGREEF WJ, 1987, ACTA ENDOCRINOL-COP, V116, P350, DOI 10.1530/acta.0.1160350; DUBEY AK, 1985, BIOL REPROD, V33, P423, DOI 10.1095/biolreprod33.2.423; EBERWINE JH, 1984, J BIOL CHEM, V259, P2166; EVAIN D, 1976, J STEROID BIOCHEM, V7, P1135, DOI 10.1016/0022-4731(76)90045-5; FEDER HH, 1971, J ENDOCRINOL, V50, P29, DOI 10.1677/joe.0.0500029; FEDER HH, 1969, ENDOCRINOLOGY, V84, P171, DOI 10.1210/endo-84-1-171; GRAY GD, 1978, NEUROENDOCRINOLOGY, V25, P247, DOI 10.1159/000122746; GREENBLATT RB, 1956, FERTIL STERIL, V7, P203; HAGINO N, 1969, ENDOCRINOLOGY, V84, P308, DOI 10.1210/endo-84-2-308; HAMBURGH M, 1974, TERATOLOGY, V10, P31, DOI 10.1002/tera.1420100106; HARFSTRAND A, 1989, ACTA PHYSIOL SCAND, V135, P3, DOI 10.1111/j.1748-1716.1989.tb08544.x; HARFSTRAND A, 1986, P NATL ACAD SCI USA, V83, P9779, DOI 10.1073/pnas.83.24.9779; HIGUCHI T, 1986, J ENDOCRINOL, V110, P245, DOI 10.1677/joe.0.1100245; HISANO S, 1988, NEUROSCI LETT, V95, P1318; HSUEH AJW, 1978, STEROIDS, V32, P639, DOI 10.1016/0039-128X(78)90074-0; KAMEL F, 1987, ENDOCRINOLOGY, V121, P561, DOI 10.1210/endo-121-2-561; KITTINGER JW, 1980, ENDOCRINOLOGY, V107, P616, DOI 10.1210/endo-107-2-616; KIZER JS, 1974, ENDOCRINOLOGY, V95, P799, DOI 10.1210/endo-95-3-799; LAWTON IE, 1972, ENDOCRINOLOGY, V90, P575, DOI 10.1210/endo-90-2-575; MACFARLAND LA, 1977, BIOL REPROD, V16, P306, DOI 10.1095/biolreprod16.3.306; Mahesh V B, 1987, Adv Exp Med Biol, V219, P237; MANN DR, 1985, NEUROENDOCRINOLOGY, V40, P297, DOI 10.1159/000124090; MANN DR, 1975, P SOC EXP BIOL MED, V150, P115, DOI 10.3181/00379727-150-38985; MCEWEN BS, 1986, PHYSIOL REV, V66, P1121, DOI 10.1152/physrev.1986.66.4.1121; MEIJSROELOFS HMA, 1977, J ENDOCRINOL, V75, P419, DOI 10.1677/joe.0.0750419; MOBERG GP, 1987, OXFORD REV REPROD B, V9, P456; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; PAPIRKRICHELI D, 1981, ISRAEL J MED SCI, V17, P1185; PARIS A, 1973, FERTIL STERIL, V24, P546; PARKER CR, 1981, OBSTET GYNECOL, V58, P26; PEPPLER RD, 1976, BIOL REPROD, V15, P173, DOI 10.1095/biolreprod15.2.173; PETRAGLIA F, 1986, ENDOCRINOLOGY, V119, P2445, DOI 10.1210/endo-119-6-2445; PUTNAM CD, 1991, ENDOCRINOLOGY, V128, P2558, DOI 10.1210/endo-128-5-2558; RADOVICK S, 1988, ENDOCRINOLOGY, V122, P68; RAMALEY JA, 1974, LIFE SCI, V14, P1623, DOI 10.1016/0024-3205(74)90264-1; RAMALEY JA, 1980, NEUROENDOCRINOLOGY, V30, P213, DOI 10.1159/000123003; Rees HD, 1975, ANATOMICAL NEUROENDO, P262; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; RINGSTROM S J, 1989, Biology of Reproduction, V40, P102; ROSEN H, 1988, ENDOCRINOLOGY, V122, P2873, DOI 10.1210/endo-122-6-2873; SCHREIBER JR, 1982, STEROIDS, V35, P569; SHAIKH AA, 1975, ENDOCRINOLOGY, V96, P37, DOI 10.1210/endo-96-1-37; SMITH ER, 1971, NEUROENDOCRINOLOGY, V8, P94, DOI 10.1159/000121997; SPEEG KV, 1979, ENDOCRINOLOGY, V104, P1364, DOI 10.1210/endo-104-5-1364; SUTER DE, 1989, BIOL REPROD, V41, P1091, DOI 10.1095/biolreprod41.6.1091; SUTER DE, 1985, ENDOCRINOLOGY, V117, P849, DOI 10.1210/endo-117-3-849; SUTER DE, 1988, AM J PHYSIOL, V254, pE595, DOI 10.1152/ajpendo.1988.254.5.E595; TACHE Y, 1978, NEUROENDOCRINOLOGY, V26, P208, DOI 10.1159/000122828; TONG Y, 1990, Molecular and Cellular Neuroscience, V1, P78; WANG C, 1989, ENDOCRINOLOGY, V124, P1595, DOI 10.1210/endo-124-4-1595; YASUKAWA N, 1978, LIFE SCI, V22, P1381, DOI 10.1016/0024-3205(78)90631-8	73	120	125	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2691	2698		10.1096/fasebj.5.12.1655548	http://dx.doi.org/10.1096/fasebj.5.12.1655548			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1655548	Bronze			2022-12-28	WOS:A1991GE81100010
J	MILLER, A; HAFLER, DA; WEINER, HL				MILLER, A; HAFLER, DA; WEINER, HL			TOLERANCE AND SUPPRESSOR MECHANISMS IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS - IMPLICATIONS FOR IMMUNOTHERAPY OF HUMAN AUTOIMMUNE-DISEASES	FASEB JOURNAL			English	Article						AUTOIMMUNITY; IMMUNOTHERAPY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TOLERANCE	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; COLLAGEN-INDUCED ARTHRITIS; MULTIPLE-SCLEROSIS; T-CELLS; MONOCLONAL-ANTIBODY; I-A; LYMPHOCYTES-T; ENCEPHALITOGENIC DETERMINANT; PROTEOLIPID PROTEIN	Recent advances in understanding antigen recognition at the level of the trimolecular complex have provided new approaches for selective immunotherapy. Many of these approaches have been applied successfully to the animal model experimental autoimmune encephalomyelitis, and some are being tested in the human disease multiple sclerosis. In addition, new approaches utilizing nonspecific modulation of immune function are being explored in animals and humans. Immunospecific therapy in autoimmune diseases will ultimately be based on understanding how the normal immune system maintains unresponsiveness to self and how this state of self-tolerance is broken. Strategies for specific immune intervention in human diseases based on components of the trimolecular complex will have to take into account the polymorphism of the major histocompatibility complex in humans and the degree of heterogeneity among autoimmune T cells that react with an autoantigen.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	MILLER, A (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV NEUROL,CTR NEUROL DIS,BOSTON,MA 02115, USA.			Miller, Ariel/0000-0001-5843-6841				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ADORINI L, 1979, J EXP MED, V150, P293, DOI 10.1084/jem.150.2.293; ALVORD EC, 1984, P CLIN BIOL RES, V146; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; BOITARD C, 1988, P NATL ACAD SCI USA, V85, P9719, DOI 10.1073/pnas.85.24.9719; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; BOTTAZZO GF, 1983, LANCET, V2, P1115; BROD SA, 1991, ANN NEUROL, V29, P615, DOI 10.1002/ana.410290608; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Chelmicka-Schorr E, 1988, Ann N Y Acad Sci, V540, P707, DOI 10.1111/j.1749-6632.1988.tb27220.x; DRISCOLL BF, 1974, J IMMUNOL, V112, P392; FEUER C, 1985, J NEUROIMMUNOL, V10, P159; FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; GARRATTY G, 1975, AM J MED, V58, P398, DOI 10.1016/0002-9343(75)90606-3; GASSER DL, 1973, SCIENCE, V181, P872, DOI 10.1126/science.181.4102.872; GERSHON RK, 1971, IMMUNOLOGY, V21, P903; HAFLER DA, 1988, J EXP MED, V167, P1313, DOI 10.1084/jem.167.4.1313; HAFLER DA, 1989, IMMUNOL TODAY, V10, P104, DOI 10.1016/0167-5699(89)90236-3; HAFLER DA, 1987, ANN NEUROL, V22, P89, DOI 10.1002/ana.410220121; HAFLER DA, 1986, NEUROLOGY, V36, P777, DOI 10.1212/WNL.36.6.777; HAFLER DA, 1988, J IMMUNOL, V141, P131; HAPP MP, 1988, J IMMUNOL, V141, P1489; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JOHNSON RT, 1983, VIRUSES DEMYELINATIN, P7; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARPUS WJ, 1989, J IMMUNOL, V143, P3492; KELLEY VE, 1988, J IMMUNOL, V140, P59; KENNEDY MK, 1988, J IMMUNOL, V141, P2986; KENNEDY MK, 1990, J IMMUNOL, V144, P909; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LAMONT AG, 1990, J IMMUNOL, V145, P1687; LANDO Z, 1979, J IMMUNOL, V123, P2156; LANDO Z, 1980, NATURE, V287, P551, DOI 10.1038/287551a0; LIDER O, 1989, J CLIN INVEST, V83, P752, DOI 10.1172/JCI113953; LIDER O, 1989, J IMMUNOL, V142, P748; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; LING PD, 1985, J IMMUNOL, V135, P1857; LUSSIER M L, 1988, Neurology, V38, P236; MACPHEE IAM, 1989, J EXP MED, V169, P431, DOI 10.1084/jem.169.2.431; MARX J, 1990, SCIENCE, V249, P246, DOI 10.1126/science.2374924; MASSA PT, 1987, P NATL ACAD SCI USA, V84, P4219, DOI 10.1073/pnas.84.12.4219; MATTINGLY JA, 1984, CELL IMMUNOL, V86, P46, DOI 10.1016/0008-8749(84)90357-5; MAYER L, 1987, J EXP MED, V166, P1471, DOI 10.1084/jem.166.5.1471; MCCARRON RM, 1990, J NEUROIMMUNOL, V29, P73, DOI 10.1016/0165-5728(90)90149-H; MILLER A, 1991, IN PRESS J EXP MED; MOKHTARIAN F, 1984, NATURE, V309, P356, DOI 10.1038/309356a0; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; OFFNER H, 1989, J EXP MED, V170, P355, DOI 10.1084/jem.170.2.355; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; PERRY LL, 1982, J EXP MED, V156, P480, DOI 10.1084/jem.156.2.480; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; Salgame P, 1989, Int Immunol, V1, P121, DOI 10.1093/intimm/1.2.121; SCHLUESENER HJ, 1987, J IMMUNOL, V139, P4016; SCHLUESENER HJ, 1988, J NEUROIMMUNOL, V18, P341, DOI 10.1016/0165-5728(88)90055-0; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SHAW SY, 1986, FEBS LETT, V207, P266, DOI 10.1016/0014-5793(86)81502-2; SIBLEY WA, 1985, LANCET, V1, P1313; SRIRAM S, 1986, J IMMUNOL, V136, P4464; SRIRAM S, 1983, CELL IMMUNOL, V75, P378, DOI 10.1016/0008-8749(83)90335-0; SRIRAM S, 1983, J EXP MED, V158, P1362, DOI 10.1084/jem.158.4.1362; STAMENKOVIC I, 1988, P NATL ACAD SCI USA, V85, P1179, DOI 10.1073/pnas.85.4.1179; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; SWANBORG RH, 1975, J IMMUNOL, V114, P191; SWIERKOSZ JE, 1975, J IMMUNOL, V115, P631; TADA T, 1989, RES IMMUNOL, V140, P291, DOI 10.1016/0923-2494(89)90064-3; TEITELBAUM D, 1988, P NATL ACAD SCI USA, V85, P9724, DOI 10.1073/pnas.85.24.9724; THOMPSON HSG, 1986, CLIN EXP IMMUNOL, V64, P581; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TUOHY VK, 1989, J IMMUNOL, V142, P1523; URBAN JL, 1989, CELL, V59, P257, DOI 10.1016/0092-8674(89)90288-2; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574; WEINER H L, 1989, Neurology, V39, P172; WEINER HL, 1988, ANN NEUROL, V23, P211, DOI 10.1002/ana.410230302; Wells HG, 1911, J INFECT DIS, V9, P147, DOI 10.1093/infdis/9.2.147; WILLIAMS RM, 1982, J NEUROPATH EXP NEUR, V41, P508, DOI 10.1097/00005072-198209000-00004; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; ZAMVIL SS, 1987, J IMMUNOL, V139, P1075; ZANG ZJ, 1990, J IMMUNOL, V145, P2489	94	43	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2560	2566		10.1096/fasebj.5.11.1868980	http://dx.doi.org/10.1096/fasebj.5.11.1868980			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868980				2022-12-28	WOS:A1991GB09400009
J	SEI, Y; MCINTYRE, T; FRIDE, E; YOSHIMOTO, K; SKOLNICK, P; ARORA, PK				SEI, Y; MCINTYRE, T; FRIDE, E; YOSHIMOTO, K; SKOLNICK, P; ARORA, PK			INHIBITION OF CALCIUM MOBILIZATION IS AN EARLY EVENT IN OPIATE-INDUCED IMMUNOSUPPRESSION	FASEB JOURNAL			English	Article						OPIATES; OPIATE, RECEPTORS; CENTRAL NERVOUS SYSTEM; CALCIUM MOBILIZATION; T-CELLS; B-CELLS; IMMUNOSUPPRESSION	FLUORESCENT INDICATORS; BETA-ENDORPHIN; MORPHINE; MICE; IMMUNOMODULATION; LYMPHOCYTES; CELLS	Morphine administered as a subcutaneous implant inhibits the initial increase in cytoplasmic free-calcium [Ca2+]i induced by mitogens in mouse splenocytes. This effect was not reproduced by incubation of splenocytes with morphine (10(-8)-10(-4) M). Analysis of splenocyte subpopulations demonstrates that this effect was manifest in both B and T cells. However, within T cell subpopulations, CD4+ but not CD8+ cells were affected. Adrenalectomy abolished this effect of morphine in CD4+ T but not CD4-, CD8- spleen cells (most likely Thy 1.2- B cells). Moreover, simultaneous administration of the opiate antagonist naltrexone blocked the effect of morphine in CD4-, CD8- spleen cells, but not in CD4+ T cells. These data indicate that the effects of morphine on mitogen-stimulated increase in [Ca2+]i may be mediated through distinct glucocorticoid-dependent and -independent mechanisms. The morphine-induced inhibition of an increase in [Ca2+]i in immune cells reported here may be an early event mediating opiate-induced immunosuppression.	NIDDKD, NEUROSCI LAB, BLDG 8, ROOM 111, BETHESDA, MD 20892 USA; NIMH, CEREBRAL METAB LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ARORA PK, 1990, CELL IMMUNOL, V126, P343, DOI 10.1016/0008-8749(90)90326-M; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BRIGGS JH, 1967, LANCET, V2, P1227; BRYANT HU, 1988, J PHARMACOL EXP THER, V245, P913; BRYANT HU, 1987, LIFE SCI, V41, P1731, DOI 10.1016/0024-3205(87)90601-1; BRYANT HU, 1990, J PHARMACOL EXP THER, V255, P410; CARR DJJ, 1988, CELL IMMUNOL, V116, P44, DOI 10.1016/0008-8749(88)90208-0; CHERUBIN CE, 1971, ARCH INTERN MED, V128, P309, DOI 10.1001/archinte.1971.00310200145021; DELITALA G, 1984, OPIOID MODULATION EN, P65; GELFAND EW, 1987, IMMUNOL REV, V95, P59, DOI 10.1111/j.1600-065X.1987.tb00500.x; GEORGE R, 1955, BRIT J PHARM CHEMOTH, V10, P260, DOI 10.1111/j.1476-5381.1955.tb00092.x; GIBSON A, 1979, BRIT J PHARMACOL, V65, P139, DOI 10.1111/j.1476-5381.1979.tb17342.x; Gibson R D, 1970, J Pharm Sci, V59, P426, DOI 10.1002/jps.2600590338; HARACZ JL, 1981, NEUROENDOCRINOLOGY, V33, P170, DOI 10.1159/000123224; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KREEK MJ, 1983, LIFE SCI, V33, P409, DOI 10.1016/0024-3205(83)90529-5; LINCH DC, 1987, IMMUNOL REV, V95, P137, DOI 10.1111/j.1600-065X.1987.tb00503.x; LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1; LUCKHOFF A, 1986, CELL CALCIUM, V7, P233, DOI 10.1016/0143-4160(86)90003-5; MINTA A, 1989, J BIOL CHEM, V264, P8171; SEI Y, 1991, J IMMUNOL, V146, P194; SEI Y, 1991, IN PRESS J IMMUNOL M; SIBINGA NES, 1988, ANNU REV IMMUNOL, V6, P219; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; TUBARO E, 1983, J INFECT DIS, V148, P656, DOI 10.1093/infdis/148.4.656; Weber R J, 1987, NIDA Res Monogr, V76, P341; WEBER RJ, 1989, SCIENCE, V245, P188, DOI 10.1126/science.2749256; YAHYA MD, 1987, LIFE SCI, V41, P2503	28	34	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2194	2199		10.1096/fasebj.5.8.2022315	http://dx.doi.org/10.1096/fasebj.5.8.2022315			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022315				2022-12-28	WOS:A1991FK11100012
J	GERMANN, UA; CHIN, KV; PASTAN, I; GOTTESMAN, MM				GERMANN, UA; CHIN, KV; PASTAN, I; GOTTESMAN, MM			RETROVIRAL TRANSFER OF A CHIMERIC MULTIDRUG RESISTANCE-ADENOSINE DEAMINASE GENE	FASEB JOURNAL			English	Article									NCI, MOLEC BIOL LAB, BLDG 37, 2E18, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019; Chin, Khew-Voon/F-2670-2013	pastan, ira/0000-0002-9223-0270; 				BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; DEUCHARS KL, 1987, MOL CELL BIOL, V7, P718, DOI 10.1128/MCB.7.2.718; GALSKI H, 1989, MOL CELL BIOL, V9, P4357, DOI 10.1128/MCB.9.10.4357; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GERMANN UA, 1989, J BIOL CHEM, V264, P7418; GIBLETT ER, 1972, LANCET, V2, P1067; GILBOA E, 1986, BIOTECHNIQUES, V4, P504; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GUILD BC, 1988, J VIROL, V62, P3795, DOI 10.1128/JVI.62.10.3795-3801.1988; GUILD BC, 1988, P NATL ACAD SCI USA, V85, P1595, DOI 10.1073/pnas.85.5.1595; HIRSCHHORN R, 1986, CLIN IMMUNOL IMMUNOP, V40, P157, DOI 10.1016/0090-1229(86)90081-4; KANE SE, 1988, MOL CELL BIOL, V8, P3316, DOI 10.1128/MCB.8.8.3316; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KREDICH NM, 1982, METABOLIC BASIS INHE, P1157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGLI MC, 1987, P NATL ACAD SCI USA, V84, P789, DOI 10.1073/pnas.84.3.789; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCIVOR RS, 1987, MOL CELL BIOL, V7, P838, DOI 10.1128/MCB.7.2.838; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SHIMOTOHNO K, 1981, CELL, V26, P67, DOI 10.1016/0092-8674(81)90034-9; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANAKA S, 1990, IN PRESS BIOCH BIOPH; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; YEUNG CY, 1983, J BIOL CHEM, V258, P8330	34	31	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1990	4	5					1501	1507		10.1096/fasebj.4.5.1968408	http://dx.doi.org/10.1096/fasebj.4.5.1968408			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CT176	1968408				2022-12-28	WOS:A1990CT17600011
J	LONAI, P; ORRURTREGER, A				LONAI, P; ORRURTREGER, A			HOMEOGENES IN MAMMALIAN DEVELOPMENT AND THE EVOLUTION OF THE CRANIUM AND CENTRAL-NERVOUS-SYSTEM	FASEB JOURNAL			English	Review											LONAI, P (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.			Orr-Urtreger, Avi/0000-0001-9305-6203				AKAM M, 1987, DEVELOPMENT, V101, P1; ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA AR, 1989, NATURE, V341, P33; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BEEMAN RW, 1987, NATURE, V327, P247, DOI 10.1038/327247a0; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DO MS, 1988, GENOMICS, V3, P195, DOI 10.1016/0888-7543(88)90079-1; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FIENBERG AA, 1987, CURR TOP DEV BIOL, V23, P233; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HART CP, 1985, CELL, V43, P9, DOI 10.1016/0092-8674(85)90007-8; HARVEY RP, 1988, CELL, V53, P687, DOI 10.1016/0092-8674(88)90087-6; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HOGAN B, 1985, TRENDS GENET, V1, P67, DOI 10.1016/0168-9525(85)90029-0; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; LEWIS EB, 1980, NATURE, V287, P795; LONAI P, 1987, DNA-J MOLEC CELL BIO, V6, P409, DOI 10.1089/dna.1987.6.409; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MEIER S, 1982, DIFFERENTIATION, V21, P95, DOI 10.1111/j.1432-0436.1982.tb01202.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; OCONNOR MB, 1988, EMBO J, V7, P435, DOI 10.1002/j.1460-2075.1988.tb02831.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0	42	22	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1990	4	5					1436	1443		10.1096/fasebj.4.5.1968407	http://dx.doi.org/10.1096/fasebj.4.5.1968407			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CT176	1968407				2022-12-28	WOS:A1990CT17600003
J	BOLEN, JB; ROWLEY, RB; SPANA, C; TSYGANKOV, AY				BOLEN, JB; ROWLEY, RB; SPANA, C; TSYGANKOV, AY			THE SRC FAMILY OF TYROSINE PROTEIN-KINASES IN HEMATOPOIETIC SIGNAL TRANSDUCTION	FASEB JOURNAL			English	Article						TYROSINE PROTEIN KINASE; INTRACELLULAR SIGNALING; HEMATOPOIETIC CELLS	CELL ANTIGEN RECEPTOR; CYTOPLASMIC DOMAINS; IMMUNOGLOBULIN-E; HUMAN PLATELETS; LYMPHOCYTES-B; CD4 RECEPTOR; ACTIVATION; PHOSPHORYLATION; P56LCK; ASSOCIATION	The Src family of tyrosine protein kinases represent an expanding class of closely related intracellular enzymes that participate in the signal transduction pathways of a variety of surface receptors. One of the more surprising aspects of the information relating Src protein kinases to receptor signaling is the apparent diversity of receptor types with which the Src-related enzymes are reported to interact physically or functionally. Traditional biochemical and genetic approaches have yielded much information regarding the interactions between the Src tyrosine protein kinases and other cellular proteins in defined cell types, and emerging technologies, most notably homologous recombination in embryonal stem cells to achieve gene "knockouts," are providing new insights into the participation of the Src-related gene products in signal transduction and development.			BOLEN, JB (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.							ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BURKHARDT AL, 1992, J VIROL, V66, P5161, DOI 10.1128/JVI.66.8.5161-5167.1992; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CLARK EA, 1992, IN PRESS MOL CELL BI; COCHOWSKI K, 1992, J BIOL CHEM, V267, P5025; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARIECARDINE A, 1992, J IMMUNOL, V148, P3879; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARSONS JT, 1989, CURR TOP MICROBIOL, P80; PELCHENMATTHEWS A, 1992, J CELL BIOL, V117, P279, DOI 10.1083/jcb.117.2.279; PERLMUTTER RM, 1990, ENZYME, V44, P214, DOI 10.1159/000468759; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RESH MD, 1990, ONCOGENE, V5, P1437; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SILICIANO JD, 1992, IN PRESS P NATL ACAD; SLECKMAN BP, 1992, P NATL ACAD SCI USA, V898, P7566; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TOSHIHIKO T, 1992, BLOOD, V80, P617; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; TYSGANKOV A, 1992, J BIOL CHEM, V267, P18259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538	79	229	263	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1992	6	15					3403	3409		10.1096/fasebj.6.15.1281458	http://dx.doi.org/10.1096/fasebj.6.15.1281458			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1281458				2022-12-28	WOS:A1992KD39500012
J	BORNSTEIN, P				BORNSTEIN, P			THROMBOSPONDINS - STRUCTURE AND REGULATION OF EXPRESSION	FASEB JOURNAL			English	Review						CELL-MATRIX INTERACTIONS; GENE FAMILY; PROTEIN REPEATS; MOUSE DEVELOPMENT	AMINO-ACID-SEQUENCE; EXTRACELLULAR-MATRIX PROTEINS; THROMBIN-SENSITIVE PROTEIN; CALCIUM-BINDING SITES; GROWTH-FACTOR; PLATELET THROMBOSPONDIN; GENE-EXPRESSION; CIRCUMSPOROZOITE PROTEIN; ADHESIVE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES	Thrombospondin (TSP) is a large, trimeric, modular glycoprotein that is a major constituent of platelet alpha granules. TSP is also secreted by a wide variety of epithelial and mesenchymal cells in patterns that reflect developmental changes in the embryo and response to injury in the adult. In addition to its role in blood coagulation, TSP has been reported to serve both adhesive and anti-adhesive functions, to foster neurite outgrowth, stimulate and inhibit cell growth and migration, and inhibit angiogenesis. Although this diversity in apparent function can be attributed, in part, to the ability of a single TSP to interact with several different cell-surface receptors, it is now known that the TSPs are encoded by at least three homologous genes in both human and mouse. TSP1, the commonly recognized protein isolated from platelets, is similar to TSP2 in structure. Both proteins contain NH2-terminal, COOH-terminal, and procollagen homology domains, and type I (TSP or properdin), type II (EGF-like), and type III (Ca2+-binding) repeats. However, the two TSPs differ in amino acid sequence and in the regulation of their expression. TSP1 is rapidly induced by serum and growth factors. An SRE and a binding site for NF-Y have been shown to mediate the serum response of the human TSP1 gene. On the other hand, TSP2 is far less responsive to serum than TSP1 and lacks the promoter elements that mediate the serum responsiveness of TSP1. TSP3 resembles TSP1 and TSP2 in its COOH-terminal domain and type III repeats, but contains four rather than three type II repeats and lacks type I repeats and a procollagen homology. The NH2-terminal domain of TSP3 also differs from that of either TSP1 or TSP2. All three TSPs demonstrate characteristic patterns of expression in the developing and adult mouse. It is therefore likely that each protein subserves a discrete function. In the future it will be necessary to distinguish among the three TSPs in addressing the function of these proteins.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	BORNSTEIN, P (corresponding author), UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline; NIDCR NIH HHS [DE08229] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ASCH AS, 1989, PROG HEMOST THROMB, V9, P157; ASCH AS, 1991, J BIOL CHEM, V266, P1740; BAENZIGE.NL, 1971, P NATL ACAD SCI USA, V68, P240, DOI 10.1073/pnas.68.1.240; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; BARON M, 1992, PROTEIN SCI, V1, P81; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; COLIGAN JE, 1984, J BIOL CHEM, V259, P3944; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DIXIT VM, 1984, J BIOL CHEM, V259, P100; DIXIT VM, 1986, P NATL ACAD SCI USA, V83, P5449, DOI 10.1073/pnas.83.15.5449; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FOUSER L, 1991, P NATL ACAD SCI USA, V88, P10158, DOI 10.1073/pnas.88.22.10158; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HOLT GD, 1990, J BIOL CHEM, V265, P2852; HORLEIN D, 1979, EUR J BIOCHEM, V99, P31, DOI 10.1111/j.1432-1033.1979.tb13227.x; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; JAFFE E, 1990, GENOMICS, V7, P123, DOI 10.1016/0888-7543(90)90528-3; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; JOHNSTON IG, 1990, NEURON, V4, P165, DOI 10.1016/0896-6273(90)90452-L; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOBAYASHI S, 1986, BIOCHEMISTRY-US, V25, P8418, DOI 10.1021/bi00374a014; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER J, 1986, BLOOD, V67, P1197; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MAJACK RA, 1987, CELL MEMBRANES METHO, V3, P55; MARGOSSIAN SS, 1981, J BIOL CHEM, V256, P7495; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MOSHER DF, 1990, ANNU REV MED, V41, P85; MUMBY SM, 1984, J CELL BIOL, V98, P646, DOI 10.1083/jcb.98.2.646; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; OSTERHOUT DJ, 1992, DEV BIOL, V150, P256, DOI 10.1016/0012-1606(92)90240-H; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; RAUGI GJ, 1990, AM J PATHOL, V137, P179; RAUGI GJ, 1984, THROMB RES, V36, P165, DOI 10.1016/0049-3848(84)90338-4; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SHERBINA NV, 1992, BONE, V13, P197, DOI 10.1016/8756-3282(92)90012-L; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMITH KF, 1991, BIOCHEMISTRY-US, V30, P8000, DOI 10.1021/bi00246a018; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VOS HL, 1992, J BIOL CHEM, V267, P12192; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704; WOLF FW, 1990, GENOMICS, V6, P685, DOI 10.1016/0888-7543(90)90505-O; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	92	313	329	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1992	6	14					3290	3299		10.1096/fasebj.6.14.1426766	http://dx.doi.org/10.1096/fasebj.6.14.1426766			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426766				2022-12-28	WOS:A1992JZ73400011
J	CAZZULO, JJ				CAZZULO, JJ			AEROBIC FERMENTATION OF GLUCOSE BY TRYPANOSOMATIDS	FASEB JOURNAL			English	Review						LEISHMANIAS; PASTEUR EFFECT; GLUCOSE CATABOLISM; ANAEROBIC; GLYCOLYTIC ENZYMES; CARBOHYDRATE	MAGNETIC-RESONANCE ANALYSIS; LEISHMANIA-MAJOR PROMASTIGOTES; PYRUVATE-KINASE; D-LACTATE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; CARBOHYDRATE-METABOLISM; CRITHIDIA-FASCICULATA; CRUZI EPIMASTIGOTES; ENZYME-ACTIVITIES; CO2 FIXATION	The consumption of glucose by trypanosomatid protozoa such as Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., and Crithidia spp. is characterized by the excretion of reduced products such as succinate, pyruvate, ethanol, L-alanine, or lactate (depending on the species) not only in anaerobiosis, but also under aerobic conditions. The "aerobic fermentation" of glucose is accompanied by a complete lack, or even a reversal, of the Pasteur effect. This peculiar catabolism is mediated by a so-far unique compartmentation of the glycolytic enzymes, most of which are placed in an organelle called the glycosome; by an almost complete lack of inhibitory controls at the level of hexokinase and phosphofructokinase; and by a central role of CO2 fixation through the reaction catalyzed by phosphoenolpyruvate carboxykinase. The production of fermentative products seems to be due to a relative inefficiency of the respiratory chain, which lacks NADH dehydrogenase and the first phosphorylation site and preferentially uses succinate as substrate.			CAZZULO, JJ (corresponding author), UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,CONSEJO NACL INVEST CENT & TECN,FDN CAMPOMAR,RA-1405 BUENOS AIRES,ARGENTINA.							ADROHER FJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P252, DOI 10.1016/0003-9861(88)90030-6; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BOVERIS A, 1986, MOL BIOCHEM PARASIT, V19, P163, DOI 10.1016/0166-6851(86)90121-0; BOWMAN IBR, 1976, BIOLOGY KINETOPLASTI, V1, P435; CALLENS M, 1991, MOL BIOCHEM PARASIT, V47, P19, DOI 10.1016/0166-6851(91)90144-U; CANNATA JJB, 1984, COMP BIOCHEM PHYS B, V79, P297, DOI 10.1016/0305-0491(84)90380-8; CAZZULO JJ, 1989, FEMS MICROBIOL LETT, V59, P259, DOI 10.1111/j.1574-6968.1989.tb03121.x; CAZZULO JJ, 1985, COMP BIOCHEM PHYS B, V81, P1019, DOI 10.1016/0305-0491(85)90106-3; CAZZULO JJ, 1985, MOL BIOCHEM PARASIT, V16, P329, DOI 10.1016/0166-6851(85)90074-X; CAZZULO JJ, 1988, FEMS MICROBIOL LETT, V51, P187, DOI 10.1016/0378-1097(88)90398-9; DARLING TN, 1988, MOL BIOCHEM PARASIT, V28, P121, DOI 10.1016/0166-6851(88)90059-X; DARLING TN, 1987, P NATL ACAD SCI USA, V84, P7129, DOI 10.1073/pnas.84.20.7129; DARLING TN, 1988, MOL BIOCHEM PARASIT, V30, P253, DOI 10.1016/0166-6851(88)90094-1; DARLING TN, 1989, MOL BIOCHEM PARASIT, V33, P191, DOI 10.1016/0166-6851(89)90033-9; DEFLOMBAUM MAC, 1979, COMP BIOCH PHYSL B, V65, P103; DELOSSANTOS C, 1985, EUR J BIOCHEM, V149, P421, DOI 10.1111/j.1432-1033.1985.tb08942.x; DURIEUX PO, 1991, MOL BIOCHEM PARASIT, V45, P19, DOI 10.1016/0166-6851(91)90023-Y; DUSCHAK VG, 1991, FEMS MICROBIOL LETT, V832, P131; ENGEL JC, 1987, MOL BIOCHEM PARASIT, V25, P1; ETGES R, 1988, MOL BIOCHEM PARASIT, V27, P281, DOI 10.1016/0166-6851(88)90048-5; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FRYDMAN B, 1990, EUR J BIOCHEM, V192, P363, DOI 10.1111/j.1432-1033.1990.tb19235.x; GILROY FV, 1988, MOL BIOCHEM PARASIT, V31, P107, DOI 10.1016/0166-6851(88)90161-2; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; HIGA AI, 1981, MOL BIOCHEM PARASIT, V3, P357, DOI 10.1016/0166-6851(81)90036-0; MACKENZIE NE, 1982, BIOSCIENCE REP, V3, P141; MARR JJ, 1980, BIOCH PHYSL PROTOZOA, V3, P313; MOTTRAM JC, 1985, EXP PARASITOL, V59, P151, DOI 10.1016/0014-4894(85)90067-0; OPPERDOES FR, 1976, FEBS LETT, V62, P169, DOI 10.1016/0014-5793(76)80045-2; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; RAINEY PM, 1991, MOL BIOCHEM PARASIT, V45, P307, DOI 10.1016/0166-6851(91)90099-R; SHAPIRO TA, 1982, EXP PARASITOL, V54, P379, DOI 10.1016/0014-4894(82)90047-9; SOLARI AJ, 1980, CHROMOSOMA, V78, P239, DOI 10.1007/BF00328395; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; SYLVESTER D, 1976, COMP BIOCHEM PHYS B, V55, P443, DOI 10.1016/0305-0491(76)90318-7; TAYLOR MB, 1987, EXP PARASITOL, V63, P84, DOI 10.1016/0014-4894(87)90081-6; TURRENS JF, 1989, BIOCHEM J, V259, P363, DOI 10.1042/bj2590363; URBINA JA, 1990, ARCH BIOCHEM BIOPHYS, V282, P91, DOI 10.1016/0003-9861(90)90091-C; VANSCHAFTINGEN E, 1985, EUR J BIOCHEM, V153, P403, DOI 10.1111/j.1432-1033.1985.tb09316.x; VICKERMAN K, 1976, BIOL KINETOPLASTIDA, V1, P1; Von Brand T., 1979, BIOCH PHYSL ENDOPARA; WALSH C, 1991, TRENDS BIOCHEM SCI, V16, P305, DOI 10.1016/0968-0004(91)90124-E; WILLIAMS N, 1990, MOL BIOCHEM PARASIT, V43, P125, DOI 10.1016/0166-6851(90)90137-B	43	170	171	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1992	6	13					3153	3161		10.1096/fasebj.6.13.1397837	http://dx.doi.org/10.1096/fasebj.6.13.1397837			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397837	Bronze			2022-12-28	WOS:A1992JU51200007
J	NESTLER, JE; CLORE, JN; BLACKARD, WG				NESTLER, JE; CLORE, JN; BLACKARD, WG			DEHYDROEPIANDROSTERONE - THE MISSING LINK BETWEEN HYPERINSULINEMIA AND ATHEROSCLEROSIS	FASEB JOURNAL			English	Review						DEHYDROEPIANDROSTERONE; INSULIN; ATHEROSCLEROSIS; AGING; OBESITY	GLUCOSE-TOLERANCE TEST; INSULIN RESISTANCE; CARDIOVASCULAR-DISEASE; PLASMA DEHYDROEPIANDROSTERONE; MYOCARDIAL-INFARCTION; HYPERANDROGENIC WOMEN; ACANTHOSIS NIGRICANS; METABOLIC-CLEARANCE; TYROSINE KINASE; BODY-FAT	A well-established epidemiologic association exists between hyperinsulinemia and macrovascular disease. However, the mechanism or mechanisms by which hyperinsulinemia promotes atherogenesis is unknown. Recent evidence indicates that the adrenal steroid dehydroepiandrosterone (DHEA) exerts multiple antiatherogenic effects and also suggests that hyperinsulinemia may reduce serum DHEA and DHEA-sulfate levels by decreasing production and enhancing metabolic clearance. We advance the hypothesis that hyperinsulinemia promotes macrovascular disease in part by reducing serum DHEA and DHEA-sulfate levels and illustrate how this may be the case in two clinical conditions characterized by hyperinsulinemic insulin resistance: aging and obesity.			NESTLER, JE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV ENDOCRINOL & METAB,MCV STN,BOX 111,RICHMOND,VA 23298, USA.							ADLERCREUTZ H, 1972, EUR J CLIN INVEST, V2, P91, DOI 10.1111/j.1365-2362.1972.tb00575.x; ARAD Y, 1989, ARTERIOSCLEROSIS, V9, P159, DOI 10.1161/01.ATV.9.2.159; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BENDAVID M, 1967, P SOC EXP BIOL MED, V125, P1136; BOIZEL R, 1986, CLIN ENDOCRINOL, V25, P363, DOI 10.1111/j.1365-2265.1986.tb01702.x; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DIAMOND MP, 1991, J CLIN ENDOCR METAB, V72, P883, DOI 10.1210/jcem-72-4-883; EICH DM, 1990, CLIN RES, V38, pA2; ELLISON PT, 1984, ANN HUM BIOL, V11, P327, DOI 10.1080/03014468400007231; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FALCONE T, 1990, J CLIN ENDOCR METAB, V71, P1653, DOI 10.1210/jcem-71-6-1653; FARAH MJ, 1990, J CLIN ENDOCR METAB, V70, P1075, DOI 10.1210/jcem-70-4-1075; FEHER T, 1975, CAN J BIOCHEM CELL B, V53, P215, DOI 10.1139/o75-030; FINK RI, 1983, J CLIN INVEST, V71, P1523, DOI 10.1172/JCI110908; FINK RI, 1985, DIABETES, V34, P275, DOI 10.2337/diabetes.34.3.275; GORDON GB, 1988, J CLIN INVEST, V82, P712, DOI 10.1172/JCI113652; GORDON GB, 1986, CANCER RES, V46, P3389; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; GRAY A, 1991, J CLIN ENDOCR METAB, V73, P1016, DOI 10.1210/jcem-73-5-1016; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HENDRIKX A, 1968, J CLIN ENDOCR METAB, V28, P1525, DOI 10.1210/jcem-28-11-1525; HERRINGTON DM, 1990, J AM COLL CARDIOL, V16, P862; HUBERT GD, 1991, J CLIN ENDOCR METAB, V73, P781, DOI 10.1210/jcem-73-4-781; JESSE R, 1991, Journal of the American College of Cardiology, V17, p376A; KALIMI M, 1990, BIOL ROLE DEHYDROEPI; KIRSCHNER MA, 1983, J STEROID BIOCHEM, V19, P607, DOI 10.1016/0022-4731(83)90225-X; KREISBERG RA, 1987, GERIATRICS, V42, P67; KURTZ BR, 1987, J CLIN ENDOCR METAB, V64, P1261, DOI 10.1210/jcem-64-6-1261; KURZMAN ID, 1990, INT J OBESITY, V14, P95; LIU CH, 1990, J CLIN ENDOCR METAB, V71, P900, DOI 10.1210/jcem-71-4-900; LOPEZ SA, 1984, RISK FACTORS SENILIT, P210; MARMORSTON J, 1957, Geriatrics, V12, P297; MIGEON CJ, 1957, J CLIN ENDOCR METAB, V17, P1051, DOI 10.1210/jcem-17-9-1051; NESTLER JE, 1992, J CLIN ENDOCR METAB, V74, P362, DOI 10.1210/jc.74.2.362; NESTLER JE, 1989, J CLIN ENDOCR METAB, V69, P1040, DOI 10.1210/jcem-69-5-1040; NESTLER JE, 1988, J CLIN ENDOCR METAB, V66, P57, DOI 10.1210/jcem-66-1-57; NESTLER JE, 1987, J CLIN ENDOCR METAB, V64, P180, DOI 10.1210/jcem-64-1-180; NESTLER JE, 1991, ENDOCRINOLOGY, V129, P2951, DOI 10.1210/endo-129-6-2951; NISSLEY SP, 1984, CLIN ENDOCRINOL META, V13, P43; ORCHARD TJ, 1982, J CHRON DIS, V35, P123, DOI 10.1016/0021-9681(82)90113-8; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; PARKER CR, 1980, SCIENCE, V208, P512, DOI 10.1126/science.6445079; RAO LGS, 1970, LANCET, V2, P390; REAVEN GM, 1991, DIABETES CARE, V14, P195, DOI 10.2337/diacare.14.3.195; SAENGER P, 1977, EXPERIENTIA, V33, P966, DOI 10.1007/BF01951309; SALTIEL AR, 1990, DIABETES CARE, V13, P244, DOI 10.2337/diacare.13.3.244; SCHRIOCK ED, 1988, J CLIN ENDOCR METAB, V66, P1329, DOI 10.1210/jcem-66-6-1329; SHIMOKATA H, 1991, DIABETES, V40, P44, DOI 10.2337/diabetes.40.1.44; SLOWINSKASRZEDNICKA J, 1989, ATHEROSCLEROSIS, V79, P197; SMITH S, 1987, FERTIL STERIL, V48, P72; SONKA J, 1968, J LIPID RES, V9, P769; STOUT RW, 1991, AM J MED, V90, pS62, DOI 10.1016/0002-9343(91)90041-U; [No title captured]	53	109	112	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1992	6	12					3073	3075		10.1096/fasebj.6.12.1387859	http://dx.doi.org/10.1096/fasebj.6.12.1387859			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1387859				2022-12-28	WOS:A1992JN50500008
J	FERLINI, A; FINI, S; SALVI, F; PATROSSO, MC; VEZZONI, P; FORABOSCO, A				FERLINI, A; FINI, S; SALVI, F; PATROSSO, MC; VEZZONI, P; FORABOSCO, A			MOLECULAR STRATEGIES IN GENETIC DIAGNOSIS OF TRANSTHYRETIN-RELATED HEREDITARY AMYLOIDOSIS	FASEB JOURNAL			English	Article						TRANSTHYRETIN GENE; HEREDITARY AMYLOIDOSIS; RG-PCR SEQUENCE ANALYSIS	PRE-ALBUMIN; DNA	Transthyretin-related hereditary (TTR) amyloidoses represent a clinically heterogeneous group of diseases associated with various point mutations of the TTR gene. We propose a molecular strategy for the diagnosis of this group of disorders.	BELLARIA HOSP, DEPT NEUROL, BOLOGNA, ITALY; CNR, IST TECNOL BIOMED AVANZATE, I-20133 MILAN, ITALY	AUSL di Bologna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	FERLINI, A (corresponding author), UNIV MODENA, IST ANAT UMANA NORMALE, CATTEDRA ISTOL & EMBRIOL GEN, POLICLIN VIA POZZO 71, I-41100 MODENA, ITALY.		Vezzoni, Paolo/R-3416-2019; Salvi, Fabrizio/AAC-1956-2020; Vezzoni, Paolo/K-3197-2018	FERLINI, ALESSANDRA/0000-0001-8385-9870; Vezzoni, Paolo/0000-0002-6382-3923	Telethon [146] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMEIDA MR, 1991, AMYLOID AMYLOIDOSIS, P559; ALMEIDA MR, 1992, IN PRESS HUMAN MUTAT; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; BENSON MD, 1991, J MED GENET, V28, P73, DOI 10.1136/jmg.28.2.73; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; COSTA PP, 1978, P NATL ACAD SCI USA, V75, P4499, DOI 10.1073/pnas.75.9.4499; FERLINI A, 1991, CYTOGENET CELL GENET, V55, P2026; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606; II S, 1991, NEUROLOGY, V41, P893, DOI 10.1212/WNL.41.6.893; JONES LA, 1991, AM J HUM GENET, V48, P979; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; SARAIVA MJM, 1991, AM J HUM GENET, V48, P1004	12	38	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2864	2866		10.1096/fasebj.6.10.1353040	http://dx.doi.org/10.1096/fasebj.6.10.1353040			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1353040				2022-12-28	WOS:A1992JD95400017
J	CURRY, FE				CURRY, FE			MODULATION OF VENULAR MICROVESSEL PERMEABILITY BY CALCIUM INFLUX INTO ENDOTHELIAL-CELLS	FASEB JOURNAL			English	Article						INDIVIDUALLY PERFUSED CAPILLARIES; CAPILLARY PERMEABILITY; ENDOTHELIAL MONOLAYERS; HYDRAULIC CONDUCTIVITY; ENDOTHELIAL CYTOPLASMIC CALCIUM; EDRF; ENDOTHELIAL POTASSIUM CHANNELS; CALCIUM CHANNELS; INFLAMMATORY MEDIATORS	DENSITY LIPOPROTEIN TRANSPORT; CYTOPLASMIC FREE CALCIUM; VASCULAR SMOOTH-MUSCLE; HUMAN UMBILICAL VEIN; CYTOSOLIC CALCIUM; INTRACELLULAR CALCIUM; ELECTRICAL-RESISTANCE; ALBUMIN PERMEABILITY; IONIC CURRENTS; STRESS FIBERS	It has been proposed that calcium ion influx into endothelial cells modulates the permeability of venular microvessels via a calcium-dependent contractile process. The results of recent investigations using permeabilized endothelial cell monolayers conform to this hypothesis by demonstrating a calcium-dependent interaction of endothelial actin and myosin during the retraction of adjacent endothelial cells exposed to inflammatory agents. Little is known about the pathway for calcium influx into endothelial cells after exposure to mediators of inflammation, but evidence suggests that the properties of the calcium entry pathways are similar to the calcium entry pathways that regulate the release of endothelium-derived relaxing factor (EDRF). Substances that stimulate EDRF release from arterial endothelium also increase venular microvessel permeability. Recently developed methods to measure cytoplasmic calcium concentration in the endothelial cells forming the walls of individually perfused microvessels enable a direct investigation of the modulation of the permeability of venular microvessels by calcium influx. These experiments demonstrate that the magnitude of the initial increase in the permeability of microvessels after exposure to an agent that increases permeability, such as a calcium ionophore, is determined by the magnitude of calcium ion influx into the endothelial cells. Furthermore, the magnitude of the calcium influx into endothelial cells is modulated by the membrane potential of the endothelial cells. Depolarization of the endothelial cell membrane reduces calcium influx and attenuates increases in permeability whereas hyperpolarization of the endothelial membrane increases calcium influx and potentiates increases in permeability. These data conform to the hypothesis that a passive conductance channel for calcium is a major pathway for calcium ion flux responsible to eliciting an increase in the permeability of the endothelial barrier in microvessels.			CURRY, FE (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT HUMAN PHYSIOL,DAVIS,CA 95616, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028607, R37HL028607] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28607] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ALBELDA SM, 1988, J APPL PHYSIOL, V64, P308, DOI 10.1152/jappl.1988.64.1.308; ALEXANDER JS, 1988, MICROVASC RES, V35, P308, DOI 10.1016/0026-2862(88)90085-4; ALVAREZ OA, 1969, J PHYSIOL-LONDON, V202, P45, DOI 10.1113/jphysiol.1969.sp008794; ANDERSON GL, 1984, MICROVASC RES, V28, P51, DOI 10.1016/0026-2862(84)90028-1; BOTTARO D, 1986, MICROVASC RES, V32, P389, DOI 10.1016/0026-2862(86)90073-7; BREGESTOVSKI P, 1988, BRIT J PHARMACOL, V95, P429, DOI 10.1111/j.1476-5381.1988.tb11663.x; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; CANNELL MB, 1989, J PHYSIOL-LONDON, V419, P555, DOI 10.1113/jphysiol.1989.sp017886; CLOUGH G, 1988, Q J EXP PHYSIOL CMS, V73, P123, DOI 10.1113/expphysiol.1988.sp003109; COLDENSTANFIELD M, 1990, J MEMBRANE BIOL, V116, P227, DOI 10.1007/BF01868462; COLDENSTANFIELD M, 1987, CIRC RES, V61, P632, DOI 10.1161/01.RES.61.5.632; CRONE C, 1988, ENDOTHELIAL CELLS, V3, P92; CURRY FE, 1990, AM J PHYSIOL, V258, pH587, DOI 10.1152/ajpheart.1990.258.2.H587; CURRY FE, 1989, P INT UNION PHYSL SC, V17, P230; Curry FE, 1983, CARDIOVASCULAR PHY P, P1; CURRY FE, 1988, ENDOTHELIAL CELLS, V1, P3; CURRY FRE, 1986, CIRC RES, V59, P367, DOI 10.1161/01.RES.59.4.367; DRENCKHAHN D, 1986, J CELL BIOL, V102, P1738, DOI 10.1083/jcb.102.5.1738; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FURIE MB, 1984, J CELL BIOL, V98, P1033, DOI 10.1083/jcb.98.3.1033; GALEY F, 1978, MICROVASC RES, V15, P263; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; HAGIWARA S, 1981, ANNU REV NEUROSCI, V4, P69, DOI 10.1146/annurev.ne.04.030181.000441; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; HALLAM TJ, 1986, FEBS LETT, V207, P95, DOI 10.1016/0014-5793(86)80019-9; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HASELTON FR, 1989, J APPL PHYSIOL, V67, P2032, DOI 10.1152/jappl.1989.67.5.2032; HE P, 1990, AM J PHYSIOL, V258, pH1366; HE P, 1990, FASEB Journal, V4, pA835; HE P, 1990, FASEB J, V4, pA1254; HE P, 1992, AM J PHYSIOL, V261, pH1246; HUANG AJ, 1988, J CELL PHYSIOL, V135, P355, DOI 10.1002/jcp.1041350302; HULSTROM D, 1979, J PATHOL, V129, P125, DOI 10.1002/path.1711290304; HURLEY JV, 1984, EDEMA, P463; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JOHNS A, 1987, TISSUE CELL, V19, P733, DOI 10.1016/0040-8166(87)90015-2; JORIS I, 1972, VIRCHOWS ARCH B, V12, P73; JORIS I, 1987, AM J PATHOL, V126, P19; JOYNER WL, 1986, FASEB J, V45, P583; KELLEY C, 1987, J CELL BIOL, V104, P483, DOI 10.1083/jcb.104.3.483; KILLACKEY JJF, 1986, AM J PATHOL, V122, P50; KUBES K, 1991, FASEB J, V5, pA1388; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LIDDELL RHA, 1980, MICROVASC RES, V20, P255; LUCKHOFF A, 1988, BRIT J PHARMACOL, V95, P189; LUCKHOFF A, 1990, PFLUG ARCH EUR J PHY, V416, P305, DOI 10.1007/BF00392067; MADARA JL, 1989, J CLIN INVEST, V83, P1089, DOI 10.1172/JCI113987; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P607, DOI 10.1083/jcb.11.3.607; MAYHAN WG, 1984, MICROVASC RES, V28, P159; MEHRKE G, 1990, J PHYSIOL-LONDON, V430, P252; Michel C. C., 1984, HDB PHYSL 2, VIV, P375; MINEAUHANSCHKE R, 1990, MICROVASC RES, V39, P140, DOI 10.1016/0026-2862(90)90066-Z; MORREL NM, 1989, J CELL PHYSL, V141, P653; NAVAB M, 1986, J CLIN INVEST, V78, P389, DOI 10.1172/JCI112589; NILIUS B, 1991, NEWS PHYSIOL SCI, V6, P110; NORTHOVER AM, 1969, J PATHOL, V98, P265, DOI 10.1002/path.1710980406; Northover BJ, 1980, ADV MICROCIRCULAT, V9, P135; PEACH MJ, 1987, AM J CARDIOL, V59, pA34; Persson CGA, 1985, HDB INFLAMMATION, V5, P61; REES DD, 1990, NITRIC OXIDE L ARGIN, P427; RENKIN EM, 1978, MEMBRANE TRANSPORT B, P1; ROTROSEN D, 1986, J CELL BIOL, V103, P2379, DOI 10.1083/jcb.103.6.2379; RUTLEDGE JC, 1990, CIRC RES, V66, P486, DOI 10.1161/01.RES.66.2.486; RUTLEDGE JC, 1991, 5TH P WORLD C MICR L; SAGE SO, 1989, J BIOL CHEM, V264, P6; SAUVE R, 1988, PFLUG ARCH EUR J PHY, V412, P469, DOI 10.1007/BF00582535; SAUVE R, 1988, AM J PHYSIOL, V257, pH778; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHNITTLER HJ, 1990, J PHYSIOL-LONDON, V431, P379, DOI 10.1113/jphysiol.1990.sp018335; SHASBY DM, 1986, J APPL PHYSIOL, V60, P71, DOI 10.1152/jappl.1986.60.1.71; SIFLINGERBIRNBOIM A, 1987, J CELL PHYSIOL, V132, P111, DOI 10.1002/jcp.1041320115; SINGER HA, 1982, HYPERTENSION, V4, P19, DOI 10.1161/01.HYP.4.3_Pt_2.19; SUTTORP N, 1989, LAB INVEST, V61, P183; SUTTORP N, 1988, AM J PHYSIOL, V255, pC368, DOI 10.1152/ajpcell.1988.255.3.C368; TAKEDA K, 1987, PFLUG ARCH EUR J PHY, V410, P385, DOI 10.1007/BF00586515; TAKEDA K, 1990, BLOOD VESSELS, V27, P169; TERRITO M, 1984, J CLIN INVEST, V74, P2279, DOI 10.1172/JCI111655; TRAPJENS.J, 1971, AM J PHYSIOL, V220, P371, DOI 10.1152/ajplegacy.1971.220.2.371; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WELLES SL, 1985, J CELL PHYSIOL, V123, P337, DOI 10.1002/jcp.1041230307; WYSOLMERSKI R, 1985, AM J PATHOL, V119, P505; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; ZHANG RS, 1992, AM J PHYSIOL, V262, pH144, DOI 10.1152/ajpheart.1992.262.1.H144	88	133	133	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2456	2466		10.1096/fasebj.6.7.1563597	http://dx.doi.org/10.1096/fasebj.6.7.1563597			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563597				2022-12-28	WOS:A1992HP03000012
J	KOESLING, D; BOHME, E; SCHULTZ, G				KOESLING, D; BOHME, E; SCHULTZ, G			GUANYLYL CYCLASES, A GROWING FAMILY OF SIGNAL-TRANSDUCING ENZYMES	FASEB JOURNAL			English	Review						TRANSDUCER; TRANSMEMBRANE SIGNALING; PEPTIDE HORMONE	ATRIAL NATRIURETIC FACTOR; PROTEIN-TYROSINE-PHOSPHATASES; HEAT-STABLE ENTEROTOXIN; RAT LUNG; ADENYLYL CYCLASE; BOVINE LUNG; CYCLIC-GMP; CATALYTIC ACTIVITY; MOLECULAR-CLONING; ESCHERICHIA-COLI	Guanylyl cyclases, which catalyze the formation of the intracellular signal molecule cyclic GMP from GTP, display structural features similar to other signal-transducing enzymes such as protein tyrosine-kinases and protein tyrosine-phosphatases. So far, three isoforms of mammalian membrane-bound guanylyl cyclases (GC-A, GC-B, GC-C), which are stimulated by either natriuretic peptides (GC-A, GC-B) or by the enterotoxin of Escherichia coli (GC-C), have been identified. These proteins belong to the group of receptor-linked enzymes, with different NH2-terminal extracellular receptor domains coupled to a common intracellular catalytic domain. In contrast to the membrane-bound enzymes, the heme-containing soluble guanylyl cyclase is stimulated by NO and NO-containing compounds and consists of two subunits (alpha-1 and beta-1). Both subunits contain the putative catalytic domain, which is conserved in the membrane-bound guanylyl cyclases and is found twice in adenylyl cyclases. Coexpression of the alpha-1- and beta-1-subunit is required to yield a catalytically active enzyme. Recently, another subunit of soluble guanylyl cyclase was identified and designated beta-2, revealing heterogeneity among the subunits of soluble guanylyl cyclase. Thus, different enzyme subunits may be expressed in a tissue-specific manner, leading to the assembly of various heterodimeric enzyme forms. The implications concerning the physiological regulation of soluble guanylyl cyclase are not known, but different mechanisms of soluble enzyme activation may be due to heterogeneity among the subunits of soluble guanylyl cyclase.			KOESLING, D (corresponding author), FREE UNIV BERLIN, INST PHARMAKOL, THIELALLEE 67-73, W-1000 BERLIN 33, GERMANY.							BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BEUVE A, 1990, J BACTERIOL, V172, P2614, DOI 10.1128/jb.172.5.2614-2621.1990; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Bohme E, 1978, Adv Cyclic Nucleotide Res, V9, P131; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FISCHER EH, 1990, ADV SEC MESS PHOSPH, V24, P273; FORTE LR, 1988, AM J PHYSIOL, V255, pF1040, DOI 10.1152/ajprenal.1988.255.5.F1040; FULLER F, 1988, J BIOL CHEM, V263, P9395; FURCHGOTT RF, 1989, BIOCHEM PHARMACOL, V38, P1709; GARBERS D L, 1990, New Biologist, V2, P499; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUNO T, 1986, J BIOL CHEM, V261, P5817; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAUL AK, 1987, SCIENCE, V235, P1224, DOI 10.1126/science.2881352; RADANY EW, 1983, J BIOL CHEM, V258, P8346; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHULTZ JE, 1984, ADV CYCLIC NUCL PROT, V17, P275; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHIMOMURA H, 1986, J BIOL CHEM, V261, P5778; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; TAKAYANAGI R, 1987, BIOCHEM BIOPH RES CO, V144, P244, DOI 10.1016/S0006-291X(87)80502-8; THORPE DS, 1989, J BIOL CHEM, V264, P6545; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; XIA ZG, 1990, J BIOL CHEM, V265, P6517; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002	51	148	150	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1991	5	13					2785	2791		10.1096/fasebj.5.13.1680765	http://dx.doi.org/10.1096/fasebj.5.13.1680765			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1680765				2022-12-28	WOS:A1991GJ47100006
J	VANDENBURGH, HH; SWASDISON, S; KARLISCH, P				VANDENBURGH, HH; SWASDISON, S; KARLISCH, P			COMPUTER-AIDED MECHANOGENESIS OF SKELETAL-MUSCLE ORGANS FROM SINGLE CELLS-INVITRO	FASEB JOURNAL			English	Article						DEVELOPMENT; MECHANICAL FORCES; ORGANOGENESIS; DYSTROPHIN; SKIN	CHICK MYOTENDINOUS ANTIGEN; POSITIONAL INFORMATION; MECHANICAL TENSION; TISSUE-CULTURE; GROWTH; MORPHOGENESIS; IMMUNOFLUORESCENCE; LOCALIZATION; HYPERTROPHY; MYOGENESIS	Complex mechanical forces generated in the growing embryo play an important role in organogenesis. Computerized mechanical application of similar forces to differentiating skeletal muscle myoblasts in vitro generate three-dimensional artificial muscle organs. These organs contain parallel networks of long unbranched myofibers organized into fascicle-like structures. Tendon development is initiated and the muscle's are capable of performing directed, functional work. Kinetically engineered organs provide a new method for studying the growth and development of normal and diseased tissue.	BROWN UNIV,DEPT PATHOL,PROVIDENCE,RI 02912; UNIV ALABAMA,DEPT CELL BIOL & ANAT,BIRMINGHAM,AL 35294	Brown University; University of Alabama System; University of Alabama Birmingham	VANDENBURGH, HH (corresponding author), MIRIAM HOSP,DEPT PATHOL,164 SUMMIT AVE,PROVIDENCE,RI 02906, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039998, R01AR036266] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05818] Funding Source: Medline; NIAMS NIH HHS [AR39998, AR36266] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BISCHOFF R, 1978, MEMBRANE FUSION, P127; BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; BURKE JF, 1981, ANN SURG, V194, P413, DOI 10.1097/00000658-198110000-00005; CERNY LC, 1986, J CELL BIOL, V103, P2153, DOI 10.1083/jcb.103.6.2153; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUET M, 1981, DEV BIOL, V88, P220, DOI 10.1016/0012-1606(81)90166-4; CURTIS ASG, 1978, NATURE, V274, P52, DOI 10.1038/274052a0; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; DENT JA, 1989, DEVELOPMENT, V105, P61; DEWITT MT, 1984, CONNECT TISSUE RES, V12, P97, DOI 10.3109/03008208408992775; EDE DA, 1976, CELL SURFACE ANIMAL, P495; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; HALL BK, 1971, CLIN ORTHOP RELAT R, V74, P249; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; KAMIYA A, 1980, AM J PHYSIOL, V239, pH14, DOI 10.1152/ajpheart.1980.239.1.H14; KELLY AM, 1983, HDB PHYSL 10, P507; KIENY M, 1979, J EMBRYOL EXP MORPH, V49, P153; KLEINNULEND J, 1987, J BIOL CHEM, V262, P15490; LANDMESSER LT, 1984, J PHYSIOL-LONDON, V347, P189, DOI 10.1113/jphysiol.1984.sp015061; LEUNG DYM, 1976, SCIENCE, V191, P475; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MIRANDA AF, 1985, ADV CELL CULT, V4, P1; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; PEARSON ML, 1982, MUSCLE DEV MOL CELLU; RANNELS DE, 1989, AM J PHYSIOL, V257, pL179, DOI 10.1152/ajplung.1989.257.4.L179; RYAN TJ, 1989, J AM ACAD DERMATOL, V21, P115, DOI 10.1016/S0190-9622(89)70156-0; SANDERSON RD, 1986, J CELL BIOL, V102, P740, DOI 10.1083/jcb.102.3.740; Shellswell G., 1977, VERTEBRATE LIMB SOMI, P71; SHELLSWELL GB, 1980, J EMBRYOL EXP MORPH, V60, P245; Stewart D.M, 1972, REGULATION ORGAN TIS, P77; STROHMAN RC, 1990, IN VITRO CELL DEV B, V26, P201; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P227; TOMANEK RJ, 1975, DEV BIOL, V42, P305, DOI 10.1016/0012-1606(75)90337-1; VANDENBURGH H, 1979, SCIENCE, V203, P265, DOI 10.1126/science.569901; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1982, DEV BIOL, V93, P438, DOI 10.1016/0012-1606(82)90131-2; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P609; VANDENBURGH HH, 1989, IN VITRO CELL DEV B, V25, P607; VANDENBURGH HH, 1987, MED SCI SPORT EXER, V19, pS142; VONDERMARK K, 1976, DEV BIOL, V53, P153, DOI 10.1016/0012-1606(76)90220-7; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WEISS P, 1933, AM NAT, V118, P389; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	48	95	111	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2860	2867		10.1096/fasebj.5.13.1916108	http://dx.doi.org/10.1096/fasebj.5.13.1916108			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916108	Green Submitted			2022-12-28	WOS:A1991GJ47100016
J	AHMAD, PM; AHMAD, F				AHMAD, PM; AHMAD, F			MAMMALIAN PYRUVATE-CARBOXYLASE - EFFECT OF BIOTIN ON THE SYNTHESIS AND TRANSLOCATION OF APOENZYME INTO 3T3-L ADIPOCYTE MITOCHONDRIA	FASEB JOURNAL			English	Note						BIOTIN; ADIPOCYTES; TRANSLOCATION; MITOCHONDRIA	CELLS; DIFFERENTIATION; SYNTHETASE; DEFICIENCY; INDUCTION; PROTEINS; IMPORT; FORMS	The effect of biotin on the induction (and possible requirement for uptake into mitochondria) of apopyruvate carboxylase has been examined in 3T3-L adipocytes. Cells fed biotin-sufficient medium contained only holoenzyme in mitochondria and no apoenzyme was detected. The amount of apoenzyme elaborated in biotin-deficient 3T3-L adipocytes was comparable to the holopyruvate carboxylase protein found in cells maintained on biotin-sufficient medium. Like the holoenzyme, the apoenzyme was detected exclusively in the mitochondrial fraction of 3T3-L adipocytes. This indicates that the synthesis of apopyruvate carboxylase and its translocation into mitochondria occur independently of the cofactor, biotin.	UNIV MIAMI,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101	University of Miami				Ahmad, Farhan/0000-0002-0740-8573	NIDDK NIH HHS [DK-36739] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036739] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1986, BIOCHEM J, V236, P527, DOI 10.1042/bj2360527; AHMAD PM, 1979, BIOCHEM J, V182, P509, DOI 10.1042/bj1820509; ATKIN BM, 1979, PEDIATR RES, V13, P38, DOI 10.1203/00006450-197901000-00009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG HI, 1983, ARCH BIOCHEM BIOPHYS, V225, P237, DOI 10.1016/0003-9861(83)90026-7; FREYTAG SO, 1980, P NATL ACAD SCI-BIOL, V77, P1321, DOI 10.1073/pnas.77.3.1321; FREYTAG SO, 1983, J BIOL CHEM, V258, P6307; GRATZNER HG, 1980, CELL BIOL INT REP, V4, P497, DOI 10.1016/0309-1651(80)90037-5; GREEN NM, 1973, BIOCHEM J, V133, P687, DOI 10.1042/bj1330687; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; KOSOW DP, 1962, J BIOL CHEM, V237, P3633; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; MCALLISTER HC, 1966, J BIOL CHEM, V241, P2855; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PESCE A, 1964, J BIOL CHEM, V239, P1753; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	21	11	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2482	2485		10.1096/fasebj.5.10.2065895	http://dx.doi.org/10.1096/fasebj.5.10.2065895			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065895				2022-12-28	WOS:A1991FW08700020
J	CULLEN, BR				CULLEN, BR			REGULATION OF HIV-1 GENE-EXPRESSION	FASEB JOURNAL			English	Review						HIV-1 GENE EXPRESSION; NF-KAPPA-B; TAT; REV; RNA, PROTEIN BINDING	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; REV TRANS-ACTIVATOR; VIRAL MESSENGER-RNA; NF-KAPPA-B; TAT PROTEIN; TRANSCRIPTIONAL REGULATION; TARGET SEQUENCE; NEF PROTEIN; TYPE-1	The quantity and quality of HIV-1 gene expression is temporally controlled by a cascade of sequential regulatory interactions. Basal HIV-1 transcription is determined by interaction of cellular regulatory proteins with specific DNA target sequences within the HIV-1 long-terminal repeat. The most notable of these protein: DNA interactions involves NF-kappa-B, a transcription factor that plays a pivotal role in the activation of genes important for cellular responses to infection and inflammation. A second level of control involves the virally encoded Tat trans-activator. Tat, in combination with as yet unidentified cellular proteins, activates HIV-1 gene expression through a specific interaction with the viral TAR RNA stem-loop target sequence. A final level of regulation is mediated by the viral Rev protein. Rev acts posttranscriptionally to induce the expression of HIV-1 structural proteins and thereby commits HIV-1 to the late, cytopathic phase of the viral replication cycle. Rev activity appears to require a critical, threshold level of Rev protein expression, thus preventing entry into this late phase in cells that are unable to support efficient HIV-1 gene expression. In total, this cascade of regulatory levels allows the HIV-1 provirus to respond appropriately to the intracellular milieu present in each infected cell. In activated cells, the combination of Tat and Rev can stimulate a very high level of viral gene expression and replication. In quiescent or resting cells, in contrast, these same regulatory proteins are predicted to maintain the HIV-1 provirus in a latent or nonproductive state.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University	CULLEN, BR (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.							AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CULLEN BR, 1990, VIROLOGY, V178, P1, DOI 10.1016/0042-6822(90)90373-Y; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATZ RA, 1990, MOL CELL BIOL, V10, P696, DOI 10.1128/MCB.10.2.696; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LU YC, 1990, J VIROL, V64, P5226, DOI 10.1128/JVI.64.10.5226-5229.1990; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; SCHWARTZ S, 1990, J VIROL, V64, P5448, DOI 10.1128/JVI.64.11.5448-5456.1990; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; VARMUS H, 1989, MOBILE DNA, P53; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	50	222	227	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2361	2368		10.1096/fasebj.5.10.1712325	http://dx.doi.org/10.1096/fasebj.5.10.1712325			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	1712325				2022-12-28	WOS:A1991FW08700006
J	ALOUSI, AA; JASPER, JR; INSEL, PA; MOTULSKY, HJ				ALOUSI, AA; JASPER, JR; INSEL, PA; MOTULSKY, HJ			STOICHIOMETRY OF RECEPTOR-GS-ADENYLATE CYCLASE INTERACTIONS	FASEB JOURNAL			English	Note						G-PROTEINS; FORSKOLIN; RECEPTORS	BETA-ADRENERGIC RECEPTORS; S49 LYMPHOMA-CELLS; REGULATORY PROTEIN; BINDING-PROTEIN; MULTIPLE SITES; FORSKOLIN; STIMULATION; MEMBRANES; MECHANISM; AFFINITY	Little is known about the relative stoichiometry of guanine nucleotide-binding (G) proteins relative to the effector systems to which they link. We addressed this question for the stimulatory G protein (G(s)) linked to adenylate cyclase. Forskolin stimulates the catalytic subunit of adenylate cyclase (C), but it has a higher efficacy and potency when C also interacts with the G protein G(s). Accordingly, we measured high-affinity [H-3]forskolin binding to intact cells to assay alpha-s-C complexes. No high-affinity specific binding occurred with unstimulated cells. The beta-adrenergic agonist isoproterenol promoted the binding of [H-3]forskolin to about 3000 sites per cell, suggesting that each receptor on average activates at least several G(s) molecules. Activating G(s) directly with cholera toxin maximally promoted [H-3]forskolin binding to a similar number of sites, suggesting that this is the maximal number of alpha-s-C complexes formed per cell. We conclude that each cell likely contains only a few thousand functional copies of C, and that the availability of C (rather than G(s), which exists in more than 100,000 copies per cell) is likely to be limiting for agonist stimulation of adenylate cyclase activity.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL 0636,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARBER R, 1989, 2 MESSENGERS PHOSPHO, V12, P59; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; DARFLER FJ, 1982, J BIOL CHEM, V257, P1901; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; HAMMOND HK, 1988, J CLIN INVEST, V82, P2168, DOI 10.1172/JCI113840; INSEL PA, 1979, J BIOL CHEM, V254, P6554; INSEL PA, 1983, J BIOL CHEM, V258, P3597; JASPER JR, 1988, J PHARMACOL EXP THER, V244, P820; LAURENZA A, 1987, MOL PHARMACOL, V32, P133; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LONGABAUGH JP, 1988, J CLIN INVEST, V81, P420, DOI 10.1172/JCI113335; MORRIS D, 1990, BIOCHEMISTRY-US, V29, P9079, DOI 10.1021/bi00490a027; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; RANSNAS LA, 1988, J BIOL CHEM, V263, P17239; RODAN GA, 1984, ADV CYCLIC NUCL PROT, V17, P127; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135	19	139	142	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2300	2303		10.1096/fasebj.5.9.1650314	http://dx.doi.org/10.1096/fasebj.5.9.1650314			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1650314				2022-12-28	WOS:A1991FP87200012
J	WAHLI, W; MARTINEZ, E				WAHLI, W; MARTINEZ, E			SUPERFAMILY OF STEROID NUCLEAR RECEPTORS - POSITIVE AND NEGATIVE REGULATORS OF GENE-EXPRESSION	FASEB JOURNAL			English	Review						HORMONE RECEPTOR; TERPENOID HORMONE; RETINOIC ACID; LIGAND; GENE EXPRESSION; STEROID HORMONE	THYROID-HORMONE RECEPTOR; MAMMARY-TUMOR VIRUS; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; DNA-BINDING; PATTERN-FORMATION; MESSENGER-RNA; C-JUN; PROTEIN; MOUSE	The nuclear hormone receptor superfamily is characterized by an impressive functional diversity of its members despite a remarkable overall structural unity. A variety of ligands bind specifically to them and these receptors control gene networks that have profound effects on growth, development, and homeostasis. The ligand-receptor complexes recognize transcriptional enhancer DNA sequences, the hormone response elements, resulting in induction or repression of gene activity. The similarity between all these hormone response enhancer elements, as well as between the receptors themselves, indicates a conserved general strategy for the hormonal control of transcription by steroids. Thc activated receptors bind to responsive promoters and most likely mediate thc assembly of stage- and tissue-specific transcription factor complexes that stimulate or inhibit gene expression			WAHLI, W (corresponding author), UNIV LAUSANNE,INST BIOL ANIM,BATIMENT BIOL,CH-1015 LAUSANNE,SWITZERLAND.		Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019	Wahli, Walter/0000-0002-5966-9089; 				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; BARTON MC, 1988, P NATL ACAD SCI USA, V85, P7119, DOI 10.1073/pnas.85.19.7119; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; CORTHESY B, 1990, P NATL ACAD SCI USA, V87, P1120; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN B M, 1990, New Biologist, V2, P587; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Ham J, 1989, CURR OPIN CELL BIOL, V1, P503, DOI 10.1016/0955-0674(89)90012-4; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KARIN M, 1990, New Biologist, V2, P126; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LAZAR MA, 1990, DNA CELL BIOL, V9, P77, DOI 10.1089/dna.1990.9.77; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTINEZ E, 1991, NUCLEAR HORMONE RECE, P125; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOORE D D, 1990, New Biologist, V2, P100; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SLUYSER M, 1990, CANCER RES, V50, P451; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WEDDEN SE, 1988, DEVELOPMENT, V103, P31; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	58	289	299	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2243	2249		10.1096/fasebj.5.9.1860615	http://dx.doi.org/10.1096/fasebj.5.9.1860615			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860615				2022-12-28	WOS:A1991FP87200004
J	BEATO, M				BEATO, M			TRANSCRIPTIONAL CONTROL BY NUCLEAR RECEPTORS	FASEB JOURNAL			English	Article						GENE EXPRESSION; STEROID HORMONE RECEPTOR; REGULATORY PROTEIN; HORMONE LIGAND; NUCLEAR RECEPTOR; ZINC FINGER; PHOSPHORYLATION	MAMMARY-TUMOR VIRUS; STEROID-HORMONE RECEPTORS; TARGET GENE SPECIFICITY; GLUCOCORTICOID RECEPTOR; HYPERSENSITIVE SITES; ESTROGEN-RECEPTOR; BINDING DOMAIN; DNA-BINDING; ZINC FINGER; AMINO-ACIDS	Gene regulation by steroid hormones is accomplished by a variety of different mechanisms leading to induction or repression of particular genes. These mechanisms are all mediated by a single class of intracellular hormone receptors, which in the unliganded state are maintained in an inactive form by association with other cellular proteins, including hsp90. Induction of the mouse mammary tumor virus (MMTV) requires binding of the hormone receptor to a hormone-responsive element (HRE) that is precisely organized in a phased nucleosome. After receptor binding, changes in chromatin structure are detected that correlate with binding of transcription factors, including nuclear factor I, to the MMTV promoter. However, although nuclear factor I acts as a basal transcription factor on the MMTV promoter it does not cooperate with the hormone receptors in terms of binding to free DNA, and mutation of the nuclear factor I binding site does not eliminate hormonal stimulation. This residual induction is mediated by octamer motifs upstream of the TATA box that bind the ubiquitous transcription factor OTF-1. Mutation of these octamer motifs does not influence basal transcription in vitro, but completely abolishes the stimulatory effect of progesterone receptor. Glucocorticoids also inhibit expression of many genes. The effect on the gene for the alpha-subunit of chorionic gonadotropin is due to DNA binding competition between the receptor and the protein mediating cAMP induction, whereas repression of the collagenase gene involves an interaction of the receptor with components of the AP1 complex, Jun and Fos. - Beato, M. Transcriptional control by nuclear receptors.			BEATO, M (corresponding author), INST MOLEK BIOL & TUMORFORSCHUNG,W-3550 MARBURG,GERMANY.		Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CARBALLO M, 1990, DNA CELL BIOL, V9, P519, DOI 10.1089/dna.1990.9.519; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CARR KD, 1990, IN PRESS P NATL ACAD; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DALMAN FC, 1990, J BIOL CHEM, V265, P2615; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; PRATT WB, 1988, J BIOL CHEM, V263, P267; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0	42	225	228	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2044	2051		10.1096/fasebj.5.7.2010057	http://dx.doi.org/10.1096/fasebj.5.7.2010057			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010057				2022-12-28	WOS:A1991FF44200006
J	FLORINECASTEEL, K; LEMASTERS, JJ; HERMAN, B				FLORINECASTEEL, K; LEMASTERS, JJ; HERMAN, B			LIPID ORDER IN HEPATOCYTE PLASMA-MEMBRANE BLEBS DURING ATP DEPLETION MEASURED BY DIGITIZED VIDEO FLUORESCENCE POLARIZATION MICROSCOPY	FASEB JOURNAL			English	Note						FLUORESCENCE POLARIZATION; DIGITIZED VIDEO MICROSCOPY; MEMBRANE FLUIDITY; TRIMETHYLAMMONIUMDIPHENYLHEXATRIENE; HYPOXIA	ACCELERATED PHOSPHOLIPID DEGRADATION; RAT-LIVER; CELL-DEATH; FLUIDITY; INJURY; PEROXIDATION; PREVENTION; ISCHEMIA; INCREASE; BILAYERS	Low-light digitized video fluorescence polarization microscopy was used to measure lipid order parameters in plasma membrane blebs of single, cultured rat hepatocytes during ATP depletion with the metabolic inhibitors cyanide and iodoacetic acid. Hepatocytes were labeled on the microscope stage with the plasma membrane probe trimethylammoniumdiphenylhexatriene at successive stages of cell injury. A pair of fluorescence polarization ratio images was obtained from a series of four fluorescence images recorded with a polarizer in the emission path oriented first parallel and then perpendicular to each of two orthogonal excitation light polarization directions. From the polarization ratio images, the lipid order parameter S was determined in individual plasma membrane blebs. Results indicate that the plasma membrane becomes uniformly rigid within a few minutes of the addition of metabolic inhibitors when small surface blebs have formed and ATP levels have fallen by > 95%. The measured order parameter of S almost-equal-to 0.95 in plasma membrane blebs, compared with S almost-equal-to 0.75 in normoxic cell plasma membranes, remained unchanged throughout the course of bleb development and ultimate cell death. These findings demonstrate that significant alteration in hepatocyte plasma membrane structure occurs early in hypoxic cell injury.	UNIV N CAROLINA, DEPT CELL BIOL & ANAT, CB 7090, 232 TAYLOR HALL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULM TOXICOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER CANC RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIA NIH HHS [AG07218] Funding Source: Medline; NIEHS NIH HHS [ES07126] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG007218] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLOCK ER, 1989, AM J PHYSIOL, V257, pC223, DOI 10.1152/ajpcell.1989.257.2.C223; CHIEN KR, 1978, J BIOL CHEM, V253, P4809; EICHENBERGER K, 1982, FEBS LETT, V142, P59, DOI 10.1016/0014-5793(82)80219-6; FARBER JL, 1978, AM J PATHOL, V92, P713; FARBER JL, 1981, AM J PATHOL, V102, P271; FARBER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312, DOI 10.1016/0003-9861(81)90459-8; FLORINECASTEEL K, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P559; FLORINECASTEEL K, 1990, BIOPHYS J, V57, P1199, DOI 10.1016/S0006-3495(90)82639-4; FREDERIKS WM, 1984, VIRCHOWS ARCH B, V46, P269, DOI 10.1007/BF02890316; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; HERMAN B, 1988, FASEB J, V2, P146, DOI 10.1096/fasebj.2.2.3342967; HERMAN B, 1991, IN PRESS CRC CRITICA; HEYN MP, 1979, FEBS LETT, V108, P359, DOI 10.1016/0014-5793(79)80564-5; JONES RL, 1989, AM J PATHOL, V135, P541; KUHRY JG, 1983, CELL BIOPHYS, V5, P129, DOI 10.1007/BF02796139; LEMASTERS JJ, 1983, J CELL BIOL, V97, P778, DOI 10.1083/jcb.97.3.778; NACHBAUR J, 1972, BIOCHIM BIOPHYS ACTA, V274, P426, DOI 10.1016/0005-2736(72)90189-7; NEWKIRK JD, 1973, BIOCHIM BIOPHYS ACTA, V298, P562, DOI 10.1016/0005-2736(73)90074-6; NIEMINEN AL, 1988, CELL CALCIUM, V9, P237, DOI 10.1016/0143-4160(88)90004-8; OHYASHIKI T, 1986, BIOCHIM BIOPHYS ACTA, V861, P311, DOI 10.1016/0005-2736(86)90433-5; OKAYASU T, 1984, AM J PATHOL, V117, P163; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; RICEEVANS C, 1981, BIOCHEM BIOPH RES CO, V100, P1537, DOI 10.1016/0006-291X(81)90693-8; STORCH J, 1985, BIOCHIM BIOPHYS ACTA, V812, P473, DOI 10.1016/0005-2736(85)90322-0; STUBBS CD, 1981, BIOCHEMISTRY-US, V20, P4257, DOI 10.1021/bi00518a004; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; VICTORIA EJ, 1971, BIOCHIM BIOPHYS ACTA, V239, P443, DOI 10.1016/0005-2760(71)90036-1	28	33	33	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1991	5	7					2078	2084		10.1096/fasebj.5.7.2010060	http://dx.doi.org/10.1096/fasebj.5.7.2010060			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010060				2022-12-28	WOS:A1991FF44200010
J	BANSAL, N; HOULE, A; MELNYKOVYCH, G				BANSAL, N; HOULE, A; MELNYKOVYCH, G			APOPTOSIS - MODE OF CELL-DEATH INDUCED IN T-CELL LEUKEMIA LINES BY DEXAMETHASONE AND OTHER AGENTS	FASEB JOURNAL			English	Article						APOPTOSIS; DEXAMETHASONE; CEM CELLS; ENDONUCLEASE; DNA FRAGMENTATION; RU 486	DNA FRAGMENTATION; GLUCOCORTICOIDS; ENDONUCLEASE; THYMOCYTES; ACTIVATION; INDUCTION; CLEAVAGE; NUCLEASE; RECEPTOR; LEADS	Glucocorticoids can mediate the destruction of thymocytes and T cell-derived leukemia cells through a mechanism known as apoptosis. The characteristic feature of apoptosis is fragmentation of DNA at internucleosomal linkers through the activity of a specific endonuclease. In this study, an attempt was made to compare dexamethasone-induced apoptosis in two T cell-derived human leukemia lines (CEM-C1 and CEM-C7) to the cell killing brought about by selected cytotoxic agents. In the CEM-C7 cell line (dexamethasone-sensitive), apoptosis was induced not only by dexamethasone but by actinomycin D, cycloheximide, and 25-OH cholesterol. In the CEM-C1 cell line (dexamethasone-resistant) cycloheximide, 25-OH cholesterol, or cell starvation could induce apoptosis. It appears that in leukemic cells apoptosis may be induced by a variety of unrelated toxic agents and is not limited to glucocorticoids.	VET AFFAIRS MED CTR,RES SERV 151,4801 LINWOOD BLVD,KANSAS CITY,MO 64128; UNIV KANSAS,MED CTR,DEPT MICROBIOL MOLEC GENET & IMMUNOL,KANSAS CITY,KS 66103	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas; University of Kansas Medical Center								ALNEMRI ES, 1989, J BIOL CHEM, V264, P4104; BANSAL N, 1990, J CELL PHYSIOL, V143, P105, DOI 10.1002/jcp.1041430114; BANSAL N, 1989, LEUKEMIA RES, V13, P875, DOI 10.1016/0145-2126(89)90040-4; BAXTER GD, 1989, BIOCHEM BIOPH RES CO, V162, P30, DOI 10.1016/0006-291X(89)91957-8; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; COHEN JJ, 1984, J IMMUNOL, V132, P38; COMPTON MM, 1986, ENDOCRINOLOGY, V118, P38, DOI 10.1210/endo-118-1-38; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDEN EA, 1986, CANCER RES, V46, P617; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; SELLINS KS, 1987, J IMMUNOL, V139, P3199; THOMPSON EB, 1985, KLIN WOCHENSCHR, V63, P689, DOI 10.1007/BF01733111; VANDENBOGERT C, 1989, J STEROID BIOCHEM, V33, P955, DOI 10.1016/0022-4731(89)90246-X; VEDECKIS WV, 1983, MOL CELL ENDOCRINOL, V30, P215, DOI 10.1016/0303-7207(83)90049-7; WIRA CR, 1974, J BIOL CHEM, V249, P5328; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZAWYDIWSKI R, 1983, CANCER RES, V43, P3865	24	131	134	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					211	216		10.1096/fasebj.5.2.2004665	http://dx.doi.org/10.1096/fasebj.5.2.2004665			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004665				2022-12-28	WOS:A1991EZ00200011
J	SUZUKI, T				SUZUKI, T			SIGNAL TRANSDUCTION MECHANISMS THROUGH FC-GAMMA RECEPTORS ON THE MOUSE MACROPHAGE SURFACE	FASEB JOURNAL			English	Article						FC-GAMMA RECEPTOR; PHOSPHOLIPASE-A2; CASEIN KINASE-II; PHAGOCYTOSIS; ADENYLATE CYCLASE; MACROPHAGES	CASEIN KINASE-II; FC-GAMMA-RECEPTOR; CELL-LINE P388D1; FC-GAMMA-2B RECEPTOR; INSULIN-RECEPTOR; MEDIATED PHAGOCYTOSIS; PHOSPHOLIPASE-A2 ACTIVITY; PROSTAGLANDIN SYNTHESIS; ADENYLATE-CYCLASE; PROTEIN-KINASES	Mouse macrophages and macrophage cell lines such as P388D1 or J774 carry at least two distinct Fc-gamma receptors (Fc-gamma-R): one specific for the Fc portion of IgG2a (Fc-gamma-2aR, also classified as Fc-gamma-RI) and another for IgG2b (Fc-gamma-2bR, also classified as Fc-gamma-RII-beta). These Fc-gamma-Rs should transmit, upon binding of an appropriate ligand, a specific signal that leads to the regulation of macrophage functions, as the interaction of immune complex with cell surface receptor has been shown to lead to suppression of the humoral immune response or B cell differentiation, to the destruction of target cells by antibody-dependent cell-mediated cytotoxicity, to activiation of arachidonic acid metabolic cascade, to the phagocytosis of opsonized particles, or to the generation of superoxide anion. In this review, we first describe evidence that Fc-gamma-2aR and Fc-gamma-2bR are associated with casein kinase II and phospholipase A2 activity, respectively. We will then discuss a potential role for these enzymatic activities in signal transduction pathways that leads to the activation of the arachidonic acid metabolic cascade and adenylate cyclase, to the regulation of phagocytosis, and to the suppression of interferon-gamma action to induce Ia antigens.			SUZUKI, T (corresponding author), UNIV KANSAS, MED CTR, DEPT MICROBIOL MOLEC GENET & IMMUNOL, KANSAS CITY, KS 66103 USA.				NCI NIH HHS [CA 35977] Funding Source: Medline; NIAID NIH HHS [AI 22742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM AA, 1986, J EXP MED, V163, P139, DOI 10.1084/jem.163.1.139; BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; BARZVI D, 1986, J BIOL CHEM, V261, P9614; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; COHEN S, 1980, J BIOL CHEM, V255, P4834; DIAMOND B, 1978, J IMMUNOL, V121, P1329; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FERNANDEZBOTRAN R, 1986, BIOCHEMISTRY-US, V25, P4388, DOI 10.1021/bi00363a032; GAMMELTOFT S, 1986, BIOCHEM J, V235, P1; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HANAUMI K, 1984, J IMMUNOL, V133, P2852; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HEUSSER CH, 1977, J EXP MED, V145, P1316, DOI 10.1084/jem.145.5.1316; HIRATA Y, 1987, BIOCHEMISTRY-US, V26, P4183, DOI 10.1021/bi00388a002; HIRATA Y, 1987, BIOCHEMISTRY-US, V26, P8189, DOI 10.1021/bi00399a025; HOSEY MM, 1977, BIOCHEMISTRY-US, V16, P4578, DOI 10.1021/bi00640a007; KAGAMI M, 1989, J LEUKOCYTE BIOL, V45, P311, DOI 10.1002/jlb.45.4.311; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KISHIMOTO A, 1987, J BIOL CHEM, V262, P1344; KOLSCH E, 1980, IMMUNOL REV, V49, P61, DOI 10.1111/j.1600-065X.1980.tb00426.x; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; LEWIS VA, 1986, NATURE, V324, P372, DOI 10.1038/324372a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; NATHAN CF, 1981, J EXP MED, V153, P767, DOI 10.1084/jem.153.4.766; NELSON DJ, 1985, J CLIN INVEST, V76, P500, DOI 10.1172/JCI111999; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NITTA T, 1984, J LEUKOCYTE BIOL, V36, P493, DOI 10.1002/jlb.36.4.493; NITTA T, 1982, J IMMUNOL, V128, P2527; NITTA T, 1982, J IMMUNOL, V129, P2708; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PERLMANN P, 1972, TRANSPLANT REV, V13, P91; PFEFFERKORN LC, 1984, J CELL BIOL, V99, P2231, DOI 10.1083/jcb.99.6.2231; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RHODES J, 1985, PROSTAGLANDINS LEUKO, P531; ROCK CO, 1975, J BIOL CHEM, V250, P6564; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; ROSSI F, 1989, J IMMUNOL, V142, P1652; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; SCHNECK J, 1981, J IMMUNOL, V126, P745; SEARS DW, 1990, J IMMUNOL, V144, P371; STOSSEL TP, 1988, BASIC PRINCIPLES CLI, V67, P672; SUZUKI T, 1982, P NATL ACAD SCI-BIOL, V79, P591, DOI 10.1073/pnas.79.2.591; TRISCHITTA V, 1989, J BIOL CHEM, V264, P5041; Uhr J W, 1968, Adv Immunol, V8, P81, DOI 10.1016/S0065-2776(08)60465-4; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; WALKER WS, 1977, J IMMUNOL, V119, P367; WALKER WS, 1976, J IMMUNOL, V116, P911; WILSON HA, 1987, J IMMUNOL, V138, P1712; YAMADA A, 1989, J MOL CELL IMMUNOL, V4, P191; YAMADA A, 1989, J IMMUNOL, V142, P2457; YOUNG JDE, 1983, NATURE, V306, P186, DOI 10.1038/306186a0	56	35	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1991	5	2					187	193		10.1096/fasebj.5.2.1706281	http://dx.doi.org/10.1096/fasebj.5.2.1706281			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	1706281				2022-12-28	WOS:A1991EZ00200007
J	WEINBERG, RA				WEINBERG, RA			THERE ARE 2 LARGE QUESTIONS	FASEB JOURNAL			English	Editorial Material											WEINBERG, RA (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.								0	3	3	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					78	78		10.1096/fasebj.5.1.1991593	http://dx.doi.org/10.1096/fasebj.5.1.1991593			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991593				2022-12-28	WOS:A1991ET60900017
J	AMES, GF; LECAR, H				AMES, GF; LECAR, H			ATP-DEPENDENT BACTERIAL TRANSPORTERS AND CYSTIC-FIBROSIS - ANALOGY BETWEEN CHANNELS AND TRANSPORTERS	FASEB JOURNAL			English	Review						HISTIDINE PERMEASE; PERIPLASMIC PERMEASE; CHLORIDE CHANNELS; TRAFFIC ATPASES; CFTR; MDR	PERIPLASMIC-BINDING-PROTEIN; MEMBRANE-COMPONENTS; ESCHERICHIA-COLI; MULTIDRUG RESISTANCE; SYSTEMS; HOMOLOGY; SITES; MALF	The traffic ATPases superfamily includes known transporters, both prokaryotic and eukaryotic, including the medically important proteins, P-glycoprotein, and the cystic fibrosis gene product (CFTR), which is known to be a Cl- channel. The structure and mechanism of action of the best-studied members of the superfamily, the periplasmic permeases, are described and related to that of CFTR and eukaryotic traffic ATPases in general. The contention is put forward that the distinction between the architecture and mechanisms of action of channels and transporters is blurred.	UNIV CALIF BERKELEY, DIV BIOPHYS & CELL PHYSIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	AMES, GF (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.							ADAMS MD, 1989, J BIOL CHEM, V256, P560; AMES GF, 1986, CELL, V47, P323, DOI 10.1016/0092-8674(86)90585-4; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; Harold F. M., 1986, VITAL FORCE STUDY BI; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KANG CH, 1991, J BIOL CHEM, V266, P23893; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KNAUF PA, 1979, CURRENT TOPICS MEMBR, V12, P250; KUHNAU S, 1991, J BACTERIOL, V173, P2180; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; RAMIREZ JA, 1990, BIOPHYS J, V57, pA321; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; WAGNER R, 1989, EMBO J, V8, P2827, DOI 10.1002/j.1460-2075.1989.tb08429.x	34	96	97	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1992	6	9					2660	2666		10.1096/fasebj.6.9.1377140	http://dx.doi.org/10.1096/fasebj.6.9.1377140			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1377140				2022-12-28	WOS:A1992HZ48100006
J	KASLOW, HR; BURNS, DL				KASLOW, HR; BURNS, DL			PERTUSSIS TOXIN AND TARGET EUKARYOTIC CELLS - BINDING, ENTRY, AND ACTIVATION	FASEB JOURNAL			English	Review						ADP-RIBOSYLTRANSFERASE; DETERGENT; DISULFIDE; DTT; G-PROTEIN; GLUTATHIONE; GLYCOLIPID; LIPID; NUCLEOTIDE; PHOSPHOLIPID; VACCINE	NAD-GLYCOHYDROLASE ACTIVITY; ADP-RIBOSYLTRANSFERASE; BORDETELLA-PERTUSSIS; MONOCLONAL-ANTIBODIES; ADENINE-NUCLEOTIDES; REGULATORY COMPONENT; ADENYLATE-CYCLASE; MEMBRANE-PROTEIN; DIPHTHERIA-TOXIN; CHOLERA-TOXIN	Pertussis toxin, a protein virulence factor produced by Bordetella pertussis, is composed of an A protomer and a B oligomer. The A protomer consists of a single polypeptide, termed the S1 subunit, which disrupts transmembrane signaling by ADP-ribosylating eukaryotic G-proteins. The B oligomer, containing five polypeptides, binds to cell receptors (most likely containing carbohydrate) and delivers the S1 subunit. Current knowledge suggests that expression of ADP-ribosyltransferase activity in target eukaryotic cells arises after 1) nucleotides and membrane lipids allosterically promote the release of the S1 subunit; and 2) the single disulfide bond in the S1 subunit is reduced by reductants such as glutathione. This model suggests conditions for the proper use of the toxin as an experimental reagent.	USDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	United States Department of Agriculture (USDA); US Food & Drug Administration (FDA)	KASLOW, HR (corresponding author), UNIV SO CALIF,SCH MED,DEPT PHYSIOL & BIOPHYS,ROOM 250D,MUDD MEM RES BLDG,1333 SAN PABLO ST,LOS ANGELES,CA 90033, USA.							ADLER A, 1973, INFECT IMMUN, V7, P461, DOI 10.1128/IAI.7.3.461-467.1973; ARMSTRONG GD, 1988, J BIOL CHEM, V263, P8677; BARBIERI JT, 1988, INFECT IMMUN, V56, P1934, DOI 10.1128/IAI.56.8.1934-1941.1988; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; BURNETTE WN, 1991, VACCINE RES SERIES A, V1, P143; BURNETTE WN, 1991, IN PRESS INFECT IMMU; BURNS DL, 1987, INFECT IMMUN, V55, P24, DOI 10.1128/IAI.55.1.24-28.1987; BURNS DL, 1986, J BIOL CHEM, V261, P4324; BURNS DL, 1989, J BIOL CHEM, V264, P564; CHERRY J D, 1988, Pediatrics, V81, P939; CLARK CG, 1990, INFECT IMMUN, V58, P3840, DOI 10.1128/IAI.58.12.3840-3846.1990; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; FARFEL Z, 1979, BIOCHEM BIOPH RES CO, V90, P1237, DOI 10.1016/0006-291X(79)91169-0; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Furman BL, 1988, PATHOGENESIS IMMUNIT, P147; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; HAUSMAN SZ, 1990, BIOCHEMISTRY-US, V29, P6128, DOI 10.1021/bi00478a003; ISHIDA S, 1970, JPN J MED SCI BIOL, V23, P67, DOI 10.7883/yoken1952.23.67; JANICOT M, 1991, J BIOL CHEM, V266, P12858; KASLOW HR, 1987, BIOCHEMISTRY-US, V26, P4397, DOI 10.1021/bi00388a031; KASLOW HR, 1990, INFECT IMMUN, V58, P746, DOI 10.1128/IAI.58.3.746-752.1990; KASLOW HR, 1989, J BIOL CHEM, V264, P6386; KASLOW HR, 1980, J BIOL CHEM, V255, P3736; KASLOW HR, 1987, BIOCHEMISTRY-US, V26, P123, DOI 10.1021/bi00375a018; KATADA T, 1983, ARCH BIOCHEM BIOPHYS, V224, P290, DOI 10.1016/0003-9861(83)90212-6; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KENIMER JG, 1989, HYBRIDOMA, V8, P37, DOI 10.1089/hyb.1989.8.37; KRUEGER KM, 1991, J BIOL CHEM, V266, P8122; LANG AB, 1989, INFECT IMMUN, V57, P2660, DOI 10.1128/IAI.57.9.2660-2665.1989; LI E, 1988, J EXP MED, V167, P1725, DOI 10.1084/jem.167.5.1725; LIM LK, 1985, J BIOL CHEM, V260, P2585; LINNEMANN CC, 1977, ANNU REV MED, V28, P179, DOI 10.1146/annurev.me.28.020177.001143; LOBET Y, 1991, INFECT IMMUN, V59, P2870, DOI 10.1128/IAI.59.9.2870-2879.1991; LOCHT C, 1990, J BIOL CHEM, V265, P4552; LOCHT C, 1987, INFECT IMMUN, V55, P2546, DOI 10.1128/IAI.55.11.2546-2553.1987; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; MATTERA R, 1986, J BIOL CHEM, V261, P1173; MONTECUCCO C, 1986, FEBS LETT, V194, P301, DOI 10.1016/0014-5793(86)80105-3; MOSS J, 1983, J BIOL CHEM, V258, P1879; MOSS J, 1986, BIOCHEMISTRY-US, V25, P2720, DOI 10.1021/bi00357a066; MUNOZ JJ, 1981, INFECT IMMUN, V33, P820, DOI 10.1128/IAI.33.3.820-826.1981; MUNOZ JJ, 1988, PATHOGENESIS IMMUNIT, P173; NICOSIA A, 1986, P NATL ACAD SCI USA, V83, P4631, DOI 10.1073/pnas.83.13.4631; PITTMAN M, 1979, REV INFECT DIS, V1, P401; PIZZA M, 1991, INFECT IMMUN, V59, P1177, DOI 10.1128/IAI.59.3.1177-1179.1991; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; SALEINGER CB, 1990, TRAFFICKING BACTERIA, P26; SATO H, 1987, INFECT IMMUN, V55, P909, DOI 10.1128/IAI.55.4.909-915.1987; SAUKKONEN K, 1991, J EXP MED, V173, P1143, DOI 10.1084/jem.173.5.1143; SCHMIDT MA, 1991, INFECT IMMUN, V59, P1402, DOI 10.1128/IAI.59.4.1402-1408.1991; SCHMIDT MA, 1989, INFECT IMMUN, V57, P3828, DOI 10.1128/IAI.57.12.3828-3833.1989; Sekura R. D., 1985, PERTUSSIS TOXIN, P45; SEKURA RD, 1983, J BIOL CHEM, V258, P4647; STEWART SJ, 1989, J CLIN INVEST, V83, P234, DOI 10.1172/JCI113865; STRNAD CF, 1987, FEBS LETT, V225, P16, DOI 10.1016/0014-5793(87)81123-7; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; TAMURA M, 1983, J BIOL CHEM, V258, P6756; TUOMANEN E, 1988, J EXP MED, V168, P267, DOI 10.1084/jem.168.1.267; UI M, 1990, ADP RIBOSYLATING TOX, P45; VANDOP C, 1984, J BIOL CHEM, V259, P23; VANTWOUT J, 1991, 91ST GEN M AM SOC MI, P113; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WITVLIET MH, 1989, INFECT IMMUN, V57, P3324, DOI 10.1128/IAI.57.11.3324-3330.1989	65	147	151	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2684	2690		10.1096/fasebj.6.9.1612292	http://dx.doi.org/10.1096/fasebj.6.9.1612292			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612292				2022-12-28	WOS:A1992HZ48100009
J	KARIN, M				KARIN, M			SIGNAL TRANSDUCTION FROM CELL-SURFACE TO NUCLEUS IN DEVELOPMENT AND DISEASE	FASEB JOURNAL			English	Review						SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR; PROTEIN PHOSPHORYLATION	NF-KAPPA-B; RECEPTOR TYROSINE KINASES; ELEGANS VULVAR INDUCTION; DEPENDENT PROTEIN-KINASE; DNA-BINDING PROTEIN; GROWTH-HORMONE; CYCLIC-AMP; C-FOS; TRANSCRIPTION FACTOR; ONCOGENE JUN	Recent studies indicate that extracellular signals affect cell proliferation and differentiation by modulating transcription factor activity via protein phosphorylation cascades. This review discusses the basic outline of the eukaryotic signal transduction systems used to transmit information from the cell surface to the transcriptional machinery in the nucleus. Several examples that illustrate how these pathways control cell proliferation, differentiation and development are discussed.			KARIN, M (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.							ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BENTEL GJ, 1990, NATURE, V348, P503; BERRIDGE MJ, 1988, PROC R SOC SER B-BIO, V234, P359, DOI 10.1098/rspb.1988.0054; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BINTERUY B, 1991, NATURE, V351, P122; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRALLA JD, 1991, CELL, V66, P413; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENWALD I, 1990, CELL, V63, P1113, DOI 10.1016/0092-8674(90)90403-2; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIRAI SI, 1990, ONCOGENE, V5, P39; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MOZAN MF, 1991, MOL CELL BIOL, V11, P1804; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OFFIR R, 1990, NATURE, V348, P78; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHENG M, 1991, SCIENCE, V252, P1422; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; YANG-YEN H-F, 1990, New Biologist, V2, P351; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	87	256	259	4	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2581	2590		10.1096/fasebj.6.8.1317309	http://dx.doi.org/10.1096/fasebj.6.8.1317309			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1317309				2022-12-28	WOS:A1992HU42300011
J	APOSHIAN, HV; BRUCE, DC; ALTER, W; DART, RC; HURLBUT, KM; APOSHIAN, MM				APOSHIAN, HV; BRUCE, DC; ALTER, W; DART, RC; HURLBUT, KM; APOSHIAN, MM			URINARY MERCURY AFTER ADMINISTRATION OF 2,3-DIMERCAPTOPROPANE-1-SULFONIC ACID - CORRELATION WITH DENTAL AMALGAM SCORE	FASEB JOURNAL			English	Article						DENTAL AMALGAM TOXICITY; AMALGAM; MERCURY TOXICITY; AMALGAM SCORE; TEETH; URINARY; MERCURY	SILVER TOOTH FILLINGS; 2,3-DIMERCAPTOSUCCINIC ACID; DIMERCAPTOSUCCINIC ACID; LEAD; RATS; MOBILIZATION; EXCRETION; EXPOSURE; CHILDREN; CHLORIDE	There is considerable controversy as to whether dental amalgams may cause systemic health effects in humans because they liberate elemental mercury. Most such amalgams contain as much as 50% metallic mercury. To determine the influence of dental amalgams on the mercury body burden of humans, we have given volunteers, with and without amalgams in their mouth, the sodium salt of 2,3-dimercaptopropane-1-sulfonic acid (DMPS), a chelating agent safely used in the Soviet Union and West Germany for a number of years. The diameters of dental amalgams of the subjects were determined to obtain the amalgam score. Administration of 300 mg DMPS by mouth increased the mean urinary mercury excretion of the amalgam group from 0.70 to 17.2-mu-g and that of the nonamalgam group from 0.27 to 5.1-mu-g over a 9-h period. Two-thirds of the mercury excreted in the urine of those with dental amalgams appears to be derived originally from the mercury vapor released from their amalgams. Linear regression analysis indicated a highly significant positive correlation between the mercury excreted in the urine 2 h after DMPS administration and the dental amalgam scores. DMPS can be used to increase the urinary excretion of mercury and thus increase the significance and reliability of this measure of mercury exposure or burden, especially in cases of micromercurialism.	UNIV ARIZONA,DEPT PHARMACOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT SURG,EMERGENCY MED SECT,TUCSON,AZ 85721; UNIV ARIZONA,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721; ASSOCIATES GEN DENT,TUCSON,AZ 85712; BIOMET,TUCSON,AZ 85733	University of Arizona; University of Arizona; University of Arizona	APOSHIAN, HV (corresponding author), UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,LIFE SCI S BLDG,TUCSON,AZ 85721, USA.			Dart, Richard/0000-0001-5989-9354	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003356, P42ES004940] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-03356, ES-04940] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		APOSHIAN HV, 1983, ANNU REV PHARMACOL, V23, P193, DOI 10.1146/annurev.pa.23.040183.001205; APOSHIAN HV, 1990, ANNU REV PHARMACOL, V30, P279; BERGLUND A, 1990, J DENT RES, V69, P1646, DOI 10.1177/00220345900690100401; Berlin M., 1986, HDB TOXICOLOGY METAL, P387; BUCHET JP, 1989, TOXICOLOGY, V54, P323, DOI 10.1016/0300-483X(89)90067-X; CAMPBELL JR, 1986, JAMA-J AM MED ASSOC, V256, P3127, DOI 10.1001/jama.256.22.3127; CARTER DE, 1988, BIOL MONITORING TOXI, P455; CHERIAN MG, 1988, J PHARMACOL EXP THER, V245, P479; CHISOLM JJ, 1985, J PHARMACOL EXP THER, V235, P665; CHISOLM JJ, 1987, AM J DIS CHILD, V141, P1256; CLARKSON TW, 1990, NEW ENGL J MED, V323, P1137, DOI 10.1056/NEJM199010183231610; CLARKSON TW, 1988, BIOL MONITORING TOXI, P199; DING GS, 1991, J APPL TOXICOL, V11, P7, DOI 10.1002/jat.2550110103; DODES JE, 1990, FASEB J, V4, P1542, DOI 10.1096/fasebj.4.5.2307333; ELEY BM, 1987, BRIT DENT J, V163, P221, DOI 10.1038/sj.bdj.4806247; Elinder C. G., 1988, BIOL MONITORING TOXI, P1, DOI DOI 10.1007/978-1-4613-0961-1_1.; ENWONWU CO, 1987, ENVIRON RES, V42, P257, DOI 10.1016/S0013-9351(87)80027-0; FOURNIER L, 1988, MED TOXICOL ADV DRUG, V3, P499, DOI 10.1007/BF03259898; GRAZIANO JH, 1985, CLIN PHARMACOL THER, V37, P431, DOI 10.1038/clpt.1985.67; GRAZIANO JH, 1988, J PEDIATR-US, V113, P751, DOI 10.1016/S0022-3476(88)80396-2; HAHN LJ, 1990, FASEB J, V4, P3256, DOI 10.1096/fasebj.4.14.2227216; HAHN LJ, 1989, FASEB J, V3, P2641, DOI 10.1096/fasebj.3.14.2636872; HANSON M, 1991, EXPERIENTIA, V47, P9, DOI 10.1007/BF02041243; KEMPER FH, 1990, BASIC SCIENCE IN TOXICOLOGY, P523; KLIMOVA L K, 1958, Farmakol Toksikol, V21, P53; Kroncke A, 1980, Dtsch Zahnarztl Z, V35, P803; LANGWORTH S, 1991, INT ARCH OCC ENV HEA, V63, P161, DOI 10.1007/BF00381563; LARSSON KS, 1990, LANCET, V336, P1251, DOI 10.1016/0140-6736(90)92865-F; LIANG Y., 1956, Acta Physiologica Sinica, V20, P133; MAIORINO RM, 1991, J PHARMACOL EXP THER, V259, P808; MOLIN M, 1991, INT ARCH OCC ENV HEA, V63, P187, DOI 10.1007/BF00381567; NILSSON B, 1986, SWED DENT J, V10, P221; OLSTAD ML, 1987, J DENT RES, V66, P1179, DOI 10.1177/00220345870660061701; PLANASBOHNE F, 1981, TOXICOLOGY, V19, P275, DOI 10.1016/0300-483X(81)90138-4; ROELS HA, 1991, BRIT J IND MED, V48, P247; SIKORSKI R, 1987, INT ARCH OCC ENV HEA, V59, P551, DOI 10.1007/BF00377918; VIMY MJ, 1990, AM J PHYSIOL, V258, pR939, DOI 10.1152/ajpregu.1990.258.4.R939; Wallis G, 1986, Am Ind Hyg Assoc J, V47, pA784; 1991, ENV HLTH CRITERIA, P118; [No title captured]	40	66	67	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2472	2476		10.1096/fasebj.6.7.1563599	http://dx.doi.org/10.1096/fasebj.6.7.1563599			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563599				2022-12-28	WOS:A1992HP03000014
J	LAURENT, TC; FRASER, JRE				LAURENT, TC; FRASER, JRE			HYALURONAN	FASEB JOURNAL			English	Article						HYALURONAN (HYALURONIC ACID); STRUCTURE; METABOLISM; PHYSIOLOGICAL FUNCTIONS; CELL BIOLOGICAL FUNCTIONS; CLINICAL APPLICATIONS; INTERSTITIAL EDEMA	ENDOTHELIAL-CELLS; ACID; FIBROBLASTS; CARTILAGE; RECEPTOR; PROTEIN; TISSUE; LIVER; RAT; ACCUMULATION	Hyaluronan (hyaluronic acid) is a high-molecular-mass polysaccharide found in the extracellular matrix, especially of soft connective tissues. It is synthesized in the plasma membrane of fibroblasts and other cells by addition of sugars to the reducing end of the polymer, whereas the nonreducing end protrudes into the pericellular space. The polysaccharide is catabolized locally or carried by lymph to lymph nodes or the general circulation, from where it is cleared by the endothelial cells of the liver sinusoids. The overall turnover rate is surprisingly rapid for a connective tissue matrix component (t1/2 0.5 to a few days). Hyaluronan has been assigned various physiological functions in the intercellular matrix, e.g., in water and plasma protein homeostasis. Hyaluronan production increases in proliferating cells and the polymer may play a role in mitosis. Extensive hyaluronidase-sensitive coats have been identified around mesenchymal cells. They are either anchored firmly in the plasma membrane or bound via hyaluronan-specific binding proteins (receptors). Such receptors have now been identified on many different cells, e.g., the lymphocyte homing receptor CD 44. Interaction between a hyaluronan receptor and extracellular polysaccharide has been connected with locomotion and cell migration. Hyaluronan seems to play an important role during development and differentiation and has other cell regulatory activities. Hyaluronan has also been recognized in clinical medicine. A concentrated solution of hyaluronan (10 mg/ml) has, through its tissue protective and rheological properties, become a device in ophthalmic surgery. Analysis of serum hyaluronan is promising in the diagnosis of liver disease and various inflammatory conditions, e.g., rheumatoid arthritis. Interstitial edema caused by accumulation of hyaluronan may cause dysfunction in various organs.	UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, MELBOURNE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; University of Melbourne	LAURENT, TC (corresponding author), UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL, BOX 575, S-75123 UPPSALA, SWEDEN.							ADAMS DH, 1989, TRANSPLANTATION, V47, P479, DOI 10.1097/00007890-198903000-00016; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALAZS EA, 1989, CIBA F SYMP, V143, P265; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; Brimacombe J. S., 1964, MUCOPOLYSACCHARIDES; BROWN TJ, 1991, EXP PHYSIOL, V76, P125, DOI 10.1113/expphysiol.1991.sp003474; CAMPBELL P, 1990, HEPATOLOGY, V11, P199, DOI 10.1002/hep.1840110207; CASADEL A, 1989, CUTANEOUS DEV AGING, P189; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DAHL LB, 1988, ANAL BIOCHEM, V175, P397, DOI 10.1016/0003-2697(88)90563-5; DELPECH B, 1989, CIBA F S, V143, P228; ENGSTROMLAURENT A, 1989, CIBA F SYMP, V143, P233; ENGSTROMLAURENT A, 1987, ARTHRITIS RHEUM, V30, P1333, DOI 10.1002/art.1780301203; FESSLER JH, 1966, P NATL ACAD SCI USA, V56, P141, DOI 10.1073/pnas.56.1.141; FORSBERG N, 1991, BIOCHIM BIOPHYS ACTA, V1078, P12, DOI 10.1016/0167-4838(91)90085-E; FRASER JRE, 1988, BIOCHEM J, V256, P153, DOI 10.1042/bj2560153; FRASER JRE, 1989, CIBA F SYMP, V143, P41; GIBBS DA, 1968, BIOPOLYMERS, V6, P777, DOI 10.1002/bip.1968.360060603; GIRARD N, 1986, J HISTOCHEM CYTOCHEM, V34, P539, DOI 10.1177/34.4.2419397; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HAKANSSON L, 1987, J IMMUNOL, V138, P4347; HALLGREN R, 1990, J EXP MED, V171, P2063, DOI 10.1084/jem.171.6.2063; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; HELLSTROM S, 1987, ACTA OTO-LARYNGOL, P54; HIRO D, 1986, BIOCHEM BIOPH RES CO, V140, P715, DOI 10.1016/0006-291X(86)90790-4; KING SR, 1991, SURGERY, V109, P76; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KNUDSON W, 1984, P NATL ACAD SCI-BIOL, V81, P6767, DOI 10.1073/pnas.81.21.6767; KNUDSON W, 1991, J CELL SCI, V99, P227; LAURENT C, 1991, CELL TISSUE RES, V263, P201, DOI 10.1007/BF00318761; Laurent T.C, 1970, CHEM MOL BIOL INTERC, P703; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1987, ACTA OTO-LARYNGOL, P7; LAURENT TC, 1986, CIBA F SYMP, V124, P9; LAURENT UBG, 1981, BIOCHEM INT, V2, P195; LAURENT UBG, 1991, ADV DRUG DELIVER REV, V7, P237, DOI 10.1016/0169-409X(91)90004-V; LAURENT UBG, 1991, EXP PHYSIOL, V76, P695, DOI 10.1113/expphysiol.1991.sp003536; LAURENT UBG, 1988, EXP EYE RES, V46, P49, DOI 10.1016/S0014-4835(88)80092-7; LAURENT UBG, 1992, IN PRESS MATRIX; LEBEL L, 1989, PHARMACEUT RES, V6, P677, DOI 10.1023/A:1015982204926; LEBEL L, 1989, TURNOVER CIRCULATING; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; LINDQVIST U, 1992, CLIN CHEM, V38, P127; Meyer K, 1934, J BIOL CHEM, V107, P629; Miller D, 1983, HEALON SODIUM HYALUR, P5; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NETTELBLADT O, 1989, AM J PHYSIOL, V257, pL379, DOI 10.1152/ajplung.1989.257.6.L379; OGSTON AG, 1953, J PHYSIOL-LONDON, V119, P244, DOI 10.1113/jphysiol.1953.sp004842; PERTOFT H, 1987, CELL SEPARATION METH, V4, P1; PREHM P, 1989, CIBA F SYMP, V143, P21; REED RK, 1990, AM J PHYSIOL, V259, pH532, DOI 10.1152/ajpheart.1990.259.2.H532; REED RK, 1988, ACTA PHYSIOL SCAND, V134, P405, DOI 10.1111/j.1748-1716.1988.tb08508.x; RODEN L, 1989, CIBA F SYMP, V143, P60; RYDELL NW, 1970, ACTA VET SCAND, V11, P139; SCOTT JE, 1991, BIOCHEM J, V274, P699, DOI 10.1042/bj2740699; SCOTT JE, 1989, CIBA F SYMP, V143, P6; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STRACHAN RK, 1990, ANN RHEUM DIS, V49, P949, DOI 10.1136/ard.49.11.949; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; TOOLE BP, 1984, ROLE EXTRACELLULAR M, P43; Toole BP, 1989, CIBA F SYMP, V143, P138; TURLEY EA, 1990, EXP CELL RES, V187, P243, DOI 10.1016/0014-4827(90)90087-Q; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1989, CIBA F S, V143, P11; UNDERHILL CB, 1989, CIBA F SYMP, V143, P87; VANDERGAAG R, 1987, CURR EYE RES, V6, P1433, DOI 10.3109/02713688709044507; WELLS AF, 1990, TRANSPLANTATION, V50, P240, DOI 10.1097/00007890-199008000-00014; WNGSTROMLAURENT A, 1989, CLIN IMPACT BONE CON, P235	74	1984	2081	12	341	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1992	6	7					2397	2404		10.1096/fasebj.6.7.1563592	http://dx.doi.org/10.1096/fasebj.6.7.1563592			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563592				2022-12-28	WOS:A1992HP03000004
J	CLANDININ, MT; CHEEMA, S; FIELD, CJ; GARG, ML; VENKATRAMAN, J; CLANDININ, TR				CLANDININ, MT; CHEEMA, S; FIELD, CJ; GARG, ML; VENKATRAMAN, J; CLANDININ, TR			DIETARY-FAT - EXOGENOUS DETERMINATION OF MEMBRANE-STRUCTURE AND CELL-FUNCTION	FASEB JOURNAL			English	Review						DIET FAT; MEMBRANE STRUCTURE; MEMBRANE FUNCTION	PROTEIN KINASE-C; ADENYLATE-CYCLASE ACTIVITY; LIVER NUCLEAR ENVELOPES; ACID COMPOSITION; PLASMA-MEMBRANE; LIPID-COMPOSITION; INSULIN BINDING; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; RAT; TRANSPORT	Evidence indicates that principal features of the membrane involve structural organization of lipids in the form of a bilayer with functional proteins either bound to the bilayer surface or inserted into the bilayer and interacting within specific domains in the lipid milieux. In homeotherms, intrinsic and extrinsic factors apparently form the basis for determination of membrane lipid composition and thus membrane physicochemical properties. Moreover, many intrinsic metabolic controls, such as fatty acid desaturation and phospholipid biosynthesis, may be attenuated by change in the nature of the extrinsic or dietary influence. This review will focus on the role of dietary fat as a determinant of subcellular structural constituents to illustrate that feeding nutritionally adequate diets differing in fatty acid composition can induce physiological transitions in membrane function involving the activity of enzymes responsible for synthesis of membrane constituents, hormone-activated functions and expression of activity in the cell nucleus.	UNIV ALBERTA,DEPT FOODS & NUTR,EDMONTON T6G 2E1,ALBERTA,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON T6G 2E1,ALBERTA,CANADA; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Alberta; University of Alberta; University of Texas System; University of Texas Health San Antonio; University of Calgary	CLANDININ, MT (corresponding author), UNIV ALBERTA,NUTR & METAB RES GRP,533 NEWTON RES BLDG,EDMONTON T6G 2C2,ALBERTA,CANADA.		Garg, Manohar L/A-5795-2009	Garg, Manohar/0000-0003-0514-0865; Field, Catherine/0000-0001-7285-4767				AGUTTER PS, 1979, BIOCHEM J, V182, P811, DOI 10.1042/bj1820811; AGUTTER PS, 1982, BIOCHIM BIOPHYS ACTA, V696, P308, DOI 10.1016/0167-4781(82)90062-8; AGUTTER PS, 1985, NUCLEAR ENVELOPE STR, P561; ALOIA RC, 1989, BIOCHIM BIOPHYS ACTA, V988, P123, DOI 10.1016/0304-4157(89)90007-5; Bennett V, 1990, CURR OPIN CELL BIOL, V2, P51, DOI 10.1016/S0955-0674(05)80030-4; BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BROWN MS, 1981, SCIENCE, V212, P628, DOI 10.1126/science.6261329; CAPALDI RA, 1977, MEMBRANE PROTEINS TH, V1; CHEEMA SK, 1991, FASEB J, V5, pA1305; CINADER B, 1983, IMMUNOL LETT, V6, P331, DOI 10.1016/0165-2478(83)90077-9; CLANDININ MT, 1985, CAN J PHYSIOL PHARM, V63, P546, DOI 10.1139/y85-094; FAAS FH, 1980, LIPIDS, V15, P953, DOI 10.1007/BF02534421; FIELD CJ, 1989, J NUTR, V119, P1483, DOI 10.1093/jn/119.10.1483; FIELD CJ, 1988, BIOCHEM J, V253, P417, DOI 10.1042/bj2530417; FIELD CJ, 1990, J BIOL CHEM, V265, P11143; FIELD CJ, 1989, BIOMEMBRANES NUTRITI, V195, P319; FISHKIND DJ, 1990, DEV BIOL, V142, P453, DOI 10.1016/0012-1606(90)90367-R; GARG ML, 1988, BIOCHIM BIOPHYS ACTA, V958, P139, DOI 10.1016/0005-2760(88)90256-1; GARG ML, 1988, BIOCHEM J, V249, P351, DOI 10.1042/bj2490351; GARG ML, 1990, CAN J PHYSIOL PHARM, V68, P636, DOI 10.1139/y90-093; GOULD RJ, 1982, J BIOL CHEM, V257, P477; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARGREAVES KM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P262, DOI 10.1016/0005-2760(89)90109-4; HARGREAVES KM, 1987, BIOCHEM BIOPH RES CO, V145, P309, DOI 10.1016/0006-291X(87)91322-2; HARGREAVES KM, 1987, BIOCHIM BIOPHYS ACTA, V918, P97, DOI 10.1016/0005-2760(87)90183-4; HERLAN G, 1979, EXP CELL RES, V118, P305, DOI 10.1016/0014-4827(79)90155-1; INNIS SM, 1981, BIOCHEM J, V198, P231, DOI 10.1042/bj1980231; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIMELBERG HK, 1977, CELL SURF REV, V3, P205; Kuksis A., 1978, HDB LIPID RES, V1; LEFEBVRE TA, 1984, P INT S, P155; LEMENOVSKAYA AF, 1976, BIOCHEMISTRY-MOSCOW+, V41, P818; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MARINETTI GV, 1982, BIOCHIM BIOPHYS ACTA, V685, P109, DOI 10.1016/0005-2736(82)90086-4; MCMURCHIE EJ, 1988, ADV MEMBRANE FLUIDIT, V3, P189; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MORSON LA, 1986, J NUTR, V116, P2355, DOI 10.1093/jn/116.12.2355; NEELANDS PJ, 1983, BIOCHEM J, V212, P573, DOI 10.1042/bj2120573; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NELSON WJ, 1984, CELL MEMBR METH REV, V2, P219; PUMPLIN DW, 1990, CELL MOTIL CYTOSKEL, V15, P121, DOI 10.1002/cm.970150208; RENNER R, 1979, J NUTR, V109, P378, DOI 10.1093/jn/109.3.378; SANDRA A, 1984, BIOCHIM BIOPHYS ACTA, V778, P511, DOI 10.1016/0005-2736(84)90401-2; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SMITH CD, 1983, J BIOL CHEM, V258, P9368; SPECTOR AA, 1985, J LIPID RES, V26, P1015; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353; THOMSON ABR, 1987, LIPIDS, V22, P22, DOI 10.1007/BF02534870; TIWARI RK, 1986, NUTR RES, V6, P1379, DOI 10.1016/S0271-5317(86)80023-9; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VENKATRAMAN JT, 1985, BIOCHEM BIOPH RES CO, V132, P35, DOI 10.1016/0006-291X(85)90984-2; VENKATRAMAN JT, 1986, BIOCHEM BIOPH RES CO, V135, P655, DOI 10.1016/0006-291X(86)90043-4; VENKATRAMAN JT, 1988, BIOCHIM BIOPHYS ACTA, V940, P33, DOI 10.1016/0005-2736(88)90005-3; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614	57	243	250	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2761	2769		10.1096/fasebj.5.13.1916101	http://dx.doi.org/10.1096/fasebj.5.13.1916101			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916101				2022-12-28	WOS:A1991GJ47100003
J	RAETZ, CRH; ULEVITCH, RJ; WRIGHT, SD; SIBLEY, CH; DING, AH; NATHAN, CF				RAETZ, CRH; ULEVITCH, RJ; WRIGHT, SD; SIBLEY, CH; DING, AH; NATHAN, CF			GRAM-NEGATIVE ENDOTOXIN - AN EXTRAORDINARY LIPID WITH PROFOUND EFFECTS ON EUKARYOTIC SIGNAL TRANSDUCTION	FASEB JOURNAL			English	Article						ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE; ENDOTOXIN; LIPID-A; CD-14; NF-KAPPA-B; TAXOL; BACTERIAL OUTER MEMBRANE; MICROTUBULES; SCAVENGER RECEPTOR; LIPOPOLYSACCHARIDE-BINDING PROTEIN	NF-KAPPA-B; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; NECROSIS-FACTOR RECEPTORS; ACUTE PHASE REACTANT; ESCHERICHIA-COLI; TUMOR-NECROSIS; A PRECURSORS; BACTERIAL LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN EXPRESSION; INTERFERON-GAMMA	The lipid A domain of lipopolysaccharide (LPS) is a unique, glucosamine-based phospholipid that makes up the outer monolayer of the outer membrane of most gram-negative bacteria. Because of its profound pharmacological effects on animal cells, especially those of the immune system, lipid A is also known as endotoxin. Despite decades of earlier work, the precise chemistry of endotoxins and the biochemical pathways for their enzymatic synthesis have been elucidated only within the past 5 years. In this review, we summarize the essentials of endotoxin biochemistry and also present recent experiments aimed at identifying surface receptors, signal-transducing elements, transcriptional factors, and key intracellular targets involved in the response of animal cells to endotoxins.	ROCKEFELLER UNIV, CELLULAR PHYSIOL & IMMUNOL LAB, NEW YORK, NY 10021 USA; SCRIPPS CLIN & RES FDN, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA	Rockefeller University; Scripps Research Institute; University of Washington; University of Washington Seattle; Cornell University	RAETZ, CRH (corresponding author), MERCK SHARP & DOHME LTD, DEPT BIOCHEM, RAHWAY, NJ 07065 USA.				NCI NIH HHS [CA-45218, CA-43610] Funding Source: Medline; NIGMS NIH HHS [GM-42508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043610, R01CA045218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1988, BIOCHEMISTRY-US, V27, P1908, DOI 10.1021/bi00406a017; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; [Anonymous], 1989, PUSANSISA, V4, P787; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BRISKIN M, 1988, SCIENCE, V242, P1036, DOI 10.1126/science.3143155; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; CALALB MB, 1987, J BIOL CHEM, V262, P3680; CALAME KL, 1985, ANNU REV IMMUNOL, V3, P159, DOI 10.1146/annurev.iy.03.040185.001111; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; CROWELL DN, 1987, J BACTERIOL, V169, P5727, DOI 10.1128/jb.169.12.5727-5734.1987; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; DING AH, 1990, J EXP MED, V171, P715, DOI 10.1084/jem.171.3.715; DING AH, 1989, J BIOL CHEM, V264, P3924; DING AH, 1987, J IMMUNOL, V139, P1971; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KELLEY DE, 1988, MOL CELL BIOL, V8, P930, DOI 10.1128/MCB.8.2.930; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MATHISON JC, 1979, J IMMUNOL, V123, P2133; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MORRISON DC, 1989, MICROB PATHOGENESIS, V7, P389, DOI 10.1016/0882-4010(89)90019-3; NELSON KJ, 1984, NUCLEIC ACIDS RES, V12, P1911, DOI 10.1093/nar/12.4.1911; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; NUNN WD, 1986, MICROBIOL REV, V50, P179, DOI 10.1128/MMBR.50.2.179-192.1986; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; PARSLOW TG, 1983, NUCLEIC ACIDS RES, V11, P4775, DOI 10.1093/nar/11.14.4775; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; RAMADORI G, 1990, PATHOBIOLOGY, V58, P89, DOI 10.1159/000163569; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIETSCHLE E T, 1988, P1; ROONEY JW, 1990, IMMUNOGENETICS, V31, P73, DOI 10.1007/BF00661216; ROONEY JW, 1990, IMMUNOGENETICS, V31, P65, DOI 10.1007/BF00661215; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SETOGUCHI M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P213, DOI 10.1016/0167-4781(80)90012-3; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIBLEY CH, 1988, J BIOL CHEM, V263, P5098; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1988, J BIOL CHEM, V263, P13479; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; VOSBECK K, 1990, J LEUKOCYTE BIOL, V47, P97, DOI 10.1002/jlb.47.2.97; WEEKS RS, 1987, SOMAT CELL MOLEC GEN, V13, P205, DOI 10.1007/BF01535203; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; WRIGHT SD, 1990, J IMMUNOL, V144, P2566; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	69	511	522	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1991	5	12					2652	2660		10.1096/fasebj.5.12.1916089	http://dx.doi.org/10.1096/fasebj.5.12.1916089			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916089				2022-12-28	WOS:A1991GE81100005
J	PITOT, HC; DRAGAN, YP				PITOT, HC; DRAGAN, YP			FACTS AND THEORIES CONCERNING THE MECHANISMS OF CARCINOGENESIS	FASEB JOURNAL			English	Review						HEPATOCARCINOGENESIS; INITIATION-PROMOTION FORMAT; NEOPLASIA; CARCINOGENIC AGENTS; MULTISTAGE CARCINOGENESIS	ALTERED HEPATIC FOCI; MOUSE SKIN; RAT-LIVER; CHEMICAL CARCINOGENESIS; MULTISTAGE HEPATOCARCINOGENESIS; CELL-CYCLE; INDUCTION; CANCER; DIETHYLNITROSAMINE; HEPATOCYTES	Carcinogenesis can be induced experimentally by exposure to exogenous agents or it can occur spontaneously without intentional or active intervention Carcinogenesis can be actively induced by chemicals radiation, infectious biological agents, transgenesis, or selective breeding. In the human and occasionally when testing potential carcinogens in animals, cancer may result from passive exposure to carcinogens encountered in the ambient environment or from changes in the internal milieu of the animal. Many carcinogens alter the structure of DNA resulting in carcinogenesis, but a significant number of carcinogens do not appear to act through this mechanism. When the action of specific carcinogenic agents is considered in relation to the stages of cancer development, initiation, promotion, and progression, the mechanism of the induction of carcinogenesis by DNA-reactive agents that alter genomic structure can be reconciled with those agents that do not act in this manner. As some cells are fortuitously initiated by uncontrolled variables such as irradiation and through changes in normal processes, the stimulation of growth and altered genetic expression by nongenotoxic agents may result indirectly in cancer development. The final stage of carcinogenesis, progression, can occur spontaneously, enhanced by formation and propagation of genetic errors due to increased cellular proliferation associated with the promotion stage. In addition, chemical and viral agents that lack the capacity for initiation and promotion may actively convert cells in the stage of promotion to the stage of progression. Therefore, the diverse mechanisms of action of carcinogenic agents in relation to their effects on specific stages in the natural history of cancer development allow for greater congruence of many of the theories of carcinogenesis. The influence of the roles of nongenotoxic carcinogenic agents and the potential role of progressor agents on the carcinogenesis process allow a more accurate identification of the potential risk that specific carcinogenic agents pose for increasing human cancer.	UNIV WISCONSIN,MCARDLE LAB CANC RES,DEPT PATHOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	PITOT, HC (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,DEPT ONCOL,MADISON,WI 53706, USA.							ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; ASHBY J, 1988, MUTAT RES, V204, P17, DOI 10.1016/0165-1218(88)90114-0; BERENBLUM I, 1947, BRIT J CANCER, V1, P383, DOI 10.1038/bjc.1947.36; BIAGLOW JE, 1981, J CHEM EDUC, V58, P144, DOI 10.1021/ed058p144; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; BRAND KG, 1976, J NATL CANCER I, V57, P973, DOI 10.1093/jnci/57.5.973; EHLING UH, 1983, MUTAT RES, V123, P281, DOI 10.1016/0165-1110(83)90026-X; ELMWOOD JM, 1984, MODELS MECHANISMS ET, P421; ENOMOTO K, 1982, CANCER RES, V42, P2330; ENOMOTO M, 1990, J TOXICOL PATHOL, V3, P1; ETHIER SP, 1982, CANCER RES, V42, P1753; FARBER E, 1973, METHOD CANCER RES, V7, P345; FOULDS L, 1954, CANCER RES, V14, P327; GALAND P, 1988, INT J CANCER, V41, P155, DOI 10.1002/ijc.2910410127; GARRO AJ, 1990, ANNU REV PHARMACOL, V30, P219, DOI 10.1146/annurev.pa.30.040190.001251; GOLDSWORTHY T, 1984, CARCINOGENESIS, V5, P67, DOI 10.1093/carcin/5.1.67; GOLDSWORTHY TL, 1990, CIIT ACTIVITIES, V10, P1; HASELTINE WA, 1983, CELL, V33, P13, DOI 10.1016/0092-8674(83)90329-X; HENDERSON BE, 1982, CANCER RES, V42, P3232; HENDRICH S, 1986, CARCINOGENESIS, V7, P2041, DOI 10.1093/carcin/7.12.2041; HENNINGS H, 1985, J NATL CANCER I, V74, P735; HORSFALL DJ, 1986, BRIT J CANCER, V53, P23, DOI 10.1038/bjc.1986.4; ISHIKAWA T, 1980, CANCER RES, V40, P4261; KIEFF E, 1982, J INFECT DIS, V146, P506, DOI 10.1093/infdis/146.4.506; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LESCH R, 1973, VIRCHOWS ARCH B, V12, P285; LUTZ WK, 1990, CARCINOGENESIS, V11, P1243, DOI 10.1093/carcin/11.8.1243; MCCORMICK PJ, 1982, P NATL ACAD SCI-BIOL, V79, P4342, DOI 10.1073/pnas.79.14.4342; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; MOOLGAVKAR SH, 1981, J NATL CANCER I, V66, P1037, DOI 10.1093/jnci/66.6.1037; MOORE MA, 1987, CARCINOGENESIS, V8, P483, DOI 10.1093/carcin/8.3.483; Mottram JC, 1944, J PATHOL BACTERIOL, V56, P181, DOI 10.1002/path.1700560207; NOBLE RL, 1977, CANCER RES, V37, P82; NOWELL PC, 1986, CANCER RES, V46, P2203; OCONNELL JF, 1986, CANCER RES, V46, P2863; PARIZA MW, 1986, P SOC EXP BIOL MED, V183, P293, DOI 10.3181/00379727-183-42422; Pitot H, 1986, FUNDAMENTALS ONCOLOG; PITOT HC, 1978, NATURE, V271, P456, DOI 10.1038/271456a0; PITOT HC, 1990, ANNU REV PHARMACOL, V30, P465; PITOT HC, 1987, CARCINOGENESIS, V8, P1491, DOI 10.1093/carcin/8.10.1491; PITOT HC, 1986, CLIN LAB MED, V6, P167, DOI 10.1016/S0272-2712(18)30832-1; PITOT HC, 1985, CANCER PRINCIPLES PR, P79; Pitot HK, 1987, S FUND CANCER RES, V39, P187; POTTER VR, 1981, CARCINOGENESIS, V2, P1375, DOI 10.1093/carcin/2.12.1375; REISS M, 1986, CANCER TREAT REP, V70, P201; Rous P, 1941, J EXP MED, V73, P365, DOI 10.1084/jem.73.3.365; SARGENT L, 1989, CARCINOGENESIS, V10, P387, DOI 10.1093/carcin/10.2.387; SATOH K, 1989, CARCINOGENESIS, V10, P2107, DOI 10.1093/carcin/10.11.2107; SCHERER E, 1975, EUR J CANCER, V11, P689, DOI 10.1016/0014-2964(75)90042-0; SCHERER E, 1984, IARC SCI PUBL, V56, P57; SCHULTEHERMANN R, 1990, CANCER RES, V50, P5127; SEITZ HK, 1988, ANNU REV NUTR, V8, P99, DOI 10.1146/annurev.nu.08.070188.000531; SHELBY MD, 1984, ENVIRON MUTAGEN, V6, P871, DOI 10.1002/em.2860060613; STENBACK F, 1978, Z KREBSFORSCH KLIN O, V91, P249, DOI 10.1007/BF00312287; VANBOGAERT LJ, 1984, BREAST CANCER PERSPE, V40, P173; VANDUUREN BL, 1975, CANCER RES, V35, P502; VERMA AK, 1980, CARCINOGENESIS, V1, P271, DOI 10.1093/carcin/1.3.271; WAINSCOAT JS, 1990, CANCER RES, V50, P1355; WARD JM, 1983, PROG EXP TUMOR RES, V26, P241; WARD JM, 1990, CANCER LETT, V52, P187, DOI 10.1016/0304-3835(90)90186-2; WARWICK GP, 1971, FED PROC, V30, P1760; WATTENBERG LW, 1978, JNCI-J NATL CANCER I, V60, P11, DOI 10.1093/jnci/60.1.11; XU YH, 1990, CANCER RES, V50, P472	64	193	201	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2280	2286		10.1096/fasebj.5.9.1860619	http://dx.doi.org/10.1096/fasebj.5.9.1860619			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860619				2022-12-28	WOS:A1991FP87200009
J	KUIVANIEMI, H; TROMP, G; PROCKOP, DJ				KUIVANIEMI, H; TROMP, G; PROCKOP, DJ			MUTATIONS IN COLLAGEN GENES - CAUSES OF RARE AND SOME COMMON DISEASES IN HUMANS	FASEB JOURNAL			English	Article						OSTEOGENESIS IMPERFECTA; FAMILIAL ANEURYSMS; COLLAGEN FIBRILLOGENESIS; EHLERS-DANLOS SYNDROME; OSTEOPOROSIS; OSTEOARTHRITIS; CHONDRODYSPLASIAS	OSTEOGENESIS IMPERFECTA; III DEFICIENCY; PROCOLLAGEN; ANEURYSMS; SUBSTITUTION	More than 70 mutations in the two structural genes for type I procollagen (COL1A1 and COL1A2) have been found in probands with osteogenesis imperfecta, a heritable disease of children characterized by fragility of bone and other tissues rich in type I collagen. The mutations, and single-base substitutions that convert a codon for glycine to a codon for an amino acid with a bulkier side chain. With a few exceptions, the most severe phenotypes of the disease are explained largely by synthesis of structurally defective pro-alpha chains of type I procollagen that either interfere with the folding of the triple helix or with self-assembly of collagen into fibrils. The results emphasize the extent to which the zipperlike folding of the collagen triple helix and the self-assembly of collagen fibrils depend on the principle of nucleated growth whereby a few subunits form a nucleus and the nucleus is then propagated to generate a large structure with a precisely defined architecture. The principle of nucleated growth is a highly efficient mechanism for the assembly of large structures, but biological systems that depend extensively on nucleated growth are highly vulnerable to mutations that cause synthesis of structurally abnormal but partially functional subunits. Recently, several mutations in three other collagen genes (COL2A1, COL3A1, and COL4A5) have been found in probands with genetic diseases involving tissues rich in these collagens. Most of the probands have rare genetic diseases but a few appear to have phenotypes that are difficult to distinguish from more common disorders such as osteoarthritis, osteoporosis, and aortic aneurysms. Therefore, the results suggest that mutations in procollagen genes may cause a wide spectrum of both rare and common human diseases.			KUIVANIEMI, H (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA.		Tromp, Gerard/B-2677-2017; Kuivaniemi, Helena/Q-8178-2019	Tromp, Gerard/0000-0002-7761-0806; Kuivaniemi, Helena/0000-0001-5753-8766	NIAMS NIH HHS [AR38188] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038188] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHMAD NN, 1990, AM J HUM GENET, V47, pA206; ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; CONSTANTINOU CD, 1989, CYTOGENET CELL GENET, V51, P979; DEAK S B, 1990, Matrix, V10, P237; DEPAEPE A, 1988, CLIN NEUROL NEUROSUR, V90, P53, DOI 10.1016/S0303-8467(88)80010-6; ENGEL J, 1991, IN PRESS ANN REV BIO; FRANCOMANO C A, 1987, Genomics, V1, P293, DOI 10.1016/0888-7543(87)90027-9; FRANCOMANO C A, 1988, American Journal of Human Genetics, V43, pA83; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; KHILLAN JS, 1990, AM J HUM GENET, V47, pA224; KNOWLTON RG, 1989, AM J HUM GENET, V45, P681; KNOWLTON RG, 1990, NEW ENGL J MED, V322, P526, DOI 10.1056/NEJM199002223220807; KONTUSAARI S, 1990, J CLIN INVEST, V86, P1465, DOI 10.1172/JCI114863; KONTUSAARI S, 1990, AM J HUM GENET, V47, P112; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; McKusick V.A., 1983, MENDELIAN INHERITANC; NEILDWYER G, 1983, J NEUROSURG, V59, P16, DOI 10.3171/jns.1983.59.1.0016; NICHOLLS AC, 1990, IN PRESS AM J MED GE; OSTERGAARD JR, 1987, J NEUROSURG, V67, P690, DOI 10.3171/jns.1987.67.5.0690; PALOTIE A, 1989, LANCET, V1, P924; POPE FM, 1983, J ROY SOC MED, V76, P518, DOI 10.1177/014107688307600614; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PROCKOP DJ, 1990, ANN NY ACAD SCI, V580, P330, DOI 10.1111/j.1749-6632.1990.tb17942.x; PROCKOP DJ, 1989, AM J MED GENET, V34, P60, DOI 10.1002/ajmg.1320340112; PROCKOP DJ, 1989, SPRINGER SERIES BIOP, V3, P81; SCHWARTZ R C, 1989, American Journal of Human Genetics, V45, pA218; SHAPIRO JR, 1989, CONNECT TISSUE RES, V21, P447, DOI 10.3109/03008208909050002; SILLENCE D, 1981, CLIN ORTHOP RELAT R, P11; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; SPOTILA LD, 1990, AM J HUM GENET, V47, pA237; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; SYKES B, 1990, AM J HUM GENET, V46, P293; TILLER GE, 1990, P NATL ACAD SCI USA, V87, P3889, DOI 10.1073/pnas.87.10.3889; VISSING H, 1989, J BIOL CHEM, V264, P18265; VOGEL BE, 1988, J BIOL CHEM, V263, P19249	38	430	447	0	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1991	5	7					2052	2060		10.1096/fasebj.5.7.2010058	http://dx.doi.org/10.1096/fasebj.5.7.2010058			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010058				2022-12-28	WOS:A1991FF44200007
J	GERLACH, TH; ZILE, MH				GERLACH, TH; ZILE, MH			EFFECT OF RETINOIC ACID AND APO-RBP ON SERUM RETINOL CONCENTRATION IN ACUTE-RENAL-FAILURE	FASEB JOURNAL			English	Note						SERUM RETINOL; RENAL FAILURE; VITAMIN-A; RETINOIC ACID; FEEDBACK SIGNAL; APO-RBP	VITAMIN-A HOMEOSTASIS; BINDING PROTEIN; ALL-TRANS; RATS; LIVER; METABOLISM; PLASMA	We recently demonstrated a rapid upregulation of serum retinol-retinol binding protein-transthyretin concentration in rats with short-term acute renal failure. We examine the effect of retinoic acid and apo-retinol binding protein (apo-RBP) on the up-regulation of serum retinol in renal failure. Injection of retinoic acid (10-mu-g) into rats with acute renal failure or sham-operated rats increased circulatory retinoic acid concentration 29-fold within 2 h but did not influence serum retinol concentration in either group. Injection of a large dose of retinoic acid (100-mu-g) decreased serum retinol concentration in rats with acute renal failure (19%) and sham-operated rats (29%). These results suggest that changes in serum retinoic acid concentration within the near-physiological range have no effect on regulation of hepatic retinol release. Injection of a large dose of retinoic acid may depress serum retinol indirectly via a retinol sparing effect in target tissues. In rats with renal failure the serum retinol concentration, elevated 44-52% above that of sham-operated controls, was also increased to 70-164% above controls by the injection of 52-63-mu-g of apo-RBP. This suggests that circulatory apo-RBP can up-regulate serum retinol. Circulatory apo-RBP may be a positive physiological feedback signal from peripheral tissues for hepatic release of retinol.	MICHIGAN STATE UNIV,DEPT FOOD SCI & HUMAN NUTR,E LANSING,MI 48824	Michigan State University								BERNARD A, 1988, CLIN CHIM ACTA, V171, P85, DOI 10.1016/0009-8981(88)90293-8; CULLUM ME, 1986, ANAL BIOCHEM, V153, P23, DOI 10.1016/0003-2697(86)90055-2; CULLUM ME, 1985, TOXICOL APPL PHARM, V81, P177, DOI 10.1016/0041-008X(85)90133-4; CULLUM ME, 1985, J BIOL CHEM, V260, P590; DARLINGTON RB, 1975, STATISTICAL METHODS, P229; GERBER LE, 1980, J NUTR, V110, P343, DOI 10.1093/jn/110.2.343; GERLACH HT, 1990, FASEB J, V4, P2511; GOODMAN DS, 1972, J LIPID RES, V13, P338; Goodman DS, 1984, RETINOIDS, V2, P42; IKEGAMI S, 1989, 14TH P INT C NUTR SE; JENSEN RK, 1988, J NUTR, V118, P416, DOI 10.1093/jn/118.3.416; KEILSON B, 1979, J NUTR, V109, P787, DOI 10.1093/jn/109.5.787; KLEINERB.A, 1971, ARCH BIOCHEM BIOPHYS, V142, P371, DOI 10.1016/0003-9861(71)90295-5; KRISHNAMURTHY S, 1963, J NUTR, V79, P503, DOI 10.1093/jn/79.4.503; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASAKI K, 1986, TOHOKU J EXP MED, V150, P249, DOI 10.1620/tjem.150.249; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; RINGLER DH, 1979, LAB RAT, V1, P108; UNDERWOOD BA, 1979, J NUTR, V109, P796, DOI 10.1093/jn/109.5.796; VAHLQUIS.A, 1973, EUR J CLIN INVEST, V3, P352, DOI 10.1111/j.1365-2362.1973.tb00362.x; VAHLQUIST A, 1979, AM J CLIN NUTR, V32, P1433, DOI 10.1093/ajcn/32.7.1433; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873	23	28	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					86	92		10.1096/fasebj.5.1.1991596	http://dx.doi.org/10.1096/fasebj.5.1.1991596			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991596				2022-12-28	WOS:A1991ET60900019
J	YONEZAWA, K; ROTH, RA				YONEZAWA, K; ROTH, RA			VARIOUS PROTEINS MODULATE THE KINASE-ACTIVITY OF THE INSULIN-RECEPTOR	FASEB JOURNAL			English	Article									STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University					NIDDK NIH HHS [DK34926] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034926, R37DK034926] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELGHANY M, 1989, P NATL ACAD SCI USA, V86, P1761, DOI 10.1073/pnas.86.6.1761; ABDELGHANY M, 1987, P NATL ACAD SCI USA, V84, P8888, DOI 10.1073/pnas.84.24.8888; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLARKE FM, 1975, BIOCHIM BIOPHYS ACTA, V381, P37, DOI 10.1016/0304-4165(75)90187-7; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DENTON RM, 1975, MOL CELL BIOCHEM, V9, P27, DOI 10.1007/BF01731731; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELLIS L, 1988, J VIROL, V62, P1634, DOI 10.1128/JVI.62.5.1634-1639.1988; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; HERRERA R, 1988, J BIOL CHEM, V263, P5560; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALLER JL, 1986, NATURE, V320, P459; MINTON AP, 1981, BIOCHEMISTRY-US, V20, P4821, DOI 10.1021/bi00520a003; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MORRISON BD, 1989, J BIOL CHEM, V264, P9994; ROACH PJ, 1977, FEBS LETT, V80, P95, DOI 10.1016/0014-5793(77)80414-6; ROSEN OM, 1981, J BIOL CHEM, V256, P3630; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1986, J BIOL CHEM, V261, P3753; SACKS DB, 1988, J BIOL CHEM, V263, P2377; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WANG YH, 1986, J BIOL CHEM, V261, P6909; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1985, EUR J BIOCHEM, V148, P177, DOI 10.1111/j.1432-1033.1985.tb08822.x	28	7	7	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1990	4	2					194	200		10.1096/fasebj.4.2.2153593	http://dx.doi.org/10.1096/fasebj.4.2.2153593			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CM418	2153593				2022-12-28	WOS:A1990CM41800008
J	NATHAN, C				NATHAN, C			NITRIC-OXIDE AS A SECRETORY PRODUCT OF MAMMALIAN-CELLS	FASEB JOURNAL			English	Review						NO BIOSYNTHESIS; CEREBELLAR NITRIC OXIDE SYNTHASE; L-ARGININE	TUMOR-NECROSIS-FACTOR; LONG-TERM POTENTIATION; DEPENDENT EFFECTOR MECHANISM; NEURONAL NADPH DIAPHORASE; L-ARGININE; RELAXING FACTOR; ACTIVATED MACROPHAGES; NITRATE BIOSYNTHESIS; MURINE MACROPHAGES; RIBONUCLEOTIDE REDUCTASE	Evolution has resorted to nitric oxide (NO), a tiny, reactive radical gas, to mediate both servoregulatory and cytotoxic functions. This article reviews how different forms of nitric oxide synthase help confer specificity and diversity on the effects of this remarkable signaling molecule.			NATHAN, C (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, BEATRICE & SAMUEL A SEAVER LAB, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER; NCI NIH HHS [CA43610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; ALBINA JE, 1991, J IMMUNOL, V147, P144; AMBER IJ, 1988, J LEUKOCYTE BIOL, V43, P187, DOI 10.1002/jlb.43.2.187; AOKI N, 1990, AM J PHYSIOL, V258, pG275, DOI 10.1152/ajpgi.1990.258.2.G275; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; BILLIAR TR, 1991, BIOL NITRIC OXIDE; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BREZIS M, 1991, J CLIN INVEST, V88, P390, DOI 10.1172/JCI115316; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CATTELL V, 1990, KIDNEY INT, V38, P1056, DOI 10.1038/ki.1990.312; CHEN PY, 1991, J CLIN INVEST, V88, P1559, DOI 10.1172/JCI115467; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1988, J IMMUNOL, V141, P2407; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DUPUY PM, 1992, IN PRESS J CLIN INVE; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GALEA E, IN PRESS P NATL ACAD; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GEROULANOS S, 1992, LANCET, V339, P435; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927; GRIFFITH OW, 1991, BIOL NITRIC OXIDE; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1990, INT CONGR SER, V897, P189; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUGHES SR, 1990, EUR J PHARMACOL, V191, P481, DOI 10.1016/0014-2999(90)94184-Y; HUTCHESON IR, 1990, BRIT J PHARMACOL, V101, P815, DOI 10.1111/j.1476-5381.1990.tb14163.x; IGHARRO JJ, 1990, ANN REV PHARM TOXICO, V30, P535; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JOHNSON C, 1992, NATURE, V355, P69, DOI 10.1038/355069a0; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KLATT P, 1992, J BIOL CHEM, V267, P11374; KRONCKE KD, 1991, BIOCHEM BIOPH RES CO, V175, P752, DOI 10.1016/0006-291X(91)91630-U; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAYCHOCK SG, 1991, ENDOCRINOLOGY, V129, P3043, DOI 10.1210/endo-129-6-3043; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; LOWENSTEIN CJ, 1992, IN PRESS P NATL ACAD; LUKIC ML, 1991, BIOCHEM BIOPH RES CO, V178, P913, DOI 10.1016/0006-291X(91)90978-G; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAGRINAT GC, 1992, CLIN RES, V40, pA297; MALAWISTA SE, 1992, IN PRESS J CLIN INVE; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MARSDEN PA, 1990, J EXP MED, V172, P1843, DOI 10.1084/jem.172.6.1843; MATHEIS G, 1992, AM J PHYSIOL, V262, pH616, DOI 10.1152/ajpheart.1992.262.2.H616; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MCCALL T, 1992, TRENDS PHARMACOL SCI, V13, P1, DOI 10.1016/0165-6147(92)90002-N; MELLION BT, 1981, BLOOD, V57, P946; MELLOUK S, 1991, J IMMUNOL, V146, P3971; MILLS CD, 1991, J IMMUNOL, V146, P2179; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; MURPHY S, 1990, J NEUROCHEM, V55, P349, DOI 10.1111/j.1471-4159.1990.tb08860.x; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; NOWAK R, 1992, J NIH RES, V4, P49; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PARK KH, 1992, IN PRESS CIRC RES; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; PERSSON MG, 1990, ACTA PHYSIOL SCAND, V140, P449, DOI 10.1111/j.1748-1716.1990.tb09021.x; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; ROBERTS JD, 1991, CIRCULATION S2, V84, pA1279; ROUSSAINT R, 1992, IN PRESS N ENGL J ME; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHW, 1991, BIOCHEM BIOPH RES CO, V181, P1372, DOI 10.1016/0006-291X(91)92090-7; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SIMMONS ML, 1992, IN PRESS J NEUROCHEM; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STUEHR D, 1992, ADV ENZ REL AREAS MO, V65, P287; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VIERECK RA, 1991, NATURE, V354, P48, DOI 10.1038/354048a0; WAGNER DA, 1983, P NATL ACAD SCI-BIOL, V80, P4518, DOI 10.1073/pnas.80.14.4518; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WHITE KA, 1992, IN PRESS BIOCHEMISTR; WILCOX CS, 1992, IN PRESS P NATL ACAD; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WOLFF DJ, 1992, IN PRESS J NEUROCHEM; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1992, CELLULAR MOL MECHANI; YUI Y, 1991, J BIOL CHEM, V266, P12544; YUI Y, 1991, J BIOL CHEM, V266, P3369; ZATZ R, 1991, AM J PHYSIOL, V261, pF360	163	4188	4315	2	149	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3051	3064		10.1096/fasebj.6.12.1381691	http://dx.doi.org/10.1096/fasebj.6.12.1381691			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1381691				2022-12-28	WOS:A1992JN50500006
J	RUDERMAN, NB; WILLIAMSON, JR; BROWNLEE, M				RUDERMAN, NB; WILLIAMSON, JR; BROWNLEE, M			GLUCOSE AND DIABETIC VASCULAR-DISEASE	FASEB JOURNAL			English	Article						PATHOGENESIS; SORBITOL PATHWAY; DIACYLGLYCEROL SYNTHESIS; PROTEIN KINASE-C; MYOINOSITOL TRANSPORT; NA/K-ATPASE; REDOX STATE; GLYCATION; PHARMACOLOGY	PROTEIN-KINASE-C; NONENZYMATICALLY GLYCOSYLATED COLLAGEN; POLYOL PATHWAY ACTIVITY; ENDOTHELIAL-CELLS; MESANGIAL EXPANSION; FILTRATION CHANGES; ALDOSE REDUCTASE; END-PRODUCTS; RATS; COMPLICATIONS	The central therapeutic problem in diabetes mellitus is prevention and treatment of the chronic vascular disease associated with this disorder. Prolonged exposure to hyperglycemia is the primary factor associated with the development of diabetes-specific microvascular disease, and the relationship between deranged glucose metabolism and arterial disease is complicated by many other factors that influence atherogenesis in nondiabetics. Until relatively recently, knowledge about diabetic vascular disease was limited mainly to clinical description. New information about abnormal vascular physiology, ultrastructure, biochemistry, cell biology, and molecular biology now makes it possible to understand in an integrated fashion the major specific mechanisms by which hyperglycemia damages diabetic vessels. Continued progress in this area will further optimize the development of safe and effective drugs for the treatment of diabetic vascular disease.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED,DIABET RES CTR,1300 MORRIS PK AVE,F-531, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PATHOL, BRONX, NY 10461 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02118 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Boston University; Boston University; Washington University (WUSTL)				Ruderman, Neil/0000-0002-6589-6587				BAINES JW, 1989, AGING DIABETES NUTRI, P410; BANK N, 1989, AM J PHYSIOL, V256, pF1000, DOI 10.1152/ajprenal.1989.256.6.F1000; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BRESNICK GH, 1977, ARCH OPHTHALMOL-CHIC, V95, P1215, DOI 10.1001/archopht.1977.04450070113010; BROWNLEE M, 1983, J EXP MED, V158, P1739, DOI 10.1084/jem.158.5.1739; BROWNLEE M, 1985, DIABETES, V34, P938, DOI 10.2337/diabetes.34.9.938; BROWNLEE M, 1979, DIABETES, V28, P121, DOI 10.2337/diabetes.28.2.121; BROWNLEE M, 1981, ANNU REV BIOCHEM, V50, P385, DOI 10.1146/annurev.bi.50.070181.002125; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BROWNLEE M, 1990, DIABETES MELLITUS TH, P279; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; BUNN HF, 1981, SCIENCE, V213, P222, DOI 10.1126/science.12192669; CAGLIERO E, 1991, DIABETES, V40, P102, DOI 10.2337/diabetes.40.1.102; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; CRAVEN PA, 1989, METABOLISM, V38, P649, DOI 10.1016/0026-0495(89)90102-9; CROWLEY ST, 1991, DIABETES, V40, P540, DOI 10.2337/diabetes.40.5.540; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FRANGOS M, 1990, DIABETES S1, V39, pA274; GARNER MH, 1990, J BIOL CHEM, V265, P15058; GONZALEZ RG, 1984, DIABETES, V33, P196, DOI 10.2337/diabetes.33.2.196; GREENE DA, 1988, DIABETES METAB REV, V4, P202; GREENE DA, 1989, NEUROPATHY PREVENTIO, P93; GUPTA S, 1992, IN PRESS J CLIN INVE; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HICKS M, 1989, ARCH BIOCHEM BIOPHYS, V268, P249, DOI 10.1016/0003-9861(89)90586-9; IDO Y, 1990, DIABETES S1, V39, pA93; KADOR PF, 1990, SEP NAT EY I JUV DIA; KAWAMURA T, 1990, DIABETES S1, V39, pA192; KELLY SB, 1989, J INVEST DERMATOL, V93, P327, DOI 10.1111/1523-1747.ep12280239; KERN T, 1990, 1990 NAT EY I JUV DI, P65; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; KIRSTEIN M, 1990, DIABETES S1, V39, pA182; KLEIN DJ, 1989, DIABETES, V38, P130, DOI 10.2337/diabetes.38.1.130; KOHNER EM, 1982, COMPLICATIOSN DIABET; LAWRENCE D, 1991, DIABETES S1, V40, pA491; LEE AT, 1987, P NATL ACAD SCI USA, V84, P8311, DOI 10.1073/pnas.84.23.8311; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; LEE TS, 1989, J CLIN INVEST, V83, P90, DOI 10.1172/JCI113889; LONGO FM, 1986, MUSCLE NERVE, V9, P385, DOI 10.1002/mus.880090502; LORNEZI M, 1986, J CLIN INVEST, V77, P322; LUBEC G, 1980, Renal Physiology, V3, P4; MARANO CW, 1989, DIABETES METAB REV, V5, P1, DOI 10.1002/dmr.5610050102; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MONNIER V, 1988, MAILLARD REACTION AG, P1; MORAN A, 1991, DIABETES, V40, P1346, DOI 10.2337/diabetes.40.10.1346; MORRISON AD, 1970, BIOCHEM BIOPH RES CO, V40, P199, DOI 10.1016/0006-291X(70)91066-1; MULLARKEY CJ, 1991, TXB DIABETES, P534; MULLOKANDOV E, 1991, DIABETES S1, V40, pA1075; NICHOLLS K, 1989, LAB INVEST, V60, P486; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OSTERBY R, 1990, DIABETES, V39, P1057, DOI 10.2337/diabetes.39.9.1057; PUGLIESE G, 1990, DIABETES, V39, P323, DOI 10.2337/diabetes.39.3.323; PUGLIESE G, 1990, METABOLISM, V39, P690, DOI 10.1016/0026-0495(90)90102-I; PUGLIESE G, 1990, DIABETES, V39, P312, DOI 10.2337/diabetes.39.3.312; ROGERS D, 1988, DIABETES, V37, P1689, DOI 10.2337/diabetes.37.12.1689; ROHRBACH DH, 1982, DIABETES, V31, P185, DOI 10.2337/diabetes.31.2.185; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAITO Y, 1988, KIDNEY INT, V34, P389, DOI 10.1038/ki.1988.193; SHILTON BH, 1991, J BIOL CHEM, V266, P5587; SIMMONS DA, 1989, DIABETOLOGIA, V32, P402, DOI 10.1007/BF00271258; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; SKYLER JS, 1990, DIABETES MELLITUS TH, P856; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; STEVENS VJ, 1977, J BIOL CHEM, V252, P2998; STRIBLING D, 1988, POLYOL PATHWAY ITS R, P32; TANAKA S, 1988, J MOL BIOL, V203, P495, DOI 10.1016/0022-2836(88)90015-0; TESFAMARIAM B, 1991, J CLIN INVEST, V87, P1643, DOI 10.1172/JCI115179; TILTON R G, 1990, Investigative Ophthalmology and Visual Science, V31, P342; TILTON RG, 1989, DIABETES, V38, P1258, DOI 10.2337/diabetes.38.10.1258; TRAVIS SF, 1971, J CLIN INVEST, V50, P2104, DOI 10.1172/JCI106704; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; TSILIBARY EC, 1990, DIABETES, V39, pA194; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WALKER JD, 1991, TXB DIABETES, P526; WILLIAMSON JR, 1988, DIABETES METAB REV, V4, P339, DOI 10.1002/dmr.5610040404; WILLIAMSON JR, 1990, J CLIN INVEST, V85, P1167, DOI 10.1172/JCI114549; WILLIAMSON JR, 1991, SERONO SYM, V69, P45; WILLIAMSON JR, 1988, DIABETES S1, V37, pA95; WILLIAMSON JR, 1990, DIABETES, V39, pA157; WILLIAMSON JR, 1989, DIABETES S2, V38, pA94; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; 1987, 03274 HLTH CAR FIN A; 1984, NIH851468 PUBL; 1990, ARCH OPHTHALMOL-CHIC, V108, P1234	93	344	357	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2905	2914		10.1096/fasebj.6.11.1644256	http://dx.doi.org/10.1096/fasebj.6.11.1644256			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644256				2022-12-28	WOS:A1992JJ66500004
J	PEGG, AE; BYERS, TL				PEGG, AE; BYERS, TL			REPAIR OF DNA CONTAINING O6-ALKYLGUANINE	FASEB JOURNAL			English	Review						ALKYLATION; DNA REPAIR; MUTAGENESIS; CARCINOGENESIS; CHEMOTHERAPY	HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; MAMMALIAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ESCHERICHIA-COLI; HUMAN-CELLS; ADAPTIVE RESPONSE; ALKYLATING-AGENTS; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; N-NITROSOUREA; ADA PROTEIN; RAT-LIVER	O6-Alkylguanines, important DNA adducts formed by alkylating agents, can lead to mutations and to cell death unless repaired. The major pathway of repair involves the transfer of the alkyl group from the DNA to a cysteine acceptor site in the protein O6-alkylguanine-DNA alkyltransferase. The alkyltransferase brings about this transfer without need for cofactors and the DNA is restored completely by the action of a single protein, but the cysteine acceptor site is not regenerated and the number of O6-alkylguanines that can be repaired is equal to the number of active alkyltransferase molecules. The alkylated form of the protein is unstable in mammalian cells and is degraded rapidly. Cloning of the cDNAs for the alkyltransferase proteins from bacteria, yeast, and mammals indicates a significant similarity, particularly in the region surrounding the cysteine acceptor site. There is a major difference in the regulation of the alkyltransferase between mammalian cells and certain bacteria, where it is induced as part of the adaptive response to alkylating agents. Regulation of the content of alkyltransferase in mammalian cells differs with species and cell type and, in some cases, the level of the protein is increased by exposure to alkylating agents or X rays. A significant fraction of human tumor cell lines do not express the alkyltransferase gene and, thus, are much more sensitive to mutagenesis and killing by alkylating agents. The frequency of primary tumor cells that lack alkyltransferase protein is not yet clear. However, it is known that the level of alkyltransferase in tumors is a significant factor in resistance to both methylating agents and bifunctional chloroethylating agents. Inactivation of the alkyltransferase, which can be brought about by pretreatment with an alkylating agent or by exposure to O6-benzylguanine (a powerful nontoxic inhibitor), sensitizes tumor cells to these chemotherapeutic alkylating agents and may prove a useful therapeutic strategy.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT PHARMACOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	PEGG, AE (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,HERSHEY,PA 17033, USA.				NCI NIH HHS [CA-18137] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018137, R37CA018137] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; ARITA I, 1990, CARCINOGENESIS, V11, P1733, DOI 10.1093/carcin/11.10.1733; BELINSKY SA, 1989, CANCER RES, V49, P5305; BERTINI R, 1990, CARCINOGENESIS, V11, P181, DOI 10.1093/carcin/11.1.181; BHATTACHARYYA D, 1990, EUR J BIOCHEM, V193, P337, DOI 10.1111/j.1432-1033.1990.tb19343.x; BRENT TP, 1988, P NATL ACAD SCI USA, V85, P1759, DOI 10.1073/pnas.85.6.1759; CHAN CL, 1990, CARCINOGENESIS, V11, P1217, DOI 10.1093/carcin/11.7.1217; CITRON M, 1991, CANCER RES, V51, P4131; DAY RS, 1991, MUTAT RES, V254, P153, DOI 10.1016/0921-8777(91)90006-B; DEMPLE B, 1990, PROTEIN METHYLATION, P285; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; DOLAN ME, 1991, CANCER RES, V51, P3367; DOLAN ME, 1990, CANCER COMMUN, V2, P371, DOI 10.3727/095535490820873985; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; DUMENCO LL, 1991, CANCER RES, V51, P3391; DUNN WC, 1991, CARCINOGENESIS, V12, P83, DOI 10.1093/carcin/12.1.83; ESPINA N, 1988, CARCINOGENESIS, V9, P761, DOI 10.1093/carcin/9.5.761; FAN CY, 1990, NUCLEIC ACIDS RES, V18, P5723, DOI 10.1093/nar/18.19.5723; FORNACE AJ, 1990, CANCER RES, V50, P7908; FROSINA G, 1990, CANCER LETT, V55, P153, DOI 10.1016/0304-3835(90)90026-T; Futscher B W, 1989, Cancer Commun, V1, P65; GERSON SL, 1988, CANCER RES, V48, P5368; GONZAGA PE, 1990, NUCLEIC ACIDS RES, V18, P3961, DOI 10.1093/nar/18.13.3961; GREEN MHL, 1990, CARCINOGENESIS, V11, P185, DOI 10.1093/carcin/11.1.185; HAKURA A, 1991, J BACTERIOL, V173, P3663, DOI 10.1128/JB.173.12.3663-3672.1991; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; KARRAN P, 1990, CANCER RES, V50, P1532; KOHDA K, 1991, CHEM-BIOL INTERACT, V78, P23, DOI 10.1016/0009-2797(91)90100-L; KOIKE G, 1990, J BIOL CHEM, V265, P14754; LAVAL F, 1991, BIOCHEM BIOPH RES CO, V176, P1086, DOI 10.1016/0006-291X(91)90395-N; LAVAL F, 1990, MUTAT RES, V233, P211, DOI 10.1016/0027-5107(90)90164-Y; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; LUKASH LL, 1991, MUTAT RES, V250, P397, DOI 10.1016/0027-5107(91)90196-U; MAHER VM, 1990, MUTAT RES, V233, P235, DOI 10.1016/0027-5107(90)90166-2; MARGISON GP, 1990, MUTAT RES, V233, P15, DOI 10.1016/0027-5107(90)90146-U; MOROHOSHI F, 1990, NUCLEIC ACIDS RES, V18, P5473, DOI 10.1093/nar/18.18.5473; NAKATSURU Y, 1991, MUTAT RES, V254, P225, DOI 10.1016/0921-8777(91)90060-3; OSTROWSKI LE, 1991, CANCER RES, V51, P3339; PEGG AE, 1991, CARCINOGENESIS, V12, P1679, DOI 10.1093/carcin/12.9.1679; PEGG AE, 1990, CANCER RES, V50, P6119; PEGG AE, 1991, CARCINOGENESIS, V12, P1671, DOI 10.1093/carcin/12.9.1671; PEGG AE, 1989, DNA REPAIR MECHANISM, P45; PIEPER RO, 1991, CANCER RES, V51, P1581; PIEPER RO, 1991, CANCER COMMUN, V3, P241, DOI 10.3727/095535491820873092; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; POTTER PM, 1991, CARCINOGENESIS, V12, P727, DOI 10.1093/carcin/12.4.727; RAHDENSTARON I, 1991, BIOCHEM BIOPH RES CO, V177, P597, DOI 10.1016/0006-291X(91)91830-6; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; RICHARDSON FC, 1990, MUTAT RES, V233, P127, DOI 10.1016/0027-5107(90)90157-Y; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SAMSON L, 1988, EMBO J, V7, P2261, DOI 10.1002/j.1460-2075.1988.tb03066.x; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; SCHOLD SC, 1989, J NEUROSURG, V70, P573, DOI 10.3171/jns.1989.70.4.0573; SHEVELL DE, 1990, MUTAT RES, V233, P53, DOI 10.1016/0027-5107(90)90151-S; SIKPI MO, 1990, MOL CARCINOGEN, V3, P30, DOI 10.1002/mc.2940030108; SINGER B, 1990, MUTAT RES, V233, P45, DOI 10.1016/0027-5107(90)90150-3; SWANN PF, 1990, MUTAT RES, V233, P81, DOI 10.1016/0027-5107(90)90153-U; TANO K, 1991, MUTAT RES, V255, P175, DOI 10.1016/0921-8777(91)90051-P; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; THOMALE J, 1990, P NATL ACAD SCI USA, V87, P9883, DOI 10.1073/pnas.87.24.9883; TOPAL MD, 1988, CARCINOGENESIS, V9, P691, DOI 10.1093/carcin/9.5.691; VAUGHAN P, 1991, CARCINOGENESIS, V12, P263, DOI 10.1093/carcin/12.2.263; VONWRONSKI MA, 1991, J BIOL CHEM, V266, P1064; WANG AM, 1991, CANCER CHEMOTH PHARM, V27, P278, DOI 10.1007/BF00685112; WANG Y, 1990, CANCER RES, V50, P1591; XIAO W, 1991, EMBO J, V10, P2179, DOI 10.1002/j.1460-2075.1991.tb07753.x; YAROSH DB, 1985, MUTAT RES, V145, P1, DOI 10.1016/0167-8817(85)90034-3	68	262	271	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2302	2310		10.1096/fasebj.6.6.1544541	http://dx.doi.org/10.1096/fasebj.6.6.1544541			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544541				2022-12-28	WOS:A1992HJ25200007
J	GLAVIN, GB; SZABO, S				GLAVIN, GB; SZABO, S			EXPERIMENTAL GASTRIC-MUCOSAL INJURY - LABORATORY MODELS REVEAL MECHANISMS OF PATHOGENESIS AND NEW THERAPEUTIC STRATEGIES	FASEB JOURNAL			English	Review						ULCER; GASTRIC; GASTROPROTECTION; ANIMAL MODEL; STRESS; ETHANOL; NONSTEROIDAL ANTIINFLAMMATORY DRUG; GASTRIC MUCOSAL INJURY	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ULCER FORMATION; DUODENAL-ULCER; ACID SECRETION; RAT STOMACH; ETHANOL; DAMAGE; CYTOPROTECTION; ADENOSINE; STRESS	Gastric ulcer is a multifaceted, pluricausal illness. Knowledge of the pathophysiology of gastric ulcer disease remains incomplete. Current pharmacological management of gastric ulceration is directed primarily at the reduction or neutralization of gastric acid secretion despite evidence that patients with this disease often exhibit normal gastric secretory activity. Attempts have been made to prevent or reduce gastric mucosal injury by cytoprotective agents without diminishing gastric acidity. We review several alternate explanations for the cause of gastric ulcers by examining various experimental models of gastric mucosal damage, including ethanol-, stress-, and nonsteroidal antiinflammatory drug-induced gastric lesions. We also discuss possible new strategies for the treatment of ulcer disease, particularly novel pharmacological targets arising from research conducted with these models. Growing realization that factors other than gastric secretion contribute significantly to the development of gastric ulcer disease prompts the conclusion that these same factors represent viable treatment alternatives.	UNIV MANITOBA, FAC MED, DEPT SURG, WINNIPEG R3E 0W3, MANITOBA, CANADA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	University of Manitoba; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	GLAVIN, GB (corresponding author), UNIV MANITOBA, FAC MED, DEPT PHARMACOL & THERAPEUT, 770 BANNATYNE AVE, WINNIPEG R3E 0W3, MANITOBA, CANADA.							CHO CH, 1990, DIGEST DIS SCI, V35, P1334, DOI 10.1007/BF01536737; GEIGER JD, 1985, EUR J PHARMACOL, V115, P185, DOI 10.1016/0014-2999(85)90690-9; GERBER JG, 1985, J PHARMACOL EXP THER, V233, P623; GLAVIN G, 1991, NEUROENDOCRINOLOGY G; GLAVIN GB, 1990, DIGEST DIS SCI, V35, P1153, DOI 10.1007/BF01537589; GLAVIN GB, 1986, TOXICOL APPL PHARM, V83, P386, DOI 10.1016/0041-008X(86)90315-7; GLAVIN GB, 1989, EUR J PHARMACOL, V160, P323, DOI 10.1016/0014-2999(89)90087-3; GLAVIN GB, 1986, EUR J PHARMACOL, V124, P121, DOI 10.1016/0014-2999(86)90131-7; GLAVIN GB, 1990, DIGEST DIS SCI, V35, P1017; GRANGER DN, 1986, VIEWPOINTS DIG DIS, V18, P13; GUTH PH, 1986, SCAND J GASTROENTERO, V21, P86, DOI 10.3109/00365528609093822; HERNANDEZ D, 1989, GASTROENTEROLOGY, V96, pA206; HERNANDEZ DE, 1989, DIGEST DIS SCI, V34, P543, DOI 10.1007/BF01536330; ISENBERG JI, 1987, NEW ENGL J MED, V316, P374, DOI 10.1056/NEJM198702123160704; ISHII K, 1990, RES EXP MED, V190, P389, DOI 10.1007/BF00000045; KIVILAAKSO E, 1981, GASTROENTEROLOGY, V81, P921; KONTUREK SJ, 1986, DIGEST DIS SCI, V31, pS6, DOI 10.1007/BF01309317; KOO MWL, 1986, EUR J PHARMACOL, V120, P355, DOI 10.1016/0014-2999(86)90477-2; KWOK YN, 1990, J PHARMACOL EXP THER, V255, P781; LACY ER, 1982, GASTROENTEROLOGY, V83, P619; MACNAUGHTON WK, 1989, LIFE SCI, V45, P1869, DOI 10.1016/0024-3205(89)90540-7; MOZSIK G, 1988, DIGEST DIS SCI, V33, P92, DOI 10.1007/BF01536637; NISHIMURA E, 1986, GASTROENTEROLOGY, V91, P1084, DOI 10.1016/S0016-5085(86)80002-6; OGLE C, 1989, ULCER DISEASE NEW AS, P335; OHISALO JJ, 1987, MED BIOL, V65, P181; PALITZSCH K D, 1989, Gastroenterology, V96, pA381; PARE W, 1992, IN PRESS METHODS BEH; PIHAN G, 1986, GASTROENTEROLOGY, V91, P1415, DOI 10.1016/0016-5085(86)90195-2; RAY A, 1988, BRAIN RES, V442, P195, DOI 10.1016/0006-8993(88)91452-7; ROBERT A, 1979, GASTROENTEROLOGY, V77, P433; ROBERT A, 1991, LIFE SCI, V48, P123, DOI 10.1016/0024-3205(91)90405-Z; ROBERT A, 1984, SCAND J GASTROENTERO, V19, P69; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; ROBERT A, 1984, MECHANISMS MUCOSAL P, P381; SCHOEN RT, 1989, AM J MED, V86, P449, DOI 10.1016/0002-9343(89)90344-6; SILEN W, 1988, AM J PHYSIOL, V255, pG395, DOI 10.1152/ajpgi.1988.255.4.G395; SZABO S, 1987, SCAND J GASTROENTERO, V22, P21, DOI 10.3109/00365528709090946; SZABO S, 1981, SCIENCE, V214, P200, DOI 10.1126/science.7280691; SZABO S, 1987, TRENDS PHARMACOL SCI, V8, P149, DOI 10.1016/0165-6147(87)90185-4; SZABO S, 1985, GASTROENTEROLOGY, V88, P228, DOI 10.1016/S0016-5085(85)80176-1; TARIQ M, 1990, J PHARMACOL EXP THER, V253, P944; TILL M, 1988, EUR J PHARMACOL, V150, P325, DOI 10.1016/0014-2999(88)90014-3; Trier JS, 1987, GASTROENTEROLOGY, V92, P13, DOI 10.1016/0016-5085(87)90834-1; TYTGAT GNJ, 1990, GASTROENTEROL CLIN N, V19, P183; WALLACE JL, 1985, AM J PHYSIOL, V248, pG35, DOI 10.1152/ajpgi.1985.248.1.G35; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; WALLACE JL, 1989, EUR J PHARMACOL, V167, P41, DOI 10.1016/0014-2999(89)90745-0; WALLACE JL, 1986, GASTROENTEROLOGY, V91, P603, DOI 10.1016/0016-5085(86)90629-3; WALLACE JL, 1990, EUR J PHARMACOL, V186, P279, DOI 10.1016/0014-2999(90)90444-B; WALLACE JL, 1990, GASTROENTEROLOGY, V99, P295, DOI 10.1016/0016-5085(90)91009-U; WALLACE JL, 1986, PROSTAGLANDINS, V31, P989, DOI 10.1016/0090-6980(86)90028-6; WONG WSF, 1990, LIFE SCI, V47, P1483; XU Y, 1989, GASTROENTEROLOGY, V96, pA553	53	141	148	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1992	6	3					825	831		10.1096/fasebj.6.3.1740232	http://dx.doi.org/10.1096/fasebj.6.3.1740232			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740232	Bronze			2022-12-28	WOS:A1992HE39000004
J	HARDINGHAM, TE; FOSANG, AJ				HARDINGHAM, TE; FOSANG, AJ			PROTEOGLYCANS - MANY FORMS AND MANY FUNCTIONS	FASEB JOURNAL			English	Article						GLYCOSAMINOGLYCANS; GLYCOSYLATION; PROTEIN CORE; EXTRACELLULAR MATRIX; CELL SURFACE; GROWTH FACTORS	FIBROBLAST GROWTH-FACTOR; HOMING RECEPTOR; VITREOUS-HUMOR; HUMAN SYNDECAN; LINK PROTEIN; II COLLAGEN; CARTILAGE; BINDING; IDENTIFICATION; DECORIN	Proteoglycans are produced by most eukaryotic cells and are versatile components of pericellular and extracellular matrices. They belong to many different protein families. Their functions vary from the physical effects of the proteoglycan aggrecan, which binds with link protein to hyaluronan to form multi-molecular aggregates in cartilage; to the intercalated membrane protein CD44 that has a proteoglycan form and is a receptor and a cell-binding site for hyaluronan; to heparan sulfate proteoglycans of the syndecan and other families that provide matrix binding sites and cell-surface receptors for growth factors such as fibroblast growth factor (FGF). One feature that recurs in proteoglycan biology is that their structure is open to extensive modulation during cellular expression. Examples of protein changes are known, but a major source of structural variation is in the glycosaminoglycan chains. The number of chains and their length can vary, as well as their pattern of sulfation. This may result in the switching of different chain types with different properties, e.g., chondroitin sulfate and heparan sulfate, and it may also result in the selective expression of sulfated chain sequences that have specific functions. The control of glycosaminoglycan structure is not well understood, but it does appear to be used to change the properties of proteoglycans to suit different biological needs. Proteoglycan forms of proteins are thus important modifiers of the organization of the pericellular and extracellular matrices and modulators of the processes that occur there.	UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; University of Melbourne	HARDINGHAM, TE (corresponding author), KENNEDY INST,DIV BIOCHEM,LONDON W6 7DW,ENGLAND.			Fosang, Amanda/0000-0002-5523-5427; Hardingham, Timothy/0000-0001-8271-6763				BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CATERSON B, 1990, J CELL SCI, V97, P411; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ESMON CT, 1989, J BIOL CHEM, V264, P4743; EVERED D, 1986, CIBA F S, V124; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOETINCK PF, 1991, BIOCH PHYSL SKIN; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HARDINGHAM TE, 1990, SEMIN ARTHRITIS RH S, V1, P12; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HUBER S, 1986, J BIOL CHEM, V261, P5965; Lindahl U., 1989, HEPARIN CHEM BIOL PR; MALI M, 1990, J BIOL CHEM, V265, P6884; MANN DM, 1990, J BIOL CHEM, V265, P5317; MURAKAMI S, 1991, J IMMUNOL, V146, P1422; ODNNELL CM, 1988, J BIOL CHEM, V263, P17749; PERIDES G, 1989, J BIOL CHEM, V264, P5981; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; PULKKINEN L, 1990, J BIOL CHEM, V265, P17780; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SANDY JD, 1989, BIOCHEM J, V258, P875, DOI 10.1042/bj2580875; SCOTT JE, 1988, BIOCHEM J, V253, P607, DOI 10.1042/bj2530607; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; Thompson RW, 1990, GROWTH FACTORS, V3, P221, DOI 10.3109/08977199009043906; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WRIGHT DW, 1988, J ULTRA MOL STRUCT R, V100, P224, DOI 10.1016/0889-1605(88)90039-0; YADA T, 1990, J BIOL CHEM, V265, P6992; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	45	988	1009	3	110	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					861	870		10.1096/fasebj.6.3.1740236	http://dx.doi.org/10.1096/fasebj.6.3.1740236			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740236	Bronze			2022-12-28	WOS:A1992HE39000009
J	HOSEY, MM				HOSEY, MM			DIVERSITY OF STRUCTURE, SIGNALING AND REGULATION WITHIN THE FAMILY OF MUSCARINIC CHOLINERGIC RECEPTORS	FASEB JOURNAL			English	Article						RECEPTOR PHOSPHORYLATION; ACETYLCHOLINE	PROTEIN-KINASE-C; AGONIST-DEPENDENT PHOSPHORYLATION; A9 L-CELLS; ACETYLCHOLINE-RECEPTOR; CHICK HEART; PHOSPHOINOSITIDE HYDROLYSIS; DIFFERENTIAL REGULATION; ADENYLYL CYCLASE; BINDING PROTEINS; PHORBOL ESTER	Acetylcholine signals through two types of unrelated membrane receptors referred to as nicotinic (nAChR) and muscarinic (mAChR) acetylcholine receptors. Nicotinic acetylcholine receptors were the first neurotransmitter receptors to be purified, cloned, and sequenced, and much is known about these proteins. In contrast, until 5 years ago relatively little was known about the muscarinic receptors. Since then there has been an explosion of information concerning the structure, signaling, and regulation of what is now known to be a family of muscarinic receptors. This review discusses the five identified members of the mAChR family and their coupling to the multiple G proteins that allow mAChRs to modulate many different types of signal transduction pathways. The five members of this family that have been identified so far have striking homology in their hydrophobic membrane domains but possess distinct cytoplasmic domains between the fifth and sixth membrane-spanning regions. These cytoplasmic domains appear to contain important determinants for receptor/G protein interaction and are likely to contain phosphorylation sites that regulate these interactions. mAChR agonists have been shown to induce phosphorylation of mAChR in intact cells, and the evidence that suggests that receptor phosphorylation may play a role in the regulation of receptor function is discussed.			HOSEY, MM (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31601] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BIRDSALL N, 1989, TRENDS PHARM SCI S, V7; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; BURGOYNE RD, 1980, FEBS LETT, V122, P288, DOI 10.1016/0014-5793(80)80458-3; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; CURTIS CAM, 1989, J BIOL CHEM, V264, P489; ELFAKAHANY EE, 1988, FASEB J, V2, P2575, DOI 10.1096/fasebj.2.10.2838363; EVANS T, 1984, MOL PHARMACOL, V26, P395; FOSTERMANN U, 1990, MOL PHARMACOL, V38, P7; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAGA K, 1983, J BIOL CHEM, V258, P3575; HAMMER R, 1980, NATURE, V283, P90, DOI 10.1038/283090a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HO AKS, 1987, BIOCHEM BIOPH RES CO, V142, P911, DOI 10.1016/0006-291X(87)91500-2; IKEGAYA T, 1990, J MOL CELL CARDIOL, V22, P343, DOI 10.1016/0022-2828(90)91467-L; JONES SVP, 1988, MOL PHARMACOL, V34, P421; JONES SVP, 1988, P NATL ACAD SCI USA, V85, P4056, DOI 10.1073/pnas.85.11.4056; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LILES WC, 1986, J BIOL CHEM, V261, P5307; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; NEHER E, 1988, FEBS LETT, V240, P88, DOI 10.1016/0014-5793(88)80345-4; Numa S, 1987, Harvey Lect, V83, P121; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PETERSON GL, 1984, P NATL ACAD SCI-BIOL, V81, P4993, DOI 10.1073/pnas.81.15.4993; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; RICHARDSON RM, 1991, MOL PHARMACOL, V40, P908; ROSENBAUM LC, 1987, BIOCHEMISTRY-US, V26, P8183, DOI 10.1021/bi00399a024; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; VINCENTINI LM, 1985, BIOCHEM BIOPH RES CO, V127, P310; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	56	173	176	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					845	852		10.1096/fasebj.6.3.1740234	http://dx.doi.org/10.1096/fasebj.6.3.1740234			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740234	Bronze			2022-12-28	WOS:A1992HE39000007
J	YANG, J; ISENBERG, KE; ZORUMSKI, CF				YANG, J; ISENBERG, KE; ZORUMSKI, CF			VOLATILE ANESTHETICS GATE A CHLORIDE CURRENT IN POSTNATAL RAT HIPPOCAMPAL-NEURONS	FASEB JOURNAL			English	Note						GABA(A)-MIMETIC; VOLATILE ANESTHETICS; ISOFLURANE; HIPPOCAMPAL CULTURE	SPINAL NEURONS; GABA RECEPTOR; CULTURE; ISOFLURANE; CONDUCTANCE; PHARMACOLOGY	A volatile anesthetic-gated current was characterized in patch-clamped cultured postnatal rat hippocampal neurons. In this preparation, the major volatile anesthetics, isoflurane, halothane, and enflurane, open an anion-selective conductance. This volatile anesthetic-gated current exhibits anion selectivity with a chloride-to-acetate permeability ratio of 15, shows outward rectification well described by the constant field equation, and is activated in a dose-dependent fashion with half-maximal response to isoflurane at 0.8 mM (0.032 atm). The current persists in the absence of external Ca2+ and is not blocked by strychnine, a glycine antagonist. However, the gamma-aminobutyric acid(A) (GABA(A)) antagonists, bicuculline and picrotoxinin, and the non-specific anion channel blocker, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), completely block the response. These observations suggest that volatile anesthetics, like several other general anesthetics such as barbiturates, steroids, and etomidate, have a GABA-mimetic effect on vertebrate central neurons in culture. It is not clear whether this GABA(A)-gating property is a prerequisite for all general anesthetics. However, under normal physiological conditions of low intracellular Cl-, it is likely that drugs with both direct GABA agonist and GABA modulatory properties will produce overall depression of the central nervous system by increasing the normal inhibitory synaptic influence and by directly hyperpolarizing neurons.	UNIV MARYLAND,SCH MED,DEPT ANESTHESIOL,655 W BALTIMORE ST,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201; WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Washington University (WUSTL); Washington University (WUSTL)					NIMH NIH HHS [MH00630, MH 00635] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K11MH000635, K11MH000630] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARKER JL, 1987, J PHYSIOL-LONDON, V386, P485, DOI 10.1113/jphysiol.1987.sp016547; BARKER JL, 1978, J PHYSIOL-LONDON, V280, P355, DOI 10.1113/jphysiol.1978.sp012388; BERGJOHNSEN J, 1990, BRAIN RES, V507, P28, DOI 10.1016/0006-8993(90)90517-F; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; EVANS RH, 1978, EXPERIENTIA, V34, P1325, DOI 10.1007/BF01981448; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; FUJIWARA N, 1988, J PHYSIOL-LONDON, V402, P155, DOI 10.1113/jphysiol.1988.sp017198; INOUE M, 1986, NATURE, V324, P156, DOI 10.1038/324156a0; KRISHTAL OA, 1988, NEUROSCI LETT, V84, P271, DOI 10.1016/0304-3940(88)90519-8; LEDEZ KM, 1987, ANESTHESIOLOGY, V67, P301, DOI 10.1097/00000542-198709000-00004; MADISON DV, 1986, NATURE, V321, P695, DOI 10.1038/321695a0; MAYER ML, 1985, J PHYSIOL-LONDON, V364, P217, DOI 10.1113/jphysiol.1985.sp015740; MIU P, 1989, EXP BRAIN RES, V75, P354; MODY I, 1991, BRAIN RES, V538, P319, DOI 10.1016/0006-8993(91)90447-4; NAKAHIRO M, 1989, FASEB J, V3, P1850, DOI 10.1096/fasebj.3.7.2541038; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; NICOLL RA, 1982, SCIENCE, V217, P1055, DOI 10.1126/science.7112112; OBRIEN RJ, 1986, J NEUROSCI, V6, P3275; OWEN DG, 1984, NATURE, V311, P567, DOI 10.1038/311567a0; PROCTOR WR, 1986, J NEUROSCI, V6, P3164; RICHTER JJ, 1989, CLIN ANESTH, P281; SEGAL M, 1984, J NEUROPHYSIOL, V51, P500, DOI 10.1152/jn.1984.51.3.500; VLACHOVA V, 1987, J PHYSIOL-LONDON, V386, P425, DOI 10.1113/jphysiol.1987.sp016542; WALKER RJ, 1989, COMP BIOCHEM PHYS A, V93, P25, DOI 10.1016/0300-9629(89)90188-6; YANG J, 1989, Society for Neuroscience Abstracts, V15, P78; ZORUMSKI C F, 1988, Society for Neuroscience Abstracts, V14, P889	27	52	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					914	918		10.1096/fasebj.6.3.1740240	http://dx.doi.org/10.1096/fasebj.6.3.1740240			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740240				2022-12-28	WOS:A1992HE39000016
J	ELBEIN, AD				ELBEIN, AD			GLYCOSIDASE INHIBITORS - INHIBITORS OF N-LINKED OLIGOSACCHARIDE PROCESSING	FASEB JOURNAL			English	Article						GLYCOPROTEIN PROCESSING INHIBITORS; N-LINKED GLYCOPROTEINS; PROCESSING MANNOSIDASES; PROCESSING GLUCOSIDASES; SWAINSONINE; CASTANOSPERMINE; KIFUNENSINE; MANNOSTATIN; PLANT ALKALOIDS	SUBSTITUTED VALIOLAMINE DERIVATIVES; ORAL ANTIDIABETIC AGENTS; GOLGI MANNOSIDASE-II; ALPHA-D-MANNOSIDASE; PHYSICOCHEMICAL PROPERTIES; SECRETORY GLYCOPROTEINS; GLUCOSIDASE INHIBITOR; SYNCYTIUM FORMATION; MANNOSTATIN-A; BIOSYNTHESIS	The biosynthesis of the various types of N-linked oligosaccharide structures involves two series of reactions: 1) the formation of the lipid-linked saccharide precursor, Glc3Man9(GlcNAc)2-pyrophosphoryl-dolichol, by the stepwise addition of GlcNAc, mannose and glucose to dolichyl-P, and 2) the removal of glucose and mannose by membrane-bound glycosidases and the addition of GlcNAc, galactose, sialic acid, and fucose by Golgi-localized glycosyltransferases to produce different complex oligosaccharide structures. For most glycoproteins, the precise role of the carbohydrate is still not known, but specific N-linked oligosaccharide structures are key players in targeting of lysosomal hydrolases to the lysosomes, in the clearance of asialoglycoproteins from the serum, and in some cases of cell:cell adhesion. Furthermore, many glycoproteins have more than one N-linked oligosaccharide, and these oligosaccharides on the same protein frequently have different structures. Thus, one oligosaccharide may be of the high-mannose type whereas another may be a complex chain. One approach to determining the role of specific structures in glycoprotein function is to use inhibitors that block the modification reactions at different steps, causing the cell to produce glycoproteins with altered carbohydrate structures. The function of these glycoproteins can then be assessed. A number of alkaloid-like compounds have been identified that are specific inhibitors of the glucosidases and mannosidases involved in glycoprotein processing. These compounds cause the formation of glycoproteins with glucose-containing high mannose structures, or various high-mannose or hybrid chains, depending on the site of inhibition. These inhibitors have also been useful for studying the processing pathway and for comparing processing enzymes from different organisms.			ELBEIN, AD (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205, USA.							AOYAGI T, 1989, J ANTIBIOT, V42, P883, DOI 10.7164/antibiotics.42.883; ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BOSCH JV, 1985, VIROLOGY, V143, P342; CAPON B, 1969, CHEM REV, V69, P407, DOI 10.1021/cr60260a001; CARD PJ, 1985, J ORG CHEM, V50, P891, DOI 10.1021/jo00206a037; CARON G, 1989, BIOCHEM BIOPH RES CO, V163, P495, DOI 10.1016/0006-291X(89)92164-5; DENNIS JW, 1986, CANCER RES, V46, P5131; EDWARDS EH, 1989, BIOCHEMISTRY-US, V28, P7679, DOI 10.1021/bi00445a024; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; ELBEIN AD, 1984, J BIOL CHEM, V259, P2409; ELBEIN AD, 1984, ARCH BIOCHEM BIOPHYS, V235, P579, DOI 10.1016/0003-9861(84)90232-7; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELBEIN AD, 1979, ANNU REV PLANT PHYS, V30, P239, DOI 10.1146/annurev.pp.30.060179.001323; FLEET GWJ, 1984, J CHEM SOC CHEM COMM, P1240, DOI 10.1039/c39840001240; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; GROSS V, 1985, EUR J BIOCHEM, V150, P41, DOI 10.1111/j.1432-1033.1985.tb08985.x; GRUTERS RA, 1987, NATURE, V330, P74, DOI 10.1038/330074a0; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HALAZY S, 1989, J AM CHEM SOC, V111, P3484, DOI 10.1021/ja00191a085; HARPAZ N, 1980, J BIOL CHEM, V255, P4885; HAZATO T, 1978, J ANTIBIOT, V32, P217; HORII S, 1986, J MED CHEM, V29, P1038, DOI 10.1021/jm00156a023; HSIEH P, 1983, J BIOL CHEM, V258, P2555; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUMPHRIES MJ, 1986, CANCER RES, V46, P5215; INOUYE S, 1986, TETRAHEDRON, V24, P2125; James L. F., 1989, SWAINSONINE RELATED; JUNGE B, 1984, CARBOHYD RES, V128, P235, DOI 10.1016/0008-6215(84)85333-1; KAUSHAL GP, 1988, J BIOL CHEM, V263, P17278; KAYAKIRI H, 1990, TETRAHEDRON LETT, V31, P225, DOI 10.1016/S0040-4039(00)94377-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Legler G, 1977, Methods Enzymol, V46, P368; LEGLER G, 1984, CARBOHYD RES, V128, P61, DOI 10.1016/0008-6215(84)85084-3; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; MARSHALL PJ, 1980, J CHEM SOC T, V1, P366; MOLYNEUX RJ, 1988, J NAT PROD, V51, P1198, DOI 10.1021/np50060a024; MONTEFIORI DC, 1988, P NATL ACAD SCI USA, V85, P9248, DOI 10.1073/pnas.85.23.9248; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; NAMIKI S, 1982, J ANTIBIOT, V35, P1234, DOI 10.7164/antibiotics.35.1234; NEUFELD EF, 1975, ANNU REV BIOCHEM, V44, P357, DOI 10.1146/annurev.bi.44.070175.002041; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PALAMARCZYK G, 1985, ARCH BIOCHEM BIOPHYS, V243, P35, DOI 10.1016/0003-9861(85)90771-4; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROMERO PA, 1985, FEBS LETT, V183, P29, DOI 10.1016/0014-5793(85)80947-9; SAUNIER B, 1982, J BIOL CHEM, V257, P4155; SUNKARA PS, 1988, 17TH ANN M SOC COMPL; TONG MK, 1988, J AM CHEM SOC, V110, P312, DOI 10.1021/ja00209a062; TROPEA JE, 1989, BIOCHEMISTRY-US, V28, P2027, DOI 10.1021/bi00431a010; TROPEA JE, 1990, BIOCHEMISTRY-US, V29, P10062, DOI 10.1021/bi00495a008; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1985, ARCH BIOCHEM BIOPHYS, V236, P427, DOI 10.1016/0003-9861(85)90643-5; WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120; WINKLER DA, 1989, J MED CHEM, V32, P2084, DOI 10.1021/jm00129a011; YOKOSE K, 1983, J ANTIBIOT TOKYO, V36, P1165	59	341	373	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1991	5	15					3055	3063		10.1096/fasebj.5.15.1743438	http://dx.doi.org/10.1096/fasebj.5.15.1743438			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1743438				2022-12-28	WOS:A1991GU84200008
J	ZHANG, YZ; NALEWAY, JJ; LARISON, KD; HUANG, ZJ; HAUGLAND, RP				ZHANG, YZ; NALEWAY, JJ; LARISON, KD; HUANG, ZJ; HAUGLAND, RP			DETECTING LACZ-GENE EXPRESSION IN LIVING CELLS WITH NEW LIPOPHILIC, FLUOROGENIC BETA-GALACTOSIDASE SUBSTRATES	FASEB JOURNAL			English	Article						FLUORESCEIN DI-BETA-D-GALACTOPYRANOSIDE; BETA-GALACTOSIDASE SUBSTRATES; LACZ-GENE EXPRESSION; QUANTITATION OF PROMOTER EFFICIENCY	ESCHERICHIA-COLI-LACZ; SACCHAROMYCES-CEREVISIAE; DROSOPHILA; RETROVIRUS; LINEAGE	Current methods for detecting lacZ expression in transformed cells are limited because they require such harsh conditions that viability of the cells after detection is drastically reduced. To overcome this problem, we developed a series of new substrates for detection of lacZ expression in living cells under standard culture or physiological conditions. After incubation with these fluorogenic substrates, cultured lacZ-positive mammalian cells appear morphologically normal, continue to divide, and retain the fluorescent product. Because the product is so well retained, fluorescence intensity can be quantitatively related to the level of gene expression. We have demonstrated this correlation using transformed yeast cells bearing various plasmids, each containing the lacZ gene and a unique promoter sequence with known capabilities for promoting gene expression in yeast.	MOLEC PROBES INC,POB 22010,EUGENE,OR 97402		HAUGLAND, RP (corresponding author), MOLEC PROBES INC,POB 22010,EUGENE,OR 97402, USA.			Naleway, John/0000-0002-7038-3807	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM038987, R44GM038987] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bassford P., 1978, OPERON, P245; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; EMILIE D, 1989, EUR J IMMUNOL, V19, P1619, DOI 10.1002/eji.1830190915; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; HOMAN R, 1988, BIOCHIM BIOPHYS ACTA, V938, P155, DOI 10.1016/0005-2736(88)90155-1; IKENAKA K, 1990, DNA CELL BIOL, V9, P279, DOI 10.1089/dna.1990.9.279; ITOH H, 1983, J BACTERIOL, V153, P163; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; Koenigs W, 1901, BER DTSCH CHEM GES, V34, P957, DOI 10.1002/cber.190103401162; Miller J.H., 1972, EXPT MOL GENETICS; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROSE M, 1981, P NATL ACAD SCI-BIOL, V78, P2460, DOI 10.1073/pnas.78.4.2460; ROTMAN B, 1963, P NATL ACAD SCI USA, V50, P1; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1224, DOI 10.1177/28.11.6159392; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0	21	98	98	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1991	5	15					3108	3113		10.1096/fasebj.5.15.1720751	http://dx.doi.org/10.1096/fasebj.5.15.1720751			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1720751				2022-12-28	WOS:A1991GU84200015
J	DEAN, RA; CHRISTIAN, CD; SAMPLE, RHB; BOSRON, WF				DEAN, RA; CHRISTIAN, CD; SAMPLE, RHB; BOSRON, WF			HUMAN LIVER COCAINE ESTERASES - ETHANOL-MEDIATED FORMATION OF ETHYLCOCAINE	FASEB JOURNAL			English	Article						COCAINE; ESTERASE; ALCOHOL; HUMAN; LIVER	ECGONINE METHYL-ESTER; METABOLITES; HYDROLYSIS; ALCOHOL; INVITRO; SERUM	A new, pharmacologically active metabolite of cocaine, ethylcocaine, has been reported in individuals after concurrent use of cocaine and ethanol. Formation of ethylcocaine may contribute to the common coabuse of these two drugs and the apparent danger of this practice. We have identified a nonspecific carboxyl-esterase that catalyzes the ethyl transesterification of cocaine to ethylcocaine in the presence of ethanol. In the absence of ethanol, this human liver esterase catalyzes the hydrolysis of cocaine to benzoylecgonine, a metabolite that is inactive as a psychomotor stimulant. A second human liver esterase is also described. This enzyme catalyzes hydrolysis of cocaine to ecgonine methyl ester, also inactive as a stimulant. These two liver esterases may play important roles in regulating the metabolic inactivation of cocaine.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MICROBIOL,MED SCI BLDG 405,635 BARNHILL DR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NIAAA NIH HHS [P50-AA07611] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007611] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adams E H, 1985, NIDA Res Monogr, V61, P1; AMBRE J, 1988, J ANAL TOXICOL, V12, P301, DOI 10.1093/jat/12.6.301; DEAN RA, 1991, 3RD INT S PHARM BIOM; ELSWORTH JD, 1990, NEUR ABSTR, V16; FOLTIN RW, 1989, PHARM BIOCH BEHAV, V31, P877; HEARN WL, 1991, J NEUROCHEM, V56, P698, DOI 10.1111/j.1471-4159.1991.tb08205.x; ISENSCHMID DS, 1989, J ANAL TOXICOL, V13, P250, DOI 10.1093/jat/13.5.250; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; Jain N C, 1977, J Forensic Sci, V22, P7; JATLOW P, 1979, ANESTH ANALG, V58, P235; JOHNSON CE, 1989, PHARMACOL REV, V41, P3; JONES RT, 1987, COCAINE CLIN HDB, P55; LEIGHTY EG, 1974, RES COMMUN CHEM PATH, V8, P65; LIN MF, 1989, PHARMACOLOGIST, V31, P159; MADDEN JA, 1990, LIFE SCI, V47, P1109, DOI 10.1016/0024-3205(90)90169-R; MASH DC, 1990, NEUR ABSTR, V16; MASUR J, 1989, ALCOHOL, V6, P181, DOI 10.1016/0741-8329(89)90015-3; MATSUBARA K, 1984, FORENSIC SCI INT, V26, P169, DOI 10.1016/0379-0738(84)90215-9; MISERA AL, 1975, J PHARM PHARMACOL, V27, P784; RAFLA FK, 1979, J ANAL TOXICOL, V3, P59, DOI 10.1093/jat/3.2.59; ROSE S, 1990, NEUR ABSTR, V16; SAMPLE RHB, 1991, 3RD INT S PHARM BIOM; SHARKEY J, 1988, J PHARMACOL EXP THER, V246, P1048; SMITH RM, 1984, J ANAL TOXICOL, V8, P38, DOI 10.1093/jat/8.1.38; SPEALMAN RD, 1989, J PHARMACOL EXP THER, V251, P142; STEWART DJ, 1977, LIFE SCI, V20, P1557, DOI 10.1016/0024-3205(77)90448-9; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; TAYLOR D, 1976, RES COMMUN CHEM PATH, V14, P249; WEISS RD, 1988, J NERV MENT DIS, V176, P719, DOI 10.1097/00005053-198812000-00004; 1988, INSTRUCTION MANUAL	30	207	222	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2735	2739		10.1096/fasebj.5.12.1916095	http://dx.doi.org/10.1096/fasebj.5.12.1916095			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916095				2022-12-28	WOS:A1991GE81100016
J	VLESSIS, AA; MULLER, P; BARTOS, D; TRUNKEY, D				VLESSIS, AA; MULLER, P; BARTOS, D; TRUNKEY, D			MECHANISM OF PEROXIDE-INDUCED CELLULAR INJURY IN CULTURED ADULT CARDIAC MYOCYTES	FASEB JOURNAL			English	Note						PEROXIDE METABOLISM; CARDIOMYOCYTES; REPERFUSION INJURY; PYRUVATE DEHYDROGENASE; CELLULAR METABOLISM	MYOCARDIAL INFARCT SIZE; REPERFUSION INJURY; FREE-RADICALS; GLUTATHIONE PEROXIDASE; LIPID-PEROXIDATION; POTENTIAL ROLE; BLOOD-FLOW; RAT-HEART; ISCHEMIA; METABOLISM	Reactive oxygen species contribute to the tissue injury seen after reperfusion of ischemic myocardium. We propose that toxicity originates from the effect that mitochondrial peroxide metabolism has on substrate entry into oxidative pathways. To support our contention, cultured adult rat cardiomyocytes were incubated with physiological concentrations of peroxide. The cellular extract and incubation medium were analyzed for adenine nucleotides and purines by reverse-phase high-pressure liquid chromatography. Cellular glutathione efflux was determined by enzymatic analysis of the incubation medium. Pyruvate dehydrogenase (PDH) activity was determined in the cultured myocytes as well as in freshly isolated cardiac mitochondria using [1-C-14]pyruvate. Extracellular glutathione rose 3.3-fold in response to small doses of peroxide (almost-equal-to 108 nmol/mg protein). Likewise, small quantities of peroxide reduced total cellular adenine nucleotides to 50-60% of control values with only a modest (0.95-0.91) reduction in energy charge ((ATP + 1/2 ADP)/(ATP + ADP + AMP)). Peroxide-treated myocytes selectively release inosine and adenosine, as only these two purine degradation products were detected in the incubation medium. The most dramatic response was a peroxide dose-dependent inhibition of PDH activity in cultured myocytes as well as freshly isolated mitochondria; just 65 and 30 nmol peroxide/mg protein induced a 50% reduction in cellular and mitochondrial PDH activity, respectively. In conclusion, physiological quantities of peroxide potently inhibit PDH in cultured cardiomyocytes and isolated cardiac mitochondria. PDH inhibition blocks the aerobic oxidation of glucose and inhibits the oxidative phosphorylation of ADP, which in turn leads to cellular adenine nucleotide degradation.	OREGON HLTH SCI UNIV,DEPT SURG BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								ACHTERBERG PW, 1988, AM J PHYSIOL, V254, pH1091, DOI 10.1152/ajpheart.1988.254.6.H1091; ARNOLD PE, 1986, AM J PHYSIOL, V250, pF357, DOI 10.1152/ajprenal.1986.250.2.F357; BANDO K, 1989, J SURG RES, V46, P152, DOI 10.1016/0022-4804(89)90219-9; BERNE RM, 1980, CIRC RES, V47, P807, DOI 10.1161/01.RES.47.6.807; BRASCH H, 1989, J MOL CELL CARDIOL, V21, P697, DOI 10.1016/0022-2828(89)90611-1; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; BULKLEY BH, 1977, CIRCULATION, V56, P906, DOI 10.1161/01.CIR.56.6.906; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; CHATHAM JC, 1989, EUR J BIOCHEM, V184, P657, DOI 10.1111/j.1432-1033.1989.tb15063.x; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; FERRARI R, 1990, J THORAC CARDIOV SUR, V99, P919; GAMELIN LM, 1988, AM J PHYSIOL, V255, pF450, DOI 10.1152/ajprenal.1988.255.3.F450; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; ISHIKAWA T, 1984, J BIOL CHEM, V259, P3838; JENNINGS RB, 1969, LAB INVEST, V20, P548; JENNINGS RB, 1986, J MOL CELL CARDIOL, V18, P769, DOI 10.1016/S0022-2828(86)80952-X; JONES DP, 1983, FUNCTIONS GLUTATHION, P109; KLONER RA, 1974, AM J PATHOL, V74, P399; KOYAMA I, 1985, TRANSPLANTATION, V40, P590, DOI 10.1097/00007890-198512000-00003; LITT MR, 1989, CIRCULATION, V80, P1816, DOI 10.1161/01.CIR.80.6.1816; LITTLE C, 1970, J BIOL CHEM, V245, P3632; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCCHESI BR, 1990, ANNU REV PHYSIOL, V52, P561, DOI 10.1146/annurev.ph.52.030190.003021; McCord J M, 1985, Adv Myocardiol, V5, P183; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1978, ANN INTERN MED, V89, P122, DOI 10.7326/0003-4819-89-1-122; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MENASCHE P, 1989, ANN THORAC SURG, V47, P939, DOI 10.1016/0003-4975(89)90047-7; NAG AC, 1981, TISSUE CELL, V13, P515, DOI 10.1016/0040-8166(81)90023-9; Novelli G P, 1988, Prog Clin Biol Res, V264, P397; OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4; PRZYKLENK K, 1989, CIRC RES, V64, P86, DOI 10.1161/01.RES.64.1.86; REED DJ, 1986, BIOCHEM PHARMACOL, V35, P7, DOI 10.1016/0006-2952(86)90545-9; RENSTROM B, 1990, CIRC RES, V66, P282, DOI 10.1161/01.RES.66.2.282; SIES H, 1978, EUR J BIOCHEM, V84, P377, DOI 10.1111/j.1432-1033.1978.tb12178.x; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SINGH A, 1989, CIRCULATION, V80, P1795, DOI 10.1161/01.CIR.80.6.1795; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; VLADIMIROV YA, 1980, ADV LIPID RES, V17, P173; VLESSIS AA, 1989, PEDIATR RES, V26, P220, DOI 10.1203/00006450-198909000-00013; VLESSIS AA, 1989, AM J PHYSIOL, V256, pC1196, DOI 10.1152/ajpcell.1989.256.6.C1196; VLESSIS AA, 1990, J BIOL CHEM, V265, P1448; VLESSIS AA, 1990, J NEUROCHEM, V54, P1412, DOI 10.1111/j.1471-4159.1990.tb01977.x; VLESSIS AA, 1990, BIOCHEM BIOPH RES CO, V170, P1281, DOI 10.1016/0006-291X(90)90532-R; WIELAND OH, 1982, REV PHYSIOL BIOCH P, V96, P123, DOI 10.1007/BFb0031008; WOOD JM, 1979, CIRC RES, V44, P52, DOI 10.1161/01.RES.44.1.52; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	47	63	63	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2600	2605		10.1096/fasebj.5.11.1868984	http://dx.doi.org/10.1096/fasebj.5.11.1868984			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868984				2022-12-28	WOS:A1991GB09400015
J	MITSUYA, H; YARCHOAN, R; KAGEYAMA, S; BRODER, S				MITSUYA, H; YARCHOAN, R; KAGEYAMA, S; BRODER, S			TARGETED THERAPY OF HUMAN IMMUNODEFICIENCY VIRUS-RELATED DISEASE	FASEB JOURNAL			English	Review						AZT; REVERSE TRANSCRIPTASE INHIBITORS; DDI; DDC; PROTEASE INHIBITORS	AIDS-RELATED COMPLEX; RECOMBINANT SOLUBLE CD4; HIV-1 REPLICATION INVITRO; PLACEBO-CONTROLLED TRIAL; PHASE-I TRIAL; DEXTRAN SULFATE; REVERSE-TRANSCRIPTASE; ZIDOVUDINE AZT; 2',3'-DIDEOXYINOSINE DDI; TYPE-1 INFECTION	Since the discovery of human immunodeficiency virus (HIV) as a pathogenic retrovirus linked to acquired immunodeficiency syndrome (AIDS), a number of potentially useful strategies for antiretroviral therapy of AIDS and its related diseases have emerged. One such strategy involves use of the broad family of 2',3'-dideoxynucleosides, to which 3'-azido-2',3'-dideoxythymidine (AZT) belongs. AZT has been shown to reduce the replication of HIV in vivo and to confer significant clinical benefits in patients in both early and advanced stages of infection. Other members of the family, 2',3'-dideoxycytidine (ddC), 2',3'-dideoxyinosine (ddI), and 2',3'-didehydro-2',3'-dideoxythymidine (d4T), have also been reported to be active against HIV in short-term clinical trials. The armamentarium of antiretroviral agents is rapidly growing. Various nonnucleoside agents have recently been identified to be active against HIV in vitro. HIV-1 protease inhibitors are notable as possible new therapies for HIV-1-related diseases. However, we have faced several new challenges in the antiretroviral therapy in AIDS. These include long-term drug-related toxicities; emergence of drug-resistant HIV variants; and development of various cancers, particularly as effective therapies prolong survival. Progress in understanding structure-activity relations and clinical effectiveness will continue with dideoxynucleoside analogs. However, it seems certain that a variety of nonnucleoside analogs affecting multiple steps in viral replication will become available before long, and combination therapies using multiple antiretroviral drugs will be available. Such therapies will exert major effects against the moribidity and mortality caused by HIV.			MITSUYA, H (corresponding author), NCI, DIV CANC TREATMENT, CLIN ONCOL PROGRAM, BETHESDA, MD 20892 USA.		Kageyama, Seiji/I-1145-2019; Kageyama, Seiji/M-5237-2019	Kageyama, Seiji/0000-0002-5220-6137				ABRAMS DI, 1989, ANN INTERN MED, V110, P183, DOI 10.7326/0003-4819-110-3-183; AOKI S, 1990, AIDS RES HUM RETROV, V6, P1331, DOI 10.1089/aid.1990.6.1331; BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BROWNE MJ, 1990, 6TH P INT C AIDS SAN, P200; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; BYRN RA, 1990, NATURE, V344, P667, DOI 10.1038/344667a0; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DAHLBERG JE, 1987, P NATL ACAD SCI USA, V84, P2469, DOI 10.1073/pnas.84.8.2469; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEXNER C, 1991, IN PRESS ANTIVIRAL S; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; HAMAMOTO Y, 1987, ANTIMICROB AGENTS CH, V31, P907, DOI 10.1128/AAC.31.6.907; HARTMAN NR, 1990, AIDS RES HUM RETROV, V6, P805, DOI 10.1089/aid.1990.6.805; HARTSHORN KL, 1987, ANTIMICROB AGENTS CH, V31, P168, DOI 10.1128/AAC.31.2.168; HAYASHI S, 1990, ANTIMICROB AGENTS CH, V34, P82, DOI 10.1128/AAC.34.1.82; HO DD, 1985, LANCET, V1, P602; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; JOHNSON VA, 1990, J INFECT DIS, V161, P1059, DOI 10.1093/infdis/161.6.1059; KAHN JO, 1990, ANN INTERN MED, V112, P254, DOI 10.7326/0003-4819-112-4; KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9229, DOI 10.1073/pnas.85.23.9229; KATOH I, 1987, NATURE, V329, P654, DOI 10.1038/329654a0; KOVACS JA, 1989, ANN INTERN MED, V111, P280, DOI 10.7326/0003-4819-111-4-280; KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; LOONEY DJ, 1990, J ACQ IMMUN DEF SYND, V3, P649; LORENTSEN KJ, 1989, ANN INTERN MED, V111, P561, DOI 10.7326/0003-4819-111-7-561; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MARQUEZ VE, 1987, BIOCHEM PHARMACOL, V36, P2719, DOI 10.1016/0006-2952(87)90254-1; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MERUELO D, 1988, P NATL ACAD SCI USA, V85, P5230, DOI 10.1073/pnas.85.14.5230; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; PAL R, 1988, P NATL ACAD SCI USA, V85, P9283, DOI 10.1073/pnas.85.23.9283; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; PAUZA CD, 1989, J VIROL, V63, P3700, DOI 10.1128/JVI.63.9.3700-3707.1989; PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933; PERNO CF, 1988, J EXP MED, V168, P1111, DOI 10.1084/jem.168.3.1111; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; PIZZO PA, 1990, J PEDIATR-US, V117, P799, DOI 10.1016/S0022-3476(05)83348-7; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; RICHMAN DD, 1990, REV INFECT DIS, V12, pS507; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; RUPRECHT RM, 1986, NATURE, V323, P467, DOI 10.1038/323467a0; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCHINAZI RF, 1987, J CELL BIOCHEM, P74; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SHIRASAKA T, 1990, P NATL ACAD SCI USA, V87, P9426, DOI 10.1073/pnas.87.23.9426; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; SZEBENI J, 1989, P NATL ACAD SCI USA, V86, P3842, DOI 10.1073/pnas.86.10.3842; TAKEDA A, 1990, J VIROL, V64, P5605, DOI 10.1128/JVI.64.11.5605-5610.1990; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; UENO R, 1987, LANCET, V1, P1379; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; YARCHOAN R, 1986, LANCET, V1, P575; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1987, LANCET, V1, P132, DOI 10.1016/S0140-6736(87)91968-4; YARCHOAN R, 1989, 5TH INT C AIDS MONTR, P564; [No title captured]	99	79	98	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2369	2381		10.1096/fasebj.5.10.1712326	http://dx.doi.org/10.1096/fasebj.5.10.1712326			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	1712326				2022-12-28	WOS:A1991FW08700007
J	PALLOTTA, BS				PALLOTTA, BS			SINGLE ION CHANNELS VIEW OF CLASSICAL RECEPTOR THEORY	FASEB JOURNAL			English	Article						ION CHANNELS; AGONISM; RECEPTOR THEORY; EFFICACY; AFFINITY	NICOTINIC ACETYLCHOLINE-RECEPTOR; ACTIVATED POTASSIUM CHANNELS; FROG NEUROMUSCULAR-JUNCTION; MAMMALIAN BC3H-1 CELLS; CULTURED RAT MUSCLE; GLUTAMATE RECEPTOR; TORPEDO-CALIFORNICA; CHLORIDE CHANNEL; SKELETAL-MUSCLE; FRACTAL MODELS	The nature of drug agonism has been the central mystery of two conceptually different approaches: classical receptor theory, which does not require any knowledge of mechanism, and mechanistic theories, which do. Ligand-activated ion channel macromolecules that contain both the agonist receptor site and molecular machinery to generate a response present a unique experimental system with which to explore agonism and antagonism. Electrical recordings from one channel at a time offer phenomena and a perspective quite different from that usually encountered in studies of the drug-receptor interaction. This review describes patch-clamp recordings that illustrate the ligand-evoked behavior that gives rise to classical phenomena. A comparison of the channel currents recorded in the presence of different agonist reveals how these drugs act as full or partial agonists. At higher concentrations of agonist, the conformational and kinetic transitions that underlie desensitization can be observed. Receptor conformational changes induced by agonist and antagonist binding further expand our ideas about what these drugs do, and contribute to the growth of concepts that will further our understanding of drug agonism.			PALLOTTA, BS (corresponding author), UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,FLOB,CB 7365,CHAPEL HILL,NC 27599, USA.							Albuquerque E X, 1988, Ion Channels, V1, P95; [Anonymous], [No title captured]; BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BLATZ AL, 1989, J PHYSIOL-LONDON, V410, P561, DOI 10.1113/jphysiol.1989.sp017549; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; CHABALA LD, 1986, J PHYSIOL-LONDON, V371, P407, DOI 10.1113/jphysiol.1986.sp015983; CHANGEUX JP, 1987, TRENDS NEUROSCI, V10, P245, DOI 10.1016/0166-2236(87)90167-6; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; COLQUHOUN D, 1979, RECEPTORS, V1, P93; COLQUHOUN D, 1987, PERSPECTIVES RECEPTO, P103; CULLCANDY SG, 1983, SINGLE CHANNEL RECOR, P389; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; DIONNE VE, 1978, J PHYSIOL-LONDON, V281, P421, DOI 10.1113/jphysiol.1978.sp012431; DUDEL J, 1988, NEUROSCI LETT, V88, P33, DOI 10.1016/0304-3940(88)90311-4; FAHR A, 1985, EUR J BIOCHEM, V147, P483; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; Furchgott RF., 1966, ADV DRUG RES, V3, P21; FURCHGOTT RF, 1955, PHARMACOL REV, V7, P184; GOLOWASCH J, 1986, J EXP BIOL, V124, P5; Hille B, 1984, IONIC CHANNELS EXCIT; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; JACKSON MB, 1983, BIOPHYS J, V42, P109, DOI 10.1016/S0006-3495(83)84375-6; KARLIN A, 1987, PROTEINS EXCITABLE M, P43; KENAKIN TP, 1989, TRENDS PHARMACOL SCI, V10, P18, DOI 10.1016/0165-6147(89)90102-8; KENAKIN TP, 1985, J PHARMACOL METHOD, V13, P281, DOI 10.1016/0160-5402(85)90011-7; KERRY CJ, 1987, BIOPHYS J, V51, P137, DOI 10.1016/S0006-3495(87)83318-0; KERRY CJ, 1988, BIOPHYS J, V53, P39, DOI 10.1016/S0006-3495(88)83064-9; KERRY CJ, 1986, BIOPHYS J, V50, P367, DOI 10.1016/S0006-3495(86)83470-1; KISTLER J, 1982, BIOPHYS J, V37, P371, DOI 10.1016/S0006-3495(82)84685-7; KORN SJ, 1988, BIOPHYS J, V54, P871, DOI 10.1016/S0006-3495(88)83023-6; Kuhn T.S., 1970, STRUCTURE SCI REVOLU, P174; LABARCA P, 1985, BIOPHYS J, V47, P469, DOI 10.1016/S0006-3495(85)83939-4; LAUGER P, 1985, BIOPHYS J, V47, P581, DOI 10.1016/S0006-3495(85)83954-0; LIEBOVITCH LS, 1987, BIOPHYS J, V52, P979, DOI 10.1016/S0006-3495(87)83290-3; MACDONALD RL, 1989, J PHYSIOL-LONDON, V410, P479, DOI 10.1113/jphysiol.1989.sp017545; MACKAY D, 1990, TRENDS PHARMACOL SCI, V11, P17, DOI 10.1016/0165-6147(90)90036-8; MAGLEBY KL, 1983, J PHYSIOL-LONDON, V344, P585, DOI 10.1113/jphysiol.1983.sp014957; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; Mandelbrot BB, 1977, FRACTALS FORM CHANCE; MCCARTHY MP, 1989, J BIOL CHEM, V264, P10911; MCCARTHY MP, 1989, BIOCHEMISTRY-US, V28, P40, DOI 10.1021/bi00427a007; MCMANUS OB, 1988, BIOPHYS J, V54, P859, DOI 10.1016/S0006-3495(88)83022-4; MCMANUS OB, 1989, BIOPHYS J, V55, P383, DOI 10.1016/S0006-3495(89)82817-6; Miller C., 1986, ION CHANNEL RECONSTI; MILLHAUSER GL, 1988, P NATL ACAD SCI USA, V85, P1503, DOI 10.1073/pnas.85.5.1503; MORRIS CE, 1983, J NEUROSCI, V3, P2525; OCHOA ELM, 1989, CELL MOL NEUROBIOL, V9, P141, DOI 10.1007/BF00713026; OGDEN DC, 1985, PROC R SOC SER B-BIO, V225, P329, DOI 10.1098/rspb.1985.0065; OGDEN DC, 1983, PFLUG ARCH EUR J PHY, V399, P246, DOI 10.1007/BF00656725; PALLOTTA BS, 1985, J PHYSIOL-LONDON, V363, P501, DOI 10.1113/jphysiol.1985.sp015724; PAPKE RL, 1989, J GEN PHYSIOL, V93, P785, DOI 10.1085/jgp.93.5.785; PAPKE RL, 1988, BIOPHYS J, V53, P1, DOI 10.1016/S0006-3495(88)83059-5; PATLAK J, 1982, J GEN PHYSIOL, V79, P333, DOI 10.1085/jgp.79.3.333; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SAKMANN B, 1983, SINGLE CHANNEL RECOR; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; SINE SM, 1987, J PHYSIOL-LONDON, V385, P325, DOI 10.1113/jphysiol.1987.sp016496; SINE SM, 1986, J PHYSIOL-LONDON, V373, P129, DOI 10.1113/jphysiol.1986.sp016039; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN N, 1988, J CELL BIOL, V107, P1123, DOI 10.1083/jcb.107.3.1123; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507	64	17	17	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2035	2043		10.1096/fasebj.5.7.1707020	http://dx.doi.org/10.1096/fasebj.5.7.1707020			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	1707020				2022-12-28	WOS:A1991FF44200005
J	HOLLENBERG, MD				HOLLENBERG, MD			STRUCTURE-ACTIVITY-RELATIONSHIPS FOR TRANSMEMBRANE SIGNALING - THE RECEPTORS TURN	FASEB JOURNAL			English	Article						PHARMACOLOGICAL RECEPTOR; PHOSPHORYLATION; CELL SIGNALING; GLUTAMATE RECEPTOR; MUTAGENESIS; GLYCOSYLATION; NH2-TERMINAL DOMAIN	EPIDERMAL GROWTH-FACTOR; BETA-ADRENERGIC-RECEPTOR; INSULIN-RECEPTOR; LIGAND-BINDING; MOLECULAR-STRUCTURE; GLUTAMATE RECEPTOR; ALPHA-SUBUNIT; EXPRESSION; PROTEINS; MEMBRANE	The cloning, sequencing, and functional expression in host cells of a variety of receptors has led to a focus on the structural determinants of pharmacologic receptors involved in the complex processes of ligand binding and cell activation. The three basic mechanisms of receptor-mediated transmembrane signaling (ligand-regulated ion flux; ligand-regulated receptor-enzymes; ligand-regulated receptor-G protein activation) can now be placed in the structural context of at least three receptor superfamilies: 1) ligand-regulated oligomeric ion channels, 2) ligand-regulated tyrosine kinases, and 3) G protein-linked rhodopsin-related receptors. For each of these receptor superfamilies, structure-activity studies that use 1) site-directed mutagenesis, 2) cassette switching to form receptor chimeras, and 3) sequence-specific antireceptor antibodies are beginning to delineate the domains responsible for specific receptor functions. Analyses of such receptor domains related to: 1) ligand binding, 2) membrane insertion, 3) catalytic activity (in the case of receptor-enzymes), 4) internalization and interaction with other membrane constituents, 5) substrate or G protein binding, and 6) regulatory sites of receptor phosphorylation are discussed, using as principal examples the nicotinic receptor for acetylcholine, the epidermal growth factor-urogastrone receptor, and the beta-adrenergic receptor. These studies illustrate that in terms of structure-activity studies, which have traditionally emphasized the ligand, it is now the receptor's turn for intense attention.	UNIV CALGARY,FAC MED,DEPT MED,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary	HOLLENBERG, MD (corresponding author), UNIV CALGARY,FAC MED,DEPT PHARMACOL & THERAPEUT,ENDOCRINE RES GRP,CALGARY T2N 4N1,ALBERTA,CANADA.		Hollenberg, Morley/AFV-6966-2022					AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586, DOI 10.1152/ajplegacy.1948.153.3.586; ARIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CONN PM, 1982, NATURE, V296, P653, DOI 10.1038/296653a0; CONTITRONCONI BM, 1982, ANNU REV BIOCHEM, V51, P491, DOI 10.1146/annurev.bi.51.070182.002423; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; Cuatrecasas P, 1976, Adv Protein Chem, V30, P251, DOI 10.1016/S0065-3233(08)60481-7; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; EHRLICH P, 1908, COLLECTED PAPERS P E, V3, P183; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GREGORY H, 1982, NATURE, V300, P269, DOI 10.1038/300269a0; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HOLLENBERG MD, 1987, CLIN INVEST MED, V10, P475; HOLLENBERG MD, 1986, EXPERIENTIA, V42, P718, DOI 10.1007/BF01941517; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; Kahn C R, 1981, Recent Prog Horm Res, V37, P477; KLEIN HH, 1985, BIOCHEM BIOPH RES CO, V127, P254, DOI 10.1016/S0006-291X(85)80152-2; Langley JN, 1906, P R SOC LOND B-CONTA, V78, P170, DOI 10.1098/rspb.1906.0056; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LINDSTROM J, 1987, MOL NEUROBIOL, V1, P281, DOI 10.1007/BF02935740; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MIESFELD RL, 1989, CRIT REV BIOCHEM MOL, V24, P101, DOI 10.3109/10409238909086395; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; PRITCHETT DB, 1989, NATURE, V338, P583; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SCHIMERLIK MI, 1989, ANNU REV PHYSIOL, V51, P217, DOI 10.1146/annurev.ph.51.030189.001245; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; SLIEKER LJ, 1985, J BIOL CHEM, V260, P687; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; STEPHENSON RP, 1970, COMPANION MED STUDIE, V2; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; VALENTINEBRAUN KA, 1987, ARCH BIOCHEM BIOPHYS, V259, P262, DOI 10.1016/0003-9861(87)90494-2; WATERFIELD MD, 1989, BRIT MED BULL, V45, P541, DOI 10.1093/oxfordjournals.bmb.a072341; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WEISS ER, 1988, FASEB J, V2, P2841, DOI 10.1096/fasebj.2.13.3139484; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	59	46	47	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					178	186		10.1096/fasebj.5.2.1848518	http://dx.doi.org/10.1096/fasebj.5.2.1848518			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	1848518				2022-12-28	WOS:A1991EZ00200006
J	Zhou, B; Basu, J; Kazmi, HR; Chitrala, KN; Mo, X; Preston-Alp, S; Cai, KQ; Kappes, D; Zaidi, MR				Zhou, Bo; Basu, Jayati; Kazmi, Hasan Raza; Chitrala, Kumaraswamy Naidu; Mo, Xuan; Preston-Alp, Sarah; Cai, Kathy Q. Q.; Kappes, Dietmar; Zaidi, M. Raza			Interferon-gamma signaling promotes melanoma progression and metastasis	ONCOGENE			English	Article; Early Access							DELTA T-LYMPHOCYTES; IFN-GAMMA; ULTRAVIOLET-RADIATION; ANTIPROLIFERATIVE ACTIVITY; MOLECULAR-MECHANISMS; CELL; CANCER; ALPHA; ROLES; STAT1	Interferon-gamma (IFNG) has long been regarded as the flag-bearer for the anti-cancer immunosurveillance mechanisms. However, relatively recent studies have suggested a dual role of IFNG, albeit there is no direct experimental evidence for its potential pro-tumor functions. Here we provide in vivo evidence that treatment of mouse melanoma cell lines with Ifng enhances their tumorigenicity and metastasis in lung colonization allograft assays performed in immunocompetent syngeneic host mice, but not in immunocompromised host mice. We also show that this enhancement is dependent on downstream signaling via Stat1 but not Stat3, suggesting an oncogenic function of Stat1 in melanoma. The experimental results suggest that melanoma cell-specific Ifng signaling modulates the tumor microenvironment and its pro-tumorigenic effects are partially dependent on the gamma delta T cells, as Ifng-enhanced tumorigenesis was inhibited in the TCR-delta knockout mice. Overall, these results show that Ifng signaling may have tumor-promoting effects in melanoma by modulating the immune cell composition of the tumor microenvironment.	[Zhou, Bo; Kazmi, Hasan Raza; Chitrala, Kumaraswamy Naidu; Mo, Xuan; Preston-Alp, Sarah; Zaidi, M. Raza] Temple Univ, Fels Canc Inst Personalized Med, Lewis Katz Sch Med, Philadelphia, PA 19122 USA; [Zhou, Bo; Kazmi, Hasan Raza; Chitrala, Kumaraswamy Naidu; Mo, Xuan; Preston-Alp, Sarah; Zaidi, M. Raza] Temple Univ, Lewis Katz Sch Med, Dept Canc & Cellular Biol, Philadelphia, PA 19122 USA; [Basu, Jayati; Cai, Kathy Q. Q.; Kappes, Dietmar] Fox Chase Canc Ctr, Philadelphia, PA USA; [Basu, Jayati] Cleveland Clin, Lerner Res Inst, Dept Inflammat & Immun, Cleveland, OH USA; [Chitrala, Kumaraswamy Naidu] Univ Houston, Dept Engn Technol, Houston, TX USA; [Zhou, Bo] MEI Pharm, San Diego, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Fox Chase Cancer Center; Cleveland Clinic Foundation; University of Houston System; University of Houston	Zaidi, MR (corresponding author), Temple Univ, Fels Canc Inst Personalized Med, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.; Zaidi, MR (corresponding author), Temple Univ, Lewis Katz Sch Med, Dept Canc & Cellular Biol, Philadelphia, PA 19122 USA.	zaidi@temple.edu			USA National Institutes of Health [R01CA193711, R01CA236391, R01AI068907, P30CA006927]	USA National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	USA National Institutes of Health, R01CA193711 (MRZ); R01CA236391 (DJK), R01AI068907 (DJK), P30CA006927 (FCCC Comprehensive Cancer Center Core Grant)	Austin MT, 2013, J PEDIATR SURG, V48, P2207, DOI 10.1016/j.jpedsurg.2013.06.002; Balkhy HH, 1999, J IMMUNOL, V162, P3633; Bennett DC, 2008, PIGM CELL MELANOMA R, V21, P520, DOI 10.1111/j.1755-148X.2008.00500.x; Bialasiewicz AA, 1999, BRIT J OPHTHALMOL, V83, P1069, DOI 10.1136/bjo.83.9.1069; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Brucet M, 2004, GENES IMMUN, V5, P26, DOI 10.1038/sj.gene.6364035; Byeseda SE, 2009, AM J PATHOL, V175, P571, DOI 10.2353/ajpath.2009.090112; Callahan MK, 2013, CLIN DERMATOL, V31, P191, DOI 10.1016/j.clindermatol.2012.08.006; Chan SR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3100; Cordova A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049878; Drake CG, 2014, NAT REV CLIN ONCOL, V11, P24, DOI 10.1038/nrclinonc.2013.208; Dummer R, 2004, BLOOD, V104, P1631, DOI 10.1182/blood-2004-01-0360; Gandini S, 2005, EUR J CANCER, V41, P45, DOI 10.1016/j.ejca.2004.10.016; Garibyan L, 2010, CURR ONCOL REP, V12, P319, DOI 10.1007/s11912-010-0119-y; Garland CF, 2003, ANN EPIDEMIOL, V13, P395, DOI 10.1016/S1047-2797(02)00461-1; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gordon-Alonso M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00925-6; Grasso CS, 2020, CANCER CELL, V38, P500, DOI 10.1016/j.ccell.2020.08.005; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; Hsu KS, 2017, J BIOL CHEM, V292, P10048, DOI 10.1074/jbc.M116.771071; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Ilkovitch D, 2008, EXP DERMATOL, V17, P977, DOI 10.1111/j.1600-0625.2008.00779.x; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; Jin CC, 2019, CELL, V176, P998, DOI 10.1016/j.cell.2018.12.040; Kabelitz D, 2003, CRIT REV IMMUNOL, V23, P339, DOI 10.1615/CritRevImmunol.v23.i56.10; Kachroo P, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-97; Kortylewski M, 2004, J INVEST DERMATOL, V122, P414, DOI 10.1046/j.0022-202X.2004.22237.x; Leibowitz MS, 2011, CANCER IMMUNOL IMMUN, V60, P525, DOI 10.1007/s00262-010-0961-7; Lesinski GB, 2003, J CLIN INVEST, V112, P170, DOI 10.1172/JCI200316603; Ma CL, 2012, J IMMUNOL, V189, P5029, DOI 10.4049/jimmunol.1201892; Maddodi N, 2008, PHOTOCHEM PHOTOBIOL, V84, P528, DOI 10.1111/j.1751-1097.2007.00283.x; Matsumura Y, 2002, FRONT BIOSCI-LANDMRK, V7, pD765, DOI 10.2741/matsumur; Meeth K, 2016, PIGM CELL MELANOMA R, V29, P590, DOI 10.1111/pcmr.12498; Mo X, 2022, PIGM CELL MELANOMA R, V35, P342, DOI 10.1111/pcmr.13036; Moan J, 2008, ADV EXP MED BIOL, V624, P104, DOI 10.1007/978-0-387-77574-6_9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Murtas D, 2013, BRIT J CANCER, V109, P76, DOI 10.1038/bjc.2013.335; Natarajan VT, 2014, P NATL ACAD SCI USA, V111, P2301, DOI 10.1073/pnas.1304988111; Nguyen KB, 1999, J IMMUNOL, V162, P5238; Nikolaou V, 2014, BRIT J DERMATOL, V170, P11, DOI 10.1111/bjd.12492; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Noonan FP, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1893; Norval M, 2008, PHOTOCHEM PHOTOBIOL, V84, P19, DOI 10.1111/j.1751-1097.2007.00239.x; Peng G, 2007, IMMUNITY, V27, P334, DOI 10.1016/j.immuni.2007.05.020; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Raspollini MR, 2005, ANN ONCOL, V16, P590, DOI 10.1093/annonc/mdi112; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Rodriguez T, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-34; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Singh S, 2020, NAT CELL BIOL, V22, P591, DOI 10.1038/s41556-020-0495-y; Slade AD, 2014, CURR OPIN PEDIATR, V26, P356, DOI 10.1097/MOP.0000000000000082; Son J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12190; TAMURA K, 1987, CANCER, V59, P1059, DOI 10.1002/1097-0142(19870315)59:6<1059::AID-CNCR2820590602>3.0.CO;2-M; Togashi Y, 2017, CURR TOP MICROBIOL, V410, P3, DOI 10.1007/82_2017_58; Tran TNT, 2008, PIGM CELL MELANOMA R, V21, P509, DOI 10.1111/j.1755-148X.2008.00498.x; Wall L, 2003, GYNECOL ONCOL, V88, pS149, DOI 10.1006/gyno.2002.6707; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Zaidi MR, 2019, J INTERF CYTOK RES, V39, P30, DOI 10.1089/jir.2018.0087; Zaidi MR, 2011, CLIN CANCER RES, V17, P6118, DOI 10.1158/1078-0432.CCR-11-0482; Zaidi MR, 2011, NATURE, V469, P548, DOI 10.1038/nature09666; Zhang Y, 2017, DISCOV MED, V24, P19; Zhang Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-791; Zhao YJ, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-017-1378-2	64	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02561-x	http://dx.doi.org/10.1038/s41388-022-02561-x		DEC 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6T1WQ	36463370	Green Submitted			2022-12-28	WOS:000893472600001
J	Song, FF; Zhang, YH; Chen, Q; Bi, DX; Yang, MQ; Lu, L; Li, M; Zhu, HY; Liu, Y; Wei, Q; Qin, HL; Li, JY				Song, Feifei; Zhang, Youhua; Chen, Qi; Bi, Dexi; Yang, Muqing; Lu, Ling; Li, Man; Zhu, Huiyuan; Liu, Ying; Wei, Qing; Qin, Huanlong; Li, Jiyu			Mast cells inhibit colorectal cancer development by inducing ER stress through secreting Cystatin C	ONCOGENE			English	Article; Early Access							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; PROGNOSTIC-SIGNIFICANCE; TUMOR ANGIOGENESIS; BREAST-CANCER; DENSITY; SURVIVAL; PATHWAY; PROGRESSION; CONTRIBUTE	Mast cells (MCs) are abundantly distributed in the human intestinal mucosa and submucosa. However, their roles and mechanisms in the development of colorectal cancer (CRC) are still unclear. In the present research, we found that the infiltration density of MCs in CRC tissues was positively correlated with improved patients' prognoses. Moreover, MCs suppressed the growth and induced the apoptosis of CRC cells in vitro and in vivo but had no effect on normal colonic epithelial cells. The present study revealed that MCs specifically induced endoplasmic reticulum stress (ERS) and activated the unfolded protein response (UPR) in CRC cells but not in normal cells, which led to the suppression of CRC development in vivo. Furthermore, we found that the secreted Cystatin C protein was the key factor for the MC-induced ERS in CRC cells. This work is of significance for uncovering the antitumor function of MCs in CRC progression and identifying the potential of CRC to respond to MC-targeted immunotherapy.	[Song, Feifei; Zhang, Youhua; Bi, Dexi; Lu, Ling; Li, Man; Zhu, Huiyuan; Wei, Qing] Tongji Univ, Dept Pathol, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Chen, Qi] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol & Hepatol, Shanghai 200031, Peoples R China; [Yang, Muqing] Tongji Univ, Ctr Difficult & Complicated Abdominal Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Liu, Ying; Li, Jiyu] Tongji Univ, Dept Gen Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Qin, Huanlong] Tongji Univ, Dept Gastrointestinal Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China; [Li, Jiyu] Fudan Univ, Geriatr Canc Ctr, HuaDong Hosp, Shanghai 200040, Peoples R China	Tongji University; Fudan University; Tongji University; Tongji University; Tongji University; Fudan University	Wei, Q (corresponding author), Tongji Univ, Dept Pathol, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.; Li, JY (corresponding author), Tongji Univ, Dept Gen Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.; Qin, HL (corresponding author), Tongji Univ, Dept Gastrointestinal Surg, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.; Li, JY (corresponding author), Fudan Univ, Geriatr Canc Ctr, HuaDong Hosp, Shanghai 200040, Peoples R China.	weiqing1971@tongji.edu.cn; qinhuanlong@tongji.edu.cn; lijiyu@fudan.edu.cn			National Natural Science Foundation of China [82072647, 31741087, 81602262, 82173190]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was financially supported by the National Natural Science Foundation of China (Nos. 82072647, 31741087, 81602262 and 82173190).	Acikalin MF, 2005, DIGEST LIVER DIS, V37, P162, DOI 10.1016/j.dld.2004.09.028; Amicarella F, 2017, GUT, V66, P692, DOI 10.1136/gutjnl-2015-310016; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Blatner NR, 2010, P NATL ACAD SCI USA, V107, P6430, DOI 10.1073/pnas.0913683107; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022; Chan JK, 2005, GYNECOL ONCOL, V99, P20, DOI 10.1016/j.ygyno.2005.05.042; Chen WQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1824-6; Chen Y, 2017, ONCOGENE, V36, P2879, DOI 10.1038/onc.2016.442; Cheng SJ, 2021, CELL, V184, P792, DOI 10.1016/j.cell.2021.01.010; Dabiri S, 2004, MODERN PATHOL, V17, P690, DOI 10.1038/modpathol.3800094; Dantas RCM, 2017, APPL IMMUNOHISTO M M, V25, pE83, DOI 10.1097/PAI.0000000000000587; Della Rovere F, 2007, ANTICANCER RES, V27, P2465; Dowling P, 2011, PROTEOMICS, V11, P794, DOI 10.1002/pmic.201000530; Dudeck A, 2019, J ALLERGY CLIN IMMUN, V144, pS4, DOI 10.1016/j.jaci.2018.10.054; Ferrone C, 2010, J CLIN ONCOL, V28, P4045, DOI 10.1200/JCO.2010.27.9992; Fu HC, 2017, ANN SURG ONCOL, V24, P1435, DOI 10.1245/s10434-016-5702-5; Fu SN, 2011, NATURE, V473, P528, DOI 10.1038/nature09968; Glab JA, 2017, CELL DEATH DIFFER, V24, P944, DOI 10.1038/cdd.2017.53; Gulubova M, 2009, J GASTROEN HEPATOL, V24, P1265, DOI 10.1111/j.1440-1746.2007.05009.x; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79; Hempel HA, 2017, PROSTATE, V77, P412, DOI 10.1002/pros.23280; Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017; Huber AL, 2013, MOL CELL, V49, P1049, DOI 10.1016/j.molcel.2013.01.009; Hughes MR, 2015, METHODS MOL BIOL, V1220, pVII; Tran H, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00056; Ji XL, 2015, FEBS LETT, V589, P3938, DOI 10.1016/j.febslet.2015.11.029; Kim JL, 2019, CANCERS, V11, DOI 10.3390/cancers11050642; Kyritsi K, 2021, HEPATOLOGY, V73, P2397, DOI 10.1002/hep.31497; Leto G, 2018, LIFE SCI, V202, P152, DOI 10.1016/j.lfs.2018.04.013; Lin C, 2017, BRIT J SURG, V104, P1037, DOI 10.1002/bjs.10546; Ma Y, 2013, CANCER RES, V73, P3927, DOI 10.1158/0008-5472.CAN-12-4479; Maciel Thiago T, 2015, F1000Prime Rep, V7, P09, DOI 10.12703/P7-09; Majorini MT, 2020, CANCER RES, V80, P2311, DOI 10.1158/0008-5472.CAN-19-3596; Malfettone A, 2013, J CELL MOL MED, V17, P1025, DOI 10.1111/jcmm.12073; Mao YH, 2018, INT J CANCER, V143, P2271, DOI 10.1002/ijc.31613; da Silva EZM, 2014, J HISTOCHEM CYTOCHEM, V62, P698, DOI 10.1369/0022155414545334; Marichal T, 2013, CANCER IMMUNOL RES, V1, P269, DOI 10.1158/2326-6066.CIR-13-0119; Marone G, 2016, EUR J PHARMACOL, V778, P146, DOI 10.1016/j.ejphar.2015.03.088; Mehdawi L, 2016, ACTA ONCOL, V55, P1434, DOI 10.1080/0284186X.2016.1198493; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Mussap M, 2004, CRIT REV CL LAB SCI, V41, P467, DOI 10.1080/10408360490504934; Nielsen HJ, 1999, J PATHOL, V189, P487, DOI 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I; Pihan P, 2017, CELL DEATH DIFFER, V24, P1478, DOI 10.1038/cdd.2017.82; Poh AR, 2017, CANCER CELL, V31, P563, DOI 10.1016/j.ccell.2017.03.006; Rajput AB, 2008, BREAST CANCER RES TR, V107, P249, DOI 10.1007/s10549-007-9546-3; Reissfelder C, 2015, J CLIN INVEST, V125, P739, DOI 10.1172/JCI74894; Ribatti D, 2016, EUR J PHARMACOL, V778, P152, DOI 10.1016/j.ejphar.2015.02.056; Ribatti D, 2013, IMMUNOL LETT, V152, P83, DOI 10.1016/j.imlet.2013.05.003; Rigoni A, 2015, CANCER MICROENVIRON, V8, P167, DOI 10.1007/s12307-014-0152-8; Saito T, 2016, NAT MED, V22, P679, DOI 10.1038/nm.4086; Segura-Villalobos D, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11030349; Shikotra A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38352; Sinnamon MJ, 2008, CARCINOGENESIS, V29, P880, DOI 10.1093/carcin/bgn040; Song FF, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.10; Song FF, 2019, EBIOMEDICINE, V41, P156, DOI 10.1016/j.ebiom.2019.02.051; Suzuki S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1863-z; Tan SY, 2005, WORLD J GASTROENTERO, V11, P1210, DOI 10.3748/wjg.v11.i8.1210; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Vis MAM, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00911; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Wu JJ, 2019, J EXP MED, V216, P867, DOI 10.1084/jem.20182192; Wu MS, 2020, CANCERS, V12, DOI 10.3390/cancers12010097; Xu YK, 2015, IMMUNOL CELL BIOL, V93, P442, DOI 10.1038/icb.2014.121; Yodavudh Sirisanpang, 2008, Journal of the Medical Association of Thailand, V91, P723; Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327; Zhu PJ, 2018, REDOX BIOL, V16, P157, DOI 10.1016/j.redox.2018.02.019	70	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02543-z	http://dx.doi.org/10.1038/s41388-022-02543-z		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H4PP	36402931				2022-12-28	WOS:000885424000001
J	TAGA, T; KISHIMOTO, T				TAGA, T; KISHIMOTO, T			CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION	FASEB JOURNAL			English	Article						RECEPTOR FAMILY; CYTOPLASMIC SIGNAL; MOLECULAR CLONING	COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; LEUKEMIA-INHIBITORY FACTOR; INTERFERON-GAMMA RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; CILIARY NEUROTROPHIC FACTOR; MOLECULAR-CLONING; EXPRESSION CLONING; CYTOPLASMIC REGION	Most of the recently cloned cytokine receptors that operate in the immune and hematopoietic systems contain no tyrosine kinase domains in their cytoplasmic regions, unlike the family of growth factor receptors defined earlier. However, they can be assigned to several new types of receptor families based on structural similarities among them. It is characteristic of these receptors that many of them require a receptor-associated molecule in order to achieve high-affinity ligand binding and/or transmission of cytoplasmic signals. Receptor-associated molecules have been found that transduce cytoplasmic signals and are shared by different cytokine receptors. Phosphorylation of the receptors and of various cytoplasmic proteins after ligand stimulation seems to be a common event in cytokine systems. Insight into the pleiotropic and redundant nature of cytokine action is provided by the discovery of several new cytokine receptor families and of shared signal transduction molecules and by the idea that several cytoplasmic kinases may be able to functionally substitute for one another in transmitting cytokine signals.	OSAKA UNIV, SCH MED, DEPT MED 3, OSAKA 553, JAPAN	Osaka University	TAGA, T (corresponding author), OSAKA UNIV, INST MOLEC & CELLULAR BIOL, DIV IMMUNOL, 1-3 YAMADA CHO, SUITA, OSAKA 565, JAPAN.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Demaeyer E., 1988, INTERFERONS OTHER RE; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, CELL, V66, P9, DOI 10.1016/0092-8674(91)90131-H; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HELLER RA, 1992, CELL, V70, P47; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MERBERG DM, 1992, IMMUNOL TODAY, V13, P77, DOI 10.1016/0167-5699(92)90140-3; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SATOH T, 1992, J BIOL CHEM, V267, P2537; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SPIEGEL A M, 1992, Current Opinion in Cell Biology, V4, P203, DOI 10.1016/0955-0674(92)90034-A; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, IN PRESS P NATL ACAD; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOJO A, 1987, EXP CELL RES, V171, P16, DOI 10.1016/0014-4827(87)90247-3; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YIN TG, 1992, J BIOL CHEM, V267, P8347	93	252	270	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1992	6	15					3387	3396		10.1096/fasebj.6.15.1334470	http://dx.doi.org/10.1096/fasebj.6.15.1334470			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1334470	Bronze			2022-12-28	WOS:A1992KD39500010
J	ALBRIGHT, JF; OPPENHEIM, JJ				ALBRIGHT, JF; OPPENHEIM, JJ			CONTEMPORARY TOPICS IN IMMUNOLOGY - APPROACHES TO IMMUNOTHERAPY EMERGING FROM BASIC RESEARCH	FASEB JOURNAL			English	Article						T-CELL RECEPTOR MHC PEPTIDE INTERACTIONS; B-CELL TOLERANCE; ANERGY-INFLAMMATORY DISEASE; TRANSGENIC RATS; INTERLEUKIN-10; TRANSFORMING GROWTH FACTOR-BETA	CELL STIMULATORY FACTOR; B-CELLS	The seventh symposium in thc series "Contemporary Topics in Immunology" was held on April 21, 1991, at the FASEB meeting in Atlanta, Georgia. It was sponsored by the National Institute of Allergy and Infectious Diseases, The American Association of Immunologists, and the Clinical Immunology Society. Five topics were discussed by leading researchers in areas of immunology that currently are of exceptional interest and show promise of leading to new advances in the prevention and treatment of human diseases. The topics included: the interactions between immunogenic peptides, class I MHC molecules and T cell receptors; initiation, maintenance, and breakdown of self-tolerance in B lymphocytes; inflammatory disease in HLA-B27 transgenic rats; properties and functions of interleukin-10; and transforming growth factor-beta in reproductive immunology. The exceptional quality of the presentations in this seventh symposium exemplified perfectly the path of basic research that often leads from the laboratory to the clinic.	NCI,FREDERICK CANC RES FACIL,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ALBRIGHT, JF (corresponding author), NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,BASIC IMMUNOL BRANCH,BETHESDA,MD 20892, USA.							ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; ALTMAN DJ, 1990, J EXP MED, V172, P1391, DOI 10.1084/jem.172.5.1391; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; VANBLEEK GM, 1990, NATURE, V348, P213	6	3	3	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2890	2894		10.1096/fasebj.6.11.1644254	http://dx.doi.org/10.1096/fasebj.6.11.1644254			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644254				2022-12-28	WOS:A1992JJ66500002
J	MCGOWAN, SE				MCGOWAN, SE			EXTRACELLULAR-MATRIX AND THE REGULATION OF LUNG DEVELOPMENT AND REPAIR	FASEB JOURNAL			English	Article						ELASTIN; ALVEOLAR SEPTUM; AIRWAY BRANCHING	TRANSFORMING GROWTH-FACTOR; HUMAN ALVEOLAR MACROPHAGES; FIBRONECTIN MESSENGER-RNA; ELASTIN GENE-EXPRESSION; CELL-SURFACE PROTEOGLYCAN; RAT PULMONARY FIBROBLASTS; SMOOTH-MUSCLE CELLS; FACTOR-BETA; ENDOTHELIAL-CELLS; FETAL LUNG	During lung development the extracellular matrix regulates cellular growth, migration, and differentiation. Pulmonary cells reciprocate and regulate extracellular matrix formation by elaborating a variety of peptides that affect gene transcription, RNA processing, translation, and posttranslational modifications of proteins. This regulation involves prenatal events such as the branching of airways and postnatal events such as alveolar septal formation. Normal airway branching requires multiple extracellular matrix proteins, proteoglycans, and the expression of cellular receptors for these molecules. Alveolar septal formation exemplifies how cells regulate the production, export, and deposition of an important structural protein, elastin, which is essential for the development of normal gas exchange units. Repair after injury to the adult lung engages some of the same factors that regulate lung development. However, in this case, inflammatory cells that enter the lung after injury elaborate many of these regulatory peptides. The effects of these peptides on the resident cells, which produce extracellular matrix, are a major determinant of whether the repair restores normal pulmonary architecture or progresses to fibrosis and additional impairment of gas exchange.	DEPT VET AFFAIRS, RES SERV, IOWA CITY, IA USA; UNIV IOWA, COLL MED, IOWA CITY, IA 52242 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa				McGowan, Stephen/0000-0003-3084-1962				AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195, DOI 10.1165/ajrcmb/4.3.195; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BERK JL, 1991, J BIOL CHEM, V266, P3192; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; BRODY JS, 1983, AM REV RESPIR DIS, V127, P763; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; BROWN GP, 1989, AM J PHYSIOL, V256, pC260, DOI 10.1152/ajpcell.1989.256.2.C260; BRUCE MC, 1991, J LAB CLIN MED, V117, P226; BRUCE MC, 1991, AM J RESP CELL MOL, V5, P344, DOI 10.1165/ajrcmb/5.4.344; BUCHER U., 1961, THORAX, V16, P219, DOI 10.1136/thx.16.3.219; Burri P.H., 1985, HDB PHYSL RESPIRATOR, V1, P1; BURRI PH, 1974, ANAT REC, V180, P77, DOI 10.1002/ar.1091800109; CLEMMONS DR, 1985, J CLIN INVEST, V75, P1914, DOI 10.1172/JCI111906; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; DEAN DC, 1989, AM J RESP CELL MOL, V1, P5, DOI 10.1165/ajrcmb/1.1.5; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FOSTER JA, 1990, J GERONTOL, V45, pB113, DOI 10.1093/geronj/45.4.B113; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; FOSTER JA, 1990, AM J PHYSIOL, V259, pL13; FRANZBLAU C, 1989, J BIOL CHEM, V264, P15115; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GOLDSTEIN RH, 1989, ENDOCRINOLOGY, V124, P964, DOI 10.1210/endo-124-2-964; GOLDSTEIN RH, 1991, LUNG CELL MOL PHYSL, V5, pL29; GROSS I, 1990, AM J PHYSIOL, V259, pL337, DOI 10.1152/ajplung.1990.259.6.L337; HEFFNER JE, 1987, AM REV RESPIR DIS, V135, P482; HEINE UI, 1990, DEVELOPMENT, V109, P29; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HILFER SR, 1985, TISSUE CELL, V17, P523, DOI 10.1016/0040-8166(85)90029-1; HIRAI Y, 1989, DEVELOPMENT, V105, P263; JACKSON LE, 1991, BIOCHEM BIOPH RES CO, V179, P939, DOI 10.1016/0006-291X(91)91909-V; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KELLEY J, 1991, AM J PHYSIOL, V260, pL123, DOI 10.1152/ajplung.1991.260.2.L123; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KIDA K, 1980, AM REV RESPIR DIS, V122, P467; KING RJ, 1989, AM J PHYSIOL, V257, pL23; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCHER O, 1990, AM J PATHOL, V137, P1509; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LIN Y, 1991, AM J RESP CELL MOL, V4, P59, DOI 10.1165/ajrcmb/4.1.59; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASSARO D, 1986, AM J PHYSIOL, V251, pR218, DOI 10.1152/ajpregu.1986.251.2.R218; MASSARO D, 1985, J CLIN INVEST, V76, P1297, DOI 10.1172/JCI112103; MASSARO D, 1986, AM J PHYSIOL, V250, pR51; MCGOWAN SE, 1990, AM J RESP CELL MOL, V3, P369, DOI 10.1165/ajrcmb/3.4.369; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MITCHELL JJ, 1990, AM J RESP CELL MOL, V3, P515, DOI 10.1165/ajrcmb/3.6.515; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; NOGUCHI A, 1990, PEDIATR RES, V28, P379, DOI 10.1203/00006450-199010000-00015; NOGUCHI A, 1991, PEDIATR RES, V30, P248, DOI 10.1203/00006450-199109000-00009; ODELL BL, 1978, AM J PATHOL, V91, P413; OYAMA F, 1990, CANCER RES, V50, P1075; PAGANI F, 1991, J CELL BIOL, V113, P1223, DOI 10.1083/jcb.113.5.1223; PAUL WE, 1989, FUNDAMENTAL IMMUNOLO; PIERCE RA, 1990, BIOCHEMISTRY-US, V29, P9677, DOI 10.1021/bi00493a024; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; POST M, 1986, J BIOL CHEM, V261, P2179; POWELL JT, 1991, AM J PHYSIOL, V261, pL236, DOI 10.1152/ajplung.1991.261.4.L236; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROM WN, 1988, J CLIN INVEST, V82, P1685, DOI 10.1172/JCI113781; ROMAN J, 1991, DEVELOPMENT, V112, P551; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANNES PL, 1991, EXP LUNG RES, V17, P639, DOI 10.3109/01902149109062871; SCHELLENBERG JC, 1987, PEDIATR RES, V21, P603, DOI 10.1203/00006450-198706000-00019; SCHUGER L, 1990, DEV BIOL, V137, P26, DOI 10.1016/0012-1606(90)90004-3; SHANNON JM, 1990, AM J RESP CELL MOL, V2, P183, DOI 10.1165/ajrcmb/2.2.183; Spooner BS, 1986, DEV BIOL COMPREHENSI, V3, P225; TANSWELL AK, 1991, J DEV PHYSIOL, V15, P199; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRAUTMAN MS, 1991, DEVELOPMENT, V111, P213; WARBURTON D, 1991, CHEST, V99, pS15; WITSCHI H, 1991, CHEST, V99, pS22	84	174	181	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2895	2904		10.1096/fasebj.6.11.1644255	http://dx.doi.org/10.1096/fasebj.6.11.1644255			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644255				2022-12-28	WOS:A1992JJ66500003
J	TENEICK, RE; WHALLEY, DW; RASMUSSEN, HH				TENEICK, RE; WHALLEY, DW; RASMUSSEN, HH			CONNECTIONS - HEART-DISEASE, CELLULAR ELECTROPHYSIOLOGY, AND ION CHANNELS	FASEB JOURNAL			English	Review						SODIUM CHANNELS; CALCIUM CHANNELS; POTASSIUM CHANNELS; CHLORIDE CHANNELS; ATP-SENSITIVE POTASSIUM CHANNELS; MYOCARDIAL ISCHEMIA; MYOCARDIAL HYPERTROPHY; INTRACELLULAR ION ACTIVITIES; EXTRACELLULAR ION ACTIVITIES; LYSOPHOSPHATIDYLCHOLINE; CHANNEL PHOSPHORYLATION; ION CHANNEL REGULATION	TRANSIENT OUTWARD CURRENT; PIG VENTRICULAR CELLS; BETA-ADRENERGIC MODULATION; SENSITIVE K+ CHANNELS; GUINEA-PIG; ELECTRICAL-ACTIVITY; INTRACELLULAR PROTONS; ISCHEMIC MYOCARDIUM; POTASSIUM CHANNELS; PURKINJE-FIBERS	Our purpose in this article is to examine the hypothesis that both myocardial disease and ischemia can alter the electrophysiologic function of the ion channels responsible for the cellular electrical activity of the heart. Changes in the intracellular and extracellular milieus occur during ischemia and can alter the electrophysiology of several species of ionic channels and the cellular electrophysiologic activity of cardiac myocytes. Included are 1) changes in extracellular [K+] and pH and in intracellular [Na+], [Ca2+], and pH; 2) accumulation of noxious metabolic products such as lysophosphatidylcholine; and 3) depletion of intracellular ATP. Finally, ischemia or disease (e.g., hypertrophy) can alter the electrophysiology of at least two types of K+ channels, the A-like channels underlying the transient outward current and the inward rectifier, by mechanisms that apparently do not involve alteration of either the intra- or extracellular milieus. Findings suggest that the expression of cardiac A-like channel function can be altered by hypertrophy and that at least one intrinsic conductance property of the inward rectifier can be altered by ischemia. We speculate that the control of expression, function, and regulation of cardiac ion channels can be affected at the molecular level by heart disease and myocardial ischemia.	ROYAL N SHORE HOSP, DEPT CARDIOL, ST LEONARDS, NSW 2065, AUSTRALIA	Royal North Shore Hospital	TENEICK, RE (corresponding author), NORTHWESTERN UNIV, DEPT PHARMACOL, 320 E SUPERIOR ST, CHICAGO, IL 60611 USA.			Rasmussen, Helge/0000-0003-2409-4083	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027026, R01HL038041] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-27026, HL-38041] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNSDORF MF, 1981, CIRC RES, V49, P16, DOI 10.1161/01.RES.49.1.16; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BIGGER JT, 1977, PROG CARDIOVASC DIS, V19, P255, DOI 10.1016/0033-0620(77)90005-6; BRAASCH W, 1968, CIRC RES, V23, P429, DOI 10.1161/01.RES.23.3.429; CAMERON JS, 1988, AM J PHYSIOL, V255, pH1254, DOI 10.1152/ajpheart.1988.255.5.H1254; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CLARKSON CW, 1983, CIRC RES, V52, P543, DOI 10.1161/01.RES.52.5.543; CORABOEUF E, 1978, AM J PHYSIOL, V234, pH101, DOI 10.1152/ajpheart.1978.234.2.H101; CORR PB, 1981, CIRC RES, V49, P354, DOI 10.1161/01.RES.49.2.354; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; FERRIER GR, 1977, PROG CARDIOVASC DIS, V19, P459, DOI 10.1016/0033-0620(77)90010-X; FOZZARD HA, 1986, HEART CARDIOVASCULAR, P1; FRY CH, 1981, J PHYSIOL-LONDON, V313, P141, DOI 10.1113/jphysiol.1981.sp013655; GARLICK PB, 1979, BIOCHEM J, V184, P547, DOI 10.1042/bj1840547; GILES WR, 1985, J PHYSIOL-LONDON, V368, P243, DOI 10.1113/jphysiol.1985.sp015856; HAGIWARA S, 1978, J PHYSIOL-LONDON, V279, P167, DOI 10.1113/jphysiol.1978.sp012338; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS AS, 1954, SCIENCE, V119, P200, DOI 10.1126/science.119.3085.200; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HARVEY RD, 1991, P NATL ACAD SCI USA, V88, P6946, DOI 10.1073/pnas.88.16.6946; HARVEY RD, 1989, J GEN PHYSIOL, V94, P329, DOI 10.1085/jgp.94.2.329; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; HIRAOKA M, 1989, J PHYSIOL-LONDON, V410, P187, DOI 10.1113/jphysiol.1989.sp017528; HISATOME I, 1989, BIOPHYS J, V55, P288; HOFFMAN BF, 1964, AM J MED, V37, P670, DOI 10.1016/0002-9343(64)90017-8; HUME J, 1989, MOL CELLULAR MECHANI, P113; IRISAWA H, 1986, CIRC RES, V59, P348, DOI 10.1161/01.RES.59.3.348; JANUARY CT, 1988, PHARMACOL REV, V40, P219; JENNINGS RB, 1981, CIRC RES, V49, P892, DOI 10.1161/01.RES.49.4.892; KAIBARA M, 1988, J PHYSIOL-LONDON, V403, P621, DOI 10.1113/jphysiol.1988.sp017268; KAMEYAMA M, 1984, NATURE, V309, P354, DOI 10.1038/309354a0; KATZ AM, 1981, CIRC RES, V48, P1; KIRSCH GE, 1990, AM J PHYSIOL, V259, pH820, DOI 10.1152/ajpheart.1990.259.3.H820; KLEBER AG, 1987, J MOL CELL CARDIOL, V19, P35, DOI 10.1016/S0022-2828(87)80608-9; KLEIMAN RB, 1989, AM J PHYSIOL, V256, pH1450, DOI 10.1152/ajpheart.1989.256.5.H1450; KLEIMAN RB, 1988, AM J PHYSIOL, V255, pH1434, DOI 10.1152/ajpheart.1988.255.6.H1434; KRAFTE DS, 1988, J GEN PHYSIOL, V91, P641, DOI 10.1085/jgp.91.5.641; KURACHI Y, 1982, PFLUG ARCH EUR J PHY, V394, P264, DOI 10.1007/BF00589102; LEU WM, 1989, CIRCULATION S2, V80, P500; LINDPAINTNER K, 1988, CIRCULATION, V77, P18; MAISEL AS, 1985, SCIENCE, V230, P183, DOI 10.1126/science.2994229; MCCULLOUGH JR, 1990, CIRC RES, V66, P191, DOI 10.1161/01.RES.66.1.191; MOGUL DJ, 1989, BIOPHYS J, V56, P565, DOI 10.1016/S0006-3495(89)82704-3; MOORMAN JR, 1986, J PHARMACOL EXP THER, V238, P159; MOORMAN JR, 1989, CIRC RES, V65, P1804, DOI 10.1161/01.RES.65.6.1804; NAKAYAMA T, 1988, CIRC RES, V62, P162, DOI 10.1161/01.RES.62.1.162; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; NICHOLS CG, 1991, CIRC RES, V68, P280, DOI 10.1161/01.RES.68.1.280; NOBLE D, 1984, J PHYSIOL-LONDON, V353, P1; NOMA A, 1985, J PHYSIOL-LONDON, V363, P463, DOI 10.1113/jphysiol.1985.sp015722; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; PODZUWEIT T, 1978, J MOL CELL CARDIOL, V10, P81, DOI 10.1016/0022-2828(78)90008-1; RASMUSSEN HH, 1986, AM J PHYSIOL, V251, pH331, DOI 10.1152/ajpheart.1986.251.2.H331; SAKATA K, 1989, CARDIOVASC RES, V23, P505, DOI 10.1093/cvr/23.6.505; SATO R, 1985, CIRC RES, V57, P553, DOI 10.1161/01.RES.57.4.553; SCHACKOW TE, 1990, BIOPHYS J, V57, pA140; SCHACKOW TE, 1991, J MOL CELL CARDIOL, V23, pS97; SCHACKOW TE, 1991, BIOPHYS J, V59, P97; SCHACKOW TE, 1989, BIOPHYS J, V55, P295; SCHUBERT B, 1988, P NATL ACAD SCI USA, V85, P8360; SOBEL BE, 1978, J CLIN INVEST, V62, P546, DOI 10.1172/JCI109159; STEENBERGEN C, 1985, CIRC RES, V57, P864, DOI 10.1161/01.RES.57.6.864; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TANI M, 1989, CIRC RES, V65, P1045, DOI 10.1161/01.RES.65.4.1045; Ten Eick R E, 1979, Circ Res, V44, P545; TENEICK RE, 1981, PROG CARDIOVASC DIS, V24, P157, DOI 10.1016/0033-0620(81)90003-7; TENEICK RE, 1989, PHYSL PATHOPHYSIOLOG, P573; TENEICK RE, 1983, PERSPECTIVES CARDIOV, V7, P245; TENEICK RE, 1990, CARDIAC ELECTROPHYSI, P3; TOHSE N, 1990, AM J PHYSIOL, V258, pH1200, DOI 10.1152/ajpheart.1990.258.4.H1200; TORO L, 1990, AM J PHYSIOL, V258, pH912, DOI 10.1152/ajpheart.1990.258.3.H912; TSENG GN, 1989, CIRC RES, V64, P633, DOI 10.1161/01.RES.64.4.633; UGURBIL K, 1985, CIRCULATION, V72, P94; WALSH KB, 1988, PFLUG ARCH EUR J PHY, V411, P232, DOI 10.1007/BF00582323; WASSERSTROM JA, 1991, ELECTROPHYSIOLOGY PH, P199; YATANI A, 1984, J MEMBRANE BIOL, V78, P163, DOI 10.1007/BF01869203; YEH JZ, 1991, BIOPHYS J, V59, P26; YUE DT, 1988, PFLUG ARCH EUR J PHY, V413, P127, DOI 10.1007/BF00582522; ZHANG K, 1991, BIOPHYS J, V59, P279; ZHANG K, 1991, BIOPHYS J, V59, P588; ZHANG K, 1991, J MOL CELL CARDIOL S, V23, pS102; ZYGMUNT AC, 1991, CIRC RES, V68, P424, DOI 10.1161/01.RES.68.2.424	83	50	50	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1992	6	8					2568	2580		10.1096/fasebj.6.8.1375569	http://dx.doi.org/10.1096/fasebj.6.8.1375569			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1375569				2022-12-28	WOS:A1992HU42300010
J	KHAN, MA; WORTHAM, JW; WATZMAN, N; GREEN, JG				KHAN, MA; WORTHAM, JW; WATZMAN, N; GREEN, JG			THE NATIONAL-INSTITUTES-OF-HEALTH IS GOING HIGH-TECH IN PEER-REVIEW	FASEB JOURNAL			English	Article											KHAN, MA (corresponding author), NIH,DIV RES GRANTS,BETHESDA,MD 20892, USA.							CHERFAS J, 1990, SCIENCE, V250, P367, DOI 10.1126/science.250.4979.367	1	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2384	2385		10.1096/fasebj.6.7.1563590	http://dx.doi.org/10.1096/fasebj.6.7.1563590			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563590				2022-12-28	WOS:A1992HP03000002
J	CARR, CJ				CARR, CJ			FROM SULFANILAMIDE TO AZT	FASEB JOURNAL			English	Editorial Material											CARR, CJ (corresponding author), SCI INFORMAT ASSOCIATES,6546 BELLEVIEW DR,COLUMBIA,MD 21046, USA.								0	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					793	793		10.1096/fasebj.6.2.1537470	http://dx.doi.org/10.1096/fasebj.6.2.1537470			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537470				2022-12-28	WOS:A1992GZ44000025
J	CHIEN, KR; KNOWLTON, KU; ZHU, H; CHIEN, S				CHIEN, KR; KNOWLTON, KU; ZHU, H; CHIEN, S			REGULATION OF CARDIAC GENE-EXPRESSION DURING MYOCARDIAL GROWTH AND HYPERTROPHY - MOLECULAR STUDIES OF AN ADAPTIVE PHYSIOLOGICAL-RESPONSE	FASEB JOURNAL			English	Article						TRANSCRIPTION; MYOCYTES; ANF; MYOSIN; ONCOGENE	ATRIAL NATRIURETIC FACTOR; CONGESTIVE HEART-FAILURE; MYOSIN LIGHT CHAIN-2; SPONTANEOUSLY HYPERTENSIVE RATS; GERM-LINE TRANSMISSION; IMMEDIATE-EARLY GENES; EMBRYONIC STEM-CELLS; PROTEIN-SYNTHESIS; MESSENGER-RNA; ALPHA-1-ADRENERGIC STIMULATION	Studies from both in vivo and in vitro model systems have provided an initial skeleton of the potential signaling pathways that might regulate cardiac genes during growth and hypertrophy. One of the first detectable changes in cardiac gene expression is the activation of a program of immediate early gene expression, which is distinct for the hypertrophic response, and is conserved in multiple models of both in vivo and in vitro hypertrophy. Diverse and distinct hormonal stimuli have been documented to activate several features of the hypertrophic response, including several autocrine and paracrine factors. Although the signaling mechanisms that link these factors with the activation of cardiac gene expression are unclear, recent studies suggest that the activation of protein kinase C may represent one of the most proximal common events in this signaling cascade. The activation of cardiac target genes induces a program of embryonic gene expression, including the atrial natriuretic factor (ANF) gene. The cis sequences that mediate cardiac-specific and inducible expression of an embryonic marker gene (ANF) can be segregated by studies in both cultured cell models and in vivo models of hypertrophy in transgenic mice, suggesting that specific sets of regulatory elements may exist for inducible expression of this class of cardiac gene responses. However, the induction of a constitutively expressed contractile protein gene (MLC-2) is mediated by a set of conserved elements that regulate both cardiac-specific and inducible expression. Finally, a subset of cardiac muscle genes appears to be noninducible during in vivo or in vitro hypertrophy in myocardial cells, demonstrating specificity of transcriptional activation during the hypertrophic process. The development of a bona fide in vivo pressure overload model of hypertrophy in a small animal model that can be genetically manipulated, such as the in vivo murine model recently described, should allow a rigorous analysis of the role of these specific signaling mechanisms in the activation of the responses of cardiac genes during the hypertrophic process in vivo.	UNIV CALIF SAN DIEGO, AHA BUGHER FDN CTR MOLEC BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, AMES BIOENGN, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	CHIEN, KR (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, BASIC SCI BLDG, 0613C, LA JOLLA, CA 92093 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345, R01HL036139] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26, HL-46345, HL-36139] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAI H, 1988, CIRC RES, V62, P926, DOI 10.1161/01.RES.62.5.926; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BLOCH KD, 1986, CELL, V47, P695, DOI 10.1016/0092-8674(86)90512-X; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIEN KR, 1989, CIRCULATION, V80, P219, DOI 10.1161/01.CIR.80.2.219; CHIEN S, 1990, MOL BIOL CARDIOVASCU, P221; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DAY ML, 1987, HYPERTENSION, V9, P485, DOI 10.1161/01.HYP.9.5.485; DOETSCHMAN T, 1988, P NATL ACAD SCI USA, V85, P8583, DOI 10.1073/pnas.85.22.8583; DREXLER H, 1989, CIRCULATION, V79, P620, DOI 10.1161/01.CIR.79.3.620; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; EDWARDS BS, 1988, J CLIN INVEST, V81, P82, DOI 10.1172/JCI113314; EID H, 1990, CIRCULATION, V82, P689; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; FRANCH HA, 1988, CIRC RES, V62, P31, DOI 10.1161/01.RES.62.1.31; GUTKOWSKA J, 1986, HYPERTENSION, V8, P137; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HENDERSON SA, 1988, NUCLEIC ACIDS RES, V16, P4722, DOI 10.1093/nar/16.10.4722; IWAKI K, 1990, J BIOL CHEM, V265, P13809; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JACKSON T, 1990, MOL CELL BIOL, V10, P3709, DOI 10.1128/MCB.10.7.3709; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KARLINER JS, 1990, EXPERIENTIA, V46, P81, DOI 10.1007/BF01955423; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOMURO I, 1990, J BIOL CHEM, V265, P3595; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARBAN E, 1990, HYPERTENSION, V15, P652, DOI 10.1161/01.HYP.15.6.652; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RASCHER W, 1985, LANCET, V2, P303; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; ROSS RS, 1991, CLIN RES, V39, pA296; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SEN A, 1988, J BIOL CHEM, V263, P19132; SEN S, 1990, J BIOL CHEM, V265, P16635; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHENKER Y, 1985, J CLIN INVEST, V76, P1684, DOI 10.1172/JCI112154; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SHUBEITA HE, 1990, IN PRESS P NATL ACAD; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WU JP, 1988, AM J PHYSIOL, V255, pE388, DOI 10.1152/ajpendo.1988.255.3.E388; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	68	732	770	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1991	5	15					3037	3046		10.1096/fasebj.5.15.1835945	http://dx.doi.org/10.1096/fasebj.5.15.1835945			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1835945				2022-12-28	WOS:A1991GU84200006
J	DAVIS, FB; DAVIS, PJ; LAWRENCE, WD; BLAS, SD				DAVIS, FB; DAVIS, PJ; LAWRENCE, WD; BLAS, SD			SPECIFIC INOSITOL PHOSPHATES INHIBIT BASAL AND CALMODULIN-STIMULATED CA2+-ATPASE ACTIVITY IN HUMAN ERYTHROCYTE-MEMBRANES INVITRO AND INHIBIT BINDING OF CALMODULIN TO MEMBRANES	FASEB JOURNAL			English	Article						INOSITOL TRISPHOSPHATE; HEPARIN; CALMODULIN BINDING	THYROID-HORMONE; CA-2+-ATPASE ACTIVITY; CA-2+ PUMP; 1,4,5-TRISPHOSPHATE; TRISPHOSPHATE; CALCIUM; BRAIN	D-Myo-inositol 1,4,5-trisphosphate (Ins[1,4-,5]P3) inhibits rat heart sarcolemmal Ca2+-ATPase activity (T. H. Kuo, Biochem. Biophys. Res. Commun. 152: 1111, 1988). We have studied the effect and mechanism of action of Ins(1,4,5)P3 and related inositol phosphates on human red cell membrane Ca2+-ATPase (EC 3.6.1.3) activity in vitro. At 10(-6) M, Ins(1,4,5)P3 and D-myo-inositol 4,5-bisphosphate (Ins[4,5]P2) inhibited human erythrocyte membrane Ca2+-ATPase activity in vitro by 42 and 31%, respectively. D-Myo-inositol 1,3,4,5-tetrakisphosphate, D-myo-inositol 1,4-bisphosphate, and D-myo-inositol 1-phosphate were not inhibitory. Enzyme inhibition by Ins(1,4,5)P3 was blocked by heparin. Exogenous purified calmodulin also stimulated red cell membrane Ca2+-ATPase activity; this stimulation was inhibited by Ins(1,4,5)P3. Ins(4,5)P2 and Ins(1,4,5)P3, but not Ins(1,4)P2, inhibited the binding of [I-125]calmodulin to red cell membranes. Thus, specific inositol phosphates reduce plasma membrane Ca2+-ATPase activity and enhancement of the latter in vitro by purified calmodulin. The mechanism of these effects may in part relate to inhibition by inositol phosphates of binding of calmodulin to erythrocyte membranes.	UNION UNIV, DEPT MED, ALBANY, NY 12208 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT MED, BUFFALO, NY 14214 USA; SAMUEL S STRATTON VET AFFAIRS MED CTR, MED SERV, ALBANY, NY 12208 USA	Union College; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								AGRE P, 1983, J BIOL CHEM, V258, P6258; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BURGESS GM, 1984, BIOCHEM J, V224, P741, DOI 10.1042/bj2240741; CATT KJ, 1989, ANNU REV MED, V40, P487; CHARBONNEAU H, 1983, METHOD ENZYMOL, V102, P17; DAVIS FB, 1983, J CLIN INVEST, V71, P579, DOI 10.1172/JCI110803; DAVIS FB, 1990, J CLIN INVEST, V85, P1999, DOI 10.1172/JCI114664; DAVIS FB, 1987, BIOCHEM J, V248, P511, DOI 10.1042/bj2480511; DAVIS PJ, 1981, BIOCHEM BIOPH RES CO, V99, P1073, DOI 10.1016/0006-291X(81)90728-2; DEZIEL MR, 1989, ARCH BIOCHEM BIOPHYS, V274, P463, DOI 10.1016/0003-9861(89)90459-1; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRASER CL, 1990, J CLIN INVEST, V86, P2169, DOI 10.1172/JCI114956; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KUO TH, 1988, BIOCHEM BIOPH RES CO, V152, P1111, DOI 10.1016/S0006-291X(88)80399-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MAYR GW, 1989, BIOCHEM J, V259, P463, DOI 10.1042/bj2590463; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; SCHARFF O, 1981, CELL CALCIUM, V2, P1, DOI 10.1016/0143-4160(81)90043-9; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; TAKAZAWA K, 1989, BIOCHEM J, V261, P1059; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; WARNICK PR, 1988, BIOCHEM PHARMACOL, V37, P2619, DOI 10.1016/0006-2952(88)90255-9; Weiss B, 1978, Adv Cyclic Nucleotide Res, V9, P285; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	29	20	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1991	5	14					2992	2995		10.1096/fasebj.5.14.1836436	http://dx.doi.org/10.1096/fasebj.5.14.1836436			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1836436				2022-12-28	WOS:A1991GP26900016
J	HEARING, VJ; TSUKAMOTO, K				HEARING, VJ; TSUKAMOTO, K			ENZYMATIC CONTROL OF PIGMENTATION IN MAMMALS	FASEB JOURNAL			English	Review						MELANIN; PIGMENTATION; MELANOGENESIS	MELANOCYTE-STIMULATING HORMONE; HAIR FOLLICULAR MELANOCYTES; TYROSINASE-RELATED PROTEIN; IA OCULOCUTANEOUS ALBINISM; CULTURED HUMAN MELANOCYTES; ENCODING MOUSE TYROSINASE; MESSENGER-RNA LEVELS; MOLECULAR-BASIS; DOPACHROME OXIDOREDUCTASE; METAL-IONS	Visible pigmentation in mammals results from the synthesis and distribution of melanin in the skin, hair bulbs, and eyes. The melanins are produced in melanocytes and can be of two basic types: eumelanins, which are brown or black, and phaeomelanins, which are red or yellow. In mammals typically there are mixtures of both types. The most essential enzyme in this melanin biosynthetic pathway is tyrosinase and it is the only enzyme absolutely required for melanin production. However, recent studies have shown that mammalian melanogenesis is not regulated solely by tyrosinase at the enzymatic level, and have identified additional melanogenic factors that can modulate pigmentation in either a positive or negative fashion. In addition, other pigment-specific genes that are related to tyrosinase have been cloned which encode proteins that apparently work together at the catalytic level to specify the quantity and quality of the melanins synthesized. Future research should provide a greater understanding of the enzymatic interactions, processing, and tissue specificity that are important to pigmentation in mammals.	YAMANASHI MED COLL, DEPT DERMATOL, YAMANASHI 40938, JAPAN	University of Yamanashi	HEARING, VJ (corresponding author), NCI, CELL BIOL LAB, ROOM 1B22, BETHESDA, MD 20892 USA.							ABDELMALEK ZA, 1987, CANCER RES, V47, P3141; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BARBER JI, 1985, J HERED, V76, P59, DOI 10.1093/oxfordjournals.jhered.a110019; BARBER JI, 1984, J INVEST DERMATOL, V83, P145, DOI 10.1111/1523-1747.ep12263381; BARTON D E, 1988, Genomics, V3, P17, DOI 10.1016/0888-7543(88)90153-X; BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1990, DEVELOPMENT, V110, P471; BOLOGNIA J, 1989, J INVEST DERMATOL, V92, P651, DOI 10.1111/1523-1747.ep12696836; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; BRUSH AH, 1990, FASEB J, V4, P2969, DOI 10.1096/fasebj.4.12.2394316; BURCHILL SA, 1986, J ENDOCRINOL, V109, P15, DOI 10.1677/joe.0.1090015; BURCHILL SA, 1990, J INVEST DERMATOL, V95, P558, DOI 10.1111/1523-1747.ep12504908; BURCHILL SA, 1989, J INVEST DERMATOL, V93, P236, DOI 10.1111/1523-1747.ep12277579; BURCHILL SA, 1986, J ENDOCRINOL, V111, P225, DOI 10.1677/joe.0.1110225; BURCHILL SA, 1988, J ENDOCRINOL, V116, P17, DOI 10.1677/joe.0.1160017; CHAKRABORTY AK, 1989, J INVEST DERMATOL, V93, P616, DOI 10.1111/1523-1747.ep12319736; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; DISCHIA M, 1991, BIOCHIM BIOPHYS ACTA, V1073, P423, DOI 10.1016/0304-4165(91)90152-7; ELLER M, 1990, J INVEST DERMATOL, V94, P521; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, BRIT J DERMATOL, V123, P145, DOI 10.1111/j.1365-2133.1990.tb01841.x; FULLER BB, 1987, J BIOL CHEM, V262, P4024; GHANEM GE, 1988, INT J CANCER, V41, P248, DOI 10.1002/ijc.2910410216; GIEBEL LB, 1990, P NATL ACAD SCI USA, V87, P3255, DOI 10.1073/pnas.87.9.3255; GORDON PR, 1989, J INVEST DERMATOL, V92, P565, DOI 10.1111/1523-1747.ep12709595; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; GRANHOLM NH, 1991, J INVEST DERMATOL, V96, P78, DOI 10.1111/1523-1747.ep12515889; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; HALABAN R, 1988, P NATL ACAD SCI USA, V85, P7241, DOI 10.1073/pnas.85.19.7241; HATTA S, 1988, J INVEST DERMATOL, V91, P181, DOI 10.1111/1523-1747.ep12464454; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x; HEARING VJ, 1982, J INVEST DERMATOL, V79, P16, DOI 10.1111/1523-1747.ep12510422; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HOGANSON GE, 1989, SOMAT CELL MOLEC GEN, V15, P255, DOI 10.1007/BF01534876; IWATA M, 1990, IN VITRO CELL DEV B, V26, P554; JACKSON IJ, 1990, GENETICS, V126, P451; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1990, P NATL ACAD SCI USA, V87, P7010, DOI 10.1073/pnas.87.18.7010; JARA JR, 1990, J CELL SCI, V97, P479; JARA JR, 1988, BIOCHIM BIOPHYS ACTA, V967, P296, DOI 10.1016/0304-4165(88)90023-2; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KAMEYAMA K, 1989, DIFFERENTIATION, V42, P28, DOI 10.1111/j.1432-0436.1989.tb00604.x; KAMEYAMA K, 1989, J CLIN INVEST, V83, P213, DOI 10.1172/JCI113861; KING RA, 1985, AM J MED GENET, V20, P49, DOI 10.1002/ajmg.1320200108; KING RA, 1991, MOL BIOL MED, V8, P19; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KORNER AM, 1980, J INVEST DERMATOL, V75, P192, DOI 10.1111/1523-1747.ep12522650; KWON BS, 1989, BIOCHEM BIOPH RES CO, V161, P252, DOI 10.1016/0006-291X(89)91588-X; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; KWON BS, 1987, MOL BIOL MED, V4, P339; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; Lerch K, 1988, Prog Clin Biol Res, V256, P85; MARTINEZ JH, 1985, BIOCHEM INT, V11, P729; MISHIMA Y, 1988, PIGM CELL RES, V1, P367, DOI 10.1111/j.1600-0749.1988.tb00136.x; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; PALUMBO A, 1990, BIOCHIM BIOPHYS ACTA, V1033, P256, DOI 10.1016/0304-4165(90)90129-K; PALUMBO A, 1988, BIOCHIM BIOPHYS ACTA, V964, P193, DOI 10.1016/0304-4165(88)90166-3; PAWELEK J, 1991, IN PRESS J CLIN INVE; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PAWELEK JM, 1991, PIGM CELL RES, V4, P53, DOI 10.1111/j.1600-0749.1991.tb00315.x; PAWELEK JM, 1985, YALE J BIOL MED, V58, P571; PORTER S, 1991, GENE, V97, P277, DOI 10.1016/0378-1119(91)90063-H; PROTA G, 1988, MED RES REV, V8, P525, DOI 10.1002/med.2610080405; Prota G, 1988, Prog Clin Biol Res, V256, P101; PROTA G, 1980, NATURAL SULFUR COMPO, P391; QUEVEDO WC, 1987, DERMATOLOGY GENERAL, V1, P224; RORSMAN H, 1990, CUTANEOUS MELANOMA B, P79; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1988, TOHOKU J EXP MED, V156, P403, DOI 10.1620/tjem.156.403; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; Shibahara S, 1988, Prog Clin Biol Res, V256, P263; SLOMINSKI A, 1987, BIOSCIENCE REP, V7, P949, DOI 10.1007/BF01122128; SPRITZ RA, 1990, NEW ENGL J MED, V322, P1724, DOI 10.1056/NEJM199006143222407; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; TAKEDA A, 1989, TOHOKU J EXP MED, V159, P333, DOI 10.1620/tjem.159.333; TAKEDA A, 1990, J BIOL CHEM, V265, P17792; TAKEUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P470, DOI 10.1016/S0006-291X(88)81110-0; TAMATE HB, 1981, DEV GENET, V2, P349, DOI 10.1002/dvg.1020020404; TAMATE HB, 1989, J EXP ZOOL, V250, P304, DOI 10.1002/jez.1402500310; TANAKA S, 1990, DEVELOPMENT, V108, P223; TERAO M, 1989, BIOCHEM BIOPH RES CO, V159, P848, DOI 10.1016/0006-291X(89)90072-7; TOMITA Y, 1989, BIOCHEM BIOPH RES CO, V164, P990, DOI 10.1016/0006-291X(89)91767-1; TSUKAMOTO K, 1991, IN RPRESS 14 P INT P; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; VIJAYASARADHI S, 1991, INT J CANCER, V47, P298, DOI 10.1002/ijc.2910470221; WICK MM, 1987, DERMATOLOGY GENERAL, V1, P251; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121; YAMAMOTO H, 1987, JPN J GENET, V62, P271, DOI 10.1266/jjg.62.271; ZDARSKY E, 1990, GENETICS, V126, P443	100	651	677	2	120	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1991	5	14					2902	2909		10.1096/fasebj.5.14.1752358	http://dx.doi.org/10.1096/fasebj.5.14.1752358			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752358				2022-12-28	WOS:A1991GP26900004
J	KHEWGOODALL, Y; GRILLO, M; GETCHELL, ML; DANHO, W; GETCHELL, TV; MARGOLIS, FL				KHEWGOODALL, Y; GRILLO, M; GETCHELL, ML; DANHO, W; GETCHELL, TV; MARGOLIS, FL			VOMEROMODULIN, A PUTATIVE PHEROMONE TRANSPORTER - CLONING, CHARACTERIZATION, AND CELLULAR-LOCALIZATION OF A NOVEL GLYCOPROTEIN OF LATERAL NASAL GLAND	FASEB JOURNAL			English	Article						OLFACTION; SECRETION; PERIRECEPTOR EVENTS; PHEROMONE; LATERAL NASAL GLAND; VOMEROMODULIN	ODORANT-BINDING PROTEIN; OLFACTORY MARKER PROTEIN; N-GLYCOSIDASE-F; CHEMOSENSORY PROCESSES; VOMERONASAL ORGAN; NERVOUS-SYSTEM; MOUSE; EVENTS; MUCOSA; CDNA	Vomeromodulin, a novel glycoprotein of lateral nasal gland, has been cloned by differential hybridization from nasal/olfactory tissue. The 2.2-kb mRNA directs the in vitro synthesis of a 60-kDa primary translation product in reticulocyte lysates. Differential sensitivity to endoglycosidases indicates that vomeromodulin is posttranslationally modified in vivo by N-glycosylation to form a 70-kDa glycoprotein of the complex type. Immunocytochemical localization with two different antipeptide antisera demonstrates that vomeromodulin is abundant in the lateral nasal glands and is also present in the posterior septal and vomeronasal glands. Most striking is the observation that it is highly concentrated in the mucus of the vomeronasal organ of Jacobson but is not detectable in the mucus of the main olfactory neuroepithelium. Evaluation of mRNA and protein distribution by Northern and Western analyses, respectively, indicates that vomeromodulin is absent from 15 other tissues. The glandular and mucosal distribution of this glycoprotein implies a transport function that may be related to the mechanisms by which pheromones of low volatility gain access to their receptors in the vomeronasal organ. These observations support our hypothesis that vomeromodulin participates in perireceptor events that facilitate the process of pheromone access and detection.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT NEUROSCI, NUTLEY, NJ 07110 USA; UNIV KENTUCKY, COLL MED, DEPT SURG, DIV OTOLARYNGOL HEAD & NECK SURG, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, COLL MED, SANDERS BROWN CTR AGING, LEXINGTON, KY 40536 USA; HOFFMANN LA ROCHE INC, PEPTIDE RES DEPT, NUTLEY, NJ 07110 USA; UNIV KENTUCKY, COLL MED, DEPT PHYSIOL & BIOPHYS, LEXINGTON, KY 40536 USA; INST MED & VET SCI, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA	Roche Holding; University of Kentucky; University of Kentucky; Roche Holding; University of Kentucky; Institute Medical & Veterinary Science Australia					NIDCD NIH HHS [DC-00159] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMS DR, 1981, J ANAT, V132, P29; ANHOLT RRH, 1990, BIOCHEMISTRY-US, V29, P4049, DOI 10.1021/bi00469a004; BAKER H, 1989, J COMP NEUROL, V285, P246, DOI 10.1002/cne.902850207; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; BIFFO S, 1991, MOL BRAIN RES, V10, P13, DOI 10.1016/0169-328X(91)90051-X; BIGNETTI E, 1985, EUR J BIOCHEM, V149, P227, DOI 10.1111/j.1432-1033.1985.tb08916.x; BOJSENMOLLER F, 1964, ANAT REC, V150, P11, DOI 10.1002/ar.1091500103; CARR WES, 1990, CHEM SENSES, V15, P181, DOI 10.1093/chemse/15.2.181; CARR WES, 1990, TRENDS NEUROSCI, V13, P212, DOI 10.1016/0166-2236(90)90162-4; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; CUSCHIERI A, 1974, HISTOCHEM J, V6, P543, DOI 10.1007/BF01003270; Dahl A.R., 1988, MOL NEUROBIOLGY OLFA, P51, DOI [10.1016/j.semcdb.2012.09.001, DOI 10.1016/J.SEMCDB.2012.09.001]; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DELONG RE, 1987, CHEM SENSES, V12, P3, DOI 10.1093/chemse/12.1.3; DING X, 1988, BIOCHEMISTRY-US, V27, P8330, DOI 10.1021/bi00422a007; EHRLICH ME, 1990, MOL BRAIN RES, V7, P115, DOI 10.1016/0169-328X(90)90088-U; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; FOSTER JD, 1991, ANAT REC, V229, P525, DOI 10.1002/ar.1092290414; FREEZE HH, 1986, BIOCHEM BIOPH RES CO, V140, P967, DOI 10.1016/0006-291X(86)90730-8; GETCHELL TV, 1990, CHEM SENSES, V15, P223, DOI 10.1093/chemse/15.2.223; GETCHELL TV, 1984, PROG NEUROBIOL, V23, P317, DOI 10.1016/0301-0082(84)90008-X; GUBLER U, 1987, GUIDE MOL CLONING TE, P325; HEMPSTEAD JL, 1983, CHEM SENSES, V8, P107, DOI 10.1093/chemse/8.1.107; HORNUNG DE, 1987, BRAIN RES, V413, P147, DOI 10.1016/0006-8993(87)90163-6; KRAEVSKAYA MA, 1987, SENSORNYE SISTEMY, V1, P127; LANCET D, 1988, COLD SPRING HARB SYM, V53, P343, DOI 10.1101/SQB.1988.053.01.041; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LEE KH, 1987, SCIENCE, V235, P1053, DOI 10.1126/science.3493528; LERNER MR, 1990, CHEM SENSES, V15, P191, DOI 10.1093/chemse/15.2.191; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MARGOLIS FL, 1988, MOL NEUROBIOLOGY OLF, P237; MENDOZA AS, 1986, CHEM SENSES, V11, P541, DOI 10.1093/chemse/11.4.541; MEREDITH M, 1979, J PHYSIOL-LONDON, V286, P301, DOI 10.1113/jphysiol.1979.sp012620; MEREDITH M, 1988, CHEM SENSES, V13, P487, DOI 10.1093/chemse/13.4.487; Meredith M, 1980, CHEM SIGNALS VERTEBR, P303; MORGAN JI, 1988, MOL NEUROBIOLOGY OLF, P269; NAKASHIMA T, 1984, ARCH OTOLARYNGOL, V110, P641; NEF P, 1989, J BIOL CHEM, V264, P6780, DOI 10.1016/S0021-9258(18)83497-4; PELOSI P, 1990, CHEM SENSES, V15, P205, DOI 10.1093/chemse/15.2.205; PEVSNER J, 1990, CHEM SENSES, V15, P217, DOI 10.1093/chemse/15.2.217; PEVSNER J, 1988, P NATL ACAD SCI USA, V85, P2383, DOI 10.1073/pnas.85.7.2383; RANDALL HW, 1987, AM J ANAT, V179, P10, DOI 10.1002/aja.1001790103; REED CJ, 1988, BIOCHEM J, V253, P569, DOI 10.1042/bj2530569; ROGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704, DOI 10.1073/pnas.84.6.1704; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SINGER AG, 1987, ANN NY ACAD SCI, V519, P287; SINGER AG, 1990, CHEM SENSES, V15, P199, DOI 10.1093/chemse/15.2.199; SNYDER DA, 1991, IN PRESS BIKOCHEMIST; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; VIDIC B, 1971, AM J ANAT, V132, P491, DOI 10.1002/aja.1001320407; VOGT RG, 1988, J BIOL CHEM, V263, P3952; WIRSIG CR, 1986, BRAIN RES, V385, P10, DOI 10.1016/0006-8993(86)91541-6; WYSOCKI CJ, 1980, SCIENCE, V207, P781, DOI 10.1126/science.7352288; WYSOCKI CJ, 1979, NEUROSCI BIOBEHAV R, V3, P301, DOI 10.1016/0149-7634(79)90015-0; WYSOCKI CJ, 1979, NEUROBIOLOGY TASTE S, P125	57	51	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1991	5	14					2976	2982		10.1096/fasebj.5.14.1752363	http://dx.doi.org/10.1096/fasebj.5.14.1752363			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752363				2022-12-28	WOS:A1991GP26900014
J	PARKER, DC; EYNON, EE				PARKER, DC; EYNON, EE			ANTIGEN PRESENTATION IN ACQUIRED IMMUNOLOGICAL-TOLERANCE	FASEB JOURNAL			English	Review						IMMUNOLOGICAL TOLERANCE; ANTIGEN PRESENTATION; LYMPHOCYTE-T; LYMPHOCYTE-B; CLONAL ANERGY	MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL TOLERANCE; INCOMPATIBLE STRAIN C3H; TRANSGENIC MICE; LYMPHOCYTES-T; PRESENTING CELLS; SELF-TOLERANCE; CLONAL ANERGY; B-CELLS; NEGATIVE SELECTION	In acquired tolerance, previous exposure to antigen under certain conditions induces specific unresponsiveness instead of specific immunological memory. It has been studied as an approach to the mechanisms of self-tolerance that operate on immunocompetent T and B lymphocytes once they leave their sites of origin in the thymus and the bone marrow. Possible mechanisms involve induction of specific suppressor cells or inactivation of antigen-specific lymphocytes (clonal anergy) as a consequence of abortive antigen presentation, in which the antigen receptor is effectively engaged but certain poorly defined accessory signals the T lymphocytes require are lacking. We propose that small, resting B lymphocytes, which lack these accessory signals, are the inactivating antigen-presenting cells in acquired tolerance to proteins and to the class II transplantation antigens. B lymphocytes, which can use their antigen receptors to gather and process antigens that are present at very low concentrations, may play a role in self-tolerance. In addition, B lymphocytes and T lymphocytes rendered anergic by encounter with self antigens could persist as self-specific suppressor cells to block an autoimmune response of autoreactive clones that had escaped deletion or anergy.			PARKER, DC (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT MOLEC GENET & MICROBIOL, 55 LAKE AVE N, WORCESTER, MA 01655 USA.		Parker, David C/A-5428-2008	Parker, David/0000-0003-4456-2788	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024303, R01AI029544] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI24303, R01 AI29544] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHWELL JD, 1988, J IMMUNOL, V140, P3697; BANDEIRA A, 1987, EUR J IMMUNOL, V17, P901, DOI 10.1002/eji.1830170702; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BURKLY LC, 1990, SCIENCE, V248, P1364, DOI 10.1126/science.1694042; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; Carbone F. R., 1989, Fundamental immunology., P541; COUTINHO A, 1989, IMMUNOL TODAY, V10, P264, DOI 10.1016/0167-5699(89)90138-2; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DIETRICH FM, 1964, J IMMUNOL, V92, P167; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; DRESSER DW, 1962, IMMUNOLOGY, V5, P378; EYNON EE, 1991, TRANSPLANT P, V23, P729; FAUSTMAN D, 1982, SCIENCE, V217, P157, DOI 10.1126/science.6806903; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FREEMAN GJ, 1990, BLOOD, V76, pA206; GAHRING LC, 1989, J IMMUNOL, V143, P2094; GASPARI AA, 1988, J IMMUNOL, V141, P2216; GERMAIN RN, 1986, NATURE, V322, P845; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1990, SCIENCE, V248, P1373, DOI 10.1126/science.2356469; GOSSELIN EJ, 1988, J IMMUNOL, V140, P1408; GUNTHER J, 1982, EUR J IMMUNOL, V12, P247, DOI 10.1002/eji.1830120315; HARDING CV, 1988, IMMUNOL REV, V106, P77, DOI 10.1111/j.1600-065X.1988.tb00774.x; HAWRYLOWICZ CM, 1988, J IMMUNOL, V141, P4083; HORI S, 1989, J IMMUNOL, V143, P1447; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; JACOBSSON H, 1975, SCAND J IMMUNOL, V4, P181, DOI 10.1111/j.1365-3083.1975.tb02615.x; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAMB JR, 1984, NATURE, V308, P72, DOI 10.1038/308072a0; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LASSILA O, 1988, NATURE, V334, P253, DOI 10.1038/334253a0; LAU H, 1983, SCIENCE, V221, P754, DOI 10.1126/science.6410509; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LILLIEHOOK B, 1975, SCAND J IMMUNOL, V4, P209, DOI 10.1111/j.1365-3083.1975.tb02619.x; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; METLAY JP, 1989, ADV IMMUNOL, V47, P45, DOI 10.1016/S0065-2776(08)60662-8; MILLER RG, 1986, IMMUNOL TODAY, V7, P112, DOI 10.1016/0167-5699(86)90151-9; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NOSSAL GJV, 1989, FUNDAMENTAL IMMUNOLO, P571; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; QUILL H, 1987, J IMMUNOL, V138, P3704; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; RUDENSKY AY, 1990, EUR J IMMUNOL, V20, P2235, DOI 10.1002/eji.1830201012; RYAN JJ, 1984, J IMMUNOL, V133, P2343; SCHILD H, 1990, SCIENCE, V247, P1587, DOI 10.1126/science.2321019; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHELLAM GR, 1968, IMMUNOLOGY, V14, P273; SHINOHARA N, 1988, NATURE, V336, P481, DOI 10.1038/336481a0; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SPRENT J, 1990, SCIENCE, V248, P1357, DOI 10.1126/science.1694041; SPRENT J, 1980, J IMMUNOL, V125, P2089; SPRENT J, 1984, ANN INST PASTEUR IMM, VD135, P98, DOI 10.1016/S0769-2625(84)80164-6; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOCKINGER B, 1988, EUR J IMMUNOL, V18, P249, DOI 10.1002/eji.1830180211; TITE JP, 1986, J EXP MED, V163, P189, DOI 10.1084/jem.163.1.189; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; TONY HP, 1985, J EXP MED, V162, P1695, DOI 10.1084/jem.162.5.1695; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; WALDMANN TA, 1988, IMMUNOLOGICAL DISEAS, P411; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; WEAVER CT, 1990, IMMUNOL TODAY, V11, P49; WHITELEY PJ, 1990, J IMMUNOL, V145, P1376; WILSON DB, 1989, IMMUNOL REV, V107, P159, DOI 10.1111/j.1600-065X.1989.tb00008.x; ZAUDERER M, 1990, IMMUNOL REV, V116, P159, DOI 10.1111/j.1600-065X.1990.tb00809.x	83	48	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1991	5	13					2777	2784		10.1096/fasebj.5.13.1916102	http://dx.doi.org/10.1096/fasebj.5.13.1916102			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916102				2022-12-28	WOS:A1991GJ47100005
J	BLATTNER, WA				BLATTNER, WA			HIV EPIDEMIOLOGY - PAST, PRESENT, AND FUTURE	FASEB JOURNAL			English	Review						HIGH-RISK INDIVIDUAL; T-CELL LEUKEMIA VIRUS; LIFE-STYLE	HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL MEN; TYPE-1 INFECTION; AIDS; RETROVIRUS; TRANSMISSION; LYMPHOCYTES; PROSTITUTES; LYMPHOMA; CHILDREN	The worldwide pandemic of acquired immunodeficiency syndrome (AIDS) has the potential to cause catastrophic medical and social effects that will influence world health well into the 21st century. The causative agent, a lentiretrovirus called human immunodeficiency virus (HIV-1), is spread by intimate exposure to blood and bodily fluids through sexual, parenteral, and mother-to-infant exposure. The natural history from exposure to disease has a median incubation period of 8-10 years and is characterized by progressive depletion of CD-4 positive T lymphocytes as well as effects on other immune and central nervous system cell populations. The World Health Organization (WHO) estimates that between 8 and 10 million persons are currently infected with the virus worldwide, with 8 to 10 times this level projected by some estimates into the 21st century. Recent leveling off of AIDS incidence in the U.S. appears to represent the positive benefits of antiretroviral therapy, and considerable benefit could be seen if such therapies were made more widely available to medically underserved populations. With prolonged survival, however, other long-term sequelae such as cancer and lymphoma may emerge as significant complications of prolonged immunodeficiency. Furthermore, the large pool of already infected persons and continued spread of the virus make the development of additional therapies and an effective anti-HIV vaccine priorities of medical research.			BLATTNER, WA (corresponding author), NCI, VIRAL EPIDEMIOL SECT, BETHESDA, MD 20892 USA.							ALLAIN JP, 1986, LANCET, V2, P1233; ANDERSON RM, 1988, NATURE, V332, P228, DOI 10.1038/332228a0; ANZALA A, 1990, INT C AIDS, V6, P143; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BARTHOLOMEW C, 1987, LANCET, V2, P1469; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLATTNER W, 1988, SCIENCE, V241, P515, DOI 10.1126/science.3399881; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; COOPER DA, 1985, LANCET, V1, P537; CORBITT G, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91561-N; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DESJARLAIS DC, 1988, J ACQ IMMUN DEF SYND, V1, P267; DREW WL, 1986, MT SINAI J MED, V53, P622; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GAIL MH, 1991, IN PRESS J NATL CANC; GALLO RC, 1990, J ACQ IMMUN DEF SYND, V3, P380; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GOEDERT JJ, 1982, LANCET, V1, P412; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GOEDERT JJ, 1984, LANCET, V2, P711; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOEDERT JJ, 1989, LANCET, V2, P1351; GOEDERT JJ, 1988, AIDS ETIOLOGY DIAGNO, P33; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LIFSON AR, 1990, J INFECT DIS, V161, P436, DOI 10.1093/infdis/161.3.436; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; MANN JM, 1990, J ACQ IMMUN DEF SYND, V3, P438; MOFENSON LM, 1991, TXB PEDIATRIC INFECT; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PALCA J, 1991, SCIENCE, V252, P372, DOI 10.1126/science.2017676; PATRASCU IV, 1990, LANCET, V335, P672, DOI 10.1016/0140-6736(90)90466-I; PIOT P, 1990, J ACQ IMMUN DEF SYND, V3, P403; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POKROVSKY VV, 1990, 6TH INT C AIDS SAN F; RHANUPHAK P, 1989, 5TH INT C AIDS MONTR; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; SHEPPARD HW, 1991, IN PRESS J AIDS; SIMONSEN JN, 1990, AIDS, V4, P139, DOI 10.1097/00002030-199002000-00007; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; 1991, MORBID MORTAL WKLY R, V40, P41; 1986, MORBID MORTAL WK SS6, V38; 1990, NATIONAL HIV SEROPRE; 1981, MORBID MORTAL WKLY R, V30, P250; 1990, AIDS, V4, P1173; 1987, MORBID MORTAL WKLY R, V36, P285	54	44	44	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2340	2348		10.1096/fasebj.5.10.2065886	http://dx.doi.org/10.1096/fasebj.5.10.2065886			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065886				2022-12-28	WOS:A1991FW08700004
J	YANG, XC; KARSCHIN, A; LABARCA, C; ELROYSTEIN, O; MOSS, B; DAVIDSON, N; LESTER, HA				YANG, XC; KARSCHIN, A; LABARCA, C; ELROYSTEIN, O; MOSS, B; DAVIDSON, N; LESTER, HA			EXPRESSION OF ION CHANNELS AND RECEPTORS IN XENOPUS OOCYTES USING VACCINIA VIRUS	FASEB JOURNAL			English	Article						XENOPUS OOCYTES; HETEROLOGOUS EXPRESSION; ION CHANNELS; NEUROTRANSMITTER RECEPTORS; VACCINIA VIRUS	POTASSIUM CHANNELS; CDNA; SYSTEM; RAT; DROSOPHILA; CLONING; BRAIN	The cytoplasmic injection of mRNA synthesized in vitro into Xenopus oocytes is widely used for heterologous expression of ion channels and neurotransmitter receptors. We report two new methods for expression of ion channels and receptors in oocytes using vaccinia virus (VV). 1) A recombinant VV carrying the Shaker H4 K+ channel cDNA driven by the VV P7.5 early promoter was injected into oocytes. 2) A recombinant VV containing the bacteriophage T7 RNA polymerase driven by the P7.5 promoter was coinjected along with plasmids containing a T7 promoter and cDNAs for channels and receptors. The functionally expressed proteins include a) voltage-gated ion channels: the Shaker H4 K+ channel and the rat brain IIA Na+ channel, b) a ligand-gated ion channel: the mouse muscle nicotinic acetylcholine receptor (AChR), and c) a G protein-coupled receptor: the rat brain 5HT1C receptor. After virus/cDNA injection into oocytes, these channels and receptors generally showed characteristics and expression levels similar to those observed in mRNA-injected oocytes. However, the AChR expressed at lower levels in virus/cDNA-injected oocytes than in mRNA-injected oocytes. Because our methods bypass mRNA synthesis, they are more rapid and convenient than the mRNA injection method. Potential applications to structure-function studies and expression cloning are discussed.	CALTECH,DIV BIOL 156-29,PASADENA,CA 91125; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	California Institute of Technology; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Elroy-Stein, Orna/0000-0002-3716-1540; Moss, Bernard/0000-0002-2154-8564	NIGMS NIH HHS [GM-10991] Funding Source: Medline; NINDS NIH HHS [NS-11756] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; Colman A., 1984, TRANSCRIPTION TRANSL, P49; CONTRERAS R, 1981, ANAL BIOCHEM, V113, P185, DOI 10.1016/0003-2697(81)90063-4; DAHL G, 1987, SCIENCE, V236, P1290, DOI 10.1126/science.3035715; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KARSCHIN A, 1991, FEBS LETT, V278, P229, DOI 10.1016/0014-5793(91)80123-K; KEGEL DR, 1985, J NEUROSCI METH, V12, P317, DOI 10.1016/0165-0270(85)90016-0; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; LEONARD RJ, 1989, P NATL ACAD SCI USA, V86, P7629, DOI 10.1073/pnas.86.19.7629; LESTER HA, 1988, SCIENCE, V241, P1057, DOI 10.1126/science.2457947; MASSUNG RF, 1990, J VIROL, V64, P2280, DOI 10.1128/JVI.64.5.2280-2289.1990; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; SOLC CK, 1987, SCIENCE, V236, P1094, DOI 10.1126/science.2437657; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0	22	13	13	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1991	5	8					2209	2216		10.1096/fasebj.5.8.1708738	http://dx.doi.org/10.1096/fasebj.5.8.1708738			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1708738				2022-12-28	WOS:A1991FK11100014
J	PASATIEMPO, AMG; KINOSHITA, M; TAYLOR, CE; ROSS, AC				PASATIEMPO, AMG; KINOSHITA, M; TAYLOR, CE; ROSS, AC			ANTIBODY-PRODUCTION IN VITAMIN A-DEPLETED RATS IS IMPAIRED AFTER IMMUNIZATION WITH BACTERIAL POLYSACCHARIDE OR PROTEIN ANTIGENS	FASEB JOURNAL			English	Article									MED COLL PENN,DEPT PHYSIOL & BIOCHEM,DIV NUTR,3300 HENRY AVE,PHILADELPHIA,PA 19129; MED COLL PENN,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19129	Drexel University; Drexel University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041479, R01DK044179, R29DK044179] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-00691] Funding Source: Medline; NIDCR NIH HHS [DE-07686] Funding Source: Medline; NIDDK NIH HHS [R01 DK041479, DK-44179] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMSBAUGH DF, 1972, J EXP MED, V136, P931, DOI 10.1084/jem.136.4.931; AOTSUKA S, 1979, J IMMUNOL METHODS, V28, P149, DOI 10.1016/0022-1759(79)90337-5; BAKER PJ, 1971, IMMUNOLOGY, V20, P481; BAKER PJ, 1969, APPL MICROBIOL, V17, P422, DOI 10.1128/AEM.17.3.422-426.1969; BAKER PJ, 1971, IMMUNOLOGY, V20, P469; BAKER PJ, 1981, REV INFECT DIS, V3, P322; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; BOSWELL HS, 1980, J IMMUNOL, V125, P1340; BOSWELL HS, 1980, J IMMUNOL, V124, P989; CARMAN JA, 1989, J IMMUNOL, V142, P388; Chandra R. K., 1981, Nutrient Research, V1, P181, DOI 10.1016/S0271-5317(81)80100-5; CHILLER JM, 1973, P NATL ACAD SCI USA, V70, P2129, DOI 10.1073/pnas.70.7.2129; CHUSED TM, 1976, J IMMUNOL, V116, P1579; DAVIES AJS, 1970, IMMUNOLOGY, V19, P945; DAVILA ME, 1985, J NUTR, V115, P1033, DOI 10.1093/jn/115.8.1033; ELDRIDGE JH, 1985, J IMMUNOL, V134, P2236; GOTTLIEB CF, 1974, J IMMUNOL, V113, P51; GREEN HN, 1928, BRIT MED J, V2, P691; HOWARD JG, 1971, CELL IMMUNOL, V2, P614, DOI 10.1016/0008-8749(71)90009-8; JERNE NK, 1974, TRANSPLANT REV-DENMA, V18, P130; KIMURA S, 1985, J IMMUNOL, V134, P2839; KRISHNAN S, 1974, IMMUNOLOGY, V27, P383; LETVIN NL, 1981, P NATL ACAD SCI-BIOL, V78, P5113, DOI 10.1073/pnas.78.8.5113; MILTON RC, 1987, AM J CLIN NUTR, V46, P827, DOI 10.1093/ajcn/46.5.827; MOND JJ, 1982, IMMUNOL REV, V64, P99, DOI 10.1111/j.1600-065X.1982.tb00420.x; MOND JJ, 1983, J IMMUNOL, V131, P633; MOND JJ, 1987, IMMUNOL REV, V99, P105, DOI 10.1111/j.1600-065X.1987.tb01174.x; MOND JJ, 1980, J IMMUNOL, V125, P1066; MOSIER DE, 1977, J IMMUNOL, V119, P1874; MOSIER DE, 1975, J EXP MED, V141, P216, DOI 10.1084/jem.141.1.216; NAUSS KM, 1985, J NUTR, V115, P909, DOI 10.1093/jn/115.7.909; NAUSS KM, 1985, J NUTR, V115, P1300, DOI 10.1093/jn/115.10.1300; NAUSS KM, 1979, J NUTR, V109, P1815, DOI 10.1093/jn/109.10.1815; Nauss KM, 1986, VITAMIN A DEFICIENCY, P207; NORDIN AA, 1982, J IMMUNOL, V129, P557; PASATIEMPO A M G, 1989, FASEB Journal, V3, pA663; PASATIEMPO AMG, 1989, AM J CLIN NUTR, V49, P501, DOI 10.1093/ajcn/49.3.501; SKIDMORE BJ, 1975, J IMMUNOL, V114, P770; SKIDMORE BJ, 1976, J EXP MED, V143, P143, DOI 10.1084/jem.143.1.143; SMITH SM, 1987, J NUTR, V117, P857, DOI 10.1093/jn/117.5.857; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; SOMMER A, 1989, J NUTR, V119, P96, DOI 10.1093/jn/119.1.96; STEINMETZ JE, 1981, BEHAV RES METH INSTR, V13, P702, DOI 10.3758/BF03202100; TARWOTJO I, 1987, AM J CLIN NUTR, V45, P1466, DOI 10.1093/ajcn/45.6.1466; TAYLOR CE, 1983, J EXP MED, V158, P703, DOI 10.1084/jem.158.3.703; WEST KP, 1989, ANNU REV NUTR, V9, P63, DOI 10.1146/annurev.nu.09.070189.000431	47	76	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1990	4	8					2518	2527		10.1096/fasebj.4.8.2110538	http://dx.doi.org/10.1096/fasebj.4.8.2110538			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DE393	2110538				2022-12-28	WOS:A1990DE39300013
J	LEE, YC				LEE, YC			BIOCHEMISTRY OF CARBOHYDRATE-PROTEIN INTERACTION	FASEB JOURNAL			English	Review						ANIMAL LECTINS; RESONANCE ENERGY TRANSFER; OLIGOSACCHARIDE CONFORMATION; CARBOHYDRATE-PROTEIN INTERACTION; HEPATOCYTES	ACETYLGALACTOSAMINE-SPECIFIC LECTIN; ISOLATED CHICKEN HEPATOCYTES; ASIALOGLYCOPROTEIN RECEPTOR; TRIANTENNARY GLYCOPEPTIDE; N-ACETYLGALACTOSAMINE; CLUSTER GLYCOSIDES; BINDING-PROTEIN; HEPATIC LECTIN; RABBIT HEPATOCYTES; RAT HEPATOCYTES	Recognition of glycoconjugates is an important event in biological systems, and is frequently in the form of carbohydrate-protein interactions. To thoroughly understand these interactions, well-defined carbohydrate ligands must be available. Naturally derived glycoconjugates can be highly purified, and their structures (including conformational structures) can be elucidated to provide such ligands. This requires highly effective methods of separation, such as various forms of high-performance liquid chromatography. Alternatively, structurally well-defined glycoconjugates can be synthesized for this purpose. These include conjugates of carbohydrate derivatives to proteins, lipids, and nonbiological carriers and polymers. The efficacy of these conjugates is amply demonstrated in the studies of carbohydrate-binding proteins from animals. Hepatic carbohydrate receptors, requiring calcium for binding, recognize only the terminal sugar residues. Although different sugar specificities are manifested by different species, there is some commonality in the requirement of the substituents of the sugar rings. Clustering of the target sugars in proper geometric arrangement greatly enhances the binding by these proteins. Some other animal carbohydrate-binding proteins, however, may require penultimate sugars for optimal binding.			LEE, YC (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.							BOCK K, 1982, EUR J BIOCHEM, V129, P171, DOI 10.1111/j.1432-1033.1982.tb07036.x; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FISCHER HD, 1980, J BIOL CHEM, V255, P9608; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ICHIKAWA Y, 1990, J CARBOHYD CHEM, V9, P707, DOI 10.1080/07328309008543865; ICHIKAWA Y, 1990, GLYCOCONJUGATE J, V7, P335, DOI 10.1007/BF01073377; KAWAGUCHIH K, 1989, TRENDS GLYCOSCI GLYC, V1, P14; KOBATA A, 1989, METHOD ENZYMOL, V179, P46; KRANTZ MJ, 1976, BIOCHEMISTRY-US, V15, P3963, DOI 10.1021/bi00663a009; KUHLENSCHMIDT TB, 1984, BIOCHEMISTRY-US, V23, P6437, DOI 10.1021/bi00321a025; KUHLENSCHMIDT TB, 1984, BIOCHEMISTRY-US, V23, P3569, DOI 10.1021/bi00311a001; LEE RT, 1987, BIOCHEMISTRY-US, V26, P6320, DOI 10.1021/bi00394a005; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE RT, 1986, BIOCHEMISTRY-US, V25, P6835, DOI 10.1021/bi00370a016; LEE RT, 1980, BIOCHEMISTRY-US, V19, P156, DOI 10.1021/bi00542a024; LEE RT, 1984, BIOCHEMISTRY-US, V23, P4255, DOI 10.1021/bi00313a037; LEE RT, 1989, BIOCHEMISTRY-US, V28, P8351, DOI 10.1021/bi00447a013; LEE RT, 1991, LIVER DISEASES TARGE, P65; LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008; LEE YC, 1991, PURE APPL CHEM, V63, P499, DOI 10.1351/pac199163040499; LEE YC, 1983, J BIOL CHEM, V258, P199; LEE YC, 1978, CARBOHYD RES, V67, P509; LEE YC, 1984, BIOCH BIOPHYSICAL ST, P349; LEE YC, 1989, CIBA F S, V145, P80; LEE YC, 1982, GLYCOCONJUGATES, V4, P57; LOEB JA, 1987, J BIOL CHEM, V262, P3022; LUNNEY J, 1976, P NATL ACAD SCI USA, V73, P341, DOI 10.1073/pnas.73.2.341; MORELL AG, 1968, J BIOL CHEM, V243, P155; PISKAREV VE, 1990, BIOCHEM J, V270, P755, DOI 10.1042/bj2700755; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RICE KG, 1991, BIOCHEMISTRY-US, V30, P6646, DOI 10.1021/bi00241a003; RICE KG, 1990, ANAL BIOCHEM, V184, P249, DOI 10.1016/0003-2697(90)90676-Z; RICE KG, 1990, J BIOL CHEM, V265, P18423; SHEPHERD VL, 1981, P NATL ACAD SCI-BIOL, V78, P1019, DOI 10.1073/pnas.78.2.1019; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; Stowell C P, 1980, Adv Carbohydr Chem Biochem, V37, P225; STOWELL CP, 1980, BIOCHEMISTRY-US, V19, P4904, DOI 10.1021/bi00562a031; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TOWNSEND RR, 1986, BIOCHEMISTRY-US, V25, P5716, DOI 10.1021/bi00367a055; WONG TC, 1987, CARBOHYD RES, V170, P27, DOI 10.1016/0008-6215(87)85003-6; WU PG, 1991, P NATL ACAD SCI USA, V88, P9355, DOI 10.1073/pnas.88.20.9355	45	211	226	2	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1992	6	13					3193	3200		10.1096/fasebj.6.13.1397841	http://dx.doi.org/10.1096/fasebj.6.13.1397841			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397841				2022-12-28	WOS:A1992JU51200012
J	HEYES, MP; SAITO, K; JACOBOWITZ, D; MARKEY, SP; TAKIKAWA, O; VICKERS, JH				HEYES, MP; SAITO, K; JACOBOWITZ, D; MARKEY, SP; TAKIKAWA, O; VICKERS, JH			POLIOVIRUS INDUCES INDOLEAMINE-2,3-DIOXYGENASE AND QUINOLINIC ACID SYNTHESIS IN MACAQUE BRAIN	FASEB JOURNAL			English	Article						ENTEROVIRUS; INFLAMMATION; NEURODEGENERATION; EXCITOTOXIN; KYNURENINE PATHWAY; INDOLEAMINE 2,3-DIOXYGENASE; CYTOKINES	CENTRAL NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; INTERFERON-GAMMA; KYNURENIC ACID; INDOLEAMINE 2,3-DIOXYGENASE; HUNTINGTONS-DISEASE; RAT-BRAIN; ALZHEIMERS-DISEASE; RHESUS MACAQUES; REGIONAL BRAIN	Accumulation of the neurotoxin quinolinic acid within the brain occurs in a broad spectrum of patients with inflammatory neurologic disease and may be of neuropathologic significance. The production of quinolinic acid was postulated to reflect local induction of indoleamine 2,3-dioxygenase by cytokines in reactive cells and inflammatory cell infiltrates within the central nervous system. To test this hypothesis, macaques received an intraspinal injection of poliovirus as a model of localized inflammatory neurologic disease. Seventeen days later, spinal cord indoleamine 2,3-dioxygenase activity and quinolinic acid concentrations in spinal cord and cerebrospinal fluid were both increased in proportion to the degree of inflammatory responses and neurologic damage in the spinal cord, as well as the severity of motor paralysis. The absolute concentrations of quinolinic acid achieved in spinal cord and cerebrospinal fluid exceeded levels reported to kill spinal cord neurons in vitro. Smaller increases in indoleamine 2,3-dioxygenase activity and quinolinic acid concentrations also occurred in parietal cortex, a poliovirus target area. In frontal cortex, which is not a target for poliovirus, indoleamine 2,3-dioxygenase was not affected. A monoclonal antibody to human indoleamine 2,3-dioxygenase was, used to visualize indoleamine 2,3-dioxygenase predominantly in grey matter of poliovirus-infected spinal cord, in conjunction with local inflammatory lesions. Macrophage/monocytes in vitro synthesized [C-13(6)]quinolinic acid from [C-13(6)]L-tryptophan, particularly when stimulated by interferon-gamma. Spinal cord slices from poliovirus-inoculated macaques in vitro also converted [C-13(6)]L-tryptophan to [C-13(6)]quinolinic acid. We conclude that local synthesis of quinolinic acid from L-tryptophan within the central nervous system follows the induction of indoleamine-2,3-dioxygenase, particularly within macrophage/microglia. In view of this link between immune stimulation and the synthesis of neurotoxic amounts of quinolinic acid, we propose that attenuation of local inflammation, strategies to reduce the synthesis of neuroactive kynurenine pathway metabolites, or drugs that interfere with the neurotoxicity of quinolinic acid offer new approaches to therapy in inflammatory neurologic disease.	NIMH, CLIN SCI LAB, HISTOPHARMACOL SECT, BETHESDA, MD 20892 USA; OSAKA BIOSCI INST, DEPT CELL BIOL, OSAKA 565, JAPAN; US FDA, CTR BIOL EVALUAT & RES, PATHOBIOL & PRIMATOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); US Food & Drug Administration (FDA)	HEYES, MP (corresponding author), NIMH, CLIN SCI LAB, ANALYT BIOCHEM SECT, BLDG 10, ROOM 3D40, BETHESDA, MD 20892 USA.							ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; ARYA SC, 1977, J BIOL STAND, V5, P275, DOI 10.1016/S0092-1157(77)80012-7; BEAL MF, 1990, J NEUROCHEM, V55, P1327, DOI 10.1111/j.1471-4159.1990.tb03143.x; BIANCHI M, 1988, BIOCHEM BIOPH RES CO, V152, P237, DOI 10.1016/S0006-291X(88)80705-8; BOEGMAN RJ, 1990, ANN NY ACAD SCI, V585, P261, DOI 10.1111/j.1749-6632.1990.tb28059.x; BROUWERS P, 1991, 7TH INT C AIDS FLOR, P190; CARLIN JM, 1989, EXPERIENTIA, V45, P535, DOI 10.1007/BF01990503; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; FOSTER AC, 1984, NEUROSCI LETT, V48, P273, DOI 10.1016/0304-3940(84)90050-8; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; GAGNON J, 1989, SUPERANOVA ABACUS CO; GLIGHT AR, 1991, J NEUROL SCI, V103, P156; GOGATE N, 1991, J NEUROIMMUNOL, V31, P19, DOI 10.1016/0165-5728(91)90082-I; GRIFFIN DE, 1991, NEUROLOGY, V41, P69, DOI 10.1212/WNL.41.1.69; HALPERIN JJ, 1992, NEUROLOGY, V42, P43, DOI 10.1212/WNL.42.1.43; HEYES MP, 1990, J CHROMATOGR-BIOMED, V530, P108, DOI 10.1016/S0378-4347(00)82308-7; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1992, BRAIN RES, V570, P237, DOI 10.1016/0006-8993(92)90587-Y; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1991, NEUROSCI LETT, V122, P265, DOI 10.1016/0304-3940(91)90874-S; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1988, BIOMED ENVIRON MASS, V15, P291, DOI 10.1002/bms.1200150509; HEYES MP, 1988, J NEUROCHEM, V51, P1446, DOI 10.1111/j.1471-4159.1988.tb01183.x; HEYES MP, 1990, BRAIN RES, V531, P148, DOI 10.1016/0006-8993(90)90768-7; HEYES MP, 1988, NEUROCHEM INT, V13, P405, DOI 10.1016/0197-0186(88)90015-0; HEYES MP, 1990, J CEREBR BLOOD F MET, V10, P660, DOI 10.1038/jcbfm.1990.119; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; HEYES MP, 1990, ANN NEUROL, V27, P666, DOI 10.1002/ana.410270614; HEYES MP, 1991, FIDIA RES F S SERIES, P353; HEYES MP, IN PRESS J NEUROIMMU; HEYES MP, 1992, IN PRESS BRAIN; HOLMES EW, 1988, ANAL BIOCHEM, V172, P518, DOI 10.1016/0003-2697(88)90478-2; LJUNGDAHL A, 1989, J NEUROSCI RES, V24, P451, DOI 10.1002/jnr.490240316; MARTIN A, 1992, IN PRESS J NEUROPSYC; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORONI F, 1986, NEUROBIOL AGING, V7, P249, DOI 10.1016/0197-4580(86)90003-5; MOURDIAN MM, 1989, NEUROSCI LETT, V105, P233, DOI 10.1016/0304-3940(89)90043-8; OGRA PL, 1973, INFECT IMMUN, V8, P931, DOI 10.1128/IAI.8.6.931-937.1973; PERKINS MN, 1985, EXP NEUROL, V88, P570, DOI 10.1016/0014-4886(85)90072-X; PERKINS MN, 1983, BRAIN RES, V259, P172, DOI 10.1016/0006-8993(83)91084-3; PFEFFERKORN ER, 1986, MOL BIOCHEM PARASIT, V20, P215, DOI 10.1016/0166-6851(86)90101-5; PRETUS HA, 1989, J TRAUMA, V29, P1152, DOI 10.1097/00005373-198908000-00014; SAITO K, 1991, BRAIN RES, V546, P151, DOI 10.1016/0006-8993(91)91171-V; SAITO K, 1991, BRAIN RES, V540, P353, DOI 10.1016/0006-8993(91)90536-5; SAITO K, 1992, IN PRESS NEUROSCIENC; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SCHWARCZ R, 1988, ANN NEUROL, V24, P580, DOI 10.1002/ana.410240417; SPECIALE C, 1989, NEUROSCI LETT, V104, P345, DOI 10.1016/0304-3940(89)90601-0; STEINMAN L, 1990, PATHOPHYSIOLOGY BLOO, P453; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; TURSKI WA, 1989, J NEUROCHEM, V52, P1629, DOI 10.1111/j.1471-4159.1989.tb09218.x; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; WOOD MJ, 1988, NEUROLOGICAL INFECTI; YAMAZAKI F, 1985, BIOCHEM J, V230, P635, DOI 10.1042/bj2300635	55	99	102	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1992	6	11					2977	2989		10.1096/fasebj.6.11.1322853	http://dx.doi.org/10.1096/fasebj.6.11.1322853			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1322853				2022-12-28	WOS:A1992JJ66500012
J	PORAT, R; POUTSIAKA, DD; MILLER, LC; GRANOWITZ, EV; DINARELLO, CA				PORAT, R; POUTSIAKA, DD; MILLER, LC; GRANOWITZ, EV; DINARELLO, CA			INTERLEUKIN-1 (IL-1) RECEPTOR BLOCKADE REDUCES ENDOTOXIN AND BORRELIA BURGDORFERI-STIMULATED IL-8 SYNTHESIS IN HUMAN MONONUCLEAR-CELLS	FASEB JOURNAL			English	Article						IL-1; LPS; IL-8; IRAP; PBMC	TUMOR-NECROSIS-FACTOR; MICROVASCULAR INJURY; ACUTE-INFLAMMATION; FACTOR TNF; EXPRESSION; ANTAGONIST; PURIFICATION; NEUTROPHILS; CYTOKINES; INDUCTION	Interleukin-1 (IL-1) is a potent stimulator of IL-8 production by fibroblasts and monocytes. In the present study, we asked how much of endotoxin (LPS)-induced IL-8 production by human peripheral blood mononuclear cells was due to IL-1 induced by LPS. Cells were stimulated with either IL-1-beta, LPS, or Borrelia burgdorferi, and total IL-8 was determined by a specific radioimmunoassay. The addition of saturating concentrations of IL-1 receptor antagonist protein (IRAP) reduced the IL-1-beta-, LPS-, and B. burgdorferi-induced IL-8 synthesis by 85, 50, and 40%, respectively. Increasing the concentration of LPS did not affect the reduction in IL-8 synthesis observed in the presence of IRAP. Significant inhibition of the IL-1-beta-induced IL-8 synthesis was observed when IRAP was added 60 or 90 min after IL-1-beta; similarly, IL-8 synthesis after LPS was also reduced by delayed addition of IRAP. These data suggest that the ameliorative effects of IL-1 receptor blockade in models of inflammation and infection may be due, in part, to suppression of IL-1-induced IL-8.	NEW ENGLAND MED CTR HOSP,DEPT MED,DIV GEOG MED & INFECT DIS,BOX 68,750 WASHINGTON ST,BOSTON,MA 02111	Tufts Medical Center					NIAID NIH HHS [AI 15614] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015614, R56AI015614, R37AI015614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; CYBULSKY M I, 1987, Annales de l'Institut Pasteur Immunology, V138, P505; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ENDRES S, 1988, CLIN IMMUNOL IMMUNOP, V49, P424, DOI 10.1016/0090-1229(88)90130-4; GEORGILIS K, 1991, ARTHRITIS RHEUM-US, V34, P770, DOI 10.1002/art.1780340620; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; GRANOWITZ EV, IN PRESS BLOOD; IKEJIMA T, 1990, J INFECT DIS, V162, P215, DOI 10.1093/infdis/162.1.215; KAROLLE BL, 1991, M AM HEART ASS ANAHE; KUSNER DJ, 1991, KIDNEY INT, V39, P1240, DOI 10.1038/ki.1991.157; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; MOVAT HZ, 1987, FASEB J, V46, P97; MOVAT HZ, 1987, PATHOL IMMUNOPATH R, V6, P153, DOI 10.1159/000157043; MOVAT HZ, 1987, AM J PATHOL, V129, P463; PEICHL P, 1991, SCAND J IMMUNOL, V34, P333, DOI 10.1111/j.1365-3083.1991.tb01554.x; PETERSEN F, 1991, LYMPHOKINE CYTOK RES, V10, P35; POUTSIAKA DD, 1991, BLOOD, V78, P1275; REDL H, 1991, J INFECT DIS, V164, P383, DOI 10.1093/infdis/164.2.383; SCHINDLER R, 1990, BLOOD, V75, P40; SCHWAB JH, 1991, INFECT IMMUN, V59, P4436, DOI 10.1128/IAI.59.12.4436-4442.1991; SEITZ M, 1991, J CLIN INVEST, V87, P463, DOI 10.1172/JCI115018; TEKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894; Van Damme J, 1990, Cytokine, V2, P106, DOI 10.1016/1043-4666(90)90004-D; VANDAMME J, 1988, J EXP MED, V167, P1364, DOI 10.1084/jem.167.4.1364; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WOOLEY P H, 1990, Arthritis and Rheumatism, V33, pS20; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; ZOJA C, 1991, AM J PATHOL, V138, P991	35	93	96	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2482	2486		10.1096/fasebj.6.7.1532945	http://dx.doi.org/10.1096/fasebj.6.7.1532945			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1532945				2022-12-28	WOS:A1992HP03000016
J	HARGRAVE, PA; MCDOWELL, JH				HARGRAVE, PA; MCDOWELL, JH			RHODOPSIN AND PHOTOTRANSDUCTION - A MODEL SYSTEM FOR G-PROTEIN-LINKED RECEPTORS	FASEB JOURNAL			English	Review						RHODOPSIN; ROD CELL; RETINA; DISK MEMBRANE; RECEPTOR; G-PROTEIN-COUPLED RECEPTOR; G-PROTEIN; RHODOPSIN KINASE; ARRESTIN	BETA-ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT PHOSPHORYLATION; ROD OUTER SEGMENTS; SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; PHOTORECEPTOR-MEMBRANES; FUNCTIONAL EXPRESSION; CYSTEINE RESIDUE-110; VISUAL PIGMENTS; 48-KDA PROTEIN	Rhodopsin is the photoreceptor protein in rod cells of the vertebrate retina and the first member of the class of G protein-coupled receptors for which the amino acid sequence was determined. Rhodopsin is available in greater quantities than any other receptor of its class and therefore has been studied biochemically and biophysically by methods difficult or impossible to apply to its fellow receptors. Such studies support a model in which rhodopsin consists of seven transmembrane helices that form a binding pocket for its ligand, 11-cis retinal. Insights into the structure and function of rhodopsin serve as a model for understanding the structure and function of other members of the receptor class. Rhodopsin undergoes a change in conformation upon photoexcitation and activates a G protein, transducin, and is phosphorylated by a receptor-specific kinase, rhodopsin kinase. The phosphorylated photoactivated rhodopsin is bound by arrestin, thereby terminating activity of the receptor in the signal transduction process. These auxiliary proteins that function with rhodopsin in rod cells serve as models for understanding how other members of the receptor family may function in conjunction with other G proteins, kinases, and arrestin-like proteins.	UNIV FLORIDA, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida	HARGRAVE, PA (corresponding author), UNIV FLORIDA, DEPT OPHTHALMOL, GAINESVILLE, FL 32610 USA.				NATIONAL EYE INSTITUTE [R01EY006226, R37EY006226] Funding Source: NIH RePORTER; NEI NIH HHS [EY06226, EY06225] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; CORLESS JM, 1982, P NATL ACAD SCI-BIOL, V79, P1116, DOI 10.1073/pnas.79.4.1116; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; FRANK RN, 1973, J BIOL CHEM, V248, P596; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HARGRAVE PA, 1991, OPIN STRUC BIOL, V1, P575; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1974, NATURE, V250, P588, DOI 10.1038/250588a0; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P937, DOI 10.1021/bi00456a013; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1011; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P4201; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHOFIELD PR, 1987, NUCLEIC ACIDS RES, V15, P3636, DOI 10.1093/nar/15.8.3636; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SHINOHARA T, 1989, PROGR RETINAL RES, V8, P51; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	61	263	265	2	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1992	6	6					2323	2331		10.1096/fasebj.6.6.1544542	http://dx.doi.org/10.1096/fasebj.6.6.1544542			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544542				2022-12-28	WOS:A1992HJ25200009
J	REITER, RJ; RICHARDSON, BA				REITER, RJ; RICHARDSON, BA			MAGNETIC-FIELD EFFECTS ON PINEAL INDOLEAMINE METABOLISM AND POSSIBLE BIOLOGICAL CONSEQUENCES	FASEB JOURNAL			English	Review						PINEAL GLAND; MELATONIN; STATIC MAGNETIC FIELDS; SEROTONIN; METABOLISM	N-ACETYLTRANSFERASE ACTIVITY; ELECTROMAGNETIC-FIELDS; MELATONIN CONTENT; GLAND; RAT; CELLS; EXPOSURE; CANCER	In recent years, there has been a great deal of publicity concerning the possible health effects of electric and/or magnetic field exposure. One of the most frequently reported observations after the exposure of animals to either electric or magnetic fields relates to alterations in the metabolism of serotonin (5HT) to melatonin within the pineal gland. This review summarizes these results particularly in animals exposed to intermittently inverted, non-time varying magnetic fields, i.e., pulsed static magnetic fields. When exposure occurs at night, the conversion of 5HT to melatonin is typically depressed, not unlike that after light exposure at night. The mechanisms by which pulsed magnetic fields alter the ability of the pineal to convert 5HT to the chief pineal hormone melatonin remains unknown but may involve effects on any or all of the following: the retinas, the suprachiasmatic nuclei, the peripheral sympathetic nervous system, and the pinealocytes. Results to date suggest that induced electrical currents (eddy currents) produced by the pulsed magnetic fields are particularly detrimental to pineal indoleamine metabolism and may be an important causative factor in the metabolic changes measured. The physiological consequences of perturbations in the melatonin rhythm induced by magnetic field exposure remain unknown.	UNIV MICHIGAN, DEPT BIOL, FLINT, MI 48502 USA	University of Michigan System; University of Michigan; University of Michigan Flint	REITER, RJ (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.							ADEY WR, 1981, PHYSIOL REV, V61, P435, DOI 10.1152/physrev.1981.61.2.435; ARENDT J, 1987, ERGONOMICS, V30, P1379, DOI 10.1080/00140138708966031; ARENDT J, 1989, BRIT J PSYCHIAT, V155, P585; ARMSTRONG SM, 1989, EXPERIENTIA, V45, P932, DOI 10.1007/BF01953050; BARLOW HB, 1947, AM J PHYSIOL, V148, P372, DOI 10.1152/ajplegacy.1947.148.2.372; BYUS CV, 1987, CARCINOGENESIS, V8, P1385, DOI 10.1093/carcin/8.10.1385; GOODMAN EM, 1986, FEBS LETT, V199, P275, DOI 10.1016/0014-5793(86)80494-X; GOODMAN R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P216, DOI 10.1016/0167-4781(89)90105-X; GOULD JL, 1984, ANNU REV PHYSIOL, V46, P585, DOI 10.1146/annurev.ph.46.030184.003101; JAFFE R A, 1980, Bioelectromagnetics, V1, P131, DOI 10.1002/bem.2250010204; LERCHL A, 1990, BIOCHEM BIOPH RES CO, V169, P102, DOI 10.1016/0006-291X(90)91439-Y; LERCHL A, 1991, J PINEAL RES, V10, P109, DOI 10.1111/j.1600-079X.1991.tb00826.x; LIBOFF AR, 1984, SCIENCE, V223, P818, DOI 10.1126/science.6695183; LOVSUND P, 1980, MED BIOL ENG COMPUT, V18, P326, DOI 10.1007/BF02443387; MAESTRONI GJM, 1988, ANN NY ACAD SCI, V521, P140; OLCESE J, 1985, BRAIN RES, V333, P382, DOI 10.1016/0006-8993(85)91598-7; OSTER G, 1970, SCI AM, V222, P83, DOI 10.1038/scientificamerican0270-82; PHILLIPS RG, 1987, AM J EPIDEMIOL, V125, P556; QUAY WB, 1974, PINEAL CHEM, P143; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1981, AM J ANAT, V162, P287, DOI 10.1002/aja.1001620402; REITER RJ, 1985, ANN NY ACAD SCI, V453, P215, DOI 10.1111/j.1749-6632.1985.tb11812.x; REITER RJ, 1986, J OBSTET GYNAECOL, V6, pS77, DOI 10.3109/01443618609081730; REITER RJ, 1986, J NEURAL TRANSM, P35; REUSS S, 1983, NEUROSCI LETT, V40, P23, DOI 10.1016/0304-3940(83)90086-1; RUDOLPH K, 1988, BRAIN RES, V446, P159, DOI 10.1016/0006-8993(88)91307-8; SEMM P, 1980, NATURE, V288, P607, DOI 10.1038/288607a0; STANLEY M, 1988, PSYCHOPHARMACOL BULL, V24, P484; STEHLE J, 1988, PHYSIOL BEHAV, V44, P91, DOI 10.1016/0031-9384(88)90350-2; SUGDEN D, 1989, EXPERIENTIA, V45, P922, DOI 10.1007/BF01953049; TAMARKIN L, 1982, SCIENCE, V216, P1003, DOI 10.1126/science.7079745; VALENTINE M, 1962, AM J MED ELECTRON, V1, P112; VILLA M, 1991, LIFE SCI, V49, P85, DOI 10.1016/0024-3205(91)90021-3; WELKER HA, 1983, EXP BRAIN RES, V50, P426; WILSON BW, 1989, LIFE SCI, V45, P1319, DOI 10.1016/0024-3205(89)90018-0; WILSON BW, 1988, PINEAL GLAND CANCER, P245	36	61	61	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1992	6	6					2283	2287		10.1096/fasebj.6.6.1544540	http://dx.doi.org/10.1096/fasebj.6.6.1544540			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544540	Green Submitted			2022-12-28	WOS:A1992HJ25200004
J	KOOP, DR				KOOP, DR			OXIDATIVE AND REDUCTIVE METABOLISM BY CYTOCHROME-P450-2E1	FASEB JOURNAL			English	Article						P450-2E1; ETHANOL-INDUCIBLE; LIPID PEROXIDATION; HEPATOTOXICITY	ETHANOL-INDUCIBLE CYTOCHROME-P-450; LIVER MICROSOMAL CYTOCHROME-P-450; RAT-LIVER; CARBON-TETRACHLORIDE; RABBIT LIVER; N-NITROSODIMETHYLAMINE; LIPID-PEROXIDATION; HEPATIC MICROSOMES; OXIDASE ACTIVITY; ALCOHOL	We are constantly exposed to many potentially toxic chemicals. Most require metabolic activation to species responsible for cell injury. Although cytochrome P450 2E1 is only one of many different forms of cytochrome P450 that catalyze these reactions, it has an important role in human health as a result of being readily induced by acute and chronic alcohol ingestion. The enzyme efficiently catalyzes the low K(m) metabolism of compounds commonly used as solvents in industry and at home as well as components found in cigarette smoke, many of which are established carcinogens and hepatotoxins. As a result, there is the potential for increased risk to low level exposure to such chemicals while cytochrome P450 2E1 is induced. Many substrates have been identified for cytochrome P450 2E1. Of the 52 substrates for the enzyme identified in this review, the demethylation of N,N-dimethylnitrosamine and the hydroxylation of p-nitrophenol and chlorzoxazone are the most effective for monitoring the level of this enzyme. In addition to oxidative reactions, cytochrome P450 2E1 is also an efficient catalyst of reductive reactions. CCl4-induced hepatotoxicity is one of the best-documented cases for the participation of cytochrome P450 2E1 in a toxicologically important reductive reaction. The reduction of oxygen to superoxide and peroxide are also important reductive reactions of the enzyme and could be important in lipid peroxidation. However, the role of this reaction in vivo remains controversial.			KOOP, DR (corresponding author), OREGON HLTH SCI UNIV,DEPT PHARMACOL,PORTLAND,OR 97201, USA.				NIAAA NIH HHS [AA-08608] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008608, R37AA008608] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BRADY JF, 1990, ARCH TOXICOL, V64, P157, DOI 10.1007/BF01974403; BRADY JF, 1989, TOXICOL APPL PHARM, V100, P342, DOI 10.1016/0041-008X(89)90320-7; BRADY JF, 1991, TOXICOL APPL PHARM, V108, P366, DOI 10.1016/0041-008X(91)90125-X; BRADY JF, 1988, MOL PHARMACOL, V33, P148; CLEJAN LA, 1990, BIOCHIM BIOPHYS ACTA, V1034, P233, DOI 10.1016/0304-4165(90)90082-8; DICKER E, 1987, ALCOHOL CLIN EXP RES, V11, P309, DOI 10.1111/j.1530-0277.1987.tb01314.x; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; EKSTROM G, 1987, BIOCHEMISTRY-US, V26, P7348, DOI 10.1021/bi00397a023; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P689, DOI 10.1016/0006-2952(89)90217-7; FEIERMAN DE, 1985, ALCOHOL CLIN EXP RES, V9, P95, DOI 10.1111/j.1530-0277.1985.tb05525.x; FEIERMAN DE, 1989, CHEM RES TOXICOL, V2, P359, DOI 10.1021/tx00012a002; FIALA ES, 1981, INHIBITION TUMOR IND, P23; GANNETT PM, 1990, BIOORG CHEM, V18, P185, DOI 10.1016/0045-2068(90)90041-3; GARRO AJ, 1990, ANNU REV PHARMACOL, V30, P219, DOI 10.1146/annurev.pa.30.040190.001251; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GRUENKE LD, 1988, J PHARMACOL EXP THER, V246, P454; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; HOFFMAN J, 1989, BRIT J ANAESTH, V63, P103, DOI 10.1093/bja/63.1.103; ISHIZAKI H, 1990, XENOBIOTICA, V20, P255, DOI 10.3109/00498259009046845; JOHANSSON I, 1985, FEBS LETT, V183, P265, DOI 10.1016/0014-5793(85)80790-0; JOHANSSON I, 1988, CANCER RES, V48, P5387; JOHANSSON I, 1988, BIOCHEMISTRY-US, V27, P1925, DOI 10.1021/bi00406a019; KAUL KL, 1987, J PHARM EXPT THERAPE, V43, P384; KEEFER LK, 1990, CHEM RES TOXICOL, V3, P540, DOI 10.1021/tx00018a008; KIM SG, 1988, J PHARMACOL EXP THER, V246, P1175; KIM SG, 1990, CANCER RES, V50, P5333; KOOP DR, 1991, J PHARMACOL EXP THER, V258, P1072; KOOP DR, 1990, BIOESSAYS, V12, P429, DOI 10.1002/bies.950120906; KOOP DR, 1986, MOL PHARMACOL, V29, P399; KOOP DR, 1986, ALCOHOL CLIN EXP RES, V10, pS44, DOI 10.1111/j.1530-0277.1986.tb05179.x; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KOOP DR, 1989, TOXICOL APPL PHARM, V98, P278, DOI 10.1016/0041-008X(89)90233-0; KOOP DR, 1990, CHEM RES TOXICOL, V3, P377, DOI 10.1021/tx00016a017; KRIETER PA, 1985, BIOCHEM PHARMACOL, V34, P955, DOI 10.1016/0006-2952(85)90596-9; KRIKUN G, 1986, FEBS LETT, V208, P292, DOI 10.1016/0014-5793(86)81035-3; LATRIANO L, 1986, P NATL ACAD SCI USA, V83, P8356, DOI 10.1073/pnas.83.21.8356; LIEBER CS, 1990, PHARMACOL THERAPEUT, V46, P1, DOI 10.1016/0163-7258(90)90032-W; LIEBER CS, 1984, HEPATOLOGY, V4, P1243, DOI 10.1002/hep.1840040625; LINDROS KO, 1990, HEPATOLOGY, V12, P1092, DOI 10.1002/hep.1840120503; LUCAS D, 1990, ALCOHOL CLIN EXP RES, V14, P590, DOI 10.1111/j.1530-0277.1990.tb01207.x; MCCOY GD, 1988, CANCER RES, V48, P3987; MIKALSEN A, 1991, CARCINOGENESIS, V12, P825, DOI 10.1093/carcin/12.5.825; OLSON MJ, 1991, DRUG METAB DISPOS, V19, P298; PATTEN CJ, 1986, ARCH BIOCHEM BIOPHYS, V251, P629, DOI 10.1016/0003-9861(86)90373-5; PERSSON JO, 1990, XENOBIOTICA, V20, P887, DOI 10.3109/00498259009046904; PETER R, 1990, CHEM RES TOXICOL, V3, P566, DOI 10.1021/tx00018a012; RANDO RR, 1984, PHARMACOL REV, V36, P111; RAUCY J, 1987, BIOCHEM PHARMACOL, V36, P2921, DOI 10.1016/0006-2952(87)90203-6; REINKE LA, 1988, XENOBIOTICA, V18, P1311, DOI 10.3109/00498258809042255; SOHN OS, 1991, CARCINOGENESIS, V12, P127, DOI 10.1093/carcin/12.1.127; TERELIUS Y, 1986, EUR J BIOCHEM, V161, P303, DOI 10.1111/j.1432-1033.1986.tb10447.x; UMENO M, 1988, BIOCHEMISTRY-US, V27, P9006, DOI 10.1021/bi00425a019; VAZ ADN, 1990, P NATL ACAD SCI USA, V87, P5499, DOI 10.1073/pnas.87.14.5499; WINTERS DK, 1988, BIOCHEM BIOPH RES CO, V153, P612, DOI 10.1016/S0006-291X(88)81139-2; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; YOO JSH, 1987, CANCER RES, V47, P3378; ZIMMERMAN HJ, 1986, ALCOHOL CLIN EXP RES, V10, P3, DOI 10.1111/j.1530-0277.1986.tb05605.x	58	548	579	1	57	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					724	730		10.1096/fasebj.6.2.1537462	http://dx.doi.org/10.1096/fasebj.6.2.1537462			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537462				2022-12-28	WOS:A1992GZ44000013
J	NOELLE, RJ; SNOW, EC				NOELLE, RJ; SNOW, EC			T-HELPER CELL-DEPENDENT B-CELL ACTIVATION	FASEB JOURNAL			English	Review						HELPER T-CELLS; COGNATE INTERACTION; B-CELLS	PROTEIN-TYROSINE KINASE; HUMAN IGE SYNTHESIS; LYMPHOCYTES-B; SIGNAL TRANSDUCTION; MEMBRANE IMMUNOGLOBULIN; COGNATE INTERACTIONS; MYC PROTOONCOGENE; ANTIGEN RECEPTOR; BINDING LIGANDS; C-FOS	Small, resting B lymphocytes are driven into the cell cycle as a consequence of receiving multiple signals from elements found within their local environment. The first of these signals results from the binding of specific antigen to membrane immunoglobulin (mIg) receptors on the B cells. Pursuant to antigen binding, signals are transduced and the B cell commences to endocytose and degrade the antigen. Fragments of the antigen are expressed on the B cell surface in noncovalent association with class II major histocompatibility complex (MHC) molecules. The antigen-class II MHC complex serves as a recognition complex for CD4+ helper T cells (T(h)). As a consequence of recognition, T(h) form stable physical conjugates with the B cells. Over an extended period of time the T(h) and B cells bilaterally signal one another. This interchange of signals results in the growth and differentiation of both cells. This review will discuss the sequence of events that culminate in the growth and differentiation of B lymphocytes to antibody-producing cells.	UNIV KENTUCKY, MED CTR, DEPT MICROBIOL & IMMUNOL, LEXINGTON, KY 40536 USA	University of Kentucky	NOELLE, RJ (corresponding author), DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT MICROBIOL, HANOVER, NH 03756 USA.							ALBEROLAILA J, 1991, J IMMUNOL, V146, P1085; ALDERSON MR, 1987, J IMMUNOL, V138, P1056; BARTLETT WC, 1990, J IMMUNOL, V145, P3956; BARTLETT WC, 1991, T CELL DEPENDENT IND; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRIAN AA, 1988, P NATL ACAD SCI USA, V85, P564, DOI 10.1073/pnas.85.2.564; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; CAMBIER JC, 1982, J EXP MED, V156, P1635, DOI 10.1084/jem.156.6.1635; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CAMBIER JC, 1988, SCAND J IMMUNOL, V27, P59, DOI 10.1111/j.1365-3083.1988.tb02323.x; CAMBIER JC, 1987, IMMUNOL REV, V95, P37, DOI 10.1111/j.1600-065X.1987.tb00499.x; Casten L A, 1987, Adv Exp Med Biol, V225, P155; CHARTASH EK, 1988, J IMMUNOL, V140, P1974; CHEN ZZ, 1986, J IMMUNOL, V136, P2300; CHESNUT RW, 1982, J IMMUNOL, V129, P2382; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COGGESHALL KM, 1984, J IMMUNOL, V133, P3382; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DEKRUYFF RH, 1989, J EXP MED, V170, P1477, DOI 10.1084/jem.170.5.1477; DEKRUYFF RH, 1989, J IMMUNOL, V142, P2575; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EXTON JH, 1990, J BIOL CHEM, V265, P1; FROHMAN M, 1985, J IMMUNOL, V134, P2269; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRUPP SA, 1987, CELL IMMUNOL, V109, P181, DOI 10.1016/0008-8749(87)90303-0; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HIROHATA S, 1988, J IMMUNOL, V140, P3726; HODGKIN PD, 1990, J IMMUNOL, V145, P2025; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KEARSE KP, 1988, J IMMUNOL, V140, P1770; KLEMSZ MJ, 1989, J IMMUNOL, V143, P1032; KRIEGER J, 1988, J IMMUNOL, V140, P388; KRUSEMEIER M, 1988, J IMMUNOL, V140, P367; LANE PJL, 1991, J IMMUNOL, V146, P715; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEDBETTER JA, 1990, BLOOD, V75, P1531; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MONROE JG, 1988, J IMMUNOL, V140, P1454; MYERS CD, 1987, J IMMUNOL, V138, P1705; NEL AE, 1984, BIOCHEM BIOPH RES CO, V125, P859, DOI 10.1016/0006-291X(84)91362-7; NOELLE RJ, 1989, J IMMUNOL, V143, P1807; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; NOELLE RJ, 1991, J IMMUNOL, V146, P1118; OWENS T, 1988, EUR J IMMUNOL, V18, P395, DOI 10.1002/eji.1830180312; PARRONCHI P, 1990, J IMMUNOL, V144, P2102; POLLOK KE, 1991, J IMMUNOL, V146, P1633; POLLOK KE, 1991, IN PRESS CELL SIGNAL; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; RANSOM JT, 1986, J IMMUNOL, V137, P708; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RUDICH SM, 1987, MOL IMMUNOL, V24, P809, DOI 10.1016/0161-5890(87)90183-0; RUDICH SM, 1988, J EXP MED, V168, P247, DOI 10.1084/jem.168.1.247; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SMELAND E, 1985, P NATL ACAD SCI USA, V82, P6255, DOI 10.1073/pnas.82.18.6255; SNOW EC, 1987, IMMUNOL REV, V99, P173, DOI 10.1111/j.1600-065X.1987.tb01177.x; SNOW EC, 1986, J EXP MED, V164, P944, DOI 10.1084/jem.164.3.944; SNOW EC, 1983, J IMMUNOL, V130, P614; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STPIERRE Y, 1989, J IMMUNOL, V143, P808; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TONY HP, 1985, J EXP MED, V162, P1695, DOI 10.1084/jem.162.5.1695; VANSEVENTER GA, 1991, IN PRESS OPIN IMMUNO; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; WEAVER CT, 1990, IMMUNOL TODAY, V11, P49; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WHITMAN M, 1989, BIOCHIM BIOPHYS ACTA, V948, P327, DOI 10.1016/0304-419X(89)90005-X	78	81	82	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1991	5	13					2770	2776		10.1096/fasebj.5.13.1833257	http://dx.doi.org/10.1096/fasebj.5.13.1833257			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1833257				2022-12-28	WOS:A1991GJ47100004
J	PASTAN, I; WILLINGHAM, MC; GOTTESMAN, M				PASTAN, I; WILLINGHAM, MC; GOTTESMAN, M			MOLECULAR MANIPULATIONS OF THE MULTIDRUG TRANSPORTER - A NEW ROLE FOR TRANSGENIC MICE	FASEB JOURNAL			English	Article						CHEMOTHERAPY; CANCER; TRANSPORT PROTEIN; DRUG RESISTANCE	RESISTANCE GENE; P-GLYCOPROTEIN; EXPRESSION; CELLS; MDR1; TISSUES; LOCALIZATION; VINBLASTINE; MUTATIONS; SITES	Multidrug resistance in human cancer is associated with overexpression of the MDR1 gene which encodes a 170,000 molecular weight membrane glycoprotein that transports cytotoxic drugs out of cancer cells. The MDR1 gene is normally expressed in intestine, kidney, liver, and adrenal glands, and in tumors derived from these tissues, but it is not expressed in normal bone marrow. Transgenic mice that express the MDR1 gene in their bone marrow have been developed, and because of this expression these mice are resistant to the bone marrow-suppressive effects of daunomycin, doxorubicin, taxol, and several other anticancer drugs. These mice can be used in several different ways to develop new types of drugs to treat human cancer.	NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	PASTAN, I (corresponding author), NCI,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				AKIYAMA SI, 1988, MOL PHARMACOL, V33, P144; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; CURRIER SJ, 1989, J BIOL CHEM, V264, P14376; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GALSKI H, 1989, MOL CELL BIOL, V9, P4357, DOI 10.1128/MCB.9.10.4357; GERMANN UA, 1989, J BIOL CHEM, V264, P7418; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1989, J BIOL CHEM, V264, P14880; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; LAI SL, 1989, J NATL CANCER I, V81, P1144, DOI 10.1093/jnci/81.15.1144; LOTHSTEIN L, 1989, J BIOL CHEM, V264, P16054; MICKISCH GH, 1991, P NATL ACAD SCI USA, V88, P547, DOI 10.1073/pnas.88.2.547; MILLER TP, 1991, J CLIN ONCOL, V9, P17, DOI 10.1200/JCO.1991.9.1.17; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SATO H, 1990, LEUKEMIA RES, V14, P11, DOI 10.1016/0145-2126(90)90141-U; SATO H, 1990, BRIT J HAEMATOL, V75, P340, DOI 10.1111/j.1365-2141.1990.tb04346.x; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Tsuruo T, 1989, Cancer Treat Res, V48, P73	28	52	54	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2523	2528		10.1096/fasebj.5.11.1868977	http://dx.doi.org/10.1096/fasebj.5.11.1868977			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868977	Bronze			2022-12-28	WOS:A1991GB09400004
J	ZHOU, DH; MUNSTER, A; WINCHURCH, RA				ZHOU, DH; MUNSTER, A; WINCHURCH, RA			PATHOLOGICAL CONCENTRATIONS OF INTERLEUKIN-6 INHIBIT T-CELL RESPONSES VIA INDUCTION OF ACTIVATION OF TGF-BETA	FASEB JOURNAL			English	Note						MACROPHAGES; IMMUNOSUPPRESSION; CON-A	GROWTH-FACTOR-BETA; BURN PATIENTS; IL-6; ENDOTOXEMIA; INFECTION; HIV	Interleukin 6 levels are increased in a variety of clinical conditions including bacterial and viral infections, HIV infection, autoimmune diseases, certain neoplasias, and traumatic injury. In general, all these conditions are characterized by suppression of one or more manifestations of the immune response. Concentrations of IL 6 comparable to those found in the sera of immunosuppressed, thermally injured patients selectively inhibit T cell proliferative responses. This suppression is independent of IL 2-mediated responses, is dependent on macrophage activity, and is reversed by antisera specific for transforming growth factor-beta (TGF-beta).	JOHNS HOPKINS UNIV,SCH MED,DEPT SURG,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE REG BURN CTR,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins University								AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BAUMANN H, 1984, J BIOL CHEM, V259, P7331; BREEN EC, 1990, J IMMUNOL, V144, P480; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; ERTEL W, 1990, J SURG RES, V48, P622, DOI 10.1016/0022-4804(90)90242-T; FONG YM, 1989, J IMMUNOL, V142, P2321; GUO Y, 1990, CLIN IMMUNOL IMMUNOP, V54, P361, DOI 10.1016/0090-1229(90)90050-Z; HELLE M, 1988, EUR J IMMUNOL, V18, P957, DOI 10.1002/eji.1830180619; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HOUSSIAU FA, 1988, CLIN EXP IMMUNOL, V71, P320; LOTZ M, 1990, J IMMUNOL, V144, P4189; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; PETERSON PK, 1991, J IMMUNOL, V146, P81; SHORR RM, 1984, J TRAUMA, V24, P319, DOI 10.1097/00005373-198404000-00006; VANOERS MHJ, 1988, CLIN EXP IMMUNOL, V71, P314; WAHL SM, 1988, J IMMUNOL, V140, P3026; WARDEN GD, 1981, IMMUNE CONSEQUENCES, P1; WEISSENBACH J, 1980, P NATL ACAD SCI-BIOL, V77, P7152, DOI 10.1073/pnas.77.12.7152; WINCHURCH RA, 1987, SURGERY, V102, P808; WINCHURCH RA, 1988, CLIN IMMUNOL IMMUNOP, V49, P215, DOI 10.1016/0090-1229(88)90111-0	20	84	84	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2582	2585		10.1096/fasebj.5.11.1868982	http://dx.doi.org/10.1096/fasebj.5.11.1868982			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868982				2022-12-28	WOS:A1991GB09400012
J	GOLDSTEIN, MA; SCHROETER, JP; MICHAEL, LH				GOLDSTEIN, MA; SCHROETER, JP; MICHAEL, LH			ROLE OF THE Z-BAND IN THE MECHANICAL-PROPERTIES OF THE HEART	FASEB JOURNAL			English	Review						MUSCLE CONTRACTION; CARDIAC ULTRASTRUCTURE; Z-BAND; ELASTIC PROPERTIES	LENGTH-TENSION RELATIONS; SKINNED CARDIAC CELLS; SKELETAL-MUSCLE; SARCOMERE-LENGTH; RESTING TENSION; FILAMENTS; LATTICE; RAT; MICROTUBULES; MORPHOLOGY	In striated muscle the mechanism of contraction involves the cooperative movement of contractile and elastic components. This review emphasizes a structural approach that describes the cellular and extracellular components with known anatomical, biochemical, and physical properties that make them candidates for these contractile and elastic components. Classical models of contractile and elastic elements and their underlying assumptions are presented. Mechanical properties of cardiac and skeletal muscle are compared and contrasted and then related to ultrastructure. Information from these approaches leads to the conclusion that the Z band is essential for muscle contraction. Our review of Z band structure shows the Z band at the interface where extracellular components meet the cell surface. The Z band is also the interface from cell surface to myofibril, from extramyofibrillar to myofibril, and finally from sarcomere to sarcomere. Our studies of Z band in defined physiologic states show that this lattice is an integral part of the contractile elements and can function as an elastic component. The Z band is a complex dynamic lattice uniquely suited to play several roles in muscle contraction.			GOLDSTEIN, MA (corresponding author), BAYLOR UNIV, DEPT MED, HOUSTON, TX 77030 USA.							ABBOTT BC, 1975, CIRC RES, V36, P1, DOI 10.1161/01.RES.36.1.1; ALLEN DG, 1985, J MOL CELL CARDIOL, V17, P821, DOI 10.1016/S0022-2828(85)80097-3; BERNE R, 1988, PHYSIOLOGY, P315; BORG TK, 1980, TISSUE CELL, V12, P197, DOI 10.1016/0040-8166(80)90061-0; BRADY AJ, 1986, AM J PHYSIOL, V250, pH932, DOI 10.1152/ajpheart.1986.250.6.H932; BRADY AJ, 1984, PHYSL PATHOPHYSIOLOG, P279; CAULFIELD JB, 1979, LAB INVEST, V40, P364; EDWARDS RJ, 1989, J ULTRA MOL STRUCT R, V102, P59, DOI 10.1016/0889-1605(89)90033-5; EGHBALI M, 1989, CARDIOVASC RES, V23, P723, DOI 10.1093/cvr/23.8.723; EISENBERG BR, 1984, AM J ANAT, V171, P273, DOI 10.1002/aja.1001710304; FABIATO A, 1975, NATURE, V256, P54, DOI 10.1038/256054a0; FABIATO A, 1978, J GEN PHYSIOL, V72, P667, DOI 10.1085/jgp.72.5.667; FAWCETT DW, 1969, J CELL BIOL, V42, P1, DOI 10.1083/jcb.42.1.1; Forbes MS, 1984, PHYSL PATHOPHYSIOLOG, P3; FUNATSU T, 1990, J CELL BIOL, V110, P53, DOI 10.1083/jcb.110.1.53; GAY WA, 1967, CIRC RES, V21, P33, DOI 10.1161/01.RES.21.1.33; GOLDSTEIN MA, 1980, EXP NEUROL, V70, P83, DOI 10.1016/0014-4886(80)90007-2; GOLDSTEIN MA, 1988, J GEN PHYSIOL, V92, P113, DOI 10.1085/jgp.92.1.113; GOLDSTEIN MA, 1990, ELECTRON MICROSC REV, V3, P227, DOI 10.1016/0892-0354(90)90003-B; GOLDSTEIN MA, 1982, J MUSCLE RES CELL M, V3, P333, DOI 10.1007/BF00713041; GOLDSTEIN MA, 1986, J MUSCLE RES CELL M, V7, P527, DOI 10.1007/BF01753569; GOLDSTEIN MA, 1979, J CELL BIOL, V83, P187, DOI 10.1083/jcb.83.1.187; GOLDSTEIN MA, 1987, FASEB J, V1, P133, DOI 10.1096/fasebj.1.2.3609610; GOLDSTEIN MA, 1979, J CELL BIOL, V80, P183, DOI 10.1083/jcb.80.1.183; GOLDSTEIN MA, 1989, AM J PHYSIOL, V256, pH552, DOI 10.1152/ajpheart.1989.256.2.H552; GOLDSTEIN MA, 1990, 12TH P INT C EL MICR, P460; GORDON AM, 1966, J PHYSIOL-LONDON, V184, P170, DOI 10.1113/jphysiol.1966.sp007909; GRIMM AF, 1966, AM J PHYSIOL, V210, P1362, DOI 10.1152/ajplegacy.1966.210.6.1362; HILL DK, 1968, J PHYSIOL-LONDON, V199, P637, DOI 10.1113/jphysiol.1968.sp008672; HOROWITS R, 1989, J CELL BIOL, V109, P2169, DOI 10.1083/jcb.109.5.2169; JULIAN FJ, 1975, CIRC RES, V37, P299, DOI 10.1161/01.RES.37.3.299; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; MAGID A, 1985, SCIENCE, V230, P1280, DOI 10.1126/science.4071053; MATSUBARA I, 1974, CIBA F S, V24, P31; POLLACK GH, 1974, AM J PHYSIOL, V227, P383, DOI 10.1152/ajplegacy.1974.227.2.383; PRICE M, 1990, ADV STRUCTURAL BIOL, V1; RAPPAPORT L, 1988, INT REV CYTOL, V113, P101; ROBINSON TF, 1979, J PHYSIOL-LONDON, V286, P607, DOI 10.1113/jphysiol.1979.sp012640; ROBINSON TF, 1987, CELL TISSUE RES, V249, P247; SCHROETER JP, 1991, J ELECTRON MICR TECH, V18, P296, DOI 10.1002/jemt.1060180312; SHEAR CR, 1985, J CELL BIOL, V101, P240, DOI 10.1083/jcb.101.1.240; Sommer J, 1986, HEART CARDIOVASCULAR, P61; SONNENBLICK EH, 1974, CIRC RES, V35, P517, DOI 10.1161/01.RES.35.4.517; SPIRO D, 1964, CIRC RES, V15, P14; TARR M, 1979, CIRC RES, V45, P554, DOI 10.1161/01.RES.45.4.554; TRAEGER L, 1983, J CELL BIOL, V96, P100, DOI 10.1083/jcb.96.1.100; Wang K, 1985, Cell Muscle Motil, V6, P315; WANG K, 1988, J CELL BIOL, V107, P2199, DOI 10.1083/jcb.107.6.2199; YU LC, 1985, J MOL BIOL, V185, P211; YUNG R, 1986, J ULTRA MOL STRUCT R, V96, P160, DOI 10.1016/0889-1605(86)90017-0	50	27	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2167	2174		10.1096/fasebj.5.8.2022313	http://dx.doi.org/10.1096/fasebj.5.8.2022313			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022313				2022-12-28	WOS:A1991FK11100008
J	BODMER, WF				BODMER, WF			HUGO - THE HUMAN-GENOME-ORGANIZATION	FASEB JOURNAL			English	Article											BODMER, WF (corresponding author), IMPERIAL CANC RES FUND,HUGO,LONDON WC2A 3PX,ENGLAND.			Bodmer, Walter/0000-0001-6244-9792					0	4	4	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					73	74		10.1096/fasebj.5.1.1991589	http://dx.doi.org/10.1096/fasebj.5.1.1991589			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991589				2022-12-28	WOS:A1991ET60900013
J	Klouch, KZ; Stern, MH; Trabelsi-Grati, O; Kiavue, N; Cabel, L; Silveira, AB; Hego, C; Rampanou, A; Popova, T; Bataillon, G; Nasr, S; Proudhon, C; Michel, M; Renault, V; Planchon, JM; Vincent-Salomon, A; Pierga, JY; Bieche, I; Renault, S; Bidard, FC				Klouch, Khadidja Zeyneb; Stern, Marc-Henri; Trabelsi-Grati, Olfa; Kiavue, Nicolas; Cabel, Luc; Silveira, Amanda Bortolini; Hego, Caroline; Rampanou, Aurore; Popova, Tatiana; Bataillon, Guillaume; Nasr, Sarah; Proudhon, Charlotte; Michel, Marc; Renault, Victor; Planchon, Julien Masliah; Vincent-Salomon, Anne; Pierga, Jean-Yves; Bieche, Ivan; Renault, Shufang; Bidard, Francois-Clement			Microsatellite instability detection in breast cancer using drop-off droplet digital PCR	ONCOGENE			English	Article							COLORECTAL-CANCER; MARKERS; TUMORS	The use of conventional methods (immunohistochemistry, pentaplex PCR) for detecting microsatellite instability (MSI), a predictive biomarker of immunotherapy efficacy, is debated for cancers with low MSI prevalence, such as breast cancer (BC). We developed two multiplex drop-off droplet digital PCR (ddPCR) assays targeting four microsatellites, initially identified from public BC whole-genome sequencing dataset. Performances of the assays were investigated and 352 tumor DNA and 28 circulating cell-free DNA from BC patients, with unknown MSI status were blindly screened. Cross-validation of ddPCR MSI status with other MSI detection methods was performed. We then monitored circulating tumor DNA (ctDNA) dynamics before and during pembrolizumab immunotherapy in one patient with MSI-high (MSI-H) metastatic BC. The assays showed high analytical specificity and sensitivity (limit of detection = 0.16%). Among N = 380 samples, seven (1.8%) were found as MSI-H by ddPCR with six of them confirmed by next-generation sequencing (NGS). Specificity was 100% in N = 133 microsatellite stable BC submitted to NGS. In the patient with MSI-H metastatic BC, ctDNA monitoring revealed an early decrease of microsatellite mutant allelic frequencies during immunotherapy. These results demonstrated MSI detection by ddPCR, a non-invasive, fast and cost-effective approach, allowing for large pre-screening of BC patients who may benefit from immunotherapy.	[Klouch, Khadidja Zeyneb; Cabel, Luc; Silveira, Amanda Bortolini; Hego, Caroline; Rampanou, Aurore; Proudhon, Charlotte; Michel, Marc; Pierga, Jean-Yves; Renault, Shufang; Bidard, Francois-Clement] Inst Curie, Dept Translat Res, Circulating Tumor Biomarkers Lab, Inserm CIC BT 1428, Paris, France; [Stern, Marc-Henri; Popova, Tatiana] PSL Res Univ, Inst Curie, DNA Repair & Uveal Melanoma DRUM Team, Inserm U830, Paris, France; [Trabelsi-Grati, Olfa; Bataillon, Guillaume; Nasr, Sarah; Renault, Victor; Planchon, Julien Masliah; Vincent-Salomon, Anne; Bieche, Ivan] PSL Res Univ, Inst Curie, Dept Diagnost & Theranost Med, Paris, France; [Kiavue, Nicolas; Cabel, Luc; Pierga, Jean-Yves; Bidard, Francois-Clement] Inst Curie, Dept Med Oncol, Paris, France; [Kiavue, Nicolas; Cabel, Luc; Pierga, Jean-Yves; Bidard, Francois-Clement] Inst Curie, Dept Med Oncol, St Cloud, France; [Cabel, Luc; Pierga, Jean-Yves] Univ Paris, Paris, France; [Proudhon, Charlotte; Michel, Marc] CNRS, Inserm U934, UMR3215, Paris, France; [Bidard, Francois-Clement] Paris Saclay Univ, UVSQ, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Renault, S; Bidard, FC (corresponding author), Inst Curie, Dept Translat Res, Circulating Tumor Biomarkers Lab, Inserm CIC BT 1428, Paris, France.; Bidard, FC (corresponding author), Inst Curie, Dept Med Oncol, Paris, France.; Bidard, FC (corresponding author), Inst Curie, Dept Med Oncol, St Cloud, France.; Bidard, FC (corresponding author), Paris Saclay Univ, UVSQ, Paris, France.	shufang.renault@curie.fr; francois-clement.bidard@curie.fr	Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272; Michel, Marc/0000-0001-6613-8027				Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Cicek MS, 2011, J MOL DIAGN, V13, P271, DOI 10.1016/j.jmoldx.2010.12.004; Cortes-Ciriano I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15180; Davies H, 2017, CANCER RES, V77, P4755, DOI 10.1158/0008-5472.CAN-17-1083; Fusco N, 2018, JNCI CANCER SPECT, V2, DOI 10.1093/jncics/pky056; Gallon R, 2020, HUM MUTAT, V41, P332, DOI 10.1002/humu.23906; Georgiadis A, 2019, CLIN CANCER RES, V25, P7024, DOI 10.1158/1078-0432.CCR-19-1372; Gilson P, 2021, CANCERS, V13, DOI 10.3390/cancers13071491; Guardant Health, 2020, GUARDANT360 CDX 1 FD; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Hechtman JF, 2020, MODERN PATHOL, V33, P871, DOI 10.1038/s41379-019-0414-6; Hempelmann JA, 2015, J MOL DIAGN, V17, P705, DOI 10.1016/j.jmoldx.2015.05.008; Horimoto Y, 2020, CANCER SCI, V111, P2647, DOI 10.1111/cas.14500; Huggett JF, 2020, CLIN CHEM, V66, P1012, DOI 10.1093/clinchem/hvaa125; Huggett JF, 2013, CLIN CHEM, V59, P892, DOI 10.1373/clinchem.2013.206375; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee SC, 2001, AM J CLIN PATHOL, V115, P823; Long DR, 2020, CLIN CHEM, V66, P1310, DOI 10.1093/clinchem/hvaa177; Lorenzi M, 2020, J ONCOL, V2020, DOI 10.1155/2020/1807929; McConechy MK, 2015, GYNECOL ONCOL, V137, P306, DOI 10.1016/j.ygyno.2015.01.541; Middha S, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00084; Mosele F, 2020, ANN ONCOL, V31, P1491, DOI 10.1016/j.annonc.2020.07.014; Schmitt FC, 1999, INT J CANCER, V82, P644, DOI 10.1002/(SICI)1097-0215(19990827)82:5<644::AID-IJC5>3.0.CO;2-S; Silveira AB, 2020, CLIN CHEM, V66, P606, DOI 10.1093/clinchem/hvaa013; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Willis J, 2019, CLIN CANCER RES, V25, P7035, DOI 10.1158/1078-0432.CCR-19-1324; Woodhouse R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237802; Yu FY, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1175; Zhu LZ, 2018, J MOL DIAGN, V20, P225, DOI 10.1016/j.jmoldx.2017.11.007	31	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5289	5297		10.1038/s41388-022-02504-6	http://dx.doi.org/10.1038/s41388-022-02504-6		NOV 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36329125				2022-12-28	WOS:000878459600001
J	Wang, YN; Ruan, DY; Wang, ZX; Yu, K; Rong, DL; Liu, ZX; Wang, F; Hu, JJ; Jin, Y; Wu, QN; Pu, HY; Wang, M; Xu, RH; Zeng, ZL				Wang, Ying-Nan; Ruan, Dan-Yun; Wang, Zi-Xian; Yu, Kai; Rong, Dai-Lin; Liu, Ze-Xian; Wang, Feng; Hu, Jia-Jia; Jin, Ying; Wu, Qi-Nian; Pu, Heng-Ying; Wang, Min; Xu, Rui-Hua; Zeng, Zhao-Lei			Targeting the cholesterol-ROR alpha/gamma axis inhibits colorectal cancer progression through degrading c-myc	ONCOGENE			English	Article							ORPHAN NUCLEAR RECEPTORS; DOUBLE-BLIND; CELL-PROLIFERATION; PHASE-III; ALPHA; METABOLISM; MULTICENTER; SIMVASTATIN; OXYSTEROLS; SURVIVAL	Dysregulated cholesterol metabolism is a hallmark of colorectal cancer (CRC). However, the usage of cholesterol-lowering agents seemed to have no benefit in CRC patients. In this study, we focused on the cholesterol-nuclear receptors (NRs) axis as a strategy. Cholesterol and its derivatives work as ligands for different nuclear receptors, thus promoting cancer progression. The key NR downstream of cholesterol in CRC is unknown. Here, we treated CRC cells with a cholesterol-lowering agent and lipoprotein-depleted conditioned medium, and then detected the change of the putative NRs. The results revealed that ROR alpha/gamma (Retinoic acid receptor-related Orphan Receptor alpha/gamma) levels exhibited the most obvious increases in CRC cells subjected them to cholesterol deprivation. ROR alpha/gamma agonists significantly inhibited CRC cells proliferation and migration in vitro and in vivo. Also, ROR alpha/gamma overexpression repressed CRC cells proliferation and migration in vitro and in vivo and ROR alpha/gamma knockdown promoted it. Mechanistically, ROR alpha/gamma agonists promoted c-myc degradation by activating the transcription of the ubiquitinase NEDD4. Intriguingly, the combination of ROR alpha/gamma agonists and atorvastatin had a synergistic effect on inhibiting CRC cells. These findings demonstrate that the cholesterol- ROR alpha/gamma axis is important for maintaining c-myc protein levels. Combination therapy with atorvastatin and ROR alpha/gamma agonist is a promising therapeutic strategy for CRC.	[Wang, Ying-Nan; Wang, Zi-Xian; Wang, Feng; Jin, Ying; Xu, Rui-Hua] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Wang, Ying-Nan; Ruan, Dan-Yun; Wang, Zi-Xian; Yu, Kai; Liu, Ze-Xian; Wang, Feng; Hu, Jia-Jia; Jin, Ying; Wu, Qi-Nian; Pu, Heng-Ying; Wang, Min; Xu, Rui-Hua; Zeng, Zhao-Lei] Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China; [Ruan, Dan-Yun] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Clin Res, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Yu, Kai; Liu, Ze-Xian; Hu, Jia-Jia; Pu, Heng-Ying; Wang, Min; Zeng, Zhao-Lei] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Rong, Dai-Lin] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Radiol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China; [Wu, Qi-Nian] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Wu, Qi-Nian] State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Wu, Qi-Nian] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China	Xu, RH (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Xu, RH; Zeng, ZL (corresponding author), Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China.; Zeng, ZL (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.	xurh@sysucc.org.cn; zengzhl@sysucc.org.cn			National Natural Science Foundation of China [81930065, 82173128, 81903163, 82072612]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-036]; Natural Science Foundation of Guangdong Province [2019A1515010233]; China Postdoctoral Science Foundation [2020M673000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81930065, 82173128, 81903163, 82072612), the CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-036), the Natural Science Foundation of Guangdong Province (2019A1515010233), and the China Postdoctoral Science Foundation (2020M673000).	Adhyaru BB, 2018, NAT REV CARDIOL, V15, P757, DOI 10.1038/s41569-018-0098-5; Baek SH, 2014, ANNU REV PHYSIOL, V76, P177, DOI 10.1146/annurev-physiol-030212-183758; Bardou M, 2010, GUT, V59, P1572, DOI 10.1136/gut.2009.190900; Bovenga F, 2015, CELL METAB, V21, P517, DOI 10.1016/j.cmet.2015.03.002; Brautbar A, 2011, NAT REV CARDIOL, V8, P253, DOI 10.1038/nrcardio.2011.2; Brown AJ, 2021, BRIT J PHARMACOL, V178, P3089, DOI 10.1111/bph.15073; Buren S, 2016, CANCER CELL, V30, P290, DOI 10.1016/j.ccell.2016.06.023; Cai DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12529-3; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Cheng CM, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0301-4; Choi WS, 2019, NATURE, V566, P254, DOI 10.1038/s41586-019-0920-1; Dejure FR, 2017, EMBO J, V36, P3409, DOI 10.15252/embj.201796438; Dejure FR, 2017, EMBO J, V36, P1854, DOI 10.15252/embj.201796662; Dobrzycka M, 2020, EXP CLIN ENDOCR DIAB, V128, P255, DOI 10.1055/a-0668-5692; Du J, 2012, INT J MOL SCI, V13, P15755, DOI 10.3390/ijms131215755; Duffy MJ, 2021, CANCER TREAT REV, V94, DOI 10.1016/j.ctrv.2021.102154; Fan JH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01187; Gouw AM, 2019, CELL METAB, V30, P556, DOI 10.1016/j.cmet.2019.07.012; Hadjiphilippou S, 2019, CIRC RES, V124, P354, DOI 10.1161/CIRCRESAHA.118.313245; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kim H, 2011, MOL CELL, V44, P797, DOI 10.1016/j.molcel.2011.09.023; Kim ST, 2014, EUR J CANCER, V50, P2822, DOI 10.1016/j.ejca.2014.08.005; Kloudova A, 2017, TRENDS ENDOCRIN MET, V28, P485, DOI 10.1016/j.tem.2017.03.002; Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lee JM, 2010, MOL CELL, V37, P183, DOI 10.1016/j.molcel.2009.12.022; Lim SH, 2015, BRIT J CANCER, V113, P1421, DOI 10.1038/bjc.2015.371; Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621; Liu J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15112-3; Ma LQ, 2019, MOL CELL ENDOCRINOL, V484, P42, DOI 10.1016/j.mce.2019.01.016; Marciano DP, 2014, CELL METAB, V19, P193, DOI 10.1016/j.cmet.2013.12.009; Mutemberezi V, 2016, PROG LIPID RES, V64, P152, DOI 10.1016/j.plipres.2016.09.002; Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720; Qiu RM, 2018, J MED CHEM, V61, P5794, DOI 10.1021/acs.jmedchem.7b01314; Raza S, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0422-x; Rene O, 2015, ACS MED CHEM LETT, V6, P276, DOI 10.1021/ml500420y; Riscal R, 2019, MOL CELL, V76, P220, DOI 10.1016/j.molcel.2019.09.008; Roshan-Moniri M, 2014, CANCER TREAT REV, V40, P1137, DOI 10.1016/j.ctrv.2014.10.005; Seckl MJ, 2017, J CLIN ONCOL, V35, P1506, DOI 10.1200/JCO.2016.69.7391; Sever R, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a006098; Silvente-Poirot S, 2018, CANCER RES, V78, P4803, DOI [10.1158/0008-5472.CAN-18-1487, 10.1158/0008-5472.can-18-1487]; Solt LA, 2012, TRENDS ENDOCRIN MET, V23, P619, DOI 10.1016/j.tem.2012.05.012; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793; Tian Y, 2015, PUBLIC HEALTH NUTR, V18, P3355, DOI 10.1017/S1368980015000646; Villa GR, 2016, CANCER CELL, V30, P683, DOI 10.1016/j.ccell.2016.09.008; Wang C, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00500-y; Wang JJ, 2016, NAT MED, V22, P488, DOI 10.1038/nm.4070; Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z; Wang YJ, 2010, ACS CHEM BIOL, V5, P1029, DOI 10.1021/cb100223d; Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0; Ward NC, 2019, CIRC RES, V124, P328, DOI 10.1161/CIRCRESAHA.118.312782; Xiao L, 2015, AM J PHYSIOL-CELL PH, V308, pC385, DOI 10.1152/ajpcell.00091.2014; Xiong GF, 2014, MOL CELL BIOL, V34, P3066, DOI 10.1128/MCB.00279-14; Xiong GF, 2012, CANCER RES, V72, P1728, DOI 10.1158/0008-5472.CAN-11-2762	57	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5266	5278		10.1038/s41388-022-02515-3	http://dx.doi.org/10.1038/s41388-022-02515-3		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316442	hybrid, Green Published			2022-12-28	WOS:000876857500002
J	STERN, MD; LAKATTA, EG				STERN, MD; LAKATTA, EG			EXCITATION-CONTRACTION COUPLING IN THE HEART - THE STATE OF THE QUESTION	FASEB JOURNAL			English	Article						EXCITATION-CONTRACTION COUPLING; SARCOPLASMIC RETICULUM; CALCIUM; CHANNELS; HEART	CARDIAC SARCOPLASMIC-RETICULUM; CALCIUM RELEASE CHANNEL; RYANODINE RECEPTOR; SKELETAL-MUSCLE; VENTRICULAR MYOCYTES; SINGLE-CHANNEL; ADENINE-NUCLEOTIDE; FEET STRUCTURES; ACTIVATION; CA-2+	Recent developments have led to great progress toward determining the mechanism by which calcium is released from the sarcoplasmic reticulum in the heart. The data support the notion of calcium-induced calcium release via a calcium-sensitive release channel. Calcium release channels have been isolated and cloned. This situation creates a paradox, as it has also been found that calcium release is smoothly graded and closely-responsive to sarcolemmal membrane potential, properties that would not be expected of calcium-induced calcium release, which has intrinsic positive feedback. There is, therefore, no quantitative understanding of how the properties of the calcium release channel can lead to the macroscopic physiology of the whole cell. This problem could, in principle, be solved by various schemes involving heterogeneity at the ultrastructural level. The simplest of these require only that the sarcolemmal calcium channel be located in close proximity to one or more sarcoplasmic reticulum release channels. Theoretical modeling shows that such arrangements can, in fact, resolve the positive feedback paradox. An agenda is proposed for future studies required in order to reach a specific, quantitative understanding of the functioning of calcium-induced calcium release.	NIA, GERONTOL RES CTR, CARDIOVASC SCI LAB, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	STERN, MD (corresponding author), JOHNS HOPKINS MED INST, DIV CARDIOL, 592 CARNEGIE BLDG, 600 N WOLFE ST, BALTIMORE, MD 21205 USA.		Lakatta, Edward G/AAL-1447-2020	Stern, Michael/0000-0003-4476-7425; Lakatta, Edward/0000-0002-4772-0035				ASHLEY RH, 1990, J GEN PHYSIOL, V95, P981, DOI 10.1085/jgp.95.5.981; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CALLEWAERT G, 1988, P NATL ACAD SCI USA, V85, P2009, DOI 10.1073/pnas.85.6.2009; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; COHEN NM, 1988, J PHYSIOL-LONDON, V406, P115, DOI 10.1113/jphysiol.1988.sp017372; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1985, J GEN PHYSIOL, V85, P189, DOI 10.1085/jgp.85.2.189; FABIATO A, 1986, BIOPHYS J, V49, pA190; FABIATO A, 1989, MOL CELL BIOCHEM, V89, P135; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; KAWANO S, 1991, Biophysical Journal, V59, p600A; LAI FA, 1988, BIOCHEM BIOPH RES CO, V151, P441, DOI 10.1016/0006-291X(88)90613-4; LAI FA, 1988, NATURE LONDON, V331; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NAGASAKI K, 1988, CELL CALCIUM, V9, P1, DOI 10.1016/0143-4160(88)90032-2; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SIPIDO KR, 1991, J PHYSIOL-LONDON, V435, P605, DOI 10.1113/jphysiol.1991.sp018528; SITSAPESAN R, 1990, J PHYSIOL-LONDON, V423, P425, DOI 10.1113/jphysiol.1990.sp018031; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SMITH JS, 1986, BIOPHYS J, V50, P921, DOI 10.1016/S0006-3495(86)83533-0; SOMMER JR, 1991, ACTA PHYSIOL SCAND, V142, P5; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; STERN MD, 1984, BIOPHYS J, V45, pA94; STERN MD, 1992, IN PRESS BIOPHYS J; SUAREZISLA BA, 1986, P NATL ACAD SCI USA, V83, P7741, DOI 10.1073/pnas.83.20.7741; TALO A, 1990, J GEN PHYSIOL, V96, P1085, DOI 10.1085/jgp.96.5.1085; WIBO M, 1991, CIRC RES, V68, P662, DOI 10.1161/01.RES.68.3.662; WILLIAMS AJ, 1989, ANN NY ACAD SCI, V560, P163, DOI 10.1111/j.1749-6632.1989.tb24093.x	44	71	73	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3092	3100		10.1096/fasebj.6.12.1325933	http://dx.doi.org/10.1096/fasebj.6.12.1325933			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1325933				2022-12-28	WOS:A1992JN50500011
J	SATO, M; GRASSER, W; HARM, S; FULLENKAMP, C; GORSKI, JP				SATO, M; GRASSER, W; HARM, S; FULLENKAMP, C; GORSKI, JP			BONE ACIDIC GLYCOPROTEIN-75 INHIBITS RESORPTION ACTIVITY OF ISOLATED RAT AND CHICKEN OSTEOCLASTS	FASEB JOURNAL			English	Article						OSTEOCLAST; BONE RESORPTION; POLYMERIZATION; BONE MATRIX; PHOSPHOPROTEINS	VITRONECTIN RECEPTOR; COLLAGENASE PRODUCTION; EXTRACELLULAR-MATRIX; RESORBING AGENTS; CELLS; FIBRONECTIN; BINDING; CULTURE; OSTEOPONTIN; ATTACHMENT	Matrix protein effects on the differentiated activity of osteoclasts were examined in order to understand the functional significance of bone protein interactions with osteoclasts. Bone acidic glycoprotein 75 (BAG 75) from rat calvariae inhibited the resorption of bone by isolated rat osteoclasts with IC50 = 1 nM compared to IC50 = 10 nM for chicken osteoclasts. By contrast, other phosphoproteins similarly isolated from bone were less effective in inhibiting resorption with IC50 = 100 nM osteopontin and IC50 > 100 nM bone sialoprotein. Likewise, RGD-containing matrix proteins vitronectin, thrombospondin, and fibronectin all displayed IC50 greater-than-or-equal-to 100 nM. Mechanistically, 10 nM BAG 75 marginally slowed, but did not block, the association of bone particles with chicken osteoclasts compared with osteopontin or control media. Pretreatment of osteoclasts with 50 nM BAG 75 had no effect on subsequent bone resorption; however, pretreatment of bone with BAG 75 before incubation with osteoclasts reduced the extent of resorption by 55%. These data suggest that a BAG 75/bone surface complex, rather than BAG 75 alone, represents the inhibitory form. Consistent with this hypothesis, direct binding studies provided no evidence of specific, high-affinity receptors on osteoclasts for BAG 75, nor was an excess of BAG 75 (100 nM) able to compete with 0.3 nM sechistatin for osteoclastic a(v)B3-like receptors. However, BAG 75 displayed cooperative binding to tissue fragments and bone particles at concentrations greater than 10 nM, suggesting that BAG 75 self-associates into higher-order species on bone surfaces. Electron microscopy confirmed the time-dependent polymerization of BAG 75 into interconnecting filaments. These data suggest a novel, inhibitory activity for surface-bound BAG 75 on bone resorption that does not appear to involve the osteoclastic a(v)B3-like integrin.	MERCK SHARP & DOHME LTD,DEPT BONE BIOL & OSTEOPOROSIS RES,W POINT,PA 19486; UNIV MISSOURI,SCH BASIC LIFE SCI,DIV MOLEC BIOL & BIOCHEM,KANSAS CITY,MO 64110	Merck & Company; University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R15AR040923] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; BARON R, 1990, PRIMER METABOLIC BON, P3; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; CHAMBERS TJ, 1984, J CELL SCI, V70, P61; CHAMBERS TJ, 1989, BONE MINERAL RES, V6, P1; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; DELAISSE JM, 1985, BIOCHEM BIOPH RES CO, V133, P483, DOI 10.1016/0006-291X(85)90932-5; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; GRASSER WA, 1992, IN VITRO IN VIVO AUT; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; Heinegard D, 1989, Connect Tissue Res, V21, P3, DOI 10.3109/03008208909049990; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HORTON MA, 1988, ISI ATLAS-IMMUNOL, V1, P35; JILKA RL, 1984, ENDOCRINE CONTROL BO, P136; JOHANSSON S, 1985, J BIOL CHEM, V260, P1557; KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756-3282(88)90106-8; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; MCABEE DD, 1983, J CELL BIOL, V97, P1515, DOI 10.1083/jcb.97.5.1515; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OTSUKA K, 1984, EUR J BIOCHEM, V145, P123, DOI 10.1111/j.1432-1033.1984.tb08530.x; POLLARD TD, 1982, CELL MUSCLE MOTILITY, V2, P15; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROULEAU MF, 1988, ENDOCRINOLOGY, V123, P187, DOI 10.1210/endo-123-1-187; SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SATO M, 1990, CELL MOTIL CYTOSKEL, V17, P250, DOI 10.1002/cm.970170311; SATO M, 1989, CELL SHAPE DETERMINA, P329; SHEN V, 1988, J BONE MINER RES, V3, P657; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; STREGE DW, 1990, J BONE MINER RES, V5, P963; SUDA T, 1991, PREDICTABLE ADV ORAL, P80; TERMINE JD, 1990, EXP GERONTOL, V25, P217, DOI 10.1016/0531-5565(90)90055-7; TYREE B, 1989, J BONE MINER RES, V4, P877; Vaes G., 1988, CLIN ORTHOP RELAT R, V231, P239; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; ZAMBONINZALLONE A, 1983, J ANAT, V137, P57	44	25	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2966	2976		10.1096/fasebj.6.11.1644260	http://dx.doi.org/10.1096/fasebj.6.11.1644260			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644260				2022-12-28	WOS:A1992JJ66500011
J	SOMMER, SS				SOMMER, SS			ASSESSING THE UNDERLYING PATTERN OF HUMAN GERMLINE MUTATIONS - LESSONS FROM THE FACTOR-IX GENE	FASEB JOURNAL			English	Review						EVOLUTION; SERINE PROTEASES; SPACER MODEL; HEMOPHILIA-B; FOUNDER EFFECTS; MUTATION RATE, X-CHROMOSOME	COAGULATION FACTOR-IX; HEMOPHILIA-B; BLOOD-COAGULATION; MOLECULAR-BASIS; HAEMOPHILIA-B; CPG; SEQUENCES; HOTSPOTS; DISEASE; SUBSTITUTIONS	Germline mutations cause or predispose to most diseases. Hemophilia B is a useful model for studying the underlying pattern of recent germline mutations in humans because the observed pattern of mutation in factor IX more closely reflects the underlying pattern of mutation than the observed pattern for many other genes. In addition, it is possible to identify and correct for biases inherent in ascertaining only those mutations that cause hemophilia. Aspects of the pattern of germline mutation in the factor IX gene are becoming clear: 1) in the United States, two-thirds of mutations causing mild disease arose from three founders whereas almost all the mutations resulting in either moderate or severe disease arose independently, generally within the past 150 years; 2) direct estimates of the rates of mutation in humans indicate that transitions are more frequent than transversions, which in turn are more frequent than deletions and insertions; 3) transitions at CpG are elevated approximately 24-fold relative to transitions at non-CpG dinucleotides; 4) transversions at CpG are elevated approximately eightfold relative to transversions at non-CpG dinucleotides; 5) the sum total of the dinucleotide mutation rates produces a bias against G and C bases that would be sufficient to maintain the G+C content of the factor IX gene at its evolutionarily conserved level of 40%; and 6) the pattern of mutation is similar for Caucasians residing in the United States and for Asians residing in Asia. Two ideas emerge from this and from an analysis of the pattern of recent deleterious mutations compared with ancient neutral mutations that have been fixed during evolution into the factor IX gene. First, the bulk of germline mutations are likely to arise from endogenous processes rather than environmental mutagens. Second, the factor IX protein is composed mostly of two classes of amino acids: critical residues in which all single-base missense changes will disrupt protein function, and "spacer" residues in which the precise nature of the residue is unimportant but the peptide bond is necessary to keep the critical residues in register. More work is necessary to assess the veracity and generality of these ideas.			SOMMER, SS (corresponding author), MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905, USA.							BOTTEMA CDK, 1989, LANCET, V2, P526; BOTTEMA CDK, 1990, BRIT J HAEMATOL, V75, P212, DOI 10.1111/j.1365-2141.1990.tb02651.x; BOTTEMA CDK, 1990, AM J HUM GENET, V47, P835; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P839; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BROWNLEE GG, 1988, RECENT ADV HAEMATOLO, P251; CHEN SH, 1991, HUM GENET, V87, P177, DOI 10.1007/BF00204177; COOPER DN, 1990, HUM GENET, V85, P55; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DOOLITTLE RF, 1987, COLD SPRING HARB SYM, V52, P869, DOI 10.1101/SQB.1987.052.01.095; EVANS JP, 1989, BLOOD, V74, P207; EYSTER ME, 1980, AM J HEMATOL, V9, P277, DOI 10.1002/ajh.2830090306; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1990, NUCLEIC ACIDS RES, V18, P4053, DOI 10.1093/nar/18.14.4053; GIANNELLI F, 1983, NATURE, V303, P181, DOI 10.1038/303181a0; GIANNELLI F, 1992, IN PRESS NUCLEIC ACI; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GREEN PM, 1990, NUCLEIC ACIDS RES, V18, P3227, DOI 10.1093/nar/18.11.3227; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; Haldane JBS, 1935, J GENET, V31, P317, DOI 10.1007/BF02982403; HEDNER U, 1989, METABOLIC BASIS INHE, P2107; IKKALA E, 1960, THESIS U HELSINKI FI, P82; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KETTERLING RP, 1991, HUM GENET, V87, P333; KETTERLING RP, 1991, GENOMICS, V10, P1093, DOI 10.1016/0888-7543(91)90207-U; KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425; KIMURA M, 1973, GENETICS, V73, P19; KOEBERL DD, 1990, AM J MED GENET, V35, P600, DOI 10.1002/ajmg.1320350435; KOEBERL DD, 1990, HUM GENET, V84, P387; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; KOEBERL DD, 1989, AM J HUM GENET, V45, P448; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; LUDWIG M, 1992, AM J HUM GENET, V50, P164; MANDEL JL, 1989, NATURE, V339, P584, DOI 10.1038/339584a0; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MILES C, 1989, MUTAT RES, V227, P97, DOI 10.1016/0165-7992(89)90004-3; MONTANDON AJ, 1990, HUM GENET, V85, P200; NEEL JV, 1986, P NATL ACAD SCI USA, V83, P389, DOI 10.1073/pnas.83.2.389; ROSENDAAL FR, 1990, HUM GENET, V86, P139, DOI 10.1007/BF00197695; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; SARKAR G, 1990, GENOMICS, V6, P133, DOI 10.1016/0888-7543(90)90458-7; SOMMER SS, 1980, J MOL EVOL, V15, P37, DOI 10.1007/BF01732582; SOMMER SS, 1992, IN PRESS HUM GENET; STAMATOYANNOPOULOS G, 1982, HUM GENET, V60, P181, DOI 10.1007/BF00569709; SUZUKI DT, 1986, INTRO GENETIC ANAL, P333; TAYLOR SAM, 1991, P NATL ACAD SCI USA, V88, P39, DOI 10.1073/pnas.88.1.39; Thompson A R, 1991, Prog Hemost Thromb, V10, P175; VOGEL F, 1986, HUMAN GENETICS PROBL, P433; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WU SM, 1990, GENE, V86, P275, DOI 10.1016/0378-1119(90)90290-8; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	55	46	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1992	6	10					2767	2774		10.1096/fasebj.6.10.1634040	http://dx.doi.org/10.1096/fasebj.6.10.1634040			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634040				2022-12-28	WOS:A1992JD95400002
J	BATEN, A; SAKAMOTO, K; SHAMSUDDIN, AM				BATEN, A; SAKAMOTO, K; SHAMSUDDIN, AM			LONG-TERM CULTURE OF NORMAL HUMAN COLONIC EPITHELIAL-CELLS INVITRO	FASEB JOURNAL			English	Note						CYTOKERATIN; ELECTRON MICROSCOPY; IMMUNOCYTOCHEMISTRY; LARGE INTESTINE	EPIDERMAL GROWTH-FACTOR; SERUM-FREE MEDIUM; EXPLANT CULTURE; ORGAN-CULTURE; CLONAL GROWTH; RAT COLON; KERATINOCYTES; METABOLISM; TISSUE; TUMORS	Studies of normal cellular function as well as the understanding of cellular mechanisms of carcinogenesis and other diseases of the large intestine have been limited, particularly due to the lack of long-term culture of normal human large intestinal epithelial cells (NHLIEC). Using the epithelia from surgically resected human colon, we have dissociated a sufficient number of viable NHLIEC and maintained them in in vitro culture for up to 5 months. Normal-appearing human large intestinal mucosal fragments (1 mm2) were treated with 0.01 mg/ml trypsin, 0.2 mg/ml collagenase + 0.1 mm EGTA or 0.1 mg/ml trypsin + 0.1 mm EGTA in a Stomacher laboratory blender to isolate the cells. Compared with other methods, the use of the Stomacher blender combined with low concentrations of proteolytic enzymes yielded greater numbers of cells per gram of tissue, with up to 84% viable cells. Primary and serially passaged NHLIEC were cultured in CMRL-1066, MEM with 5% serum, and serum-free KGM. These media were all supplemented with insulin, hydrocortisone, epithelial growth factor, and bovine pituitary extract. CMRL-1066 was found to be the best medium for NHLIEC. Contaminating fibroblasts were selectively removed by briefly allowing the cells to adhere to the culture vessel and adding 25 U/ml collagenase to the culture media at the first subculture treatment. The epithelial nature and secretory function of the established cells were confirmed by morphological criteria (light microscopy, phase contrast microscopy and electron microscopy), immunoreactivity to cytokeratin, and positive mucin cytochemistry. We propose that using this methodology for the culture and maintenance of NHLIEC for an extended period of time would serve as a valuable model for a variety of investigations.	UNIV MARYLAND,SCH MED,DEPT PATHOL,ROOM 600-C,MSTF,10 S PINE ST,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore								AUTRUP H, 1978, IN VITRO CELL DEV B, V14, P868; AUTRUP H, 1978, CANCER RES, V38, P3689; BERTOLERO F, 1984, EXP CELL RES, V155, P64, DOI 10.1016/0014-4827(84)90768-7; BUSET M, 1987, IN VITRO CELL DEV B, V23, P403; CHOPRA DP, 1987, GASTROENTEROLOGY, V92, P891, DOI 10.1016/0016-5085(87)90962-0; DANES BS, 1982, J NATL CANCER I, V69, P1271; DEOCA HM, 1973, TISSUE CULTURE METHO, P8; FRIEDMAN EA, 1981, IN VITRO CELL DEV B, V17, P632; GIBSONDAMBROSIO RE, 1986, IN VITRO CELL DEV B, V22, P529; HAY RJ, 1984, TISSUE CULTURE, P331; IYENGAR V, 1991, FASEB J, V5, P2856, DOI 10.1096/fasebj.5.13.1655550; JANSING R, 1984, TISSUE CELL, V16, P157, DOI 10.1016/0040-8166(84)90040-5; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOYER MP, 1983, P SOC EXP BIOL MED, V174, P12; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; SHAMSUDDIN AKM, 1978, PATHOL RES PRACT, V163, P362, DOI 10.1016/S0344-0338(78)80033-8; SHAMSUDDIN AKM, 1981, J NATL CANCER I, V66, P403; SHAMSUDDIN AKM, 1986, GANO MONOGR, V31, P59; SHAMSUDDIN AM, 1982, ARCH PATHOL LAB MED, V106, P140; SHAMSUDDIN AM, 1982, HUM PATHOL, V13, P790, DOI 10.1016/S0046-8177(82)80075-0; SHAMSUDDIN AM, 1990, COLON CANCER CELLS, P137; SHAMSUDDIN AM, 1991, DIAGNOSTIC ASSAYS CO; SHAMSUDDIN AM, 1989, GASTROINTESTINAL OES, P41; SIDDIQUI KM, 1984, IN VITRO CELL DEV B, V20, P859; SPICER SS, 1965, J HISTOCHEM CYTOCHEM, V13, P211, DOI 10.1177/13.3.211; SUN TT, 1981, VISION RES, V21, P55, DOI 10.1016/0042-6989(81)90137-1; TSAO MC, 1982, J CELL PHYSIOL, V110, P219, DOI 10.1002/jcp.1041100217; VIDRICH A, 1985, ANN NY ACAD SCI, V455, P354, DOI 10.1111/j.1749-6632.1985.tb50422.x; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; YU QC, 1990, PATHOBIOLOGY, V58, P138, DOI 10.1159/000163575	33	39	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2726	2734		10.1096/fasebj.6.9.1377141	http://dx.doi.org/10.1096/fasebj.6.9.1377141			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1377141				2022-12-28	WOS:A1992HZ48100015
J	DIGIROLAMO, M; NEWBY, FD; LOVEJOY, J				DIGIROLAMO, M; NEWBY, FD; LOVEJOY, J			LACTATE PRODUCTION IN ADIPOSE-TISSUE - A REGULATED FUNCTION WITH EXTRA-ADIPOSE IMPLICATIONS	FASEB JOURNAL			English	Article						ADIPOCYTES; GLUCOSE METABOLISM; LACTATE PRODUCTION; NUTRITIONAL STATE; OBESITY; INSULIN RESISTANCE	DEPENDENT DIABETES-MELLITUS; ISOLATED FAT-CELLS; INSULIN RESISTANCE; GLUCOSE-METABOLISM; RAT ADIPOCYTES; CARBOHYDRATE-TOLERANCE; SKELETAL-MUSCLE; OBESITY; RELEASE; INVIVO	Estimates of the quantitative contribution of adipose tissue to whole-body glucose metabolism, previously reported as 1-3%, have been revised to be on the order of 10-30%. These revised estimates come, in part, from a recognition that adipose tissue uses glucose to produce lactate and pyruvate, in addition to CO2 and triglycerides. Lactate production by adipose tissue is modulated in vitro by changes in glucose, insulin, and epinephrine concentrations. In vivo, lactate production is regulated acutely by the animal's nutritional state (fed or fasted) and chronically by the degree of obesity. A strong positive correlation exists between rat fat cell size and relative conversion of glucose to lactate (r = 0.89, P < 0.001). Diabetes is also associated with markedly increased lactate production in adipocytes. Fat cells from obese or diabetic rats (or humans) can metabolize to lactate as much as 50-70% of the glucose taken up. From these recent studies, a picture is emerging in which the adipose organ may provide lactate for hepatic gluconeogenesis during fasting, and also lactate for hepatic glycogen synthesis after food ingestion. Modulation of adipocyte lactate production and contribution of adipose tissue lactate to the body's fuel economy in physiological and pathological states are the focus of this review.			DIGIROLAMO, M (corresponding author), EMORY UNIV,SCH MED,DEPT MED,69 BUTLER ST SE,ATLANTA,GA 30303, USA.				NIDDK NIH HHS [R01 DK 39326, F32 DK 08264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039326, F32DK008264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN T, 1986, METABOLISM, V35, P147, DOI 10.1016/0026-0495(86)90116-2; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ATAL S, 1991, INT J OBES S3, V15, P55; BARNETT AH, 1981, BRIT MED J, V282, P1656, DOI 10.1136/bmj.282.6277.1656; BERNSTEIN RS, 1981, J NUTR, V111, P237, DOI 10.1093/jn/111.2.237; BUCHALTER SE, 1989, DIABETES METAB REV, V5, P379, DOI 10.1002/dmr.5610050405; CARO JF, 1989, DIABETES METAB REV, V5, P665, DOI 10.1002/dmr.5610050804; CONNOR H, 1982, METABOLIC ACIDOSIS, P214; CONSOLI A, 1990, AM J PHYSIOL, V259, pE677, DOI 10.1152/ajpendo.1990.259.5.E677; CRANDALL DL, 1990, FASEB J, V4, P141, DOI 10.1096/fasebj.4.2.2404816; CRANDALL DL, 1983, HORM METAB RES, V15, P326, DOI 10.1055/s-2007-1018710; CZECH MP, 1976, J CLIN INVEST, V57, P1523, DOI 10.1172/JCI108422; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DIGIROLAMO M, 1974, J LIPID RES, V15, P332; DiGirolamo M, 1989, INT J OBESITY, V13, P394; DIGIROLAMO M, 1987, BIOL ADIPOCYTE RES A, P120; DOAR JWH, 1968, METABOLISM, V17, P690, DOI 10.1016/0026-0495(68)90053-X; FEDERSPIL G, 1980, DIABETES, V29, P33, DOI 10.2337/diabetes.29.1.33; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERY F, 1990, AM J PHYSIOL, V259, pE770, DOI 10.1152/ajpendo.1990.259.6.E770; FISHER AB, 1984, AM J PHYSIOL, V246, pE426, DOI 10.1152/ajpendo.1984.246.5.E426; FLATT JP, 1964, J BIOL CHEM, V239, P675; FOSTER DW, 1984, DIABETES, V33, P1188, DOI 10.2337/diab.33.12.1188; FRAYN KN, 1989, CLIN SCI, V76, P509, DOI 10.1042/cs0760509; GROFF JL, 1992, J LAB CLIN MED, V119, P216; HAGSTROM E, 1990, AM J PHYSIOL, V258, pE888, DOI 10.1152/ajpendo.1990.258.5.E888; JACKSON RA, 1987, METABOLISM, V36, P144, DOI 10.1016/0026-0495(87)90008-4; Jacobs I, 1981, Acta Physiol Scand Suppl, V495, P1; JANSSON PA, 1990, DIABETOLOGIA, V33, P253, DOI 10.1007/BF00404805; JANSSON PA, 1991, INT J OBES S1, V15, P81; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; KATHER H, 1972, BIOCHEM J, V128, P1089, DOI 10.1042/bj1281089; Kissebah A H, 1988, Acta Med Scand Suppl, V723, P79; KREISBERG RA, 1980, ANN INTERN MED, V92, P227, DOI 10.7326/0003-4819-92-2-227; LANDAU BR, 1988, FASEB J, V2, P2368, DOI 10.1096/fasebj.2.8.3282961; LAVAU M, 1979, J LIPID RES, V20, P8; LOVEJOY J, 1992, METABOLISM, V41, P22, DOI 10.1016/0026-0495(92)90185-D; LOVEJOY J, 1990, INT J OBESITY, V14, P843; LYNN WS, 1960, J BIOL CHEM, V235, P1904; MALAISSE WJ, 1979, ARCH BIOCHEM BIOPHYS, V194, P49, DOI 10.1016/0003-9861(79)90594-0; MARIN P, 1987, METABOLISM, V36, P1154, DOI 10.1016/0026-0495(87)90242-3; MOLNAR D, 1985, EUR J PEDIATR, V144, P27, DOI 10.1007/BF00491920; MOODY AJ, 1968, EXPERIENTIA, V24, P628, DOI 10.1007/BF02153817; NEWBY FD, 1990, AM J PHYSIOL, V259, pE865, DOI 10.1152/ajpendo.1990.259.6.E865; NEWBY FD, 1988, AM J PHYSIOL, V255, pE716, DOI 10.1152/ajpendo.1988.255.5.E716; NEWBY FD, 1989, DIABETES, V38, P237, DOI 10.2337/diabetes.38.2.237; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; OHLSON LO, 1988, DIABETOLOGIA, V31, P798; PEARCE FJ, 1980, AM J PHYSIOL, V238, pC149, DOI 10.1152/ajpcell.1980.238.5.C149; PEIRIS AN, 1986, J CLIN INVEST, V78, P1648, DOI 10.1172/JCI112758; RADZIUK J, 1983, DIABETES, V32, P977, DOI 10.2337/diabetes.32.11.977; RANDLE PJ, 1964, BIOCHEM J, V93, P652, DOI 10.1042/bj0930652; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; SEGAL KR, 1990, METABOLISM, V39, P985, DOI 10.1016/0026-0495(90)90312-Z; SMITH S, 1975, J LIPID RES, V16, P324; STANLEY WC, 1991, FASEB J, V5, P2155, DOI 10.1096/fasebj.5.8.1827082; STORLIEN LH, 1986, AM J PHYSIOL, V251, pE576, DOI 10.1152/ajpendo.1986.251.5.E576; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570; THACKER S, 1987, INT J OBESITY, V11, pA457; THACKER SV, 1987, AM J PHYSIOL, V253, pE336, DOI 10.1152/ajpendo.1987.253.4.E336; VENDSBORG PB, 1977, SCAND J CLIN LAB INV, V37, P317, DOI 10.3109/00365517709092635; WATFORD M, 1991, TRENDS BIOCHEM SCI, V16, P201, DOI 10.1016/0968-0004(91)90082-7; WATTS NB, 1990, AM J MED SCI, V299, P250, DOI 10.1097/00000441-199004000-00006; YKIJARVINEN H, 1990, METABOLISM, V39, P859, DOI 10.1016/0026-0495(90)90133-W; YOUN JH, 1991, DIABETES, V40, P738, DOI 10.2337/diabetes.40.6.738; ZUNIGAGUAJARDO S, 1985, METABOLISM, V34, P926, DOI 10.1016/0026-0495(85)90140-4	67	211	212	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2405	2412		10.1096/fasebj.6.7.1563593	http://dx.doi.org/10.1096/fasebj.6.7.1563593			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563593				2022-12-28	WOS:A1992HP03000005
J	GOLDSTEIN, M; DEUTCH, AY				GOLDSTEIN, M; DEUTCH, AY			DOPAMINERGIC MECHANISMS IN THE PATHOGENESIS OF SCHIZOPHRENIA	FASEB JOURNAL			English	Article						DOPAMINE; ANTIPSYCHOTIC DRUGS; CHOLECYSTOKININ; CORTEX; EXCITATORY AMINO ACIDS; NEUROTENSIN; DOPAMINE RECEPTORS	POSITRON EMISSION TOMOGRAPHY; ATYPICAL ANTIPSYCHOTIC-DRUGS; MEDIAL PREFRONTAL CORTEX; STRIATAL DOPAMINE; AGONIST BINDING; HUMAN-BRAIN; RECEPTORS; RAT; RELEASE; INVIVO	The dopamine hypothesis of schizophrenia has been the dominant theoretical construction guiding research and treatment of the schizophrenic disorders over the past generation. This hypothesis, in its simplest guise, posits the presence of a functional alteration in central dopaminergic systems in the brains of schizophrenic patients. Recent findings have resulted in a greater understanding of the complexity of the central dopaminergic systems and have led to revisions of the hypothesis of a simple functional hyperactivity of central dopaminergic systems. These recent data suggest that there may be regionally restricted changes in the function of the mesotelencephalic dopamine system, and that these changes may be in opposite directions. Such changes may be associated with dysfunctions of interactions between distinct dopaminergic terminal field regions, and may be subserved by functional derangements in other transmitter systems or reflect regionally restricted changes in expression or function of distinct dopamine receptors or catecholamine synthetic enzymes. A recent FASEB symposium reviewed new advances in molecular biology, biochemistry, pharmacology, anatomy, and systems neuroscience as they relate to schizophrenia, and discussed the implications of these data for guiding future research and treatment strategies.	NYU, SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10016 USA; YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06510 USA; DEPT VET AFFAIRS MED CTR, West Haven, CT 06516 USA	New York University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System					NIMH NIH HHS [MH-45124, MH-43230, MH-02717] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045124, P01MH043230] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P1008; ARNOLD SE, 1991, ARCH GEN PSYCHIAT, V48, P625; BARBEITO L, 1990, EUR J NEUROSCI, V2, P304, DOI 10.1111/j.1460-9568.1990.tb00422.x; BARNETT A, 1988, CENTRAL D1 DOPAMINE, P137; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BERMAN KF, 1990, PROGR BRAIN RES, V85, P357; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Bunney BS, 1987, PSYCHOPHARMACOLOGY 3, P113; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CARLSSON M, 1989, J NEURAL TRANSM, V75, P221, DOI 10.1007/BF01258633; CARLSSON M, 1990, SCHIZOPHRENIA BULL, V16, P425, DOI 10.1093/schbul/16.3.425; CARON MG, 1991, NEUROSCI FACTS, V2, P1; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DEKEYSER J, 1989, J NEUROCHEM, V53, P1096; DEKEYSER J, 1989, BRAIN RES, V484, P36, DOI 10.1016/0006-8993(89)90345-4; DEUTCH AY, 1990, PROG BRAIN RES, V85, P367; DEUTCH AY, 1992, NEUROSCIENCE, V46, P49, DOI 10.1016/0306-4522(92)90007-O; DEUTCH AY, 1991, SCHIZOPHR RES, V4, P121, DOI 10.1016/0920-9964(91)90030-U; DEUTCH AY, 1990, BRAIN RES, V521, P311, DOI 10.1016/0006-8993(90)91557-W; DEUTCH AY, 1992, IN PRESS MOL CELL NE; DEUTCH AY, 1991, IN PRESS ANN NY ACAD; DIVAC I, 1984, CIBA F SYMP, V107, P201; ELAZAR Z, 1991, J NEUROCHEM, V56, P75, DOI 10.1111/j.1471-4159.1991.tb02564.x; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; FUXE K, 1991, ACTA PHYSIOL SCAND, V141, P577, DOI 10.1111/j.1748-1716.1991.tb09121.x; FUXE K, 1986, RECENT DEV PARKINSON, P17; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GLAGGETTDAME M, 1989, ARCH BIOCHEM BIOPHYS, V274, P145; HOGBERG T, 1987, ACTA PHARM SUEC, V24, P289; HOKFELT T, 1984, SCIENCE, V225, P1326, DOI 10.1126/science.6147896; JARVIE KR, 1988, MOL PHARMACOL, V34, P91; JELLINGER K, 1985, PATHOCHEMICAL MARKER, P1; KIRCH DG, 1986, HDB SCHIZOPHRENIA, V1, P325; LEE KY, 1990, FASEB J, pA601; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; LEW JY, 1984, J NEUROCHEM, V42, P1298, DOI 10.1111/j.1471-4159.1984.tb02787.x; LEW JY, 1990, EUR J PHARM-MOLEC PH, V188, P329, DOI 10.1016/0922-4106(90)90193-2; LONART G, 1991, J PHARMACOL EXP THER, V256, P1132; MEADORWOODRUFF JH, 1991, NEUROPSYCHOPHARMACOL, V5, P231; MELTZER HY, 1989, J PHARMACOL EXP THER, V251, P238; MOGHADDAM B, 1990, BRAIN RES, V518, P55, DOI 10.1016/0006-8993(90)90953-9; MOGHADDAM B, 1990, J NEUROCHEM, V54, P1755, DOI 10.1111/j.1471-4159.1990.tb01230.x; MOGHADDAM B, 1990, PROG NEURO-PSYCHOPH, V14, pS51, DOI 10.1016/0278-5846(90)90086-V; MOISES HW, 1991, ARCH GEN PSYCHIAT, V48, P643; OGREN SO, 1988, ISI ATLAS-PHARMACOL, V2, P141; OGREN SO, 1990, ACTA PSYCHIAT SCAND, V82, P21, DOI 10.1111/j.1600-0447.1990.tb05281.x; PALACIOS JM, 1989, BRAIN RES, V488, P369, DOI 10.1016/0006-8993(89)90733-6; PYCOCK CJ, 1980, J NEUROCHEM, V34, P91, DOI 10.1111/j.1471-4159.1980.tb04625.x; ROBERTS GW, 1990, TRENDS NEUROSCI, V13, P207, DOI 10.1016/0166-2236(90)90161-3; ROSIN DL, 1992, IN PRESS NEUROSCIENC; SCHALLING M, 1990, P NATL ACAD SCI USA, V87, P8427, DOI 10.1073/pnas.87.21.8427; SEEMAN P, 1989, P NATL ACAD SCI USA, V86, P10156, DOI 10.1073/pnas.86.24.10156; SEEMAN P, 1990, FASEB J, V4, P2737, DOI 10.1096/fasebj.4.10.2197154; SEEMAN P, 1990, ACTA PSYCHIAT SCAND, V82, P14, DOI 10.1111/j.1600-0447.1990.tb05280.x; SESACK SR, 1989, J PHARMACOL EXP THER, V248, P1323; STUDLER JM, 1988, NEUROPEPTIDES, V11, P95, DOI 10.1016/0143-4179(88)90076-5; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; TAMMINGA CA, 1988, ANN NY ACAD SCI, V537, P443, DOI 10.1111/j.1749-6632.1988.tb42126.x; TAMMINGA CA, 1991, IN PRESS ARCH GEN PS; TANGANELLI S, 1989, BRAIN RES, V502, P319, DOI 10.1016/0006-8993(89)90627-6; VENABLES P H, 1964, Prog Exp Pers Res, V72, P1; WACHTEL H, 1990, TRENDS PHARMACOL SCI, V11, P219, DOI 10.1016/0165-6147(90)90243-2; WEINBERGER DR, 1986, HDB SCHIZOPHRENIA, V1, P397; WEINER DM, 1991, P NATL ACAD SCI USA, V88, P1859, DOI 10.1073/pnas.88.5.1859; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495	67	144	149	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1992	6	7					2413	2421		10.1096/fasebj.6.7.1348713	http://dx.doi.org/10.1096/fasebj.6.7.1348713			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1348713				2022-12-28	WOS:A1992HP03000006
J	HOEK, JB; THOMAS, AP; ROONEY, TA; HIGASHI, K; RUBIN, E				HOEK, JB; THOMAS, AP; ROONEY, TA; HIGASHI, K; RUBIN, E			ETHANOL AND SIGNAL TRANSDUCTION IN THE LIVER	FASEB JOURNAL			English	Article						LIVER; ETHANOL; SIGNAL TRANSDUCTION; ADENYLATE CYCLASE; PHOSPHOLIPASE-C; PHOSPHOLIPASE-D; CALCIUM; INOSITOL PHOSPHATE; PHOSPHATIDYLETHANOL	ADENYLATE-CYCLASE ACTIVITY; PHOSPHOLIPASE-C ACTIVATION; PROTEIN-KINASE; PHOSPHATIDYLCHOLINE BREAKDOWN; ISOLATED HEPATOCYTES; BIOLOGIC MEMBRANES; HUMAN-PLATELETS; FREE CALCIUM; PHOSPHATIDYLETHANOL; CELLS	The liver is a major target for both short- and long-term actions of ethanol. The mechanisms that mediate the response of cells and tissues to chronic intake of ethanol are unknown, but it is likely that both adaptive and deleterious responses are triggered by short-term interactions of the cell with ethanol. Cellular signaling processes are candidates to mediate the connection between short- and long-term actions of ethanol. Receptor-coupled signal transduction systems in the plasma membrane of many different cell types are affected by ethanol. In the liver, the signaling processes associated with phospholipases C and D are particularly responsive to ethanol. In this review, we investigate the direct and indirect short-term effects of ethanol on the signal transduction systems in liver and discuss the possible implications for the responses of the liver to chronic ethanol exposure.			HOEK, JB (corresponding author), THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,JEFFERSON ALUMNI HALL,RM 271,PHILADELPHIA,PA 19107, USA.		Thomas, Andrew/C-6755-2013	Hoek, Jan/0000-0001-7127-4218; Thomas, Andrew/0000-0002-9026-7467	NIAAA NIH HHS [AA07186, AA07215, AA08714] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008714, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLING C, 1984, BIOCHIM BIOPHYS ACTA, V793, P119, DOI 10.1016/0005-2760(84)90060-2; ASAOKA Y, 1988, FEBS LETT, V231, P221, DOI 10.1016/0014-5793(88)80735-X; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BODE DC, 1988, J PHARMACOL EXP THER, V246, P1040; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; CHATELAIN P, 1986, J MEMBRANE BIOL, V93, P23, DOI 10.1007/BF01871015; DAVIDSON M, 1988, NEUROSCI LETT, V89, P165, DOI 10.1016/0304-3940(88)90375-8; DEITRICH RA, 1989, PHARMACOL REV, V41, P489; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; EXTON JH, 1990, J BIOL CHEM, V265, P1; FAUSTO N, 1989, LAB INVEST, V60, P4; FRENCH SW, 1976, RES COMMUN CHEM PATH, V13, P283; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gonzales R A, 1987, Alcohol Alcohol Suppl, V1, P567; GONZALES RA, 1991, ALCOHOL, V8, P131, DOI 10.1016/0741-8329(91)91321-R; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; HARPER JC, 1991, ALCOHOL ALCOHOLISM, V26, P33; HIGASHI K, 1991, J BIOL CHEM, V266, P2178; HOEK JB, 1990, ALCOHOL ALCOHOLISM, V25, P143, DOI 10.1093/oxfordjournals.alcalc.a044989; HOEK JB, 1990, BIOCHEM J, V272, P59, DOI 10.1042/bj2720059; HOEK JB, 1988, BIOCHEM J, V251, P865, DOI 10.1042/bj2510865; HOEK JB, 1987, J BIOL CHEM, V262, P682; HOEK JB, 1988, SEMIN LIVER DIS, V8, P36, DOI 10.1055/s-2008-1040527; HOEK JB, 1991, ANN NY ACAD SCI, V625, P375, DOI 10.1111/j.1749-6632.1991.tb33865.x; HOEK JB, 1988, BIOMEDICAL SOCIAL AS, P651; HOFFMAN PL, 1986, MOL PHARMACOL, V30, P13; HOFFMAN PL, 1990, FASEB J, V4, P2612, DOI 10.1096/fasebj.4.9.2161371; HOUSLAY MD, 1983, CURR TOP MEMBR TRANS, V18, P179; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; KAWAHARA H, 1990, LIFE SCI, V47, P859, DOI 10.1016/0024-3205(90)90598-L; KISS Z, 1991, EUR J BIOCHEM, V197, P785, DOI 10.1111/j.1432-1033.1991.tb15972.x; KURIYAMA K, 1977, DRUG ALCOHOL DEPEN, V2, P335, DOI 10.1016/0376-8716(77)90036-9; LANGE LG, 1991, ANN NY ACAD SCI, V625, P802, DOI 10.1111/j.1749-6632.1991.tb33922.x; LIEBER CS, 1991, ALCOHOL CLIN EXP RES, V15, P573, DOI 10.1111/j.1530-0277.1991.tb00563.x; LUTHIN GR, 1984, J PHARMACOL EXP THER, V228, P579; MESSING RO, 1990, J NEUROCHEM, V55, P1383, DOI 10.1111/j.1471-4159.1990.tb03150.x; MOCHLYROSEN D, 1988, NATURE, V333, P848, DOI 10.1038/333848a0; MUELLER GC, 1988, P NATL ACAD SCI USA, V85, P9778, DOI 10.1073/pnas.85.24.9778; OMODEOSALE F, 1991, BIOCHEMISTRY-US, V30, P2477, DOI 10.1021/bi00223a026; POLOKOFF MA, 1985, BIOCHEMISTRY-US, V24, P3114, DOI 10.1021/bi00334a007; RABE CS, 1988, J PHARMACOL EXP THER, V244, P417; RABIN RA, 1986, BIOCHEM PHARMACOL, V35, P2331, DOI 10.1016/0006-2952(86)90459-4; RABIN RA, 1983, J PHARMACOL EXP THER, V227, P551; REINLIB L, 1990, BIOCHEM BIOPH RES CO, V173, P774, DOI 10.1016/S0006-291X(05)80854-X; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROONEY TA, 1989, J BIOL CHEM, V264, P6817; RUBIN R, 1987, ARCH BIOCHEM BIOPHYS, V256, P29, DOI 10.1016/0003-9861(87)90422-X; RUBIN R, 1988, BIOCHEM J, V254, P147, DOI 10.1042/bj2540147; RUBIN R, 1988, ARCH BIOCHEM BIOPHYS, V260, P480, DOI 10.1016/0003-9861(88)90472-9; RUBIN R, 1989, BIOCHEM PHARMACOL, V37, P2461; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; SIMONSSON P, 1989, ALCOHOL, V6, P475, DOI 10.1016/0741-8329(89)90055-4; SIMONSSON P, 1988, LIFE SCI, V42, P385, DOI 10.1016/0024-3205(88)90076-8; SIMONSSON P, 1991, J NEUROCHEM, V536, P2018; SKWISH S, 1990, LIFE SCI, V47, P1037, DOI 10.1016/0024-3205(90)90476-8; SMITH TL, 1990, LIFE SCI, V47, pPL115, DOI 10.1016/0024-3205(90)90292-Y; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; TARASCHI TF, 1985, LAB INVEST, V52, P120; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Thomas A.P., 1989, CELL CALCIUM METABOL, P169; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; VOLICER L, 1975, ADV EXP MED BIOL, V56, P221; WHETTON AD, 1983, BIOCHEM PHARMACOL, V32, P1601, DOI 10.1016/0006-2952(83)90334-9; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; ZEDERMAN R, 1977, FEBS LETT, V75, P291, DOI 10.1016/0014-5793(77)80105-1	71	146	148	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2386	2396		10.1096/fasebj.6.7.1563591	http://dx.doi.org/10.1096/fasebj.6.7.1563591			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563591				2022-12-28	WOS:A1992HP03000003
J	ARAGON, JJ; SOLS, A				ARAGON, JJ; SOLS, A			REGULATION OF ENZYME-ACTIVITY IN THE CELL - EFFECT OF ENZYME CONCENTRATION	FASEB JOURNAL			English	Review						ENZYME REGULATION; ENZYME-ENZYME INTERACTIONS; PERMEABILIZED CELLS; PHOSPHOFRUCTOKINASE	ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; RAT-LIVER PHOSPHOFRUCTOKINASE; ALLOSTERIC BEHAVIOR; POLYETHYLENE-GLYCOL; CITRATE SYNTHASE; MUSCLE PHOSPHOFRUCTOKINASE; MALATE-DEHYDROGENASE; KINETIC-BEHAVIOR; FRUCTOSE 2,6-BISPHOSPHATE; ERYTHROCYTE-MEMBRANES	The rapid development in our understanding of the regulation of enzyme activity makes it a high priority to ascertain whether the behavior of purified enzymes reflects their functional characteristics in vivo. Enzyme concentration is usually the most significant difference between routine in vitro assays and in vivo conditions, as it is well known that many intracellular enzymes are present in vivo at much higher concentrations than used in vitro. Various procedures are suitable for kinetic analysis at physiological concentrations of enzyme. Those more frequently used have been cell permeabilization, the utilization of purified enzymes at concentrations close to the in vivo range, and the addition of polyethylene glycol to increase the local protein concentration. In this review we briefly summarize observations on enzymes reported to exhibit concentration-dependent activity. The effect of enzyme concentration has been most thoroughly investigated in the case of phosphofructokinase. These studies may provide insight into the regulation of this important enzyme in the cell. The implications of both homologous and heterologous protein-protein interactions for the effect of enzyme concentration and their roles in the control of enzyme activity in vivo are also discussed.	UNIV AUTONOMA MADRID,FAC MED,CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	ARAGON, JJ (corresponding author), UNIV AUTONOMA MADRID,FAC MED,DEPT BIOQUIM,ARZOBISPO MORCILLO 4,E-28029 MADRID,SPAIN.							ARAGON JJ, 1980, P NATL ACAD SCI-BIOL, V77, P6324, DOI 10.1073/pnas.77.11.6324; ARAGON JJ, 1986, EUR J BIOCHEM, V161, P757, DOI 10.1111/j.1432-1033.1986.tb10504.x; ARAGON JJ, 1985, BIOCHEM BIOPH RES CO, V131, P849, DOI 10.1016/0006-291X(85)91317-8; ARAGON JJ, 1978, DYNAMICS BIOCH SYSTE, V117, P197; BACKMAN L, 1976, FEBS LETT, V65, P39, DOI 10.1016/0014-5793(76)80616-3; BAR J, 1986, EUR J BIOCHEM, V56, P311; BAR J, 1990, BIOCHEM BIOPH RES CO, V67, P1214; BATKE J, 1989, FEBS LETT, V251, P13, DOI 10.1016/0014-5793(89)81419-X; BAUMANN P, 1968, BIOCHEMISTRY-US, V7, P3653, DOI 10.1021/bi00850a044; BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BERKOWITZ BA, 1989, METHOD ENZYMOL, V1176, P330; BIJLEVELD C, 1987, BIOCHIM BIOPHYS ACTA, V918, P274, DOI 10.1016/0005-2760(87)90231-1; BOON MR, 1988, BIOCHEM J, V249, P645, DOI 10.1042/bj2490645; BOSCA L, 1985, J BIOL CHEM, V260, P2100; CASTELLOT JJ, 1979, J BIOL CHEM, V254, P6904; CASTELLOT JJ, 1978, P NATL ACAD SCI USA, V75, P351, DOI 10.1073/pnas.75.1.351; CHEN JJ, 1979, J BIOL CHEM, V224, P2697; COHEN NS, 1987, J BIOL CHEM, V262, P203; DATTA A, 1985, J BIOL CHEM, V260, P5008; EAGLE GR, 1981, ARCH BIOCHEM BIOPHYS, V210, P540, DOI 10.1016/0003-9861(81)90220-4; FAHIEN LA, 1983, ARCH BIOCHEM BIOPHYS, V220, P386, DOI 10.1016/0003-9861(83)90428-9; FELIX H, 1982, ANAL BIOCHEM, V120, P211, DOI 10.1016/0003-2697(82)90340-2; GANKEMA HS, 1981, EUR J BIOCHEM, V119, P409, DOI 10.1111/j.1432-1033.1981.tb05623.x; GOWDA LR, 1988, ANAL BIOCHEM, V175, P531, DOI 10.1016/0003-2697(88)90579-9; HALPER LA, 1977, ARCH BIOCHEM BIOPHYS, V184, P529, DOI 10.1016/0003-9861(77)90462-3; HARDS RG, 1986, ENZYME, V35, P117, DOI 10.1159/000469333; HESS B, 1972, PROTEIN PROTEIN INTE, P271; HESTERBERG LK, 1981, BIOCHEMISTRY-US, V20, P2974, DOI 10.1021/bi00513a040; HIGASHI T, 1979, J BIOL CHEM, V254, P9542; HILDERMAN RH, 1975, J BIOL CHEM, V220, P4796; Hue L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P247; HULME EC, 1971, FEBS LETT, V12, P197, DOI 10.1016/0014-5793(71)80019-4; JHOFER HW, 1971, HOPPESEYLERS Z PHYSL, V352, P997; JORGENSON RA, 1980, J BIOL CHEM, V225, P5907; KASAHARA M, 1977, ARCH BIOCHEM BIOPHYS, V184, P400, DOI 10.1016/0003-9861(77)90367-8; Katz J, 1976, Curr Top Cell Regul, V10, P237; KELETI T, 1988, CURR TOP CELL REGUL, V29, P1; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; Lazo PA, 1980, BIOCHEM SOC T, V8, P579, DOI 10.1042/bst0080579; MARETZKI D, 1989, TRENDS BIOCHEM SCI, V14, P93, DOI 10.1016/0968-0004(89)90128-X; MARTINEK K, 1982, SCIENCE, V218, P889, DOI 10.1126/science.6753152; MAYR GW, 1984, EUR J BIOCHEM, V143, P513, DOI 10.1111/j.1432-1033.1984.tb08400.x; MEDINA R, 1985, FEBS LETT, V180, P77, DOI 10.1016/0014-5793(85)80235-0; MORTBERG M, 1987, BIOCHEM BIOPH RES CO, V146, P41, DOI 10.1016/0006-291X(87)90687-5; OVADI J, 1986, BIOCHEM BIOPH RES CO, V135, P852, DOI 10.1016/0006-291X(86)91006-5; PORPACZY Z, 1983, BIOCHIM BIOPHYS ACTA, V749, P172, DOI 10.1016/0167-4838(83)90249-2; REEVES RE, 1973, BIOCHEM BIOPH RES CO, V50, P459, DOI 10.1016/0006-291X(73)90862-0; REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1484, DOI 10.1021/bi00548a035; REINHART GD, 1980, J BIOL CHEM, V255, P576; REINHART GD, 1987, ARCH BIOCHEM BIOPHYS, V258, P65, DOI 10.1016/0003-9861(87)90323-7; ROBERTS SJ, 1987, BIOCHEMISTRY-US, V26, P3437, DOI 10.1021/bi00386a028; ROBINSON JB, 1987, J BIOL CHEM, V262, P1786; RODRIGUEZFERNANDEZ JL, 1987, BIOCHEM INT, V14, P539; SALTER M, 1984, BIOCHEM J, V221, P431, DOI 10.1042/bj2210431; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Sols A., 1970, CURRENT TOPICS CELLU, V2, P227; SOLS A, 1976, METABOLIC INTERCONVE, P191; SOLS A, 1981, METABOLIC INTERCONVE, P111; SRERE PA, 1967, SCIENCE, V158, P936, DOI 10.1126/science.158.3803.936; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; SRIVASTAVA DK, 1987, BIOCHEMISTRY-US, V26, P1240, DOI 10.1021/bi00379a006; SUMEGI B, 1983, BIOCHIM BIOPHYS ACTA, V749, P163, DOI 10.1016/0167-4838(83)90248-0; SUMEGI B, 1990, BIOCHEMISTRY-US, V29, P9106, DOI 10.1021/bi00491a002; SWEEZEY RR, 1988, P NATL ACA DSCI US, V85, P812; THOMAS AP, 1986, BIOCHEM J, V238, P93, DOI 10.1042/bj2380093; UYEDA K, 1974, J BIOL CHEM, V249, P4562; VALDEZ BC, 1989, J BIOL CHEM, V264, P131; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; WALSH JL, 1987, BIOCHIM BIOPHYS ACTA, V952, P83; WEBER JP, 1982, BIOCHEMISTRY-US, V21, P4189, DOI 10.1021/bi00260a042; WEITZMAN PD, 1973, FEBS LETT, V36, P227, DOI 10.1016/0014-5793(73)80374-6; WENZEL KW, 1976, EUR J BIOCHEM, V61, P181, DOI 10.1111/j.1432-1033.1976.tb10010.x; WIAME JM, 1971, CURRENT TOPICS CELLU, V4, P1; WRIGHT JA, 1981, ADV ENZYME REGUL, V19, P105; WU XM, 1991, P NATL ACAD SCI USA, V88, P497, DOI 10.1073/pnas.88.2.497	76	65	66	12	75	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2945	2950		10.1096/fasebj.5.14.1752361	http://dx.doi.org/10.1096/fasebj.5.14.1752361			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752361				2022-12-28	WOS:A1991GP26900009
J	MERRILL, JE; CHEN, ISY				MERRILL, JE; CHEN, ISY			HIV-1, MACROPHAGES, GLIAL-CELLS, AND CYTOKINES IN AIDS NERVOUS-SYSTEM DISEASE	FASEB JOURNAL			English	Review						ASTROGLIOSIS; MICROGLIA NODULES; CYTOKINES; ASTROCYTES	HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; IMMUNE-DEFICIENCY-SYNDROME; DISTINCT CELLULAR TROPISMS; PERIPHERAL-BLOOD MONOCYTES; COLONY-STIMULATING FACTORS; MULTIPLE-SCLEROSIS BRAIN; FACTOR-ALPHA; MONONUCLEAR PHAGOCYTES; CEREBROSPINAL-FLUID	Hallmarks of central nervous system (CNS) disease in AIDS patients are headaches, fever, subtle cognitive changes, abnormal reflexes, and ataxia. Dementia and severe sensory and motor dysfunction characterize more severe disease. Autoimmune-like peripheral neuropathies, cerebrovascular disease, and brain tumors are also observed. Histological changes include inflammation, astrocytosis, microglial nodule formation, and diffuse de- or dysmyelination. Focal demyelination can also be seen. It is clear that AIDS-associated neurological diseases are correlated with greater levels of HIV-1 antigen or genome in tissues. In AIDS dementia, macrophages and microglial cells of the CNS are the predominant cell types infected and producing HIV-1. However, manifestations of the disease make it unlikely that direct infection by HIV-1 is responsible. It seems more likely that the effects are mediated through secretion of viral proteins or viral induction of cytokines that bind to glial cells and neurons. HIV-1 induction of such cytokines as interleukin 1 (IL 1) and tumor necrosis factor-alpha (TNF-alpha) may lead to an autocrine feedback loop involving further productive virus replication and induction of other cytokines such as interleukin 6 (IL 6) and granulocyte-macrophage colony-stimulating factor (GMCSF). Interleukin 1 and TNF-alpha in combination with IL 6 and GMCSF could account for many clinical and histopathological findings in AIDS nervous system diseases. As HIV-1 infected patients produce elevated levels of IL 1, TNF-alpha, and IL 6, it will be important to make a formal connection between the presence of these factors in the CNS, which are all products of activated macrophages, astroglia, and microglia, their in vivo induction directly by virus or indirectly by virus-induced intermediates, and the clinical and pathological conditions seen in the nervous system in this disease.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	MERRILL, JE (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, LOS ANGELES, CA 90024 USA.							AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; BLUME AJ, 1989, NEUROBIOL AGING, V10, P406, DOI 10.1016/0197-4580(89)90077-8; BREEN EC, 1990, J IMMUNOL, V144, P480; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHIODI F, 1987, J VIROL, V61, P1244, DOI 10.1128/JVI.61.4.1244-1247.1987; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLOUSE KA, 1989, J IMMUNOL, V142, P431; CORNBLATH DR, 1987, ANN NEUROL, V21, P32, DOI 10.1002/ana.410210107; DELAMONTE SM, 1987, NEUROLOGY, V37, P562, DOI 10.1212/WNL.37.4.562; DEWHURST S, 1987, FEBS LETT, V213, P133, DOI 10.1016/0014-5793(87)81478-3; DICKSON DW, 1989, APMIS, V97, P40; DIEDERICH N, 1988, EUR NEUROL, V28, P93, DOI 10.1159/000116238; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; DREYER E B, 1990, Society for Neuroscience Abstracts, V16, P610; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FARRAR WL, 1987, J IMMUNOL, V139, P459; FONTANA A, 1982, J IMMUNOL, V129, P2413; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FUNKE I, 1987, J EXP MED, V165, P1230, DOI 10.1084/jem.165.4.1230; GABUZDA DH, 1986, ANN NEUROL, V20, P289, DOI 10.1002/ana.410200304; GALLO P, 1989, J NEUROIMMUNOL, V23, P41, DOI 10.1016/0165-5728(89)90071-4; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; GENDELMAN HE, 1990, J EXP MED, V172, P1433, DOI 10.1084/jem.172.5.1433; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GORIN FA, 1985, ARCH NEUROL-CHICAGO, V42, P162, DOI 10.1001/archneur.1985.04060020076020; GORMAN SD, 1987, P NATL ACAD SCI USA, V84, P7644, DOI 10.1073/pnas.84.21.7644; GRANT I, 1988, J ROY COLL PHYS LOND, V22, P149; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; GRAY F, 1990, NEUROSURG REV, V13, P189, DOI 10.1007/BF00313017; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HILLMAN K, 1990, J IMMUNOL, V144, P2131; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HO DD, 1987, NEW ENGL J MED, V317, P278; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HOFMAN FM, 1986, J IMMUNOL, V136, P3239; HORI T, 1988, BRAIN RES BULL, V20, P75, DOI 10.1016/0361-9230(88)90010-X; ISRAEL N, 1989, J IMMUNOL, V143, P3956; JOHNSON RT, 1988, FASEB J, V2, P2970, DOI 10.1096/fasebj.2.14.2846395; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLEIHUES P, 1985, ACTA NEUROPATHOL, V68, P333, DOI 10.1007/BF00690837; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUNSCH C, 1990, INTERVIROLOGY, V31, P147, DOI 10.1159/000150149; KURE K, 1990, AM J PATHOL, V136, P1085; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; LEIST TP, 1988, J EXP MED, V167, P1743, DOI 10.1084/jem.167.5.1743; LEPEZUNIGA JL, 1987, J CLIN MICROBIOL, V25, P1695, DOI 10.1128/JCM.25.9.1695-1700.1987; LEVY JA, 1986, SCIENCE, V232, P998, DOI 10.1126/science.3010461; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LIPTON SA, 1990, SOC NEUR ABSTR, V16, P268; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAIER H, 1989, ACTA NEUROPATHOL, V78, P497, DOI 10.1007/BF00687711; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; MANN DL, 1990, J IMMUNOL, V144, P2152; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1991, IN PRESS DEV NEUROSC; MICHAELS J, 1988, ACTA NEUROPATHOL, V76, P373, DOI 10.1007/BF00686974; MOLINA JM, 1989, J CLIN INVEST, V84, P733, DOI 10.1172/JCI114230; MOLINA JM, 1990, J INFECT DIS, V161, P888, DOI 10.1093/infdis/161.5.888; MOLINA JM, 1990, J VIROL, V64, P2901, DOI 10.1128/JVI.64.6.2901-2906.1990; MUNIS JR, 1990, J CLIN INVEST, V85, P591, DOI 10.1172/JCI114478; NAKAJIMA K, 1989, J IMMUNOL, V142, P531; NAVIA BA, 1987, ARCH NEUROL-CHICAGO, V44, P65, DOI 10.1001/archneur.1987.00520130051017; NISHIDA T, 1989, FEBS LETT, V243, P25, DOI 10.1016/0014-5793(89)81210-4; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PERRY SW, 1990, AM J PSYCHIAT, V147, P696; PETITO CK, 1986, J NEUROPATH EXP NEUR, V45, P635, DOI 10.1097/00005072-198611000-00003; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; PORTEGIES P, 1989, BRIT MED J, V299, P819, DOI 10.1136/bmj.299.6703.819; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PUMAROLASUNE T, 1987, ANN NEUROL, V21, P490, DOI 10.1002/ana.410210513; RATNER L, 1987, AIDS RES HUM RETROV, V3, P147, DOI 10.1089/aid.1987.3.147; RHODES RH, 1987, HUM PATHOL, V18, P636, DOI 10.1016/S0046-8177(87)80365-9; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; SALAHUDDIN SZ, 1987, INT J CANCER, V39, P198, DOI 10.1002/ijc.2910390213; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SMITH TW, 1990, J NEUROPATH EXP NEUR, V49, P357, DOI 10.1097/00005072-199007000-00001; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360; VYAKARNAM A, 1990, AIDS, V4, P21, DOI 10.1097/00002030-199001000-00003; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILEY CA, 1988, AM J PATHOL, V133, P73; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; WRIGHT SC, 1988, J IMMUNOL, V141, P99; YAMATO K, 1990, J CLIN INVEST, V86, P1109, DOI 10.1172/JCI114815	102	371	373	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2391	2397		10.1096/fasebj.5.10.2065887	http://dx.doi.org/10.1096/fasebj.5.10.2065887			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065887				2022-12-28	WOS:A1991FW08700009
J	SHIMIZU, Y; SHAW, S				SHIMIZU, Y; SHAW, S			LYMPHOCYTE INTERACTIONS WITH EXTRACELLULAR-MATRIX	FASEB JOURNAL			English	Review						LYMPHOCYTE; EXTRACELLULAR MATRIX; INTEGRIN; MIGRATION	T-CELL ACTIVATION; CHICKEN GIZZARD 5'-NUCLEOTIDASE; FIBRONECTIN RECEPTOR COMPLEX; ADHESION MOLECULES; FUNCTIONAL INVOLVEMENT; MONOCLONAL-ANTIBODIES; COLLAGEN RECEPTOR; INTEGRIN FAMILY; LAMININ; RECOGNITION	To mediate an immune response, lymphocytes must be able to interact with and respond to the surrounding extracellular environment. In addition to cell surface molecules that facilitate adhesion of lymphocytes to other cells, recent studies have demonstrated that lymphocytes interact with glycoproteins and glycosaminoglycans that are major components of the extracellular matrix (ECM). Although many receptors mediating the effects of ECM components on lymphocyte function remain poorly defined, a number of lymphocyte ECM receptors have recently been identified; these include members of the integrin family of adhesion molecules as receptors have recently been identified; these include members of the integrin family of adhesion molecules as well as structurally unrelated molecules such as CD44 and CD26. Furthermore, as lymphocytes must be able to move and analyze various modes of regulation of cell-ECM interactions. As with other cell types, the ECM has been shown to have multiple effect of lymphocytes; functional analysis reveals effects of the ECM on lymphocyte migration, recognition/activation, and differentiation. These studies emphasize: 1) the importance of lymphocytes as a model system for identifying and analyzing ECM receptor expression and function, and 2) the multiple roles that the ECM plays in the function of the immune system in vivo.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Shimizu, Yoji/0000-0001-9760-0288				AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ARENCIBIA I, 1989, EUR J IMMUNOL, V19, P929, DOI 10.1002/eji.1830190521; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BRITZ JS, 1983, J IMMUNOL, V130, P1848; CARDARELLI PM, 1987, J CELL BIOL, V105, P499, DOI 10.1083/jcb.105.1.499; CHIQUETEHRISMANN R, 1990, FASEB J, V4, P2598, DOI 10.1096/fasebj.4.9.1693347; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DAVIS JM, 1990, CELL IMMUNOL, V129, P67, DOI 10.1016/0008-8749(90)90187-V; DAVIS LS, 1990, J IMMUNOL, V145, P785; EASTER DW, 1988, J SURG RES, V45, P370, DOI 10.1016/0022-4804(88)90133-3; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FLEISCHER B, 1987, J IMMUNOL, V138, P1346; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GISMONDI A, 1991, J IMMUNOL, V146, P384; GODFREY HP, 1990, LYMPHOKINE RES, V9, P435; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JANOSSY G, 1989, IMMUNOLOGY, V66, P517; KLINGEMANN HG, 1986, TRANSPLANTATION, V42, P412, DOI 10.1097/00007890-198610000-00017; KUBOTA K, 1988, IMMUNOL LETT, V18, P119, DOI 10.1016/0165-2478(88)90051-X; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; MAKGOBA MW, 1989, IMMUNOL TODAY, V10, P417, DOI 10.1016/0167-5699(89)90039-X; MASSAIA M, 1990, J IMMUNOL, V145, P1664; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NOJIMA Y, 1990, J EXP MED, V172, P1185, DOI 10.1084/jem.172.4.1185; OFOSUAPPIAH W, 1989, SCAND J IMMUNOL, V29, P517, DOI 10.1111/j.1365-3083.1989.tb01154.x; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; PICKER LJ, 1990, J IMMUNOL, V145, P3247; RUEGG CR, 1989, P NATL ACAD SCI USA, V86, P7437, DOI 10.1073/pnas.86.19.7437; RYBSKI JA, 1989, J LEUKOCYTE BIOL, V45, P35, DOI 10.1002/jlb.45.1.35; SALTINI C, 1988, CLIN IMMUNOL IMMUNOP, V46, P221, DOI 10.1016/0090-1229(88)90185-7; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANTONI A, 1989, J IMMUNOL, V143, P2415; SCHWARZ RE, 1988, J IMMUNOL, V141, P3318; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STOCHAJ U, 1990, EUR J CELL BIOL, V51, P335; STOCHAJ U, 1989, BIOCHIM BIOPHYS ACTA, V992, P385, DOI 10.1016/0304-4165(89)90101-3; Tanzer ML, 1989, CURR OPIN CELL BIOL, V1, P968, DOI 10.1016/0955-0674(89)90067-7; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YAMADA A, 1991, J IMMUNOL, V146, P53; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YOKOYAMA WM, 1989, IMMUNOL REV, V109, P153, DOI 10.1111/j.1600-065X.1989.tb00024.x; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	66	356	359	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2292	2299		10.1096/fasebj.5.9.1860621	http://dx.doi.org/10.1096/fasebj.5.9.1860621			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860621				2022-12-28	WOS:A1991FP87200011
J	WATSON, PA				WATSON, PA			FUNCTION FOLLOWS FORM - GENERATION OF INTRACELLULAR SIGNALS BY CELL-DEFORMATION	FASEB JOURNAL			English	Review						ADENYLATE CYCLASE; CELL SHAPE; ION CHANNEL; CYTOSKELETAL STRUCTURE; ENDOTHELIAL CELLS; CLUSTERING; ACTIN CYTOSKELETON	ARACHIDONIC-ACID RELEASE; CYCLIC-AMP ACCUMULATION; S49 LYMPHOMA-CELLS; PLATELET ACTIVATION; NA+/H+ ANTIPORTER; VOLUME REGULATION; PROTEIN-SYNTHESIS; SKELETAL-MUSCLE; CYTOCHALASIN-B; RAT-HEART	Cells are exposed during their lifetimes to an array of physical forces ranging from those generated by association with other cells and extracellular matrices to the constant forces placed on cells by gravity. Alterations in these forces, either with differentiation and development or changes in activity or behavior, result in modifications in the biochemistry and adaptation in structure and function of cells. Also, a variety of differentiated cells have unique shapes that relate to extremely specilized functions, with structure and function emerging concurrently. These observations lead to the concept that the forces perceived by cells may dictate their shape, and the combined effects of external physical stimuli and internal forces responsible for maintaining cell shape may stimulate alterations in cellular biochemistry. This review examines the state of our knowledge concerning the mechanisms through which physical forces are converted to biochemical signals (mechanotransduction), and speculates on the molecular structures that may be involved in mechanotransduction.			WATSON, PA (corresponding author), WEIS CTR RES,GEISINGER CLIN,DANVILLE,PA 17822, USA.							BENYA PD, 1988, J CELL BIOL, V106, P161, DOI 10.1083/jcb.106.1.161; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1, DOI 10.1152/ajprenal.1987.252.1.F1; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOSKETT JK, 1985, AM J PHYSIOL, V248, pC27, DOI 10.1152/ajpcell.1985.248.1.C27; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODMAN SR, 1983, AM J PHYSIOL, V244, pC121, DOI 10.1152/ajpcell.1983.244.3.C121; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HOFFMAN EP, 1987, NATURE, V330, P754, DOI 10.1038/330754a0; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; Ingber DE., 1985, GENE EXPRESSION NORM, P13; INSEL PA, 1982, J BIOL CHEM, V257, P9717; KAY MMB, 1973, NATURE, V244, P288, DOI 10.1038/244288a0; KENNEDY MS, 1979, MOL PHARMACOL, V16, P215; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KONG SK, 1989, BIOCHEM BIOPH RES CO, V165, P131, DOI 10.1016/0006-291X(89)91044-9; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEWIS SA, 1990, NEWS PHYSIOL SCI, V5, P112; LONDON RD, 1989, AM J PHYSIOL, V257, pF985, DOI 10.1152/ajprenal.1989.257.6.F985; MCDONALD JA, 1989, AM J PHYSIOL, V257, pL331, DOI 10.1152/ajplung.1989.257.6.L331; MELMED RN, 1981, J CELL BIOL, V90, P761, DOI 10.1083/jcb.90.3.761; MILLS JW, 1986, AM J PHYSIOL, V250, pC319, DOI 10.1152/ajpcell.1986.250.2.C319; MORGAN HE, 1989, J APPL CARDIOL, V4, P415; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; RICHTER EA, 1987, FEBS LETT, V217, P232, DOI 10.1016/0014-5793(87)80669-5; RUSSO LA, 1989, AM J PHYSIOL, V257, pE261, DOI 10.1152/ajpendo.1989.257.2.E261; SACHS F, 1987, FASEB J, V46, P12; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARKADI B, 1984, J GEN PHYSIOL, V83, P513, DOI 10.1085/jgp.83.4.513; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SCHWARTZ MA, 1990, J BIOL CHEM, V265, P1327; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; SWEATT JD, 1985, J BIOL CHEM, V260, P2910; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021; VONHARSDORF R, 1988, FEBS LETT, V233, P201, DOI 10.1016/0014-5793(88)81384-X; WATSON PA, 1990, J BIOL CHEM, V265, P6569; WATSON PA, 1989, AM J PHYSIOL, V256, pC1257, DOI 10.1152/ajpcell.1989.256.6.C1257; WATSON PA, 1989, J BIOL CHEM, V264, P14735; XENOPHONTOS XP, 1989, CIRC RES, V65, P647, DOI 10.1161/01.RES.65.3.647; ZIMMER HG, 1986, BASIC RES CARDIOL, V81, P127	49	325	329	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2013	2019		10.1096/fasebj.5.7.1707019	http://dx.doi.org/10.1096/fasebj.5.7.1707019			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	1707019				2022-12-28	WOS:A1991FF44200002
J	FALVEY, E; SCHIBLER, U				FALVEY, E; SCHIBLER, U			HOW ARE THE REGULATORS REGULATED	FASEB JOURNAL			English	Review						TRANSCRIPTION FACTOR; REGULATORY GENE; HOMEODOMAIN; DIFFERENTIAL SPLICING; PHOSPHORYLATION; DIMERIZATION	DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; DROSOPHILA EMBRYO; GENE-EXPRESSION; POU DOMAIN; PROMOTERS; CELLS; ACTIVATION; EXTINCTION; MORPHOGEN	The cell-type-specific expression of many genes is determined at the level of transcription. Transcription factors, acting as promoter and enhancer elements, are involved in the control of this process. To understand the basis of this regulation it has become important to analyze the control of transcription factors themselves. A variety of transcriptional, translational, and posttranslational mechanisms have been described, and are discussed in this review article.			FALVEY, E (corresponding author), UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND.							Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1990, IN PRESS MOL ASPECTS; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DESCOMBES P, 1990, IN PRESS GENES DEV; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KHUL D, 1987, CELL, V50, P1057; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, IN PRESS GENES DEV; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M., 1986, A GENETIC SWITCH; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	51	39	39	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					309	314		10.1096/fasebj.5.3.2001790	http://dx.doi.org/10.1096/fasebj.5.3.2001790			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001790				2022-12-28	WOS:A1991FC55600008
J	BAKER, ME				BAKER, ME			A COMMON ANCESTOR FOR HUMAN PLACENTAL 17-BETA-HYDROXYSTEROID DEHYDROGENASE, STREPTOMYCES-COELICOLOR ACTIII PROTEIN, AND DROSOPHILA-MELANOGASTER ALCOHOL-DEHYDROGENASE	FASEB JOURNAL			English	Article									UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	BAKER, ME (corresponding author), GE,CORP RES & DEV,BIOL SCI LAB,BLDG K1,ROOM 3C19,POB 8,SCHENECTADY,NY 12301, USA.			Baker, Michael/0000-0003-4387-3269				AGARWAL AK, 1989, 71ST END SOC ANN M, P182; BAKER ME, 1980, J STEROID BIOCHEM, V13, P993, DOI 10.1016/0022-4731(80)90175-2; BAKER ME, 1988, BIOCHEM J, V255, P748; BAKER ME, 1989, MOL ENDOCRINOL, V3, P881, DOI 10.1210/mend-3-5-881; BENNER SA, 1985, J AM CHEM SOC, V107, P5513, DOI 10.1021/ja00305a031; BENYAJATI C, 1981, P NATL ACAD SCI-BIOL, V78, P2717, DOI 10.1073/pnas.78.5.2717; BERGMAN K, 1988, J BACTERIOL, V170, P3249, DOI 10.1128/jb.170.7.3249-3254.1988; CAETANOANOLLES G, 1988, J BACTERIOL, V170, P3164, DOI 10.1128/jb.170.7.3164-3169.1988; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; COLEMAN JP, 1988, J BACTERIOL, V170, P2070, DOI 10.1128/jb.170.5.2070-2077.1988; DAVIS S, 1980, J CLIN ENDOCR METAB, V51, P1293, DOI 10.1210/jcem-51-6-1293; DAVIS T, 1988, MOL MICROBIOL, V2, P405, DOI 10.1111/j.1365-2958.1988.tb00045.x; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DOTHIE JM, 1985, BIOCHEM J, V230, P569, DOI 10.1042/bj2300569; DUESTER G, 1986, NUCLEIC ACIDS RES, V14, P1931, DOI 10.1093/nar/14.5.1931; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELDMAN D, 1988, UCLA S MOL CELLULAR, V75, P169; FIRMIN JL, 1986, NATURE, V324, P90, DOI 10.1038/324090a0; FISHER RF, 1987, GENETICS, V117, P191; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HERSHCOPF RJ, 1985, J CLIN ENDOCR METAB, V61, P1071, DOI 10.1210/jcem-61-6-1071; JANY KD, 1984, FEBS LETT, V165, P6, DOI 10.1016/0014-5793(84)80003-4; JORNVALL H, 1984, FEBS LETT, V165, P190, DOI 10.1016/0014-5793(84)80167-2; KITSON TM, 1986, BIOCHEMISTRY-US, V25, P4718, DOI 10.1021/bi00364a040; KREITMAN M, 1983, NATURE, V304, P412, DOI 10.1038/304412a0; LEROITH D, 1986, ROLE RECEPTORS BIOL, P127; LIN ECC, 1976, BIOSCIENCE, V26, P548, DOI 10.2307/1297270; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; MALPARTIDA F, 1987, NATURE, V325, P818, DOI 10.1038/325818a0; MARKAVERICH BM, 1988, J STEROID BIOCHEM, V30, P71, DOI 10.1016/0022-4731(88)90078-7; MARTIN PM, 1978, ENDOCRINOLOGY, V103, P1860, DOI 10.1210/endo-103-5-1860; MATSUMOTO N, 1985, J BIOCHEM-TOKYO, V97, P1501, DOI 10.1093/oxfordjournals.jbchem.a135205; MCEVILY AJ, 1988, BIOCHEMISTRY-US, V27, P4284, DOI 10.1021/bi00412a013; MORRIS HR, 1974, BIOCHEM J, V141, P701, DOI 10.1042/bj1410701; MURDOCK GL, 1986, BIOCHEMISTRY-US, V25, P641, DOI 10.1021/bi00351a019; NAVRE M, 1988, J CELL BIOL, V107, P279, DOI 10.1083/jcb.107.1.279; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; PETERS NK, 1986, SCIENCE, V233, P977, DOI 10.1126/science.3738520; PLACE AR, 1986, MULTIDOMAIN PROTEINS, P175; SCHNEIDER J, 1982, P NATL ACAD SCI-BIOL, V79, P3047, DOI 10.1073/pnas.79.9.3047; STACHEL SE, 1985, NATURE, V318, P624, DOI 10.1038/318624a0; STEFFENS JC, 1982, ANN BOT-LONDON, V50, P1; THONY B, 1987, NUCLEIC ACIDS RES, V15, P8479, DOI 10.1093/nar/15.20.8479; TOMKINS GM, 1975, SCIENCE, V189, P760, DOI 10.1126/science.169570; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAMADA M, 1987, J BIOL CHEM, V262, P5455; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	51	48	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1990	4	2					222	226		10.1096/fasebj.4.2.2153594	http://dx.doi.org/10.1096/fasebj.4.2.2153594			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CM418	2153594				2022-12-28	WOS:A1990CM41800012
J	MANCHESTER, JK; CHI, MMY; NORRIS, B; FERRIER, B; KRASNOV, I; NEMETH, PM; MCDOUGAL, DB; LOWRY, OH				MANCHESTER, JK; CHI, MMY; NORRIS, B; FERRIER, B; KRASNOV, I; NEMETH, PM; MCDOUGAL, DB; LOWRY, OH			EFFECT OF MICROGRAVITY ON METABOLIC ENZYMES OF INDIVIDUAL MUSCLE-FIBERS	FASEB JOURNAL			English	Article									WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; MINIST PUBL HLTH USSR,INST BIOMED PROBLEMS,MOSCOW,USSR; INSERM,F-69008 LYONS,FRANCE	Washington University (WUSTL); Russian Academy of Sciences; Institute of Biomedical Problems of the Russian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm)	MANCHESTER, JK (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS008862] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38375] Funding Source: Medline; NINDS NIH HHS [R01-NS08862] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; BURCH HB, 1963, J BIOL CHEM, V238, P2267; CHI MMY, 1988, BIOL REPROD, V39, P295, DOI 10.1095/biolreprod39.2.295; CHI MMY, 1986, AM J PHYSIOL, V251, pC633, DOI 10.1152/ajpcell.1986.251.4.C633; ESSEN B, 1975, ACTA PHYSIOL SCAND, V95, P153, DOI 10.1111/j.1748-1716.1975.tb10038.x; GRINDELAND RE, 1990, FASEB J, V4, P10, DOI 10.1096/fasebj.4.1.2403949; HENRIKSSON J, 1986, AM J PHYSIOL, V251, pC614, DOI 10.1152/ajpcell.1986.251.4.C614; HINTZ CS, 1980, AM J PHYSIOL, V239, pC58, DOI 10.1152/ajpcell.1980.239.3.C58; LOWRY CV, 1978, J BIOL CHEM, V253, P8269; MIU B, 1990, FASEB J, V4, P64, DOI 10.1096/fasebj.4.1.2136839; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PETTE D, 1973, PFLUG ARCH EUR J PHY, V338, P257, DOI 10.1007/BF00587391	12	41	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1990	4	1					55	63		10.1096/fasebj.4.1.1967237	http://dx.doi.org/10.1096/fasebj.4.1.1967237			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH311	1967237				2022-12-28	WOS:A1990CH31100011
J	Wang, L; Li, D; Su, XT; Zhao, YC; Huang, AX; Li, H; Li, J; Xia, W; Jia, TQ; Zhang, HW; Dong, J; Liu, XM; Shao, NS				Wang, Lin; Li, Da; Su, Xueting; Zhao, Yuechao; Huang, Aixue; Li, Hui; Li, Jie; Xia, Wei; Jia, Tianqi; Zhang, Hongwen; Dong, Jie; Liu, Xuemei; Shao, Ningsheng			AGO4 suppresses tumor growth by modulating autophagy and apoptosis via enhancing TRIM21-mediated ubiquitination of GRP78 in a p53-independent manner	ONCOGENE			English	Article; Early Access							ARGONAUTE PROTEINS; AUTOANTIGEN RO52; METASTASIS; GENERATION; HALLMARKS; TARGET; SENSOR; HSPA5	Argonaute proteins, which consist of AGO1, AGO2, AGO3 and AGO4, are key players in microRNA-mediated gene silencing. So far, few non-microRNA related biological roles of AGO4 have been reported. Here, we first found that AGO4 had low expression in non-small cell lung cancer (NSCLC) patient tumor tissues and could suppress NSCLC cell proliferation and metastasis. Subsequent studies on the mechanism showed that AGO4 could interact with the tripartite motif-containing protein 21 (TRIM21) and the glucose-regulated protein 78 (GRP78). AGO4 promoted ubiquitination of GRP78 by stabilizing TRIM21, a new specific ubiquitin E3 ligase for promoting K48-linked polyubiquitination of GRP78 confirmed in this paper, which resulted in induced cell apoptosis and inhibited autophagy by activating mTOR signal pathway. Further studies showed that p53 had dominant effects on TRIM21-GRP78 axis by directly increasing the expression of TRIM21 in p53 wild-type cells and AGO4 may alternatively regulate TRIM21-GRP78 axis in p53-deficient cells. We also found that overexpression of AGO4 results in suppression of multiple p53-deficient cell growth both in vivo and vitro. Together, we showed for the first time that the AGO4-TRIM21-GRP78 axis, as a new regulatory pathway, may be a novel potential therapeutic target for p53-deficient tumor treatment.	[Wang, Lin; Li, Da; Su, Xueting; Zhao, Yuechao; Huang, Aixue; Li, Hui; Li, Jie; Xia, Wei; Jia, Tianqi; Dong, Jie; Liu, Xuemei; Shao, Ningsheng] Beijing Inst Basic Med Sci, Beijing 100850, Peoples R China; [Li, Da] Chinese Acad Sci, Inst Zool, Beijing 100101, Peoples R China; [Su, Xueting] Chinese PLA Ctr Dis Control & Prevent, Beijing 100071, Peoples R China; [Zhang, Hongwen] Dongfang Hosp, Intervent Ward, Fuzhou 350025, Peoples R China	Academy of Military Medical Sciences - China; Chinese Academy of Sciences; Institute of Zoology, CAS	Dong, J; Liu, XM; Shao, NS (corresponding author), Beijing Inst Basic Med Sci, Beijing 100850, Peoples R China.	13661363367@163.com; luckjinjin@hotmail.com; shaoningsheng@bmi.ac.cn			National Natural Science Foundation of China [3120566, 31370794]; key R&D of the Ministry of Science and Technology of China [2016YFC1309604]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); key R&D of the Ministry of Science and Technology of China	This work was supported by the National Natural Science Foundation of China (3120566, 31370794) and the key R&D of the Ministry of Science and Technology of China (2016YFC1309604).	Adiliaghdam F, 2020, CELL REP, V30, P1690, DOI 10.1016/j.celrep.2020.01.021; Alomari M, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2021.105443; Bailly C, 2019, BIOCHEM PHARMACOL, V163, P269, DOI 10.1016/j.bcp.2019.02.038; Casas C, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00177; Chae YC, 2012, CANCER CELL, V22, P331, DOI 10.1016/j.ccr.2012.07.015; Chang YW, 2016, ONCOGENE, V35, P1517, DOI 10.1038/onc.2015.214; Du TD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10824-7; Espinosa A, 2009, J EXP MED, V206, P1661, DOI 10.1084/jem.20090585; Farshbaf M, 2020, J CONTROL RELEASE, V328, P932, DOI 10.1016/j.jconrel.2020.10.055; Fletcher AJ, 2015, P NATL ACAD SCI USA, V112, P10014, DOI 10.1073/pnas.1507534112; Fu YS, 2021, MOL CELL, V81, P3187, DOI 10.1016/j.molcel.2021.05.031; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hauptmann J, 2014, RNA, V20, P1532, DOI 10.1261/rna.045203.114; Hauptmann J, 2013, NAT STRUCT MOL BIOL, V20, P814, DOI 10.1038/nsmb.2577; Higgs R, 2008, J IMMUNOL, V181, P1780, DOI 10.4049/jimmunol.181.3.1780; Higgs R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011776; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kato H, 2012, CELL DEATH DIFFER, V19, P310, DOI 10.1038/cdd.2011.98; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim SY, 2018, AUTOPHAGY, V14, P385, DOI 10.1080/15548627.2017.1414126; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kong HJ, 2007, J IMMUNOL, V179, P26, DOI 10.4049/jimmunol.179.1.26; Kunishita Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00098; Lazzari E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103609; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Madhavan S, 2020, BIOCHIMIE, V175, P69, DOI 10.1016/j.biochi.2020.05.005; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; McEwan WA, 2013, NAT IMMUNOL, V14, P327, DOI 10.1038/ni.2548; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462; Modzelewski AJ, 2012, DEV CELL, V23, P251, DOI 10.1016/j.devcel.2012.07.003; Pobre KFR, 2019, J BIOL CHEM, V294, P2098, DOI 10.1074/jbc.REV118.002804; Qian Y, 2017, CANCER RES, V77, P1968, DOI 10.1158/0008-5472.CAN-16-1595; Shen JL, 2017, P NATL ACAD SCI USA, V114, pE4020, DOI 10.1073/pnas.1616060114; Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6; Wada K, 2006, BIOCHEM BIOPH RES CO, V342, P253, DOI 10.1016/j.bbrc.2006.01.144; Wada K, 2006, BIOCHEM BIOPH RES CO, V339, P415, DOI 10.1016/j.bbrc.2005.11.029; Wang P, 2020, SEMIN CANCER BIOL, V67, P131, DOI 10.1016/j.semcancer.2020.05.002; Wen X, 2020, SEMIN CANCER BIOL, V66, P3, DOI 10.1016/j.semcancer.2019.11.005; Xia SK, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-02786-6; Yamauchi K, 2008, FEBS J, V275, P1540, DOI 10.1111/j.1742-4658.2008.06313.x; Yang B, 2013, CELL MOL IMMUNOL, V10, P190, DOI 10.1038/cmi.2013.12; Yang LT, 2018, J INVEST DERMATOL, V138, P2568, DOI 10.1016/j.jid.2018.05.016; Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679; Zhang ZQ, 2013, NAT IMMUNOL, V14, P172, DOI 10.1038/ni.2492; Zuo YB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14948-z	51	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02526-0	http://dx.doi.org/10.1038/s41388-022-02526-0		NOV 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C9US	36371565				2022-12-28	WOS:000882350000001
J	Lakshmanan, I; Marimuthu, S; Chaudhary, S; Seshacharyulu, P; Rachagani, S; Muniyan, S; Chirravuri-Venkata, R; Atri, P; Rauth, S; Nimmakayala, RK; Siddiqui, JA; Gautam, SK; Shah, A; Natarajan, G; Parte, S; Bhyravbhatla, N; Mallya, K; Haridas, D; Talmon, GA; Smith, LM; Kumar, S; Ganti, AK; Jain, M; Ponnusamy, MP; Batra, SK				Lakshmanan, Imayavaramban; Marimuthu, Saravanakumar; Chaudhary, Sanjib; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Chirravuri-Venkata, Ramakanth; Atri, Pranita; Rauth, Sanchita; Nimmakayala, Rama Krishna; Siddiqui, Jawed Akhtar; Gautam, Shailendra K.; Shah, Ashu; Natarajan, Gopalakrishnan; Parte, Seema; Bhyravbhatla, Namita; Mallya, Kavita; Haridas, Dhanya; Talmon, Geoffrey A.; Smith, Lynette M.; Kumar, Sushil; Ganti, Apar Kishor; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.			Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							CANCER-CELLS; JAK2	MUC16, membrane-bound mucin, plays an oncogenic role in pancreatic ductal adenocarcinoma (PDAC). However, the pathological role of MUC16 in the PDAC progression, tumor microenvironment, and metastasis in cooperation with Kras(G12D) and Trp53(R172H) mutations remains unknown. Deletion of Muc16 with activating mutations Kras(G12D/+) and Trp53(R172H/+) in mice significantly decreased progression and prolonged overall survival in Kras(G12D/+); Trp53(R172H/+); Pdx-1-Cre; Muc16(-/-) (KPCM) and Kras(G12D/+); Pdx-1-Cre; Muc16(-/-) (KCM), as compared to Kras(G12D/+); Trp53(R172H/+); Pdx-1-Cre (KPC) and Kras(G12D/+); Pdx-1-Cre (KC) mice, respectively. Muc16 knockout pancreatic tumor (KPCM) displays decreased tumor microenvironment factors and significantly reduced incidence of liver and lung metastasis compared to KPC. Furthermore, in silico data analysis showed a positive correlation of MUC16 with activated stroma and metastasis-associated genes. KPCM mouse syngeneic cells had significantly lower metastatic and endothelial cell binding abilities than KPC cells. Similarly, KPCM organoids significantly decreased the growth rate compared to KPC organoids. Interestingly, RNA-seq data revealed that the cytoskeletal proteins Actg2, Myh11, and Pdlim3 were downregulated in KPCM tumors. Further knockdown of these genes showed reduced metastatic potential. Overall, our results demonstrate that Muc16 alters the tumor microenvironment factors during pancreatic cancer progression and metastasis by changing the expression of Actg2, Myh11, and Pdlim3 genes.	[Lakshmanan, Imayavaramban; Marimuthu, Saravanakumar; Chaudhary, Sanjib; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana; Muniyan, Sakthivel; Chirravuri-Venkata, Ramakanth; Atri, Pranita; Rauth, Sanchita; Nimmakayala, Rama Krishna; Siddiqui, Jawed Akhtar; Gautam, Shailendra K.; Shah, Ashu; Natarajan, Gopalakrishnan; Parte, Seema; Bhyravbhatla, Namita; Mallya, Kavita; Haridas, Dhanya; Kumar, Sushil; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Talmon, Geoffrey A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA; [Ganti, Apar Kishor; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Ganti, Apar Kishor] VA Nebraska Western Iowa Hlth Care Syst, Div Oncol Hematol, Dept Internal Med, Omaha, NE 68105 USA; [Ganti, Apar Kishor] Univ Nebraska Med Ctr, Omaha, NE 68105 USA; [Batra, Surinder K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	mpalanim@unmc.edu; sbatra@unmc.edu	Nimmakayala, Rama Krishna/CAG-5670-2022; Parte, Seema C/AAT-5014-2021	Nimmakayala, Rama Krishna/0000-0003-4637-4828; Parte, Seema C/0000-0002-2879-9534; Seshacharyulu, Parthasarathy/0000-0002-2348-3901; Muniyan, Sakthivel/0000-0001-9405-7857; CHAUDHARY, SANJIB/0000-0001-9630-1235	National Institutes of Health [P01 CA217798, R01 CA263575, R01 CA256973, R01 CA273349, R01 CA247471, R01 CA254036, R01 CA206444, R01 CA210637, R01 CA228524, F99 CA234962, U01 CA200466, U01 CA210240]; Nebraska Department of Health and Human Services [LB595]; US Department of Veterans Affairs [I01 BX004676]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Department of Health and Human Services; US Department of Veterans Affairs(US Department of Veterans Affairs)	We thank Dr. Richard R. Behringer, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, for providing the Muc16 whole-body knockout (C57BL/6J) mice. We thank Corinn Grabow for all the technical support. We thank the University of Nebraska Medical Center core facilities such as Advanced Microscopy Core Facility, Genomics Core Facility, and Tissue Science Facility. This work was, in parts, supported by the support from the National Institutes of Health P01 CA217798, R01 CA263575, R01 CA256973, R01 CA273349, R01 CA247471, R01 CA254036, R01 CA206444, R01 CA210637, R01 CA228524, F99 CA234962, U01 CA200466, and U01 CA210240, and the Nebraska Department of Health and Human Services LB595, US Department of Veterans Affairs (I01 BX004676).	Akita K, 2013, EUR J CELL BIOL, V92, P257, DOI 10.1016/j.ejcb.2013.10.005; Alistar A, 2017, LANCET ONCOL, V18, P770, DOI 10.1016/S1470-2045(17)30314-5; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Belisle JA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-118; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Buscail L, 2020, NAT REV GASTRO HEPAT, V17, P153, DOI 10.1038/s41575-019-0245-4; Caffrey T, 2019, FEBS LETT, V593, P2751, DOI 10.1002/1873-3468.13532; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chen SH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01870; Chen SH, 2012, FASEB J, V26, P1349, DOI 10.1096/fj.11-195669; Cheon DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004675; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; Connor AA, 2019, CANCER CELL, V35, P267, DOI 10.1016/j.ccell.2018.12.010; Das S, 2015, CANCER RES, V75, P4669, DOI 10.1158/0008-5472.CAN-15-1050; Das S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09759; Das S, 2015, ONCOTARGET, V6, P5772, DOI 10.18632/oncotarget.3308; Encarnacion-Rosado J, 2021, NAT REV GASTRO HEPAT, V18, P482, DOI 10.1038/s41575-021-00431-7; Felder M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-129; Gubbels JAA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-50; Haridas D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026839; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hingorani SR, 2018, J CLIN ONCOL, V36, P359, DOI 10.1200/JCO.2017.74.9564; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kaushik G, 2021, ONCOGENE, V40, P848, DOI 10.1038/s41388-020-01564-w; Lakshmanan I, 2016, ONCOGENE, V35, P4112, DOI 10.1038/onc.2015.478; Lakshmanan I, 2012, ONCOGENE, V31, P805, DOI 10.1038/onc.2011.297; Lakshmanan I, 2017, CLIN CANCER RES, V23, P3906, DOI 10.1158/1078-0432.CCR-16-2530; Lakshmanan I, 2015, ONCOTARGET, V6, P21085, DOI 10.18632/oncotarget.3912; Lee Jae W, 2016, Curr Protoc Pharmacol, V73, DOI 10.1002/cpph.2; Lennon S, 2019, CLIN CANCER RES, V25, P3352, DOI 10.1158/1078-0432.CCR-18-2811; Li GL, 2003, J IMMUNOL, V171, P669, DOI 10.4049/jimmunol.171.2.669; Mallya K, 2020, BIOL OPEN, V9, DOI 10.1242/bio.052878; Marimuthu S, 2022, MOL CANCER RES, V20, P1208, DOI 10.1158/1541-7786.MCR-21-0888; Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0; Muniyan Sakthivel, 2016, Genes Cancer, V7, P110, DOI 10.18632/genesandcancer.104; Nallasamy P, 2021, GASTROENTEROLOGY, V161, P1998, DOI 10.1053/j.gastro.2021.08.023; Nimmakayala RK, 2021, ONCOGENE, V40, P215, DOI 10.1038/s41388-020-01518-2; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Rauth S, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2021.188527; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sperb N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155486; Tian CX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22490-9; Tian CX, 2019, P NATL ACAD SCI USA, V116, P19609, DOI 10.1073/pnas.1908626116; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169	45	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5147	5159		10.1038/s41388-022-02493-6	http://dx.doi.org/10.1038/s41388-022-02493-6		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271032				2022-12-28	WOS:000870984500004
J	CROW, JF				CROW, JF			GENETICS 50 YEARS AGO	FASEB JOURNAL			English	Editorial Material											CROW, JF (corresponding author), UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706, USA.							Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; Cockayne EA, 1933, INHERITED ABNORMALIT; CROW JFH, 1990, WIS ACAD REV, V36, P19; Dobzhansky T., 1941, GENETICS ORIGIN SPEC; Haldane JBS, 1942, NEW PATHS GENETICS; LEDERBERG J, 1991, GENETICS, V129, P313; MULLER HJ, 1947, PROC R SOC SER B-BIO, V134, P1, DOI 10.1098/rspb.1947.0001; MULLER HJ, 1922, AM NAT, V46, P32; ROBERTS DAF, 1940, INTRO MED GENETICS; Schrodinger E, 1944, WHAT IS LIFE; SNYDER LH, 1941, MED GENETICS; STURTEVANT AH, 1939, INTRO GENETICS; WAARDENBURG PJ, 1932, MENSCHLICHE AUGE SEI; Wright S, 1941, PHYSIOL REV, V21, P487, DOI 10.1152/physrev.1941.21.3.487	14	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1992	6	10					2867	2869		10.1096/fasebj.6.10.1634051	http://dx.doi.org/10.1096/fasebj.6.10.1634051			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634051				2022-12-28	WOS:A1992JD95400018
J	CADOSSI, R; BERSANI, F; COSSARIZZA, A; ZUCCHINI, P; EMILIA, G; TORELLI, G; FRANCESCHI, C				CADOSSI, R; BERSANI, F; COSSARIZZA, A; ZUCCHINI, P; EMILIA, G; TORELLI, G; FRANCESCHI, C			LYMPHOCYTES AND LOW-FREQUENCY ELECTROMAGNETIC-FIELDS	FASEB JOURNAL			English	Review						LYMPHOCYTE; ELECTROMAGNETIC FIELDS; LECTIN; GENOTOXICITY	HUMAN PERIPHERAL LYMPHOCYTES; PULSED MAGNETIC-FIELDS; HUMAN LYMPHOID-CELLS; ELECTRIC-FIELDS; LOW-LEVEL; MITOGENIC STIMULATION; SURFACE-RECEPTORS; DOWNS-SYNDROME; DNA-SYNTHESIS; T-CELLS	Human lymphocytes have been used by several researchers to investigate the biological effect of electromagnetic fields (EMF). EMF modulate the response by lymphocytes to lectin stimulation. The size and direction of the effect depends both on the lymphocyte physiology and on the physical parameters characterizing the EMF. Lymphocytes have also been used to investigate the genotoxicity of EMP exposure.	UNIV MODENA,INST CLIN MED 2,I-41100 MODENA,ITALY; UNIV BOLOGNA,DEPT PHYS,I-40126 BOLOGNA,ITALY; UNIV MODENA,INST GEN PATHOL,I-41100 MODENA,ITALY	Universita di Modena e Reggio Emilia; University of Bologna; Universita di Modena e Reggio Emilia			Franceschi, Claudio/L-4484-2017	Franceschi, Claudio/0000-0001-9841-6386; Cossarizza, Andrea/0000-0002-5381-1558				BASERGA R, 1985, BIOL CELL REPRODUCTI; BASSETT CAL, 1982, JAMA-J AM MED ASSOC, V247, P623, DOI 10.1001/jama.247.5.623; BATTINI R, 1991, J BIOELECTRICITY, V10, P131, DOI 10.3109/15368379109031404; BAWIN SM, 1978, P NATL ACAD SCI USA, V75, P6314, DOI 10.1073/pnas.75.12.6314; BERSANI F, 1989, ALTA FREQ, V58, P375; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P1, DOI 10.1002/bem.2250060102; BORSALINO G, 1988, CLIN ORTHOP RELAT R, V237, P256; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; BRINKMANN K, 1987, 9TH BIOEL SOC ANN M; BYUS CV, 1984, BIOELECTROMAGNETICS, V5, P341, DOI 10.1002/bem.2250050307; CADOSSI R, 1989, EXP HEMATOL, V17, P88; CADOSSI R, 1991, EXP HEMATOL, V19, P196; CADOSSI R, 1988, BIOELECTROCH BIOENER, V19, P315, DOI 10.1016/0302-4598(88)80012-6; CADOSSI R, 1988, MODERN BIOELECTRICIT, P457; CANTINI M, 1986, J BIOELECTRICITY, V5, P91, DOI 10.3109/15368378609027720; CECCHERLLI G, 1987, BRAGS T, V7, P87; CHIABRERA A, 1984, BIOELECTROMAGNETICS, V5, P173, DOI 10.1002/bem.2250050206; CHIABRERA A, 1990, BRAGS T, V10, P14; CHIRICOLO M, 1984, GERONTOLOGY, V30, P145, DOI 10.1159/000212622; CLEARY SF, 1990, BIOELECTROMAGNETICS, V11, P47, DOI 10.1002/bem.2250110107; COHEN MM, 1986, BIOELECTROMAGNETICS, V7, P415, DOI 10.1002/bem.2250070409; COHEN MM, 1986, MUTAT RES, V172, P177, DOI 10.1016/0165-1218(86)90073-X; CONE RB, 1977, LYMPHOCYTES STRUCTUR; CONTI P, 1983, FEBS LETT, V162, P156, DOI 10.1016/0014-5793(83)81069-2; CONTI P, 1985, J BIOELECTRICITY, V4, P227, DOI 10.3109/15368378509040375; CONTI P, 1986, FEBS LETT, V199, P130, DOI 10.1016/0014-5793(86)81238-8; CONTI P, 1985, FEBS LETT, V181, P228; CORPS AN, 1982, BIOCHEM J, V204, P229, DOI 10.1042/bj2040229; Cossarizza A, 1990, Am J Med Genet Suppl, V7, P213; COSSARIZZA A, 1989, RADIAT RES, V118, P161, DOI 10.2307/3577431; COSSARIZZA A, 1989, BIOCHEM BIOPH RES CO, V160, P692, DOI 10.1016/0006-291X(89)92488-1; Cossarizza A, 1991, Aging (Milano), V3, P241; COSSARIZZA A, 1991, BLOOD, V77, P1263; COSSARIZZA A, 1989, J BIOELECTRICITY, V8, P227, DOI 10.3109/15368378909020959; DAMBROSIO G, 1985, J BIOELECTRICITY, V4, P279, DOI 10.3109/15368378509040379; EMILIA G, 1985, J BIOELECTRICITY, V4, P145, DOI 10.3109/15368378509040369; EMILIA G, 1983, BRAGS T, V3, P69; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; FITZSIMMONS RJ, 1989, J CELL PHYSIOL, V139, P586, DOI 10.1002/jcp.1041390319; FRANCESCHI C, 1981, J IMMUNOL, V126, P2161; FRANCESCHI C, 1986, TOPICS AGING RES EUR, V9, P77; FRAZIER ME, 1990, BIOELECTROMAGNETICS, V11, P229, DOI 10.1002/bem.2250110304; FREEDMAN MH, 1975, NATURE, V255, P378, DOI 10.1038/255378a0; GARCIASAGREDO JM, 1990, ENVIRON MOL MUTAGEN, V16, P185, DOI 10.1002/em.2850160306; GIGANTE GE, 1987, BRAGS T, V7, P55; GOODMAN EM, 1986, FEBS LETT, V199, P275, DOI 10.1016/0014-5793(86)80494-X; GOODMAN R, 1983, SCIENCE, V220, P1283, DOI 10.1126/science.6857248; GOODMAN R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P216, DOI 10.1016/0167-4781(89)90105-X; GRATTAROLA M, 1982, STUD BIOPHYS, V91, P117; GREENE JJ, 1991, BIOCHEM BIOPH RES CO, V174, P742, DOI 10.1016/0006-291X(91)91480-Z; HELLMAN KB, 1985, 7TH ANN M BIOEL SOC; HENRY PH, 1977, HEMATOLOGY, P895; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; IERAN M, 1990, J ORTHOPAED RES, V8, P276, DOI 10.1002/jor.1100080217; INMAN DR, 1963, J CELL BIOL, V19, P441, DOI 10.1083/jcb.19.2.441; JAUCHEM JR, 1990, LANCET, V336, P884, DOI 10.1016/0140-6736(90)92397-Z; KHALIL AM, 1991, MUTAT RES, V247, P141, DOI 10.1016/0027-5107(91)90041-L; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LIBOFF AR, 1991, BIOELECTROMAGNETICS, V12, P77, DOI 10.1002/bem.2250120203; LIBOFF AR, 1987, J BIOELECTRICITY, V6, P13; LIBOFF AR, 1984, SCIENCE, V223, P818, DOI 10.1126/science.6695183; LICHTMAN AH, 1983, BLOOD, V61, P413; LINLIU S, 1984, BIOPHYS J, V45, P1211, DOI 10.1016/S0006-3495(84)84270-8; LIVINGSTON GK, 1991, ENVIRON MOL MUTAGEN, V17, P49, DOI 10.1002/em.2850170108; LUBEN RA, 1982, P NATL ACAD SCI-BIOL, V79, P4180, DOI 10.1073/pnas.79.13.4180; LYLE DB, 1991, BIOELECTROMAGNETICS, V12, P145, DOI 10.1002/bem.2250120303; LYLE DB, 1988, BIOELECTROMAGNETICS, V9, P303, DOI 10.1002/bem.2250090311; LYLE DB, 1989, 11TH BIOEL SOC ANN M; MAIZEL AL, 1981, J IMMUNOL, V127, P1058; MARRON MT, 1988, FEBS LETT, V230, P13, DOI 10.1016/0014-5793(88)80631-8; MCLEOD BR, 1986, BIOELECTROMAGNETICS, V7, P177, DOI 10.1002/bem.2250070208; MILLER RA, 1987, J CELL PHYSIOL, V132, P337, DOI 10.1002/jcp.1041320220; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; MONSON RR, 1990, AM J EPIDEMIOL, V131, P774, DOI 10.1093/oxfordjournals.aje.a115567; MONTI MG, 1991, J BIOELECTRICITY, V10, P119, DOI 10.3109/15368379109031403; MOONEY NA, 1986, BIOELECTROMAGNETICS, V7, P387, DOI 10.1002/bem.2250070406; MOORHEAD PS, 1960, EXP CELL RES, V20, P613, DOI 10.1016/0014-4827(60)90138-5; NEWMAN ME, 1991, J NATL CANCER I, V83, P164, DOI 10.1093/jnci/83.3.164; NORDENSON I, 1984, RADIAT ENVIRON BIOPH, V23, P191, DOI 10.1007/BF01213221; NOWELL PC, 1960, CANCER RES, V20, P462; OTTANI V, 1984, J ANAT, V139, P253; PERRY P, 1975, NATURE, V258, P121, DOI 10.1038/258121a0; PETRINI M, 1990, J BIOELECTRICITY, V9, P159, DOI 10.3109/15368379009119803; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; POLIDORI R, 1988, Medical Science Research, V16, P1117; POOL R, 1990, SCIENCE, V249, P1378, DOI 10.1126/science.2402634; POOL R, 1991, NATURE, V349, P554; RODAN GA, 1978, SCIENCE, V199, P690, DOI 10.1126/science.625660; ROSENTHAL M, 1989, MUTAT RES, V210, P329, DOI 10.1016/0027-5107(89)90094-8; RUNDLES RW, 1972, HEMATOLOGY, P880; SAVITZ DA, 1990, AM J EPIDEMIOL, V131, P763; SCARFI MR, 1991, BIOCHEM BIOPH RES CO, V176, P194, DOI 10.1016/0006-291X(91)90908-P; SHARRARD WJW, 1990, J BONE JOINT SURG BR, V72, P347, DOI 10.1302/0301-620X.72B3.2187877; SMITH GK, 1983, BIOCHIM BIOPHYS ACTA, V763, P325, DOI 10.1016/0167-4889(83)90093-9; SPECKART SF, 1978, BLOOD, V52, P681; TANAKA Y, 1963, BLOOD, V22, P614, DOI 10.1182/blood.V22.5.614.614; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WEI LX, 1990, BIOELECTROMAGNETICS, V11, P269, DOI 10.1002/bem.2250110403; WINTERS WD, 1985, 7TH ANN M BIOEL SOC	102	137	140	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2667	2674		10.1096/fasebj.6.9.1612290	http://dx.doi.org/10.1096/fasebj.6.9.1612290			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612290				2022-12-28	WOS:A1992HZ48100007
J	SCOTT, JE				SCOTT, JE			SUPRAMOLECULAR ORGANIZATION OF EXTRACELLULAR-MATRIX GLYCOSAMINOGLYCANS, INVITRO AND IN THE TISSUES	FASEB JOURNAL			English	Review						HYALURONAN; CHONDROITIN SULFATE; SECONDARY STRUCTURE; CORNEA; ULTRASTRUCTURE	DERMATAN SULFATE PROTEOGLYCANS; HYALURONATE SOLUTIONS; COLLAGEN INTERACTIONS; SELF-ASSOCIATION; CORNEAL STROMA; CONFORMATIONS; SEGMENTS; CHAINS	Connective tissues maintain shape against external and internal stress. They are molecular hierarchies in which fundamental building units come together in tiers of increasing complexity and mutual interactions, based on information carried in the precursor molecules secreted by cells. The collagen fibril is thc end product of well-understood self-aggregation controlled by its amino acid sequences, but the interfibrillar amorphous ground substance has not hitherto been seen as structured by analogous aggregations prescribed by the primary structures of the characteristic glycosaminoglycans dissolved therein. Transmission electron microscopy with morphometry and stereology has demonstrated their existence in tissues. Nuclear magnetic resonance defined their secondary structures, rotary shadowing electron microscopy delineated their aggregates in vitro, and molecular dynamics stimulations showed how the latter can spring from the former. The driving forces to aggregation are hydrophobic and hydrogen bonding, offset by electrostatic repulsion between polyanionic charges. The relative stabilities of the aggregates are determined by this balance, and hence by the position and number of their charges, particularly the sulfate ester groups. Corneal stroma is a system of collagen fibrils, highly ordered to ensure transparency, in which glycosaminoglycan aggregates are suggested to determine the ordered spacing as yardsticks in a way that has parallels in all connective tissues.			SCOTT, JE (corresponding author), UNIV MANCHESTER, MANCHESTER M13 9PL, LANCS, ENGLAND.							ARNOTT S, 1983, MOL BIOPHYSICS EXTRA; ATKINS EDT, 1980, INT J BIOL MACROMOL, V2, P318, DOI 10.1016/0141-8130(80)90053-7; ATKINS EDT, 1985, TOPICS STRUCTURE MOR; BALAZS EA, 1985, EYE, P533; BEATY NB, 1985, ANAL BIOCHEM, V147, P387, DOI 10.1016/0003-2697(85)90287-8; CASU B, 1986, NATURE, V322, P215, DOI 10.1038/322215b0; CHANG NS, 1985, MOL IMMUNOL, V22, P391; CLARKE DN, 1988, INT J MICROCIRC, V7, pS153; DARKE A, 1975, J MOL BIOL, V99, P477, DOI 10.1016/S0022-2836(75)80139-2; FESSLER JH, 1966, P NATL ACAD SCI USA, V56, P141, DOI 10.1073/pnas.56.1.141; FRANSSON LA, 1979, BIOCHIM BIOPHYS ACTA, V586, P179, DOI 10.1016/0304-4165(79)90416-1; FRANSSON LA, 1976, BIOCHIM BIOPHYS ACTA, V437, P106, DOI 10.1016/0304-4165(76)90351-2; GIBBS DA, 1968, BIOPOLYMERS, V6, P777, DOI 10.1002/bip.1968.360060603; GROSS J, 1948, J BIOL CHEM, V172, P511; GYI TJ, 1988, INT J BIOL MACROMOL, V10, P265, DOI 10.1016/0141-8130(88)90002-5; HOUSELL E, 1989, KERATAN SULFATE CHEM, P12; LAURENT T, 1989, CIBA F SYMP, V143, P1; MITRA AK, 1983, J MOL BIOL, V169, P873, DOI 10.1016/S0022-2836(83)80141-7; PFEILER E, 1988, FISH PHYSIOL BIOCHEM, V4, P175, DOI 10.1007/BF01871744; PRESTON BN, 1965, BIOCHEM J, V96, P449, DOI 10.1042/bj0960449; REN ZX, 1991, J STRUCT BIOL, V106, P57, DOI 10.1016/1047-8477(91)90062-2; SCOTT JE, 1990, BIOCHEM J, V270, P491, DOI 10.1042/bj2700491; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; SCOTT JE, 1991, BIOCHEM J, V275, P267, DOI 10.1042/bj2750267; SCOTT JE, 1978, BIOCHEM J, V173, P103, DOI 10.1042/bj1730103; SCOTT JE, 1991, BIOCHEM J, V274, P699, DOI 10.1042/bj2740699; SCOTT JE, 1989, CIBA F SYMP, V143, P6; SCOTT JE, 1983, EUR J BIOCHEM, V130, P491, DOI 10.1111/j.1432-1033.1983.tb07177.x; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1988, BIOCHEM J, V253, P607, DOI 10.1042/bj2530607; SCOTT JE, 1991, BIOCHEM SOC T, V19, P877, DOI 10.1042/bst0190877; SCOTT JE, 1975, PHILOS T ROY SOC B, V271, P235, DOI 10.1098/rstb.1975.0047; SCOTT JE, 1992, J ANAT, V180, P155; SCOTT JE, 1989, KERATAN SULFATE CHEM, P123; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; STASKUS PW, 1988, BIOCHEMISTRY-US, V27, P1528, DOI 10.1021/bi00405a020; TURLEY EA, 1980, NATURE, V283, P268, DOI 10.1038/283268a0; TURNER RE, 1988, ARCH BIOCHEM BIOPHYS, V265, P484, DOI 10.1016/0003-9861(88)90153-1; WARD NP, 1987, BIOCHEM J, V242, P761, DOI 10.1042/bj2420761; WELSH EJ, 1980, J MOL BIOL, V138, P375, DOI 10.1016/0022-2836(80)90293-4	40	308	313	5	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1992	6	9					2639	2645		10.1096/fasebj.6.9.1612287	http://dx.doi.org/10.1096/fasebj.6.9.1612287			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612287				2022-12-28	WOS:A1992HZ48100003
J	WALKER, FJ; FAY, PJ				WALKER, FJ; FAY, PJ			REGULATION OF BLOOD-COAGULATION BY THE PROTEIN-C SYSTEM	FASEB JOURNAL			English	Review						THROMBOMODULIN; FACTOR-5; FACTOR-VIII; PROTEIN-S	HUMAN FACTOR-VIII; THROMBIN-CATALYZED ACTIVATION; DENSITY LIPOPROTEIN RECEPTOR; GAMMA-CARBOXYGLUTAMIC ACID; PORCINE FACTOR-VIII; FACTOR-V; HUMAN THROMBOMODULIN; FACTOR-XA; RABBIT THROMBOMODULIN; VONWILLEBRAND-FACTOR	Protein C is a plasma, vitamin K-dependent zymogen of a serine protease that can inhibit blood coagulation. Protein C is regulated by a series of reactions known as the protein C pathway. The importance of this pathway is seen in the occurrence of thrombosis in individuals with deficiencies in elements of the pathway like protein C and protein S. Work on several steps in this pathway has revealed that mechanisms involved in activation of protein C and the expression of its anticoagulant activity have features that allow for the expression of the anticoagulant activity away from sites in which procoagulant reactions occur, but not systemically. Thrombin, the principal procoagulant enzyme at the site of an injury, is converted to an anticoagulant enzyme at distant sites through its interaction with the endothelial cell protein thrombomodulin. Structural and functional studies have revealed the importance of several domain structures in the modulation of thrombin activity. Structural features of both activated protein C and its substrates (coagulation factors V and VIII) are such that they require the localization of enzyme and substrate on the surface of phosphatidyl serine containing membranes for optimum activity.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT LAB MED,FARMINGTON,CT 06032; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14627; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14627	University of Connecticut; University of Connecticut; University of Rochester; University of Rochester	WALKER, FJ (corresponding author), AMER RED CROSS,BLOOD SERV,209 FARMINGTON AVE,FARMINGTON,CT 06032, USA.							BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON NL, 1983, J BIOL CHEM, V258, P2238; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FAY PJ, 1989, BIOCHIM BIOPHYS ACTA, V294, P142; FAY PJ, 1991, IN PRESS J BIOL CHEM; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FULCHER CA, 1984, BLOOD, V63, P486; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HAYASHI T, 1990, J BIOL CHEM, V265, P20156; HIRAHARA K, 1990, THROMB RES, V57, P117, DOI 10.1016/0049-3848(90)90200-V; HOFSTEENGE J, 1987, EUR J BIOCHEM, V168, P49, DOI 10.1111/j.1432-1033.1987.tb13385.x; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; JACKMAN RW, 1987, P NATL ACAD SCI USA, V84, P6425, DOI 10.1073/pnas.84.18.6425; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; KANE WH, 1988, BLOOD, V71, P539; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; MARLAR RA, 1982, BLOOD, V59, P1067; MISCI G, 1988, BIOCHEMISTRY-US, V27, P769; MUSCI G, 1987, J BIOL CHEM, V262, P13889; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PETERSEN TE, 1988, FEBS LETT, V231, P51, DOI 10.1016/0014-5793(88)80700-2; PREISSNER KT, 1990, DOMAIN STRUCTURE END; RICK ME, 1990, J LAB CLIN MED, V115, P415; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STENFLO J, 1988, J BIOL CHEM, V263, P21; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1990, J BIOL CHEM, V265, P1834	48	177	181	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2561	2567		10.1096/fasebj.6.8.1317308	http://dx.doi.org/10.1096/fasebj.6.8.1317308			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1317308				2022-12-28	WOS:A1992HU42300009
J	JOHNSON, LN				JOHNSON, LN			GLYCOGEN-PHOSPHORYLASE - CONTROL BY PHOSPHORYLATION AND ALLOSTERIC EFFECTORS	FASEB JOURNAL			English	Review						GLYCOGEN PHOSPHORYLASE; PHOSPHORYLATION; CATALYSIS; ALLOSTERIC CONTROL; GLYCOGEN METABOLISM	PYRIDOXAL 5'-PHOSPHATE; STRUCTURAL-CHANGES; REGULATORY SITES; PROTEIN; MUSCLE; ALPHA; MECHANISM; SYNTHASE; BINDING; 1-PHOSPHATE	Structural studies of muscle glycogen phosphorylase during the last two decades have provided a detailed mechanism for the molecular basis of the control by phosphorylation and by allosteric effectors and the catalytic mechanism. Control by phosphorylation is effected by a disorder to order transition of the NH2-terminal residues that promotes localized changes in the structure of the protein at the region of subunit-subunit contacts and larger changes in the quaternary structure. The covalently attached phosphate group acts like an allosteric effector but the full manifestation of the response is also dependent on the NH2-terminal tail residues. The noncovalently bound allosteric effectors produce similar shifts in the structural states although these are bound at sites that are remote from the serine-phosphate site. The communication from these sites to the catalytic site is through long-range interactions that result in activation of the enzyme through opening access to the buried catalytic site and through creation of the substrate phosphate recognition site by an interchange of an acidic group with a basic group. Recent advances in expression systems have opened the way to a study of properties both for the muscle and other isozymes and other species that should illuminate the different regulatory roles of the enzyme in different tissues and organisms. The allosteric mechanism of activation of phosphorylase by phosphorylation may be relevant to other enzymes although it is now known that other mechanisms such as electrostatic steric blocking mechanisms also exist.			JOHNSON, LN (corresponding author), UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND.							Acharya K.R., 1991, GLYCOGEN PHOSPHORYLA, V2nd; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BARFORD D, IN PRESS BIOCH BIOPS; BARFORD D, 1992, IN PRESS PROTEIN SCI; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; COATS WS, 1991, J BIOL CHEM, V266, P16113; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; GOLDSMITH EJ, 1989, T AM CHEM ASS, V25, P87; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUSEV NB, 1979, BIOCHEM BIOPH RES CO, V90, P70, DOI 10.1016/0006-291X(79)91591-2; HAJDU J, 1987, EMBO J, V6, P539, DOI 10.1002/j.1460-2075.1987.tb04786.x; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KASVINSKY PJ, 1981, CAN J BIOCHEM CELL B, V59, P387, DOI 10.1139/o81-054; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P3343; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P1290; KASVINSKY PJ, 1976, J BIOL CHEM, V251, P6852; KLEIN HW, 1984, BIOCHEMISTRY-US, V23, P5853, DOI 10.1021/bi00319a027; KLEIN HW, 1986, EUR J BIOCHEM, V157, P107, DOI 10.1111/j.1432-1033.1986.tb09645.x; KOKESH FC, 1977, BIOCHEMISTRY-US, V16, P2467, DOI 10.1021/bi00630a023; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; LEONIDAS DD, 1990, FEBS LETT, V261, P23, DOI 10.1016/0014-5793(90)80627-U; LEONIDAS DD, 1991, BIOCHIM BIOPHYS ACTA, V1076, P305, DOI 10.1016/0167-4838(91)90282-5; MADSEN NB, 1986, COENZYMES COFACTORS, P1; MADSEN NB, 1986, ENZYMES, V17, P366; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; MARTIN JL, 1989, THESIS U OXFORD OXFO; MEYER F, 1970, J BIOL CHEM, V245, P6642; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAKANO K, 1986, J BIOL CHEM, V261, P8230; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; OKONOMAKOS NG, 1991, POSTRANSLATIONAL MOD; PALM D, 1985, NATURE, V313, P500, DOI 10.1038/313500a0; PALM D, 1990, BIOCHEMISTRY-US, V29, P1099, DOI 10.1021/bi00457a001; PARRISH RF, 1977, BIOCHEMISTRY-US, V16, P139; PHILIP G, 1987, BIOCHEMISTRY-US, V21, P3042; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SCHINZEL R, 1991, J BIOL CHEM, V266, P9428; SCHINZEL R, 1990, BIOCHEMISTRY-US, V29, P9956, DOI 10.1021/bi00494a028; SCHINZEL R, 1991, FEBS LETT, V286, P125, DOI 10.1016/0014-5793(91)80956-4; SHIMOMURA S, 1978, BIOCHEMISTRY-US, V17, P5359, DOI 10.1021/bi00618a006; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; SPRANG S, 1982, BIOCHEMISTRY-US, V21, P2036, DOI 10.1021/bi00538a010; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Wang J. H, 1972, ENZYMES, V7, P435; WITHERS SG, 1981, J BIOL CHEM, V256, P759; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005	58	255	261	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1992	6	6					2274	2282		10.1096/fasebj.6.6.1544539	http://dx.doi.org/10.1096/fasebj.6.6.1544539			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544539				2022-12-28	WOS:A1992HJ25200003
J	MAKI, A; BEREZESKY, IK; FARGNOLI, J; HOLBROOK, NJ; TRUMP, BF				MAKI, A; BEREZESKY, IK; FARGNOLI, J; HOLBROOK, NJ; TRUMP, BF			ROLE OF [CA2+]I IN INDUCTION OF C-FOS, C-JUN, AND C-MYC MESSENGER-RNA IN RAT PTE AFTER OXIDATIVE STRESS	FASEB JOURNAL			English	Note						GENE EXPRESSION; FREE RADICAL; PROTOONCOGENE; CALCIUM; PROXIMAL TUBULAR EPITHELIUM	OXYGEN FREE-RADICALS; SEQUENTIAL PROTOONCOGENE EXPRESSION; BRONCHIAL EPITHELIAL-CELLS; PROTEIN KINASE-C; HYDROGEN-PEROXIDE; XANTHINE-OXIDASE; CYTO-TOXICITY; DNA-SYNTHESIS; 3T3 CELLS; ACTIVATION	Oxidative stress plays an important role in various types of cell injury and tumor promotion. Cells respond to oxidative stress in many ways including changes in membrane organization, ion movements, and altered gene expression, all of which contribute to the subsequent fate of affected cells. In this study, we investigated the expression of the proto-oncogenes c-fos, c-myc, and c-jun, which play a key role in proliferation and differentiation, using primary cultures of rat proximal tubular epithelium exposed to oxidative stress generated by the xanthine/xanthine oxidase system. This system generates superoxide and H2O2 in the extracellular space stimulating the release of active oxygen species from inflammatory cells. c-fos mRNA was expressed within 15 min, peaked at 30 min, and returned to constitutive levels by 3 h. c-jun mRNA began to rise after 30 min, peaked at 120 min, and remained above the constitutive levels up to 180 min. c-myc mRNA expression was less affected by the treatment, with levels increasing gradually over the 180 min period. The expression of c-fos was inhibited by superoxide dismutase but not by catalase and was super-induced by cycloheximide. H2O2 alone did not induce any c-fos mRNA in this system. Chelation of extracellular ionized calcium by EGTA or of intracellular ionized calcium by Quin 2/AM resulted in a marked decrease of c-fos expression. Two protein kinase C inhibitors, H-7 and staurosporine, partly diminished the expression of c-fos, whereas a third, 2-aminopurine, which has a broader spectrum of inhibiting protein kinases, almost completely abolished it. A poly ADP-ribosylation inhibitor, 3-aminobenzamide, had no effect on c-fos expression in this system. Our results show that oxidative stress provokes sequential expression of c-fos, c-jun, and c-myc, mRNA in this order. This c-fos expression appears to be largely controlled by calcium ion movement, which could include protein kinase C activation. Another protein kinase or kinases also appear to play an important role.	UNIV MARYLAND,SCH MED,DEPT PATHOL,10 S PINE ST,BALTIMORE,MD 21201; MARYLAND INST EMERGENCY MED SERV SYST,BALTIMORE,MD 21201; NIA,MOLEC GENET LAB,BALTIMORE,MD 21224	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015440] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15440] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAKER GL, 1985, ANN SURG, V202, P628, DOI 10.1097/00000658-198511000-00016; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTONI O, 1989, EUR J BIOCHEM, V182, P209, DOI 10.1111/j.1432-1033.1989.tb14819.x; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COWLEY BD, 1989, J BIOL CHEM, V264, P8389; CRAWFORD D, 1988, ONCOGENE, V3, P27; ELLIGET KA, 1991, CELL BIOL TOXICOL, V7, P263; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; FRANCESCHI D, 1990, SURGERY, V108, P292; FREEMAN BA, 1985, J BIOL CHEM, V261, P6590; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GLAUMANN B, 1975, VIRCHOWS ARCH B, V19, P303; HERRLICH P, 1990, MOL BIOL CANCER GENE, P150; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KOLBER MA, 1990, FASEB J, V4, P3021, DOI 10.1096/fasebj.4.12.2394319; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LINK EM, 1988, BIOCHEM J, V249, P391, DOI 10.1042/bj2490391; MILLER AD, 1984, CELL, V36, P51; MIYASHITA M, 1989, CANCER RES, V49, P63; MOORE JP, 1986, J BIOL CHEM, V261, P8158; NAKAMURA Y, 1988, CARCINOGENESIS, V9, P203, DOI 10.1093/carcin/9.2.203; NITTA N, 1989, CIRC SHOCK, V27, P333; OPIE LH, 1989, CIRCULATION, V80, P1049, DOI 10.1161/01.CIR.80.4.1049; OYANAGUI Y, 1977, BIOCHEM PHARMACOL, V26, P473; PALLER MS, 1984, J CLIN INVEST, V74, P1156, DOI 10.1172/JCI111524; PARKS DA, 1983, SURGERY, V94, P428; PARKS DA, 1983, SURGERY, V94, P415; PRASAD K, 1988, ANGIOLOGY, V39, P417, DOI 10.1177/000331978803900503; ROOTS R, 1975, RADIAT RES, V64, P306, DOI 10.2307/3574267; SCHACHTELE C, 1988, BIOCHEM BIOPH RES CO, V151, P542, DOI 10.1016/0006-291X(88)90628-6; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MW, 1991, P NATL ACAD SCI USA, V88, P4926, DOI 10.1073/pnas.88.11.4926; SWANN JD, 1991, TOXICOL PATHOL, V19, P128, DOI 10.1177/019262339101900207; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAMURA M, 1988, J BIOL CHEM, V263, P17621; THOMPSON NL, 1986, CANCER RES, V46, P3111; TRUMP BF, 1989, COMMENTS TOXICOL, V3, P47; VERMA IM, 1985, CANCER CELL, V3, P275; WANG ZW, 1983, J CELL BIOL, V96, P1743, DOI 10.1083/jcb.96.6.1743; WHITFIELD JF, 1990, CALCIUM CELL CYCLES, P201; WILLEY JC, 1984, CANCER RES, V44, P5124; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	51	158	158	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					919	924		10.1096/fasebj.6.3.1740241	http://dx.doi.org/10.1096/fasebj.6.3.1740241			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740241				2022-12-28	WOS:A1992HE39000017
J	HOLLENBERG, PF				HOLLENBERG, PF			MECHANISMS OF CYTOCHROME-P450 AND PEROXIDASE-CATALYZED XENOBIOTIC METABOLISM	FASEB JOURNAL			English	Article						CYTOCHROME-P450; PEROXIDASE; MONOOXYGENASE; MIXED-FUNCTION OXIDASE; HYDROXYLATION	N-DEMETHYLATION REACTIONS; LIVER MICROSOMAL CYTOCHROME-P-450; HORSERADISH-PEROXIDASE; ELECTRON-TRANSFER; CHLOROPEROXIDASE; OXIDATION; HYDROXYLATION; AMINE; DEPROTONATION; CARBINOLAMINE	The cytochrome P450 enzyme systems catalyze the metabolism of a wide variety of naturally occurring and foreign compounds by reactions requiring NADPH and O2. Cytochrome P450 also catalyzes peroxide-dependent hydroxylation of substrates in the absence of NADPH and O2. Peroxidases such as chloroperoxidase and horseradish peroxidase catalyze peroxide-dependent reactions similar to those catalyzed by cytochrome P450. The kinetic and chemical mechanisms of the NADPH and O2-supported dealkylation reactions catalyzed by P450 have been investigated and compared with those catalyzed by P450 and peroxidases when the reactions are supported by peroxides. Detailed kinetic studies demonstrated that chloroperoxidase- and horseradish peroxidase-catalyzed N-demethylations proceed by a Ping Pong Bi Bi mechanism whereas P450-catalyzed O-dealkylations proceed by sequential mechanisms. Intramolecular isotope effect studies demonstrated that N-demethylations catalyzed by P450s and peroxidases proceed by different mechanisms. Most hemeproteins investigated catalyzed these reactions via abstraction of an alpha-carbon hydrogen whereas reactions catalyzed by P-450 and chloroperoxidase proceeded via an initial one-electron oxidation followed by alpha-carbon deprotonation. O-18-Labeling studies of the metabolism of NMC also demonstrated differences between the peroxidases and P450s. Because the hemeprotein prosthetic groups of P450, chloroperoxidase, and horseradish peroxidase are identical, the differences in the catalytic mechanisms result from differences in the environments provided by the proteins for the heme active site. It is suggested that the axial heme-iron thiolate moiety in P450 and chloroperoxidase may play a critical role in determining the mechanism of N-demethylation reactions catalyzed by these proteins.			HOLLENBERG, PF (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,DETROIT,MI 48201, USA.		Hollenberg, Paul F/A-7538-2009		NCI NIH HHS [CA 16954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA016954, R01CA016954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELMONEM MM, 1975, J MED CHEM, V18, P427, DOI 10.1021/jm00238a021; BLACK SD, 1986, CYTOCHROME P450 STRU, P161; BLANKE SR, 1988, J BIOL CHEM, V263, P18739; CHEN CD, 1985, ARCH BIOCHEM BIOPHYS, V238, P195, DOI 10.1016/0003-9861(85)90156-0; CROWLEY JR, 1991, FASEB J, V5, pA1517; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DINNOCENZO JP, 1989, J AM CHEM SOC, V111, P8646, DOI 10.1021/ja00205a014; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; GUENGERICH FP, 1984, J MED CHEM, V27, P1101, DOI 10.1021/jm00375a002; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P21, DOI 10.1021/tx00013a004; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; HEWSON WD, 1979, PORPHYRINS, V7, P295; HOLLENBERG PF, 1973, J BIOL CHEM, V248, P2630; HOLLENBERG PF, 1974, J BIOL CHEM, V249, P5816; HOLLENBERG PF, 1985, DRUG METAB DISPOS, V13, P272; JONES JP, 1990, J MED CHEM, V33, P1242, DOI 10.1021/jm00166a024; KADLUBAR FF, 1973, BIOCHEM BIOPH RES CO, V54, P1225; KEDDERIS GL, 1986, J BIOL CHEM, V261, P5910; KEDDERIS GL, 1983, J BIOL CHEM, V258, P2413; KEDDERIS GL, 1983, MOL PHARMACOL, V23, P758; KEDDERIS GL, 1980, J BIOL CHEM, V255, P174; KEDDERIS GL, 1983, J BIOL CHEM, V258, P8129; KOOP DR, 1980, J BIOL CHEM, V255, P9685; LEWIS FD, 1980, J AM CHEM SOC, V102, P1751, DOI 10.1021/ja00525a061; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; MIWA GT, 1980, J BIOL CHEM, V255, P6049; MIWA GT, 1983, J BIOL CHEM, V258, P4445; MIWA GT, 1980, MICROSOMES DRUG OXID, V1, P363; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PANDEY RN, 1989, BIOCHEM PHARMACOL, V38, P2181, DOI 10.1016/0006-2952(89)90074-9; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POTTER DW, 1987, J BIOL CHEM, V262, P974; RAHIMTULA AD, 1974, BIOCHEM BIOPH RES CO, V60, P440, DOI 10.1016/0006-291X(74)90223-X; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; ROSENBLATT DH, 1968, J ORG CHEM, V33, P1649, DOI 10.1021/jo01268a076; SHEA JP, 1982, BIOCHEM BIOPH RES CO, V109, P231, DOI 10.1016/0006-291X(82)91589-3; SHONO T, 1982, J AM CHEM SOC, V104, P2639, DOI 10.1021/ja00373a053; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WISLOCKI PG, 1980, ENZYMATIC BASIS DETO, V1, P135; ZIEGLER DM, 1964, BIOCHEM BIOPH RES CO, V15, P188, DOI 10.1016/0006-291X(64)90322-5	45	82	85	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					686	694		10.1096/fasebj.6.2.1537457	http://dx.doi.org/10.1096/fasebj.6.2.1537457			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537457				2022-12-28	WOS:A1992GZ44000007
J	HANSON, RW				HANSON, RW			WOOD,HARLAND,G. - SEPTEMBER 2, 1907 SEPTEMBER 12, 1991	FASEB JOURNAL			English	Item About an Individual											HANSON, RW (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106, USA.							KATZ J, 1963, J BIOL CHEM, V238, P517; LANDAU BR, 1964, J BIOL CHEM, V239, P686; WOOD HP, PUBLICATION LIST	3	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1991	5	15					3015	3017		10.1096/fasebj.5.15.1743434	http://dx.doi.org/10.1096/fasebj.5.15.1743434			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1743434				2022-12-28	WOS:A1991GU84200002
J	BURT, DR; KAMATCHI, GL				BURT, DR; KAMATCHI, GL			GABA-A RECEPTOR SUBTYPES - FROM PHARMACOLOGY TO MOLECULAR-BIOLOGY	FASEB JOURNAL			English	Review						GAMMA-AMINOBUTYRIC ACID; GABA RECEPTORS; BENZODIAZEPINES; BARBITURATES; ALCOHOL	GAMMA-AMINOBUTYRIC-ACID; GATED ION CHANNELS; PROTEIN-KINASE-C; A-RECEPTOR; ALPHA-SUBUNIT; BENZODIAZEPINE RECEPTORS; RAT-BRAIN; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; XENOPUS OOCYTES	GABA(A) receptors are GABA (gamma-aminobutyric acid)-gated chloride channels, which are major mediators of neuronal inhibition in the brain and are modulated by benzodiazepines, barbiturates, alcohol, and other important centrally acting drugs. Although previous pharmacological and biochemical data had suggested a degree of heterogeneity, recent cloning of at least 15 different receptor subunits, thought to be combined in groups of five, indicates that the brain may contain a truly astonishing variety of GABA(A) receptor subtypes. This review describes the little that is known about these subtypes, emphasizing possible molecular bases of receptor heterogeneity. We also discuss approaches to establishing the subunit composition of subtypes.			BURT, DR (corresponding author), UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201, USA.				NIAAA NIH HHS [AA07559] Funding Source: Medline; NINDS NIH HHS [NS25525] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025525] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ALLAN AM, 1988, BRAIN RES, V452, P118, DOI 10.1016/0006-8993(88)90016-9; BATESON AN, 1991, J NEUROCHEM, V56, P1437, DOI 10.1111/j.1471-4159.1991.tb11443.x; BENDER AS, 1987, J NEUROSCI RES, V18, P366, DOI 10.1002/jnr.490180215; BENKE D, 1991, J BIOL CHEM, V266, P4478; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BORMANN J, 1985, P NATL ACAD SCI USA, V82, P2168, DOI 10.1073/pnas.82.7.2168; BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BRAESTRUP C, 1981, J NEUROCHEM, V37, P333, DOI 10.1111/j.1471-4159.1981.tb00460.x; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; BUREAU M, 1990, MOL PHARMACOL, V37, P497; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CLEVELAND D W, 1989, New Biologist, V1, P121; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DENG L, 1991, J NEUROCHEM, V56, P968, DOI 10.1111/j.1471-4159.1991.tb02016.x; DINGLEDINE R, 1990, FASEB J, V4, P2636, DOI 10.1096/fasebj.4.9.2161372; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; FUCHS K, 1990, FEBS LETT, V261, P52, DOI 10.1016/0014-5793(90)80634-U; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; KATO K, 1990, J MOL BIOL, V214, P619, DOI 10.1016/0022-2836(90)90276-R; KEIR WJ, 1991, GENOMICS, V9, P390, DOI 10.1016/0888-7543(91)90272-G; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEEBLUNDBERG LMF, 1983, MOL PHARMACOL, V23, P315; LEIDENHEIMER NJ, 1991, TRENDS PHARMACOL SCI, V12, P84, DOI 10.1016/0165-6147(91)90509-Q; LEIDENHEIMER NJ, 1990, MOL PHARMACOL, V38, P823; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; LUDDENS H, 1991, TRENDS PHARMACOL SCI, V12, P49, DOI 10.1016/0165-6147(91)90495-E; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MOSS SJ, 1991, NEUROSCI LETT, V123, P265, DOI 10.1016/0304-3940(91)90947-R; MOSS SJ, 1990, EUR J PHARM-MOLEC PH, V189, P77, DOI 10.1016/0922-4106(90)90232-M; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1990, J CHEM NEUROANAT, V3, P58; OLSEN RW, 1986, RECEPTOR BIOCH METHO, V5; PORTER NM, 1990, NEURON, V5, P789, DOI 10.1016/0896-6273(90)90338-G; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1991, P NATL ACAD SCI USA, V88, P1421, DOI 10.1073/pnas.88.4.1421; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SCHOFIELD PR, 1989, FEBS LETT, V244, P361, DOI 10.1016/0014-5793(89)80563-0; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHWARTZ RD, 1989, BRAIN RES, V481, P169, DOI 10.1016/0006-8993(89)90499-X; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIEGHART W, 1980, NATURE, V286, P285, DOI 10.1038/286285a0; SIGEL E, 1989, FEBS LETT, V257, P377, DOI 10.1016/0014-5793(89)81576-5; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMART TG, 1991, IN PRESS BR J PHARM; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SQUIRES RF, 1979, PHARMACOL BIOCHEM BE, V10, P825, DOI 10.1016/0091-3057(79)90341-1; SWEETNAM PM, 1986, MOL PHARMACOL, V29, P299; TICKU MK, 1990, MOL PHARMACOL, V38, P719; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VONBLANKENFELD G, 1990, NEUROSCI LETT, V115, P269, DOI 10.1016/0304-3940(90)90467-N; WAFFORD KA, 1990, SCIENCE, V249, P291, DOI 10.1126/science.1695761; WAFFORD KA, 1991, IN PRESS NEURON; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; WILSONSHAW D, 1991, FEBS LETT, V284, P211, DOI 10.1016/0014-5793(91)80687-X; YMER S, 1990, EMBO J, V9, P3261, DOI 10.1002/j.1460-2075.1990.tb07525.x; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; YMER S, 1989, FEBS LETT, V258, P119, DOI 10.1016/0014-5793(89)81630-8	75	469	474	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2916	2923		10.1096/fasebj.5.14.1661244	http://dx.doi.org/10.1096/fasebj.5.14.1661244			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1661244	Bronze			2022-12-28	WOS:A1991GP26900006
J	ALLES, A; ALLEY, K; BARRETT, JC; BUTTYAN, R; COLUMBANO, A; COPE, FO; COPELAN, EA; DUKE, RC; FAREL, PB; GERSHENSON, LE; GOLDGABER, D; GREEN, DR; HONN, KV; HULLY, J; ISAACS, JT; KERR, JFR; KRAMMER, PH; LOCKSHIN, RA; MARTIN, DP; MCCONKEY, DJ; MICHAELSON, J; SCHULTEHERMANN, R; SERVER, AC; SZENDE, B; TOMEI, LD; TRITTON, TR; UMANSKY, SR; VALERIE, K; WARNER, HR				ALLES, A; ALLEY, K; BARRETT, JC; BUTTYAN, R; COLUMBANO, A; COPE, FO; COPELAN, EA; DUKE, RC; FAREL, PB; GERSHENSON, LE; GOLDGABER, D; GREEN, DR; HONN, KV; HULLY, J; ISAACS, JT; KERR, JFR; KRAMMER, PH; LOCKSHIN, RA; MARTIN, DP; MCCONKEY, DJ; MICHAELSON, J; SCHULTEHERMANN, R; SERVER, AC; SZENDE, B; TOMEI, LD; TRITTON, TR; UMANSKY, SR; VALERIE, K; WARNER, HR			APOPTOSIS - A GENERAL COMMENT	FASEB JOURNAL			English	Article							DEATH				ALLES, A (corresponding author), OHIO STATE UNIV, ARTHUR G JAMES CANC HOSP & RES INST, COLUMBUS, OH 43210 USA.		Valerie, Kristoffer/AAL-8299-2021	Columbano, Amedeo/0000-0002-6956-9030				GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GROMKOWSKI SH, 1988, J IMMUNOL, V141, P774; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	7	83	83	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2127	2128		10.1096/fasebj.5.8.2022310	http://dx.doi.org/10.1096/fasebj.5.8.2022310			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022310				2022-12-28	WOS:A1991FK11100002
J	SAMAREL, AM				SAMAREL, AM			INVIVO MEASUREMENTS OF PROTEIN-TURNOVER DURING MUSCLE GROWTH AND ATROPHY	FASEB JOURNAL			English	Article						PROTEIN SYNTHESIS; PROTEIN DEGRADATION; GROWTH REGULATION; AMINO ACIDS; METABOLISM	MYOSIN HEAVY-CHAIN; LEUCYL-TRANSFER RNA; MESSENGER-RNA; MYOFIBRILLAR PROTEINS; SYNTHESIS RATES; PRECURSOR POOL; DEGRADATION; SKELETAL; HEART; ACTIN	To investigate the influence of alterations in protein synthetic and degradative rates to the regulation of muscle mass, a variety of laboratory techniques have been developed in order to estimate the rates of total protein and individual contractile protein turnover in the intact experimental animal. These techniques are based on well-established methods of compartmental analysis, and rely on the intravenous administration and biosynthetic incorporation of radiolabeled amino acids into newly synthesized muscle proteins. In this review, the two most widely used procedures (the constant and flooding infusion methods) are examined with respect to the major assumptions and pitfalls in the two procedures. The theoretical and practical limitations of these biosynthetic labeling techniques are critically analyzed with the aim of providing a clear rationale for the application of these techniques to the future study of skeletal and cardiac muscle growth and atropy in vivo.			SAMAREL, AM (corresponding author), LOYOLA UNIV,STRITCH SCH MED,MED CTR,DEPT MED,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.		Samarel, Allen/Q-9810-2019		NHLBI NIH HHS [HL-43582, HL-34328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034328, R01HL043582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINS GL, 1969, MULTICOMPARTMENT MOD, P1; BATES PC, 1983, BIOCHEM J, V214, P593, DOI 10.1042/bj2140593; BATES PC, 1983, BIOCHEM J, V214, P587, DOI 10.1042/bj2140587; BIGGS RB, 1990, AM J PHYSIOL, V258, pH207, DOI 10.1152/ajpheart.1990.258.1.H207; CLARK AF, 1986, J BIOL CHEM, V261, P3168; CLARK WA, 1988, BIOL ISOLATED ADULT, P131; COLEMAN PS, 1989, J MOL CELL CARDIOL, V21, P911, DOI 10.1016/0022-2828(89)90759-1; CZERWINSKI SM, 1989, J APPL PHYSIOL, V67, P2311, DOI 10.1152/jappl.1989.67.6.2311; EVERETT AW, 1979, J MOL CELL CARDIOL, V11, P1253, DOI 10.1016/0022-2828(79)90005-1; EVERETT AW, 1981, BIOCHEM J, V194, P365, DOI 10.1042/bj1940365; EVERETT AW, 1983, J BIOL CHEM, V258, P2421; EVERETT AW, 1980, DEGRADATIVE PROCESSE, P31; GARLICK PJ, 1973, BIOCHEM J, V136, P935, DOI 10.1042/bj1360935; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; GOLDFINE SM, 1989, CELLULAR MOL BIOL MU, P271; HORVATH BZ, 1971, BIOCHIM BIOPHYS ACTA, V263, P779; KARIM MA, 1991, AM J PHYSIOL, pC316; KELLEY J, 1984, BIOCHEM J, V222, P77, DOI 10.1042/bj2220077; LAURENT GJ, 1982, BIOCHEM J, V206, P535, DOI 10.1042/bj2060535; LAURENT GJ, 1978, BIOCHEM J, V176, P393, DOI 10.1042/bj1760393; MARTIN AF, 1981, J BIOL CHEM, V256, P964; MARTIN AF, 1977, J BIOL CHEM, V252, P3422; MOALIC JM, 1984, J MOL CELL CARDIOL, V16, P875, DOI 10.1016/S0022-2828(84)80024-3; MORGAN HE, 1980, HDB PHYSL 2, V1, P845; MORKIN E, 1970, SCIENCE, V167, P1499, DOI 10.1126/science.167.3924.1499; MORRISON PR, 1987, AM J PHYSIOL, V253, pC205, DOI 10.1152/ajpcell.1987.253.2.C205; NAGAI R, 1987, CIRC RES, V60, P692, DOI 10.1161/01.RES.60.5.692; PARMACEK MS, 1986, AM J PHYSIOL, V251, pC727, DOI 10.1152/ajpcell.1986.251.5.C727; POMPOSELLI JJ, 1985, BIOCHEM J, V226, P37, DOI 10.1042/bj2260037; RANNELS DE, 1977, BIOCHEM ACTION HORM, V4, P135; ROBINSON ME, 1990, J MOL CELL CARDIOL, V22, P607, DOI 10.1016/0022-2828(90)90962-2; SAMAREL AM, 1987, CIRC RES, V60, P933, DOI 10.1161/01.RES.60.6.933; SAMAREL AM, 1989, CIRC RES, V64, P193, DOI 10.1161/01.RES.64.2.193; SAMAREL AM, 1981, ANAL BIOCHEM, V118, P155, DOI 10.1016/0003-2697(81)90172-X; SAMAREL AM, 1986, CIRC RES, V73, P166; SANGER JM, 1986, J CELL SCI S, V5, P17; SCORNIK OA, 1974, J BIOL CHEM, V249, P3876; THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300; VANDERWESTHUYZEN DR, 1981, J BIOL CHEM, V256, P1791; Waterlow J. C., 1978, PROTEIN TURNOVER MAM; WATERLOW JC, 1968, CLIN SCI, V35, P287; ZAK R, 1979, PHYSIOL REV, V59, P407, DOI 10.1152/physrev.1979.59.2.407; ZAK R, 1977, J BIOL CHEM, V252, P3430; ZILVERSMIT DB, 1960, AM J MED, V29, P832, DOI 10.1016/0002-9343(60)90117-0	44	51	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2020	2028		10.1096/fasebj.5.7.2010055	http://dx.doi.org/10.1096/fasebj.5.7.2010055			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010055				2022-12-28	WOS:A1991FF44200003
J	OBRIEN, JS; KISHIMOTO, Y				OBRIEN, JS; KISHIMOTO, Y			SAPOSIN PROTEINS - STRUCTURE, FUNCTION, AND ROLE IN HUMAN LYSOSOMAL STORAGE DISORDERS	FASEB JOURNAL			English	Review						SPHINGOLIPID ACTIVATOR PROTEINS; GAUCHER DISEASE; FUCOSIDOSIS; LYSOSOMAL STORAGE DISEASE; TAY-SACHS DISEASE	NIEMANN-PICK DISEASE; AMINO-ACID-SEQUENCE; ENZYMIC SPHINGOMYELIN DEGRADATION; SPHINGOLIPID ACTIVATOR PROTEIN-2; METACHROMATIC LEUKODYSTROPHY; DEFICIENCY; VARIANT; GLUCOSYLCERAMIDE; BIOSYNTHESIS; SAP-1	Saposins are sphingolipid activator proteins, four of which are derived from a single precursor, prosaposin, by proteolytic processing. These small heat-stable glycoproteins (12-14 kDa) are required for the lysosomal hydrolysis of a variety of sphingolipids. Characterization of these four activator proteins, two of which were recently discovered, and their importance in human health and disease are reviewed in this article.			OBRIEN, JS (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT NEUROSCI,M-034J,LA JOLLA,CA 92093, USA.				NICHD NIH HHS [HD-18983] Funding Source: Medline; NINDS NIH HHS [NS-08628, NS-13559] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013559] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AERTS JMFG, 1987, EUR J BIOCHEM, V163, P583, DOI 10.1111/j.1432-1033.1987.tb10907.x; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; CHRISTOMANOU H, 1980, H-S Z PHYSIOL CHEM, V361, P1489, DOI 10.1515/bchm2.1980.361.2.1489; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; DATTA SC, 1986, BIOCHIM BIOPHYS ACTA, V877, P387, DOI 10.1016/0005-2760(86)90204-3; FUJIBAYASHI S, 1985, CLIN CHIM ACTA, V146, P147, DOI 10.1016/0009-8981(85)90053-1; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; GLEW RH, 1988, LAB INVEST, V58, P5; HAKOMORI S, 1986, SCI AM, V254, P44, DOI 10.1038/scientificamerican0586-44; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; INUI K, 1983, P NATL ACAD SCI-BIOL, V80, P3074, DOI 10.1073/pnas.80.10.3074; KAO FT, 1988, SOMAT CELL MOLEC GEN, V13, P685; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P1571, DOI 10.1515/bchm3.1987.368.2.1571; KLEINSCHMIDT T, 1988, BIOL CHEM H-S, V369, P1361, DOI 10.1515/bchm3.1988.369.2.1361; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; LI SC, 1988, J BIOL CHEM, V263, P6588; LI YT, 1984, MOL BASIS LYSOSOMAL, P79; MORIMOTO S, 1990, ANAL BIOCHEM, V190, P154, DOI 10.1016/0003-2697(90)90173-7; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MORIMOTO S, 1990, P NATL ACAD SCI USA, V87, P3493, DOI 10.1073/pnas.87.9.3493; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P503; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PATON BC, 1988, BIOCHEM J, V254, P77, DOI 10.1042/bj2540077; PENTCHEV PG, 1986, J BIOL CHEM, V261, P2772; POTIER M, 1988, BIOCHEM BIOPH RES CO, V155, P32, DOI 10.1016/S0006-291X(88)81045-3; POTIER M, 1990, 5TH INT C INB ERR ME, P66; RADIN NS, 1984, MOL BASIS LYSOSOMAL, P93; RAFI MA, 1990, BIOCHEM BIOPH RES CO, V166, P1017, DOI 10.1016/0006-291X(90)90912-7; RANIERI E, 1986, BIOCHEM J, V233, P763, DOI 10.1042/bj2330763; ROBERTS DD, 1988, ARCH BIOCHEM BIOPHYS, V267, P405, DOI 10.1016/0003-9861(88)90046-X; Sandhoff KCE, 1989, METABOLIC BASIS INHE, V2, P1807; SANO A, 1988, J BIOL CHEM, V263, P19597; SANO A, 1989, BIOCHEM BIOPH RES CO, V165, P1191, DOI 10.1016/0006-291X(89)92728-9; SANO A, 1988, BIOCHEM BIOPH RES CO, V154, P1197, DOI 10.1016/0006-291X(88)90267-7; SINGER H, 1987, ANIMAL MODELS DEMENT; STEVENS RL, 1981, AM J HUM GENET, V33, P900; SYLVESTER SR, 1989, BIOL REPROD, V41, P941, DOI 10.1095/biolreprod41.5.941; TAMARU T, 1986, HISTOCHEMISTRY, V86, P195, DOI 10.1007/BF00493387; WEILER S, 1989, American Journal of Human Genetics, V45, pA12; WENGER D A, 1989, American Journal of Human Genetics, V45, pA13; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223; WENGER DA, 1984, MOL BASIS LYSOSOMAL, P1	49	307	324	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					301	308		10.1096/fasebj.5.3.2001789	http://dx.doi.org/10.1096/fasebj.5.3.2001789			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001789				2022-12-28	WOS:A1991FC55600007
J	CURRIN, RT; GORES, GJ; THURMAN, RG; LEMASTERS, JJ				CURRIN, RT; GORES, GJ; THURMAN, RG; LEMASTERS, JJ			PROTECTION BY ACIDOTIC PH AGAINST ANOXIC CELL KILLING IN PERFUSED-RAT-LIVER - EVIDENCE FOR A PH PARADOX	FASEB JOURNAL			English	Article						ANOXIA; ISCHEMIA; LACTATE DEHYDROGENASE; REOXYGENATION; REPERFUSION	LIPID-PEROXIDATION; REPERFUSION INJURY; CHEMICAL HYPOXIA; HEPATOCYTES; ACIDOSIS; DEATH; HEPATOTOXICITY; PRESERVATION; VIABILITY; STORAGE	Reperfusion of ischemic tissues causes a paradoxical injury. Here, we measured lactate dehydrogenase (LDH) release as an indicator of tissue damage in perfused rat livers during anoxia and reoxygenation. During anoxia, LDH release was substantially reduced at acidotic pH (pH 6.1-6.9). Using anoxia at pH 6.1 followed by reoxygenation at pH 7.3 to model ischemia and reperfusion, an abrupt release of LDH occurred after reperfusion. A similar release of LDH occurred when pH of anoxic livers was increased to 7.3 without reoxygenation, but LDH release did not occur after reoxygenation at pH 6.1. Thus, a rapid increase of pH rather than reoxygenation accounted for tissue injury after reperfusion of ischemic liver.	UNIV N CAROLINA, SCH MED,DEPT CELL BIOL & ANAT,CELL BIOL LABS, CAMPUS BOX 7090,236 TAYLOR HALL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, HEPATOBIOL & TOXICOL LAB, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIDDK NIH HHS [DK30874] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ADKISON D, 1986, ACTA PHYSIOL SCAND, V126, P101; BADR MZ, 1986, J PHARMACOL EXP THER, V238, P1138; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; BING OHL, 1973, SCIENCE, V180, P1297, DOI 10.1126/science.180.4092.1297; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; BRADFORD BU, 1986, J PHARMACOL EXP THER, V236, P263; CALDWELLKENKEL JC, 1989, HEPATOLOGY, V10, P292, DOI 10.1002/hep.1840100307; CASINI AF, 1987, BIOCHEM PHARMACOL, V36, P3689, DOI 10.1016/0006-2952(87)90021-9; CHIEN KR, 1981, CIRC RES, V48, P711, DOI 10.1161/01.RES.48.5.711; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GORES GJ, 1989, AM J PHYSIOL, V257, pC347, DOI 10.1152/ajpcell.1989.257.2.C347; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; HEARSE DJ, 1978, J MOL CELL CARDIOL, V10, P641, DOI 10.1016/S0022-2828(78)80004-2; KALLERHOFF M, 1985, TRANSPLANTATION, V39, P485, DOI 10.1097/00007890-198505000-00005; KLONER RA, 1974, AM J PATHOL, V74, P399; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; NIEMINEN AL, 1990, BIOCHEM BIOPH RES CO, V167, P600, DOI 10.1016/0006-291X(90)92067-A; PENTTILA A, 1974, SCIENCE, V185, P277, DOI 10.1126/science.185.4147.277; ROUSLIN W, 1986, J MOL CELL CARDIOL, V18, P1187, DOI 10.1016/S0022-2828(86)80044-X; SIEGERS CP, 1979, TOXICOLOGY, V15, P55, DOI 10.1016/0300-483X(79)90019-2; STARKE PE, 1986, J BIOL CHEM, V261, P3006; THOMAS CE, 1988, J PHARMACOL EXP THER, V245, P493; THURMAN RG, 1988, TRANSPLANTATION, V46, P502, DOI 10.1097/00007890-198810000-00006	25	146	150	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1991	5	2					207	210		10.1096/fasebj.5.2.2004664	http://dx.doi.org/10.1096/fasebj.5.2.2004664			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004664				2022-12-28	WOS:A1991EZ00200010
J	MURRAY, TH				MURRAY, TH			ETHICAL ISSUES IN HUMAN GENOME RESEARCH	FASEB JOURNAL			English	Article						ETHICS; GENE THERAPY; INSURANCE TESTING; GENETIC SCREENING	HUMAN-GENE THERAPY; DISEASE	In addition to provocative questions about science policy, research on the human genome will generate important ethical questions in at least three categories. First, the possibility of greatly increased genetic information about individuals and populations will require choices to be made about what that information should be and about who should control the generation and dissemination of genetic information. Presymptomatic testing, carrier screening, workplace genetic screening, and testing by insurance companies pose significant ethical problems. Second, the burgeoning ability to manipulate human genotypes and phenotypes raises a number of important ethical questions. Third, increasing knowledge about genetic contributions to ethically and politically significant traits and behaviors will challenge our self-understanding and social institutions.			MURRAY, TH (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH 44106 USA.							ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; ANDERSON WF, 1985, J MED PHILOS, V10, P275, DOI 10.1093/jmp/10.3.275; ANNAS GJ, 1989, HASTINGS CENT REP, V19, P19, DOI 10.2307/3562296; BIRD SJ, 1985, JAMA-J AM MED ASSOC, V253, P3286, DOI 10.1001/jama.253.22.3286; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; Callahan Daniel J., 1970, ABORTION LAW CHOICE; CASKEY CT, 1990, AM J HUM GENET, V46, P393; CULLITON BJ, 1989, SCIENCE, V244, P913; GORDIS E, 1990, JAMA-J AM MED ASSOC, V263, P2094, DOI 10.1001/jama.263.15.2094; Haldane John Burdon Sanderson, 1938, HEREDITY POLITICS; HOLTZMAN NA, 1978, PEDIATRICS, V62, P1056; JENKINS JB, 1989, AM J HUM GENET, V45, P169; JENSEN AR, 1973, ED GROUP DIFFERENCES; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; KOOP BF, 1986, NATURE, V319, P234, DOI 10.1038/319234a0; Luker, 1984, ABORTION POLITICS MO; MARWICK C, JAMA-J AM MED ASSOC, V262, P1909; McKusick VA, 1990, MENDELIAN INHERITANC; MURRAY TH, 1983, HASTINGS CENT REP, V13, P5, DOI 10.2307/3561543; MURRAY TH, 1983, HASTINGS CENT REP, V13, P24, DOI 10.2307/3561718; Murray Thomas, 1987, Discover, V8, P92; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Severo R, 1980, NY TIMES        0203, P1; STOKINGER HE, 1963, ARCH ENVIRON HEALTH, V6, P495, DOI 10.1080/00039896.1963.10663432; WALTERS L, 1986, NATURE, V320, P225, DOI 10.1038/320225a0; WEXLER NS, 1989, MOL GENETICS DISEASE; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; 1989, HUMAN GENE THERAPY S; 1989, POTENTIAL ROLE GENET; 1984, OTABPBA32 US C OFF T; 1982, SPLICING LIFE SOCIAL; 1983, ROLE GENETIC TESTING	32	20	20	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1991	5	1					55	60		10.1096/fasebj.5.1.1825074	http://dx.doi.org/10.1096/fasebj.5.1.1825074			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1825074				2022-12-28	WOS:A1991ET60900009
J	SCHRODER, HC; UGARKOVIC, D; MERZ, H; KUCHINO, Y; OKAMOTO, T; MULLER, WEG				SCHRODER, HC; UGARKOVIC, D; MERZ, H; KUCHINO, Y; OKAMOTO, T; MULLER, WEG			PROTECTION OF HELA-T4+ CELLS AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION AFTER STABLE TRANSFECTION WITH HIV LTR-2',5'-OLIGOADENYLATE SYNTHETASE HYBRID GENE	FASEB JOURNAL			English	Article									UNIV MAINZ, INST PHYSIOL CHEM, ANGEW MOLEK BIOL ABT, DUESBERGWEG 6, W-6500 MAINZ, GERMANY; RUDJER BOSKOVIC INST, CTR ORGAN CHEM & BIOCHEM, YU-41001 Zagreb, YUGOSLAVIA; NATL CANC CTR, RES INST, DIV BIOPHYS, CHUO KU, TOKYO 104, JAPAN; NATL CANC CTR, RES INST, DIV VIROL, CHUO KU, TOKYO 104, JAPAN	Johannes Gutenberg University of Mainz; Rudjer Boskovic Institute; National Cancer Center - Japan; National Cancer Center - Japan			Müller, W. E. G./AAR-8651-2020	Müller, W. E. G./0000-0002-8223-3689; Schroder, Heinz C./0000-0003-0992-6427				ALDOVINI A, 1986, P NATL ACAD SCI USA, V83, P6672, DOI 10.1073/pnas.83.18.6672; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAGLIONI C, 1978, NATURE, V273, P684, DOI 10.1038/273684a0; BAGLIONI C, 1979, BIOCHEMISTRY-US, V18, P1765, DOI 10.1021/bi00576a020; Battey, 1986, BASIC METHODS MOL BI; BEDNARIK DP, 1989, P NATL ACAD SCI USA, V86, P4958, DOI 10.1073/pnas.86.13.4958; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIEHLSEIFERT B, 1985, EUR J BIOCHEM, V147, P517; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HO DD, 1985, LANCET, V1, P602; IKEDA H, 1988, GENE, V71, P19, DOI 10.1016/0378-1119(88)90073-X; JOHNSTON MI, 1987, J BIOL CHEM, V262, P8377; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MONTEFIORI DC, 1987, P NATL ACAD SCI USA, V84, P2985, DOI 10.1073/pnas.84.9.2985; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; MULLER WE, 1980, H-S Z PHYSIOL CHEM, V361, P469; MULLER WEG, 1990, J BIOL CHEM, V265, P3803; MULLER WEG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P208, DOI 10.1016/0167-4781(80)90011-1; MULLER WEG, 1988, J ACQ IMMUN DEF SYND, V1, P453; NILSEN TW, 1982, MOL CELL BIOL, V2, P154, DOI 10.1128/MCB.2.2.154; NILSEN TW, 1979, P NATL ACAD SCI USA, V76, P2600, DOI 10.1073/pnas.76.6.2600; NILSEN TW, 1982, J BIOL CHEM, V257, P1602; NILSEN TW, 1982, J VIROL, V42, P1039, DOI 10.1128/JVI.42.3.1039-1045.1982; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; ROSSOL S, 1989, J INFECT DIS, V159, P815, DOI 10.1093/infdis/159.5.815; SARIN PS, 1987, J NATL CANCER I, V78, P663; SCHRODER HC, 1990, AIDS RES HUM RETROV, V6, P659, DOI 10.1089/aid.1990.6.659; SCHRODER HC, 1988, BIOL CHEM H-S, V369, P985, DOI 10.1515/bchm3.1988.369.2.985; SCHRODER HC, 1989, J BIOL CHEM, V264, P5669; SCHRODER HC, 1980, J BIOL CHEM, V255, P4535; SEN GC, 1982, PROG NUCLEIC ACID RE, V27, P105, DOI 10.1016/S0079-6603(08)60599-1; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STLAURENT G, 1983, CELL, V33, P95; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693	47	30	33	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1990	4	13					3124	3130		10.1096/fasebj.4.13.1698680	http://dx.doi.org/10.1096/fasebj.4.13.1698680			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EC625	1698680				2022-12-28	WOS:A1990EC62500008
J	HARRIS, RC; MUNGER, KA; BADR, KF; TAKAHASHI, K				HARRIS, RC; MUNGER, KA; BADR, KF; TAKAHASHI, K			MEDIATION OF RENAL VASCULAR EFFECTS OF EPIDERMAL GROWTH-FACTOR BY ARACHIDONATE METABOLITES	FASEB JOURNAL			English	Note											HARRIS, RC (corresponding author), VANDERBILT UNIV, MED CTR, DIV NEPHROL, NASHVILLE, TN 37212 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, P01DK038226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38226, DK 39261] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; BADR KF, 1987, BIOCHEM BIOPH RES CO, V145, P408, DOI 10.1016/0006-291X(87)91337-4; BADR KF, 1989, AM J PHYSIOL, V256, pF35, DOI 10.1152/ajprenal.1989.256.1.F35; BERK BC, 1985, J CLIN INVEST, V75, P1083, DOI 10.1172/JCI111772; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CARROLL MA, 1987, EUR J PHARMACOL, V138, P281, DOI 10.1016/0014-2999(87)90445-6; DEMEY JG, 1982, J PHARMACOL EXP THER, V222, P166; GAN BS, 1987, J CLIN INVEST, V80, P199, DOI 10.1172/JCI113048; GAN BS, 1987, J PHARMACOL EXP THER, V242, P331; GOSPODAROWICZ D, 1981, J CELL BIOL, V89, P568, DOI 10.1083/jcb.89.3.568; GREENE RM, 1985, BIOCHEM BIOPH RES CO, V130, P1037, DOI 10.1016/0006-291X(85)91720-6; HARRIS RC, 1989, AM J PHYSIOL, V256, pF1117, DOI 10.1152/ajprenal.1989.256.6.F1117; HARRIS RC, 1988, J CLIN INVEST, V82, P1028, DOI 10.1172/JCI113659; ICHIKAWA I, 1978, Renal Physiology, V1, P121; KUROBE M, 1986, BIOCHEM INT, V13, P729; LEFKOWITH JB, 1987, J CLIN INVEST, V80, P947, DOI 10.1172/JCI113187; LEVINE L, 1977, BIOCHEM BIOPH RES CO, V76, P1181, DOI 10.1016/0006-291X(77)90980-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARGOLIS BL, 1988, BIOCHEM J, V249, P587, DOI 10.1042/bj2490587; MENE P, 1988, AM J PHYSIOL, V255, pF1059, DOI 10.1152/ajprenal.1988.255.6.F1059; MILLER VM, 1985, AM J PHYSIOL, V248, pH432, DOI 10.1152/ajpheart.1985.248.4.H432; MITCHELL MD, 1987, BIOCHIM BIOPHYS ACTA, V928, P240, DOI 10.1016/0167-4889(87)90127-3; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; MURAMATSU I, 1985, Canadian Journal of Physiology and Pharmacology, V63, P994; MURAMATSU I, 1986, CAN J PHYSIOL PHARM, V64, P1561, DOI 10.1139/y86-262; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OKA Y, 1983, J CLIN INVEST, V72, P249, DOI 10.1172/JCI110964; OLIW EH, 1984, BIOCHIM BIOPHYS ACTA, V795, P384, DOI 10.1016/0005-2760(84)90089-4; OLIW EH, 1984, J BIOL CHEM, V259, P2716; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; PATEL P, 1988, CAN J PHYSIOL PHARM, V66, P1308, DOI 10.1139/y88-214; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; TAKAHASHI K, IN PRESS AM J PHYSL; YOKOTA K, 1986, J BIOL CHEM, V261, P5410	40	25	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1990	4	6					1654	1660		10.1096/fasebj.4.6.2138579	http://dx.doi.org/10.1096/fasebj.4.6.2138579			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CY582	2138579				2022-12-28	WOS:A1990CY58200012
J	Zhang, Y; Song, YX; Ren, S; Zhang, MQ; Zhang, Z; Fan, SQ; Liu, X; Peng, XY; Qi, Q; Shen, XC; Chen, Y				Zhang, Yue; Song, Yuxuan; Ren, Shuang; Zhang, Minqin; Zhang, Zhao; Fan, Shuangqin; Liu, Xing; Peng, Xiaoyu; Qi, Qi; Shen, Xiangchun; Chen, Yan			GPER-mediated stabilization of HIF-1 alpha contributes to upregulated aerobic glycolysis in tamoxifen-resistant cells	ONCOGENE			English	Article; Early Access							COUPLED ESTROGEN-RECEPTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BREAST-CANCER CELLS; EXPRESSION; ALPHA; ACTIVATION; MEMBRANE; UCH-L1; AXIS	Tamoxifen is a first-line therapeutic drug for oestrogen-receptor positive breast cancer; however, like other therapeutics, its clinical use is limited by acquired resistance. Tamoxifen-resistant cells have demonstrated enhanced aerobic glycolysis; however, the mechanisms underlying this upregulation remain unclear. Here, we demonstrated that G-protein coupled oestrogen receptor (GPER) was involved in the upregulation of aerobic glycolysis via induction of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression and transcriptional activity in tamoxifen-resistant cells. Additionally, GPER stabilized HIF-1 alpha through inhibiting its hydroxylation and ubiquitin-mediated degradation, which were associated with upregulation of C-terminal hydrolase-L1 (UCH-L1), downregulation of prolyl hydroxylase 2 (PHD2) and von Hippel-Lindau tumour suppressor protein (pVHL), induction of HIF-1 alpha/UCH-L1 interaction, and suppression of HIF-1 alpha/PHD2-pVHL association. The GPER/HIF-1 alpha axis was functionally responsible for regulating tamoxifen sensitivity both in vitro and in vivo. Moreover, there was a positive correlation between GPER and HIF-1 alpha expression in clinical breast cancer tissues, and high levels of GPER combined with nuclear HIF-1 alpha indicated poor overall survival. High levels of the GPER/HIF-1 alpha axis were also correlated with shorter relapse-free survival in patients receiving tamoxifen. Hence, our findings support a critical role of GPER/HIF-1 alpha axis in the regulation of aerobic glycolysis in tamoxifen-resistant cells, offering a potential therapeutic target for tamoxifen-resistant breast cancer. [GRAPHICS] .	[Zhang, Yue; Song, Yuxuan; Ren, Shuang; Zhang, Minqin; Fan, Shuangqin; Liu, Xing; Peng, Xiaoyu; Shen, Xiangchun; Chen, Yan] Guizhou Med Univ, Sch Pharmaceut Sci, High Efficacy Applicat Nat Med Resources Engn Ctr, Guiyang 550025, Guizhou, Peoples R China; [Song, Yuxuan; Ren, Shuang; Zhang, Minqin; Fan, Shuangqin; Liu, Xing; Peng, Xiaoyu; Shen, Xiangchun; Chen, Yan] Guizhou Med Univ, Translat Med Res Ctr, Guiyang 550025, Guizhou, Peoples R China; [Song, Yuxuan; Ren, Shuang; Zhang, Minqin; Fan, Shuangqin; Liu, Xing; Peng, Xiaoyu; Shen, Xiangchun; Chen, Yan] Guizhou Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Pollut Monitoring & Dis Control, Guiyang 550025, Guizhou, Peoples R China; [Zhang, Zhao] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Med Examinat Ctr, Shanghai 200021, Peoples R China; [Qi, Qi] Jinan Univ, Sch Med, Dept Pharmacol, MOE Key Lab Tumor Mol Biol,Clin Translat Ctr Targ, Guangzhou 510632, Peoples R China	Guizhou Medical University; Guizhou Medical University; Guizhou Medical University; Shanghai University of Traditional Chinese Medicine; Jinan University	Shen, XC; Chen, Y (corresponding author), Guizhou Med Univ, Sch Pharmaceut Sci, High Efficacy Applicat Nat Med Resources Engn Ctr, Guiyang 550025, Guizhou, Peoples R China.; Shen, XC; Chen, Y (corresponding author), Guizhou Med Univ, Translat Med Res Ctr, Guiyang 550025, Guizhou, Peoples R China.; Shen, XC; Chen, Y (corresponding author), Guizhou Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Pollut Monitoring & Dis Control, Guiyang 550025, Guizhou, Peoples R China.; Qi, Q (corresponding author), Jinan Univ, Sch Med, Dept Pharmacol, MOE Key Lab Tumor Mol Biol,Clin Translat Ctr Targ, Guangzhou 510632, Peoples R China.	qiqikc@jnu.edu.cn; sxc@gmc.edu.cn; chenyan@gmc.edu.cn			National Natural Science Foundation of China [81860648, 81973341]; Excellent Young Talents Plan of Guizhou Province [QKHPTRC(2021)-5632]; Guizhou Provincial Science and Technology Projects [QKHJC-ZK(2021)-YB527]; Excellent Young Talents Plan of Guizhou Medical University [2020-101]; Science and Technology Innovation Fund for Advanced Individuals of the Guizhou Department of Education [QJHKY[2018]048]; Science Foundation of Administration of Traditional Chinese Medicine of Guizhou Province [QZYY-2022-025]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Excellent Young Talents Plan of Guizhou Province; Guizhou Provincial Science and Technology Projects; Excellent Young Talents Plan of Guizhou Medical University; Science and Technology Innovation Fund for Advanced Individuals of the Guizhou Department of Education; Science Foundation of Administration of Traditional Chinese Medicine of Guizhou Province	This work was financially supported by the National Natural Science Foundation of China (81860648, 81973341), the Excellent Young Talents Plan of Guizhou Province (QKHPTRC(2021)-5632), the Guizhou Provincial Science and Technology Projects (QKHJC-ZK(2021)-YB527), the Excellent Young Talents Plan of Guizhou Medical University (2020-101), the Science and Technology Innovation Fund for Advanced Individuals of the Guizhou Department of Education (QJHKY[2018]048), and the Science Foundation of Administration of Traditional Chinese Medicine of Guizhou Province (QZYY-2022-025).	Abdel-Wahab AF, 2019, PHARMACOL RES, V150, DOI 10.1016/j.phrs.2019.104511; Alam MW, 2016, ONCOTARGET, V7, P11238, DOI 10.18632/oncotarget.7167; Barua D, 2020, CANCER LETT, V486, P29, DOI 10.1016/j.canlet.2020.05.020; Catalano S, 2014, BREAST CANCER RES TR, V146, P273, DOI 10.1007/s10549-014-3017-4; Chang M, 2012, BIOMOL THER, V20, P256, DOI 10.4062/biomolther.2012.20.3.256; Chen XS, 2020, THERANOSTICS, V10, P1833, DOI 10.7150/thno.39814; Cowman SJ, 2022, TRENDS CANCER, V8, P28, DOI 10.1016/j.trecan.2021.10.004; Das CK, 2019, BBA-MOL CELL RES, V1866, P1004, DOI 10.1016/j.bbamcr.2019.03.004; Daurio NA, 2016, CANCER RES, V76, P3295, DOI 10.1158/0008-5472.CAN-15-2197; De Francesco EM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072011; De Francesco EM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0923-5; De Francesco EM, 2014, CANCER RES, V74, P4053, DOI 10.1158/0008-5472.CAN-13-3590; De Francesco EM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3458; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Generali D, 2009, J CLIN ONCOL, V27, P227, DOI 10.1200/JCO.2007.13.7083; Goto Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6994; Gruber G, 2004, BREAST CANCER RES, V6, pR191, DOI 10.1186/bcr775; Gyorffy B, 2021, COMPUT STRUCT BIOTEC, V19, P4101, DOI 10.1016/j.csbj.2021.07.014; He MJ, 2019, ONCOGENE, V38, P5551, DOI 10.1038/s41388-019-0817-3; Hoefflin R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17873-3; Hsu LH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020306; Ignatov A, 2011, BREAST CANCER RES TR, V128, P457, DOI 10.1007/s10549-011-1584-1; Ignatov A, 2010, BREAST CANCER RES TR, V123, P87, DOI 10.1007/s10549-009-0624-6; Ignatov T, 2020, ARCH GYNECOL OBSTET, V301, P565, DOI 10.1007/s00404-019-05384-6; Ignatov T, 2019, BREAST CANCER RES TR, V174, P121, DOI 10.1007/s10549-018-5064-8; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacenik D, 2016, MOL CELL ENDOCRINOL, V429, P10, DOI 10.1016/j.mce.2016.04.011; Jogi A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226150; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Kazi AA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3609; Kierans SJ, 2021, J PHYSIOL-LONDON, V599, P23, DOI 10.1113/JP280572; Kim MR, 2009, MOL CANCER THER, V8, P2163, DOI 10.1158/1535-7163.MCT-08-1061; Lappano R, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01667-y; Liu SS, 2020, THERANOSTICS, V10, P10729, DOI 10.7150/thno.46297; Liu XC, 2019, MOL CELL PROTEOMICS, V18, P2273, DOI 10.1074/mcp.RA119.001576; Ma LS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00005; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mo ZQ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3581; Molina L, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.563165; Najim O, 2019, BBA-REV CANCER, V1872, DOI 10.1016/j.bbcan.2019.188315; Ning KA, 2017, J SURG ONCOL, V115, P932, DOI 10.1002/jso.24614; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Padro M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3140-9; Powles TJ, 2007, JNCI-J NATL CANCER I, V99, P283, DOI 10.1093/jnci/djk050; Raez LE, 2013, CANCER CHEMOTH PHARM, V71, P523, DOI 10.1007/s00280-012-2045-1; Ranganathan P, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00708; Recchia AG, 2011, J BIOL CHEM, V286, P10773, DOI 10.1074/jbc.M110.172247; San-Millan I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127; Schroder C, 2013, J CANCER RES CLIN, V139, P1745, DOI 10.1007/s00432-013-1496-z; Sjostrom M, 2014, BREAST CANCER RES TR, V145, P61, DOI 10.1007/s10549-014-2936-4; Vallee A, 2021, CANCERS, V13, DOI 10.3390/cancers13215557; Vaupel P, 2021, J PHYSIOL-LONDON, V599, P1745, DOI 10.1113/JP278810; Wang KK, 2017, EXPERT OPIN THER TAR, V21, P627, DOI 10.1080/14728222.2017.1321635; Wang LJ, 2013, ONCOL REP, V29, P1563, DOI 10.3892/or.2013.2245; Wang MZ, 2021, EUR J MED CHEM, V220, DOI 10.1016/j.ejmech.2021.113487; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wang WJ, 2016, MOL CARCINOGEN, V55, P1329, DOI 10.1002/mc.22376; Woo YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132285; Yang J, 2015, P NATL ACAD SCI USA, V112, P15172, DOI 10.1073/pnas.1422015112; Yao JW, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.592912; Yin H, 2017, INT J ONCOL, V51, P1191, DOI 10.3892/ijo.2017.4117; Yu T, 2017, ONCOGENE, V36, P2131, DOI 10.1038/onc.2016.370; Yu TH, 2020, MOL CELL ENDOCRINOL, V506, DOI 10.1016/j.mce.2020.110762; Yuan J, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0579-y; Zhang L, 2017, FERTIL STERIL, V107, P439, DOI 10.1016/j.fertnstert.2016.11.008	67	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene											s41388-022-02506-4	10.1038/s41388-022-02506-4	http://dx.doi.org/10.1038/s41388-022-02506-4		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H1YQ	36400971				2022-12-28	WOS:000885244700003
J	REBOUCHE, CJ				REBOUCHE, CJ			CARNITINE FUNCTION AND REQUIREMENTS DURING THE LIFE-CYCLE	FASEB JOURNAL			English	Article						CARNITINE; DIETARY REQUIREMENTS; INFANTS; AGING	TOTAL PARENTERAL-NUTRITION; INTRAVENOUS L-CARNITINE; BIRTH-WEIGHT INFANTS; NEWBORN-INFANTS; HUMAN ADULTS; METABOLISM; PLASMA; RAT; BIOSYNTHESIS; DEFICIENCY	L-Carnitine has been described as a "conditionally essential" nutrient for humans. Segments of the human population suggested as having a requirement for carnitine include infants (premature and full-term), patients on long-term parenteral nutrition, and perhaps children. The evidence to support these claims includes 1) low circulating carnitine concentrations; 2) abnormal (or at least different) circulating metabolite concentrations (free fatty acids, triglycerides, ketone bodies), and 3) very limited and inconsistent growth data. A number of subjective observations and anecdotal case reports have been offered in support of a requirement for carnitine. Exogenous carnitine is required to maintain "normal" (in the epidemiologic sense) plasma or serum carnitine concentrations in humans of all ages. But "functional carnitine deficiency," defined by abnormal clinical presentation correctable by carnitine administration, has not been demonstrated in an otherwise normal (nonpathologic) population. On the other hand, nutritional or pharmacological intervention with carnitine or its esters may be beneficial for very premature infants, infants and children with various dinical conditions associated with low circulating carnitine concentrations, and in some chronic diseases associated with the aging process.			REBOUCHE, CJ (corresponding author), UNIV IOWA, DEPT PEDIAT, 100 OAKDALE RES PK, RM A138, IOWA CITY, IA 52242 USA.							ARDUINI A, 1992, AM HEART J, V123, P1726, DOI 10.1016/0002-8703(92)90850-U; ARDUINI A, 1992, J BIOL CHEM, V267, P12673; BORUM PR, 1987, AM J CLIN NUTR, V46, P437, DOI 10.1093/ajcn/46.3.437; BOWYER BA, 1986, AM J CLIN NUTR, V43, P85, DOI 10.1093/ajcn/43.1.85; BOWYER BA, 1989, AM J CLIN NUTR, V49, P618, DOI 10.1093/ajcn/49.4.618; CHERCHI A, 1990, CARDIOVASC DRUG THER, V4, P481, DOI 10.1007/BF01857757; COSTELL M, 1989, BIOCHEM BIOPH RES CO, V161, P1135, DOI 10.1016/0006-291X(89)91360-0; DAVIS AT, 1986, J NUTR, V116, P760, DOI 10.1093/jn/116.5.760; DELANY JP, 1986, FASEB J, V45, P815; Fomon S. J., 1992, NEW PROTEIN FOODS HU, P75; HAHN P, 1982, AM J CLIN NUTR, V36, P569, DOI 10.1093/ajcn/36.4.569; HANSFORD RG, 1982, MECH AGEING DEV, V19, P191, DOI 10.1016/0047-6374(82)90010-0; HELMS RA, 1990, JPEN-PARENTER ENTER, V14, P448, DOI 10.1177/0148607190014005448; LANGE HW, 1973, H-S Z PHYSIOL CHEM, V354, P117, DOI 10.1515/bchm2.1973.354.1.117; LOMBARD KA, 1989, AM J CLIN NUTR, V50, P301, DOI 10.1093/ajcn/50.2.301; MOUKARZEL AA, 1992, J PEDIATR-US, V120, P759, DOI 10.1016/S0022-3476(05)80243-4; NAKAMURA T, 1990, J PEDIATR GASTR NUTR, V10, P66, DOI 10.1097/00005176-199001000-00013; NAKANO C, 1989, EARLY HUM DEV, V19, P21, DOI 10.1016/0378-3782(89)90101-1; NOVAK M, 1988, J PEDIATR GASTR NUTR, V7, P220, DOI 10.1097/00005176-198803000-00011; NOVAK M, 1983, ACTA CHIR SCAND, P149; OCONNOR JE, 1987, BIOCHEM PHARMACOL, V36, P3169, DOI 10.1016/0006-2952(87)90628-9; OHTSUKA Y, 1991, BIOCHEM PHARMACOL, V41, P1957, DOI 10.1016/0006-2952(91)90136-S; OLSON AL, 1989, AM J CLIN NUTR, V49, P624, DOI 10.1093/ajcn/49.4.624; OLSON AL, 1987, J NUTR, V117, P1024, DOI 10.1093/jn/117.6.1024; PACKER L, 1992, FASEB J, V6, pA1369; PALOMBO JD, 1987, JPEN-PARENTER ENTER, V11, P88, DOI 10.1177/014860718701100188; PENN D, 1981, J PEDIATR-US, V98, P976, DOI 10.1016/S0022-3476(81)80609-9; PICHARD C, 1989, AM J CLIN NUTR, V49, P283, DOI 10.1093/ajcn/49.2.283; REBOUCHE CJ, 1991, J NUTR, V121, P539, DOI 10.1093/jn/121.4.539; REBOUCHE CJ, 1984, J CLIN INVEST, V73, P857, DOI 10.1172/JCI111281; REBOUCHE CJ, 1991, AM J CLIN NUTR, V54, pS1147, DOI 10.1093/ajcn/54.6.1147s; REBOUCHE CJ, 1989, J NUTR, V119, P1907, DOI 10.1093/jn/119.12.1907; REBOUCHE CJ, 1986, ANNU REV NUTR, V6, P41, DOI 10.1146/annurev.nu.06.070186.000353; REBOUCHE CJ, 1986, J NUTR, V116, P751; RONCERO C, 1992, ARCH BIOCHEM BIOPHYS, V295, P258, DOI 10.1016/0003-9861(92)90516-Y; SCHMIDTSOMMERFELD E, 1990, BIOL NEONATE, V58, P81, DOI 10.1159/000243302; SCHMIDTSOMMERFELD E, 1988, EUR J PEDIATR, V147, P356, DOI 10.1007/BF00496410; SHENAI JP, 1984, PEDIATR RES, V18, P679, DOI 10.1203/00006450-198407000-00024; SPAGNOLI A, 1991, NEUROLOGY, V41, P1726, DOI 10.1212/WNL.41.11.1726; SULKERS EJ, 1990, AM J CLIN NUTR, V52, P889, DOI 10.1093/ajcn/52.5.889; TAKEYAMA N, 1989, AM J PHYSIOL, V256, pE31, DOI 10.1152/ajpendo.1989.256.1.E31; WINTER SC, 1987, AM J DIS CHILD, V141, P660, DOI 10.1001/archpedi.1987.04460060076039; WORTHLEY LIG, 1983, JPEN-PARENTER ENTER, V7, P176, DOI 10.1177/0148607183007002176; ZASPEL BJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P192, DOI 10.1016/0304-4165(80)90067-7; 1991, NIH922309 NAT CTR RE, P13; [No title captured]	46	272	282	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1992	6	15					3379	3386		10.1096/fasebj.6.15.1464372	http://dx.doi.org/10.1096/fasebj.6.15.1464372			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1464372				2022-12-28	WOS:A1992KD39500009
J	WALLECZEK, J				WALLECZEK, J			ELECTROMAGNETIC-FIELD EFFECTS ON CELLS OF THE IMMUNE-SYSTEM - THE ROLE OF CALCIUM SIGNALING	FASEB JOURNAL			English	Review						IMMUNE SYSTEM; SIGNAL TRANSDUCTION; CALCIUM; CELLULAR MECHANISMS; ELF ELECTROMAGNETIC FIELDS	BRAIN-TISSUE INVITRO; HUMAN PERIPHERAL LYMPHOCYTES; VARYING MAGNETIC-FIELDS; LOW-FREQUENCY; ELECTRIC-FIELDS; BIOLOGICAL-SYSTEMS; CANCER PROMOTION; CEREBRAL TISSUE; ACTIVATION; EXPOSURE	During the past decade considerable evidence has accumulated demonstrating that nonthermal exposures of cells of the immune system to extremely low-frequency (ELF) electromagnetic fields (< 300 Hz) can elicit cellular changes that might be relevant to in vivo immune activity. A similar responsiveness to nonionizing electromagnetic energy in this frequency range has also been documented for tissues of the neuroendocrine and musculoskeletal system. However, knowledge about the underlying biological mechanisms by which such fields can induce cellular changes is still very limited. It is generally believed that the cell membrane and Ca2+-regulated activity is involved in bioactive ELF field coupling to living systems. This article begins with a short review of the current state of knowledge concerning the effects of nonthermal levels of ELF electromagnetic fields on the biochemistry and activity of immune cells and then closely examines new results that suggest a role for Ca2+ in the induction of these cellular field effects. Based on these findings it is proposed that membrane-mediated Ca2+ signaling processes are involved in the mediation of field effects on the immune system.	LAWRENCE BERKELEY LAB,DIV RES MED & RADIAT BIOPHYS,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory								ADEY WR, 1981, PHYSIOL REV, V61, P435, DOI 10.1152/physrev.1981.61.2.435; ADEY WR, 1988, NEUROCHEM RES, V13, P671, DOI 10.1007/BF00973286; ADEY WR, 1984, NONLINEAR ELECTROCYN; BASSETT CAL, 1989, CRIT REV BIOMED ENG, V17, P451; BAWIN SM, 1976, P NATL ACAD SCI USA, V73, P1999, DOI 10.1073/pnas.73.6.1999; BAWIN SM, 1978, P NATL ACAD SCI USA, V75, P6314, DOI 10.1073/pnas.75.12.6314; BELLOSSI A, 1989, In Vivo (Attiki), V3, P29; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P327, DOI 10.1002/bem.2250060402; BLACKMAN CF, 1982, RADIAT RES, V92, P510, DOI 10.2307/3575923; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P1, DOI 10.1002/bem.2250060102; BLANK M, 1990, BIOELECTROCH BIOENER, V24, P51, DOI 10.1016/0302-4598(80)85006-9; BLANK M, 1987, BIOCHIM BIOPHYS ACTA, V906, P277, DOI 10.1016/0304-4157(87)90014-1; BUDFINGER TF, 1991, J COMPUT ASSIST TOMO, V15, P909; BYUS CV, 1987, CARCINOGENESIS, V8, P1385, DOI 10.1093/carcin/8.10.1385; CADOSSI R, 1988, P451; CADOSSI R, 1985, BIOELECTROCH BIOENER, V14, P115, DOI 10.1016/0302-4598(85)85014-5; CARSON JJL, 1990, AM J PHYSIOL, V259, pC687, DOI 10.1152/ajpcell.1990.259.4.C687; CHIABRERA A, 1984, BIOELECTROMAGNETICS, V5, P173, DOI 10.1002/bem.2250050206; COHEN MM, 1986, BIOELECTROMAGNETICS, V7, P415, DOI 10.1002/bem.2250070409; CONTI P, 1985, FEBS LETT, V181, P28, DOI 10.1016/0014-5793(85)81107-8; CONTI P, 1983, FEBS LETT, V162, P156, DOI 10.1016/0014-5793(83)81069-2; CONTI P, 1985, J BIOELECTRICITY, V4, P227, DOI 10.3109/15368378509040375; CONTI P, 1986, FEBS LETT, V199, P130, DOI 10.1016/0014-5793(86)81238-8; COSSARIZZA A, 1989, FEBS LETT, V248, P141, DOI 10.1016/0014-5793(89)80449-1; COSSARIZZA A, 1989, BIOCHEM BIOPH RES CO, V160, P692, DOI 10.1016/0006-291X(89)92488-1; Findl, 1987, MECHANISTIC APPROACH; FISCHER G, 1987, MED KLIN, V82, P566; Frohlich H, 1988, BIOL COHERENCE RESPO; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GOODMAN R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P216, DOI 10.1016/0167-4781(89)90105-X; GRAUSZ JD, 1986, EUR J IMMUNOL, V16, P1217; GREENE JJ, 1991, BIOCHEM BIOPH RES CO, V174, P742, DOI 10.1016/0006-291X(91)91480-Z; GRUNDLER W, 1992, IN PRESS NATURWISSEN; HARRIS DT, 1988, J IMMUNOL, V140, P921; HOWELL DM, 1988, J IMMUNOL, V140, P1982; KAISER F, 1988, BIOL COHERENCE RESPO, P25; LECHNER F, 1989, ELEKTROSTIMULATION M; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LICHTMAN AH, 1983, BLOOD, V61, P413; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LIVINGSTON GK, 1991, ENVIRON MOL MUTAGEN, V17, P49, DOI 10.1002/em.2850170108; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; LYLE DB, 1991, BIOELECTROMAGNETICS, V12, P145, DOI 10.1002/bem.2250120303; LYLE DB, 1988, BIOELECTROMAGNETICS, V9, P303, DOI 10.1002/bem.2250090311; MARINO AA, 1988, MODERN BIOELECTRICIT; MCLEAN JRN, 1991, BIOELECTROMAGNETICS, V12, P273, DOI 10.1002/bem.2250120503; MOONEY NA, 1986, BIOELECTROMAGNETICS, V7, P387, DOI 10.1002/bem.2250070406; Nair I., 1989, BIOL EFFECTS POWER F; OROZA MA, 1987, J BIOELECTRICITY, V6, P139, DOI 10.3109/15368378709027734; PAPATHEOFANIS FJ, 1990, RADIAT RES, V122, P24, DOI 10.2307/3577578; PETRINI M, 1990, J BIOELECTRICITY, V9, P159, DOI 10.3109/15368379009119803; PHILLIPS JL, 1986, IMMUNOL LETT, V13, P295, DOI 10.1016/0165-2478(86)90061-1; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; Polk C, 1986, CRC HDB BIOL EFFECTS; ROSENTHAL M, 1989, MUTAT RES, V210, P329, DOI 10.1016/0027-5107(89)90094-8; ROZEK RJ, 1987, CELL CALCIUM, V8, P413, DOI 10.1016/0143-4160(87)90025-X; SAVITZ DA, 1987, J OCCUP ENVIRON MED, V29, P47; Schwan, 1985, INTERACTIONS ELECTRO; SERPERSU EH, 1984, J BIOL CHEM, V259, P7155; STUCHLY MA, 1990, CRIT REV BIOMED ENG, V18, P89; STUCHLY MA, 1988, TERATOLOGY, V38, P461, DOI 10.1002/tera.1420380509; TSONG TY, 1990, ANNU REV BIOPHYS BIO, V19, P83, DOI 10.1146/annurev.bb.19.060190.000503; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WILSON BW, 1990, EXTREMELY LOW FREQUE; ZECCA L, 1985, BIOELECTROCH BIOENER, V14, P39, DOI 10.1016/0302-4598(85)85005-4; [No title captured]	69	282	291	2	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1992	6	13					3177	3185		10.1096/fasebj.6.13.1397839	http://dx.doi.org/10.1096/fasebj.6.13.1397839			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397839				2022-12-28	WOS:A1992JU51200010
J	WHELAN, WJ				WHELAN, WJ			ON THE INITIATION OF GLYCOGEN AND STARCH SYNTHESIS	FASEB JOURNAL			English	Editorial Material							RABBIT-MUSCLE GLYCOGEN; BIOGENESIS; PROTEIN; PRIMER; BIOSYNTHESIS; LINKAGE				WHELAN, WJ (corresponding author), UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,POB 016129,MIAMI,FL 33101, USA.							BAILEY JM, 1950, J CHEM SOC, P3692; Cori GT, 1940, J BIOL CHEM, V135, P733; GIEOWARSINGH D, 1992, FASEB J, V6, pA1520; GREEN AA, 1940, J BIOL CHEM, V142, P447; Green DE, 1942, J BIOL CHEM, V142, P355; Hanes CS, 1940, PROC R SOC SER B-BIO, V129, P174, DOI 10.1098/rspb.1940.0035; JUDD C, 1992, FASEB J, V6, pA1520; Kennedy L., 1985, MEMBRANES MUSCLE, P65; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; KULZ R, 1886, Z BIOL, V22, P161; LOMAKO J, 1991, FEBS LETT, V279, P223, DOI 10.1016/0014-5793(91)80154-U; LOMAKO J, 1990, BIOCHEM INT, V21, P251; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; LOMAKO J, 1992, CARBOHYD RES, V227, P331, DOI 10.1016/0008-6215(92)85082-B; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; RODRIGUEZ IR, 1985, BIOCHEM BIOPH RES CO, V132, P829, DOI 10.1016/0006-291X(85)91206-9; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; WHELAN WJ, 1976, TRENDS BIOCHEM SCI, V1, P13, DOI 10.1016/0968-0004(76)90257-7; WHELAN WJ, 1986, BIOESSAYS, V5, P136, DOI 10.1002/bies.950050312	20	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1992	6	13					3218	3219		10.1096/fasebj.6.13.1397844	http://dx.doi.org/10.1096/fasebj.6.13.1397844			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397844				2022-12-28	WOS:A1992JU51200015
J	IRVINE, RF				IRVINE, RF			INOSITOL PHOSPHATES AND CA2+ ENTRY - TOWARD A PROLIFERATION OR A SIMPLIFICATION	FASEB JOURNAL			English	Review						INOSITOL TRISPHOSPHATE; INOSITOL TETRAKISPHOSPHATE; CA2+ ENTRY	DIVALENT-CATION ENTRY; LACRIMAL ACINAR-CELLS; RAT HEPATOCYTES; CALCIUM ENTRY; 1,3,4,5-TETRAKISPHOSPHATE RECEPTOR; CA-2+ ENTRY; TRISPHOSPHATE; THAPSIGARGIN; CHANNELS; TETRAKISPHOSPHATE	Intracellular mobilization of Ca2+ by inositol trisphosphate (IP3) is only a temporary phenomenon; the more crucial process of stimulated entry of Ca2+ by inositol phosphates is still poorly understood, with apparently conflicting data and hypotheses arising from different tissues and experimental protocols. There is clear evidence that the intracellular Ca2+ stores themselves can control Ca2+ entry and that IP3 may exert a direct effect on Ca2+ entry over and above its function in emptying those stores. There is also clear evidence that inositol tetrakisphosphate (IP4) can control Ca2+ entry, but there is controversy over whether it is actually necessary. Thus at present the combined evidence suggests that there must be a multiplicity of mechanisms extant, with different mechanisms being emphasized in different tissues. Alternatively, there could be one common mechanism, discussed here, which may lead to apparently different emphases as a result of the various experimental protocols.			IRVINE, RF (corresponding author), AFRC, INST ANIM PHYSIOL & GENET RES, DEPT BIOCHEM, CAMBRIDGE CB2 4AT, ENGLAND.							ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; CULLEN PJ, 1992, IN PRESS BIOCH J; DELISLE S, 1992, AM J PHYSIOL, V262, pC1456, DOI 10.1152/ajpcell.1992.262.6.C1456; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; DONIE F, 1991, BIOCHEM J, V275, P453, DOI 10.1042/bj2750453; ELY JA, 1991, J BIOL CHEM, V266, P18635; FELDBERG W, 1975, PROC R SOC SER B-BIO, V191, P199, DOI 10.1098/rspb.1975.0124; GELFAND EW, 1988, EUR J IMMUNOL, V18, P917, DOI 10.1002/eji.1830180613; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; IRVINE RF, 1992, INOSITOL PHOSPHATE C, P161; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; LLOPIS J, 1991, BIOCHEM J, V277, P553, DOI 10.1042/bj2770553; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MISSIAEN L, 1991, IN PRESS J PHYSL LON; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NUNN DL, 1992, MOL PHARMACOL, V41, P115; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; POGGIOLI J, 1985, J BIOL CHEM, V260, P3289; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REISER G, 1991, BIOCHEM J, V280, P533, DOI 10.1042/bj2800533; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SMITH PM, 1992, BIOCHEM J, V283, P27, DOI 10.1042/bj2830027; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SORBERA LA, 1990, SCIENCE, V247, P969, DOI 10.1126/science.2154853; STAUDERMAN KA, 1989, J BIOL CHEM, V264, P18349; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; Wodehouse P. G., 1952, PIGS HAVE WINGS; YAMAGAMI K, 1991, J NEUROCHEM, V57, P1681, DOI 10.1111/j.1471-4159.1991.tb06368.x	47	198	198	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3085	3091		10.1096/fasebj.6.12.1325932	http://dx.doi.org/10.1096/fasebj.6.12.1325932			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1325932				2022-12-28	WOS:A1992JN50500010
J	BARKER, HA				BARKER, HA			THE PATH FROM ACETYLPHOSPHATE TO ACETYL COA	FASEB JOURNAL			English	Editorial Material											BARKER, HA (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA.							BERG P, 1956, J BIOL CHEM, V222, P991; JONES ME, 1953, BIOCHIM BIOPHYS ACTA, V12, P141, DOI 10.1016/0006-3002(53)90133-4; KAPLAN NO, 1948, J BIOL CHEM, V174, P37; LIMANN F, 1945, J BIOL CHEM, V160, P173; LIPMANN F, 1950, J BIOL CHEM, V186, P235; Lipmann F, 1944, J BIOL CHEM, V155, P55; LIPMANN F, 1947, J BIOL CHEM, V167, P869; LIPMANN F, 1954, SCIENCE, V120, P855, DOI 10.1126/science.120.3126.855; Lipmann F, 1941, ADV ENZYMOL REL S BI, V1, P99, DOI 10.1002/9780470122464.ch4; Lipmann F., 1939, COLD SPRING HARB SYM, V7, P248, DOI [10.1101/SQB.1939.007.01.021, DOI 10.1101/SQB.1939.007.01.021]; LYNEN F, 1951, LIEBIGS ANN CHEM, V574, P1; LYNEN F, 1969, PERSPECT BIOL MED, V12, P204; LYNEN F, 1951, ANGEW CHEM-GER EDIT, V63, P47, DOI 10.1002/ange.19510630207; Nachmansohn D, 1943, J NEUROPHYSIOL, V6, P397, DOI 10.1152/jn.1943.6.5.397; NOVELLI GD, 1950, J BIOL CHEM, V182, P213; SNELL EE, 1950, J AM CHEM SOC, V72, P5349, DOI 10.1021/ja01167a546; STADTMAN ER, 1950, J BIOL CHEM, V184, P769; STADTMAN ER, 1949, J BIOL CHEM, V180, P1117; STADTMAN ER, 1951, J BIOL CHEM, V191, P365; STADTMAN ER, 1952, J BIOL CHEM, V196, P527; STADTMAN ER, 1952, J BIOL CHEM, V196, P535	21	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1992	6	11					3014	3015		10.1096/fasebj.6.11.1644265	http://dx.doi.org/10.1096/fasebj.6.11.1644265			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644265				2022-12-28	WOS:A1992JJ66500017
J	SOMA, Y; DVONCH, V; GROTENDORST, GR				SOMA, Y; DVONCH, V; GROTENDORST, GR			PLATELET-DERIVED GROWTH FACTOR-AA HOMODIMER IS THE PREDOMINANT ISOFORM IN HUMAN PLATELETS AND ACUTE HUMAN WOUND FLUID	FASEB JOURNAL			English	Article						PLATELETS; PDGF; WOUND REPAIR; ATHEROSCLEROSIS; GROWTH REGULATION	SIMIAN SARCOMA-VIRUS; SMOOTH-MUSCLE CELLS; B-CHAIN; PDGF; RECEPTOR; PURIFICATION; EXPRESSION; MIGRATION; MOLECULES; CLONING	Platelet-derived growth factor (PDGF) is a dimeric protein composed of A- and B-chains (AA, AB, and BB). PDGF purified from human platelets has been shown to bc composed primarily of the AB heterodimer. Immunoblots of total platelet extracts, cell-bound PDGF from the platelet extracts, and acute human wound fluid with PDGF A- and B-chain-specific antisera all demonstrate that the PDGF A-chain is the predominant peptide. Chemotactic and immunochemical assays of chromatographic fractions during PDGF isolation support these observations and demonstrate that PDGF AA can be separated from PDGF AB and BB by ion exchange chromatography. These studies indicate that the AA isoform constitutes the major PDGF dimer contained in human platelets and is the major form present at sites of injury during the acute phase of the wound repair response.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,1600 NW 10TH AVE,MIAMI,FL 33136; UNIV ALABAMA,SCH MED,DEPT PATHOL,BIRMINGHAM,AL 35294	University of Miami; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037223] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONIADES HN, 1979, P NATL ACAD SCI USA, V76, P1809, DOI 10.1073/pnas.76.4.1809; ANTONIADES HN, 1981, P NATL ACAD SCI USA, V78, P6314; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1991, J CELL PHYSIOL, V149, P235, DOI 10.1002/jcp.1041490209; GROTENDORST GR, 1987, METHOD ENZYMOL, V147, P144; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; GROTENDORST GR, 1984, SOFT HARD TISSUE REP, P20; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; KAZLAUKAS A, 1988, EMBO J, V7, P1387; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUOKA J, 1989, P NATL ACAD SCI USA, V86, P4416, DOI 10.1073/pnas.86.12.4416; Pencev D, 1988, Oncogene Res, V3, P333; RAINES EW, 1982, J BIOL CHEM, V257, P5154; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1983, GROWTH MATURATION FA, P73	28	45	47	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2996	3001		10.1096/fasebj.6.11.1644262	http://dx.doi.org/10.1096/fasebj.6.11.1644262			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644262				2022-12-28	WOS:A1992JJ66500014
J	SARETT, HP				SARETT, HP			1940S STUDIES OF NICOTINIC-ACID METABOLISM AND THE RELATIONSHIP OF VITAMIN-B UTILIZATION TO PROTEIN LEVEL IN THE DIET	FASEB JOURNAL			English	Article																		Huff JW, 1943, J BIOL CHEM, V150, P395; PERLZWEIG W. A., 1940, Journal of Biological Chemistry, V133, plxxiv; Perlzweig WA, 1940, J BIOL CHEM, V136, P729; SARETT H. P., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P132; SARETT HP, 1947, J BIOL CHEM, V167, P293; Sarett HP, 1940, J BIOL CHEM, V135, P483; Sarett HP, 1942, J NUTR, V24, P295, DOI 10.1093/jn/24.3.295; Sarett HP, 1943, J NUTR, V25, P173, DOI 10.1093/jn/25.2.173; Sarett HP, 1942, J NUTR, V23, P35, DOI 10.1093/jn/23.1.35; Sarett HP, 1942, J NUTR, V23, P23, DOI 10.1093/jn/23.1.23; Sarett HP, 1943, J BIOL CHEM, V150, P159	11	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2487	2488		10.1096/fasebj.6.7.1563600	http://dx.doi.org/10.1096/fasebj.6.7.1563600			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563600				2022-12-28	WOS:A1992HP03000017
J	BYLUND, DB				BYLUND, DB			SUBTYPES OF ALPHA-1-ADRENERGIC AND ALPHA-2-ADRENERGIC RECEPTORS	FASEB JOURNAL			English	Article						RECEPTOR CLASSIFICATION; 2ND MESSENGERS; CAMP; MOLECULAR CLONING	ALPHA-1B-ADRENOCEPTOR BINDING-SITES; ALPHA-2 ADRENERGIC-RECEPTORS; RAT-BRAIN; MOLECULAR-CLONING; ALPHA-2B-ADRENERGIC RECEPTOR; INOSITOL PHOSPHATES; CELL-LINES; EXPRESSION; GENE; CDNA	The adrenergic receptors are members of the superfamily of G protein-coupled receptors. There are three major types of adrenergic receptors: alpha(1), alpha(2), and beta. Each of these three major types can be divided into three subtypes. Within the alpha(1)-adrenergic receptors, alpha(1A) and alpha(1B) subtypes have been defined pharmacologically on the basis of reversible antagonists, such as WB4101 and phentolamine, and the irreversible antagonist chloroethylclonidine. In at least some tissues the mechanism of action of the alpha(1A) subtype is related to activation of a calcium channel, whereas the alpha(1B) receptor exerts its effect through the second messenger inositol trisphosphate. Both of these receptor subtypes as well as a third, the alpha(1C), have been identified by molecular cloning. Three pharmacological subtypes of the alpha(2)-adrenergic receptor have also been identified. Prototypic tissues and cell lines in continuous culture have been developed for each of these subtypes, which facilitated their study. The definition of the alpha(2) subtypes has been based on radioligand binding data and more limited functional data. All three subtypes have been shown to inhibit the activation of adenylate cyclase and thus reduce the levels of cAMP. Three alpha(2)-adrenergic receptor subtypes have been identified by molecular cloning in both the human and rat species. There is reasonable agreement between the pharmacological identified subtypes and those identified by molecular cloning.			BYLUND, DB (corresponding author), UNIV NEBRASKA,MED CTR,COLL MED,DEPT PHARMACOL,OMAHA,NE 68198, USA.		Bylund, David/A-9344-2009		NIGMS NIH HHS [GM40784] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST RP, 1948, AM J PHYSIOL, V153, P586, DOI 10.1152/ajplegacy.1948.153.3.586; BATTAGLIA G, 1983, J NEUROCHEM, V41, P538, DOI 10.1111/j.1471-4159.1983.tb04772.x; BLAXALL HS, 1991, J PHARMACOL EXP THER, V259, P323; BYLUND DB, 1989, J PHARMACOL EXP THER, V251, P640; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; BYLUND DB, 1985, PHARMACOL BIOCHEM BE, V22, P835, DOI 10.1016/0091-3057(85)90536-2; BYLUND DB, 1988, ALPHA 2 ADRENERGIC R, P1; CHALBERG SC, 1990, MOL CELL BIOCHEM, V97, P161; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; GROSS G, 1989, EUR J PHARMACOL, V169, P325, DOI 10.1016/0014-2999(89)90032-0; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAN C, 1990, EUR J PHARMACOL, V190, P97; HAN C, 1987, MOL PHARMACOL, V32, P505; HAN C, 1990, MOL PHARMACOL, V37, P903; HANFT G, 1990, BRIT J CLIN PHARMACO, V30, pS125, DOI 10.1111/j.1365-2125.1990.tb05482.x; HANFT G, 1989, BRIT J PHARMACOL, V97, P691, DOI 10.1111/j.1476-5381.1989.tb12005.x; HARRISON JK, 1991, TRENDS PHARMACOL SCI, V12, P62, DOI 10.1016/0165-6147(91)90499-I; HARRISON JK, 1991, MOL PHARMACOL, V40, P407; ISOM LL, 1988, ALPHA 2 ADRENERGIC R, P323; JOHNSON RD, 1987, MOL PHARMACOL, V31, P239; KLIJN K, 1991, MOL PHARMACOL, V39, P407; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LANIER SM, 1988, J BIOL CHEM, V263, P14491; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LEHMANN J, 1989, LIFE SCI, V45, P1609, DOI 10.1016/0024-3205(89)90270-1; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MCGEHEE RE, 1990, MOL CELL ENDOCRINOL, V74, P1, DOI 10.1016/0303-7207(90)90200-R; MCGRATH JC, 1989, MED RES REV, V9, P407, DOI 10.1002/med.2610090403; MICHEL AD, 1989, BRIT J PHARMACOL, V98, P890, DOI 10.1111/j.1476-5381.1989.tb14618.x; MICHEL MC, 1990, N-S ARCH PHARMACOL, V341, P385; MIGNOT E, 1989, BRAIN RES, V486, P56, DOI 10.1016/0006-8993(89)91277-8; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MORROW AL, 1986, MOL PHARMACOL, V29, P321; MURPHY TJ, 1988, J PHARMACOL EXP THER, V244, P571; ORIOWO MA, 1989, J PHARMACOL EXP THER, V251, P16; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SHIMURA H, 1990, J ENDOCRINOL, V124, P433, DOI 10.1677/joe.0.1240433; SHIMURA H, 1990, J ENDOCRINOL, V126, P317, DOI 10.1677/joe.0.1260317; SIMONNEAUX V, 1991, MOL PHARMACOL, V40, P235; SUZUKI E, 1990, MOL PHARMACOL, V38, P725; TERMAN BI, 1990, MOL PHARMACOL, V37, P526; TIMMERMANS PBM, 1982, J MED CHEM, V25, P1390; TSUJIMOTO G, 1989, MOL PHARMACOL, V36, P166; VOIGT MM, 1991, FEBS LETT, V278, P45, DOI 10.1016/0014-5793(91)80080-M; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; WILSON KM, 1989, J NEUROCHEM, V53, P1782, DOI 10.1111/j.1471-4159.1989.tb09243.x; WILSON KM, 1990, J BIOL CHEM, V265, P17601; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102; ZILLES K, 1991, NEUROSCIENCE, V40, P307, DOI 10.1016/0306-4522(91)90122-5	55	398	406	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					832	839		10.1096/fasebj.6.3.1346768	http://dx.doi.org/10.1096/fasebj.6.3.1346768			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1346768	Bronze			2022-12-28	WOS:A1992HE39000005
J	ZANGER, UM; KAGAWA, N; LUND, J; WATERMAN, MR				ZANGER, UM; KAGAWA, N; LUND, J; WATERMAN, MR			DISTINCT BIOCHEMICAL-MECHANISMS FOR CAMP-DEPENDENT TRANSCRIPTION OF CYP17 AND CYP21	FASEB JOURNAL			English	Article						ADRENAL CORTEX; CAMP-DEPENDENT TRANSCRIPTION; STEROIDOGENIC TISSUES	CYCLIC-AMP; STEROID 11-BETA-HYDROXYLASE; GENE-TRANSCRIPTION; PROTEIN-KINASE; EXPRESSION; ELEMENT; REGION; IDENTIFICATION; SYSTEM; CELLS	Optimal steroidogenic capacity in the adrenal cortex is regulated by ACTH via cAMP and involves transcription of the genes encoding the adrenocortical steroid hydroxylases. The microsomal steroid hydroxylases, P45017-alpha and P450C21, are encoded by CYP17 and CYP21, respectively. These genes are thought to have arisen from a common progenitor gene and are coordinately regulated by ACTH. The cAMP responsive sequences (CRS) located in the 5'-flanking regions of these genes are distinct from one another and from known consensus sequences imparting cAMP responsiveness in other genes. The CYP21 CRS binds a putative adrenal-specific nuclear protein. In contrast, the CYP17 CRSI binds a ubiquitous protein that is apparently active only in steroidogenic cells. Thus the ACTH-dependent transcription of these two genes, which have a common evolutionary origin and are coordinately expressed in the adrenal cortex, involves distinct biochemical mechanisms.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET & GYNECOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Zanger, Ulrich M./A-9364-2012	Zanger, Ulrich M./0000-0002-5276-2002	NIDDK NIH HHS [DK28350] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; BOGERD AM, 1990, MOL ENDOCRINOL, V4, P845, DOI 10.1210/mend-4-6-845; HANDLER JD, 1988, J BIOL CHEM, V263, P13068; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KAGAWA N, 1991, J BIOL CHEM, V266, P11199; LUND J, 1990, J BIOL CHEM, V265, P3304; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; RICE DA, 1989, J BIOL CHEM, V264, P14011; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; ZANGER UM, 1991, J BIOL CHEM, V266, P11417	21	32	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN 6	1992	6	2					719	723		10.1096/fasebj.6.2.1311271	http://dx.doi.org/10.1096/fasebj.6.2.1311271			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1311271				2022-12-28	WOS:A1992GZ44000012
J	CATERINA, MJ; DEVREOTES, PN				CATERINA, MJ; DEVREOTES, PN			MOLECULAR INSIGHTS INTO EUKARYOTIC CHEMOTAXIS	FASEB JOURNAL			English	Article						LEUKOCYTES; CAMP; G-PROTEINS; MOTILITY; PHOSPHORYLATION	PEPTIDE RECEPTOR MODULATION; DICTYOSTELIUM-DISCOIDEUM; POLYMORPHONUCLEAR LEUKOCYTES; GROWTH-FACTOR; CHEMICAL GRADIENTS; ADENYLATE-CYCLASE; BINDING PROTEINS; CELL MOTILITY; CYCLIC-AMP; CHEMOATTRACTANT	Many cells display directed migration toward specific compounds. The best-studied eukaryotic models of chemotaxis are polymorphonuclear leukocytes, which respond to formylated peptides and Dictyostelium amoebas, which respond to extracellular cAMP. In both cell types, chemoattractants bind to surface receptors that contain seven transmembrane domains and interact with G proteins. Some cells, such as fibroblasts, undergo chemotaxis toward compounds whose receptors lack this motif and transmit their signals by other mechanisms. The cytosolic changes elicited by chemoattractants include increased levels of cAMP, cGMP, inositol phosphates, and calcium. These changes are correlated with actin polymerization and other cytoskeletal events that result in preferential extention of pseudopods toward the chemoattractant. Dictyostelium cell lines in which specific genes have been disrupted have demonstrated the necessity of a cAMP receptor (cAR1) and a G protein alpha-subunit (G-alpha-2) for responsiveness to cAMP. Other proteins, such as myosin heavy chain and several actin binding proteins, are dispensible although their absence docs affect the details of chemotaxis. The disruption of other relevant genes and the genetic reconstitution of chemotaxis in cells lacking crucial proteins should reveal many clues about this complicated and fascinating process.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University	DEVREOTES, PN (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM39933, GM28007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028007, R37GM028007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERCROMBIE M, 1970, EXP CELL RES, V59, P393, DOI 10.1016/0014-4827(70)90646-4; AERTS RJ, 1987, FEBS LETT, V220, P366, DOI 10.1016/0014-5793(87)80848-7; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BOMINAAR AA, 1991, DEV GENET, V12, P19, DOI 10.1002/dvg.1020120106; BOYD A, 1982, ANNU REV PHYSIOL, V44, P501, DOI 10.1146/annurev.ph.44.030182.002441; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DINAUER MC, 1980, J CELL BIOL, V86, P537, DOI 10.1083/jcb.86.2.537; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2664; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EGELHOFF TT, 1991, IN PRESS TRENDS GENE; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISHER PR, 1989, J CELL BIOL, V108, P973, DOI 10.1083/jcb.108.3.973; GAUSSMULLER V, 1980, J LAB CLIN MED, V96, P1071; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HALL AL, 1989, DEV BIOL, V136, P517, DOI 10.1016/0012-1606(89)90277-7; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KNECHT D A, 1990, Journal of Cell Biology, V111, p7A; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEICHLEITER J, 1991, SCIENCE, V252, P123; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MATO JM, 1975, P NATL ACAD SCI USA, V72, P4991, DOI 10.1073/pnas.72.12.4991; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; Newell P C, 1990, Semin Cell Biol, V1, P105; PEREZ HD, 1989, J CLIN INVEST, V83, P1963, DOI 10.1172/JCI114105; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; POLAKIS PG, 1988, FASEB J, V2, pA669; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAXE CL, 1991, GENE DEV, V5, P1, DOI 10.1101/gad.5.1.1; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIMCHOWITZ L, 1986, J BIOL CHEM, V261, P6492; SNAARJAGALSKA BE, 1988, FEBS LETT, V236, P139, DOI 10.1016/0014-5793(88)80302-8; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; THEIBERT A, 1986, DEV BIOL, V114, P529, DOI 10.1016/0012-1606(86)90216-2; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; TITUS MA, 1990, J CELL BIOL, V11, pA168; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1869; VANDUIJN B, 1990, J CELL SCI, V95, P177; VANHAASTERT PJM, 1987, J BIOL CHEM, V262, P7700; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P347, DOI 10.1083/jcb.96.2.347; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WALRAFF E, 1986, EMBO J, V5, P61; WEIS RM, 1990, J BIOL CHEM, V265, P6817; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WILDE MW, 1989, J BIOL CHEM, V264, P190; WRIGHT TM, 1988, P NATL ACAD SCI USA, V85, P1869, DOI 10.1073/pnas.85.6.1869; ZIGMOND SH, 1981, J CELL BIOL, V88, P644, DOI 10.1083/jcb.88.3.644; ZIGMOND SH, 1974, NATURE, V249, P450, DOI 10.1038/249450a0; ZIGMOND SH, 1982, J CELL BIOL, V92, P34, DOI 10.1083/jcb.92.1.34; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606	66	104	105	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1991	5	15					3078	3085		10.1096/fasebj.5.15.1743439	http://dx.doi.org/10.1096/fasebj.5.15.1743439			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1743439				2022-12-28	WOS:A1991GU84200011
J	MALDONADO, D; SCHUMANN, M; NGHIEM, P; DONG, Y; GARDNER, P				MALDONADO, D; SCHUMANN, M; NGHIEM, P; DONG, Y; GARDNER, P			PROSTAGLANDIN-E1 ACTIVATES A CHLORIDE CURRENT IN JURKAT-T LYMPHOCYTES VIA CAMP-DEPENDENT PROTEIN-KINASE	FASEB JOURNAL			English	Article						CYCLIC AMP; CYSTIC FIBROSIS; ION CHANNEL; CHLORIDE CHANNEL	EPITHELIAL-CELL LINE; CYSTIC-FIBROSIS; CYCLIC-AMP; IMMUNE-RESPONSE; CHANNELS; CONDUCTANCE; CA-2+; PHOSPHORYLATION; MODULATION; INHIBITION	Patch-clamp studies have identified a cAMP-dependent Cl- conductance in lymphocytes that is defectively regulated in cystic fibrosis. In this study we used I-125 efflux and whole-cell patch-clamp studies to investigate whether prostaglandin E1 (PGE1), an agonist that generates intracellular cAMP in Jurkat T lymphocytes, activates a Cl- conductance. Stimulation of T cells by externally applied PGE, stimulated I-125 efflux and activated a slowly developing membrane current. When external and internal Cl- were about equal, the current reversed at about zero mV, but when external Cl- was lowered from 157 to 7 mM the reversal potential shifted 75 mV in the positive direction, demonstrating that the current carrier was Cl-. In addition, the current was blocked by 10-mu-M 5-nitro-2(3-phenylpropylamino) benzoic acid (NPPB), a potent Cl- channel blocker. A membrane-permeable cAMP analog mimicked the effect of PGE1, whereas intracellular application of a cAMP antagonist Rp-cAMP blocked the effect of PGE1. Addition of purified catalytic subunit of cAMP-dependent protein kinase (PKA) plus ATP to the recording pipette also activated a similar current, whereas internally applied Walsh inhibitor, the synthetic peptide inhibitor of PKA, blocked the PGE1 effect. These results suggest that PGE1, acting through PKA, activates a Cl- current in Jurkat T cells.	STANFORD UNIV, MED CTR,SCH MED,FALK CARDIOVASC RES CTR,DEPT MED, STANFORD, CA 94305 USA	Stanford University			Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041324] Funding Source: NIH RePORTER; NCI NIH HHS [CA09302] Funding Source: Medline; NIDDK NIH HHS [DK41324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAKER PE, 1981, CELL IMMUNOL, V61, P52, DOI 10.1016/0008-8749(81)90353-1; Beavo J A, 1974, Methods Enzymol, V38, P299; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLANCY J P, 1989, FASEB Journal, V3, pA562; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DAILEY MO, 1988, J IMMUNOL, V140, P2931; DEMAREST JR, 1989, SCIENCE, V245, P402, DOI 10.1126/science.2474200; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRANCIOLINI F, 1990, BIOCHIM BIOPHYS ACTA, V1031, P247, DOI 10.1016/0304-4157(90)90009-2; GOODWIN JS, 1979, CELL IMMUNOL, V43, P150, DOI 10.1016/0008-8749(79)90158-8; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GOODWIN JS, 1977, NEW ENGL J MED, V197, P263; GRAY LS, 1986, J IMMUNOL, V136, P3032; GREGER R, 1989, ANN NY ACAD SCI, V574, P403; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESCHELER J, 1987, PFLUG ARCH EUR J PHY, V410, P23, DOI 10.1007/BF00581891; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JENTSCH TJ, 1989, BIOCHEM J, V261, P155, DOI 10.1042/bj2610155; KAILA K, 1987, NATURE, V330, P163, DOI 10.1038/330163a0; KELLY RH, 1982, AGENTS ACTIONS, V12, P471, DOI 10.1007/BF01965929; KIRBY PJ, 1976, PROSTAGLANDINS, V11, P621, DOI 10.1016/0090-6980(76)90065-4; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORCHAK HM, 1980, P NATL ACAD SCI-BIOL, V77, P2721, DOI 10.1073/pnas.77.5.2721; LEE SC, 1988, AM J PHYSIOL, V254, pC286, DOI 10.1152/ajpcell.1988.254.2.C286; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LEWIS RS, 1987, HESCJU, V51, pA397; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MAKOUL GT, 1985, J IMMUNO, V133, P1283; MARY D, 1989, J BIOL CHEM, V264, P14498; NORDSTEDT C, 1987, FEBS LETT, V220, P57, DOI 10.1016/0014-5793(87)80875-X; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSOFF PM, 1988, J BIOL CHEM, V263, P19535; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH MJ, 1987, PHYSIOL REV, V67, P657; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; WOLINSKY SI, 1980, CLIN IMMUNOL IMMUNOP, V17, P31, DOI 10.1016/0090-1229(80)90070-7; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	48	15	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1991	5	14					2965	2970		10.1096/fasebj.5.14.1721593	http://dx.doi.org/10.1096/fasebj.5.14.1721593			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1721593				2022-12-28	WOS:A1991GP26900012
J	VANDERREST, M; GARRONE, R				VANDERREST, M; GARRONE, R			COLLAGEN FAMILY OF PROTEINS	FASEB JOURNAL			English	Review						COLLAGENS; EXTRACELLULAR MATRIX; GENE FAMILIES; CONNECTIVE TISSUES; PROTEIN STRUCTURE; SUPRAMOLECULAR AGGREGATES	TRIPLE-HELICAL DOMAINS; FIBRILLAR COLLAGEN; VIII COLLAGEN; ANCHORING FIBRILS; CHICK CARTILAGE; GENE FAMILIES; ALPHA-3 CHAIN; III COLLAGEN; XII COLLAGEN; V COLLAGEN	Collagen molecules are structural macro-molecules of the extracellular matrix that include in their structure one or several domains that have a characteristic triple helical conformation. They have been classified by types that define distinct sets of polypeptide chains that can form homo- and heterotrimeric assemblies. All the collagen molecules participate in supramolecular aggregates that are stabilized in part by interactions between triple helical domains. Fourteen collagen types have been defined so far. They form a wide range of structures. Most notable are 1) fibrils that are found in most connective tissues and are made by alloys of fibrillar collagens (types I, II, III, V, and XI) and 2) sheets constituting basement membranes (type IV collagen), Descemet's membrane (type VIII collagen), worm cuticle, and organic exoskeleton of sponges. Other collagens, present in smaller quantities in tissues, play the role of connecting elements between these major structures and other tissue components. The fibril-associated collagens with interrupted triple helices (FACITs) (types IX, XII, and XIV) appear to connect fibrils to other matrix elements. Type VII collagen assemble into anchoring fibrils that bind epithelial basement membranes and entrap collagen fibrils from the underlying stroma to glue the two structures together. Type VI collagen forms thin-beaded filaments that may interact with fibrils and cells.	ECOLE NORMALE SUPER LYON,LYONS,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)	VANDERREST, M (corresponding author), UNIV LYON 1,INST BIOL & CHEM PROT,CNRS,UPR 412,BATIMENT 403,F-69622 VILLEURBANNE,FRANCE.							ADACHI E, 1989, MATRIX, V9, P232, DOI 10.1016/S0934-8832(89)80055-1; BENYA PD, 1986, J BIOL CHEM, V261, P4160; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BREWTON RG, 1991, J BIOL CHEM, V266, P4752; BRODSKY B, 1985, ANN NY ACAD SCI, V460, P73, DOI 10.1111/j.1749-6632.1985.tb51158.x; BRUCKNERTUDERMAN L, 1989, J INVEST DERMATOL, V93, P3, DOI 10.1111/1523-1747.ep12277331; CECCHINI JP, 1987, EUR J BIOCHEM, V165, P587, DOI 10.1111/j.1432-1033.1987.tb11480.x; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; COX GN, 1990, ACTA TROP, V47, P269, DOI 10.1016/0001-706X(90)90028-X; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; DUBLET B, 1989, J BIOL CHEM, V264, P13150; DUBLET B, 1991, J BIOL CHEM, V266, P6853; Eastoe J. E, 1967, TREATISE COLLAGEN, V1, P1; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; FLEISCHMAJER R, 1985, ANN NY ACAD SCI, V460, P246, DOI 10.1111/j.1749-6632.1985.tb51172.x; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FRISCHAUF AM, 1978, BIOCHEMISTRY-US, V17, P3243, DOI 10.1021/bi00609a011; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; GROSS J, 1956, J BIOPHYS BIOCH CY S, V2, P26; HENKEL W, 1982, EUR J BIOCHEM, V122, P205, DOI 10.1111/j.1432-1033.1982.tb05868.x; Hodge A, 1963, ASPECTS PROTEIN STRU, P289; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KEENE DR, 1987, J CELL BIOL, V105, P2393, DOI 10.1083/jcb.105.5.2393; Kefalides N A, 1973, Int Rev Connect Tissue Res, V6, P63; KIELTY CM, 1990, BIOCHEM J, V272, P787, DOI 10.1042/bj2720787; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Mayne R., 1987, STRUCTURE FUNCTION C; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MILLER EJ, 1969, P NATL ACAD SCI USA, V64, P1264, DOI 10.1073/pnas.64.4.1264; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; MURAGAKI Y, 1991, EUR J BIOCHEM, V197, P615, DOI 10.1111/j.1432-1033.1991.tb15951.x; MURAGAKI Y, 1990, P NATL ACAD SCI USA, V87, P2400, DOI 10.1073/pnas.87.7.2400; MURRAY LW, 1985, BIOL INVERTEBRATE LO, P243; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; PELTONEN L, 1985, J CELL BIOCHEM, V28, P15, DOI 10.1002/jcb.240280104; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; Ramachandran G. N., 1976, BIOCH COLLAGEN; REGAUER S, 1990, J CELL BIOL, V111, P2109, DOI 10.1083/jcb.111.5.2109; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SAUS J, 1988, J BIOL CHEM, V263, P13374; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; Schmitt FO, 1942, J CELL COMPAR PHYSL, V20, P11, DOI 10.1002/jcp.1030200103; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VANDERREST M, 1990, BIOCHIMIE, V72, P473, DOI 10.1016/0300-9084(90)90071-N; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022; Yamauchi M, 1989, Connect Tissue Res, V21, P159, DOI 10.3109/03008208909050006; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	61	949	977	7	221	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2814	2823		10.1096/fasebj.5.13.1916105	http://dx.doi.org/10.1096/fasebj.5.13.1916105			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916105				2022-12-28	WOS:A1991GJ47100010
J	BORN, WK; OBRIEN, RL; MODLIN, RL				BORN, WK; OBRIEN, RL; MODLIN, RL			ANTIGEN-SPECIFICITY OF GAMMA-DELTA LYMPHOCYTES-T	FASEB JOURNAL			English	Article						GAMMA-DELTA T-CELLS; INFECTION; SPECIFICITY; FUNCTION	INTESTINAL INTRAEPITHELIAL LYMPHOCYTES; PLASMODIUM-FALCIPARUM MALARIA; RHEUMATOID-ARTHRITIS PATIENTS; RECEPTOR-BEARING LYMPHOCYTES; DENDRITIC EPIDERMAL-CELLS; HUMAN PERIPHERAL-BLOOD; HEAT-SHOCK PROTEIN; MYCOBACTERIUM-TUBERCULOSIS; LIMITED DIVERSITY; DIFFERENT FORMS	Gamma-delta-T cells represent a new lymphocyte subset without a definitive functional assignment. Although in many ways similar to alpha-beta-T lymphocytes, they are clearly distinguished by their expression of a different set of T cell receptor genes, a different distribution in normal tissues, and perhaps also different ligand specificities. Because gamma-delta-T cells appear to be involved in a variety of human diseases, the determination of their biological role has become an important challenge for immunologists and researchers in related areas.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262; UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040312] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27903-A] Funding Source: Medline; NIAMS NIH HHS [AR 40312] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO T, 1990, INT IMMUNOL, V2, P775, DOI 10.1093/intimm/2.8.775; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; AUTRAN B, 1989, CLIN EXP IMMUNOL, V75, P206; BALBI B, 1990, J CLIN INVEST, V85, P1353, DOI 10.1172/JCI114579; BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; BORN W, 1990, IMMUNOL TODAY, V11, P40; BORN W, 1987, NATURE, V330, P572, DOI 10.1038/330572a0; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; BRENNAN FM, 1988, J AUTOIMMUN, V1, P319, DOI 10.1016/0896-8411(88)90002-9; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; BUCY RP, 1990, J IMMUNOL, V144, P1161; CARBONARI M, 1990, NEW ENGL J MED, V322, P73, DOI 10.1056/NEJM199001113220201; CARDING SR, 1990, J EXP MED, V172, P1225, DOI 10.1084/jem.172.4.1225; CHIEN YH, 1987, NATURE, V327, P677, DOI 10.1038/327677a0; CHRISTMAS SE, 1990, IMMUNOLOGY, V71, P486; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DEPAOLI P, 1990, J INFECT DIS, V161, P1013, DOI 10.1093/infdis/161.5.1013; FALINI B, 1989, J IMMUNOL, V143, P2480; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FISCH P, 1990, J EXP MED, V171, P1567, DOI 10.1084/jem.171.5.1567; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; FLAHERTY L, 1990, CRIT REV IMMUNOL, V10, P131; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HALSTENSEN TS, 1989, SCAND J IMMUNOL, V30, P665, DOI 10.1111/j.1365-3083.1989.tb02474.x; HAPP MP, 1989, NATURE, V342, P696, DOI 10.1038/342696a0; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HAREGEWOIN A, 1990, J INFECT DIS, V163, P156; HATA S, 1989, J EXP MED, V169, P41, DOI 10.1084/jem.169.1.41; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HEDRICK SM, 1990, RES IMMUNOL, V141, P588, DOI 10.1016/0923-2494(90)90061-3; HO M, 1990, IMMUNOL LETT, V25, P139, DOI 10.1016/0165-2478(90)90105-Y; HOLOSHITZ J, 1986, LANCET, V2, P305; HOLOSHITZ J, 1989, NATURE, V339, P226, DOI 10.1038/339226a0; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; ITO K, 1989, P NATL ACAD SCI USA, V86, P631, DOI 10.1073/pnas.86.2.631; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; JONES B, 1986, NATURE, V323, P635, DOI 10.1038/323635a0; JONES B, 1988, EUR J IMMUNOL, V18, P1907, DOI 10.1002/eji.1830181207; JUTTE NHPM, 1990, HUM IMMUNOL, V28, P170, DOI 10.1016/0198-8859(90)90015-H; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KAUFMANN SHE, IN PRESS CURR TOP MI; KJELDSENKRAGH J, 1990, SCAND J IMMUNOL, V32, P651, DOI 10.1111/j.1365-3083.1990.tb03207.x; KOZBOR D, 1989, J EXP MED, V169, P1847, DOI 10.1084/jem.169.5.1847; KRATZ LE, 1990, ARTHRITIS RHEUM-US, V33, P569, DOI 10.1002/art.1780330415; LEW AM, 1986, SCIENCE, V234, P1401, DOI 10.1126/science.3787252; Mackay C R, 1989, Int Immunol, V1, P540, DOI 10.1093/intimm/1.5.540; MAEDA K, 1987, P NATL ACAD SCI USA, V84, P6536, DOI 10.1073/pnas.84.18.6536; MATIS LA, 1989, SCIENCE, V245, P746, DOI 10.1126/science.2528206; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; Minoprio P, 1989, Int Immunol, V1, P176, DOI 10.1093/intimm/1.2.176; MODLIN RL, 1989, NATURE, V339, P554; MORIO T, 1990, J IMMUNOL, V144, P1270; MORIO T, 1989, CLIN IMMUNOL IMMUNOP, V52, P279, DOI 10.1016/0090-1229(89)90179-7; MORISSET J, 1988, EUR J IMMUNOL, V18, P387, DOI 10.1002/eji.1830180311; MUNK ME, 1990, J IMMUNOL, V145, P2434; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; OBRIEN RL, 1991, IMMUNOL REV, V121, P155, DOI 10.1111/j.1600-065X.1991.tb00827.x; OBRIEN RL, 1990, YEAR IMMUNOLOGY 1989, P51; OHGA S, 1990, EUR J IMMUNOL, V20, P533, DOI 10.1002/eji.1830200311; PARKER CM, 1990, J EXP MED, V171, P1597, DOI 10.1084/jem.171.5.1597; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; QUERE P, 1990, IMMUNOLOGY, V71, P517; RAJAGOPALAN S, 1990, P NATL ACAD SCI USA, V87, P7020, DOI 10.1073/pnas.87.18.7020; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; REARDON C, 1990, J EXP MED, V172, P1263, DOI 10.1084/jem.172.4.1263; ROUSSILHON C, 1990, J INFECT DIS, V162, P283, DOI 10.1093/infdis/162.1.283-a; RUST CJJ, 1990, NATURE, V346, P572, DOI 10.1038/346572a0; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; SEKI S, 1990, J CLIN INVEST, V86, P409, DOI 10.1172/JCI114726; SETTE A, 1989, J IMMUNOL, V142, P35; SIOUD M, 1990, SCAND J IMMUNOL, V31, P415, DOI 10.1111/j.1365-3083.1990.tb02787.x; SMITH MD, 1990, SCAND J IMMUNOL, V32, P585, DOI 10.1111/j.1365-3083.1990.tb03200.x; SPENCER J, 1989, EUR J IMMUNOL, V19, P1335, DOI 10.1002/eji.1830190728; SPITS H, 1990, J IMMUNOL, V144, P4156; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; TAMURA N, 1990, J EXP MED, V172, P169, DOI 10.1084/jem.172.1.169; VERKASALO MA, 1990, GUT, V31, P422, DOI 10.1136/gut.31.4.422; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; VIETOR H, 1990, IMMUNOGENETICS, V31, P340, DOI 10.1007/BF02115008; VILMER E, 1988, J CLIN INVEST, V82, P755, DOI 10.1172/JCI113675; WOLF PR, 1990, J EXP MED, V172, P1795, DOI 10.1084/jem.172.6.1795	92	57	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2699	2705		10.1096/fasebj.5.12.1717333	http://dx.doi.org/10.1096/fasebj.5.12.1717333			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1717333				2022-12-28	WOS:A1991GE81100011
J	KINOSHITA, M; PASATIEMPO, AMG; TAYLOR, CE; ROSS, AC				KINOSHITA, M; PASATIEMPO, AMG; TAYLOR, CE; ROSS, AC			IMMUNOLOGICAL MEMORY TO TETANUS TOXOID IS ESTABLISHED AND MAINTAINED IN THE VITAMIN-A-DEPLETED RAT	FASEB JOURNAL			English	Note						LEWIS RAT; RETINOL; IGM; IGG; ENZYME-LINKED IMMUNOABSORPTION ASSAY	MURINE-B-CELLS; IMMUNE-RESPONSE; DEFICIENT RATS; RETINOIC ACID; MACROPHAGE FUNCTION; ANTIBODY-RESPONSE; INTERFERON-GAMMA; MILD VITAMIN; MICE; CHILDREN	We have previously shown that vitamin A deficiency severely impairs the young rat's ability to produce specific antibodies after primary immunization with tetanus toxoid (TT). In the present studies, we asked whether immunologic memory to TT is established even in the vitamin A-depleted animal, and if so, whether such memory can be elicited after subsequent repletion with retinol. Vitamin A-depleted rats produced very low concentrations of TT-specific IgM and IgG antibodies in both the primary and secondary responses; however, the ratios of secondary to primary IgM anti-TT and of IgG anti-TT were normal. When rats were repleted with retinol 1 day after immunization, IgM and IgG anti-TT concentrations in both the primary and secondary responses were at least as great as those of control rats. For rats repleted with retinol 2 days before the booster immunization, secondary IgM and IgG anti-TT concentrations were equal in magnitude to those of vitamin A-sufficient controls. For all groups, the kinetics of the antibody response were similar. We conclude that immunological memory is intact in the vitamin A-depleted animal, as shown by 1) the normal ratio of its secondary to primary antibody responses, 2) the restoration of a quantitatively normal secondary antibody response in previously vitamin A-depleted animals repleted with retinol just before boosting with TT, and 3) a normal class switch from IgM to IgG. Retinol deficiency is also characterized by an abnormal elevation of total plasma IgG, despite the inability of the vitamin A-depleted animal to produce normal quantities of specific antibodies after challenge with antigen.	MED COLL PENN, DEPT PHYSIOL & BIOCHEM, DIV NUTR, 3300 HENRY AVE, PHILADELPHIA, PA 19129 USA; MED COLL PENN, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19129 USA	Drexel University; Drexel University					NICHD NIH HHS [1K05HD-00691] Funding Source: Medline; NIDDK NIH HHS [1R01DK-41479, R01 DK041479] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041479] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANZANO MA, 1979, J NUTR, V109, P1419, DOI 10.1093/jn/109.8.1419; AOTSUKA S, 1988, CLIN EXP IMMUNOL, V73, P436; ATHANASSIADES TJ, 1981, J NATL CANCER I, V67, P1153; BIERI JG, 1969, SCIENCE, V163, P574, DOI 10.1126/science.163.3867.574; BIXLER GS, 1980, J IMMUNOL, V125, P893; BOWMAN TA, 1990, J NUTR, V120, P1264, DOI 10.1093/jn/120.10.1264; BROWN KH, 1980, AM J CLIN NUTR, V33, P212, DOI 10.1093/ajcn/33.2.212; BUERKI H, 1974, J IMMUNOL, V112, P1961; CARMAN JA, 1989, J IMMUNOL, V142, P388; Chandra R. K., 1981, Nutrient Research, V1, P181, DOI 10.1016/S0271-5317(81)80100-5; CHANDRA RK, 1988, BRIT MED J, V297, P834, DOI 10.1136/bmj.297.6652.834; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1977, J IMMUNOL, V118, P1806; DILLEHAY DL, 1988, J LEUKOCYTE BIOL, V44, P353, DOI 10.1002/jlb.44.5.353; DRESSER DW, 1968, NATURE, V217, P527, DOI 10.1038/217527a0; FINKELMAN FD, 1986, J IMMUNOL, V137, P2878; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FRIEDMAN A, 1989, J NUTR, V119, P790, DOI 10.1093/jn/119.5.790; GERSHWIN ME, 1984, J IMMUNOL, V133, P222; GOLDMAN R, 1984, J CELL PHYSIOL, V120, P91, DOI 10.1002/jcp.1041200113; Green HN, 1928, BRIT MED J, V1928, P691, DOI 10.1136/bmj.2.3537.691; HATCHIGIAN EA, 1989, P SOC EXP BIOL MED, V191, P47; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734; JELINEK DF, 1987, ADV IMMUNOL, V40, P1, DOI 10.1016/S0065-2776(08)60237-0; KRAFT R, 1989, CLIN EXP IMMUNOL, V76, P138; KRISHNAN S, 1974, IMMUNOLOGY, V27, P383; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MALKOVSKY M, 1983, NATURE, V302, P338, DOI 10.1038/302338a0; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MILTON RC, 1987, AM J CLIN NUTR, V46, P827, DOI 10.1093/ajcn/46.5.827; MORIGUCHI S, 1985, IMMUNOLOGY, V56, P169; MUHILAL, 1988, AM J CLIN NUTR, V48, P1265, DOI 10.1093/ajcn/48.5.1265; MUHILAL, 1988, AM J CLIN NUTR, V48, P1271, DOI 10.1093/ajcn/48.5.1271; NAUSS KM, 1985, J NUTR, V115, P1300, DOI 10.1093/jn/115.10.1300; NAUSS KM, 1985, J NUTR, V115, P1316, DOI 10.1093/jn/115.10.1316; Nauss KM, 1986, VITAMIN A DEFICIENCY, P207; ONGSAKUL M, 1985, P SOC EXP BIOL MED, V178, P204, DOI 10.3181/00379727-178-41999; PASATIEMPO AMG, 1989, AM J CLIN NUTR, V49, P501, DOI 10.1093/ajcn/49.3.501; PASATIEMPO AMG, 1990, FASEB J, V4, P2518, DOI 10.1096/fasebj.4.8.2110538; PASATIEMPO AMG, 1991, J NUTR, V121, P556, DOI 10.1093/jn/121.4.556; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; ROBERTS AB, 1984, RETINOIDS, V2, P209; SCRIMSHAW NS, 1968, INTERACTIONS NUTRITI; SIDELL N, 1984, CELL IMMUNOL, V88, P374, DOI 10.1016/0008-8749(84)90170-9; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; SIRISINHA S, 1980, CLIN EXP IMMUNOL, V40, P127; SMITH SM, 1987, P NATL ACAD SCI USA, V84, P5878, DOI 10.1073/pnas.84.16.5878; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNAPPER CM, 1987, J IMMUNOL, V139, P10; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; SPORN MB, 1985, RETINOIDS DIFFERENTI, P1; STEINMETZ JE, 1981, BEHAV RES METH INSTR, V13, P702, DOI 10.3758/BF03202100; STONER RD, 1975, J INFECT DIS, V131, P230, DOI 10.1093/infdis/131.3.230; SWAIN SL, 1988, IMMUNOL REV, V102, P77, DOI 10.1111/j.1600-065X.1988.tb00742.x; TRECHSEL U, 1985, BIOCHEM J, V230, P339, DOI 10.1042/bj2300339; UNDERWOOD BA, 1990, NUTR REV, V48, P265, DOI 10.1111/j.1753-4887.1990.tb02955.x; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; VYAS D, 1990, NUTRITION DISEASE RE, P325; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	62	24	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2473	2481		10.1096/fasebj.5.10.2065894	http://dx.doi.org/10.1096/fasebj.5.10.2065894			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065894				2022-12-28	WOS:A1991FW08700019
J	WIGZELL, H				WIGZELL, H			PROSPECTS FOR AN HIV-VACCINE	FASEB JOURNAL			English	Review						T-CELL IMMUNITY; VIRAL DISEASE; ANTIBODIES; AUTOIMMUNITY; IMMUNODEFICIENCY	SIMIAN IMMUNODEFICIENCY VIRUS; ENVELOPE GLYCOPROTEIN GP120; INFECTION INVITRO; RHESUS MACAQUES; CHIMPANZEES; ANTIBODIES; NEUTRALIZATION; RECOMBINANT; PROTECTION; EPITOPES	A vaccine against HIV is badly needed. In the average clinical situation the virus displays a low-rate capacity to transfer infection. The frequency is significantly below 1 per contact situation, that is, a single infectious unit is the normal cause of infection. The time to induce disease in the adult is between 5 and 10 years. These facts are considered positive in relation to producing an HIV vaccine to achieve sterilizing and/or protective immunity. A summary of animal and human HIV/SIV vaccine studies is made giving certain support for the prospects of producing an HIV vaccine.	NATL BACTERIOL LAB,S-10521 STOCKHOLM,SWEDEN		WIGZELL, H (corresponding author), KAROLINSKA INST,DEPT IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN.							ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; BERMAN PW, 1988, P NATL ACAD SCI USA, V85, P5200, DOI 10.1073/pnas.85.14.5200; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; GARDNER MB, 1989, J MED PRIMATOL, V18, P321; GARDNER MB, 1990, AIDS RES HUMAN RETRO, V6; GIBBS CJ, 1989, 2ND P ANN M NAT COOP; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; HOM RC, 1991, J VIROL, V65, P220, DOI 10.1128/JVI.65.1.220-224.1991; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; KLIKS SC, 1980, NATURE, V285, P504, DOI 10.1038/285504a0; MARTHAS ML, 1990, J VIROL, V64, P3694, DOI 10.1128/JVI.64.8.3694-3700.1990; MONTEFIORI DC, 1990, J VIROL, V64, P5223, DOI 10.1128/JVI.64.10.5223-5225.1990; MONTELARO R, 1989, 1989 M LAB TUM CELL; MURPHEYCORB M, 1990, VACCINES 90, P393; MURPHEYCORB M, 1990, INT C ADV AIDS VACCI; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; PALKER TJ, 1989, J IMMUNOL, V142, P3612; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; PRINCE AM, 1990, VACCINES 90, P347; PROFY AT, 1990, J IMMUNOL, V144, P4641; PUTKONEN P, 1991, AIDS RES HUM RETROV, V7, P271, DOI 10.1089/aid.1991.7.271; PUTKONEN P, 1990, AIDS, V4, P783, DOI 10.1097/00002030-199008000-00010; REDFIELD R, 1990, INT C ADV AIDS VACCI; ROBINSON WE, 1989, P NATL ACAD SCI USA, V86, P4710, DOI 10.1073/pnas.86.12.4710; ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; SALK J, 1987, NATURE, V327, P473, DOI 10.1038/327473a0; SHAFFERMAN A, 1989, AIDS RES HUM RETROV, V5, P327, DOI 10.1089/aid.1989.5.327; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1990, INT C ADV AIDS VACCI; SUTJIPTO S, 1990, J VIROL, V64, P2290, DOI 10.1128/JVI.64.5.2290-2297.1990; WIGZELL H, 1988, J ACQ IMMUN DEF SYND, V1, P559; WIGZELL H, 1988, IMMUNOBIOLOGY PATHOG; ZAGURY D, 1987, NATURE, V326, P249, DOI 10.1038/326249a0	39	17	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2406	2411		10.1096/fasebj.5.10.2065889	http://dx.doi.org/10.1096/fasebj.5.10.2065889			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065889	Bronze			2022-12-28	WOS:A1991FW08700011
J	BURK, RF				BURK, RF			MOLECULAR-BIOLOGY OF SELENIUM WITH IMPLICATIONS FOR ITS METABOLISM	FASEB JOURNAL			English	Review						SELENOCYSTEINES; SELENOPROTEINS; GLUTATHIONE PEROXIDASE; SELENOPROTEIN-P	DEPENDENT GLUTATHIONE-PEROXIDASE; RAT-LIVER; TRANSFER-RNA; ESCHERICHIA-COLI; MESSENGER-RNA; IMMUNOLOGICAL INVESTIGATIONS; NUCLEOTIDE-SEQUENCE; SODIUM SELENITE; SELENOPROTEIN-P; GENE-EXPRESSION	Selenium has a highly specific metabolism centered around its incorporation as selenocysteine into selenoproteins. An outline of this metabolism has emerged from recent molecular biological and biochemical studies of bacteria and animals. A unique tRNA, designated tRNA[Ser]Sec, is charged with L-serine, which is then converted through at least two steps to selenocysteine. With the aid of a unique translation factor, the selenocysteinyl-tRNA[Ser]Sec, recognizes specific UGA codons in mRNA to insert selenocysteine into the primary structure of selenoproteins. Turnover of selenoproteins presumably liberates selenocysteine which is toxic in its free form. Selenocysteine beta-lyase catabolizes free selenocysteine and makes its selenium available for reuse. Proteins contain almost all the selenium in animals. Of the known selenoproteins, the glutathione peroxidases contain the most selenium. Cellular and plasma glutathione peroxidases are products of different genes but have 44% identity of amino acid sequence. There is evidence for other proteins of this family. Selenoprotein P is an unrelated protein with multiple selenocysteines in its primary structure. It contains most of the selenium in rat plasma. Studies of the regulation of cellular glutathione peroxidase by selenium have yielded conflicting results, but there is a strong suggestion that mRNA levels of the rodent liver glutathione peroxidase decrease in selenium deficiency. This could be a mechanism for directing selenium to the synthesis of other selenoproteins. Although present knowledge allows construction of an outline of selenium metabolism, several steps have not been characterized and little is known about mechanisms of its regulation.	VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University	BURK, RF (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV GASTROENTEROL,C2104 MED CTR N,1161 21ST AVE S,NASHVILLE,TN 37232, USA.				NHLBI NIH HHS [HL 36371] Funding Source: Medline; NIEHS NIH HHS [ES 02497] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497, R37ES002497] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVISSAR N, 1989, BLOOD, V73, P318; AVISSAR N, 1989, J BIOL CHEM, V264, P15850; BEHNE D, 1983, J NUTR, V113, P456, DOI 10.1093/jn/113.2.456; BURK RF, 1982, ARCH BIOCHEM BIOPHYS, V213, P73, DOI 10.1016/0003-9861(82)90441-6; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; BURK RF, 1990, IN PRESS AM J PHYSL; CHADA S, 1989, BLOOD, V74, P2535; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHEN CS, 1980, P NATL ACAD SCI-BIOL, V77, P1403, DOI 10.1073/pnas.77.3.1403; CHOCAT P, 1985, J BACTERIOL, V163, P669, DOI 10.1128/JB.163.2.669-676.1985; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; CONE JE, 1976, P NATL ACAD SCI USA, V73, P2659, DOI 10.1073/pnas.73.8.2659; COX JC, 1981, J BACTERIOL, V145, P1317, DOI 10.1128/JB.145.3.1317-1324.1981; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; DUNN DK, 1989, NUCLEIC ACIDS RES, V17, P6390, DOI 10.1093/nar/17.15.6390; ESAKI N, 1981, BIOCHEMISTRY-US, V20, P4492, DOI 10.1021/bi00518a039; ESAKI N, 1982, J BIOL CHEM, V257, P4386; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORSCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; FORSCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORSTER C, 1990, NUCLEIC ACIDS RES, V18, P487, DOI 10.1093/nar/18.3.487; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; HADDOCK BA, 1982, BIOCHEM SOC T, V10, P478, DOI 10.1042/bst0100478; HATFIELD D, 1985, TRENDS BIOCHEM SCI, V10, P201, DOI 10.1016/0968-0004(85)90192-6; HAWKES WC, 1985, J INORG BIOCHEM, V23, P77, DOI 10.1016/0162-0134(85)83011-7; HAWKES WC, 1982, BIOCHIM BIOPHYS ACTA, V699, P183, DOI 10.1016/0167-4781(82)90106-3; HEIDER J, 1989, NUCLEIC ACIDS RES, V13, P4765; HERRMAN JL, 1977, BIOCHIM BIOPHYS ACTA, V500, P61, DOI 10.1016/0304-4165(77)90046-0; HILL KE, 1991, FASEB J, V5, pA580; KNIGHT SAB, 1987, J NUTR, V117, P732, DOI 10.1093/jn/117.4.732; KRAMER GF, 1988, J BACTERIOL, V170, P736, DOI 10.1128/jb.170.2.736-743.1988; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; LI NQ, 1990, J BIOL CHEM, V265, P108; MARTIN JL, 1976, PHOSPHORUS SULFUR, V1, P295, DOI 10.1080/03086647608073336; MOTSENBOCKER MA, 1982, BIOCHIM BIOPHYS ACTA, V719, P147, DOI 10.1016/0304-4165(82)90318-X; MOZIER NM, 1988, J BIOL CHEM, V263, P4527; PINSENT J, 1954, BIOCHEM J, V57, P10, DOI 10.1042/bj0570010; READ R, 1990, J BIOL CHEM, V265, P17899; REDDY AP, 1988, NUCLEIC ACIDS RES, V16, P5557, DOI 10.1093/nar/16.12.5557; SAEDI MS, 1988, BIOCHEM BIOPH RES CO, V153, P855, DOI 10.1016/S0006-291X(88)81174-4; SCHWARZ K, 1957, J AM CHEM SOC, V79, P3292, DOI 10.1021/ja01569a087; STADTMAN T C, 1989, Biofactors, V2, P35; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; SUNDE RA, 1987, J BIOL CHEM, V262, P933; SUNDE RA, 1990, ANNU REV NUTR, V10, P451, DOI 10.1146/annurev.nu.10.070190.002315; SUNDE RA, 1980, BIOCHEM BIOPH RES CO, V93, P1181, DOI 10.1016/0006-291X(80)90614-2; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAKAHASHI K, 1986, BLOOD, V68, P640; TOYODA H, 1989, BIOCHIM BIOPHYS ACTA, V1008, P301, DOI 10.1016/0167-4781(89)90020-1; TOYODA H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P213, DOI 10.1016/0167-4781(90)90042-Z; WEN TN, 1988, PLANT SCI, V57, P185; WITTWER A J, 1989, Biofactors, V2, P27; YANG JG, 1987, J BIOL CHEM, V262, P13372; YANG JG, 1989, J NUTR, V119, P1010, DOI 10.1093/jn/119.7.1010; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650; 1979, CHIN MED J, V92, P471; [No title captured]	63	121	124	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2274	2279		10.1096/fasebj.5.9.1830557	http://dx.doi.org/10.1096/fasebj.5.9.1830557			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1830557				2022-12-28	WOS:A1991FP87200008
J	ZEISEL, SH; DACOSTA, KA; FRANKLIN, PD; ALEXANDER, EA; LAMONT, JT; SHEARD, NF; BEISER, A				ZEISEL, SH; DACOSTA, KA; FRANKLIN, PD; ALEXANDER, EA; LAMONT, JT; SHEARD, NF; BEISER, A			CHOLINE, AN ESSENTIAL NUTRIENT FOR HUMANS	FASEB JOURNAL			English	Note						CHOLINE DEFICIENCY; LIPOTROPES; HUMAN; LIVER; KIDNEY; NUTRIENT REQUIREMENTS	RAT-LIVER; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; MALNOURISHED PATIENTS; BRAIN ACETYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; DEFICIENCY; HEPATOCYTES; DIET; HYPERALIMENTATION; SUPPLEMENTATION	Choline is required to make essential membrane phospholipids. It is precursor for the biosynthesis of the neurotransmitter acetylcholine and also is an important source of labile methyl groups. Mammals fed a choline-deficient diet develop liver dysfunction; however, choline is not considered an essential nutrient in humans. Healthy male volunteers were hospitalized and fed a semisynthetic diet devoid of choline supplemented with 500 mg/day choline for 1 wk. Subjects were randomly divided into two groups, one that continued to receive choline (control), and the other that received no choline (deficient) for three additional wk. During the 5th wk of the study all subjects received choline. The semisynthetic diet contained adequate, but no excess, methionine. In the choline-deficient group, plasma choline and phosphatidylcholine concentrations decreased an average of 30% during the 3-wk period when a choline-deficient diet was ingested; plasma and erthrocyte phosphatidylcholine decreased 15%; no such changes occurred in the control group. In the choline-deficient group, serum alanine aminotransferase activity increased steadily from a mean of 0.42-mu-kat/liter to a mean of 0.62-mu-kat/liter during the 3-wk period when a choline-deficient diet was ingested; no such change occurred in the control group. Other tests of liver and renal function were unchanged in both groups during the study. Serum cholesterol decreased an average of 15% in the deficient group and did not change in the control group. Healthy humans consuming a choline-deficient diet for 3 wk had depleted stores of choline in tissues and developed signs of incipient liver dysfunction. Our observations support the conclusion and choline is an essential nutrient for humans when excess methionine and folate are not available in the diet.	BOSTON UNIV HOSP,SCH MED,DEPT RADIOL,BOSTON,MA 02218; BOSTON UNIV,BOSTON CITY HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02118; BOSTON UNIV HOSP,SCH MED,DEPT MED,GASTROENTEROL SECT,BOSTON,MA 02218; UNIV MASSACHUSETTS,DEPT FOOD SCI & NUTR,AMHERST,MA 01003; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02118	Boston University; Boston Medical Center; Boston University; Boston University; University of Massachusetts System; University of Massachusetts Amherst; Boston University	ZEISEL, SH (corresponding author), UNIV N CAROLINA,DEPT NUTR,CB 7400 MCGAURAN,GREENBERG HALL,CHAPEL HILL,NC 27599, USA.			Beiser, Alexa/0000-0001-8551-7778	NCRR NIH HHS [RR-00533] Funding Source: Medline; NICHD NIH HHS [HD-16727] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016727] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BJORNSTAD P, 1966, J LIPID RES, V7, P38; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUSZTAJN JK, 1979, BRAIN RES, V179, P319, DOI 10.1016/0006-8993(79)90447-5; BLUSZTAJN JK, 1985, BIOCHEM J, V232, P505, DOI 10.1042/bj2320505; BREMER J, 1961, BIOCHIM BIOPHYS ACTA, V46, P205, DOI 10.1016/0006-3002(61)90745-4; BURT ME, 1980, LANCET, V2, P638; CARROLL C, 1982, NUTR REP INT, V25, P773; CHAWLA RK, 1985, AM J CLIN NUTR, V42, P577, DOI 10.1093/ajcn/42.4.577; CHAWLA RK, 1989, GASTROENTEROLOGY, V97, P1514, DOI 10.1016/0016-5085(89)90397-1; COHEN EL, 1975, LIFE SCI, V16, P1095, DOI 10.1016/0024-3205(75)90194-0; DEGERTEKIN H, 1986, ACTA ANAT, V125, P174; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; FALLON HJ, 1969, BIOCHIM BIOPHYS ACTA, V187, P94, DOI 10.1016/0005-2760(69)90136-2; FINKELSTEIN JD, 1982, ARCH BIOCHEM BIOPHYS, V218, P169, DOI 10.1016/0003-9861(82)90332-0; GHOSHAL AK, 1984, CARCINOGENESIS, V5, P1367, DOI 10.1093/carcin/5.10.1367; GHOSHAL AK, 1983, AM J PATHOL, V113, P309; HAINES DSM, 1966, CAN J BIOCHEM CELL B, V44, P45, DOI 10.1139/o66-006; HALL RI, 1985, JPEN-PARENTER ENTER, V9, P597, DOI 10.1177/0148607185009005597; HAUBRICH DR, 1975, LIFE SCI, V17, P975, DOI 10.1016/0024-3205(75)90451-8; HOFFMAN DR, 1981, CAN J BIOCHEM CELL B, V59, P543, DOI 10.1139/o81-075; KAMINSKI DL, 1980, AM J PHYSIOL, V239, pG358, DOI 10.1152/ajpgi.1980.239.5.G358; KAMINSKI DL, 1980, SURGERY, V88, P93; KATES M, 1975, LABORATORY TECHNIQUE; LOMBARDI B, 1968, J LIPID RES, V9, P437; PASCALE R, 1982, FEBS LETT, V145, P293, DOI 10.1016/0014-5793(82)80186-5; POMFRET EA, 1989, ANAL BIOCHEM, V180, P85, DOI 10.1016/0003-2697(89)90091-2; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; Shapira G, 1986, NUTR INT, V2, P334; SHEARD NF, 1986, AM J CLIN NUTR, V43, P219, DOI 10.1093/ajcn/43.2.219; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TAYEK JA, 1990, J AM COLL NUTR, V9, P76; WECKER L, 1986, CAN J PHYSIOL PHARM, V64, P329, DOI 10.1139/y86-054; YANG EK, 1988, BIOCHEM J, V256, P821, DOI 10.1042/bj2560821; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; Zeisel S.H., 1988, MODERN NUTR HLTH DIS, P440; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P55, DOI 10.1016/0955-2863(90)90101-P; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P332, DOI 10.1016/0955-2863(90)90001-2	38	370	393	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2093	2098		10.1096/fasebj.5.7.2010061	http://dx.doi.org/10.1096/fasebj.5.7.2010061			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010061	Green Submitted			2022-12-28	WOS:A1991FF44200012
J	ADKISSON, HD; RISENER, FS; ZARRINKAR, PP; WALLA, MD; CHRISTIE, WW; WUTHIER, RE				ADKISSON, HD; RISENER, FS; ZARRINKAR, PP; WALLA, MD; CHRISTIE, WW; WUTHIER, RE			UNIQUE FATTY-ACID COMPOSITION OF NORMAL CARTILAGE - DISCOVERY OF HIGH-LEVELS OF N-9 EICOSATRIENOIC ACID AND LOW-LEVELS OF N-6 POLYUNSATURATED FATTY-ACIDS	FASEB JOURNAL			English	Note						ESSENTIAL FATTY ACID DEFICIENCY; N-9 EICOSATRIENOIC ACID; GROWTH PLATE CARTILAGE; ARTICULAR CARTILAGE	STEAROYL-COA DESATURASE; EPIPHYSEAL CARTILAGE; ACYL COMPOSITION; MATRIX VESICLES; RAT-LIVER; CHROMATOGRAPHY; BIOSYNTHESIS; CHONDROCYTES; CELLS	We report here the finding that normal, young cartilages, in distinction from all other tissues examined, have unusually high levels of n-9 eicosatrienoic (20:3 cis-DELTA-5,8,11) acid and low levels of n-6 polyunsaturated fatty acids (n-6 PUFA). This pattern is identical to that found in tissues of animals subjected to prolonged depletion of nutritionally essential n-6 polyunsaturated fatty acids (EFA). This apparent deficiency is consistently observed in cartilage of all species so far studied (young chicken, fetal calf, newborn pig, rabbit, and human), even though levels of n-6 PUFA in blood and all other tissues is normal. The n-9 20:3 acid is particularly abundant in phosphatidylethanolamine, phosphatidyl-inositol, and the free fatty acid fractions from the young cartilage. Several factors appear to contribute to the reduction in n-6 PUFA and the appearance of high levels of the n-9 20:3 acid in cartilage: 1) limited access to nutritional sources of EFA due to the impermeability and avascularity of cartilage, 2) rapid metabolism of n-6 PUFA to prostanoids by chondrocytes, and 3) a unique fatty acid metabolism by cartilage. Evidence is presented that each of these factors contributes. Previously, EFA deficiency has been shown to greatly suppress the inflammatory response of leukocytes and rejection of tissues transplanted into allogeneic recipients. Because eicosanoids, which are derived from EFA, have been implicated in the inflammatory responses associated with arthritic disease, reduction of n-6 PUFA and accumulation of the n-9 20:3 acid in cartilage may be important for maintaining normal cartilage structure.	UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208; UNIV GLASGOW,HANNAH RES INST,AYR KA6 5HL,SCOTLAND	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Glasgow	ADKISSON, HD (corresponding author), UNIV S CAROLINA,DEPT CHEM,COLUMBIA,SC 29208, USA.				NIAMS NIH HHS [AR18983] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018983] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADKISSON HD, 1990, ORTHOP T, V14, P423; BOMBARDIERI S, 1981, BRIT J PHARMACOL, V73, P893, DOI 10.1111/j.1476-5381.1981.tb08743.x; BONTA I L, 1981, Progress in Lipid Research, V20, P617; CHRISTIE WW, 1986, LIPIDS, V21, P657, DOI 10.1007/BF02537217; CHRISTIE WW, 1987, J HIGH RES CHROMATOG, V10, P148, DOI 10.1002/jhrc.1240100309; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAVIVI E, 1969, P SOC EXP BIOL MED, V131, P1300, DOI 10.3181/00379727-131-34092; HEINEGARD D, 1987, METHOD ENZYMOL, V145, P336; HOLMAN RT, 1960, J NUTR, V70, P405, DOI 10.1093/jn/70.3.405; HUNZIKER EB, 1984, J CELL BIOL, V98, P277, DOI 10.1083/jcb.98.1.277; ISHIKAWA Y, 1985, J CELL PHYSIOL, V123, P79, DOI 10.1002/jcp.1041230113; KAWASHIMA Y, 1989, BIOCHEM J, V263, P897, DOI 10.1042/bj2630897; KAWASHIMA Y, 1985, BIOCHIM BIOPHYS ACTA, V837, P222; KEMICK MLS, 1989, ADV PROSTAGLANDIN TH, V18, P423; MEAD JF, 1956, J BIOL CHEM, V219, P705; MORRISON WR, 1964, J LIPID RES, V5, P600; NORTHINGTON FK, 1978, CALC TISS RES, V26, P227, DOI 10.1007/BF02013263; OGLESBY TD, 1981, SEMIN ARTHRITIS RHEU, V11, P88, DOI 10.1016/0049-0172(81)90054-8; ROUSER G, 1968, BIOL MEMBRANES PHYSI, P28; SCHREINER GF, 1988, SCIENCE, V240, P1032, DOI 10.1126/science.3285468; STILLO JV, 1980, THESIS U S CAROLINA, P11; WOLINSKY I, 1970, CALC TISS RES, V6, P113, DOI 10.1007/BF02196190; WONG PYK, 1977, PROSTAGLANDINS, V14, P839, DOI 10.1016/0090-6980(77)90301-X; WUTHIER RE, 1975, BIOCHIM BIOPHYS ACTA, V409, P128, DOI 10.1016/0005-2760(75)90087-9; WUTHIER RE, 1978, BIOCHEMISTRY-US, V17, P1431, DOI 10.1021/bi00601a011; WUTHIER RE, 1979, SKELETAL RES EXPT AP, P121; WUTHIER RE, 1973, CLIN ORTHOP RELAT R, V90, P191	27	60	63	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					344	353		10.1096/fasebj.5.3.2001795	http://dx.doi.org/10.1096/fasebj.5.3.2001795			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001795				2022-12-28	WOS:A1991FC55600014
J	BAYEV, AA				BAYEV, AA			1ST MOVES OF THE USSR HUMAN-GENOME-PROJECT	FASEB JOURNAL			English	Article							LIBRARIES; GENE; SELECTION; CLONING; PROTEIN; LAMBDA; PHAGES; SITES				BAYEV, AA (corresponding author), VA ENGELHARDT MOLEC BIOL INST,MOSCOW,USSR.							BAYEV AA, 1989, HUMAN GENOME GENERAL; BERITASHVILI DR, Patent No. 4329887; BLATTNER FR, 1977, SCIENCE, V196, P161, DOI 10.1126/science.847462; BROUDE NE, 1989, FEBS LETT, V257, P1, DOI 10.1016/0014-5793(89)81773-9; DUBININ NP, 1990, GENETICS PAGES HIST; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; KORDIUM VA, 1990, POLYM CELL, V6, P12; YANKOVSKY NK, 1989, CONSTRUCTION ANAL GE; ZABAROVSKY ER, 1989, NUCLEIC ACIDS RES, V17, P4408, DOI 10.1093/nar/17.11.4408; ZABAROVSKY ER, 1989, NUCLEIC ACIDS RES, V17, P4407, DOI 10.1093/nar/17.11.4407; ZABAROVSKY ER, 1989, NUCLEIC ACIDS RES, V17, P3310, DOI 10.1093/nar/17.8.3310; ZABAROVSKY ER, 1989, NUCLEIC ACIDS RES, V17, P3309, DOI 10.1093/nar/17.8.3309; 1990, 1ST ALL UN C HUM GEN	14	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					70	72		10.1096/fasebj.5.1.1991588	http://dx.doi.org/10.1096/fasebj.5.1.1991588			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991588				2022-12-28	WOS:A1991ET60900012
J	Ma, D; Liu, P; Hu, CJ; Zhou, Z; Wang, P; Wang, Y; Zhang, YM; Ran, YS; Li, PH; Zhao, JY; Wang, JS; Zhang, CL; Tang, L				Ma, Dan; Liu, Ping; Hu, Chujiao; Zhou, Zhen; Wang, Ping; Wang, Yan; Zhang, Yaming; Ran, Yunsheng; Li, Pinghao; Zhao, Jiangyuan; Wang, Jishi; Zhang, Chengliang; Tang, Lei			Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia	ONCOGENE			English	Article; Early Access							SRC FAMILY KINASES; BONE-MARROW; STEM-CELLS; DRUG-RESISTANCE; TYROSINE KINASE; STAT5; ANGIOGENESIS; EXPRESSION; IMATINIB; INHIBITORS	Drug resistance from BCR-ABL tyrosine kinase inhibitors (TKIs) and other chemotherapeutics results in treatment failure and disease progression in chronic myeloid leukemia (CML). However, the mechanism is still uncertain. In this study, we investigated the role of angiopoietin-1 (ANG-1) as a potential prognostic factor for drug resistance in CML. Both intracellular and secretory ANG-1 (iANG-1 and sANG-1) were overexpressed in multidrug-resistant CML samples. The IC50 value was higher in primary CD34(+) CD38(-) cells with more ANG-1. Silencing ANG-1significantly sensitized three TKI-resistant CML cell lines to imatinib (IM) while recombinant human ANG-1 failed to retain cell survival in vitro. This indicated the important role of iANG-1 as opposed to sANG-1 in CML drug resistance. Moreover, a similar effect was observed in xenograft mice models bearing ANG-1-silenced CML cells. Subsequently, pathway analysis and protein validation experiments showed activation of the JAK/STAT pathway and augmentation of STAT5a phosphorylation in ANG-1 restored CML cells. Upstream Src phosphorylation, which plays a crucial role in CML drug resistance, was also upregulated as a key event in iANG-1-related JAK/STAT pathway activation. In conclusion, our study elucidated a new BCR-ABL independent molecular mechanism induced by intracytoplasmic ANG-1 overexpression as a potential strategy for overcoming CML resistance.	[Ma, Dan; Liu, Ping; Wang, Ping; Wang, Yan; Zhang, Yaming; Zhao, Jiangyuan; Wang, Jishi] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Key Lab Hematol Dis Diagnost & Treat Ctr Guizhou, Guiyang 550004, Peoples R China; [Ma, Dan; Hu, Chujiao; Ran, Yunsheng; Tang, Lei] Guizhou Med Univ, Guizhou Prov Engn Technol Res Ctr Chem Drug R &, Guiyang 550004, Peoples R China; [Zhou, Zhen] Guizhou Med Univ, Dept Pharm, Affiliated Baiyun Hosp, Guiyang 550014, Peoples R China; [Li, Pinghao] Guizhou Med Univ, Dept Pathol, Affiliated Hosp, Guiyang 550004, Peoples R China; [Zhang, Chengliang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan, Hubei, Peoples R China	Guizhou Medical University; Guizhou Medical University; Guizhou Medical University; Guizhou Medical University; Huazhong University of Science & Technology	Wang, JS (corresponding author), Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Key Lab Hematol Dis Diagnost & Treat Ctr Guizhou, Guiyang 550004, Peoples R China.; Tang, L (corresponding author), Guizhou Med Univ, Guizhou Prov Engn Technol Res Ctr Chem Drug R &, Guiyang 550004, Peoples R China.; Zhang, CL (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan, Hubei, Peoples R China.	wangjishi96461@163.com; clzhang@tjh.tjmu.edu.cn; tlei1974@163.com			National Natural Science Foundation of China [82003835, 82160704, 82160665]; Basic Research Program of Guizhou Province Technology Bureau [ZK[2021] General-399, ZK[2022]General-451, ZK[2021] General-568]; Science and Technology Program of Guizhou Province Health Committee [gzwkj2021-466, gzwkj2021-158, gzwkj2021-442]; National-Local Joint EngineeringResearch Center for Innovative & Generic Chemical Drug, Guizhou; High-level Innovative Talents Supporting Program [2016-4015]; Guiyang City Technology Bureau Planned Project [2019-9-14-8]; public experimental platform of Department of Pathology of Affiliated Hospital of Guizhou Medical University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Research Program of Guizhou Province Technology Bureau; Science and Technology Program of Guizhou Province Health Committee; National-Local Joint EngineeringResearch Center for Innovative & Generic Chemical Drug, Guizhou; High-level Innovative Talents Supporting Program; Guiyang City Technology Bureau Planned Project; public experimental platform of Department of Pathology of Affiliated Hospital of Guizhou Medical University	This study was supported, in part, by the National Natural Science Foundation of China (Nos. 82003835, 82160704 and 82160665), Basic Research Program of Guizhou Province Technology Bureau(No. ZK[2021] General-399, No.ZK[2022]General-451 and No. ZK[2021] General-568), Science and Technology Program of Guizhou Province Health Committee(Nos. gzwkj2021-466, Nos. gzwkj2021-158 and Nos. gzwkj2021-442), National-Local Joint EngineeringResearch Center for Innovative & Generic Chemical Drug, Guizhou. High-level Innovative Talents Supporting Program (2016-4015)Guiyang City Technology Bureau Planned Project (No. 2019-9-14-8). And we gratefully appreciated the support from public experimental platform of Department of Pathology of Affiliated Hospital of Guizhou Medical University.	Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Aranda-Tavio H, 2021, BIOMED PHARMACOTHER, V144, DOI 10.1016/j.biopha.2021.112330; Atesoglu EB, 2016, INDIAN J HEMATOL BLO, V32, P162, DOI 10.1007/s12288-015-0548-8; Bavaro L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246141; Bibi S, 2014, HAEMATOLOGICA, V99, P417, DOI 10.3324/haematol.2013.098442; Bower H, 2016, J CLIN ONCOL, V34, P2851, DOI 10.1200/JCO.2015.66.2866; Braun TP, 2020, CANCER CELL, V37, P530, DOI 10.1016/j.ccell.2020.03.006; Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616; Cheng CL, 2011, BRIT J CANCER, V105, P975, DOI 10.1038/bjc.2011.340; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Cortes JE, 2013, NEW ENGL J MED, V369, P1783, DOI 10.1056/NEJMoa1306494; Cortes JE, 2011, BLOOD, V118, P4567, DOI 10.1182/blood-2011-05-355594; Dong BW, 2018, SCI CHINA LIFE SCI, V61, P999, DOI 10.1007/s11427-018-9324-y; Fagiani E, 2011, CANCER RES, V71, P5717, DOI 10.1158/0008-5472.CAN-10-4635; Gleixner KV, 2017, HAEMATOLOGICA, V102, P1519, DOI 10.3324/haematol.2016.163436; Grenga I, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0096-7; Hashiyama M, 1996, BLOOD, V87, P93; Hochhaus A, 2017, NEW ENGL J MED, V376, P917, DOI 10.1056/NEJMoa1609324; Huang HH, 2010, NAT REV CANCER, V10, P575, DOI 10.1038/nrc2894; Ichim CV, 2014, STEM CELL TRANSL MED, V3, P405, DOI 10.5966/sctm.2012-0159; Jiang XX, 2019, LEUKEMIA LYMPHOMA, V60, P1709, DOI 10.1080/10428194.2018.1543875; Juen L, 2017, J MED CHEM, V60, P6119, DOI 10.1021/acs.jmedchem.7b00369; Ku M, 2015, LEUKEMIA LYMPHOMA, V56, P577, DOI 10.3109/10428194.2014.907897; Lee CY, 2007, BRIT J CANCER, V97, P877, DOI 10.1038/sj.bjc.6603966; Liu XH, 2008, WORLD J GASTROENTERO, V14, P1575, DOI 10.3748/wjg.14.1575; Ma D, 2021, J CELL PHYSIOL, V236, P6312, DOI 10.1002/jcp.30301; Minciacchi VR, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010117; Mirmohammadsadegh A, 2006, J INVEST DERMATOL, V126, P2272, DOI 10.1038/sj.jid.5700385; Mitchell R, 2018, JNCI-J NATL CANCER I, V110, P467, DOI 10.1093/jnci/djx236; Muller J, 2008, CHEMBIOCHEM, V9, P723, DOI 10.1002/cbic.200700701; O'Hare T, 2005, CLIN CANCER RES, V11, P6987, DOI 10.1158/1078-0432.CCR-05-0622; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Orlova A, 2019, CANCERS, V11, DOI 10.3390/cancers11121930; Parikh SM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5537; Pinz S, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0063-y; Schliemann C, 2006, HAEMATOLOGICA, V91, P1203; Teufel M, 2019, GASTROENTEROLOGY, V156, P1731, DOI 10.1053/j.gastro.2019.01.261; Tolomeo M, 2019, ANTI-CANCER AGENT ME, V19, P2036, DOI 10.2174/1871520619666190906160848; Torimura T, 2004, J HEPATOL, V40, P799, DOI 10.1016/j.jhep.2004.01.027; Warsch W, 2013, CELL CYCLE, V12, P1813, DOI 10.4161/cc.25116	40	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02536-y	http://dx.doi.org/10.1038/s41388-022-02536-y		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6G3AQ	36385374				2022-12-28	WOS:000884628600001
J	WEIS, L; REINBERG, D				WEIS, L; REINBERG, D			TRANSCRIPTION BY RNA POLYMERASE-II - INITIATOR-DIRECTED FORMATION OF TRANSCRIPTION-COMPETENT COMPLEXES	FASEB JOURNAL			English	Article						RNA POLYMERASE-II; TRANSCRIPTION; GENE REGULATION	MAJOR LATE PROMOTER; BINDING-PROTEIN; PREINITIATION COMPLEX; FUNCTIONAL-ANALYSIS; LESS PROMOTER; TATA; SEQUENCE; SITE; ACTIVATION; GENE	Studies of transcription by RNA polymerase II have revealed two promoter elements, the TATA motif and the initiator (Inr), capable of directing specific transcription initiation. Although binding to the TATA motif by one of the components of the transcription machinery has been shown to be the initial recognition step in transcription complex formation, many promoters that lack a traditional TATA motif have recently been described. In such TATA-less promoters, the Inr element is critical in positioning RNA polymerase II. Various Inr elements have been described and classified according to sequence homology. These Inr elements are recognized specifically by Inr-binding proteins. Interaction between these Inr-binding proteins and components of the basal transcription machinery provides a means through which a transcription competent complex can be formed.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center				Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047484, R37GM037120, R01GM037120] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47484, GM37120] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHUNG S, 1991, GENE, V100, P173, DOI 10.1016/0378-1119(91)90363-G; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1992, J BIOL CHEM, V267, P2786; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LICEN X, 1991, NUCLEIC ACIDS RES, V19, P6699; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OSHEAGEENFIELD, 1992, J BIOL CHEM, V267, P1391; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REINBERG D, 1987, J BIOL CHEM, V262, P3322; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFER B, 1991, J BIOL CHEM, V266, P10989; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P1; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILSON SH, 1989, EUKARYOTIC NUCLEUS M, P198; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1992, IN PRESS PROG NUCLEI; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZHERING WA, 1988, P NATL ACAD SCI USA, V85, P3698	67	397	405	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1992	6	14					3300	3309		10.1096/fasebj.6.14.1426767	http://dx.doi.org/10.1096/fasebj.6.14.1426767			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426767				2022-12-28	WOS:A1992JZ73400012
J	LANDS, WEM				LANDS, WEM			BIOCHEMISTRY AND PHYSIOLOGY OF N-3 FATTY-ACIDS	FASEB JOURNAL			English	Review						EICOSANOIDS; HIGHLY UNSATURATED FATTY ACIDS; POLYUNSATURATED FATTY ACIDS; PROSTAGLANDINS; THROMBOSIS	ARACHIDONOYL-COA SYNTHETASE; CELLS; PROSTAGLANDINS; REQUIREMENTS; BIOSYNTHESIS; METABOLISM; RELEASE; TISSUES; LIPIDS	Considering the n-3 fatty acids to be partial agonists relative to n-6 fatty acids helps consolidate into a unified interpretation the many diverse reports and controversies on the actions of these two types of essential fatty acids. Some research reports illustrate the similarities between these two types and some emphasize the differences, leaving readers to evaluate the status of n-3 fatty acids from a viewpoint that is conceptually similar to regarding a glass of water as half empty or half full. Both n-3 and n-6 types of fatty acids must be obtained through the diet because they are not synthesized de novo by vertebrates. Both types can support important physiological and developmental processes, can form eicosanoids (prostaglandins, leukotrienes, lipoxins, etc.), can be esterified to and hydrolyzed from tissue glycerolipids, and can be metabolically elongated and desaturated to a variety of highly unsaturated fatty acids. However, some nonesterified n-6 acids are vigorously converted to potent n-6 eicosanoids that exert intense agonist actions at eicosanoid receptors, whereas the n-3 acids less vigorously form n-3 eicosanoids that often produce less intense (partial) actions. Because both types owe their presence in vertebrate tissues to dietary intake, important physiological consequences follow the inadvertent selection of different average daily dietary supplies of these two types of polyunsaturated fatty acids.			LANDS, WEM (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM, CHICAGO, IL 60612 USA.							AAESJORGENSEN E, 1961, PHYSIOL REV, V41, P1; BERGSTROM S, 1964, J BIOL CHEM, V239, P4006; BOTTIGER LE, 1990, J INTERN MED, V227, P1; BROUGHTON KS, 1991, J NUTR, V121, P155, DOI 10.1093/jn/121.2.155; Burr GO, 1930, J BIOL CHEM, V86, P0587; BURR ML, 1989, LANCET, V2, P757; CUTHBERTSON WFJ, 1976, AM J CLIN NUTR, V29, P559, DOI 10.1093/ajcn/29.5.559; DOLECEK TA, 1991, WORLD REV NUTR DIET, V66, P205; DYERBERG J, 1978, LANCET, V2, P117, DOI 10.1016/s0140-6736(78)91505-2; GREENBERG SM, 1951, P SOC EXP BIOL MED, V78, P552, DOI 10.3181/00379727-78-19137; GRYGLEWSKI RJ, 1976, P NATL ACAD SCI USA, V76, P4275; HAEFFNER EW, 1973, J NUTR, V103, P74, DOI 10.1093/jn/103.1.74; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HANSEN A. E., 1963, Pediatrics, V31, P171; HOLMAN RT, 1958, NUTR REV, V16, P33, DOI 10.1111/j.1753-4887.1958.tb00660.x; Holman RT., 1971, PROGR CHEM FATS OTHE, V9, P275, DOI DOI 10.1016/0079-6832(71)90030-9; HULTING AL, 1985, P NATL ACAD SCI USA, V82, P3834, DOI 10.1073/pnas.82.11.3834; HWANG DH, 1988, J NUTR, V118, P427, DOI 10.1093/jn/118.4.427; LANDS WEM, 1990, AM J CLIN NUTR, V51, P991, DOI 10.1093/ajcn/51.6.991; LANDS WEM, 1979, ANNU REV PHYSIOL, V41, P633, DOI 10.1146/annurev.ph.41.030179.003221; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LANDS WEM, 1991, ANNU REV NUTR, V11, P41, DOI 10.1146/annurev.nu.11.070191.000353; LANDS WEM, 1980, HERZ, V5, P34; LANDS WEM, 1985, PROSTAGLANDINS, V30, P819, DOI 10.1016/0090-6980(85)90010-3; LANDS WEM, 1990, LIPIDS, V25, P505, DOI 10.1007/BF02537156; LANDS WEM, 1991, WORLD REV NUTR DIET, V66, P177; LANDS WEM, 1991, IN PRESS AOCS SHORT; LANDS WEM, 1986, FISH HUMAN HLTH, P1; LANDS WEM, 1977, MEMBRANE BOUND ENZYM, P3; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LANDS WEM, 1987, AOCS SHORT COURSE PO, P1; LANDS WEM, 1985, ADV DRUG RES, V14, P147; LANDS WEM, 1991, MICRONUTRIENTS HLTH, P9; LAPOSATA M, 1985, J BIOL CHEM, V260, P1016; LEAT W M F, 1981, Progress in Lipid Research, V20, P819, DOI 10.1016/0163-7827(81)90154-5; LEE TH, 1988, CLIN SCI, V74, P467, DOI 10.1042/cs0740467; MACHLIN LJ, 1962, NATURE, V194, P868, DOI 10.1038/194868a0; MOHRHAUER H, 1963, J NUTR, V81, P67, DOI 10.1093/jn/81.1.67; MOHRHAUER H, 1963, J LIPID RES, V4, P151; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; NEUFELD EJ, 1984, J LIPID RES, V25, P288; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; OHTA A, 1990, LIPIDS, V25, P742, DOI 10.1007/BF02544044; OJEDA SR, 1981, PHYSIOPATHOLOGY ENDO, P229; PENDLETON R, 1990, THESIS U ILLINOIS CH; PRASAD MR, 1987, J BIOSCIENCE, V11, P443, DOI 10.1007/BF02704693; Shichikawa K, 1981, Ryumachi, V21 Suppl, P35; SIMOPOULOS AP, 1991, HLTH EFFECTS W3 POLY, P1; SPRECHER H, 1991, HLTH EFFECTS W3 POLY, P166; SPRECHER H, 1987, P AM OIL CHEM SOC SH, P154; TINOCO J, 1983, PROG LIPID RES, V21, P1, DOI 10.1016/0163-7827(82)90015-7; Turpeinen O, 1938, J NUTR, V15, P351, DOI 10.1093/jn/15.4.351; 1988, DHHS PHS8850210 PUBL	54	270	287	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1992	6	8					2530	2536		10.1096/fasebj.6.8.1592205	http://dx.doi.org/10.1096/fasebj.6.8.1592205			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592205				2022-12-28	WOS:A1992HU42300005
J	DEMONTELLANO, PRO; CHAN, WK; TUCK, SF; KAIKAUS, RM; BASS, NM; PETERSON, JA				DEMONTELLANO, PRO; CHAN, WK; TUCK, SF; KAIKAUS, RM; BASS, NM; PETERSON, JA			MECHANISM-BASED PROBES OF THE TOPOLOGY AND FUNCTION OF FATTY-ACID HYDROXYLASES	FASEB JOURNAL			English	Article						PEROXISOME INDUCTION; PHENYLDIAZENE; 1-AMINOBENZOTRIAZOLE	PEROXISOMAL BETA-OXIDATION; LAURIC-ACID; BACILLUS-MEGATERIUM; OMEGA-HYDROXYLASE; ALKANE HYDROXYLATION; HYPOLIPEMIC AGENTS; ARACHIDONIC-ACID; GENE FAMILY; RAT-LIVER; INDUCTION	The use of three mechanism-based probes to investigate the topology and function of fatty acid hydroxylases is discussed. 1) The observation of protein rather than heme alkylation in the reaction of cytochrome P4504A1 with 10-undecynoic acid supports the argument that the enzyme circumvents the inherent preference for omega-1 hydroxylation by restricting access to the ferryl oxygen. 2) The regiochemistry of the ferricyanide-mediated iron-to-nitrogen shift of the cytochrome P450102 (P450BM-3) phenyl-iron complex indicates that the active site of this bacterial fatty acid hydroxylase is open primarily above pyrrole ring A of the prosthetic heme group, 3) Inhibition of clofibrate-mediated peroxisome proliferation in cultured rat hepatocytes by inactivation of cytochrome P4504A1 indicates that omega-hydroxylation of fatty acids provides a signal for peroxisome proliferation.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DEMONTELLANO, PRO (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK02056, DK32926] Funding Source: Medline; NIGMS NIH HHS [GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032926, K08DK002056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anders M.W., 1985, BIOACTIVATION FOREIG, P121; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; CAJACOB CA, 1986, BIOCHEMISTRY-US, V25, P4705, DOI 10.1021/bi00364a038; COOK BR, 1986, J AM CHEM SOC, V108, P7281, DOI 10.1021/ja00283a024; DEMONTELLANO PRO, 1984, J BIOL CHEM, V259, P4136; DEMONTELLANO PRO, 1986, ARCH BIOCHEM BIOPHYS, V251, P514, DOI 10.1016/0003-9861(86)90359-0; ESCALANTE B, 1991, SCIENCE, V251, P299; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GIBSON GG, 1989, XENOBIOTICA, V19, P1123; GIBSON GG, 1982, BIOCHEM J, V203, P161, DOI 10.1042/bj2030161; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; HO PP, 1976, BIOCHIM BIOPHYS ACTA, V431, P249, DOI 10.1016/0005-2760(76)90145-4; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOHNSON EF, 1990, BIOCHEMISTRY-US, V29, P873, DOI 10.1021/bi00456a004; KAUSER K, 1991, CIRC RES, V68, P1154, DOI 10.1161/01.RES.68.4.1154; KERR JA, 1966, CHEM REV, V66, P465, DOI 10.1021/cr60243a001; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P503, DOI 10.1089/dna.1.1989.8.503; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; KUPFER D, 1980, PHARMACOL THERAPEUT, V11, P469, DOI 10.1016/0163-7258(80)90038-8; LAKE BG, 1984, XENOBIOTICA, V14, P269, DOI 10.3109/00498258409151411; LALWANI ND, 1987, P NATL ACAD SCI USA, V84, P5442; LI HY, 1991, J BIOL CHEM, V266, P11909; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; LU AYH, 1968, J BIOL CHEM, V243, P1331; MANSUY D, 1982, TETRAHEDRON LETT, V23, P2781, DOI 10.1016/S0040-4039(00)87457-2; MATSUBARA S, 1987, J BIOL CHEM, V262, P13366; MILTON MN, 1988, BIOCHEM PHARMACOL, V37, P793, DOI 10.1016/0006-2952(88)90163-3; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MUERHOFF AS, 1989, J BIOL CHEM, V264, P749; NAPPA MJ, 1985, INORG CHEM, V24, P4711, DOI 10.1021/ic00220a056; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NEAT CE, 1980, BIOCHEM J, V186, P369, DOI 10.1042/bj1860369; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REICH NO, 1986, BIOCHEM PHARMACOL, V35, P1227, DOI 10.1016/0006-2952(86)90264-9; ROMANO MC, 1988, ANAL BIOCHEM, V170, P83, DOI 10.1016/0003-2697(88)90093-0; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SHARMA R, 1988, BIOCHEM PHARMACOL, V37, P1193, DOI 10.1016/0006-2952(88)90770-8; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; TANAKA S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P177, DOI 10.1016/0005-2760(90)90293-7; YOKOTANI N, 1989, J BIOL CHEM, V264, P21655	47	44	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					695	699		10.1096/fasebj.6.2.1537458	http://dx.doi.org/10.1096/fasebj.6.2.1537458			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537458				2022-12-28	WOS:A1992GZ44000008
J	MARSHALL, S; GARVEY, WT; TRAXINGER, RR				MARSHALL, S; GARVEY, WT; TRAXINGER, RR			NEW INSIGHTS INTO THE METABOLIC-REGULATION OF INSULIN ACTION AND INSULIN RESISTANCE - ROLE OF GLUCOSE AND AMINO-ACIDS	FASEB JOURNAL			English	Article						INSULIN RESISTANCE; GLUCOSE; INSULIN; GLUTAMINE; ADIPOCYTES	PRIMARY CULTURED ADIPOCYTES; DEPENDENT DIABETES-MELLITUS; RAT ADIPOSE CELL; TRANSPORT SYSTEM; PROTEIN-SYNTHESIS; PLASMA-MEMBRANE; TRANSLOCATION; MECHANISM; RESPONSIVENESS; STIMULATION	In primary cultured adipocytes, metabolic substrates such as glucose and amino acids have profound effects on modulating insulin's stimulatory actions on glucose uptake and protein synthesis. Insights into how substrates modulate insulin action were recently obtained when we discovered that the routing of incoming glucose through the hexosamine biosynthesis pathway leads to a refractory state over a period of several hours in which the ability of insulin to stimulate glucose uptake is severely impaired-a state known as insulin resistance. Glutamine: fructose-6-phosphate amidotransferase was found to play a central role in the development of insulin resistance as this enzyme catalyzes the first and rate-limiting step in the formation of hexosamine products. Collectively, these results are consistent with the idea that the hexosamine biosynthesis pathway serves as a glucose sensor coupled to a negative feedback system that can limit the extent of glucose uptake in response to hyperglycemic and hyperinsulinemic conditions.	INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA; RICHARD L ROUDEBUSH VET ADM MED CTR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	MARSHALL, S (corresponding author), UNIV TENNESSEE, SCH MED, DEPT BIOCHEM, MEMPHIS, TN 38164 USA.							BECKER AB, 1990, ANNU REV MED, V41, P99; BUSE MG, 1975, J CLIN INVEST, V56, P1250, DOI 10.1172/JCI108201; CHUA B, 1979, J BIOL CHEM, V254, P8358; CIARALDI TP, 1982, DIABETES, V31, P1016, DOI 10.2337/diacare.31.11.1016; CORY JG, 1986, TXB BIOCH CLIN CORRE, P489; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CUSHMAN SW, 1931, ADIPOCYTE OBESITY CE, P105; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; FERRANNINI E, 1988, PATHOGENESIS NONINSU, P201; FLIER JS, 1983, ANNU REV MED, V34, P145, DOI 10.1146/annurev.me.34.020183.001045; GARVEY WT, 1988, DIABETES METAB REV, V4, P543, DOI 10.1002/dmr.5610040602; GARVEY WT, 1989, ENDOCRINOLOGY, V124, P2063, DOI 10.1210/endo-124-5-2063; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GARVEY WT, 1989, MOL ENDOCRINOL, V3, P1132, DOI 10.1210/mend-3-7-1132; GARVEY WT, 1989, DIABETES METAB REV, V5, P727, DOI 10.1002/dmr.5610050807; GARVEY WT, 1988, PATHOGENESIS NONINSU, P171; HISSIN PJ, 1982, J CLIN INVEST, V70, P780, DOI 10.1172/JCI110674; KAHN CR, 1978, METABOLISM, V27, P1893; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MARSHALL S, 1989, J BIOL CHEM, V264, P2029; MARSHALL S, 1983, DIABETES, V32, P319, DOI 10.2337/diab.32.4.319; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 1989, J BIOL CHEM, V264, P2037; OLEFSKY JM, 1989, ENDOCRINOLOGY, P1369; POSO AR, 1982, J BIOL CHEM, V257, P2114; REVERS RR, 1984, J CLIN ENDOCR METAB, V58, P353, DOI 10.1210/jcem-58-2-353; SEINO S, 1990, DIABETES, V39, P129, DOI 10.2337/diabetes.39.2.129; SHAFRIR E, 1987, ENDOCRINOL METAB, P1043; SMITH U, 1988, PATHOGENESIS NONINSU, P221; SOMMERCORN JM, 1981, J BIOL CHEM, V256, P4816; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAYLOR SI, 1989, INSULIN ACTION MOL C, P97; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; YKIJARVINEN H, 1987, DIABETES, V36, P892, DOI 10.2337/diabetes.36.8.892; Zubay G., 1988, BIOCHEMISTRY	38	145	160	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1991	5	15					3031	3036		10.1096/fasebj.5.15.1743436	http://dx.doi.org/10.1096/fasebj.5.15.1743436			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1743436	Bronze			2022-12-28	WOS:A1991GU84200005
J	SHER, E; BIANCARDI, E; PASSAFARO, M; CLEMENTI, F				SHER, E; BIANCARDI, E; PASSAFARO, M; CLEMENTI, F			PHYSIOPATHOLOGY OF NEURONAL VOLTAGE-OPERATED CALCIUM CHANNELS	FASEB JOURNAL			English	Article						VOLTAGE-OPERATED CALCIUM CHANNEL; NEUROTRANSMITTER RELEASE; OMEGA-CONOTOXIN; LAMBERT-EATON MYASTHENIC SYNDROME	EATON MYASTHENIC SYNDROME; OMEGA-CONOTOXIN GVIA; PHEOCHROMOCYTOMA CELL-LINES; CHICK SENSORY NEURONS; CA-2+ CHANNELS; DIHYDROPYRIDINE; RECEPTOR; SOLUBILIZATION; AUTOANTIBODIES; SENSITIVITY	Voltage-operated calcium channels are multimeric transmembrane proteins crucially involved in control of calcium homeostasis. Multiple types of voltage-operated calcium channels have been described in both the nervous system and peripheral tissues. Different channels can be classified according to either their biophysical properties or their pharmacology, biochemical and molecular structure, and localization and functional role. Concentrating on neuronal cells, this paper reviews the different properties of low- and high-voltage activated channels, as well as various attempts to subdivide high-voltage activated channels into different subtypes (L, N, omega, P, etc.). The availability of selective drugs (such as dihydropyridines) and natural toxins (such as omega-Conotoxin, omega-agatoxin, and funnel-web spider toxins), which bind to specific channel subtypes, has greatly helped in channel classification. The emerging view is that there are many members of the family of voltage-operated calcium channels, each with its own molecular structure, a different pharmacology, a different localization, and possibly a different physiological role. Different calcium subtypes are selectively affected in human and animal diseases. The use of omega-Conotoxin has led to identification of the channel subtype-(omega) specifically affected in Lambert-Eaton myasthenic syndrome (a human disease of neurotransmission), and has permitted development of new diagnostic approaches to the disease.	UNIV MILAN,DEPT MED PHARMACOL,I-20122 MILAN,ITALY	University of Milan	SHER, E (corresponding author), CNR,CTR CYTOPHARMACOL,VIA VANVITELLI 32,I-20129 MILAN,ITALY.							ADAMS ME, 1990, J BIOL CHEM, V265, P861; AHLIDANIAN MK, 1990, NEURON, V3, P819; AKAIKE N, 1989, J PHYSIOL-LONDON, V412, P181, DOI 10.1113/jphysiol.1989.sp017610; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; BARHANIN J, 1988, BIOCHEM BIOPH RES CO, V150, P1051, DOI 10.1016/0006-291X(88)90736-X; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BRADFISCH GA, 1990, TOXICON, V28, P1249, DOI 10.1016/0041-0101(90)90090-T; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CARBONE E, 1990, NEUROSCI LETT, V111, P315, DOI 10.1016/0304-3940(90)90281-D; CARBONE E, 1990, PFLUG ARCH EUR J PHY, V416, P170, DOI 10.1007/BF00370239; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; DEAIZPURUA HJ, 1988, CANCER RES, V48, P4719; GLOSSMANN H, 1988, ISI ATLAS-PHARMACOL, V2, P202; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; HERDON H, 1989, N-S ARCH PHARMACOL, V340, P36; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; LENNON VA, 1989, MAYO CLIN PROC, V64, P1498, DOI 10.1016/S0025-6196(12)65705-X; LLINAS RR, 1989, ANN NY ACAD SCI, V560, P103, DOI 10.1111/j.1749-6632.1989.tb24084.x; MATSUSHITA T, 1989, ANN NY ACAD SCI, V560, P426, DOI 10.1111/j.1749-6632.1989.tb24127.x; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCKENNA E, 1990, BIOCHEM PHARMACOL, V39, P1145, DOI 10.1016/0006-2952(90)90255-J; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SHER E, 1990, LANCET, V335, P413, DOI 10.1016/0140-6736(90)90248-4; SHER E, 1989, LANCET, V2, P640; SHER E, 1990, CANCER RES, V50, P3892; SHER E, 1988, FEBS LETT, V235, P178, DOI 10.1016/0014-5793(88)81258-4; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SWANDULLA D, 1988, J GEN PHYSIOL, V92, P197, DOI 10.1085/jgp.92.2.197; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; TRIGGLE DJ, 1987, ANNU REV PHARMACOL, V27, P347; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; WAGNER JA, 1988, J NEUROSCI, V8, P3354; YAMAGUCHI T, 1988, J BIOL CHEM, V263, P9491	40	76	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2677	2683		10.1096/fasebj.5.12.1655547	http://dx.doi.org/10.1096/fasebj.5.12.1655547			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1655547	Bronze			2022-12-28	WOS:A1991GE81100008
J	WOESSNER, JF				WOESSNER, JF			MATRIX METALLOPROTEINASES AND THEIR INHIBITORS IN CONNECTIVE-TISSUE REMODELING	FASEB JOURNAL			English	Review						EXTRACELLULAR MATRIX; PROTEINASE (METALLO); COLLAGENASE; TIMP; CONNECTIVE TISSUE	RHEUMATOID SYNOVIAL FIBROBLASTS; HUMAN ARTICULAR-CARTILAGE; PROTEOGLYCAN DEGRADATION; COLLAGENASE GENE; IV COLLAGENASE; CLEAVAGE SITES; MESSENGER-RNAS; RAT UTERUS; PURIFICATION; STROMELYSIN	Matrix metalloproteinases are an important group of zinc enzymes responsible for degradation of the extracellular matrix components such as collagen and proteoglycans in normal embryogenesis and remodeling and in many disease processes such as arthritis,cancer, periodontitis, and osteoporosis. A matrixin family is defined, comprising at least seven members that range in size from M(r) 28000 to 92000 and are related in gene sequence to collagenase. All family members are secreted as zymogens that lose peptides of about 10,000 daltons upon activation. Latency is due to a conserved cysteine that binds to zinc at the active center. Latency is overcome by physical (chaotropic agents), chemical (HOCl, mercurials), and enzymatic (trypsin,plasmin) treatments that separate the cysteine residue from the zinc. Expression of the metalloproteinases is switched on by a variety of agents acting through regulatory elements of the gene, particularly the AP-1 binding site. A family of protein inhibitors of M(r) 28,500 or less binds strongly and stoichiometrically in noncovalent fashion to inhibit members of the family. The serum protein alpha-2-macroglobulin and relatives are also strongly inhibitory.			WOESSNER, JF (corresponding author), UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOLEC BIOL, R 127, POB 016960, MIAMI, FL 33101 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016940, R37AR016940] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-16940] Funding Source: Medline; NICHD NIH HHS [HD-06773] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AZZO W, 1986, J BIOL CHEM, V261, P5434; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BIRKEDALHANSEN H, 1988, J ORAL PATHOL MED, V17, P445, DOI 10.1111/j.1600-0714.1988.tb01313.x; BIRKEDALHANSEN H, 1989, IN PRESS MATRIX S, V11; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BRANNSTROM M, 1988, ENDOCRINOLOGY, V122, P1715; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; BRINCKERHOFF CE, 1990, ANN NY ACAD SCI, V580, P355, DOI 10.1111/j.1749-6632.1990.tb17944.x; CAPUTO CB, 1987, BIOCHEM PHARMACOL, V36, P995, DOI 10.1016/0006-2952(87)90405-9; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; Cawston T.E., 1986, PROTEINASE INHIBITOR, P589; CAWSTON TE, 1990, BIOCHEM J, V269, P183, DOI 10.1042/bj2690183; CHANDRASEKHAR S, 1988, BIOCHEM BIOPH RES CO, V157, P1352, DOI 10.1016/S0006-291X(88)81024-6; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; COULOMBE B, 1988, J BIOL CHEM, V263, P1439; DARLAK K, 1990, J BIOL CHEM, V265, P5199; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; EMONARD H, 1990, CELL MOL BIOL, V36, P131; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FIELDS GB, 1990, BIOCHEMISTRY-US, V29, P6670, DOI 10.1021/bi00480a017; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; FRISCH SM, 1990, ONCOGENE, V5, P75; FRISCH SM, 1989, COLLAGEN, V4, P85; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GROSS J, 1965, P NATL ACAD SCI USA, V54, P1197, DOI 10.1073/pnas.54.4.1197; GUNJASMITH Z, 1989, BIOCHEM J, V258, P115, DOI 10.1042/bj2580115; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HOROWITZ S, 1989, J BIOL CHEM, V264, P7092; HOWELL DS, 1991, DISORDERS BONE MINER; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; Jeffrey J. J., 1986, REGULATION MATRIX AC, P53; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KORTYLEWICZ ZP, 1990, J MED CHEM, V33, P263, DOI 10.1021/jm00163a044; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LLOYD LF, 1989, J MOL BIOL, V210, P237, DOI 10.1016/0022-2836(89)90304-5; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, BIOCHEM J, V261, P1031, DOI 10.1042/bj2611031; NAGASE H, 1991, IN PRESS MATRIX S; NAKANO T, 1987, BIOCHEM CELL BIOL, V65, P286, DOI 10.1139/o87-037; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; RAJABI M, 1987, OBSTET GYNECOL, V69, P179; SAGE H, 1981, BIOCHEMISTRY-US, V20, P3778, DOI 10.1021/bi00516a017; SAKAMOTO S, 1988, MOL ASPECTS MED, V10, P299, DOI 10.1016/0098-2997(88)90025-8; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SOTTILE J, 1988, COLLAGEN REL RES, V8, P361; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TEAHAN J, 1989, BIOCHEMISTRY-US, V28, P8497, DOI 10.1021/bi00447a034; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WEEKS JG, 1976, BIOCHIM BIOPHYS ACTA, V445, P205, DOI 10.1016/0005-2744(76)90173-X; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WOESSNER J F JR, 1989, Steroids, V54, P491, DOI 10.1016/0039-128X(89)90043-3; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	78	3113	3222	1	173	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2145	2154		10.1096/fasebj.5.8.1850705	http://dx.doi.org/10.1096/fasebj.5.8.1850705			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1850705				2022-12-28	WOS:A1991FK11100005
J	ZHENG, W; PERRY, DF; NELSON, DL; APOSHIAN, HV				ZHENG, W; PERRY, DF; NELSON, DL; APOSHIAN, HV			CHOROID-PLEXUS PROTECTS CEREBROSPINAL-FLUID AGAINST TOXIC METALS	FASEB JOURNAL			English	Article						CHOROID PLEXUS; HEAVY METALS; CENTRAL NERVOUS SYSTEM; NEUROTOXICITY; BLOOD-CSF BARRIER	LIQUID-CHROMATOGRAPHY; BRAIN; TRANSPORT; CADMIUM; BARRIER; ACID; LEAD	Although heavy metal ions are known to be toxic to the central nervous system (CNS), the mechanisms by which the CNS may protect itself from initial challenges of such toxic ions is unknown. The choroid plexus is the principal site of formation of the cerebrospinal fluid (CSF) which bathes the brain. We have determined in rats and rabbits that after intraperitoneal administration of lead, cadmium, mercury, and arsenic compounds, these toxic metal ions accumulated in the lateral choroid plexus at concentrations of Pb, Hg, and As that were 70-, 95-, and 40-fold higher, respectively, than those found in the CSF. Cd was not detected in the CSF. In addition, concentrations of these heavy metal ions were found to be many fold greater in the choroid plexus than in the brain or blood. The accumulation of Pb in the choroid plexus was dose-dependent and time-related. When the choroid plexus was preincubated, in vitro, with ouabain (1.5 mM), the uptake of Cd from the CSF side of the choroid plexus was inhibited 57%. Cadmium metallothionein was not found in the choroid plexus. Whereas the concentration of reduced glutathione in the choroid plexus was less than that in the brain cortex, the concentration of cystine was fourfold greater. The lateral choroid plexus sequesters Pb, Cd, As, and Hg. It appears to be one of the important mechanisms that protects the CSF and the brain from the fluxes of toxic heavy metals in the blood.	UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,BIOSCI W,ROOM 308,TUCSON,AZ 85721; UNIV ARIZONA,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT VET SCI,TUCSON,AZ 85721	University of Arizona; University of Arizona; University of Arizona					NATIONAL CANCER INSTITUTE [R01CA049252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004940, R01ES003356] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49252] Funding Source: Medline; NIEHS NIH HHS [ES-03356, ES-04940] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON ME, 1989, FASEB J, V3, P1632, DOI 10.1096/fasebj.3.5.2920877; ANDERSON ME, 1989, FASEB J, V3, P2527, DOI 10.1096/fasebj.3.13.2572501; BERLIN M, 1963, ARCH ENVIRON HEALTH, V6, P589, DOI 10.1080/00039896.1963.10663447; Bradbury M W, 1988, Ann N Y Acad Sci, V529, P1, DOI 10.1111/j.1749-6632.1988.tb51414.x; Clarkson T.W., 1988, BIOL MONITORING TOXI; DAVSON H, 1963, J PHYSIOL-LONDON, V167, P239, DOI 10.1113/jphysiol.1963.sp007144; DEANE R, 1990, J NEUROCHEM, V54, P905, DOI 10.1111/j.1471-4159.1990.tb02337.x; DIBENEDETTO FE, 1986, J NEUROCHEM, V46, P1725; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FRIEDHEIM E, 1983, LANCET, V1, P981; HERSHEY CO, 1987, TRACE ELEM MED, V4, P21; HIDALGO J, 1990, J NEUROCHEM, V55, P651, DOI 10.1111/j.1471-4159.1990.tb04182.x; JACOBSON KB, 1980, TOXICOLOGY, V16, P1, DOI 10.1016/0300-483X(80)90107-9; Kagi J.H.R., 1979, METALLOTHIONEIN; KRYNITSKY AJ, 1987, ANAL CHEM, V59, P1884, DOI 10.1021/ac00141a034; LEHMAN LD, 1986, ANAL BIOCHEM, V153, P305, DOI 10.1016/0003-2697(86)90097-7; LINDVALL M, 1978, SCIENCE, V201, P176, DOI 10.1126/science.663649; MAIORINO RM, 1986, J CHROMATOGR, V374, P297, DOI 10.1016/S0378-4347(00)83285-5; MANTON WI, 1984, LANCET, V2, P351; MIHORAT TH, 1976, INT REV CYTOL, V47, P225; NOHJOH T, 1989, J PHARMACOL EXP THER, V250, P324; OTUAMA LA, 1976, TOXICOL APPL PHARM, V36, P1, DOI 10.1016/0041-008X(76)90021-1; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SIGNHAL RK, 1987, FASEB J, V1, P220; SPECTOR R, 1989, J NEUROCHEM, V53, P1667, DOI 10.1111/j.1471-4159.1989.tb09229.x; SPECTOR R, 1974, J PHARMACOL EXP THER, V188, P55; VALOIS AA, 1989, TOXICOLOGY, V55, P193, DOI 10.1016/0300-483X(89)90186-8; 1977, MED BIOL EFFECTS ENV	28	87	96	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1991	5	8					2188	2193		10.1096/fasebj.5.8.1850706	http://dx.doi.org/10.1096/fasebj.5.8.1850706			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1850706				2022-12-28	WOS:A1991FK11100011
J	MALHOTRA, RK; BHAVE, SV; WAKADE, TD; BHAVE, AS; WAKADE, AR				MALHOTRA, RK; BHAVE, SV; WAKADE, TD; BHAVE, AS; WAKADE, AR			EFFECTS OF NEUROTRANSMITTERS AND PEPTIDES ON PHOSPHOLIPID HYDROLYSIS IN SYMPATHETIC AND SENSORY NEURONS	FASEB JOURNAL			English	Article									WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,GORDON SCOTT HALL,540 E CANFIELD,DETROIT,MI 48201	Wayne State University			Bhave, Sanjiv/K-2398-2012					BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BHAVE SV, 1988, NEUROSCI LETT, V90, P234, DOI 10.1016/0304-3940(88)90818-X; BROWN E, 1984, J NEUROCHEM, V42, P1379, DOI 10.1111/j.1471-4159.1984.tb02798.x; CARSWELL H, 1986, BRIT J PHARMACOL, V89, P809, DOI 10.1111/j.1476-5381.1986.tb11186.x; CASTAGNA M, 1982, J BIOL CHEM, V257, P7874; DOWNES CP, 1983, TRENDS NEUROSCI, V6, P313, DOI 10.1016/0166-2236(83)90146-7; DOWNES CP, 1986, TRENDS NEUROSCI, V9, P394, DOI 10.1016/0166-2236(86)90126-8; EDGAR D, 1981, NATURE, V289, P294, DOI 10.1038/289294a0; HORWITZ J, 1985, J PHARMACOL EXP THER, V237, P312; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LITOSCH I, 1986, LIFE SCI, V39, P187, DOI 10.1016/0024-3205(86)90529-1; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MALHOTRA RK, 1988, J NEUROCHEM, V51, P967, DOI 10.1111/j.1471-4159.1988.tb01834.x; MALHOTRA RK, 1988, J BIOL CHEM, V263, P2123; NEARY JT, 1988, J NEUROCHEM, V50, P1179, DOI 10.1111/j.1471-4159.1988.tb10590.x; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; WAKADE AR, 1982, J PHARMACOL EXP THER, V223, P125; WAKADE AR, 1988, NEUROSCIENCE, V27, P1007, DOI 10.1016/0306-4522(88)90205-9; WAKADE AR, 1988, J NEUROCHEM, V51, P975, DOI 10.1111/j.1471-4159.1988.tb01835.x; WEISS S, 1989, J NEUROCHEM, V52, P530, DOI 10.1111/j.1471-4159.1989.tb09152.x; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; YAMANISHI J, 1983, BIOCHEM BIOPH RES CO, V112, P778, DOI 10.1016/0006-291X(83)91529-2	25	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1990	4	8					2492	2498		10.1096/fasebj.4.8.1970791	http://dx.doi.org/10.1096/fasebj.4.8.1970791			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DE393	1970791				2022-12-28	WOS:A1990DE39300009
J	Tsang, SV; Rainusso, N; Liu, M; Nomura, M; Patel, TD; Nakahata, K; Kim, H; Huang, SX; Rajapakshe, K; Coarfa, C; Man, TK; Rao, PH; Yustein, JT				Tsang, Susan, V; Rainusso, Nino; Liu, Meng; Nomura, Motonari; Patel, Tajhal D.; Nakahata, Kengo; Kim, Ha Ram; Huang, Shixia; Rajapakshe, Kimal; Coarfa, Cristian; Man, Tsz-Kwong; Rao, Pulivarthi H.; Yustein, Jason T.			LncRNA PVT-1 promotes osteosarcoma cancer stem-like properties through direct interaction with TRIM28 and TSC2 ubiquitination	ONCOGENE			English	Article; Early Access							LONG NONCODING RNA; CELLS; IDENTIFICATION; RESISTANCE; DISCOVERY; ONCOGENE	Osteosarcoma, the most common pediatric bone tumor, is an aggressive heterogeneous malignancy defined by complex chromosomal aberrations. Overall survival rates remain at similar to 70%, but patients with chemoresistant or metastatic disease have extremely poor outcomes of <30%. A subgroup of tumors harbor amplification of chromosome 8q24.2 and increased expression of the oncogenic long noncoding RNA (IncRNA) Plasmacytoma Variant Translocation-1 (PVT-1), which is associated with an extremely poor clinical prognosis. This study demonstrates that PVT-7 is critical for osteosarcoma tumor-initiation potential. Chromatin Hybridization by RNA Purification analysis identified Tripartite-Motif Containing Family 28 (TRIM28) as a novel PVT-1 binding partner. Mechanistically, co-immunoprecipitation studies showed the PVT-1/TRIM28 complex binds and increases SUMOylation of phosphatidylinositol 3-kinase catalytic subunit type 3 (Vps34), which leads to enhanced ubiquitination and degradation of tumor suppressor complex 2 (TSC2), thus contributing to increased self-renewal and stem cell phenotypes. Furthermore, we identified that osteosarcoma cells with increased PVT-1 have enhanced sensitivity to the SUMOylation inhibitor, TAK-981. Altogether, this study elucidated a role for PVT-1 in the enhancement of cancer stem-like behaviors, including migration and invasion, in osteosarcoma, and identified the novel PVT-1/TRIM28 axis signaling cascade as a potential therapeutic target for osteosarcoma treatment.	[Tsang, Susan, V; Rainusso, Nino; Liu, Meng; Patel, Tajhal D.; Nakahata, Kengo; Kim, Ha Ram; Man, Tsz-Kwong; Rao, Pulivarthi H.; Yustein, Jason T.] Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA; [Tsang, Susan, V; Rainusso, Nino; Liu, Meng; Patel, Tajhal D.; Nakahata, Kengo; Kim, Ha Ram; Man, Tsz-Kwong; Rao, Pulivarthi H.; Yustein, Jason T.] Baylor Coll Med, Faris D Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA; [Tsang, Susan, V; Yustein, Jason T.] Baylor Coll Med, Integrat Mol & Biomed Sci Program, Houston, TX 77030 USA; [Rainusso, Nino; Coarfa, Cristian; Yustein, Jason T.] Baylor Coll Med, Dan L Duncan Canc Comprehens Ctr, Houston, TX 77030 USA; [Nomura, Motonari; Nakahata, Kengo] Osaka Univ, Grad Sch Med, Dept Pediat Surg, Suita, Osaka, Japan; [Huang, Shixia; Coarfa, Cristian] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Rajapakshe, Kimal] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Coarfa, Cristian; Yustein, Jason T.] Baylor Coll Med, Canc & Cell Biol Program, Houston, TX 77030 USA; [Yustein, Jason T.] Emory Univ, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Osaka University; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Emory University	Yustein, JT (corresponding author), Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Faris D Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Integrat Mol & Biomed Sci Program, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Dan L Duncan Canc Comprehens Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Canc & Cell Biol Program, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Emory Univ, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA.	yustein@bcm.edu		Coarfa, Cristian/0000-0002-4183-4939	Cancer Prevention Institute of Texas (CPRIT) [RP160283, RP170005]; NIEHS P30 Center [1P30ES030285]; CPRIT Core Facility Support Award [CPRIT-RP180672]; NIH [CA125123, RR024574]; Core Facility Award [CPRIT-RP170005]; NIEHS P30 Center grant [1P30ES030285]	Cancer Prevention Institute of Texas (CPRIT); NIEHS P30 Center; CPRIT Core Facility Support Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Core Facility Award; NIEHS P30 Center grant	We would like to acknowledge the Advanced Technologies Core services at the Baylor College of Medicine. This work was funded by The Faris D. Virani Ewing Sarcoma Center (to JTY). SVT was partially supported by Cancer Prevention Institute of Texas (CPRIT) RP160283, KR and CC were partially supported by (CPRIT) RP170005, NIH P30 shared resource grant CA125123, and NIEHS P30 Center grant 1P30ES030285; CPRIT Core Facility Support Award (CPRIT-RP180672), the NIH (CA125123 and RR024574 to the Cytometry and Cell Sorting Core at Baylor College of Medicine); and Core Facility Award (CPRIT-RP170005 to Proteomics and Metabolomics Core at Baylor College of Medicine). We thank Dr. Suzanne Fuqua and Dr. Xiang Zhang for generously providing the breast cancer cell lines.	Adriaens C, 2016, NAT MED, V22, P861, DOI 10.1038/nm.4135; Al-Romaih K, 2003, CANCER GENET CYTOGEN, V144, P91, DOI 10.1016/S0165-4608(02)00929-9; Assouline S, 2019, BLOOD, V134, DOI 10.1182/blood-2019-128773; Brisbin AG, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-156; Brown HK, 2017, CANCER LETT, V386, P189, DOI 10.1016/j.canlet.2016.11.019; Carramusa L, 2007, J CELL PHYSIOL, V213, P511, DOI 10.1002/jcp.21133; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Chen SS, 2017, ONCOTARGET, V8, P110685, DOI 10.18632/oncotarget.22161; Chu C, 2015, CELL, V161, P404, DOI 10.1016/j.cell.2015.03.025; Colombo T, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/304208; Czerwinska P, 2017, ONCOTARGET, V8, P863, DOI 10.18632/oncotarget.13273; Dasgupta A, 2021, CANCER RES, V81, P199, DOI 10.1158/0008-5472.CAN-20-0854; Du PZ, 2019, J ONCOL, V2019, DOI 10.1155/2019/9325407; Fan H, 2018, MOL MED REP, V17, P8309, DOI 10.3892/mmr.2018.8907; Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455; Feng Y, 2014, METHODS MOL BIOL, V1165, P115, DOI 10.1007/978-1-4939-0856-1_10; Fong KW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07475-5; Fu C, 2018, NEUROTHERAPEUTICS, V15, P1139, DOI 10.1007/s13311-018-0649-9; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; Han D, 2015, CANCER LETT, V361, P13, DOI 10.1016/j.canlet.2015.03.002; Houthuijzen J, 2012, BRIT J CANCER, V106, P1901, DOI 10.1038/bjc.2012.201; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Lang B, 2019, NUCLEIC ACIDS RES, V47, pD601, DOI 10.1093/nar/gky967; Langston SP, 2021, J MED CHEM, V64, P2501, DOI 10.1021/acs.jmedchem.0c01491; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Li J, 2017, ONCOGENE, V36, P2991, DOI 10.1038/onc.2016.453; Liu XK, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0164-y; Madsen RR, 2020, BIOCHEM SOC T, V48, P301, DOI 10.1042/BST20190778; Livi CM, 2016, BIOINFORMATICS, V32, P773, DOI 10.1093/bioinformatics/btv629; Mirabello L, 2010, CARCINOGENESIS, V31, P1400, DOI 10.1093/carcin/bgq117; Misaghi A, 2018, SICOT-J, V4, DOI 10.1051/sicotj/2017028; Mohan N, 2016, ONCOTARGET, V7, P52239, DOI 10.18632/oncotarget.10469; Moschos SJ, 2007, ONCOGENE, V26, P4216, DOI 10.1038/sj.onc.1210216; Muff R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125611; Nomura M, 2019, JNCI-J NATL CANCER I, V111, P1216, DOI 10.1093/jnci/djz026; Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1; Peitzsch C, 2017, SEMIN CANCER BIOL, V44, P10, DOI 10.1016/j.semcancer.2017.02.011; Ping GF, 2018, AM J TRANSL RES, V10, P138; Pradhan SA, 2014, NUCLEIC ACIDS RES, V42, P6243, DOI 10.1093/nar/gku278; Rainusso N, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27579; Schiavone K, 2019, ADV EXP MED BIOL, V1139, P187, DOI 10.1007/978-3-030-14366-4_11; Tang JM, 2018, ONCOGENE, V37, P4723, DOI 10.1038/s41388-018-0310-4; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang HT, 2020, CANCER MANAG RES, V12, P7993, DOI 10.2147/CMAR.S263383; Xia P, 2015, AM J CANCER RES, V5, P1602; Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110	47	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02538-w	http://dx.doi.org/10.1038/s41388-022-02538-w		NOV 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D2TY	36348010	Green Submitted			2022-12-28	WOS:000882550800003
J	PURKERSON, J; ISAKSON, P				PURKERSON, J; ISAKSON, P			A 2-SIGNAL MODEL FOR REGULATION OF IMMUNOGLOBULIN ISOTYPE SWITCHING	FASEB JOURNAL			English	Review						IMMUNOGLOBULIN ISOTYPES; SWITCH RECOMBINATION; HEAVY CHAIN GENES; CYTOKINES	HUMAN B-CELLS; HEAVY-CHAIN TRANSCRIPTS; HUMAN IGE SYNTHESIS; STIMULATORY FACTOR-I; HUMAN LYMPHOCYTES-B; HELPER T-CELLS; INTERFERON-GAMMA; GROWTH-FACTOR; DIFFERENTIATION FACTOR; ANTI-IMMUNOGLOBULIN	A characteristic feature of the humoral immune response is a switch from IgM to other Ig isotypes that typically occurs subsequent to a first exposure to antigen. Ultimately, isotype switching involves a DNA rearrangement that recombines a variable region gene, initially juxtaposed to the mu constant region gene (Cmu), with a constant region gene located downstream of Cmu. Isotype switching is controlled by T lymphocyte-derived cytokines, such as interleukin-4 (IL-4), gamma-interferon (gamma-IFN), and TGFbeta, which direct B lymphocytes to switch to specific Ig classes. For example, IL-4, directs murine B cells to produce IgG1 and IgE, and human B cells to produce IgE and IgG4. IL-4 appears to direct switching to IgE and IgG1 by inducing transcription of the epsilon and gamma1 constant region genes before switch recombination. However, IL-4 is not a sufficient stimulus for isotype switching, and additional signals are required to complete this process. This second signal can be provided by physical contact with activated T cells, which may involve, at least in part, ligation of the CD40 molecule. For murine B cells the second signal may also be provided by IL-5. Isotype switching in B lymphocytes may provide a useful model for directed DNA recombination in higher eukaryotes.	MONSANTO CO,SEARLE RES & DEV,DEPT IMMUNOINFLAMMATORY DIS RES,700 CHESTERFIELD PKWY N,ST LOUIS,MO 63198	Monsanto; Pfizer								ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; COFFMAN RL, 1986, J IMMUNOL, V136, P949; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; COUTELIER JP, 1987, J EXP MED, V165, P64, DOI 10.1084/jem.165.1.64; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; DEKRUYFF RH, 1989, J EXP MED, V170, P1477, DOI 10.1084/jem.170.5.1477; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GRAVALLESE EM, 1991, J IMMUNOL, V147, P2377; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734; ISAKSON PC, 1986, J EXP MED, V164, P303, DOI 10.1084/jem.164.1.303; ISLAM KB, 1991, INT IMMUNOL, V3, P1099, DOI 10.1093/intimm/3.11.1099; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JABARA HH, 1991, J IMMUNOL, V147, P1557; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KATAOKA T, 1980, P NATL ACAD SCI-BIOL, V77, P919, DOI 10.1073/pnas.77.2.919; KEARNEY JF, 1975, J IMMUNOL, V115, P671; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; LEBMAN DA, 1990, P NATL ACAD SCI USA, V87, P3962, DOI 10.1073/pnas.87.10.3962; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MAGGI E, 1989, IMMUNOLOGY, V68, P300; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MCHEYZERWILLIAMS MG, 1989, EUR J IMMUNOL, V19, P2025, DOI 10.1002/eji.1830191109; NOELLE RJ, 1989, J IMMUNOL, V143, P1807; NOELLE RJ, 1991, FASEB J, V5, P2770, DOI 10.1096/fasebj.5.13.1833257; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; PASRRONCHI P, 1991, J IMMUNOL, V144, P2101; PAUL WE, 1989, FUNDAMENTAL IMMUNOLO; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PETRINI J, 1989, J IMMUNOL, V142, P2932; PURKERSON JM, 1988, J EXP MED, V168, P1175, DOI 10.1084/jem.168.3.1175; PURKERSON JM, 1991, EUR J IMMUNOL, V21, P707, DOI 10.1002/eji.1830210325; PURKERSON JM, 1992, J EXP MED, V175, P973, DOI 10.1084/jem.175.4.973; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; ROSENBERG YJ, 1982, IMMUNOL REV, V67, P33, DOI 10.1111/j.1600-065X.1982.tb01054.x; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; ROTHMAN P, 1990, INT IMMUNOL, V2, P621, DOI 10.1093/intimm/2.7.621; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5561; SAVELKOUL HFJ, 1988, J IMMUNOL, V141, P749; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHMITZ J, 1989, INT IMMUNOL, V1, P13; SCHWEDLER U, 1990, NATURE, V345, P452; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; SEVERINSONGRONOWICZ E, 1979, J IMMUNOL, V123, P2057; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; SHIMIZU A, 1991, J EXP MED, V173, P1385, DOI 10.1084/jem.173.6.1385; SHOCKETT P, 1991, J IMMUNOL, V147, P4374; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNAPPER CM, 1992, J EXP MED, V175, P1367, DOI 10.1084/jem.175.5.1367; SNAPPER CM, 1991, J IMMUNOL, V147, P1163; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VANVLASSELAER P, 1992, J IMMUNOL, V148, P2062; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; VITETTA ES, 1985, J EXP MED, V162, P1726, DOI 10.1084/jem.162.5.1726; VOEIKEIMELMAN K, 1987, CELL, V48, P1071; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388; YUAN D, 1990, J IMMUNOL, V145, P3491	75	84	84	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1992	6	14					3245	3252		10.1096/fasebj.6.14.1385241	http://dx.doi.org/10.1096/fasebj.6.14.1385241			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1385241				2022-12-28	WOS:A1992JZ73400005
J	GORDON, JI; SCHMIDT, GH; ROTH, KA				GORDON, JI; SCHMIDT, GH; ROTH, KA			STUDIES OF INTESTINAL STEM-CELLS USING NORMAL, CHIMERIC, AND TRANSGENIC MICE	FASEB JOURNAL			English	Article						STEM CELLS; LINEAGE ALLOCATION; GUT EPITHELIAL CELL DIFFERENTIATION; DEVELOPMENT; AXIAL PATTERN FORMATION; CHIMERIC AND TRANSGENIC MICE	MOUSE SMALL-INTESTINE; ACID-BINDING-PROTEIN; DOLICHOS-BIFLORUS AGGLUTININ; HORMONE FUSION GENES; AGGREGATION CHIMERAS; ADULT-MOUSE; PROGENITOR CELLS; SUBEPITHELIAL FIBROBLASTS; PANETH CELLS; MUCOUS CELLS	The mouse intestinal epithelium represents a continuous developmental system. Its four principal differentiated cell types-enterocytes, goblet, enteroendocrine, and Paneth cells-are derived from a common multipotent stem cell located near the base of monoclonal crypts. Members of these four lineages undergo rapid and perpetual renewal along an anatomically well-defined pathway. The gut epithelium provides a unique mammalian model for studying the biological features of stem cells (e.g., their ability to undergo asymmetric division, their enormous proliferative potential, their capacity for functional anchorage in a niche), examining how stem cell hierarchies are established and maintained in renewing cell populations, analyzing the relationships between passage through the cell cycle and lineage allocation (commitment), and defining the mechanisms that give stem cells a "positional address" along the cephalocaudal axis, allowing them to generate regional differences in the differentiation programs of their derived lineages (axial pattern formation).	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; SCION HLTH LTD,CAMBRIDGE CB3 0JQ,ENGLAND	Washington University (WUSTL)	GORDON, JI (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Roth, Kevin/0000-0002-0643-995X				AAMODT EJ, 1991, SCIENCE, V252, P579, DOI 10.1126/science.2020855; ALNAFUSSI AI, 1982, VIRCHOWS ARCH B, V40, P51, DOI 10.1007/BF02932850; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1985, ANAT REC, V211, P420, DOI 10.1002/ar.1092110408; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; COHN SM, 1991, P NATL ACAD SCI USA, V88, P1034, DOI 10.1073/pnas.88.3.1034; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GORDON JI, 1991, CURR OPIN LIPIDOL, V2, P125; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; HAFFEN K, 1983, DIFFERENTIATION, V23, P226; HAFFEN K, 1987, J PEDIATR GASTR NUTR, V6, P14, DOI 10.1097/00005176-198701000-00005; HAGEMANN RF, 1970, AM J ANAT, V129, P41, DOI 10.1002/aja.1001290104; HANSBROUGH JR, 1991, AM J PHYSIOL, V260, pG929, DOI 10.1152/ajpgi.1991.260.6.G929; HAUFT SM, 1989, J BIOL CHEM, V264, P8419; HENDRY JH, 1989, RADIAT RES, V118, P364, DOI 10.2307/3577450; HORNSEY S, 1985, CELL CLONES, P44; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; INOUE M, 1988, AM J PATHOL, V132, P49; JAMES R, 1991, J BIOL CHEM, V266, P3246; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KEDINGER M, 1986, DEV BIOL, V113, P474, DOI 10.1016/0012-1606(86)90183-1; MARSH MN, 1974, GASTROENTEROLOGY, V67, P636; MARSH MN, 1974, GASTROENTEROLOGY, V67, P622; MASKENS AP, 1979, GUT, V20, P775, DOI 10.1136/gut.20.9.775; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McLaren A., 1976, MAMMALIAN CHIMAERAS; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MEAD R, 1987, DEV BIOL, V121, P273, DOI 10.1016/0012-1606(87)90159-X; MINTZ B., 1971, Methods in mammalian embryology, P186; MOORE MAS, 1991, BLOOD, V78, P1; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; OBUOFORIBO AA, 1977, J ANAT, V24, P779; OCONNOR TM, 1966, AM J ANAT, V118, P525, DOI 10.1002/aja.1001180212; PARTRIDGE BT, 1980, MICRON, V11, P63, DOI 10.1016/0047-7206(80)90140-5; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; PONDER BAJ, 1983, DEV BIOL, V96, P535, DOI 10.1016/0012-1606(83)90191-4; PONDER BAJ, 1985, J EMBRYOL EXP MORPH, V87, P229; PONDER BAJ, 1986, HISTOCHEM J, V18, P217, DOI 10.1007/BF01676230; PONDER BAJ, 1983, J EMBRYOL EXP MORPH, V76, P83; PONDER BAJ, 1983, J HISTOCHEM CYTOCHEM, V31, P991; Potten C, 1983, STEM CELLS THEIR IDE, V155-99; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POTTEN CS, 1977, J ULTRA MOL STRUCT R, V60, P272, DOI 10.1016/S0022-5320(77)80071-3; Potten CS, 1985, CELL CLONES MANUAL M, P50; QUESENBERRY PJ, 1990, HEMATOLOGY, P129; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; ROTH KA, 1992, AM J PHYSIOL, V26, pG174; RUBIN DC, 1992, J BIOL CHEM, V267, P15122; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SCHMIDT GH, 1990, MUTAT RES, V228, P149, DOI 10.1016/0027-5107(90)90071-B; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SCHMIDT GH, 1985, J EMBRYOL EXP MORPH, V85, P121; SCHMIDT GH, 1985, J EMBRYOL EXP MORPH, V88, P219; SCHMIDT GH, 1986, J EMBRYOL EXP MORPH, V91, P197; SCHMIDT GH, 1984, ANAT REC, V210, P407, DOI 10.1002/ar.1092100216; SNELL GEORGE D., 1966, P205; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SUNTER JP, 1979, J ANAT, V129, P833; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TAVASSOLI M, 1990, BLOOD, V76, P1059; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; UITERDIJK HG, 1986, GENET RES, V47, P125, DOI 10.1017/S0016672300022953; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059; WINTON DJ, 1989, MUTAGENESIS, V4, P404, DOI 10.1093/mutage/4.5.404; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WINTON DJ, 1991, NATURE, V352, P201, DOI 10.1038/352201a0; WITHERS HR, 1969, RADIAT RES, V38, P598, DOI 10.2307/3572619; WITHERS HR, 1970, INT J RADIAT BIOL RE, V17, P261, DOI 10.1080/09553007014550291; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; WRIGHT NA, 1984, BIOL EPITHELIAL CELL, P688	90	143	147	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1992	6	12					3039	3050		10.1096/fasebj.6.12.1521737	http://dx.doi.org/10.1096/fasebj.6.12.1521737			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521737				2022-12-28	WOS:A1992JN50500005
J	CARSON, DA				CARSON, DA			GENETIC-FACTORS IN THE ETIOLOGY AND PATHOGENESIS OF AUTOIMMUNITY	FASEB JOURNAL			English	Review						HISTOCOMPATIBILITY COMPLEX; LYMPHOCYTE; IMMUNOGLOBULIN	REPERTOIRE; CELLS; MICE	Family and population studies indicate that several different genes can increase susceptibility to autoimmune diseases. Established genetic risk factors include genes encoding histocompatibility molecules, complement proteins, immunoglobulins, peptide transporter proteins, and genes controlling the production of sex hormones. Each factor may independently enhance the immunogenicity of autoantigens, either by increasing their processing and presentation by B lymphocytes and macrophages or by increasing the chance for recognition by autoreactive T and B lymphocytes. Genetic factors may also influence immune responses to infectious agents that can trigger autoimmunity. Because of the somatic generation of immune diversity, genetically identical individuals have different immune systems. The ability of genetic diagnosis to predict autoimmune disease in out-bred populations cannot easily exceed the disease concordance rates in monozygotic twins, which usually are less than 50%. However, genetic diagnosis can target populations that should be monitored for serologic evidence of autoimmunity, which may precede clinical signs and symptoms. In the future, it may be possible to match different forms of immunotherapy with specific genetic defects.	UNIV CALIF SAN DIEGO, SAM & ROSE STEIN INST RES AGING, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	CARSON, DA (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770, R01AR025443, R37AR025443] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40770, AR25443] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; ADAMS S, 1991, P NATL ACAD SCI USA, V88, P11271, DOI 10.1073/pnas.88.24.11271; ALBANI S, 1992, J CLIN INVEST, V89, P327, DOI 10.1172/JCI115580; ANDERSON GD, 1991, J IMMUNOL, V147, P1189; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BORN WK, 1991, FASEB J, V5, P2699, DOI 10.1096/fasebj.5.12.1717333; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CARSON DA, 1991, J CLIN INVEST, V87, P379, DOI 10.1172/JCI115007; CHEN PP, 1991, IN PRESS AUTOIMMUNIT; CLYNNE R, 1991, NATURE, V353, P357; DEIGHTON CM, 1991, ANN RHEUM DIS, V50, P62, DOI 10.1136/ard.50.1.62; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; EISENBERG RA, 1987, J CLIN INVEST, V80, P691, DOI 10.1172/JCI113123; EYNOR EE, J EXP MED, V175, P131; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FAUSTMAN D, 1991, SCIENCE, V254, P1756, DOI 10.1126/science.1763324; GATENBY PA, 1991, AUTOIMMUNITY, V11, P61, DOI 10.3109/08916939108994709; GROSSMAN CJ, 1991, J STEROID BIOCHEM, V40, P649, DOI 10.1016/0960-0760(91)90287-F; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; Janeway C A Jr, 1991, Semin Immunol, V3, P153; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KIPPS TJ, 1990, J EXP MED, V171, P189, DOI 10.1084/jem.171.1.189; LACHMANN DJ, 1986, BR J RHEUM, V26, P409; LANZAVECCHIA A, 1987, IMMUNOL REV, V99, P39, DOI 10.1111/j.1600-065X.1987.tb01171.x; LIBLAU R, 1991, EUR J IMMUNOL, V21, P1391, DOI 10.1002/eji.1830210610; MARTIN T, 1992, IN PRESS J EXP MED; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MCMURRAY R, 1991, J IMMUNOL, V147, P3780; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OHNO S, 1991, P NATL ACAD SCI USA, V88, P3065, DOI 10.1073/pnas.88.8.3065; OKSENBERG JR, 1989, P NATL ACAD SCI USA, V86, P988, DOI 10.1073/pnas.86.3.988; OLEE T, 1991, J CLIN INVEST, V88, P193, DOI 10.1172/JCI115277; OLEE T, 1992, IN PRESS J EXP MED; PASCUAL V, 1991, ADV IMMUNOL, V49, P1; POLAN ML, 1989, J CLIN ENDOCR METAB, V69, P1200, DOI 10.1210/jcem-69-6-1200; RASSENTI LZ, 1991, J IMMUNOL, V147, P1060; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCHROEDER HW, 1987, SCIENCE, V238, P791, DOI 10.1126/science.3118465; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SMILEK DE, 1990, IMMUNOL REV, V118, P37, DOI 10.1111/j.1600-065X.1990.tb00813.x; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TRUCCO M, 1989, CRIT REV IMMUNOL, V9, P201	49	39	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2800	2805		10.1096/fasebj.6.10.1634042	http://dx.doi.org/10.1096/fasebj.6.10.1634042			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634042				2022-12-28	WOS:A1992JD95400006
J	MCINTOSH, I; CUTTING, GR				MCINTOSH, I; CUTTING, GR			CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR AND THE ETIOLOGY AND PATHOGENESIS OF CYSTIC-FIBROSIS	FASEB JOURNAL			English	Review						CHLORIDE CHANNEL; MUTATIONS; STRUCTURE FUNCTION RELATIONSHIPS; PHOSPHORYLATION; GENETIC DISEASE, HUMAN; POSITIONAL CLONING	NUCLEOTIDE-BINDING FOLD; COMPLEMENTARY-DNA; MESSENGER-RNA; GENE; IDENTIFICATION; TRANSPORT; MUTATIONS; DISEASE; EXPRESSION; SEQUENCES	Cystic fibrosis (CF) is an inherited disorder causing pancreatic, pulmonary, and sinus disease in children and young adults. Abnormal viscosity of mucous secretions is a hallmark of the disease, and is believed to be the result of altered electrolyte transport across epithelial cell membranes. The monogenic etiology of this disease has been apparent for more than 40 years, but the defective gene has only recently been identified. This was made possible because of a revolution in genetic technology, called positional cloning, which can pinpoint disease genes without previous knowledge of the abnormal protein product. The protein encoded by the gene defective in CF has been termed the CF transmembrane conductance regulator (CFTR) because of its postulated role in electrolyte transport. Studies investigating the normal function of CFTR and how mutations affect that function, thereby causing CF, have required the combined skills of clinicians, geneticists, molecular biologists, and physiologists. From this collaborative effort a greater understanding of the pathogenesis of this disorder is now emerging. It may soon be possible to introduce novel therapies derived from this new knowledge that will be aimed directly at the basic defect. An ever-increasing number of genes of unknown function will be identified by continuing advances in molecular genetic technology and the advent of the genome sequencing project. The experience in cystic fibrosis research may prove to be a paradigm for investigation of the function of genes isolated by positional cloning methods.	JOHNS HOPKINS UNIV, SCH MED, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								ADAMS JG, 1990, SEMIN HEMATOL, V27, P229; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BONDUELLE M, 1990, HUM GENET, V85, P436; CARROLL TP, 1991, PEDIATR PULM S, V6, P223; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CHU CS, 1992, IN PRESS J CLIN INVE; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CRYSTAL RG, 1989, TRENDS GENET, V5, P411, DOI 10.1016/0168-9525(89)90200-X; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; CUTTING GR, 1990, NEW ENGL J MED, V323, P1685, DOI 10.1056/NEJM199012133232407; CUTTING GR, 1992, AM J HUM GENET, V50, P1185; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; DITULLIO P, 1992, BIO-TECHNOL, V10, P74, DOI 10.1038/nbt0192-74; Dorin Julia R., 1992, Transgenic Research, V1, P101, DOI 10.1007/BF02513027; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HAMOSH A, 1992, Pediatric Research, V31, p133A; HAMOSH A, 1992, IN PRESS AM J HUM GE; HAMOSH A, 1992, IN PRESS CURRENT TOP; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JONES CT, 1992, HUM MOL GENET, V1, P11, DOI 10.1093/hmg/1.1.11; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KOBAYASHI K, 1990, AM J HUM GENET, V47, P611; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; LERER I, 1992, J MED GENET, V29, P131, DOI 10.1136/jmg.29.2.131; MAROTTA CA, 1977, J BIOL CHEM, V252, P5040; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; NUNES V, 1991, HUM GENET, V87, P737; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROZEN R, 1992, AM J MED GENET, V42, P360, DOI 10.1002/ajmg.1320420322; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Tsui L C, 1991, Adv Hum Genet, V20, P153; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	75	40	41	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2775	2782		10.1096/fasebj.6.10.1378801	http://dx.doi.org/10.1096/fasebj.6.10.1378801			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1378801				2022-12-28	WOS:A1992JD95400003
J	WEXLER, NS				WEXLER, NS			THE TIRESIAS COMPLEX - HUNTINGTONS-DISEASE AS A PARADIGM OF TESTING FOR LATE-ONSET DISORDERS	FASEB JOURNAL			English	Review						HEREDITARY; GENETIC COUNSELING; GENETIC DECISION MAKING; PSYCHOSOCIAL REACTION TO GENETIC INFORMATION; NEURODEGENERATIVE DISEASE	DNA MARKERS; GENE; PREGNANCY	Huntington's disease represents the first disorder for which positional cloning techniques successfully localized an autosomal gene-in 1983. Events since that time have proved the gene recalcitrant to identification and characterization. Since 1986, presymptomatic and prenatal testing for Huntington's disease has been available internationally, although on a limited basis. Testing for Huntington's disease provides an excellent model for designing service programs for genetic testing for late-onset, fatal disorders, particularly when the gene is not yet in hand and no therapeutic intervention is possible. Special training and precautions must be in place before presymptomatic genetic testing should be offered.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY 10032	Columbia University	WEXLER, NS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032, USA.							BALL DM, 1992, FASEB J, V6; CONNEALLY PM, 1988, NUCLEIC ACID PROBES, P137; CONNEALLY PM, 1985, PROG CLIN BIOL RES, V77, P53; GILLIAM TC, 1987, CELL, V50, P565, DOI 10.1016/0092-8674(87)90029-8; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, 1991, AM J HUM GENET S62, V49; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; HAYDEN MR, 1987, LANCET, V1, P1284; HOLTZMAN NA, 1989, PROCEED CAUTION, V157; HUGGINS M, 1990, AM J HUM GENET, V47, P4; KAHNEMAN D, 1982, SCI AM, V246, P161; MACDONALD ME, 1989, J CLIN INVEST, V84, P1013, DOI 10.1172/JCI114222; MACDONALD ME, 1989, NEURON, V3, P183, DOI 10.1016/0896-6273(89)90031-7; MEISSEN GJ, 1991, AM J MED GENET, V39, P404, DOI 10.1002/ajmg.1320390408; QUAID KA, 1989, CLIN GENET, V36, P431; QUARRELL OWJ, 1987, LANCET, V1, P1281; SOPHOCLES, 1957, 8 GREAT TRAGEDIES, P65; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TYLER A, 1990, J MED GENET, V27, P488, DOI 10.1136/jmg.27.8.488; Wexler N., 1992, CODE CODES SCI SOCIA, P211; WEXLER NS, 1985, ARCH NEUROL-CHICAGO, V42, P20, DOI 10.1001/archneur.1985.04060010026009; WEXLER NS, 1991, GENETICS ETHICS HUMA; World Federation of Neurology, 1989, J NEUROL SCI, V94, P327; 1990, J MED GENET, V27, P34	24	50	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1992	6	10					2820	2825		10.1096/fasebj.6.10.1386047	http://dx.doi.org/10.1096/fasebj.6.10.1386047			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1386047				2022-12-28	WOS:A1992JD95400010
J	RUPP, H; ELIMBAN, V; DHALLA, NS				RUPP, H; ELIMBAN, V; DHALLA, NS			MODIFICATION OF SUBCELLULAR ORGANELLES IN PRESSURE-OVERLOADED HEART BY ETOMOXIR, A CARNITINE PALMITOYLTRANSFERASE-I INHIBITOR	FASEB JOURNAL			English	Article						HEART HYPERTROPHY; MYOSIN ISOZYMES; SARCOPLASMIC RETICULUM; CA2+-STIMULATED ATPASE; ETOMOXIR	RETICULUM CA-2+-PUMP ATPASE; FATTY-ACID OXIDATION; CARDIAC-HYPERTROPHY; SARCOPLASMIC-RETICULUM; GLUCOSE-METABOLISM; INSULIN RESISTANCE; HYPERTENSIVE RATS; MYOSIN ISOENZYMES; 2-TETRADECYLGLYCIDATE; PREVENTION	To examine the signals regulating cardiac growth and molecular structure of subcellular organelles, cardiac hypertrophy was induced in rats by constriction of the abdominal aorta for 12-13 wk or by treatment with a carnitine palmitoyltransferase I inhibitor, etomoxir (12-15 mg/kg body wt) for 12-13 wk. In contrast to pressure overload, etomoxir redistributed the myosin isozyme population from V3 to V1 and increased the sarcoplasmic reticulum (SR) Ca2+-stimulated ATPase activity. When rats with pressure-overloaded hearts were treated with etomoxir, the cardiac hypertrophy was increased whereas the shift in myosin isozymes from V1 to V3 was prevented and the depression in SR Ca2+-stimulated ATPase activity was reversed. Plasma thyroid hormone and insulin concentrations were not altered but triglyceride concentrations were reduced in etomoxir-treated rats with pressure overload. The data demonstrate a dissociation between cardiac muscle growth and changes in subcellular organelles and indicate that a shift in myocardial substrate utilization may represent an important signal for molecular remodeling of the heart.	ST BONIFACE GEN HOSP, DIV CARDIOVASC SCI, 351 TACHE AVE, WINNIPEG R2H 2A6, MANITOBA, CANADA; UNIV MANITOBA, FAC MED, DEPT PHYSIOL, WINNIPEG R2H 2A6, MANITOBA, CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba			Dhalla, Naranjan/C-8279-2014	Dhalla, Naranjan/0000-0002-4894-4727				AGIUS L, 1985, EUR J BIOCHEM, V152, P699, DOI 10.1111/j.1432-1033.1985.tb09250.x; Alder H, 1972, INTRO PROBABILITY ST; ALTO LE, 1981, CIRC RES, V48, P17, DOI 10.1161/01.RES.48.1.17; BRESSLER R, 1989, LIFE SCI, V44, P1897, DOI 10.1016/0024-3205(89)90401-3; BUTTRICK P, 1988, CIRC RES, V63, P173, DOI 10.1161/01.RES.63.1.173; DHALLA NS, 1982, BASIC RES CARDIOL, V77, P117, DOI 10.1007/BF01908167; DHALLA NS, 1978, J MOL CELL CARDIOL, V10, P363, DOI 10.1016/0022-2828(78)90384-X; DHALLA NS, 1984, EUR HEART J, V5, P323, DOI 10.1093/eurheartj/5.suppl_F.323; Dillmann W H, 1986, Adv Exp Med Biol, V194, P469; EISTETTER K, 1986, Drugs of the Future, V11, P1034; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; GUPTA M, 1989, CIRC RES, V64, P398, DOI 10.1161/01.RES.64.2.398; Higgins A J, 1985, Adv Myocardiol, V6, P329; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; KOUNDAKJIAN PP, 1984, BIOCHEM PHARMACOL, V33, P465, DOI 10.1016/0006-2952(84)90242-9; LECARPENTIER Y, 1987, CIRC RES, V61, P107, DOI 10.1161/01.RES.61.1.107; LEE SM, 1985, BIOCHEM MED METAB B, V33, P104, DOI 10.1016/0006-2944(85)90132-2; LEE SM, 1982, DIABETES, V31, P12, DOI 10.2337/diabetes.31.1.12; LIMAS CJ, 1980, J MOL CELL CARDIOL, V12, P1103, DOI 10.1016/0022-2828(80)90035-8; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; PANOS TC, 1953, J NUTR, V49, P397, DOI 10.1093/jn/49.3.397; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; Randle PJ, 1979, HDB PHYSL          2, P805, DOI DOI 10.1074/JBC.M306409200; ROSEN P, 1984, METABOLISM, V33, P177, DOI 10.1016/0026-0495(84)90132-X; ROSEN P, 1991, IN PRESS CARDIOVASCU; RUPP H, 1991, CIRC RES, V68, P1164, DOI 10.1161/01.RES.68.4.1164; RUPP H, 1990, J APPL PHYSIOL, V68, P973, DOI 10.1152/jappl.1990.68.3.973; RUPP H, 1989, BIOCHEM BIOPH RES CO, V164, P319, DOI 10.1016/0006-291X(89)91720-8; RUPP H, 1988, BIOCHEM BIOPH RES CO, V156, P917, DOI 10.1016/S0006-291X(88)80931-8; RUPP H, 1989, CIRC RES, V65, P370, DOI 10.1161/01.RES.65.2.370; RUPP H, 1990, DEV CARDIOVASC MED, P135; RUPP H, 1991, IN PRESS BASIC RES S; SCHEUER J, 1982, J CLIN INVEST, V70, P1300, DOI 10.1172/JCI110729; SELBY PL, 1989, TRENDS PHARMACOL SCI, V10, P495, DOI 10.1016/0165-6147(89)90049-7; SHERRATT HSA, 1983, BIOCHEM BIOPH RES CO, V117, P653, DOI 10.1016/0006-291X(83)91646-7; SRETER FA, 1982, ARCH INT PHARMACOD T, V260, P159; UMEDA PK, 1987, AM J CARDIOL, V59, pA49, DOI 10.1016/0002-9149(87)90176-7; VAARTJES WJ, 1986, BIOCHEM PHARMACOL, V35, P4267, DOI 10.1016/0006-2952(86)90705-7; WIKMANCOFFELT J, 1979, CIRC RES, V45, P697, DOI 10.1161/01.RES.45.6.697; WOLF HPO, 1985, EUR J BIOCHEM, V146, P359, DOI 10.1111/j.1432-1033.1985.tb08661.x; WOLF HPO, 1982, DIABETOLOGIA, V22, P456, DOI 10.1007/BF00282590; Zak R., 1984, GROWTH HEART HLTH DI	42	69	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1992	6	6					2349	2353		10.1096/fasebj.6.6.1531968	http://dx.doi.org/10.1096/fasebj.6.6.1531968			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1531968				2022-12-28	WOS:A1992HJ25200013
J	FISHER, CW; CAUDLE, DL; MARTINWIXTROM, C; QUATTROCHI, LC; TUKEY, RH; WATERMAN, MR; ESTABROOK, RW				FISHER, CW; CAUDLE, DL; MARTINWIXTROM, C; QUATTROCHI, LC; TUKEY, RH; WATERMAN, MR; ESTABROOK, RW			HIGH-LEVEL EXPRESSION OF FUNCTIONAL HUMAN CYTOCHROME-P450 1A2 IN ESCHERICHIA-COLI	FASEB JOURNAL			English	Note						CYTOCHROME-P450; ESCHERICHIA-COLI EXPRESSION; ESTRADIOL HYDROXYLATION; 1A2; O-DEETHYLATION	BOVINE GROWTH-HORMONE; SACCHAROMYCES-CEREVISIAE; O-DEALKYLATION; MESSENGER-RNA; CDNA; ACTIVATION; METABOLISM	Enzymatically active human cytochrome P450 1A2 was expressed in Escherichia coli utilizing the pCWori+ vector containing a modified cDNA. The coding sequence for the NH2-terminal region of the protein was modified by the alignment and substitution of a 27 bp segment from a modified bovine P450 17A1 cDNA onto the 5' end of the open reading frame of P450 1A2 at amino acid 21. The expressed chimeric P450 was produced at a high level in a functionally intact form, as assayed by the formation in vivo of the 449 nm absorbance band of the CO complex of the reduced hemoprotein. E. coli membrane preparations were shown to contain P450 1A2, which was active in the 2-hydroxylation of estradiol, and the O-deethylation of 7-ethoxycoumarin and 7-ethoxyresorufin, when reconstituted with recombinant rat liver NADPH-cytochrome P450 reductase.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV CALIF SAN DIEGO, CTR CANC, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, DEPT MED, LA JOLLA, CA 92093 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego; University of California System; University of California San Diego					NIGMS NIH HHS [GM36590, NIGMS 16488] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1989, MOL CARCINOGEN, V2, P192, DOI 10.1002/mc.2940020405; AOYAMA T, 1990, ENDOCRINOLOGY, V126, P3101, DOI 10.1210/endo-126-6-3101; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P4790, DOI 10.1073/pnas.87.12.4790; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; BUCHELER US, 1990, GENE, V96, P271, DOI 10.1016/0378-1119(90)90263-Q; BURKE MD, 1974, DRUG METAB DISPOS, V2, P583; CHING MS, 1991, BIOCHEM PHARMACOL, V42, P753, DOI 10.1016/0006-2952(91)90032-Z; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; GEORGE HJ, 1985, DNA-J MOLEC CELL BIO, V4, P273, DOI 10.1089/dna.1985.4.273; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LI YC, 1991, J BIOL CHEM, V266, P19186; LIU G, 1991, ARCH BIOCHEM BIOPHYS, V284, P400, DOI 10.1016/0003-9861(91)90315-A; MACDONALD PC, 1966, STEROIDS, V8, P589, DOI 10.1016/0039-128X(66)90001-8; MCMANUS ME, 1990, CANCER RES, V50, P3367; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; SAMI AJ, 1990, BIOCHEM SOC T, V18, P567, DOI 10.1042/bst0180567; SCHONER BE, 1984, P NATL ACAD SCI-BIOL, V81, P5403, DOI 10.1073/pnas.81.17.5403; SESARDIC D, 1990, BIOCHEM PHARMACOL, V39, P499, DOI 10.1016/0006-2952(90)90056-Q; SHEN LA, 1987, J BIOL CHEM, V264, P7584; TARTOF KD, 1987, FOCUS, V9, P12; ULLRICH V, 1972, H-S Z PHYSIOL CHEM, V353, P1171, DOI 10.1515/bchm2.1972.353.2.1171; WATSON N, 1990, GENE, V86, P137, DOI 10.1016/0378-1119(90)90272-S; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	28	116	120	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN 6	1992	6	2					759	764		10.1096/fasebj.6.2.1537466	http://dx.doi.org/10.1096/fasebj.6.2.1537466			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537466				2022-12-28	WOS:A1992GZ44000019
J	JOHNSON, HM; RUSSELL, JK; PONTZER, CH				JOHNSON, HM; RUSSELL, JK; PONTZER, CH			STAPHYLOCOCCAL-ENTEROTOXIN MICROBIAL SUPERANTIGENS	FASEB JOURNAL			English	Article						STAPHYLOCOCCAL ENTEROTOXIN; SUPERANTIGEN; T-CELL RECEPTOR; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II MOLECULE; MINOR LYMPHOCYTE STIMULATING (MLS) ANTIGEN	CLASS-II MOLECULES; RECEPTOR BETA-CHAIN; HUMAN T-CELLS; HUMAN PERIPHERAL LYMPHOCYTES; SHOCK SYNDROME TOXIN-1; HIGH-AFFINITY BINDING; HLA-DR; MONOCLONAL-ANTIBODIES; STRUCTURAL-ANALYSIS; CLONAL DELETION	Staphylococcal enterotoxins are a family of structurally related proteins that are produced by Staphylococcus aureus. In addition to their role in the pathogenicity of food poisoning, these microbial superantigens have profound effects on the immune system, which makes them useful tools for understanding its mechanism of action. These molecules (24-30 kDa) are highly hydrophilic and exhibit low alpha-helix and high-beta pleated sheet content, suggesting a flexible, accessible structure. Staphylococcal enterotoxins are among the most potent activators of T lymphocytes known. The receptors for staphylococcal enterotoxins on antigen-presenting cells are major histocompatibility complex (MHC) class II molecules. Further, the alpha-helical regions of the class II molecule are essential for function and appear to interact directly with the NH2-terminal region of staphylococcal enterotoxins such as SEA. Recent studies have shown that a complex of staphylococcal enterotoxin and MHC class II molecules is required for binding to the V-beta-region of the T cell antigen receptor. Staphylococcal enterotoxin mitogenic activity is dependent on induction of interleukin 2, which may be intimately involved in the mechanism of toxicity. The mouse minor lymphocyte stimulating (Mls) "endogenous" self-superantigen has been shown to be a retroviral gene product, so this too is apparently a microbial superantigen. An understanding of the mechanism of action of these microbial superantigens has implications for normal and pathological immune functions.			JOHNSON, HM (corresponding author), UNIV FLORIDA,DEPT MICROBIOL & CELL SCI,GAINESVILLE,FL 32611, USA.				NIAID NIH HHS [AI 25904] Funding Source: Medline; PHS HHS [4910 2908415-11] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025904, R37AI025904] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBER G, 1990, J IMMUNOL, V144, P4501; BEERY JT, 1984, INFECT IMMUN, V44, P234, DOI 10.1128/IAI.44.2.234-240.1984; Bergdoll M. S., 1983, STAPHYLOCOCCI STAPHY, V2, P559; BERGDOLL MS, 1971, INFECT IMMUN, V4, P593, DOI 10.1128/IAI.4.5.593-595.1971; Bergdoll MS., 1985, STAPHYLOCOCCI, P247; BETLEY MJ, 1988, J BACTERIOL, V170, P34, DOI 10.1128/jb.170.1.34-41.1988; BLOMSTERHAUTAMAA DA, 1986, J IMMUNOL, V137, P3572; BOHACH GA, 1988, INFECT IMMUN, V57, P23; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CARLSSON R, 1988, J IMMUNOL, V140, P2484; CARLSSON R, 1985, CELL IMMUNOL, V96, P175, DOI 10.1016/0008-8749(85)90349-1; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FISCHER H, 1990, J IMMUNOL, V144, P4663; FISCHER H, 1989, J IMMUNOL, V142, P3151; FLEISCHER B, 1991, J IMMUNOL, V146, P11; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GASCOIGNE NRJ, 1990, J BIOL CHEM, V265, P9296; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GROSSMAN D, 1990, J EXP MED, V172, P1831, DOI 10.1084/jem.172.6.1831; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; IANDOLO JJ, 1989, ANNU REV MICROBIOL, V43, P375, DOI 10.1146/annurev.micro.43.1.375; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JOHNSON H M, 1975, IRCS (International Research Communications System) Medical Science Library Compendium, V3, P398; JOHNSON HM, 1988, INT ARCH ALLER A IMM, V87, P87, DOI 10.1159/000234654; JOHNSON HM, 1972, INFECT IMMUN, V5, P645, DOI 10.1128/IAI.5.5.645-647.1972; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; KOBANMOORE NP, 1989, REV INFECT DIS, V11, pS125; LANGFORD MP, 1978, INFECT IMMUN, V22, P62, DOI 10.1128/IAI.22.1.62-68.1978; LEE JM, 1990, J IMMUNOL, V145, P3360; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MIDDLEBROOK JL, 1980, BIOCHIM BIOPHYS ACTA, V621, P233, DOI 10.1016/0005-2795(80)90175-0; MOLLICK JA, 1991, J IMMUNOL, V146, P463; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; MUNOZ PA, 1976, BIOCHEMISTRY-US, V15, P4666, DOI 10.1021/bi00666a019; NOSKOVA VP, 1984, INT J BIOCHEM, V16, P201, DOI 10.1016/0020-711X(84)90073-9; PEAVY DL, 1970, J IMMUNOL, V105, P1453; PONTZER CH, 1991, P NATL ACAD SCI USA, V88, P125, DOI 10.1073/pnas.88.1.125; PONTZER CH, 1989, J IMMUNOL, V143, P280; PONTZER CH, 1990, INT ARCH ALLER A IMM, V93, P107, DOI 10.1159/000235288; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; RECK B, 1988, P NATL ACAD SCI USA, V85, P3170, DOI 10.1073/pnas.85.9.3170; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; RUSSELL JK, 1990, BIOCHEM BIOPH RES CO, V168, P696, DOI 10.1016/0006-291X(90)92377-C; RUSSELL JK, 1991, P NATL ACAD SCI USA, V88, P7228, DOI 10.1073/pnas.88.16.7228; RUST CJJ, 1990, NATURE, V346, P572, DOI 10.1038/346572a0; SCHEUBER PH, 1987, INT ARCH ALLER A IMM, V82, P289, DOI 10.1159/000234209; SCHIMMEL P, 1990, BIOCHEMISTRY-US, V29, P9495, DOI 10.1021/bi00493a001; SCHOLL PR, 1990, J IMMUNOL, V144, P226; SINGH BR, 1988, BIOCHEMISTRY-US, V27, P8735, DOI 10.1021/bi00424a008; SINGH BR, 1989, J BIOL CHEM, V264, P4404; SINGH BR, 1988, BIOCHEMISTRY-US, V27, P8730, DOI 10.1021/bi00424a007; SMITH BG, 1975, J IMMUNOL, V115, P575; SPERO L, 1978, J BIOL CHEM, V253, P8787; SPERO L, 1973, J BIOL CHEM, V248, P7289; SPERO L, 1979, J IMMUNOL, V122, P1285; THOMPSON NE, 1984, INFECT IMMUN, V45, P281, DOI 10.1128/IAI.45.1.281-285.1984; VROEGOP SM, 1989, INFECT IMMUN, V57, P1816, DOI 10.1128/IAI.57.6.1816-1824.1989; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	69	99	104	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2706	2712		10.1096/fasebj.5.12.1916093	http://dx.doi.org/10.1096/fasebj.5.12.1916093			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916093	Bronze			2022-12-28	WOS:A1991GE81100012
J	NARA, PL; GARRITY, RR; GOUDSMIT, J				NARA, PL; GARRITY, RR; GOUDSMIT, J			NEUTRALIZATION OF HIV-1 - A PARADOX OF HUMORAL PROPORTIONS	FASEB JOURNAL			English	Review						ENVELOPE PLASTICITY; IMMUNOGENICITY; V3 EPITOPE; ONTOGENY OF B-CELLS; ANTIGENIC VARIATION; CLONAL DOMINANCE; CROSS REACTIVITY; LAW OF MASS ACTION	HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTIOUS-ANEMIA VIRUS; PURIFIED ENVELOPE GLYCOPROTEINS; ENCODED SYNTHETIC PEPTIDES; RETROVIRUSES HTLV-III; MOUTH-DISEASE VIRUS; IMMUNE-RESPONSE; MONOCLONAL-ANTIBODIES; PERSISTENT INFECTION; OLIGOMERIC STRUCTURE	The production of immunoglobulin capable of neutralizing the infectivity of a virus represents one of the most remarkable molecular accomplishments of the host's available immune defenses. It should be no surprise that a virus that has existed in the parenchyma of the immune system has evolved as an equally dynamic molecule (i.e., viral envelope) for survival. Neutralizing immunoglobulin (Ig) can best serve the host under conditions where the invading pathogen requires a well-defined cell-free state for establishing an infection or transmission. Evidence for a controlling and therefore protective role of neutralizing Ig against lentiviruses has been defined in natural and experimental infections with equine infectious anemia virus of ungulate members in the family equidae. Rapid replication of the virus immediately after infection and its release in a cell-free state leads to the production of neutralizing Ig and subsequent control of the primary viremia. A similar cause-effect relationship exists in humans between the high-titered viremia, observed shortly after HIV-1 infection, and the subsequent production of neutralizing Ig. Partially controlling this acute stage of viral replication by neutralizing Ig and thus preventing an otherwise acute form of immunosuppression or immune complex disease may be viewed paradoxically as a survival property of the virus. Immunologically mediated control, in a Darwinian sense, selects for viruses that have optimized the parameters of longevity and transmission from host to host. This paradox of neutralization in HIV-1 infection appears to be mediated by the convergence of structural and functional roles of the third variable domain (V3) of the external envelope glycoprotein. During infection or envelope-based vaccination, antibody to this cross-reactive, immunodominant epitope dominates the antigenic repertoire. Once this occurs, the host is less able to respond to emerging viruses containing closely related V3 structures. Thus a relatively restricted clonal-dominance of the neutralization response results. The V3 domain, apparently in concert with the rest of the molecule, provides an epitope that can tolerate and utilize its conformational flexibility to allow immune escape while maintaining its functional role in infectivity. Sixteen other putative epitopes have been described as being involved in the induction of neutralizing Ig. Currently the biologically functional role of neutralizing Ig to these other epitopes are complicated by a prior lack of knowledge and appreciation of the in vitro variables affecting their measurements. Thus it appears that the mechanisms of neutralization, the immunologic complexities of the viral envelope, and the design of in vitro assays to more accurately reflect in vivo conditions should greatly improve our future chances of designing, identifying, and eliciting protective immune responses through vaccination.	UNIV AMSTERDAM, ACAD MED CTR, HUMAN RETROVIRUS LAB, 1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	NARA, PL (corresponding author), NCI, FREDERICK CANC RES & DEV CTR,VIRUS BIOL SECT, TUMOR CELL BIOL LAB,BLDG 560, ROOM 12-92, FREDERICK, MD 21702 USA.		Dr. Peter L. Nara, M.Sc./I-7432-2019					ALBERT J, 1987, J MED VIROL, V23, P67, DOI 10.1002/jmv.1890230108; ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; ALBERT J, 1990, UCLA S MOL CELL D S, V14, P163; ANGELOVA LA, 1982, IMMUNOLOGY, V46, P183; BACK NKT, 1990, J MED VIROL, V31, P200, DOI 10.1002/jmv.1890310306; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BLANK SE, 1972, J IMMUNOL, V108, P665; BLONDEL B, 1986, J VIROL, V57, P81, DOI 10.1128/JVI.57.1.81-90.1986; BOURINBAIAR AS, 1991, NATURE, V349, P111, DOI 10.1038/349111b0; BRILES DE, 1980, J EXP MED, V152, P151, DOI 10.1084/jem.152.1.151; CARPENTER S, 1987, J VIROL, V61, P3783, DOI 10.1128/JVI.61.12.3783-3789.1987; Cease K B, 1990, Int Rev Immunol, V7, P85, DOI 10.3109/08830189009061767; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DAVID JR, 1990, HOST PARASITE INTERF, P117; DAY ED, 1990, AFFINITY, P469; DESTGROTH SF, 1962, ADV VIRUS RES, V9, P1; DIMMOCK NJ, 1984, J GEN VIROL, V65, P1015, DOI 10.1099/0022-1317-65-6-1015; DOBSON CM, 1990, NATURE, V348, P198, DOI 10.1038/348198a0; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; FENNER F, 1974, BIOL ANIMAL VIRUSES, P417; FRANCIS T, 1953, ANN INTERN MED, V39, P203, DOI 10.7326/0003-4819-39-2-203; GAINES H, 1987, LANCET, V1, P1317; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GELDERBLOM HR, 1985, LANCET, V2, P1016; GELDERBLOM HR, 1988, MICRON MICROSC ACTA, V19, P41, DOI 10.1016/0739-6260(88)90039-1; GORMAN JJ, 1990, VIROLOGY, V177, P339, DOI 10.1016/0042-6822(90)90489-E; GOUDSMIT J, 1988, AIDS, V2, P157; GOUDSMIT J, 1988, AIDS, V2, pS41, DOI 10.1097/00002030-198800001-00006; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GOUDSMIT J, 1989, AIDS, V3, pS119, DOI 10.1097/00002030-198901001-00017; GOUDSMIT J, 1991, FASEB J, V5, P2427, DOI 10.1096/fasebj.5.10.2065891; GOUDSMIT J, 1988, P UCLA S HUMAN RETRO, P241; GOUDSMIT J, 1990, 5 C CENT GARD, P73; HAIGWOOD NL, 1990, MODERN APPROACHES NE, P8; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; HORNICK CL, 1972, IMMUNOCHEMISTRY, V9, P325, DOI 10.1016/0019-2791(72)90096-1; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KANG CY, 1991, IN PRESS P NATL ACAD; KATZENSTEIN DA, 1990, J ACQ IMMUN DEF SYND, V3, P810; KENNEDYSTOSKOPF S, 1986, J VIROL, V59, P37, DOI 10.1128/JVI.59.1.37-44.1986; KENNY AJ, 1987, MAMMALIAN ECTOENZYME, P168; KIDO H, 1990, J BIOL CHEM, V265, P21979; Koito A, 1989, Int Immunol, V1, P613, DOI 10.1093/intimm/1.6.613; KONO Y, 1973, ARCH GES VIRUSFORSCH, V41, P1, DOI 10.1007/BF01249923; KONO Y, 1971, ARCH GES VIRUSFORSCH, V34, P202, DOI 10.1007/BF01242993; KONO Y, 1969, NATL I ANIM HEALTH Q, V9, P1; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LAURENCE J, 1990, IMMUNOLOGY, V70, P338; LAYNE SP, 1991, J VIROL, V65, P3293, DOI 10.1128/JVI.65.6.3293-3300.1991; LAYNE SP, 1990, NATURE, V346, P277, DOI 10.1038/346277a0; LAYNE SP, 1990, MODERN APPROACHES NE, P30; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LOONEY DJ, 1988, SCIENCE, V241, P357, DOI 10.1126/science.3388046; Mandel B, 1978, Adv Virus Res, V23, P205, DOI 10.1016/S0065-3527(08)60101-3; MANDEL B, 1979, COMPREHENSIVE VIROLO, V15, P37; MCCAHON D, 1989, J GEN VIROL, V70, P639, DOI 10.1099/0022-1317-70-3-639; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; MCKEATING JA, 1989, RETROVIRUSES HUMAN A, P195; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; MOORE JP, 1991, J VIROL, V65, P1133, DOI 10.1128/JVI.65.3.1133-1140.1991; NARA P, 1990, DEV BIOLOGICALS, V72, P315; NARA PL, 1988, J VIROL, V62, P2622, DOI 10.1128/JVI.62.8.2622-2628.1988; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; NARA PL, 1987, J VIROL, V61, P3173, DOI 10.1128/JVI.61.10.3173-3180.1987; NARA PL, 1989, RETROVIRUSES HUMAN A, P203; NARA PL, 1990, VACCINES, V90, P297; NARA PL, 1991, VACCINES 91 MODERN A, P1; NARA PL, 1988, RETROVIRUSES HUMAN A, P138; NARA PL, 1989, VACCINES 89 MODERN A, P137; NARAYAN O, 1978, J GEN VIROL, V41, P343, DOI 10.1099/0022-1317-41-2-343; NARAYAN O, 1988, MICROB PATHOGENESIS, V5, P149, DOI 10.1016/0882-4010(88)90017-4; NEURATH AR, 1990, J GEN VIROL, V71, P85, DOI 10.1099/0022-1317-71-1-85; NEURATH AR, 1990, MOL IMMUNOL, V27, P539, DOI 10.1016/0161-5890(90)90073-9; NICOLAISENSTROUSS K, 1987, J VIROL, V61, P3410, DOI 10.1128/JVI.61.11.3410-3415.1987; NIEDRIG M, 1989, J VIROL, V63, P3525, DOI 10.1128/JVI.63.8.3525-3528.1989; NOVOTNY J, 1987, IMMUNOL TODAY, V8, P26, DOI 10.1016/0167-5699(87)90828-0; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; PERRYMAN LE, 1988, J VIROL, V62, P3073, DOI 10.1128/JVI.62.8.3073-3076.1988; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PROFY AT, 1990, J IMMUNOL, V144, P4641; PYLE SW, 1989, VACCINE, V7, P465, DOI 10.1016/0264-410X(89)90164-3; READ RJ, 1986, RES MONOGRAPHS CELL, V12, P301; ROBERTGUROFF M, 1985, NATURE, V316, P72, DOI 10.1038/316072a0; ROBERTGUROFF M, 1986, J IMMUNOL, V137, P3306; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; ROBEY WG, 1986, P NATL ACAD SCI USA, V83, P7023, DOI 10.1073/pnas.83.18.7023; RONCO J, 1991, AIDS RES HUM RETROV, V7, P1; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SALINOVICH O, 1986, J VIROL, V57, P71, DOI 10.1128/JVI.57.1.71-80.1986; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; SCHAWALLER M, 1989, VIROLOGY, V172, P367, DOI 10.1016/0042-6822(89)90142-6; SCHNEIDER J, 1986, J GEN VIROL, V67, P2533, DOI 10.1099/0022-1317-67-11-2533; STANLEY J, 1987, J VIROL, V61, P1019, DOI 10.1128/JVI.61.4.1019-1028.1987; STERNBERG GM, 1982, T ASSOC AM PHYSICIAN, V7, P67; TREMBLAY M, 1990, J INFECT DIS, V162, P735, DOI 10.1093/infdis/162.3.735; WEISS RA, 1986, NATURE, V324, P572, DOI 10.1038/324572a0; WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0; WHITE JR, 1990, J GEN VIROL, V71, P1325, DOI 10.1099/0022-1317-71-6-1325; WILLEY RL, 1989, J VIROL, V63, P3595, DOI 10.1128/JVI.63.9.3595-3600.1989; WIMMER E, 1986, CONCEPTS CLIN PATHOG, V2, P159; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; ZWART G, 1990, LANCET, V335, P473	109	172	184	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2437	2455		10.1096/fasebj.5.10.1712328	http://dx.doi.org/10.1096/fasebj.5.10.1712328			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	1712328	Bronze			2022-12-28	WOS:A1991FW08700015
J	ALBRIGHT, JF; OPPENHEIM, JJ				ALBRIGHT, JF; OPPENHEIM, JJ			CONTRIBUTIONS OF BASIC IMMUNOLOGY TO HUMAN HEALTH	FASEB JOURNAL			English	Article						MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; HEMATOPOIETIC STEM CELL; CELL ADHESION MOLECULE; LYMPHOCYTE HOMING RECEPTOR; AUTOIMMUNITY; CHIMERIC INTERFERONS; TRANSFORMING GROWTH FACTOR; COLONY STIMULATING FACTOR		The sixth symposium in the series "Contemporary Topics in Immunology" was held in New Orleans on June 3, 1990, at the joint meeting of The American Association of Immunologists and the American Society of Biochemistry and Molecular Biology. The symposium was sponsored jointly by The American Association of Immunologists, the Clinical Immunology Society, and the National Institute of Allergy and Infectious Diseases, and was titled "The Contributions of Basic Immunology to Human Health." Five speakers, whose research has clear relevance to the treatment and prevention of major human diseases, discussed topics of great current interest: hematopoietic stem cells, cell adhesion and lymphocyte homing; the complexities of autoimmunity and approaches to diverting or depressing autoaggressive immunity; structure and functions of the interferons and the construction of designer and chimeric interferons; the varied functions of transforming growth factors and molecular events that regulate the synthesis of TGF-beta; and the roles of cytokines in the expression of human immuno-deficiency virus and the prospects for controlling HIV infections by regulating selected cytokines. This symposium will be remembered for the exceptional clarity with which each speaker illustrated how fundamental knowledge in immunology fuels advances in the treatment and prevention of those human disorders that involve the immune system.	NCI,FREDERICK CANC RES FACIL,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ALBRIGHT, JF (corresponding author), NIAID,DIV ALLERGY IMMUNOL & TRANSPLANTAT,BASIC IMMUNOL BRANCH,BETHESDA,MD 20892, USA.								0	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					265	270		10.1096/fasebj.5.3.1705905	http://dx.doi.org/10.1096/fasebj.5.3.1705905			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	1705905				2022-12-28	WOS:A1991FC55600002
J	LOLLEY, RN; LEE, RH				LOLLEY, RN; LEE, RH			CYCLIC-GMP AND PHOTORECEPTOR FUNCTION	FASEB JOURNAL			English	Article									VET ADM MED CTR,NEUROL LAB,SEPULVEDA,CA 91343	US Department of Veterans Affairs; Veterans Health Administration (VHA)	LOLLEY, RN (corresponding author), UNIV CALIF LOS ANGELES,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024, USA.							APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; FLEISCHMAN D, 1979, BIOCHEMISTRY-US, V18, P5060, DOI 10.1021/bi00590a006; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HAGINS WA, 1970, BIOPHYS J, V10, P380, DOI 10.1016/S0006-3495(70)86308-1; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HO Y-K, 1990, Investigative Ophthalmology and Visual Science, V31, P215; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LIEBMAN PA, 1979, VISION RES, V19, P37; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PAJARES MA, 1989, J BIOL CHEM, V264, P6804; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PFISTER C, 1985, SCIENCE, V228, P891, DOI 10.1126/science.2988124; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	39	56	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1990	4	12					3001	3008		10.1096/fasebj.4.12.1697545	http://dx.doi.org/10.1096/fasebj.4.12.1697545			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DY288	1697545				2022-12-28	WOS:A1990DY28800006
J	WELSH, MJ				WELSH, MJ			ABNORMAL REGULATION OF ION CHANNELS IN CYSTIC-FIBROSIS EPITHELIA	FASEB JOURNAL			English	Review									UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa	WELSH, MJ (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029851, R37HL029851, P50HL042385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42385, HL 29851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1989, CLIN RES, V37, pA917; ANDERSON MP, 1990, IN PRESS AM J PHYSL; ANDERSON MP, 1990, IN PRESS P NATL ACAD; BARTHELSON R, 1987, J CLIN INVEST, V80, P1799, DOI 10.1172/JCI113274; BARTHELSON RA, 1987, AM J PHYSIOL, V253, pC802, DOI 10.1152/ajpcell.1987.253.6.C802; BEAR CE, 1988, FEBS LETT, V237, P145, DOI 10.1016/0014-5793(88)80189-3; BIJMAN J, 1987, CELLULAR MOL BASIS C, P133; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CLANCY JP, 1989, CLIN RES, V37, pA918; CLANCY JP, 1990, AM J PHYSIOL, V258, pL25, DOI 10.1152/ajplung.1990.258.2.L25; DISSER J, 1989, PEDIATR PULM S, V4, P115; DUSZYK M, 1989, CAN J PHYSIOL PHARM, V67, P1362, DOI 10.1139/y89-217; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; HAGIWARA G, 1989, SCIENCE, V246, P1049, DOI 10.1126/science.2479979; HALM DR, 1988, AM J PHYSIOL, V254, pC505, DOI 10.1152/ajpcell.1988.254.4.C505; HANRAHAN JW, 1989, BICARBONATE CHLORIDE, V574, P30; HAYSLETT JP, 1987, PFLUG ARCH EUR J PHY, V410, P487, DOI 10.1007/BF00586530; HWANG TC, 1990, BIOPHYS J, V57, pA88; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JORIS L, 1989, PFLUG ARCH EUR J PHY, V414, P369, DOI 10.1007/BF00584641; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KROUSE ME, 1989, AM J PHYSIOL, V257, pC129, DOI 10.1152/ajpcell.1989.257.1.C129; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V415, P172, DOI 10.1007/BF00370589; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V414, P297, DOI 10.1007/BF00584630; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LEW TS, 1989, PED PULMONOL S, V4, P117; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LI M, 1990, IN PRESS AM J PHYSL; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TILLY BC, 1989, PEDIATR PULM S, V4, P124; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391; WELSH MJ, 1987, AM J PHYSIOL, V253, pC828, DOI 10.1152/ajpcell.1987.253.6.C828; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1985, P NATL ACAD SCI USA, V82, P8823, DOI 10.1073/pnas.82.24.8823; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WIDDICOMBE JH, 1986, AM J PHYSIOL, V251, pR818, DOI 10.1152/ajpregu.1986.251.4.R818; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226	48	239	247	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1990	4	10					2718	2725		10.1096/fasebj.4.10.1695593	http://dx.doi.org/10.1096/fasebj.4.10.1695593			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DP783	1695593				2022-12-28	WOS:A1990DP78300006
J	CHIQUETEHRISMANN, R				CHIQUETEHRISMANN, R			WHAT DISTINGUISHES TENASCIN FROM FIBRONECTIN	FASEB JOURNAL			English	Review											CHIQUETEHRISMANN, R (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.							AUFDERHEIDE E, 1988, J CELL BIOL, V107, P1341; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BOURDON MA, 1983, CANCER RES, V43, P2796; BRONNERFRASER M, 1988, J NEUROSCI RES, V21, P135, DOI 10.1002/jnr.490210206; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUET M, 1989, DEV NEUROSCI-BASEL, V11, P266, DOI 10.1159/000111905; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DANILOFF JK, 1989, J CELL BIOL, V108, P625, DOI 10.1083/jcb.108.2.625; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; ERICKSON HP, 1988, ADV CELL BIOL, V2, P55; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GROBSTEIN C, 1954, ASPECTS SYNTHESIS OR, P233; GRUMET M, 1985, P NATL ACAD SCI USA, V82, P8075, DOI 10.1073/pnas.82.23.8075; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HURLE JM, 1989, CELL DIFFER DEV, V27, P103, DOI 10.1016/0922-3371(89)90740-5; INAGUMA Y, 1988, DEV BIOL, V128, P245, DOI 10.1016/0012-1606(88)90288-6; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KOYAMA T, 1987, P NATL ACAD SCI USA, V84, P1609, DOI 10.1073/pnas.84.6.1609; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MACKIE EJ, 1987, J CELL BIOL, V105, P2569, DOI 10.1083/jcb.105.6.2569; McDonald JA, 1989, CURR OPIN CELL BIOL, V1, P995, DOI 10.1016/0955-0674(89)90071-9; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; RIOU JF, 1990, DEV BIOL, V137, P305, DOI 10.1016/0012-1606(90)90256-I; RUEGG CR, 1989, P NATL ACAD SCI USA, V86, P7437, DOI 10.1073/pnas.86.19.7437; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STEINDLER DA, 1989, DEV BIOL, V131, P243, DOI 10.1016/S0012-1606(89)80056-9; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAUGHAN L, 1987, EMBO J, V6, P349, DOI 10.1002/j.1460-2075.1987.tb04761.x; YAMADA KM, 1975, P NATL ACAD SCI USA, V72, P3158, DOI 10.1073/pnas.72.8.3158	43	215	218	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1990	4	9					2598	2604		10.1096/fasebj.4.9.1693347	http://dx.doi.org/10.1096/fasebj.4.9.1693347			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DJ088	1693347				2022-12-28	WOS:A1990DJ08800003
J	REINHOLD, SL; PRESCOTT, SM; ZIMMERMAN, GA; MCINTYRE, TM				REINHOLD, SL; PRESCOTT, SM; ZIMMERMAN, GA; MCINTYRE, TM			ACTIVATION OF HUMAN NEUTROPHIL PHOSPHOLIPASE-D BY 3 SEPARABLE MECHANISMS	FASEB JOURNAL			English	Article									UNIV UTAH,NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INST,SALT LAKE CITY,UT 84112; UNIV UTAH,NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INST,DEPT MED,SALT LAKE CITY,UT 84112; UNIV UTAH,NORA ECCLES HARRISON CARDIOVASC RES & TRAINING INST,DEPT BIOCHEM,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL35828, HL34127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828, R01HL034127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGWU DE, 1989, J BIOL CHEM, V264, P1405; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BASS DA, 1989, J BIOL CHEM, V264, P19610; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; DEWALD B, 1988, J BIOL CHEM, V263, P16179; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HAROLDSEN PE, 1987, J LIPID RES, V28, P42; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; IMAGAWA W, 1989, P NATL ACAD SCI USA, V86, P4122, DOI 10.1073/pnas.86.11.4122; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; NISHIHIRA J, 1986, BIOCHEM BIOPH RES CO, V134, P587, DOI 10.1016/S0006-291X(86)80460-0; PAI JK, 1988, J BIOL CHEM, V263, P12472; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PREISS J, 1986, J BIOL CHEM, V261, P8597; SIEGMANN DW, 1987, BIOCHEM BIOPH RES CO, V145, P228, DOI 10.1016/0006-291X(87)91310-6; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; WIESINGE.D, 1974, EXPERIENTIA, V30, P135, DOI 10.1007/BF01927691; YANG SF, 1967, J BIOL CHEM, V242, P477; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; [No title captured]	32	233	236	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1990	4	2					208	214		10.1096/fasebj.4.2.2105252	http://dx.doi.org/10.1096/fasebj.4.2.2105252			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CM418	2105252				2022-12-28	WOS:A1990CM41800010
J	Tippett, VL; Tattersall, L; Ab Latif, NB; Shah, KM; Lawson, MA; Gartland, A				Tippett, Victoria L.; Tattersall, Luke; Ab Latif, Norain B.; Shah, Karan M.; Lawson, Michelle A.; Gartland, Alison			The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review	ONCOGENE			English	Review; Early Access							P-GLYCOPROTEIN EXPRESSION; HIGH-GRADE OSTEOSARCOMA; DOXORUBICIN-RESISTANCE; CELL-LINES; NEOADJUVANT CHEMOTHERAPY; METHOTREXATE RESISTANCE; CISPLATIN RESISTANCE; PROGNOSTIC-FACTORS; DIHYDROFOLATE-REDUCTASE; DOWN-REGULATION	Over the last 40 years osteosarcoma (OS) survival has stagnated with patients commonly resistant to neoadjuvant MAP chemotherapy involving high dose methotrexate, adriamycin (doxorubicin) and platinum (cisplatin). Due to the rarity of OS, the generation of relevant cell models as tools for drug discovery is paramount to tackling this issue. Four literature databases were systematically searched using pre-determined search terms to identify MAP resistant OS cell lines and patients. Drug exposure strategies used to develop cell models of resistance and the impact of these on the differential expression of resistance associated genes, proteins and non-coding RNAs are reported. A comparison to clinical studies in relation to chemotherapy response, relapse and metastasis was then made. The search retrieved 1891 papers of which 52 were relevant. Commonly, cell lines were derived from Caucasian patients with epithelial or fibroblastic subtypes. The strategy for model development varied with most opting for continuous over pulsed chemotherapy exposure. A diverse resistance level was observed between models (2.2-338 fold) with 63% of models exceeding clinically reported resistance levels which may affect the expression of chemoresistance factors. In vitro p-glycoprotein overexpression is a key resistance mechanism; however, from the available literature to date this does not translate to innate resistance in patients. The selection of models with a lower fold resistance may better reflect the clinical situation. A comparison of standardised strategies in models and variants should be performed to determine their impact on resistance markers. Clinical studies are required to determine the impact of resistance markers identified in vitro in poor responders to MAP treatment, specifically with respect to innate and acquired resistance. A shift from seeking disputed and undruggable mechanisms to clinically relevant resistance mechanisms may identify key resistance markers that can be targeted for patient benefit after a 40-year wait.	[Tippett, Victoria L.; Tattersall, Luke; Ab Latif, Norain B.; Shah, Karan M.; Lawson, Michelle A.; Gartland, Alison] Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England; [Ab Latif, Norain B.] Univ Kuala Lumpur, Royal Coll Med Perak, 3 Jalan Greentown, Ipoh 30450, Perak, Malaysia	University of Sheffield; University of Kuala Lumpur	Gartland, A (corresponding author), Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Dept Oncol & Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	a.gartland@sheffield.ac.uk	Tattersall, Luke/GLU-1614-2022; Shah, Karan/B-2940-2012	Tattersall, Luke/0000-0001-8835-0627; Gartland, Alison/0000-0002-3712-2437; Tippett, Victoria/0000-0003-1601-3546; Shah, Karan/0000-0001-9909-6409; Lawson, Michelle/0000-0002-5446-923X; Ab.Latif, Norain Binti/0000-0003-1499-9049	Hannah's Willberry Wonder Pony; University of Sheffield Faculty of Medicine, Dentistry & Health, University Post Graduate Research Committee (UPGRC) Scholarship	Hannah's Willberry Wonder Pony; University of Sheffield Faculty of Medicine, Dentistry & Health, University Post Graduate Research Committee (UPGRC) Scholarship	This research was funded by Hannah's Willberry Wonder Pony and by The University of Sheffield Faculty of Medicine, Dentistry & Health, University Post Graduate Research Committee (UPGRC) Scholarship.	Abou Ali B, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.17.00241; Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872; ARCAMONE F, 1969, BIOTECHNOL BIOENG, V11, P1101, DOI 10.1002/bit.260110607; Bacci G, 2006, CANCER-AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724; Bacci G, 1998, J CLIN ONCOL, V16, P658, DOI 10.1200/JCO.1998.16.2.658; Bacci G, 2005, EUR J CANCER, V41, P2079, DOI 10.1016/j.ejca.2005.03.036; Bacci G, 2005, ACTA ONCOL, V44, P748, DOI 10.1080/02841860500327503; Baldini N, 1999, J ORTHOPAED RES, V17, P629, DOI 10.1002/jor.1100170502; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; Bertino JR, 1996, STEM CELLS, V14, P5, DOI 10.1002/stem.140005; BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11; Cavalcanti AD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184891; Cheng M, 2018, EUR J PHARMACOL, V840, P1, DOI 10.1016/j.ejphar.2018.09.032; Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Dai XW, 2008, NANOMED-NANOTECHNOL, V4, P49, DOI 10.1016/j.nano.2007.12.002; Eljack ND, 2014, METALLOMICS, V6, P2126, DOI 10.1039/c4mt00238e; Eselgrim M, 2006, PEDIATR BLOOD CANCER, V47, P42, DOI 10.1002/pbc.20608; Fan GT, 2021, BIOCHEM BIOPH RES CO, V554, P214, DOI 10.1016/j.bbrc.2020.12.109; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; Francis MN., R1205 NCIN, P1; Gao Y, 2016, J ORTHOP RES, V34, P1606, DOI 10.1002/jor.23173; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Guan HP, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02016-5; Guo W, 1999, CLIN CANCER RES, V5, P621; Hall MD, 2014, CANCER RES, V74, P3913, DOI 10.1158/0008-5472.CAN-14-0247; Han T, 2014, ONCOL REP, V32, P1133, DOI 10.3892/or.2014.3314; Hattinger CM, 2009, GENE CHROMOSOME CANC, V48, P289, DOI 10.1002/gcc.20640; Hauben EI, 2002, EUR J CANCER, V38, P1218, DOI 10.1016/S0959-8049(02)00037-0; Hawkins DS, 2003, CANCER-AM CANCER SOC, V98, P2447, DOI 10.1002/cncr.11799; HEGEWISCHBECKER S, 1993, BRIT J CANCER, V67, P430, DOI 10.1038/bjc.1993.83; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Hu YH, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23045; Ifergan I, 2003, CANCER-AM CANCER SOC, V98, P1958, DOI 10.1002/cncr.11741; Iwata S, 2021, ONCOL REP, V46, DOI 10.3892/or.2021.8086; Jiang KB, 2017, AM J CANCER RES, V7, P1407; Joo MW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172155; Kang JW, 2017, INT J CLIN EXP PATHO, V10, P359; Kelly RJ, 2011, CLIN CANCER RES, V17, P569, DOI 10.1158/1078-0432.CCR-10-1725; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Kubota Daisuke, 2016, Sarcoma, V2016, P1390571, DOI 10.1155/2016/1390571; Kuijjer ML, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-66; Kumta SM, 2001, INT ORTHOP, V25, P279; Li CY, 2018, INT J MOL MED, V42, P1799, DOI 10.3892/ijmm.2018.3753; Li R, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.632206; Liu L, 2020, ONCOTARGETS THER, V13, P3853, DOI 10.2147/OTT.S232918; Liu XG, 2018, EUR REV MED PHARMACO, V22, P1249, DOI 10.26355/eurrev_201803_14465; Liu YY, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20193045; Liu YC, 2021, BIOL PHARM BULL, V44, P861, DOI 10.1248/bpb.b21-00163; Lourda M, 2007, INT J CANCER, V120, P611, DOI 10.1002/ijc.22327; Ma WL, 2020, BIOCHEM BIOPH RES CO, V521, P204, DOI 10.1016/j.bbrc.2019.10.108; Ma XL, 2017, INT J CLIN EXP PATHO, V10, P6254; MARCOVE RC, 1970, J BONE JOINT SURG AM, VA 52, P411, DOI 10.2106/00004623-197052030-00001; McDermott M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00040; Meschini S, 2003, INT J ONCOL, V23, P1505; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299; Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72; Mukherjee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179203; National Institutes of Health (NIH), 2021, STUD QUAL ASS TOOLS; Oda Y, 2000, ONCOL REP, V7, P859; OZOLS RF, 1987, J CLIN ONCOL, V5, P641, DOI 10.1200/JCO.1987.5.4.641; Pakbaz S, 2009, IRAN RED CRESCENT ME, V11, P277; Pakos EE, 2003, CANCER-AM CANCER SOC, V98, P581, DOI 10.1002/cncr.11546; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; Posl M, 1997, Gen Diagn Pathol, V142, P317; PRICE CHG, 1958, J BONE JOINT SURG BR, V40, P574, DOI 10.1302/0301-620X.40B3.574; Pusztai L, 2005, CANCER-AM CANCER SOC, V104, P682, DOI 10.1002/cncr.21227; Quaresma M, 2015, LANCET, V385, P1206, DOI 10.1016/S0140-6736(14)61396-9; Rajkumar T, 2008, ANTI-CANCER DRUG, V19, P257, DOI 10.1097/CAD.0b013e3282f435b6; Roncuzzi L, 2014, ONCOL REP, V32, P389, DOI 10.3892/or.2014.3181; Rooney AA, 2014, ENVIRON HEALTH PERSP, V122, P711, DOI 10.1289/ehp.1307972; Salah S, 2014, MOL CLIN ONCOL, V2, P811, DOI 10.3892/mco.2014.325; SAMUELS BL, 1991, CANCER RES, V51, P521; Schneider K, 2009, TOXICOL LETT, V189, P138, DOI 10.1016/j.toxlet.2009.05.013; Scionti I, 2008, ANN ONCOL, V19, P1500, DOI 10.1093/annonc/mdn148; Scotlandi K, 1999, ONCOGENE, V18, P739, DOI 10.1038/sj.onc.1202330; SERRA M, 1993, ANTICANCER RES, V13, P323; Serra M, 1995, EUR J CANCER, V31A, P1998, DOI 10.1016/0959-8049(95)00335-5; Serra M, 2004, ANN ONCOL, V15, P151, DOI 10.1093/annonc/mdh004; Serra M, 2003, J CLIN ONCOL, V21, P536, DOI 10.1200/JCO.2003.03.144; Serra M, 2006, INT J ONCOL, V29, P1459; Sha HH, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171440; Shen P, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2573-2; Shu H, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018-021-02204-z; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; SLAPAK CA, 1990, CANCER RES, V50, P7895; Song L, 2019, J CELL BIOCHEM, V120, P9656, DOI 10.1002/jcb.28244; Song L, 2017, INT J ONCOL, V50, P535, DOI 10.3892/ijo.2016.3820; Struck RF, 2000, CANCER CHEMOTH PHARM, V45, P59, DOI 10.1007/PL00006744; Sugiu K, 2021, CANCER CHEMOTH PHARM, V88, P513, DOI 10.1007/s00280-021-04310-5; Swensen AR, 1999, CANC INCIDENCE SURVI, P99; TABONE MD, 1994, J CLIN ONCOL, V12, P2614, DOI 10.1200/JCO.1994.12.12.2614; Takemura Y, 1996, INT J CANCER, V66, P29, DOI 10.1002/(SICI)1097-0215(19960328)66:1<29::AID-IJC6>3.0.CO;2-0; Thomas Hilary, 2003, Cancer Control, V10, P159; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; Wang JJ, 2015, ONCOL LETT, V9, P940, DOI 10.3892/ol.2014.2773; Wang YJ, 2019, EPIGENOMICS-UK, V11, P1693, DOI 10.2217/epi-2019-0262; Watson MB, 2007, ANTI-CANCER DRUG, V18, P749, DOI 10.1097/CAD.0b013e3280a02f43; Wells G.A., 2009, NEWCASTLE OTTAWA SCA; Whelan JS, 2015, ANN ONCOL, V26, P407, DOI 10.1093/annonc/mdu526; WICK MR, 1981, AM J SURG PATHOL, V5, P47, DOI 10.1097/00000478-198101000-00008; Wouters OJ, 2020, JAMA-J AM MED ASSOC, V323, P844, DOI 10.1001/jama.2020.1166; Wu DP, 2017, ONCOTARGET, V8, P63857, DOI 10.18632/oncotarget.19148; Xu RD, 2016, ONCOL REP, V35, P1757, DOI 10.3892/or.2015.4497; Xu W, 2018, MED SCI MONITOR, V24, P8812, DOI 10.12659/MSM.911972; Yan XD, 2007, ONCOL REP, V17, P1163; Yang JZ, 2016, MOL MED REP, V14, P3269, DOI 10.3892/mmr.2016.5590; Yuan JJ, 2021, CANCER MANAG RES, V13, P4433, DOI 10.2147/CMAR.S295147; Zhang CL, 2017, CANCER LETT, V396, P66, DOI 10.1016/j.canlet.2017.03.018; Zhang CL, 2016, TUMOR BIOL, V37, P2737, DOI 10.1007/s13277-015-4130-7; Zhang ZH, 2021, HUM CELL, V34, P1558, DOI 10.1007/s13577-021-00564-6; Zhang Z, 2015, INT J CLIN EXP MED, V8, P18032; Zhao PQ, 2018, MOL IMMUNOL, V101, P471, DOI 10.1016/j.molimm.2018.08.010; Zhou Y, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-12; Zhu KP, 2019, J CELL PHYSIOL, V234, P6927, DOI 10.1002/jcp.27435; Zhu KP, 2018, EPIGENOMICS-UK, V10, P1327, DOI 10.2217/epi-2018-0023; Zhu KP, 2018, INT J BIOL SCI, V14, P321, DOI 10.7150/ijbs.24360; Zhu KP, 2017, ONCOTARGET, V8, P71881, DOI 10.18632/oncotarget.17985; Zou YG, 2018, ONCOL LETT, V15, P1097, DOI 10.3892/ol.2017.7432	120	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02529-x	http://dx.doi.org/10.1038/s41388-022-02529-x		NOV 2022	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M2DF	36434179	hybrid			2022-12-28	WOS:000888684000001
J	Zhao, SL; Li, BY; Zhao, RR; Pan, ZW; Zhang, SJ; Qiu, W; Guo, QD; Qi, YH; Gao, ZJ; Fan, Y; Xu, H; Li, M; Zhang, J; Wang, HZ; Xu, JY; Wang, SB; Wang, QT; Qiu, JW; Deng, L; Guo, X; Zhang, P; Xue, H; Li, G				Zhao, Shulin; Li, Boyan; Zhao, Rongrong; Pan, Ziwen; Zhang, Shouji; Qiu, Wei; Guo, Qindong; Qi, Yanhua; Gao, Zijie; Fan, Yang; Xu, Hao; Li, Ming; Zhang, Jian; Wang, Huizhi; Xu, Jianye; Wang, Shaobo; Wang, Qingtong; Qiu, Jiawei; Deng, Lin; Guo, Xing; Zhang, Ping; Xue, Hao; Li, Gang			Hypoxia-induced circADAMTS6 in a TDP43-dependent manner accelerates glioblastoma progression via ANXA2/ NF-kappa B pathway	ONCOGENE			English	Article; Early Access							CENTRAL-NERVOUS-SYSTEM; ANNEXIN A2; POSTTRANSLATIONAL MODIFICATION; CIRCULAR RNAS; RESISTANCE; TUMORS; IDENTIFICATION; ACTIVATION; CELL	Circular RNAs (circRNAs) play important roles in the malignant progression of tumours. Herein, we identified an unreported circRNA (hsa-circ-0072688, also named circADAMTS6) that is specifically upregulated in the hypoxic microenvironment of glioblastoma and closely correlated with poor prognosis of gliblastoma patients. We found that circADAMTS6 promotes the malignant progression of glioblastoma by promoting cell proliferation and inhibiting apoptosis. Mechanistically, the hypoxic tumour microenvironment upregulates circADAMTS6 expression through transcription factor activator protein 1 (AP-1) and RNA-binding protein TAR DNA-binding protein 43 (TDP43). Moreover, circADAMTS6 accelerates glioblastoma progression by recruiting and stabilising annexin A2 (ANXA2) in a proteasomes-dependent manner. Furthermore, we found T-5224 (AP-1 inhibitor) treatment induces downregulation of circADAMTS6 and then inhibits tumour growth. In conclusion, our findings highlight the important role of the circADAMTS6/ANXA2 axis based on hypoxic microenvironment in glioblastoma progression, as well as its regulation in NF-kappa B pathway. Targeting circADAMTS6 is thus expected to become a novel therapeutic strategy for glioblastoma.	[Zhao, Shulin; Li, Boyan; Zhao, Rongrong; Pan, Ziwen; Zhang, Shouji; Qiu, Wei; Guo, Qindong; Qi, Yanhua; Gao, Zijie; Fan, Yang; Wang, Huizhi; Xu, Jianye; Wang, Shaobo; Wang, Qingtong; Qiu, Jiawei; Deng, Lin; Guo, Xing; Zhang, Ping; Xue, Hao; Li, Gang] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurosurg, Jinan, Shandong, Peoples R China; [Zhao, Shulin; Li, Boyan; Zhao, Rongrong; Pan, Ziwen; Zhang, Shouji; Qiu, Wei; Guo, Qindong; Qi, Yanhua; Gao, Zijie; Fan, Yang; Wang, Huizhi; Xu, Jianye; Wang, Shaobo; Wang, Qingtong; Qiu, Jiawei; Deng, Lin; Guo, Xing; Zhang, Ping; Xue, Hao; Li, Gang] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China; [Zhao, Shulin; Li, Boyan; Zhao, Rongrong; Pan, Ziwen; Zhang, Shouji; Qiu, Wei; Guo, Qindong; Qi, Yanhua; Gao, Zijie; Fan, Yang; Xu, Hao; Li, Ming; Zhang, Jian; Wang, Huizhi; Xu, Jianye; Wang, Shaobo; Wang, Qingtong; Qiu, Jiawei; Deng, Lin; Guo, Xing; Zhang, Ping; Xue, Hao; Li, Gang] Shandong Key Lab Brain Funct Remodeling, Jinan, Shandong, Peoples R China; [Xu, Hao] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai, Shandong, Peoples R China; [Li, Ming] Taian Cent Hosp, Dept Neurosurg, Tai An, Shandong, Peoples R China; [Zhang, Jian] Dezhou Peoples Hosp, Dept Neurosurg, Dezhou, Peoples R China	Shandong University; Shandong University; Qingdao University	Xue, H; Li, G (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurosurg, Jinan, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan, Shandong, Peoples R China.	xuehao@sdu.edu.cn; dr.ligang@sdu.edu.cn			National Natural Science Foundation of China [82273195, 81874083, 82072776, 82273286, 82072775, 82203419]; Natural Science Foundation of Shandong Province of China [ZR2019BH057, ZR2020QH174, ZR2021LSW025]; Jinan Science and Technology Bureau of Shandong Province [2021GXRC029]; Key Clinical Research Project of Clinical Research Center of Shandong University [2020SDUCRCA011]; Taishan Pandeng Scholar Program of Shandong Province [tspd20210322]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province of China(Natural Science Foundation of Shandong Province); Jinan Science and Technology Bureau of Shandong Province; Key Clinical Research Project of Clinical Research Center of Shandong University; Taishan Pandeng Scholar Program of Shandong Province	We are grateful to Dr. Frederick F Lang and Dr. Krishna P.L. Bhat for providing GSC cell lines used in our study; and CGGA, TCGA, GEO, Granvendeel and Rembrandt for public sequence data. This work was supported by grants from the National Natural Science Foundation of China (Nos. 82273195; 81874083; 82072776; 82273286; 82072775; 82203419;), Natural Science Foundation of Shandong Province of China (Nos. ZR2019BH057;ZR2020QH174; ZR2021LSW025), the Jinan Science and Technology Bureau of Shandong Province (2021GXRC029), Key Clinical Research Project of Clinical Research Center of Shandong University (2020SDUCRCA011) and Taishan Pandeng Scholar Program of Shandong Province (No. tspd20210322).	Chen D, 2020, CANCER LETT, V495, P100, DOI 10.1016/j.canlet.2020.07.040; Chen J, 2017, ACS NANO, V11, P12849, DOI 10.1021/acsnano.7b08225; Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y; Deng Shishan, 2012, Genomics Proteomics & Bioinformatics, V10, P153, DOI 10.1016/j.gpb.2011.12.001; Dudekulay DB, 2016, RNA BIOL, V13, P34, DOI 10.1080/15476286.2015.1128065; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Gao XY, 2021, NAT CELL BIOL, V23, P278, DOI 10.1038/s41556-021-00639-4; Gibbings D, 2012, NAT CELL BIOL, V14, P1314, DOI 10.1038/ncb2611; Goodall GJ, 2021, NAT REV CANCER, V21, P22, DOI 10.1038/s41568-020-00306-0; Hambardzumyan D, 2015, TRENDS CANCER, V1, P252, DOI 10.1016/j.trecan.2015.10.009; Hsieh CH, 2015, CLIN CANCER RES, V21, P460, DOI 10.1158/1078-0432.CCR-14-0618; Huang SL, 2019, CIRCULATION, V139, P2857, DOI 10.1161/CIRCULATIONAHA.118.038361; Kamide D, 2016, CANCER SCI, V107, P666, DOI 10.1111/cas.12914; Khan IN, 2018, SEMIN CANCER BIOL, V52, P85, DOI 10.1016/j.semcancer.2017.07.004; Kpetemey M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0428-8; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Li LF, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0152-8; Li SL, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0629-7; Liu J, 2016, IMMUNITY, V45, P15, DOI 10.1016/j.immuni.2016.06.020; Liu RY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022779118; Liu Y, 2021, NEURO-ONCOLOGY, V23, P743, DOI 10.1093/neuonc/noaa279; Lou JC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01253-y; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Man JH, 2018, CELL STEM CELL, V22, P104, DOI 10.1016/j.stem.2017.10.005; Ni J, 2020, IMMUNITY, V52, P1075, DOI 10.1016/j.immuni.2020.05.001; Niu Y, 2021, HEPATOLOGY, V74, P1461, DOI 10.1002/hep.31846; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/nov189, 10.1093/neuonc/noaa200, 10.1093/neuonc/noab200]; Qing GY, 2017, ADV MATER, V29, DOI 10.1002/adma.201604670; Qiu W, 2021, MOL THER, V29, P3449, DOI 10.1016/j.ymthe.2021.06.023; Reardon DA, 2006, J CLIN ONCOL, V24, P1253, DOI 10.1200/JCO.2005.04.5302; Sablok G, 2016, MOL PLANT, V9, P192, DOI 10.1016/j.molp.2015.12.021; Sarkar S, 2011, GASTROENTEROLOGY, V140, P583, DOI 10.1053/j.gastro.2010.08.054; Shang QF, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0934-6; Shen SY, 2021, ANN RHEUM DIS, V80, P1209, DOI 10.1136/annrheumdis-2021-219969; Sheu-Gruttadauria J, 2018, CELL, V173, P946, DOI 10.1016/j.cell.2018.02.051; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Stupp R, 2014, LANCET ONCOL, V15, P1100, DOI 10.1016/S1470-2045(14)70379-1; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tu YM, 2019, J CELL MOL MED, V23, P6907, DOI 10.1111/jcmm.14574; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wang Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0581-6; Wang YS, 2018, PROTEIN CELL, V9, P568, DOI 10.1007/s13238-018-0513-z; Wei WS, 2018, CANCER LETT, V435, P10, DOI 10.1016/j.canlet.2018.07.036; Wei YT, 2021, NEURO-ONCOLOGY, V23, P611, DOI 10.1093/neuonc/noaa214; Wen GX, 2021, PROTEIN CELL, V12, P911, DOI 10.1007/s13238-020-00799-3; Wick W, 2017, NEW ENGL J MED, V377, P1954, DOI 10.1056/NEJMoa1707358; Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025; Zhang P, 2020, NUCLEIC ACIDS RES, V48, P1779, DOI 10.1093/nar/gkaa005; Zhang S, 2019, NEURO-ONCOLOGY, V21, P1284, DOI 10.1093/neuonc/noz128; Zhang YJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00486-7	50	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02542-0	http://dx.doi.org/10.1038/s41388-022-02542-0		NOV 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H9DW	36396726				2022-12-28	WOS:000885732000002
J	Xu, CJ; Gu, L; Kuerbanjiang, M; Jiang, CH; Hu, LP; Liu, Y; Xue, HB; Li, J; Zhang, ZG; Xu, Q				Xu, Chunjie; Gu, Lei; Kuerbanjiang, Manzila; Jiang, Chunhui; Hu, Lipeng; Liu, Ye; Xue, Hanbing; Li, Jun; Zhang, Zhigang; Xu, Qing			Adaptive activation of EFNB2/EPHB4 axis promotes post-metastatic growth of colorectal cancer liver metastases by LDLR-mediated cholesterol uptake	ONCOGENE			English	Article; Early Access							PROTEINS	The microenvironment of distant organ plays vital roles in regulating tumor metastases. However, little is known about the crosstalk between metastasized tumor cells and target organs. Herein, we found that EFNB2 expression was upregulated in liver metastases (LM) of colorectal cancer (CRC), but not in pulmonary metastases (PM) or primary CRC tumors. EFNB2 played a tumor-promoting role in CRC LM in vitro and in vivo. Through forward signaling, EFNB2-promoted CRC LM by interacting with the EPHB4 receptor. EFNB2/EPHB4 axis enhances LDLR-mediated cholesterol uptake in CRC LM. Subsequently, EFNB2/EPHB4 axis promotes LDLR transcription by regulating STAT3 phosphorylation. Blocking LDLR reversed the role of the EFNB2/EPHB4 axis in promoting CRC LM. Using clinical data, survival analysis revealed that the survival time of patients with CRC LM was decreased in patients with high EFNB2 expression, compared with low EFNB2 expression. Inhibition of the EFNB2/EPHB4 axis markedly prolonged the survival time of BALB/c nude mice with CRC LM with a high cholesterol diet. These findings revealed a key step in the regulation of cholesterol uptake by EFNB2/EPHB4 axis and its tumor-promoting role in CRC LM.	[Xu, Chunjie; Gu, Lei; Kuerbanjiang, Manzila; Jiang, Chunhui; Liu, Ye; Xu, Qing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Gastrointestinal Surg, 160 Pujian Rd, Shanghai, Peoples R China; [Hu, Lipeng; Li, Jun; Zhang, Zhigang] Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China; [Xue, Hanbing] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai, Peoples R China; [Xue, Hanbing] Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Minist Hlth, 145 Middle Shandong Rd, Shanghai, Peoples R China; [Xue, Hanbing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, 145 Middle Shandong Rd, Shanghai, Peoples R China; [Xue, Hanbing] Shanghai Inst Digest Dis, 145 Middle Shandong Rd, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xu, Q (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Gastrointestinal Surg, 160 Pujian Rd, Shanghai, Peoples R China.; Li, J; Zhang, ZG (corresponding author), Shanghai Jiao Tong Univ, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China.; Xue, HB (corresponding author), Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai, Peoples R China.; Xue, HB (corresponding author), Shanghai Jiao Tong Univ, Key Lab Gastroenterol & Hepatol, Minist Hlth, 145 Middle Shandong Rd, Shanghai, Peoples R China.; Xue, HB (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, 145 Middle Shandong Rd, Shanghai, Peoples R China.; Xue, HB (corresponding author), Shanghai Inst Digest Dis, 145 Middle Shandong Rd, Shanghai, Peoples R China.	junli@shsci.org; zzhang@shsci.org; renjixuqing@163.com		Hu, Lipeng/0000-0002-5941-3825; Zhang, Zhi-gang/0000-0001-8965-223X; Li, Jun/0000-0003-0423-3381	National Natural Science Foundation of China [82072671]; Research Fund for medical engineering cross project of Shanghai Jiao Tong University [ZH2018ZDA08]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for medical engineering cross project of Shanghai Jiao Tong University	This study was supported by the National Natural Science Foundation of China (82072671) and Research Fund for medical engineering cross project of Shanghai Jiao Tong University (ZH2018ZDA08).	Baeriswyl T, 2021, ELIFE, V10, DOI 10.7554/eLife.64767; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bertocchi A, 2021, CANCER CELL, V39, P708, DOI 10.1016/j.ccell.2021.03.004; Bhatia S, 2020, MOL CARCINOGEN, V59, P1064, DOI 10.1002/mc.23237; Bhatia S, 2018, CLIN CANCER RES, V24, P4539, DOI 10.1158/1078-0432.CCR-18-0327; Bu PC, 2018, CELL METAB, V27, P1249, DOI 10.1016/j.cmet.2018.04.003; Chandra R, 2021, CANCERS, V13, DOI 10.3390/cancers13246206; Chedotal A, 2019, NAT REV NEUROSCI, V20, P380, DOI 10.1038/s41583-019-0168-7; de Boer JF, 2018, TRENDS ENDOCRIN MET, V29, P123, DOI 10.1016/j.tem.2017.11.006; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Gallagher EJ, 2017, ONCOGENE, V36, P6462, DOI 10.1038/onc.2017.247; Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591-020-01195-4; Jurcak NR, 2019, GASTROENTEROLOGY, V157, P838, DOI 10.1053/j.gastro.2019.05.065; Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16; Koohini Z, 2019, PATHOL ONCOL RES, V25, P1285, DOI 10.1007/s12253-018-00568-y; Kopecka J, 2020, DRUG RESIST UPDATE, V49, DOI 10.1016/j.drup.2019.100670; Lai KO, 2004, J BIOL CHEM, V279, P13383, DOI 10.1074/jbc.M313356200; Li J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0702-0; Lin WH, 2021, ONCOGENE, V40, P791, DOI 10.1038/s41388-020-01566-8; Liu AM, 2019, PHARMACOL THERAPEUT, V195, P54, DOI 10.1016/j.pharmthera.2018.10.004; Liu W, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25354-4; Luo J, 2020, NAT REV MOL CELL BIO, V21, P225, DOI 10.1038/s41580-019-0190-7; Magic Z, 2019, INT J ONCOL, V55, P1275, DOI 10.3892/ijo.2019.4892; Minniti ME, 2020, HEPATOLOGY, V72, P656, DOI 10.1002/hep.31052; Neufeld G, 2016, DRUG RESIST UPDATE, V29, P1, DOI 10.1016/j.drup.2016.08.001; Sato S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.132447; Schoop V, 2021, BBA-MOL CELL BIOL L, V1866, DOI 10.1016/j.bbalip.2021.158989; Song XY, 2020, NATURE, V577, P410, DOI 10.1038/s41586-019-1865-0; Sun XW, 2012, NEOPLASIA, V14, P1122, DOI 10.1593/neo.121252; Tsilimigras DI, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00261-6; Van Battum EY, 2015, LANCET NEUROL, V14, P532, DOI 10.1016/S1474-4422(14)70257-1; Vos DY, 2020, MOL METAB, V50, DOI 10.1016/j.molmet.2020.101146; Waku T, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103180; Wang J, 2021, PHYTOMEDICINE, V91, DOI 10.1016/j.phymed.2021.153688; Wei QY, 2020, ONCOGENE, V39, P6139, DOI 10.1038/s41388-020-01432-7; Xu CJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.557730; Yang HX, 2020, CLIN CHIM ACTA, V500, P81, DOI 10.1016/j.cca.2019.09.022; Zhang XL, 2021, ONCOGENE, V40, P3959, DOI 10.1038/s41388-021-01827-0; Zhu F, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109972	39	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02519-z	http://dx.doi.org/10.1038/s41388-022-02519-z		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6E3DK	36376513	hybrid			2022-12-28	WOS:000883260200001
J	Mo, JL; Tan, KZ; Dong, Y; Lu, WJ; Liu, F; Mei, YQ; Huang, HT; Zhao, KW; Lv, ZB; Ye, YQ; Tang, YJ				Mo, Jialin; Tan, Kezhe; Dong, Yu; Lu, Wenjie; Liu, Fang; Mei, Yanqing; Huang, Hongting; Zhao, Kewen; Lv, Zhibao; Ye, Youqiong; Tang, Yujie			Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex	ONCOGENE			English	Article; Early Access							EXPRESSION; REVEALS; ELEMENTS; GROWTH; RNA; SUSCEPTIBILITY; SENSITIVITY; METASTASIS; RESISTANCE; PROTEIN	EWS/ETS fusion transcription factors, most commonly EWSR1::FLI1, drives initiation and progression of Ewing sarcoma (EwS). Even though direct targeting EWSR1::FLI1 is a formidable challenge, epigenetic/transcriptional modulators have been proved to be promising therapeutic targets for indirectly disrupting its expression and/or function. Here, we identified structure-specific recognition protein 1 (SSRP1), a subunit of the Facilitates Chromatin Transcription (FACT) complex, to be an essential tumor-dependent gene directly induced by EWSR1::FLI1 in EwS. The FACT-targeted drug CBL0137 exhibits potent therapeutic efficacy against multiple EwS preclinical models both in vitro and in vivo. Mechanistically, SSRP1 and EWSR1::FLI1 form oncogenic positive feedback loop via mutual transcriptional regulation and activation, and cooperatively promote cell cycle/DNA replication process and IGF1R-PI3K-AKT-mTOR pathway to drive EwS oncogenesis. The FACT inhibitor drug CBL0137 effectively targets the EWSR1::FLI1-FACT circuit, resulting in transcriptional disruption of EWSR1::FLI1, SSRP1 and their downstream effector oncogenic signatures. Our study illustrates a crucial role of the FACT complex in facilitating the expression and function of EWSR1::FLI1 and demonstrates FACT inhibition as a novel and effective epigenetic/transcriptional-targeted therapeutic strategy against EwS, providing preclinical support for adding EwS to CBL0137's future clinical trials.	[Mo, Jialin; Liu, Fang; Mei, Yanqing; Zhao, Kewen; Tang, Yujie] Shanghai Jiao Tong Univ, Sch Med,Res Ctr Translat Med, Dept Pathophysiol,Shanghai Childrens Hosp, Natl Minist Educ,Key Lab Cell Differentiat & Apop, Shanghai 200025, Peoples R China; [Mo, Jialin; Lu, Wenjie; Tang, Yujie] Shanghai Jiao Tong Univ, Sch Med, Dept Histoembryol Genet & Dev Biol, Shanghai Key Lab Reprod Med, Shanghai 200025, Peoples R China; [Tan, Kezhe; Lv, Zhibao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Hosp, Dept Gen Surg, Shanghai 200062, Peoples R China; [Dong, Yu; Ye, Youqiong] Shanghai Jiao Tong Univ, Sch Med, Dept Immunol & Microbiol, Thanghai Inst Immunol, Shanghai 200025, Peoples R China; [Huang, Hongting] Shanghai Jiao Tong Univ, Sch Med, Dept Hepat Surg, Renji Hosp, Shanghai 200127, Peoples R China; [Huang, Hongting] Shanghai Jiao Tong Univ, Liver Transplantat Ctr, Renji Hosp, Sch Med, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Tang, YJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med,Res Ctr Translat Med, Dept Pathophysiol,Shanghai Childrens Hosp, Natl Minist Educ,Key Lab Cell Differentiat & Apop, Shanghai 200025, Peoples R China.; Tang, YJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Histoembryol Genet & Dev Biol, Shanghai Key Lab Reprod Med, Shanghai 200025, Peoples R China.; Lv, ZB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Hosp, Dept Gen Surg, Shanghai 200062, Peoples R China.; Ye, YQ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Immunol & Microbiol, Thanghai Inst Immunol, Shanghai 200025, Peoples R China.	zhibaolyu@163.com; youqiong.ye@shsmu.edu.cn; yujietang@shsmu.edu.cn		Ye, Youqiong/0000-0001-8332-4710	Chinese Universities Scientific Fund, Innovative Research Team of High-Level Local Universities in Shanghai [SHSMU-ZDCX20212700]; National Natural Science Foundation of China [81772655, 81972646, 82002978]; Shanghai Frontiers Science Center of Cellular Homeostasis and Human Diseases; Innovation Program of Shanghai Municipal Education Commission (China) [2019-01-07-00-01-E00036]; Recruitment Program of Global Experts of China; Postdoctoral Science Foundation of China [2019M651527]; National Research Center for Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine	Chinese Universities Scientific Fund, Innovative Research Team of High-Level Local Universities in Shanghai; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Frontiers Science Center of Cellular Homeostasis and Human Diseases; Innovation Program of Shanghai Municipal Education Commission (China)(Innovation Program of Shanghai Municipal Education Commission); Recruitment Program of Global Experts of China; Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); National Research Center for Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine	This work was supported by Chinese Universities Scientific Fund, Innovative Research Team of High-Level Local Universities in Shanghai (SHSMU-ZDCX20212700), National Natural Science Foundation of China (81772655, 81972646 to YT, 82002978 to JM), Shanghai Frontiers Science Center of Cellular Homeostasis and Human Diseases, the Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-01-E00036, China), the Recruitment Program of Global Experts of China (YT), Postdoctoral Science Foundation of China (2019M651527 to JM), and National Research Center for Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine (Open research program to YT). We thank Jing Xue (Shanghai Renji Hospital) and Bing Li (Shanghai Jiao Tong University School of Medicine) for reagents and/or helpful suggestions.	Adane B, 2021, CANCER CELL, V39, P827, DOI 10.1016/j.ccell.2021.05.007; Amin HM, 2020, CANCERS, V12, DOI 10.3390/cancers12071768; Barone TA, 2017, NEURO-ONCOLOGY, V19, P186, DOI 10.1093/neuonc/now141; Bilke S, 2013, GENOME RES, V23, P1797, DOI 10.1101/gr.151340.112; Boulay G, 2018, GENE DEV, V32, P1008, DOI 10.1101/gad.315192.118; Carter DR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1803; Chang HW, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aav2131; Chiou YY, 2018, J BIOL CHEM, V293, P2476, DOI 10.1074/jbc.RA117.000971; Feng JX, 2012, BIOINFORMATICS, V28, P2782, DOI 10.1093/bioinformatics/bts515; Flores G, 2021, J BONE ONCOL, V31, DOI 10.1016/j.jbo.2021.100404; Formosa T, 2020, NUCLEIC ACIDS RES, V48, P11929, DOI 10.1093/nar/gkaa912; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Gollavilli PN, 2018, CANCER RES, V78, P4760, DOI 10.1158/0008-5472.CAN-18-0484; Goss KL, 2016, ONCOTARGET, V7, P63003, DOI 10.18632/oncotarget.11416; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Grunewald TGP, 2015, NAT GENET, V47, P1073, DOI 10.1038/ng.3363; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/NMETH.3853, 10.1038/nmeth.3853]; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Heitzeneder S, 2019, JNCI-J NATL CANCER I, V111, P970, DOI 10.1093/jnci/djy209; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kim M, 2016, CANCER RES, V76, P6620, DOI 10.1158/0008-5472.CAN-15-2764; Kirschner A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1273301; Lamhamedi-Cherradi SE, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw182; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin LH, 2019, NUCLEIC ACIDS RES, V47, P1255, DOI 10.1093/nar/gky1207; Liu DM, 2013, J GERONTOL A-BIOL, V68, P1035, DOI 10.1093/gerona/glt015; Liu F, 2019, P NATL ACAD SCI USA, V116, P12986, DOI 10.1073/pnas.1815780116; Loganathan SN, 2019, MOL CANCER THER, V18, P929, DOI 10.1158/1535-7163.MCT-18-1151; Martins AS, 2006, CLIN CANCER RES, V12, P3532, DOI 10.1158/1078-0432.CCR-05-1778; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Mo JL, 2018, GLIA, V66, P1346, DOI 10.1002/glia.23308; Mo JL, 2021, CANCER RES, V81, P3105, DOI 10.1158/0008-5472.CAN-20-3186; Musa J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12071-2; Ohmura S, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01393-9; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Pishas KI, 2018, MOL CANCER THER, V17, P1902, DOI 10.1158/1535-7163.MCT-18-0373; Postel-Vinay S, 2012, NAT GENET, V44, P323, DOI 10.1038/ng.1085; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2021, NEW ENGL J MED, V384, P154, DOI 10.1056/NEJMra2028910; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Sanchez-Molina S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3058; Savola Suvi, 2011, ISRN Oncol, V2011, P168712, DOI 10.5402/2011/168712; Schmidt O, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02125-z; Scotlandi K, 2009, J CLIN ONCOL, V27, P2209, DOI 10.1200/JCO.2008.19.2542; Sen N, 2018, MOL CARCINOGEN, V57, P1342, DOI 10.1002/mc.22849; Seong BKA, 2021, CANCER CELL, V39, P1262, DOI 10.1016/j.ccell.2021.07.003; Somers K, 2020, INT J CANCER, V146, P1902, DOI 10.1002/ijc.32582; Song HY, 2021, CANCER LETT, V520, P201, DOI 10.1016/j.canlet.2021.07.020; Surdez D, 2021, CANCER CELL, V39, P810, DOI 10.1016/j.ccell.2021.04.001; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613; Tomazou EM, 2015, CELL REP, V10, P1082, DOI 10.1016/j.celrep.2015.01.042; Toretsky JA, 1999, CANCER RES, V59, P5745; Volchenboum SL, 2015, J PATHOL CLIN RES, V1, P83, DOI 10.1002/cjp2.9; Wakahara K, 2008, MOL CANCER RES, V6, P1937, DOI 10.1158/1541-7786.MCR-08-0054; Wang JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03201-6; Wang S, 2019, CLIN CANCER RES, V25, P4552, DOI 10.1158/1078-0432.CCR-17-0375; Xiao L, 2021, CLIN CANCER RES, V27, P4338, DOI 10.1158/1078-0432.CCR-20-2357; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	66	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02533-1	http://dx.doi.org/10.1038/s41388-022-02533-1		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C0KZ	36357572				2022-12-28	WOS:000881714300001
J	Ma, ML; Zhang, CH; Cao, R; Tang, DM; Sang, XB; Zou, SL; Wang, XX; Xu, HX; Liu, G; Dai, LZ; Tian, Y; Gao, X; Fu, XH				Ma, Meilin; Zhang, Changhui; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Wang, Xiuxuan; Xu, Haixia; Liu, Geng; Dai, Lunzhi; Tian, Yan; Gao, Xiang; Fu, Xianghui			UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; QUALITY-CONTROL; E2 ENZYMES; EXPRESSION	Cancer cells rely on heightened protein quality control mechanisms, including the ubiquitin-proteosome system that is predominantly driven by ubiquitination comprising E1, E2, and E3 trienzyme cascades. Although E3s have been extensively studied, the implication of E2s in tumorigenesis is poorly defined. Here we reveal a critical E2 in the pathogenesis of hepatocellular carcinoma (HCC). Among all of E2s, UBE2O shows the strongest association with HCC survival prognosis, and its expression is increased in HCC tumors. Accordingly, UBE2O deficiency inhibits HCC growth and metastasis both in vitro and in vivo, while its overexpression has opposite effects. Depending on both E2 and E3 enzymatic activities, UBE2O can interact with and mediate the ubiquitination and degradation of HADHA, a mitochondrial beta-oxidation enzyme, thereby modulating lipid metabolic reprogramming. HADHA is reduced in HCC tumors and inversely correlated with UBE2O levels. Importantly, HADHA acts as a tumor suppressor and primarily mediates UBE2O's function on HCC. Moreover, liver-specific deletion of Ube2o in mice are resistant to DEN-induced hepatocarcinogenesis, along with HADHA upregulation and reduced hepatic lipid accumulation. These data reveal UBE2O as a novel oncogenic driver for metabolic reprogramming and HCC development, highlighting the potential of targeting UBE2O/HADHA axis for HCC therapy.	[Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Sichuan Univ, West China Hosp, Div Endocrinol & Metab, State Key Lab Biotherapy, Changchun 610041, Peoples R China; [Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Sichuan Univ, West China Hosp, Canc Ctr, Changchun 610041, Peoples R China; [Ma, Meilin; Cao, Rong; Tang, Dongmei; Sang, Xiongbo; Zou, Sailan; Xu, Haixia; Liu, Geng; Tian, Yan; Fu, Xianghui] Collaborat Innovat, Changchun 610041, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi; Gao, Xiang] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Changhui; Wang, Xiuxuan; Dai, Lunzhi; Gao, Xiang] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Gao, Xiang] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Sichuan, Peoples R China; [Gao, Xiang] Sichuan Univ, West China Hosp, Inst Neurosurg, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University; Sichuan University	Fu, XH (corresponding author), Sichuan Univ, West China Hosp, Div Endocrinol & Metab, State Key Lab Biotherapy, Changchun 610041, Peoples R China.; Fu, XH (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Changchun 610041, Peoples R China.; Fu, XH (corresponding author), Collaborat Innovat, Changchun 610041, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu 610041, Sichuan, Peoples R China.; Gao, X (corresponding author), Sichuan Univ, West China Hosp, Inst Neurosurg, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.	xianggao@scu.edu.cn; xfu@scu.edu.cn		Dai, Lunzhi/0000-0002-3003-8910	National Natural Science Foundation of China [82103128, 92157205, 81970561, 81802836]; National Key Research and Development Program of China [2018YFC2000305]; Ministry of Science and Technology of China [2018ZX09201018-005]; China National Postdoctoral Program for Innovative Talents [BX2021201]; China Postdoctoral Science Foundation [2021M692302]; 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University [ZYJC18049]; Sichuan Science & Technology Program [2019JDTD0013]; Post-Doctor Research Project, West China Hospital, Sichuan University [2020HXBH121]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Ministry of Science and Technology of China(Ministry of Science and Technology, China); China National Postdoctoral Program for Innovative Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University; Sichuan Science & Technology Program; Post-Doctor Research Project, West China Hospital, Sichuan University	This work was supported by the National Natural Science Foundation of China (82103128, 92157205, 81970561, and 81802836), the National Key Research and Development Program of China (2018YFC2000305), the Ministry of Science and Technology of China (2018ZX09201018-005), China National Postdoctoral Program for Innovative Talents (BX2021201), China Postdoctoral Science Foundation (2021M692302), the 1.3.5 Project for Disciplines Excellence, West China Hospital, Sichuan University (ZYJC18049), Sichuan Science & Technology Program (2019JDTD0013), and the Post-Doctor Research Project, West China Hospital, Sichuan University (2020HXBH121).	Amoedo ND, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI133081; Chen SP, 2018, J BIOL CHEM, V293, P11296, DOI 10.1074/jbc.RA117.001432; Chi ZX, 2020, MOL CELL, V80, P43, DOI 10.1016/j.molcel.2020.08.015; Costa-Mattioli M, 2020, SCIENCE, V368, P384, DOI 10.1126/science.aat5314; Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0094-0; Faust TB, 2018, ELIFE, V7, DOI 10.7554/eLife.31879; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao YH, 2013, CELL, V152, P1051, DOI 10.1016/j.cell.2013.01.051; Huang YM, 2021, CELL DEATH DIFFER, V28, P671, DOI 10.1038/s41418-020-00616-8; Khare T, 2020, INT J CANCER, V147, P1461, DOI 10.1002/ijc.32943; Kim Y, 2016, NAT PROTOC, V11, P937, DOI 10.1038/nprot.2016.050; Lectez B, 2014, J PROTEOME RES, V13, P3016, DOI 10.1021/pr5001913; Liang KW, 2017, CELL, V168, P59, DOI 10.1016/j.cell.2016.12.011; Lim HY, 2013, ANN SURG ONCOL, V20, P3747, DOI 10.1245/s10434-013-3070-y; Liu J, 2022, THERANOSTICS, V12, P1342, DOI 10.7150/thno.65778; Liu S, 2019, EXP CELL RES, V384, DOI 10.1016/j.yexcr.2019.111558; Liu XM, 2020, HEPATOLOGY, V72, P2029, DOI 10.1002/hep.31222; Liu X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2194-9; Liu YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14190-2; Liu Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0841-3; Ljubkovic M, 2019, DIABETES, V68, P1924, DOI 10.2337/db19-0423; Ma ML, 2019, HEPATOLOGY, V70, P215, DOI 10.1002/hep.30602; Mashtalir N, 2014, MOL CELL, V54, P392, DOI 10.1016/j.molcel.2014.03.002; McGlynn KA, 2021, HEPATOLOGY, V73, P4, DOI 10.1002/hep.31288; Meng Z, 2017, ONCOGENE, V36, P2446, DOI 10.1038/onc.2016.400; Mi BB, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00624-3; Miklas JW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12482-1; Minguez B, 2011, J HEPATOL, V55, P1325, DOI 10.1016/j.jhep.2011.02.034; Muto Y, 2019, J EXP MED, V216, P950, DOI 10.1084/jem.20180900; Nguyen AT, 2017, SCIENCE, V357, DOI 10.1126/science.aan0218; Osada T, 1997, J HEPATOL, V26, P1266, DOI 10.1016/S0168-8278(97)80461-8; Osborne HC, 2021, TRENDS CELL BIOL, V31, P628, DOI 10.1016/j.tcb.2021.01.009; Pan A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28044-x; Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769; Shi Z, 2021, INT J MED SCI, V18, P3749, DOI 10.7150/ijms.63220; Shirahashi H, 2002, LIVER, V22, P413, DOI 10.1034/j.1600-0676.2002.01541.x; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stewart MD, 2016, CELL RES, V26, P423, DOI 10.1038/cr.2016.35; Tanaka M, 2013, MOL MED REP, V7, P365, DOI 10.3892/mmr.2012.1201; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tian Y, 2022, MOL THER-NUCL ACIDS, V30, P1, DOI 10.1016/j.omtn.2022.08.036; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Vila IK, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128269; Vila IK, 2017, CANCER CELL, V31, P208, DOI 10.1016/j.ccell.2017.01.003; Villa E, 2016, GUT, V65, P861, DOI 10.1136/gutjnl-2014-308483; Wang JX, 2019, J HEPATOL, V71, P742, DOI 10.1016/j.jhep.2019.05.027; Xia CW, 2019, P NATL ACAD SCI USA, V116, P6069, DOI 10.1073/pnas.1816317116; Xu HX, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000603; Xu H, 2019, EMBO J, V38, DOI 10.15252/embj.2019101996; Yamamoto K, 2020, LAB INVEST, V100, P353, DOI 10.1038/s41374-019-0318-6; Yanagitani K, 2017, SCIENCE, V357, P472, DOI 10.1126/science.aan0178; Yokota T, 2001, GENE, V267, P95, DOI 10.1016/S0378-1119(01)00407-3; Yokoyama Y, 2004, PROTEOMICS, V4, P2111, DOI 10.1002/pmic.200300712; Yu HS, 2020, HEPATOLOGY, V72, P518, DOI 10.1002/hep.31045; Zheng N, 2017, ANNU REV BIOCHEM, V86, P129, DOI 10.1146/annurev-biochem-060815-014922	56	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5199	5213		10.1038/s41388-022-02509-1	http://dx.doi.org/10.1038/s41388-022-02509-1		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36273042				2022-12-28	WOS:000871165700001
J	CRAMER, WA; ENGELMAN, DM; VONHEIJNE, G; REES, DC				CRAMER, WA; ENGELMAN, DM; VONHEIJNE, G; REES, DC			FORCES INVOLVED IN THE ASSEMBLY AND STABILIZATION OF MEMBRANE-PROTEINS	FASEB JOURNAL			English	Article						CYTOCHROME-B6F COMPLEX; GLYCOPHORIN; POSITIVE-INSIDE RULE; PHOTOSYNTHETIC REACTION CENTER	PHOTOSYNTHETIC REACTION CENTER; POSITIVELY CHARGED RESIDUES; RHODOPSEUDOMONAS-VIRIDIS; THYLAKOID MEMBRANE; COMPLEX; MODEL; RESOLUTION; TOPOLOGY; BACTERIORHODOPSIN; INSERTION	Hydrophobic organization: Determination of the structure of the bacterial photosynthetic reaction center, bacterial porins, and bacteriorhodopsin allows a comparison of the basic structural features of integral membrane proteins. Structure parameters of membrane- and water-soluble proteins are surprisingly similar, given the different dielectric environments, except for the polarity of residues on the protein surface. Hydrophobic and electrostatic forces: 1) Intramembrane helix-helix interactions that are sensitive to small structure changes can dictate assembly of membrane proteins, as indicated by reconstitution of bacteriorhodopsin from proteolytic fragments and specific dimer formation of the human erythrocyte sialoglycoprotein glycophorin A. 2) Electrostatic interactions have an important role in determining the trans-membrane orientation of integral membrane proteins of the bacterial inner membrane, as expressed by the "positive-inside" rule for the distribution of basic residues on the cis relative to the trans side of the membrane-spanning alpha-helices. The use of this charge asymmetry rule, in conjunction with a hydrophobicity algorithm for prediction of membrane-spanning domains, allows accurate prediction of the folding patterns of such polypeptides across the membrane. A role of electrostatic interactions in assembly and maintenance of the structure of oligomeric integral membrane protein complexes is also implied by the separation and extrusion from the membrane, at high pH, of the major hydrophobic subunits of the cytochrome b6f complex from the chloroplast thylakoid membrane. It is inferred that the hydrophobic helix-helix interactions between the subunits of this complex, whose function is electron transfer and proton translocation, are relatively weak compared to those in bacteriorhodopsin.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; KAROLINSKA INST,NOVUM,CTR STRUCT BIOL,DEPT MOLEC BIOL,S-14157 HUDDINGE,SWEDEN	Yale University; Karolinska Institutet	CRAMER, WA (corresponding author), PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907, USA.		von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569	NIGMS NIH HHS [GM45162, GM39546, GM38323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039546, R37GM045162, R01GM045162, R01GM038323, R56GM038323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; CHANG CH, 1991, BIOCHEMISTRY-US, V30, P5352, DOI 10.1021/bi00236a005; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HUNT J F, 1991, Biophysical Journal, V59, p400A; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1988, Q REV BIOPHYS, V21, P429, DOI 10.1017/S0033583500004625; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; MICHEL H, 1991, CRYSTALLIZATION MEMB; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; REES DC, 1992, MEMBRANE PROTEIN STR; Singer S. J., 1971, STRUCTURE FUNCTION B, P145; SZCZEPANIAK A, 1991, EMBO J, V10, P2757, DOI 10.1002/j.1460-2075.1991.tb07824.x; SZCZEPANIAK A, 1990, J BIOL CHEM, V265, P17720; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WIDGER WR, 1991, CELL CULTURE SOMATIC, V7, P149	36	62	64	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1992	6	15					3397	3402		10.1096/fasebj.6.15.1464373	http://dx.doi.org/10.1096/fasebj.6.15.1464373			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1464373	Bronze			2022-12-28	WOS:A1992KD39500011
J	SILBERGELD, EK				SILBERGELD, EK			MECHANISMS OF LEAD NEUROTOXICITY, OR LOOKING BEYOND THE LAMPPOST	FASEB JOURNAL			English	Review						BRAIN DEVELOPMENT; LEAD NEUROTOXICITY; ZINC; CALCIUM	PROTEIN-KINASE-C; INORGANIC LEAD; BINDING-SITES; EXPOSURE; INTOXICATION; HIPPOCAMPAL; BRAIN	Despite several decades of research on the neurotoxicology of lead and its continued prominence as a major environmental and occupational health hazard, the mechanisms of its toxic action in the nervous system are still unknown. The differential effects of lead exposure in young children and adults, as well as inconsistencies between in vivo and in vitro studies, suggest that lead toxicity may have multiple mechanisms in the central nervous system (CNS). Two are: neurodevelopmental toxicity, possibly involving interference with cell adhesion molecules, resulting in miswiring of the CNS during early development and possibly permanent dysfunction; and neuropharma-cological toxicity, which might involve interactions between lead and calcium and lead and zinc, resulting in interference with neurotransmission at the synapse. This may be reversible.			SILBERGELD, EK (corresponding author), UNIV MARYLAND, PROGRAM TOXICOL, BALTIMORE, MD 21201 USA.							ALKONDON M, 1990, FEBS LETT, V261, P124, DOI 10.1016/0014-5793(90)80652-Y; ALTMANN L, 1991, NEUROSCI LETT, V128, P109, DOI 10.1016/0304-3940(91)90771-K; [Anonymous], 1988, NATURE EXTENT LEAD P; [Anonymous], 1991, PREVENTING LEAD POIS; AUDESIRK G, 1985, PROG NEUROBIOL, V24, P199, DOI 10.1016/0301-0082(85)90006-1; AUDESIRK T, 1991, NEUROTOXICOLOGY, V12, P529; BELLINGER D, 1991, HUMAN LEAD EXPOSURE, P191; BHATTACHARYA A, 1988, NEUROTOXICOLOGY, V9, P327; Blackman SS, 1937, B JOHNS HOPKINS HOSP, V61, P1; BRESSLER JP, 1991, BIOCHEM PHARMACOL, V41, P479, DOI 10.1016/0006-2952(91)90617-E; Byers RK, 1943, AM J DIS CHILD, V66, P471; CORYSLECHTA A, 1988, SCI TOTAL ENVIRON, V71, P433, DOI 10.1016/0048-9697(88)90215-X; CORYSLECHTA DA, 1983, TOXICOL APPL PHARM, V71, P342, DOI 10.1016/0041-008X(83)90021-2; CULLEN MR, 1983, MEDICINE, V62, P221, DOI 10.1097/00005792-198307000-00003; DAVIS JM, 1987, NATURE, V329, P297, DOI 10.1038/329297a0; DUVAL G, 1989, BIOCHEM BIOPH RES CO, V159, P177, DOI 10.1016/0006-291X(89)92420-0; EWERS U, 1980, TOXICOLOGY, V16, P227, DOI 10.1016/0300-483X(80)90119-5; FOWLER BA, 1989, COMMENTS TOXICOL, V3, P27; FOX DA, 1991, HUMAN LEAD EXPOSURE, P105; GOLDSTEIN GW, 1974, ARCH NEUROL-CHICAGO, V31, P382, DOI 10.1001/archneur.1974.00490420048005; HUBBARD SR, 1991, SCIENCE, V254, P1776; JACOBSON M, 1990, DEV NEUROBIOLOGY; KLANN E, 1989, J BIOL CHEM, V264, P16969; KOSTIAL K, 1957, BRIT J PHARM CHEMOTH, V12, P219, DOI 10.1111/j.1476-5381.1957.tb00123.x; LASLEY SM, 1988, TOXICOL APPL PHARM, V95, P474, DOI 10.1016/0041-008X(88)90365-1; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; MCGIVERN RF, 1991, TOXICOL APPL PHARM, V110, P206, DOI 10.1016/S0041-008X(05)80003-1; MINNEMA DJ, 1986, TOXICOL APPL PHARM, V84, P400, DOI 10.1016/0041-008X(86)90148-1; MOORHOUSE SR, 1988, BIOCHEM PHARMACOL, V37, P4539, DOI 10.1016/0006-2952(88)90670-3; MORESCO RM, 1988, TOXICOLOGY, V53, P315, DOI 10.1016/0300-483X(88)90223-5; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; PENTSCHEW A, 1966, ACTA NEUROPATHOL, V6, P266, DOI 10.1007/BF00687857; PETIT TL, 1983, NEUROTOXICOLOGY, V4, P79; POUNDS JG, 1984, NEUROTOXICOLOGY, V5, P295; REGAN CM, 1989, NEUROTOXICOL TERATOL, V11, P533, DOI 10.1016/0892-0362(89)90033-0; SEPPALAINEN AMH, 1988, CRC CR REV TOXICOL, V18, P245, DOI 10.3109/10408448809037468; SHIGETA S, 1989, J EXP CLIN MED, V14, P147; SILBERGE.EK, 1974, NATURE, V247, P49, DOI 10.1038/247049a0; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SILBERGELD EK, 1977, RES COMMUN CHEM PATH, V17, P715; SILBERGELD EK, 1978, BRAIN RES, V148, P451, DOI 10.1016/0006-8993(78)90732-1; SILBERGELD EK, 1987, ANN NY ACAD SCI, V514, P297; SILBERGELD EK, 1991, HUMAN LEAD EXPOSURE, P89; SILBERGELD EK, 1992, IN PRESS NEUROTOXICO; SULZER D, 1987, J NEUROBIOL, V18, P467, DOI 10.1002/neu.480180507; UJIHARA H, 1991, NEUR ABSTGR, V17, P1535; WINDER C, 1984, PROG NEUROBIOL, V22, P59, DOI 10.1016/0301-0082(84)90018-2	48	143	152	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1992	6	13					3201	3206		10.1096/fasebj.6.13.1397842	http://dx.doi.org/10.1096/fasebj.6.13.1397842			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397842				2022-12-28	WOS:A1992JU51200013
J	BROWN, MD; VOLJAVEC, AS; LOTT, MT; MACDONALD, I; WALLACE, DC				BROWN, MD; VOLJAVEC, AS; LOTT, MT; MACDONALD, I; WALLACE, DC			LEBER HEREDITARY OPTIC NEUROPATHY - A MODEL FOR MITOCHONDRIAL NEURODEGENERATIVE DISEASES	FASEB JOURNAL			English	Review						LEBER HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL DNA MUTATIONS; OXIDATIVE PHOSPHORYLATION; GENOTYPE	GENE ORGANIZATION; DNA MUTATION; NUCLEOTIDE-SEQUENCE; READING FRAMES; GENOME; CONTAINS	A number of human diseases have been attributed to defects in oxidative pbosphorylation (OXPHOS) resulting from mutations in the mitochondrial DNA (mtDNA). One such disease is Leber's hereditary optic neuropathy (LHON), a neurodegenerative disease of young adults that results in blindness due to atrophy of the optic nerve. The etiology of LHON is genetically heterogeneous and in some cases multifactorial. Eleven mtDNA mutations have been associated with LHON, all of which are missense mutations in the subunit genes for the subunits of the electron transport chain complexes I, III, and IV. Molecular, biochemical, and population genetic studies have categorized these mutations as high risk (class I), low risk (class II), or intermediate risk (class I/II). Class I mutations appear to be primary genetic causes of LHON, while class II mutations are frequently found associated with class I genotypes and may serve as exacerbating genetic factors. Different LHON pedigrees can harbor different combinations of class I, II, or I/II mtDNA mutations, as shown by the complete sequence analysis of the mtDNAs of four LHON probands. The various mtDNA genotypes included an isolated class I mutation, combined class I + II mutations, and combined class I/II + II mutations. The occurrence of such genotypes supports the hypothesis that LHON may result from the additive effects of various genetic and environmental insults to OXPHOS, each of which increases the probability of blindness.	EMORY UNIV, SCH MED,DEPT GENET & MOLEC MED,1462 CLIFTON RD, ROOM 403, ATLANTA, GA 30322 USA; NIH, BETHESDA, MD 20892 USA; UNIV OTTAWA, FAC MED, OTTAWA K1H 8M5, ONTARIO, CANADA	Emory University; National Institutes of Health (NIH) - USA; University of Ottawa				Lott, Marie/0000-0003-2035-479X	NIGMS NIH HHS [GM46915] Funding Source: Medline; NINDS NIH HHS [NS09042, NS21328] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; BALLINGER SW, 1992, GENETICS, V130, P139; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BROWN MD, 1992, GENETICS, V130, P163; BROWN MD, 1992, IN PRESS AM J HUM GE; BROWN TA, 1983, EMBO J, V2, P427, DOI 10.1002/j.1460-2075.1983.tb01440.x; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; BURGER G, 1985, J MOL BIOL, V186, P231, DOI 10.1016/0022-2836(85)90100-7; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; DESJARDINS P, 1990, J MOL BIOL, V212, P599, DOI 10.1016/0022-2836(90)90225-B; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; HENSGENS LAM, 1984, NUCLEIC ACIDS RES, V12, P7327, DOI 10.1093/nar/12.19.7327; HOLT IJ, 1988, HUM GENET, V79, P53, DOI 10.1007/BF00291710; HORAI S, 1984, HUM GENET, V68, P324, DOI 10.1007/BF00292594; HOWELL N, 1991, AM J HUM GENET, V48, P935; HOWELL N, 1991, AM J HUM GENET, V49, P939; HUOPONEN K, 1991, AM J HUM GENET, V48, P1147; HUYSMANS E, 1986, NUCLEIC ACIDS RES, V14, pR73, DOI 10.1093/nar/14.suppl.r73; JACOBS HT, 1988, J MOL BIOL, V202, P185, DOI 10.1016/0022-2836(88)90452-4; JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P1324, DOI 10.1016/0006-291X(91)91567-V; JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V181, P1358, DOI 10.1016/0006-291X(91)92088-2; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511; MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8; MARZUKI S, 1991, HUM GENET, V88, P139; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; Newman N.J., 1993, OPHTHALMOL CLIN N AM, V4, P431; NEWMAN NJ, 1991, AM J OPHTHALMOL, V111, P750, DOI 10.1016/S0002-9394(14)76784-4; NEWMAN NJ, 1990, AM J OPHTHALMOL, V109, P726, DOI 10.1016/S0002-9394(14)72445-6; NOER AS, 1991, AM J HUM GENET, V49, P715; PRITCHARD AE, 1990, NUCLEIC ACIDS RES, V18, P163, DOI 10.1093/nar/18.1.163; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; ROE BA, 1985, J BIOL CHEM, V260, P9759; SINGH G, 1989, NEW ENGL J MED, V320, P1300, DOI 10.1056/NEJM198905183202002; STONEKING M, 1990, GENETICS, V124, P717; TORRONI A, 1992, GENETICS, V130, P153; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; YONEDA M, 1990, BIOCHEM INT, V21, P789	42	181	186	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2791	2799		10.1096/fasebj.6.10.1634041	http://dx.doi.org/10.1096/fasebj.6.10.1634041			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634041				2022-12-28	WOS:A1992JD95400005
J	MCMAHON, SB; MONROE, JG				MCMAHON, SB; MONROE, JG			ROLE OF PRIMARY RESPONSE GENES IN GENERATING CELLULAR-RESPONSES TO GROWTH-FACTORS	FASEB JOURNAL			English	Review						GROWTH FACTORS; PRIMARY RESPONSE GENES; IMMEDIATE EARLY GENES; SIGNAL TRANSDUCTION; CELLULAR ACTIVATION	ZINC FINGER PROTEIN; C-FOS GENE; HORMONE RECEPTOR SUPERFAMILY; HUMAN OSTEOCALCIN GENE; RAT MYOCARDIAL-CELLS; DNA-BINDING ACTIVITY; LEUCINE ZIPPER; TRANSCRIPTION FACTOR; INDUCIBLE GENE; 3T3 CELLS	Cellular responses to growth and differentiation factors involve a complex cascade of signals that begins at the cell surface, traverses the cytoplasm, and eventually enters the nucleus. Although a great deal is known about the surface and cytoplasmic stages of this cascade, the nuclear events involved in transducing and translating growth and differentiation signals are less well understood. Recent work has implicated a set of genes known as primary response genes as critical for this process. To propagate the activation signal, these genes possess the ability not only to directly respond to upstream biochemical events, but also to transmit the signal downstream by modulating the unique changes in gene expression necessary for a particular cellular response. In this review we discuss how transcription factors encoded by primary response genes may be responsible for regulating tissue- or stimulus-specific responses associated with cellular activation.			MCMAHON, SB (corresponding author), UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA.			McMahon, Steven/0000-0002-3405-1768				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARENANDER AT, 1989, J NEUROSCI RES, V23, P257, DOI 10.1002/jnr.490230303; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRUVAND MW, 1988, J BIOL CHEM, V263, P18904; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMBIER JC, 1987, IMMUNOL REV, V95, P37, DOI 10.1111/j.1600-065X.1987.tb00499.x; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; DAY ML, 1990, J BIOL CHEM, V265, P15253; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARELBELLAN A, 1988, J IMMUNOL, V140, P2431; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; KARIN M, 1990, New Biologist, V2, P126; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUI M, 1990, ONCOGENE, V5, P249; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MONROE JG, 1991, IN PRESS ADV MOL CEL; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SEYFERT VL, 1990, J IMMUNOL, V145, P3647; SEYFERT VL, 1991, ADV REGULATION CELL, P201; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUKHATME VP, 1991, AM J KIDNEY DIS, V17, P615, DOI 10.1016/S0272-6386(12)80333-7; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TOURAY M, 1991, ONCOGENE, V6, P1227; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1990, CANCER BIOL, V1, P47; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YELLEN AJ, 1991, J IMMUNOL, V146, P1446; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	125	127	131	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1992	6	9					2707	2715		10.1096/fasebj.6.9.1612295	http://dx.doi.org/10.1096/fasebj.6.9.1612295			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612295				2022-12-28	WOS:A1992HZ48100012
J	WARD, ES				WARD, ES			ANTIBODY ENGINEERING - THE USE OF ESCHERICHIA-COLI AS AN EXPRESSION HOST	FASEB JOURNAL			English	Article						VH AND VL GENES; POLYMERASE CHAIN REACTION; RECOMBINANT ANTIBODY FRAGMENTS; BACTERIOPHAGE SURFACE EXPRESSION	POLYMERASE CHAIN-REACTION; IMMUNOGLOBULIN VARIABLE DOMAINS; PRIMARY INVITRO IMMUNIZATION; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; HYBRIDOMA CELLS; MIXED PRIMERS; BINDING-SITE; CLONING; GENES	The hypervariable loops of an antibody molecule are supported on the relatively conserved beta-sheeted frameworks of the heavy- and light-chain variable domains (designated VH and VL domains, respectively). Residues within and flanking these loops interact with antigen and confer the specificity and affinity of antigen binding on the immunoglobulin molecule. Thus, the isolation and expression of VH and VL domain genes are of particular interest both for analysis of the determinants of antibody specificity and for generation of fragments with binding affinities for use in therapy and diagnosis. The PCR can now be used to isolate diverse repertoires of antibody VH and VL domain genes from antibody-producing cells from different species, including humans and mice. The genes can be expressed as either secreted or surface-bound Fv or Fab fragments, using Escherichia coli expression systems, and the desired antigen-binding specificity screened for or, preferably, selected. The use of E. coli as an expression host allows the required antigen-binding specificity to be isolated in clonal form in a matter of days. The VH and VL domain genes can also be hypermutated and higher-affinity variants isolated by screening or selection. Thus, the use of this technology should allow the isolation of novel binding specificities or specificities that are difficult to generate by hybridoma technology. It will also facilitate the isolation of human-derived Fv/Fab fragments that may be less immunogenic in therapy. This approach therefore has almost unlimited potential in the generation of therapeutics with binding specificities to order. The fragments can be used either alone or linked to effector functions in the form of antibody-constant domains or toxins. The new technology could prove to be a method of choice for the rapid and convenient production of designer antibodies.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WARD, ES (corresponding author), UNIV TEXAS,SW MED CTR,CTR CANC IMMUNOBIOL,DALLAS,TX 75235, USA.			Ward, E. Sally/0000-0003-3232-7238				AHMAD A, 1988, TRENDS BIOTECHNOL, V6, P246, DOI 10.1016/0167-7799(88)90056-X; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BORREBAECK CAK, 1988, P NATL ACAD SCI USA, V85, P3995, DOI 10.1073/pnas.85.11.3995; BORREBAECK CAK, 1988, IMMUNOL TODAY, V9, P355, DOI 10.1016/0167-5699(88)91337-0; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; Burton D.R., 1987, NEW COMPREHENSIVE BI, VVolume 17, P1; Carson D A, 1986, Adv Immunol, V38, P275, DOI 10.1016/S0065-2776(08)60009-7; CATON AJ, 1990, P NATL ACAD SCI USA, V87, P6450, DOI 10.1073/pnas.87.16.6450; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; CHIANG YL, 1989, BIOTECHNIQUES, V7, P360; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CHOVNICK A, 1991, CANCER RES, V51, P465; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; COVALL DG, 1986, CANCER RES, V46, P3969; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; GIBBS RA, 1991, P NATL ACAD SCI USA, V88, P4001, DOI 10.1073/pnas.88.9.4001; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kabat EA, 1991, SEQUENCES PROTEINS I; KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LARRICK JW, 1989, BIOCHEM BIOPH RES CO, V160, P1250, DOI 10.1016/S0006-291X(89)80138-X; LARRICK JW, 1989, BIO-TECHNOL, V7, P934, DOI 10.1038/nbt0989-934; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MUELLER BM, 1990, P NATL ACAD SCI USA, V87, P5702, DOI 10.1073/pnas.87.15.5702; MULLINAX RL, 1990, P NATL ACAD SCI USA, V87, P8095, DOI 10.1073/pnas.87.20.8095; NEUBERGER MS, 1985, TRENDS BIOCHEM SCI, V10, P347, DOI 10.1016/0968-0004(85)90109-4; OHARE M, 1990, FEBS LETT, V273, P200, DOI 10.1016/0014-5793(90)81084-2; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANZ I, 1989, EMBO J, V8, P3741, DOI 10.1002/j.1460-2075.1989.tb08550.x; SASTRY L, 1989, P NATL ACAD SCI USA, V86, P5728, DOI 10.1073/pnas.86.15.5728; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SUTHERLAND R, 1987, CANCER RES, V47, P1627; TAUB R, 1989, J BIOL CHEM, V264, P259; THOMPSON KM, 1988, IMMUNOL TODAY, V9, P113, DOI 10.1016/0167-5699(88)91281-9; VITETTA ES, 1985, ANNU REV IMMUNOL, V3, P197; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WARD ES, 1989, PROGR IMMUNOLOGY, V7, P1144; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537	54	29	33	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2422	2427		10.1096/fasebj.6.7.1563594	http://dx.doi.org/10.1096/fasebj.6.7.1563594			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563594				2022-12-28	WOS:A1992HP03000007
J	MORALES, RE; JOHNSON, BR; SZABO, S				MORALES, RE; JOHNSON, BR; SZABO, S			ENDOTHELIN INDUCES VASCULAR AND MUCOSAL LESIONS, ENHANCES THE INJURY BY HC1 ETHANOL, AND THE ANTIBODY EXERTS GASTROPROTECTION	FASEB JOURNAL			English	Article						ENDOTHELIN; VASCULAR INJURY; MUCOSAL LESIONS; ENDOTHELIN-3 ANTIBODY; GASTROPROTECTION	GASTRIC INJURY; RAT; PEPTIDE; CYTOPROTECTION; PROSTAGLANDIN; PERMEABILITY; PROTECTION; NEURONS; RELEASE; DAMAGE	Vascular factors play an important role in the pathogenesis and prevention of acute gastric mucosal lesions. Endothelin-3 (ET-3), a potent vasoactive peptide, was infused intra-arterially to induce gastric microvascular and hemorrhagic mucosal lesions, and to enhance the damaging effects of dilute HCl and ethanol. ET-3 antibody was injected intravenously to decrease hemorrhagic mucosal lesions induced by ethanol. Locally infused ET (0.01, 0.1, and 1.0 nmol . 100 g-1 . min-1 for up to 15 min) was followed in some cases by intragastric dilute ethanol or HCl, which alone caused no or only mild vascular and mucosal lesions. Monastral blue was used to visualize and quantify vascular injury. ET-3 produced dose-dependent vascular lesions that affected the walls of mucosal capillaries and venules and induced mucosal congestion and focal endothelial labeling in vessels of the gastric muscular layers. The highest dose of ET induced hemorrhagic gastric mucosal lesions, mortality, and periods of hyper- and hypotension in the rat. Medium and low doses of ET-3 caused vascular injury, and dose-dependently potentiated the vascular and hemorrhagic mucosal lesions caused by dilute HCl and ethanol. Indomethacin slightly enhanced damage induced by ET and 50% ethanol, suggesting a limited mediatory role of prostaglandins in the ET-induced mucosal lesions. Anti-ET-3 serum dose-dependently decreased but did not abolish the hemorrhagic gastric mucosal lesions induced by 75% ethanol. Thus, ET-3 causes endothelial damage in capillaries and venules of rat stomach and predisposes to mucosal damage even after exposure to dilute ethanol or HCl. ET is more potent than leukotrienes and histamine and thus may play an important role in the mechanisms of acute gastric mucosal injury and protection where the vascular network appears to be a major target.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, 75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								AKIHIRI N, 1989, LANCET, V1, P747; BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; DUPUY D, 1986, GASTROENTEROLOGY, V91, P966, DOI 10.1016/0016-5085(86)90701-8; DUPUY D, 1989, ULCER DISEASE NEW AS, P421; FORTES ZB, 1989, J CARDIOVASC PHARM, V13, pS200, DOI 10.1097/00005344-198900135-00056; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; GUTH PH, 1984, GASTROENTEROLOGY, V87, P1083; GYOMBER E, 1990, ACTA BIOMEDICA HUNGA, V2, P4; HERMAN F, 1989, BRIT J PHARMACOL, V98, P38, DOI 10.1111/j.1476-5381.1989.tb16859.x; LEUNG FW, 1985, GASTROENTEROLOGY, V88, P1948, DOI 10.1016/0016-5085(85)90024-1; LIDBURY PS, 1990, EUR J PHARMACOL, V186, P205, DOI 10.1016/0014-2999(90)90435-9; MACCUMBER MW, 1989, P NATL ACAD SCI USA, V86, P7285, DOI 10.1073/pnas.86.18.7285; MILLER VM, 1989, AM J PHYSIOL, V257, pH1127, DOI 10.1152/ajpheart.1989.257.4.H1127; MORALES R E, 1990, Gastroenterology, V98, pA663; MORALES RE, 1989, DIGEST DIS SCI, V34, P1318; OHYA Y, 1988, DIGEST DIS SCI, V33, P883, DOI 10.1007/BF01550980; PIHAN G, 1986, GASTROENTEROLOGY, V91, P1415, DOI 10.1016/0016-5085(86)90195-2; PIHAN G, 1988, DIGEST DIS SCI, V33, P625, DOI 10.1007/BF01798368; PRUESS K E, 1991, Gastroenterology, V100, pA837; SAKATA K, 1989, BRIT J PHARMACOL, V98, P483, DOI 10.1111/j.1476-5381.1989.tb12621.x; SZABO S, 1981, SCIENCE, V214, P200, DOI 10.1126/science.7280691; SZABO S, 1986, SCAND J GASTROENTERO, V21, P92, DOI 10.3109/00365528609093823; SZABO S, 1982, GASTROENTEROLOGY, V82, P1191; SZABO S, 1985, GASTROENTEROLOGY, V88, P228, DOI 10.1016/S0016-5085(85)80176-1; Szabo S., 1984, MECH MUCOSAL PROTECT, P287; TARNAWSKI A, 1985, GASTROEN CLIN BIOL, V9, P88; TSURU H, 1987, J PHARMACOL EXP THER, V243, P696; WALLACE JL, 1989, AM J PHYSIOL, V256, pG661, DOI 10.1152/ajpgi.1989.256.4.G661; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WHITTLE BJR, 1988, BRIT J PHARMACOL, V95, P1011, DOI 10.1111/j.1476-5381.1988.tb11733.x; WOODS KL, 1988, DIGEST DIS SCI, V33, P769, DOI 10.1007/BF01550961; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIMI H, 1989, PEPTIDES, V10, P805, DOI 10.1016/0196-9781(89)90117-4; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X	34	41	42	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1992	6	6					2354	2360		10.1096/fasebj.6.6.1544545	http://dx.doi.org/10.1096/fasebj.6.6.1544545			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544545				2022-12-28	WOS:A1992HJ25200014
J	MAK, TW; WIGZELL, H				MAK, TW; WIGZELL, H			AIDS - 10 YEARS LATER	FASEB JOURNAL			English	Review									UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA; KAROLINSKA INST,DEPT IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN; NATL BACTERIOL LAB,S-10521 STOCKHOLM,SWEDEN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Karolinska Institutet	MAK, TW (corresponding author), UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA.							BERZOFSKY JA, 1991, FASEB J, V5, P2412, DOI 10.1096/fasebj.5.10.1712327; BLATTNER WA, 1991, FASEB J, V5, P2340, DOI 10.1096/fasebj.5.10.2065886; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; GOUDSMIT J, 1991, FASEB J, V5, P2427, DOI 10.1096/fasebj.5.10.2065891; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; JOLICOEUR P, 1991, FASEB J, V5, P2398, DOI 10.1096/fasebj.5.10.2065888; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; NARA PL, 1991, FASEB J, V5, P2437, DOI 10.1096/fasebj.5.10.1712328; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; ROSSI P, 1991, FASEB J, V5, P2419, DOI 10.1096/fasebj.5.10.2065890; WIGZELL H, 1991, FASEB J, V5, P2406, DOI 10.1096/fasebj.5.10.2065889	12	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2338	2339		10.1096/fasebj.5.10.2065885	http://dx.doi.org/10.1096/fasebj.5.10.2065885			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065885				2022-12-28	WOS:A1991FW08700003
J	BEVAN, JA; LAHER, I				BEVAN, JA; LAHER, I			PRESSURE AND FLOW-DEPENDENT VASCULAR TONE	FASEB JOURNAL			English	Review						FLOW-CONSTRICTION; FLOW-DILATION; PRESSURE CONSTRICTION; MYOGENIC TONE; SODIUM; CALCIUM; VASCULAR SMOOTH MUSCLE; STRETCH	CAT CEREBRAL-ARTERIES; ENDOTHELIAL CONTRACTILE FACTOR; STRETCH-INDUCED CONTRACTION; CANINE CORONARY-ARTERIES; ACTIVATED ION CHANNELS; RABBIT FACIAL VEIN; PROTEIN KINASE-C; RESISTANCE ARTERY; BLOOD-FLOW; AUTO-REGULATION	Most small arteries are partially constricted in vivo. After excluding neurogenic, metabolic, and circulating as well as local hormonal influences, a sizeable component of tone persists which is commonly called basal tone. In the absence of such tone, cardiac output would be insufficient to maintain the circulation. This review focuses on the contribution of stretch, induced by changes in transmural pressure, and flow acting through shear forces exerted at the blood vessel wall interface, to basal tone. Evidence concerning the cellular processes that may be activated by these physical forces - the mechanotransducing systems - are discussed. The involvement of the endothelium and the role of change in membrane potential are evaluated and lead to the conclusion that pressure and flow effects do not depend exclusively on the release of endothelial factors nor the activation of voltage-gated Ca2+ channels. Stretch/pressure-induced changes in tone show distinctive pharmacological profiles. They are dependent on extracellular calcium and yet in many instances are only weakly affected by organic Ca2+-entry inhibitors. Flow-dependent vascular effects, both constrictor and dilator, are both exquisitely sensitive to changes in extracellular Na+ and appear to be related to its transmembrane gradient. Stretch/pressure cause activation of protein kinase C, an intracellular modulator of Ca2+-dependent contractile processes. The existence of separate and distinctive cellular sensing and responding systems to pressure and flow raise the possibility that the smooth muscle tone of the vascular system can be influenced independently by the pressure and rate of flow of the blood.	UNIV VERMONT, COLL MED, VERMONT CTR VASC RES, BURLINGTON, VT 05405 USA	University of Vermont	BEVAN, JA (corresponding author), UNIV VERMONT, COLL MED, DEPT PHARMACOL, BURLINGTON, VT 05405 USA.		Laher, Ismail/L-3947-2013; Laher, Ismail/X-3323-2019	Laher, Ismail/0000-0002-3917-4417; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032985, R37HL032985, R01HL032383, R29HL042880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32985, HL 42880, HL 32383] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASANO M, 1987, J PHARMACOL EXP THER, V243, P646; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; BEVAN J A, 1988, P55; Bevan J A, 1981, HDB PHYSL          2, VII, P515; BEVAN JA, 1990, AM J PHYSIOL, V259, pH23, DOI 10.1152/ajpheart.1990.259.1.H23; BEVAN JA, 1990, BLOOD VESSELS, V27, P369; BEVAN JA, 1990, AM J PHYSIOL, V258, pH663, DOI 10.1152/ajpheart.1990.258.3.H663; BEVAN JA, 1988, BLOOD VESSELS, V25, P261; BEVAN JA, 1988, CIRC RES, V63, P980, DOI 10.1161/01.RES.63.5.980; BEVAN JA, 1991, IN PRESS RESISTANCE; BEVAN JA, 1991, IUPHAR BLOOD VESSELS, V28, P164; BEVAN JA, 1991, IN PRESS J VAC MED B; BOGNER J, 1991, IN PRESS P AUSTR PHY; CABANAC M, 1986, NEWS PHYSIOL SCI, V1, P41; COLANTUONI A, 1984, AM J PHYSIOL, V246, pH508, DOI 10.1152/ajpheart.1984.246.4.H508; DULING BR, 1981, AM J PHYSIOL, V241, pH108, DOI 10.1152/ajpheart.1981.241.1.H108; ESKINDER H, 1990, CIRC RES, V66, P1427, DOI 10.1161/01.RES.66.5.1427; FEIGEN LP, 1981, J PHARMACOL EXP THER, V219, P679; FEIGL EO, 1989, J HYPERTENS, V7, pS55; FOLKOW B, 1964, CIRC RES, V15, P279; FUNAKI S, 1964, NATURE, V203, P192, DOI 10.1038/203192b0; GARCIAROLDAN JL, 1990, CIRCULATION, V82, P704; GARCIAROLDAN JL, 1990, CIRC RES, V66, P1445, DOI 10.1161/01.RES.66.5.1445; GOLENHOFEN K, 1981, BASIC RES CARDIOL, V76, P480, DOI 10.1007/BF01908347; GRIFFITH TM, 1987, NATURE, V329, P442, DOI 10.1038/329442a0; GUSTAVSSON H, 1981, BIOCHIM BIOPHYS ACTA, V677, P23, DOI 10.1016/0304-4165(81)90141-0; HALPERN W, 1991, IN PRESS RESISTANCE; HARDER DR, 1989, CIRC RES, V65, P193, DOI 10.1161/01.RES.65.1.193; HARDER DR, 1987, CIRC RES, V60, P102, DOI 10.1161/01.RES.60.1.102; HARDER DR, 1987, AM J PHYSIOL, V253, pF778, DOI 10.1152/ajprenal.1987.253.4.F778; HARRIS RJ, 1982, STROKE, V13, P759, DOI 10.1161/01.STR.13.6.759; HILL MA, 1990, AM J PHYSIOL, V258, pH127, DOI 10.1152/ajpheart.1990.258.1.H127; HILL MA, 1990, AM J PHYSIOL, V259, pH1586, DOI 10.1152/ajpheart.1990.259.5.H1586; HWA JJ, 1986, AM J PHYSIOL, V251, pH182, DOI 10.1152/ajpheart.1986.251.1.H182; HWA JJ, 1986, AM J PHYSIOL, V250, pH87, DOI 10.1152/ajpheart.1986.250.1.H87; JACKSON PA, 1989, AM J PHYSIOL, V257, pH1147, DOI 10.1152/ajpheart.1989.257.4.H1147; JOHANSSON B, 1975, CIRC RES, V36, P76, DOI 10.1161/01.RES.36.1.76; JOHANSSON B, 1989, J HYPERTENS, V7, pS5; JOHNSON PC, 1986, CIRC RES, V59, P483, DOI 10.1161/01.RES.59.5.483; JOHNSON PC, 1989, J HYPERTENS, V7, pS33; JOYCE EH, 1991, FASEB J, V5, pA1751; KALSNER S, 1989, J PHARMACOL EXP THER, V250, P461; KATUSIC ZS, 1987, AM J PHYSIOL, V252, pH671, DOI 10.1152/ajpheart.1987.252.3.H671; KIRBER MT, 1988, PFLUG ARCH EUR J PHY, V412, P339, DOI 10.1007/BF01907549; KOLLER A, 1990, CIRC RES, V67, P529, DOI 10.1161/01.RES.67.2.529; KOLLER A, 1990, AM J PHYSIOL, V258, pH916, DOI 10.1152/ajpheart.1990.258.3.H916; KULIK TJ, 1988, AM J PHYSIOL, V255, pH1391, DOI 10.1152/ajpheart.1988.255.6.H1391; KUO L, 1990, CIRC RES, V66, P860, DOI 10.1161/01.RES.66.3.860; KUO L, 1990, AM J PHYSIOL, V259, pH1063, DOI 10.1152/ajpheart.1990.259.4.H1063; LAHER I, 1988, CIRC RES, V63, P669, DOI 10.1161/01.RES.63.3.669; LAHER I, 1988, ANN NY ACAD SCI, V522, P216; LAHER I, 1989, J HYPERTENS, V7, pS17; LAHER I, 1987, J PHARMACOL EXP THER, V242, P566; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; MCCALDEN TA, 1989, EXPERIENTIA, V45, P305, DOI 10.1007/BF01951818; MCCARRON JG, 1989, BLOOD VESSELS, V26, P315; MELLANDER S, 1989, J HYPERTENS, V7, pS21; MULVANY MJ, 1985, J HYPERTENS, V3, P429; NAKAYAMA T, 1988, RESISTANCE ARTERIES, P212; OGAWA N, 1988, J CARDIOVASC PHARM, V11, P147; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; OSOL G, 1989, BLOOD VESSELS, V26, P320; OSOL G, 1985, AM J PHYSIOL, V249, pH914, DOI 10.1152/ajpheart.1985.249.5.H914; OSOL G, 1991, CIRC RES, V68, P359, DOI 10.1161/01.RES.68.2.359; PALMER LG, 1988, FASEB J, V2, P3061, DOI 10.1096/fasebj.2.15.2461326; PEARCE WJ, 1987, J PHARMACOL EXP THER, V242, P812; PEIPER U, 1974, BASIC RES CARDIOL, V69, P1; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; RUBANYI GM, 1988, AM J PHYSIOL, V255, pH783, DOI 10.1152/ajpheart.1988.255.4.H783; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SACHS F, 1988, CRIT REV BIOMED ENG, V16, P141; Schretzenmayr A, 1933, PFLUG ARCH GES PHYS, V232, P743, DOI 10.1007/BF01754829; SEGAL SS, 1987, CIRC RES, V61, P20; SMEDA JS, 1988, CIRC RES, V62, P1104, DOI 10.1161/01.RES.62.6.1104; SMIESKO V, 1989, AM J PHYSIOL, V257, pH1958, DOI 10.1152/ajpheart.1989.257.6.H1958; UCHIDA E, 1969, AM J PHYSIOL, V216, P1343, DOI 10.1152/ajplegacy.1969.216.6.1343; WEINHEIMER G, 1983, J CARDIOVASC PHARM, V5, P989, DOI 10.1097/00005344-198311000-00012; WINQUIST RJ, 1980, SCIENCE, V207, P1001, DOI 10.1126/science.7352293	78	164	165	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1991	5	9					2267	2273		10.1096/fasebj.5.9.1860618	http://dx.doi.org/10.1096/fasebj.5.9.1860618			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860618				2022-12-28	WOS:A1991FP87200007
J	BERDANIER, CD				BERDANIER, CD			THE BHE RAT - AN ANIMAL-MODEL FOR THE STUDY OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS	FASEB JOURNAL			English	Review						OBESITY; GLYCEMIA; GLUCOSE TOLERANCE; LIPOGENESIS; GENETIC TRAIT; BHE RAT	MITOCHONDRIAL ACTIVITY; DIETARY CARBOHYDRATE; ISOLATED HEPATOCYTES; METABOLIC PATTERNS; HEPATIC-METABOLISM; STRAIN DIFFERENCES; WISTAR RATS; 2 STRAINS; SUCROSE; GLUCONEOGENESIS	Most rodents that spontaneously develop non-insulin-dependent diabetes mellitus are obese. The exception is the BHE rat. This rat develops abnormal glucose tolerance by 300 days of age, is lipemic, has a fatty liver, and yet is not obese. The strain has existed for at least 40 years and almost 100 research papers have been published describing its metabolic characteristics and responses to diet manipulation. A subline that has a higher percentage of diabetic animals has been produced. These animals may be useful in the study of mild diabetes that exists in the absence of obesity.			BERDANIER, CD (corresponding author), UNIV GEORGIA,DEPT FOOD & NUTR,ATHENS,GA 30602, USA.							ADAMS M, 1964, 24 HOM EC RES REP; ARNOLD TS, 1977, AM J CLIN NUTR, V30, P391; BERDAINER CD, 1988, FRONTIERS DIABETIC R, P427; BERDANIER CD, 1975, AM J CLIN NUTR, V28, P1416, DOI 10.1093/ajcn/28.12.1416; BERDANIER CD, 1979, J NUTR, V109, P261, DOI 10.1093/jn/109.2.261; BERDANIER CD, 1979, J NUTR, V109, P247, DOI 10.1093/jn/109.2.247; BERDANIER CD, 1974, J NUTR, V104, P1246, DOI 10.1093/jn/104.10.1246; BERDANIER CD, 1982, P SOC EXP BIOL MED, V169, P74; BERDANIER CD, 1978, P SOC EXP BIOL MED, V157, P5, DOI 10.3181/00379727-157-39979; BERDANIER CD, 1971, LIFE SCI, V10, P105, DOI 10.1016/0024-3205(71)90083-X; BERDANIER CD, 1974, DIABETOLOGIA, V10, P691, DOI 10.1007/BF01222006; BERDANIER CD, 1980, EXP GERONTOL, V15, P519, DOI 10.1016/0531-5565(80)90004-2; BERDANIER CD, 1971, P SOC EXP BIOL MED, V137, P668; BERDANIER CD, 1988, NUTRITION, V4, P295; BERDANIER CD, 1975, FED PROC, V35, P2295; BOUILLON DJ, 1983, J NUTR, V113, P2205, DOI 10.1093/jn/113.11.2205; BUE JM, 1989, AM J OBSTET GYNECOL, V161, P234, DOI 10.1016/0002-9378(89)90272-X; CAHILL GF, 1985, JOSLINS DIABETES MEL, P1; DEAVER OE, 1986, J NUTR, V116, P1148, DOI 10.1093/jn/116.7.1148; DULIN WE, 1983, DIABETES MELLITUS TH, P361; DURAND AMA, 1964, ARCH PATHOL, V77, P268; DURAND ANNA M. ALLEN, 1968, ARCH PATHOL, V85, P318; GARDNER LB, 1977, J NUTR, V107, P1884, DOI 10.1093/jn/107.10.1884; KAHN CR, 1985, JOSLINS DIABETES MEL, P43; KIM MJC, 1989, P SOC EXP BIOL MED, V192, P172, DOI 10.3181/00379727-192-42974; KIM MJC, 1990, DIABETES RES, V10, P1; KIM MJC, 1990, IN PRESS P SOC EXP B; KOH E, 1974, J NUTR, V104, P1227, DOI 10.1093/jn/104.10.1227; Krolewski A.S., 1985, JOSLINS DIABETES MEL, P12; LAKSHMANAN FL, 1981, P SOC EXP BIOL MED, V167, P224, DOI 10.3181/00379727-167-41154; LAKSHMANAN MR, 1977, ARCH BIOCHEM BIOPHYS, V183, P355, DOI 10.1016/0003-9861(77)90369-1; LAU HC, 1979, J NUTR, V109, P495, DOI 10.1093/jn/109.3.495; LEITER EH, 1989, FASEB J, V3, P2231, DOI 10.1096/fasebj.3.11.2673897; MARSHALL MW, 1967, METABOLISM, V16, P763, DOI 10.1016/0026-0495(67)90027-3; MARSHALL MW, 1969, 4TH INT S ICLA NATL; MCCUSKER RH, 1983, J NUTR, V113, P1327, DOI 10.1093/jn/113.7.1327; MCINTOSH MK, 1987, NUTR REP INT, V36, P183; MORDES JP, 1985, JOSLINS DIABETES MEL, P110; MORRIS R S, 1970, Nutrition Reports International, V2, P119; MOSER PB, 1974, J NUTR, V104, P687, DOI 10.1093/jn/104.6.687; NOLLHERNDON J, 1986, NUTR REP INT, V32, P403; OBRIEN BC, 1977, J NUTR, V107, P1444, DOI 10.1093/jn/107.8.1444; PAN JS, 1989, THESIS U GEORGIA ATH; PARK JHY, 1983, NUTR REP INT, V28, P287; PARK JHY, 1986, J NUTR, V116, P1193, DOI 10.1093/jn/116.7.1193; SEIFTER S, 1983, DIABETES MELLITUS TH, P1; SHAFRIR E, 1986, LESSONS ANIMAL DIABE; SHAFRIR E, 1988, FRONTIERS DIABETES R, V2; TAYLOR DD, 1967, J NUTR, V91, P275, DOI 10.1093/jn/91.2.275; WANDER RC, 1985, J NUTR, V115, P190, DOI 10.1093/jn/115.2.190; WANDER RC, 1986, J NUTR, V116, P1156, DOI 10.1093/jn/116.7.1156	51	44	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1991	5	8					2139	2144		10.1096/fasebj.5.8.2022312	http://dx.doi.org/10.1096/fasebj.5.8.2022312			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022312				2022-12-28	WOS:A1991FK11100004
J	BLOMHOFF, R; WAKE, K				BLOMHOFF, R; WAKE, K			PERISINUSOIDAL STELLATE CELLS OF THE LIVER - IMPORTANT ROLES IN RETINOL METABOLISM AND FIBROSIS	FASEB JOURNAL			English	Review						PERISINUSOIDAL STELLATE CELLS; PERICYTES; MYOFIBROBLASTS; RETINOL; FIBROSIS	FAT-STORING CELLS; RAT HEPATIC LIPOCYTES; NON-PARENCHYMAL CELLS; VITAMIN-A; BINDING-PROTEIN; GROWTH-FACTOR; PRIMARY CULTURES; LIPID DROPLETS; COLLAGEN; PROLIFERATION	In mammals, liver perisinusoidal stellate cells play an important role as a main store of body retinol (vitamin A). This fat-soluble vitamin is essential for vision, and regulates differentiation and growth of many cell types during embryonal development as well as in adult tissues. Thus, many cell types require a continuous supply of retinol. The storage of retinol (as retinyl esters) in stellate cells ascertains ample access of retinol to such cells also during periods with a low dietary intake. In lower vertebrates such as fish, vitamin A-storing stellate cells are found not only in the hepatic lobule, but also in the connective tissues of organs like intestine, kidney, ovaries, testes, and gills. Extrahepatic vitamin A-storing stellate cells are found in higher vertebrates when excessive doses of vitamin A are administered. It is not clear at present whether these cells also play a role in retinol metabolism under normal conditions. Stellate cells proliferate in a fibrotic liver, and they have been found to synthesize connective tissue compounds such as collagen. It was recently demonstrated that stellate cells are the principal cellular source of collagen and other extracellular substances in normal as well as fibrotic livers. Therefore, stellate cells, which seem to be a specialized type of pericyte, have a central role in the pathological changes observed during the development of liver fibrosis.	TOKYO MED & DENT UNIV,FAC MED,DEPT ANAT,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)	BLOMHOFF, R (corresponding author), UNIV OSLO,SCH MED,INST NUTR RES,POB 1046,N-0316 OSLO 3,NORWAY.							ANDERSEN KB, 1991, IN PRESS CELLS HEPAT; BACHEM MG, 1989, BIOCHEM BIOPH RES CO, V162, P708, DOI 10.1016/0006-291X(89)92368-1; BATRES RO, 1987, J NUTR, V117, P77, DOI 10.1093/jn/117.1.77; BATRES RO, 1987, J NUTR, V117, P874, DOI 10.1093/jn/117.5.874; BLOMHOFF R, 1982, P NATL ACAD SCI-BIOL, V79, P7326, DOI 10.1073/pnas.79.23.7326; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3571; BLOMHOFF R, 1988, P NATL ACAD SCI USA, V85, P3455, DOI 10.1073/pnas.85.10.3455; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3560; DAVIS BH, 1988, J CELL PHYSIOL, V136, P547, DOI 10.1002/jcp.1041360323; DAVIS BH, 1988, HEPATOLOGY, V8, P788, DOI 10.1002/hep.1840080416; DELEEUW AM, 1982, CELL TISSUE RES, V223, P201, DOI 10.1007/BF00221510; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; DELEEUW AM, 1983, HEPATOLOGY, V3, P497; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; GARD AL, 1985, J NEUROIMMUNOL, V8, P359, DOI 10.1016/S0165-5728(85)80073-4; GEERTS A, 1990, J ELECTRON MICR TECH, V14, P247, DOI 10.1002/jemt.1060140306; GJOEN T, 1987, J BIOL CHEM, V262, P10926; GOODMAN DS, 1984, RETINOIDS, V2; HENDRIKS HFJ, 1988, EUR J BIOCHEM, V171, P237, DOI 10.1111/j.1432-1033.1988.tb13782.x; LEO MA, 1983, HEPATOLOGY, V3, P1; MAHER JJ, 1988, J CLIN INVEST, V82, P450, DOI 10.1172/JCI113618; MILANI S, 1990, GASTROENTEROLOGY, V98, P175, DOI 10.1016/0016-5085(90)91307-R; MORIWAKI H, 1988, J LIPID RES, V29, P1523; Motta P, 1988, BIOPATHOLOGY LIVER U, P23, DOI [10.1007/978-94-009-1239-7_3, DOI 10.1007/978-94-009-1239-7_3]; NAGY P, 1989, MOL CARCINOGEN, V2, P345, DOI 10.1002/mc.2940020609; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; RAMADORI G, 1989, CELLS HEPATIC SINUSO, V2, P464; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; SEIFERT WF, 1989, CELLS HEPATIC SINUSO, V2, P43; SENOO H, 1984, BIOMED RES-TOKYO, V5, P451; SENOO H, 1985, LAB INVEST, V52, P182; von Kupffer C., 1876, ARCH MIKROSK ANAT, V12, P353; WAKE K, 1971, AM J ANAT, V132, P429, DOI 10.1002/aja.1001320404; Wake K, 1980, Int Rev Cytol, V66, P303; WAKE K, 1974, J CELL BIOL, V63, P683, DOI 10.1083/jcb.63.2.683; WAKE K, 1987, CELL TISSUE RES, V249, P289; WAKE K, 1986, STAIN TECHNOL, V61, P193, DOI 10.3109/10520298609109937; WAKE K, 1990, INPRESS BIOMED RES; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425; ZAJICEK G, 1988, LIVER, V8, P213	44	330	337	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					271	277		10.1096/fasebj.5.3.2001786	http://dx.doi.org/10.1096/fasebj.5.3.2001786			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001786				2022-12-28	WOS:A1991FC55600003
J	CHIN, JE; HORUK, R				CHIN, JE; HORUK, R			INTERLEUKIN-1 RECEPTORS ON RABBIT ARTICULAR CHONDROCYTES - RELATIONSHIP BETWEEN BIOLOGICAL-ACTIVITY AND RECEPTOR-BINDING KINETICS	FASEB JOURNAL			English	Article									DUPONT CO,DEPT MED PROD,GLENOLDEN,PA 19036	DuPont								BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; CHIN J, 1988, J CLIN INVEST, V82, P420, DOI 10.1172/JCI113614; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; CHIN JE, 1988, ARTHRITIS RHEUM, V31, P1290, DOI 10.1002/art.1780311011; COSMAN DJ, 1987, IMMUNOLOGY SERIES, V35, P125; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DINGLE JT, 1987, ANN RHEUM DIS, V46, P527, DOI 10.1136/ard.46.7.527; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GOWEN M, 1984, BIOCHIM BIOPHYS ACTA, V797, P186, DOI 10.1016/0304-4165(84)90121-1; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HUANG JJ, 1987, FEBS LETT, V223, P294, DOI 10.1016/0014-5793(87)80307-1; HUANG JJ, 1987, MOL BIOL MED, V4, P169; IKEBE T, 1988, J IMMUNOL, V140, P827; KERMODE JC, 1988, BIOCHEM J, V255, P521; MARSHALL S, 1979, J BIOL CHEM, V254, P153; MATSUSHIMA K, 1986, J IMMUNOL, V137, P3183; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PETTIPHER ER, 1986, P NATL ACAD SCI USA, V83, P8749, DOI 10.1073/pnas.83.22.8749; SAKLATVALA J, 1986, LYMPHOKINE RES, V5, pS99; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH RJ, 1989, INFLAMMATION, V13, P367, DOI 10.1007/BF00914921; SMITH RL, 1989, CONNECT TISSUE RES, V18, P307, DOI 10.3109/03008208909019079; XIAO DM, 1986, PROSTAGLANDINS, V32, P709, DOI 10.1016/0090-6980(86)90193-0	27	36	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1990	4	5					1481	1487		10.1096/fasebj.4.5.2137805	http://dx.doi.org/10.1096/fasebj.4.5.2137805			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CT176	2137805				2022-12-28	WOS:A1990CT17600008
J	Burke, A; Borot, F; Du, X; Churchill, M; Ding, J; Grass, AM; DeSouza, P; Ali, AM; Mukherjee, S				Burke, Alan; Borot, Florence; Du, Xing; Churchill, Michael; Ding, Jian; Grass, Albert Mridul; DeSouza, Philip; Ali, Abdullah Mahmood; Mukherjee, Siddhartha			A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia	ONCOGENE			English	Article; Early Access							ANTIBODY	Many therapeutic bispecific T-cell engagers (BiTEs) are in clinical trials. A modular and efficient process to create BiTEs would accelerate their development and clinical applicability. In this study, we present the design, production, and functional activity of a novel bispecific format utilizing synthetic orthogonal heterodimers to form a multichain modular design. Further addition of an immunoglobulin hinge region allowed a stable covalent linkage between the heterodimers. As proof-of-concept, we utilized CD33 and CD3 binding scFvs to engage leukemia cells and T-cells respectively. We provide evidence that this novel bispecific T-cell engager (termed IgGlue-BiTE) could bind both CD3+ and CD33+ cells and facilitates robust T-cell mediated cytotoxicity on AML cells in vitro. In a mouse model of minimal residual disease, we showed that the novel IgGlue-BiTE greatly extended survival, and mice of this treatment group were free of leukemia in the bone marrow. These findings suggest that the IgGlue-BiTE allows for robust simultaneous engagement with both antigens of interest in a manner conducive to T cell cytotoxicity against AML. These results suggest a compelling modular system for bispecific antibodies, as the CD3- and CD33-binding domains can be readily swapped with domains binding to other cancer- or immune cell-specific antigens.	[Burke, Alan; Borot, Florence; Du, Xing; Grass, Albert Mridul; Ali, Abdullah Mahmood; Mukherjee, Siddhartha] Columbia Univ, Dept Med, Irving Med Ctr, New York, NY 10032 USA; [Burke, Alan] Columbia Univ, Irving Med Ctr, Dept Mol Pharmacol & Therapeut, New York, NY 10032 USA; [Churchill, Michael; Ding, Jian; DeSouza, Philip] Brahma Therapeut Inc, Cambridge, MA 02139 USA; [Ali, Abdullah Mahmood; Mukherjee, Siddhartha] Columbia Univ, Edward P Evans Ctr Myelodysplast Syndromes, Irving Med Ctr, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Ali, AM; Mukherjee, S (corresponding author), Columbia Univ, Dept Med, Irving Med Ctr, New York, NY 10032 USA.; Ali, AM; Mukherjee, S (corresponding author), Columbia Univ, Edward P Evans Ctr Myelodysplast Syndromes, Irving Med Ctr, New York, NY 10032 USA.	ama2241@cumc.columbia.edu; sm3252@cumc.columbia.edu		Burke, Alan/0000-0003-2018-2342	Office of the Director, National Institutes of Health [S10RR027050, S10OD020056]; NIH [P30 CA013696]	Office of the Director, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Research reported in this publication was performed in the CCTI Flow Cytometry Core, supported in part by the Office of the Director, National Institutes of Health under awards S10RR027050 (LSRII) and S10OD020056 (Influx sorter). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Mice imaging were performed using instrumentation maintained by the Cancer Center Small Animal Imaging Shared Resource with NIH grant #P30 CA013696 (National Cancer Institute).	Borot F, 2019, P NATL ACAD SCI USA, V116, P11978, DOI 10.1073/pnas.1819992116; Brinkmann U, 2021, SCIENCE, V372, P916, DOI 10.1126/science.abg1209; Chen ZB, 2019, NATURE, V565, P106, DOI 10.1038/s41586-018-0802-y; deKruif J, 1996, J BIOL CHEM, V271, P7630, DOI 10.1074/jbc.271.13.7630; Evans R, 2010, PROTEIN COMPLEX PRED, V2004; Golay J, 2016, J IMMUNOL, V196, P3199, DOI 10.4049/jimmunol.1501592; Ha JH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00394; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; Krah S, 2017, NEW BIOTECHNOL, V39, P167, DOI 10.1016/j.nbt.2016.12.010; Li HL, 2020, CELL MOL IMMUNOL, V17, P451, DOI 10.1038/s41423-020-0417-8; Metz S, 2012, PROTEIN ENG DES SEL, V25, P571, DOI 10.1093/protein/gzs064; Mirdita M., 2022, NAT METHODS, V19, P679, DOI 10.1038/s41592-022-01488-1; Molhoj M, 2007, MOL IMMUNOL, V44, P1935, DOI 10.1016/j.molimm.2006.09.032; Payne G, 2003, CANCER CELL, V3, P207, DOI 10.1016/S1535-6108(03)00057-6; Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; Roux KH, 1997, J IMMUNOL, V159, P3372; Schneider D, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00539	18	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02532-2	http://dx.doi.org/10.1038/s41388-022-02532-2		NOV 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C0KZ	36357573	Green Submitted			2022-12-28	WOS:000881714300002
J	BEYER, KH				BEYER, KH			VITAMIN-C AND SERENDIPITY, 50 YEARS AGO	FASEB JOURNAL			English	Editorial Material											BEYER, KH (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, SCH MED, DEPT PHARMACOL, HERSHEY, PA 17033 USA.							Bernheim F, 1940, J BIOL CHEM, V133, P485; Beyer K. H., 1944, SURG GYNECOL AND OBSTET, V79, P49; BEYER K. H., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P7; Beyer KH, 1942, J AM CHEM SOC, V64, P1318, DOI 10.1021/ja01258a026; Beyer KH, 1942, J PHARMACOL EXP THER, V76, P149; Beyer KH, 1941, J PHARMACOL EXP THER, V71, P394; Beyer KH, 1941, J PHARMACOL EXP THER, V71, P151; Beyer KH, 1942, J PHARMACOL EXP THER, V74, P155; Beyer KH, 1940, J PHARMACOL EXP THER, V68, P419; Blaschko H, 1937, BIOCHEM J, V31, P2187, DOI 10.1042/bj0312187; EULER H. v., 1934, HELVETICA CHIM ACTA, V17, P157; Keilin D, 1938, PROC R SOC SER B-BIO, V125, P171, DOI 10.1098/rspb.1938.0019; Lamson PD, 1923, J PHARMACOL EXP THER, V22, P215; Peyer KH, 1943, ARCH INTERN MED, V71, P315, DOI 10.1001/archinte.1943.00210030016002; Stotz E, 1938, J BIOL CHEM, V122, P407; Wells HG, 1908, J EXP MED, V10, P457, DOI 10.1084/jem.10.4.457	16	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1992	6	14					3316	3317		10.1096/fasebj.6.14.1426769	http://dx.doi.org/10.1096/fasebj.6.14.1426769			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426769				2022-12-28	WOS:A1992JZ73400014
J	WONG, DL; LESAGE, A; SIDDALL, B; FUNDER, JW				WONG, DL; LESAGE, A; SIDDALL, B; FUNDER, JW			GLUCOCORTICOID REGULATION OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE INVIVO	FASEB JOURNAL			English	Article						RU28362; DEXAMETHASONE; TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL CONTROL; RAT ADRENAL MEDULLA	S-ADENOSYLMETHIONINE; NUCLEOTIDE-SEQUENCE; CHROMAFFIN CELLS; ADRENAL-MEDULLA; MESSENGER-RNA; GENE; CLONING; CORTICOSTERONE; EXPRESSION; ACID	In vivo, supraphysiological doses of glucocorticoids are required to restore adrenal medullary, phenylethanolamine N-methyltransferase (PNMT, E.C. 2.1.1.28) activity after hypophysectomy. However, in vitro, phenylethanolamine N-methyltransferase gene expression appears normally glucocorticoid-responsive. To explore this paradox, rats were given dexamethasone or the type II-specific glucocorticoid RU28362 (1-1000 mug/day), and adrenal phenylethanolamine N-methyltransferase activity and mRNA levels were determined. At low doses (1-30 mug/day), neither steroid altered mRNA whereas at higher doses (100-1000 mug/day), mRNA rose 10- to 20-fold, with dexamethasone approximately 3 times as potent as RU28362. In contrast, enzyme activity fell with low doses of either steroid, consistent with suppression of ACTH and endogenous steroidogenesis. At higher doses of RU28362, enzyme activity remained low and unchanged despite increased mRNA expression, whereas higher doses of dexamethasone progressively restored the enzyme to normal. These findings suggest 1) that glucocorticoid regulation of phenylethanolamine N-methyltransferase activity occurs largely independent of gene expression; 2) that glucocorticoid effects on enzyme activity are primarily indirect, probably through cosubstrate regulation and/or enzyme stabilization; and 3) that these effects are not mediated via a classical (type II) glucocorticoid receptor mechanism, given the high doses of dexamethasone and corticosterone required and the inability of RU28362 to mimic the effects of these less selective steroids.			WONG, DL (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PSYCHIAT & BEHAV SCI,NANCY PRITZKER LAB DEV & MOLEC NEUROBIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH039437] Funding Source: NIH RePORTER; NIMH NIH HHS [MH39437] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BANERJI TK, 1985, LIFE SCI, V38, P343; BATTER DK, 1988, J NEUROSCI RES, V19, P367, DOI 10.1002/jnr.490190313; BOHN MC, 1981, DEV BIOL, V82, P1, DOI 10.1016/0012-1606(81)90423-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARANELLO RD, 1978, MOL PHARMACOL, V14, P478; DAVIS LG, 1986, METHOD MOL BIOL, P143; GYERMAK L, 1975, ANESTHESIOLOGY, V442, P419; JIANG W, 1989, INT J DEV NEUROSCI, V7, P513, DOI 10.1016/0736-5748(89)90010-5; JINGDONG Z, 1985, BIOTECHNOLOGY, V3, P1014; KANEDA N, 1988, J BIOL CHEM, V263, P7672; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; LEGASCOGNE C, 1987, SCIENCE, V237, P1212; MARGOLIS FL, 1966, SCIENCE, V154, P275, DOI 10.1126/science.154.3746.275; MEZEY E, 1989, NUCLEIC ACIDS RES, V17, P2125, DOI 10.1093/nar/17.5.2125; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PARKER LN, 1967, SOC EXP BIOL MED, V126, P734; ROSS ME, 1990, J NEUROSCI, V10, P520; SAMBROOK J, 1990, MOL CLONING LABORATO; WAN DCC, 1989, EUR J PHARM-MOLEC PH, V172, P107, DOI 10.1016/0922-4106(89)90002-3; WONG DL, 1982, J NEUROSCI, V2, P758; WONG DL, 1985, BRAIN RES, V330, P209, DOI 10.1016/0006-8993(85)90679-1; WONG DL, 1987, BRAIN RES, V410, P32, DOI 10.1016/S0006-8993(87)80017-3; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301	26	62	63	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1992	6	14					3310	3315		10.1096/fasebj.6.14.1426768	http://dx.doi.org/10.1096/fasebj.6.14.1426768			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426768				2022-12-28	WOS:A1992JZ73400013
J	OREN, M				OREN, M			P53 - THE ULTIMATE TUMOR SUPPRESSOR GENE	FASEB JOURNAL			English	Review						P53; TUMOR SUPPRESSOR GENES; DOMINANT NEGATIVE MUTANTS; TUMORIGENESIS	WILD-TYPE P53; MUTANT P53; CELL-CYCLE; T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; DNA-REPLICATION; BREAST-CANCER; SV40 ORIGIN; PROTEIN; MUTATIONS	Alterations in the gene encoding the cellular p53 protein are perhaps the most frequent type of genetic lesions in human cancer. At the heart of these alterations is the abrogation of the tumor suppressor activity of the normal p53. In many cases this is achieved through point mutations in p53, which often result in pronounced conformational changes. Such mutant polypeptides, which tend to accumulate to high levels in cancer cells, are believed to exert a dominant negative effect over coexpressed normal p53. Extensive research on p53, especially in the course of the last 3 years, has already provided much insight into the biological and biochemical mechanisms that underlie its capacity to act as a potent tumor suppressor. There are now many indications that p53 may play a central role in the control of cell proliferation, cell survival, and differentiation. Nevertheless, despite the purported importance of p53 for such crucial processes, mice can develop apparently without any defect in the total absence of p53. This raises the possibility that p53 may become critically limiting only when normal growth control is lost.			OREN, M (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.				NCI NIH HHS [R01 CA 40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1992, CANCER RES, V52, P222; CHIBA I, 1990, ONCOGENE, V5, P1603; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALEVY O, 1991, ONCOGENE, V6, P1593; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1988, ONCOGENE HDB, P403; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; OREN M, 1991, BIOCH MOL ASPECTS SE, P373; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SHOHAT F, 1991, NUCLEIC ACIDS RES, V19, P5191; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1988, ONCOGENE, V3, P405; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WIMAN KG, 1991, ONCOGENE, V6, P1633; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	66	250	255	3	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1992	6	13					3169	3176		10.1096/fasebj.6.13.1397838	http://dx.doi.org/10.1096/fasebj.6.13.1397838			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397838				2022-12-28	WOS:A1992JU51200009
J	BROWN, GC				BROWN, GC			THE LEAKS AND SLIPS OF BIOENERGETIC MEMBRANES	FASEB JOURNAL			English	Review						PROTON PERMEABILITY; PROTON STOICHIOMETRY; MEMBRANE PERMEABILITY; BIOENERGETICS; MITOCHONDRIA	MITOCHONDRIAL INNER MEMBRANE; RAT-LIVER MITOCHONDRIA; RELATIVE PROTON STOICHIOMETRIES; OXIDATIVE-PHOSPHORYLATION; CHARGE TRANSLOCATION; CYTOCHROME-OXIDASE; RESPIRATION RATE; MOTIVE FORCE; H+-PUMPS; PERMEABILITY	Bioenergetic membranes use proton gradients to transduce energy. However, when the proton gradient is large 1) there is a passive leak of protons (and other ions) across these membranes, and 2) some proton pumps may fail to pump protons (a phenomenon known as slip). Leaks and slips may be an unavoidable consequence of membrane structure and cause significant wastage of free energy, but they may also have functional roles beneficial to the organism.			BROWN, GC (corresponding author), UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND.		Brown, Guy C./HHC-1102-2022	Brown, Guy/0000-0002-3610-1730				BOGUCKA K, 1990, BIOCHIM BIOPHYS ACTA, V1015, P503, DOI 10.1016/0005-2728(90)90084-H; BOUGESBOCQUET B, 1981, BIOCHIM BIOPHYS ACTA, V635, P327, DOI 10.1016/0005-2728(81)90031-1; BRAND MD, 1991, BIOCHEM J, V275, P81, DOI 10.1042/bj2750081; BRAND MD, 1990, J THEOR BIOL, V145, P267, DOI 10.1016/S0022-5193(05)80131-6; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BROWN GC, 1989, J BIOL CHEM, V264, P14704; BROWN GC, 1991, BIOCHIM BIOPHYS ACTA, V1059, P55, DOI 10.1016/S0005-2728(05)80187-2; BROWN GC, 1986, BIOCHEM J, V234, P75, DOI 10.1042/bj2340075; BROWN GC, 1990, EUR J BIOCHEM, V192, P355, DOI 10.1111/j.1432-1033.1990.tb19234.x; CLARK AJ, 1983, BIOCHIM BIOPHYS ACTA, V723, P440, DOI 10.1016/0005-2728(83)90051-8; COTTON NPJ, 1984, EUR J BIOCHEM, V142, P193, DOI 10.1111/j.1432-1033.1984.tb08269.x; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DEAMER DW, 1989, J MEMBRANE BIOL, V107, P91, DOI 10.1007/BF01871715; DILGER JP, 1979, SCIENCE, V206, P1196, DOI 10.1126/science.228394; EVRON Y, 1990, BIOCHIM BIOPHYS ACTA, V1019, P115, DOI 10.1016/0005-2728(90)90131-M; FINEL M, 1986, BIOCHIM BIOPHYS ACTA, V851, P99, DOI 10.1016/0005-2728(86)90253-7; FOWLER CF, 1976, BIOCHIM BIOPHYS ACTA, V423, P510, DOI 10.1016/0005-2728(76)90204-8; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; GRABER P, 1976, BIOCHIM BIOPHYS ACTA, V423, P141, DOI 10.1016/0005-2728(76)90174-2; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x; HAFNER RP, 1991, BIOCHEM J, V275, P75, DOI 10.1042/bj2750075; HASLAM JM, 1977, BIOCHEM J, V166, P565, DOI 10.1042/bj1660565; Kell DB, 1978, BIOCHEM SOC T, V6, P1292, DOI 10.1042/bst0061292; KLUG GA, 1984, BIOCHIM BIOPHYS ACTA, V764, P272, DOI 10.1016/0005-2728(84)90097-5; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; MALONEY PC, 1979, J BACTERIOL, V140, P197, DOI 10.1128/JB.140.1.197-205.1979; MANDOLINO G, 1983, BIOCHIM BIOPHYS ACTA, V723, P428, DOI 10.1016/0005-2728(83)90050-6; MITCHELL P, 1967, BIOCHEM J, V105, P1147, DOI 10.1042/bj1051147; MURPHY MP, 1988, EUR J BIOCHEM, V173, P637, DOI 10.1111/j.1432-1033.1988.tb14046.x; MURPHY MP, 1988, EUR J BIOCHEM, V173, P645, DOI 10.1111/j.1432-1033.1988.tb14047.x; MURPHY MP, 1989, BIOCHIM BIOPHYS ACTA, V977, P123, DOI 10.1016/S0005-2728(89)80063-5; MURPHY MP, 1987, NATURE, V329, P170, DOI 10.1038/329170a0; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NOBES CD, 1990, J BIOL CHEM, V265, P12903; PIETROBON D, 1981, EUR J BIOCHEM, V117, P389, DOI 10.1111/j.1432-1033.1981.tb06350.x; PIETROBON D, 1983, BIOCHIM BIOPHYS ACTA, V723, P317, DOI 10.1016/0005-2728(83)90131-7; RAVEN JA, 1981, FEMS MICROBIOL LETT, V10, P1; RICH PR, 1988, BIOCHIM BIOPHYS ACTA, V932, P33, DOI 10.1016/0005-2728(88)90137-5; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; SCHONFELD M, 1977, FEBS LETT, V73, P51, DOI 10.1016/0014-5793(77)80013-6; SHINOHARA Y, 1991, FEBS LETT, V293, P173, DOI 10.1016/0014-5793(91)81179-C; SORGATO MC, 1979, BIOCHEMISTRY-US, V18, P5737, DOI 10.1021/bi00592a034; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; VALCARCE C, 1990, J BIOCHEM, V108, P642; VILLALOBO A, 1990, BIOCHIM BIOPHYS ACTA, V1017, P1, DOI 10.1016/0005-2728(90)90176-5; WESTERHOFF HV, 1984, TRENDS BIOCHEM SCI, V9, P112, DOI 10.1016/0968-0004(84)90107-5; WOJTCZAK L, 1976, J BIOENERG BIOMEMBR, V8, P293; ZOLKIEWSKA A, 1989, ARCH BIOCHEM BIOPHYS, V275, P580; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004	51	46	47	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1992	6	11					2961	2965		10.1096/fasebj.6.11.1644259	http://dx.doi.org/10.1096/fasebj.6.11.1644259			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644259				2022-12-28	WOS:A1992JJ66500010
J	BEHARA, AMP; WESTCOTT, AJ; CHANG, PL				BEHARA, AMP; WESTCOTT, AJ; CHANG, PL			INTRATHYMIC IMPLANTS OF GENETICALLY MODIFIED FIBROBLASTS	FASEB JOURNAL			English	Article						GENE THERAPY; HUMAN GROWTH HORMONE; CYCLOSPORINE-A; THYMUS; TRANSPLANTATION	HUMAN-GENE THERAPY; T-CELL RECEPTOR; ENDOTHELIAL-CELLS; SKIN FIBROBLASTS; CYCLOSPORINE-A; EXPRESSION; TOLERANCE; HEPATOCYTES; DELETIONS; VECTORS	Implantation of autologous rodent fibroblasts genetically altered to express human growth hormone has recently been shown to be a feasible approach to the delivery of new gene products in,somatic gene therapy. However, the novel gene product elicited in its recipients an intense antibody response that would have curtailed the effectiveness of such therapy. The possibility of inducing tolerance to foreign gene product was explored by implanting allogeneic fibroblasts transfected with the human growth hormone gene into rat thymus, a site recently shown to be immunologically privileged and able to induce donor-specific tolerance to transplanted tissues. In the circulation of the implanted rats, human growth hormone was detected at 4-15 ng/ml serum within the first day and subsided to 0.6-9 ng/ml within the first wk in all animals implanted either thymically or intraperitoneally. Within 2-3 wk, high titers of anti-human growth hormone were detected in all animals regardless of the site of implantation. The failure of the thymus to offer immune protection for the foreign antigen was further confirmed when the animals were subsequently challenged with purified human growth hormone. An immediate twofold increase in titer within the first week of challenge was detected in animals previously implanted thymically. In contrast, animals implanted intraperitoneally but treated with short-term daily injection of cyclosporine A (28-41 days) did not mount any significant antibody response to human growth hormone throughout the experiment or even when challenged subsequently at weeks 8-10 with purified growth hormone. In conclusion, implantation of genetically modified fibroblasts in the thymus does not lead to tolerization toward soluble novel gene product secreted by these cells. However, a limited course of cyclosporine A treatment was effective for prolonged suppression of antibody response to novel gene products.	MCMASTER UNIV, MED CTR,DEPT PEDIAT,ROOM HSC 3N18,1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT BIOMED SCI, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University								ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; BENNETT VJ, 1990, MOL BIOL MED, V7, P471; BENNETT VJ, 1991, LIFE SCI, V48, P1455, DOI 10.1016/0024-3205(91)90182-B; BLAESE M, 1991, 8TH INT C HUM GEN WA; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CHANG PL, 1986, EXP CELL RES, V167, P407, DOI 10.1016/0014-4827(86)90181-3; CHANG PL, 1990, MOL BIOL MED, V7, P461; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; GARVER RI, 1987, P NATL ACAD SCI USA, V84, P1050, DOI 10.1073/pnas.84.4.1050; GRAHAM FL, 1983, NUCLEIC ACIDS BIOC B, V506, P1; HOBBS HH, 1988, J CLIN INVEST, V81, P909, DOI 10.1172/JCI113402; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KUNKEL LM, 1986, NATURE, V322, P73, DOI 10.1038/322073a0; LANCE EM, 1973, ADV IMMUNOL, V17, P1; LEDLEY FD, 1987, P NATL ACAD SCI USA, V84, P5335, DOI 10.1073/pnas.84.15.5335; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MCCORMICK D, 1985, BIO-TECHNOL, V3, P689; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; OSBORNE WRA, 1988, P NATL ACAD SCI USA, V85, P6851, DOI 10.1073/pnas.85.18.6851; PALMER TD, 1987, P NATL ACAD SCI USA, V84, P1055, DOI 10.1073/pnas.84.4.1055; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; REIS MD, 1989, ADV CANCER RES, V52, P45; REMUZZI G, 1991, LANCET, V337, P750, DOI 10.1016/0140-6736(91)91368-5; SCHALCH DS, 1964, NATURE, V203, P1141, DOI 10.1038/2031141a0; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SELDEN RF, 1987, SCIENCE, V236, P714, DOI 10.1126/science.3472348; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; TEUMER J, 1990, FASEB J, V4, P3245, DOI 10.1096/fasebj.4.14.2227214; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2281; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WILSON JM, 1991, 8TH INT C HUM GEN WA; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZWIEBEL JA, 1989, SCIENCE, V243, P220, DOI 10.1126/science.2911735	40	11	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2853	2858		10.1096/fasebj.6.10.1634049	http://dx.doi.org/10.1096/fasebj.6.10.1634049			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634049				2022-12-28	WOS:A1992JD95400015
J	MELNICK, RL				MELNICK, RL			DOES CHEMICALLY-INDUCED HEPATOCYTE PROLIFERATION PREDICT LIVER CARCINOGENESIS	FASEB JOURNAL			English	Review						CELL PROLIFERATION; CELL LOSS; CHEMICAL CARCINOGENESIS; LIVER; S-PHASE HEPATOCYTES; ALTERED HEPATIC LOCI; NONGENOTOXIC CARCINOGENS; INITIATION; PROMOTION	<4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO>ACETIC ACID WY-14,643; INDUCED CELL-PROLIFERATION; UNSCHEDULED DNA-SYNTHESIS; CHOLINE-DEVOID DIET; MALE B6C3F1 MICE; RAT-LIVER; PEROXISOME PROLIFERATOR; INDUCED HYPERPLASIA; HEPATIC TUMORIGENESIS; CHRONIC TOXICITY	Cell proliferation has long been recognized as having an important role in chemically induced carcinogenesis. Based on findings that certain nongenotoxic chemical carcinogens induced cell proliferation in the same organ that had an increased incidence of tumors, it has been hypothesized that a chemically induced response of enhanced DNA synthesis and cellular division causes cancer by increasing the rate of spontaneous mutations. It was further suggested that there would be no increased human risk of cancer by non-DNA-reactive compounds at doses that do not cause a proliferative response. An evaluation of the literature on the relationship between chemically induced cell proliferation and liver carcinogenesis reveals that very few systematic cell proliferation studies have been conducted over periods of extended exposure, and in many cases the exposure concentrations were not similar to those used in the cancer studies. The proliferative response resulting from exposure to many nongenotoxic carcinogens is not well sustained, whereas the carcinogenic response by these chemicals often requires prolonged exposure. The available literature leads to the conclusion that quantitative correspondences between cellular proliferation and carcinogenic responses have not been demonstrated and do not support the hypothesis that chemically induced cell proliferation is the primary mechanism by which nongenotoxic chemicals cause liver cancer. Studies of liver carcinogenesis in two-stage models point out the need to better understand chemical effects on cell loss as well as on cell replication, and demonstrate that measurements of cell proliferation alone are not sufficient to elucidate mechanisms of tumor development.			MELNICK, RL (corresponding author), NIEHS, POB 12233, RES TRIANGLE PK, NC 27709 USA.							ABANOBI SE, 1982, CANCER RES, V42, P412; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BECKER FF, 1979, CANCER RES, V39, P5177; BURSCH W, 1984, CARCINOGENESIS, V5, P453, DOI 10.1093/carcin/5.4.453; BUTTERWORTH BE, 1987, TOXICOL IND HEALTH, V3, P129, DOI 10.1177/074823378700300210; BUTTERWORTH BE, 1990, MUTAT RES, V239, P117, DOI 10.1016/0165-1110(90)90033-8; CASCIANO DA, 1990, NCTR6425 TECHN REP; CAYAMA E, 1978, NATURE, V275, P60, DOI 10.1038/275060a0; COLUMBANO A, 1987, CARCINOGENESIS, V8, P345, DOI 10.1093/carcin/8.2.345; COLUMBANO A, 1987, CANCER RES, V47, P5557; COLUMBANO A, 1990, CARCINOGENESIS, V11, P771, DOI 10.1093/carcin/11.5.771; COLUMBANO A, 1981, CANCER RES, V41, P2079; EACHO PI, 1991, CARCINOGENESIS, V12, P1557, DOI 10.1093/carcin/12.9.1557; ELDRIDGE SR, 1991, TOXICOLOGIST, V11, P126; FARBER E, 1991, DIGEST DIS SCI, V36, P973, DOI 10.1007/BF01297150; Farber E., 1982, CANCER COMPREHENSIVE, P485; GOLDSWORTHY TL, CHEM INDUCED CELL PR, P253; GRASSO P, 1987, ARCH TOXICOL, P75; HAGIWARA A, 1986, FUND APPL TOXICOL, V7, P376, DOI 10.1016/0272-0590(86)90087-4; HOEL DG, 1988, CARCINOGENESIS, V9, P2045, DOI 10.1093/carcin/9.11.2045; KOCIBA RJ, 1978, TOXICOL APPL PHARM, V46, P279, DOI 10.1016/0041-008X(78)90075-3; LEDDACOLUMBANO GM, 1989, CARCINOGENESIS, V10, P847, DOI 10.1093/carcin/10.5.847; LIJINSKY, 1990, J ENV SCI HLTH C, V8, P45; LIJINSKY W, 1984, FOOD CHEM TOXICOL, V22, P27, DOI 10.1016/0278-6915(84)90048-6; LOURY DJ, 1986, TOXICOL APPL PHARM, V85, P11, DOI 10.1016/0041-008X(86)90383-2; LOURY DJ, 1987, BANBURY REPORT, V25, P119; LUCIER GW, 1991, CANCER RES, V51, P1391; MARSMAN DS, 1988, CANCER RES, V48, P6739; MIRSALIS JC, 1985, CARCINOGENESIS, V6, P1521, DOI 10.1093/carcin/6.10.1521; MIRSALIS JC, 1987, CELL BIOL TOXICOL, V3, P165, DOI 10.1007/BF00058454; NEWBERNE PM, 1987, ARCH TOXICOL, P54; PERAINO C, 1973, CANCER RES, V33, P2701; POUND AW, 1978, BRIT J CANCER, V37, P585, DOI 10.1038/bjc.1978.88; PRICE RJ, 1991, TOXICOLOGIST, V11, P127; RAO MS, 1984, CANCER RES, V44, P1072; RAO PM, 1983, CARCINOGENESIS, V4, P1541, DOI 10.1093/carcin/4.12.1541; REDDY JK, 1979, CANCER RES, V39, P152; REDDY JK, 1977, J NATL CANCER I, V59, P1645, DOI 10.1093/jnci/59.6.1645; ROSSI L, 1977, INT J CANCER, V19, P179, DOI 10.1002/ijc.2910190207; ROTSTEIN J, 1984, CANCER RES, V44, P2913; ROTSTEIN J, 1986, CANCER RES, V46, P2377; RUSH RE, 1991, TOXICOLOGIST, V11, P125; SCHULTE-HERMANN R, 1989, Toxicologic Pathology, V17, P642; Schulte-Hermann R, 1982, Toxicol Pathol, V10, P63, DOI 10.1177/019262338201000209; SCHULTEHERMANN R, 1986, CARCINOGENESIS, V7, P1651, DOI 10.1093/carcin/7.10.1651; SCHULTEHERMANN R, 1983, ENVIRON HEALTH PERSP, V50, P185, DOI 10.2307/3429549; SCHULTEHERMANN R, 1990, CANCER RES, V50, P5127; SHINOZUKA H, 1980, CANCER RES, V40, P3846; SMITHOLIVER T, 1987, MUTAT RES, V188, P21, DOI 10.1016/0165-1218(87)90110-8; SOLT D, 1976, NATURE, V263, P701, DOI 10.1038/263701a0; STEINMETZ KL, 1988, CARCINOGENESIS, V9, P959, DOI 10.1093/carcin/9.6.959; STOTT WT, 1981, FOOD COSMET TOXICOL, V19, P567, DOI 10.1016/0015-6264(81)90507-1; TILBURY LF, 1991, TOXICOLOGIST, V11, P126; WARD JM, 1988, TOXICOL APPL PHARM, V96, P494, DOI 10.1016/0041-008X(88)90009-9; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; YELDANDI AV, 1989, CANCER LETT, V47, P21, DOI 10.1016/0304-3835(89)90172-9; 1976, NCI2 NIH TECHN REP; 1982, NTP219 NIH NAT TOX P; 1978, NCI74 NIH TECHN REP; 1977, NCI8 NIH TECHN REP; 1976, PB264018; 1982, NTP217 NIH NAT TOX P; 1978, NCI27 NIH TECHN REP	63	75	75	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1992	6	9					2698	2706		10.1096/fasebj.6.9.1612294	http://dx.doi.org/10.1096/fasebj.6.9.1612294			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612294				2022-12-28	WOS:A1992HZ48100011
J	KRIEG, AM; GOURLEY, MF; PERL, A				KRIEG, AM; GOURLEY, MF; PERL, A			ENDOGENOUS RETROVIRUSES - POTENTIAL ETIOLOGIC AGENTS IN AUTOIMMUNITY	FASEB JOURNAL			English	Review						RETROVIRUS; AUTOIMMUNITY; ANTISENSE; PATHOGENESIS; LUPUS	MAMMARY-TUMOR VIRUS; MURINE LEUKEMIA-VIRUS; PROTEIN-KINASE-C; HUMAN DNA; SJOGRENS-SYNDROME; TRANSFER RNAPRO; HUMAN-CELLS; SEQUENCES; EXPRESSION; ELEMENTS	The genomes of all organisms, from yeast to humans, contain thousands of endogenous retroviruses (ERV). In most species all or almost all ERV are noninfectious, but some ERV retain open reading frames capable of encoding proteins. RNA and proteins derived from ERV are expressed in humans and other species. Until recently, there was little evidence that this ERV expression resulted in any immunologic effects. Recent studies make it increasingly clear that some ERV have important immunologic effects. The immune effects of ERV expression raise the question of a possible pathogenic role in idiopathic autoimmune diseases. Interest in this question has been heightened by the observation that some infectious retroviruses cause manifestations of autoimmunity. Nonetheless, attempts to isolate infectious retroviruses from patients with idiopathic autoimmune diseases have generally failed. The possible role of ERV in idiopathic autoimmune diseases has not yet been fully explored. This review focuses on the known and the potential immune effects of ERV, especially as they may relate to autoimmune diseases.	NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT MOLEC MED & IMMUNOL, BUFFALO, NY 14263 USA; NIAMSD, CELLULAR IMMUNOL SECT, BETHESDA, MD 20892 USA	Roswell Park Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	KRIEG, AM (corresponding author), UNIV IOWA, COLL MED, DEPT MED, DIV RHEUMATOL, 540 EMRB, IOWA CITY, IA 52242 USA.		Krieg, Arthur M/K-8109-2019; Krieg, Art/R-6166-2019	Perl, Andras/0000-0002-5017-1348				ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BACCALA R, 1991, P NATL ACAD SCI USA, V88, P2908, DOI 10.1073/pnas.88.7.2908; BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BANKI K, 1992, P NATL ACAD SCI USA, V89, P1939, DOI 10.1073/pnas.89.5.1939; BJORK RL, 1991, IMMUNOL LETT, V28, P91, DOI 10.1016/0165-2478(91)90104-I; BONNER TI, 1982, P NATL ACAD SCI-BIOL, V79, P4709, DOI 10.1073/pnas.79.15.4709; BROOKES S M, 1991, Arthritis and Rheumatism, V34, pS135; BULLER RS, 1989, J EXP MED, V169, P865, DOI 10.1084/jem.169.3.865; CALLAHAN R, 1982, P NATL ACAD SCI-BIOL, V79, P5503, DOI 10.1073/pnas.79.18.5503; CALLAHAN R, 1988, BANBURY REPORT, V30, P91; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; FRANKEL WN, 1990, GENETICS, V124, P221; FRANKLIN GC, 1988, J VIROL, V62, P1203, DOI 10.1128/JVI.62.4.1203-1210.1988; FRIEDMAN SM, 1991, ARTHRITIS RHEUM-US, V34, P468, DOI 10.1002/art.1780340412; GARRY RF, 1990, SCIENCE, V250, P1127, DOI 10.1126/science.1701273; GARRY RF, 1990, AIDS RES HUM RETROV, V6, P1361, DOI 10.1089/aid.1990.6.1361; GOTTLIEB RA, 1990, J IMMUNOL, V145, P2566; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HARADA F, 1987, NUCLEIC ACIDS RES, V15, P9153, DOI 10.1093/nar/15.22.9153; HORWITZ MS, 1991, IN PRESS J VIROL; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; KAMBHU S, 1990, P NATL ACAD SCI USA, V87, P4927, DOI 10.1073/pnas.87.13.4927; KANNAN P, 1991, J VIROL, V65, P6343, DOI 10.1128/JVI.65.11.6343-6348.1991; KATO N, 1987, J VIROL, V61, P2182, DOI 10.1128/JVI.61.7.2182-2191.1987; KION TA, 1991, IN PRESS SCIENCE; KOKA P, 1991, J IMMUNOL, V146, P2417; KRIEG AM, 1988, J VIROL, V62, P3545, DOI 10.1128/JVI.62.10.3545-3550.1988; KRIEG AM, 1990, J AUTOIMMUN, V3, P137, DOI 10.1016/0896-8411(90)90137-H; KRIEG AM, 1989, J IMMUNOL, V143, P2448; KRIEG AM, 1990, J CLIN INVEST, V86, P809, DOI 10.1172/JCI114778; KRIEG AM, 1991, J IMMUNOL, V146, P3002; KROGER B, 1987, J VIROL, V61, P2071; LAMANTIA G, 1991, NUCLEIC ACIDS RES, V19, P1513; LARSSON E, 1989, CURR TOP MICROBIOL, V148, P115; LEIBMOSCH C, 1990, CANCER RES, V50, pS5636; LEIBMOSCH C, 1986, VIROLOGY, V155, P666, DOI 10.1016/0042-6822(86)90226-6; LEIBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990, DOI 10.1073/pnas.87.18.6990; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MAEDA N, 1990, GENOMICS, V8, P671, DOI 10.1016/0888-7543(90)90254-R; MAGER DL, 1989, AM J HUM GENET, V45, P848; MAGER DL, 1987, J VIROL, V61, P4060, DOI 10.1128/JVI.61.12.4060-4066.1987; MARIANICOSTANTINI R, 1989, J VIROL, V63, P4982, DOI 10.1128/JVI.63.11.4982-4985.1989; MARTIN MA, 1981, P NATL ACAD SCI-BIOL, V78, P4892, DOI 10.1073/pnas.78.8.4892; MARTINELLI SC, 1990, VIROLOGY, V174, P135, DOI 10.1016/0042-6822(90)90062-V; NODA M, 1982, NUCLEIC ACIDS RES, V10, P2865, DOI 10.1093/nar/10.9.2865; OCONNELL C, 1984, VIROLOGY, V138, P225, DOI 10.1016/0042-6822(84)90347-7; ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; PERL A, 1989, NUCLEIC ACIDS RES, V17, P6841, DOI 10.1093/nar/17.17.6841; PERL A, 1991, GENOMICS, V11, P1172, DOI 10.1016/0888-7543(91)90052-G; PERL A, 1991, ARTHRITIS RHEUM, V34, P1313, DOI 10.1002/art.1780341017; RUBIN L A, 1991, Arthritis and Rheumatism, V34, pS60; RUEGG CL, 1990, J VIROL, V64, P2175, DOI 10.1128/JVI.64.5.2175-2180.1990; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SATO K, 1991, ARTHRITIS RHEUM, V34, P714, DOI 10.1002/art.1780340612; SHIH A, 1989, J VIROL, V63, P64, DOI 10.1128/JVI.63.1.64-75.1989; SILVER J, 1987, MOL CELL BIOL, V7, P1559, DOI 10.1128/MCB.7.4.1559; STEELE PE, 1984, SCIENCE, V225, P943, DOI 10.1126/science.6089336; STOYE JP, 1985, MOL BIOL TUMOR VIR 3, V2, P357; TALAL N, 1990, ARTHRITIS RHEUM, V33, P774, DOI 10.1002/art.1780330603; TALAL N, 1990, J CLIN INVEST, V85, P1866, DOI 10.1172/JCI114647; TRAUGER RJ, 1990, J BIOL CHEM, V265, P3674; TSICHLIS PN, 1991, P NATL ACAD SCI USA, V88, P4611, DOI 10.1073/pnas.88.11.4611; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WEISS R, 1985, RNA TUMOR VIRUSES, V2, P1205; WERNER T, 1990, VIROLOGY, V174, P225, DOI 10.1016/0042-6822(90)90071-X; WILKINSON DA, 1990, J VIROL, V64, P2157, DOI 10.1128/JVI.64.5.2157-2167.1990; YAMADA M, 1991, J VIROL, V65, P1370, DOI 10.1128/JVI.65.3.1370-1376.1991; YANG JN, 1991, J VIROL, V65, P3911, DOI 10.1128/JVI.65.7.3911-3914.1991; ZIEGLER B, 1989, AM J PATHOL, V135, P1; ZIEGLER BL, 1991, ACTA HISTOCHEM CYTOC, V24, P1, DOI 10.1267/ahc.24.1; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	74	136	136	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1992	6	8					2537	2544		10.1096/fasebj.6.8.1592206	http://dx.doi.org/10.1096/fasebj.6.8.1592206			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592206				2022-12-28	WOS:A1992HU42300006
J	SECKLER, R; JAENICKE, R				SECKLER, R; JAENICKE, R			PROTEIN FOLDING AND PROTEIN REFOLDING	FASEB JOURNAL			English	Review						PROTEIN STRUCTURE; PROTEIN STABILITY; FOLDING; AGGREGATION; MOLECULAR CHAPERONES	HEAT-SHOCK PROTEINS; PANCREATIC TRYPSIN-INHIBITOR; ESCHERICHIA-COLI; PEPTIDE-FRAGMENTS; RIBONUCLEASE-A; INTERMEDIATE; MECHANISM; NMR; TRANSLOCATION; STABILITY	The functional three-dimensional structure of proteins is determined solely by their amino acid sequences. Protein folding occurs spontaneously beginning with the formation of local secondary structure concomitant with a compaction of the molecule. Secondary structure elements subsequently interact to form subdomains and domains stabilized by tertiary interactions. Disulfide bond formation, and cis-trans isomerization of X-Pro peptide bonds, as the rate-limiting folding reactions, are enzymatically catalyzed during protein folding in the cell. Although folding of domains is fast enough to occur cotranslationally in vivo, such vectorial folding on the ribosome is not essential for attainment of the native structure of a protein. Slow steps on the pathway to the functional protein structure are docking reactions of domains, association of subunits, or reshuffling reactions at the oligomer level. Aggregation as a competing side reaction is prevented, and the kinetic partition between competing polypeptide folding and translocation reactions is regulated by chaperone proteins binding to incompletely folded polypeptides.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, UNIV STR 31, W-8400 REGENSBURG, GERMANY	University of Regensburg								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ANSON ML, 1945, ADV PROTEIN CHEM, V2, P361, DOI 10.1016/S0065-3233(08)60629-4; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BLONDELGUINDI S, 1990, BIOCHEMISTRY-US, V29, P2409, DOI 10.1021/bi00461a026; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P6922, DOI 10.1021/bi00242a016; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHAN HS, 1990, P NATL ACAD SCI USA, V87, P6388, DOI 10.1073/pnas.87.16.6388; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P5, DOI 10.1016/0959-440X(91)90004-D; CRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GOLDENBERG DP, 1984, J MOL BIOL, V179, P527, DOI 10.1016/0022-2836(84)90078-0; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; HARDING MM, 1991, BIOCHEMISTRY-US, V30, P3120, DOI 10.1021/bi00226a020; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HUBER R, 1988, ANGEW CHEM INT EDIT, V27, P79, DOI 10.1002/anie.198800791; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P6475, DOI 10.1021/bi00479a020; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KING J, 1990, N HORIZ TH, P59; KING J, 1989, CHEM ENG NEWS, V67, P32, DOI 10.1021/cen-v067n015.p032; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Matthews BW, 1991, CURR OPIN STRUC BIOL, V1, P17, DOI 10.1016/0959-440X(91)90005-E; Matthews CR, 1991, CURR OPIN STRUC BIOL, V1, P28; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MURPHY KP, 1990, THERMOCHIM ACTA, V172, P11, DOI 10.1016/0040-6031(90)80555-D; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; REHABER P, 1990, BIOCHEMISTRY-US, V29, P8217, DOI 10.1021/bi00488a004; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; RUDOLPH R, 1990, P NATL ACAD SCI USA, V87, P4625, DOI 10.1073/pnas.87.12.4625; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; SHOEMAKER KR, 1987, COLD SPRING HARB SYM, V52, P391, DOI 10.1101/SQB.1987.052.01.045; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5655; VITA C, 1989, EUR J BIOCHEM, V183, P513, DOI 10.1111/j.1432-1033.1989.tb21079.x; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETLAUFER DB, 1984, PROTEIN FOLDING PROB, P29; WIECH H, 1991, FEBS LETT, V285, P182, DOI 10.1016/0014-5793(91)80800-I; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001	72	92	94	1	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2545	2552		10.1096/fasebj.6.8.1592207	http://dx.doi.org/10.1096/fasebj.6.8.1592207			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592207	Bronze			2022-12-28	WOS:A1992HU42300007
J	KERPPOLA, TK; KANE, CM				KERPPOLA, TK; KANE, CM			RNA-POLYMERASE - REGULATION OF TRANSCRIPT ELONGATION AND TERMINATION	FASEB JOURNAL			English	Review						GENE REGULATION; ATTENUATION; ANTITERMINATION	DNA-BINDING PROTEIN; HIV-1 TAT PROTEIN; MAJOR LATE PROMOTER; ESCHERICHIA-COLI; NUSA PROTEIN; TERNARY COMPLEXES; CHAIN ELONGATION; FACTOR-SII; BACTERIOPHAGE-LAMBDA; 3'-END FORMATION	Expanded interest in studying the mechanisms of elongation and termination during transcription has come as a result of several recent findings that highlight the importance of the regulation of these processes in human health. Several cellular proto-oncogenes contain regulated blocks to elongation (1), and the human immunodeficiency viruses also control gene expression in part by regulating the efficiency of elongation in response to the trans-activating protein, TAT (2). This review considers these recent findings and compares potential mechanisms of regulation used by prokaryotic and eukaryotic RNA polymerases during elongation and termination. In all these systems, many of the detailed mechanisms of transcription elongation and termination are still to be defined; however, we have tried to group examples that may share some common regulatory elements into simplified categories.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,401 BARKER HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley			Kerppola, Tom/AFK-6155-2022; Kerppola, Tom/AAG-4457-2022	Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446				ALBRECHTSEN B, 1990, J MOL BIOL, V213, P123, DOI 10.1016/S0022-2836(05)80125-1; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BAEK KH, 1986, P NATL ACAD SCI USA, V83, P7623, DOI 10.1073/pnas.83.20.7623; BARTSCH I, 1988, MOL CELL BIOL, V8, P3891, DOI 10.1128/MCB.8.9.3891; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; COULTER DE, 1985, J BIOL CHEM, V260, P3190; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FISHER RF, 1983, J BIOL CHEM, V258, P8146; FLORES O, 1989, J BIOL CHEM, V264, P8913; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; GRALLA JD, 1989, CELL, V57, P193, DOI 10.1016/0092-8674(89)90955-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; JAMES P, 1991, J BIOL CHEM, V266, P5616; JENG ST, 1990, J BIOL CHEM, V265, P3823; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; KUMAR SA, 1981, PROG BIOPHYS MOL BIO, V38, P165, DOI 10.1016/0079-6107(81)90013-4; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LANDICK R, 1991, IN PRESS TRANSCRIPTI; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE DN, 1990, J BIOL CHEM, V265, P15145; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LYNN SP, 1988, J BIOL CHEM, V263, P472; MANLEY JL, 1989, GENE DEV, V3, P2218, DOI 10.1101/gad.3.12b.2218; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MCSTAY B, 1990, MOL CELL BIOL, V10, P2793, DOI 10.1128/MCB.10.6.2793; MOK M, 1984, MOL CELL BIOL, V4, P2031, DOI 10.1128/MCB.4.10.2031; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PRIBYL TM, 1988, MOL CELL BIOL, V8, P5369, DOI 10.1128/MCB.8.12.5369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1989, J BIOL CHEM, V264, P10799; RESNEKOV O, 1988, GENE, V72, P91, DOI 10.1016/0378-1119(88)90130-8; REYNOLDS RR, 1991, IN PRESS J MOL BIOL; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SAWADOGO M, 1980, BIOCHEM BIOPH RES CO, V96, P258, DOI 10.1016/0006-291X(80)91208-5; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; SCHMIDT MC, 1984, BIOCHEMISTRY-US, V23, P197, DOI 10.1021/bi00297a004; SCHMIDT MC, 1984, J BIOL CHEM, V259, P5000; SEIBERG M, 1989, J VIROL, V63, P1134, DOI 10.1128/JVI.63.3.1134-1141.1989; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SELITTI MA, 1987, P NATL ACAD SCI USA, V84, P3199; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SKARNES WC, 1988, J MOL BIOL, V203, P153, DOI 10.1016/0022-2836(88)90099-X; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SOUSA R, 1989, PROTEINS, V5, P266, DOI 10.1002/prot.340050403; SPENCER CA, 1990, ONCOGENE, V5, P777; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073; ZENGEL JM, 1990, P NATL ACAD SCI USA, V87, P2675, DOI 10.1073/pnas.87.7.2675	94	130	130	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2833	2842		10.1096/fasebj.5.13.1916107	http://dx.doi.org/10.1096/fasebj.5.13.1916107			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916107	Bronze			2022-12-28	WOS:A1991GJ47100012
J	BILLMAN, GE; MCILROY, B; JOHNSON, JD				BILLMAN, GE; MCILROY, B; JOHNSON, JD			ELEVATED MYOCARDIAL CALCIUM AND ITS ROLE IN SUDDEN CARDIAC DEATH	FASEB JOURNAL			English	Note						CARDIAC ARRHYTHMIAS; VENTRICULAR FIBRILLATION; CYTOSOLIC CALCIUM; ALPHA-ADRENERGIC AND BETA-ADRENERGIC RECEPTORS	ISCHEMIC VENTRICULAR-FIBRILLATION; HEART-RATE VARIABILITY; DELAYED AFTERDEPOLARIZATIONS; CHANNEL; INFARCTION; RYANODINE; ARRHYTHMIAS; MECHANISMS; CAFFEINE; MUSCLE	The contribution of intracellular calcium to ventricular fibrillation (VF) was investigated using chronically instrumented dogs with healed myocardial infarctions. A 2-minute coronary occlusion was initiated during the last minute of exercise. Fourteen animals developed ventricular fibrillation (susceptible) whereas the remaining 12 did not (resistant) during this exercise plus ischemia test. The test was then repeated for the susceptible animals after pretreatment with the intracellular calcium chelator BAPTA-AM (1.0 mg/kg). BAPTA-AM significantly reduced left ventricular dp/dt max and prevented VF in 8 of 12 susceptible animals. Conversely, myocardial cytosolic calcium levels were increased in resistant animals using the calcium channel agonist Bay K 8644 (30-mu-g/kg) or phenylephrine (10-mu-g.kg-1.min-1 3-5 min before occlusion). Bay K 8644 induced VF in all 5 resistant animals tested whereas phenylephrine induced VF in 8 of 12 resistant animals. BAPTA-AM pretreatment attenuated the hemodynamic effects of Bay K 8644 or phenylephrine and prevented VF in five of five Bay K 8644- and four of seven phenylephrine-treated animals. Finally, the endogenous level of calcium/calmodulin (Ca-CaM)-dependent phosphorylation of 170- and 55-kDa substrate proteins was measured (as an index of intracellular free calcium concentration). In the susceptible dog heart, the endogenous level of Ca-CaM-dependent phosphorylation was estimated to be two- to threefold higher than that observed in resistant dog heart. Treatment of resistant dog tissue with the calcium ionophore A23187 increased the level of Ca-CaM-dependent phosphorylation of these two proteins to the level observed in susceptible dog heart. These data suggest that elevated cytosolic calcium facilitates development of malignant arrhythmias and that elevated cytosolic calcium levels may be present in animals particularly susceptible to ventricular fibrillation.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University	BILLMAN, GE (corresponding author), OHIO AGR RES & DEV CTR,DEPT PHYSIOL,4196 GRAVES HALL,333 W 10TH AVE,COLUMBUS,OH 43210, USA.		Billman, George E/E-2758-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005917] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36336] Funding Source: Medline; NIDA NIH HHS [DA05917] Funding Source: Medline; NIDDK NIH HHS [DK33727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKHTAR M, 1989, CIRCULATION, V80, P31; AUFFERMANN W, 1989, AM HEART J, V118, P1219, DOI 10.1016/0002-8703(89)90013-6; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BIGGER JT, 1988, AM J CARDIOL, V61, P208, DOI 10.1016/0002-9149(88)90917-4; BILLMAN GE, 1982, CIRCULATION, V66, P874, DOI 10.1161/01.CIR.66.4.874; BILLMAN GE, 1989, J PHARMACOL EXP THER, V248, P1334; BILLMAN GE, 1990, FRONTIERS SMOOTH MUS, P755; BILLMAN GE, 1989, CIRCULATION, V80, P874; BOUTJDIR M, 1990, CIRCULATION, V81, P1393, DOI 10.1161/01.CIR.81.4.1393; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNING JL, 1977, COMPUTATIONAL HDB ST, P230; CLUSIN WT, 1982, CIRC RES, V50, P518, DOI 10.1161/01.RES.50.4.518; CLUSIN WT, 1982, AM J CARDIOL, V49, P606, DOI 10.1016/S0002-9149(82)80019-2; COLLINS MN, 1989, AM J PHYSIOL, V257, pH1886, DOI 10.1152/ajpheart.1989.257.6.H1886; CORR PB, 1986, HEART CARDIOVASCULAR, P1597; EVANS DB, 1986, J CARDIOVASC PHARM, V8, pS22, DOI 10.1097/00005344-198611001-00003; GOLOVINA VA, 1988, J MOL CELL CARDIOL, V20, P303, DOI 10.1016/S0022-2828(88)80064-6; JANUARY CT, 1988, CIRC RES, V62, P563, DOI 10.1161/01.RES.62.3.563; JANUARY CT, 1988, PHARMACOL REV, V40, P219; JOHNSON JD, 1986, MED RES REV, V6, P341, DOI 10.1002/med.2610060304; KAHN M, 1964, AM J CARDIOL, V14, P658, DOI 10.1016/0002-9149(64)90057-8; KIMURA S, 1984, CIRCULATION, V70, P1074, DOI 10.1161/01.CIR.70.6.1074; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LEVY MN, 1989, CIRCULATION, V80, P23; MARBAN E, 1986, J CLIN INVEST, V78, P1185, DOI 10.1172/JCI112701; MERILLAT JC, 1990, CIRC RES, V67, P1115, DOI 10.1161/01.RES.67.5.1115; RECTER M, 1988, PHARMACOL REV, V40, P189; SCHRAMM M, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1268; SHERIDAN DJ, 1980, J CLIN INVEST, V65, P161, DOI 10.1172/JCI109647; THANDROYEN FT, 1988, CIRC RES, V62, P306, DOI 10.1161/01.RES.62.2.306; TOHSE N, 1990, PFLUG ARCH EUR J PHY, V415, P575, DOI 10.1007/BF02583508; TSEIN RY, 1981, NATURE, V290, P527; Watanabe A.M., 1984, P130; WINER BJ, 1971, STATISTICAL PRINCIPL, P514; 1990, AM J CARDIOL, V66, P779	35	40	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2586	2592		10.1096/fasebj.5.11.1714409	http://dx.doi.org/10.1096/fasebj.5.11.1714409			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1714409				2022-12-28	WOS:A1991GB09400013
J	TAMKUN, MM; KNOTH, KM; WALBRIDGE, JA; KROEMER, H; RODEN, DM; GLOVER, DM				TAMKUN, MM; KNOTH, KM; WALBRIDGE, JA; KROEMER, H; RODEN, DM; GLOVER, DM			MOLECULAR-CLONING AND CHARACTERIZATION OF 2 VOLTAGE-GATED K+ CHANNEL CDNAS FROM HUMAN VENTRICLE	FASEB JOURNAL			English	Note						DELAYED RECTIFIER; TRANSIENT OUTWARD CURRENT; HUMAN K+ CHANNEL CDNA; K+ CHANNEL GENES; CARDIAC EXPRESSION	POTASSIUM CHANNEL; MEMBRANE-PROTEIN; RAT-BRAIN; EXPRESSION; GENE; DNA; DROSOPHILA; SYSTEMS; KINASE	K+ channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. In the heart these channels are responsible for the rapid repolarizing phases of the action potential and are the targets of several antiarrhythmic drugs. Full-length cDNA clones were isolated from human ventricular libraries that encode two voltage-gated K+ channels. These two cDNAs, designated HK1 and HK2, encode proteins of 653 and 605 amino acids, respectively. HK1 is the human equivalent (98% identity) of an inactivating K+ channel previously described in rat heart (RHK1) whereas the HK2 channel is 86% identical to a cloned rat brain K+ channel (Kv1). The only amino acid sequence identity (72%) between HK1 and HK2 is within the central region containing the membrane spanning domains. Northern blot analysis of human mRNA indicated that HK1 is slightly more abundant in ventricle than atrium whereas HK2 is much more abundant in atrium relative to ventricle. Both channel transcripts are present in ventricle at levels equivalent to voltage-gated Na+ channels. Analysis of the gene encoding HK1 suggests the coding sequence is intronless and is represented once in the human genome.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37205	Vanderbilt University	TAMKUN, MM (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37205, USA.		Roden, Dan/ABD-5412-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32694] Funding Source: Medline; NIGMS NIH HHS [GM 07347, GM 41325] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BACANER MB, 1986, P NATL ACAD SCI USA, V83, P2223, DOI 10.1073/pnas.83.7.2223; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CHRISTIE MJ, 1990, NEURON, V2, P405; COOK NS, 1988, TRENDS PHARMACOL SCI, V9, P21, DOI 10.1016/0165-6147(88)90238-6; DOUGLASS J, 1990, J IMMUNOL, V144, P4841; EVANS WE, 1990, IN PRESS MOL PHARM; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GANONG WF, 1979, REV MED PHYSL, P415; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HAWORTH RA, 1989, CIRC RES, V65, P1157, DOI 10.1161/01.RES.65.4.1157; Hille B, 1984, IONIC CHANNELS EXCIT; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1990, J NEUROSCI, V10, P2903; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MURAI T, 1989, BIOCHEM BIOPH RES CO, V161, P176, DOI 10.1016/0006-291X(89)91577-5; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; ROBERTSON DW, 1990, J MED CHEM, V33, P1529, DOI 10.1021/jm00168a001; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; ZETTERQVIST O, 1982, FEBS LETT, V139, P287, DOI 10.1016/0014-5793(82)80872-7	36	247	257	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					331	337		10.1096/fasebj.5.3.2001794	http://dx.doi.org/10.1096/fasebj.5.3.2001794			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001794				2022-12-28	WOS:A1991FC55600012
J	IKAWA, Y				IKAWA, Y			HUMAN GENOME EFFORTS IN JAPAN	FASEB JOURNAL			English	Article						GENE REGULATION; SEQUENCE DATA; YAC CLONES; HUMAN GENOME PROJECTS; SEQUENCING TECHNOLOGY		Some project-oriented biosciences have been promoted cooperatively by three governmental agencies in Japan: the Ministry of Education, Science and Culture, the Ministry of Health and Welfare, and the Science and Technology Agency. All three agencies have increased their budgetary requests for human genome analyses for FY 1991. The Panel on Life Sciences (chaired by Dr. W. Mori, former president of the University of Tokyo) of the Science and Technology Council of Japan which is chaired by the Prime Minister has decided to organize a working group to suggest how best to coordinate efforts in human genome analyses in Japan. The genome project was initially promoted by the Science and Technology Agency through a program for the design and construction of automated machines for DNA sequencing. Work is ongoing at the Institute of Physical and Chemical Research to integrate, by system engineering, instruments that can separate DNA fragments, perform plaque selection, carry out dideoxy reaction, and read the resulting DNA sequence. However, scientists now realize the enormity of the tasks of compiling DNA sequence data and of mapping the genes and fragments obtained, and efforts are being made to solve these problems. Academic societies have organized symposia to promote general interest in this subject. The most important way for Japan to contribute to research on human genome analyses, however, may be in the evaluation of supporting mechanisms (technical assistance and research resources) and in the recognition and preparation of the transition of biology to a big science approach.	RIKEN,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	IKAWA, Y (corresponding author), TOKYO MED & DENT UNIV,BUNKYO KU,TOKYO 113,JAPAN.							ENDO I, 1990, HUMAN GENOME, V2, P28; IKAWA Y, 1989, RECENT PROGR LIFE SC; IMAI T, 1990, HUMAN GENOME, V2, P35; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4	4	1	1	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					66	69		10.1096/fasebj.5.1.1991587	http://dx.doi.org/10.1096/fasebj.5.1.1991587			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991587	Bronze			2022-12-28	WOS:A1991ET60900011
J	ROSSITER, BJF; CASKEY, CT				ROSSITER, BJF; CASKEY, CT			MOLECULAR STUDIES OF HUMAN GENETIC-DISEASE	FASEB JOURNAL			English	Article						MUTATION DETECTION; NEW MUTATION DISORDER; SINGLE GENE DISORDER; LINKAGE ANALYSIS; GENOME PROJECT	POLYMERASE CHAIN-REACTION; GRADIENT GEL-ELECTROPHORESIS; SINGLE BASE SUBSTITUTIONS; MUSCULAR-DYSTROPHY LOCUS; REACTION-AMPLIFIED DNA; OLIGONUCLEOTIDE PROBES; VARIABLE NUMBER; NUCLEIC-ACIDS; HUMAN GENOME; GC-CLAMP	A wide variety of techniques are available for detecting disease-causing mutations within human genes; this report provides a brief review of such procedures. Good communication and exchange of materials between the clinical genetics field and the Human Genome Initiative will benefit both.	BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor University; Howard Hughes Medical Institute	ROSSITER, BJF (corresponding author), BAYLOR UNIV,INST MOLEC GENET,T809,ONE BAYLOR PLAZA,HOUSTON,TX 77030, USA.							ALI S, 1988, NUCLEIC ACIDS RES, V16, P8487, DOI 10.1093/nar/16.17.8487; Alwine J C, 1979, Methods Enzymol, V68, P220; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; BAKKER E, 1989, J INHERIT METAB DIS, V12, P174, DOI 10.1007/BF01799293; BALLABIO A, 1990, NATURE, V343, P220, DOI 10.1038/343220a0; BAUMBACH LL, 1989, NEUROLOGY, V39, P465, DOI 10.1212/WNL.39.4.465; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CASKEY CT, 1991, IN PRESS REPRODUCTIO; Chamberlain J.S., 1990, PCR PROTOCOLS GUIDE, P272; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CHEHAB FF, 1989, P NATL ACAD SCI USA, V86, P3178; CHEN JD, 1989, GENOMICS, V4, P105, DOI 10.1016/0888-7543(89)90322-4; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; CORBO L, 1990, SCIENCE, V249, P652, DOI 10.1126/science.2382140; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DENDUNNEN JT, 1987, NATURE, V329, P640, DOI 10.1038/329640a0; EDWARDS A, 1989, T ASSOC AM PHYSICIAN, V102, P185; GALL JG, 1986, SCIENCE, V233, P1367, DOI 10.1126/science.233.4771.1367-e; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GEEVER RF, 1981, P NATL ACAD SCI-BIOL, V78, P5081, DOI 10.1073/pnas.78.8.5081; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GIBBS RA, 1989, NUCLEIC ACIDS RES, V17, P2437, DOI 10.1093/nar/17.7.2437; GIBBS RA, 1987, SCIENCE, V236, P303, DOI 10.1126/science.3563511; GROMPE M, 1989, P NATL ACAD SCI USA, V86, P5888, DOI 10.1073/pnas.86.15.5888; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HYLAND VJ, 1990, HUM GENET, V84, P286; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KORNHER JS, 1989, NUCLEIC ACIDS RES, V17, P7779, DOI 10.1093/nar/17.19.7779; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCBRIDE LJ, 1989, CLIN CHEM, V35, P2196; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3111, DOI 10.1093/nar/13.9.3111; NAKAMAYE KL, 1988, NUCLEIC ACIDS RES, V16, P9947, DOI 10.1093/nar/16.21.9947; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NUSSBAUM RL, 1983, P NATL ACAD SCI-BIOL, V80, P4035, DOI 10.1073/pnas.80.13.4035; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RIESNER D, 1989, ELECTROPHORESIS, V10, P377, DOI 10.1002/elps.1150100516; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENBAUM V, 1987, BIOPHYS CHEM, V26, P235, DOI 10.1016/0301-4622(87)80026-1; ROSSITER BJF, 1990, J BIOL CHEM, V265, P12753; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOWALTER DB, 1990, GENOMICS, V6, P23, DOI 10.1016/0888-7543(90)90444-Y; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SMEETS H, 1990, AM J HUM GENET, V46, P492; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; TRENT RJ, 1989, J MED GENET, V26, P6, DOI 10.1136/jmg.26.1.6; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WARTELL RM, 1990, NUCLEIC ACIDS RES, V18, P2699, DOI 10.1093/nar/18.9.2699; WATSON JD, 1990, SCIENCE, V248, P44, DOI 10.1126/science.2181665; WU DY, 1989, GENOMICS, V4, P560, DOI 10.1016/0888-7543(89)90280-2; YAMAOKA LH, 1990, NEUROLOGY, V40, P222, DOI 10.1212/WNL.40.2.222; YANG TP, 1988, SOMAT CELL MOLEC GEN, V14, P293, DOI 10.1007/BF01534590; YANG TP, 1984, NATURE, V310, P412, DOI 10.1038/310412a0	68	16	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					21	27		10.1096/fasebj.5.1.1846832	http://dx.doi.org/10.1096/fasebj.5.1.1846832			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1846832				2022-12-28	WOS:A1991ET60900004
J	ZHENG, LM; OJCIUS, DM; LIU, CC; KRAMER, MD; SIMON, MM; PARR, EL; YOUNG, JDE				ZHENG, LM; OJCIUS, DM; LIU, CC; KRAMER, MD; SIMON, MM; PARR, EL; YOUNG, JDE			IMMUNOGOLD LABELING OF PERFORIN AND SERINE ESTERASES IN GRANULATED METRIAL GLAND-CELLS	FASEB JOURNAL			English	Note						PERFORIN; SERINE ESTERASE; NATURAL KILLER CELL; GRANULATED METRIAL GLAND CELL; PLACENTA	NATURAL-KILLER CELLS; PORE-FORMING PROTEIN; TOXIC LYMPHOCYTES-T; TROPHOBLAST CELLS; CYTO-TOXICITY; MOUSE; LOCALIZATION; MECHANISM; DIFFERENTIATION; IMMUNOGLOBULIN	Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells are cytolytic lymphocytes known to produce a pore-forming protein, named perforin or cytolysin, that lyses target cells by creating large pores on the target plasma membrane. Besides perforin, the granules of CTL and NK cells contain a family of serine esterases. Perforin has also been localized in granulated metrial gland (GMG) cells of the murine embryo implantation site by light microscopic immunostaining. Ultrastructural immunogold labeling with antibodies against perforin and a serine esterase (MTSP 1 or granzyme A) shows that GMG cells contain both perforin and serine esterases in the fine granular matrix of their granules. Perforin has been located in all of the granules, whereas gold particles corresponding to serine esterases have been found in most of the granules. Results from the double immunogold technique indicate that perforin and serine esterases colocalize to most of the same granules in GMG cells. This study supports the view that GMG cells are related to cytolytic lymphocytes.	LAB MOLEC BIOL & IMMUNOL,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY; SO ILLINOIS UNIV,SCH MED,CARBONDALE,IL 62901	Max Planck Society; Southern Illinois University System; Southern Illinois University	ZHENG, LM (corresponding author), ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021, USA.							BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BULMER D, 1968, J ANAT, V103, P479; GROSCURTH P, 1987, J IMMUNOL, V138, P2749; HALLER O, 1977, J EXP MED, V145, P1411, DOI 10.1084/jem.145.5.1411; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HERBERMAN RB, 1986, ANNU REV IMMUNOL, V4, P651, DOI 10.1146/annurev.iy.04.040186.003251; JANEWAY CA, 1989, NATURE, V341, P108, DOI 10.1038/341108a0; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; KRAMER MD, 1989, EUR J IMMUNOL, V19, P151, DOI 10.1002/eji.1830190124; MITCHELL BS, 1981, J REPROD IMMUNOL, V3, P237, DOI 10.1016/0165-0378(81)90045-0; MITCHELL BS, 1984, IMMUNOLOGY, V53, P63; MITCHELL BS, 1987, J REPROD FERTIL, V81, P59; MUKHTAR DDY, 1989, J REPROD IMMUNOL, V15, P269, DOI 10.1016/0165-0378(89)90017-X; OJCIUS DM, 1990, CANCER CELL-MON REV, V2, P138; ORTALDO JR, 1984, ANNU REV IMMUNOL, V2, P359, DOI 10.1146/annurev.iy.02.040184.002043; PARR EL, 1987, BIOL REPROD, V37, P1327, DOI 10.1095/biolreprod37.5.1327; PEEL S, 1983, CELL TISSUE RES, V233, P647; PEEL S, 1984, J ANAT, V139, P593; PEEL S, 1977, J ANAT, V123, P687; PERSECHINI PM, 1989, J IMMUNOL METHODS, V124, P7, DOI 10.1016/0022-1759(89)90179-8; PETERS PJ, 1990, IMMUNOL TODAY, V11, P28; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; SANTOLI D, 1979, IMMUNOL REV, V44, P125, DOI 10.1111/j.1600-065X.1979.tb00269.x; STEWART I, 1984, J ANAT, V139, P627; STEWART I, 1977, CELL TISSUE RES, V184, P517; STEWART I, 1988, PLACENTA, V9, P417, DOI 10.1016/0143-4004(88)90054-9; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; YOUNG JDE, 1986, CELL, V44, P849, DOI 10.1016/0092-8674(86)90007-3; YOUNG JDE, 1989, PHYSIOL REV, V69, P250, DOI 10.1152/physrev.1989.69.1.250; YOUNG JDE, 1986, SCIENCE, V233, P180	31	48	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					79	85		10.1096/fasebj.5.1.1991594	http://dx.doi.org/10.1096/fasebj.5.1.1991594			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991594				2022-12-28	WOS:A1991ET60900018
J	WOLFFE, AP				WOLFFE, AP			NEW INSIGHTS INTO CHROMATIN FUNCTION IN TRANSCRIPTIONAL CONTROL	FASEB JOURNAL			English	Article						CHROMATIN; GENE REGULATION; HISTONE; TRANSCRIPTION; NUCLEOSOME	POSITION-EFFECT VARIEGATION; TUMOR VIRUS PROMOTER; DROSOPHILA-MELANOGASTER; TOPOISOMERASE-II; RNA GENES; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; REPLICATING DNA; NUCLEOSOME; PROTEIN	Transcription requires the recognition of numerous DNA sequences by diverse transcription factors, which together assemble large nucleoprotein complexes that tether RNA polymerase and facilitate the initiation of RNA synthesis. In vivo the assembly of these transcription complexes occurs in a nuclear environment where the template DNA is compacted more than 10(5)-fold through the assembly of chromatin. Our current knowledge of chromatin structure raises the major issues of the accessibility of DNA to both transcription factors and RNA polymerase and of the progression of RNA polymerase along the chromatin fiber. Novel genetic and biochemical approaches have established that specific chromatin structures have a major impact on the transcription process. Precise alterations in histone sequence, nucleosome structure, and folding of the chromatin fiber influence both the activation and repression of genes. These results offer substantial insight into the role of modulations in chromosome structure during vertebrate development. Transcription factors, histones, and the organization of DNA within the chromosome are intimately linked, and only when the correct framework is assembled can they function together to achieve correct genetic regulation.			WOLFFE, AP (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.							ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; AUBERT D, 1991, J CELL BIOL, V113, P497, DOI 10.1083/jcb.113.3.497; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; CHAN S, 1988, J BIOL CHEM, V263, P15643; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIMITRI P, 1989, GENETICS, V122, P793; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HILL CS, 1990, EUR J BIOCHEM, V187, P145, DOI 10.1111/j.1432-1033.1990.tb15288.x; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KIROV N, 1992, EMBO J, V11, P1941, DOI 10.1002/j.1460-2075.1992.tb05247.x; LIN RL, 1991, GENE DEV, V5, P1601, DOI 10.1101/gad.5.9.1601; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MOORE GD, 1983, GENETICS, V105, P327; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PARKER CS, 1977, P NATL ACAD SCI USA, V74, P44, DOI 10.1073/pnas.74.1.44; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PERLMANN T, 1992, P NATL ACAD SCI USA, V89, P3884, DOI 10.1073/pnas.89.9.3884; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; ROTH SY, 1988, J CELL BIOL, V107, P2473, DOI 10.1083/jcb.107.6.2473; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1991, J CELL SCI, V99, P201; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WOLFFE AP, 1991, CURR BIOL, V1, P364; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X	77	73	73	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1992	6	15					3354	3361		10.1096/fasebj.6.15.1464369	http://dx.doi.org/10.1096/fasebj.6.15.1464369			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1464369				2022-12-28	WOS:A1992KD39500006
J	LYNCH, JJ; SANGUINETTI, MC; KIMURA, S; BASSETT, AL				LYNCH, JJ; SANGUINETTI, MC; KIMURA, S; BASSETT, AL			THERAPEUTIC POTENTIAL OF MODULATING POTASSIUM CURRENTS IN THE DISEASED MYOCARDIUM	FASEB JOURNAL			English	Article						SULFONYLUREA; POTASSIUM CHANNEL OPENER; CLASS-III ANTIARRHYTHMIC AGENT; CARDIAC ARRHYTHMIA	III ANTIARRHYTHMIC AGENTS; SUDDEN CORONARY DEATH; CARDIAC PURKINJE-FIBERS; CONSCIOUS CANINE MODEL; ARTERIAL SMOOTH-MUSCLE; REGULATED K+ CHANNELS; ISOLATED RAT HEARTS; GUINEA-PIG; VENTRICULAR ARRHYTHMIAS; METABOLIC INHIBITION	Myocardial disease states are characterized by multiple electrophysiologic abnormalities, including alterations in potassium channel activities. During acute myocardial ischemia, activation of ATP-regulated K+ current (I(K)(ATP))) results in shortening of action potential duration and elevation of extracellular K+ concentration. In hypertrophied myocardium, increases in inward rectifier K+ current (I(K1)) and decreases in delayed rectifier K+ current (I(K)) are observed. Alterations in K+ channel activity in myocardial disease states suggest the potential to therapeutically modify cardiac rhythm and function with K+ channel modulators. Class III antiarrhythmic agents, which prolong myocardial refractoriness predominantly via a blockade of I(K), have demonstrated efficacy in suppressing reentrant atrial and ventricular arrhythmias in animal models as well as promising efficacy in initial clinical studies. Potassium channel openers (PCOs), which activate cardiac I(K(ATP)), have demonstrated both antiarrhythmic and proarrhythmic activities in various experimental settings, and also are being investigated as potential cardioprotective agents. Sulfonylureas, which block cardiac I(K(ATP)), also have been investigated as potential antiarrhythmic agents with equivocal results, and have displayed a propensity to exacerbate ischemic myocardial dysfunction in experimental studies. A more comprehensive understanding of K+ channel activity in various myocardial disease states, including concomitant disorders such as myocardial ischemia and hypertrophy, will facilitate the development of more useful potassium channel modulators, as well as a clearer recognition of the undesirable effects of such agents.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DIV CARDIOL,MIAMI,FL 33101	University of Miami; University of Miami	LYNCH, JJ (corresponding author), MERCK SHARP & DOHME LTD,DEPT PHARMACOL,WP26 265,W POINT,PA 19486, USA.		Sanguinetti, Michael/AAN-2615-2020					ADANIYA H, 1990, J CARDIOVASC PHARM, V15, P976, DOI 10.1097/00005344-199006000-00016; ARENA JP, 1988, MOL PHARMACOL, V34, P60; ARGENTIERI TM, 1988, FASEB J, V2, pA1556; ARONSON RS, 1984, EUR HEART J SF, P339; BASKIN EP, 1991, J CARDIOVASC PHARM, V18, P406, DOI 10.1097/00005344-199109000-00014; BEECH DJ, 1989, BRIT J PHARMACOL, V98, P851, DOI 10.1111/j.1476-5381.1989.tb14614.x; BELICHARD P, 1991, J CARDIOVASC PHARM, V17, pS141, DOI 10.1097/00005344-199117002-00034; BEREGI JP, 1991, CARDIOVASC DRUG THER, V5, P365; BERGER F, 1989, N-S ARCH PHARMACOL, V340, P696, DOI 10.1007/BF00717747; BILLMAN G E, 1991, Journal of the American College of Cardiology, V17, p165A; BUCHANAN L V, 1991, Journal of the American College of Cardiology, V17, p43A; BUCHANAN LV, 1992, J CARDIOVASC PHARM, V19, P256, DOI 10.1097/00005344-199202000-00014; CAMERON JS, 1989, AM J PHYSIOL, V256, pH1006; CARLSSON L, 1990, J CARDIOVASC PHARM, V16, P276, DOI 10.1097/00005344-199008000-00014; CARLSSON L, 1990, European Heart Journal, V11, P441; CARLSSON L, 1992, J CARDIOVASC PHARM, V18, P882; CARMELIET E, 1985, J PHARMACOL EXP THER, V232, P817; CASTLE NA, 1991, J PHARMACOL EXP THER, V257, P343; CHI L, 1989, Journal of Molecular and Cellular Cardiology, V21, pS89; CHI L, 1990, J CARDIOVASC PHARM, V15, P452, DOI 10.1097/00005344-199003000-00016; CHI L, 1991, J CARDIOVASC PHARM, V17, P285, DOI 10.1097/00005344-199102000-00015; CHI L, 1991, FASEB J, V5, pA495; CHI LG, 1990, J CARDIOVASC PHARM, V16, P312, DOI 10.1097/00005344-199008000-00019; COLE WC, 1991, CIRC RES, V69, P571, DOI 10.1161/01.RES.69.3.571; CUEVAS J, 1991, AM J PHYSIOL, V261, pH755, DOI 10.1152/ajpheart.1991.261.3.H755; DIDIEGO JM, 1990, CIRCULATION, V82, P528; DORIAN P, 1990, CIRCULATION, V82, P528; DUFF H J, 1991, Journal of the American College of Cardiology, V17, p136A; ECHT DS, 1991, CIRCULATION S2, V84, P714; EDWARDS G, 1990, PHARMACOL THERAPEUT, V48, P237, DOI 10.1016/0163-7258(90)90082-D; ELLIOTT AC, 1989, CIRC RES, V64, P583, DOI 10.1161/01.RES.64.3.583; ESCANDE D, 1989, PFLUG ARCH EUR J PHY, V414, P669, DOI 10.1007/BF00582134; FINDLAY I, 1988, PFLUG ARCH EUR J PHY, V412, P37, DOI 10.1007/BF00583729; FISH FA, 1990, CIRCULATION, V82, P1362, DOI 10.1161/01.CIR.82.4.1362; FURUKAWA T, 1990, CIRCULATION, V82, P522; GELBAND CH, 1990, P ROY SOC B-BIOL SCI, V242, P23, DOI 10.1098/rspb.1990.0098; GHALI JK, 1991, J AM COLL CARDIOL, V17, P2177; GOTTLIEB C, 1991, PACE, V14, P744; GROSS GJ, 1991, POTASSIUM CHANNEL MO; GROVER GJ, 1990, J CARDIOVASC PHARM, V16, P853, DOI 10.1097/00005344-199012000-00001; GWILT M, 1991, J PHARMACOL EXP THER, V256, P318; GWILT M, 1989, Journal of Molecular and Cellular Cardiology, V21, pS11; GWILT M, 1991, J CARDIOVASC PHARM, V17, P376, DOI 10.1097/00005344-199103000-00004; HAMADA E, 1990, JPN J PHARMACOL, V54, P473, DOI 10.1254/jjp.54.473; HONDEGHEM LM, 1990, CIRCULATION, V81, P686, DOI 10.1161/01.CIR.81.2.686; INOUE H, 1991, J CARDIOVASC PHARM, V18, P137, DOI 10.1097/00005344-199107000-00018; IRISAWA H, 1983, J PHYSIOL-LONDON, V338, P321, DOI 10.1113/jphysiol.1983.sp014675; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; KAJIOKA S, 1990, J PHARMACOL EXP THER, V254, P905; KAMIYA J, 1992, JPN J PHARMACOL, V58, P107, DOI 10.1254/jjp.58.107; KAMIYA J, 1990, Journal of Molecular and Cellular Cardiology, V22, pS70, DOI 10.1016/0022-2828(90)91735-P; KANTOR PF, 1990, CIRC RES, V66, P478, DOI 10.1161/01.RES.66.2.478; KATOH H, 1990, J PHARMACOL EXP THER, V253, P1077; KERR MJ, 1985, J CARDIOVASC PHARM, V7, P875, DOI 10.1097/00005344-198509000-00010; KIMURA S, 1991, CIRCULATION, V84, P768, DOI 10.1161/01.CIR.84.2.768; KLEBER AG, 1990, EXPERIENTIA, V46, P1162; KLEIMAN RB, 1989, AM J PHYSIOL, V256, pH1450, DOI 10.1152/ajpheart.1989.256.5.H1450; KOWEY PR, 1991, CIRCULATION, V83, P2067, DOI 10.1161/01.CIR.83.6.2067; LEE EW, 1990, J MOL CELL CARDIO S1, V22, pS15; LIU B, 1988, DRUG DEVELOP RES, V14, P123, DOI 10.1002/ddr.430140204; LYNCH JJ, 1990, J CARDIOVASC PHARM, V15, P764, DOI 10.1097/00005344-199005000-00012; MCCARTHY JJ, 1989, CIRCULATION S2, V80, P193; MESTRE M, 1990, EUR J PHARMACOL, V183, P1239, DOI 10.1016/0014-2999(90)94340-4; MESTRE M, 1989, CIRCULATION, V80, P139; NADEMANEE K, 1990, CIRCULATION, V82, P198; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; NICHOLS CG, 1991, CIRC RES, V68, P280, DOI 10.1161/01.RES.68.1.280; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1992, HYPERTENSION, V19, P228, DOI 10.1161/01.HYP.19.3.228; SMALLWOOD JK, 1990, N-S ARCH PHARMACOL, V342, P214, DOI 10.1007/BF00166967; SPINELLI W, 1990, EUR J PHARMACOL, V179, P243, DOI 10.1016/0014-2999(90)90162-Y; SPINELLI W, 1991, CIRC RES, V68, P1127, DOI 10.1161/01.RES.68.4.1127; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; STEINBERG MI, 1979, LIFE SCI, V25, P1397, DOI 10.1016/0024-3205(79)90417-X; TANDE PM, 1990, J CARDIOVASC PHARM, V16, P401, DOI 10.1097/00005344-199009000-00008; TENEICK RE, 1989, PHYSL PATHOPHYSIOLOG, P573; VENKATESH N, 1991, CIRC RES, V69, P623, DOI 10.1161/01.RES.69.3.623; WALLACE AA, 1991, J CARDIOVASC PHARM, V18, P687, DOI 10.1097/00005344-199111000-00006; WEISS JN, 1989, AM J PHYSIOL, V256, pH1165, DOI 10.1152/ajpheart.1989.256.4.H1165; WIGGINS J, 1987, CARDIOVASC DRUG THER, V1, P302; WILDE AAM, 1986, CIRC RES, V58, P249, DOI 10.1161/01.RES.58.2.249; WINQUIST RJ, 1989, J PHARMACOL EXP THER, V248, P149; WOLLEBEN CD, 1989, J MOL CELL CARDIOL, V21, P783, DOI 10.1016/0022-2828(89)90717-7; ZUANETTI G, 1991, J PHARMACOL EXP THER, V256, P325; 1991, CIRCULATION, V84, P1831	86	41	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2952	2960		10.1096/fasebj.6.11.1386585	http://dx.doi.org/10.1096/fasebj.6.11.1386585			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1386585				2022-12-28	WOS:A1992JJ66500009
J	BALL, DM; HARPER, PS				BALL, DM; HARPER, PS			PRESYMPTOMATIC TESTING FOR LATE-ONSET GENETIC-DISORDERS - LESSONS FROM HUNTINGTONS-DISEASE	FASEB JOURNAL			English	Review						PREDICTIVE TESTING; HIGH-RISK PARENT; EARLY GENE DETECTION; LINKED MARKERS; INFORMED CONSENT		Huntington's disease is an inherited, neurodegenerative disorder, usually of adult onset. Since the identification of linked markers, more than 1000 presymptomatic tests have been performed worldwide and multiple ethical issues have been encountered in relation to informed consent, testing of children, exclusion testing during pregnancy, and confidentiality. Further ethical problems are anticipated after identification of the causal mutation (or mutations). As Huntington's disease is a model for other disorders of adult onset for which testing is becoming possible, the successful resolution of these ethical issues is of great importance. A failure to do so might discredit genetic testing as a whole.			BALL, DM (corresponding author), UNIV WALES COLL MED, INST MED GENET, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.							[Anonymous], 1989, J NEUROL SCI, V94, P327; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, 1991, AM J HUM GENET, V49, P62; HARPER PS, HUNTINGTONS DISEASE, P373; HARPER PS, 1991, HUNTINGTONS DISEASE, P127; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; MORRIS M, 1988, LANCET, V2, P1069, DOI 10.1016/S0140-6736(88)90078-5; QUARRELL OWJ, 1987, LANCET, V1, P1281; TYLER A, 1990, J MED GENET, V27, P488, DOI 10.1136/jmg.27.8.488; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047	11	6	6	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2818	2819		10.1096/fasebj.6.10.1386046	http://dx.doi.org/10.1096/fasebj.6.10.1386046			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1386046				2022-12-28	WOS:A1992JD95400009
J	GROOT, PC; MOEN, CJA; DIETRICH, W; STOYE, JP; LANDER, ES; DEMANT, P				GROOT, PC; MOEN, CJA; DIETRICH, W; STOYE, JP; LANDER, ES; DEMANT, P			THE RECOMBINANT CONGENIC STRAINS FOR ANALYSIS OF MULTIGENIC TRAITS - GENETIC COMPOSITION	FASEB JOURNAL			English	Article						MULTIGENIC TRAITS; RECOMBINANT CONGENIC STRAINS; SIMPLE SEQUENCE REPEATS; GENETIC MAPPING	LINKAGE; MOUSE; MAP	The genetic control of susceptibility to many common diseases, including cancer, is multigenic both in humans and in animals. This genetic complexity has presented a major obstacle in mapping the relevant genes. As a consequence, most geneticists and molecular biologists presently focus on "single gene" diseases. To make the multigenic diseases accessible to genetic and molecular analysis, we developed a novel genetic tool, the recombinant congenic strains (RCS) in the mouse (4). The RC strains are produced by inbreeding of mice of the second backcross generation between two inbred strains, one of which serves as the "donor" and the other as the "background" strain. A series of RCS consists of approximately 20 strains, each carrying a different set of genes: approximately 12.5% genes from the common donor inbred strain, the remaining 87.5% from the common background inbred strain. As the set of donor strain genes in each RC strain is different, the nonlinked genes of the donor strain involved in the control of a multigenic trait, e.g., cancer susceptibility, become distributed into different RC strains where they can be analyzed one by one. Hence, the RCS system transforms a multigenic trait into a series of single gene traits, where each gene contributing to the multigenic control can be mapped and studied separately. Recently we demonstrated that the RCS system is indeed capable of resolving multigenic traits, which are hardly analyzable other-wise, by mapping four new colon tumor susceptibility loci (8; P. C. Groot, C. J. A. Moen, W. Dietrich, L. F. M. van Zutphen, E. S. Lander, and P. Demant, unpublished results). For successful application of the RCS system, extensive genetic characterization of the individual recombinant congenic strains is essential. In this paper we present detailed information about the genetic composition of three series of RC strains on the basis of typing of 120-180 markers distributed along all autosomes. The data indicate that the relative representation of the donor strain genes in the RC strains does not deviate from the theoretical expectation, and that the RC strains achieved a very high degree of genetic homogeneity and for all practical purposes can be considered inbred strains. The density and distribution of markers reported here permits an effective mapping of unknown genes of donor strain origin at almost all autosomal locations. Much of this information has been obtained using the new class of genetic markers, the simple sequence repeat polymorphisms. The extensive application of these PCR-typable markers greatly increases the possibilities of the effective use of the RC strains for mapping of genes involved in multigenic control. The data presented here can be used by investigators interested in functional effects of a specific region of the mouse genome to select RC strains that differ at this region from the background strain. This information is of interest to investigators working with mice, as well as those analyzing a specific region of the human genome and interested in the structure or function of the homologous part of the mouse genome.	NETHERLANDS CANC INST, DIV MOLEC GENET, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS; WHITEHEAD INST, CAMBRIDGE, MA 02142 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Netherlands Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; MRC National Institute for Medical Research				Stoye, Jonathan/0000-0003-3377-323X; Groot, Peter C./0000-0003-3339-1469				AITMAN TJ, 1991, MAMM GENOME, V1, P206, DOI 10.1007/BF00352326; BAILEY DW, 1971, TRANSPLANTATION, V11, P325, DOI 10.1097/00007890-197103000-00013; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; DAVISSON MT, 1989, GENETIC VARIANTS STR, P416; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DEMANT P, 1989, ADV CANCER RES, V53, P117; DEMANT P, 1992, SEMIN CANCER BIOL, V3, P157; DIETRICH W, IN PRESS GENETICS; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANKEL WN, 1990, GENETICS, V124, P221; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; LANDER ES, 1989, GENETICS, V121, P185; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MCALEER MA, 1992, IN PRESS MAMMALIAN G; MOEN CJA, 1992, ONCOGENE, V7, P563; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; NADEAU J, 1990, MOUSE GENOME, V87, P55; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; RIELE HT, 1992, IN PRESS P NATL ACAD; RISCH N, 1992, SCIENCE, V255, P803, DOI 10.1126/science.1536004; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; VANZUTPHEN LFM, 1991, LAB ANIM, V25, P193, DOI 10.1258/002367791780808329; WEBER JL, 1989, AM J HUM GENET, V44, P388; [No title captured]	25	75	75	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2826	2835		10.1096/fasebj.6.10.1634045	http://dx.doi.org/10.1096/fasebj.6.10.1634045			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634045				2022-12-28	WOS:A1992JD95400011
J	VEMURU, RP; DAVIDSON, A; ARAGONA, E; CHOWDHURY, JR; BURK, RD; GUPTA, S				VEMURU, RP; DAVIDSON, A; ARAGONA, E; CHOWDHURY, JR; BURK, RD; GUPTA, S			IMMUNE TOLERANCE TO A DEFINED HETEROLOGOUS ANTIGEN AFTER INTRASPLENIC HEPATOCYTE TRANSPLANTATION - IMPLICATIONS FOR GENE-THERAPY	FASEB JOURNAL			English	Article						HEPATOCYTE TRANSPLANTATION; TRANSGENIC; HEPATITIS-B VIRUS; IMMUNE TOLERANCE; GENE THERAPY	HEPATITIS-B VIRUS; MICROCARRIER-ATTACHED HEPATOCYTES; TRANSGENIC MICE; EXPRESSION; HBSAG; RABBIT; SYSTEM; REGION; CELLS; RATS	Development of a host immune response against gene products expressed by genetically modified cells could be a serious limitation for gene therapy. During examination of whether site-specific differences in antigen presentation could regulate the host immune response, we observed an absence of antibodies against hepatitis B virus surface antigen (HBsAg) when HBsAg producing transgenic hepatocytes were transplanted into the spleen. Intrasplenic transplantation resulted in translocation of a large number of cells into the portal vascular bed and liver sinusoids. In these recipients, HBsAg secreted by the transplanted hepatocytes circulated indefinitely in the blood. In contrast, subcutaneous or intraperitoneal transplantation of the transgenic hepatocytes induced an anti-HBs response, followed by clearance of serum HBsAg. Rechallenge with HBsAg in a highly immunogenic form failed to break the tolerance in intrasplenic hepatocyte recipients even though these animals responded to another antigen (key-hole limpet hemocyanin). Immunization with HBsAg in intraperitoneal recipients of HBsAg producing hepatocytes further elevated anti-HBs titers. Our results indicate that hepatocyte transplantation into the portal vascular bed via injection into the spleen can confer immune tolerance to secreted heterologous antigens. This finding should have important implications for human gene therapy as well as for analyzing the mechanisms of immune tolerance.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, ULLMAN 625, 1300 MORRIS PK AVE, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT OBSTET & GYNECOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [R01CA045476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001909, R01DK034357] Funding Source: NIH RePORTER; NCI NIH HHS [CA 45476] Funding Source: Medline; NIDDK NIH HHS [DK 34357, DK 01909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS TE, 1990, MOL BIOL MED, V7, P341; ARAGONA E, 1990, HEPATOLOGY, V12, P875; ARMENTANO D, 1990, P NATL ACAD SCI USA, V87, P6141, DOI 10.1073/pnas.87.16.6141; BATTISTO JR, 1962, P SOC EXP BIOL MED, V111, P111; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BURK RD, 1988, J VIROL, V62, P649, DOI 10.1128/JVI.62.2.649-654.1988; CHANG PL, 1990, MOL BIOL MED, V7, P461; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; DEMETRIOU AA, 1986, SCIENCE, V233, P1190, DOI 10.1126/science.2426782; DEMETRIOU AA, 1986, P NATL ACAD SCI USA, V83, P7475, DOI 10.1073/pnas.83.19.7475; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; GUPTA S, 1992, HEPATOLOGY, V15, P156, DOI 10.1002/hep.1840150126; GUPTA S, 1990, TRANSPLANTATION, V50, P472; GUPTA S, 1991, HEPATOLOGY, V14, P144, DOI 10.1002/hep.1840140124; GUPTA S, 1990, CURRENT HEPATOLOGY, P61; GUPTA S, 1992, CURRENT HEPATOLOGY, P75; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HOSONO M, 1991, CELL IMMUNOL, V136, P373, DOI 10.1016/0008-8749(91)90360-N; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KALEKO M, 1991, HUM GENE THER, V2, P27, DOI 10.1089/hum.1991.2.1-27; LEDLEY FD, 1987, P NATL ACAD SCI USA, V84, P5335, DOI 10.1073/pnas.84.15.5335; MILICH DR, 1985, P NATL ACAD SCI USA, V82, P8168, DOI 10.1073/pnas.82.23.8168; MILICH DR, 1982, J IMMUNOL, V129, P320; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PENG H, 1988, P NATL ACAD SCI USA, V85, P8146, DOI 10.1073/pnas.85.21.8146; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; Schneider W J, 1983, Mol Biol Med, V1, P353; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOTH LE, 1987, P NATL ACAD SCI USA, V84, P6790, DOI 10.1073/pnas.84.19.6790; VANTWUYVER E, 1991, NEW ENGL J MED, V325, P1210, DOI 10.1056/NEJM199110243251704; VEMURU RP, 1991, HEPATOLOGY, V14, pA96; VEMURU RP, 1991, HEPATOLOGY, V14, pA49; WANDS JR, 1975, J CLIN INVEST, V55, P930, DOI 10.1172/JCI108022; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P3014, DOI 10.1073/pnas.85.9.3014; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421; WOLFF JA, 1987, P NATL ACAD SCI USA, V84, P3344, DOI 10.1073/pnas.84.10.3344	43	27	31	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2836	2842		10.1096/fasebj.6.10.1634046	http://dx.doi.org/10.1096/fasebj.6.10.1634046			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634046				2022-12-28	WOS:A1992JD95400012
J	TRUETT, AP; BOCCKINO, SB; MURRAY, JJ				TRUETT, AP; BOCCKINO, SB; MURRAY, JJ			REGULATION OF PHOSPHATIDIC-ACID PHOSPHOHYDROLASE ACTIVITY DURING STIMULATION OF HUMAN POLYMORPHONUCLEAR LEUKOCYTES	FASEB JOURNAL			English	Note						DIACYLGLYCEROL; PHOSPHOLIPASE-D; SUPEROXIDE ANION; NEUTROPHIL; SIGNAL TRANSDUCTION	PHOSPHOLIPASE-D ACTIVATION; ISOLATED RAT HEPATOCYTES; HUMAN NEUTROPHILS; DIACYLGLYCEROL PRODUCTION; SUPEROXIDE PRODUCTION; HUMAN-GRANULOCYTES; DIGLYCERIDES; CALCIUM; ASSAY; GLYCEROL	Phosphatidic acid phosphohydrolase (PPH) activity was determined in human polymorphonuclear leukocytes (PMNs) by measuring the hydrolysis of [P-32]phosphatidic acid (PA) added to cell sonicates. Enzyme activity was localized primarily to a soluble fraction. Soluble and particulate activities required magnesium and were inhibited by calcium, N-ethylmaleimide, sphingosine, and propranolol. The activity in unstimulated PMNs was 0.64 +/- 0.11 nmol of PA hydrolyzed.mg protein-1.min-1 in particulate and 4.20 +/- 0.42 in soluble fractions. Stimulation of PMNs with 1-mu-M f-Met-Leu-Phe (FMLP) for 10 min caused a slight decrease in soluble activity and a small increase in the activity of particulate fractions. Preincubation with 10-mu-M cytochalasin B for 5 min before FMLP stimulation markedly enhanced both of these changes. The effect of FMLP plus cytochalasin B was rapid (< 10 s), whereas the calcium ionophore A23187 (1-mu-M) and phorbol myristate acetate (100 ng/ml) caused slower and smaller changes in enzyme activity. These results indicate that after chemoattractant stimulation; PPH activity decreases in the soluble fraction and increases in the particulate fraction suggesting that PPH may participate in signal transduction in the PMN.	VANDERBILT UNIV,MED CTR,DEPT MED,ALLERGY LAB,843 LIGHT HALL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-05424] Funding Source: Medline; NIAMS NIH HHS [AR/AI-08130-01] Funding Source: Medline; NIGMS NIH HHS [GM-15431] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BEVINGTON A, 1989, ANAL BIOCHEM, V181, P130, DOI 10.1016/0003-2697(89)90405-3; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BRINDLEY DN, 1987, CRC SERIES ENZYME BI, V1, P1; CASCALES C, 1984, BIOCHEM J, V219, P911, DOI 10.1042/bj2190911; COX CC, 1986, J IMMUNOL, V136, P4611; ENGLISH D, 1991, BIOCHEM BIOPH RES CO, V175, P423, DOI 10.1016/0006-291X(91)91581-V; GAY JC, 1990, BLOOD S, V76, pA180; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JONES GS, 1981, J CELL PHYSIOL, V106, P75, DOI 10.1002/jcp.1041060109; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; MARTIN A, 1991, PHOSPHOLIPASES, V197, P553; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; PITTNER RA, 1986, BIOCHEM J, V240, P253, DOI 10.1042/bj2400253; PITTNER RA, 1985, BIOCHEM J, V225, P455, DOI 10.1042/bj2250455; PREISS JE, 1987, J IMMUNOL, V138, P1542; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SMITH RJ, 1988, J LEUKOCYTE BIOL, V43, P411, DOI 10.1002/jlb.43.5.411; STURTON RG, 1978, BIOCHEM J, V171, P263, DOI 10.1042/bj1710263; TAYLOR SJ, 1986, BIOCHEM J, V239, P275, DOI 10.1042/bj2390275; TRUETT AP, 1989, J ALLERGY CLIN IMMUN, V83, P311; TRUETT AP, 1989, BIOCHEM J, V260, P909, DOI 10.1042/bj2600909; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; WALTON PA, 1985, ANAL BIOCHEM, V151, P479, DOI 10.1016/0003-2697(85)90208-8; WELLS GN, 1986, BIOCHIM BIOPHYS ACTA, V878, P225, DOI 10.1016/0005-2760(86)90150-5; WHITIN JC, 1985, J IMMUNOL, V134, P1206	33	23	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2720	2725		10.1096/fasebj.6.9.1612297	http://dx.doi.org/10.1096/fasebj.6.9.1612297			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612297				2022-12-28	WOS:A1992HZ48100014
J	CLEJAN, LA; CEDERBAUM, AI				CLEJAN, LA; CEDERBAUM, AI			ROLE OF CYTOCHROME-P450 IN THE OXIDATION OF GLYCEROL BY RECONSTITUTED SYSTEMS AND MICROSOMES	FASEB JOURNAL			English	Note						GLYCEROL; P4502E1; OXYGEN RADICALS; MICROSOMES; RECONSTITUTED SYSTEMS	RAT-LIVER MICROSOMES; ETHANOL-INDUCIBLE CYTOCHROME-P-450; HYDROXYL RADICAL PRODUCTION; NADPH-DEPENDENT PRODUCTION; FUNCTION OXIDASE SYSTEM; NADPH-CYTOCHROME-P-450 REDUCTASE; PURIFIED COMPONENTS; LIPID-PEROXIDATION; METABOLIC ENZYMES; OXY RADICALS	Glycerol can be oxidized by rat liver microsomes to formaldehyde in a reaction that requires the production of reactive oxygen intermediates. Studies with inhibitors, antibodies, and reconstituted systems with purified cytochrome P4502E1 were carried out to evaluate whether P450 was required for glycerol oxidation. A purified system containing phospholipid, NADPH-cytochrome P450 reductase, P4502E1, and NADPH oxidized glycerol to formaldehyde. Formaldehyde production was dependent on NADPH, reductase, and P450, but not phospholipid. Formaldehyde production was inhibited by substrates and ligands for P4502E1, as well as by anti-pyrazole P4502E1 IgG. The oxidation of glycerol by the reconstituted system was sensitive to catalase, desferrioxamine, and EDTA but not to superoxide dismutase or mannitol, indicating a role for H2O2 plus non-heme iron, but not superoxide or hydroxyl radical in the overall glycerol oxidation pathway. The requirement for reactive oxygen intermediates for glycerol oxidation is in contrast to the oxidation of typical substrates for P450. In microsomes from pyrazole-treated, but not phenobarbital-treated rats, glycerol oxidation was inhibited by anti-pyrazole P450 IgG, anti-hamster ethanol-induced P450 IgG, and monoclonal antibody to ethanol-induced P450, although to a lesser extent than inhibition of dimethylnitrosamine oxidation. Anti-rabbit P4503a IgG did not inhibit glycerol oxidation at concentrations that inhibited oxidation of dimethylnitrosamine. Inhibition of glycerol oxidation by antibodies and by aminotriazole and miconazole was closely associated with inhibition of H2O2 production. These results indicate that P450 is required for glycerol oxidation to formaldehyde; however, glycerol is not a direct substrate for oxidation to formaldehyde by P450 but is a substrate for an oxidant derived from interaction of iron with H2O2 generated by cytochrome P450.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIAAA NIH HHS [AA-06610, AA-03312, AA-03508] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006610, R01AA003312, R56AA003312, R01AA006610, P50AA003508] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ARDIES CM, 1987, BIOCHEM PHARMACOL, V36, P3613, DOI 10.1016/0006-2952(87)90010-4; CEDERBAUM AI, 1987, ANN NY ACAD SCI, V492, P35, DOI 10.1111/j.1749-6632.1987.tb48651.x; CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P559, DOI 10.1016/0891-5849(89)90033-6; CLEJAN LA, 1991, ARCH BIOCHEM BIOPHYS, V285, P83, DOI 10.1016/0003-9861(91)90331-C; CLEJAN LA, 1990, BIOCHIM BIOPHYS ACTA, V1034, P233, DOI 10.1016/0304-4165(90)90082-8; CLEJAN LA, 1989, DRUG METAB DISPOS, V17, P694; DICKER E, 1988, FASEB J, V2, P2901, DOI 10.1096/fasebj.2.13.3169467; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; FEIERMAN DE, 1986, BIOCHEM J, V239, P671, DOI 10.1042/bj2390671; FEIERMAN DE, 1987, DRUG METAB DISPOS, V15, P634; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1980, ARCH BIOCHEM BIOPHYS, V205, P365, DOI 10.1016/0003-9861(80)90119-8; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; INGELMANSUNDBERG M, 1984, J BIOL CHEM, V259, P6447; KO IY, 1987, CANCER RES, V47, P3101; KOMIYAMA T, 1985, BIOCHEM PHARMACOL, V34, P977, DOI 10.1016/0006-2952(85)90599-4; KOOP DR, 1984, ARCH BIOCHEM BIOPHYS, V235, P228, DOI 10.1016/0003-9861(84)90272-8; KOOP DR, 1990, CHEM RES TOXICOL, V3, P377, DOI 10.1021/tx00016a017; Koppenol W. H., 1985, ADV FREE RADICALS BI, V1, P91, DOI DOI 10.1016/8755-9668(85)90005-5; KRIKUN G, 1984, BIOCHEMISTRY-US, V23, P5489, DOI 10.1021/bi00318a017; MOREHOUSE LA, 1984, ARCH BIOCHEM BIOPHYS, V232, P366, DOI 10.1016/0003-9861(84)90552-6; MORGAN ET, 1982, J BIOL CHEM, V257, P3951; NAKAMURA K, 1985, ARCH BIOCHEM BIOPHYS, V240, P319, DOI 10.1016/0003-9861(85)90037-2; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; PALAKODETY RB, 1988, J BIOL CHEM, V263, P878; PUNTARULO S, 1988, ARCH BIOCHEM BIOPHYS, V266, P435, DOI 10.1016/0003-9861(88)90275-5; RYAN DE, 1985, J BIOL CHEM, V260, P6385; RYAN DE, 1986, ARCH BIOCHEM BIOPHYS, V246, P633, DOI 10.1016/0003-9861(86)90319-X; SCHUTTE H, 1976, EUR J BIOCHEM, V62, P151, DOI 10.1111/j.1432-1033.1976.tb10108.x; TERELIUS Y, 1988, BIOCHEM PHARMACOL, V37, P1383, DOI 10.1016/0006-2952(88)90798-8; WINSTON GW, 1983, J BIOL CHEM, V258, P1514; WINSTON GW, 1984, ARCH BIOCHEM BIOPHYS, V232, P378, DOI 10.1016/0003-9861(84)90553-8; WINSTON GW, 1983, J BIOL CHEM, V258, P1508; WINTERS DK, 1990, BIOCHEM PHARMACOL, V39, P697, DOI 10.1016/0006-2952(90)90148-E; YAMAZAKI I, 1990, J BIOL CHEM, V265, P652; YANG CS, 1985, BIOCHEM BIOPH RES CO, V128, P1007, DOI 10.1016/0006-291X(85)90147-0; YOO JSH, 1987, CANCER RES, V47, P3378; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0	39	21	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					765	770		10.1096/fasebj.6.2.1537467	http://dx.doi.org/10.1096/fasebj.6.2.1537467			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537467				2022-12-28	WOS:A1992GZ44000020
J	VENNESLAND, B				VENNESLAND, B			ISOTOPE TIME - 50 YEARS AGO .7.	FASEB JOURNAL			English	Editorial Material											VENNESLAND, B (corresponding author), UNIV HAWAII MANOA,DEPT BIOCHEM & BIOPHYS,HONOLULU,HI 96734, USA.							BARNES F. W., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P99; CAMPBELL WW, 1942, FED PROC, V1, P104; Conant JB, 1941, J BIOL CHEM, V137, P557; EVANS E. A., 1941, JOUR BIOL CHEM, V141, P439; Evans EA, 1940, J BIOL CHEM, V136, P301; EVANS EA, 1942, FED PROC, V1, P109; FLOCK EV, 1942, FED PROC, V1, P109; GURIN S, 1942, FED PROC, V1, P114; HEMINGWAY A, 1942, FED PROC, V1, P115; KAMEN MD, 1963, SCIENCE, V140, P584, DOI 10.1126/science.140.3567.584; Ruben S, 1940, P NATL ACAD SCI USA, V26, P418, DOI 10.1073/pnas.26.6.418; Ruben S, 1939, SCIENCE, V90, P570, DOI 10.1126/science.90.2346.570; Solomon AK, 1941, J BIOL CHEM, V140, P171; SWENDSEID MO, 1942, FED PROC, V1, P137; TARVER H., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P138; Vennesland B, 1942, J BIOL CHEM, V142, P371; Vennesland B, 1942, J BIOL CHEM, V142, P379; WOOD H. G., 1941, JOUR BIOL CHEM, V139, P365; WOOD H. G., 1941, JOUR BIOL CHEM, V139, P377; Wood HG, 1940, J BIOL CHEM, V135, P789	20	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2868	2869		10.1096/fasebj.5.13.1916109	http://dx.doi.org/10.1096/fasebj.5.13.1916109			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916109				2022-12-28	WOS:A1991GJ47100018
J	JUKES, TH				JUKES, TH			THE GOLDEN-AGE OF FEDERATION MEETINGS - 1936-1942	FASEB JOURNAL			English	Editorial Material											JUKES, TH (corresponding author), UNIV CALIF BERKELEY,SPACE SCI LAB,BERKELEY,CA 94720, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2740	2741		10.1096/fasebj.5.12.1916096	http://dx.doi.org/10.1096/fasebj.5.12.1916096			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916096				2022-12-28	WOS:A1991GE81100017
J	KOLE, HK; LENARD, J				KOLE, HK; LENARD, J			INSULIN-INDUCED STIMULATION OF PROTEIN-PHOSPHORYLATION IN NEUROSPORA-CRASSA CELLS	FASEB JOURNAL			English	Article						TYROSINE PROTEIN KINASE; PHOSPHOAMINO ACIDS; SIGNAL TRANSDUCTION PATHWAYS; NEUROSPORA-CRASSA MEMBRANE; 2-DIMENSIONAL GEL ELECTROPHORESIS	RECEPTOR TYROSINE KINASE; WALL-LESS STRAIN; EPIDERMAL GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; MAMMALIAN INSULIN; FACTOR-I; AUTOPHOSPHORYLATION; METABOLISM; SUBSTRATE; ACTIVATION	1) Insulin stimulated the phosphorylation of at least 14 discrete proteins in Neurospora crassa cells. Specific proteins were phosphorylated at serine, threonine, and tyrosine residues, as determined by phosphoamino acid analysis of discrete spots on two-dimensional gels. 2) Insulin stimulated the phosphorylation by [gamma-P-32]ATP of at least six discrete proteins in solubilized N. crassa membrane preparations at serine and tyrosine residues. 3) A phosphotyrosine-containing protein of 38 kDa, pI 7.0-7.2, reacted by both immunoblotting and immunoprecipitation with antiserum to P2, a peptide from the human insulin receptor that contains an autophosphorylated tyrosine residue. In N. crassa cells, therefore, as in mammalian cells, insulin induces a variety of protein phosphorylations, some of which may be part of an evolutionarily conserved signal transduction pathway.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHYSIOL & BIOPHYS,675 HOES LANE,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NIDDK NIH HHS [DK-39502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039502] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1990, NATURE, V348, P286, DOI 10.1038/348286a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FAWELL SE, 1988, BIOCHEM BIOPH RES CO, V155, P59, DOI 10.1016/S0006-291X(88)81049-0; FAWELL SE, 1988, ENDOCRINOLOGY, V122, P518, DOI 10.1210/endo-122-2-518; FLAWIA MM, 1973, J BIOL CHEM, V248, P4517; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GREENFIELD NJ, 1988, BIOCHEMISTRY-US, V27, P8526, DOI 10.1021/bi00423a004; GREENFIELD NJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P15, DOI 10.1016/0005-2736(90)90185-Q; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAMATA T, 1987, BIOCHEM BIOPH RES CO, V144, P19, DOI 10.1016/S0006-291X(87)80469-2; KOKE HK, 1991, BIOCHEMISTRY-US, V30, P682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROITH D, 1985, CAN J BIOCHEM CELL B, V63, P839, DOI 10.1139/o85-106; LEROITH D, 1980, P NATL ACAD SCI-BIOL, V77, P6184; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MCKENZIE MA, 1988, ENDOCRINOLOGY, V122, P511, DOI 10.1210/endo-122-2-511; MERMELSTEIN FH, 1989, MOL PHARMACOL, V36, P848; MUTHUKUMAR G, 1991, UNPUB PREPROINSULIN; NAVARRO J, 1982, BIOCHEMISTRY-US, V21, P6138, DOI 10.1021/bi00267a018; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PETRUZELLI LM, 1985, P NATL ACAD SCI USA, V83, P4710; PONZIO G, 1988, EMBO J, V7, P4111, DOI 10.1002/j.1460-2075.1988.tb03305.x; ROSEN OM, 1987, SCIENCE, V237, P1451; SALE EM, 1987, J CELL BIOCHEM, V33, P15, DOI 10.1002/jcb.240330103; SANDERS MM, 1980, ANAL BIOCHEM, V103, P157, DOI 10.1016/0003-2697(80)90250-X; SCARBOROUGH GA, 1985, EXP MYCOL, V9, P275; SCHULTE TH, 1975, J BACTERIOL, V122, P1076, DOI 10.1128/JB.122.3.1076-1080.1975; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; SUNG CK, 1989, J BIOL CHEM, V264, P18951; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2	38	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2728	2734		10.1096/fasebj.5.12.1717334	http://dx.doi.org/10.1096/fasebj.5.12.1717334			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1717334				2022-12-28	WOS:A1991GE81100015
J	MCKUSICK, VA				MCKUSICK, VA			CURRENT TRENDS IN MAPPING HUMAN GENES	FASEB JOURNAL			English	Article						CHROMOSOME; PEDIGREE PATTERN; FAMILY LINKAGE; GENE MAPPING; HYBRIDIZATION; GENOMICS	POLYMERASE CHAIN-REACTION; HUMAN GENOME; CLINICAL MEDICINE; MORBID ANATOMY; HUMAN-CHROMOSOMES; SINGLE-SPERM	The human is estimated to have at least 50,000 expressed genes (gene loci). Some information is available concerning about 5000 of these gene loci and about 1900 have been mapped, i.e., assigned to specific chromosomes (and in most instances particular chromosome regions). Progress has been achieved by a combination of physical mapping (e.g., study of somatic cell hybrids and chromosomal in situ hybridization) and genetic mapping (e.g., genetic linkage studies). New methods for both physical and genetic mapping are expanding the armamentarium. The usefulness of the mapping information is already evident; the spin-off from the Human Genome Project (HGP) begins immediately. The complete nucleotide sequence is the ultimate map of the human genome. Sequencing, although already under way for limited segments of the genome, will await further progress in gene mapping, and in particular creation of contig maps for each chromosome. Meanwhile the technology of sequencing and sequence information handling will be developed. It is argued that the HGP is a new form of coordinated, interdisciplinary science; that its primary objective must be seen as the creation of a tool for biomedical research - a source book that will be the basis of study of variation and function for a long time; that the impact on scientist training will be salutary by relieving graduate students of useless drudgery and by training scientist competent in both molecular genetics and computational science; and that the funding of the HGP will have an insignificant negative effect on science funding generally, and indeed may have a beneficial effect through economy of scale and a focusing of attention on the excitement of biology and medical science.			MCKUSICK, VA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							BOEHNKE M, 1989, AM J HUM GENET, V45, P21; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; COX DR, 1989, GENOMICS, V4, P397, DOI 10.1016/0888-7543(89)90347-9; CUI XF, 1989, P NATL ACAD SCI USA, V86, P9389, DOI 10.1073/pnas.86.23.9389; DONAHUE RP, 1968, P NATL ACAD SCI USA, V61, P949, DOI 10.1073/pnas.61.3.949; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; GOODFELLOW PJ, 1990, SOMAT CELL MOLEC GEN, V16, P163, DOI 10.1007/BF01233046; GOSS SJ, 1975, NATURE, V255, P680, DOI 10.1038/255680a0; Haldane JBS, 1915, J GENET, V5, P133, DOI 10.1007/BF02985370; HORNER JF, 1876, AMTL BER UEBER VERWA, V31, P208; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LAWRENCE JB, 1988, CELL, V52, P51; MCKUSICK VA, 1987, MEDICINE, V66, P1; MCKUSICK VA, 1988, MEDICINE, V67, P1; MCKUSICK VA, 1986, MEDICINE, V65, P1; McKusick VA, 1990, MENDELIAN INHERITANC; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OTT J, 1985, ANAL HUMAN GENETIC L; ROBERTS L, 1990, SCIENCE, V248, P1310, DOI 10.1126/science.2356467; Taylor BA., 1989, GENETIC VARIANTS STR; Wilson EB, 1911, ARCH MIKROSK ANAT, V77, P249; 1988, COMMITTEE MAPPING SE	22	49	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					12	20		10.1096/fasebj.5.1.1991580	http://dx.doi.org/10.1096/fasebj.5.1.1991580			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991580	Bronze			2022-12-28	WOS:A1991ET60900003
J	STUEHR, DJ; FASEHUN, OA; KWON, NS; GROSS, SS; GONZALEZ, JA; LEVI, R; NATHAN, CF				STUEHR, DJ; FASEHUN, OA; KWON, NS; GROSS, SS; GONZALEZ, JA; LEVI, R; NATHAN, CF			INHIBITION OF MACROPHAGE AND ENDOTHELIAL-CELL NITRIC-OXIDE SYNTHASE BY DIPHENYLENEIODONIUM AND ITS ANALOGS	FASEB JOURNAL			English	Note						L-ARGININE; FAD; FLAVOPROTEIN; INTERFERON-GAMMA; ENDOTHELIUM-DERIVED RELAXING FACTOR	L-ARGININE; RELAXING FACTOR; NITROGEN-OXIDES; MURINE MACROPHAGES; GUANYLATE-CYCLASE; ORGANIC NITRATES; TARGET-CELLS; MECHANISM; OXIDATION; SYSTEM	The cofactor requirements of macrophage nitric oxide (NO.) synthase suggest involvement of an NADPH-dependent flavoprotein. This prompted us to test the effect of the flavoprotein inhibitors diphenyleneiodonium (DPI), di-2-thienyliodonium (DTI), and iodoniumdiphenyl (ID) on the NO. synthases of macrophages and endothelium. DPI, DTI, and ID completely inhibited NO. synthesis by mouse macrophages, their lysates, and partially purified macrophage NO. synthase. Inhibiton of NO. synthase by these agents was potent (IC50's 50-150 nM), irreversible, dependent on time and temperature, and independent of enzyme catalysis. The inhibition by DPI was blocked by NADPH, NADP+, or 2'5'-ADP, but not by NADH. Likewise, FAD or FMN, but not riboflavin or adenosine 5-diphosphoribose, protected NO. synthase from inhibition by DPI. Neither NADPH nor FAD reacted with DPI. Once NO. synthase was inhibited by DPI, neither NADPH nor FAD could restore its activity. DPI also inhibited acetylcholine-induced relaxation of norepinephrine-preconstricted rabbit aortic rings (IC50 300 nM). Inhibition of acetylcholine-induced relaxation persisted for at least 2 h after DPI was washed out. In contrast, DPI had no effect on norepinephrine-induced vasoconstriction itself nor on vasorelaxation induced by the NO.-generating agent sodium nitroprusside. These results suggest that NO. synthesis in both macrophages and endothelial cells depends on an NADPH-utilizing flavoprotein. As a new class of NO. synthase inhibitors, DPI and its analogs are likely to prove useful in analyzing the physiologic and pathophysiologic roles of NO..	CORNELL UNIV,MED CTR,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Cornell University	STUEHR, DJ (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV HEMATOL,BEATRICE & SAMUEL A SEAVER LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034215] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43610] Funding Source: Medline; NHLBI NIH HHS [HL34215] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBER IJ, 1988, J LEUKOCYTE BIOL, V44, P58, DOI 10.1002/jlb.44.1.58; BANKS DF, 1966, CHEM REV, V66, P243, DOI 10.1021/cr60241a001; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; GATLEY SJ, 1976, BIOCHEM J, V158, P307, DOI 10.1042/bj1580307; GORSKY LD, 1990, FASEB J, V4, P1494, DOI 10.1096/fasebj.4.5.2155150; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN SJ, 1990, J IMMUNOL, V144, P278; HANCOCK JT, 1987, BIOCHEM J, V242, P103, DOI 10.1042/bj2420103; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOLLAND PC, 1973, J BIOL CHEM, V248, P6050; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KWON NS, 1989, J BIOL CHEM, V264, P20496; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; NATHAN CF, 1990, J NATL CANCER I, V82, P726, DOI 10.1093/jnci/82.9.726; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1990, BIOCHEM BIOPH RES CO, V168, P558, DOI 10.1016/0006-291X(90)92357-6; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1989, BIOCHEM BIOPH RES CO, V161, P420, DOI 10.1016/0006-291X(89)92615-6; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAYEH MA, 1989, J BIOL CHEM, V264, P19654	40	440	443	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					98	103		10.1096/fasebj.5.1.1703974	http://dx.doi.org/10.1096/fasebj.5.1.1703974			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1703974				2022-12-28	WOS:A1991ET60900021
J	Wang, MF; Yan, Q; Song, YF; Zhang, ZB; Chen, XJ; Gao, K; Wan, XP				Wang, Mengfei; Yan, Qin; Song, Yunfeng; Zhang, Zhenbo; Chen, Xiaojun; Gao, Kun; Wan, Xiaoping			Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer	ONCOGENE			English	Article; Early Access							TEAD-YAP COMPLEX; TUMOR-SUPPRESSOR; DIFFERENTIATION; CABOZANTINIB; CHROMATIN; PROTEINS; ACTS	Aberrant hyperactivation of the Hippo pathway effector YAP/TEAD complex causes tissue overgrowth and tumorigenesis in various cancers, including endometrial cancer (EC). The transcription factor SOX17 (SRY [sex-determining region Y]-box 17) is frequently mutated in EC; however, SOX17 mutations are rare in other cancer types. The molecular mechanisms underlying SOX17 mutation-induced EC tumorigenesis remain poorly understood. Here, we demonstrate that SOX17 serves as a tumor suppressor to restrict the proliferation, migration, invasion, and anchorage-independent growth of EC cells, partly by suppressing the transcriptional outputs of the Hippo-YAP/TEAD pathway. SOX17 binds to TEAD transcription factors through its HMG domain and attenuates the DNA-binding ability of TEAD. SOX17 loss by inactivating mutations leads to the malignant transformation of EC cells, which can be reversed by small-molecule inhibitors of YAP/TEAD or cabozantinib, an FDA-approved drug targeting the YAP/TEAD transcriptional target AXL. Our findings reveal novel molecular mechanisms underlying Hippo-YAP/TEAD pathway-driven EC tumorigenesis, and suggest potential therapeutic strategies targeting the Hippo-YAP/TEAD pathway in SOX17-mutated EC.	[Wang, Mengfei; Yan, Qin; Song, Yunfeng; Wan, Xiaoping] Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Gynecol, Shanghai 201204, Peoples R China; [Zhang, Zhenbo] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Obstet & Gynecol, Shanghai 200080, Peoples R China; [Chen, Xiaojun] Fudan Univ, Dept Gynecol, Obstet & Gynecol Hosp, Shanghai 200011, Peoples R China; [Gao, Kun] Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Clin Lab, Shanghai 201204, Peoples R China; [Wan, Xiaoping] Shanghai First Matern & Infant Hosp, Shanghai Key Lab Maternal & Fetal Med, Shanghai, Peoples R China	Tongji University; Shanghai Jiao Tong University; Fudan University; Tongji University	Wan, XP (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Gynecol, Shanghai 201204, Peoples R China.; Gao, K (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Sch Med, Dept Clin Lab, Shanghai 201204, Peoples R China.; Wan, XP (corresponding author), Shanghai First Matern & Infant Hosp, Shanghai Key Lab Maternal & Fetal Med, Shanghai, Peoples R China.	kungao@tongji.edu.cn; Wanxiaoping@tongji.edu.cn			National Natural Science Foundation of China [91954106, 81872109, 81972438, 82172975]; Natural Science Foundation of Shanghai [18ZR1430100]; Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center [SHDC12020107]; Shanghai Sailing Program [22YF1434700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center; Shanghai Sailing Program	This work was supported by the National Natural Science Foundation of China (No. 91954106 and 81872109 to K.G., No. 81972438 and 82172975 to X.W.), Natural Science Foundation of Shanghai ((No. 18ZR1430100 to K.G.), Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center (SHDC12020107 to X.W.), and Shanghai Sailing Program (No. 22YF1434700 to Y.S.).	Azad T, 2020, ONCOGENE, V39, P334, DOI 10.1038/s41388-019-0988-y; Dhani NC, 2020, CLIN CANCER RES, V26, P2477, DOI 10.1158/1078-0432.CCR-19-2576; Diepenbruck M, 2014, J CELL SCI, V127, P1523, DOI 10.1242/jcs.139865; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kim I, 2007, CELL, V130, P470, DOI 10.1016/j.cell.2007.06.011; Kinnear S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51751-3; Kobayashi T, 2017, NATURE, V546, P416, DOI 10.1038/nature22812; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Li L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0782-8; Lilly AJ, 2017, SEMIN CELL DEV BIOL, V63, P50, DOI 10.1016/j.semcdb.2016.07.021; Lin KC, 2017, TRENDS BIOCHEM SCI, V42, P862, DOI 10.1016/j.tibs.2017.09.003; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Markowitz JN, 2018, PHARMACOTHERAPY, V38, P357, DOI 10.1002/phar.2076; Merino-Azpitarte M, 2017, J HEPATOL, V67, P72, DOI 10.1016/j.jhep.2017.02.017; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0; Mukherjee S, 2020, ELIFE, V9, DOI 10.7554/eLife.58029; Qiao Y, 2016, ONCOGENE, V35, P2664, DOI 10.1038/onc.2015.338; Sakamoto Y, 2007, BIOCHEM BIOPH RES CO, V360, P539, DOI 10.1016/j.bbrc.2007.06.093; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stanger BZ, 2012, GENE DEV, V26, P1263, DOI 10.1101/gad.196501.112; Walker CJ, 2017, ONCOTARGET, V8, P68758, DOI 10.18632/oncotarget.20213; Wang XQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06652-w; Wen XL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0170-6; Wissmuller S, 2006, NUCLEIC ACIDS RES, V34, P1735, DOI 10.1093/nar/gkl105; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Ying L, 2015, STEM CELL REP, V5, P490, DOI 10.1016/j.stemcr.2015.08.014; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhang YL, 2016, ONCOTARGET, V7, P76036, DOI 10.18632/oncotarget.12582; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhu CJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1090-3; Zhu N, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0566-x; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	36	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02550-0	http://dx.doi.org/10.1038/s41388-022-02550-0		NOV 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6O2TJ	36446891				2022-12-28	WOS:000890096600001
J	He, YT; OuYang, ZB; Liu, WW; Chen, Y; Zhang, QS				He, Yutian; OuYang, Zhenbo; Liu, Wenwen; Chen, Yu; Zhang, Qiushi			TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing	ONCOGENE			English	Article; Early Access							VEGF; TDP-43	Disruptions in alternative splicing regulation play an essential role in ovarian cancer progression. However, the underlying mechanism remains unclear. TAR DNA-binding protein (TARDBP) plays a crucial role in alternative splicing regulation. Herein we found that TARDBP expression was significantly upregulated in OC tissue samples, particularly in cases of metastasis; further, TARDBP expression was markedly upregulated in OC patients with poor prognosis. These findings were validated by extensive tissue microarray data. TARDBP was also found to promote tumorigenesis and metastasis of OC cells in vitro and in vivo. Mechanistically, TARDBP increased the binding of the splicing factor serine/arginine-rich splicing factor 1 (SRSF1) to intron 7 of vascular endothelial growth factor (VEGF), increasing the formation of the proangiogenic VEGF(165) isoform and decreasing that of the antiangiogenic VEGF(165)b isoform. The abnormal alternative splicing event was responsible for the activation of angiogenesis and contributed to the progression of OC. To conclude, TARDBP was found to regulate the alternative splicing of VEGF via SRSF1, induce the formation of VEGF(165) but inhibit that of VEGF(165)b, and promote OC angiogenesis. Hence, TARDBP can serve as an independent prognostic factor and new target for OC cancer therapy.	[He, Yutian; OuYang, Zhenbo; Liu, Wenwen; Chen, Yu; Zhang, Qiushi] Guangdong Second Prov Gen Hosp, Dept Gynecol, 466 Xin Gang Zhong Rd, Guangzhou 510317, Peoples R China; [Zhang, Qiushi] Guangdong Second Prov Gen Hosp, Inst Maternal & Child Hlth, 466 Xin Gang Zhong Rd, Guangzhou 510317, Peoples R China		He, YT; Zhang, QS (corresponding author), Guangdong Second Prov Gen Hosp, Dept Gynecol, 466 Xin Gang Zhong Rd, Guangzhou 510317, Peoples R China.; Zhang, QS (corresponding author), Guangdong Second Prov Gen Hosp, Inst Maternal & Child Hlth, 466 Xin Gang Zhong Rd, Guangzhou 510317, Peoples R China.	heyutian@stu.gzhmu.edu.cn; qiushizhangzx@aliyun.com			Doctoral workstation foundation of Guangdong Second Provincial General Hospital [2020072]; GuangDong Basic and Applied Basic Research Foundation [2021A1515111033]	Doctoral workstation foundation of Guangdong Second Provincial General Hospital; GuangDong Basic and Applied Basic Research Foundation	This work was supported by the Doctoral workstation foundation of Guangdong Second Provincial General Hospital (2020072) and the GuangDong Basic and Applied Basic Research Foundation (2021A1515111033).	Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Bao M, 2022, ANGIOGENESIS, V25, P71, DOI 10.1007/s10456-021-09804-7; Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27; Barbagallo D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041678; Bonnal SC, 2020, NAT REV CLIN ONCOL, V17, P457, DOI 10.1038/s41571-020-0350-x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen XW, 2018, PROTEIN CELL, V9, P848, DOI 10.1007/s13238-017-0480-9; Clery A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20481-w; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Das S, 2014, MOL CANCER RES, V12, P1195, DOI 10.1158/1541-7786.MCR-14-0131; de Boer EMJ, 2021, J NEUROL NEUROSUR PS, V92, P86, DOI 10.1136/jnnp-2020-322983; Di Matteo A, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01753-1; Du JX, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01978-8; Gao J, 2018, J NEUROCHEM, V146, P7, DOI 10.1111/jnc.14327; Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Guo FX, 2020, AM J CANCER RES, V10, P3285; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Karaman S, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.151019; Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115; Kedzierska H, 2017, CANCER LETT, V396, P53, DOI 10.1016/j.canlet.2017.03.013; Koutsioumpa M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0287-3; Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559; Liu HD, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01877-y; Lv YS, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00495-6; Ma XY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.755096; Nonaka T, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a024463; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Peres LC, 2019, JNCI-J NATL CANCER I, V111, P60, DOI 10.1093/jnci/djy071; Puszko AK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010072; Suk TR, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00397-1; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Xiong XS, 2021, NAT GENET, V53, P1156, DOI 10.1038/s41588-021-00890-3; Zeng QH, 2017, CANCER BIOL THER, V18, P8, DOI 10.1080/15384047.2016.1250984; Zhou XX, 2019, J CLIN INVEST, V129, P676, DOI 10.1172/JCI120279	39	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02539-9	http://dx.doi.org/10.1038/s41388-022-02539-9		NOV 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D4SS	36369320				2022-12-28	WOS:000882683100001
J	GROSS, G; ESHHAR, Z				GROSS, G; ESHHAR, Z			ENDOWING T-CELLS WITH ANTIBODY SPECIFICITY USING CHIMERIC T-CELL RECEPTORS	FASEB JOURNAL			English	Article						T-CELLS; T-CELL RECEPTORS; CHIMERIC RECEPTORS	MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN-TYROSINE KINASE; IMMUNOGLOBULIN VARIABLE DOMAINS; ANTIGEN RECEPTOR; LYMPHOCYTE-T; ZETA-CHAIN; FUNCTIONAL RECEPTORS; ESCHERICHIA-COLI; FOREIGN ANTIGEN; MHC MOLECULES	T cells recognize antigen in the form of a peptide associated with a cell surface molecule encoded by the major histocompatibility gene complex (MHC). The elaborate requirements for the T cell receptor (TCR)-antigen interaction stand in contrast to the simple and defined nature of the antigenic determinants recognized by antibodies. The similarity in the molecular structure and gene organization between antibodies and the TCR has prompted attempts to interchange the antigen-binding, variable regions of these molecules. To this end, chimeric TCR (cTCR) genes, composed of the variable domains of antibodies linked to TCR constant regions, have been used to confer antibody-type specificity on T cells. cTCR-expressing T cells respond to stimulator cells as well as to immobilized antigen in an MHC unrestricted and independent manner. The antibody-like specificity of the resulting T cells has been exploited, using defined ligands, to elucidate the physicochemical parameters that govern TCR-mediated signaling, and to provide a useful experimental system to study the role of MHC and cell-adhesion/accessory molecules in T cell activation. The successful expression of such cTCR in transgenic mice opens new avenues to explore the role of the MHC in T cell development and maturation. Eventually, chimeric receptors specific to tumor or viral antigens might be used for in vivo targeting of T cells in the framework of immuno- and gene therapy.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science	ESHHAR, Z (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.							ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BEAR R, 1987, CELL, V50, P97; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BIRD RE, 1991, BIOTEC, V9, P133; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DENNY CT, 1986, NATURE, V320, P549, DOI 10.1038/320549a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; ESHHAR Z, 1990, BRIT J CANCER, V62, P27; ESHHAR Z, 1992, IN PRESS P NATL ACAD; Exley M, 1991, Semin Immunol, V3, P283; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GASCOIGNE NRJ, 1987, P NATL ACAD SCI USA, V84, P2936, DOI 10.1073/pnas.84.9.2936; GIVOL D, 1991, MOL IMMUNOL, V28, P1379, DOI 10.1016/0161-5890(91)90040-Q; GOROCHOV G, 1990, CELLULAR IMMUNITY IM, P97; GOROCHOV G, 1992, IN PRESS INT J CANCE; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; GROSS G, 1989, TRANSPLANT P, V21, P127; GROSS G, 1990, THESIS WEIZMANN I SC; GROSS G, 1989, CELLULAR BASIS IMMUN, P97; HERRMANN SH, 1986, J IMMUNOL, V136, P2816; HOCHMAN J, 1973, BIOCHEMISTRY-US, V12, P1130, DOI 10.1021/bi00730a018; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KANG JS, 1990, P NATL ACAD SCI USA, V87, P9803, DOI 10.1073/pnas.87.24.9803; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; KAUFMANN Y, 1981, P NATL ACAD SCI-BIOL, V78, P2502, DOI 10.1073/pnas.78.4.2502; KAWASAKI H, 1991, NEW BIOL, V3, P487; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; KUWANA Y, 1987, BIOCHEM BIOPH RES CO, V149, P960, DOI 10.1016/0006-291X(87)90502-X; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LUSTGARTEN J, 1991, EUR J IMMUNOL, V21, P2507, DOI 10.1002/eji.1830211030; MALONEY DG, 1985, HYBRIDOMA, V4, P191, DOI 10.1089/hyb.1985.4.191; MARIUZZA RA, 1989, J BIOL CHEM, V264, P7310; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MCCLUSKEY J, 1988, J IMMUNOL, V141, P1451; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PAINTER RG, 1972, BIOCHEMISTRY-US, V11, P1327, DOI 10.1021/bi00758a001; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROSENBERG SA, 1992, J CLIN ONCOL, V10, P180, DOI 10.1200/JCO.1992.10.2.180; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SEGAL DM, 1988, CANCER INVEST, V6, P83, DOI 10.3109/07357908809077031; SIEGEL JN, 1991, SEMIN IMMUNOL, V5, P325; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TRAUNECKER A, 1989, IMMUNOL TODAY, V10, P29, DOI 10.1016/0167-5699(89)90062-5; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; WALDEN P, 1985, NATURE, V315, P327; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WATTS TH, 1988, J IMMUNOL, V141, P3708; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1991, SEMIN IMMUNOL, V5, P313	80	71	119	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1992	6	15					3370	3378		10.1096/fasebj.6.15.1464371	http://dx.doi.org/10.1096/fasebj.6.15.1464371			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1464371				2022-12-28	WOS:A1992KD39500008
J	ARNON, R; VANREGENMORTEL, MHV				ARNON, R; VANREGENMORTEL, MHV			STRUCTURAL BASIS OF ANTIGENIC SPECIFICITY AND DESIGN OF NEW VACCINES	FASEB JOURNAL			English	Review						EPITOPES; SYNTHETIC PEPTIDES; ANTIBODIES	MOUTH-DISEASE VIRUS; SYNTHETIC PEPTIDES; PROTEIN ANTIGENICITY; INFLUENZA-VIRUS; B-SUBUNIT; T-CELL; CROSS-REACTIVITY; CHOLERA-TOXIN; LYMPHOCYTES-T; ANTIBODIES	This manuscript describes the design of new vaccines based on synthetic peptides. To this end, we first analyze the structural basis of antigenic reactivity and specificity and the various types of epitopes that form the mosaics of macromolecular antigens, as well as the regulatory mechanisms involved in immune recognition. A distinction is made between sequential or continuous epitopes, and discontinuous or conformational ones, which are the majority of epitopes in globular proteins. In this context it is of particular interest to identify epitopes reacting with B cells and T cells, respectively, or with cytotoxic T cells, in association with the major histocompatibility cell-surface antigens, and the role of these interactions in protective immunity. Identification of such epitopes in proteins of viral, bacterial, or parasitic organisms led to the synthesis of peptides, which when used in conjunction with appropriate carriers and/or adjuvants induced neutralizing antibodies. Particular examples are described, including: bacterial epitopes and mainly those of toxins of diphtheria, cholera, and shigella, leading not only to neutralizing antibodies but also to protective immunity against the deleterious effects of the respective toxins; parasite epitopes, such as those leading to anti-malaria vaccine, based on either the sporozoite or the merozoite stage antigens; viral epitopes leading to protective immunity, with special emphasis on influenza virus where induction of CTL is crucial; and finally, synthetic peptide vaccines against HIV, which should lead to broad specificity protective immunity while avoiding the risks of a vaccine based on the infectious agent. The rapid recent progress in this field, as described in this review, increases the prospect of constructing successful synthetic peptide vaccines in the not too distant future.	CNRS, INST BIOL MOLEC & CELLULAIRE, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	ARNON, R (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.							ARNON R, 1991, MOL IMMUNOL, V28, P209, DOI 10.1016/0161-5890(91)90063-P; ARNON R, 1990, NEW GENERATION VACCI, P688; AUDIBERT F, 1982, P NATL ACAD SCI-BIOL, V79, P5042, DOI 10.1073/pnas.79.16.5042; AUDIBERT F, 1981, NATURE, V289, P593, DOI 10.1038/289593a0; BEACHEY EH, 1981, NATURE, V292, P457, DOI 10.1038/292457a0; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BERZOFSKY JA, 1981, MOL IMMUNOL, V18, P751, DOI 10.1016/0161-5890(81)90067-5; BERZOFSKY JA, 1987, ANTIGENS, V7, P1; BUTLER JE, 1992, STRUCTURE ANTIGENS, V1, P29; CHEDID L, 1987, SYNTHETIC VACCINES, V1, P93; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DARST SA, 1988, BIOPHYS J, V53, P533, DOI 10.1016/S0006-3495(88)83133-3; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; DIMMOCK NJ, 1987, TRENDS BIOCHEM SCI, V12, P70, DOI 10.1016/0968-0004(87)90034-X; DONOHUEROLFE A, 1984, J EXP MED, V160, P1767, DOI 10.1084/jem.160.6.1767; DUBS MC, 1992, J CHROMATOGR, V597, P391, DOI 10.1016/0021-9673(92)80136-I; DYSON HJ, 1988, ANNU REV BIOPHYS BIO, V17, P305; FRANCIS MJ, 1991, IMMUNOLOGY, V73, P249; FRANCIS MJ, 1987, NATURE, V330, P168, DOI 10.1038/330168a0; FRISCH B, 1991, EUR J IMMUNOL, V21, P185, DOI 10.1002/eji.1830210128; GARCON NMJ, 1991, J IMMUNOL, V146, P3697; GETZOFF ED, 1988, ADV IMMUNOL, V43, P1; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; HARARI I, 1988, INFECT IMMUN, V56, P1618, DOI 10.1128/IAI.56.6.1618-1624.1988; HART MK, 1991, P NATL ACAD SCI USA, V88, P9448, DOI 10.1073/pnas.88.21.9448; HOPP TP, 1986, J IMMUNOL METHODS, V88, P1, DOI 10.1016/0022-1759(86)90045-1; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; JACOB CO, 1984, EMBO J, V3, P2889, DOI 10.1002/j.1460-2075.1984.tb02226.x; JACOB CO, 1983, P NATL ACAD SCI-BIOL, V80, P7611, DOI 10.1073/pnas.80.24.7611; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; JEMMERSON R, 1987, J IMMUNOL, V139, P1939; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JEMMERSON R, 1986, Biotechniques, V4, P18; JEMMERSON R, 1989, MOL IMMUNOL, V26, P301, DOI 10.1016/0161-5890(89)90084-9; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KUBITSCHECK U, 1992, IN PRESS SCAND J IMM; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LERNER RA, 1984, ADV IMMUNOL, V36, P1, DOI 10.1016/S0065-2776(08)60898-6; MAEJI N J, 1991, Peptide Research, V4, P142; MILICH DR, 1989, ADV IMMUNOL, V45, P195, DOI 10.1016/S0065-2776(08)60694-X; Mozes E, 1972, Curr Top Microbiol Immunol, V59, P167; MULLER GM, 1982, P NATL ACAD SCI-BIOL, V79, P569, DOI 10.1073/pnas.79.2.569; MULLER S, 1990, VACCINE, V8, P308, DOI 10.1016/0264-410X(90)90086-2; MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217; NARDELLI B, 1992, J IMMUNOL, V148, P914; NOVOTNY J, 1987, IMMUNOL TODAY, V8, P26, DOI 10.1016/0167-5699(87)90828-0; PADLAN EA, 1992, STRUCTURE ANTIGENS, V1, P29; PAGE GS, 1988, J VIROL, V62, P1781, DOI 10.1128/JVI.62.5.1781-1794.1988; PARRY NR, 1989, J GEN VIROL, V70, P1493, DOI 10.1099/0022-1317-70-6-1493; PELLEQUER JL, 1991, METHOD ENZYMOL, V203, P176; PESSI A, 1991, EUR J IMMUNOL, V21, P2273, DOI 10.1002/eji.1830210941; PLAUE S, 1990, INT J PEPT PROT RES, V35, P510; SAUL A, 1992, J IMMUNOL, V148, P208; SCHULZEGAHMEN U, 1986, EUR J BIOCHEM, V159, P283, DOI 10.1111/j.1432-1033.1986.tb09865.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELA M, 1967, COLD SPRING HARB SYM, V32, P537, DOI 10.1101/SQB.1967.032.01.065; SHAPIRA M, 1985, MOL IMMUNOL, V22, P23, DOI 10.1016/0161-5890(85)90030-6; SHAPIRA M, 1985, INT J IMMUNOPHARMACO, V7, P719, DOI 10.1016/0192-0561(85)90157-2; SOUTAR AJ, 1986, PROTIDES BIOL FLUIDS, P34; TAINER JA, 1985, ANNU REV IMMUNOL, V3, P501, DOI 10.1146/annurev.iy.03.040185.002441; TAKAHASHI H, 1992, SCIENCE, V255, P333, DOI 10.1126/science.1372448; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TAM JP, 1989, J IMMUNOL METHODS, V124, P53, DOI 10.1016/0022-1759(89)90185-3; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TOWNSEND AR, 1989, CELL, V44, P959; TRIFILIEFF E, 1991, MOL IMMUNOL, V28, P889, DOI 10.1016/0161-5890(91)90053-M; van Regenmortel MHV, 1992, STRUCTURE ANTIGENS, V1, P1; VANREGENMORTEL MHV, 1989, IMMUNOL TODAY, V10, P266, DOI 10.1016/0167-5699(89)90140-0; VANREGENMORTEL MHV, 1989, PHILOS T ROY SOC B, V323, P451; VANREGENMORTEL MHV, 1988, IMMUNOL LETT, V17, P95, DOI 10.1016/0165-2478(88)90076-4; VANREGENMORTEL MHV, 1990, IMMUNOCHEMISTRY VIRU, V2, P1; VANREGENMORTEL MHV, 1988, LABORATORY TECHNIQUE, V19, P1; VUILLEUMIER S, 1992, STRUCTURE ANTIGENS, V1, P43; WATTS TH, 1986, NATURE, V320, P179, DOI 10.1038/320179a0; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	78	90	100	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1992	6	14					3265	3274		10.1096/fasebj.6.14.1385242	http://dx.doi.org/10.1096/fasebj.6.14.1385242			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1385242				2022-12-28	WOS:A1992JZ73400008
J	FIELDING, CJ				FIELDING, CJ			LIPOPROTEIN RECEPTORS, PLASMA-CHOLESTEROL METABOLISM, AND THE REGULATION OF CELLULAR FREE-CHOLESTEROL CONCENTRATION	FASEB JOURNAL			English	Review						LIPOPROTEIN RECEPTORS; CHOLESTEROL ESTERIFICATION; CHOLESTERYL ESTER TRANSFER; LOW DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN	LOW-DENSITY-LIPOPROTEIN; HUMAN APOLIPOPROTEIN-E; CHYLOMICRON REMNANTS; ALPHA-2-MACROGLOBULIN RECEPTOR; BINDING PROTEINS; HEPATIC-UPTAKE; HIGH-AFFINITY; HUMAN-LIVER; FOAM CELLS; LDL	Classical concepts of the regulation of plasma cholesterol levels involve roles for the "forward" delivery of low density lipoprotein (LDL) cholesterol from the liver to the peripheral tissues, mediated by the LDL receptor, and a "reverse" delivery of cholesterol in the form of high density lipoprotein (HDL) from the peripheral tissues to the liver. Candidate receptors for HDL in peripheral tissues and for chylomicrons in the liver have more recently been described, and a receptor of uncertain function recognizing chemically modified LDL has also been identified. The activities of all the well-characterized lipoprotein receptors, as well of major catalytic factors in plasma that regulate cholesterol esterification and cholesteryl ester transfer between lipoproteins, reflect the need to maintain plasma membrane free cholesterol level, and its direct and indirect effects within the membrane, within well-defined limits.			FIELDING, CJ (corresponding author), UNIV CALIF SAN FRANCISCO,MED CTR,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL 14237] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014237] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGDADE JD, 1990, ARTERIOSCLEROSIS, V10, P232, DOI 10.1161/01.ATV.10.2.232; BARBARAS R, 1990, BIOCHEM J, V269, P767, DOI 10.1042/bj2690767; BEISIEGEL U, 1988, ARTERIOSCLEROSIS, V8, P288, DOI 10.1161/01.ATV.8.3.288; BORK P, 1991, FEBS LETT, V286, P47, DOI 10.1016/0014-5793(91)80937-X; BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; CASTRO GR, 1984, J LIPID RES, V25, P58; DIEPLINGER H, 1986, J CLIN INVEST, V77, P1071, DOI 10.1172/JCI112406; EISENBERG S, 1984, J LIPID RES, V25, P1017; ELOVSON J, 1988, J LIPID RES, V29, P1461; FIELDING CJ, 1984, J LIPID RES, V25, P1624; FIELDING PE, 1991, BIOCHEMISTRY-US, V30, P8551, DOI 10.1021/bi00099a009; FIELDING PE, 1989, J BIOL CHEM, V264, P12462; FLOREN CH, 1981, J BIOL CHEM, V256, P425; FRANCONE OL, 1990, J LIPID RES, V31, P2195; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HARPEL PC, 1983, ANN NY ACAD SCI, V421, P1, DOI 10.1111/j.1749-6632.1983.tb18088.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; ISHII K, 1990, ANN NY ACAD SCI, V598, P496, DOI 10.1111/j.1749-6632.1990.tb42321.x; ISHIKAWA Y, 1988, J BIOL CHEM, V263, P2744; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KHOO C, 1986, J BIOL CHEM, V261, P11194; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; MCGILL HC, 1984, ARTERIOSCLEROSIS, V4, P443, DOI 10.1161/01.ATV.4.5.443; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; Patsch J. R, 1987, PLASMA LIPOPROTEINS, P221; PFEIFFER S, 1985, NATURE, V313, P184; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; RANKIN SM, 1991, J LIPID RES, V32, P449; REDGRAVE TG, 1979, J LIPID RES, V20, P217; REIHNER E, 1990, J LIPID RES, V31, P2219; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; SCHMITZ G, 1982, J LIPID RES, V23, P903; SPADY DK, 1983, J LIPID RES, V24, P303; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUCKLING KE, 1985, J LIPID RES, V26, P647; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; UTERMANN G, 1977, NATURE, V269, P604, DOI 10.1038/269604a0; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WINDLER E, 1991, BIOCHEM J, V276, P79, DOI 10.1042/bj2760079; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YEAGLE PL, 1988, BIOL CHOLESTEROL, P121; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495	58	61	62	2	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1992	6	13					3162	3168		10.1096/fasebj.6.13.1327930	http://dx.doi.org/10.1096/fasebj.6.13.1327930			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1327930	Bronze			2022-12-28	WOS:A1992JU51200008
J	LIEDTKE, CM				LIEDTKE, CM			ELECTROLYTE TRANSPORT IN THE EPITHELIUM OF PULMONARY SEGMENTS OF NORMAL AND CYSTIC-FIBROSIS LUNG	FASEB JOURNAL			English	Article						EPITHELIA; ION TRANSPORT; CHANNEL; COTRANSPORT; POLYPHOSPHOINOSITIDES; CYSTIC FIBROSIS	TRANSMEMBRANE CONDUCTANCE REGULATOR; ALPHA-ADRENERGIC REGULATION; MODULATES INTRACELLULAR PH; HUMAN AIRWAY EPITHELIUM; ION-TRANSPORT; BIOELECTRIC PROPERTIES; TRACHEAL EPITHELIUM; SODIUM-TRANSPORT; II CELLS; CHLORIDE TRANSPORT	The epithelium f pulmonary segments from trachea to aveoli actively transports electrolytes and allows osmotic movement of water to maintain the ionic environment in the airway lumen. Models of airway absorption and secretion depict the operation of transporters localized to apical or basolateral membrane. In many epithelia, a variety of electrolyte transporters operate in different combinations to produce absorption or secretion. This also applies to pulmonary epithelium of the large airways (trachea, main-stem bronchi), bronchioles, and alveoli. Na+ absorption occurs in all three pulmonary segments but by different transporters: apical Na+ channels in large airways and bronchioles; Na+/H+ exchange and Na+ channels in adult alveoli. The Na+ channels in each pulmonary segment share a sensitivity to amiloride, a potent inhibitory of epithelial Na+ channels. Fetal alveoli display spontaneous Cl- secretion, as do the large airways of some mammals, such as dog and bovine trachea. Cl- channels differ in conductance properties and in regulation by intracellular second messengers, osmolarity, and voltage mediate stimulated Cl- secretion. Electroneutral carriers, such as NaCl(K) cotransport, Cl-/HCO3- exchange, and Na+/HCO3- exchange, operate in large airways and alveoli during absorption and secretion. Abnormal ion transport in airways of cystic fibrosis (CF) patients is manifest as a reduced Cl- conductance and increased Na+ conductance. Isolation of the CF gene and identification of its product CFTR now allow investigations into the basic defect. Intrinsic to these investigations is the development of systems to study the function of CFTR and its relation to electrolyte transporters and their regulation.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University	LIEDTKE, CM (corresponding author), RAINBOW BABIES & CHILDRENS HOSP,CTR CYST FIBROSIS,DEPT PEDIAT,CLEVELAND,OH 44106, USA.							ALBAZZAZ FJ, 1991, AM J PHYSIOL, V260, pL594, DOI 10.1152/ajplung.1991.260.6.L594; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BALLARD ST, 1991, J APPL PHYSIOL, V70, P63, DOI 10.1152/jappl.1991.70.1.63; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BUTT AG, 1990, AM J PHYSIOL, V258, pC630, DOI 10.1152/ajpcell.1990.258.4.C630; CHAN HC, 1991, IN PRESS J BIOL CHEM; CHAN HC, 1992, IN PRESS AM J PHYSL; CHEEK JM, 1989, AM J PHYSIOL, V256, pC688, DOI 10.1152/ajpcell.1989.256.3.C688; CLANCY JP, 1990, AM J PHYSIOL, V258, pL25, DOI 10.1152/ajplung.1990.258.2.L25; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COTT GR, 1986, AM J PHYSIOL, V250, pC222, DOI 10.1152/ajpcell.1986.250.2.C222; COTT GR, 1989, AM J PHYSIOL, V257, pC678, DOI 10.1152/ajpcell.1989.257.4.C678; COTTON CU, 1983, J APPL PHYSIOL, V55, P1542, DOI 10.1152/jappl.1983.55.5.1542; DECOURSEY TE, 1988, J PHYSIOL-LONDON, V395, P487, DOI 10.1113/jphysiol.1988.sp016931; DUSZYK M, 1989, CAN J PHYSIOL PHARM, V67, P1362, DOI 10.1139/y89-217; FARLEY JM, 1991, LIFE SCI, V48, P873, DOI 10.1016/0024-3205(91)90033-8; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GOODMAN BE, 1989, AM J PHYSIOL, V257, pL86, DOI 10.1152/ajplung.1989.257.2.L86; GOODMAN BE, 1984, J APPL PHYSIOL, V57, P703, DOI 10.1152/jappl.1984.57.3.703; GOODMAN BE, 1983, AM J PHYSIOL, V245, pC78, DOI 10.1152/ajpcell.1983.245.1.C78; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; JORISSEN M, 1991, BIOCHIM BIOPHYS ACTA, V1096, P52; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V414, P297, DOI 10.1007/BF00584630; LIEDTKE CM, 1990, AM J PHYSIOL, V259, pL66, DOI 10.1152/ajplung.1990.259.2.L66; LIEDTKE CM, 1989, AM J PHYSIOL, V257, pL125, DOI 10.1152/ajplung.1989.257.2.L125; LIEDTKE CM, 1992, IN PRESS AM J PHYSL; LUBMAN RL, 1991, AM J PHYSIOL, V260, pL555, DOI 10.1152/ajplung.1991.260.6.L555; MASON RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6033, DOI 10.1073/pnas.79.19.6033; MATALON S, 1991, AM J PHYSIOL, V260, pL90, DOI 10.1152/ajplung.1991.260.2.L90; MCCANN JD, 1990, AM J PHYSIOL, V258, pL343, DOI 10.1152/ajplung.1990.258.6.L343; MCCANN JD, 1990, AM J PHYSIOL, V258, pL334, DOI 10.1152/ajplung.1990.258.6.L334; MCCRAY PB, 1991, AM J PHYSIOL, V260, pL494, DOI 10.1152/ajplung.1991.260.6.L494; NORD EP, 1987, AM J PHYSIOL, V252, pC490, DOI 10.1152/ajpcell.1987.252.5.C490; NORD EP, 1988, J BIOL CHEM, V263, P5599; OLVER RE, 1986, J PHYSIOL-LONDON, V375, P377, DOI 10.1113/jphysiol.1986.sp016122; RAO AK, 1991, AM J PHYSIOL, V261, pL178, DOI 10.1152/ajplung.1991.261.2.L178; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; SANO K, 1988, BIOCHIM BIOPHYS ACTA, V939, P449, DOI 10.1016/0005-2736(88)90091-0; SAUMON G, 1987, PFLUG ARCH EUR J PHY, V410, P464, DOI 10.1007/BF00586526; SCHOPPA N, 1989, J MEMBRANE BIOL, V108, P73, DOI 10.1007/BF01870427; SHAW AM, 1990, BIOCHIM BIOPHYS ACTA, V1028, P9, DOI 10.1016/0005-2736(90)90258-P; SHOEMAKER RL, 1986, BIOCHIM BIOPHYS ACTA, V858, P235, DOI 10.1016/0005-2736(86)90328-7; TESSIER GJ, 1990, AM J PHYSIOL, V259, pL459, DOI 10.1152/ajplung.1990.259.6.L459; VANSCOTT MR, 1989, AM J PHYSIOL, V256, pC893, DOI 10.1152/ajpcell.1989.256.4.C893; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1045, DOI 10.1152/ajpcell.1989.256.5.C1045; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC319, DOI 10.1152/ajpcell.1991.261.2.C319; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC332, DOI 10.1152/ajpcell.1991.261.2.C332; ZEITLIN PL, 1988, AM J PHYSIOL, V254, pC691, DOI 10.1152/ajpcell.1988.254.5.C691	57	21	24	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1992	6	12					3076	3084		10.1096/fasebj.6.12.1521739	http://dx.doi.org/10.1096/fasebj.6.12.1521739			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521739				2022-12-28	WOS:A1992JN50500009
J	HAYES, KC; KHOSLA, P				HAYES, KC; KHOSLA, P			DIETARY FATTY-ACID THRESHOLDS AND CHOLESTEROLEMIA	FASEB JOURNAL			English	Article						FATTY ACIDS; PLASMA CHOLESTEROL; MYRISTIC ACID; LINOLEIC ACID; CEBUS MONKEYS	LOW-DENSITY; LIPOPROTEINS; TRIGLYCERIDES; MONKEYS; LIPIDS	Results obtained with cebus monkeys indicate that dietary myristic (14:0) and palmitic (16:0) acids exert disparate effects on cholesterol metabolism, whereas the ability of linoleic acid (18:2) to decrease total plasma cholesterol displays an upper limit or threshold. Reanalysis of published data suggests a similar situation pertains in humans. In agreement with an earlier human study, 14:0 appears to be the principal saturated fatty acid that raises plasma cholesterol whereas 18:2 lowers it. Oleic acid (18:1) appears neutral. The effect of 16:0 may vary. In normocholesterolemic subjects consuming diets containing less-than-or-equal-to 300 mg/day of cholesterol, 16:0 appears to be without effect on plasma cholesterol. However, in hypercholesterolemic subjects (> 225 mg/dl) and especially those consuming diets providing cholesterol intakes of greater-than-or-equal-to 400 mg/day, dietary 16:0 may expand the plasma cholesterol pool.			HAYES, KC (corresponding author), BRANDEIS UNIV,FOSTER BIOMED RES LAB,WALTHAM,MA 02254, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035375] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35375] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		GRUNDY SM, 1990, J LIPID RES, V31, P1149; HAYES KC, 1991, AM J CLIN NUTR, V53, P491, DOI 10.1093/ajcn/53.2.491; HAYES KC, 1992, IN PRESS CHOLESTEROL; HAYES KC, 1989, NEW ENGL J MED, V322, P402; Hegsted D. M., 1991, Health effects of dietary fatty acids., P50; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KHOSLA P, 1992, AM J CLIN NUTR, V55, P51, DOI 10.1093/ajcn/55.1.51; KHOSLA P, 1991, BIOCHIM BIOPHYS ACTA, V1083, P46, DOI 10.1016/0005-2760(91)90123-Y; KHOSLA P, 1992, FASEB J, V6, pA1361; MATTSON FH, 1985, J LIPID RES, V26, P194; MENSINK RP, 1989, NEW ENGL J MED, V321, P436, DOI 10.1056/NEJM198908173210705; NG TKW, 1992, J AM COLL NUTR, V11; NICOLOSI RJ, 1990, ARTERIOSCLEROSIS, V10, P119, DOI 10.1161/01.ATV.10.1.119; PRONCZUK A, 1991, LIPIDS, V26, P213, DOI 10.1007/BF02543974; RUDEL LL, 1990, J LIPID RES, V31, P1873; SPADY DK, 1988, J CLIN INVEST, V81, P300, DOI 10.1172/JCI113321; SPADY DK, 1990, J LIPID RES, V31, P1809; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; Sundram K., 1991, ARTERIOSCLER THROMB, V11, p1614a	20	199	211	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2600	2607		10.1096/fasebj.6.8.1592210	http://dx.doi.org/10.1096/fasebj.6.8.1592210			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592210				2022-12-28	WOS:A1992HU42300013
J	JOSEPH, DR; BAKER, ME				JOSEPH, DR; BAKER, ME			SEX HORMONE-BINDING GLOBULIN, ANDROGEN-BINDING PROTEIN, AND VITAMIN K-DEPENDENT PROTEIN-S ARE HOMOLOGOUS TO LAMININ-A, MEROSIN, AND DROSOPHILA CRUMBS PROTEIN	FASEB JOURNAL			English	Article						ANDROGEN-BINDING PROTEIN; LAMININ; BASEMENT MEMBRANE; PROTEIN-S	AMINO-ACID SEQUENCE; C4B-BINDING PROTEIN; MESSENGER-RNA; LONG ARM; B-CHAINS; RAT; CELLS; RECEPTOR; MEMBRANES; DOMAINS	Androgen-binding protein (ABP) and sex hormone-binding globulin (SHBG) are extracellular steroid-binding proteins that are homologous to the COOH-terminal domain of vitamin K-dependent protein S, a protein important in blood clotting. We find that the sequences of ABP, SHBG, and protein S are also similar to two basement membrane proteins, laminin and merosin, and to an integral membrane protein, Drosophila crumbs protein. These latter three proteins have important roles in regulating differentiation and development. The sequence similarity corresponds to the G domain of laminin A chain, which binds heparin and type IV collagen. Analysis of a multiple alignment of these proteins reveals one well-conserved segment corresponding to the part of SHBG that binds to its membrane receptor and another corresponding to the part of protein S that binds to C4b-binding protein. The similarities suggest that ABP, SHBG, and protein S may also have functions related to that of laminin and merosin.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	JOSEPH, DR (corresponding author), UNIV N CAROLINA,DEPT PEDIAT,REPROD BIOL LABS,CHAPEL HILL,NC 27599, USA.			Baker, Michael/0000-0003-4387-3269	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021744] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 21744] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAKER ME, 1987, BIOCHEM J, V243, P293, DOI 10.1042/bj2430293; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHARONIS AS, 1986, J CELL BIOL, V103, P1689, DOI 10.1083/jcb.103.5.1689; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DAMASSA DA, 1991, ENDOCRINOLOGY, V129, P75, DOI 10.1210/endo-129-1-75; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GERARD A, 1988, ENDOCRINOLOGY, V122, P1297, DOI 10.1210/endo-122-4-1297; HALL DE, 1988, J CELL BIOL, V107, P687, DOI 10.1083/jcb.107.2.687; HAMMOND GL, 1989, MOL ENDOCRINOL, V3, P1869, DOI 10.1210/mend-3-11-1869; HESSING M, 1991, BIOCHEM J, V277, P581, DOI 10.1042/bj2770581; HOSKINS J, 1987, P NATL ACAD SCI USA, V84, P349, DOI 10.1073/pnas.84.2.349; HRYB DJ, 1989, J BIOL CHEM, V264, P5378; HRYB DJ, 1990, J BIOL CHEM, V265, P6048; JOSEPH DR, 1987, P NATL ACAD SCI USA, V84, P339, DOI 10.1073/pnas.84.2.339; JOSEPH DR, 1988, MOL ENDOCRINOL, V2, P3, DOI 10.1210/mend-2-1-3; KAHN MS, 1990, J BIOL CHEM, V265, P18362; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; NAKHLA AM, 1990, J CLIN ENDOCR METAB, V71, P398, DOI 10.1210/jcem-71-2-398; OLSEN D, 1989, LAB INVEST, V60, P772; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PLYMATE SR, 1991, J STEROID BIOCHEM, V40, P833, DOI 10.1016/0960-0760(91)90309-S; PORTO CS, 1991, ENDOCRINOLOGY, V129, P436, DOI 10.1210/endo-129-1-436; ROSNER W, 1990, ENDOCR REV, V11, P80, DOI 10.1210/edrv-11-1-80; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHWALBE RA, 1990, J BIOL CHEM, V265, P21749; STRELCHYONOK OA, 1984, BIOCHIM BIOPHYS ACTA, V802, P459, DOI 10.1016/0304-4165(84)90365-9; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; VEERAMACHANENI DNR, 1991, J ANDROL, V12, P288; WALKER FJ, 1989, J BIOL CHEM, V264, P17645; WALSH KA, 1986, BIOCHEMISTRY-US, V25, P7584, DOI 10.1021/bi00371a048; WANG YM, 1990, ENDOCRINOLOGY, V127, P3124, DOI 10.1210/endo-127-6-3124; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN RE, 1990, J CLIN INVEST, V86, P1928, DOI 10.1172/JCI114926; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	45	101	108	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2477	2481		10.1096/fasebj.6.7.1532944	http://dx.doi.org/10.1096/fasebj.6.7.1532944			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1532944				2022-12-28	WOS:A1992HP03000015
J	MAURICE, M; PICHARD, L; DAUJAT, M; FABRE, I; JOYEUX, H; DOMERGUE, J; MAUREL, P				MAURICE, M; PICHARD, L; DAUJAT, M; FABRE, I; JOYEUX, H; DOMERGUE, J; MAUREL, P			EFFECTS OF IMIDAZOLE DERIVATIVES ON CYTOCHROMES-P450 FROM HUMAN HEPATOCYTES IN PRIMARY CULTURE	FASEB JOURNAL			English	Note						CELL LYSATE; HEPATOCYTE CULTURE; MICROSOME	OXIDATIVE DRUG-METABOLISM; HUMAN-LIVER MICROSOMES; GENETIC-POLYMORPHISM; ANTIMYCOTIC AGENTS; KETOCONAZOLE; CYTOCHROME-P-450; INDUCTION; RAT; CYCLOSPORINE; INHIBITION	The expression of several forms of cytochrome P450 including P450 1A2, 2D6, 2E1 and 3A was investigated in human hepatocytes maintained in primary culture for 96 h in the absence or presence of 50-mu-M of various imidazole derivatives. These included ketoconazole, clotrimazole, miconazole, fluconazole, secnidazole and metronidazole. In addition, the typical inducers rifampicin and beta-naphthoflavone were used for comparison. Western and Northern blot analysis of microsomes and RNA prepared from these cultures as well as de novo synthesis experiments revealed that, among the imidazole derivatives tested, only clotrimazole was a strong rifampicin-like inducer of P450 3A. The expression of the other forms of P450 tested was not affected by the treatments. Analysis of the inhibition of 13 monoxygenase activities, including ethoxyresorufin and phenacetin O-deethylases, coumarin 7-alpha-, lauric acid 11- and 12-, mephenytoin 4-, debrisoquin 4-, and aniline hydroxylases, benzphetamine, aminopyrine, mephenytoin and erythromycin demethylases, and cyclosporin oxidase (representative of 10 different forms of P450 in human liver microsomes) revealed that ketoconazole was a strong and selective in vitro inhibitor of P450 3A (cyclosporin oxidase) with a K(i) < 1-mu-M. Clotrimazole and miconazole were also strong inhibitors of P450 3A-mediated activities in contrast to the other imidazole derivatives.	CNRS, INSERM, U128, ROUTE MENDE, BP 5051, F-34033 MONTPELLIER, FRANCE; CTR PAUL LAMARQUE, INST CANC, DEPT CHIRURG & NUTR, F-34094 MONTPELLIER, FRANCE; HOP ST ELOI, SERV CHIRURG C, F-34059 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; CHU de Montpellier			Daujat-Chavanieu, Martine/AAU-2908-2020; Daujat-Chavanieu, Martine/T-5155-2018	Daujat-Chavanieu, Martine/0000-0001-5560-1610; Daujat-Chavanieu, Martine/0000-0001-5560-1610				ATIBA JO, 1989, BRIT J CLIN PHARMACO, V28, P161, DOI 10.1111/j.1365-2125.1989.tb05409.x; BACK DJ, 1989, BRIT J CLIN PHARMACO, V28, P166, DOI 10.1111/j.1365-2125.1989.tb05410.x; BALLARD SA, 1988, BIOCHEM PHARMACOL, V37, P4643, DOI 10.1016/0006-2952(88)90333-4; BEGUE JM, 1983, BIOCHEM PHARMACOL, V32, P1643, DOI 10.1016/0006-2952(83)90341-6; BONFILS C, 1990, EUR J BIOCHEM, V188, P187, DOI 10.1111/j.1432-1033.1990.tb15387.x; BORK RW, 1989, J BIOL CHEM, V264, P910; BURKE MD, 1975, DRUG METAB DISPOS, V3, P245; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; COLLIGNON P, 1989, LANCET, V1, P1262; DAUJAT M, 1991, IN PRESS LIFE SCI; DAUJAT M, 1991, METHOD ENZYMOL, V206, P345; DIAZ D, 1990, GASTROENTEROLOGY, V99, P737, DOI 10.1016/0016-5085(90)90963-2; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; EHNINGER G, 1989, LANCET, V2, P104; FABRE G, 1988, BIOCHEM PHARMACOL, V37, P4389, DOI 10.1016/0006-2952(88)90622-3; FERGUSON RM, 1982, LANCET, V2, P882; FIRST MR, 1989, LANCET, V2, P1198, DOI 10.1016/S0140-6736(89)91802-3; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; HARMSWORTH WL, 1990, XENOBIOTICA, V20, P1053, DOI 10.3109/00498259009046826; HOSTETLER KA, 1989, MOL PHARMACOL, V35, P279; HOUSTON JB, 1988, BIOCHEM PHARMACOL, V37, P401, DOI 10.1016/0006-2952(88)90206-7; Jefcoate C R, 1978, Methods Enzymol, V52, P258; KIRSCH DR, 1988, GENE, V68, P229, DOI 10.1016/0378-1119(88)90025-X; LAVRIJSEN K, 1986, BIOCHEM PHARMACOL, V35, P1867, DOI 10.1016/0006-2952(86)90305-9; MAURICE M, 1991, EUR J BIOCHEM, V200, P511, DOI 10.1111/j.1432-1033.1991.tb16212.x; MEREDITH CG, 1985, DRUG METAB DISPOS, V13, P156; MOREL F, 1990, EUR J BIOCHEM, V191, P437, DOI 10.1111/j.1432-1033.1990.tb19140.x; MORGENSTERN GR, 1982, LANCET, V2, P1342; NIEMEGEERS CJE, 1981, ARCH INT PHARMACOD T, V251, P26; OTTON SV, 1988, J PHARMACOL EXP THER, V247, P242; PASANEN M, 1988, BIOCHEM PHARMACOL, V37, P3861, DOI 10.1016/0006-2952(88)90067-6; PICHARD L, 1990, DRUG METAB DISPOS, V18, P711; PICHARD L, 1990, DRUG METAB DISPOS, V18, P595; RITTER JK, 1987, BIOCHEM PHARMACOL, V36, P2783, DOI 10.1016/0006-2952(87)90265-6; RITTER JK, 1987, DRUG METAB DISPOS, V15, P335; SALAUN JP, 1986, LIPIDS, V21, P776, DOI 10.1007/BF02535411; SESARDIC D, 1990, BRIT J CLIN PHARMACO, V29, P651, DOI 10.1111/j.1365-2125.1990.tb03686.x; Shaw J. T. B., 1987, Recent trends in the discovery, development and evaluation of antifungal agents., P125; SHEETS JJ, 1984, DRUG METAB DISPOS, V12, P603; SHIMADA T, 1986, J BIOL CHEM, V261, P909; THOMSON RG, 1988, BIOCHEM PHARMACOL, V37, P3975, DOI 10.1016/0006-2952(88)90082-2; VERONESE ME, 1990, DRUG METABOLIZING EN, P203; WHITE DJG, 1984, TRANSPLANTATION, V37, P214	43	281	285	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN 6	1992	6	2					752	758		10.1096/fasebj.6.2.1371482	http://dx.doi.org/10.1096/fasebj.6.2.1371482			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1371482				2022-12-28	WOS:A1992GZ44000018
J	YANG, CS; BRADY, JF; HONG, JY				YANG, CS; BRADY, JF; HONG, JY			DIETARY-EFFECTS ON CYTOCHROMES-P450, XENOBIOTIC METABOLISM, AND TOXICITY	FASEB JOURNAL			English	Article						DIET; NUTRITION; CYTOCHROME-P450; ENZYME REGULATION; XENOBIOTICS; DRUG METABOLISM; TOXICITY; CARCINOGENS	N-NITROSODIMETHYLAMINE DEMETHYLASE; DRUG-NUTRIENT INTERACTIONS; RAT-LIVER; ISOZYME 3A; CYTOCHROME-P-450; INDUCTION; ETHANOL; CARCINOGENESIS; MECHANISMS; MICROSOMES	The levels and activities of cytochrome P450 enzymes are influenced by a variety of factors, including the diet. In this article, the effects of selected non-nutritive dietary chemicals, macronutrients, micronutrients, and ethanol on cytochromes P450 and xenobiotic metabolism are reviewed in the light of our current understanding of the multiplicity and substrate specificity of cytochrome P450 enzymes. Although the mechanisms of action of several dietary chemicals on specific cytochrome P450 isozymes have been established, those for macro- and micronutrients are largely unknown. It is known, however, that specific nutrients may have varied effects on different cytochrome P450 forms and thus may affect the metabolism of various drugs differently. Nutritional deficiencies generally cause lowered rates of xenobiotic metabolism. In certain cases, such as thiamin deficiency and mild riboflavin deficiency, however, enhanced rates of metabolism of xenobiotics were observed. The effects of dietary modulation of xenobiotic metabolism on chemical toxicity and carcinogenicity are discussed.			YANG, CS (corresponding author), RUTGERS STATE UNIV,COLL PHARM,DEPT CHEM BIOL & PHARMACOGNOSY,CANC RES LAB,PISCATAWAY,NJ 08855, USA.				NCI NIH HHS [CA37037, CA46535] Funding Source: Medline; NIEHS NIH HHS [ES03938] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037037, R37CA037037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON KE, 1985, FED PROC, V44, P130; ANDERSON LM, 1988, CARCINOGENESIS, V9, P1717, DOI 10.1093/carcin/9.9.1717; BAILEY DG, 1990, CLIN PHARMACOL THER, V47, P180; BAILEY GS, 1978, J NATL CANCER I, P931; BIDLACK WR, 1986, FASEB J, V45, P142; BIRT DF, 1983, TOXICOL APPL PHARM, V68, P77, DOI 10.1016/0041-008X(83)90356-3; BRADFIELD CA, 1987, J TOXICOL ENV HEALTH, V21, P311, DOI 10.1080/15287398709531021; BRADY JF, 1991, TOXICOL APPL PHARM, V108, P342, DOI 10.1016/0041-008X(91)90123-V; BRADY JF, 1991, CHEM RES TOXICOL, V4, P642, DOI 10.1021/tx00024a008; CAMPBELL TC, 1974, PHARMACOL REV, V26, P171; CONNEY AH, 1982, CANCER RES, V42, P4875; CORREA P, 1981, CANCER RES, V41, P3685; DING XX, 1986, MOL PHARMACOL, V30, P370; DONG ZG, 1988, ARCH BIOCHEM BIOPHYS, V263, P29, DOI 10.1016/0003-9861(88)90610-8; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; FARINATI F, 1984, GASTROENTEROLOGY, V86, P1073; FONG AT, 1990, BIOCHEM PHARMACOL, V39, P19, DOI 10.1016/0006-2952(90)90643-Y; GIGER U, 1981, J BIOL CHEM, V256, P1182; GILLNER M, 1985, MOL PHARMACOL, V28, P357; GRICIUTE L, 1981, CANCER LETT, V13, P345, DOI 10.1016/0304-3835(81)90063-X; GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275; GUENGERICH FP, 1984, ANNU REV NUTR, V4, P207, DOI 10.1146/annurev.nu.04.070184.001231; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; HATHCOCK JN, 1985, FED PROC, V44, P124; HONG JY, 1987, BIOCHEM BIOPH RES CO, V142, P1077, DOI 10.1016/0006-291X(87)91525-7; HONG JY, 1987, CANCER RES, V47, P5948; IMAIDA K, 1983, CARCINOGENESIS, V4, P895, DOI 10.1093/carcin/4.7.895; ISHIZAKI H, 1990, XENOBIOTICA, V20, P255, DOI 10.3109/00498259009046845; KATO R, 1965, J PHARMACOL EXP THER, V150, P279; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LIEBER CS, 1986, NEW YORK STATE J MED, V86, P297; MA Q, 1989, BIOCHEM PHARMACOL, V38, P3179; MICHNOVICZ JJ, 1990, J NATL CANCER I, V82, P947, DOI 10.1093/jnci/82.11.947; MILLER KW, 1984, ARCH BIOCHEM BIOPHYS, V229, P483, DOI 10.1016/0003-9861(84)90179-6; MORSE MA, 1989, CANCER RES, V49, P2894; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; PAN JM, 1991, FASEB J, V5, pA1161; PERROT N, 1989, EUR J CLIN INVEST, V19, P549, DOI 10.1111/j.1365-2362.1989.tb00273.x; SEITZ HK, 1985, DRUG NUTR INTERACT, V4, P143; SMITH TJ, 1990, CANCER RES, V50, P6817; SONG BJ, 1986, J BIOL CHEM, V261, P6689; STONER GD, 1991, CANCER RES, V51, P2063; STROTHER A, 1971, J PHARMACOL EXP THER, V179, P490; TINEL M, 1987, BIOCHEM PHARMACOL, V36, P951, DOI 10.1016/0006-2952(87)90190-0; VANG O, 1990, CARCINOGENESIS, V11, P1259, DOI 10.1093/carcin/11.8.1259; WADE AE, 1986, J ENVIRON PATHOL TOX, V6, P161; WANG TY, 1985, J NATL CANCER I, V74, P1291; WARGOVICH MJ, 1988, CANCER RES, V48, P6872; WATTENBERG LW, 1978, JNCI-J NATL CANCER I, V60, P11, DOI 10.1093/jnci/60.1.11; WATTENBERG LW, 1971, CANCER-AM CANCER SOC, V28, P99, DOI 10.1002/1097-0142(197107)28:1<99::AID-CNCR2820280118>3.0.CO;2-M; WORTELBOER HM, 1990, DRUG METABOLIZING EN; YANG CS, 1988, PHARMACOL THERAPEUT, V38, P53, DOI 10.1016/0163-7258(88)90102-7; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; YANG CS, 1991, IN PRESS NUTRITION T; YOO JSH, 1991, J NUTR, V121, P959, DOI 10.1093/jn/121.7.959; YOO JSH, 1990, J NUTR, V120, P1718, DOI 10.1093/jn/120.12.1718; YOO JSH, 1990, BIOCHEM PHARMACOL, V39, P519, DOI 10.1016/0006-2952(90)90059-T; YOU WC, 1989, J NATL CANCER I, V81, P162, DOI 10.1093/jnci/81.2.162	60	194	197	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					737	744		10.1096/fasebj.6.2.1537464	http://dx.doi.org/10.1096/fasebj.6.2.1537464			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537464				2022-12-28	WOS:A1992GZ44000015
J	ENGEL, RW				ENGEL, RW			EARLY CHOLINE RESEARCH AND THE AFTERMATH	FASEB JOURNAL			English	Article											ENGEL, RW (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM & NUTR,BLACKSBURG,VA 24060, USA.							COPELAND DH, 1946, AM J PATHOL, V22, P1059; ENGEL R. W., 1948, JOUR NUTRITION, V36, P739; ENGEL R. W., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P189; Engel RW, 1942, J BIOL CHEM, V144, P701; Engel RW, 1943, P SOC EXP BIOL MED, V52, P281, DOI 10.3181/00379727-52-14121P; Engel RW, 1941, J NUTR, V22, P109, DOI 10.1093/jn/22.1.109; ENGEL RW, 1952, FED PROC, V11, P441; GHOSHAL AK, 1984, CARCINOGENESIS, V5, P1367, DOI 10.1093/carcin/5.10.1367; GYORGY P, 1954, ANN NY ACAD SCI, V57, P925, DOI 10.1111/j.1749-6632.1954.tb36471.x; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; NEWBERNE PM, 1968, J NUTR, V94, P331, DOI 10.1093/jn/94.3.331; POIRIER LA, 1986, ADV EXPT MED BIOL, V206; SALMON WD, 1962, J NUTR, V76, P483, DOI 10.1093/jn/76.4.483; SALMON WD, 1963, CANCER RES, V23, P571; SCHAEFER AE, J NUTR, V43, P201; SPENSLEY PC, 1963, ENDEAVOUR, V22, P75, DOI 10.1016/0160-9327(63)90097-8	16	0	0	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					3002	3003		10.1096/fasebj.5.14.1752365	http://dx.doi.org/10.1096/fasebj.5.14.1752365			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752365				2022-12-28	WOS:A1991GP26900018
J	TAYLOR, MW; FENG, GS				TAYLOR, MW; FENG, GS			RELATIONSHIP BETWEEN INTERFERON-GAMMA, INDOLEAMINE 2,3-DIOXYGENASE, AND TRYPTOPHAN CATABOLISM	FASEB JOURNAL			English	Review						INTERFERON; TRYPTOPHAN; PTERIDINE BIOSYNTHESIS; INTRACELLULAR PARASITES AND INTERFERON	TUMOR NECROSIS FACTOR; HUMAN-FIBROBLASTS; HUMAN-CELLS; DEGRADE TRYPTOPHAN; TOXOPLASMA-GONDII; HUMAN MACROPHAGES; BETA-INTERFERON; CANCER-PATIENTS; MOUSE LUNG; INDUCTION	Interferons have been shown to be potential anti-cancer agents and to inhibit tumor cell growth in culture. The in vivo mechanism of the anti-proliferative effect may be direct or indirect through the immune system; however, in vitro a primary mechanism of cytotoxicity is through the depletion of tryptophan. In particular, interferon-gamma (IFN-gamma) induces an enzyme of tryptophan catabolism, indoleamine 2,3-dioxygenase (IDO), which is responsible for conversion of tryptophan and other indole derivatives to kynurenine. The inhibitory effect of interferon on many intracellular parasites such as Toxoplasma gondii and Chlamydia trachomatis is by the same mechanism. Elevated kynurenine levels have been found in humans in a number of diseases and after interferon treatment, and the enzyme is induced in rodents after administration of interferon inducers, or influenza virus. IDO induction also occurs in vivo during rejection of allogeneic tumors, indicating a possible role for this enzyme in the tumor rejection process. The gene for IDO has been cloned and shown to be differentially regulated by IFN-alpha and IFN-gamma. IDO induction has been correlated with induction of GTP-cyclohydrolase, the key enzyme in pteridine biosynthesis. A direct role for IDO in pteridine synthesis has not been shown, and this parallel induction may reflect coordinate regulation of genes induced by IFN-gamma. A possible role for IDO in O2-radical scavenging and in inflammation is discussed.			TAYLOR, MW (corresponding author), INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA.							AUNE TM, 1989, J CLIN INVEST, V84, P863, DOI 10.1172/JCI114247; BETT IM, 1962, ANN RHEUM DIS, V21, P63, DOI 10.1136/ard.21.1.63; BIANCHI M, 1988, BIOCHEM BIOPH RES CO, V152, P237, DOI 10.1016/S0006-291X(88)80705-8; BORDEN EC, 1988, PHARMACOL THERAPEUT, V37, P213, DOI 10.1016/0163-7258(88)90026-5; BROWN RR, 1989, CANCER RES, V49, P4941; BUTENANDT A, 1940, NATURWISSENSCHAFTEN, V28, P632; BYRNE GI, 1986, J INTERFERON RES, V6, P389, DOI 10.1089/jir.1986.6.389; BYRNE GI, 1986, INFECT IMMUN, V53, P347, DOI 10.1128/IAI.53.2.347-351.1986; CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CARLIN JM, 1987, J IMMUNOL, V139, P2414; CHRISTEN S, 1990, P NATL ACAD SCI USA, V87, P2506, DOI 10.1073/pnas.87.7.2506; CONTENT J, 1987, NATO ASI SER, V36, P163; DAI W, 1990, J BIOL CHEM, V265, P19871; DAI W, 1990, BIOCHEM BIOPH RES CO, V168, P1, DOI 10.1016/0006-291X(90)91666-G; DELAMAZA LM, 1988, CANCER RES, V48, P346; DELAMAZA LM, 1985, J IMMUNOL, V135, P4198; Demaeyer E., 1988, INTERFERONS OTHER RE; FENG GS, 1989, P NATL ACAD SCI USA, V86, P7144, DOI 10.1073/pnas.86.18.7144; FENG GS, 1990, THESIS INDIANA U BLO; GRESSER I, 1989, ACTA ONCOL, V28, P347, DOI 10.3109/02841868909111205; GROSECLOSE EE, 1982, BIOCHIM BIOPHYS ACTA, V705, P341, DOI 10.1016/0167-4838(82)90256-4; Hayaishi O, 1984, PROGR TRYPTOPHAN SER, P33; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; HIGUCHI K, 1963, FED PROC, V22, P243; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P268, DOI 10.1098/rspb.1957.0049; KNOX WE, 1951, SCIENCE, V113, P237, DOI 10.1126/science.113.2931.237; KOTAKE Y, 1937, HOPPESEYLERS Z PHYSL, V243, P237; MURREN JR, 1989, YALE J BIOL MED, V62, P271; OZAKI Y, 1987, BIOCHEM BIOPH RES CO, V144, P1147, DOI 10.1016/0006-291X(87)91431-8; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; PFEFFERKORN ER, 1986, J INTERFERON RES, V6, P267, DOI 10.1089/jir.1986.6.267; RECHT M, 1990, J INTERFERON RES, V10, P511; RUBIN BY, 1988, J INTERFERON RES, V8, P691, DOI 10.1089/jir.1988.8.691; SAYAMA S, 1981, P NATL ACAD SCI-BIOL, V78, P7327, DOI 10.1073/pnas.78.12.7327; SCHMITZ JL, 1989, INFECT IMMUN, V57, P3254, DOI 10.1128/IAI.57.10.3254-3256.1989; SHEMERAVNI Y, 1988, INFECT IMMUN, V56, P2503, DOI 10.1128/IAI.56.9.2503-2506.1988; SHIMIZU T, 1978, J BIOL CHEM, V253, P4700; TAHIJA SG, 1990, CHLAMYDIAL INFECTION; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAKIKAWA O, 1990, J IMMUNOL, V145, P1246; TONE S, 1990, NUCLEIC ACIDS RES, V18, P367, DOI 10.1093/nar/18.2.367; TURCO J, 1986, INFECT IMMUN, V53, P38, DOI 10.1128/IAI.53.1.38-46.1986; WACHTER H, 1989, ADV CLIN CHEM, V27, P81, DOI 10.1016/S0065-2423(08)60182-1; WATANABE Y, 1981, J HISTOCHEM CYTOCHEM, V29, P623, DOI 10.1177/29.5.6788834; WERNER ER, 1989, BIOCHEM J, V262, P861, DOI 10.1042/bj2620861; WERNER ER, 1987, LIFE SCI, V41, P273, DOI 10.1016/0024-3205(87)90149-4; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNER ER, 1988, BIOL CHEM H-S, V369, P337, DOI 10.1515/bchm3.1988.369.1.337; WERNERFELMAYER G, 1990, CANCER RES, V50, P2863; WERNERFELMAYER G, 1989, BIOL CHEM H-S, V370, P1063, DOI 10.1515/bchm3.1989.370.2.1063; WERNERFELMAYER G, 1989, BIOCHIM BIOPHYS ACTA, V1012, P140, DOI 10.1016/0167-4889(89)90087-6; YAMAZAKI F, 1985, BIOCHEM J, V230, P635, DOI 10.1042/bj2300635; YASUI H, 1986, P NATL ACAD SCI USA, V83, P6622, DOI 10.1073/pnas.83.17.6622; YOSHIDA R, 1988, J IMMUNOL, V141, P2819; YOSHIDA R, 1979, P NATL ACAD SCI USA, V76, P4084, DOI 10.1073/pnas.76.8.4084; YOSHIDA R, 1978, P NATL ACAD SCI USA, V75, P3998, DOI 10.1073/pnas.75.8.3998; YOSHIDA R, 1981, P NATL ACAD SCI-BIOL, V78, P129, DOI 10.1073/pnas.78.1.129	60	872	927	0	61	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1991	5	11					2516	2522		10.1096/fasebj.5.11.1907934	http://dx.doi.org/10.1096/fasebj.5.11.1907934			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1907934				2022-12-28	WOS:A1991GB09400003
J	BERZOFSKY, JA				BERZOFSKY, JA			DEVELOPMENT OF ARTIFICIAL VACCINES AGAINST HIV USING DEFINED EPITOPES	FASEB JOURNAL			English	Review						T-CELLS; CYTOTOXIC LYMPHOCYTES-T; SYNTHETIC PEPTIDES; NEUTRALIZING ANTIBODIES; ANTIGENIC DETERMINANTS	HUMAN-IMMUNODEFICIENCY-VIRUS; TOXIC LYMPHOCYTES-T; MAJOR HISTOCOMPATIBILITY COMPLEX; CELL ANTIGENIC SITES; SYNTHETIC PEPTIDES; NEUTRALIZING ANTIBODIES; INFLUENZA NUCLEOPROTEIN; INFECTION INVITRO; ENVELOPE PROTEIN; SEROPOSITIVE INDIVIDUALS	HIV may not follow the paradigm that has been used successfully for developing most viral vaccines, namely, that the best vaccine is the one that most closely mimics natural infection. This approach is based on the premise that natural infection leads to long-lasting protective immunity, which may not be applicable to HIV. Also, some immune responses elicited by infection with HIV may enhance infection or contribute to the development of immune deficiency. To overcome these problems, an artificial vaccine could be constructed using only antigenic epitopes that elicit neutralizing antibodies, helper T cells, and CD8+ cytotoxic T cells, and avoiding epitopes that elicit deleterious responses. Progress has been made in identifying all three of these types of epitopes, in characterizing their activity in animals, and in demonstrating that at least two of these can be linked to induce neutralizing antibodies without a carrier. Methods have also been developed to induce cytotoxic T cells. It is therefore feasible to construct an artificial vaccine for HIV that should be safer and more effective than a natural whole viral or subunit vaccine.			BERZOFSKY, JA (corresponding author), NCI, METAB BRANCH, MOLEC IMMUNOGENET & VACCINE RES SECT, BETHESDA, MD 20892 USA.							ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; BENACERRAF B, 1978, J IMMUNOL, V120, P1809; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BENNINK JR, 1988, J EXP MED, V168, P1935, DOI 10.1084/jem.168.5.1935; BERKOWER I, 1989, J EXP MED, V170, P1681, DOI 10.1084/jem.170.5.1681; BERZOFSKY JA, 1988, J CLIN INVEST, V82, P1811, DOI 10.1172/JCI113796; BERZOFSKY JA, 1988, IMMUNOL REV, V106, P5, DOI 10.1111/j.1600-065X.1988.tb00771.x; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; BERZOFSKY JA, 1987, IMMUNOL REV, V98, P9, DOI 10.1111/j.1600-065X.1987.tb00518.x; BERZOFSKY JA, 1991, IN PRESS J CLIN INVE; BERZOFSKY JA, 1987, ANTIGENS, P1; BOKISCH VA, 1973, NEW ENGL J MED, V289, P996, DOI 10.1056/NEJM197311082891902; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1991, J IMMUNOL, V146, P2214; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; CULMANN B, 1989, EUR J IMMUNOL, V19, P2383, DOI 10.1002/eji.1830191231; DELISI C, 1985, P NATL ACAD SCI USA, V82, P7048, DOI 10.1073/pnas.82.20.7048; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; DEVASH Y, 1990, AIDS RES HUM RETROV, V6, P307, DOI 10.1089/aid.1990.6.307; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOEDERT JJ, 1989, LANCET, V2, P1351; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HART MK, 1990, J IMMUNOL, V145, P2677; HOSMALIN A, 1990, P NATL ACAD SCI USA, V87, P2344, DOI 10.1073/pnas.87.6.2344; HOSMALIN A, 1991, J IMMUNOL, V146, P1667; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; KOENIG S, 1990, J IMMUNOL, V145, P127; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MOREIN B, 1987, IMMUNOL TODAY, V8, P333, DOI 10.1016/0167-5699(87)90008-9; MOREIN B, 1988, NATURE, V332, P287, DOI 10.1038/332287a0; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NARA P, 1990, DEV BIOLOGICALS, V72, P315; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PALKER TJ, 1989, J IMMUNOL, V142, P3612; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; PROFY AT, 1990, J IMMUNOL, V144, P4641; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; ROBERTGUROFF M, 1986, J IMMUNOL, V137, P3306; ROBINSON WE, 1989, P NATL ACAD SCI USA, V86, P4710, DOI 10.1073/pnas.86.12.4710; ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SCHRIER RD, 1989, J IMMUNOL, V142, P1166; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SHEARER GM, 1977, ADV IMMUNOL, V25, P55, DOI 10.1016/S0065-2776(08)60931-1; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SPOUGE JL, 1987, J IMMUNOL, V138, P204; STILLE CJ, 1987, MOL IMMUNOL, V24, P1021, DOI 10.1016/0161-5890(87)90068-X; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TAKAHASHI H, 1989, J EXP MED, V170, P2023, DOI 10.1084/jem.170.6.2023; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; TAKAHASHI H, 1990, J EXP MED, V171, P571, DOI 10.1084/jem.171.2.571; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; TAKEDA A, 1988, SCIENCE, V242, P580, DOI 10.1126/science.2972065; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1984, CELL, V39, P13, DOI 10.1016/0092-8674(84)90187-9; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TOWNSEND ARM, 1984, J EXP MED, V160, P552, DOI 10.1084/jem.160.2.552; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; WAHREN B, 1989, J ACQ IMMUN DEF SYND, V2, P448; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEINHOLD KJ, 1989, J IMMUNOL, V142, P3091; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	86	56	64	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2412	2418		10.1096/fasebj.5.10.1712327	http://dx.doi.org/10.1096/fasebj.5.10.1712327			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	1712327	Bronze			2022-12-28	WOS:A1991FW08700012
J	STEVENSON, FK				STEVENSON, FK			TUMOR VACCINES	FASEB JOURNAL			English	Review						TUMOR; VACCINE; IMMUNOTHERAPY; IDIOTYPE; DORMANCY	ANTI-IDIOTYPIC ANTIBODIES; B-CELL LYMPHOMA; INTERNAL IMAGE; INFILTRATING LYMPHOCYTES; ADOPTIVE IMMUNOTHERAPY; KILLER CELLS; CANCER; TARGET; VIRUS; VACCINATION	Vaccination against tumor, either as a prophylactic procedure or as a mode of treatment, has been a distant goal of immunologists for many years. Ideally, the less specific therapies such as chemotherapy would be replaced by an anti-tumor immune response in the host that would be present on a continuing basis.. However, progress has been hampered by a lack of understanding of the role of viruses in human tumor development and the molecular nature of tumor-associated antigens. Recent developments using the techniques of molecular biology and monoclonal antibody reagents are beginning to remedy this deficiency so that vaccination has become a real possibility for certain human cancers. The natural fluctuations in growth rates of some human tumors, and the observation that tumors can occasionally remain dormant for years, has led to the idea that the host has an intrinsic ability to control tumor growth, and that this ability is a property of the immune system. Attempts to enhance this putative control are being made by treating the host with defined biological modifiers that stimulate cells involved in immunity in vivo, and by seeking and expanding such cells in vitro before reinfusing them into the host. These attempts to harness the immune system to attack tumor cells that have evaded the host's defenses might be considered optimistic, but they will at least tell us a great deal about tumor cell behavior and the ability of the host to influence it.			STEVENSON, FK (corresponding author), SOUTHAMPTON GEN HOSP, TENOVUS LAB, LYMPHOMA RES UNIT, HOST IMMUN TUMOR GRP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.			Stevenson, Freda/0000-0002-0933-5021				BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69; BERNARDS R, 1987, P NATL ACAD SCI USA, V84, P6854, DOI 10.1073/pnas.84.19.6854; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLUMBERG BS, 1985, JNCI-J NATL CANCER I, V74, P267; BYSTRYN JC, 1988, CANCER, V61, P1065, DOI 10.1002/1097-0142(19880315)61:6<1065::AID-CNCR2820610602>3.0.CO;2-L; CHURCHILL AE, 1969, NATURE, V221, P744, DOI 10.1038/221744a0; DALGLEISH AG, 1988, VACCINE, V6, P215, DOI 10.1016/0264-410X(88)90213-7; DYKE RJ, IN PRESS CELL IMMUNO; EHRLICH P, 1957, IMMUNOLOGY CANCER RE, P550; ESTIN CD, 1988, P NATL ACAD SCI USA, V85, P1052, DOI 10.1073/pnas.85.4.1052; George A J, 1989, Int Rev Immunol, V4, P271, DOI 10.3109/08830188909044783; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GULLICK WJ, 1990, INT J CANCER, P55; HEARING VJ, 1986, J IMMUNOL, V137, P379; HELLSTROM KE, 1989, FASEB J, V3, P1715, DOI 10.1096/fasebj.3.6.2649402; HERLYN D, 1986, SCIENCE, V232, P100, DOI 10.1126/science.3952496; HIRAI H, 1975, ANN NY ACAD SCI, V259, P5, DOI 10.1111/j.1749-6632.1975.tb25396.x; HOOVER HC, 1985, CANCER, V55, P1236, DOI 10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; LAMM DL, 1989, J UROLOGY, V141, pA249; LENNOX ES, 1981, TRANSPLANT P, V13, P1759; LYNCH RG, 1979, IMMUNOL REV, V48, P45, DOI 10.1111/j.1600-065X.1979.tb00298.x; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; OJO E, 1978, SCAND J IMMUNOL, V7, P297, DOI 10.1111/j.1365-3083.1978.tb00457.x; OLD LJ, 1964, ANNU REV MED, V15, P167, DOI 10.1146/annurev.me.15.020164.001123; OSTERHAUS A, 1985, J IMMUNOL, V135, P591; PARHAM P, 1989, IMMUNOL TODAY, V10, P206, DOI 10.1016/0167-5699(89)90326-5; RAYCHAUDHURI S, 1986, J IMMUNOL, V137, P1743; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; ROSENSTEIN M, 1984, J IMMUNOL, V132, P2117; SMITH MEF, 1988, LANCET, V1, P823; SPRINGER GF, 1976, CANCER, V37, P169, DOI 10.1002/1097-0142(197601)37:1<169::AID-CNCR2820370124>3.0.CO;2-#; STEVENSON FK, 1990, CHEM IMMUNOL, V48, P126; STEVENSON GT, 1985, CANCER SURV, V4, P213; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VOSE BM, 1985, SEMIN HEMATOL, V22, P27; WHEELOCK EF, 1983, LAB INVEST, V48, P120; ZIEGLER JL, 1982, LANCET, V2, P631	44	23	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1991	5	9					2250	2257		10.1096/fasebj.5.9.1860616	http://dx.doi.org/10.1096/fasebj.5.9.1860616			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860616				2022-12-28	WOS:A1991FP87200005
J	BILLINGS, PR; SMITH, CL; CANTOR, CR				BILLINGS, PR; SMITH, CL; CANTOR, CR			NEW TECHNIQUES FOR PHYSICAL MAPPING OF THE HUMAN GENOME	FASEB JOURNAL			English	Article						GENETIC ANALYSIS; MAPPING STRATEGY; PHYSICAL MAP; GENOMIC DNA; PHENOTYPE; CHROMOSOMAL REGION	YEAST ARTIFICIAL CHROMOSOMES; INSITU HYBRIDIZATION; HIGH-RESOLUTION; ENZYMATIC AMPLIFICATION; ESCHERICHIA-COLI; DNA; CLONING; LINKAGE; MAP; MOUSE	We describe improvements in techniques and strategies used for making maps of the human genome. The methods currently used are changing and evolving rapidly. Today's techniques can produce ordered arrays of DNA fragments and overlapping sets of DNA clones covering extensive genomic regions, but they are relatively slow and tedious. Methods under development will speed the process considerably. New developments include a range of applications of the polymerase chain reaction, enhanced procedures for high resolution in situ hybridization, and improved methods for generating, manipulating, and cloning large DNA fragments. More detailed genetic and physical maps will be useful for finding genes, including those associated with human diseases, long before the complete DNA sequence of the human genome is available.	PACIFIC PRESBYTERIAN MED CTR,DEPT MED,SAN FRANCISCO,CA 94115; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	California Pacific Medical Center; University of California System; University of California Berkeley	BILLINGS, PR (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,CTR HUMAN GENOME,BERKELEY,CA 94720, USA.			Smith, Cassandra/0000-0002-0346-8907				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CANTOR CR, 1988, ANNU REV BIOPHYS BIO, V17, P287; CANTOR CR, 1989, JIKKEN IGAKU, V8, P15; CARRANO AV, 1989, GENOMICS, V4, P129, DOI 10.1016/0888-7543(89)90291-7; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; CRAIG AG, 1990, NUCLEIC ACIDS RES, V18, P2653; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DRMANAC R, 1989, GENOMICS, V4, P114; ERICKSON RP, 1989, TRENDS GENET, V5, P1, DOI 10.1016/0168-9525(89)90002-4; EVANS GA, 1989, P NATL ACAD SCI USA, V86, P5030, DOI 10.1073/pnas.86.13.5030; FAN JB, 1989, NUCLEIC ACIDS RES, V12, P2801; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; HANISH J, 1990, NUCLEIC ACIDS RES, V18, P3287, DOI 10.1093/nar/18.11.3287; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HELENE C, 1989, TRENDS BIOTECHNOL, V7, P310, DOI 10.1016/0167-7799(89)90113-3; IMAI T, 1990, GENOMICS, V8, P297, DOI 10.1016/0888-7543(90)90285-3; ITO T, 1988, NUCLEIC ACIDS RES, V16, P9177, DOI 10.1093/nar/16.19.9177; JOHNSON DH, 1990, GENOMICS, V6, P243, DOI 10.1016/0888-7543(90)90563-A; KANDPAL RP, 1990, NUCLEIC ACIDS RES, V18, P3081, DOI 10.1093/nar/18.10.3081; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; KUSPA A, 1989, P NATL ACAD SCI USA, V86, P8917, DOI 10.1073/pnas.86.22.8917; LANDER ES, 1989, GENETICS, V121, P185; LEDBETTER SA, 1990, GENOMICS, V6, P475, DOI 10.1016/0888-7543(90)90477-C; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; LUDECKE HJ, 1989, NATURE, V338, P348, DOI 10.1038/338348a0; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MELMER G, 1990, DNA CELL BIOL, V9, P377, DOI 10.1089/dna.1990.9.377; MINOSHIMA S, 1990, CYTOMETRY, V11, P539, DOI 10.1002/cyto.990110413; MORLEY AA, 1990, CANCER RES, V50, P4584; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NELSON JM, 1990, NUCLEIC ACIDS RES, V18, P2061, DOI 10.1093/nar/18.8.2061; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; OLIVA R, 1990, IN PRESS ENCY HUMAN; OLIVA R, 1990, IN PRESS MAPPING HUM; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; ORKIN S, 1986, CELL, V47, P847; OTT J, 1990, AM J HUM GENET, V46, P219; OTT J, 1974, AM J HUM GENET, V26, P598; PALOTIE A, 1989, LANCET, V1, P924; PATEL Y, 1990, NUCLEIC ACIDS RES, V18, P1603, DOI 10.1093/nar/18.6.1603; ROSENTHAL A, 1990, NUCLEIC ACIDS RES, V18, P3095, DOI 10.1093/nar/18.10.3095; RUANO G, 1990, P NATL ACAD SCI USA, V87, P6296, DOI 10.1073/pnas.87.16.6296; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAUNDERS RDC, 1989, NUCLEIC ACIDS RES, V17, P9027, DOI 10.1093/nar/17.22.9027; SAWYER JR, 1986, SCIENCE, V232, P1632; SCHWARZ K, 1990, NUCLEIC ACIDS RES, V18, P1079, DOI 10.1093/nar/18.4.1079; SEARLE A G, 1987, Genomics, V1, P3, DOI 10.1016/0888-7543(87)90099-1; SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194; SMITH CL, 1990, J BACTERIOL, V172, P1167, DOI 10.1128/jb.172.3.1167-1172.1990; SMITH CL, 1987, METHOD ENZYMOL, V151, P461; SMITH DR, 1990, P NATL ACAD SCI USA, V87, P8242, DOI 10.1073/pnas.87.21.8242; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; STERNBERG N, 1990, New Biologist, V2, P151; STRAUS D, 1990, P NATL ACAD SCI USA, V87, P1889, DOI 10.1073/pnas.87.5.1889; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; TAUTZ N, 1990, NUCLEIC ACIDS RES, V18, P3087, DOI 10.1093/nar/18.10.3087; VANBRUNT J, 1990, BIO-TECHNOL, V8, P291; WATERBURY PG, 1989, NUCLEIC ACIDS RES, V17, P9493, DOI 10.1093/nar/17.22.9493; WESLEY CS, 1990, NUCLEIC ACIDS RES, V18, P599, DOI 10.1093/nar/18.3.599; WHITE R, 1988, ANNU REV GENET, V22, P259; WIELAND I, 1990, P NATL ACAD SCI USA, V87, P2720, DOI 10.1073/pnas.87.7.2720; YUNIS JJ, 1981, HUM GENET, V56, P293, DOI 10.1007/BF00274682; ZISCHLER H, 1989, HUM GENET, V82, P227, DOI 10.1007/BF00291160; [No title captured]; 1990, UNDERSTANDING OUR GE, P5	75	17	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					28	34		10.1096/fasebj.5.1.1846833	http://dx.doi.org/10.1096/fasebj.5.1.1846833			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1846833				2022-12-28	WOS:A1991ET60900005
J	GASSMANN, M; THOMMES, P; WEISER, T; HUBSCHER, U				GASSMANN, M; THOMMES, P; WEISER, T; HUBSCHER, U			EFFICIENT PRODUCTION OF CHICKEN EGG-YOLK ANTIBODIES AGAINST A CONSERVED MAMMALIAN PROTEIN	FASEB JOURNAL			English	Article									UNIV ZURICH, DEPT PHARMACOL & BIOCHEM, CH-8057 ZURICH, SWITZERLAND	University of Zurich								ALTSCHUH D, 1984, J IMMUNOL METHODS, V69, P1, DOI 10.1016/0022-1759(84)90270-9; ANKERSTROM B, 1985, J IMMUNOL, V135, P2589; BADE H, 1984, J IMMUNOL METHODS, V72, P421, DOI 10.1016/0022-1759(84)90010-3; BAUWENS RM, 1987, CLIN CHIM ACTA, V170, P37, DOI 10.1016/0009-8981(87)90381-0; BURGER D, 1985, THROMB RES, V40, P283, DOI 10.1016/0049-3848(85)90340-8; BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; BURGERS PMJ, 1989, PROG NUCLEIC ACID RE, V37, P235; CARROLL SB, 1983, J BIOL CHEM, V258, P24; FERTEL R, 1981, BIOCHEM BIOPH RES CO, V102, P1028, DOI 10.1016/0006-291X(81)91641-7; FRENCH VI, 1970, IMMUNOLOGY, V18, P645; GOTTSTEIN B, 1985, Z PARASITENKD, V71, P273, DOI 10.1007/BF00926279; HASSL A, 1988, J IMMUNOL METHODS, V110, P225, DOI 10.1016/0022-1759(88)90107-X; KUHLMANN R, 1988, J VET MED B, V35, P610; LESLIE GA, 1969, J EXP MED, V130, P1337, DOI 10.1084/jem.130.6.1337; LOSCH U, 1986, J VET MED B, V33, P609; PATTERSON R, 1962, J GEN PHYSIOL, V45, P501, DOI 10.1085/jgp.45.3.501; POLSON A, 1980, IMMUNOL COMMUN, V9, P495, DOI 10.3109/08820138009066011; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; RICKE SC, 1988, APPL ENVIRON MICROB, V54, P596, DOI 10.1128/AEM.54.2.596-599.1988; ROSE ME, 1974, EUR J IMMUNOL, V4, P521, DOI 10.1002/eji.1830040715; SONG CS, 1985, J IMMUNOL, V135, P3354; SPADARI S, 1989, MUTAT RES, V219, P147, DOI 10.1016/0921-8734(89)90009-X; TAM LQ, 1975, P SOC EXP BIOL MED, V150, P340; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA JGH, 1984, J IMMUNOASSAY, V5, P121, DOI 10.1080/01971528408063002; YOLKEN RH, 1988, PEDIATRICS, V81, P291	27	309	328	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1990	4	8					2528	2532		10.1096/fasebj.4.8.1970792	http://dx.doi.org/10.1096/fasebj.4.8.1970792			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DE393	1970792				2022-12-28	WOS:A1990DE39300014
J	Dumetier, B; Zadoroznyj, A; Berthelet, J; Causse, S; Allegre, J; Bourgeois, P; Cattin, F; Racoeur, C; Paul, C; Garrido, C; Dubrez, L				Dumetier, Baptiste; Zadoroznyj, Aymeric; Berthelet, Jean; Causse, Sebastien; Allegre, Jennifer; Bourgeois, Pauline; Cattin, Florine; Racoeur, Cindy; Paul, Catherine; Garrido, Carmen; Dubrez, Laurence			cIAP1/TRAF2 interplay promotes tumor growth through the activation of STAT3	ONCOGENE			English	Article; Early Access							NF-KAPPA-B; UBIQUITIN LIGASE; TRAF2; CIAP1; KINASE; C-IAP1; INHIBITOR; DEGRADATION; COMPLEX; CANCER	Cellular inhibitor of apoptosis-1 (cIAP1) is a signaling regulator with oncogenic properties. It is involved in the regulation of signaling pathways controlling inflammation, cell survival, proliferation, differentiation and motility. It is recruited into membrane-receptor-associated signaling complexes thanks to the molecular adaptor TRAF2. However, the cIAP1/TRAF2 complex exists, independently of receptor engagement, in several subcellular compartments. The present work strengthens the importance of TRAF2 in the oncogenic properties of cIAP1. cIAPs-deficient mouse embryonic fibroblasts (MEFs) were transformed using the HRas-V12 oncogene. Re-expression of cIAP1 enhanced tumor growth in a nude mice xenograft model, and promoted lung tumor nodes formation. Deletion or mutation of the TRAF2-binding site completely abolished the oncogenic properties of cIAP1. Further, cIAP1 mediated the clustering of TRAF2, which was sufficient to stimulate tumor growth. Our TRAF2 interactome analysis showed that cIAP1 was critical for TRAF2 to bind to its protein partners. Thus, cIAP1 and TRAF2 would be two essential subunits of a signaling complex promoting a pro-tumoral signal. cIAP1/TRAF2 promoted the activation of the canonical NF-kappa B and ERK1/2 signaling pathways. NF-kappa B-dependent production of IL-6 triggered the activation of the JAK/STAT3 axis in an autocrine manner. Inhibition or downregulation of STAT3 specifically compromised the growth of cIAP1-restored MEFs but not that of MEFs expressing a cIAP1-mutant and treating mice with the STAT3 inhibitor niclosamide completely abrogated cIAP1/TRAF2-mediated tumor growth. Altogether, we demonstrate that cIAP1/TRAF2 binding is essential to promote tumor growth via the activation of the JAK/STAT3 signaling pathway.	[Dumetier, Baptiste; Zadoroznyj, Aymeric; Berthelet, Jean; Causse, Sebastien; Allegre, Jennifer; Bourgeois, Pauline; Cattin, Florine; Garrido, Carmen; Dubrez, Laurence] Inst Natl Sante & Rech Med Inserm, LNC UMR1231, Team Label Excellence Ligue Natl Canc, LabEx LIpSTIC, F-21000 Dijon, France; [Dumetier, Baptiste; Zadoroznyj, Aymeric; Berthelet, Jean; Causse, Sebastien; Allegre, Jennifer; Bourgeois, Pauline; Cattin, Florine; Garrido, Carmen; Dubrez, Laurence] Univ Bourgogne Franche Comte, F-21000 Dijon, France; [Racoeur, Cindy; Paul, Catherine] Univ Bourgogne Franche Comte, EA7269, LIIC, F-21000 Paris, France; [Racoeur, Cindy; Paul, Catherine] PSL Res Univ, Lab Immunol & Immunotherapy Canc, EPHE, F-75000 Paris, France; [Garrido, Carmen] Anticanc Ctr Georges Francois Leclerc Unicanc, Dijon, France; [Berthelet, Jean] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); La Trobe University; Olivia Newton-John Cancer Research Institute	Dubrez, L (corresponding author), Inst Natl Sante & Rech Med Inserm, LNC UMR1231, Team Label Excellence Ligue Natl Canc, LabEx LIpSTIC, F-21000 Dijon, France.; Dubrez, L (corresponding author), Univ Bourgogne Franche Comte, F-21000 Dijon, France.	ldubrez@u-bourgogne.fr	; Garrido, Carmen/G-1633-2018	Berthelet, Jean/0000-0003-2562-0575; DUMETIER, Baptiste/0000-0001-9087-2344; Garrido, Carmen/0000-0003-1368-1493	'Comites de Cote d'Or et de l'Yonne' of the 'Ligue Contre le Cancer'; La Ligue Nationale contre le Cancer; European Union; 'Conseil Regional de Bourgogne', a French Government [ANR-11-LABX-0021]; 'Ministere de l'Enseignement Superieur et de la Recherche' of France; Fondation ARC pour la Recherche sur le Cancer; FEDER	'Comites de Cote d'Or et de l'Yonne' of the 'Ligue Contre le Cancer'; La Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); European Union(European Commission); 'Conseil Regional de Bourgogne', a French Government; 'Ministere de l'Enseignement Superieur et de la Recherche' of France; Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); FEDER(European Commission)	We thank Pauline Maes from the CLIPP proteomic platform, University of Burgundy, Philippe Hammann from the Strasbourg proteomic platform, IBMC, Valerie Saint Gorgio from zootechny center, University of Burgundy, and Romain Aucagne from the Crigen platform, University of Burgundy. This work was supported by grants from the 'Comites de Cote d'Or et de l'Yonne' of the 'Ligue Contre le Cancer' (LD), La Ligue Nationale contre le Cancer (CG's team), the European Union and the `Conseil Regional de Bourgogne', a French Government grant managed by the French National Research Agency under the program 'Investissements d'Avenir' with reference ANR-11-LABX-0021, and fellowships from the 'Ministere de l'Enseignement Superieur et de la Recherche' of France (to BD, AZ, JB and JA), the 'Fondation ARC pour la Recherche sur le Cancer' (to BD). We thank the FEDER for their financial support.	Annibaldi A, 2018, TRENDS MOL MED, V24, P49, DOI 10.1016/j.molmed.2017.11.002; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bishop GA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00326; Borghi A, 2016, BIOCHEM PHARMACOL, V116, P1, DOI 10.1016/j.bcp.2016.03.009; Ceccarelli A, 2015, BIOCHEMISTRY-US, V54, P6153, DOI 10.1021/acs.biochem.5b00674; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Cheng L, 2010, ONCOGENE, V29, P5700, DOI 10.1038/onc.2010.300; Csomos RA, 2009, J BIOL CHEM, V284, P20531, DOI 10.1074/jbc.M109.029983; Dhillon B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00104; Didelot C, 2008, CELL DEATH DIFFER, V15, P859, DOI 10.1038/sj.cdd.4402320; Dogan T, 2008, NAT CELL BIOL, V10, P1447, DOI 10.1038/ncb1804; Dubrez L, 2013, ONCOTARGETS THER, V6, P1285, DOI 10.2147/OTT.S33375; Dumetier B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051118; Dupoux A, 2009, BLOOD, V113, P175, DOI 10.1182/blood-2008-02-137919; Hrdinka M, 2019, GENES IMMUN, V20, P641, DOI 10.1038/s41435-019-0078-8; Jin J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6930; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Korchnak AC, 2009, CELL SIGNAL, V21, P1620, DOI 10.1016/j.cellsig.2009.06.008; Kreckel J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02024; Li HY, 2018, P NATL ACAD SCI USA, V115, pE9317, DOI 10.1073/pnas.1807711115; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Ma O, 2009, CANCER RES, V69, P2559, DOI 10.1158/0008-5472.CAN-08-2929; Mace PD, 2010, J MOL BIOL, V400, P8, DOI 10.1016/j.jmb.2010.04.055; Marivin A, 2014, ONCOGENE, V33, P5534, DOI 10.1038/onc.2013.499; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park HH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01999; Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015; Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515; Peng C, 2012, J BIOL CHEM, V287, P25881, DOI 10.1074/jbc.M112.359521; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Sondarva G, 2010, CELL RES, V20, P89, DOI 10.1038/cr.2009.125; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Vischioni B, 2004, EXP CELL RES, V298, P535, DOI 10.1016/j.yexcr.2004.04.040; Vu NT, 2016, CANCER RES, V76, P2977, DOI 10.1158/0008-5472.CAN-15-2512; Xu L, 2007, MOL CELL, V28, P914, DOI 10.1016/j.molcel.2007.10.027; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Yin Q, 2009, BIOCHEMISTRY-US, V48, P10558, DOI 10.1021/bi901462e; Zadoroznyj A, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020322; Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhao YG, 2007, J BIOL CHEM, V282, P7777, DOI 10.1074/jbc.M609146200; Zheng C, 2010, MOL CELL, V38, P101, DOI 10.1016/j.molcel.2010.03.009; Zhou AY, 2013, CELL REP, V3, P724, DOI 10.1016/j.celrep.2013.01.031; Zhu SN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02111	47	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02544-y	http://dx.doi.org/10.1038/s41388-022-02544-y		NOV 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H1YQ	36400972	Green Submitted			2022-12-28	WOS:000885244700002
J	HAJJAR, DP; POMERANTZ, KB				HAJJAR, DP; POMERANTZ, KB			SIGNAL TRANSDUCTION IN ATHEROSCLEROSIS - INTEGRATION OF CYTOKINES AND THE EICOSANOID NETWORK	FASEB JOURNAL			English	Review						SMOOTH MUSCLE CELLS; ENDOTHELIUM; CHOLESTEROL; TRANSFORMING GROWTH FACTOR-BETA; PLATELET-DERIVED GROWTH FACTOR; CYCLIC AMP BLOOD VESSELS	SMOOTH-MUSCLE CELLS; LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; MICROVASCULAR ENDOTHELIAL-CELLS; CHOLESTERYL ESTER ACCUMULATION; ARACHIDONIC-ACID METABOLITES; MOUSE PERITONEAL-MACROPHAGES; HUMAN MONONUCLEAR LEUKOCYTES; HUMAN MONOCYTE-MACROPHAGES	Atherosclerosis can be defined in broad terms as a vascular disease accompanied by dysregulation of cholesterol metabolism and the accumulation of smooth muscle cells and macrophages within the vessel wall. At the interface of the blood and the vessel wall is the endothelium, which actively participates in a plethora of critical homeostatic functions in addition to affecting cholesterol trafficking in the underlying smooth muscle cell and macrophage. These events include: 1) inflammation resulting in release of cytokines, 2) changes in vascular reactivity causing release of endothelial cell derived relaxing factor (EDRF) and PGI2, and 3) control of vascular smooth cell proliferation via release of growth factors and growth suppressor molecules. Each process has been linked to the regulation of cholesterol accretion in the arterial cell. Furthermore, each homeostatic process is regulated by transmembrane signaling mechanisms at the lipid-protein interface of the membrane. Data have emerged recently indicating that biological response modifiers that trigger transmembrane signaling work in a sequential manner to control cell function. We review studies of the regulatory mechanisms of transmembrane signal transduction that advance the concept that phosphorylation of the specific protein components of the receptor machinery may result in a cooperative cellular response to ligands that will ultimately affect cholesterol delivery and trafficking within cells. We review recent data demonstrating that eicosanoids and cytokines released from one cell activate their receptors on neighboring cells, and interact with each other during this "cross-talk phenomenon." Cross-talking among phosphorylation reactions involving, for example, protein kinases A and C and tyrosine protein kinase, coupled with the highly regulated eicosanoid pathways and the diacylglycerol-phosphatidyl inositol (DG-PI) system, are discussed in terms of their metabolic impact on cholesterol delivery, intracellular processing, and efflux.			HAJJAR, DP (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT BIOCHEM,A-626,1300 YORK AVE,NEW YORK,NY 10021, USA.			Pomerantz, Kenneth/0000-0001-9443-5301				AKOPOV SE, 1988, ATHEROSCLEROSIS, V72, P245, DOI 10.1016/0021-9150(88)90087-1; AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; AVIRAM M, 1989, METABOLISM, V38, P445, DOI 10.1016/0026-0495(89)90196-0; BALSINDE J, 1990, J IMMUNOL, V144, P4298; BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BEG ZH, 1987, METABOLISM, V36, P900, DOI 10.1016/0026-0495(87)90101-6; BELL L, 1989, CIRC RES, V65, P1057, DOI 10.1161/01.RES.65.4.1057; BERLINER JA, 1986, ARTERIOSCLEROSIS, V6, P254, DOI 10.1161/01.ATV.6.3.254; BLAY J, 1989, J CELL PHYSIOL, V139, P524, DOI 10.1002/jcp.1041390311; BULL HA, 1990, BRIT J DERMATOL, V122, P153, DOI 10.1111/j.1365-2133.1990.tb08261.x; BURCH RM, 1989, J CELL PHYSIOL, V141, P85, DOI 10.1002/jcp.1041410113; CHAIT A, 1980, P NATL ACAD SCI-BIOL, V77, P4084, DOI 10.1073/pnas.77.7.4084; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; COTRAN RS, 1989, KIDNEY INT, V35, P969, DOI 10.1038/ki.1989.80; COUGHLIN SR, 1981, P NATL ACAD SCI-BIOL, V78, P7134, DOI 10.1073/pnas.78.11.7134; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DAVIES PF, 1982, BIOCHIM BIOPHYS ACTA, V712, P26, DOI 10.1016/0005-2760(82)90080-7; DAVIES PF, 1978, J CELL BIOL, V79, P663, DOI 10.1083/jcb.79.3.663; FALCONE DJ, 1980, AM J PATHOL, V99, P81; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FOGELMAN AM, 1982, P NATL ACAD SCI-BIOL, V79, P922, DOI 10.1073/pnas.79.3.922; FUKUMOTO Y, 1988, BIOCHEM BIOPH RES CO, V157, P337, DOI 10.1016/S0006-291X(88)80052-4; GAGNON L, 1989, AGENTS ACTIONS, V26, P142; GOERIG M, 1988, J BIOL CHEM, V263, P19384; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; Gryglewski R J, 1988, Adv Exp Med Biol, V243, P21; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1989, BIOCHEMISTRY-US, V28, P8885, DOI 10.1021/bi00448a030; HAJJAR DP, 1987, J BIOL CHEM, V262, P6976; HAJJAR DP, 1986, ARCH BIOCHEM BIOPHYS, V247, P49, DOI 10.1016/0003-9861(86)90531-X; HORI T, 1991, BIOCHEM BIOPH RES CO, V174, P758, DOI 10.1016/0006-291X(91)91482-R; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; KATZ Y, 1989, J IMMUNOL, V142, P3862; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KHOO JC, 1981, J BIOL CHEM, V256, P2659; KORN JH, 1983, J CLIN INVEST, V71, P1240, DOI 10.1172/JCI110873; KRONE W, 1985, BIOCHIM BIOPHYS ACTA, V835, P154, DOI 10.1016/0005-2760(85)90042-6; KRONE W, 1988, J LIPID RES, V29, P1663; KUNKEL SL, 1985, BIOCHEM BIOPH RES CO, V128, P892, DOI 10.1016/0006-291X(85)90130-5; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MORISHITA H, 1990, J CLIN INVEST, V86, P1885, DOI 10.1172/JCI114920; MORITA I, 1984, BIOCHIM BIOPHYS ACTA, V792, P304; NAKAO J, 1983, BIOCHEM BIOPH RES CO, V112, P866, DOI 10.1016/0006-291X(83)91697-2; NICHOLSON A C, 1989, FASEB Journal, V3, pA612; ONEILL LAJ, 1989, EUR J PHARMACOL, V166, P131, DOI 10.1016/0014-2999(89)90052-6; ONO H, 1988, THROMB HAEMOSTASIS, V60, P174; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PFANNKUCHE HJ, 1989, BIOCHEM J, V260, P471, DOI 10.1042/bj2600471; PHILLIPS MC, 1980, ATHEROSCLEROSIS, V36, P409, DOI 10.1016/0021-9150(80)90220-8; PIETILA K, 1980, ATHEROSCLEROSIS, V36, P241, DOI 10.1016/0021-9150(80)90232-4; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PLOUET J, 1989, J CELL PHYSIOL, V141, P392, DOI 10.1002/jcp.1041410221; POMERANTZ K, 1991, CELL CELL INTERACTIO; POMERANTZ KB, 1984, CIRC RES, V54, P554, DOI 10.1161/01.RES.54.5.554; POMERANTZ KB, 1990, BIOCHEMISTRY-US, V29, P1892, DOI 10.1021/bi00459a033; POMERANTZ KB, 1989, ARTERIOSCLEROSIS, V9, P413, DOI 10.1161/01.ATV.9.4.413; RAZ A, 1988, J BIOL CHEM, V263, P3022; RISTIMAKI A, 1990, ARTERIOSCLEROSIS, V10, P653, DOI 10.1161/01.ATV.10.4.653; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; RUSTIN MHA, 1989, BRIT J DERMATOL, V120, P153; SCHROEFF JG, 1985, BIOCHEM BIOPH RES CO, V127, P366; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SHAKHOV Y, 1989, J MOL CELL CARDIOL, V21, P461, DOI 10.1016/0022-2828(89)90786-4; SHERMAN ML, 1988, J CLIN ONCOL, V6, P344, DOI 10.1200/JCO.1988.6.2.344; SHERMAN ML, 1990, J CLIN INVEST, V85, P442, DOI 10.1172/JCI114457; SOUTHGATE K, 1990, ATHEROSCLEROSIS, V82, P113, DOI 10.1016/0021-9150(90)90150-H; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STOUT RW, 1982, DIABETOLOGIA, V22, P51, DOI 10.1007/BF00253870; SUZUKI K, 1990, BIOCHIM BIOPHYS ACTA, V1042, P352, DOI 10.1016/0005-2760(90)90164-S; SUZUKI T, 1991, FASEB J, V5, P187, DOI 10.1096/fasebj.5.2.1706281; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; UNDEM BJ, 1990, J BIOL CHEM, V265, P6750; VANLENTEN BJ, 1985, J IMMUNOL, V134, P3718; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; WHATLEY RE, 1990, PROG LIPID RES, V29, P45, DOI 10.1016/0163-7827(90)90005-6; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILSON AC, 1990, ARTERIOSCLEROSIS, V10, P208, DOI 10.1161/01.ATV.10.2.208; WILSON DE, 1989, J CLIN ONCOL, V7, P1573, DOI 10.1200/JCO.1989.7.10.1573; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	90	124	132	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					2933	2941		10.1096/fasebj.6.11.1644257	http://dx.doi.org/10.1096/fasebj.6.11.1644257			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644257				2022-12-28	WOS:A1992JJ66500007
J	FEARON, ER; JONES, PA				FEARON, ER; JONES, PA			PROGRESSING TOWARD A MOLECULAR DESCRIPTION OF COLORECTAL-CANCER DEVELOPMENT	FASEB JOURNAL			English	Review						COLORECTAL CANCER; ONCOGENES; TUMOR SUPPRESSOR GENES; SOMATIC MUTATION	FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN GENETIC-DISEASE; P53 GENE; RAS ONCOGENES; LUNG-CANCER; MUTATIONS; RETINOBLASTOMA; SUSCEPTIBILITY; TUMORIGENESIS; CHROMOSOME-5	During the past decade, the powerful techniques of molecular biology and genetics have been applied to the study of human cancer. Colorectal tumors have proved to be an excellent system in which to search for and study the mutations involved in the development and progression of a common human cancer because of their natural history and several inherited syndromes that strongly predispose to colorectal cancer. A current view is that colorectal cancer results, at least in part, from the accumulation of multiple mutations in oncogenes and tumor suppressor genes in an affected cell. Although the genetic alterations often occur in a preferred sequence, the total accumulation of changes, rather than their order with respect to one another, appears to be a critical determinant of the biological properties of the tumor cell. Study of the inherited and somatic mutations in colorectal tumor cells may provide insights not only into the pathogenesis of cancer, but may also lead to future understanding of the mechanisms of the origin of mutations and the role of environmental and dietary factors in colorectal tumor development.	JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, BALTIMORE, MD 21205 USA; UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, LOS ANGELES, CA 90033 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Southern California								ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Boveri T, 1929, ORIGIN MALIGNANT TUM; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CAVENEE WK, 1983, SCIENCE, V288, P501; CHIBA I, 1990, ONCOGENE, V5, P1603; COOPER DN, 1990, HUM GENET, V85, P55; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HANSEN MF, 1987, CANCER RES, V47, P5518; HARRIS H, 1988, CANCER RES, V48, P3302; HARRIS H, 1969, NATURE, V224, P1314; HENSEL CH, 1991, ONCOGENE, V6, P1067; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISHIOKA C, 1991, BIOCHEM BIOPH RES CO, V177, P901, DOI 10.1016/0006-291X(91)90623-F; JONES PA, 1991, CANCER RES, V51, P3617; JONES PA, 1992, IN PRESS BIOESSAYS; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KLINGER HP, 1982, CYTOGENET CELL GENET, V32, P68, DOI 10.1159/000131688; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOEBERL DD, 1990, AM J HUM GENET, V47, P202; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIPKIN M, 1988, CANCER RES, V48, P235; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PONDER BAJ, 1986, J NATL CANCER I, V77, P967; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; SASAKI M, 1989, CANCER RES, V49, P4402; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; STANBRIDGE EJ, 1989, ONCOGENES MOL ORIGIN, P281; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SU LK, 1992, IN PRESS SCIENCE; Suqarbaker J, 1985, CANCER PRINCIPLES PR, P800; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TOGUCHIDA J, 1992, IN PRESS N ENGL J ME; TUDEK B, 1989, CANCER RES, V49, P1236; UTSUNOMIYA J, 1990, HEREDITY COLORECTAL; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	77	162	166	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2783	2790		10.1096/fasebj.6.10.1321771	http://dx.doi.org/10.1096/fasebj.6.10.1321771			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1321771				2022-12-28	WOS:A1992JD95400004
J	ZIPORI, D				ZIPORI, D			THE RENEWAL AND DIFFERENTIATION OF HEMATOPOIETIC STEM-CELLS	FASEB JOURNAL			English	Review						FEEDBACK REGULATION; CYTOKINES; COLONY-FORMING CELLS; STEM CELLS; RESTRICTIONS	MOUSE BONE-MARROW; STROMAL CELLS; GROWTH-FACTOR; SI-LOCUS; C-KIT; HEMATOPOIETIC PROGENITORS; MOLECULAR-CLONING; LIGAND; INVITRO; MICE	Blood-forming tissues are organized in well-defined microenvironments composed of hemopoietic cells and a supportive stroma of connective tissue and endothelium. Hemopoietic cells segregate to various lineages, all derived from a small population of pluripotent stem cells residing in the bone marrow. Regulation of growth and differentiation, particularly under conditions of perturbations, damage, and disease, is mediated by inducer colony-stimulating factors and interleukins counteracted by inhibitory cytokines. Whereas much is known about the mode of induction of differentiation, insufficient information is available to explain the process of stem cell renewal that is crucial for the longevity of the hemopoietic system. It is also only partially known how inhibition of hemopoietic processes occurs, and what molecules in blood-forming tissues signal organization into discrete patterns. This paper reviews recent progress that has opened new avenues to a better understanding of this highly complex issue.			ZIPORI, D (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; EAVES CJ, 1991, BLOOD, V78, P110; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRASER CC, 1990, BLOOD, V76, P1071; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HONIGWACHSSHAANANI J, 1991, ANN NY ACAD SCI, V628, P287, DOI 10.1111/j.1749-6632.1991.tb17259.x; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; LEARY AG, 1989, P NATL ACAD SCI USA, V86, P4535, DOI 10.1073/pnas.86.12.4535; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LYMAN SD, 1991, IN PRESS INT J CELL; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCULLOCH EA, 1964, RADIAT RES, V22, P383, DOI 10.2307/3571667; MULDER AH, 1987, EXP HEMATOL, V15, P99; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PLOEMACHER RE, 1989, BLOOD, V74, P2755; QUESENBERRY P, 1991, J CELL BIOCHEM, V45, P273, DOI 10.1002/jcb.240450309; RENNICK D, 1987, BLOOD, V69, P682; RESNICK M, 1990, J INFECT DIS, V162, P1202, DOI 10.1093/infdis/162.5.1202; SACHS L, 1970, REGULATION HEMATOPOI, V1, P217; TSUJI K, 1991, BLOOD, V78, P1223; VANZANT G, 1990, J EXP MED, V171, P1547, DOI 10.1084/jem.171.5.1547; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; VISSER JWM, 1991, SEMIN HEMATOL, V28, P117; WEISS L, 1991, S STROMAL REGULATION; ZIPORI D, 1985, J CELL PHYSIOL, V122, P81, DOI 10.1002/jcp.1041220113; ZIPORI D, 1990, CANCER CELL-MON REV, V2, P205; ZIPORI D, 1980, EXP HEMATOL, V8, P816; ZIPORI D, 1988, NAT IMMUN CELL GROW, V7, P185; ZIPORI D, 1981, EXP HEMATOL, V9, P663; ZIPORI D, 1981, EXP HEMATOL, V9, P656; ZIPORI D, 1988, BLOOD, V71, P586; ZIPORI D, 1986, P NATL ACAD SCI USA, V83, P4547, DOI 10.1073/pnas.83.12.4547; ZIPORI D, 1989, EUR J HAEMATOL, V42, P225; ZIPORI D, 1982, EXPT HEMATOLOGY TODA, P19; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	50	37	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2691	2697		10.1096/fasebj.6.9.1612293	http://dx.doi.org/10.1096/fasebj.6.9.1612293			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612293				2022-12-28	WOS:A1992HZ48100010
J	GERSCHENSON, LE; ROTELLO, RJ				GERSCHENSON, LE; ROTELLO, RJ			APOPTOSIS - A DIFFERENT TYPE OF CELL-DEATH	FASEB JOURNAL			English	Article						APOPTOSIS; PROGRAMMED CELL DEATH; INTERNUCLEOSOMAL DNA FRAGMENTATION	KILLS IMMATURE THYMOCYTES; RABBIT UTERINE EPITHELIUM; TUMOR-NECROSIS-FACTOR; DNA FRAGMENTATION; TARGET-CELL; ENDONUCLEASE ACTIVATION; PROGRAMMED DEATH; MESSENGER-RNA; T-CELLS; LYMPHOCYTES	Apoptosis is a type of cell death that plays an important role in early development and growth of normal adult tissues. It is regulated by physiological stimuli and is present in many species and tissues. The main morphological characteristics are nuclear fragmentation and cellular breakdown in apoptotic vesicles. Internucleosomal DNA fragmentation is an important biochemical feature that is the result of a yet to be isolated endonuclease activity. Experiments using RNA and protein synthesis inhibitors suggest the presence of either intracellular repressors or inducers of apoptosis.			GERSCHENSON, LE (corresponding author), UNIV COLORADO, HLTH SCI CTR, SCH MED, DEPT PATHOL, DENVER, CO 80262 USA.							ALLES A, 1991, FASEB J, V5, P2127, DOI 10.1096/fasebj.5.8.2022310; ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BANSAL N, 1991, FASEB J, V5, P211, DOI 10.1096/fasebj.5.2.2004665; BISHOP CJ, 1983, BRIT J CANCER, V48, P441, DOI 10.1038/bjc.1983.211; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; COHEN JJ, 1984, J IMMUNOL, V132, P38; COMPTON MM, 1986, ENDOCRINOLOGY, V118, P38, DOI 10.1210/endo-118-1-38; DON MM, 1977, AUST J EXP BIOL MED, V55, P407, DOI 10.1038/icb.1977.38; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DURANT S, 1980, BIOCHEM BIOPH RES CO, V93, P385, DOI 10.1016/0006-291X(80)91088-8; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FARBMAN AI, 1968, DEV BIOL, V18, P93, DOI 10.1016/0012-1606(68)90038-9; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GROMKOWSKI SH, 1988, J IMMUNOL, V141, P774; GROMKOWSKI SH, 1986, J IMMUNOL, V136, P752; HAMMAR SP, 1971, J CELL SCI, V8, P229; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HINCHLIFFE JR, 1981, CELL DEATH BIOL PATH, P35; Kerr J.F.R., 1987, P93; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210; KERR JFR, 1972, J PATHOL, V107, P41, DOI 10.1002/path.1711070107; KERR JFR, 1974, J CELL SCI, V14, P571; KOLBER MA, 1990, FASEB J, V4, P3021, DOI 10.1096/fasebj.4.12.2394319; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lockshin R. A, 1981, CELL DEATH BIOL PATH, P79; LOCKSHIN RA, 1977, J INSECT PHYSIOL, V23, P1117, DOI 10.1016/0022-1910(77)90142-1; LOCKSHIN RA, 1991, FASEB J, V5, pA518; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCKENZIE EA, 1990, MOL ENDOCRINOL, V4, P807, DOI 10.1210/mend-4-6-807; Moore J.V., 1987, P295; NAWAZ S, 1987, AM J PATHOL, V127, P51; NELIPOVICH PA, 1988, INT J RADIAT BIOL, V53, P749, DOI 10.1080/09553008814551111; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; OSHEA JD, 1978, J REPROD FERTIL, V54, P183, DOI 10.1530/jrf.0.0540183; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PENFOLD PL, 1986, GRAEF ARCH CLIN EXP, V224, P549, DOI 10.1007/BF02154744; RADLEY JM, 1983, BRIT J HAEMATOL, V53, P277, DOI 10.1111/j.1365-2141.1983.tb02022.x; ROTELLO RJ, 1992, AM J PATHOL, V140, P449; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; ROTELLO RJ, 1989, AM J PATHOL, V134, P491; SANDERSON CJ, 1977, PROC R SOC SER B-BIO, V197, P417, DOI 10.1098/rspb.1977.0078; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; TAKANO YS, 1991, J PATHOL, V163, P329, DOI 10.1002/path.1711630410; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WALKER PR, 1991, CANCER RES, V51, P1078; WARING P, 1990, J BIOL CHEM, V265, P14476; WEEKS JC, 1986, J NEUROBIOL, V17, P249, DOI 10.1002/neu.480170308; WYLLIE AH, 1973, J PATHOL, V111, P85, DOI 10.1002/path.1711110203; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1973, J PATHOL, V111, P255, DOI 10.1002/path.1711110406; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	70	528	554	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1992	6	7					2450	2455		10.1096/fasebj.6.7.1563596	http://dx.doi.org/10.1096/fasebj.6.7.1563596			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563596				2022-12-28	WOS:A1992HP03000011
J	KLOTZ, IM				KLOTZ, IM			COOKING AND TRIMMING BY SCIENTIFIC GIANTS	FASEB JOURNAL			English	Article											KLOTZ, IM (corresponding author), NORTHWESTERN UNIV,DEPT CHEM,2145 SHERIDAN RD,EVANSTON,IL 60208, USA.							Fisher R. A., 1936, Ann Sci London, V1, P115, DOI 10.1080/00033793600200111; GILLISPIE CC, 1975, DICT SCI BIOGRAPHY, V9, P495; HOLTON G, 1986, ADV SCI ITS BURDENS; KELLSTROM G, 1936, PHYS REV, V50, P190; Klotz I.M., 1986, DIAMOND DEALERS FEAT; POLANYI M, 1965, LANCET, P921; Sturtevant Alfred, 1965, HIST GENETICS; TAIT PG, 1877, THERMODYNAMICS, P57; [No title captured]; [No title captured]	10	6	6	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2271	2273		10.1096/fasebj.6.6.1544538	http://dx.doi.org/10.1096/fasebj.6.6.1544538			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544538				2022-12-28	WOS:A1992HJ25200002
J	BARNETT, LA; FUJINAMI, RS				BARNETT, LA; FUJINAMI, RS			MOLECULAR MIMICRY - A MECHANISM FOR AUTOIMMUNE INJURY	FASEB JOURNAL			English	Article						MOLECULAR MIMICRY; AUTOIMMUNITY; VIRUS; TOLERANCE	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HUMAN IMMUNODEFICIENCY VIRUS; MYELIN BASIC-PROTEIN; HERPES-SIMPLEX VIRUS; INTERMEDIATE FILAMENTS; MONOCLONAL-ANTIBODIES; MEASLES-VIRUS; ACETYLCHOLINE-RECEPTOR; RHEUMATOID-ARTHRITIS; CROSS-REACTIVITY	Many mechanisms may account for immune-mediated pathology after viral infections. Although several means have been hypothesized to play a role in disease, a widely accepted mechanism for viral-induced autoimmunity is molecular mimicry. It is thought that damage could result from an immune response to similar regions shared between virus and the host. Using computer-aided analysis, many sequence homologies have been identified between virus and host antigens. Using peptides corresponding to these regions, immunologic cross-reactivity has been found. In some cases, monoclonal antibodies to peptides of these regions have been shown to directly induce or augment disease in animal models. Using this approach to identify similar regions, it is possible to associate a known autoantigen with an infectious agent in autoimmune diseases in which there is no known etiologic agent. Conversely, it would also be possible to associate a known viral constituent with an unknown host antigen. Furthermore, identification of disease-inducing regions of autoantigens or viral proteins may lead to immunotherapeutic approaches to establish tolerance or anergy to such disease-inducing regions.	UNIV UTAH, DEPT NEUROL, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah								APPELBAUM E, 1953, JAMA-J AM MED ASSOC, V151, P188; BAKER JR, 1988, ANN INTERN MED, V108, P26, DOI 10.7326/0003-4819-108-1-26; BARNETT LA, 1991, FASEB J, V5, pA1678; BIRKENFELD P, 1990, CLIN IMMUNOL IMMUNOP, V54, P14, DOI 10.1016/0090-1229(90)90002-8; COHEN IR, 1991, ANNU REV IMMUNOL, V9, P567, DOI 10.1146/annurev.iy.09.040191.003031; CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998; DALES S, 1983, J IMMUNOL, V131, P1546; DAMIAN RT, 1964, AM NAT, V98, P129, DOI 10.1086/282313; FITZPATRICK DR, 1990, IMMUNOLOGY, V70, P504; Fujinami R S, 1988, Ann N Y Acad Sci, V540, P210, DOI 10.1111/j.1749-6632.1988.tb27063.x; FUJINAMI RS, 1988, J VIROL, V62, P100, DOI 10.1128/JVI.62.1.100-105.1988; FUJINAMI RS, 1989, APMIS, V97, P1, DOI 10.1111/j.1699-0463.1989.tb00746.x; FUJINAMI RS, 1983, P NATL ACAD SCI-BIOL, V80, P2346, DOI 10.1073/pnas.80.8.2346; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; FUJINAMI RS, 1988, J NEUROIMMUNOL, V20, P25, DOI 10.1016/0165-5728(88)90110-5; GABBIANI G, 1973, AM J PATHOL, V72, P473; GIUFFRE RM, 1982, J VIROL, V42, P963, DOI 10.1128/JVI.42.3.963-968.1982; GNANN JW, 1987, J VIROL, V61, P2639, DOI 10.1128/JVI.61.8.2639-2641.1987; GNANN JW, 1987, J INFECT DIS, V156, P261, DOI 10.1093/infdis/156.2.261; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; GULDNER HH, 1990, J EXP MED, V171, P819, DOI 10.1084/jem.171.3.819; KAPLAN MH, 1964, NEW ENGL J MED, V271, P637, DOI 10.1056/NEJM196409242711301; LANE D, 1982, NATURE, V296, P200, DOI 10.1038/296200a0; LIEBERT UG, 1990, J NEUROIMMUNOL, V29, P139, DOI 10.1016/0165-5728(90)90156-H; MASSANARI RM, 1979, J INFECT DIS, V139, P297, DOI 10.1093/infdis/139.3.297; MCCARTHY MP, 1986, ANNU REV NEUROSCI, V9, P383; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OLESZAK EL, 1990, VIROLOGY, V176, P70, DOI 10.1016/0042-6822(90)90231-F; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SCHATTNER A, 1990, REV INFECT DIS, V12, P204; SCHWIMMBECK PL, 1989, J CLIN INVEST, V84, P1174, DOI 10.1172/JCI114282; SINGH VK, 1990, J IMMUNOL, V144, P1282; SKOWRONSKI J, 1990, P NATL ACAD SCI USA, V87, P7487, DOI 10.1073/pnas.87.19.7487; SRINIVASAPPA J, 1986, J VIROL, V57, P397, DOI 10.1128/JVI.57.1.397-401.1986; SULITZEANU D, 1989, IMMUNOL LETT, V20, P89, DOI 10.1016/0165-2478(89)90089-8; TOH BH, 1979, CLIN EXP IMMUNOL, V37, P76; TUOHY VK, 1989, J IMMUNOL, V142, P1523; YAMADA M, 1990, J EXP MED, V171, P1893, DOI 10.1084/jem.171.6.1893; YAMADA M, 1991, J VIROL, V65, P1370, DOI 10.1128/JVI.65.3.1370-1376.1991; YASUDA T, 1975, JPN J EXP MED, V45, P423; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0	44	81	84	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1992	6	3					840	844		10.1096/fasebj.6.3.1740233	http://dx.doi.org/10.1096/fasebj.6.3.1740233			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740233				2022-12-28	WOS:A1992HE39000006
J	APPLING, DR				APPLING, DR			COMPARTMENTATION OF FOLATE-MEDIATED ONE-CARBON METABOLISM IN EUKARYOTES	FASEB JOURNAL			English	Article						MITOCHONDRIA; FOLATE-BINDING PROTEIN; SUBSTRATE CHANNELING	RAT-LIVER MITOCHONDRIA; DENOVO PURINE BIOSYNTHESIS; HAMSTER OVARY CELLS; DEHYDROGENASE-METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; BINDING-PROTEINS; SERINE HYDROXYMETHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; DEPENDENT ENZYMES; INTRAMITOCHONDRIAL LOCALIZATION	Folate coenzymes supply the activated one-carbon units required in nucleic acid biosynthesis, mitochondrial and chloroplast protein biosynthesis, amino acid metabolism, methyl group biogenesis, and vitamin metabolism. Because of its central role in purine and thymidylate biosynthesis, folate-mediated one-carbon metabolism has been the target of many anticancer drug therapies. This review is a summary of recent results that suggest that folate-mediated one-carbon metabolism is highly compartmentalized in eukaryotic cells. Evidence exists for compartmentation of folate coenzymes and their one-carbon units between intracellular organelles, for substrate channeling of folate coenzymes, and for compartmentation by intracellular folate-binding proteins. Metabolic, regulatory, and therapeutic implications of these processes are discussed.	UNIV TEXAS, CLAYTON FDN BIOCHEM INST, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	APPLING, DR (corresponding author), UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036913] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36913] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; BARLOWE C K, 1988, Biofactors, V1, P171; BARLOWE CK, 1990, BIOCHEMISTRY-US, V29, P7089, DOI 10.1021/bi00482a020; BARLOWE CK, 1990, MOL CELL BIOL, V10, P5679, DOI 10.1128/MCB.10.11.5679; BARLOWE CK, 1989, BIOCHEMISTRY-US, V28, P2099, DOI 10.1021/bi00431a020; BROWN SS, 1965, BIOCHEM J, V97, pC34, DOI 10.1042/bj0970034C; CAPERELLI CA, 1989, J BIOL CHEM, V264, P5053; CAPERELLI CA, 1980, J BIOL CHEM, V255, P1885; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; COHEN L, 1978, BIOCHIM BIOPHYS ACTA, V522, P311, DOI 10.1016/0005-2744(78)90065-7; COOK RJ, 1979, BIOCHEM J, V178, P651, DOI 10.1042/bj1780651; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; COSSINS EA, 1972, PHYTOCHEMISTRY, V11, P587, DOI 10.1016/0031-9422(72)80016-5; Cossins EA, 1984, FOLATES PTERINS, V1, P1; CYBULSKI RL, 1981, BIOCHIM BIOPHYS ACTA, V646, P329, DOI 10.1016/0005-2736(81)90339-4; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; DAUBNER SC, 1985, BIOCHEMISTRY-US, V24, P7059, DOI 10.1021/bi00346a006; FOO SK, 1982, J BIOL CHEM, V257, P13587; FRISELL WR, 1965, J BIOL CHEM, V240, P1829; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; JONES EW, 1972, GENETICS, V70, P233; KARLSSON JL, 1949, J BIOL CHEM, V177, P597; KIKUCHI G, 1973, MOL CELL BIOCHEM, V1, P169, DOI 10.1007/BF01659328; LEWIS KF, 1978, ARCH BIOCHEM BIOPHYS, V185, P443, DOI 10.1016/0003-9861(78)90187-X; MACKENZIE RE, 1980, BIOCHIM BIOPHYS ACTA, V611, P187, DOI 10.1016/0005-2744(80)90054-6; MATHERLY LH, 1990, CANCER RES, V50, P3262; MATHERLY LH, 1990, BIOCHEM PHARMACOL, V39, P2005, DOI 10.1016/0006-2952(90)90622-R; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCAIRNS E, 1983, J BIOL CHEM, V258, P1851; MEEK TD, 1985, BIOCHEMISTRY-US, V24, P678, DOI 10.1021/bi00324a021; MEJIA NR, 1988, BIOCHEM BIOPH RES CO, V155, P1, DOI 10.1016/S0006-291X(88)81040-4; MIN H, 1988, BIOCHIM BIOPHYS ACTA, V967, P348, DOI 10.1016/0304-4165(88)90097-9; Mitchell HK, 1941, J AM CHEM SOC, V63, P2284, DOI 10.1021/ja01853a512; MOTOKAWA Y, 1971, ARCH BIOCHEM BIOPHYS, V146, P461, DOI 10.1016/0003-9861(71)90149-4; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; REYNOLDS PHS, 1984, ARCH BIOCHEM BIOPHYS, V229, P623, DOI 10.1016/0003-9861(84)90195-4; ROWE PB, 1978, J BIOL CHEM, V253, P7711; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH L, 1978, ARCH BIOCHEM BIOPHYS, V189, P283, DOI 10.1016/0003-9861(78)90214-X; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SHANE B, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P891; SHANE B, 1989, VITAM HORM, V45, P263; SHANNON KW, 1986, J BIOL CHEM, V261, P2266; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; SMITH GK, 1980, BIOCHEMISTRY-US, V19, P4313, DOI 10.1021/bi00559a026; SPIVEY HO, 1989, BIOESSAYS, V10, P127, DOI 10.1002/bies.950100409; Staben C., 1984, FOLATES PTERINS, VI, P457; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P9430, DOI 10.1021/bi00450a028; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; TAYLOR RT, 1979, ARCH BIOCHEM BIOPHYS, V197, P36, DOI 10.1016/0003-9861(79)90215-7; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; WANG FK, 1967, BIOCHEM Z, V346, P458; WASSERMAN GF, 1983, BIOCHEMISTRY-US, V22, P1005, DOI 10.1021/bi00274a002; WITTWER AJ, 1981, J BIOL CHEM, V256, P4109; WITTWER AJ, 1981, J BIOL CHEM, V256, P4102; ZAMIEROWSKI M, 1974, BIOCHEM BIOPH RES CO, V60, P81, DOI 10.1016/0006-291X(74)90175-2; ZAMIEROWSKI MM, 1977, J BIOL CHEM, V252, P933; ZAMIEROWSKI MM, 1977, J NUTR, V107, P1937, DOI 10.1093/jn/107.10.1937; ZELIKSON R, 1977, EUR J BIOCHEM, V79, P285, DOI 10.1111/j.1432-1033.1977.tb11808.x	61	279	289	3	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1991	5	12					2645	2651		10.1096/fasebj.5.12.1916088	http://dx.doi.org/10.1096/fasebj.5.12.1916088			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916088	Bronze			2022-12-28	WOS:A1991GE81100004
J	HUI, KY; MANETTA, JV; GYGI, T; BOWDON, BJ; KEITH, KA; SHANNON, WM; LAI, MHT				HUI, KY; MANETTA, JV; GYGI, T; BOWDON, BJ; KEITH, KA; SHANNON, WM; LAI, MHT			A RATIONAL APPROACH IN THE SEARCH FOR POTENT INHIBITORS AGAINST HIV PROTEINASE	FASEB JOURNAL			English	Note						HIV PROTEASE; INHIBITORS; ANTIVIRAL	CONCENTRATION FLUORESCENCE IMMUNOASSAY; IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOTIDE-SEQUENCE; 3-DIMENSIONAL STRUCTURE; RETROVIRAL PROTEASES; ANTIVIRAL ACTIVITY; ANALOG INHIBITORS; RENIN INHIBITORS; AIDS VIRUS; PEPSTATIN	Synthetic peptides described as dog renin inhibitors were found to effectively inhibit the aspartyl protease of human immunodeficiency virus (HIV). The selection of oligopeptides for the HIV protease inhibition study was based on 1) the current strategy of inhibiting aspartyl proteases with transition state analogs, and 2) our previous observations regarding optimal structural differentiation at the P2 position among human, dog, and rat renin inhibitors. In an in vitro assay system consisting of recombinant HIV protease and a synthetic decapeptide substrate (at pH 5.5), results show that HIV protease was unaffected by statine-containing analogs carrying histidine at the P2 position whereas analogs containing valine at the same position yielded anti-protease IC50 values ranging from 50 to 500 nm. As anticipated, some analogs were also shown to inhibit processing of recombinant polyprotein substrate by HIV protease in vitro. The antiviral activity of three inhibitors was studied in HIV-infected CEM and MT-2 cells. Results showed that one compound, Ac-Naphthylalanyl-Pro-Phe-Val-Statine-Leu-Phe-NH2 (antiprotease IC50 value = 0.4-mu-M), protected the infected cells effectively with IC50 values (0.73-mu-M for CEM cells and 0.88-mu-M for MT-2 cells). This antiviral effect is comparable to those obtained with AZT and ddC in parallel studies of MT-2 cells.	SO RES INST,BIRMINGHAM,AL 35255		HUI, KY (corresponding author), ELI LILLY & CO,LILLY RES LAB,LILLY CORP CTR,INDIANAPOLIS,IN 46285, USA.							BILLICH S, 1988, J BIOL CHEM, V263, P17905; BOGER J, 1983, NATURE, V303, P81, DOI 10.1038/303081a0; BOGER J, 1985, J MED CHEM, V28, P1779, DOI 10.1021/jm00150a007; BOTT R, 1982, BIOCHEMISTRY-US, V21, P6956, DOI 10.1021/bi00269a052; DREYER GB, 1989, P NATL ACAD SCI USA, V86, P9752, DOI 10.1073/pnas.86.24.9752; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GRINDE B, 1990, ARCH VIROL, V114, P167, DOI 10.1007/BF01310746; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HUI KY, 1987, J MED CHEM, V30, P1287, DOI 10.1021/jm00391a005; HUI KY, 1988, J MED CHEM, V31, P1679, DOI 10.1021/jm00117a003; HUI KY, 1990, PEPTIDES CHEM STRUCT, P399; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JAMES MNG, 1982, P NATL ACAD SCI-BIOL, V79, P6137, DOI 10.1073/pnas.79.20.6137; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KATOH I, 1987, NATURE, V329, P654, DOI 10.1038/329654a0; KAY J, 1985, ASPARTIC PROTEINASES, P401; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAI MT, 1990, RETROVIRAL PROTEASES, P63; LAPATTO P, 1989, NATURE, V342, P299; MACCRINDLE C, 1985, CLIN CHEM, V31, P1487; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088; MARGOLIN N, 1990, BIOCHEM BIOPH RES CO, V167, P554, DOI 10.1016/0006-291X(90)92060-D; MARSHALL GR, 1976, FED PROC, V35, P2494; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Stewart JM, 1984, SOLID PHASE PEPTIDE; SZELKE M, 1982, NATURE, V299, P555, DOI 10.1038/299555a0; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	46	18	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2606	2610		10.1096/fasebj.5.11.1868985	http://dx.doi.org/10.1096/fasebj.5.11.1868985			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868985				2022-12-28	WOS:A1991GB09400016
J	GOUDSMIT, J; BACK, NKT; NARA, PL				GOUDSMIT, J; BACK, NKT; NARA, PL			GENOMIC DIVERSITY AND ANTIGENIC VARIATION OF HIV-1 - LINKS BETWEEN PATHOGENESIS, EPIDEMIOLOGY AND VACCINE DEVELOPMENT	FASEB JOURNAL			English	Review						AIDS VIRUS EVOLUTION; CYTOPATHICITY DETERMINANTS; V3 DOMAIN; NEUTRALIZATION-RESISTANT MUTANTS; VACCINE DEVELOPMENT	HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC LYMPHOCYTE-T; CELL-FUSION INHIBITION; MOUTH-DISEASE VIRUS; INFLUENZA-VIRUS; VISNA VIRUS; B-CELL; NUCLEOTIDE SUBSTITUTION; NEUTRALIZATION EPITOPE; ACID SEQUENCE	Recent analysis of primate lentivirus genomes (1) indicates that lentiviruses have infected primates for hundreds of years. The pathogenicity of such viruses may fluctuate due to the high evolution rate of some parts of the viral genome. Fixed nucleic acid substitutions in the gag gene appear to be caused by random fixation of selectively neutral mutants, whereas nonrandom fixation of selectively advantageous mutants, as has been observed for MHC molecules and serine protease inhibitors, appears to be operational for some hypervariable env gene regions. The former is characterized by an excess of silent mutations independent of the rate of change, the latter by an excess of nonsilent mutations. This latter type of selection may especially characterize the third variable region of the external HIV envelope (V3), which contains the principal neutralization domain.	FREDERICK CANC RES DEV CTR, VIRUS BIOL SECT, FREDERICK, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	GOUDSMIT, J (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, HUMAN RETROVIRUS LAB, MEIBERGDREEF 15, 1105 AZ AMSTERDAM, NETHERLANDS.		Back, Nicole/K-3884-2013; Dr. Peter L. Nara, M.Sc./I-7432-2019					AIR GM, 1990, J VIROL, V64, P5797, DOI 10.1128/JVI.64.12.5797-5803.1990; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BARNETT BC, 1989, EUR J IMMUNOL, V19, P515, DOI 10.1002/eji.1830190316; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BRAUN MJ, 1987, J VIROL, V61, P4046, DOI 10.1128/JVI.61.12.4046-4054.1987; BROWN AL, 1988, AIDS RES HUM RETROV, V4, P399, DOI 10.1089/aid.1988.4.399; BROWN LE, 1988, J VIROL, V62, P305, DOI 10.1128/JVI.62.1.305-312.1988; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DELASSUS S, 1991, J VIROL, V65, P225, DOI 10.1128/JVI.65.1.225-231.1991; EIGEN M, 1990, AIDS (London), V4, pS85; EPSTEIN LG, 1991, VIROLOGY, V180, P583, DOI 10.1016/0042-6822(91)90072-J; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GAINES H, 1987, LANCET, V1, P1317; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOUDSMIT J, 1988, AIDS, V2, P231; GOUDSMIT J, 1986, LANCET, V2, P177; GOUDSMIT J, 1989, RES VIROLOGY, V140, P405, DOI 10.1016/S0923-2516(89)80119-0; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GOUDSMIT J, 1988, VIRAL IMMUNOL, V1, P225; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HIOE CE, 1990, J VIROL, V64, P6246, DOI 10.1128/JVI.64.12.6246-6251.1990; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; KANG CY, 1991, IN PRESS P NATL ACAD; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LASKOWSKI M, 1987, BIOCHEMISTRY-US, V26, P202, DOI 10.1021/bi00375a028; LI WH, 1988, MOL BIOL EVOL, V5, P313; MATEU MG, 1989, P NATL ACAD SCI USA, V86, P5883, DOI 10.1073/pnas.86.15.5883; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MELOEN RH, 1989, J GEN VIROL, V70, P1505, DOI 10.1099/0022-1317-70-6-1505; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; NARA PL, 1991, FASEB J, V5, P2437, DOI 10.1096/fasebj.5.10.1712328; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; NARAYAN O, 1978, J GEN VIROL, V41, P343, DOI 10.1099/0022-1317-41-2-343; NARAYAN O, 1981, INFECT IMMUN, V32, P1045, DOI 10.1128/IAI.32.3.1045-1050.1981; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; PHILPOTT M, 1989, J VIROL, V63, P3453, DOI 10.1128/JVI.63.8.3453-3458.1989; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990; SWEETSER MT, 1989, J EXP MED, V170, P1357, DOI 10.1084/jem.170.4.1357; TAKAHASHI H, 1989, SCIENCE, V246, P118, DOI 10.1126/science.2789433; TAKAHASHI H, 1990, J EXP MED, V171, P571, DOI 10.1084/jem.171.2.571; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; ZWART G, 1990, LANCET, V335, P473; ZWART G, 1991, VIROLOGY, V181, P481, DOI 10.1016/0042-6822(91)90880-K	53	74	74	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2427	2436		10.1096/fasebj.5.10.2065891	http://dx.doi.org/10.1096/fasebj.5.10.2065891			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065891				2022-12-28	WOS:A1991FW08700014
J	HAHNER, L; MCQUILKIN, S; HARRIS, RA				HAHNER, L; MCQUILKIN, S; HARRIS, RA			CEREBELLAR GABA-B RECEPTORS MODULATE FUNCTION OF GABA-A RECEPTORS	FASEB JOURNAL			English	Note						GABA-A RECEPTORS; GABA-B RECEPTORS; CHLORIDE CHANNELS; CEREBELLUM; GUANINE NUCLEOTIDES; PROTEIN PHOSPHORYLATION; PROTEIN KINASE-C; PHOSPHOLIPASE-C	PROTEIN-KINASE-C; INOSITOL PHOSPHATE FORMATION; AMINOBUTYRIC ACID RECEPTORS; CENTRAL-NERVOUS-SYSTEM; RAT CEREBRAL-CORTEX; SYNAPTIC POTENTIALS; CHLORIDE EXCHANGE; FLUX MEASUREMENTS; BRAIN MEMBRANES; SPINAL-CORD	Interactions between GABA(A) and GABA(B) receptors were studied using muscimol-stimulated uptake of Cl-36- by membrane vesicles from mouse cerebellum. Baclofen inhibited muscimol-stimulated Cl-36- uptake and this action was more pronounced with longer flux times (30 vs. 3 s) and after predesensitization of GABA(A) receptors. Baclofen also inhibited Cl-36- flux by cortical membranes but was more effective with cerebellar preparations. The action of baclofen was stereoselective, calcium-dependent, and blocked by the GABA(B) receptor antagonist 2-OH-saclofen. It was mimicked by GTP-gamma-S but not by GDP-beta-S, which suggests that baclofen may be acting via a G protein. The action of baclofen was inhibited by U73122, an inhibitor of phospholipase C. However, the potassium channel blockers tetraethylammonium or Ba2+ did not affect the action of baclofen. The results show that activation of GABA(B) receptors can inhibit the function of GABA(A) receptors and suggest that this action involves either a nondesensitizing subtype of GABA(A) receptor or the rate of recycling of desensitized to nondesensitized receptors. We speculate that this action of baclofen results from activation of phospholipase C and phosphorylation of a subtype of GABA(A) receptor by protein kinase C.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,CAMPUS BOX C-236,4200 E 9TH AVE,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIAAA NIH HHS [AA03527, AA06399] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, P50AA003527, R37AA006399] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGEY MW, 1989, BIOCHEMISTRY-US, V28, P4200, DOI 10.1021/bi00436a012; ALLAN AM, 1989, LIFE SCI, V45, P1771, DOI 10.1016/0024-3205(89)90516-X; ALLAN AM, 1991, IN PRESS ALCOHOLISM; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BOWERY N, 1989, TRENDS PHARMACOL SCI, V10, P401, DOI 10.1016/0165-6147(89)90188-0; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; CASH DJ, 1987, BIOCHEMISTRY-US, V26, P7556, DOI 10.1021/bi00398a004; CASH DJ, 1989, J MEMBRANE BIOL, V111, P229, DOI 10.1007/BF01871008; CASTRO E, 1989, J NEUROSCI RES, V23, P290, DOI 10.1002/jnr.490230307; CRAWFORD MLA, 1988, J NEUROCHEM, V51, P1441, DOI 10.1111/j.1471-4159.1988.tb01109.x; CRAWFORD MLA, 1990, BRIT J PHARMACOL, V100, P867, DOI 10.1111/j.1476-5381.1990.tb14106.x; DESARMENIEN M, 1984, BRIT J PHARMACOL, V81, P327, DOI 10.1111/j.1476-5381.1984.tb10082.x; DINGLEDINE R, 1985, J PHYSIOL-LONDON, V366, P387, DOI 10.1113/jphysiol.1985.sp015804; DOLPHIN AC, 1989, BRIT J PHARMACOL, V97, P263, DOI 10.1111/j.1476-5381.1989.tb11950.x; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FALCH E, 1982, J NEUROCHEM, V38, P1123, DOI 10.1111/j.1471-4159.1982.tb05357.x; GALLAGHER JP, 1989, J PHYSIOL-LONDON, V418, P367, DOI 10.1113/jphysiol.1989.sp017846; GODFREY PP, 1988, EUR J PHARMACOL, V152, P185, DOI 10.1016/0014-2999(88)90854-0; HARRIS RA, 1985, SCIENCE, V228, P1108, DOI 10.1126/science.2581319; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; HARRISON NL, 1988, NEUROSCI LETT, V85, P105, DOI 10.1016/0304-3940(88)90437-5; HOWE JR, 1987, J PHYSIOL-LONDON, V384, P539, DOI 10.1113/jphysiol.1987.sp016469; KAMATCHI GL, 1990, MOL PHARMACOL, V38, P342; KARDOS J, 1990, J NEUROCHEM, V55, P1095, DOI 10.1111/j.1471-4159.1990.tb03110.x; KARDOS J, 1989, BIOCHEM PHARMACOL, V38, P2587, DOI 10.1016/0006-2952(89)90542-X; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEIDENHEIMER NJ, 1990, MOL PHARMACOL, V38, P823; LI XH, 1990, NEUROCHEM RES, V15, P725, DOI 10.1007/BF00973654; MEHTA AK, 1990, EUR J PHARMACOL, V182, P473, DOI 10.1016/0014-2999(90)90044-7; NISHIO M, 1990, BRAIN RES, V518, P283, DOI 10.1016/0006-8993(90)90982-H; OLSEN RW, 1978, BRAIN RES, V139, P277, DOI 10.1016/0006-8993(78)90929-0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1990, J CHEM NEUROANAT, V3, P59; PRICE GW, 1984, NATURE, V307, P71, DOI 10.1038/307071a0; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; YASUI S, 1985, BRAIN RES, V344, P176, DOI 10.1016/0006-8993(85)91206-5	38	43	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2466	2472		10.1096/fasebj.5.10.1648524	http://dx.doi.org/10.1096/fasebj.5.10.1648524			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	1648524				2022-12-28	WOS:A1991FW08700018
J	HASELTINE, WA				HASELTINE, WA			MOLECULAR-BIOLOGY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	FASEB JOURNAL			English	Review						AIDS; HIV-1 PATHOGENESIS; HIV-1 REPLICATION; GENE CONTROL OF HIV-1	LONG TERMINAL REPEAT; OPEN READING FRAME; T-CELL ACTIVATION; VIRION-ASSOCIATED PROTEIN; MURINE LEUKEMIA-VIRUS; VIRAL MESSENGER-RNA; REV TRANS-ACTIVATOR; III HTLV-III/LAV; TAT PROTEIN; ENVELOPE GLYCOPROTEIN	The immunodeficiency virus type 1 is a complex retrovirus. In addition to genes that specify the proteins of the virus particle and the replicative enzymes common to all retroviruses, HIV-1 specifies at least six additional proteins that regulate the virus life cycle. Two of these regulatory genes, tat and rev, specify proteins essential for replication. These proteins bind to specific sequences of newly synthesized virus RNA and profoundly affect virus protein expression. Tat and rev appear to be prototypes of novel eukaryotic regulatory proteins. These two genes may play a central role in regulating the rate of virus replication. Three other viral genes, vif, vpu, and vpr, affect the assembly and replication capacity of newly made virus particles. These genes may play a critical role in spread of the virus from tissue to tissue and from person to person. Our understanding of the contribution of each of the virus structural proteins and regulatory genes to the complex life cycle of the virus in natural infections is incomplete. However, enough insight has been gained into the structure and function of each of these components to provide a firm basis for rational antiviral drug development.			HASELTINE, WA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ALLEN JS, 1985, SCIENCE, V228, P1091; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BARRY PA, 1991, J VIROL, V65, P1392, DOI 10.1128/JVI.65.3.1392-1399.1991; BOLOGNESI DP, 1978, SCIENCE, V199, P183, DOI 10.1126/science.202022; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COCHRANE A, 1989, VIROLOGY, V171, P264, DOI 10.1016/0042-6822(89)90535-7; COHEN EA, 1988, NATURE, V334, P532, DOI 10.1038/334532a0; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEDERA D, 1989, J VIROL, V63, P3205, DOI 10.1128/JVI.63.7.3205-3208.1989; DEROSSI A, 1986, P NATL ACAD SCI USA, V83, P4297, DOI 10.1073/pnas.83.12.4297; DREYER GG, 1989, P NATL ACAD SCI USA, V86, P9737; EMERMAN M, 1989, CELL, V57, P115; FARNET C, 1991, IN PRESS J VIROL; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GELDERBLOM H, 1987, VIROLOGY, V168, P171; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GOTTLINGER HG, 1991, IN PRESS P NATL ACAD, V88; GUATELLI JC, 1990, J VIROL, V64, P4093, DOI 10.1128/JVI.64.9.4093-4098.1990; GUY B, 1991, J VIROL, V65, P1325, DOI 10.1128/JVI.65.3.1325-1331.1991; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KATZ R, 1991, CELL, V63, P87; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; KOWALSKI M, 1991, J VIROL, V65, P281, DOI 10.1128/JVI.65.1.281-291.1991; KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163; LANGHOFF E, 1991, IN PRESS P NATL ACAD; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LU YC, 1990, J VIROL, V64, P5226, DOI 10.1128/JVI.64.10.5226-5229.1990; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARIE C, 1986, J VIROL, V60, P450; MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; OROSZLAN S, 1990, CURRENT TOPICS MICRO; PAL R, 1990, AIDS RES HUM RETROV, V6, P721, DOI 10.1089/aid.1990.6.721; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; PONANSKY M, 1991, J VIROL, V65, P532; POPOVIC MMG, 1984, SCIENCE, V224, P297; RAPPAPORT J, 1989, New Biologist, V1, P101; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROBEY WG, 1985, SCIENCE, V228, P593, DOI 10.1126/science.2984774; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; RUBEN S, 1989, J VIROL, V63, P1; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHUPBACH J, 1984, SCIENCE, V224, P503, DOI 10.1126/science.6200937; SCHWARTZ S, 1990, J VIROL, V64, P5448, DOI 10.1128/JVI.64.11.5448-5456.1990; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P8526, DOI 10.1073/pnas.86.21.8526; SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TRAUNECKER A, 1988, NATURE, V331, P64; VARMUS H, 1985, RNA TUMOR VIRUSES, P75; VENKATESH LK, 1990, VIROLOGY, V176, P39, DOI 10.1016/0042-6822(90)90228-J; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WILSON W, 1988, CELL, V55, P1159, DOI 10.1016/0092-8674(88)90260-7; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; YASUDA Y, 1990, J ACQ IMMUN DEF SYND, V3, P1046; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	120	136	148	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2349	2360		10.1096/fasebj.5.10.1829694	http://dx.doi.org/10.1096/fasebj.5.10.1829694			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	1829694				2022-12-28	WOS:A1991FW08700005
J	CELIS, JE; RASMUSSEN, HH; LEFFERS, H; MADSEN, P; HONORE, B; GESSER, B; DEJGAARD, K; VANDEKERCKHOVE, J				CELIS, JE; RASMUSSEN, HH; LEFFERS, H; MADSEN, P; HONORE, B; GESSER, B; DEJGAARD, K; VANDEKERCKHOVE, J			HUMAN CELLULAR PROTEIN-PATTERNS AND THEIR LINK TO GENOME DNA-SEQUENCE DATA - USEFULNESS OF 2-DIMENSIONAL GEL-ELECTROPHORESIS AND MICROSEQUENCING	FASEB JOURNAL			English	Article						HUMAN PROTEIN PATTERNS; 2-DIMENSIONAL GEL PROTEIN DATABASES; GENE EXPRESSION; MICROSEQUENCING; CDNA CLONING; LINKING PROTEIN AND DNA INFORMATION; GENOME MAPPING AND SEQUENCING	POLYVINYLIDENE DIFLUORIDE MEMBRANES; TWO-DIMENSIONAL GELS; COATED GLASS-FIBER; POLYACRYLAMIDE GELS; PICOMOLE QUANTITIES; DATABASES; DIGESTION	Analysis of cellular protein patterns by computer-aided 2-dimensional gel electrophoresis together with recent advances in protein sequence analysis have made possible the establishment of comprehensive 2-dimensional gel protein database that may link protein and DNA information and that offer a global approach to the study of the cell. Using the integrated approach offered by 2-dimensional gel protein databases it is now possible to reveal phenotype specific protein (or proteins), to microsequence them, to search for homology with previously identified proteins, to clone the cDNAs, to assign partial protein sequence to genes for which the full DNA sequence and the chromosome location is known, and to study the regulatory properties and function of groups of proteins that are coordinately expressed in a given biological process. Human 2-dimensional gel protein databases are becoming increasingly important in view of the concerted effort to map and sequence the entire genome.	AARHUS UNIV, HUMAN GENOME RES CTR, DK-8000 AARHUS, DENMARK	Aarhus University	CELIS, JE (corresponding author), AARHUS UNIV, INST MED BIOCHEM, OLE WORMS ALLE, BLDG 170, UNIV PK, DK-8000 AARHUS, DENMARK.		Honoré, Bent/ABF-3650-2021	Madsen, Peder Sondergaard/0000-0002-8845-4802; Honore, Bent/0000-0002-3459-7429				AEBERSOLD R, 1990, ELECTROPHORESIS, V11, P517, DOI 10.1002/elps.1150110702; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AEBERSOLD RH, 1986, J BIOL CHEM, V261, P4229; ANDERSON NG, 1982, CLIN CHEM, V28, P739; ANDERSON NL, 1984, CLIN CHEM, V30, P2031; APPEL R, 1988, ELECTROPHORESIS, V9, P136, DOI 10.1002/elps.1150090307; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1988, J PROTEIN CHEM, V7, P194; BAUW G, 1990, ELECTROPHORESIS, V11, P528, DOI 10.1002/elps.1150110703; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; Celis J, 1984, 2 DIMENSIONAL GEL EL; CELIS JE, 1989, FEBS LETT, V244, P247, DOI 10.1016/0014-5793(89)80538-1; CELIS JE, 1990, BIOESSAYS, V12, P93, DOI 10.1002/bies.950120209; CELIS JE, 1990, ELECTROPHORESIS, V11, P1072, DOI 10.1002/elps.1150111203; CELIS JE, 1988, LEUKEMIA, V2, P561; CELIS JE, 1990, ELECTROPHORESIS, V11, P242, DOI 10.1002/elps.1150110308; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CELIS JE, 1989, ELECTROPHORESIS, V10, P76, DOI 10.1002/elps.1150100204; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CELIS JE, 1989, ELECTROPHORESIS, V2; CELIS JE, 1989, ADV ELECTROPHORESIS; Celis JE, 1990, ELECTROPHORESIS, V11; ECKERSKORN C, 1990, ELECTROPHORESIS, V11, P554, DOI 10.1002/elps.1150110705; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GARRELS JI, 1990, ELECTROPHORESIS, V11, P1114, DOI 10.1002/elps.1150111204; GARRELS JI, 1984, 2 DIMENSIONAL GEL EL, P37; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KENNEDY TE, 1988, P NATL ACAD SCI USA, V85, P7008, DOI 10.1073/pnas.85.18.7008; LEMKIN PF, 1989, ELECTROPHORESIS, V10, P122, DOI 10.1002/elps.1150100207; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER MJ, 1989, ADV ELECTROPHORESIS, V3, P182; MOOS M, 1988, J BIOL CHEM, V263, P6005; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSON AD, 1988, ANAL BIOCHEM, V169, P49, DOI 10.1016/0003-2697(88)90255-2; RASMUSSEN HH, 1991, ADV LIF SCI, P103; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; VANBOGELEN RA, 1990, ELECTROPHORESIS, V11, P1131, DOI 10.1002/elps.1150111205; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x; VINCENS P, 1988, INT J BIOCHEM, V20, P499, DOI 10.1016/0020-711X(88)90498-3; VINCENS P, 1986, ELECTROPHORESIS, V7, P347, DOI 10.1002/elps.1150070802; Weber K., 1975, PROTEINS, VI, P179; 1982, CLIN CHEM, V28; [No title captured]	46	51	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2200	2208		10.1096/fasebj.5.8.1827083	http://dx.doi.org/10.1096/fasebj.5.8.1827083			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1827083				2022-12-28	WOS:A1991FK11100013
J	VARKI, A				VARKI, A			RADIOACTIVE-TRACER TECHNIQUES IN THE SEQUENCING OF GLYCOPROTEIN OLIGOSACCHARIDES	FASEB JOURNAL			English	Article						SURFACE LABELING; MONOSACCHARIDE PRECURSOR; GLYCOSYLATION; ISOTOPE; METABOLIC PATHWAY; NUCLEOTIDE; SEQUENTIAL CHROMATOGRAPHY	ASPARAGINE-LINKED OLIGOSACCHARIDES; GLYCANASE-RELEASED OLIGOSACCHARIDES; PERFORMANCE LIQUID-CHROMATOGRAPHY; MAGNETIC-RESONANCE SPECTROSCOPY; LECTIN AFFINITY-CHROMATOGRAPHY; COMPLEX-TYPE OLIGOSACCHARIDES; MANNOSE-TYPE OLIGOSACCHARIDES; VIRUS-G PROTEIN; STRUCTURAL-ANALYSIS; DICTYOSTELIUM-DISCOIDEUM	Complete sequencing of the oligosaccharide units of glycoproteins can be performed by conventional physical techniques if nanomole quantities of pure molecules are available. However, isolation of sufficient quantities of a glycoprotein may not be technically feasible (e.g., the analysis of biosynthetic intermediates, or rare molecules). Alternatively, partial structural analyses may answer the biological question at hand. In both instances, radioactive sugars can be used to metabolically label the oligosaccharide units of a glycoprotein, permitting substantial structural characterization. Several aspects of this approach are discussed in this overview, including selection of the labeled precursor, maximization of uptake and incorporation, determinants of the specificity of labeling, and general principles for the release and structural analysis of labeled oligosaccharides. Particular advantages include simplicity, ease of use without sophisticated instrumentation, and the fact that purification to radiometric homogeneity is sufficient. Radioactive tracer techniques cannot replace conventional approaches to sequencing oligosaccharides. However, they do provide a rapid, relatively simple approach to obtaining considerable information from limited amounts of material. For molecules such as short-lived biosynthetic intermediates, there is no substitute for these techniques. This approach has been responsible for the initial identification and characterization of many novel oligosaccharides of biological interest.	UNIV CALIF SAN DIEGO, DEPT MED, DIV HEMATOL ONCOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	VARKI, A (corresponding author), UNIV CALIF SAN DIEGO, CTR CANC, CANC BIOL PROGRAM, LA JOLLA, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI023287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-38701] Funding Source: Medline; NIAID NIH HHS [P01 AI23287] Funding Source: Medline; NIGMS NIH HHS [R01-GM-32373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER S, 1984, SCIENCE, V226, P1328, DOI 10.1126/science.6505693; ALEXANDER S, 1989, METHOD ENZYMOL, V179, P505; AMANO J, 1989, METHOD ENZYMOL, V179, P261; CEBON J, 1990, J BIOL CHEM, V265, P4483; CHAN JY, 1979, J BIOL CHEM, V254, P7060; COWAN EP, 1982, J BIOL CHEM, V257, P1241; CREEK KE, 1987, ARCH BIOCHEM BIOPHYS, V254, P482, DOI 10.1016/0003-9861(87)90127-5; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; CUMMINGS RD, 1989, METHOD CELL BIOL, V32, P141; DAHMS NM, 1985, J IMMUNOL, V134, P3978; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; DUBE S, 1988, J BIOL CHEM, V263, P17516; FLEISCHER B, 1989, METHOD ENZYMOL, V174, P173; FREEZE HH, 1989, J BIOL CHEM, V264, P5653; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FUKUDA M, 1989, METHOD ENZYMOL, V179, P17; GABEL CA, 1989, J VIROL, V63, P4264, DOI 10.1128/JVI.63.10.4264-4276.1989; GAHMBERG CG, 1982, BIOCHIM BIOPHYS ACTA, V651, P65, DOI 10.1016/0304-419X(82)90007-5; GEYER H, 1988, J BIOL CHEM, V263, P11760; GOLDBERG DE, 1981, J BIOL CHEM, V256, P3060; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GOWDA DC, 1986, J BIOL CHEM, V261, P4935; GREEN ED, 1987, J BIOL CHEM, V262, P12018; GREEN ED, 1987, ANAL BIOCHEM, V167, P62, DOI 10.1016/0003-2697(87)90134-5; GREEN ED, 1986, J BIOL CHEM, V261, P6309; HARADA H, 1987, ANAL BIOCHEM, V164, P374, DOI 10.1016/0003-2697(87)90507-0; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HASILIK A, 1980, J BIOL CHEM, V255, P4946; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HSIEH P, 1983, J BIOL CHEM, V258, P2548; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HULL SR, 1984, J BIOL CHEM, V259, P4866; ITO M, 1989, METHOD ENZYMOL, V179, P488; KAUFMAN RL, 1968, EXP CELL RES, V50, P127, DOI 10.1016/0014-4827(68)90400-X; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KORNFELD S, 1978, J BIOL CHEM, V253, P7771; LAZZARINO DA, 1989, J BIOL CHEM, V264, P5015; LI E, 1978, J BIOL CHEM, V253, P7762; LI YT, 1989, METHOD ENZYMOL, V179, P479; LIU T, 1979, J BIOL CHEM, V254, P4554; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MUCHMORE EA, 1989, J BIOL CHEM, V264, P20216; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; NYAME K, 1989, J BIOL CHEM, V264, P3235; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; POWELL LD, 1987, J IMMUNOL, V139, P1206; REARICK JI, 1981, J BIOL CHEM, V256, P6255; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROSNER MR, 1982, METHOD ENZYMOL, V83, P399; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAIRAM MR, 1989, FASEB J, V3, P1915, DOI 10.1096/fasebj.3.8.2542111; SHEN L, 1967, ARCH BIOCHEM BIOPHYS, V122, P474, DOI 10.1016/0003-9861(67)90221-4; SILBERT CK, 1989, ARCH BIOCHEM BIOPHYS, V268, P393, DOI 10.1016/0003-9861(89)90600-0; SWEELEY CC, 1985, ANNU REV BIOCHEM, V54, P765, DOI 10.1146/annurev.biochem.54.1.765; SZILAGYI PJ, 1985, ANAL BIOCHEM, V148, P260, DOI 10.1016/0003-2697(85)90655-4; TABAS I, 1980, J BIOL CHEM, V255, P6633; TABAS I, 1982, METHOD ENZYMOL, V83, P416; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; THONAR EJMA, 1983, J BIOL CHEM, V258, P1564; TOWNSEND RR, 1989, METHOD ENZYMOL, V179, P65; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P847; VIJAY IK, 1982, EUR J BIOCHEM, V126, P167, DOI 10.1111/j.1432-1033.1982.tb06762.x; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WHITEHEART SW, 1989, METHOD ENZYMOL, V179, P82; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; Yurchenco P D, 1978, Methods Enzymol, V50, P175	80	68	77	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1991	5	2					226	235		10.1096/fasebj.5.2.2004668	http://dx.doi.org/10.1096/fasebj.5.2.2004668			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004668				2022-12-28	WOS:A1991EZ00200014
J	FERGUSONSMITH, MA				FERGUSONSMITH, MA			EUROPEAN APPROACH TO THE HUMAN GENE PROJECT	FASEB JOURNAL			English	Article						GENETIC MAPPING; RECOMBINANT DNA TECHNOLOGY; HUMAN GENETIC MAP; DATABASE; GENOME SEQUENCING PROJECT	GENOME	In the history of gene mapping, which extends through most of the present century, Europe has played an important role. This has continued during the evolution of the 10 International Human Gene Mapping Workshops that have been held in seven different countries since 1973. Nationally coordinated programs have been a recent development, and several European countries, including the United Kingdom and Italy, have followed the lead of the United States in investing substantial sums of money in research on the human genome. In addition, the European Community has launched a multi-national program of research on Human Genome Analysis to complement the various national initiatives. The particular approach in Europe has been to support those in the field by establishing resource centers for distributing biomaterials and accessing databases, by assisting in the training of scientists, and by funding programs of research directed at present needs in both physical and genetic mapping.			FERGUSONSMITH, MA (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND.							ALWEN J, 1990, GENOMICS, V6, P386, DOI 10.1016/0888-7543(90)90582-F; BARNHART BJ, 1989, GENOMICS, V5, P657, DOI 10.1016/0888-7543(89)90041-4; BODMER WF, 1991, FASEB J, V5, P73, DOI 10.1096/fasebj.5.1.1991589; COUTELLE C, 1990, GENOMICS, V8, P182, DOI 10.1016/0888-7543(90)90244-O; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DULBECCO R, 1990, GENOMICS, V7, P294, DOI 10.1016/0888-7543(90)90555-9; MCKUSICK VA, 1989, GENOMICS, V5, P385, DOI 10.1016/0888-7543(89)90077-3; WATSON JD, 1989, GENOMICS, V5, P654, DOI 10.1016/0888-7543(89)90040-2	8	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					61	65		10.1096/fasebj.5.1.1991586	http://dx.doi.org/10.1096/fasebj.5.1.1991586			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991586				2022-12-28	WOS:A1991ET60900010
J	MILLER, RJ				MILLER, RJ			RECEPTOR-MEDIATED REGULATION OF CALCIUM CHANNELS AND NEUROTRANSMITTER RELEASE	FASEB JOURNAL			English	Review						2ND MESSENGER; NEUROTRANSMITTER RELEASE; G PROTEIN; PRESYNAPTIC INHIBITION; K+ CHANNELS	GTP-BINDING-PROTEIN; ROOT GANGLION NEURONS; PRESYNAPTIC INHIBITION; SENSORY NEURONS; SYMPATHETIC NEURONS; CA-2+ CURRENT; TRANSMITTER RELEASE; HIPPOCAMPAL-NEURONS; PERIPHERAL NEURONS; POTASSIUM CHANNELS	Ca2+ influx into the nerve terminal is normally the trigger for the release of neurotransmitters. Many neurons possess presynaptic receptors whose activation results in changes in the quantity of neurotransmitter released by an action potential. This paper reviews studies that show that presynaptic receptors can regulate the activity of Ca2+ channels in the nerve terminal, resulting in changes in the influx of Ca2+ and in neurotransmitter release. Neurons possess several different types of voltage-sensitive Ca2+ channels. Ca2+ influx through N-type channels appears to trigger transmitter release in many instances. In other cases Ca2+ influx through L channels can influence transmitter release. Neurotransmitters can inhibit N channels through a G protein-mediated transduction mechanism. The G proteins are frequently pertussis toxin substrates. Inhibition of N channels appears to involve changes in their voltage dependence. Neurotransmitters can also regulate neuronal K+ channels. Activation of these K+ channels can lead to a reduction in Ca2+ influx and neurotransmitter release; these effects are also mediated by G proteins. Thus neurotransmitters may often regulate both presynaptic Ca2+ and K+ channels. These two effects may be synergistic mechanisms for the regulation of Ca2+ influx and neurotransmitter release.			MILLER, RJ (corresponding author), UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH040165, R01MH040165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121, R01DA002575] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-02121, DA-02575] Funding Source: Medline; NIMH NIH HHS [MH-40165] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON AJ, 1987, NEUROSCI LETT, V82, P177, DOI 10.1016/0304-3940(87)90125-X; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BELARDETTI F, 1988, TRENDS NEUROSCI, V11, P232, DOI 10.1016/0166-2236(88)90132-4; BELARDETTI F, 1987, NATURE, V325, P153, DOI 10.1038/325153a0; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; BLEY KR, 1990, NEURON, V3, P379; BREZINA V, 1988, J PHYSIOL-LONDON, V407, P15, DOI 10.1113/jphysiol.1988.sp017401; BREZINA V, 1989, J GEN PHYSIOL, V94, P1; BREZINA V, 1988, CALCIUM ION CHANNEL, P275; BROWN DA, 1990, ANNU REV PHYSIOL, V52, P215; BUG W, 1989, Society for Neuroscience Abstracts, V15, P177; COLMERS WF, 1989, BRAIN RES, V498, P99, DOI 10.1016/0006-8993(89)90403-4; COLMERS WF, 1988, NEUROSCI LETT, V93, pL300; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DOERNER D, 1988, J NEUROSCI, V8, P4069; DOERNER D, 1988, NEURON, V1, P693, DOI 10.1016/0896-6273(88)90168-7; DOLPHIN AC, 1985, NATURE, V316, P148, DOI 10.1038/316148a0; DOLPHIN AC, 1988, PFLUG ARCH EUR J PHY, V411, P628, DOI 10.1007/BF00580858; DOLPHIN AC, 1987, J PHYSIOL-LONDON, V386, P1; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; DUNLAP K, 1978, NATURE, V276, P837, DOI 10.1038/276837a0; DUNLAP K, 1987, TRENDS NEUROSCI, V10, P241, DOI 10.1016/0166-2236(87)90166-4; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; EDMONDS B, 1990, IN PRESS SCIENCE; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; FORSCHER P, 1986, J PHYSIOL-LONDON, V379, P131, DOI 10.1113/jphysiol.1986.sp016244; GOTTMANN K, 1990, NEUROSCI LETT, V110, P34, DOI 10.1016/0304-3940(90)90783-6; GRAY R, 1988, Society for Neuroscience Abstracts, V14, P68; GRAY R, 1987, NATURE, V327, P620, DOI 10.1038/327620a0; GREEN KA, 1988, BRIT J PHARMACOL, V94, P235, DOI 10.1111/j.1476-5381.1988.tb11520.x; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; GROSS RA, 1987, P NATL ACAD SCI USA, V84, P5469, DOI 10.1073/pnas.84.15.5469; GROSS RA, 1990, J MOL PHARMACOL, V37, P546; HARRISON NL, 1990, IN PRESS J PHYSL LON; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HIRNING LD, 1990, IN PRESS BRAIN RES; HOLZ GG, 1989, J NEUROSCI, V9, P657; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; IKEDA SR, 1987, NEUROSCI LETT, V81, P123, DOI 10.1016/0304-3940(87)90351-X; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KASEI H, 1989, PFLUEGERS ARCH, V414, P145; KONGSAMUT S, 1986, P NATL ACAD SCI USA, V83, P2243, DOI 10.1073/pnas.83.7.2243; KRETZ R, 1986, J NEUROPHYSIOL, V55, P131, DOI 10.1152/jn.1986.55.1.131; KRETZ R, 1986, J NEUROPHYSIOL, V55, P1131; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LINDGREN CA, 1989, J PHYSIOL-LONDON, V414, P201, DOI 10.1113/jphysiol.1989.sp017684; LIPSCOMBE D, 1989, NATURE, V340, P637; LLINAS RR, 1989, ANN NY ACAD SCI, V560, P103, DOI 10.1111/j.1749-6632.1989.tb24084.x; MANSONHING H, 1989, NATURE, V341, P237, DOI 10.1038/341237a0; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MIDDLEMISS D, 1988, NATURE, V314, P94; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MILLER RJ, 1987, STRUCTURE PHYSL SLOW, P161; MILLER RJ, 1990, IN PRESS INTRACELLUL; MUDGE AW, 1979, P NATL ACAD SCI USA, V76, P527; NAKAJIMA S, 1989, Society for Neuroscience Abstracts, V15, P176; NAKAJIMA Y, 1988, P NATL ACAD SCI USA, V85, P3643, DOI 10.1073/pnas.85.10.3643; NGSEE JK, 1990, J NEUROSCI, V10, P317; Nicoll R A, 1979, Int Rev Neurobiol, V21, P217; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PENINGTON NJ, 1990, NEURON, V4, P751, DOI 10.1016/0896-6273(90)90201-P; PERNEY TM, 1986, P NATL ACAD SCI USA, V83, P6656, DOI 10.1073/pnas.83.17.6656; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; RANE SG, 1987, PFLUG ARCH EUR J PHY, V409, P361, DOI 10.1007/BF00583789; REBER BFX, 1990, IN PRESS NEUROCHEM I; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHOFIELD GG, 1988, EUR J PHARMACOL, V151, P131, DOI 10.1016/0014-2999(88)90702-9; SCHROEDER JE, 1990, J NEUROSCI, V10, P947; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHAPIRO E, 1980, P NATL ACAD SCI-BIOL, V77, P1185, DOI 10.1073/pnas.77.2.1185; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; STANLEY EF, 1989, BRAIN RES, V505, P341, DOI 10.1016/0006-8993(89)91465-0; STARKE K, 1987, REV PHYSIOL BIOCH P, V107, P73, DOI 10.1007/BFb0027645; TRATTON KR, 1989, BRAIN RES, V494, P359; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; ULLRICH S, 1988, J BIOL CHEM, V263, P8615; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; USOWICZ MM, 1990, IN PRESS J PHYSL LON; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; VOLTERRA AC, 1988, P NATL ACAD SCI USA, V5, P7810; WANKE E, 1987, P NATL ACAD SCI USA, V84, P4313, DOI 10.1073/pnas.84.12.4313; WILEY JW, 1990, J NEUROPHYSIOL, V63, P1499, DOI 10.1152/jn.1990.63.6.1499	97	134	134	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1990	4	15					3291	3299		10.1096/fasebj.4.15.1979294	http://dx.doi.org/10.1096/fasebj.4.15.1979294			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EN696	1979294				2022-12-28	WOS:A1990EN69600004
J	MAGUIRE, JE; MCCARTHY, SA; SINGER, A; SINGER, DS				MAGUIRE, JE; MCCARTHY, SA; SINGER, A; SINGER, DS			INVERSE CORRELATION BETWEEN STEADY-STATE RNA AND CELL-SURFACE T-CELL RECEPTOR LEVELS	FASEB JOURNAL			English	Article									NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KRISSANSEN GW, 1987, J IMMUNOL, V138, P3513; Maniatis T., 1982, MOL CLONING; MCCARTHY SA, 1988, NATURE, V336, P76, DOI 10.1038/336076a0; SAMELSON LE, 1985, NATURE, V315, P765, DOI 10.1038/315765a0; VANDENELSEN P, 1985, NATURE, V314, P542, DOI 10.1038/314542a0; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YOSHIKAI Y, 1984, NATURE, V310, P506, DOI 10.1038/310506a0	14	26	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1990	4	13					3131	3134		10.1096/fasebj.4.13.1698681	http://dx.doi.org/10.1096/fasebj.4.13.1698681			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EC625	1698681				2022-12-28	WOS:A1990EC62500009
J	KIBAT, PG; IGARI, Y; WHEATLEY, MA; EISEN, HN; LANGER, R				KIBAT, PG; IGARI, Y; WHEATLEY, MA; EISEN, HN; LANGER, R			ENZYMATICALLY ACTIVATED MICROENCAPSULATED LIPOSOMES CAN PROVIDE PULSATILE DRUG RELEASE	FASEB JOURNAL			English	Article									MIT, DEPT CHEM ENGN, 77 MASSACHUSETTS AVE, E25-342, CAMBRIDGE, MA 02139 USA; MIT, DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, WHITAKER COLL HLTH SCI TECHNOL & MANAGEMENT, CAMBRIDGE, MA 02139 USA; CHILDRENS HOSP MED CTR, DEPT SURG, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital					PHS HHS [A1 24764, 26698, A1 25901] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson J.M., 1984, RECENT ADV DRUG DELI; BANGHAM AD, 1974, METHODS MEMBRANE BIO, V1, P1; BLACK CDV, 1976, BIOCHEM SOC T, V4, P253; DAVIS SS, 1986, SITE SPECIFIC DRUG D, V93, P93; Dennis EA, 1983, ENZYMES, P307; GREGORIA.G, 1971, FEBS LETT, V14, P95, DOI 10.1016/0014-5793(71)80109-6; JAIN MK, 1985, BIOCHIM BIOPHYS ACTA, V814, P313, DOI 10.1016/0005-2736(85)90450-X; KIBAT PG, 1986, PHARM IND, V48, P1184; LANGER RS, 1974, MED APPLICATIONS CON, V1; LANGER RS, 1974, MED APPLICATIONS CON, V2; LICHTENBERG D, 1985, COLLOID SURFACE, V14, P293; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; SENIOR JH, 1987, CRC CR REV THER DRUG, V3, P123; SUN AM, 1984, APPL BIOCHEM BIOTECH, V10, P87, DOI 10.1007/BF02783739; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TYRRELL DA, 1977, BIOCHIM BIOPHYS ACTA, V497, P469, DOI 10.1016/0304-4165(77)90204-5	16	38	52	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1990	4	8					2533	2539		10.1096/fasebj.4.8.2110539	http://dx.doi.org/10.1096/fasebj.4.8.2110539			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DE393	2110539				2022-12-28	WOS:A1990DE39300015
J	RILEY, DA; ILYINAKAKUEVA, EI; ELLIS, S; BAIN, JLW; SLOCUM, GR; SEDLAK, FR				RILEY, DA; ILYINAKAKUEVA, EI; ELLIS, S; BAIN, JLW; SLOCUM, GR; SEDLAK, FR			SKELETAL-MUSCLE FIBER, NERVE, AND BLOOD-VESSEL BREAKDOWN IN SPACE-FLOWN RATS	FASEB JOURNAL			English	Article									MINIST PUBL HLTH USSR,INST BIOMED PROBLEMS,MOSCOW,USSR; SAN JOSE STATE UNIV,DEPT CHEM,SAN JOSE,CA 95192	Russian Academy of Sciences; Institute of Biomedical Problems of the Russian Academy of Sciences; California State University System; San Jose State University	RILEY, DA (corresponding author), MED COLL WISCONSIN,DEPT ANAT & CELLULAR BIOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.							ARMSTRONG RB, 1983, J APPL PHYSIOL, V54, P80, DOI 10.1152/jappl.1983.54.1.80; BAGGIOLINI M, 1980, HDB INFLAMMATION CEL, V2, P163; BARANSKI S, 1979, AVIAT SPACE ENVIR MD, V50, P930; BENTON EV, 1979, HLTH PHYS, V35, P643; BISCHOFF R, 1986, DEV BIOL, V115, P140, DOI 10.1016/0012-1606(86)90235-6; DENNYBROWN D, 1951, J NEUROPATH EXP NEUR, V10, P94; FITTS RH, 1986, J APPL PHYSIOL, V60, P1946, DOI 10.1152/jappl.1986.60.6.1946; GRINDELAND RE, 1990, FASEB J, V4, P10, DOI 10.1096/fasebj.4.1.2403949; GUBA F, 1977, ACTA BIOL MED GER, V36, P1605; GULATI AK, 1987, J NEUROL SCI, V78, P111, DOI 10.1016/0022-510X(87)90083-9; HAAS AL, 1988, UBIQUITIN, P173; HIKIDA RS, 1989, AVIAT SPACE ENVIR MD, V60, P664; ILYINAKAKUEVA EI, 1981, KOSM BIOL AVIAK MED+, V15, P37; ILYINAKAKUEVA EI, 1987, KOSM BIOL AVIAK MED+, V21, P31; ILYINAKAKUEVA EI, 1977, AVIAT SPACE ENVIR MD, V48, P115; ILYINAKAKUEVA EI, 1976, AVIAT SPACE ENVIR MD, V47, P700; IP MC, 1983, NEUROSCIENCE, V10, P1463, DOI 10.1016/0306-4522(83)90127-6; IRINTCHEV A, 1987, CELL TISSUE RES, V249, P509; LI JB, 1976, AM J PHYSIOL, V231, P441, DOI 10.1152/ajplegacy.1976.231.2.441; MAKI T, 1986, MUSCLE NERVE, V9, P394, DOI 10.1002/mus.880090503; MARTIN TP, 1988, J APPL PHYSIOL, V65, P2318, DOI 10.1152/jappl.1988.65.5.2318; MATSUBARA S, 1987, ACTA NEUROPATHOL, V74, P158, DOI 10.1007/BF00692846; MUNSAT TL, 1977, NEUROLOGY, V27, P772, DOI 10.1212/WNL.27.8.772; NICOGOSSIAN AE, 1982, NASA SP447 SCI TECHN, P28; OGILVIE RW, 1988, AM J ANAT, V182, P335, DOI 10.1002/aja.1001820405; PORTUGALOV VV, 1973, AEROSPACE MED, V44, P764; PORTUGALOV VV, 1971, AEROSPACE MED, V42, P1041; POZDNYAKOV OM, 1988, B EXP BIOL MED, V6, P752; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; RILEY DA, 1986, J CELL BIOL, V103, pA401; RILEY DA, 1973, EXP NEUROL, V41, P690, DOI 10.1016/0014-4886(73)90061-7; RILEY DA, 1981, J NEUROCYTOL, V10, P425, DOI 10.1007/BF01262414; RILEY DA, 1973, EXP NEUROL, V40, P391, DOI 10.1016/0014-4886(73)90082-4; RILEY DA, 1987, MUSCLE NERVE, V10, P560, DOI 10.1002/mus.880100612; RILEY DA, 1988, J HISTOCHEM CYTOCHEM, V36, P621, DOI 10.1177/36.6.2835410; RILEY DA, 1988, BRAIN RES, V453, P79, DOI 10.1016/0006-8993(88)90145-X; ROKHLENKO KD, 1981, KOSM BIOL AVIAKOSM M, V1, P72; ROULEAU G, 1987, MUSCLE NERVE, V10, P428, DOI 10.1002/mus.880100509; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; TAKACS O, 1983, ACTA PHYSIOL HUNG, V62, P228; TASHPULATOV RY, 1979, ZH MIKROBIOL EPIDEMI, V12, P36	41	128	138	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1990	4	1					84	91		10.1096/fasebj.4.1.2153085	http://dx.doi.org/10.1096/fasebj.4.1.2153085			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH311	2153085				2022-12-28	WOS:A1990CH31100015
J	Li, CY; Lee, H; Jung, JH; Zhang, YW; Wang, JQ; Liu, C; Sheffmaker, RL; Segall, AM; Zeng, SX; Lu, H				Li, Caiyue; Lee, Hyemin; Jung, Ji Hoon; Zhang, Yiwei; Wang, Jieqiong; Liu, Chang; Sheffmaker, Roger L.; Segall, Allyson M.; Zeng, Shelya X.; Lu, Hua			Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from proteasome-mediated degradation	ONCOGENE			English	Article; Early Access							MDM2 PROMOTES; UBIQUITIN; LIGASE; ACTIVATION; PROTEINS; PATHWAY; E3	Coiled-coil domain containing 3 (CCDC3) was previously shown to regulate liver lipid metabolism as a secretory protein. Here, we report an unexpected intracellular role of CCDC3 as a tumor suppressor in breast cancer (BrC). Bioinformatics datasets analysis showed that CCDC3 is under-expressed in BrCs, while its higher levels are correlated with higher overall survival and lower relapse of cancer patients, and CCDC3 is positively correlated with p53 and its target genes. Ectopic CCDC3 markedly suppressed proliferation, colony formation, and xenograft tumor growth by augmenting p53 activity in BrC cells. Depletion of endogenous CCDC3 by CRISPR-Cas9 increased proliferation and drug resistance of BrC cells by alleviating 5-Fluorouracil (5-FU)-induced p53 level and activity. Mechanistically, CCDC3 bound to the C-termini of p53 and MDM2, consequently stabilizing p53 in the nucleus and impairing MDM2 recruitment of p53 to the 26S proteosome without inhibiting p53 ubiquitination. p53 induced CCDC3 expression by binding to its promoter in BrC cells. Our results unveil a unique mechanism underlying CCDC3 activation of p53 in a positive feedback fashion to suppress BrC growth.	[Li, Caiyue; Lee, Hyemin; Jung, Ji Hoon; Zhang, Yiwei; Wang, Jieqiong; Liu, Chang; Sheffmaker, Roger L.; Segall, Allyson M.; Zeng, Shelya X.; Lu, Hua] Tulane Univ, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA; [Li, Caiyue; Lee, Hyemin; Jung, Ji Hoon; Zhang, Yiwei; Wang, Jieqiong; Zeng, Shelya X.; Lu, Hua] Tulane Univ, Tulane Canc Ctr, Sch Med, New Orleans, LA 70112 USA; [Jung, Ji Hoon] Kyung Hee Univ, Coll Korean Med, Seoul 02447, South Korea; [Liu, Chang] Tulane Univ, Dept Neurosci, New Orleans, LA 70118 USA	Tulane University; Tulane University; Kyung Hee University; Tulane University	Zeng, SX; Lu, H (corresponding author), Tulane Univ, Dept Biochem & Mol Biol, Sch Med, New Orleans, LA 70112 USA.; Zeng, SX; Lu, H (corresponding author), Tulane Univ, Tulane Canc Ctr, Sch Med, New Orleans, LA 70112 USA.	szeng@tulane.edu; hlu2@tulane.edu	Jung, Jihoon/HHY-7803-2022	Wang, Jieqiong/0000-0003-3096-0208	NIH-NCI [R01CA095441, R01CA234605, R01CA127724, R21CA272890, U01CA252965]; Reynolds and Ryan Families Endowed Chair fund	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Reynolds and Ryan Families Endowed Chair fund	We thank James Jackson, Wesley D. Frey, Joe Gray, and Jean-Paul Borg for offering some BrC cell lines (Cal 51, MDA-MB-175, MPE600, SKBR7) and the CRISPR-p53KOmCherry construct (James Jackson) and Heather Machado for sharing her animal protocol (Mammary fat pad injection). HL and SXZ were supported in part by NIH-NCI grants R01CA095441, R01CA234605, and R01CA127724 as well as R21CA272890. HL was also in part supported by the Reynolds and Ryan Families Endowed Chair fund and the NIH-NCI grant U01CA252965.	Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Azad AK, 2014, CELL SIGNAL, V26, P2793, DOI 10.1016/j.cellsig.2014.08.025; Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501; Broz DK, 2010, CARCINOGENESIS, V31, P1311, DOI 10.1093/carcin/bgp331; Chao TF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13755; Choong ML, 2009, CELL CYCLE, V8, P2810, DOI 10.4161/cc.8.17.9503; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu Wenwei, 2012, Genes Cancer, V3, P199, DOI 10.1177/1947601912454734; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Ju J, 2007, CLIN CANCER RES, V13, P4245, DOI 10.1158/1078-0432.CCR-06-2890; Kobayashi S, 2015, J BIOL CHEM, V290, P7443, DOI 10.1074/jbc.M114.592493; Kobayashi S, 2010, BIOCHEM BIOPH RES CO, V392, P29, DOI 10.1016/j.bbrc.2009.12.142; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kulikov R, 2010, P NATL ACAD SCI USA, V107, P10038, DOI 10.1073/pnas.0911716107; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liao JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep23542; Liao Jun-Ming, 2013, Methods Mol Biol, V962, P201, DOI 10.1007/978-1-62703-236-0_17; Liao WJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09228-8; Liu YY, 2019, INT J ONCOL, V54, P1907, DOI 10.3892/ijo.2019.4786; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sparks A, 2014, ONCOGENE, V33, P4685, DOI 10.1038/onc.2013.413; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang Qi, 2014, Subcell Biochem, V85, P281, DOI 10.1007/978-94-017-9211-0_16; Zhang Q, 2012, EMBO MOL MED, V4, P298, DOI 10.1002/emmm.201100211; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2013, NEOPLASIA, V15, P523, DOI 10.1593/neo.13142; Zhou X, 2016, ELIFE, V5, DOI 10.7554/eLife.15099; Zhou Xiang, 2012, Genes Cancer, V3, P298, DOI 10.1177/1947601912455200; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008	43	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02541-1	http://dx.doi.org/10.1038/s41388-022-02541-1		NOV 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H9DW	36396725				2022-12-28	WOS:000885732000001
J	CENTRA, M; RATYCH, RE; CAO, GL; LI, J; WILLIAMS, E; TAYLOR, RM; ROSEN, GM				CENTRA, M; RATYCH, RE; CAO, GL; LI, J; WILLIAMS, E; TAYLOR, RM; ROSEN, GM			CULTURE OF BOVINE PULMONARY-ARTERY ENDOTHELIAL-CELLS ON GELFOAM BLOCKS	FASEB JOURNAL			English	Article						ENDOTHELIAL CELLS; GELFOAM	DIFFERENTIATION	Conventional methods of endothelial cell culture on monolayers and beads require enzymatic digestion, traumatic scraping, or centrifugation to transfer cells to other experimental systems. Gelfoam, a porous gelatin block, not only supports the growth of bovine pulmonary artery endothelial cells but also allows the rapid transfer of cell-laden blocks from one experimental system to another with minimal intervention. This property has been shown to be especially useful for the rapid fixation of endothelial cells for microscopy using standard histologic methods. Histology confirmed that the trabecular nature of the substrate allows endothelial cells to line the interstices of the sponge matrix and grow in a configuration that simulates the appearance of the endothelium in small vessels and capillaries. The inoculation of 1 x 10(5) endothelial cells on 7.5 mg Gelfoam (24 x 8 x 2 mm blocks) was enhanced by fibroblast growth factor and resulted in cell attachment by day 2 with a cell doubling time of 1.7 days. In addition, endothelial cells completely infiltrated 1, 5 and 7.5 mg Gelfoam blocks, as verified by histology. Assays to quantify cell number and protein were easily performed. To facilitate cell counting, the Gelfoam matrix was rapidly removed by the addition of 0.05 mg/ml collagenase, a concentration that interfered minimally with the assay for cellular protein concentration. The data demonstrate that Gelfoam is a suitable support growth matrix for the in vitro culture of bovine pulmonary artery endothelial cells.	UNIV MARYLAND, SCH PHARM, DEPT PHARMACOL & TOXICOL, BALTIMORE, MD 21201 USA; JOHNS HOPKINS MED INST, DEPT SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT PATHOL & DERMATOL, BALTIMORE, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-33550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD JR, 1986, J ULTRA MOL STRUCT R, V94, P30, DOI 10.1016/0889-1605(86)90049-2; BOOYSE FM, 1975, THROMB DIATH HAEMOST, V34, P825, DOI 10.1055/s-0038-1654001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HOGAN ME, 1989, AM J ANAT, V185, P296, DOI 10.1002/aja.1001850222; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KLEINSOYER C, 1989, BIOMATERIALS, V10, P85, DOI 10.1016/0142-9612(89)90036-7; LAWLEY TJ, 1989, J INVEST DERMATOL, V93, pS59, DOI 10.1111/1523-1747.ep12581070; LUNA LG, 1968, MANUAL HISTOLOGIC ST, P00012; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; RADOMSKI JS, 1987, J SURG RES, V42, P133, DOI 10.1016/0022-4804(87)90110-7; RYAN US, 1980, TISSUE CELL, V12, P619, DOI 10.1016/0040-8166(80)90017-8; RYAN US, 1978, TISSUE CELL, V10, P535, DOI 10.1016/S0040-8166(16)30347-0; SCHOR SL, 1979, J CELL SCI, V38, P267; SOROUR O, 1975, J NEUROSURG, V43, P742, DOI 10.3171/jns.1975.43.6.0742; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952	18	35	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3117	3121		10.1096/fasebj.6.12.1521742	http://dx.doi.org/10.1096/fasebj.6.12.1521742			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521742				2022-12-28	WOS:A1992JN50500014
J	RADDA, GK				RADDA, GK			CONTROL, BIOENERGETICS, AND ADAPTATION IN HEALTH AND DISEASE - NONINVASIVE BIOCHEMISTRY FROM NUCLEAR-MAGNETIC-RESONANCE	FASEB JOURNAL			English	Article						ACID BASE REGULATION; P-31-NMR; HYPERTENSION; HEART ENERGETICS; OXIDATIVE PHOSPHORYLATION	SKELETAL-MUSCLE; NMR-SPECTROSCOPY; CREATINE-KINASE; HUMAN MYOCARDIUM; HUMAN-BRAIN; INVIVO; METABOLISM; P-31; PHOSPHORYLATION; PHOSPHOCREATINE	The noninvasive study of cellular homeostasis, control, and energetics in tissues and organs within intact living systems is now possible. Nuclear magnetic resonance (NMR) spectroscopy in vivo provides information about key metabolites, reaction rates, the control of ionic equilibria and fluxes (including that of H+), and molecular diffusion and motions within the cell. When phosphorus (P-31) is measured, the processes associated with the production and utilization of adenosine triphosphate (ATP) are followed. Using C-13 for measurement, the pathways and fluxes in the synthesis and degradation of sugars (e.g., glycogen), amino acids, etc., can be observed. Intracellular, cytoplasmic pH (H+ concentration) can be determined from the P-31-NMR spectrum of organs and cells whereas Na+ and K+ (or its congener Rb+) are directly measurable by NMR. All these can be observed in physiological situations in almost any organism in the animal or plant kingdom. The bioenergetics of locust muscle in flight is as readily measured as that in human muscle in health, training, and disease. When spatially resolved, the NMR spectra can provide metabolic maps of the human heart, brain, and other organs. Thus we can now directly delineate the biochemical basis of human diseases.			RADDA, GK (corresponding author), UNIV OXFORD, DEPT BIOCHEM, MRC, BIOCHEM & CLIN MAGNET RESONANCE UNIT, S PARKS RD, OXFORD OX1 3QU, ENGLAND.							ALGER JR, 1981, SCIENCE, V214, P660, DOI 10.1126/science.7292005; ANDREW ER, 1990, CLIN MAGNETIC RESONA; ARNOLDA L, 1990, CLIN SCI, V79, P583, DOI 10.1042/cs0790583; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BEECH JS, 1989, BIOCHEM J, V263, P737, DOI 10.1042/bj2630737; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; CADOUXHUDSON TA, 1989, FASEB J, V3, P2660, DOI 10.1096/fasebj.3.14.2629743; CADOUXHUDSON TAD, 1990, CLIN SCI, V79, P1; Cannon W.B., 1932, WISDOM BODY; CERDAN S, 1990, ANNU REV BIOPHYS BIO, V19, P43; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; CHANCE B, 1985, CIRCULATION, V72, P103; CLARK BJ, 1988, AM J PHYSIOL, V254, pC258, DOI 10.1152/ajpcell.1988.254.2.C258; CONWAY MA, 1991, LANCET, V338, P973, DOI 10.1016/0140-6736(91)91838-L; CONWAY MA, 1991, TRENDS CARDIOVAS MED, V1, P300, DOI 10.1016/1050-1738(91)90047-I; CONWAY MA, 1991, BRIT HEART J, V65, P25; DUDLEY CRK, 1990, CLIN SCI, V79, P491, DOI 10.1042/cs0790491; FITZPATRICK SM, 1990, J CEREBR BLOOD F MET, V10, P170, DOI 10.1038/jcbfm.1990.32; FROM AHL, 1990, BIOCHEMISTRY-US, V29, P3731, DOI 10.1021/bi00467a020; HOOD VL, 1988, AM J PHYSIOL, V255, pF479, DOI 10.1152/ajprenal.1988.255.3.F479; INGWALL JS, 1990, EUR HEART J, V11, P108, DOI 10.1093/eurheartj/11.suppl_B.108; KENTBRAUN JA, 1990, J APPL PHYSIOL, V69, P1165, DOI 10.1152/jappl.1990.69.3.1165; KOHLER SJ, 1991, MAGNET RESON MED, V18, P15, DOI 10.1002/mrm.1910180104; NISHIZUKA Y, 1983, TRENDS BIOCHEM SCI, V8, P13, DOI 10.1016/0968-0004(83)90061-0; PAPPENHEIMER JR, 1965, AM J PHYSIOL, V208, P436, DOI 10.1152/ajplegacy.1965.208.3.436; PETROFF OAC, 1985, NEUROLOGY, V35, P1681, DOI 10.1212/WNL.35.12.1681; POSTNOV YV, 1985, PHYSIOL REV, V65, P904, DOI 10.1152/physrev.1985.65.4.904; RADDA G K, 1989, Magnetic Resonance Quarterly, V5, P122; RADDA GK, 1985, INT REV EXP PATHOL, V27, P1; RADDA GK, 1990, PHILOS T R SOC A, V333, P515, DOI 10.1098/rsta.1990.0179; RADDA GK, 1986, SCIENCE, V233, P640, DOI 10.1126/science.3726553; RADDA GK, 1991, BIOCHEM SOC T, V19, P995, DOI 10.1042/bst0190995; RITTER JM, 1990, LANCET, V335, P1243, DOI 10.1016/0140-6736(90)91305-T; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P72, DOI 10.1016/0167-4889(84)90038-7; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SPRINGER CS, 1987, ANNU REV BIOPHYS BIO, V16, P375; SYME PD, 1990, J HYPERTENS, V8, P1161, DOI 10.1097/00004872-199012000-00014; THOMPSON C H, 1991, Clinical Science (London), V81, p14P; WEGENER G, 1991, J COMP PHYSIOL B, V161, P247, DOI 10.1007/BF00262305; Weibel E R., 1984, PATHWAY OXYGEN; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; YOSHIZAKI K, 1990, BIOCHIM BIOPHYS ACTA, V1051, P144, DOI 10.1016/0167-4889(90)90186-H	43	32	32	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3032	3038		10.1096/fasebj.6.12.1521736	http://dx.doi.org/10.1096/fasebj.6.12.1521736			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521736				2022-12-28	WOS:A1992JN50500004
J	WAHLBERG, J; ALBERT, J; LUNDEBERG, J; COX, S; WAHREN, B; UHLEN, M				WAHLBERG, J; ALBERT, J; LUNDEBERG, J; COX, S; WAHREN, B; UHLEN, M			DYNAMIC CHANGES IN HIV-1 QUASI-SPECIES FROM AZIDOTHYMIDINE (AZT)-TREATED PATIENTS	FASEB JOURNAL			English	Article						POLYMERASE CHAIN REACTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; AZIDOTHYMIDINE RESISTANCE; SOLID-PHASE DNA SEQUENCING	IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE CHAIN-REACTION; ZIDOVUDINE AZT; DNA; MUTATIONS; INVITRO	The emergence of azidothymidine (AZT)-resistant human immunodeficiency virus (HIV) variants in clinical samples was studied by a direct genomic sequencing method. Sequential lymphocyte samples from four patients, who had been treated with AZT for up to 27 months, were shown to gradually accumulate multiple nucleotide changes, some of which are known to be associated with AZT resistance. Several samples were shown to contain mixtures of wild-type and mutated genomes, indicating gradual rather than sudden changes in the HIV-1 quasispecies. These results demonstrate for the first time that automated solid-phase DNA sequencing is a rapid and useful tool for investigation of antiviral drug resistance and suggest that DNA sequencing may be important in routine clinical diagnostics in the future.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,TEKNIKRINGEN 32,S-10044 STOCKHOLM 70,SWEDEN; NATL BACTERIOL LAB,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Royal Institute of Technology			Uhlen, Mathias/B-3262-2016; Uhlen, Mathias/AAV-8746-2021	Uhlen, Mathias/0000-0002-4858-8056; 				ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560, DOI 10.1128/JCM.28.7.1560-1564.1990; COX SW, 1992, IN PRESS AIDS RES HU; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FITZGIBBON JE, 1991, AIDS RES HUM RETROV, V7, P265, DOI 10.1089/aid.1991.7.265; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; INNIS MA, 1990, PCR PROTOCOLS; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MYERS G, 1991, HUMAN RETROVIRUSES A; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; SUNDQVIST VA, 1989, J MED VIROL, V29, P170, DOI 10.1002/jmv.1890290305; SYVANEN AC, 1991, GENET ANAL-BIOMOL E, V8, P117, DOI 10.1016/1050-3862(91)90027-O; UHLEN M, 1992, TRENDS BIOTECHNOL, V10, P52, DOI 10.1016/0167-7799(92)90169-V; WAHLBERG J, 1990, P NATL ACAD SCI USA, V87, P6569, DOI 10.1073/pnas.87.17.6569; WAHLBERG J, 1991, AIDS RES HUM RETROV, V7, P983, DOI 10.1089/aid.1991.7.983	21	35	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1992	6	10					2843	2847		10.1096/fasebj.6.10.1634047	http://dx.doi.org/10.1096/fasebj.6.10.1634047			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634047				2022-12-28	WOS:A1992JD95400013
J	GREENBERG, CS; BIRCKBICHLER, PJ; RICE, RH				GREENBERG, CS; BIRCKBICHLER, PJ; RICE, RH			TRANSGLUTAMINASES - MULTIFUNCTIONAL CROSS-LINKING ENZYMES THAT STABILIZE TISSUES	FASEB JOURNAL			English	Article						TRANSGLUTAMINASE; PLASMA FACTOR-XIII; PRIMARY AMINE ACCEPTORS; FIBRIN; KERATINOCYTES; CROSS-LINKING	COAGULATION FACTOR-XIII; PIG LIVER TRANSGLUTAMINASE; PLASMA FACTOR-XIII; HAIR FOLLICLE TRANSGLUTAMINASES; HUMAN EPIDERMAL-KERATINOCYTES; MEMBRANE ANCHORAGE REGION; AMINO-ACID-SEQUENCE; RETINOIC ACID; BLOOD-COAGULATION; SUBCELLULAR-LOCALIZATION	Transglutaminases catalyze the posttranslational modifications of proteins by transamidation of available glutamine residues. This action results primarily in the formation of epsilon-(gamma-glutamyl)lysine cross-links but includes the incorporation of polyamines into suitable protein substrates as well. The covalent isopeptide cross-link is stable and resistant to proteolysis, thereby increasing the resistance of tissue to chemical, enzymatic, and mechanical disruption. The plasma transglutaminase, factor XIIIa, is formed at sites of blood coagulation and impedes blood loss by stabilizing the fibrin clot. The squamous epithelium constituting the protective callus layer of skin is formed by the action of keratinocyte transglutaminase (TG(K)) and epidermal transglutaminase (TG(E)). The tissue transglutaminase (TG(C)) is a cytoplasmic enzyme present in many cells including those in the blood vessel wall. TG(C) function is unknown, although it could function to stabilize intra- and extra-cellular molecules in a wide variety of physiologic or pathologic processes. The amino acid sequences of factor XIII, TG(C), and TG(K) establish them as a homologous gene family and also reveal a striking homology to the erythrocyte membrane protein, band 4.2. This review summarizes the current information on structures, functions, and evolution of the most prominent members of this gene family.	SAMUEL ROBERTS NOBLE FDN INC, ARDMORE, OK 73401 USA; UNIV CALIF DAVIS, DEPT ENVIRONM TOXICOL, DAVIS, CA 95616 USA	Noble Research Institute; University of California System; University of California Davis	GREENBERG, CS (corresponding author), DUKE UNIV, MED CTR, DURHAM, NC 27710 USA.		Rice, Robert/AAP-7813-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P60HL028391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38245, HL 28391] Funding Source: Medline; NIAMS NIH HHS [AR 39162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; ACHYUTHAN KE, 1988, J BIOL CHEM, V263, P14296; BARRY ELR, 1990, J BIOL CHEM, V265, P9302; BARSIGIAN C, 1988, J BIOL CHEM, V263, P14015; BENINATI S, 1988, ADV EXP MED BIOL, V231, P79; BIRCKBICHLER PJ, 1983, BIOCHIM BIOPHYS ACTA, V763, P27, DOI 10.1016/0167-4889(83)90021-6; BOTTENUS RE, 1990, BIOCHEMISTRY-US, V29, P11195, DOI 10.1021/bi00503a007; CARDINALI M, 1990, CANCER RES, V50, P8010; CERIO R, 1990, AM J DERMATOPATH, V12, P221, DOI 10.1097/00000372-199006000-00002; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHIOCCA EA, 1989, J CELL BIOCHEM, V39, P293, DOI 10.1002/jcb.240390309; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; CREDO RB, 1978, P NATL ACAD SCI USA, V75, P4234, DOI 10.1073/pnas.75.9.4234; DENNING MF, 1991, BIOCHEM BIOPH RES CO, V175, P344, DOI 10.1016/S0006-291X(05)81241-0; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRANCIS CW, 1987, J CLIN INVEST, V80, P1459, DOI 10.1172/JCI113226; GENTILE V, 1991, J BIOL CHEM, V266, P478; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GOLDSMITH L. A., 1983, BIOCH PHYSL SKIN, P184; Green H, 1980, Harvey Lect, V74, P101; GREENBERG CS, 1985, BLOOD, V66, P1028; GREENBERG CS, 1987, BLOOD, V69, P867; GREENBERG CS, 1984, J BIOL CHEM, V259, P4721; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; HALKIER T, 1988, THROMB RES, V51, P313, DOI 10.1016/0049-3848(88)90108-9; HENRIKSSON P, 1985, J CLIN INVEST, V76, P528, DOI 10.1172/JCI112002; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; JETTEN AM, 1987, LAB INVEST, V56, P654; JETTEN AM, 1989, J INVEST DERMATOL, V93, P108, DOI 10.1111/1523-1747.ep12277374; JOHNSON JD, 1986, J BIOL CHEM, V261, P4982; JUPRELLESORET M, 1988, BIOCHEM J, V250, P421, DOI 10.1042/bj2500421; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KINSELLA MG, 1990, J BIOL CHEM, V265, P17891; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LEVITT ML, 1990, CANCER RES, V50, P120; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1986, ANN NY ACAD SCI, V485, P144, DOI 10.1111/j.1749-6632.1986.tb34577.x; Lorand L, 1980, Prog Hemost Thromb, V5, P245; Lorand L, 1988, Adv Exp Med Biol, V231, P79; MARTINET N, 1988, J BIOL CHEM, V263, P4236; MICHEL S, 1989, FEBS LETT, V258, P35, DOI 10.1016/0014-5793(89)81609-6; NARA K, 1989, J BIOL CHEM, V264, P19308; NEGI M, 1985, J INVEST DERMATOL, V85, P75, DOI 10.1111/1523-1747.ep12275357; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, IN PRESS J BIOL CHEM; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; POLAKOWSKA RR, 1991, CYTOGENET CELL GENET, V56, P105, DOI 10.1159/000133060; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; ROTHNAGEL JA, 1984, MOL CELL BIOCHEM, V58, P113, DOI 10.1007/BF00240610; RUBIN AL, 1986, CANCER RES, V46, P2356; SLIFE CW, 1985, ARCH BIOCHEM BIOPHYS, V241, P329, DOI 10.1016/0003-9861(85)90554-5; SUEDHOFF T, 1990, CANCER RES, V50, P7830; SUNG LA, 1990, P NATL ACAD SCI USA, V87, P955, DOI 10.1073/pnas.87.3.955; TA BM, 1990, J CELL SCI, V95, P631; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; UPCHURCH HF, 1987, IN VITRO CELL DEV B, V23, P795; WEISBERG LJ, 1987, BLOOD, V70, P579; WOLPL A, 1987, TRANSPLANTATION, V43, P151	72	942	988	2	69	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1991	5	15					3071	3077		10.1096/fasebj.5.15.1683845	http://dx.doi.org/10.1096/fasebj.5.15.1683845			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1683845				2022-12-28	WOS:A1991GU84200010
J	GUNNING, P; HARDEMAN, E				GUNNING, P; HARDEMAN, E			MULTIPLE MECHANISMS REGULATE MUSCLE-FIBER DIVERSITY	FASEB JOURNAL			English	Article						SKELETAL MUSCLE; MUSCLE EMBRYOLOGY; MYOBLAST	HEAVY-CHAIN ISOFORMS; PRENATAL RAT HINDLIMB; SKELETAL-MUSCLE; GENE-EXPRESSION; TRANSGENIC MICE; VERTEBRATE MYOGENESIS; THYROID-HORMONE; CLONAL ANALYSIS; SOLEUS MUSCLES; MESSENGER-RNAS	Adult skeletal muscles are composed of clusters of multinucleated muscle cells called myofibers. At least three different types of myofibers can be detected within mammals based on their physiological properties and their expression of different contractile protein isoforms. Different skeletal muscles display a wide range of combinations of myofibers. Recent work has demonstrated that multiple mechanisms are responsible for the generation of these myofiber types during development. Muscle progenitor cells have been dissected into two categories on the basis of which isoforms of myosin heavy chain (MHC) they express when they differentiate. Neural and other environmental influences act to modify decisions concerning the type of contractile protein a myofiber may express, and this is most apparent for MHC. The other contractile protein gene families are initially regulated independent of the MHC gene family. One or more events late in development are responsible for coordinating isoform expression between the gene families to generate the adult phenotype. Studies of muscle gene expression have revealed that regulation can occur at the levels of transcription, alternative splicing of primary transcripts, mRNA stability, and translation. The current challenge is to decipher how environmental and functional information is interpreted in terms of the activity of the regulators of muscle gene expression.	CHILDRENS MED RES FDN,MUSCLE DEV UNIT,CAMPERDOWN,NSW 2050,AUSTRALIA	Children's Medical Research Institute - Australia	GUNNING, P (corresponding author), CHILDRENS MED RES FDN,CELL BIOL UNIT,POB 61,CAMPERDOWN,NSW 2050,AUSTRALIA.		Hardeman, Edna C/F-8872-2012; Gunning, Peter W/E-9058-2010	Hardeman, Edna/0000-0003-1649-7712; Gunning, Peter/0000-0003-0833-3128				BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; BUCKINGHAM ME, 1983, EUKARYOTIC GENES THE, P365; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; CARLSON BM, 1986, FASEB J, V45, P1456; CERNY LC, 1987, DEV BIOL, V119, P350, DOI 10.1016/0012-1606(87)90040-6; CONDON K, 1990, DEV BIOL, V138, P275, DOI 10.1016/0012-1606(90)90197-Q; CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P; COX RD, 1991, DEV BIOL, V143, P36, DOI 10.1016/0012-1606(91)90052-5; CROW MT, 1986, DEV BIOL, V113, P238, DOI 10.1016/0012-1606(86)90126-0; DEVLIN RB, 1978, CELL, V13, P599, DOI 10.1016/0092-8674(78)90211-8; DRAEGER A, 1987, J NEUROL SCI, V81, P19, DOI 10.1016/0022-510X(87)90181-X; ECOBPRINCE MS, 1986, J CELL BIOL, V103, P995, DOI 10.1083/jcb.103.3.995; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; GUNNING P, 1990, DEV BIOL, V138, P443, DOI 10.1016/0012-1606(90)90210-A; HALLAUER PL, 1988, MOL CELL BIOL, V8, P5072, DOI 10.1128/MCB.8.12.5072; HARRIS AJ, 1989, DEVELOPMENT, V107, P751; HASTINGS KEM, 1982, P NATL ACAD SCI-BIOL, V79, P1553, DOI 10.1073/pnas.79.5.1553; HOH JFY, 1988, J MUSCLE RES CELL M, V9, P59; HONDA S, 1990, P NATL ACAD SCI USA, V87, P876, DOI 10.1073/pnas.87.3.876; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KAPRIELIAN Z, 1987, DEV BIOL, V124, P490, DOI 10.1016/0012-1606(87)90502-1; KELLER LR, 1980, P NATL ACAD SCI-BIOL, V77, P1020, DOI 10.1073/pnas.77.2.1020; LAFRAMBOISE WA, 1991, DEV BIOL, V144, P1, DOI 10.1016/0012-1606(91)90473-G; LEESMILLER JP, 1991, IN PRESS BIOESSAYS; MAHDAVI V, 1986, MOL BIOL MUSCLE DEV, P345; MATSUDA R, 1983, DEV BIOL, V100, P478, DOI 10.1016/0012-1606(83)90240-3; MILLER JB, 1989, DEV BIOL, V136, P393, DOI 10.1016/0012-1606(89)90265-0; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; Nadal-Ginard B, 1990, CURR OPIN CELL BIOL, V2, P1058, DOI 10.1016/0955-0674(90)90156-9; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; REISER PJ, 1985, J BIOL CHEM, V260, P9077; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; RUSSELL SD, 1988, J BIOL CHEM, V263, P6370; SALVIATI G, 1982, BIOCHEM J, V207, P261, DOI 10.1042/bj2070261; SALVIATI G, 1986, NATURE, V322, P637, DOI 10.1038/322637a0; SCHMALBRUCH H, 1985, HDB MICROSCOPIC ANAT, V11; SEED J, 1988, DEV BIOL, V128, P40, DOI 10.1016/0012-1606(88)90264-3; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; VIVARELLI E, 1988, J CELL BIOL, V107, P2191, DOI 10.1083/jcb.107.6.2191; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; WADE R, 1989, ANNU REV PHYSIOL, V51, P179, DOI 10.1146/annurev.physiol.51.1.179; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEYDERT A, 1987, CELL, V49, P121, DOI 10.1016/0092-8674(87)90762-8; WHALEN RG, 1985, J EXP BIOL, V115, P43; WHALEN RG, 1990, DEV BIOL, V141, P24, DOI 10.1016/0012-1606(90)90099-5; WHALEN RG, 1985, J CELL BIOL, V101, P603, DOI 10.1083/jcb.101.2.603; WHITE NK, 1975, DEV BIOL, V44, P346, DOI 10.1016/0012-1606(75)90405-4	54	118	118	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1991	5	15					3064	3070		10.1096/fasebj.5.15.1835946	http://dx.doi.org/10.1096/fasebj.5.15.1835946			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1835946				2022-12-28	WOS:A1991GU84200009
J	ENGLER, RL; ROTH, DM; DELBALZO, U; ITO, BR				ENGLER, RL; ROTH, DM; DELBALZO, U; ITO, BR			INTRACORONARY C5A INDUCES MYOCARDIAL-ISCHEMIA BY MECHANISMS INDEPENDENT OF THE NEUTROPHIL - LEUKOCYTE FILTERS DESENSITIZE THE MYOCARDIUM TO C5A	FASEB JOURNAL			English	Article						THROMBOXANE; LEUKOTRIENE-B4; COMPLEMENT; ANAPHYLATOXIN	CORONARY-ARTERY OCCLUSION; POLYMORPHONUCLEAR LEUKOCYTES; STUNNED MYOCARDIUM; REPERFUSION INJURY; THROMBOXANE GENERATION; COMPLEMENT ACTIVATION; SUPEROXIDE-DISMUTASE; OXIDATIVE-METABOLISM; PROTAMINE REVERSAL; FREE-RADICALS	Activation of the complement cascade with the generation of anaphylatoxins accompanies the inflammatory response elicited by acute myocardial ischemia and reperfusion. Although complement is activated in the interstitium during acute myocardial ischemia, we have studied mechanisms whereby complement might exacerbate ischemia by using a model employing intracoronary injection of C5a in nonischemic hearts. Intracoronary injection of complement component C5a induces transient myocardial ischemia, mediated through the production of the coronary vasoconstrictors thromboxane A2 and peptidoleukotrienes (LTC4, LTD4), and causes sequestration of polymorphonuclear leukocytes (PMN) in the coronary vascular bed. To further investigate the role of the PMN in the C5a-induced vasoconstriction, the left anterior descending coronary artery (LAD) in pigs was perfused at constant pressure and measurements of coronary blood flow, myocardial contractile function (sonomicrometry), arterial/coronary venous blood PMN count, and thromboxane B2 (TxB2) levels were performed. The myocardial response to intracoronary C5a (500 ng) was determined before, during, and after perfusion with blood depleted of PMNs using leukocyte filters (Sepacell R-500, Pall PL-100). In additional animals, the myocardial response to the PMN chemotactic agent, LTB4, and the effects of intracoronary C5a during constant flow perfusion were measured. Control intracoronary injection of C5a decreased flow (41% of baseline) and contractile function (39% of baseline), PMNs were trapped (5.1 X 10(3) cells/mu-l), and TxB2 concentration increased in coronary venous blood. The response to C5a during coronary perfusion with arterial blood depleted of PMNs with Sepacell or Pall filters (< 0.1 X 10(3) cells/mu-l) was greatly blunted, with flow and contractile function falling by less than 14 and 8%, respectively, from baseline, and release of TxB2 was greatly attenuated. However, the myocardial ischemia and TxB2 release remained depressed in response to C5a after removal of the filters and perfusion with either arterial blood containing normal levels of PMNs or stored arterial blood never exposed to filters. In contrast, the repeat C5a challenge resulted in equivalent myocardial extraction of PMNs, thus indicating a dissociation of PMN sequestration from the acute ischemic response and release of TxB2. In separate experiments, the intracoronary injection of LTB4 also resulted in a pronounced myocardial extraction of PMNs (8.6 x 10(3) cells/mu-l) greater than during C5a, but did not depress coronary flow or function. Perfusion at constant flow greatly diminished the ischemic response to C5a, indicating that vasoconstriction and resultant ischemia is the main cause of the contractile dysfunction. These data indicate that leukocyte filters inhibit the myocardial ischemia and release of TxB2 induced by C5a via mechanisms not related to PMN depletion. These filters may directly desensitize the myocardium or may induce the release of factors that interfere with the effects of C5a in our model. These data argue against a causal role of microvascular obstruction or PMN trapping in the acute myocardial ischemic response to intravascular activated complement C5a and suggest that the acute ischemic response may have PMN-independent components. However, the longterm contribution to injury of PMNs trapped by complement activation during ischemia requires further study.	UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093	University of California System; University of California San Diego	ENGLER, RL (corresponding author), VET ADM MED CTR,RES SERV 151,DEPT MED & PATHOL,3550 LA JOLLA VILLAGE DR,SAN DIEGO,CA 92161, USA.				NHLBI NIH HHS [HL17682-16] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017682] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARFORS KE, 1987, BLOOD, V69, P338; BJORNSSON OG, 1987, EUR J CLIN INVEST, V17, P146; BOLLI R, 1987, CIRCULATION, V76, P458, DOI 10.1161/01.CIR.76.2.458; BURKE JA, 1982, J PHARMACOL EXP THER, V221, P235; BURTON KP, 1988, FREE RADICAL BIO MED, V4, P15, DOI 10.1016/0891-5849(88)90006-8; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; ENGLER R, 1983, AM J PATHOL, V111, P93; ENGLER RL, 1986, AM J PHYSIOL, V251, pH314, DOI 10.1152/ajpheart.1986.251.2.H314; ENGLER RL, 1986, AM J PHYSIOL, V251, pH93, DOI 10.1152/ajpheart.1986.251.1.H93; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FRAME LH, 1976, CIRC RES, V39, P269, DOI 10.1161/01.RES.39.2.269; GAY JC, 1984, BLOOD, V64, P780; GIMBRONE MA, 1984, J CLIN INVEST, V74, P1552, DOI 10.1172/JCI111570; GO LO, 1988, AM J PHYSIOL, V255, pH1188, DOI 10.1152/ajpheart.1988.255.5.H1188; GOETZL EJ, 1983, FED PROC, V42, P3128; GOLDSTEIN IM, 1978, J EXP MED, V148, P787, DOI 10.1084/jem.148.3.787; GREENBERG CS, 1979, T ASSOC AM PHYSICIAN, V42, P130; GROSS GJ, 1986, AM J PHYSIOL, V250, pH372, DOI 10.1152/ajpheart.1986.250.3.H372; GUYTON RA, 1977, AM J CARDIOL, V40, P381, DOI 10.1016/0002-9149(77)90160-6; HAMMERSCHMIDT DE, 1981, AM J PATHOL, V102, P146; HARRIS TR, 1981, AM J PHYSIOL, V240, pH262, DOI 10.1152/ajpheart.1981.240.2.H262; HESS ML, 1983, ADV EXP MED BIOL, V161, P377; HILL JJH, 1970, J EXP MED, V131, P885; HUGLI TE, 1981, MOL CELL BIOCHEM, V41, P59; ITO BR, 1989, CIRC RES, V65, P1220, DOI 10.1161/01.RES.65.5.1220; ITO BR, 1990, CIRC RES, V66, P596, DOI 10.1161/01.RES.66.3.596; LITT MR, 1989, CIRCULATION, V80, P1816, DOI 10.1161/01.CIR.80.6.1816; LUNDBERG C, 1987, AM J PATHOL, V128, P471; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MAROKO PR, 1978, J CLIN INVEST, V61, P661, DOI 10.1172/JCI108978; MARTIN SE, 1988, CIRC RES, V63, P483, DOI 10.1161/01.RES.63.2.483; MAZZONI MC, 1989, CIRC SHOCK, V29, P27; MCDONALD JWD, 1983, CIRC RES, V52, P1; MOREL DR, 1987, ANESTHESIOLOGY, V66, P597, DOI 10.1097/00000542-198705000-00002; MOREL DR, 1988, CIRC RES, V62, P905, DOI 10.1161/01.RES.62.5.905; MULLANE K, 1989, PROSTAGLANDINS CLIN, P39; MULLANE KM, 1984, J PHARMACOL EXP THER, V228, P510; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OLAFSSON B, 1987, CIRCULATION, V76, P1135, DOI 10.1161/01.CIR.76.5.1135; PALMBLAD J, 1984, J IMMUNOL, V132, P3041; PINCKARD RN, 1980, J CLIN INVEST, V66, P1050, DOI 10.1172/JCI109933; POWELL WJ, 1976, CIRCULATION, V54, P603, DOI 10.1161/01.CIR.54.4.603; PRZYKLENK K, 1986, CIRC RES, V58, P148, DOI 10.1161/01.RES.58.1.148; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROSSEN RD, 1985, CIRC RES, V57, P119, DOI 10.1161/01.RES.57.1.119; ROSSEN RD, 1988, CIRC RES, V62, P572, DOI 10.1161/01.RES.62.3.572; SALZMAN PM, 1980, J PHARMACOL EXP THER, V215, P240; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P1006, DOI 10.1016/0006-291X(82)90622-2; STAHL LD, 1988, CIRCULATION, V77, P865, DOI 10.1161/01.CIR.77.4.865; STEWART JR, 1982, SURG FORUM, V33, P317; STORRS SB, 1981, J BIOL CHEM, V256, P924; SWENSON LJ, 1987, AM J PHYSIOL, V253, pH58, DOI 10.1152/ajpheart.1987.253.1.H58; WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0; WESTLIN W, 1989, CIRCULATION, V80, P1828, DOI 10.1161/01.CIR.80.6.1828; YASUDA M, 1990, CIRCULATION, V81, P156, DOI 10.1161/01.CIR.81.1.156	57	19	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2983	2991		10.1096/fasebj.5.14.1661246	http://dx.doi.org/10.1096/fasebj.5.14.1661246			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1661246				2022-12-28	WOS:A1991GP26900015
J	NIELSEN, FH				NIELSEN, FH			NUTRITIONAL-REQUIREMENTS FOR BORON, SILICON, VANADIUM, NICKEL, AND ARSENIC - CURRENT KNOWLEDGE AND SPECULATION	FASEB JOURNAL			English	Article						ARSENIC; BORON; NICKEL; SILICON; VANADIUM	DIETARY BORON; METABOLISM; MAGNESIUM; MATRIX; BONE; HEAT	Definition of specific biochemical functions in higher animals (including humans) for the ultra-trace elements boron, silicon, vanadium, nickel, and arsenic still has not been achieved although all of these elements have been described as being essential nutrients. Recently, many new findings from studies using molecular biology techniques, sophisticated equipment, unusual organisms, and newly defined enzymes have revealed possible sites of essential action for these five elements. Based on these findings and the response of animals and/or humans to low intakes of these elements, the following speculations have been presented: 1) Boron has a role that affects cell membrane characteristics and transmembrane signaling. 2) Silicon is necessary for the association between cells and one or more macromolecules such as osteonectin, which affects cartilage composition and ultimately cartilage calcification. 3) Vanadium reacts with hydrogen peroxide to form a pervanadate that is required to catalyze the oxidation of halide ions and/or stimulate the phosphorylation of receptor proteins. 4) Nickel is needed for the CO2-fixation to propionyl-CoA to form D-methylmalonyl-CoA. 5) Arsenic has an important role in the conversion of methionine to its metabolites taurine, labile methyl, and the polyamines. If any of these speculations are found to be true, the element involved will be firmly established as having a nutritional requirement because the body obviously cannot synthesize it. Based on animal findings, the dietary requirement is likely to be small; that is, expressed in micrograms per day.			NIELSEN, FH (corresponding author), USDA ARS,GRAND FORKS HUMAN NUTR RES CTR,GRAND FORKS,ND 58202, USA.							ANKE M, 1989, 6 INT TRAC EL S, V1, P17; Anke M., 1986, TRACE ELEMENTS HUMAN, V2, P347; Anke M., 1988, TRACE ELEMENTS MAN A, V6, P467; BENCKO V, 1987, ADV MOD ENV TOXICOL, V11, P1; BIBLE KC, 1988, P NATL ACAD SCI USA, V85, P4582, DOI 10.1073/pnas.85.13.4582; BLASERGRILL J, 1990, PLANT PHYSIOL, V90, P280; Boyd D W, 1984, Adv Inorg Biochem, V6, P311; Brossart B., 1990, P ND ACAD SCI, V44; CAMMACK R, 1988, ADV INORG CHEM, V32, P297, DOI 10.1016/S0898-8838(08)60234-2; CARLISLE E M, 1989, FASEB Journal, V3, pA761; CARLISLE EM, 1988, FASEB J, V2, pA841; Carlisle EM, 1984, BIOCH ESSENTIAL ULTR, P257; CATT KJ, 1989, ANNU REV MED, V40, P487; DESROSIERS R, 1986, BIOCHEM CELL BIOL, V64, P750, DOI 10.1139/o86-102; DUGGER WM, 1983, ENCY PLANT PHYSL, V15, P626; EADY RR, 1990, VANADIUM BIOL SYSTEM, P99; ELIKOVIC I, 1989, CURR TOP NUTR DIS, V22, P253; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; HEGSTED M, 1991, BIOL TRACE ELEM RES, V26, P243; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HENEGOUWEN PMPVE, 1987, EXP CELL RES, V171, P367, DOI 10.1016/0014-4827(87)90169-8; HUNT CD, 1989, BIOL TRACE ELEM RES, V22, P201, DOI 10.1007/BF02916650; HUNT CD, 1981, TRACE ELEMENT METABO, P597; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; MARME D, 1988, CALCIUM CALCIUM BIND, P202; MCCOY H, 1990, FASEB J, V4, pA1050; NIELSEN F H, 1990, Journal of Trace Elements in Experimental Medicine, V3, P45; NIELSEN F H, 1989, Journal of Trace Elements in Experimental Medicine, V2, P21; Nielsen F H., 1987, TRACE ELEMENTS HUMAN, P245; NIELSEN FH, 1987, FASEB J, V1, P394, DOI 10.1096/fasebj.1.5.3678698; NIELSEN FH, 1990, MAGNESIUM TRACE ELEM, V9, P61; NIELSEN FH, 1989, 6TH INTERNATIONAL TRACE ELEMENT SYMP 1989, VOLS 1-5, P1106; NIELSEN FH, 1991, FASEB J, V5, pA1646; NIELSEN FH, 1987, P ND ACAD SCI, V41, P48; NIELSEN FH, 1990, BIOL TRACE ELEM RES, V27, P599; NIELSEN FH, 1984, BIOCH ESSENTIAL ULTR, P319; NIELSEN FH, 1990, PRESENT KNOWLEDGE NU, P294; Nielsen FH, 1990, VANADIUM BIOL SYSTEM, P51, DOI 10.1007/978-94-009-2023-1_3; Parr A. J., 1983, ANN P PHYTOCHEM SOC, V21, P87; PENLAND JG, 1991, IN PRESS AM J CLIN N; Poellot R.A., 1990, P NATL ACAD SCI USA, V44, P80; UTHUS EO, 1990, MAGNESIUM TRACE ELEM, V9, P227; UTHUS EO, 1989, 6TH INT TRAC EL S 19, V4, P1013; UTHUS EO, 1989, 6TH INT TRAC EL S 19, V1, P44; VAHTER M, 1988, SPECIAL PUBLICATION, V66, P105; Wever R., 1990, VANADIUM BIOL SYST, P81; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; [No title captured]	50	162	166	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2661	2667		10.1096/fasebj.5.12.1916090	http://dx.doi.org/10.1096/fasebj.5.12.1916090			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916090				2022-12-28	WOS:A1991GE81100006
J	VENER, KJ; CALKINS, BM				VENER, KJ; CALKINS, BM			ANALYSIS OF SBIR PHASE-I AND PHASE-II REVIEW RESULTS AT THE NATIONAL-INSTITUTES-OF-HEALTH	FASEB JOURNAL			English	Article						COMMERCE; NATIONAL-INSTITUTES-OF-HEALTH; PROFESSIONAL COMPETENCE; RESEARCH DESIGN-STANDARDS; RESEARCH SUPPORT-ECONOMICS; UNITED-STATES		A cohort of phase I and phase II summary statements for the SBIR grant applications was evaluated to determine the strengths and weaknesses in approved and disapproved applications. An analysis of outcome variables (disapproval or unfunded status) was examined with respect to exposure variables (strengths or shortcomings). Logistic regression models were developed for comparisons to measure the predictive value of shortcomings and strengths to the outcomes. Disapproved phase I results were compared with an earlier 1985 study. Although the magnitude of the frequencies of shortcomings was greater in the present study, the relative rankings within shortcomings class were more alike than different. Also, the frequencies of shortcomings were, with one exception, not significantly different in the two studies. Differences in the summary statement review may have accounted for some differences observed between the 1985 data and results of the present study. Comparisons of Approved/Disapproved and Approved-Unfunded/Funded yielded the following observations. For phase I applicants, a lack of a clearly stated, testable hypothesis, a poorly qualified or described investigative team, and inadequate methodological approaches contributed significantly (in that order) to a rating of disapproval. A critical flaw for phase II proposals was failure to accomplish objectives of the phase I study. Methodological issues also dominate the distinctions in both comparison groups. A clear result of the data presented here and that published previously is that SBIR applicants need continuing assistance to improve the chances of their success. These results should serve as a guide to assist NIH staff as they provide information to prospective applicants focusing on key elements of the application. A continuing review of the SBIR program would be helpful to evaluate the quality of the submitted science.	UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	VENER, KJ (corresponding author), NIAMSD,BETHESDA,MD 20892, USA.				PHS HHS [NIH 88-313] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN EM, 1960, SCIENCE, V132, P1532, DOI 10.1126/science.132.3439.1532; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MURPHY DG, 1984, I INSIGHT       0301; PRICE JM, 1987, J BIOMED MATERIALS S, P35; VENER KJ, 1985, FED PROC, V44, P2679; 1990, SMALL BUSINESS INNOV	6	0	0	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2640	2644		10.1096/fasebj.5.12.1916087	http://dx.doi.org/10.1096/fasebj.5.12.1916087			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916087				2022-12-28	WOS:A1991GE81100003
J	WEIS, JR; PITAS, RE; WILSON, BD; RODGERS, GM				WEIS, JR; PITAS, RE; WILSON, BD; RODGERS, GM			OXIDIZED LOW-DENSITY-LIPOPROTEIN INCREASES CULTURED HUMAN ENDOTHELIAL-CELL TISSUE FACTOR ACTIVITY AND REDUCES PROTEIN-C ACTIVATION	FASEB JOURNAL			English	Note						ATHEROSCLEROSIS; THROMBOSIS; MODIFIED LDL	PROCOAGULANT ACTIVITY; CHOLESTEROL DEPOSITION; SMOOTH-MUSCLE; MODIFIED LDL; MACROPHAGES; INVITRO; ATHEROSCLEROSIS; EXPRESSION; THROMBOMODULIN; QUANTITATION	Increasing evidence suggests that the formation of oxidized low-density lipoprotein (Ox-LDL) in vivo is associated with the development of atherosclerotic vascular disease. We investigated the effects of Ox-LDL on two vascular endothelial cell coagulant properties, tissue factor expression, and protein C activation. The Ox-LDL increased human arterial and venous endothelial cell tissue factor activity, with 100-mu-g/ml of Ox-LDL increasing tissue factor activity fourfold. Native LDL modified by incubation with cultured human arterial and venous endothelial cells also induced endothelial cell tissue factor activity. This modification was blocked by coincubation with the antioxidants, probucol or ascorbic acid. It was determined, based on inhibition by known scavenger receptor antagonists (fucoidin, dextran sulfate), that binding of Ox-LDL via the acetyl LDL (scavenger) receptor was partially responsible for the increase in tissue factor expression. Whereas endothelial cell tissue factor expression was increased by incubation with Ox-LDL, protein C activation was reduced approximately 80% by incubating cultured endothelial cells with Ox-LDL. The effect of Ox-LDL on protein C activation was not inhibited by antagonists to the scavenger receptor. These data indicating that an atherogenic lipoprotein can regulate key vascular coagulant activities provide an additional link between vascular disease and thrombosis.	UNIV UTAH,MED CTR,DEPT MED,DIV HEMATOL ONCOL,SALT LAKE CITY,UT 84132; UNIV UTAH,MED CTR,DEPT PATHOL,SALT LAKE CITY,UT 84132; VET ADM MED CTR,SALT LAKE CITY,UT 84148; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE FDN LABS CARDIOVASC DIS,SAN FRANCISCO,CA 94143	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes					NIDDK NIH HHS [T32DK07115-15] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BOYD HC, 1989, AM J PATHOL, V135, P815; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Buege J A, 1978, Methods Enzymol, V52, P302; CHISOLM GM, 1988, AM J CARDIOL, V62, pB20, DOI 10.1016/S0002-9149(88)80046-8; DRAKE TA, 1991, AM J PATHOL, V138, P601; DUNNETT CW, 1964, BIOMETRICS, V20, P482, DOI 10.2307/2528490; EPSTEIN FH, 1986, NEW ENGL J MED, V14, P915; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FRIEDMAN M, 1966, AM J PATHOL, V48, P19; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENRIKSEN T, 1979, SCAND J CLIN LAB INV, V39, P369, DOI 10.3109/00365517909106121; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAILAL I, 1990, ATHEROSCLEROSIS, V82, P185; MOORE KL, 1989, BLOOD, V73, P159; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P1221; NEMERSON Y, 1988, BLOOD, V71, P1; NISHIGAKI I, 1981, BIOCHEM MED METAB B, V25, P373, DOI 10.1016/0006-2944(81)90096-X; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1988, FASEB J, V2, P116, DOI 10.1096/fasebj.2.2.3277885; SCHUFFWERNER P, 1989, ATHEROSCLEROSIS, V78, P109, DOI 10.1016/0021-9150(89)90214-1; SCHWARTZ BS, 1981, J CLIN INVEST, V67, P1650, DOI 10.1172/JCI110201; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P631, DOI 10.1016/0005-2760(80)90155-1; STEINBERG D, 1983, ARTERIOSCLEROSIS, V3, P283, DOI 10.1161/01.ATV.3.4.283; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SURPRENANT YM, 1989, THROMB RES, V53, P339, DOI 10.1016/0049-3848(89)90108-4; WEINBERG JB, 1991, IN PRESS ARTH RHEUM; WEIS JR, 1991, THROMB RES, V61, P171, DOI 10.1016/0049-3848(91)90245-R; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839	38	102	105	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2459	2465		10.1096/fasebj.5.10.2065893	http://dx.doi.org/10.1096/fasebj.5.10.2065893			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065893				2022-12-28	WOS:A1991FW08700017
J	KNUTSON, VP				KNUTSON, VP			CELLULAR TRAFFICKING AND PROCESSING OF THE INSULIN-RECEPTOR	FASEB JOURNAL			English	Article						INSULIN RECEPTOR; INSULIN; PROTEIN TRAFFICKING; ENDOCYTOSIS; RECYCLING; DEGRADATION	INDUCED DOWN-REGULATION; CULTURED HUMAN-LYMPHOCYTES; HEPATOMA-CELLS; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; RAT-LIVER; ULTRASTRUCTURAL ANALYSIS; MEDIATED ENDOCYTOSIS; DEGRADATION PRODUCTS; STRUCTURAL BASIS	The insulin receptor is a dynamic cellular macromolecule that moves through various compartments of the cell throughout its lifetime. This review addresses the processes involved in the synthetic assembly of the insulin receptor; the interaction of insulin with the receptor protein; the receptor-mediated endocytosis of insulin; and the role of receptor tyrosine and serine phosphorylation in both endocytosis and recycling. This discussion is concluded by examining the data available on the intracellular inactivation and degradation of the receptor protein. Emphasis is given to the cellular regulation imposed at each of these steps in receptor processing, and how the use of pharmacologic and physiologic perturbants has afforded experimental insights into the mechanisms the cell utilizes in modulating the expression and functioning of the insulin receptor.			KNUTSON, VP (corresponding author), UNIV TEXAS,SCH MED,DEPT PHARMACOL,6431 FANNIN,POB 20708,HOUSTON,TX 77225, USA.				NIDDK NIH HHS [DK35397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; BEGUINOT F, 1986, ENDOCRINOLOGY, V18, P446; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CAPEAU J, 1985, BIOCHIMIE, V67, P1133, DOI 10.1016/S0300-9084(85)80111-5; CARPENTIER JL, 1985, BIOCHIMIE, V67, P1143, DOI 10.1016/S0300-9084(85)80112-7; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DUCKWORTH WC, 1988, J BIOL CHEM, V263, P1826; DUCKWORTH WC, 1990, J BIOL CHEM, V265, P2984; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FANTUS IG, 1982, J BIOL CHEM, V257, P8277; FEHLMANN M, 1982, J CELL BIOL, V93, P82, DOI 10.1083/jcb.93.1.82; FINN FM, 1990, P NATL ACAD SCI USA, V87, P419, DOI 10.1073/pnas.87.1.419; GLIEMANN J, 1985, POLYPEPTIDE HORMONE, P1; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRUNBERGER G, 1982, AM J PHYSIOL, V243, pE319, DOI 10.1152/ajpendo.1982.243.4.E319; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; HATADA EN, 1989, J BIOL CHEM, V264, P6741; HEDO JA, 1987, J BIOL CHEM, V262, P954; HEDO JA, 1983, J BIOL CHEM, V258, P20; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON DC, 1980, VIROLOGY, V103, P407, DOI 10.1016/0042-6822(80)90200-7; JUUL SM, 1986, BIOCHIM BIOPHYS ACTA, V856, P310, DOI 10.1016/0005-2736(86)90041-6; KASUGA M, 1982, J BIOL CHEM, V257, P392; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KNUTSON VP, 1986, J BIOL CHEM, V261, P306; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KNUTSON VP, 1985, J BIOL CHEM, V260, P4180; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEWIS RE, 1990, J BIOL CHEM, V265, P947; MARSHALL S, 1988, INSULIN RECEPTORS A, P59; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; MCDONALD AR, 1987, DIABETES, V36, P779, DOI 10.2337/diabetes.36.6.779; NG DS, 1985, BIOCHEM BIOPH RES CO, V133, P154, DOI 10.1016/0006-291X(85)91854-6; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OLSON TS, 1988, J BIOL CHEM, V263, P7342; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PANG DT, 1985, J BIOL CHEM, V260, P7131; POSNER BI, 1985, ADV EXP MED BIOL, V189, P159; REED BC, 1977, P NATL ACAD SCI USA, V74, P4876, DOI 10.1073/pnas.74.11.4876; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; ROBERT A, 1984, ENDOCRINOLOGY, V114, P247, DOI 10.1210/endo-114-1-247; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; ROUILLER DG, 1987, P NATL ACAD SCI USA, V84, P126, DOI 10.1073/pnas.84.1.126; ROUILLER DG, 1988, J BIOL CHEM, V263, P13185; SBRACCIA P, 1990, J BIOL CHEM, V265, P4902; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SMITH RM, 1987, J CELL PHYSIOL, V130, P428, DOI 10.1002/jcp.1041300317; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; SMITH RM, 1983, J CELL PHYSIOL, V115, P199, DOI 10.1002/jcp.1041150215; SMITH RM, 1985, J CELL PHYSIOL, V123, P167, DOI 10.1002/jcp.1041230204; SOUBIGOU P, 1987, BIOCHEM J, V246, P567, DOI 10.1042/bj2460567; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TRISCHITTA V, 1989, J BIOL CHEM, V264, P5041; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WHITTAKER J, 1986, BIOCHEM J, V234, P463, DOI 10.1042/bj2340463; WILLIAMS FG, 1990, METABOLISM, V39, P231, DOI 10.1016/0026-0495(90)90041-A; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	73	75	75	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1991	5	8					2130	2138		10.1096/fasebj.5.8.2022311	http://dx.doi.org/10.1096/fasebj.5.8.2022311			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022311				2022-12-28	WOS:A1991FK11100003
J	SCHIMMEL, P				SCHIMMEL, P			RNA MINIHELICES AND THE DECODING OF GENETIC INFORMATION	FASEB JOURNAL			English	Review						AMINOACYL TRANSFER RNA SYNTHETASE; GENETIC CODE; TRANSFER RNAS; RNA RECOGNITION; AMINOACYLATION	PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; MOLECULAR RECOGNITION; MAJOR DETERMINANT; BINDING-SITE; IDENTITY; SYNTHETASE; AMINOACYLATION; PARAMETERS; ANTICODON	The rules of the genetic code are determined by the specific aminoacylation of transfer RNAs by aminoacyl transfer RNA synthetases. A straightforward analysis shows that a system of synthetase-tRNA interactions that relies on anticodons for specificity could, in principle, enable most synthetases to distinguish their cognate tRNA isoacceptors from all others. Although the anticodons of some tRNAs are recognition sites for the cognate aminoacyl tRNA synthetases, for other synthetases the anticodon is dispensable for specific aminoacylation. In particular, alanine and histidine tRNA synthetases aminoacylate small RNA minihelices that reconstruct the part of their cognate tRNAs that is proximate to the amino acid attachment site. Helices with as few as six base pairs can be efficiently aminoacylated. The specificity of aminoacylation is determined by a few nucleotides and can be converted from one amino acid to another by the change of only a few nucleotides. These findings suggest that, for a subgroup of the synthetases, there is a distinct code in the acceptor helix of transfer RNAs that determines aminoacylation specificity.			SCHIMMEL, P (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.				NIGMS NIH HHS [GM 15539, GM 23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539, R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURBAUM JJ, 1990, PROTEINS, V7, P99, DOI 10.1002/prot.340070202; COOLEY L, 1982, P NATL ACAD SCI-BIOL, V79, P6475, DOI 10.1073/pnas.79.21.6475; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEDUVE C, 1988, NATURE, V333, P117, DOI 10.1038/333117a0; DEDUVE C, 1991, BLUEPRINT CELL NATUR, pCH8; EIGEN M, 1989, SCIENCE, V244, P673, DOI 10.1126/science.2497522; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; HARADA F, 1972, FEBS LETT, V19, P352, DOI 10.1016/0014-5793(72)80078-4; HILL K, 1989, BIOCHEMISTRY-US, V28, P2577, DOI 10.1021/bi00432a035; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; HOU YM, 1989, TRENDS BIOCHEM SCI, V14, P233, DOI 10.1016/0968-0004(89)90033-9; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; HOUNTONDJI C, 1985, BIOCHEMISTRY-US, V24, P1175, DOI 10.1021/bi00326a018; HOUNTONDJI C, 1986, BIOCHEMISTRY-US, V25, P16, DOI 10.1021/bi00349a003; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MILLER WT, 1991, BIOCHEMISTRY-US, V30, P2635, DOI 10.1021/bi00224a011; MOLLER W, 1990, BIOCHIMIE, V72, P361, DOI 10.1016/0300-9084(90)90033-D; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PARK SJ, 1988, J BIOL CHEM, V263, P16527; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; RENAUD M, 1982, EUR J BIOCHEM, V123, P267, DOI 10.1111/j.1432-1033.1982.tb19763.x; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHIMMEL P, 1991, TRENDS BIOCHEM SCI, V16, P1, DOI 10.1016/0968-0004(91)90002-D; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHIMMEL P, 1990, NUCLEIC ACIDS MOL BI, V4, P274; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SHI JP, 1991, J BIOL CHEM, V266, P2705; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042	51	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2180	2187		10.1096/fasebj.5.8.2022314	http://dx.doi.org/10.1096/fasebj.5.8.2022314			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	2022314				2022-12-28	WOS:A1991FK11100010
J	JANICKBUCKNER, D; BARUA, AB; OLSON, JA				JANICKBUCKNER, D; BARUA, AB; OLSON, JA			INDUCTION OF HL-60 CELL-DIFFERENTIATION BY WATER-SOLUBLE AND NITROGEN-CONTAINING CONJUGATES OF RETINOIC ACID AND RETINOL	FASEB JOURNAL			English	Note						RETINOIDS; HL-60 CELLS; CELL DIFFERENTIATION	ONCOGENE EXPRESSION; CHEMICAL SYNTHESIS; BETA-GLUCURONIDE; LINE HL-60; RECEPTOR; IDENTIFICATION; GROWTH; GAMMA	Retinoids induce the promyelocytic cell line, HL-60, to differentiate along the granulocytic pathway in vitro. A number of water-soluble and nitrogen-containing retinoids were synthesized in our laboratory [retinoyl-glucose (RAGL), retinyl-glucose (ROGL), retinoyl-adenosine (RADS), retinoyl-adenine (RAD), retinoyl-beta-glucuronide (beta-RAG), and retinoyl-alpha-glucuronide (alpha-RAG)]. These retinoids (10(-5) to 10(-8) M), as well as retinoic acid (RA) and retinol (ROL), were tested for their ability to induce the differentiation of HL-60 cells in vitro and to affect cell growth and viability during a 24- to 72-h incubation period. Differentiation was assessed by measuring the percentage of cells expressing the Mac-1 antigen on their cell surfaces. RA and the conjugates of RA were all quite active in inducing HL-60 cell differentiation, whereas ROL and ROGL had much less activity at equimolar concentrations. Beta-RAG, alpha-RAG, RADS, and RAD were less toxic, whereas the glucose conjugates of retinol and retinoic acid (ROGL and RAGL) were both considerably more toxic than either RA or ROL at equimolar concentrations. All retinoids affected cell growth in a dose-dependent fashion. At 24 h, free RA or ROL was not detected in the cells after incubation with any of the retinoid conjugates.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039733] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-39733] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARUA A B, 1989, FASEB Journal, V3, pA468; BARUA AB, 1985, J LIPID RES, V26, P258; BARUA AB, 1985, FED PROC, V44, P772; BARUA AB, 1988, BIOCHEM J, V252, P415, DOI 10.1042/bj2520415; BARUA AB, 1987, BIOCHEM J, V244, P231, DOI 10.1042/bj2440231; BARUA AB, 1985, J LIPID RES, V26, P1277; BARUA AB, 1990, 9TH INT S CAR KYOT, P62; BARUA AB, 1989, Patent No. 4855463; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, EXP CELL RES, V126, P494, DOI 10.1016/0014-4827(80)90296-7; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; COLLINS SJ, 1987, BLOOD, V70, P1233; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DETHE H, 1989, EUR MOL BIOL ORG J, V8, P426; DUFER J, 1989, LEUKEMIA RES, V13, P621, DOI 10.1016/0145-2126(89)90131-8; FONTANA JA, 1986, CANCER RES, V46, P2469; GALLUP JM, 1987, P SOC EXP BIOL MED, V186, P269; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GUNNING D B, 1989, FASEB Journal, V3, pA467; GUNNING D B, 1990, FASEB Journal, V4, pA660; IMAIZUMI M, 1988, CANCER RES, V48, P6733; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER BA, 1985, J IMMUNOL, V134, P3286; NATH KAMALENDU, 1967, J NUTR, V93, P461; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SIETSEMA WK, 1982, J NUTR, V112, P1481, DOI 10.1093/jn/112.8.1481; TAKAHASHI N, 1989, J BIOL CHEM, V264, P5159; TAKAHASHI N, 1990, FASEB J, V4, pA2057; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WU X, 1988, LEUKEMIA RES, V13, P869; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZILE MH, 1987, P NATL ACAD SCI USA, V84, P2208, DOI 10.1073/pnas.84.8.2208	34	41	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					320	325		10.1096/fasebj.5.3.2001792	http://dx.doi.org/10.1096/fasebj.5.3.2001792			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001792				2022-12-28	WOS:A1991FC55600010
J	REHM, H; TEMPEL, BL				REHM, H; TEMPEL, BL			VOLTAGE-GATED K+ CHANNELS OF THE MAMMALIAN BRAIN	FASEB JOURNAL			English	Article						K+ CHANNELS; DENDROTOXIN; CHANNEL PROTEIN PURIFICATION; ELECTROPHYSIOLOGY; CONVULSIONS	CELL-DEGRANULATING PEPTIDE; DENDROTOXIN-BINDING PROTEIN; POTASSIUM-CHANNEL; BETA-BUNGAROTOXIN; RAT-BRAIN; SHAKER LOCUS; CHICK BRAIN; SYNAPTIC TRANSMISSION; NERVOUS-SYSTEM; CROSS-LINKING	Research on voltage-gated K+ channels of the mammalian brain has seen a flood of new data in the last 2 years. A genetic approach, based on the Shaker mutation of Drosophila, led to cDNA clones for mammalian voltage-gated K+ channels. K+ channel proteins were detected independently and purified with the help of channel specific toxins. From these studies the structure of two families of mammalian K+ channels emerged. One family is defined molecularly by the sequence homology of its members, the other by binding sites for the snake toxin dendrotoxin. The two families have several members in common. The voltage-gated K+ channels of mammalian brain are oligomers of glycosilated peptides of 65-95 kDa. The primary structure of these subunits is characterized by six to eight potential transmembrane regions, including the S4 region, the voltage-sensor of the channels. Associated with at least some K+ channels are 38- and 42-kDa peptides of unknown function. The channels give rise to non- or slow-inactivating K+ currents that are regulated through phosphorylation by both cAMP-dependent and an endogenous kinase.	VET ADM MED CTR, CTR GERIAT RES EDUC & CLIN, SEATTLE, WA 98108 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PHARMACOL SJ30, SEATTLE, WA 98195 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	REHM, H (corresponding author), UNIV ZURICH, INST PHARMAKOL, CH-8006 ZURICH, SWITZERLAND.				NINDS NIH HHS [NS-27206] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027206] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BENOIT E, 1986, BRAIN RES, V377, P374, DOI 10.1016/0006-8993(86)90884-X; BIDARD JN, 1987, BIOCHEM BIOPH RES CO, V143, P383, DOI 10.1016/0006-291X(87)90677-2; BLACK AR, 1986, EUR J BIOCHEM, V156, P609, DOI 10.1111/j.1432-1033.1986.tb09621.x; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; Catsch A ., 1944, Z INDUKT ABSTAMMUNGS, V82, P64; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; CHERUBINI E, 1987, NATURE, V328, P70, DOI 10.1038/328070a0; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GANDOLFO G, 1989, EUR J PHARMACOL, V160, P173, DOI 10.1016/0014-2999(89)90669-9; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HABERMANN E, 1977, N-S ARCH PHARMACOL, V300, P189, DOI 10.1007/BF00505050; HANLEY MR, 1979, NEUROSCI LETT, V11, P143, DOI 10.1016/0304-3940(79)90117-4; HARVEY AL, 1982, BRIT J PHARMACOL, V77, P153, DOI 10.1111/j.1476-5381.1982.tb09281.x; Hille B, 1984, IONIC CHANNELS EXCIT; HOUAMED K M, 1989, Society for Neuroscience Abstracts, V15, P538; HOWARD BD, 1980, ANNU REV PHARMACOL, V20, P307, DOI 10.1146/annurev.pa.20.040180.001515; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JAN YN, 1977, PROC R SOC SER B-BIO, V198, P87, DOI 10.1098/rspb.1977.0087; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MEHRABAN F, 1984, FEBS LETT, V174, P116, DOI 10.1016/0014-5793(84)81088-1; MOCZYDLOWSKI E, 1988, J MEMBRANE BIOL, V105, P95, DOI 10.1007/BF02009164; NEWITT R, 1990, IN PRESS EPILEPSY RE; OTHMAN IB, 1982, EUR J BIOCHEM, V128, P267; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; PELCHENMATTHEWS A, 1988, BRAIN RES, V441, P127, DOI 10.1016/0006-8993(88)91390-X; PETERSEN M, 1986, NEUROSCI LETT, V68, P141, DOI 10.1016/0304-3940(86)90244-2; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; REHM H, 1983, EMBO J, V2, P1119, DOI 10.1002/j.1460-2075.1983.tb01555.x; REHM H, 1988, BIOCHEMISTRY-US, V27, P1827, DOI 10.1021/bi00406a005; REHM H, 1982, J BIOL CHEM, V257, P15; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1989, FEBS LETT, V247, P28, DOI 10.1016/0014-5793(89)81233-5; REHM H, 1984, J BIOL CHEM, V259, P6865; REHM H, 1989, FEBS LETT, V249, P224, DOI 10.1016/0014-5793(89)80628-3; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REHM H, 1988, BIOCHEM BIOPH RES CO, V153, P231, DOI 10.1016/S0006-291X(88)81213-0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SALKOFF L, 1981, NATURE, V293, P228, DOI 10.1038/293228a0; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; SCHMIDT RR, 1988, BIOCHEMISTRY-US, V27, P963, DOI 10.1021/bi00403a019; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWEITZ H, 1989, BIOCHEMISTRY-US, V28, P9708, DOI 10.1021/bi00451a025; STANSFELD CE, 1987, NEUROSCIENCE, V23, P893, DOI 10.1016/0306-4522(87)90166-7; STANSFELD CE, 1986, NEUROSCI LETT, V64, P299, DOI 10.1016/0304-3940(86)90345-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TANOUYE MA, 1981, P NATL ACAD SCI-BIOL, V78, P6548, DOI 10.1073/pnas.78.10.6548; TAYLOR JW, 1984, J BIOL CHEM, V259, P3957; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	63	73	73	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1991	5	2					164	170		10.1096/fasebj.5.2.2004663	http://dx.doi.org/10.1096/fasebj.5.2.2004663			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004663				2022-12-28	WOS:A1991EZ00200004
J	WATSON, JD; COOKDEEGAN, RM				WATSON, JD; COOKDEEGAN, RM			ORIGINS OF THE HUMAN GENOME PROJECT	FASEB JOURNAL			English	Review						GENE MAPPING; NIH; DOE; HUMAN GENOME ORGANIZATION	GENETIC-LINKAGE MAP; BIOLOGY; YEAST; DNA	The Human Genome Project has become a reality. Building on a debate that dates back to 1985, several genome projects are now in full stride around the world, and more are likely to form in the next several years. Italy began its genome program in 1987, and the United Kingdom and U.S.S.R in 1988. The European communities mounted several genome projects on yeast, bacteria, Drosophila, and Arabidospis thaliana (a rapidly growing plant with a small genome) in 1988, and in 1990 commenced a new 2-year program on the human genome. In the United States, we have completed the first year of operation of the National Center for Human Genome Research at the National Institutes of Health (NIH), now the largest single funding source for genome research in the world. There have been dedicated budgets focused on genome-scale research at NIH, the U.S. Department of Energy, and the Howard Hughes Medical Institute for several years, and results are beginning to accumulate. There were three annual meetings on genome mapping and sequencing at Cold Spring Harbor, New York, in the spring of 1988, 1989, and 1990; the talks have shifted from a discussion about how to approach problems to presenting results from experiments already performed. We have finally begun to work rather than merely talk. The purpose of genome projects is to assemble data on the structure of DNA in human chromosomes and those of other organisms. A second goal is to develop new technologies to perform mapping and sequencing. There have been impressive technical advances in the past 5 years since the debate about the human genome project began. We are on the verge of beginning pilot projects to test several approaches to sequencing long stretches of DNA, using both automation and manual methods. Ordered sets of yeast artificial chromosome and cosmid clones have been assembled to span more than 2 million base pairs of several human chromosomes, and a region of 10 million base pairs has been assembled for Caenorhabditis elegans by a collaboration between Washington University and the Medical Research Council laboratory in Cambridge, U.K. This project is now turning to sequencing C. elegans DNA as a logical extension of this work. These are but the first fruits of the genome project. There is much more to come.			WATSON, JD (corresponding author), NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892, USA.			Cook-Deegan, Robert/0000-0002-8251-4237				ALBERTS BM, 1985, CELL, V41, P337, DOI 10.1016/S0092-8674(85)80001-5; ALWEN J, 1990, GENOMICS, V7, P386; [Anonymous], 1988, MAPPING SEQUENCING H; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; COOKDEEGAN RM, 1989, GENOMICS, V5, P661, DOI 10.1016/0888-7543(89)90042-6; COOKDEEGAN RM, IN PRESS HUMAN GENOM; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DELISI C, 1988, AM SCI, V76, P488; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DULBECCO R, 1986, SCIENCE, V231, P1055, DOI 10.1126/science.3945817; DULBECCO R, 1990, GENOMICS, V7, P294, DOI 10.1016/0888-7543(90)90555-9; LEWIN R, 1986, SCIENCE, V232, P1598, DOI 10.1126/science.3715466; LEWIN R, 1986, SCIENCE, V233, P157, DOI 10.1126/science.3088726; PINES M, 1986, SHALL WE GRASP OPPOR; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SINSHEIMER RL, 1989, GENOMICS, V5, P954, DOI 10.1016/0888-7543(89)90142-0; SOLOMON E, 1979, LANCET, V1, P923; 1990, DOEER0452P NAT TECHN; 1987, REPORT HUMAN GENOME; 1986, TECHNOLOGIES DETECTI; 1988, OTABA373 OFF TECHN A	23	43	45	3	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					8	11		10.1096/fasebj.5.1.1991595	http://dx.doi.org/10.1096/fasebj.5.1.1991595			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991595	Green Submitted			2022-12-28	WOS:A1991ET60900002
J	KATO, GJ; DANG, CV				KATO, GJ; DANG, CV			FUNCTION OF THE C-MYC ONCOPROTEIN	FASEB JOURNAL			English	Review						HELIX-LOOP-HELIX; LEUCINE ZIPPER; NUCLEAR LOCALIZATION SIGNAL; TRANSCRIPTIONAL ACTIVATION; MAX; DNA BINDING; TRANSCRIPTION FACTOR; ONCOGENES	DNA-BINDING DOMAIN; T-CELL LEUKEMIAS; V-MYC; BURKITT-LYMPHOMA; LEUCINE ZIPPER; N-MYC; ERYTHROLEUKEMIA-CELLS; TRANSFORMING ACTIVITY; HUMAN NEUROBLASTOMAS; GENE FAMILY	The c-Myc protein, the product of the c-myc proto-oncogene, is a nuclear phosphoprotein with DNA binding properties. Deregulated c-myc expression participates in the development of experimentally induced tumors, and its expression appears to be abnormal in many naturally occurring malignancies. Although the precise molecular mechanism of c-Myc activity in oncogenesis and in normal cell proliferation is unknown, recent advances have uncovered a series of molecular and cellular properties of c-Myc. These properties include nuclear localization, transcriptional activation, oligomerization, nonspecific and specific DNA binding. Recently, the c-Myc protein was found to heterodimerize with Max, a protein that cooperates with c-Myc to bind specifically to a core DNA sequence, CAC(G/A)TG. These characteristics suggest that c-Myc participates in the regulation of gene transcription in normal and neoplastic cells.	JOHNS HOPKINS UNIV, SCH MED,DEPT MED,1012 ROSS RES BLDG, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, DIV HEMATOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine			Kato, Gregory J/I-7615-2014; Dang, Chi/Y-3375-2019	Kato, Gregory J/0000-0003-4465-3217; Dang, Chi/0000-0002-4031-2522	NATIONAL CANCER INSTITUTE [R37CA051497, K11CA001622, R01CA051497, R29CA051497, R01CA057341] Funding Source: NIH RePORTER; NCI NIH HHS [CA57341, CA51497, K11CA01622] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; ARGAUT C, 1991, GENE, V97, P231, DOI 10.1016/0378-1119(91)90056-H; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUESBERG PH, 1977, P NATL ACAD SCI USA, V74, P4320, DOI 10.1073/pnas.74.10.4320; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRYBERG L, 1987, ONCOGENE, V1, P415; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; KERHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323; KERHOFF E, 1991, ONCOGENE, V6, P93; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PEAR WS, 1988, MOL CELL BIOL, V8, P441, DOI 10.1128/MCB.8.1.441; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	97	160	166	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3065	3072		10.1096/fasebj.6.12.1521738	http://dx.doi.org/10.1096/fasebj.6.12.1521738			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521738				2022-12-28	WOS:A1992JN50500007
J	OPGENORTH, TJ; WUWONG, JR; SHIOSAKI, K				OPGENORTH, TJ; WUWONG, JR; SHIOSAKI, K			ENDOTHELIN-CONVERTING ENZYMES	FASEB JOURNAL			English	Review						ENDOTHELIAL CELLS; PEPSTAIN; PHOSPHORAMIDON; ASPARTIC PROTEASE; METALLOPROTEASE	CATHEPSIN D-LIKE; BIG ENDOTHELIN-1; METALLOPROTEINASE INHIBITOR; VASOCONSTRICTOR ACTIVITY; C-FOS; CELLS; CONVERSION; EXPRESSION; PHOSPHORAMIDON; SECRETION	The putative endothelin-converting enzyme (ECE) has been the focus of intense research, both within academia and the pharmaceutical industry. Interest in ECE stems mainly from the hypothesis that development of inhibitors of ECE will provide an effective means of preventing production of endothelin in circumstances where it may play a pathogenic role. Both an aspartic and, a metalloprotease have been identified that have characteristics of this putative enzyme. Evidence suggests that the metalloprotease, which is inhibited by phosphoramidon, may be the physiologically relevant converting enzyme. However, it remains to be demonstrated conclusively that any inhibitor of an ECE activity directly alters endogenous endothelin production and/or the pathogenesis of a disease condition in which endothelin is thought to play a primary role.			OPGENORTH, TJ (corresponding author), ABBOTT LABS,DEPT 47V,DIV PHARMACEUT PROD,AP9-2,N CHICAGO,IL 60064, USA.				NHLBI NIH HHS [HL44512] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044512] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUDZIK GP, 1991, FASEB J, V5, pA1017; DEGOUVILLE ACL, 1991, BRIT J PHARMACOL, V104, P77; DEVINE EM, 1991, FASEB J, V5, pA1417; DICKINSON KEJ, 1991, BIOCHEM BIOPH RES CO, V176, P423, DOI 10.1016/0006-291X(91)90941-Y; DORLEANSJUSTE P, 1991, BRIT J PHARMACOL, V104, P441; DORLEANSJUSTE P, 1990, BIOCHEM PHARMACOL, V29, P821; EMORI T, 1989, BIOCHEM BIOPH RES CO, V162, P217, DOI 10.1016/0006-291X(89)91984-0; EMORI T, 1989, BIOCHEM BIOPH RES CO, V160, P93, DOI 10.1016/0006-291X(89)91625-2; FAGNY C, 1991, PEPTIDES, V12, P773, DOI 10.1016/0196-9781(91)90132-9; FIGUEIREDO AFS, 1983, BIOCHEMISTRY-US, V22, P5476, DOI 10.1021/bi00293a004; FUKURODA T, 1990, BIOCHEM BIOPH RES CO, V172, P390, DOI 10.1016/0006-291X(90)90685-G; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARDINER SM, 1991, BRIT J PHARMACOL, V103, P2009, DOI 10.1111/j.1476-5381.1991.tb12368.x; HEMSEN A, 1991, ACTA PHYSIOL SCAND, V141, P325, DOI 10.1111/j.1748-1716.1991.tb09088.x; HEXUM TD, 1990, BIOCHEM BIOPH RES CO, V167, P294, DOI 10.1016/0006-291X(90)91764-J; HICKEY KA, 1985, AM J PHYSIOL, V248, pC550, DOI 10.1152/ajpcell.1985.248.5.C550; HIOKI Y, 1991, BIOCHEM BIOPH RES CO, V174, P446, DOI 10.1016/0006-291X(91)91436-G; HISAKI K, 1991, BIOCHEM BIOPH RES CO, V177, P1127, DOI 10.1016/0006-291X(91)90656-R; HOFFMAN A, 1990, EUR J PHARMACOL, V182, P603, DOI 10.1016/0014-2999(90)90064-D; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V171, P669, DOI 10.1016/0006-291X(90)91198-2; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V167, P860, DOI 10.1016/0006-291X(90)92104-8; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KASHIWABARA T, 1989, FEBS LETT, V247, P73, DOI 10.1016/0014-5793(89)81243-8; KIMURA S, 1989, J CARDIOVASC PHARM, V13, pS5, DOI 10.1097/00005344-198900135-00003; KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; KON V, 1989, J CLIN INVEST, V83, P1762, DOI 10.1172/JCI114079; KON V, 1990, KIDNEY INT, V37, P1487, DOI 10.1038/ki.1990.139; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KRAUS GE, 1991, SURG NEUROL, V35, P20, DOI 10.1016/0090-3019(91)90197-H; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; LAGENTE V, 1991, CLIN EXP ALLERGY, V20, P343; LEAK LV, 1980, ELECTRON MICROS, V5, P87; LEES WE, 1990, FEBS LETT, V273, P99, DOI 10.1016/0014-5793(90)81060-2; LERMAN A, 1990, MAYO CLIN P, V65, P1395; LOVENBERG W, 1990, NEUROCHEM RES, V15, P407, DOI 10.1007/BF00969926; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; MASAKI T, 1990, J HYPERTENS, V8, pS107; MATSUMURA Y, 1990, FEBS LETT, V272, P166, DOI 10.1016/0014-5793(90)80475-X; MATSUMURA Y, 1990, BIOCHEM BIOPH RES CO, V167, P203, DOI 10.1016/0006-291X(90)91751-D; MATSUMURA Y, 1990, EUR J PHARMACOL, V185, P103, DOI 10.1016/0014-2999(90)90216-S; MATSUMURA Y, 1991, BIOCHEM BIOPH RES CO, V178, P899, DOI 10.1016/0006-291X(91)90976-E; MATSUMURA Y, 1991, LIFE SCI, V49, P841, DOI 10.1016/0024-3205(91)90249-B; MATSUMURA Y, 1991, BIOCHEM BIOPH RES CO, V178, P531, DOI 10.1016/0006-291X(91)90140-3; MCMAHON EG, 1991, P NATL ACAD SCI USA, V88, P703, DOI 10.1073/pnas.88.3.703; MCMAHON EG, 1989, BIOCHEM BIOPH RES CO, V161, P406, DOI 10.1016/0006-291X(89)92613-2; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; NAYLER WG, 1989, J APPL CARDIOL, V4, P495; OHNAKA K, 1990, BIOCHEM BIOPH RES CO, V168, P1128, DOI 10.1016/0006-291X(90)91146-J; OHNAKA K, 1991, BIOCHEM INT, V23, P499; OHTA K, 1990, BIOCHEM BIOPH RES CO, V169, P578, DOI 10.1016/0006-291X(90)90370-3; OKADA K, 1991, BIOCHEM BIOPH RES CO, V180, P1019, DOI 10.1016/S0006-291X(05)81167-2; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; PERICO N, 1990, J AM SOC NEPHROL, V1, P76; POLLOCK DM, 1991, AM J PHYSIOL, V261, pR257, DOI 10.1152/ajpregu.1991.261.1.R257; POLLOCK DM, 1991, BIOCHEM BIOPH RES CO, V179, P1122, DOI 10.1016/0006-291X(91)91936-7; POLLOCK DM, 1991, FASEB J, V5, pA399; RAFFA RB, 1991, LIFE SCI, V48, pPL85, DOI 10.1016/0024-3205(91)90130-4; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V172, P883, DOI 10.1016/0006-291X(90)90758-F; SAWAMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P779, DOI 10.1016/0006-291X(91)91485-U; SAWAMURA T, 1989, BIOCHEM BIOPH RES CO, V162, P1287, DOI 10.1016/0006-291X(89)90813-9; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V169, P1138, DOI 10.1016/0006-291X(90)92014-Q; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V168, P1230, DOI 10.1016/0006-291X(90)91160-T; SCHICHIRI M, 1991, J CLIN INVEST, V87, P1867; SESSA WC, 1991, BIOCHEM BIOPH RES CO, V174, P613, DOI 10.1016/0006-291X(91)91461-K; SHIELDS PP, 1991, BIOCHEM BIOPH RES CO, V177, P1006, DOI 10.1016/0006-291X(91)90638-N; SHINYAMA H, 1991, BIOCHEM BIOPH RES CO, V178, P24, DOI 10.1016/0006-291X(91)91774-7; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SUZUKI H, 1990, ACTA NEUROL SCAND, V81, P553; TAKADA J, 1991, BIOCHEM BIOPH RES CO, V176, P860, DOI 10.1016/S0006-291X(05)80265-7; TAKAOKA M, 1990, BIOCHEM BIOPH RES CO, V173, P1218, DOI 10.1016/S0006-291X(05)80916-7; TAKAOKA M, 1990, BIOCHEM J, V270, P541, DOI 10.1042/bj2700541; TAKAOKA M, 1990, BIOCHEM BIOPH RES CO, V166, P436, DOI 10.1016/0006-291X(90)91964-T; WATANABE T, 1991, CIRC RES, V69, P370, DOI 10.1161/01.RES.69.2.370; WUWONG JR, 1990, BIOCHEM BIOPH RES CO, V171, P1291, DOI 10.1016/0006-291X(90)90826-9; WUWONG JR, 1991, FASEB J, V5, pA698; WUWONG JR, 1991, J CARDIOVASC PHARM, V17, P520; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213; YONEZAWA S, 1987, ARCH BIOCHEM BIOPHYS, V256, P499, DOI 10.1016/0003-9861(87)90607-2; YOSHIZUMI M, 1989, BIOCHEM BIOPH RES CO, V161, P859, DOI 10.1016/0006-291X(89)92679-X; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R	85	217	227	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2653	2659		10.1096/fasebj.6.9.1612289	http://dx.doi.org/10.1096/fasebj.6.9.1612289			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612289				2022-12-28	WOS:A1992HZ48100005
J	REYNOLDS, LP; KILLILEA, SD; REDMER, DA				REYNOLDS, LP; KILLILEA, SD; REDMER, DA			ANGIOGENESIS IN THE FEMALE REPRODUCTIVE-SYSTEM	FASEB JOURNAL			English	Article						ANGIOGENESIS; VASCULAR GROWTH; FEMALE; OVARY; UTERUS; PLACENTA	FIBROBLAST GROWTH-FACTOR; CORPUS-LUTEUM; PLACENTAL TISSUES; RAT; OVARY; NEOVASCULARIZATION; PROLIFERATION; PREGNANCY; GESTATION; FOLLICLE	In adult tissues, capillary growth (angiogenesis) occurs normally during tissue repair, such as in healing of wounds and fractures. Rampant capillary growth is associated with various pathological conditions, including tumor growth, retinopathies, hemangiomas, fibroses and rheumatoid arthritis. The female reproductive organs (i.e., ovary, uterus, and placenta) exhibit dynamic, periodic growth and regression accompanied by equally dramatic changes in rates of blood flow. It is not surprising, therefore, that they are some of the few adult tissues in which angiogenesis occurs as a normal process. Thus, the female reproductive system provides a unique model for studying regulation of angiogenesis during growth and differentiation of normal adult tissues. Ovarian, uterine, and placental tissues recently have been shown to contain and produce angiogenic and anti-angiogenic factors. This review discusses the current state of knowledge regarding angiogenic processes and their regulation in female reproductive tissues. In addition, implications of this research for regulation of fertility as well as for control of angiogenesis in other normal and pathological processes are discussed.	N DAKOTA STATE UNIV, DEPT BIOCHEM, FARGO, ND 58105 USA	North Dakota State University Fargo	REYNOLDS, LP (corresponding author), N DAKOTA STATE UNIV, DEPT ANIM & RANGE SCI, STATE UNIV STN, POB 5727, FARGO, ND 58105 USA.		Reynolds, Lawrence P/I-5267-2015	Reynolds, Lawrence P/0000-0002-6838-7809	NICHD NIH HHS [HD22559] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022559] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABEL MH, 1985, MECHANISMS MENSTRUAL, V25, P139; ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; ANDERSON DH, 1926, CONTRIB EMBRYOL CARN, V88, P109; [Anonymous], 1989, ANIMAL GROWTH REGULA; BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; Barcroft J., 1947, RES PRENATAL LIFE; Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206; BERANEK JT, 1988, CANCER J, V2, P87; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURGOS H, 1989, J ROY SOC MED, V82, P598, DOI 10.1177/014107688908201011; CLARK JG, 1900, J HOPKINS HOSP REP, V9, P593; DENEKAMP J, 1984, PROG APPLIED MICROCI, V4, P28; DHARMARAJAN AM, 1985, AM J ANAT, V172, P87, DOI 10.1002/aja.1001720107; ECKSTEIN P, 1952, MARSHALLS PHYSL REPR, V1, P543; EISENSTEIN R, 1991, PHARMACOL THERAPEUT, V49, P1, DOI 10.1016/0163-7258(91)90019-I; ERB RE, 1961, J DAIRY SCI, V44, P888, DOI 10.3168/jds.S0022-0302(61)89829-9; FERENCZY A, 1979, AM J OBSTET GYNECOL, V133, P859, DOI 10.1016/0002-9378(79)90302-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORD SP, 1982, BIOL REPROD, V27, P878, DOI 10.1095/biolreprod27.4.878; GAEDE SD, 1985, AM J ANAT, V172, P173, DOI 10.1002/aja.1001720206; GOSPODAROWICZ D, 1978, P NATL ACAD SCI USA, V75, P847, DOI 10.1073/pnas.75.2.847; GRAZULBILSKA AT, 1992, J ANIM SCI, V70, P254, DOI 10.2527/1992.701254x; Greenwald G.S., 1988, P387; GREENWALD GS, 1989, BIOL REPROD, V41, P175, DOI 10.1095/biolreprod41.1.175; Hudlicka O., 1984, HDB PHYSL 1 2, P165; JAKOB W, 1977, EXP PATHOL-JENA, V13, P231, DOI 10.1016/S0014-4908(77)80007-0; JONES GS, 1970, AM J OBSTET GYNECOL, V108, P847, DOI 10.1016/0002-9378(70)90327-3; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOOS R, 1983, FACTORS REGULATING O, P191; KOOS RD, 1989, SEMIN REPROD ENDOCR, V7, P29, DOI 10.1055/s-2007-1021379; KOOS RD, 1989, MOL ENDOCRINOL, V3, P2041, DOI 10.1210/mend-3-12-2041; MAKRIS A, 1984, ENDOCRINOLOGY, V115, P1672, DOI 10.1210/endo-115-5-1672; Markee JE, 1932, AM J PHYSIOL, V100, P374, DOI 10.1152/ajplegacy.1932.100.2.374; MARKEE JE, 1940, CONTRIB EMBRYOL, V177, P221; MEEGDES BHLM, 1988, FERTIL STERIL, V49, P216; Meschia G., 1983, HDB PHYSL 2, VIII, P241; MILLAWAY DS, 1989, J REPROD FERTIL, V86, P689; MOOR RM, 1986, J DAIRY SCI, V69, P927, DOI 10.3168/jds.S0022-0302(86)80482-9; MOSCATELLI D, 1988, BIOCHIMIE, V70, P83, DOI 10.1016/0300-9084(88)90162-9; NEUFELD G, 1987, ENDOCRINOLOGY, V121, P597, DOI 10.1210/endo-121-2-597; Niswender G.D., 1988, P489; ODEDRA R, 1991, PHARMACOL THERAPEUT, V49, P111, DOI 10.1016/0163-7258(91)90025-H; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PRESTA M, 1988, J CELL PHYSIOL, V137, P593, DOI 10.1002/jcp.1041370329; Ramsey E. M., 1982, PLACENTA HUMAN ANIMA; REDMER D A, 1990, Journal of Cell Biology, V111, p448A; REDMER DA, 1988, J REPROD FERTIL, V82, P627, DOI 10.1530/jrf.0.0820627; REDMER DA, 1991, J ANIM SCI, V69, P237; REDMER DA, 1985, P SOC EXP BIOL MED, V179, P136; REDMER DA, 1987, REGULATION OVARIAN T, V219, P683; REDMER DA, 1985, 67TH P ANN M ENDOCRI, P151; REYNOLD LP, 1988, J REPR FERT ABSTR SE, V1, P43; Reynolds L P, 1986, J Anim Sci, V62 Suppl 2, P47; REYNOLDS LP, 1988, J REPROD FERTIL, V83, P497; REYNOLDS LP, 1987, J REPROD FERTIL, V81, P233, DOI 10.1530/jrf.0.0810233; REYNOLDS LP, 1991, BIOL REPROD S1, V44, P162; RONE JD, 1990, ENDOCRINOLOGY, V127, P2821, DOI 10.1210/endo-127-6-2821; ROSENFELD CR, 1974, GYNECOL OBSTET INVES, V5, P252, DOI 10.1159/000301658; SHEPRO D, 1984, HDB PHYSL 1 2, V4, P103; STIRLING D, 1991, J REPROD FERTIL, V91, P1, DOI 10.1530/jrf.0.0910001; TARASKA T, 1989, SERONO SYMP, P267; TEASDALE F, 1976, ANAT RECORD, V185, P187, DOI 10.1002/ar.1091850206; TIOLLIER J, 1990, INSERM C, V199, P98; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; ZELEZNIK AJ, 1981, ENDOCRINOLOGY, V109, P356, DOI 10.1210/endo-109-2-356	65	374	384	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					886	892		10.1096/fasebj.6.3.1371260	http://dx.doi.org/10.1096/fasebj.6.3.1371260			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1371260				2022-12-28	WOS:A1992HE39000012
J	LANE, BG				LANE, BG			CELLULAR DESICCATION AND HYDRATION - DEVELOPMENTALLY REGULATED PROTEINS, AND THE MATURATION AND GERMINATION OF SEED EMBRYOS	FASEB JOURNAL			English	Review						PLANT DEVELOPMENT; MOLECULAR BIOLOGY; GROWTH; CELL ENLARGEMENT	IMBIBING WHEAT EMBRYOS; TRANSLATABLE MESSENGER-RNA; LABELED EM POLYPEPTIDE; AMINO-ACID-SEQUENCE; GERM-EC-PROTEIN; ABSCISIC-ACID; MOLECULAR-CLONING; SYNTHESIZING SYSTEMS; NUCLEOTIDE-SEQUENCE; POLYADENYLATED RNA	Little more than a decade ago, 2-dimensional mapping of proteins and biochemical study of their allied coding elements (mRNA and DNA) were first used to probe possible changes in the embryo during seed germination. Because specification was of primary importance, our attention was initially directed toward the characterization of individual proteins and coding elements which, in preliminary surveys of the germinating wheat embryo, were found to be conspicuously subject to developmental regulation. Three of the proteins have become subjects of comprehensive investigations in this and other laboratories: the Em protein, the Ec protein, and germin. The Em and Ec proteins are encoded by the conserved mRNA 'stored' in the mature embryos of dry, field-ripened seeds but germin is encoded by the nascent mRNA formed after mature embryos are germinated in water. The Ec protein is the only bona fide Zn metallothionein yet found in higher plants. Studies of their biology and molecular biology suggest that the Em protein has a role in hormone-mediated abscisic acid) cellular desiccation and that germin has a role in hormone-mediated (auxin) cellular hydration. It is projected that further studies of the Em protein may help elucidate the molecular basis for a loss of desiccation tolerance during germination, and that further studies of germin may help elucidate the molecular basis of plant cell enlargement.			LANE, BG (corresponding author), UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA.							ADDICOTT FT, 1969, ANN REV PLANT PHYSIO, V20, P139, DOI 10.1146/annurev.pp.20.060169.001035; BAKER J, 1988, PLANT MOL BIOL, V11, P277, DOI 10.1007/BF00027385; BARTELS D, 1990, PLANTA, V181, P27, DOI 10.1007/BF00202321; BERNIER F, 1987, GENE, V59, P265, DOI 10.1016/0378-1119(87)90334-9; Bewley J.D., 1978, PHYSL BIOCH SEEDS RE; BROWN R, 1946, ANN BOT-LONDON, V10, P73, DOI 10.1093/oxfordjournals.aob.a083120; CATTIVELLI L, 1989, PLANTA, V178, P184, DOI 10.1007/BF00393193; CHEUNG CP, 1979, NATURE, V277, P66, DOI 10.1038/277066a0; CLELAND R, 1976, S SOC EXP BIOL, V31, P101; CLOSE TJ, 1989, PLANT MOL BIOL, V13, P95, DOI 10.1007/BF00027338; COX W, 1976, PLANT PHYSIOL, V57, P553, DOI 10.1104/pp.57.4.553; CUMING AC, 1978, CAN J BIOCHEM CELL B, V56, P365, DOI 10.1139/o78-058; CUMING AC, 1984, EUR J BIOCHEM, V145, P351, DOI 10.1111/j.1432-1033.1984.tb08561.x; CUMING AC, 1979, EUR J BIOCHEM, V99, P217, DOI 10.1111/j.1432-1033.1979.tb13248.x; CUMING AC, 1979, CAN J BIOCHEM CELL B, V57, P1170, DOI 10.1139/o79-151; CUMING AC, 1984, BIOCHIM BIOPHYS ACTA, V783, P42, DOI 10.1016/0167-4781(84)90076-9; DAPPOLONIA BL, 1978, WHEAT CHEM TTECHNOLO, P311; DEHERDT E, 1981, BIOCHEM J, V194, P9, DOI 10.1042/bj1940009; DEVRIES SC, 1985, PLANT MOL BIOL, V4, P95, DOI 10.1007/BF02418755; DOBRZANSKA M, 1973, NATURE, V244, P507, DOI 10.1038/244507a0; DOYLE JA, 1978, ANNU REV ECOL SYST, V9, P365, DOI 10.1146/annurev.es.09.110178.002053; DRATEWKAKOS E, 1989, J BIOL CHEM, V264, P4896; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; FISCHER W, 1988, BOT ACTA, V101, P344, DOI 10.1111/j.1438-8677.1988.tb00055.x; FORDIN H, 1977, GETTING KNOW HIM, P187; FUTERS TS, 1990, THEOR APPL GENET, V80, P43, DOI 10.1007/BF00224014; GALAU GA, 1981, BIOCHEMISTRY-US, V20, P4169, DOI 10.1021/bi00517a034; GIBBS CJ, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91336-9; Gorman J. A., 1980, GROWTH DIFFERENTIATI, P157; GRZELCZAK ZF, 1983, CAN J BIOCHEM CELL B, V61, P1233, DOI 10.1139/o83-159; GRZELCZAK ZF, 1985, CAN J BIOCHEM CELL B, V63, P1003, DOI 10.1139/o85-125; GRZELCZAK ZF, 1984, CAN J BIOCHEM CELL B, V62, P1351, DOI 10.1139/o84-172; GRZELCZAK ZF, 1982, CAN J BIOCHEM, V60, P38; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; HANLEYBOWDOIN LK, 1983, EUR J BIOCHEM, V6135, P9; HELM KW, 1990, PLANT PHYSIOL, V93, P1626, DOI 10.1104/pp.93.4.1626; HELM KW, 1989, PLANT PHYSIOL, V90, P598, DOI 10.1104/pp.90.2.598; HOFMANN T, 1984, CAN J BIOCHEM CELL B, V62, P908, DOI 10.1139/o84-116; HURKMAN W J, 1990, Plant Physiology (Rockville), V93, P108; HURKMAN WJ, 1989, PLANT PHYSIOL, V90, P1444, DOI 10.1104/pp.90.4.1444; Hurkman WJ, 1990, ENV INJURY PLANTS, P205; IHLE JN, 1970, BIOCHEM BIOPH RES CO, V38, P995, DOI 10.1016/0006-291X(70)90338-4; IHLE NJ, 1972, J BIOL CHEM, V247, P5048; JAIKARAN ASI, 1990, J BIOL CHEM, V265, P12503; JENDRISAK J, 1980, J BIOL CHEM, V255, P8529; JOHNSTON FB, 1957, NATURE, V179, P160, DOI 10.1038/179160b0; KENNEDY TD, 1981, J BIOL CHEM, V256, P5802; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE B, 1987, BIOCHEM CELL BIOL, V65, P1001, DOI 10.1139/o87-131; LANE B, 1987, BIOCHEM CELL BIOL, V65, P354, DOI 10.1139/o87-045; LANE BG, 1986, BIOCHEM CELL BIOL, V64, P1025, DOI 10.1139/o86-136; LANE BG, 1988, ROOTS OF MODERN BIOCHEMISTRY, P457; LANE BG, 1991, J BIOL CHEM, V266, P10461; LANE BG, 1981, EUR J BIOCHEM, V114, P457, DOI 10.1111/j.1432-1033.1981.tb05167.x; LANE BG, 1985, LIPMANN S CELLULAR R, P311; LIN CT, 1990, PLANT PHYSIOL, V94, P1078, DOI 10.1104/pp.94.3.1078; LITTS JC, 1987, NUCLEIC ACIDS RES, V15, P3607, DOI 10.1093/nar/15.8.3607; LONSDALE D, 1990, J EXP BOT, V41, P1161, DOI 10.1093/jxb/41.9.1161; LYTTLETON JW, 1960, NATURE, V187, P1026, DOI 10.1038/1871026a0; MANICKAM A, 1980, PLANTA, V149, P234, DOI 10.1007/BF00384559; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; Marcus A, 1969, Symp Soc Exp Biol, V23, P143; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCLURE BA, 1989, PLANT CELL, V1, P229, DOI 10.1105/tpc.1.2.229; MCCUBBIN WC, 1987, BIOCHEM CELL BIOL, V65, P1039, DOI 10.1139/o87-136; MCCUBBIN WD, 1985, CAN J BIOCHEM CELL B, V63, P803, DOI 10.1139/o85-102; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MISRA S, 1985, J EXP BOT, V36, P1644, DOI 10.1093/jxb/36.10.1644; MISRA S, 1986, J EXP BOT, V37, P364, DOI 10.1093/jxb/37.3.364; MORRIS CF, 1991, PLANT PHYSIOL, V95, P814, DOI 10.1104/pp.95.3.814; MORRIS PC, 1990, EUR J BIOCHEM, V190, P625, DOI 10.1111/j.1432-1033.1990.tb15618.x; Murray D. R., 1979, Plant, Cell and Environment, V2, P221, DOI 10.1111/j.1365-3040.1979.tb00073.x; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAYNE PI, 1976, BIOL REV, V51, P329, DOI 10.1111/j.1469-185X.1976.tb01129.x; Peterson RF, 1965, WHEAT; PIATKOWSKI D, 1990, PLANT PHYSIOL, V94, P1682, DOI 10.1104/pp.94.4.1682; Quatrano R. S., 1986, Oxford Surveys of Plant Molecular and Cell Biology, V3, P467; RAHMAN S, 1988, BIOCHEM CELL BIOL, V66, P100, DOI 10.1139/o88-013; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; ROGERS SO, 1983, AM J BOT, V70, P308, DOI 10.2307/2443277; RUSHTON PJ, 1987, PLANT SCI, V51, P51, DOI 10.1016/0168-9452(87)90220-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGREST JP, 1983, J BIOL CHEM, V258, P2290; SHOTWELL MA, 1989, BIOCH PLANTS COMPREH, V15, P297; Shurpalekar S R, 1977, Adv Food Res, V23, P187, DOI 10.1016/S0065-2628(08)60329-8; SIMINOVITCH D, 1983, CRYOBIOLOGY, V20, P487, DOI 10.1016/0011-2240(83)90037-8; SMITH CAD, 1982, PLANTA, V156, P413; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; THOMPSON EW, 1980, J BIOL CHEM, V255, P5965; VOLGER HG, 1975, BIOCHIM BIOPHYS ACTA, V412, P335, DOI 10.1016/0005-2795(75)90048-3; WEEKS DP, 1971, BIOCHIM BIOPHYS ACTA, V232, P671, DOI 10.1016/0005-2787(71)90759-3; WILLIAMS RF, 1972, SHOOT APEX LEAF GROW, P9; WILLIAMSON JD, 1985, EUR J BIOCHEM, V152, P501, DOI 10.1111/j.1432-1033.1985.tb09224.x; WILLIAMSON JD, 1988, PLANT PHYSIOL, V86, P208, DOI 10.1104/pp.86.1.208; WOLFE FH, 1967, BIOCHEMISTRY-US, V6, P2853, DOI 10.1021/bi00861a028; XU N, 1990, PLANTA, V182, P382, DOI 10.1007/BF02411389; [No title captured]	100	75	81	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2893	2901		10.1096/fasebj.5.14.1752357	http://dx.doi.org/10.1096/fasebj.5.14.1752357			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752357				2022-12-28	WOS:A1991GP26900003
J	NIECE, RL; BEACH, CM; COOK, RF; HATHAWAY, GM; WILLIAMS, KR				NIECE, RL; BEACH, CM; COOK, RF; HATHAWAY, GM; WILLIAMS, KR			STATE-OF-THE-ART BIOMOLECULAR CORE FACILITIES - A COMPREHENSIVE SURVEY	FASEB JOURNAL			English	Article						CORE FACILITY; BIOPOLYMER FACILITY; PROTEIN SEQUENCING; PEPTIDE SYNTHESIS; DNA SYNTHESIS; AMINO ACID ANALYSIS		A survey of 124 protein and/or nucleic acid chemistry facilities has provided a basis for estimating the resources needed to establish a facility, the financial support needed to keep it operating, and the technical capabilities it might reasonably be expected to achieve. Based on these data, an average core facility occupied 870 ft2, was staffed by three full-time personnel, and was equipped with 4-5 major instrument systems. Because user fees generated an average of about $101,000/year in income compared with an average operating budget of about $197,000/year, even a facility that charged user fees would, on average, still require an annual subsidy of about $96,000. Although most government and industrial core facilities did not assess user fees, at least 83 of the 124 respondents did have a preestablished schedule of service charges that enabled a compilation to be made of the average cost of providing a number of typical facility analyses and syntheses. The greater than 100-fold range in charges assessed in core facilities for seemingly identical services was shown to result from the equally large range in the degree of subsidization of these laboratories. Although an average facility might be expected to offer four or five of the following six major services-amino acid sequencing, amino acid analysis, HPLC peptide isolation, peptide synthesis, fragmentation of proteins and DNA synthesis-less than 10% of the responding laboratories provided mass spectrometry, capillary zone electrophoresis, or RNA synthesis. With the exception of peptide synthesis, which had an average turn-around time of about 24 days, all other major services had turn-around times that averaged in the range of 4-9 days. Additional data are summarized regarding average sample throughput in core laboratories and the amount of protein that is needed for hydrolysis/amino acid analysis and sequencing.	YALE UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; UNIV WISCONSIN,CTR BIOTECHNOL,MADISON,WI 53705; UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40536; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	Howard Hughes Medical Institute; Yale University; University of Wisconsin System; University of Wisconsin Madison; University of Kentucky; Massachusetts Institute of Technology (MIT); University of California System; University of California Riverside			Williams, Kenneth/B-5986-2016	Williams, Kenneth/0000-0001-7792-9588				Atherton D., 1989, TECHNIQUES PROTEIN C, P273; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; Crabb JW, 1990, CURRENT RES PROTEIN, P49; ERICSSON LH, 1991, METHODS PROTEIN SEQU, P143; Niece R. L., 1989, TECHNIQUES PROTEIN C, P89; WILLIAMS KR, 1988, FASEB J, V2, P3124, DOI 10.1096/fasebj.2.15.3192042	6	8	8	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2756	2760		10.1096/fasebj.5.13.1916100	http://dx.doi.org/10.1096/fasebj.5.13.1916100			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916100				2022-12-28	WOS:A1991GJ47100002
J	KENT, C; CARMAN, GM; SPENCE, MW; DOWHAN, W				KENT, C; CARMAN, GM; SPENCE, MW; DOWHAN, W			REGULATION OF EUKARYOTIC PHOSPHOLIPID-METABOLISM	FASEB JOURNAL			English	Article						PHOSPHOLIPID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOSPHATIDYLSERINE	PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; CHINESE-HAMSTER OVARY; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; YEAST PHOSPHATIDYLSERINE SYNTHASE; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; RAT-LIVER; ENDOPLASMIC-RETICULUM; PHOSPHATIDATE PHOSPHATASE; MAMMALIAN-CELLS	Phospholipids have diverse and critical roles in cellular metabolism and function. Questions about the mechanisms of regulation of phospholipid synthesis are being investigated with a variety of systems and approaches. For example, the yeast Saccharomyces cerevisiae is an organism in which both biochemical and genetic analyses are used. Biochemical approaches have yielded considerable information on the regulatory properties of enzymes of phospholipid biosynthesis. Studies of the activity of purified phosphatidylserine synthase have suggested how that enzyme is influenced by membrane phospholipids in the cell. The enzyme that regulates mammalian phosphatidylcholine biosynthesis, CTP:phosphocholine cytidylyltransferase, is also influenced by phospholipids. In addition, the activity of this enzyme often correlates with its translocation to membranes. The location of such enzymes in the cell is of particular interest in light of the possibility that thc enzymatic reactions may be efficiently coupled in vivo. Techniques to render cultured cells permeable to phosphorylated molecules indicate that the enzymes of phosphatidylcholine biosynthesis may exist in an organized compartment so that the precursors of phosphatidylcholine are efficiently channeled through the pathway. To ask how phospholipids are transported in the cell, a combined biochemical and genetic approach has been used. These studies have revealed that the phosphatidylinositol/ phosphatidylcholine transfer protein, considered to mediate intracellular phospholipid transfer, is a critical component of the secretory pathway for proteins. These results have allowed formulation of a number of new questions on the regulation of phospholipid metabolism and its relationship to general membrane processes.	RUTGERS STATE UNIV,DEPT FOOD SCI,NEW BRUNSWICK,NJ 08903; DALHOUSIE UNIV,ATLANTIC RES CTR MENTAL RETARDAT,HALIFAX B3H 4H7,NS,CANADA; UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77225	Rutgers State University New Brunswick; Dalhousie University; University of Texas System	KENT, C (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.							AITKEN JF, 1990, J BIOL CHEM, V265, P4711; BAELEE M, 1990, J BIOL CHEM, V265, P7221; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; COOK HW, 1989, J BIOL CHEM, V264, P2746; DANG CV, 1985, BIOCHIM BIOPHYS ACTA, V829, P319, DOI 10.1016/0167-4838(85)90239-0; Dennis EA, 1983, ENZYMES, P307; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; ENDO T, 1989, J BIOL CHEM, V264, P2951; FISCUS WG, 1966, J BIOL CHEM, V241, P3324; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P283, DOI 10.1016/0005-2760(89)90075-1; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HELMKAMP GM, 1985, CHEM PHYS LIPIDS, V38, P3, DOI 10.1016/0009-3084(85)90053-2; HIGGINS JA, 1987, J LIPID RES, V28, P268; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; ISHIDATE K, 1989, PHOSPHATIDYLCHOLINE, P9; JAMIL H, 1990, J BIOL CHEM, V265, P4332; KAMP HH, 1973, BIOCHIM BIOPHYS ACTA, V318, P313, DOI 10.1016/0005-2736(73)90196-X; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KENT C, 1990, IN PRESS PROG LIPID; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MASTERS CJ, 1981, CRC CR REV BIOCH MOL, V11, P105, DOI 10.3109/10409238109108700; MORAND JN, 1989, J BIOL CHEM, V264, P13785; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PATHAK RK, 1986, J CELL BIOL, V102, P2158, DOI 10.1083/jcb.102.6.2158; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P447, DOI 10.1016/0005-2760(84)90171-1; PELECH SL, 1982, J BIOL CHEM, V257, P4198; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PLUCKTHUN A, 1985, J BIOL CHEM, V260, P1099; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; SANDERMANN H, 1986, J BIOL CHEM, V261, P6201; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SLEIGHT R, 1983, J BIOL CHEM, V258, P831; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; TERCE F, 1988, J BIOL CHEM, V263, P3142; TREVES S, 1987, EXP CELL RES, V168, P285, DOI 10.1016/0014-4827(87)90001-2; TRIVEDI A, 1988, INTEGRATION MITOCHON, P87; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; WARREN G, 1990, NATURE, V345, P382, DOI 10.1038/345382a0; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WESTERMAN J, 1983, METHOD ENZYMOL, V98, P581; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615	55	41	43	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2258	2266		10.1096/fasebj.5.9.1860617	http://dx.doi.org/10.1096/fasebj.5.9.1860617			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860617				2022-12-28	WOS:A1991FP87200006
J	CAVE, WT				CAVE, WT			DIETARY N-3 (OMEGA-3) POLYUNSATURATED FATTY-ACID EFFECTS ON ANIMAL TUMORIGENESIS	FASEB JOURNAL			English	Article						PROSTAGLANDINS; LEUKOTRIENES; SOLID TUMORS; DIETARY LIPIDS; TUMOR DEVELOPMENT; MAMMARY TUMOR; COLON TUMOR; PROSTATE TUMOR	INDUCED COLON CARCINOGENESIS; INDUCED PRENEOPLASTIC LESIONS; POLY-UNSATURATED FAT; RAT MAMMARY-TUMOR; FISH OIL; MENHADEN OIL; F344 RATS; LARGE BOWEL; GROWTH; AZOXYMETHANE	Environmental variables influence the incidence and expression of disease. Dietary fat is one environmental variable that has been associated experimentally and epidemiologically with alterations in certain types of tumorigenesis. Recently, detailed biochemical analyses have shown that not all fatty acid families possess the same tumor-promoting potential. In general, diets containing high levels of the n-6 polyunsaturated fatty acids have routinely enhanced tumorigenesis in lipid sensitive carcinogen-induced and tumor transplant tumor models, whereas diets with equivalent levels of n-3 polyunsaturated fatty acids have diminished tumorigenesis. At present, there is no definitive biochemical mechanism that fully explains these observations, but several possibilities have been proposed. One of the most attractive of these hypotheses is that each polyunsaturated fatty acid family has an individual effect on eicosanoid metabolism which determines its tumor-promoting potential. Regardless of current uncertainties about mechanisms of action, however results of numerous animal models affirm the importance of qualitative, as well as quantitative, dietary lipid differences on tumorigenesis. This knowledge strengthens the probability that further advances in our understanding of lipid-tumor interrelationships will have important preventive and therapeutic medical benefits.	UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester	CAVE, WT (corresponding author), UNIV ROCHESTER, SCH MED & DENT, ENDOCRINE UNIT, ROCHESTER, NY 14642 USA.				NCI NIH HHS [CA-30629] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030629] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUELELA SH, 1989, CANCER RES, V49, P1434; ABOUELELA SH, 1988, LIPIDS, V23, P948, DOI 10.1007/BF02536342; BLANK EW, 1989, J STEROID BIOCHEM, V34, P149, DOI 10.1016/0022-4731(89)90076-9; BORGESON CE, 1989, LIPIDS, V24, P290, DOI 10.1007/BF02535165; BRADEN LM, 1986, LIPIDS, V21, P285, DOI 10.1007/BF02536414; BROITMAN SA, 1977, CANCER-AM CANCER SOC, V40, P2455, DOI 10.1002/1097-0142(197711)40:5+<2455::AID-CNCR2820400911>3.0.CO;2-E; CANNIZZO F, 1989, CANCER RES, V49, P4289; CARROLL KK, 1979, LIPIDS, V14, P155, DOI 10.1007/BF02533866; CAVE WT, 1989, CARCINOGENESIS DIETA, P85; CAVE WT, 1987, P AOCS SHORT COURSE, P261; FADY C, 1988, ANTICANCER RES, V8, P225; FISCHER S, 1989, ADV LIPID RES, V23, P169; GABOR H, 1986, J NATL CANCER I, V76, P1223; GABOR H, 1990, CANCER LETT, V52, P173, DOI 10.1016/0304-3835(90)90184-Y; Ip C, 1986, Prog Clin Biol Res, V222, P283; JURKOWSKI JJ, 1985, J NATL CANCER I, V74, P1145; Karmali R A, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P886; KARMALI RA, 1984, J NATL CANCER I, V73, P457, DOI 10.1093/jnci/73.2.457; KARMALI RA, 1987, ANTICANCER RES, V7, P1173; KARMALI RA, 1989, ANTICANCER RES, V9, P1161; KIDWELL WR, 1978, CANCER RES, V38, P4091; KORT WJ, 1987, CARCINOGENESIS, V8, P611, DOI 10.1093/carcin/8.4.611; MICHA MS, 1979, CANCER RES, V39, P426; MINOURA T, 1988, CANCER RES, V48, P4790; NELSON RL, 1988, NUTR CANCER, V11, P215, DOI 10.1080/01635588809513990; NIGRO ND, 1986, J NATL CANCER I, V77, P1309; OCONNOR TP, 1989, J NATL CANCER I, V81, P858, DOI 10.1093/jnci/81.11.858; OCONNOR TP, 1985, J NATL CANCER I, V75, P959, DOI 10.1093/jnci/75.5.959; POLLARD M, 1985, PROSTATE, V6, P1, DOI 10.1002/pros.2990060102; PRITCHARD GA, 1989, BRIT J SURG, V76, P1069, DOI 10.1002/bjs.1800761028; REDDY BS, 1985, JNCI-J NATL CANCER I, V75, P791; REDDY BS, 1986, CANCER RES, V46, P3367; REDDY BS, 1984, JNCI-J NATL CANCER I, V72, P745; REDDY BS, 1988, CANCER RES, V48, P6642; ROEBUCK BD, 1981, CANCER RES, V41, P3961; ROSE DP, 1988, CARCINOGENESIS, V9, P603, DOI 10.1093/carcin/9.4.603; SAKAGUCHI M, 1986, CANCER RES, V46, P61; SILVERSTONE H, 1950, CANCER RES, V10, P448; Tannenbaum A, 1942, CANCER RES, V12, P468; TINSLEY IJ, 1981, CANCER RES, V41, P1460; WELSCH CW, 1983, DIETARY FATS HLTH, P760; WICHA MS, 1979, CANCER RES, V39, P426; WILLIAMS D, 1987, SCIENTIST, V1, P3	43	176	181	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1991	5	8					2160	2166		10.1096/fasebj.5.8.1673664	http://dx.doi.org/10.1096/fasebj.5.8.1673664			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1673664				2022-12-28	WOS:A1991FK11100007
J	BERG, P				BERG, P			ALL OUR COLLECTIVE INGENUITY WILL BE NEEDED	FASEB JOURNAL			English	Editorial Material											BERG, P (corresponding author), STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305, USA.								0	7	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					75	75		10.1096/fasebj.5.1.1991590	http://dx.doi.org/10.1096/fasebj.5.1.1991590			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991590				2022-12-28	WOS:A1991ET60900014
J	MONTAL, M				MONTAL, M			MOLECULAR ANATOMY AND MOLECULAR DESIGN OF CHANNEL PROTEINS	FASEB JOURNAL			English	Review									UNIV CALIF SAN DIEGO, DEPT PHYS, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	MONTAL, M (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA.				NIGMS NIH HHS [GM-42340] Funding Source: Medline; NIMH NIH HHS [MH-44638, MH-00778] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000778, R01MH044638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BOSSY B, 1988, EMBO J, V7, P611, DOI 10.1002/j.1460-2075.1988.tb02854.x; BRENDEL V, 1989, NATURE, V341, P574, DOI 10.1038/341574a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANGEUX JP, 1987, TRENDS NEUROSCI, V10, P245, DOI 10.1016/0166-2236(87)90167-6; CHARNET P, 1990, IN PRESS NEURON; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DENERIS ES, 1989, CLIN CHEM, V35, P731; DREXLER KE, 1981, P NATL ACAD SCI USA, V78, P5275, DOI 10.1073/pnas.78.9.5275; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; FUROISCORBIN S, 1989, BIOCHIM BIOPHYS ACTA, V984, P339, DOI 10.1016/0005-2736(89)90301-5; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; Hille B, 1984, IONIC CHANNELS EXCIT, P426; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LINDSTROM J, 1979, BIOCHEMISTRY-US, V18, P4465, DOI 10.1021/bi00588a003; LUTHER MA, 1989, J NEUROSCI, V9, P1082; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Montal M, 1990, Ion Channels, V2, P1; MONTAL M, 1987, J MEMBRANE BIOL, V98, P101, DOI 10.1007/BF01872123; MONTAL M, 1990, IN PRESS P NATL ACAD; MULVEY D, 1989, FEBS LETT, V257, P113, DOI 10.1016/0014-5793(89)81799-5; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; NUMA S, 1989, HARVEY LECT, V83, P121; OBERTHUR W, 1988, J PROTEIN CHEM, V7, P141, DOI 10.1007/BF01025243; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RAMASWAMI M, 1989, P NATL ACAD SCI USA, V86, P2079, DOI 10.1073/pnas.86.6.2079; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROBSON B, 1986, INTRO PROTEINS PROTE, P699; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SAKMANN B, 1983, SINGLE CHANNEL RECOR, P503; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265	60	86	86	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1990	4	9					2623	2635		10.1096/fasebj.4.9.1693348	http://dx.doi.org/10.1096/fasebj.4.9.1693348			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DJ088	1693348				2022-12-28	WOS:A1990DJ08800006
J	BALDWIN, KM; HERRICK, RE; ILYINAKAKUEVA, E; OGANOV, VS				BALDWIN, KM; HERRICK, RE; ILYINAKAKUEVA, E; OGANOV, VS			EFFECTS OF ZERO GRAVITY ON MYOFIBRIL CONTENT AND ISOMYOSIN DISTRIBUTION IN RODENT SKELETAL-MUSCLE	FASEB JOURNAL			English	Article									MINIST PUBL HLTH USSR,INST BIOMED PROBLEMS,MOSCOW,USSR	Russian Academy of Sciences; Institute of Biomedical Problems of the Russian Academy of Sciences	BALDWIN, KM (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.							BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; FITTS RH, 1986, J APPL PHYSIOL, V60, P1946, DOI 10.1152/jappl.1986.60.6.1946; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRINDELAND R, 1985, PHYSIOLOGIST, V28, P375; HOH JFY, 1976, BIOCHEM J, V157, P87, DOI 10.1042/bj1570087; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN TP, 1985, PHYSIOLOGIST, V28, P375; MIU B, 1990, FASEB J, V4, P64, DOI 10.1096/fasebj.4.1.2136839; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; THOMASON DB, 1987, J APPL PHYSIOL, V63, P138, DOI 10.1152/jappl.1987.63.1.138; THOMASON DB, 1987, J APPL PHYSIOL, V63, P130, DOI 10.1152/jappl.1987.63.1.130; TSIKA RW, 1987, J APPL PHYSIOL, V62, P2180, DOI 10.1152/jappl.1987.62.6.2180; TSIKA RW, 1987, J APPL PHYSIOL, V63, P2122, DOI 10.1152/jappl.1987.63.5.2122; TSIKA RW, 1987, J APPL PHYSIOL, V63, P2101, DOI 10.1152/jappl.1987.63.5.2101; TSIKA RW, 1987, J APPL PHYSIOL, V63, P2111, DOI 10.1152/jappl.1987.63.5.2111	15	75	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1990	4	1					79	83		10.1096/fasebj.4.1.2136840	http://dx.doi.org/10.1096/fasebj.4.1.2136840			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH311	2136840				2022-12-28	WOS:A1990CH31100014
J	Coetzee, AS; Carter, EP; Rodriguez-Fernandez, L; Heward, J; Wang, QY; Karim, SA; Boughetane, L; Milton, C; Uyulur, F; Morton, JP; Kocher, HM; Grose, RP				Coetzee, Abigail S.; Carter, Edward P.; Rodriguez-Fernandez, Lucia; Heward, James; Wang, Qiaoying; Karim, Saadia A.; Boughetane, Lina; Milton, Christopher; Uyulur, Firat; Morton, Jennifer P.; Kocher, Hemant M.; Grose, Richard P.			Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of Neuregulin 1	ONCOGENE			English	Article; Early Access							CANCER; TRANSLOCATION; CHEMOTHERAPY	Pancreatic stellate cells (PSCs) are key to the treatment-refractory desmoplastic phenotype of pancreatic ductal adenocarcinoma (PDAC) and have received considerable attention as a stromal target for cancer therapy. This approach demands detailed understanding of their pro- and anti-tumourigenic effects. Interrogating PSC-cancer cell interactions in 3D models, we identified nuclear FGFR1 as critical for PSC-led invasion of cancer cells. ChIP-seq analysis of FGFR1 in PSCs revealed a number of FGFR1 interaction sites within the genome, notably NRG1, which encodes the ERBB ligand Neuregulin. We show that nuclear FGFR1 regulates transcription of NRG1, which in turn acts in autocrine fashion through an ERBB2/4 heterodimer to promote invasion. In support of this, recombinant NRG1 in 3D model systems rescued the loss of invasion incurred by FGFR inhibition. In vivo we demonstrate that, while FGFR inhibition does not affect the growth of pancreatic tumours in mice, local invasion into the pancreas is reduced. Thus, FGFR and NRG1 may present new stromal targets for PDAC therapy.	[Coetzee, Abigail S.; Carter, Edward P.; Rodriguez-Fernandez, Lucia; Wang, Qiaoying; Boughetane, Lina; Milton, Christopher; Kocher, Hemant M.; Grose, Richard P.] Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol, London EC1M 6BQ, England; [Heward, James; Uyulur, Firat] Queen Mary Univ London, Ctr Canc Genom & Computat Biol, Barts Canc Inst, London EC1M 6BQ, England; [Karim, Saadia A.; Morton, Jennifer P.] Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland; [Morton, Jennifer P.] Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland	University of London; Queen Mary University London; University of London; Queen Mary University London; Beatson Institute; University of Glasgow	Kocher, HM; Grose, RP (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol, London EC1M 6BQ, England.	h.kocher@qmul.ac.uk; r.p.grose@qmul.ac.uk		Carter, Edward/0000-0003-4499-1101	Cancer Research UK core service grant [C16420/A18066]; Pancreatic Cancer Research Fund project award, EC - CRUK; Barts Charity grants [A27781, G-002189]; Breast Cancer Now [2017NovPR988]; CRUK [A25233, A29996]; Cancer Research UK centre grants [A17196, A31287]; Barts Cancer Institute [A25137]	Cancer Research UK core service grant; Pancreatic Cancer Research Fund project award, EC - CRUK; Barts Charity grants; Breast Cancer Now; CRUK(Cancer Research UK); Cancer Research UK centre grants; Barts Cancer Institute	We thank the microscopy, bioinformatics and pathology core facilities at Barts Cancer Institute, funded by a Cancer Research UK core service grant (C16420/A18066). AC funded by a Pancreatic Cancer Research Fund project award, EC funded by CRUK and Barts Charity grants (A27781, G-002189), LF funded by a Breast Cancer Now project award (2017NovPR988), and SK and JM funded by CRUK grants (A25233, A29996). This work also supported by Cancer Research UK centre grants to the Beatson Institute (A17196, A31287) and Barts Cancer Institute (A25137). We thank Prof. Jude Fitzgibbon for feedback on the manuscript.	Adams SD, 2021, CURR BIOL, V31, P1403, DOI 10.1016/j.cub.2021.01.028; Berdiel-Acer M, 2021, ONCOGENE, V40, P2651, DOI 10.1038/s41388-021-01719-3; Bhattacharyya S, 2020, J EXP MED, V217, DOI 10.1084/jem.20191805; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; Carapuca EF, 2016, J PATHOL, V239, P286, DOI 10.1002/path.4727; Carter EP, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040847; Carter EP, 2015, TRENDS CELL BIOL, V25, P221, DOI 10.1016/j.tcb.2014.11.003; Chen Y, 2021, CANCER CELL, V39, P548, DOI 10.1016/j.ccell.2021.02.007; Chioni AM, 2012, J CELL BIOL, V197, P801, DOI 10.1083/jcb.201108077; Coetzee A, 2021, CURR TOP MICROBIOL, V430, P183, DOI 10.1007/82_2019_155; Coleman SJ, 2014, EMBO MOL MED, V6, P467, DOI 10.1002/emmm.201302698; Coombes RC, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-30666-0; Doherty GJ, 2018, FUTURE ONCOL, V14, P13, DOI 10.2217/fon-2017-0338; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Guan ZH, 2019, ONCOL LETT, V17, P2303, DOI 10.3892/ol.2018.9876; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ho WJ, 2020, NAT REV CLIN ONCOL, V17, P527, DOI 10.1038/s41571-020-0363-5; Jones MR, 2019, CLIN CANCER RES, V25, P4674, DOI 10.1158/1078-0432.CCR-19-0191; Kabacaoglu D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01878; Kadaba R, 2013, J PATHOL, V230, P107, DOI 10.1002/path.4172; Kocher HM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18636-w; Liang C, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.255; McCarroll JA, 2006, GUT, V55, P79, DOI 10.1136/gut.2005.064543; Menezes S, 2022, J PATHOL, V257, P526, DOI 10.1002/path.5926; Mota JM, 2017, ONCOTARGET, V8, P89284, DOI 10.18632/oncotarget.18467; Murray ER, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2021.110227; Neuzillet C, 2019, J PATHOL, V248, P51, DOI 10.1002/path.5224; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Servetto A, 2021, CLIN CANCER RES, V27, P4379, DOI 10.1158/1078-0432.CCR-20-3905; Stachowiak MK, 2016, J CELL PHYSIOL, V231, P1199, DOI 10.1002/jcp.25298; van Mackelenbergh MG, 2019, CANCERS, V11, DOI 10.3390/cancers11050588; Zhang ZD, 2020, CANCER CELL, V38, P279, DOI 10.1016/j.ccell.2020.06.005	34	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02513-5	http://dx.doi.org/10.1038/s41388-022-02513-5		NOV 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C0KZ	36357571	hybrid			2022-12-28	WOS:000881714300003
J	Zhang, QQ; Gao, YR; Zhang, YX; Jing, MR; Wang, D; Wang, YZ; Khattak, S; Qi, HW; Cai, CB; Zhang, J; Ngowi, EE; Khan, NH; Li, T; Ji, AL; Jiang, QY; Ji, XY; Li, YZ; Wu, DD				Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Khattak, Saadullah; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Ngowi, Ebenezeri Erasto; Khan, Nazeer Hussain; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong			Cystathionine gamma-lyase mediates cell proliferation, migration, and invasion of nasopharyngeal carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ENDOGENOUS HYDROGEN-SULFIDE; HUMAN PROSTATE-CANCER; PROMOTES; H2S; PI3K/AKT/MTOR; SUPPRESSES; MODULATION; MECHANISMS; PATHWAY	Nasopharyngeal carcinoma (NPC) is an epithelia-derived malignancy with a distinctive geographic distribution. Cystathionine gamma-lyase (CSE) is involved in cancer development and progression. Nevertheless, the role of CSE in the growth of NPC is unknown. In this study, we found that CSE levels in human NPC cells were higher than those in normal nasopharyngeal cells. CSE overexpression enhanced the proliferative, migrative, and invasive abilities of NPC cells and CSE downregulation exerted reverse effects. Overexpression of CSE decreased the expressions of cytochrome C, cleaved caspase (cas)-3, cleaved cas-9, and cleaved poly-ADP-ribose polymerase, whereas CSE knockdown exhibited reverse effects. CSE overexpression decreased reactive oxygen species (ROS) levels and the expressions of phospho (p)-extracellular signal-regulated protein kinase 1/2, p-c-Jun N-terminal kinase, and p-p38, but promoted the expressions of p-phosphatidylinositol 3-kinase (PI3K), p-AKT, and p-mammalian target of rapamycin (mTOR), whereas CSE knockdown showed oppose effects. In addition, CSE overexpression promoted NPC xenograft tumor growth and CSE knockdown decreased tumor growth by modulating proliferation, angiogenesis, cell cycle, and apoptosis. Furthermore, DL-propargylglycine (an inhibitor of CSE) dose-dependently inhibited NPC cell growth via ROS-mediated mitogen-activated protein kinase (MAPK) and PI3K/AKT/mTOR pathways without significant toxicity. In conclusion, CSE could regulate the growth of NPC cells through ROS-mediated MAPK and PI3K/AKT/mTOR cascades. CSE might be a novel tumor marker for the diagnosis and prognosis of NPC. Novel donors/drugs that inhibit the expression/activity of CSE can be developed in the treatment of NPC.	[Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong] Henan Univ, Sch Basic Med Sci, Kaifeng 475004, Henan, Peoples R China; [Zhang, Qianqian; Gao, Yingran; Zhang, Yanxia; Jing, Mirong; Wang, Di; Wang, Yizhen; Khattak, Saadullah; Qi, Huiwen; Cai, Chunbo; Zhang, Jing; Ngowi, Ebenezeri Erasto; Khan, Nazeer Hussain; Li, Tao; Ji, Ailing; Jiang, Qiying; Ji, Xinying; Li, Yanzhang; Wu, Dongdong] Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Kaifeng 475004, Henan, Peoples R China; [Khattak, Saadullah; Khan, Nazeer Hussain] Henan Univ, Sch Life Sci, Kaifeng 475004, Henan, Peoples R China; [Ngowi, Ebenezeri Erasto; Ji, Xinying] Henan Univ, Henan Prov Engn Ctr Tumor Mol Med, Kaifeng Municipal Key Lab Cell Signal Transduct, Kaifeng 475004, Henan, Peoples R China; [Ngowi, Ebenezeri Erasto] Dar Es Salaam Univ, Fac Sci, Dept Biol Sci, Coll Educ, Dar Es Salaam 2329, Tanzania; [Wu, Dongdong] Henan Univ, Sch Stomatol, Kaifeng 475004, Henan, Peoples R China	Henan University; Henan University; Henan University; Henan University; University of Dar es Salaam; Henan University	Ji, XY; Li, YZ; Wu, DD (corresponding author), Henan Univ, Sch Basic Med Sci, Kaifeng 475004, Henan, Peoples R China.; Ji, XY; Li, YZ; Wu, DD (corresponding author), Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Kaifeng 475004, Henan, Peoples R China.; Wu, DD (corresponding author), Henan Univ, Sch Stomatol, Kaifeng 475004, Henan, Peoples R China.	10190096@vip.henu.edu.cn; yanzhang206@163.com; ddwubiomed2010@163.com	Wu, Dongdong/GQP-4472-2022	Wu, Dongdong/0000-0001-6739-8437	National Natural Science Foundation of China [81802718, U1504817]; Foundation of Science & Technology Department of Henan Province, China [202102310480, 192102310151]; Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China [2020GGJS038]; Science Foundation for Young Talents of Henan University College of Medicine, China [2019013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation of Science & Technology Department of Henan Province, China; Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China; Science Foundation for Young Talents of Henan University College of Medicine, China	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81802718, U1504817), the Foundation of Science & Technology Department of Henan Province, China (Nos. 202102310480, 192102310151), the Training Program for Young Backbone Teachers of Institutions of Higher Learning in Henan Province, China (No. 2020GGJS038), and the Science Foundation for Young Talents of Henan University College of Medicine, China (No. 2019013).	Ascencao K, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2020.105393; Augsburger F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030447; Beneke S, 2004, INT J CANCER, V111, P813, DOI 10.1002/ijc.20342; Breza J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4508-1; Bruce JP, 2015, J CLIN ONCOL, V33, P3346, DOI 10.1200/JCO.2015.60.7846; Chakraborty PK, 2018, FASEB J, V32, P4145, DOI 10.1096/fj.201701095R; Chan KCA, 2017, NEW ENGL J MED, V377, P513, DOI [10.1056/NEJMoa1701717, 10.1056/nejmoa1701717]; Chen MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep35468; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Dong Q, 2019, CANCER LETT, V455, P60, DOI 10.1016/j.canlet.2019.04.031; Fan CD, 2017, CELL MOL NEUROBIOL, V37, P211, DOI 10.1007/s10571-016-0362-3; Fan K, 2014, CELL SIGNAL, V26, P2801, DOI 10.1016/j.cellsig.2014.08.023; Filipovic MR, 2018, CHEM REV, V118, P377, DOI 10.1021/acs.chemrev.7b00205; Fu DA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.582273; George BP, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6797921; Giovinazzo D, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017225118; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Han JM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052473; Hartle MD, 2016, CHEM SOC REV, V45, P6108, DOI 10.1039/c6cs00212a; Hsu HY, 2018, CANCER LETT, V432, P112, DOI 10.1016/j.canlet.2018.05.006; Hu YQ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4764071; Jiang CM, 2017, ARCH ORAL BIOL, V74, P108, DOI 10.1016/j.archoralbio.2016.11.016; Julien O, 2017, CELL DEATH DIFFER, V24, P1380, DOI 10.1038/cdd.2017.44; Jurkowska H, 2011, AMINO ACIDS, V41, P151, DOI 10.1007/s00726-010-0606-3; Ke LR, 2017, P NATL ACAD SCI USA, V114, P9683, DOI 10.1073/pnas.1705236114; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Li WP, 2021, CANCER LETT, V499, P301, DOI 10.1016/j.canlet.2020.11.001; Li WW, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4690857; Luo M, 2019, CANCER LETT, V455, P26, DOI 10.1016/j.canlet.2019.04.019; Lv HH, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5021983; Martinez-Cutillas M, 2015, PHARMACOL RES, V93, P52, DOI 10.1016/j.phrs.2015.01.002; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Pan Y, 2014, MUTAT RES-FUND MOL M, V763, P10, DOI 10.1016/j.mrfmmm.2014.03.002; Panza E, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12312; Pei YX, 2011, TOXICOL APPL PHARM, V257, P420, DOI 10.1016/j.taap.2011.09.026; Phillips CM, 2017, CANCER RES, V77, P5741, DOI 10.1158/0008-5472.CAN-16-3480; Pitchakarn P, 2011, CANCER LETT, V306, P142, DOI 10.1016/j.canlet.2011.02.041; Pupo E, 2011, FREE RADICAL BIO MED, V51, P1765, DOI 10.1016/j.freeradbiomed.2011.08.007; Sekiguchi F, 2016, BIOL PHARM BULL, V39, P887, DOI 10.1248/bpb.b15-01015; Shan BE, 2016, ONCOL REP, V36, P1551, DOI 10.3892/or.2016.4938; Shen Q, 2018, HEPATOLOGY, V67, P1360, DOI 10.1002/hep.29606; Shibuya N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2371; Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507; Sur S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111455; Szabo C, 2017, PHARMACOL REV, V69, P497, DOI 10.1124/pr.117.014050; Szabo C, 2016, NAT REV DRUG DISCOV, V15, P185, DOI 10.1038/nrd.2015.1; Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wallace JL, 2015, NAT REV DRUG DISCOV, V14, P329, DOI 10.1038/nrd4433; Wang J, 2020, INT J MED SCI, V17, P1499, DOI 10.7150/ijms.47024; Wang LP, 2019, INT J ONCOL, V55, P473, DOI 10.3892/ijo.2019.4823; Wang R, 2012, PHYSIOL REV, V92, P791, DOI 10.1152/physrev.00017.2011; Wang SSS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.18; Wang YH, 2019, EMBO REP, V20, DOI 10.15252/embr.201845986; Wu DD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3831713; Wu DD, 2019, J CELL MOL MED, V23, P1698, DOI 10.1111/jcmm.14065; Wu DD, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4391-9; Wu DD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.585860; Wu DD, 2019, MOL BIOL REP, V46, P2665, DOI 10.1007/s11033-019-04698-7; Wu DD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6927298; Wu DD, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0762-9; Wu DD, 2015, NITRIC OXIDE-BIOL CH, V50, P38, DOI 10.1016/j.niox.2015.08.004; Wu DD, 2014, CANCER LETT, V351, P13, DOI 10.1016/j.canlet.2014.05.002; Xiao Q, 2020, J DERMATOL SCI, V98, P26, DOI 10.1016/j.jdermsci.2020.02.004; Xiao Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01463-w; Xie YY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113429; Xu YJ, 2019, CANCER LETT, V447, P33, DOI 10.1016/j.canlet.2019.01.022; Ye F, 2020, LIFE SCI, V261, DOI 10.1016/j.lfs.2020.118348; Youness RA, 2021, J ADV RES, V27, P177, DOI 10.1016/j.jare.2020.07.006; Zeng Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1807-7; Zhang Y, 2019, NEW ENGL J MED, V381, P1124, DOI 10.1056/NEJMoa1905287; Zhao LF, 2015, BIOL CHEM, V396, P1247, DOI 10.1515/hsz-2015-0148; Zhao YW, 2018, BIOMED PHARMACOTHER, V98, P36, DOI 10.1016/j.biopha.2017.12.029; Zhu LS, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5905-9	75	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5238	5252		10.1038/s41388-022-02512-6	http://dx.doi.org/10.1038/s41388-022-02512-6		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36310322	Green Submitted			2022-12-28	WOS:000876210600001
J	CAZZULO, JJ; FRASCH, ACC				CAZZULO, JJ; FRASCH, ACC			SAPA TRANSSIALIDASE AND CRUZIPAIN - 2 ANTIGENS FROM TRYPANOSOMA-CRUZI CONTAIN IMMUNODOMINANT BUT ENZYMATICALLY INACTIVE DOMAINS	FASEB JOURNAL			English	Review						TRANSSIALIDASE; NEURAMINIDASE; CRUZIPAIN; TRYPANOSOMA-CRUZI; ANTIGENS	MAJOR CYSTEINE PROTEINASE; C-TERMINAL EXTENSION; SURFACE-ANTIGEN; CHAGAS-DISEASE; BACTERIAL NEURAMINIDASES; MONOCLONAL-ANTIBODIES; MAMMALIAN-CELLS; GENE FAMILY; ACUTE-PHASE; TRYPOMASTIGOTES	Trypanosoma cruzi, the parasitic protozoan that causes the American trypanosomiasis, or Chagas disease, contains a number of antigenic molecules, some of which have tandems of amino acid repeats. One of these molecules, SAPA (shed acute phase antigen), contains a so-far unique trans-sialidase activity that is essential for penetration of the parasite into mammalian cells. The enzyme consists of two different domains, one presumably enzymatic, which contains four copies of an amino acid motif conserved in bacterial neuraminidases, and the other highly antigenic, consisting of the repeats. Another enzyme that seems to be involved in the host-parasite relationship, the cysteine proteinase cruzipain, is also made up in its mature form of a catalytic domain with high homology to cathepsin L and a COOH-terminal domain that is highly antigenic in vivo. These bifunctional molecules may have arisen by incorporation of a highly antigenic domain to an essential enzyme in order to attract the immune response, thus protecting the enzyme activity.			CAZZULO, JJ (corresponding author), INST INVEST BIOQUIM FUNDACION CAMPOMAR, ANTONIO MACHADO 151, RA-1405 BUENOS AIRES, ARGENTINA.			Frasch, Alberto Carlos/0000-0001-7532-653X				AFFRANCHINO JL, 1989, MOL BIOCHEM PARASIT, V34, P221, DOI 10.1016/0166-6851(89)90050-9; AFFRANCHINO JL, 1991, FEBS LETT, V280, P316, DOI 10.1016/0014-5793(91)80320-3; ALVES MJM, 1986, MOL BIOCHEM PARASIT, V21, P75, DOI 10.1016/0166-6851(86)90081-2; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; ASLUND L, 1991, MOL BIOCHEM PARASIT, V45, P345, DOI 10.1016/0166-6851(91)90103-D; BONTEMPI E, 1990, FEMS MICROBIOL LETT, V70, P337, DOI 10.1016/S0378-1097(05)80019-9; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; CAMPETELLA O, 1990, FEMS MICROBIOL LETT, V67, P145, DOI 10.1111/j.1574-6968.1990.tb13852.x; CAMPETELLA O, 1992, MOL BIOCHEM PARASIT, V50, P225, DOI 10.1016/0166-6851(92)90219-A; Cazzulo J.J., 1991, P191; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; DAMIAN RT, 1987, PARASITOL TODAY, V3, P263, DOI 10.1016/0169-4758(87)90102-5; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; FOUTS DL, 1991, MOL BIOCHEM PARASIT, V46, P189, DOI 10.1016/0166-6851(91)90043-6; FRASCH ACC, 1991, PARASITOL TODAY, V7, P148, DOI 10.1016/0169-4758(91)90284-U; FRASCH ACC, 1990, PARASITOL TODAY, V6, P137, DOI 10.1016/0169-4758(90)90234-U; HENRIKSSON J, 1990, MOL BIOCHEM PARASIT, V42, P213, DOI 10.1016/0166-6851(90)90164-H; IBANEZ CF, 1988, MOL BIOCHEM PARASIT, V30, P27, DOI 10.1016/0166-6851(88)90129-6; KAHN S, 1991, P NATL ACAD SCI USA, V88, P4481, DOI 10.1073/pnas.88.10.4481; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; KIERSZENBAUM F, 1990, PARASITOL TODAY, V6, P261, DOI 10.1016/0169-4758(90)90187-9; KRETTLI A, 1980, INSERM I NAT SANTE R, V97, P553; LEGUIZAMON MS, 1991, PARASITOLOGY, V102, P379, DOI 10.1017/S0031182000064337; MACINA RA, 1989, FEBS LETT, V257, P365, DOI 10.1016/0014-5793(89)81573-X; MARTINEZ J, 1991, INFECT IMMUN, V59, P4275, DOI 10.1128/IAI.59.11.4275-4277.1991; MARTINEZ J, 1992, FEMS MICROBIOL LETT, V95, P225, DOI 10.1016/0378-1097(92)90433-O; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; MITCHELL G F, 1991, Immunology Today, V12, pA2; MITCHELL GF, 1987, PARASITOL TODAY, V3, P106, DOI 10.1016/0169-4758(87)90047-0; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; MURTA ACM, 1990, MOL BIOCHEM PARASIT, V43, P27, DOI 10.1016/0166-6851(90)90127-8; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PARODI AJ, 1992, EMBO J, V11, P1705, DOI 10.1002/j.1460-2075.1992.tb05221.x; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; PETERSON DS, 1986, NATURE, V322, P566, DOI 10.1038/322566a0; PIRAS MM, 1985, MOL BIOCHEM PARASIT, V14, P151, DOI 10.1016/0166-6851(85)90034-9; PIRAS MM, 1987, MOL BIOCHEM PARASIT, V22, P135, DOI 10.1016/0166-6851(87)90043-0; POLLEVICK GD, 1991, MOL BIOCHEM PARASIT, V47, P247, DOI 10.1016/0166-6851(91)90185-9; PREVIATO JO, 1985, MOL BIOCHEM PARASIT, V16, P85, DOI 10.1016/0166-6851(85)90051-9; PRIOLI RP, 1990, J IMMUNOL, V144, P4384; PRIOLI RP, 1992, MOL BIOCHEM PARASIT, V52, P85, DOI 10.1016/0166-6851(92)90038-L; RAIMONDI A, 1991, MOL BIOCHEM PARASIT, V49, P341, DOI 10.1016/0166-6851(91)90080-P; REYES MB, 1990, P NATL ACAD SCI USA, V87, P2846, DOI 10.1073/pnas.87.7.2846; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROSENBERG I, 1991, MOL BIOCHEM PARASIT, V46, P303, DOI 10.1016/0166-6851(91)90054-A; SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1991, EXP PARASITOL, V72, P76, DOI 10.1016/0014-4894(91)90123-E; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L; SOUTOPADRON T, 1990, J CELL SCI, V96, P485; TAKLE GB, 1991, MOL BIOCHEM PARASIT, V48, P185, DOI 10.1016/0166-6851(91)90114-L; VERGARA U, 1991, J CLIN MICROBIOL, V29, P2034, DOI 10.1128/JCM.29.9.2034-2037.1991; WATANABE H, 1991, J BIOL CHEM, V266, P16897; ZINGALES B, 1987, MOL BIOCHEM PARASIT, V26, P135, DOI 10.1016/0166-6851(87)90137-X	58	72	73	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1992	6	14					3259	3264		10.1096/fasebj.6.14.1426764	http://dx.doi.org/10.1096/fasebj.6.14.1426764			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426764				2022-12-28	WOS:A1992JZ73400007
J	TAYLOR, CG; BAUMAN, PF; SIKORSKI, B; BRAY, TM				TAYLOR, CG; BAUMAN, PF; SIKORSKI, B; BRAY, TM			ELEVATION OF LUNG GLUTATHIONE BY ORAL SUPPLEMENTATION OF L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE PROTECTS AGAINST OXYGEN-TOXICITY IN PROTEIN-ENERGY MALNOURISHED RATS	FASEB JOURNAL			English	Article						GLUTATHIONE; L-2-OXOTHIAZOLIDINE-4-CARBOXYLATE; HYPEROXIA; MAGNETIC RESONANCE IMAGING; MALNUTRITION	HEPATIC GLUTATHIONE; INTRACELLULAR CYSTEINE; DIETARY-PROTEIN; DEFICIENCY; ACID; MALNUTRITION; KWASHIORKOR; INHIBITION; METABOLISM; PRODRUG	The objectives of this study were to investigate whether oral supplementation of L-2-oxothiazolidine-4-carboxylate (OTC) is effective for increasing tissue glutathione (GSH) concentrations in rats fed a diet very low (0.5%) in protein - a model of wasting malnutrition - and to determine the efficacy of OTC for protection against pulmonary oxygen toxicity. Weanling rats, fed a 0.5 or 15% protein diet for 2 wk, were given an oral supplement of OTC, and tissue GSH concentrations were measured over a 24 h period. OTC supplementation to rats fed 0.5% protein significantly increased GSH concentrations in liver and lung, but not in kidney and blood, when compared with the 0.5% protein unsupplemented group. The liver GSH concentration in the 0.5% protein OTC-supplemented group was higher than the 15% control group. Daily supplementation of OTC protected rats from pulmonary oxygen toxicity during 4 days of 85% oxygen exposure as determined by lung-to-body weight ratios and in vivo proton magnetic resonance imaging. Although hyperoxia exposure increased lung GSH concentrations in all groups, OTC supplementation was effective for increasing lung GSH concentration in rats fed the 0.5% protein diet. This study demonstrated that oral administration of OTC to wasting malnourished rats is an effective procedure to increase GSH concentration rapidly in target organs such as lung, and that daily supplementation of a low dose of OTC has a sustained effect to protect against pulmonary oxygen toxicity during 4 days of hyperoxia exposure.	UNIV GUELPH, COLL BIOL SCI, DEPT NUTR SCI, GUELPH N1G 2W1, ONTARIO, CANADA	University of Guelph				Taylor, Carla G./0000-0003-3358-6418				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BAUMAN PF, 1988, CAN J PHYSIOL PHARM, V66, P1048, DOI 10.1139/y88-171; BAUMAN PF, 1988, J NUTR, V118, P1048, DOI 10.1093/jn/118.8.1048; Bieri JG., 1980, J NUTR, V110, P1726, DOI [10.1093/jn/110.8.1726, DOI 10.1093/JN/110.8.1726]; BIRNBAUM SM, 1957, ARCH BIOCHEM BIOPHYS, V72, P428, DOI 10.1016/0003-9861(57)90218-7; BISTRIAN BR, 1974, JAMA-J AM MED ASSOC, V230, P858, DOI 10.1001/jama.230.6.858; BISTRIAN BR, 1976, JAMA-J AM MED ASSOC, V235, P1567, DOI 10.1001/jama.235.15.1567; BRODEUR J, 1987, CAN J PHYSIOL PHARM, V65, P816, DOI 10.1139/y87-131; BUHL R, 1990, P NATL ACAD SCI USA, V87, P4063, DOI 10.1073/pnas.87.11.4063; BUHL R, 1989, LANCET, V2, P1294; CHO ES, 1981, J NUTR, V111, P914, DOI 10.1093/jn/111.5.914; DAVIES MH, 1984, J PHARMACOL METHOD, V12, P191, DOI 10.1016/0160-5402(84)90059-7; DENEKE SM, 1985, J NUTR, V115, P726, DOI 10.1093/jn/115.6.726; DENEKE SM, 1983, J APPL PHYSIOL, V54, P147, DOI 10.1152/jappl.1983.54.1.147; FRAHM J, 1985, J MAGN RESON, V64, P81, DOI 10.1016/0022-2364(85)90033-2; FRANK L, 1988, AM REV RESPIR DIS, V138, P725, DOI 10.1164/ajrccm/138.3.725; GOLDEN MHN, 1987, P NUTR SOC, V46, P53, DOI 10.1079/PNS19870008; GRANOT J, 1986, J MAGN RESON, V70, P488, DOI 10.1016/0022-2364(86)90142-3; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; HAZELTON GA, 1986, J PHARMACOL EXP THER, V237, P341; JACKSON AA, 1986, T ROY SOC TROP MED H, V80, P911, DOI 10.1016/0035-9203(86)90256-7; JAESCHKE H, 1985, BIOCHEM PHARMACOL, V34, P1029, DOI 10.1016/0006-2952(85)90606-9; KAPLOWITZ N, 1983, J PHARMACOL EXP THER, V224, P141; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P5296, DOI 10.1073/pnas.86.14.5296; MCFARLANE H, 1970, BMJ-BRIT MED J, V4, P268, DOI 10.1136/bmj.4.5730.268; MEISTER A, 1986, J AM COLL NUTR, V5, P137; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; NORTHWAY WH, 1990, ARCH DIS CHILD-FETAL, V65, P1076, DOI 10.1136/adc.65.10_Spec_No.1076; OLNEY JW, 1970, NATURE, V227, P609, DOI 10.1038/227609b0; PORTA P, 1991, J PHARMACOL EXP THER, V257, P331; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; TATEISHI N, 1974, J BIOCHEM, V75, P93, DOI 10.1093/oxfordjournals.jbchem.a130387; THURNHAM DI, 1990, P NUTR SOC, V49, P247, DOI 10.1079/PNS19900028; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TREMPER JC, 1981, AM REV RESPIR DIS, V123, pS118; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; VANDERWERF P, 1975, ADV ENZYMOL RAMB, V43, P519; WILLIAMSON JM, 1981, P NATL ACAD SCI-BIOL, V78, P936, DOI 10.1073/pnas.78.2.936; WILLIAMSON JM, 1982, P NATL ACAD SCI-BIOL, V79, P6246, DOI 10.1073/pnas.79.20.6246; WOODWARD B, 1990, ADV NUTR RES, V8, P11; ZLOTKIN SH, 1982, PEDIATR RES, V16, P65; 1985, SAS USERS GUIDE STAT	45	39	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3101	3107		10.1096/fasebj.6.12.1521740	http://dx.doi.org/10.1096/fasebj.6.12.1521740			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521740	Green Submitted			2022-12-28	WOS:A1992JN50500012
J	SHILO, BZ				SHILO, BZ			ROLES OF RECEPTOR TYROSINE KINASES IN DROSOPHILA DEVELOPMENT	FASEB JOURNAL			English	Review						DROSOPHILA; DEVELOPMENT; RECEPTOR TYROSINE KINASES; CELL-CELL COMMUNICATION	CELL-CELL-INTERACTION; FAINT-LITTLE-BALL; EGF RECEPTOR; SEVENLESS PROTEIN; SIGNAL TRANSDUCTION; GROWTH-FACTOR; EMBRYONIC-DEVELOPMENT; PUTATIVE RECEPTOR; TERMINAL ANLAGEN; GENE TORSO	Communication between cells is a fundamental component of development and morphogenesis. Identification of the molecules mediating cell-cell communication is crucial for elucidation of the molecular basis of these processes. Receptor tyrosine kinases (RTKs) appear to play a central role in this context by transmitting into cells information dictating their fate. The functions of RTKs in Drosophila are extremely diverse, and include maternal determination of embryonic polarity (torso and torpedo), determination of neuroblast identity (faint little ball), and guidance of tracheal cell migration in the embryo (breathless). During compound eye development, RTKs affect the number of photoreceptor clusters (Ellipse) and the determination of photoreceptor R7 identity (sevenless). The phenotypes of mutations in RTK loci serve as a starting point for understanding processes dictating cell identity at the level of the whole organism. Recently, they have also begun to provide a basis for selection of second-site suppressor mutations, encoding additional elements in their signal transduction pathway. Common themes between the functions, regulation, and signal transduction pathways of Drosophila RTKs are drawn.			SHILO, BZ (corresponding author), WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL.			Shilo, Ben Zion/0000-0003-4903-8889				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; CAMPORTEGA JA, 1985, EMBRYONIC DEV DROSOP; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CLIFFORD RJ, 1989, GENETICS, V123, P771; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAFEN E, 1991, DEVELOPMENT, P123; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; King R. C., 1970, OVARIAN DEV DROSOPHI; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MONTELL DJ, 1991, SCIENCE, V254, P290, DOI 10.1126/science.1925585; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1986, GENETICS, V113, P695; PETRUZZELLI L, 1986, P NATL ACAD SCI USA, V83, P4710, DOI 10.1073/pnas.83.13.4710; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAZ E, 1991, GENETICS, V129, P191; RAZ E, 1992, DEVELOPMENT, V114, P113; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RTOMLINSON A, 1987, DEV BIOL, V120, P264; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; Silver W. K., 1979, COAT COLORS MICE MOD, P243; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAK NB, 1990, DEVELOPMENT, V109, P865	64	37	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1992	6	11					2915	2922		10.1096/fasebj.6.11.1322852	http://dx.doi.org/10.1096/fasebj.6.11.1322852			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1322852				2022-12-28	WOS:A1992JJ66500005
J	SHUKLA, SD				SHUKLA, SD			PLATELET-ACTIVATING-FACTOR RECEPTOR AND SIGNAL TRANSDUCTION MECHANISMS	FASEB JOURNAL			English	Review						PLATELET-ACTIVATING FACTOR; RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASES; PROTEIN KINASES	PROTEIN-KINASE-C; FACTOR BINDING-SITES; FACTOR 1-O-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; RABBIT PLATELETS; MEMBRANES; CELLS; DISTINCT; PHOSPHOINOSITIDES; PHOSPHOLIPASE-A2; ACCUMULATION	Platelet-activating factor (PAF) is the most potent phospholipid agonist known to date. Radioligand binding studies using [H-3]PAF and structurally different PAF antagonists have provided the characteristics of PAF receptor(s) and its heterogeneity. Although efforts have been made to isolate the receptor, it was not until the recent cloning of the PAF receptor that the molecular architecture of the receptor can be visualized. The receptor shows homology to the G protein-coupled receptors with seven transmembrane spanning segments. Several serine, threonine, and tyrosine residues are present at the cytoplasmic side, which could serve as sites for phosphorylation. PAF activates GTPase, causes phospholipid turnover via phospholipases C, D, and A2 pathways and also activates protein kinase C and tyrosine kinase. Further, PAF stimulates Ca2+ mobilization some of which may occur via receptor operated channel. Second messengers generated by these multiple signalling pathways play role (or roles) in PAF responses and in the PAF induced expression of primary response genes. These recent developments throw light on the PAF receptor and its signal transduction mechanisms.			SHUKLA, SD (corresponding author), UNIV MISSOURI,SCH MED,DEPT PHARMACOL,COLUMBIA,MO 65212, USA.				NIDDK NIH HHS [DK35170, DK01782] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001782, R01DK035170] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVDONIN PV, 1991, EUR J BIOCHEM, V198, P267, DOI 10.1111/j.1432-1033.1991.tb16011.x; BIRKLE DL, 1988, J NEUROCHEM, V51, P1900, DOI 10.1111/j.1471-4159.1988.tb01175.x; BRAQUET P, 1987, PHARMACOL REV, V39, P97; CHAU LY, 1988, BIOCHIM BIOPHYS ACTA, V970, P103, DOI 10.1016/0167-4889(88)90168-1; CHAU LY, 1989, BIOCHEM BIOPH RES CO, V161, P1070, DOI 10.1016/0006-291X(89)91352-1; DHAR A, 1990, MOL PHARMACOL, V37, P519; DHAR A, 1991, J BIOL CHEM, V266, P18797; GANDHI CR, 1990, J BIOL CHEM, V265, P18234; GARCIASAINZ JA, 1989, TRENDS PHARMACOL SCI, V10, P10, DOI 10.1016/0165-6147(89)90093-X; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; HALLAM TJ, 1984, BIOCHEM J, V218, P819, DOI 10.1042/bj2180819; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HASLAM RJ, 1982, J BIOL CHEM, V257, P6879; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HO YS, 1987, J EXP MED, V165, P1524, DOI 10.1084/jem.165.6.1524; HOMMA H, 1987, J BIOL CHEM, V262, P10582; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; HWANG SB, 1986, J BIOL CHEM, V261, P532; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KAWAGUCHI H, 1986, HYPERTENSION, V8, P192, DOI 10.1161/01.HYP.8.3.192; KESTER M, 1986, BIOCHIM BIOPHYS ACTA, V888, P306, DOI 10.1016/0167-4889(86)90230-2; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; MAZER B, 1991, J IMMUNOL, V146, P1914; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NISHIHIRA J, 1985, TOHOKU J EXP MED, V147, P145, DOI 10.1620/tjem.147.145; OFLAHERTY JT, 1987, J IMMUNOL, V138, P1889; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P21619; OKAYASU T, 1987, J LIPID RES, V28, P760; PINCKARD RN, 1988, INFLAMMATION BASIC P, P139; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; SQUINTO SP, 1989, J NEUROSCI RES, V24, P558, DOI 10.1002/jnr.490240414; TRIPATHI YB, 1991, LIFE SCI, V49, P1761, DOI 10.1016/0024-3205(91)90319-7; UHING RJ, 1989, J BIOL CHEM, V264, P9224; VALONE FH, 1984, IMMUNOLOGY, V52, P169; YUE TL, 1991, NEUROSCIENCE, V41, P177, DOI 10.1016/0306-4522(91)90208-6	42	183	187	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2296	2301		10.1096/fasebj.6.6.1312046	http://dx.doi.org/10.1096/fasebj.6.6.1312046			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1312046				2022-12-28	WOS:A1992HJ25200006
J	NOSSAL, NG				NOSSAL, NG			PROTEIN-PROTEIN INTERACTIONS AT A DNA-REPLICATION FORK - BACTERIOPHAGE-T4 AS A MODEL	FASEB JOURNAL			English	Article						DNA REPLICATION; BACTERIOPHAGE-T4; T4 DNA POLYMERASE; POLYMERASE ACCESSORY PROTEINS; PRIMASE; HELICASE; RNASE-H	POLYMERASE ACCESSORY PROTEINS; RNA PRIMER SYNTHESIS; T4 GENE-45 PROTEIN; ESCHERICHIA-COLI; STRAND DISPLACEMENT; LEADING-STRAND; ATP HYDROLYSIS; III HOLOENZYME; 45 PROTEINS; DUPLEX DNA	The DNA replication system of bacteriophage T4 serves as a relatively simple model for the types of reactions and protein-protein interactions needed to carry out and coordinate the synthesis of the leading and lagging strands of a DNA replication fork. At least 10 phage-encoded proteins are required for this synthesis: T4 DNA polymerase, the genes 44/62 and 45 polymerase accessory proteins, gene 32 single-stranded DNA binding protein, the genes 61, 41, and 59 primase-helicase, RNase H, and DNA ligase. Assembly of the polymerase and the accessory proteins on the primed template is a stepwise process that requires ATP hydrolysis and is strongly stimulated by 32 protein. The 41 protein helicase is essential to unwind the duplex ahead of polymerase on the leading strand, and to interact with the 61 protein to synthesize the RNA primers that initiate each discontinuous fragment on the lagging strand. An interaction between the 44/62 and 45 polymerase accessory proteins and the primase-helicase is required for primer synthesis on 32 protein-covered DNA. Thus it is possible that the signal for the initiation of a new fragment by the primase-helicase is the release of the polymerase accessory proteins from the completed adjacent fragment.			NOSSAL, NG (corresponding author), NIDDKD,BIOCHEM PHARMACOL LAB,NUCLEIC ACID BIOCHEM SECT,BETHESDA,MD 20892, USA.							ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BURKE RL, 1980, J BIOL CHEM, V255, P11494; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1989, J BIOL CHEM, V264, P12220; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GILLIN FD, 1976, J BIOL CHEM, V251, P5219; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HACKER K, 1989, J CELL BIOCHEM, V13, P87; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Kornberg A., 1991, DNA REPLICATION; KUROSAWA Y, 1979, J MOL BIOL, V135, P841, DOI 10.1016/0022-2836(79)90515-1; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MAKI S, 1988, J BIOL CHEM, V263, P6555; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MUNN MM, 1991, J BIOL CHEM, V266, P20034; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NEWPORT JW, 1980, UCLA S MOL CELL BIOL, V19, P495; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; NOSSAL NG, 1979, J BIOL CHEM, V254, P6032; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; REHAKRANTZ LJ, 1989, J VIROL, V63, P4762, DOI 10.1128/JVI.63.11.4762-4766.1989; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; ROTH AC, 1982, J BIOL CHEM, V257, P1267; RUSH J, 1989, J BIOL CHEM, V264, P10943; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SILVER LL, 1982, J BIOL CHEM, V257, P1696; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511	57	92	92	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					871	878		10.1096/fasebj.6.3.1310946	http://dx.doi.org/10.1096/fasebj.6.3.1310946			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1310946				2022-12-28	WOS:A1992HE39000010
J	FUJIIKURIYAMA, Y; IMATAKA, H; SOGAWA, K; YASUMOTO, KI; KIKUCHI, Y				FUJIIKURIYAMA, Y; IMATAKA, H; SOGAWA, K; YASUMOTO, KI; KIKUCHI, Y			REGULATION OF CYP1A1 EXPRESSION	FASEB JOURNAL			English	Article						CIS-ACTING ELEMENTS; TRANS-ACTING FACTORS; AH-RECEPTOR; P450 SUPERFAMILY	PROTEIN-DNA INTERACTIONS; HEAT-SHOCK PROTEIN; XENOBIOTIC RESPONSIVE ELEMENTS; CYTOCHROME P-450C GENE; GLUCOCORTICOID RECEPTOR; DIOXIN RECEPTOR; AH RECEPTOR; BINDING ACTIVITY; MOUSE; UPSTREAM	CYP1A1 is considered to be involved mainly in oxidative metabolism of exogenous chemicals and drugs. Synthesis of this hemoprotein is induced in livers, lungs, and other tissues of experimental animals by the administration of these chemicals. Regulatory mechanisms of the induction process of the protein have been investigated by the DNA transfer method using the isolated genomic DNA. At least two kinds of cis-acting regulatory DNA sequences are localized 5' upstream of the gene. One is distributed five times in a relatively wide range from -0.5 to -3.5 kb and functions as an inducible enhancer-designated xenobiotic responsive element or XRE. The other is localized just upstream of the TATA sequence and acts as a regulatory element for the constitutive expression. The two DNA elements are required for a high level of the inducible expression. Their cognate DNA binding factors are recognized in the nuclear extracts of Hepa-1 cells and rat liver cells which show the inducible expression of CYP1A1 in response to the inducer. This paper discusses the regulatory mechanisms of CYP1A1 gene expression by summarizing the present state of knowledge about properties of the DNA regulatory elements and their cognate DNA-binding factors.			FUJIIKURIYAMA, Y (corresponding author), TOHOKU UNIV,FAC SCI,DEPT CHEM,SENDAI,MIYAGI 980,JAPAN.			Yasumoto, Ken-ichi/0000-0002-8090-1161				BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; CHU R, 1989, CELL, V59, P979; CUTHILL S, 1987, J BIOL CHEM, V262, P477; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GOFFMAN EC, 1991, SCIENCE, V252, P954; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P5040; GONZALOSANZ LM, 1989, REV ESP FISIOL, V45, P1; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KUBOTA M, 1991, J BIOCHEM-TOKYO, V110, P232, DOI 10.1093/oxfordjournals.jbchem.a123562; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MTHIS JM, 1989, ARCH BIOCHEM BIOPHYS, V269, P93; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1976, J BIOL CHEM, V251, P4936; QUATTROCHI LC, 1989, MOL PHARMACOL, V36, P66; RYAN DE, 1980, J BIOL CHEM, V255, P7941; SOGAWA K, 1985, J BIOL CHEM, V260, P5026; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470	37	108	110	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					706	710		10.1096/fasebj.6.2.1537460	http://dx.doi.org/10.1096/fasebj.6.2.1537460			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537460				2022-12-28	WOS:A1992GZ44000010
J	ENTMAN, ML; MICHAEL, L; ROSSEN, RD; DREYER, WJ; ANDERSON, DC; TAYLOR, AA; SMITH, CW				ENTMAN, ML; MICHAEL, L; ROSSEN, RD; DREYER, WJ; ANDERSON, DC; TAYLOR, AA; SMITH, CW			INFLAMMATION IN THE COURSE OF EARLY MYOCARDIAL-ISCHEMIA	FASEB JOURNAL			English	Article						ADHESION; LEUKOCYTES; COMPLEMENT; REACTIVE OXYGEN; REPERFUSION	PLATELET-ACTIVATING FACTOR; LEUKOCYTE-ENDOTHELIAL INTERACTIONS; INTERCELLULAR-ADHESION MOLECULE-1; HEART SUBCELLULAR MEMBRANES; CORONARY-ARTERY OCCLUSION; NEUTROPHIL ACTIVATION; REPERFUSION INJURY; HYDROGEN-PEROXIDE; CARDIAC LYMPH; TRANSENDOTHELIAL MIGRATION	Experimental models of acute ischemic myocardial injury indicate that the inflammatory response after the ischemic event contributes to tissue damage. This is especially apparent with reperfusion of the ischemic tissue. In such models some therapeutic strategies designed to reduce neutrophil accumulation or function have resulted in apparently beneficial effects. Although such findings are encouraging, interventions into these pathological processes using specific molecular targets will require greater understanding of specific mechanisms. Current evidence indicates that potential sites of therapeutic intervention will be found in pathways leading to complement activation, generation of lipid-derived mediators, adhesion of neutrophils to endothelial cells and cardiac myocytes, and activation of neutrophil secretory processes releasing, for example, proteolytic enzymes and reactive oxygen. Understanding the dynamic interplay between the mediators, adhesion pathways, and secretory processes that results in myocardial damage will allow a rational approach to controlling the detrimental inflammatory consequences of ischemia and reperfusion.	METHODIST HOSP, CARDIOVASC SCI SECT, HOUSTON, TX 77030 USA; VET AFFAIRS MED CTR, DEBAKEY HEART CTR, DEPT MED, HOUSTON, TX USA; VET AFFAIRS MED CTR, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX USA; BAYLOR COLL MED, DEPT PEDIAT, SPEROS P MARTEL SECT LEUKOCYTE BIOL & INFLAMMAT RE, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CTR EXPTL THERAPEUT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PHARMACOL, HOUSTON, TX 77030 USA	The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Taylor, Addison/0000-0003-3788-3137	NHLBI NIH HHS [HL-23161, HL-41408, HL-42550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041408, R01HL023161, P01HL042550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBASSI O, 1990, FASEB J, V4, pA1135; AMBROSIO G, 1989, CIRCULATION, V80, P1846, DOI 10.1161/01.CIR.80.6.1846; ANDERSON DC, 1989, METABOLIC BASIS INHE, P2751; BARROSOARANDA J, 1988, CIRC RES, V63, P437, DOI 10.1161/01.RES.63.2.437; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CARVETH HJ, 1989, BIOCHEM BIOPH RES CO, V162, P387, DOI 10.1016/0006-291X(89)92009-3; CRAWFORD MH, 1988, CIRCULATION, V78, P1449, DOI 10.1161/01.CIR.78.6.1449; DREYER WJ, 1989, CIRC RES, V65, P1751, DOI 10.1161/01.RES.65.6.1751; DREYER WJ, 1990, FASEB J, V4, pA893; ENGLER RL, 1986, AM J PHYSIOL, V251, pH314, DOI 10.1152/ajpheart.1986.251.2.H314; ENTMAN ML, 1990, CIRCULATION, V82, P701; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; ENTMAN ML, 1991, J CELL BIOCHEM     S, V15, P179; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; FURIE MB, 1987, J CELL SCI, V88, P161; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; HAHN RA, 1990, J PHARMACOL EXP THER, V253, P58; HARLAN JM, 1985, BLOOD, V65, P513; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HEYNDRICKX GR, 1985, J AM COLL CARDIOL, V6, P1299, DOI 10.1016/S0735-1097(85)80216-3; HILL JH, 1971, J EXP MED, V133, P885, DOI 10.1084/jem.133.4.885; HUGHES H, 1990, FASEB J, V4, pA115; INAUEN W, 1990, IN PRESS AM J PHYSL; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KAGIYAMA A, 1989, CIRC RES, V64, P607, DOI 10.1161/01.RES.64.3.607; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1990, J LEUK BIOL S1, V96, P272; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; LO SK, 1989, J IMMUNOL, V143, P3325; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LUCCHESI BR, 1986, ANNU REV PHARMACOL, V26, P201, DOI 10.1146/annurev.pa.26.040186.001221; Mallory GK, 1939, AM HEART J, V18, P647; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MAROKO PR, 1978, J CLIN INVEST, V61, P661, DOI 10.1172/JCI108978; MATIS WL, 1990, J INVEST DERMATOL, V94, P492, DOI 10.1111/1523-1747.ep12874665; MICHAEL LH, 1985, AM J PHYSIOL, V248, pH350, DOI 10.1152/ajpheart.1985.248.3.H350; MICHAEL LH, 1990, CIRC RES, V66, P1040, DOI 10.1161/01.RES.66.4.1040; MULLANE KM, 1984, J PHARMACOL EXP THER, V228, P510; MULLANE KM, 1987, FASEB J, V46, P2422; MULLANE KM, 1990, PATHOPHYSIOLOGY SEVE, P239; MULLANE KM, 1988, EICOSANOIDS MYOCARDI; NATHAN CF, 1989, BLOOD, V73, P301; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PINCKARD RN, 1973, J IMMUNOL, V110, P1376; PINCKARD RN, 1975, J CLIN INVEST, V56, P740, DOI 10.1172/JCI108145; ROBERTS R, 1976, CIRCULATION, V53, P204; ROMSON JL, 1982, CIRCULATION, V66, P1002, DOI 10.1161/01.CIR.66.5.1002; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; ROSSEN RD, 1985, CIRC RES, V57, P119, DOI 10.1161/01.RES.57.1.119; ROSSEN RD, 1988, CIRC RES, V62, P572, DOI 10.1161/01.RES.62.3.572; ROWZER CA, 1985, J BIOL CHEM, V263, P10980; Schmid-Schonbein G W, 1987, Am J Cardiovasc Pathol, V1, P15; SEEWALDTBECKER E, 1989, LEUKOCYTE ADHESION M, P138; SHAPPELL SB, 1990, J PHARMACOL EXP THER, V252, P531; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SHINGU M, 1984, AM J PATHOL, V117, P201; SIMPSON PJ, 1987, CIRC RES, V60, P666, DOI 10.1161/01.RES.60.5.666; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SOMMERS HM, 1964, LAB INVEST, V13, P1491; STAHL GL, 1988, J PHARMACOL EXP THER, V244, P898; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUZUKI M, 1989, AM J PHYSIOL, V257, pH1740, DOI 10.1152/ajpheart.1989.257.5.H1740; TAYLOR A, 1989, CLIN RES, V37, pA528; TEDDER TF, 1990, J IMMUNOL, V144, P532; THARP MD, 1989, J INVEST DERMATOL, V93, pS107, DOI 10.1111/1523-1747.ep12581221; VOGT W, 1987, IMMUNOL LETT, V14, P209, DOI 10.1016/0165-2478(87)90103-9; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WILLIAMS F M, 1988, Journal of Molecular and Cellular Cardiology, V20, pS33; YOUKER K, 1990, CLIN RES, V38, pA250; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	80	385	402	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1991	5	11					2529	2537		10.1096/fasebj.5.11.1868978	http://dx.doi.org/10.1096/fasebj.5.11.1868978			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868978				2022-12-28	WOS:A1991GB09400005
J	DAVIS, BD				DAVIS, BD			SOME PROBLEMS WITH A CRASH PROGRAM	FASEB JOURNAL			English	Editorial Material											DAVIS, BD (corresponding author), HARVARD UNIV,SCH MED,BACTERIAL PHYSIOL UNIT,BOSTON,MA 02115, USA.								0	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					76	77		10.1096/fasebj.5.1.1991591	http://dx.doi.org/10.1096/fasebj.5.1.1991591			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991591				2022-12-28	WOS:A1991ET60900015
J	MIU, B; MARTIN, TP; ROY, RR; OGANOV, V; ILYINAKAKUEVA, E; MARINI, JF; LEGER, JJ; BODINEFOWLER, SC; EDGERTON, VR				MIU, B; MARTIN, TP; ROY, RR; OGANOV, V; ILYINAKAKUEVA, E; MARINI, JF; LEGER, JJ; BODINEFOWLER, SC; EDGERTON, VR			METABOLIC AND MORPHOLOGIC PROPERTIES OF SINGLE MUSCLE-FIBERS IN THE RAT AFTER SPACEFLIGHT, COSMOS-1887	FASEB JOURNAL			English	Article									INSERM,U6,F-13009 MARSEILLE,FRANCE; MINIST PUBL HLTH USSR,INST BIOMED PROBLEMS,MOSCOW,USSR; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90024	Institut National de la Sante et de la Recherche Medicale (Inserm); Russian Academy of Sciences; Institute of Biomedical Problems of the Russian Academy of Sciences; University of California System; University of California Los Angeles	MIU, B (corresponding author), UNIV CALIF LOS ANGELES,INST KINESIOL,LOS ANGELES,CA 90024, USA.			Bodine, Sue/0000-0002-5742-9145	NINDS NIH HHS [NS 16333] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016333] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALFORD EK, 1987, EXP NEUROL, V96, P635, DOI 10.1016/0014-4886(87)90225-1; BALDWIN KM, 1990, FASEB J, V4, P79, DOI 10.1096/fasebj.4.1.2136840; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; Burke R E, 1975, Exerc Sport Sci Rev, V3, P31; CASTLEMAN KR, 1978, NASA TM78526, P274; CASTLEMAN KR, 1984, MONOGRAPHS CLIN CYTO, P101; Chui L A, 1980, Physiologist, V23, pS76; CLEMENT G, 1988, EXP BRAIN RES, V72, P381; FAST T, 1985, PHYSIOLOGIST, V28, P375; FITTS RH, 1986, J APPL PHYSIOL, V60, P1946, DOI 10.1152/jappl.1986.60.6.1946; GRINDELAND R, 1985, PHYSIOLOGIST, V28, P375; GRINDELAND RE, 1990, FASEB J, V4; HAUSCHKA EO, 1988, J APPL PHYSIOL, V65, P1231, DOI 10.1152/jappl.1988.65.3.1231; HAUSCHKA EO, 1987, J APPL PHYSIOL, V62, P2338, DOI 10.1152/jappl.1987.62.6.2338; HENRIKSEN EJ, 1985, PHYSIOLOGIST, V28, P376; HERBERT ME, 1988, EXP NEUROL, V102, P190, DOI 10.1016/0014-4886(88)90093-3; HYMER WC, 1985, PHYSIOLOGIST, V28, P377; ILYINAKAKUEVA EI, 1976, AVIAT SPACE ENVIR MD, V47, P700; KOZLOVSKAYA IB, 1981, ACTA ASTRONAUT, V8, P1059, DOI 10.1016/0094-5765(81)90079-5; MARINI JF, 1988, SARCOMERIC NONSARCOM, P517; MARTIN TP, 1988, J APPL PHYSIOL, V65, P2318, DOI 10.1152/jappl.1988.65.5.2318; MARTIN TP, 1985, J HISTOCHEM CYTOCHEM, V33, P1053, DOI 10.1177/33.10.4045183; MARTIN TP, 1988, CELL TISSUE RES, V254, P251; NWOYE L, 1982, AM J PHYSIOL, V242, pR401, DOI 10.1152/ajpregu.1982.242.3.R401; Oganov V S, 1980, Physiologist, V23, pS16; OGANOV VS, 1985, 2ND P C SPAC PHYS, P89; OGANOV VS, 1975, LIFE SCI SPACE RES, V14, P137; PORTUGALOV VV, 1976, AVIAT SPACE ENVIR MD, V47, P834; RAPCSAK M, 1983, ACTA PHYSIOL HUNG, V62, P225; RILEY DA, 1987, MUSCLE NERVE, V10, P560, DOI 10.1002/mus.880100612; ROY RR, 1984, J APPL PHYSIOL, V56, P1594, DOI 10.1152/jappl.1984.56.6.1594; ROY RR, 1987, J APPL PHYSIOL, V62, P2348, DOI 10.1152/jappl.1987.62.6.2348; ROY RR, 1988, IEEE ENG MED BIOL, V10, P1710; SZILAGYI T, 1981, ADV PHYSL SCI GRAVIT, V19, P97; TAKACS O, 1983, ACTA PHYSIOL HUNG, V62, P228; WINIARSKI AM, 1987, EXP NEUROL, V96, P650, DOI 10.1016/0014-4886(87)90226-3	36	58	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1990	4	1					64	72		10.1096/fasebj.4.1.2136839	http://dx.doi.org/10.1096/fasebj.4.1.2136839			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH311	2136839				2022-12-28	WOS:A1990CH31100012
J	Li, M; Tsavachidis, S; Wang, FCC; Bui, TY; Nguyen, TDT; Luo, LJ; Multani, AS; Bondy, ML; Hunt, KK; Keyomarsi, K				Li, Mi; Tsavachidis, Spiridon; Wang, Fuchenchu; Bui, Tuyen; Tuyen Duong Thanh Nguyen; Luo, Linjie; Multani, Asha S.; Bondy, Melissa L.; Hunt, Kelly K.; Keyomarsi, Khandan			Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer	ONCOGENE			English	Article; Early Access							HUMAN-CELLS; COMBINATION; SUBTYPES; ORIGINS; GROWTH	Low-molecular-weight cyclin E (LMW-E) is an N-terminus deleted (40 amino acid) form of cyclin E detected in breast cancer, but not in normal cells or tissues. LMW-E overexpression predicts poor survival in breast cancer patients independent of tumor proliferation rate, but the oncogenic mechanism of LMW-E and its unique function(s) independent of full-length cyclin E (FL-cycE) remain unclear. In the current study, we found LMW-E was associated with genomic instability in early-stage breast tumors (n = 725) and promoted genomic instability in human mammary epithelial cells (hMECs). Mechanistically, FL-cycE overexpression inhibited the proliferation of hMECs by replication stress and DNA damage accumulation, but LMW-E facilitated replication stress tolerance by upregulating DNA replication and damage repair. Specifically, LMW-E interacted with chromatin and upregulated the loading of minichromosome maintenance complex proteins (MCMs) in a CDC6 dependent manner and promoted DNA repair in a RAD51- and Cl 7orf53-dependent manner. Targeting the ATR-CHK1-RAD51 pathway with ATR inhibitor (ceralasertib), CHK1 inhibitor (rabusertib), or RAD51 inhibitor (B02) significantly decreased the viability of LMW-E-overexpressing hMECs and breast cancer cells. Collectively, our findings delineate a novel role for LMW-E in tumorigenesis mediated by replication stress tolerance and genomic instability, providing novel therapeutic strategies for LMW-E-overexpressing breast cancers.	[Li, Mi; Keyomarsi, Khandan] Univ Texas MD Anderson Canc Ctr UTHlth Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Li, Mi; Bui, Tuyen; Tuyen Duong Thanh Nguyen; Luo, Linjie; Keyomarsi, Khandan] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Tsavachidis, Spiridon] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Wang, Fuchenchu] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Multani, Asha S.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Bondy, Melissa L.] Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA; [Hunt, Kelly K.] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Stanford University; University of Texas System; UTMD Anderson Cancer Center	Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr UTHlth Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.; Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	; Keyomarsi, Khandan/H-2716-2016	Li, Mi/0000-0002-6038-4144; Keyomarsi, Khandan/0000-0002-5440-0849; Hunt, Kelly K./0000-0001-9156-8723	Cancer Prevention Research Institute of Texas - Multi-Investigator Research Award (CPRIT-MIRA) [RP180712]; National Cancer Institute (NCI) [R01CA223772, R01CA255960]; CPRIT Research Training Program [RP170067, RP210028]; NCI through MD Anderson's Cancer Center Support Grant [P30CA016672]	Cancer Prevention Research Institute of Texas - Multi-Investigator Research Award (CPRIT-MIRA); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT Research Training Program; NCI through MD Anderson's Cancer Center Support Grant	Research reported in this manuscript was supported by Cancer Prevention Research Institute of Texas - Multi-Investigator Research Award (CPRIT-MIRA #RP180712) to KK and KKH, by the National Cancer Institute (NCI) R01CA223772 and R01CA255960 to KK, CPRIT Research Training Program grant RP170067 and RP210028 to ML and by the NCI through MD Anderson's Cancer Center Support Grant (P30CA016672).	Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bianchini G, 2022, NAT REV CLIN ONCOL, V19, P91, DOI 10.1038/s41571-021-00565-2; Bonnet F, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-54; Carey JPW, 2018, CANCER RES, V78, P742, DOI 10.1158/0008-5472.CAN-17-1494; Caruso JA, 2018, CANCER RES, V78, P5481, DOI 10.1158/0008-5472.CAN-18-1235; Caruso JA, 2010, CANCER RES, V70, P7125, DOI 10.1158/0008-5472.CAN-10-1547; Chen X, 2018, CLIN CANCER RES, V24, P6594, DOI 10.1158/1078-0432.CCR-18-1446; Chu C, 2021, TRENDS CELL BIOL, V31, P732, DOI 10.1016/j.tcb.2021.05.001; Delk NA, 2009, CANCER RES, V69, P2817, DOI 10.1158/0008-5472.CAN-08-4182; Duong MT, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002538; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fagundes R, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.774845; Fragkos M, 2015, NAT REV MOL CELL BIO, V16, P360, DOI 10.1038/nrm4002; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Gorecki L, 2021, CANCERS, V13, DOI 10.3390/cancers13040795; Hills SA, 2014, CURR BIOL, V24, pR435, DOI 10.1016/j.cub.2014.04.012; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Hunt KK, 2017, CLIN CANCER RES, V23, P2991, DOI 10.1158/1078-0432.CCR-16-2217; Jabbour-Leung NA, 2016, MOL CANCER THER, V15, P593, DOI 10.1158/1535-7163.MCT-15-0519; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Kettner NM, 2019, CLIN CANCER RES, V25, P3996, DOI 10.1158/1078-0432.CCR-18-3274; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Kim R, 2022, ANN ONCOL, V33, P193, DOI 10.1016/j.annonc.2021.10.009; Kim ST, 2021, CLIN CANCER RES, V27, P4700, DOI 10.1158/1078-0432.CCR-21-0251; Loibl S, 2021, LANCET, V397, P1750, DOI 10.1016/S0140-6736(20)32381-3; Lu XY, 2009, J BIOL CHEM, V284, P35325, DOI 10.1074/jbc.M109.035949; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Masoud V, 2017, WORLD J CLIN ONCOL, V8, P120, DOI 10.5306/wjco.v8.i2.120; Nanos-Webb A, 2012, BREAST CANCER RES TR, V132, P575, DOI 10.1007/s10549-011-1638-4; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Petropoulos M, 2019, TRENDS BIOCHEM SCI, V44, P752, DOI 10.1016/j.tibs.2019.03.011; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sims AH, 2007, NAT CLIN PRACT ONCOL, V4, P516, DOI 10.1038/ncponc0908; Teixeira LK, 2015, CURR BIOL, V25, P1327, DOI 10.1016/j.cub.2015.03.022; Thompson PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023543; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Wang C, 2020, DNA REPAIR, V95, DOI 10.1016/j.dnarep.2020.102946; Yap TA, 2021, CLIN CANCER RES, V27, P5213, DOI 10.1158/1078-0432.CCR-21-1032; Zellweger R, 2015, J CELL BIOL, V208, P563, DOI 10.1083/jcb.201406099	47	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02527-z	http://dx.doi.org/10.1038/s41388-022-02527-z		NOV 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	5Z0JJ	36344674	Green Accepted			2022-12-28	WOS:000879664600002
J	Hu, HT; Zhang, HQ; Xing, Y; Zhou, Y; Chen, JN; Li, C; Xu, JJ; Guo, YY; Wang, J; He, Q; Liu, XM; Sheng, JZ; Song, EW; Wu, YT; Huang, HF				Hu, Hongtao; Zhang, Hanqiu; Xing, Yue; Zhou, Yan; Chen, Jianing; Li, Cheng; Xu, Jingjing; Guo, Yanyan; Wang, Jie; He, Qi; Liu, Xinmei; Sheng, Jianzhong; Song, Erwei; Wu, Yanting; Huang, Hefeng			The lncRNA THOR interacts with and stabilizes hnRNPD to promote cell proliferation and metastasis in breast cancer	ONCOGENE			English	Article							NONCODING RNAS; MESSENGER-RNA; LINCRNAS	Emerging evidence shows that the lncRNA THOR is deeply involved in the development of various cancers. However, the effects and underlying molecular mechanisms of THOR in breast cancer (BRCA) initiation and progression have not been fully elucidated. Here we show that THOR is critical for BRCA tumorigenesis by interacting with hnRNPD to regulate downstream signaling pathways. THOR expression was significantly higher in BRCA tissues than in normal tissues, and THOR upregulation was associated with a poor prognosis in BRCA patients. Functionally, THOR knockdown impaired cell proliferation, migration and invasion in BRCA cells in vitro and inhibited tumorigenesis and metastasis in a tumor xenograft model and THOR-deficient MMTV-PyMT model in vivo. Mechanistically, THOR bound to the hnRNPD protein and increased hnRNPD protein levels by maintaining hnRNPD protein stability through inhibition of the proteasome-dependent degradation pathway. The increased hnRNPD protein levels led to stabilization of its target mRNAs, including pyruvate dehydrogenase kinase 1 (PDK1), further activating downstream PI3K-AKT and MAPK signaling pathways to regulate BRCA cell proliferation and metastasis. Together, our findings indicate that THOR is a promising prognostic predictor for BRCA patients and that the THOR-hnRNPD-PDK1-MAPK/PI3K-AKT axis might be a potential therapeutic target for BRCA treatment.	[Hu, Hongtao] Nanjing Med Univ, Dept Gynecol, Affiliated Hosp 1, Nanjing, Peoples R China; [Hu, Hongtao; Zhang, Hanqiu; Xu, Jingjing; Guo, Yanyan; Wang, Jie; He, Qi] Shanghai Jiao Tong Univ, Int Peace Matern & Child Hlth Hosp, Sch Med, Shanghai, Peoples R China; [Hu, Hongtao; Zhang, Hanqiu; Li, Cheng; Xu, Jingjing; Liu, Xinmei; Huang, Hefeng] Shanghai Key Lab Embryo Original Dis, Shanghai, Peoples R China; [Xing, Yue; Zhou, Yan; Chen, Jianing; Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China; [Xing, Yue; Zhou, Yan; Chen, Jianing; Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Peoples R China; [Li, Cheng; Liu, Xinmei; Wu, Yanting; Huang, Hefeng] Fudan Univ, Obstet & Gynecol Hosp, Inst Reprod & Dev, Shanghai, Peoples R China; [Liu, Xinmei; Huang, Hefeng] Chinese Acad Med Sci, Res Units Embryo Original Dis, Shanghai, Peoples R China; [Sheng, Jianzhong] Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Hangzhou, Peoples R China	Nanjing Medical University; Shanghai Jiao Tong University; Sun Yat Sen University; Sun Yat Sen University; Fudan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University	Huang, HF (corresponding author), Shanghai Key Lab Embryo Original Dis, Shanghai, Peoples R China.; Wu, YT; Huang, HF (corresponding author), Fudan Univ, Obstet & Gynecol Hosp, Inst Reprod & Dev, Shanghai, Peoples R China.; Huang, HF (corresponding author), Chinese Acad Med Sci, Res Units Embryo Original Dis, Shanghai, Peoples R China.	yanting_wu@163.com; huanghefg@sjtu.edu.cn		Hu, Hongtao/0000-0003-3704-6646; Xu, Jing-Jing/0000-0002-4496-0228	National Natural Science Foundation of China [82088102, 82171686]; National Key Research and Development Program of China [2021YFC2700701]; Collaborative Innovation Program of Shanghai Municipal Health Commission [2020CXJQ01]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5064]; Clinical Research Plan of SHDC [SHDC2020CR1008A]; Shanghai Municipal Key Clinical Specialty [shslczdzk06302]; Program of Shanghai Academic Research Leader [20XD1424100]; Outstanding Youth Medical Talents of Shanghai Rising Stars of Medical Talent Youth Development Program; Interdisciplinary Program of Shanghai Jiao Tong University [ZH2018QNB15, YG2019GD04, YG2020YQ29]; Youth Talents development Program of Jiangsu Women And Children Health Hospital [FYRC202004]; Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University [PY2021009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Collaborative Innovation Program of Shanghai Municipal Health Commission; CAMS Innovation Fund for Medical Sciences; Clinical Research Plan of SHDC; Shanghai Municipal Key Clinical Specialty; Program of Shanghai Academic Research Leader; Outstanding Youth Medical Talents of Shanghai Rising Stars of Medical Talent Youth Development Program; Interdisciplinary Program of Shanghai Jiao Tong University; Youth Talents development Program of Jiangsu Women And Children Health Hospital; Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University	This work was supported by the National Natural Science Foundation of China (82088102, 82171686), National Key Research and Development Program of China (2021YFC2700701), Collaborative Innovation Program of Shanghai Municipal Health Commission (2020CXJQ01), CAMS Innovation Fund for Medical Sciences (2019-I2M-5064), Clinical Research Plan of SHDC (SHDC2020CR1008A), Shanghai Municipal Key Clinical Specialty (shslczdzk06302), Program of Shanghai Academic Research Leader (20XD1424100), Outstanding Youth Medical Talents of Shanghai Rising Stars of Medical Talent Youth Development Program, and Interdisciplinary Program of Shanghai Jiao Tong University (ZH2018QNB15, YG2019GD04, YG2020YQ29), Youth Talents development Program of Jiangsu Women And Children Health Hospital (FYRC202004), and Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University (PY2021009). The funding agencies had no role in the study design, data collection and analysis, or decision to submit the article for publication.	Abdolahi S, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-022-03405-8; Al-Khalaf HH, 2014, J BIOL CHEM, V289, P31433, DOI 10.1074/jbc.M114.593004; Amelio I, 2021, SEMIN CANCER BIOL, V72, P36, DOI 10.1016/j.semcancer.2020.06.019; Anwar S, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188568; Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Ding J, 2020, HEPATOLOGY, V72, P1666, DOI 10.1002/hep.31195; Du X, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.681736; Fabbiano F, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12043; Feng XF, 2018, INT J BIOL SCI, V14, P1630, DOI 10.7150/ijbs.26932; Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014; Ge J, 2020, J OVARIAN RES, V13, DOI 10.1186/s13048-020-00672-1; Ginsburg O, 2017, LANCET, V389, P847, DOI [10.1016/S0140-6736(16)31392-7, 10.1]; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Hosono Y, 2017, CELL, V171, P1559, DOI 10.1016/j.cell.2017.11.040; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jin X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01210-9; Li J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1150-y; Liang YR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01206-5; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Liu SJ, 2021, NAT REV CANCER, V21, P446, DOI 10.1038/s41568-021-00353-1; Ma HL, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1123-y; Ma WR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01150-4; Mattijssen S, 2021, RNA BIOL, V18, P259, DOI 10.1080/15476286.2020.1868753; Moore AE, 2014, WIRES RNA, V5, P549, DOI 10.1002/wrna.1230; Portz B, 2021, TRENDS BIOCHEM SCI, V46, P550, DOI 10.1016/j.tibs.2020.12.005; Qiu HB, 2021, CANCER COMMUN, V41, P1037, DOI 10.1002/cac2.12197; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shang YM, 2018, BIOMED PHARMACOTHER, V106, P1243, DOI 10.1016/j.biopha.2018.07.052; Song H, 2018, BIOMED PHARMACOTHER, V108, P338, DOI 10.1016/j.biopha.2018.09.057; St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Tsagakis I, 2020, J PATHOL, V250, P480, DOI 10.1002/path.5405; Tsitsipatis D, 2021, NUCLEIC ACIDS RES, V49, P1631, DOI 10.1093/nar/gkaa1246; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055; Wang BB, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923507; Wang SS, 2019, CANCER LETT, V443, P13, DOI 10.1016/j.canlet.2018.11.028; Wang Y, 2020, CELL DEATH DIFFER, V27, P695, DOI 10.1038/s41418-019-0381-y; Wang YQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21993-9; Xue J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2093-0; Yang HJ, 2019, BIOCHIMIE, V165, P9, DOI 10.1016/j.biochi.2019.06.012; Yang MH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0955-9; Yi M, 2021, BIOMARK RES, V9, DOI 10.1186/s40364-021-00310-y; Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369; Zheng F., 2021, NAT COMMUN, V12; Zhu YF, 2020, INT J SURG, V84, P3, DOI 10.1016/j.ijsu.2020.10.004	48	0	0	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5298	5314		10.1038/s41388-022-02495-4	http://dx.doi.org/10.1038/s41388-022-02495-4		NOV 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36329124				2022-12-28	WOS:000878459600002
J	BEAL, MF				BEAL, MF			MECHANISMS OF EXCITOTOXICITY IN NEUROLOGIC DISEASES	FASEB JOURNAL			English	Article						GLUTAMATE; NEUROTOXICITY; AMYOTROPHIC LATERAL SCLEROSIS; PARKINSONS DISEASE; HUNTINGTONS DISEASE; ALZHEIMERS DISEASE; ISCHEMIA	METABOTROPIC GLUTAMATE RECEPTOR; AMINO-ACID RECEPTORS; DEPENDENT PROTEIN-KINASE; CORTICAL CULTURES; NMDA RECEPTOR; NEURONAL DEGENERATION; HIPPOCAMPAL-NEURONS; MOLECULAR-CLONING; ION FLOW; NEUROTOXICITY	Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors. A substantial body of-evidence has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurologic diseases. A major recent advance has been the successful cloning and expression of the N-methyl-D-aspartate (NMDA), non-NMDA, and metabotropic glutamate receptors. The cellular mechanisms responsible for cell death after activation of these receptors are still being clarified. In acute neurologic diseases such as stroke and head trauma, excitotoxicity may be related to excessive glutamate release. In chronic neurodegenerative diseases, however, a slow excitotoxic process is more likely to occur as a consequence of either a receptor abnormality or an impairment of energy metabolism. Recent therapeutic studies have demonstrated the efficacy of non-NMDA receptor antagonists in experimental studies of global ischemia.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	BEAL, MF (corresponding author), MASSACHUSETTS GEN HOSP,NEUROL SERV,NEUROCHEM LAB,FRUIT ST,BOSTON,MA 02114, USA.				NINDS NIH HHS [NS 10828] Funding Source: Medline; DS NIH HHS [NINDS 16367] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DS NIH HHS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEAL MF, 1991, J NEUROCHEM, V57, P1068, DOI 10.1111/j.1471-4159.1991.tb08258.x; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRIDGES RJ, 1991, EUR J PHARMACOL, V192, P199, DOI 10.1016/0014-2999(91)90093-6; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI DW, 1987, J NEUROSCI, V7, P369; COPANI A, 1991, NEUROREPORT, V2, P763, DOI 10.1097/00001756-199112000-00008; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEMERLEPALLARDY C, 1991, BIOCHEM BIOPH RES CO, V181, P456, DOI 10.1016/S0006-291X(05)81441-X; EJEBJERG J, 1991, NATURE, V351, P745; FRANDSEN A, 1992, P NATL ACAD SCI USA, V89, P2590, DOI 10.1073/pnas.89.7.2590; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; GREENAMYRE JT, 1985, SCIENCE, V227, P1496, DOI 10.1126/science.2858129; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IZUMI Y, 1992, NEUROSCI LETT, V135, P227, DOI 10.1016/0304-3940(92)90442-A; JANKOWITZALEXAN.MS, 1992, J NEUROCHEM, V59, P344; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOH JY, 1991, BRAIN RES, V561, P338, DOI 10.1016/0006-8993(91)91613-6; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LEPPIN C, 1992, BRAIN RES, V581, P168, DOI 10.1016/0006-8993(92)90359-H; LUCUS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; Majewska M D, 1990, Neuroreport, V1, P194, DOI 10.1097/00001756-199011000-00004; MANEV H, 1991, J NEUROCHEM, V57, P1288, DOI 10.1111/j.1471-4159.1991.tb08292.x; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MCDONALD JW, 1992, EUR J PHARMACOL, V215, P353, DOI 10.1016/0014-2999(92)90058-C; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MIYAMOTO M, 1990, EXP NEUROL, V108, P38, DOI 10.1016/0014-4886(90)90005-D; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOSINGER JL, EXP NEUROL, V113, P10; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; NOZAKI K, 1992, J CEREBR BLOOD F MET, V12, P400, DOI 10.1038/jcbfm.1992.57; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PUTTFARCKEN PS, 1992, NEUROPHARMACOLOGY, V31, P565, DOI 10.1016/0028-3908(92)90189-V; RANDALL RD, 1992, J NEUROSCI, V12, P1882; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SMITH SE, 1992, EUR J PHARMACOL, V211, P109, DOI 10.1016/0014-2999(92)90270-E; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SONSALLA PK, 1992, J NEUROCHEM, V58, P1979, DOI 10.1111/j.1471-4159.1992.tb10081.x; SPENCER PS, 1986, LANCET, V2, P1066, DOI 10.1016/S0140-6736(86)90468-X; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; STOREY E, 1992, J NEUROCHEM, V58, P1975, DOI 10.1111/j.1471-4159.1992.tb10080.x; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TEITELBAUM JS, 1990, NEW ENGL J MED, V322, P1781, DOI 10.1056/NEJM199006213222505; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; VECSEI L, 1992, BRAIN RES BULL, V28, P233, DOI 10.1016/0361-9230(92)90184-Y; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762; ZEEVALK GD, 1990, J PHARMACOL EXP THER, V253, P1285; ZEEVALK GD, 1991, J PHARMACOL EXP THER, V257, P870	74	356	385	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1992	6	15					3338	3344		10.1096/fasebj.6.15.1464368	http://dx.doi.org/10.1096/fasebj.6.15.1464368			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1464368	Bronze			2022-12-28	WOS:A1992KD39500004
J	BEALE, EG; CLOUTHIER, DE; HAMMER, RE				BEALE, EG; CLOUTHIER, DE; HAMMER, RE			CELL-SPECIFIC EXPRESSION OF CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE IN TRANSGENIC MICE	FASEB JOURNAL			English	Article						PHOSPHOENOLPYRUVATE CARBOXYKINASE; CELL-SPECIFIC GENE EXPRESSION; TRANSGENIC MICE; LIVER; KIDNEY; ADIPOSE TISSUE	ENRICHED TRANSCRIPTION FACTOR; GROWTH-HORMONE GENE; TISSUE-SPECIFIC EXPRESSION; ENHANCER-BINDING-PROTEIN; MESSENGER-RNA; GTP GENE; RECEPTOR SUPERFAMILY; REGULATORY REGION; RESPONSE ELEMENT; HEPATOMA-CELLS	The gene encoding cytosolic phosphoenolpyruvate carboxykinase (PEPCK) is expressed in multiple cell types in diverse tissues including liver, kidney, intestine, and white and brown adipose tissues. It can thus be considered a model system for examining the regulation of cell-specific transcription. The PEPCK gene is transcribed from a single start site, but studies of transgenic mice have revealed that distinct cis-acting elements (and thus different trans-acting factors) regulate PEPCK expression in hepatocytes, renal proximal tubule epithelial cells, and adipocytes. Hepatocytes require elements between -457 and +69 bp; renal proximal tubule epithelia require elements between -363 and +69 bp; and adipocytes require elements between -2086 and -888 bp. An additional element downstream of +69 bp is required to either attenuate PEPCK mRNA levels in liver and fat or increase renal PEPCK mRNA. We hypothesize that the transcription factors C/EBP and DBP are the principal tissue-specific regulators in liver, and that HNF-1 and perhaps C/EBP are important for kidney-specific PEPCK expression. We propose that the putative downstream element is involved in regulating PEPCK mRNA turnover in liver and fat. Finally, we suggest that the fat-specific element is an enhancer that requires a novel adipogenic regulatory factor, ARF6, to function. The long-term objective will be to fine map the cis-acting elements and identify the cognate trans-acting factors that regulate PEPCK in liver, kidney and fat. This information will help elucidate the combinatorial mechanisms that control the cell-specific expression of this complex gene.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	BEALE, EG (corresponding author), TEXAS TECH UNIV, HLTH SCI CTR, DEPT CELL BIOL & ANAT, LUBBOCK, TX 79430 USA.		Beale, Elmus/GNM-8181-2022; Wilson, Matthew H/K-3193-2013; Clouthier, David/A-7062-2009	Hammer, Robert E./0000-0001-5487-7551; Beale, Elmus/0000-0002-7758-0600	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039895, R01GM039895] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEALE EG, 1985, J BIOL CHEM, V260, P748; BEALE EG, 1991, MOL ENDOCRINOL, V5, P661, DOI 10.1210/mend-5-5-661; BEALE EG, 1981, BIOCHEMISTRY-US, V20, P4878, DOI 10.1021/bi00520a012; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAMMER RE, 1984, ADV GENE TECHNOLOGY, P52; HOD Y, 1988, J BIOL CHEM, V263, P7747; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAISER S, 1991, J BIOL CHEM, V266, P9397; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LIU JS, 1991, J BIOL CHEM, V266, P19095; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; OTEY CA, 1987, J CELL BIOCHEM, V34, P113, DOI 10.1002/jcb.240340205; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; ROESLER WJ, 1990, TRENDS ENDOCRIN MET, V1, P347, DOI 10.1016/1043-2760(90)90082-E; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1992, IN PRESS J BIOL CHEM; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161	47	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1992	6	15					3330	3337		10.1096/fasebj.6.15.1281456	http://dx.doi.org/10.1096/fasebj.6.15.1281456			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1281456				2022-12-28	WOS:A1992KD39500003
J	TRANDINH, CC; PAO, GM; SAIER, MH				TRANDINH, CC; PAO, GM; SAIER, MH			STRUCTURAL AND EVOLUTIONARY RELATIONSHIPS AMONG THE IMMUNOPHILINS - 2 UBIQUITOUS FAMILIES OF PEPTIDYL-PROLYL CIS-TRANS ISOMERASES	FASEB JOURNAL			English	Note						EVOLUTION; MOLECULAR CHAPERONES; IMMUNOPHILINS; CYCLOPHILINS; CYCLOSPORINE-A-BINDING PROTEINS; FK506-BINDING PROTEINS; RAPAMYCIN-BINDING PROTEINS; PEPTIDYL-PROLYL CIS-TRANSISOMERASES; ROTAMASES; PHYLOGENETIC TREES	CYCLOPHILIN HOMOLOG NINAA; ESCHERICHIA-COLI; CYCLOSPORINE-A; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; NEUROSPORA-CRASSA; PROTEIN SEQUENCES; SECRETORY PATHWAY; BINDING PROTEIN; GENE	The immunophilins, protein receptors for the immunosuppressing drugs cyclosporin A and FK506 and related proteins from plants, fungi, and bacteria, have been analyzed structurally and evolutionarily. The cyclosporin A binding proteins (cyclophilins) represent one ubiquitous family of homologous proteins, and the FK506- and rapamycin-binding proteins (FKBPs) constitute a second, unrelated family. Multiple sequence alignments of members of each of these two protein families define the highly conserved residues that are likely to play important structural and functional roles, and mutations in representative members of these two families that abolish or alter function have been evaluated. FKBPs have undergone greater evolutionary divergence than the cyclophilins. Evolutionary trees were constructed using two distinct programs, and these trees establish the structural relationships that allow division of each of these families into subgroups. The results lead to the suggestion that several genes encoding isozymic forms of the FKBPs and possibly also of the cyclophilins existed in prokaryotes before the emergence of eukaryotes on earth and that representatives of these genes were transmitted to both kingdoms to give rise to current subfamilies of these proteins. By contrast, compartmentalization of both classes of immunophilins appears to have arisen independently in prokaryotes and eukaryotes, late in evolutionary history.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	SAIER, MH (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NIAID NIH HHS [5RO1 AI21702, 2RO1 AI14176] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702, R01AI014176] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BARISIC K, 1991, DEV GENET, V12, P50, DOI 10.1002/dvg.1020120110; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BOSSARD MJ, 1991, BIOCHEM BIOPH RES CO, V176, P1142, DOI 10.1016/0006-291X(91)90404-U; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DIETMEIER K, 1990, NUCLEIC ACIDS RES, V18, P373, DOI 10.1093/nar/18.2.373; Doolittle R., 1990, METHOD ENZYMOL, V183, P303; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P659; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ENGLEBERG NC, 1989, INFECT IMMUN, V57, P1263, DOI 10.1128/IAI.57.4.1263-1270.1989; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JIN YJ, 1992, J BIOL CHEM, V267, P10942; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KATO J, 1991, P NATL ACAD SCI USA, V88, P1760, DOI 10.1073/pnas.88.5.1760; KAWAMUKAI M, 1989, J BACTERIOL, V171, P4525, DOI 10.1128/JB.171.8.4525-4529.1989; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KLEENE KC, 1990, GENE, V95, P301, DOI 10.1016/0378-1119(90)90376-3; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LUNDEMOSE AG, 1991, MOL MICROBIOL, V5, P109, DOI 10.1111/j.1365-2958.1991.tb01831.x; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MCLAUGHLIN MM, 1992, GENE, V111, P85, DOI 10.1016/0378-1119(92)90606-P; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; ONDEK B, 1992, J BIOL CHEM, V267, P16460; PARK ST, 1992, J BIOL CHEM, V267, P3316; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY ACF, 1988, J BACTERIOL, V170, P1691, DOI 10.1128/jb.170.4.1691-1697.1988; POTEETE AR, 1992, PROTEINS, V13, P38, DOI 10.1002/prot.340130104; ROSEN MK, 1992, ANGEW CHEM INT EDIT, V31, P384, DOI 10.1002/anie.199203841; SAIER MH, 1990, RES MICROBIOL, V141, P1033, DOI 10.1016/0923-2508(90)90077-4; SAMPSON BA, 1992, P NATL ACAD SCI USA, V89, P1164, DOI 10.1073/pnas.89.4.1164; SCHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUMACHER A, 1991, BIOCHIM BIOPHYS ACTA, V1129, P13, DOI 10.1016/0167-4781(91)90207-3; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VARTAK NB, 1991, RES MICROBIOL, V142, P951, DOI 10.1016/0923-2508(91)90005-U; XU Q, 1992, J BIOL CHEM, V267, P11968	66	115	120	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1992	6	15					3410	3420		10.1096/fasebj.6.15.1464374	http://dx.doi.org/10.1096/fasebj.6.15.1464374			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1464374				2022-12-28	WOS:A1992KD39500014
J	GOETZL, EJ; SREEDHARAN, SP				GOETZL, EJ; SREEDHARAN, SP			MEDIATORS OF COMMUNICATION AND ADAPTATION IN THE NEUROENDOCRINE AND IMMUNE-SYSTEMS	FASEB JOURNAL			English	Review						NEUROPEPTIDE; INTERLEUKIN; INTERFERON; LYMPHOCYTE; MACROPHAGE; PITUITARY; IMMUNOGLOBULIN; RECEPTOR	VASOACTIVE-INTESTINAL-PEPTIDE; TUMOR NECROSIS FACTOR; NERVE GROWTH-FACTOR; T-CELLS; POSSIBLE INVOLVEMENT; MITOGENIC RESPONSE; ARACHIDONIC-ACID; SUBSTANCE-P; MAST-CELLS; IFN-GAMMA	Bidirectional interactions between the immune and neuroendocrine systems influence specifically physiological activities as diverse as tissue localization of lymphocytes, antibody responses, hypothalamic-pituitary hormone secretion, and neural signal transmission. Our understanding of intersystem communications has been increased by the delineation of the innervation of immune organs, effects of neuromediators on immune cells, and neuroendocrine responses to individual immune cytokines. Two patterns of responses to neuroimmune mediators have been defined to distinguish between direct alterations in cellular function and the more complex states of differentiation and adaptation that condition the threshold and nature of reactions to subsequent stimuli. Recent identification of the molecular mechanisms of action of neuroimmune mediators is exemplified by elucidation of the requirement for prolactin in T lymphocyte proliferation and of the effects of vasoactive intestinal peptide on B lymphocyte expression of adherence proteins. Further knowledge of the advantages of multisystem integration of functions in host defense may reveal other novel mechanisms of cellular communication and biological adaptation.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GOETZL, EJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, U-426, BOX 0724, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029912, R01AI029912] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-29912] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELMAN DC, 1991, J ALLERGY CLIN IMMUN, V87, pA260; Ader R, 1991, PSYCHONEUROIMMUNOLOG; BERCZI I, 1991, J IMMUNOL, V146, P2201; Berczi I, 1986, PITUITARY FUNCTION I; BULLOCH K, 1990, J N EUROSCI RES, V25, P20; BURRALL BA, 1988, J INVEST DERMATOL, V91, P294, DOI 10.1111/1523-1747.ep12475450; CARR DJJ, 1988, PSYCHONEUROENDOCRINO, V2, P8; CASINI A, 1989, N-S ARCH PHARMACOL, V339, P354; CHENG PPJ, 1991, FASEB J, V5, pA1228; CHUNG IY, 1990, J IMMUNOL, V144, P2999; CHUNG IY, 1991, J EXP MED, V173, P801, DOI 10.1084/jem.173.4.801; CHURCH MK, 1989, INT ARCH ALLER A IMM, V88, P70, DOI 10.1159/000234752; CLEVENGER CV, 1991, SCIENCE, V253, P77, DOI 10.1126/science.2063207; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DURSO R, 1991, PROG NEUROENDOCRINIM, V4, P20; ERICSSON A, 1991, PROG NEURO ENDOCRIN, V4, P26; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P2555, DOI 10.1073/pnas.87.7.2555; FRIESEN HG, 1991, PROG NEUROENDOCRINIM, V4, P1; FUKAYAMA M, 1990, AM J PATHOL, V136, P123; FULLER PJ, 1989, J IMMUNOL, V143, P1015; Goetzl E J, 1990, Adv Immunol, V48, P161, DOI 10.1016/S0065-2776(08)60754-3; GOMARIZ RP, 1990, BRAIN BEHAV IMMUN, V4, P151, DOI 10.1016/0889-1591(90)90017-K; GONZALEZ MC, 1990, PROG NEUROENDOCRINIM, V3, P49; HART RP, 1991, J NEUROSCI RES, V29, P282, DOI 10.1002/jnr.490290303; HARTMANN DP, 1989, FASEB J, V3, P2194, DOI 10.1096/fasebj.3.10.2787766; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; HIESTAND PC, 1986, P NATL ACAD SCI USA, V83, P2599, DOI 10.1073/pnas.83.8.2599; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; JOHNSON HM, 1982, P NATL ACAD SCI-BIOL, V79, P4171, DOI 10.1073/pnas.79.13.4171; JONAKAIT GM, 1990, J NEUROSCI RES, V26, P24, DOI 10.1002/jnr.490260104; KAMEGAI M, 1990, NEURON, V4, P429, DOI 10.1016/0896-6273(90)90055-K; KARANTH S, 1991, P NATL ACAD SCI USA, V88, P2961, DOI 10.1073/pnas.88.7.2961; LANIER LL, 1991, J IMMUNOL, V146, P4421; LEVINE JD, 1986, P NATL ACAD SCI USA, V83, P5331, DOI 10.1073/pnas.83.14.5331; LORTON D, 1991, BRAIN BEHAV IMMUN, V5, P29, DOI 10.1016/0889-1591(91)90005-U; MARSHALL JS, 1990, J IMMUNOL, V144, P1886; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MILNER RJ, 1990, ANN NY ACAD SCI, V605, P254, DOI 10.1111/j.1749-6632.1990.tb42398.x; MORIMOTO A, 1989, J PHYSIOL-LONDON, V411, P245, DOI 10.1113/jphysiol.1989.sp017571; NEZU N, 1990, J IMMUNOL, V145, P3126; OTTAWAY C A, 1987, Brain Behavior and Immunity, V1, P148, DOI 10.1016/0889-1591(87)90017-1; OTTAWAY CA, 1987, IMMUNOLOGY, V62, P291; OTTAWAY CA, 1984, J EXP MED, V160, P1054, DOI 10.1084/jem.160.4.1054; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; RETTORI V, 1991, P NATL ACAD SCI USA, V88, P2763, DOI 10.1073/pnas.88.7.2763; ROBERT F, 1991, BRAIN BEHAV IMMUN, V5, P102, DOI 10.1016/0889-1591(91)90010-8; ROBICHON A, 1990, FASEB J, V6, pA1687; SAID SI, 1988, VASOACTIVE INTESTINA; SEDGWICK JD, 1991, J EXP MED, V173, P1235, DOI 10.1084/jem.173.5.1235; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SMITH EM, 1990, P NATL ACAD SCI USA, V87, P1057, DOI 10.1073/pnas.87.3.1057; Spector NH, 1989, NEUROIMMUNE NETWORKS; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; STANISZ AM, 1986, J IMMUNOL, V136, P152; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; SUZUKI K, 1990, J BIOL CHEM, V265, P11320; TAIWO YO, 1987, BRAIN RES, V423, P333, DOI 10.1016/0006-8993(87)90858-4; TWEARDY DJ, 1990, J IMMUNOL, V144, P2233; VELASCO S, 1991, J CLIN INVEST, V87, P1674, DOI 10.1172/JCI115184; WAHL SM, 1991, J EXP MED, V173, P981, DOI 10.1084/jem.173.4.981; WEIGENT DA, 1987, FASEB J, V46, P926; WEINSTOCK JV, 1989, J IMMUNOL, V142, P3256; WEINSTOCK JV, 1990, CELL IMMUNOL, V125, P146; WHITE DM, 1990, J NEUROPHYSIOL, V63, P966, DOI 10.1152/jn.1990.63.5.966; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; YULEE LY, 1990, ANN NY ACAD SCI, V594, P146	70	105	110	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1992	6	9					2646	2652		10.1096/fasebj.6.9.1612288	http://dx.doi.org/10.1096/fasebj.6.9.1612288			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612288				2022-12-28	WOS:A1992HZ48100004
J	KAM, M; PERLTREVES, D; CASPI, D; ADDADI, L				KAM, M; PERLTREVES, D; CASPI, D; ADDADI, L			ANTIBODIES AGAINST CRYSTALS	FASEB JOURNAL			English	Article						GOUT; ANTIGEN-ANTIBODY COMPLEX; CATALYTIC ANTIBODIES; IGG; CRYSTAL-NUCLEATION	MONOSODIUM URATE MONOHYDRATE; CALCIUM PYROPHOSPHATE DIHYDRATE; 3-DIMENSIONAL STRUCTURE; PROTEINS; CRYSTALLIZATION; RESOLUTION; NUCLEATION; MONOLAYERS; COMPLEX; BINDING	We suggest that crystals, when introduced into an organism, may behave as conventional antigens, mediating the production of specific antibodies. These antibodies would bear an imprint of the crystal surface and may consequently behave as a nucleating matrix in a new crystallization event. Thus, they would behave as catalytic antibodies. We show that IgG antibodies isolated from patients suffering from gout, a joint disease caused by crystals of monosodium urate monohydrate (MSUM), accelerate the appearance of new crystals of MSUM from a supersaturated solution of the salt in vitro. The same effect is not observed for IgG antibodies isolated from the joint fluids of patients with other joint diseases, such as pseudogout, rheumatoid arthritis, or osteoarthritis. Furthermore, IgG antibodies obtained from rabbits injected subcutaneously with crystals of MSUM, were also nucleating towards MSUM crystals.	WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL; ICHILOV HOSP,DEPT RHEUMATOL,IL-64239 TEL AVIV,ISRAEL	Weizmann Institute of Science; Tel Aviv University				Perl-Treves, Daniele/0000-0001-6312-4092				ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BARDIN T, 1984, J RHEUMATOL, V11, P339; CHERIAN PV, 1986, ULTRASTRUCT PATHOL, V10, P209, DOI 10.3109/01913128609032219; COLMAN PM, 1987, IMMUNOL TODAY, V8, P323, DOI 10.1016/0167-5699(87)90004-1; DIEPPE PA, 1983, CRYSTALS JOINT DISEA; GINSBERG MH, 1978, ARTHRITIS RHEUM, V21, P896, DOI 10.1002/art.1780210805; HALL AP, 1967, AM J MED, V42, P27, DOI 10.1016/0002-9343(67)90004-6; HARVEY PRC, 1991, J BIOL CHEM, V266, P13996; HASSELBACHER P, 1979, J LAB CLIN MED, V94, P532; HASSELBACHER P, 1982, ADV INFLAMMAT RES, V4, P73; HOFFMAN WL, 1990, ARTHRITIS RHEUM, V33, P1196; HOLLANDER JL, 1965, ANN INTERN MED, V62, P271, DOI 10.7326/0003-4819-62-2-271; KOZIN F, 1977, J LAB CLIN MED, V89, P1314; KOZIN F, 1980, J LAB CLIN MED, V95, P49; LANDAU EM, 1985, NATURE, V318, P353, DOI 10.1038/318353a0; MANDEL NS, 1980, ARTHRITIS RHEUM, V23, P772, DOI 10.1002/art.1780230610; MANN S, 1989, P ROY SOC LOND A MAT, V423, P457, DOI 10.1098/rspa.1989.0065; MCCARTY DJ, 1976, ARTHRITIS RHEUM, V19, P275, DOI 10.1002/1529-0131(197605/06)19:3+<275::AID-ART1780190702>3.0.CO;2-0; PERLTREVES D, 1990, MOL CRYST LIQ CRYST, V187, P1, DOI 10.1080/00268949008036022; PERLTREVES D, 1988, PROC R SOC SER B-BIO, V235, P145, DOI 10.1098/rspb.1988.0069; SEEGMILLER JE, 1962, JAMA-J AM MED ASSOC, V180, P469; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SOHNEL O, 1988, J CRYST GROWTH, V89, P202, DOI 10.1016/0022-0248(88)90403-4; SWARTZ GM, 1988, P NATL ACAD SCI USA, V85, P1902, DOI 10.1073/pnas.85.6.1902; TAK HK, 1980, J COLLOID INTERF SCI, V772, P195; TAK HK, 1980, ARTHRITIS RHEUM, V23, P547; WEISSBUCH I, 1987, J AM CHEM SOC, V109, P1869, DOI 10.1021/ja00240a052; WEISSBUCH I, 1990, J AM CHEM SOC, V112, P7718, DOI 10.1021/ja00177a036; 1984, BIORAD B, V1152; 1988, PROTEIN G SEPHAROSE, P3	31	53	53	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2608	2613		10.1096/fasebj.6.8.1592211	http://dx.doi.org/10.1096/fasebj.6.8.1592211			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592211				2022-12-28	WOS:A1992HU42300014
J	CADENA, DL; GILL, GN				CADENA, DL; GILL, GN			RECEPTOR TYROSINE KINASES	FASEB JOURNAL			English	Review						GROWTH FACTORS; ONCOGENES; SIGNAL TRANSDUCTION; PROTEIN PHOSPHORYLATION	GROWTH-FACTOR RECEPTOR; LIGAND-INDUCED INTERNALIZATION; PROTEIN-KINASE; SELF-PHOSPHORYLATION; ACTIVATION; ONCOGENE; BINDING; REQUIREMENT; DROSOPHILA; DOMAINS	A major process through which environmental information is transmitted into cells is via activation of protein tyrosine kinases. Receptor tyrosine kinases contain extracellular ligand recognition, single membrane spanning, and cytoplasmic protein tyrosine kinase domains. The cytoplasmic kinase core is flanked by regulatory segments, which in some family members are also inserted into the core kinase domain. Ligand binding initiates receptor signaling from the cell surface. Activated receptors autophosphorylate to remove alternate substrate/inhibitory constraints and to provide loci for assembly of proteins that contain SRC homology regions. Information is transmitted and diffused by tyrosine phosphorylation of the assembled proteins and of cellular substrates that include protein kinases with specificity for serine/threonine residues. Signaling, which is strictly ligand-dependent, is attenuated by down-regulation of receptors and by feedback inhibitory loops that involve receptor phosphorylation by cellular kinases. The tyrosine kinase receptors are essential for normal growth, development, and reparative processes. Mutations that remove normal regulatory constraints on the approximately 290 amino acid kinase core of these large proteins result in constitutive function and cell transformation.			CADENA, DL (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-07044-13] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1991, J BIOL CHEM, V266, P637; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIM HK, 1991, CELL, V65, P453; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LUND KA, 1990, J BIOL CHEM, V265, P20517; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7450; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001; [No title captured]	47	221	227	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2332	2337		10.1096/fasebj.6.6.1312047	http://dx.doi.org/10.1096/fasebj.6.6.1312047			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1312047				2022-12-28	WOS:A1992HJ25200010
J	LANGER, GA				LANGER, GA			CALCIUM AND THE HEART - EXCHANGE AT THE TISSUE, CELL, AND ORGANELLE LEVELS	FASEB JOURNAL			English	Article						CONTRACTILE CONTROL; MYOCARDIAL METABOLISM; CALCIUM FUNCTIONAL RELATIONS	CARDIAC SARCOPLASMIC-RETICULUM; INDUCED RELEASE; CA EXCHANGE; CHANNEL; MUSCLE; CA-2+; MYOCYTES; RAT; PHOSPHORYLATION; SARCOLEMMA	Cellular calcium (Ca) exchange in arterially perfused whole heart is markedly perfusion-limited. Therefore, a large fraction of exchangeable Ca recycles within the cell before exchanging with extracellular Ca. Ca enters the cell via sarcolemmal (SL) transient (T) and long-lasting (L) channels activated at more negative and less negative membrane potential, respectively. The larger L currents are controlled via phosphorylation and G protein interaction to provide Ca to induce Ca release from sarcoplasmic reticulum (SR) and for direct myofilament activation. Troponin C (TNC) binds 3 mol of Ca/mol. Only the low affinity site is responsible for activation of force and regulation of myofilament ATPase rate. This occurs through a shift in troponin I (TNI) with respect to actin induced by the TNC Ca binding. Relaxation depends on reduction of cytosolic (Ca) and occurs via 1) Ca pumping into the longitudinal SR modulated by phospholamban; 2) the recently cloned high-capacity electrogenic SL Na-Ca exchanger; and 3) the SL Ca pump under complex regulation including calmodulin control. Mitochondria transport Ca, but this transport is directed primarily to the regulation of various Ca-sensitive dehydrogenases so that oxidative metabolism can be adjusted to changes in energy demand. The regulation of Ca movements consumes about 25% of the cell's total energy output. Mitochondrial Ca exchanges with extracellular Ca most slowly (t1/2 = 3.6 min), SR Ca quite rapidly (t1/2s = 3 and 19 s), and an Na-Ca exchange-dependent compartment very rapidly (t1/2 = 500 ms). After further description of Ca handling by the individual organelles, Ca movement is followed through the cell during the course of contraction, and the contribution of each organelle or compartment to overall cellular Ca exchange is defined.	UNIV CALIF LOS ANGELES, CTR HLTH SCI, SCH MED, DEPT PHYSIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LANGER, GA (corresponding author), UNIV CALIF LOS ANGELES, CTR HLTH SCI,SCH MED,DEPT MED,MACDONALD RES LABS, CARDIOVASC RES LAB, LOS ANGELES, CA 90024 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028539] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 28539-10] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLSHIRE A, 1987, BIOCHEM J, V244, P381, DOI 10.1042/bj2440381; ALNASSER I, 1986, BIOCHEM J, V239, P31, DOI 10.1042/bj2390031; BARANY K, 1977, J BIOL CHEM, V252, P4752; BERS DM, 1985, AM J PHYSIOL, V248, pH366, DOI 10.1152/ajpheart.1985.248.3.H366; BERS DM, 1983, AM J PHYSIOL, V244, pH462, DOI 10.1152/ajpheart.1983.244.3.H462; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CAMPBELL DL, 1990, CALCIUM HEART, P27; CARAFOLI E, 1990, CALCIUM HEART, P109; CARONI P, 1980, NATURE, V283, P765, DOI 10.1038/283765a0; COHEN CJ, 1982, CIRC RES, V50, P651, DOI 10.1161/01.RES.50.5.651; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; CROMPTON M, 1990, CALCIUM HEART, P167; DENTON RM, 1981, FEBS LETT, V199, P108; FABIATO A, 1986, BIOPHYS J, V49, pA190; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FABIATO A, 1991, IN PRESS EXCITATION; FEHER JJ, 1990, CALCIUM HEART, P199; FRANK JS, 1974, J CELL BIOL, V60, P586, DOI 10.1083/jcb.60.3.586; GREENAWALT JW, 1964, J CELL BIOL, V23, P21, DOI 10.1083/jcb.23.1.21; HANSFORD RG, 1987, BIOCHEM J, V241, P145, DOI 10.1042/bj2410145; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HENRY PD, 1977, AM J PHYSIOL, V233, pH677, DOI 10.1152/ajpheart.1977.233.6.H677; HILGEMANN DW, 1984, CIRC RES, V54, P461, DOI 10.1161/01.RES.54.4.461; HOLROYDE MJ, 1979, J BIOL CHEM, V254, P6478; INUI M, 1987, J BIOL CHEM, V262, P15637; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; LANGER GA, 1990, AM J PHYSIOL, V259, pH592, DOI 10.1152/ajpheart.1990.259.2.H592; LANGER GA, 1982, PHARMACOL THERAPEUT, V16, P331, DOI 10.1016/0163-7258(82)90006-7; LANGER GA, 1971, NEW ENGL J MED, V285, P1065, DOI 10.1056/NEJM197111042851910; LANGER GA, 1991, J PHYSL PHARM POLAND, V42, P27; LANGER GA, 1990, CALCIUM HEART; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEE CO, 1980, BIOPHYS J, V29, P315, DOI 10.1016/S0006-3495(80)85135-6; LEWARTOWSKI B, 1990, AM J PHYSIOL, V259, pH1222, DOI 10.1152/ajpheart.1990.259.4.H1222; LEWARTOWSKI B, 1984, PFLUENERSG ARCH, V301, P198; LI ZP, 1991, J BIOL CHEM, V266, P1014; MCCLESKEY EW, 1986, J EXP BIOL, V124, P177; MITRA R, 1986, P NATL ACAD SCI USA, V83, P5340, DOI 10.1073/pnas.83.14.5340; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NOSEK TM, 1986, AM J PHYSIOL, V250, pC807, DOI 10.1152/ajpcell.1986.250.5.C807; ONDRIAS K, 1990, CIRC RES, V67, P1167, DOI 10.1161/01.RES.67.5.1167; PHILIPSON KD, 1979, J MOL CELL CARDIOL, V11, P857, DOI 10.1016/0022-2828(79)90481-4; PHILIPSON KD, 1992, TRENDS CARDIOVAS MED, V2, P12, DOI 10.1016/1050-1738(92)90038-T; PHILIPSON KD, 1982, J BIOL CHEM, V257, P5111; PIERCE GN, 1987, CIRC RES, V61, P805, DOI 10.1161/01.RES.61.6.805; PIERCE GN, 1985, AM J PHYSIOL, V249, pC248, DOI 10.1152/ajpcell.1985.249.3.C248; Ponce-Hornos J.E., 1990, CALCIUM HEART, P269; PONCEHORNOS JE, 1989, J MOL CELL CARDIOL, V21, P115, DOI 10.1016/0022-2828(89)91499-5; POST JA, 1988, BIOCHIM BIOPHYS ACTA, V943, P256, DOI 10.1016/0005-2736(88)90557-3; POST JA, 1991, FASEB J, V5, pA1051; RICH TL, 1988, AM J PHYSIOL, V254, pH937, DOI 10.1152/ajpheart.1988.254.5.H937; RICH TL, 1991, FASEB J, V5, pA1051; ROBISHAW JD, 1989, ANNU REV PHYSIOL, V51, P229, DOI 10.1146/annurev.ph.51.030189.001305; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SHATTOCK MJ, 1989, AM J PHYSIOL, V256, pC813, DOI 10.1152/ajpcell.1989.256.4.C813; SOLARO RJ, 1988, PHYSL PATHOPHYSIOLOG, P291; SOMLYO AV, 1979, J CELL BIOL, V80, P743, DOI 10.1083/jcb.80.3.743; THOMLISON RJ, 1990, CHILD MALTREATMENT : EXPANDING OUR CONCEPT OF HELPING, P127; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; WALSH LG, 1988, AM J PHYSIOL, V255, pH929, DOI 10.1152/ajpheart.1988.255.4.H929; WARBER KD, 1986, HEART CARDIOVASCULAR, V2, P779; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	68	55	55	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1992	6	3					893	902		10.1096/fasebj.6.3.1310947	http://dx.doi.org/10.1096/fasebj.6.3.1310947			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1310947				2022-12-28	WOS:A1992HE39000013
J	GUENGERICH, FP				GUENGERICH, FP			CYTOCHROME-P450 - ADVANCES AND PROSPECTS	FASEB JOURNAL			English	Review									VANDERBILT UNIV,MED CTR,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University	GUENGERICH, FP (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.							BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; COON MJ, 1992, FASEB J, V6, P669, DOI 10.1096/fasebj.6.2.1537454; DEMONTELLANO PRO, 1992, FASEB J, V6, P695, DOI 10.1096/fasebj.6.2.1537458; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HOLLENBERG PF, 1992, FASEB J, V6, P686, DOI 10.1096/fasebj.6.2.1537457; JOHNSON EF, 1992, FASEB J, V6, P700, DOI 10.1096/fasebj.6.2.1537459; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; LEGRAVEREND C, 1992, FASEB J, V6, P711, DOI 10.1096/fasebj.6.2.1537461; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; YANG CS, 1992, FASEB J, V6, P737, DOI 10.1096/fasebj.6.2.1537464; ZANGER UM, 1992, FASEB J, V6, P719, DOI 10.1096/fasebj.6.2.1311271	13	49	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					667	668		10.1096/fasebj.6.2.1537453	http://dx.doi.org/10.1096/fasebj.6.2.1537453			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537453				2022-12-28	WOS:A1992GZ44000003
J	LIEBER, MR				LIEBER, MR			SITE-SPECIFIC RECOMBINATION IN THE IMMUNE-SYSTEM	FASEB JOURNAL			English	Article						RECOMBINATION; REARRANGEMENT; IMMUNOGLOBULIN; ANTIGEN RECEPTOR; REVIEW	TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; PRE-B CELLS; IMMUNOGLOBULIN GENE REARRANGEMENT; LYMPHOID V(D)J RECOMBINATION; ANTIGEN RECEPTOR GENES; SIGNAL SEQUENCES; CODING SEGMENTS; JOINING SIGNALS; SCID MICE; DNA	Site-specific DNA recombination has been identified in a wide variety of biological systems. In vertebrates, however, the only identified use of this genetic device is in the immune system. Here it plays a critical role in generating a diverse repertoire of surface receptors to intercept invading microbes and parasites. The mechanism and orchestration of this reaction are intriguing and are relevant to a broad array of related biological and biomedical issues.			LIEBER, MR (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.			Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345	NCI NIH HHS [CA51105] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA051105, R01CA051105] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILERA RJ, 1987, CELL, V51, P909, DOI 10.1016/0092-8674(87)90578-2; ALLISON JP, 1991, IN PRESS ANN REV IMM; BASU M, 1983, BIOCHEM BIOPH RES CO, V111, P1105, DOI 10.1016/0006-291X(83)91413-4; BERG D, 1989, MOBILE DNA AM SOC MI; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blackwell T. K., 1988, Molecular Immunology., P1; BOLLUM FJ, 1986, ADV CANCER RES, V47, P37, DOI 10.1016/S0065-230X(08)60197-9; BOSMA GC, 1989, IMMUNOGENETICS, V29, P54, DOI 10.1007/BF02341614; CARLSON LM, 1991, CELL, V64, P201, DOI 10.1016/0092-8674(91)90221-J; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; COEN ES, 1989, MOBILE DNA; CRAIG NL, 1987, ESCHERICHIA COLI SAL, V2, P1054; DAGUSTARO G, 1985, CAN J BIOCHEM CELL B, V63, P969; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DESIDERIO S, 1984, NATURE, V308, P860, DOI 10.1038/308860a0; ELLIOT J, 1988, NATURE, V330, P621; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GERMANN MW, 1990, NUCLEIC ACIDS RES, V18, P1489, DOI 10.1093/nar/18.6.1489; GRITZMACHER CA, 1989, CRIT REV IMMUNOL, V9, P173; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HENDRICKSON EA, 1991, MOL CELL BIOL, V11, P3155, DOI 10.1128/MCB.11.6.3155; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HESSE JE, 1989, THESIS U CHICAGO CHI; HOPE TJ, 1986, SCIENCE, V231, P1141, DOI 10.1126/science.3003919; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; KIM MG, 1988, J IMMUNOL, V141, P1341; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LI M, 1989, GENE DEV, V3, P1801, DOI 10.1101/gad.3.11.1801; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MATSUDA F, 1988, EMBO J, V7, P1047, DOI 10.1002/j.1460-2075.1988.tb02912.x; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; McCormack W T, 1990, Adv Immunol, V48, P41, DOI 10.1016/S0065-2776(08)60751-8; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MEEK K, 1990, SCIENCE, V250, P821; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3783; MOCIKAT R, 1987, BIOL CHEM H-S, V368, P913, DOI 10.1515/bchm3.1987.368.2.913; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OKAZAKI K, 1988, J IMMUNOL, V141, P1348; PETRINI JHJ, 1990, P NATL ACAD SCI USA, V87, P3450, DOI 10.1073/pnas.87.9.3450; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROTHENBERG E, 1983, J IMMUNOL, V130, P1627; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHROEDER HW, 1988, P NATL ACAD SCI USA, V85, P8196, DOI 10.1073/pnas.85.21.8196; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHULER W, 1990, MOL BASIS B CELL DEV, V3, P132; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; VANDERENDE A, 1981, NUCLEIC ACIDS RES, V9, P2037, DOI 10.1093/nar/9.9.2037; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; YANCOPOULOS GD, 1988, J EXP MED, V168, P417, DOI 10.1084/jem.168.1.417	62	148	153	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2934	2944		10.1096/fasebj.5.14.1752360	http://dx.doi.org/10.1096/fasebj.5.14.1752360			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752360				2022-12-28	WOS:A1991GP26900008
J	DIENER, TO				DIENER, TO			SUBVIRAL PATHOGENS OF PLANTS - VIROIDS AND VIROID-LIKE SATELLITE RNAS	FASEB JOURNAL			English	Review						PLANT DISEASES; CIRCULAR RNAS; ROLLING CIRCLE REPLICATION; RNA EVOLUTION; RNA WORLD	CENTRAL CONSERVED REGION; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; CITRUS EXOCORTIS; SELF-CLEAVAGE; REPLICATION; MODEL; EVOLUTION; ISOLATE; VIRUS	Contrary to earlier beliefs, viruses are not the smallest causative agents of infectious diseases. Single-stranded RNAs as small as 246 nucleotides exist in certain higher plants and cause more than a dozen crop diseases. These RNAs have been termed viroids. Despite their extremely limited information content, viroids replicate autonomously in susceptible cells - that is, they do not require helper functions from simultaneously replicating conventional viruses. Viroids are covalently closed circular molecules with a characteristic rodlike secondary structure in which short helical regions are interrupted by internal and bulge loops. Viroids are not translated; they are replicated by a host enzyme (or enzymes) (probably RNA polymerase II) via oligomeric RNA intermediates by a rolling circle mechanism. Viroidlike satellite RNAs resemble viroids in size and molecular structure, but are found within the capsids of specific helper viruses on which they depend for their own replication. These RNAs are of great interest to molecular biology for at least two reasons: 1) they are the smallest and simplest replicating molecules known, and 2) they may represent living fossils of precellular evolution in a hypothetical RNA world.	UNIV MARYLAND,CTR AGR BIOTECHNOL,COLLEGE PK,MD 20742; UNIV MARYLAND,DEPT BOT,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	DIENER, TO (corresponding author), USDA,AGR RES CTR W,MICROBIOL & PLANT PATHOL LAB,BLDG 011A,BELTSVILLE,MD 20705, USA.			Diener, Theodor/0000-0003-1850-9027				BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; CANDRESSE T, 1987, NUCLEIC ACIDS RES, V15, P10597, DOI 10.1093/nar/15.24.10597; CANDRESSE T, 1990, VIROLOGY, V175, P232, DOI 10.1016/0042-6822(90)90203-4; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CECH TR, 1989, NATURE, V339, P507, DOI 10.1038/339507a0; Diener T.O., 1987, VIROIDS; DIENER TO, 1989, P NATL ACAD SCI USA, V86, P9370, DOI 10.1073/pnas.86.23.9370; DIENER TO, 1971, VIROLOGY, V45, P411, DOI 10.1016/0042-6822(71)90342-4; DIENER TO, 1979, SCIENCE, V205, P859, DOI 10.1126/science.472709; DIENER TO, 1988, PLANT DIS, V72, P691, DOI 10.1094/PD-72-0691; DIENER TO, 1981, SCI AM, V244, P66, DOI 10.1038/scientificamerican0181-66; DIENER TO, 1986, P NATL ACAD SCI USA, V83, P58, DOI 10.1073/pnas.83.1.58; DIENER TO, 1989, RES CLIN LAB, V19, P105; DIENER TO, 1981, ANNU REV PLANT PHYS, V32, P313, DOI 10.1146/annurev.pp.32.060181.001525; DIENER TO, 1978, VIRUSES ENV, P113; DIENER TO, 1991, HEPATITIS DELTA VIRU, P243; DIENER TO, 1987, VIROIDS, P297; DIENER TO, 1979, VIROIDS VIROID DISEA, P1; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FORSTER AC, 1987, COLD SPRING HARB SYM, V52, P249, DOI 10.1101/SQB.1987.052.01.030; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FRANCKI RIB, 1987, VIROIDS, P205; GARCIAARENAL F, 1987, NUCLEIC ACIDS RES, V15, P4203, DOI 10.1093/nar/15.10.4203; GROSS HJ, 1978, NATURE, V273, P203, DOI 10.1038/273203a0; GROSS HJ, 1982, EUR J BIOCHEM, V121, P249, DOI 10.1111/j.1432-1033.1982.tb05779.x; GROSS HJ, 1981, BIOSCIENCE REP, V1, P235, DOI 10.1007/BF01114910; GROSS HJ, 1980, ANGEW CHEM INT EDIT, V19, P231, DOI 10.1002/anie.198002313; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMMOND RW, 1989, VIROLOGY, V170, P486, DOI 10.1016/0042-6822(89)90440-6; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HASHIMOTO J, 1987, NUCLEIC ACIDS RES, V15, P7045, DOI 10.1093/nar/15.17.7045; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JUHASZ A, 1988, BIOCHIM BIOPHYS ACTA, V950, P455, DOI 10.1016/0167-4781(88)90145-5; Keese P., 1987, VIROIDS, P37; KIEFER M, 1982, P NATL ACAD SCI USA, V80, P6234; KOLTUNOW AM, 1988, NUCLEIC ACIDS RES, V16, P849, DOI 10.1093/nar/16.3.849; KOLTUNOW AM, 1989, VIROLOGY, V170, P575, DOI 10.1016/0042-6822(89)90450-9; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; MCCLEMENTS WL, 1977, VIROLOGY, V76, P477, DOI 10.1016/0042-6822(77)90230-6; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; PUCHTA H, 1988, NUCLEIC ACIDS RES, V16, P2730, DOI 10.1093/nar/16.6.2730; REANNEY D, 1984, NATURE, V307, P318, DOI 10.1038/307318a0; RIESNER D, 1979, J MOL BIOL, V133, P85, DOI 10.1016/0022-2836(79)90252-3; RIESNER D, 1985, ANNU REV BIOCHEM, V54, P531, DOI 10.1146/annurev.biochem.54.1.531; RIESNER D, 1987, VIROIDS, P63; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; SANGER HL, 1982, NUCLEIC ACIDS PROTEI, V2, P368; SANO T, 1988, NUCLEIC ACIDS RES, V16, P347, DOI 10.1093/nar/16.1.347; SANO T, 1986, J GEN VIROL, V67, P1673, DOI 10.1099/0022-1317-67-8-1673; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SOGO JM, 1973, VIROLOGY, V55, P70, DOI 10.1016/S0042-6822(73)81009-8; SPIEKER RL, 1990, NUCLEIC ACIDS RES, V18, P3998, DOI 10.1093/nar/18.13.3998; SYMONS RH, 1985, SUBVIRAL PATHOGENS P, P235; TSAGRIS M, 1987, EMBO J, V6, P2173, DOI 10.1002/j.1460-2075.1987.tb02488.x; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VISVADER JE, 1982, FEBS LETT, V137, P288, DOI 10.1016/0014-5793(82)80369-4; VISVADER JE, 1985, NUCLEIC ACIDS RES, V13, P2907, DOI 10.1093/nar/13.8.2907; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383	61	61	62	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2808	2813		10.1096/fasebj.5.13.1717335	http://dx.doi.org/10.1096/fasebj.5.13.1717335			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1717335	Bronze			2022-12-28	WOS:A1991GJ47100009
J	BARRELL, B				BARRELL, B			DNA SEQUENCING - PRESENT LIMITATIONS AND PROSPECTS FOR THE FUTURE	FASEB JOURNAL			English	Article						MOLECULAR BIOLOGY; DNA SEQUENCING; MULTIPLEXING; METHODOLOGY	COMPLETE NUCLEOTIDE-SEQUENCE; BACTERIOPHAGE; FRAGMENTS; CLONING; GENOME; M13	As the human genome program gets under way, we examine the progress made since the first human genome meeting in Santa Cruz in 1985. The lessons of the last 5 years demonstrate that progress has been much slower than anticipated. The new technology being developed in 1985 was fluorescent sequencing and multiplexing. These techniques are now established, but they still have to produce a substantial sequence to rival those determined by conventional technology. Inspection of the EMBL and GenBank databases shows few large sequences have been determined and that there is a large discrepancy between what is theoretically possible and what has been achieved so far.			BARRELL, B (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ANDERSON S, 1981, NUCLEIC ACIDS RES, V9, P3015, DOI 10.1093/nar/9.13.3015; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BANKIER AT, 1989, NUCLEIC ACID SEQUENC, P37; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BECK S, 1989, NUCLEIC ACIDS RES, V17, P5115, DOI 10.1093/nar/17.13.5115; BECK S, 1987, ANAL BIOCHEM, V164, P514, DOI 10.1016/0003-2697(87)90526-4; CHARGAFF E, 1968, PROGR NUCLEIC ACID R, V8; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; ELDER JK, 1986, NUCLEIC ACIDS RES, V14, P417, DOI 10.1093/nar/14.1.417; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; LUCKEY JA, 1990, NUCLEIC ACIDS RES, V18, P4417, DOI 10.1093/nar/18.15.4417; MARDIS ER, 1989, BIOTECHNIQUES, V7, P840; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; ROBERTSO.HD, 1973, NATURE-NEW BIOL, V241, P38, DOI 10.1038/newbio241038a0; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Smith V, 1990, DNA Seq, V1, P73, DOI 10.3109/10425179009041349; SULSTON J, 1989, COMPUT APPL BIOSCI, V5, P101; WILSON RK, 1988, BIOTECHNIQUES, V6, P776; WU R, 1971, J MOL BIOL, V57, P491, DOI 10.1016/0022-2836(71)90105-7; ZAGURSKY RJ, 1990, BIOTECHNIQUES, V9, P74; ZIFF EB, 1973, NATURE-NEW BIOL, V241, P34, DOI 10.1038/newbio241034a0	32	11	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1991	5	1					40	45		10.1096/fasebj.5.1.1991583	http://dx.doi.org/10.1096/fasebj.5.1.1991583			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991583				2022-12-28	WOS:A1991ET60900007
J	PEARSON, ML; SOLL, D				PEARSON, ML; SOLL, D			THE HUMAN GENOME PROJECT - A PARADIGM FOR INFORMATION MANAGEMENT IN THE LIFE SCIENCES	FASEB JOURNAL			English	Article						GENOME INFORMATICS; HUMAN GENOME PROJECT; DATABASES; NETWORKS; GENETIC MAPS; GENOME SEQUENCES		The major product of the Human Genome Project will be a series of linked data sets containing the genetic and physical location of all genes on each chromosome, plus the complete nucleotide sequence of the genome for humans and several model organisms. Here we summarize the current status of attempts to collect, analyze, and distribute this information in an electronically accessible form. Although formidable problems remain to be solved in the acquisition and adequate representation of the genetic, physical, and biological data, this project is a model for the rapid dissemination of genome and related information in biology and medicine.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University	PEARSON, ML (corresponding author), DUPONT CO,DEPT CENT RES & DEV,WILMINGTON,DE 19880, USA.							BEYNON R, 1988, APPLICATIONS COMPUTE, V4; LAWTON JR, 1989, NUCLEIC ACIDS RES, V17, P5885, DOI 10.1093/nar/17.15.5885; QUARTERMAN JS, 1986, COMMUN ACM, V29, P932, DOI 10.1145/6617.6618; 1990, DOEER0452P NAT TECHN; 1990, DOEER0446P NAT TECHN	5	24	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					35	39		10.1096/fasebj.5.1.1991581	http://dx.doi.org/10.1096/fasebj.5.1.1991581			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991581				2022-12-28	WOS:A1991ET60900006
J	ROSE, EA				ROSE, EA			APPLICATIONS OF THE POLYMERASE CHAIN-REACTION TO GENOME ANALYSIS	FASEB JOURNAL			English	Article						POLYMERASE CHAIN REACTION; HUMAN GENOME PROJECT; GENETIC MAPPING; PHYSICAL MAPPING; DNA SEQUENCING	MUSCULAR-DYSTROPHY GENE; SINGLE-STRANDED-DNA; THERMUS-AQUATICUS; SEQUENCES; AMPLIFICATION; ALU; INSERTION; LINES; MAP	The objectives of the Human Genome Project are to create high-resolution genetic and physical maps, and ultimately to determine the complete nucleotide sequence of the human genome. The result of this initiative will be to localize the estimated 50,000-100,000 human genes, and acquire information that will enable development of a better understanding of the relationship between genome structure and function. To achieve these goals, new methodologies that provide more rapid, efficient, and cost effective means of genomic analysis will be required. From both conceptual and practical perspectives, the polymerase chain reaction (PCR) represents a fundamental technology for genome mapping and sequencing. The availability of PCR has allowed definition of a technically credible form that the final composite map of the human genome will take, as described in the sequence-tagged site proposal. Moreover, applications of PCR have provided efficient approaches for identifying, isolating, mapping, and sequencing DNA, many of which are amenable to automation. The versatility and power provided by PCR have encouraged its involvement in almost every aspect of human genome research, with new applications of PCR being developed on a continual basis.			ROSE, EA (corresponding author), PERKIN ELMER CETUS INSTRUMENTS,HUMAN GENOME LAB,EMERYVILLE,CA 94608, USA.							BERG CM, 1989, MOBILE DNA, P879; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BURMEISTER M, 1986, NATURE, V324, P582, DOI 10.1038/324582a0; CARUTHERS MH, 1987, METHOD ENZYMOL, V154, P287; CORBO L, 1990, SCIENCE, V249, P652, DOI 10.1126/science.2382140; DEAN M, 1990, NUCLEIC ACIDS RES, V18, P345, DOI 10.1093/nar/18.2.345; DIEHL SR, 1990, AM J HUM GENET, V47, pA177; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DRMANAC R, 1989, GENOMICS, V4, P114; DRMANAC R, 1990, COLD SPRING HARBOR G, P52; ERLICH HA, 1988, NATURE, V331, P461, DOI 10.1038/331461a0; Gelfand D.H., 1990, PC PRO, P129; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GRIMALDI G, 1984, EMBO J, V3, P1753, DOI 10.1002/j.1460-2075.1984.tb02042.x; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HWU HR, 1986, P NATL ACAD SCI USA, V83, P3875, DOI 10.1073/pnas.83.11.3875; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; INNIS MA, 1990, PCR PROTOCOLS; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEDBETTER SA, 1990, GENOMICS, V6, P475, DOI 10.1016/0888-7543(90)90477-C; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; MANUELIDIS L, 1984, CHROMOSOMA, V91, P28, DOI 10.1007/BF00286482; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; MULLER N, 1986, J ORG CHEM, V51, P263, DOI 10.1021/jo00352a032; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NELSON DL, 1990, AM J HUM GENET, V47, pA258; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; PAULSON KE, 1985, NATURE, V316, P359, DOI 10.1038/316359a0; PHADNIS SH, 1989, P NATL ACAD SCI USA, V86, P5908, DOI 10.1073/pnas.86.15.5908; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; RUANO G, 1990, IN PRESS P NATL ACAD; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; STEELE PE, 1984, SCIENCE, V225, P943, DOI 10.1126/science.6089336; STRASBAUGH LD, 1990, IN PRESS P NATL ACAD; SUN L, 1984, NUCLEIC ACIDS RES, V12, P2669, DOI 10.1093/nar/12.6.2669; 1990, UNDERSTANDING OUR GE	45	27	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					46	54		10.1096/fasebj.5.1.1991584	http://dx.doi.org/10.1096/fasebj.5.1.1991584			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991584				2022-12-28	WOS:A1991ET60900008
J	HELKE, CJ; KRAUSE, JE; MANTYH, PW; COUTURE, R; BANNON, MJ				HELKE, CJ; KRAUSE, JE; MANTYH, PW; COUTURE, R; BANNON, MJ			DIVERSITY IN MAMMALIAN TACHYKININ PEPTIDERGIC NEURONS - MULTIPLE PEPTIDES, RECEPTORS, AND REGULATORY MECHANISMS	FASEB JOURNAL			English	Article									VET ADM MED CTR,CTR BRAIN SCI,RES SERV 151,MINNEAPOLIS,MN 55417; WAYNE STATE UNIV,DEPT PSYCHIAT,CELLULAR & CLIN NEUROBIOL PROGRAM,DETROIT,MI 48235; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; SINAI HOSP,CTR CELL BIOL,DETROIT,MI 48235; UNIV MONTREAL,DEPT PHYSIOL,MONTREAL H3C 3J7,QUEBEC,CANADA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Wayne State University; Washington University (WUSTL); Universite de Montreal	HELKE, CJ (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL,BETHESDA,MD 20814, USA.			Krause, James E./0000-0002-8094-1710	NINDS NIH HHS [NS21937, NS24876, NS20991] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020991, R01NS021937, R01NS024876, R55NS021937] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAI H, 1986, BRAIN RES, V399, P240, DOI 10.1016/0006-8993(86)91514-3; BANNON MJ, 1986, J BIOL CHEM, V261, P6640; BANNON MJ, 1987, MOL BRAIN RES, V3, P31, DOI 10.1016/0169-328X(87)90041-6; BANNON MJ, 1987, HDB PSYCHOPHARMACOLO, V19, P329; BONNER TI, 1987, MOL BRAIN RES, V2, P243, DOI 10.1016/0169-328X(87)90031-3; BROWNSTEIN MJ, 1976, BRAIN RES, V116, P299, DOI 10.1016/0006-8993(76)90907-0; BUCK SH, 1986, PEPTIDES, V7, P1109, DOI 10.1016/0196-9781(86)90141-5; BURGUNDER JM, 1989, NEUROPEPTIDES, V13, P165, DOI 10.1016/0143-4179(89)90087-5; CHANG HT, 1988, BRAIN RES, V448, P391, DOI 10.1016/0006-8993(88)91284-X; CHARLTON CG, 1985, J NEUROSCI, V5, P1653; DAM TV, 1990, BRAIN RES, V506, P175, DOI 10.1016/0006-8993(90)91218-6; DAM TV, 1990, IN PRESS P NATL ACAD; DEUTCH AY, 1985, PEPTIDES, V6, P113, DOI 10.1016/0196-9781(85)90143-3; DRAPEAU G, 1987, NEUROPEPTIDES, V10, P41; HASSESSIAN H, 1988, N-S ARCH PHARMACOL, V338, P649, DOI 10.1007/BF00165629; HAVERSTICK DM, 1989, J PHARMACOL EXP THER, V248, P858; HAVERSTICK DM, 1989, J BIOL CHEM, V264, P13140; HAVERSTICK DM, 1989, SOC NEUR ABSTR, V15, P1273; HELKE CJ, 1990, SYNAPSE, V5, P144, DOI 10.1002/syn.890050209; HELKE CJ, 1986, NEUROSCIENCE, V19, P523, DOI 10.1016/0306-4522(86)90278-2; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HUNTER JC, 1985, BIOCHEM BIOPH RES CO, V127, P616, DOI 10.1016/S0006-291X(85)80205-9; JACQUES L, 1989, N-S ARCH PHARMACOL, V340, P170; JESSELL TM, 1983, HDB PSYCHOPHARMACOLO, V16, P1; KAGE R, 1988, J NEUROCHEM, V50, P1412, DOI 10.1111/j.1471-4159.1988.tb03024.x; KOTANI H, 1986, P NATL ACAD SCI USA, V83, P7074, DOI 10.1073/pnas.83.18.7074; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; KRAUSE JE, 1989, METHOD ENZYMOL, V168, P634; LANEUVILLE O, 1988, LIFE SCI, V42, P1295, DOI 10.1016/0024-3205(88)90223-8; LAVIELLE S, 1988, BIOCHEM PHARMACOL, V37, P41, DOI 10.1016/0006-2952(88)90753-8; LEE JM, 1986, BRAIN RES, V371, P152, DOI 10.1016/0006-8993(86)90820-6; LEMBECK F, 1953, N-S ARCH EX PATH PH, V219, P197; LINDEFORS N, 1989, EUR J PHARMACOL, V161, P95, DOI 10.1016/0014-2999(89)90185-4; LJUNGDAHL A, 1978, NEUROSCIENCE, V3, P861, DOI 10.1016/0306-4522(78)90116-1; MACDONALD MR, 1989, J BIOL CHEM, V264, P15578; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MANTYH CR, 1988, P NATL ACAD SCI USA, V85, P3235, DOI 10.1073/pnas.85.9.3235; MANTYH PW, 1984, NATURE, V309, P795, DOI 10.1038/309795a0; MANTYH PW, 1989, P NATL ACAD SCI USA, V86, P5193, DOI 10.1073/pnas.86.13.5193; MANTYH PW, 1989, J NEUROSCI, V9, P258; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MAUBORGNE A, 1983, BRAIN RES, V268, P167, DOI 10.1016/0006-8993(83)90403-1; MELIS MR, 1984, BRAIN RES, V295, P389, DOI 10.1016/0006-8993(84)90993-4; MILNER TA, 1988, J COMP NEUROL, V270, P427, DOI 10.1002/cne.902700311; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; NAWA H, 1983, NATURE, V306, P32, DOI 10.1038/306032a0; NICOLL RA, 1980, ANNU REV NEUROSCI, V3, P227, DOI 10.1146/annurev.ne.03.030180.001303; NOGUCHI K, 1988, MOL BRAIN RES, V4, P31, DOI 10.1016/0169-328X(88)90015-0; OGAWA T, 1985, BRAIN RES, V359, P152, DOI 10.1016/0006-8993(85)91423-4; OTSUKA M, 1977, SUBSTANCE P, V37, P207; PAPIRKRICHELI D, 1987, PAIN, V31, P263, DOI 10.1016/0304-3959(87)90041-8; PERNOW B, 1983, PHARMACOL REV, V35, P85; REGOLI D, 1988, TRENDS PHARMACOL SCI, V9, P290, DOI 10.1016/0165-6147(88)90013-2; REGOLI D, 1989, BIOPOLYMERS, V28, P81, DOI 10.1002/bip.360280111; ROACH A, 1987, P NATL ACAD SCI USA, V84, P5078, DOI 10.1073/pnas.84.14.5078; ROVERO P, 1989, NEUROPEPTIDES, V13, P263, DOI 10.1016/0143-4179(89)90080-2; SAFFROY M, 1988, PEPTIDES, V9, P227, DOI 10.1016/0196-9781(88)90255-0; SIVAM SP, 1987, J NEUROCHEM, V49, P1623, DOI 10.1111/j.1471-4159.1987.tb01036.x; TAKEDA Y, 1989, Society for Neuroscience Abstracts, V15, P346; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P392, DOI 10.1073/pnas.86.1.392; TAKEDA Y, 1990, IN PRESS REGUL PEPTI; TATEMOTO K, 1985, BIOCHEM BIOPH RES CO, V128, P947, DOI 10.1016/0006-291X(85)90138-X; TOO HP, 1989, PEPTIDES, V10, P25, DOI 10.1016/0196-9781(89)90070-3; VALENTINO KL, 1986, PEPTIDES, V7, P1043, DOI 10.1016/0196-9781(86)90134-8; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763; WARDEN MK, 1988, J COMP NEUROL, V272, P90, DOI 10.1002/cne.902720107; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649; YOUNG WS, 1986, P NATL ACAD SCI USA, V83, P9827, DOI 10.1073/pnas.83.24.9827	69	446	452	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1990	4	6					1606	1615		10.1096/fasebj.4.6.1969374	http://dx.doi.org/10.1096/fasebj.4.6.1969374			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CY582	1969374				2022-12-28	WOS:A1990CY58200006
J	Carton-Garcia, F; Brotons, B; Anguita, E; Dopeso, H; Tarragona, J; Nieto, R; Garcia-Vidal, E; Macaya, I; Zagyva, Z; Dalmau, M; Sanchez-Martin, M; van Ijzendoorn, SCD; Landolfi, S; Hernandez-Losa, J; Schwartz, S; Matias-Guiu, X; Cajal, SRY; Martinez-Barriocanal, A; Arango, D				Carton-Garcia, Fernando; Brotons, Bruno; Anguita, Estefania; Dopeso, Higinio; Tarragona, Jordi; Nieto, Rocio; Garcia-Vidal, Elia; Macaya, Irati; Zagyva, Zsuzsanna; Dalmau, Mariona; Sanchez-Martin, Manuel; van Ijzendoorn, Sven C. D.; Landolfi, Stefania; Hernandez-Losa, Javier; Schwartz Jr, Simo; Matias-Guiu, Xavier; Ramon y Cajal, Santiago; Martinez-Barriocanal, Agueda; Arango, Diego			Myosin Vb as a tumor suppressor gene in intestinal cancer	ONCOGENE			English	Article							MICROVILLUS INCLUSION DISEASE; APICAL PROTEIN LOCALIZATION; CELL POLARITY; COLORECTAL-CANCER; EPITHELIAL-CELLS; HUMAN-COLON; EXPRESSION; TRAFFICKING; MYO5B; PHOSPHORYLATION	Colorectal cancer causes >900,000 deaths every year and a deeper understanding of the molecular mechanisms underlying this disease will contribute to improve its clinical management and survival. Myosin Vb (MYO5B) regulates intracellular vesicle trafficking, and inactivation of this myosin disrupts the polarization and differentiation of intestinal epithelial cells causing microvillous inclusion disease (MVID), a rare congenital disorder characterized by intractable life-threatening diarrhea. Here, we show that the loss Myosin Vb interfered with the differentiation/polarization of colorectal cancer cells. Although modulation of Myosin Vb expression did not affect the proliferation of colon cancer cells, MYO5B inactivation increased their migration, invasion, and metastatic potential. Moreover, Myo5b inactivation in an intestine-specific knockout mouse model caused a >15-fold increase in the number of azoxymethane-initiated small intestinal tumors. Consistently, reduced expression of Myosin Vb in a cohort of 155 primary colorectal tumors was associated with shorter patient survival. In conclusion, we show here that loss of Myosin Vb reduces polarization/differentiation of colon cancer cells while enhancing their metastatic potential, demonstrating a tumor suppressor function for this myosin. Moreover, reduced expression of Myosin Vb in primary tumors identifies a subset of poor prognosis colorectal cancer patients that could benefit from more aggressive therapeutic regimens.	[Carton-Garcia, Fernando; Brotons, Bruno; Anguita, Estefania; Dopeso, Higinio; Nieto, Rocio; Garcia-Vidal, Elia; Macaya, Irati; Zagyva, Zsuzsanna; Dalmau, Mariona; Martinez-Barriocanal, Agueda; Arango, Diego] Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Biomed Res Digest Tract Tumors, Barcelona, Spain; [Brotons, Bruno; Anguita, Estefania; Dalmau, Mariona; Martinez-Barriocanal, Agueda; Arango, Diego] Biomed Res Inst Lleida IRBLleida, Grp Mol Oncol, Lleida, Spain; [Tarragona, Jordi; Matias-Guiu, Xavier] Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, Lleida, Spain; [Tarragona, Jordi; Matias-Guiu, Xavier] Inst Recerca Biomed Lleida IRBLleida, Grp Oncol Pathol, Lleida, Spain; [Sanchez-Martin, Manuel] Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Sanchez-Martin, Manuel] Univ Salamanca, Serv Transgenesis, Nucleus, Salamanca, Spain; [Sanchez-Martin, Manuel] Univ Salamanca, Dept Med, Salamanca, Spain; [van Ijzendoorn, Sven C. D.] Univ Groningen, Univ Med Ctr Groningen, Dept Biomed Sci Cells & Syst, Sect Mol Cell Biol, Groningen, Netherlands; [Landolfi, Stefania; Hernandez-Losa, Javier; Ramon y Cajal, Santiago] Univ Autonoma Barcelona UAB, Vall dHebron Res Inst VHIR, Translat Mol Pathol, Barcelona, Spain; [Landolfi, Stefania; Hernandez-Losa, Javier; Matias-Guiu, Xavier; Ramon y Cajal, Santiago] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Schwartz Jr, Simo] Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Drug Delivery & Targeting, Barcelona, Spain; [Schwartz Jr, Simo] Vall dHebron Hosp, Clin Biochem Dept, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universitat de Lleida; University Hospital Arnau de Vilanova; Institut de Recerca Biomedica - IRB Lleida; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Groningen; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron	Arango, D (corresponding author), Univ Autonoma Barcelona, Vall dHebron Univ Hosp Res Inst VHIR, Grp Biomed Res Digest Tract Tumors, Barcelona, Spain.; Arango, D (corresponding author), Biomed Res Inst Lleida IRBLleida, Grp Mol Oncol, Lleida, Spain.	darango@irblleida.cat	; Sanchez-Martin, Manuel/N-5327-2016	Tarragona, Jordi/0000-0002-1459-4087; Dopeso, Higinio/0000-0003-0060-1861; Sanchez-Martin, Manuel/0000-0001-8370-1336	World Cancer Research [AICR13-0245]; Instituto de Salud Carlos III [PI16/00540, PI19/00993, PI22/00773]; European Regional Development Fund [AC15/00066, AC19/00095, AC20/00022]; Spanish Association Against Cancer [AECC GCA15152966ARAN]; "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida	World Cancer Research; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund(European Commission); Spanish Association Against Cancer; "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida	This study was partially funded by grants of World Cancer Research (AICR13-0245), Instituto de Salud Carlos III (PI16/00540, PI19/00993, PI22/00773), the European Regional Development Fund (AC15/00066, AC19/00095, AC20/00022) and the Spanish Association Against Cancer (AECC GCA15152966ARAN) to DA. BB is supported by "Ajuts per a la Iniciacio de la Recerca" fellowship from Diputacio de Lleida-Biomedical Research Institute of Lleida.	Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bazzocco S, 2015, CLIN CANCER RES, V21, P3695, DOI 10.1158/1078-0432.CCR-14-2457; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cancer Genome Atlas N., 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Carton-Garcia F, 2015, SCI REP-UK, V5, DOI 10.1038/srep12312; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; D'Agostino L, 2019, CANCER RES, V79, P4099, DOI 10.1158/0008-5472.CAN-18-4075; Dhekne HS, 2014, J CELL SCI, V127, P1007, DOI 10.1242/jcs.137273; Dong WJ, 2012, DIGEST DIS SCI, V57, P1247, DOI 10.1007/s10620-011-1989-z; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Gandalovicova A, 2016, ONCOTARGET, V7, P25022, DOI 10.18632/oncotarget.7214; Goldenring JR, 2011, BRIT J CANCER, V104, P33, DOI 10.1038/sj.bjc.6605983; Goldenring JR, 2013, NAT REV CANCER, V13, P813, DOI 10.1038/nrc3601; Groisman GM, 2000, HUM PATHOL, V31, P1404, DOI 10.1053/hupa.2000.19831; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; Kranz A, 2010, GENESIS, V48, P512, DOI 10.1002/dvg.20641; Kravtsov D, 2014, AM J PHYSIOL-GASTR L, V307, pG992, DOI 10.1152/ajpgi.00180.2014; Kravtsov DV, 2016, AM J PHYSIOL-GASTR L, V311, pG142, DOI 10.1152/ajpgi.00041.2016; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Leng CS, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000531; Letellier E, 2017, BRIT J CANCER, V117, P1689, DOI 10.1038/bjc.2017.352; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Mariadason JM, 2002, CANCER RES, V62, P4791; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Mazzolini R, 2012, P NATL ACAD SCI USA, V109, P1530, DOI 10.1073/pnas.1108411109; Melendez J, 2013, GASTROENTEROLOGY, V145, P808, DOI 10.1053/j.gastro.2013.06.021; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muller T, 2008, NAT GENET, V40, P1163, DOI 10.1038/ng.225; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nam KT, 2010, J CLIN INVEST, V120, P840, DOI 10.1172/JCI40728; Partanen JI, 2009, CELL CYCLE, V8, P716, DOI 10.4161/cc.8.5.7786; PETERSON MD, 1992, J CELL SCI, V102, P581; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Roland JT, 2011, P NATL ACAD SCI USA, V108, P2789, DOI 10.1073/pnas.1010754108; ROWLATT C, 1970, J PATHOL, V100, pPR12; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Ruemmele FM, 2010, HUM MUTAT, V31, P544, DOI 10.1002/humu.21224; Sato T, 2007, NATURE, V448, P366, DOI 10.1038/nature05929; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Schneeberger K, 2015, P NATL ACAD SCI USA, V112, P12408, DOI 10.1073/pnas.1516672112; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sobajima T, 2015, BIOL OPEN, V4, P86, DOI 10.1242/bio.20148532; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Thoeni Cornelia E, 2014, Traffic, V15, P22, DOI 10.1111/tra.12131; Weis VG, 2016, CELL MOL GASTROENTER, V2, P131, DOI 10.1016/j.jcmgh.2015.11.009; Williams KC, 2011, J BIOL CHEM, V286, P43405, DOI 10.1074/jbc.M111.297069; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438	53	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5279	5288		10.1038/s41388-022-02508-2	http://dx.doi.org/10.1038/s41388-022-02508-2		NOV 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36316444	Bronze			2022-12-28	WOS:000876857300001
J	BORTH, W				BORTH, W			ALPHA(2)-MACROGLOBULIN, A MULTIFUNCTIONAL BINDING-PROTEIN WITH TARGETING CHARACTERISTICS	FASEB JOURNAL			English	Article						CYTOKINES; LIPOPROTEIN RECEPTOR; DISULFIDE BONDS; THIOL ESTER; TOXINS; ENDOCYTOSIS; PROCESSING	RECEPTOR-RELATED PROTEIN; TRANSFORMING GROWTH FACTOR-BETA-1; HAMSTER OVARY CELLS; RICIN-A CHAIN; ALPHA-MACROGLOBULIN; ALPHA-2-MACROGLOBULIN RECEPTOR; LIPOPROTEIN RECEPTOR; MEDIATED ENDOCYTOSIS; CULTURED FIBROBLASTS; COVALENT BINDING	Alpha2-macroglobulin (alpha2M) and related proteins share the function of binding host or foreign peptides and particles, thereby serving as humoral defense barriers against pathogens in the plasma and tissues of vertebrates. In human alpha2M, several reactive sites including high-affinity sites for zinc, transglutaminase cross-linking sites, and reactive sites derived from the activated thiol ester can mediate reversible or irreversible capture of proteins of diverse biological functions. Alpha2M interacts and captures virtually any proteinase whether self or foreign, suggesting a function as a unique "panproteinase inhibitor." Activation of alpha2M generates novel binding sites, which mediate complex formation with cytokines and other peptides. Direct evidence of physical association of cytokines with activated alpha2M indicated its role as biological response modifier in cell cultures. A mechanism commonly referred to as "clearance of activated alpha2M" involves Ca2+-dependent binding to a specific cell surface receptor, a member of the low-density lipoprotein receptor supergene family, that mediates cellular uptake by endocytosis and delivery to endosomes and lysosomes. The peptide binding function of alpha2M, therefore, may also be viewed as a mechanism that allows targeting of biologically active peptides to different cell types expressing the alpha2M receptor. Internalized complexes may be dispatched into different pathways of endocytic/lysosomal pathways in a cell type-specific manner. In addition, bioactive peptides bound to alpha2M may dissociate in the process of intracellular ligand sorting, thereby modulating cell function, or remain bound and share the catabolic fate of alpha2M. The diversified and probably programmed binding functions of alpha2M indicate that in addition to its role in trapping proteinases, it has other biological activities that remain to be fully defined. That alpha2M may function as a binding and carrier protein with targeting characteristics is predicted from 1) the known functions of alpha2M, and 2) the similarity of the fate of alpha2M with proteins whose significance in targeting and intracellular trafficking has been studied in more detail.			BORTH, W (corresponding author), CUNY MT SINAI SCH MED, DEPT MED, DIV HEMATOL, BOX 1079, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.							ARAUJOJORGE TC, 1992, PARASITOL RES, V78, P215, DOI 10.1007/BF00931729; Armstrong Peter B., 1991, P291; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BIZIK J, 1989, CANCER RES, V49, P983; BLUM JS, 1991, J BIOL CHEM, V266, P22091; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BONNER JC, 1989, AM J RESP CELL MOL, V1, P171, DOI 10.1165/ajrcmb/1.3.171; BORTH W, 1984, COLLAGEN REL RES, V4, P83; BORTH W, 1989, J BIOL CHEM, V264, P5818; BORTH W, 1990, BLOOD, V75, P2388; BORTH W, 1990, J IMMUNOL, V145, P3747; BORTH W, 1986, ARTHRITIS RHEUM, V29, P319, DOI 10.1002/art.1780290303; BORTH W, 1983, ANN NY ACAD SCI, V421, P377, DOI 10.1111/j.1749-6632.1983.tb18127.x; BORTH W, 1992, FASEB J, V6, pA1916; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CANNON JG, 1988, LYMPHOKINE RES, V7, P457; CHHATWAL GS, 1987, J BACTERIOL, V169, P3691, DOI 10.1128/jb.169.8.3691-3695.1987; Chibnall AC, 1942, PROC R SOC SER B-BIO, V131, P136, DOI 10.1038/150127a0; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; COLLINS DS, 1991, J IMMUNOL, V147, P4054; CORVERA S, 1989, J BIOL CHEM, V264, P10133; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DAVIDSEN O, 1985, BIOCHIM BIOPHYS ACTA, V846, P85, DOI 10.1016/0167-4889(85)90113-2; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; FEENER EP, 1990, J BIOL CHEM, V265, P18780; FREEDMAN SJ, 1991, COMP BIOCHEM PHYS B, V98, P549, DOI 10.1016/0305-0491(91)90252-9; GADDYKURTEN D, 1991, MOL ENDOCRINOL, V5, P1280, DOI 10.1210/mend-5-9-1280; GANROT PO, 1967, CLIN CHIM ACTA, V15, P113, DOI 10.1016/0009-8981(67)90333-6; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GHETIE MA, 1991, CANCER RES, V51, P1482; GIL G, 1991, J BIOL CHEM, V266, P20512; GIROUX EL, 1975, BIOCHEM MED METAB B, V12, P258, DOI 10.1016/0006-2944(75)90127-1; GOLDENBERG RL, 1991, OBSTET GYNECOL, V78, P594; GONIAS SL, 1992, EXP HEMATOL, V20, P302; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; Harpel P C, 1976, Methods Enzymol, V45, P639; HARPEL PC, 1973, J EXP MED, V138, P508, DOI 10.1084/jem.138.3.508; HARPEL PC, 1979, J BIOL CHEM, V254, P8669; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUSSAINI IM, 1990, J BIOL CHEM, V265, P19441; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; KOO PH, 1982, CANCER RES, V42, P1788; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIBBY P, 1985, J CELL PHYSIOL, V125, P357, DOI 10.1002/jcp.1041250302; MAEDA H, 1987, J BIOL CHEM, V262, P10946; MANNHALTER JW, 1986, J IMMUNOL, V136, P2792; MARTIN H, 1991, BIOCHEM BIOPH RES CO, V175, P123, DOI 10.1016/S0006-291X(05)81209-4; MARYNEN P, 1981, J IMMUNOL, V127, P1782; MATTHIJS G, 1992, BIOCHEM BIOPH RES CO, V184, P596, DOI 10.1016/0006-291X(92)90631-T; MAXFIELD FR, 1981, BIOCHEMISTRY-US, V20, P5353, DOI 10.1021/bi00521a041; MCCAFFREY TA, 1992, BIOCHEM BIOPH RES CO, V184, P773, DOI 10.1016/0006-291X(92)90657-7; MIYAGAWA SI, 1991, MICROB PATHOGENESIS, V11, P137, DOI 10.1016/0882-4010(91)90007-W; MIYOSHI S, 1991, J BIOCHEM-TOKYO, V110, P548, DOI 10.1093/oxfordjournals.jbchem.a123617; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1992, LEUKEMIA RES, V16, P227, DOI 10.1016/0145-2126(92)90060-K; NIMPF J, 1991, J NUTR, V121, P1471, DOI 10.1093/jn/121.9.1471; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OHLSSON K, 1971, ACTA PHYSIOL SCAND, V81, P269, DOI 10.1111/j.1748-1716.1971.tb04900.x; OSADA T, 1987, BIOCHEM BIOPH RES CO, V142, P100, DOI 10.1016/0006-291X(87)90456-6; PASTAN I, 1977, CELL, V12, P609, DOI 10.1016/0092-8674(77)90261-6; POLLER W, 1992, HUM GENET, V88, P313; PRICHETT TJ, 1989, J BIOL CHEM, V264, P9850; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; RAMADORI G, 1991, HEPATOLOGY, V14, P875, DOI 10.1002/hep.1840140520; RAMAKRISHNAN S, 1984, CANCER RES, V44, P201; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SALOMON DS, 1982, J BIOL CHEM, V257, P4093; SCHLESINGER C, 1989, MOL IMMUNOL, V26, P255, DOI 10.1016/0161-5890(89)90079-5; SHEN WC, 1985, J BIOL CHEM, V260, P905; SHI DL, 1990, J BIOL CHEM, V265, P2881; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SOTTRUPJENSEN L, 1990, COMP BIOCHEM PHYS B, V96, P621, DOI 10.1016/0305-0491(90)90066-3; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P123, DOI 10.1016/0014-5793(81)81096-4; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRAUSS S, 1992, LAB INVEST, V66, P223; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; VANLEUVEN F, 1984, MOL CELL BIOCHEM, V58, P121, DOI 10.1007/BF00240611; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4; YAMASHIRO DJ, 1989, J CELL PHYSIOL, V139, P377, DOI 10.1002/jcp.1041390221	96	398	426	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1992	6	15					3345	3353		10.1096/fasebj.6.15.1281457	http://dx.doi.org/10.1096/fasebj.6.15.1281457			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1281457				2022-12-28	WOS:A1992KD39500005
J	GUNSALUS, IC				GUNSALUS, IC			MOLECULES AND MICROBES OF MERIT - 50 YEARS AGO AND NOW	FASEB JOURNAL			English	Article											GUNSALUS, IC (corresponding author), UNIV ILLINOIS,DEPT BIOCHEM,420 RAL,1209 W CALIF ST,URBANA,IL 61801, USA.							Bellamy W. D., 1943, JOUR BACT, V46, P573; BELLAMY WD, 1945, J BACTERIOL, V50, P95, DOI 10.1128/JB.50.1.95-103.1945; BRAUNSTEIN A. E., 1937, ENZYMOLOGIA [HAGUE], V2, P129; COHEN P., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P273; Crook EM, 1941, BIOCHEM J, V35, P226, DOI 10.1042/bj0350226; ELVEHJEM C. A., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P304; Gunsalus IC, 1942, J BIOL CHEM, V145, P131; Gunsalus IC, 1941, J BIOL CHEM, V141, P853; GUNSALUS IC, 1950, FED PROC, V9, P556; GUNSALUS IC, 1988, P INT S FRONTIERS SC, P1; Handler P, 1941, J BIOL CHEM, V140, P739; HAYAISHI O, 1955, J AM CHEM SOC, V77, P5450, DOI 10.1021/ja01625a095; HORNBERGER CS, 1953, J AM CHEM SOC, V75, P1273, DOI 10.1021/ja01102a003; Kluyver A. J., 1956, MICROBES CONTRIBUTIO, P31; LIPMANN F, 1942, FEDERATION P 2, V1, P122; Lwoff A, 1937, PROC R SOC SER B-BIO, V122, P352; MASON HS, 1955, J AM CHEM SOC, V77, P2914, DOI 10.1021/ja01615a088; O'Kane D. J., 1942, JOUR BACT, V43, P7; OKANE DJ, 1948, J BACTERIOL, V56, P499, DOI 10.1128/JB.56.4.499-506.1948; OKANE DJ, 1947, J BACTERIOL, V54, P20; REED LJ, 1953, J AM CHEM SOC, V75, P1271, DOI 10.1021/ja01102a002; REED LJ, 1953, J AM CHEM SOC, V57, P1267; ROUVIRE PE, 1988, J BIOL CHEM, V26, P7913; Snell EE, 1939, IND ENG CHEM, V11, P0346, DOI 10.1021/ac50134a020; Snell EE, 1941, J BIOL CHEM, V139, P675; VENNESLAND B, 1991, FASEB J, V5, P2868, DOI 10.1096/fasebj.5.13.1916109; WATSON JD, 1992, NY TIMES        0904, pC16; WATSON JD, CITED INDIRECTLY; Wood AJ, 1942, J BACTERIOL, V44, P333, DOI 10.1128/JB.44.3.333-341.1942; WOOD HG, 1985, ANNU REV BIOCHEM, V54, P1; WOOD HG, 1935, J BACTERIOL, V30, P332	31	1	1	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1992	6	15					3423	3425		10.1096/fasebj.6.15.1464375	http://dx.doi.org/10.1096/fasebj.6.15.1464375			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1464375				2022-12-28	WOS:A1992KD39500015
J	BING, RJ				BING, RJ			DOPA - THEN AND NOW	FASEB JOURNAL			English	Editorial Material									UNIV SO CALIF,LOS ANGELES,CA 90089	University of Southern California	BING, RJ (corresponding author), HUNTINGTON MED RES INST,EXPTL CARDIOL & SCI DEV,PASADENA,CA 91109, USA.							Bing RJ, 1941, J EXP MED, V74, P235, DOI 10.1084/jem.74.3.235; BING RJ, 1942, FED PROC, V1, P14; COOMBS HC, 1942, FED PROC, V1, P17; CORCORAN AC, 1942, FED PROC, V1, P17; GREEN HD, 1942, FED PROC, V1, P33; LAMBERT EH, 1942, FED PROC, V1, P47	6	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1992	6	12					3122	3122		10.1096/fasebj.6.12.1521743	http://dx.doi.org/10.1096/fasebj.6.12.1521743			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521743				2022-12-28	WOS:A1992JN50500015
J	HATFIELD, MO				HATFIELD, MO			THE DISEASE DEFENSE BUILDUP	FASEB JOURNAL			English	Editorial Material																			0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1992	6	12					3030	3031		10.1096/fasebj.6.12.1521735	http://dx.doi.org/10.1096/fasebj.6.12.1521735			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521735				2022-12-28	WOS:A1992JN50500003
J	HARRIS, ED				HARRIS, ED			REGULATION OF ANTIOXIDANT ENZYMES	FASEB JOURNAL			English	Article						OXYGEN STRESS; OXYGEN RADICALS; SUPEROXIDE DISMUTASE; HYPEROXIA; CATALASE; GLUTATHIONE PEROXIDASE	CUZN-SUPEROXIDE-DISMUTASE; RAT CEREBRAL-CORTEX; GLUTATHIONE-PEROXIDASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; POSITIVE CONTROL; DEFICIENT RATS; MESSENGER-RNA; ADULT-RATS	Free radicals generated by a partial reduction of O2 pose a serious hazard to tissues and vital organs, especially membrane lipids, connective tissues, and the nucleic acids of cells. For protection, enzymes have evolved that specifically attack O2-, hydrogen, and organic peroxides, and repair any damage incurred to DNA. With few exceptions, antioxidant enzymes are found in all aerobic and aerotolerant anaerobic organisms. Logic assumes that a basal level of antioxidant enzyme activity is maintained at all times. This may be true. Yet cells must have ways to amplify antioxidant enzyme activity to counter sudden increases in oxygen metabolites. The full details of that regulation are slowly coming to light. Bacteria possess a series of elaborate and interacting genes that can sense specific increases in intracellular H2O2 and O2-. In higher organisms, hormones and metal ion cofactors impose pre- and posttranslational control over the genetic expression of antioxidant enzymes. Furthermore, aging, cellular differentiation, and organ specificity must also be factored into the final equation in higher organisms. This review will discuss some of the more recent findings relevant to antioxidant enzyme regulation in bacteria and higher organisms.			HARRIS, ED (corresponding author), TEXAS A&M UNIV SYST, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA.				NIDDK NIH HHS [DK41682] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041682] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RG, 1991, P SOC EXP BIOL MED, V196, P117; ASOH K, 1989, BIOCHEM BIOPH RES CO, V162, P794, DOI 10.1016/0006-291X(89)92380-2; AUTOR AP, 1982, J BIOL CHEM, V257, P2713; AVISSAR N, 1991, J NUTR, V121, P1243, DOI 10.1093/jn/121.8.1243; BARCLAY SM, 1991, PEDIATR RES, V29, P297, DOI 10.1203/00006450-199103000-00015; BERG JT, 1988, P SOC EXP BIOL MED, V187, P117; BETTGER WJ, 1978, P SOC EXP BIOL MED, V158, P279, DOI 10.3181/00379727-158-40188; BEYER WF, 1991, J BIOL CHEM, V266, P303; BOWEN SW, 1988, J BIOL CHEM, V263, P14808; CANNON RE, 1989, MOL GEN GENET, V219, P1; CARRI MT, 1991, FEBS LETT, V278, P263, DOI 10.1016/0014-5793(91)80131-L; CEBALLOS I, 1989, NEUROSCI LETT, V105, P41, DOI 10.1016/0304-3940(89)90008-6; CEBALLOSPICOT I, 1991, BRAIN RES, V552, P198, DOI 10.1016/0006-8993(91)90084-9; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHUNG K, 1988, J NUTR, V118, P859, DOI 10.1093/jn/118.7.859; CLERCH LB, 1991, AM J PHYSIOL, V260, pL428, DOI 10.1152/ajplung.1991.260.6.L428; CROUCH RK, 1984, EXP MOL PATHOL, V41, P377, DOI 10.1016/0014-4800(84)90026-1; DAMERON CT, 1987, BIOCHEM J, V248, P663, DOI 10.1042/bj2480663; DE AK, 1991, MECH AGEING DEV, V59, P123, DOI 10.1016/0047-6374(91)90078-E; DELMAESTRO R, 1989, MECH AGEING DEV, V48, P15, DOI 10.1016/0047-6374(89)90022-5; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DISILVESTRO RA, 1990, J NUTR, V120, P1223, DOI 10.1093/jn/120.10.1223; DISILVESTRO RA, 1991, P SOC EXP BIOL MED, V197, P197; FRANK L, 1989, AM J PHYSIOL, V257, pL226, DOI 10.1152/ajplung.1989.257.4.L226; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GALIAZZO F, 1991, EUR J BIOCHEM, V196, P545, DOI 10.1111/j.1432-1033.1991.tb15848.x; GIRI SN, 1983, EXP MOL PATHOL, V39, P317, DOI 10.1016/0014-4800(83)90060-6; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; HASS MA, 1989, J CLIN INVEST, V83, P1241, DOI 10.1172/JCI114007; HASS MA, 1987, AM J PHYSIOL, V253, pC66, DOI 10.1152/ajpcell.1987.253.1.C66; HASSAN HM, 1989, ADV GENET, V26, P65; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; HAYASHIBE H, 1990, PEDIATR RES, V27, P472, DOI 10.1203/00006450-199005000-00011; ISCHIROPOULOS H, 1990, MECH AGEING DEV, V52, P11, DOI 10.1016/0047-6374(90)90141-2; JENKINSON SG, 1982, J NUTR, V112, P197, DOI 10.1093/jn/112.1.197; KANEMATSU S, 1989, PLANT CELL PHYSIOL, V30, P717; KANEMATSU S, 1989, PLANT CELL PHYSIOL, V30, P381; KARLSSON K, 1988, BIOCHEM J, V255, P223; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; KELLOGG EW, 1976, J GERONTOL, V31, P405, DOI 10.1093/geronj/31.4.405; KELNER MJ, 1989, FREE RADICAL BIO MED, V6, P355, DOI 10.1016/0891-5849(89)90079-8; KOKOGLU E, 1989, LEUKEMIA RES, V13, P457, DOI 10.1016/0145-2126(89)90166-5; MAKITA T, 1990, ANN NY ACAD SCI, V598, P510, DOI 10.1111/j.1749-6632.1990.tb42327.x; MARIUCCI G, 1990, EXPERIENTIA, V46, P753, DOI 10.1007/BF01939957; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MCCORMICK ML, 1991, CARCINOGENESIS, V12, P977, DOI 10.1093/carcin/12.6.977; NICOTERA TM, 1989, CANCER RES, V49, P5239; OBERLEY LW, 1989, J CELL PHYSIOL, V138, P50, DOI 10.1002/jcp.1041380109; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OCHI T, 1990, TOXICOLOGY, V61, P229, DOI 10.1016/0300-483X(90)90173-E; PERCIVAL SS, 1991, BIOCHEM J, V274, P153, DOI 10.1042/bj2740153; PITTSCHIELER K, 1991, GASTROENTEROLOGY, V100, P1062, DOI 10.1016/0016-5085(91)90283-Q; PROHASKA JR, 1991, J NUTR, V121, P355, DOI 10.1093/jn/121.3.355; RAHMAN IU, 1991, AM J PHYSIOL, V260, pL412, DOI 10.1152/ajplung.1991.260.6.L412; SAITO H, 1989, FEBS LETT, V249, P253, DOI 10.1016/0014-5793(89)80634-9; SAITO T, 1982, CLIN SCI, V63, P251, DOI 10.1042/cs0630251; SATO M, 1991, TOXICOL APPL PHARM, V107, P98, DOI 10.1016/0041-008X(91)90334-B; SAUNDERS EL, 1991, ARCH BIOCHEM BIOPHYS, V288, P368, DOI 10.1016/0003-9861(91)90208-Z; SCHRANK IS, 1988, GENE, V73, P121, DOI 10.1016/0378-1119(88)90318-6; SCHWAIGER H, 1989, EUR J CELL BIOL, V48, P79; SETO NOL, 1989, GENE, V75, P85, DOI 10.1016/0378-1119(89)90385-5; SPALLHOLZ JE, 1991, PEROXIDASES CHEM BIO, V1, P259; SPEIER C, 1986, ARCH BIOCHEM BIOPHYS, V251, P551, DOI 10.1016/0003-9861(86)90363-2; SPENCE TH, 1986, J APPL PHYSIOL, V61, P982, DOI 10.1152/jappl.1986.61.3.982; STANGE RC, 1988, BIOCHIM BIOPHYS ACTA, V964, P260; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; STEVENS JB, 1977, J BIOL CHEM, V252, P3509; TAYLOR CG, 1990, FREE RADICAL BIO MED, V9, P229, DOI 10.1016/0891-5849(90)90033-F; TSAN MF, 1990, AM J PHYSIOL, V259, pL506, DOI 10.1152/ajplung.1990.259.6.L506; TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210; VANELLA A, 1989, J NEUROSCI RES, V22, P351, DOI 10.1002/jnr.490220316; VISNER GA, 1991, AM J PHYSIOL, V260, pL444, DOI 10.1152/ajplung.1991.260.6.L444; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WHITE CW, 1989, J APPL PHYSIOL, V66, P1003, DOI 10.1152/jappl.1989.66.2.1003; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	82	403	411	3	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1992	6	9					2675	2683		10.1096/fasebj.6.9.1612291	http://dx.doi.org/10.1096/fasebj.6.9.1612291			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612291				2022-12-28	WOS:A1992HZ48100008
J	JENKINS, MK; MILLER, RA				JENKINS, MK; MILLER, RA			MEMORY AND ANERGY - CHALLENGES TO TRADITIONAL MODELS OF LYMPHOCYTE-T DIFFERENTIATION	FASEB JOURNAL			English	Article						MEMORY; ANERGY; LYMPHOCYTE-T DIFFERENTIATION; LYMPHOKINES; CD45R	CALCIUM SIGNAL GENERATION; CELL ANTIGEN RECEPTOR; CLONAL INACTIVATION; HELPER-INDUCER; TH2 CLONES; TOLERANCE; SUBSETS; MICE; ACTIVATION; RESPONSES	Traditional paradigms suggest that encounter with an antigen converts naive peripheral T cells into memory cells with less stringent requirements for activation and increased capacities for lymphokine production. Recent evidence argues that this view may be over-simplified in two ways. First, an encounter with antigen in the absence of certain costimulatory factors can render a T cell anergic - that is, unable to respond to antigen under normal conditions. Second, although cells of the memory T cell population are more responsive than naive cells to some stimuli, these cells are hyporesponsive in other situations. Intrinsic resistance of memory T cells to elevation of intracellular calcium ion concentrations may contribute to their poor responsiveness to agents that activate naive cells. Thus, aspects of the costimulatory environment can determine whether a resting T cell is activated or rendered anergic and may also influence the kinds of stimuli to which a memory T cell will respond.	VET ADM MED CTR,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	JENKINS, MK (corresponding author), UNIV MINNESOTA,DEPT MICROBIOL,MINNEAPOLIS,MN 55455, USA.		Jenkins, Marc K/G-1063-2012	Jenkins, Marc K/0000-0001-8009-7655	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027998, R37AI027998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG003978, R37AG009801] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27998] Funding Source: Medline; NIA NIH HHS [AG03978, AG09801] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKBAR AN, 1991, IMMUNOL TODAY, V12, P184, DOI 10.1016/0167-5699(91)90050-4; ANDERSON P, 1987, J IMMUNOL, V139, P678; ARTHUR RP, 1986, J EXP MED, V163, P774, DOI 10.1084/jem.163.4.774; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; BYRNE JA, 1991, FASEB J, V5, pA1702; CHO EA, 1991, FASEB J, V5, pA1674; DESILVA DR, 1991, FASEB J, V5, pA1376; DOSREIS GA, 1991, FASEB J, V5, pA991; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; GASPARI AA, 1988, J IMMUNOL, V141, P2216; GEPPERT TD, 1991, CELL IMMUNOL, V133, P206, DOI 10.1016/0008-8749(91)90192-E; GILBERT KM, 1990, J IMMUNOL, V144, P2063; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HAYAKAWA K, 1989, J EXP MED, V169, P2245, DOI 10.1084/jem.169.6.2245; HORGAN KJ, 1990, EUR J IMMUNOL, V20, P1111, DOI 10.1002/eji.1830200525; JENKINS MK, 1991, MECHANISMS LYMPHOCYT, V3, P167; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KENNEDY MK, 1990, J IMMUNOL, V144, P909; LERNER A, 1989, EUR J IMMUNOL, V19, P977, DOI 10.1002/eji.1830190604; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; Marrack P, 1990, Semin Immunol, V2, P45; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MILLER RA, 1991, CLIN IMMUNOL IMMUNOP, V58, P305, DOI 10.1016/0090-1229(91)90122-Q; MILLER RA, 1991, J IMMUNOL, V147, P3030; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MUELLER DL, 1991, FASEB J, V5, pA1673; PHILOSOPHE B, 1989, EUR J IMMUNOL, V19, P695, DOI 10.1002/eji.1830190419; PHILOSOPHE B, 1990, J GERONTOL, V45, pB87, DOI 10.1093/geronj/45.3.B87; POWRIE F, 1989, J EXP MED, V169, P653, DOI 10.1084/jem.169.3.653; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; SALMON M, 1988, IMMUNOLOGY, V65, P81; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SWAIN SL, 1990, J IMMUNOL, V144, P1788; TEDDER TF, 1985, J IMMUNOL, V134, P2989; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEISS A, 1986, J IMMUNOL, V137, P819; WILLIAMS ME, 1991, RES IMMUNOL, V142, P23, DOI 10.1016/0923-2494(91)90006-5	48	38	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2428	2433		10.1096/fasebj.6.7.1563595	http://dx.doi.org/10.1096/fasebj.6.7.1563595			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1563595	Bronze			2022-12-28	WOS:A1992HP03000008
J	REISER, K; MCCORMICK, RJ; RUCKER, RB				REISER, K; MCCORMICK, RJ; RUCKER, RB			ENZYMATIC AND NONENZYMATIC CROSS-LINKING OF COLLAGEN AND ELASTIN	FASEB JOURNAL			English	Article						COLLAGEN; ELASTIN; CROSS-LINKING AMINO ACIDS; LYSYL OXIDASE; GLYCOSYLATION; GLYCATION; AMADORI PRODUCTS; MAILLARD PRODUCTS	AMINO-ACID-SEQUENCE; BASEMENT-MEMBRANE COLLAGEN; NON-HELICAL REGIONS; IV COLLAGEN; III COLLAGEN; LYSYL OXIDASE; IX COLLAGEN; AUTOXIDATIVE GLYCOSYLATION; EXTRACELLULAR-MATRIX; ARTICULAR-CARTILAGE	Knowledge regarding the steps and mechanisms related to the intra- and interchain cross-linking of collagen and elastin has evolved steadily during the past 30 years. Recently, effort has been directed at identifying the location and types of cross-links that are found in collagen and elastin. There are two major groups of cross-links: those initiated by the enzyme lysyl oxidase and those derived from nonenzymatically glycated lysine and hydroxylysine residues. The formation of enzymatic cross-links depends on specific enzymes, amino acid sequences, and quaternary structural arrangements. The cross-links that are derived nonenzymatically occur more adventitiously and are important to pathobiological processes. Considerable progress has been made in elucidating the pathways of synthesis for several of the enzymatically mediated cross-links, as well as possible mechanisms regulating the specificity of cross-linking. Although less is known about the chemistry of cross-links arising from nonenzymatically glycated residues, recent progress has also been made in understanding possible biosynthetic pathways and control mechanisms. This review focuses on such progress and hopes to underscore the biological importance of collagen and elastin cross-linking.	UNIV CALIF DAVIS,DEPT INTERNAL MED,DAVIS,CA 95616; UNIV WYOMING,DEPT ANIM SCI,LARAMIE,WY 82070; UNIV CALIF DAVIS,DEPT NUTR,DAVIS,CA 95616	University of California System; University of California Davis; University of Wyoming; University of California System; University of California Davis					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026777] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-15965] Funding Source: Medline; NICHD NIH HHS [HD-26777] Funding Source: Medline; NIDDK NIH HHS [DK-35747] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1988, J BIOL CHEM, V263, P8816; AHMED MU, 1986, J BIOL CHEM, V261, P4889; ANTTINEN H, 1981, BIOCHIM BIOPHYS ACTA, V674, P336, DOI 10.1016/0304-4165(81)90364-0; BABEL W, 1984, EUR J BIOCHEM, V143, P545, DOI 10.1111/j.1432-1033.1984.tb08404.x; BACHINGER HP, 1990, J BIOL CHEM, V265, P10095; BAILEY AJ, 1984, BIOCHEM J, V218, P713, DOI 10.1042/bj2180713; Baynes J. W., 1989, MAILLARD REACTION AG, P43; BENYA PD, 1986, J BIOL CHEM, V261, P4160; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BRAZEL D, 1988, EUR J BIOCHEM, V172, P35, DOI 10.1111/j.1432-1033.1988.tb13852.x; BUCKINGHAM B, 1990, J CLIN INVEST, V86, P1046, DOI 10.1172/JCI114807; CHU ML, 1988, J BIOL CHEM, V263, P18601; Cleary E.G., 1987, CONNECTIVE TISSUE DI, V12, P55; DAVISON PF, 1983, CONNECT TISSUE RES, V11, P135, DOI 10.3109/03008208309004850; DUBLET B, 1991, J BIOL CHEM, V266, P6853; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; EYRE DR, 1987, STRUCTURE FUNCTION C, P216; EYRE DR, 1982, S HERITABLE DISORDER, P43; FLEISCHMAJER R, 1990, ANN NY ACAD SCI, V580, P161, DOI 10.1111/j.1749-6632.1990.tb17927.x; GLANVILLE RW, 1985, EUR J BIOCHEM, V152, P213, DOI 10.1111/j.1432-1033.1985.tb09186.x; GORDON MK, 1990, ANN NY ACAD SCI, V580, P8, DOI 10.1111/j.1749-6632.1990.tb17913.x; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GUNJASMITH Z, 1986, MATRIX, V9, P21; HENKEL W, 1982, EUR J BIOCHEM, V122, P205, DOI 10.1111/j.1432-1033.1982.tb05868.x; HENKEL W, 1987, EUR J BIOCHEM, V165, P427, DOI 10.1111/j.1432-1033.1987.tb11456.x; HIGGINS PJ, 1981, J BIOL CHEM, V256, P5204; HORGAN DJ, 1991, MEAT SCI, V43, P251; HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KEENE DR, 1987, J CELL BIOL, V105, P2393, DOI 10.1083/jcb.105.5.2393; LAST JA, 1990, AM J RESP CELL MOL, V2, P543, DOI 10.1165/ajrcmb/2.6.543; LAST JA, 1989, BIOCHIM BIOPHYS ACTA, V990, P182, DOI 10.1016/S0304-4165(89)80032-7; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MECHANIC GL, 1987, BIOCHEMISTRY-US, V26, P3500, DOI 10.1021/bi00386a038; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MILLER EJ, 1988, COLLAGEN, V1, P140; MONNIER VM, 1989, MAILLARD REACTION AG, P1; NICHOLLS AC, 1980, BIOCHEM J, V185, P195, DOI 10.1042/bj1850195; NIEWOEHNER DE, 1982, SCIENCE, V217, P359, DOI 10.1126/science.7089570; PHILAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1981, BIOCHEMISTRY-US, V20, P7409, DOI 10.1021/bi00529a014; POWELL JT, 1980, BIOCHEM J, V188, P1; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PUISTOLA U, 1982, BIOCHEM J, V201, P215, DOI 10.1042/bj2010215; RAJU K, 1987, J BIOL CHEM, V262, P5755; RAMSHAW JAM, 1986, CONNECT TISSUE RES, V14, P307, DOI 10.3109/03008208609017473; REGINATO AM, 1991, BIOCHEM J, V273, P333, DOI 10.1042/bj2730333; REISER KM, 1991, P SOC EXP BIOL MED, V196, P17; REISER KM, 1990, DIABETES, V39, pA28; Robins S.P., 1982, METHOD BIOCHEM ANAL, V28, P330; ROBINS SP, 1983, BIOCHEM J, V215, P175, DOI 10.1042/bj2150175; ROMEROCHAPMAN N, 1991, BIOCHEM J, V275, P657, DOI 10.1042/bj2750657; ROTH M, 1983, CLIN CHEM, V29, P1991; ROYCE PM, 1985, BIOCHEM J, V230, P475, DOI 10.1042/bj2300475; SCOTT JE, 1983, BIOCHEM J, V209, P263, DOI 10.1042/bj2090263; SCOTT PG, 1980, BIOCHEMISTRY-US, V19, P6118, DOI 10.1021/bi00567a026; SELL DR, 1989, J BIOL CHEM, V264, P21597; SEYER JM, 1990, ANN NY ACAD SCI, V580, P427, DOI 10.1111/j.1749-6632.1990.tb17950.x; SHACKLETON DR, 1990, BIOCHEM J, V266, P917; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; STARCHER B, 1987, CONNECT TISSUE RES, V16, P15, DOI 10.3109/03008208709001991; TARSIO JF, 1987, BIOCHEMISTRY-US, V26, P1014, DOI 10.1021/bi00378a006; TARSIO JF, 1988, DIABETES, V37, P532, DOI 10.2337/diabetes.37.5.532; TILSON MD, 1985, BIOCHEM BIOPH RES CO, V126, P1222, DOI 10.1016/0006-291X(85)90316-X; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TINKER D, 1985, PHYSIOL REV, V65, P607, DOI 10.1152/physrev.1985.65.3.607; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRUEB B, 1989, J BIOL CHEM, V264, P136; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; WEBER S, 1988, EUR J BIOCHEM, V175, P229, DOI 10.1111/j.1432-1033.1988.tb14188.x; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; WESSEL GM, 1987, DEV BIOL, V121, P149, DOI 10.1016/0012-1606(87)90148-5; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; WU JJ, 1989, CONNECT TISSUE RES, V20, P241, DOI 10.3109/03008208909023893; WU JJ, 1987, BIOCHEM J, V248, P373, DOI 10.1042/bj2480373; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508; YAMAUCHI M, 1987, J BIOL CHEM, V262, P11428; Yamauchi M, 1988, COLLAGEN, P157; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P4906; YASUTERU M, 1991, J BIOL CHEM, V266, P7721; YEH H, 1989, ELASTIN ELASTASES, V1, P67	89	372	401	1	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2439	2449		10.1096/fasebj.6.7.1348714	http://dx.doi.org/10.1096/fasebj.6.7.1348714			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1348714				2022-12-28	WOS:A1992HP03000010
J	LEGRAVEREND, C; MODE, A; WELLS, T; ROBINSON, I; GUSTAFSSON, JA				LEGRAVEREND, C; MODE, A; WELLS, T; ROBINSON, I; GUSTAFSSON, JA			HEPATIC-STEROID HYDROXYLATING ENZYMES ARE CONTROLLED BY THE SEXUALLY DIMORPHIC PATTERN OF GROWTH-HORMONE SECRETION IN NORMAL AND DWARF RATS	FASEB JOURNAL			English	Article						RAT HEPATOCYTE; GROWTH HORMONE; TRANSCRIPTIONAL ACTIVATION; CYTOCHROME-P450	LACTOGENIC BINDING-SITES; RECEPTOR GENE-EXPRESSION; FEMALE RATS; PITUITARY REGULATION; GH RECEPTOR; LIVER CYTOCHROME-P-450; HYPOPHYSECTOMIZED RATS; MONOSODIUM GLUTAMATE; ULTRADIAN RHYTHM; FACTOR-I	In rats, the onset of the sexually dimorphic pattern of growth hormone (GH) secretion and increased hepatic GH-binding capacity at puberty are temporally correlated with the sex-dependent expression of some hepatic cytochrome P450 enzymes involved in steroid metabolism. There are indications that the expression of the GH receptor gene itself is dependent on the sexually differentiated pattern of GH secretion. However, the molecular mechanisms by which a given pattern of GH secretion turns on a specific set of genes in the hepatocyte are not yet understood. Studies of the cytochrome P450 2C gene subfamily in hypophysectomized rats and isolated hepatocytes suggest that one major mechanism of GH action in the liver occurs through modulation of gene transcriptional initiation. The occurrence, in dwarf rats and in rats treated neonatally with monosodium glutamate, of sex differences in GH secretion and liver steroid metabolism typical of normal rats, in spite of a 95% reduction in pituitary GH levels, is compatible with the notion that extremely low levels of circulating GH are sufficient to regulate the expression of liver steroid-metabolizing enzymes. This, together with the fact that single daily subcutaneous injections of GH are sufficient to masculinize the liver of a hypophysectomized rat, indicates that neither the amplitude nor the frequency of the GH pulse is recognized as male or female by the hepatocyte, but rather the complete and prolonged suppression (in males) or the persistence (in females) of circulating GH during the trough period after a GH surge.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	LEGRAVEREND, C (corresponding author), KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED NUTR,F60 NOVUM,S-14186 HUDDINGE,SWEDEN.		Wells, Timothy/A-6484-2010					ARGENTE J, 1991, ENDOCRINOLOGY, V128, P2369, DOI 10.1210/endo-128-5-2369; BANDIERA S, 1986, ARCH BIOCHEM BIOPHYS, V248, P658, DOI 10.1016/0003-9861(86)90521-7; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BAXTER RC, 1980, ENDOCRINOLOGY, V107, P1176, DOI 10.1210/endo-107-4-1176; BAXTER RC, 1984, ENDOCRINOLOGY, V115, P2009, DOI 10.1210/endo-115-5-2009; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BICK T, 1990, ENDOCRINOLOGY, V126, P1914, DOI 10.1210/endo-126-4-1914; BICK T, 1989, ENDOCRINOLOGY, V125, P1718, DOI 10.1210/endo-125-3-1718; BLOCH B, 1984, NATURE, V307, P272, DOI 10.1038/307272a0; BULLOCK P, 1991, P NATL ACAD SCI USA, V88, P5227, DOI 10.1073/pnas.88.12.5227; CARLSSON B, 1990, MOL CELL ENDOCRINOL, V73, pR1, DOI 10.1016/0303-7207(90)90048-D; CARLSSON LMS, 1990, J ENDOCRINOL, V126, P27, DOI 10.1677/joe.0.1260027; CATALIOTO RM, 1990, BIOCHEM BIOPH RES CO, V173, P840, DOI 10.1016/S0006-291X(05)80863-0; CHARLTON HM, 1988, J ENDOCRINOL, V119, P51, DOI 10.1677/joe.0.1190051; CHENG KC, 1982, J BIOL CHEM, V257, P2378; CLARK RG, 1988, ENDOCRINOLOGY, V122, P2675, DOI 10.1210/endo-122-6-2675; CLARK RG, 1988, J ENDOCRINOL, V119, P397, DOI 10.1677/joe.0.1190397; EDEN S, 1979, ENDOCRINOLOGY, V105, P555, DOI 10.1210/endo-105-2-555; Eden S., 1987, GROWTH HORMONE BASIC, P129; ENEROTH P, 1977, MOL CELL ENDOCRINOL, V7, P167, DOI 10.1016/0303-7207(77)90065-X; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FRANTZ AG, 1965, J CLIN ENDOCR METAB, V25, P1470, DOI 10.1210/jcem-25-11-1470; FRICK GP, 1990, ENDOCRINOLOGY, V126, P3076, DOI 10.1210/endo-126-6-3076; FROHMAN LA, 1986, ENDOCR REV, V7, P223, DOI 10.1210/edrv-7-3-223; GABRIEL SM, 1989, NEUROENDOCRINOLOGY, V50, P299, DOI 10.1159/000125237; GAUSE I, 1986, ENDOCRINOLOGY, V118, P119, DOI 10.1210/endo-118-1-119; GORIN E, 1988, ENDOCRINOLOGY, V123, P328, DOI 10.1210/endo-123-1-328; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRICHTING G, 1986, ENDOCRINOLOGY, V119, P847, DOI 10.1210/endo-119-2-847; GUSTAFSSON JA, 1983, ANNU REV PHYSIOL, V45, P51, DOI 10.1146/annurev.ph.45.030183.000411; GUSTAFSSON JA, 1983, J STEROID BIOCHEM, V19, P691, DOI 10.1016/0022-4731(83)90237-6; GUZELIAN PS, 1988, P NATL ACAD SCI USA, V85, P9783, DOI 10.1073/pnas.85.24.9783; HERTZ P, 1989, ENDOCRINOLOGY, V125, P581, DOI 10.1210/endo-125-2-581; HUSMAN B, 1985, ENDOCRINOLOGY, V116, P2605, DOI 10.1210/endo-116-6-2605; JANSSON JO, 1987, ENDOCRINOLOGY, V120, P1551, DOI 10.1210/endo-120-4-1551; JEFFERY S, 1990, BIOCHEM J, V266, P69, DOI 10.1042/bj2660069; JOHNSON RJ, 1988, J ENDOCRINOL, V119, P101, DOI 10.1677/joe.0.1190101; JOHNSON RM, 1990, ENDOCRINOLOGY, V127, P2099, DOI 10.1210/endo-127-5-2099; KAMATAKI T, 1985, BIOCHEM BIOPH RES CO, V130, P1247, DOI 10.1016/0006-291X(85)91748-6; KRIEG RJ, 1986, ENDOCRINOLOGY, V119, P1339, DOI 10.1210/endo-119-3-1339; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LEGRAVEREND C, 1992, IN PRESS MOL ENDOCRI; LEO MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P305, DOI 10.1016/0003-9861(84)90353-9; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MACGEOCH C, 1984, J BIOL CHEM, V259, P5433; MACGEOCH C, 1985, ENDOCRINOLOGY, V117, P2085, DOI 10.1210/endo-117-5-2085; MACGEOCH C, 1987, BIOCHEM BIOPH RES CO, V143, P782, DOI 10.1016/0006-291X(87)91422-7; MAES M, 1983, ENDOCRINOLOGY, V113, P1325, DOI 10.1210/endo-113-4-1325; MAITER D, 1991, ENDOCRINOLOGY, V128, P1709, DOI 10.1210/endo-128-4-1709; MAITER D, 1988, ENDOCRINOLOGY, V123, P1053, DOI 10.1210/endo-123-2-1053; MAITER D, 1991, ENDOCRINOLOGY, V128, P1100; MASSA G, 1990, ENDOCRINOLOGY, V126, P1976, DOI 10.1210/endo-126-4-1976; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MCCLELLANGREEN PD, 1989, J BIOL CHEM, V264, P18960; MODE A, 1989, MOL ENDOCRINOL, V3, P1142, DOI 10.1210/mend-3-7-1142; MODE A, 1983, ENDOCRINOLOGY, V113, P1250, DOI 10.1210/endo-113-4-1250; MODE A, 1982, ENDOCRINOLOGY, V111, P1692, DOI 10.1210/endo-111-5-1692; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; MORGAN ET, 1987, STEROIDS, V49, P213; ORIAN JM, 1991, ENDOCRINOLOGY, V128, P1238, DOI 10.1210/endo-128-3-1238; OSCARSSON J, 1989, ENDOCRINOLOGY, V125, P1638, DOI 10.1210/endo-125-3-1638; OSULLIVAN D, 1986, ENDOCRINOLOGY, V119, P1948, DOI 10.1210/endo-119-5-1948; POSNER BI, 1980, ENDOCRINOLOGY, V107, P1954, DOI 10.1210/endo-107-6-1954; RANKE MB, 1976, ENDOCRINOLOGY, V99, P1033, DOI 10.1210/endo-99-4-1033; REDMOND GP, 1980, PEDIATR PHARMACOL, V1, P63; ROGERS SA, 1989, P NATL ACAD SCI USA, V86, P6363, DOI 10.1073/pnas.86.16.6363; RYAN DE, 1984, J BIOL CHEM, V259, P1239; SANCHEZJIMENEZ F, 1990, ENDOCRINOLOGY, V126, P1270, DOI 10.1210/endo-126-2-1270; SCHUETZ EG, 1990, J BIOL CHEM, V265, P1188; SHAPIRO BH, 1989, ENDOCRINOLOGY, V125, P2935, DOI 10.1210/endo-125-6-2935; SHIRASU K, 1990, ENDOCRINOLOGY, V127, P344, DOI 10.1210/endo-127-1-344; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STROM A, 1988, ACTA ENDOCRINOL-COP, V118, P314, DOI 10.1530/acta.0.1180314; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; TOLLET P, IN PRESS MOL ENDOCRI; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1990, ENDOCRINOLOGY, V126, P712, DOI 10.1210/endo-126-2-712; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WEHRENBERG WB, 1986, NEUROENDOCRINOLOGY, V43, P391, DOI 10.1159/000124554; WESTIN S, 1990, MOL PHARMACOL, V38, P192; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZAPHIROPOULOS PG, 1990, DNA CELL BIOL, V9, P49, DOI 10.1089/dna.1990.9.49; ZEITLER P, 1990, ENDOCRINOLOGY, V127, P1362, DOI 10.1210/endo-127-3-1362	85	141	143	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					711	718		10.1096/fasebj.6.2.1537461	http://dx.doi.org/10.1096/fasebj.6.2.1537461			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537461				2022-12-28	WOS:A1992GZ44000011
J	DE LUCA, LM				DE LUCA, LM			RETINOIDS AND THEIR RECEPTORS IN DIFFERENTIATION, EMBRYOGENESIS, AND NEOPLASIA	FASEB JOURNAL			English	Review						DIFFERENTIATION; EMBRYOGENESIS; NEOPLASIA; VAGINAL EPITHELIUM; RETINOIC ACID RECEPTORS; RESPONSE ELEMENT; LEUKEMIA; CHROMOSOMAL TRANSLOCATION	EMBRYONAL CARCINOMA-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; ACID-RESPONSIVE ELEMENT; MOUSE TERATOCARCINOMA CELLS; THYROID-HORMONE RECEPTORS; TARGET GENE SPECIFICITY; HUMAN OSTEOCALCIN GENE; DIBUTYRYL-CYCLIC-AMP; V-ERB-A; VITAMIN-A	The crucial role of retinoids in controlling differentiation processes has become evident from studies conducted in a variety of in vivo and in vitro systems. Most striking is the role of retinoic acid as a morphogenic substance in vertebrate limb development, but equally important is its role in the maintenance of epithelial integrity in most superficial linings of the body. The similarity of the mode of action of retinoids to that of the steroid and thyroid hormones has recently been demonstrated with the discovery of the nuclear receptors for retinoic acid, which belong to the steroid/thyroid hormone receptor superfamily. These receptors act as transcriptional activators by binding as heterodimers to specific nucleotide sequences in the response elements of target genes. Response elements for retinoic acid have so far been identified for the rat growth hormone and phosphoenolpyruvate carboxykinase, the mouse complement H and laminin B1, the human and mouse retinoic acid receptor beta, the human osteocalcin, and the human alcohol dehydrogenase genes. The retinoic acid response element (RARE) for the rat growth hormone gene is also a thyroid hormone response element (TRE), and the AP-1 binding site of the human osteocalcin promoter is also a vitamin D response element (VDRE) and a RARE. Both these elements are palindromic. Other RAREs have a direct repeat configuration of the half-site motif AGGTCA separated by five nucleotides (AGGTCA xxxxx AGGTCA). The direct repeat arrangement of the same core motif AGGTCA separated by three or four nucleotides becomes a VDRE or TRE, respectively. A point mutation has been identified in the RAR-alpha-gene of embryonal carcinoma cells resistant to retinoic acid. In addition to the three retinoic acid receptors (alpha, beta, gamma) belonging to the steroid/thyroid hormone receptor superfamily, a second class of retinoid receptors (RXR) alpha, beta, gamma has also been characterized and its relatedness to a gene, XR2C, of the locus ultraspiracle required for pattern formation in Drosophila has been established. That would suggest that both vertebrates and invertebrates may require similar transcriptional activators during morphogenesis. An RXRE has been identified in the CRBPII gene promoter and it contains five repeats of the canonical sequence AGGTCA separated by one nucleotide. The importance of retinoids, both as chemopreventive agents of tumorigenesis and potent differentiation inducers of neoplastic cells, can only be emphasized by the recent finding that the t (15;17) (q21- q11-22) translocation, specifically associated with acute promyelocytic leukemia, also causes translocation of the retinoic acid receptor alpha-gene and its fusion with with a new locus, myl, of unknown function. Although the biological consequences of this translocation are unknown, the finding supports the concept that retinoids and their receptors are directly involved in neoplasia.			DE LUCA, LM (corresponding author), NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, BLDG 37, ROOM 3A-17, BETHESDA, MD 20892 USA.							BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BASHEERUDDIN K, 1987, P NATL ACAD SCI USA, V84, P709, DOI 10.1073/pnas.84.3.709; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CARLIN BE, 1983, J BIOL CHEM, V258, P7729; CASTAIGNE S, 1990, BLOOD, V76, P1704; COOPER AR, 1983, DEV BIOL, V99, P510, DOI 10.1016/0012-1606(83)90300-7; CREEK KE, 1989, J INVEST DERMATOL, V92, P283, DOI 10.1111/1523-1747.ep12276867; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; DE LUCA LM, 1990, METHOD ENZYMOL, V190, P81; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DELUCA LM, 1978, FAT SOLUBLE VITAMINS; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; ERIKSSON U, 1986, CANCER RES, V46, P717; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GORODESKI GI, 1989, DIFFERENTIATION, V42, P75, DOI 10.1111/j.1432-0436.1989.tb00609.x; GREEN MH, 1987, J NUTR, V117, P694, DOI 10.1093/jn/117.4.694; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HEINE UI, 1985, VIRCHOWS ARCH B, V50, P135; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG FL, 1986, IN VITRO CELL DEV B, V22, P223; HUANG FL, 1991, IN PRESS DIET NUTRIT; Huang M E, 1989, Haematol Blood Transfus, V32, P88; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JETTEN AM, 1990, MECHANISMS DIFFERENT, V1, P49; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1991, IN PRESS DEV PATTERI; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEWIS J, 1989, NATURE, V342, P734, DOI 10.1038/342734a0; LIE SO, 1988, EUR J HAEMATOL, V40, P460; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; LINSTEDT AD, 1986, J STEROID BIOCHEM, V24, P677, DOI 10.1016/0022-4731(86)90842-3; LOTAN R, 1990, METHOD ENZYMOL, V190, P100; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MAROTTI KR, 1985, DEV BIOL, V108, P26, DOI 10.1016/0012-1606(85)90005-3; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MCDOWELL EM, 1987, AM J PATHOL, V129, P511; MNGELSDORF DJ, 1991, CELL, V66, P555; MOON RC, 1983, CANCER RES, V43, P24696; MOSSMAN BT, 1976, EXP MOL PATHOL, V24, P405, DOI 10.1016/0014-4800(76)90074-5; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OZONO K, 1990, J BIOL CHEM, V265, P21881; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROSS SA, 1991, P AM ASSOC CANC RES, V32, P128; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, IN PRESS DEVELOPMENT; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SEGAL S, 1979, P NATL ACAD SCI USA, V76, P5611, DOI 10.1073/pnas.76.11.5611; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SPORN MB, 1976, FED PROC, V35, P1332; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THOMPSON JN, 1969, BRIT J NUTR, V23, P471, DOI 10.1079/BJN19690056; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1988, J CELL PHYSIOL, V136, P305, DOI 10.1002/jcp.1041360213; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WEDDEN S, 1990, METHOD ENZYMOL, V190, P201; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; WOLF G, 1990, J NUTR BIOCHEM, V1, P284, DOI 10.1016/0955-2863(90)90061-O; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YOUNG PR, 1984, MOL CELL BIOL, V4, P898, DOI 10.1128/MCB.4.5.898; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	102	863	879	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2924	2933						10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1661245				2022-12-28	WOS:A1991GP26900007
J	MONTGOMERY, RK; BULLER, HA; RINGS, EHHM; GRAND, RJ				MONTGOMERY, RK; BULLER, HA; RINGS, EHHM; GRAND, RJ			LACTOSE-INTOLERANCE AND THE GENETIC-REGULATION OF INTESTINAL LACTASE-PHLORIZIN HYDROLASE	FASEB JOURNAL			English	Review						LACTASE; PHLORIZIN HYDROLASE; GLYCOSYLCERAMIDASE; INTESTINE; DEVELOPMENT	RAT SMALL-INTESTINE; SUCRASE-ISOMALTASE COMPLEX; EPIDERMAL GROWTH-FACTOR; ADULT-TYPE HYPOLACTASIA; INTRACELLULAR-TRANSPORT; MICROVILLAR PROTEINS; EPITHELIAL-CELLS; RECESSIVE INHERITANCE; POSTNATAL-DEVELOPMENT; BETA-GALACTOSIDASE	Lactase-phlorizin hydrolase, which hydrolyzes lactose, the major carbohydrate in milk, plays a critical role in the nutrition of the mammalian neonate. Lactose intolerance in adult humans is common, usually due to low levels of small intestinal lactase. Low lactase levels result from either intestinal injury or (in the majority of the world's adult population) alterations in the genetic expression of lactase. Although the mechanism of decreased lactase levels has been the subject of intensive investigation, no consensus has yet emerged. Recent studies have begun to define the cellular and molecular biology of this enzyme. In animals and humans, a glycosylated precursor is proteolytically cleaved to yield the mature enzyme on the microvillus membrane of the enterocyte, bound to the lipid bilayer only by a hydrophobic anchor sequence. The enzyme hydrolyzes lactose, phlorizin, and glycosylceramides. A decline in lactase specific activity occurs at the time of weaning in most mammalian species; in most humans who have low lactase activity as adults, the decline occurs at approximately 3-5 years of age. In a few human groups, the elevated juvenile level of lactase specific activity persists throughout adulthood. These developmental patterns of lactase expression are most likely regulated at the level of gene transcription.	TUFTS UNIV, NEW ENGLAND MED CTR,FLOATING HOSP,SCH MED, DEPT PEDIAT,DIV PEDIAT GASTROENTEROL & NUTR, BOSTON, MA 02111 USA; UNIV AMSTERDAM, ACAD MED CTR, DEPT PEDIAT, DIV PEDIAT GASTROENTEROL & NUTR, 1105 AZ AMSTERDAM, NETHERLANDS	Floating Hospital For Children; Tufts Medical Center; Tufts University; University of Amsterdam; Academic Medical Center Amsterdam			Rings, Edmond/ABE-5731-2021	Rings, Edmond/0000-0001-8195-4356	NIDDK NIH HHS [DK-32658, P30 DK 34928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032658, R01DK032658, P30DK034928] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONOWICZ I, 1974, GASTROENTEROLOGY, V67, P51; ARSENAULT P, 1985, J PEDIATR GASTR NUTR, V4, P893, DOI 10.1097/00005176-198512000-00008; ASP NG, 1972, ANAL BIOCHEM, V47, P527, DOI 10.1016/0003-2697(72)90147-9; BAYLESS TM, 1966, J AMER MED ASSOC, V197, P968, DOI 10.1001/jama.197.12.968; BIRKENMEIER E, 1974, BIOCHIM BIOPHYS ACTA, V350, P100, DOI 10.1016/0005-2744(74)90207-1; BOLIN TD, 1970, AM J DIG DIS, V15, P679, DOI 10.1007/BF02236031; BOLIN TD, 1971, GASTROENTEROLOGY, V60, P432; BOLL W, 1991, AM J HUM GENET, V48, P889; BOND JH, 1976, GASTROENTEROLOGY, V70, P1058; BRADY RO, 1965, J BIOL CHEM, V240, P3766; BULLER HA, 1990, ANNU REV MED, V41, P141; BULLER HA, 1990, GASTROENTEROLOGY, V98, P667; BULLER HA, 1989, AM J PHYSIOL, V257, pG616, DOI 10.1152/ajpgi.1989.257.4.G616; BULLER HA, 1989, BIOCHEM J, V263, P249; BULLER HA, 1987, J BIOL CHEM, V262, P17206; BULLER HA, 1990, J BIOL CHEM, V265, P6978; CHU SHW, 1986, BIOCHIM BIOPHYS ACTA, V883, P496, DOI 10.1016/0304-4165(86)90289-8; CUATRECASAS P, 1965, LANCET, V1, P14; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; DAHLQVIST A, 1963, GASTROENTEROLOGY, V45, P488, DOI 10.1016/S0016-5085(19)34844-9; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DANIELSEN EM, 1986, BIOCHEM J, V240, P777, DOI 10.1042/bj2400777; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; DOELL RG, 1962, BIOCHIM BIOPHYS ACTA, V62, P353, DOI 10.1016/0006-3002(62)90097-5; EKSTROM KE, 1975, J NUTR, V105, P1032, DOI 10.1093/jn/105.8.1032; ESCHER J C, 1991, Gastroenterology, V100, pA208; FLATZ G, 1987, ADV HUM GENET, V16, P1; FOLTZERJOURDAINNE C, 1990, ENDOCRINOLOGY, V127, P1763, DOI 10.1210/endo-127-4-1763; FREUND JN, 1991, GASTROENTEROLOGY, V100, P388, DOI 10.1016/0016-5085(91)90207-2; GILAT T, 1972, GASTROENTEROLOGY, V62, P1125; GODA T, 1985, J PEDIATR GASTR NUTR, V4, P998, DOI 10.1097/00005176-198512000-00024; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GRAY GM, 1969, J CLIN INVEST, V48, P716, DOI 10.1172/JCI106029; HARINGSMA J, 1990, European Journal of Clinical Investigation, V20, pA26; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; Jacobi A., 1901, T AM PEDIATR SOC, V13, P150; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONAS MM, 1985, PEDIATR RES, V19, P956, DOI 10.1203/00006450-198509000-00018; KOBAYASHI T, 1981, J BIOL CHEM, V256, P7768; KOGUT MD, 1967, J PEDIATR-US, V71, P75, DOI 10.1016/S0022-3476(67)80234-8; KOLDOVSK.O, 1970, BIOCHEM J, V117, P467, DOI 10.1042/bj1170467; KRETCHMER N, 1967, GASTROENTEROLOGY, V53, P123; KRETCHMER N, 1971, GASTROENTEROLOGY, V61, P805; KRUSE TA, 1988, FEBS LETT, V240, P123, DOI 10.1016/0014-5793(88)80352-1; KRUSE TA, 1989, CYTOGENET CELL GENET, V51, P1026; LEBENTHAL E, 1973, GASTROENTEROLOGY, V64, P1136; LEESE HJ, 1973, J BIOL CHEM, V248, P8170; LEGLER G, 1968, Z. Physiol. Chem., V349, P767; MACLEAN WC, 1980, J PEDIATR-US, V97, P383, DOI 10.1016/S0022-3476(80)80186-7; MAIURI L, 1991, GASTROENTEROLOGY, V100, P359, DOI 10.1016/0016-5085(91)90203-W; MALO C, 1982, GASTROENTEROLOGY, V83, P28; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; Mendel LB, 1907, AM J PHYSIOL, V20, P81; MILLER D, 1961, BIOCHIM BIOPHYS ACTA, V52, P293, DOI 10.1016/0006-3002(61)90678-3; MONTGOMERY R K, 1990, Gastroenterology, V98, pA423; MONTGOMERY RK, 1981, BIOCHIM BIOPHYS ACTA, V661, P346, DOI 10.1016/0005-2744(81)90024-3; MOOG F, 1973, DEV BIOL, V35, P143, DOI 10.1016/0012-1606(73)90012-2; MURPHY BEP, 1982, AM J OBSTET GYNECOL, V144, P276; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NEWCOMER AD, 1966, GASTROENTEROLOGY, V51, P481; NORDSTROM C, 1967, J HISTOCHEM CYTOCHEM, V15, P713, DOI 10.1177/15.12.713; NSIEMVO E, 1987, CELL MOL BIOL, V33, P335; OSHIMA A, 1988, BIOCHEM BIOPH RES CO, V157, P238, DOI 10.1016/S0006-291X(88)80038-X; PALMITER RD, 1969, NATURE, V221, P912, DOI 10.1038/221912a0; Plimmer RHA, 1906, J PHYSIOL-LONDON, V35, P20; QUAN R, 1990, J BIOL CHEM, V265, P15882; QUARONI A, 1985, DEV BIOL, V111, P280, DOI 10.1016/0012-1606(85)90483-X; QUARONI A, 1976, J BIOL CHEM, V251, P3250; ROSENSWEIG NS, 1971, GASTROENTEROLOGY, V60, P464; ROUSSET M, 1986, FEBS LETT, V208, P34, DOI 10.1016/0014-5793(86)81526-5; SAHI T, 1977, GASTROENTEROLOGY, V73, P231; SAHI T, 1973, LANCET, V2, P823; SAVILAHTI E, 1983, ARCH DIS CHILD, V58, P246, DOI 10.1136/adc.58.4.246; SCRIMSHAW N S, 1988, American Journal of Clinical Nutrition, V48, P1083; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; SEETHARAM B, 1980, AM J PHYSIOL, V239, pG524, DOI 10.1152/ajpgi.1980.239.6.G524; SIMOONS FJ, 1989, DIGEST DIS SCI, V23, P963; SKOVBJERG H, 1984, BIOCHIM BIOPHYS ACTA, V798, P247, DOI 10.1016/0304-4165(84)90312-X; SMITH MW, 1987, BIOCHIM BIOPHYS ACTA, V905, P503, DOI 10.1016/0005-2736(87)90481-0; SRIVASTAVA OP, 1987, BIOCHIM BIOPHYS ACTA, V914, P143, DOI 10.1016/0167-4838(87)90057-4; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; TSUBOI KK, 1985, BIOCHIM BIOPHYS ACTA, V840, P69, DOI 10.1016/0304-4165(85)90163-1; WELSH JD, 1978, GASTROENTEROLOGY, V75, P847; WELSH JD, 1970, MEDICINE, V49, P257, DOI 10.1097/00005792-197007000-00001; WITTE J, 1990, J CLIN INVEST, V86, P1338, DOI 10.1172/JCI114843; YEH KY, 1991, AM J PHYSIOL, V260, pG371, DOI 10.1152/ajpgi.1991.260.3.G371; YEH KY, 1974, SCIENCE, V183, P77, DOI 10.1126/science.183.4120.77; YEH KY, 1991, AM J PHYSIOL, V260, pG379, DOI 10.1152/ajpgi.1991.260.3.G379; YEH KY, 1991, GASTROENTEROLOGY, V101, P312, DOI 10.1016/0016-5085(91)90005-6	92	65	67	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1991	5	13					2824	2832		10.1096/fasebj.5.13.1916106	http://dx.doi.org/10.1096/fasebj.5.13.1916106			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916106				2022-12-28	WOS:A1991GJ47100011
J	FERNANDEZBOTRAN, R				FERNANDEZBOTRAN, R			SOLUBLE CYTOKINE RECEPTORS - THEIR ROLE IN IMMUNOREGULATION	FASEB JOURNAL			English	Article						CYTOKINE ACTIVITY; CYTOKINE INHIBITOR; CARRIER PROTEINS; DIAGNOSIS; IMMUNOTHERAPY	TUMOR-NECROSIS-FACTOR; HUMAN INTERLEUKIN-2 RECEPTOR; STIMULATING FACTOR-I; HIGH-AFFINITY; MOLECULAR-CLONING; IMMUNE-RESPONSE; BINDING-PROTEIN; IL-2 RECEPTOR; CELLS-INVITRO; HUMAN-URINE	A number of cytokine receptors exist in soluble form in the biological fluids of both animals and humans, a phenomenon that might have immunoregulatory implications in vivo. Although these soluble receptors specifically inhibit binding and activity of their respective cytokines in vitro, their actual function in vivo as cytokine inhibitors or as carrier proteins is unclear. Abnormalities in the production of these substances might contribute to the pathophysiology of immune and neoplastic diseases. Besides their role in regulating cytokine activity in vivo, soluble cytokine receptors hold significant potential for therapeutic use as very specific anticytokine agents and as indicators in diagnosis and assessment of immune parameters, prognosis, disease progression, response to treatment, etc., in a variety of autoimmune and malignant diseases.			FERNANDEZBOTRAN, R (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA.		Fernandez-Botran, Rafael/J-3659-2016	Fernandez-Botran, Rafael/0000-0001-8138-8745	NIAID NIH HHS [AI-11851, AI-21229] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI011851, R01AI021229] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BARAN D, 1988, J IMMUNOL, V141, P539; BORTH W, 1989, J BIOL CHEM, V264, P5818; CANTRELL DA, 1983, J EXP MED, V158, P1895, DOI 10.1084/jem.158.6.1895; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; DOWNING JR, 1989, CLIN RES, V37, pA544; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FERNANDEZBOTRAN R, 1990, P NATL ACAD SCI USA, V87, P4202, DOI 10.1073/pnas.87.11.4202; FONTANA A, 1984, J IMMUNOL, V132, P1837; FUJIMOTO J, 1983, J EXP MED, V158, P752, DOI 10.1084/jem.158.3.752; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GATANAGA T, 1990, LYMPHOKINE RES, V9, P225; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GREENBERG SJ, 1988, NEW ENGL J MED, V319, P1019; GREENE WC, 1986, ANN INTERN MED, V105, P560, DOI 10.7326/0003-4819-105-4-560; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HONDA M, 1989, J IMMUNOL, V142, P4248; HONDA M, 1990, J IMMUNOL, V145, P4131; HONDA M, 1985, J IMMUNOL, V135, P1834; JACQUES Y, 1987, J IMMUNOL, V139, P2308; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; JOSIMOVICALASEVIC O, 1988, EUR J IMMUNOL, V18, P1855, DOI 10.1002/eji.1830181133; KONDO N, 1988, IMMUNOL LETT, V19, P299, DOI 10.1016/0165-2478(88)90159-9; KRANGEL MS, 1986, J EXP MED, V163, P1173, DOI 10.1084/jem.163.5.1173; LARRICK JW, 1989, IMMUNOL TODAY, V10, P61, DOI 10.1016/0167-5699(89)90308-3; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOUGHNAN MS, 1989, NATURE, V340, P76, DOI 10.1038/340076a0; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MACDONALD RG, 1989, J BIOL CHEM, V264, P3256; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUDA T, 1989, J IMMUNOL, V142, P148; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Muegge K, 1990, Cytokine, V2, P1, DOI 10.1016/1043-4666(90)90036-S; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; OGARRA A, 1988, IMMUNOL TODAY, V9, P45, DOI 10.1016/0167-5699(88)91259-5; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; OSAWA H, 1986, EUR J IMMUNOL, V16, P467, DOI 10.1002/eji.1830160426; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PUI CH, 1988, BLOOD, V71, P1135; RESKEKUNZ AB, 1987, J IMMUNOL, V138, P192; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SEMENZATO G, 1987, BLOOD, V70, P396; Smith K A, 1990, Eur Cytokine Netw, V1, P7; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; SYMONS JA, 1988, J IMMUNOL, V141, P2612; TREIGER BF, 1986, J IMMUNOL, V136, P4099; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; WAGNER DK, 1986, J IMMUNOL, V137, P592; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343	61	273	286	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1991	5	11					2567	2574		10.1096/fasebj.5.11.1868981	http://dx.doi.org/10.1096/fasebj.5.11.1868981			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868981				2022-12-28	WOS:A1991GB09400010
J	DAY, HG				DAY, HG			STATUS OF ZINC IN NUTRITION (REPRINTED FROM J NUTR, VOL 6, PG 289-302, 1933)	FASEB JOURNAL			English	Reprint																		DAY H. G., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P188; Day Harry G., 1947, JOUR NUTRITION, V33, P27; Day HG, 1940, P SOC EXP BIOL MED, V45, P282; Follis RH, 1941, J NUTR, V22, P223, DOI 10.1093/jn/22.3.223; Hove E, 1938, AM J PHYSIOL, V124, P750, DOI 10.1152/ajplegacy.1938.124.3.750; Hove E, 1937, AM J PHYSIOL, V119, P768, DOI 10.1152/ajplegacy.1937.119.4.768; Newell JM, 1933, J NUTR, V6, P289, DOI 10.1093/jn/6.3.289; PRASAD AS, 1966, ZINC METABOLISM, P250; STIRN FE, 1935, J BIOL CHEM, V109, P37; Todd WR, 1934, AM J PHYSIOL, V107, P146, DOI 10.1152/ajplegacy.1933.107.1.146; WU FYH, 1987, ANNU REV NUTR, V7, P251, DOI 10.1146/annurev.nu.07.070187.001343	11	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2315	2316		10.1096/fasebj.5.9.1860624	http://dx.doi.org/10.1096/fasebj.5.9.1860624			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860624				2022-12-28	WOS:A1991FP87200016
J	DENNIS, EA; RHEE, SG; BILLAH, MM; HANNUN, YA				DENNIS, EA; RHEE, SG; BILLAH, MM; HANNUN, YA			ROLE OF PHOSPHOLIPASES IN GENERATING LIPID 2ND MESSENGERS IN SIGNAL TRANSDUCTION	FASEB JOURNAL			English	Article						SIGNAL TRANSDUCTION; LIPID 2ND MESSENGERS; PHOSPHOLIPASES; PHOSPHOLIPASE-A1; PHOSPHOLIPASE-C; SPHINGOMYELINASE	PROTEIN-KINASE-C; VENOM PHOSPHOLIPASE-A2; CELLULAR-REGULATION; COMPLETE CDNA; BOVINE BRAIN; SEQUENCE; INHIBITION; ACID; PURIFICATION; MANOALIDE	Many lipids or lipid-derived products generated by phospholipases acting on phospholipids in membranes are implicated as mediators and second messengers in signal transduction. Our current understanding of the primary sequence relationships within the class of extracellular phospholipase A2's and among the numerous forms of the mammalian phosphatidylinositol-specific phospholipase C's is reviewed. New results suggesting roles for these phospholipases as well as other phospholipases such as phospholipase C and D acting on phosphatidlycholine in generating arachidonic acid for eicosanoid biosynthesis, inositol phosphates for Ca2+ mobilization, and diglyceride for protein kinase C activation through receptor-mediated processes, are discussed. In addition, the possible role of phospholipases acting on sphingolipids such as sphinglomyelinase in generating lipid mediators is considered.	UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA; SCHERING PLOUGH CORP, BLOOMFIELD, NJ 07003 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Merck & Company; Schering Plough Corporation; Duke University; Duke University	DENNIS, EA (corresponding author), UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA.		Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; DENNIS EA, 1989, UCLA S MOL CELLULAR, V106, P1; Dennis EA, 1983, ENZYMES, P307; EMORI Y, 1989, J BIOL CHEM, V264, P21885; EXTON JH, 1990, J BIOL CHEM, V265, P1; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GLASER KB, 1986, BIOCHEM PHARMACOL, V35, P449, DOI 10.1016/0006-2952(86)90218-2; GOMEZ F, 1989, EUR J BIOCHEM, V186, P23, DOI 10.1111/j.1432-1033.1989.tb15172.x; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KENNERLY DA, 1990, J IMMUNOL, V144, P3912; KRIZ R, 1990, CIBA F SYMP, V150, P112; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LISTER MD, 1988, J BIOL CHEM, V263, P7506; LISTER MD, 1989, J BIOL CHEM, V264, P8520; LOMBARDO D, 1985, J BIOL CHEM, V260, P7234; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MINNICOZZI M, 1990, BIOCHEM BIOPH RES CO, V170, P540, DOI 10.1016/0006-291X(90)92125-J; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAI JK, 1988, J BIOL CHEM, V263, P12472; PAWSON T, 1988, ONCOGENE, V3, P491; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; REYNOLDS LJ, 1988, J AM CHEM SOC, V110, P5172, DOI 10.1021/ja00223a044; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS MI, 1985, ARCH BIOCHEM BIOPHYS, V238, P247, DOI 10.1016/0003-9861(85)90162-6; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SPERKER ER, 1983, J NEUROCHEM, V40, P1182, DOI 10.1111/j.1471-4159.1983.tb08112.x; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRUETT AP, 1989, BIOCHEM J, V260, P909, DOI 10.1042/bj2600909; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; WONG PYK, 1990, PHOSPHOLIPASE A2 ROL, P1	51	555	565	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1991	5	7					2068	2077		10.1096/fasebj.5.7.1901288	http://dx.doi.org/10.1096/fasebj.5.7.1901288			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	1901288	Bronze			2022-12-28	WOS:A1991FF44200009
J	NAKAYAMA, H; SHIBATA, M; WOHLENBERG, C; ROONEY, JF; NOTKINS, AL				NAKAYAMA, H; SHIBATA, M; WOHLENBERG, C; ROONEY, JF; NOTKINS, AL			TRANSPLANTATION OF SYNGENEIC TRANSFECTED CELLS TO PROBE THE INVIVO IMMUNE-RESPONSE TO VIRAL-PROTEINS	FASEB JOURNAL			English	Note						CYTOTOXIC T-CELLS; INVIVO IMMUNE RESPONSE; TRANSPLANTATION; TRANSFECTED CELLS; VIRAL PROTEINS; HERPES SIMPLEX VIRUS; GLYCOPROTEIN-D	SIMPLEX VIRUS TYPE-1; GLYCOPROTEIN-D; INFECTED-CELLS; HERPES; GD; TRANSFORMATION; LINES; MICE; GENE; DNA	BALB/3T3 cells were transfected with the glycoprotein D(gD) gene of herpes simplex virus (HSV) and a cell line expressing gD on the cell surface was isolated. In vitro, Cr-51 release tests showed that the transfected cells were destroyed by anti-HSV antibody in the presence of complement. To investigate in vivo immune response, the gD-transfected cells were transplanted into the footpads of syngeneic HSV-immunized or unimmunized BALB/c mice. In unimmunized mice, transfected cells remained intact for 7 days or longer, and the site of injection showed only slight lymphocyte infiltration. In contrast, in immunized mice, transfected cells elicited massive lymphocyte infiltration and were mostly destroyed by day 4. Analysis of infiltrating cells revealed that they were mainly Thy1+ and CD8+ lymphoyctes along with small numbers of CD5+, CD4+, and B lymphocytes. These studies show that transfected murine cells expressing gD can be used to study the in vivo immune response to single viral proteins and they argue that the immune response contributes to the pathogenesis of HSV infection.	NIDR,ORAL MED LAB,BLDG 30,ROOM 121,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BARBACID M, 1981, J VIROL, V37, P518, DOI 10.1128/JVI.37.1.518-523.1981; BLACKLAWS BA, 1987, J GEN VIROL, V68, P1103, DOI 10.1099/0022-1317-68-4-1103; COHEN GH, 1980, J VIROL, V36, P429, DOI 10.1128/JVI.36.2.429-439.1980; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; CREMER KJ, 1985, SCIENCE, V228, P737, DOI 10.1126/science.2986288; FLEXNER C, 1988, NATURE, V335, P259, DOI 10.1038/335259a0; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JOHNSON DC, 1985, J VIROL, V54, P682, DOI 10.1128/JVI.54.3.682-689.1985; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN S, 1987, J VIROL, V61, P726, DOI 10.1128/JVI.61.3.726-734.1987; ROONEY JF, 1988, J VIROL, V62, P1530, DOI 10.1128/JVI.62.5.1530-1534.1988; ROSENTHAL KL, 1987, J VIROL, V61, P2438, DOI 10.1128/JVI.61.8.2438-2447.1987; SHIBATA M, 1989, DIABETOLOGIA, V32, P709, DOI 10.1007/BF00274529; SHOWALTER SD, 1981, INFECT IMMUN, V34, P684, DOI 10.1128/IAI.34.3.684-692.1981; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPEAR PG, 1976, J VIROL, V17, P991, DOI 10.1128/JVI.17.3.991-1008.1976; SPEAR PG, 1985, HERPESVIRUSES, V3, P315; UCHIGATA Y, 1987, J EXP MED, V165, P124, DOI 10.1084/jem.165.1.124; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	21	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					104	108		10.1096/fasebj.5.1.1846831	http://dx.doi.org/10.1096/fasebj.5.1.1846831			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1846831				2022-12-28	WOS:A1991ET60900022
J	BRANDI, ML; ORNBERG, RL; SAKAGUCHI, K; CURCIO, F; FATTOROSSI, A; LELKES, PI; MATSUI, T; ZIMERING, M; AURBACH, GD				BRANDI, ML; ORNBERG, RL; SAKAGUCHI, K; CURCIO, F; FATTOROSSI, A; LELKES, PI; MATSUI, T; ZIMERING, M; AURBACH, GD			ESTABLISHMENT AND CHARACTERIZATION OF A CLONAL LINE OF PARATHYROID ENDOTHELIAL-CELLS	FASEB JOURNAL			English	Article									NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892; NIDDKD,METAB DIS BRANCH,ENDOCRINE REGULAT SECT,BETHESDA,MD 20892; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Curcio, Francesco/K-4669-2014; Lelkes, Peter I/S-1751-2019; Lelkes, Peter/HGA-2907-2022; Matsui, Toshimitsu/E-8065-2010	CURCIO, Francesco/0000-0002-9070-4807				BANERJEE DK, 1985, P NATL ACAD SCI USA, V82, P4702, DOI 10.1073/pnas.82.14.4702; BARILE MF, 1978, HUMAN ANIMAL MYCOPLA, P425; BRANDI ML, 1986, NEW ENGL J MED, V314, P1287, DOI 10.1056/NEJM198605153142004; BRANDI ML, 1986, P NATL ACAD SCI USA, V83, P1709, DOI 10.1073/pnas.83.6.1709; BRANDI ML, 1986, P NATL ACAD SCI USA, V83, P8366, DOI 10.1073/pnas.83.21.8366; BRANDI ML, 1989, CLIN DISORDERS BONE, P323; BRUNS RR, 1968, J CELL BIOL, V37, P277, DOI 10.1083/jcb.37.2.277; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FATTOROSSI A, 1988, P NATL ACAD SCI USA, V85, P4015, DOI 10.1073/pnas.85.11.4015; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; GOODMAN AL, 1987, ENDOCRINOLOGY, V121, P2131, DOI 10.1210/endo-121-6-2131; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MIZRACHI Y, 1989, CELL TISSUE RES, V256, P356; ROBINSON RA, 1986, BRAIN RES, V384, P114, DOI 10.1016/0006-8993(86)91226-6; ROBINSON RA, 1986, LAB INVEST, V56, P579; SAKAGUCHI K, 1989, 71ST ANN M END SOC, P471; STREETEN EA, 1988, P NATL ACAD SCI USA, V86, P916; THIELE J, 1984, ULTRASTRUCTURE ENDOC, P302; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; WAGNER RC, 1975, MICROVASC RES, V10, P286, DOI 10.1016/0026-2862(75)90033-3; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	25	24	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1990	4	13					3152	3158		10.1096/fasebj.4.13.1698682	http://dx.doi.org/10.1096/fasebj.4.13.1698682			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EC625	1698682				2022-12-28	WOS:A1990EC62500013
J	DOTY, SB; MOREYHOLTON, ER; DURNOVA, GN; KAPLANSKY, AS				DOTY, SB; MOREYHOLTON, ER; DURNOVA, GN; KAPLANSKY, AS			COSMOS-1887 - MORPHOLOGY, HISTOCHEMISTRY, AND VASCULATURE OF THE GROWING-RAT TIBIA	FASEB JOURNAL			English	Article									COLUMBIA UNIV,NEW YORK,NY 10027; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; MINIST PUBL HLTH USSR,INST BIOMED PROBLEMS,MOSCOW 123007,USSR	Columbia University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Russian Academy of Sciences; Institute of Biomedical Problems of the Russian Academy of Sciences								BORNSTEIN P, 1974, ANNU REV BIOCHEM, V43, P567, DOI 10.1146/annurev.bi.43.070174.003031; CANN CE, 1983, AM J PHYSIOL, V244, pR327, DOI 10.1152/ajpregu.1983.244.3.R327; CHRYSSANTHOU CP, 1978, CLIN ORTHOP RELAT R, V130, P94; DOTY SB, 1980, 3RD INT WORKSH BON H, P201; DOTY SB, 1971, CLIN ORTHOPAEDICS, V80, P191; FOWLER SD, 1985, J HISTOCHEM CYTOCHEM, V33, P833, DOI 10.1177/33.8.4020099; GRINDELAND RE, 1990, FASEB J, V4, P105, DOI 10.1096/fasebj.4.1.2295371; JEE WSS, 1983, AM J PHYSIOL, V244, pR310, DOI 10.1152/ajpregu.1983.244.3.R310; JONES JP, 1985, ORTHOP CLIN N AM, V16, P515; Kaplansky A. S., 1987, SPACE BIOL MED, V21, P33; KRUSE NJ, 1975, J BIOL CHEM, V250, P4841; LOPEZCURTO JA, 1980, J BONE JOINT SURG AM, V62, P1362, DOI 10.2106/00004623-198062080-00017; PATTERSONBUCKENDAHL P, 1987, AM J PHYSIOL, V252, pR240, DOI 10.1152/ajpregu.1987.252.2.R240; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SMITH CE, 1980, J HISTOCHEM CYTOCHEM, V28, P16, DOI 10.1177/28.1.7351472; TROYER H, 1980, PRINCIPLES TECHNIQUE, P135; VICO L, 1988, AM J PHYSIOL, V255, pR243, DOI 10.1152/ajpregu.1988.255.2.R243; VICO L, 1987, BONE, V8, P95, DOI 10.1016/8756-3282(87)90077-9; WRONSKI TJ, 1987, AM J PHYSIOL, V252, pR252, DOI 10.1152/ajpregu.1987.252.2.R252; WRONSKI TJ, 1983, AM J PHYSIOL, V244, pR305, DOI 10.1152/ajpregu.1983.244.3.R305	20	31	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1990	4	1					16	23		10.1096/fasebj.4.1.2153083	http://dx.doi.org/10.1096/fasebj.4.1.2153083			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH311	2153083				2022-12-28	WOS:A1990CH31100005
J	Chen, J; Dong, HH; Liu, QM; Ning, D; Du, PC; Mo, J; Xu, L; Zhang, XW; Liang, HF; Chen, Y; Chen, XP; Zhang, BX				Chen Jin; Dong Han-hua; Liu Qiu-meng; Ning Deng; Du Peng-Chen; Mo Jie; Xu Lei; Zhang Xue-Wu; Liang Hui-fang; Chen Yan; Chen Xiao-ping; Zhang Bi-xiang			MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma	ONCOGENE			English	Article; Early Access							ASTROCYTE-ELEVATED GENE-1; CELL-GROWTH; CANCER; ACTIVATION; METASTASIS; METADHERIN; PROTEIN; PROLIFERATION; RESISTANCE; ONCOGENE	Metadherin (MTDH) is a well-established oncogene in various cancers including Hepatocellular Carcinoma (HCC). However, the precise mechanism through which MTDH promotes cancer-related signaling pathways in HCC remains unknown. In this study, we identified DDX17 as a novel binding partner of MTDH. Furthermore, MTDH increased the protein level of DDX17 by inhibiting its ubiquitination. We confirmed that DDX17 was a novel oncogene, with dramatically upregulated expression in HCC tissues. The increased expression of DDX17 was closely associated with vascular invasion, TNM stage, BCLC stage, and poor prognosis. In vitro and in vivo tests demonstrated that DDX17, a downstream target of MTDH, played a crucial role in tumor initiation and progression. Mechanistically, DDX17 acted as a transcriptional regulator that interacted with Y-box binding protein 1 (YB1) in the nucleus, which in turn drove the binding of YB1 to its target epidermal growth factor receptor (EGFR) gene promoter to increase its transcription. This in turn increased expression of EGFR and the activation of the downstream MEK/pERK signaling pathway. Our results identify DDX17, stabilized by MTDH, as a powerful oncogene in HCC and suggest that the DDX17/YB1/EGFR axis contributes to tumorigenesis and metastasis of HCC.	[Chen Jin; Dong Han-hua; Liu Qiu-meng; Ning Deng; Du Peng-Chen; Mo Jie; Xu Lei; Zhang Xue-Wu; Liang Hui-fang; Chen Xiao-ping; Zhang Bi-xiang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll,Hubei Key Lab Hepatopancreatobili, Hepat Surg Ctr,Clin Med Res Ctr Hepat Surg Hubei, Wuhan, Peoples R China; [Chen Yan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Gen Surg, Wuhan, Peoples R China; [Chen Xiao-ping; Zhang Bi-xiang] Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Chen Xiao-ping; Zhang Bi-xiang] Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Chen Xiao-ping; Zhang Bi-xiang] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College	Chen, XP; Zhang, BX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll,Hubei Key Lab Hepatopancreatobili, Hepat Surg Ctr,Clin Med Res Ctr Hepat Surg Hubei, Wuhan, Peoples R China.; Chen, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Gen Surg, Wuhan, Peoples R China.; Chen, XP; Zhang, BX (corresponding author), Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Chen, XP; Zhang, BX (corresponding author), Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Chen, XP; Zhang, BX (corresponding author), Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China.	c_yan66@yahoo.com; chenxiaoping1953@163.com; bixiangzhang@163.com		Liang, Huifang/0000-0001-6874-3634	National Natural Science Foundation of China [81874189, 82003003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (No. 81874189 to Bi-xiang Zhang, No. 82003003 to Jin Chen).	Berasain C, 2014, J GASTROENTEROL, V49, P9, DOI 10.1007/s00535-013-0907-x; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chen SZ, 2019, CANCER LETT, V460, P1, DOI 10.1016/j.canlet.2019.114428; Craig AJ, 2020, NAT REV GASTRO HEPAT, V17, P139, DOI 10.1038/s41575-019-0229-4; Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049; Emdad L, 2009, P NATL ACAD SCI USA, V106, P21300, DOI 10.1073/pnas.0910936106; Ezzoukhry Z, 2012, INT J CANCER, V131, P2961, DOI 10.1002/ijc.27604; Fuller-Pace FV, 2013, BBA-GENE REGUL MECH, V1829, P756, DOI 10.1016/j.bbagrm.2013.03.004; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Giraud G, 2018, BMB REP, V51, P613, DOI 10.5483/BMBRep.2018.51.12.234; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He WL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1124-1; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Lambert MP, 2018, NUCLEIC ACIDS RES, V46, P7686, DOI 10.1093/nar/gky545; Li GH, 2014, CANCER RES, V74, P5541, DOI 10.1158/0008-5472.CAN-14-0968; Li J, 2009, ONCOGENE, V28, P3188, DOI 10.1038/onc.2009.171; Li WF, 2015, INT J MOL SCI, V16, P19419, DOI 10.3390/ijms160819419; Liang YJ, 2015, CANCER RES, V75, P3672, DOI 10.1158/0008-5472.CAN-15-0930; Lyabin DN, 2014, WIRES RNA, V5, P95, DOI 10.1002/wrna.1200; Manna D, 2021, CANCERS, V13, DOI 10.3390/cancers13081792; Niu LL, 2017, BBA-REV CANCER, V1868, P564, DOI 10.1016/j.bbcan.2017.10.002; Robertson CL, 2014, CANCER RES, V74, P6184, DOI 10.1158/0008-5472.CAN-14-1357; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Srivastava J, 2015, HEPATOLOGY, V61, P915, DOI 10.1002/hep.27339; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Tang WW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0187-x; Uribe ML, 2021, CANCERS, V13, DOI 10.3390/cancers13112748; Wan LL, 2014, CANCER CELL, V26, P92, DOI 10.1016/j.ccr.2014.04.027; Wang Z, 2014, MOL CLIN ONCOL, V2, P1139, DOI 10.3892/mco.2014.392; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Xing Z, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1519; Xue Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2044-9; Yao Y, 2014, BRIT J CANCER, V111, P355, DOI 10.1038/bjc.2014.267; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Zhu HD, 2015, ONCOL REP, V34, P539, DOI 10.3892/or.2015.4024; Zhu HD, 2020, J CELL PHYSIOL, V235, P5084, DOI 10.1002/jcp.29377; Zhu K, 2020, CARCINOGENESIS, V41, P130, DOI 10.1093/carcin/bgz065; Zhu K, 2011, CLIN CANCER RES, V17, P7294, DOI 10.1158/1078-0432.CCR-11-1327	42	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02545-x	http://dx.doi.org/10.1038/s41388-022-02545-x		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6G3AQ	36385375				2022-12-28	WOS:000884628600002
J	LOKHANDWALA, MF; AMENTA, F				LOKHANDWALA, MF; AMENTA, F			ANATOMICAL DISTRIBUTION AND FUNCTION OF DOPAMINE-RECEPTORS IN THE KIDNEY	FASEB JOURNAL			English	Article						DOPAMINE; DA-1 RECEPTORS; DA-2 RECEPTORS; RENAL FUNCTION; HYPERTENSION; RENAL FAILURE; CELLULAR SIGNALING	NA+-K+-ATPASE; PROXIMAL CONVOLUTED TUBULE; CONGESTIVE HEART-FAILURE; PHOSPHOLIPASE-C ACTIVITY; ADENYLATE-CYCLASE; RAT-KIDNEY; DOPEXAMINE HYDROCHLORIDE; ESSENTIAL-HYPERTENSION; SODIUM-EXCRETION; FENOLDOPAM	Dopamine receptors of DA-1 and DA-2 subtypes are localized in various regions within the kidney including the renal vasculature (DA-1) as well as sympathetic nerve terminals innervating the renal blood vessels (DA-2). More recent studies using receptor-ligand binding and receptor autoradiography have shown that DA-1 receptors are localized at both the luminal and basolateral membranes at the level of the proximal tubules. Activation of these DA-1 receptors by dopamine and by selective DA-1 receptor agonists results in natriuresis and diuresis. The cellular signaling mechanisms responsible for this response appear to be DA-1 receptor-induced activation of adenylate cyclase and phospholipase C, which via the generation of various intracellular messenger systems cause inhibition of Na+-H+ antiport (luminal) and Na+, K+-ATPase (basolateral), respectively. Both of these events consequently inhibit sodium reabsorption leading to natriuresis and diuresis. It is also known that dopamine can be synthesized within proximal tubular cells from L-dopa, which is taken up from the tubular lumen, and this locally produced dopamine plays an important role in the regulation of sodium excretion particularly during increases in sodium intake. Furthermore, a defect in the renal dopaminergic mechanism may be one of the pathogenic factors in certain forms of hypertension. Finally, whereas DA-1 receptor agonists are shown to be of therapeutic benefit in the treatment of hypertension, heart failure, and acute renal failure, some selective DA-2 receptor agonists are effective antihypertensive agents.	UNIV ROMA TOR VERGATA, DIPARTIMENTO SANITA PUBBLICA & BIOL CELLULARE, ROME, ITALY	University of Rome Tor Vergata	LOKHANDWALA, MF (corresponding author), UNIV HOUSTON, DEPT PHARMACOL, HOUSTON, TX 77204 USA.				NHLBI NIH HHS [HL 26262] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMENTA F, 1990, J PHARMACOL EXP THER, V253, P246; AMENTA F, 1990, J AUTON PHARMACOL, V10, P373, DOI 10.1111/j.1474-8673.1990.tb00037.x; AMENTA F, 1990, J AUTON PHARMACOL, V10, pS11, DOI 10.1111/j.1474-8673.1990.tb00222.x; AOKI K, 1989, CLIN EXP HYPERTENS A, V11, P403, DOI 10.3109/10641968909045447; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BALDI E, 1988, EUR J PHARMACOL, V149, P351, DOI 10.1016/0014-2999(88)90667-X; BAUMANN G, 1990, AM J CARDIOL, V65, P748, DOI 10.1016/0002-9149(90)91382-G; BELL C, 1988, PERIPHERAL ACTIONS D; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BROOKS DP, 1990, EUR J PHARMACOL, V184, P195, DOI 10.1016/0014-2999(90)90683-W; BROOKS DP, 1990, J PHARMACOL EXP THER, V254, P375; BURNSTOCK G, 1983, BIOL PATHOLOGY VESSE, P15; CAS LD, 1982, J CARDIOVASC PHARM, V4, P436, DOI 10.1097/00005344-198205000-00014; CASAGRANDE C, 1990, J AUTON PHARMACOL, V10, pS85, DOI 10.1111/j.1474-8673.1990.tb00233.x; CASAGRANDE C, 1985, NEW DRUGS ANN CARDIO, P173; CHEN CJ, 1991, FASEB J, V5, pA664; CHINTALA MS, 1990, J AUTON PHARMACOL, V10, pS95, DOI 10.1111/j.1474-8673.1990.tb00234.x; DLEWATI A, 1991, IN PRESS DRUG DEV RE; DOUCET A, 1988, KIDNEY INT, V34, P749, DOI 10.1038/ki.1988.245; FELDER CC, 1989, KIDNEY INT, V36, P183, DOI 10.1038/ki.1989.178; FELDER CC, 1989, J BIOL CHEM, V264, P8739; FELDER CC, 1989, J PHARMACOL EXP THER, V248, P171; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; FELDER RA, 1984, AM J PHYSIOL, V246, pF557, DOI 10.1152/ajprenal.1984.246.5.F557; FELDER RA, 1990, AM J HYPERTENS, V3, pS96, DOI 10.1093/ajh/3.6.96S; FELDER RA, 1988, AM J PHYSIOL, V255, pF970, DOI 10.1152/ajprenal.1988.255.5.F970; FELDER RA, 1984, AM J PHYSIOL, V247, pF499, DOI 10.1152/ajprenal.1984.247.3.F499; FELDER RA, 1990, HYPERTENSION, V15, P560, DOI 10.1161/01.HYP.15.6.560; FELDER RA, 1988, PERIPHERAL ACTIONS D, P124; FITTON A, 1990, DRUGS, V39, P308, DOI 10.2165/00003495-199039020-00009; GOLDBERG LI, 1972, PHARMACOL REV, V24, P1; GOLDSTEIN DS, 1989, CLIN SCI, V76, P517, DOI 10.1042/cs0760517; HEGDE S S, 1989, FASEB Journal, V3, pA895; HEGDE SS, 1989, J PHARMACOL EXP THER, V251, P1237; HEGDE SS, 1989, HYPERTENSION, V13, P828, DOI 10.1161/01.HYP.13.6.828; HIEBLE JP, 1990, CARDIOVASCULAR FUNCT; IIMURA O, 1987, JPN CIRC J, V51, P1232, DOI 10.1253/jcj.51.1232; JOSE PA, 1987, AM J MED SCI, V294, P181, DOI 10.1097/00000441-198709000-00009; KINOSHITA S, 1989, J CLIN INVEST, V84, P1849, DOI 10.1172/JCI114371; LEE MR, 1982, CLIN SCI, V62, P439, DOI 10.1042/cs0620439; LEE MR, 1987, TRIANGLE, V26, P11; LOKHANDWALA MF, 1982, J AUTON PHARMACOL, V2, P189, DOI 10.1111/j.1474-8673.1982.tb00489.x; LOKHANDWALA MF, 1987, DRUG DEVELOP RES, V10, P123, DOI 10.1002/ddr.430100302; LOKHANDWALA MF, 1990, PHARMACOL TOXICOL, V66, P237, DOI 10.1111/j.1600-0773.1990.tb00741.x; LOKHANDWALA MF, 1988, ISI ATLAS-PHARMACOL, V2, P261; LOKHANDWALA MF, 1990, CLIN INTENSIVE CARE, V1, P163; LOKHANDWALA MF, 1990, J AUTON PHARMACOL S1, V10, pS57; MCCLANAHAN M, 1985, CLIN SCI, V68, P263, DOI 10.1042/cs0680263; MCDONALD RH, 1964, J CLIN INVEST, V43, P1116, DOI 10.1172/JCI104996; MUNGER MA, 1990, AM J CARDIOL, V65, P206, DOI 10.1016/0002-9149(90)90086-G; MURPHY MB, 1987, CIRCULATION, V76, P1312, DOI 10.1161/01.CIR.76.6.1312; NAKAJIMA T, 1980, JPN J PHARMACOL, V30, P891, DOI 10.1254/jjp.30.891; OATES NS, 1979, CLIN SCI, V56, P261, DOI 10.1042/cs0560261; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RICCI A, 1991, IN PRESS J AUTON PHA; ROSENBLATT JE, 1980, EUR J PHARMACOL, V67, P317, DOI 10.1016/0014-2999(80)90516-6; SERI I, 1990, AM J PHYSIOL, V258, pF52, DOI 10.1152/ajprenal.1990.258.1.F52; SHIKUMA R, 1986, LIFE SCI, V38, P915, DOI 10.1016/0024-3205(86)90259-6; SHULTZ PJ, 1987, AM J PHYSIOL, V253, pH358, DOI 10.1152/ajpheart.1987.253.2.H358; SIRAGY HM, 1989, AM J PHYSIOL, V257, pF469, DOI 10.1152/ajprenal.1989.257.3.F469; VANVELDHUISEN DJ, 1990, J AUTON PHARMACOL, V10, pS115; VYAS SJ, 1991, N-S ARCH PHARMACOL, V343, P21; VYAS SJ, 1991, FASEB J, V5, pA1066; WILLEMS JL, 1985, PHARMACOL REV, V37, P165; YOUNG JB, 1988, AM HEART J, V115, P378, DOI 10.1016/0002-8703(88)90485-1; YOUNG WS, 1979, BRAIN RES, V179, P255; ZDILAR D, 1989, EUR J PHARMACOL, V164, P159, DOI 10.1016/0014-2999(89)90243-4	67	138	141	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1991	5	15					3023	3030		10.1096/fasebj.5.15.1683844	http://dx.doi.org/10.1096/fasebj.5.15.1683844			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1683844	Bronze			2022-12-28	WOS:A1991GU84200004
J	GORSKI, A; WASIK, M; NOWACZYK, M; KORCZAKKOWALSKA, G				GORSKI, A; WASIK, M; NOWACZYK, M; KORCZAKKOWALSKA, G			IMMUNOMODULATING ACTIVITY OF HEPARIN	FASEB JOURNAL			English	Review						HEPARIN; LYMPHOCYTE TRAFFIC; HEPARANASE; IMMUNOSUPPRESSION	MEMORY T-CELLS; SULFATED POLYSACCHARIDES; ALLERGIC ENCEPHALOMYELITIS; ALLOGRAFT SURVIVAL; DEXTRAN SULFATE; LYMPHOCYTES-T; INHIBITION; ENDOGLYCOSIDASE; PROLIFERATION; CYCLOSPORINE	Aside from its well-known anticoagulant action, heparin has many other biologic effects. Recent data emphasize the immunomodulatory effects of low dose heparin. The agent alters the traffic of lymphocytes blocking their expression of heparanase, an enzyme that digests the extracellular matrix allowing cell penetration to target tissues. It also has a weak direct immunosuppressive action in vitro and in vivo. Oral administration of heparin may cause immunosuppression, although the effects are weaker than after subcutaneous administration.			GORSKI, A (corresponding author), WARSAW ACAD MED & HOSP,INST TRANSPLANTAT,DEPT IMMUNOL,PL-02006 WARSAW 22,POLAND.			Gorski, Andrzej/0000-0002-0863-6041; Korczak-Kowalska, Grazyna/0000-0001-7624-9265				BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132; BABANY G, 1988, J PHARMACOL EXP THER, V244, P259; BRENAN M, 1986, EUR J IMMUNOL, V16, P423, DOI 10.1002/eji.1830160419; CLOWES AW, 1989, TRANSPLANT P, V21, P3700; COOMBE DR, 1987, INT J CANCER, V39, P82, DOI 10.1002/ijc.2910390115; CROSS AH, 1990, LAB INVEST, V63, P162; CURRIE GA, 1967, NATURE, V215, P164, DOI 10.1038/215164a0; DOUTREMEPUICH C, 1984, PATHOL BIOL, V32, P45; DZIARSKI R, 1989, J IMMUNOL, V143, P356; ESKINAZI DP, 1988, J BIOL RESP MODIF, V7, P173; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FRIDMAN R, 1987, J CELL PHYSIOL, V130, P85, DOI 10.1002/jcp.1041300113; FRIERI M, 1983, J IMMUNOL, V131, P1942; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GORSKI A, 1991, IN PRESS TRANSPLANT; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; LAGODZINSKI Z, 1990, TRANSPLANTATION, V50, P714, DOI 10.1097/00007890-199010000-00038; LARSEN AK, 1986, P NATL ACAD SCI USA, V83, P2964, DOI 10.1073/pnas.83.9.2964; LARSEN CP, 1990, TRANSPLANTATION, V50, P294, DOI 10.1097/00007890-199008000-00025; LASEK W, 1989, TRANSPLANTATION, V47, P913, DOI 10.1097/00007890-198905000-00038; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LIDER O, 1989, J CLIN INVEST, V83, P752, DOI 10.1172/JCI113953; LIDER O, 1990, EUR J IMMUNOL, V20, P493, DOI 10.1002/eji.1830200306; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; PADAWER J, 1979, HEPARIN STRUCTURE CE, P251; SAITO T, 1987, KIDNEY INT, V32, P691, DOI 10.1038/ki.1987.262; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SASAKI S, 1967, NATURE, V214, P1041, DOI 10.1038/2141041a0; STEINOAKLEY AN, 1989, TRANSPLANTATION, V48, P787, DOI 10.1097/00007890-198911000-00012; SUE TK, 1976, CAN J PHYSIOL PHARM, V54, P613, DOI 10.1139/y76-084; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; THURN AL, 1986, J CELL PHYSIOL, V126, P352, DOI 10.1002/jcp.1041260305; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; WINDSOR E, 1964, AM J MED, V37, P408, DOI 10.1016/0002-9343(64)90197-4; YAMAMOTO H, 1985, CELL IMMUNOL, V96, P409, DOI 10.1016/0008-8749(85)90371-5	37	58	58	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2287	2291		10.1096/fasebj.5.9.1860620	http://dx.doi.org/10.1096/fasebj.5.9.1860620			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860620				2022-12-28	WOS:A1991FP87200010
J	ZIGLER, JS; RAO, PV				ZIGLER, JS; RAO, PV			ENZYME CRYSTALLINS AND EXTREMELY HIGH PYRIDINE-NUCLEOTIDE LEVELS IN THE EYE LENS	FASEB JOURNAL			English	Article						CRYSTALLINE LENS; ENZYME/CRYSTALLINS; PYRIDINE NUCLEOTIDE LEVELS		Taxon-specific crystallins are proteins present in high abundance in the lens of phylogenetically restricted groups of animals. Recently it has been found that these proteins are actually enzymes which the lens has apparently adopted to serve as structural proteins. Most of these proteins have been shown to be identical to, or related to, oxidoreductases. In guinea pig lens, which contains zeta-crystallin, a protein with an NADPH-dependent oxidoreductase activity, the levels of both NADPH and NADP+ are extremely high and correlate with the concentration of zeta-crystallin. We report here nucleotide assays on lenses from vertebrates containing other enzyme/crystallins. In each case where the enzyme/crystallin is a pyridine nucleotide-binding protein the level of that particular nucleotide is extremely high in the lens. The presence of an enzyme/crystallin does not affect the lenticular concentrations of those nucleotides which are not specifically bound. The possibility that nucleotide binding may be a factor in the selection of some enzymes to serve as enzyme/crystallins is considered.			ZIGLER, JS (corresponding author), NEI,MECHANISMS OCULAR DIS LAB,9000 ROCKVILLE PIKE,BLDG 6,RM 237,BETHESDA,MD 20892, USA.							BULLARD B, 1965, EXP EYE RES, V4, P108, DOI 10.1016/S0014-4835(65)80020-3; CARPER DA, 1989, EXP EYE RES, V49, P377, DOI 10.1016/0014-4835(89)90048-1; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; GIBLIN FJ, 1980, EXP EYE RES, V31, P601, DOI 10.1016/S0014-4835(80)80019-4; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; RAO PV, 1989, NUTR RES, V9, P1143, DOI 10.1016/S0271-5317(89)80049-1; RAO PV, 1990, BIOCHEM BIOPH RES CO, V167, P1221, DOI 10.1016/0006-291X(90)90654-6; RAO PV, 1990, IN PRESS ARCH BIOCH; SPECTOR A, 1985, OCULAR LENS STRUCTUR, P405; STEWART A, 1984, EXP EYE RES, V39, P307, DOI 10.1016/0014-4835(84)90018-6; WISTOW G, 1990, Investigative Ophthalmology and Visual Science, V31, P162; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0	12	46	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					223	225		10.1096/fasebj.5.2.2004667	http://dx.doi.org/10.1096/fasebj.5.2.2004667			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004667				2022-12-28	WOS:A1991EZ00200013
J	COLLINS, FS				COLLINS, FS			THE GENOME PROJECT AND HUMAN HEALTH	FASEB JOURNAL			English	Editorial Material											COLLINS, FS (corresponding author), HOWARD HUGHES MED INST,ANN ARBOR,MI 48109, USA.								0	13	13	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					77	77		10.1096/fasebj.5.1.1991592	http://dx.doi.org/10.1096/fasebj.5.1.1991592			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991592				2022-12-28	WOS:A1991ET60900016
J	ALKON, DL; NELSON, TJ				ALKON, DL; NELSON, TJ			SPECIFICITY OF MOLECULAR-CHANGES IN NEURONS INVOLVED IN MEMORY STORAGE	FASEB JOURNAL			English	Review											ALKON, DL (corresponding author), NINCDS, NEURAL SYST SECT, BETHESDA, MD 20892 USA.							AGRANOFF BW, 1964, SCIENCE, V146, P952, DOI 10.1126/science.146.3646.952; AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALKON D L, 1989, Society for Neuroscience Abstracts, V15, P961; ALKON DL, 1985, BEHAV NEURAL BIOL, V44, P278, DOI 10.1016/S0163-1047(85)90296-1; ALKON DL, 1982, SCIENCE, V215, P693, DOI 10.1126/science.7058334; ALKON DL, 1984, SCIENCE, V226, P1037, DOI 10.1126/science.6093258; ALKON DL, 1988, J NEUROCHEM, V51, P903, DOI 10.1111/j.1471-4159.1988.tb01827.x; ALKON DL, 1989, IN PRESS BIOL CYBER; ALKON DL, 1987, NEURAL MOL BASES LEA, P205; ALKON DL, 1989, BIOL BULL, V177, P320; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BANDYOPADHYAY SK, 1989, J BIOL CHEM, V264, P14216; BANK B, 1988, P NATL ACAD SCI USA, V85, P1988, DOI 10.1073/pnas.85.6.1988; BAR PR, 1980, BRAIN RES, V198, P478, DOI 10.1016/0006-8993(80)90764-7; BARABAN JM, 1985, P NATL ACAD SCI USA, V82, P2538, DOI 10.1073/pnas.82.8.2538; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BENOWITZ LI, 1987, J NEUROCHEM, V48, P1640, DOI 10.1111/j.1471-4159.1987.tb05713.x; BERGER TW, 1978, BRAIN RES, V145, P323, DOI 10.1016/0006-8993(78)90866-1; BERRIDGE M, 1986, NATURE, V323, P294, DOI 10.1038/323294a0; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; CASTELLUCCI VF, 1988, NEURON, V1, P321, DOI 10.1016/0896-6273(88)90080-3; CHARDIN P, 1988, BIOCHIMIE, V70, P865, DOI 10.1016/0300-9084(88)90226-X; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P19, DOI 10.1113/jphysiol.1983.sp014477; CONNOR J, 1984, J NEUROPHYSIOL, V51, P745, DOI 10.1152/jn.1984.51.4.745; COULTER DA, 1989, J NEUROPHYSIOL, V61, P971, DOI 10.1152/jn.1989.61.5.971; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DISTERHOFT JF, 1986, P NATL ACAD SCI USA, V83, P2733, DOI 10.1073/pnas.83.8.2733; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FARLEY J, 1986, NATURE, V319, P220, DOI 10.1038/319220a0; FARLEY J, 1983, SCIENCE, V221, P1201, DOI 10.1126/science.6310750; FLEXNER JB, 1962, J NEUROCHEM, V9, P595, DOI 10.1111/j.1471-4159.1962.tb04216.x; GOLSKI-BRENNAN S, 1989, Society for Neuroscience Abstracts, V15, P607; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; Hinton Geoffrey E, 1981, PARALLEL MODELS ASS; INGRAHAM CA, 1989, MOL CHEM NEUROPATHOL, V10, P1, DOI 10.1007/BF02969481; KENNEDY TE, 1988, NATURE, V336, P499, DOI 10.1038/336499a0; KISTLER HB, 1985, J NEUROSCI, V5, P72; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LOEWENSTEIN WR, 1988, ANN NY ACAD SCI, V551, P337, DOI 10.1111/j.1749-6632.1988.tb22359.x; LONGLEY RD, 1986, J NEUROBIOL, V17, P339, DOI 10.1002/neu.480170408; LOTURCO JJ, 1988, P NATL ACAD SCI USA, V85, P1672, DOI 10.1073/pnas.85.5.1672; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MANESS P, 1988, J NEUROSCI RES, V16, P127; MASON SE, 1989, NEUROSCI LETT, V101, P274; MATZEL L, 1989, NEURAL SUBSTRATES RE, P40; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NEARY JT, 1981, NATURE, V293, P658, DOI 10.1038/293658a0; NELSON T, 1990, IN PRESS SCIENCE; NELSON TJ, 1988, P NATL ACAD SCI USA, V85, P7800, DOI 10.1073/pnas.85.20.7800; NELSON TJ, 1990, P NATL ACAD SCI USA, V87, P269, DOI 10.1073/pnas.87.1.269; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; OLDS JL, 1989, SCIENCE, V245, P866, DOI 10.1126/science.2772638; RAINBOW TC, 1979, NEUROCHEM RES, V4, P297, DOI 10.1007/BF00963800; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V44, P186, DOI 10.1016/S0163-1047(85)90184-0; Rumelhart D., 1986, PARALLEL DISTRIBUTED; RUPPERT C, 1987, MOL BRAIN RES, V2, P51, DOI 10.1016/0169-328X(87)90020-9; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SAKAKIBARA M, 1986, BIOPHYS J, V50, P319, DOI 10.1016/S0006-3495(86)83465-8; SANCHEZ-ANDRES J V, 1989, Society for Neuroscience Abstracts, V15, P506; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SHASHOUA VE, 1970, P NATL ACAD SCI USA, V65, P160, DOI 10.1073/pnas.65.1.160; SHASHOUA VE, 1968, NATURE, V217, P238, DOI 10.1038/217238a0; SIMKOWITZ P, 1989, J NEUROSCI, V9, P1004; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; SNIPES GJ, 1987, J NEUROSCI, V7, P4066; STAUBLI U, 1988, BRAIN RES, V444, P153, DOI 10.1016/0006-8993(88)90922-5; STERNBERG EA, 1989, MOL CELL BIOL, V9, P594, DOI 10.1128/MCB.9.2.594; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; VANHOOFF COM, 1989, J CELL BIOL, V108, P1115, DOI 10.1083/jcb.108.3.1115; WHITE JD, 1987, MOL BRAIN RES, V3, P21, DOI 10.1016/0169-328X(87)90040-4; WORLEY PF, 1986, J NEUROSCI, V6, P199; ZEMP JW, 1966, P NATL ACAD SCI USA, V55, P1423, DOI 10.1073/pnas.55.6.1423	88	74	77	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1990	4	6					1567	1576		10.1096/fasebj.4.6.2108074	http://dx.doi.org/10.1096/fasebj.4.6.2108074			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CY582	2108074				2022-12-28	WOS:A1990CY58200002
J	Fu, ZM; Zhang, PS; Zhang, RC; Zhang, BM; Xiang, SJ; Zhang, Y; Luo, Z; Huang, C				Fu, Zhongmao; Zhang, Pengshan; Zhang, Renchao; Zhang, Bimeng; Xiang, Shijun; Zhang, Yuan; Luo, Zai; Huang, Chen			Novel hypoxia-induced HIF1 alpha-circTDRD3-positive feedback loop promotes the growth and metastasis of colorectal cancer	ONCOGENE			English	Article; Early Access							INDUCIBLE FACTORS; CIRCULAR RNAS; STATISTICS; EXPRESSION; BINDING; P53	Tumor hypoxia and circular RNAs (circRNAs) are considered to play key roles in tumor progression and malignancy, respectively. Nevertheless, the biological functions and underlying mechanisms of specific circRNAs exposed to hypoxic microenvironments in colorectal cancer (CRC) remain largely elusive. Herein, a novel circRNA, circTDRD3, which is upregulated under hypoxic conditions, was identified. The expression of circTDRD3 was highly expressed in CRC tissues and positively correlated with overall survival, tumor size, lymph node invasion and clinical stage. CircTDRD3 facilitated CRC cell proliferation, migration and metastasis in vitro and in vivo. Mechanistically, circTDRD3 promoted HIF1 alpha expression by sponging miR-1231, which facilitated CRC progression. Meanwhile, HIF1 alpha directly combined with TDRD3 promoter to increase the expression of TDRD3 pre-mRNA. Then HIF1a-induced PTBP1 accelerated the formation of circTDRD3. Our findings reveal that circTDRD3 facilitates the proliferation and metastasis of CRC through a positive feedback loop mediated by the HIF1 alpha/PTBP1/circTDRD3/miR-1231/HIF1 alpha axis. Therefore, circTDRD3 may serve as a prognostic biomarker and therapeutic target for patients with CRC.	[Fu, Zhongmao; Zhang, Pengshan; Zhang, Renchao; Xiang, Shijun; Zhang, Yuan; Luo, Zai; Huang, Chen] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gen Surg, Shanghai 200080, Peoples R China; [Zhang, Bimeng] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Acupuncture Moxibust, Shanghai 200080, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Huang, C (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gen Surg, Shanghai 200080, Peoples R China.	richard-hc@sohu.com			National Natural Science Foundation of China [81772526, 82072662]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20191425]; Shanghai Jiaotong University Medical Cross Fund [YG2017MS28]; Three year Action Plan for Clinical Skills and Clinical Innovation in Shanghai level Hospitals [SHDC2020CR4022]; Shanghai Anticancer Association Eyas Program [SACA-CY21C08]; China Postdoctoral Science Foundation [2021M702182]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Jiaotong University Medical Cross Fund; Three year Action Plan for Clinical Skills and Clinical Innovation in Shanghai level Hospitals; Shanghai Anticancer Association Eyas Program; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the National Natural Science Foundation of China (Grant nos. 81772526 and 82072662), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (Grant no. 20191425), Shanghai Jiaotong University Medical Cross Fund (Grant no. YG2017MS28), Three year Action Plan for Clinical Skills and Clinical Innovation in Shanghai level Hospitals (Grant no. SHDC2020CR4022), Shanghai Anticancer Association Eyas Program (Grant no. SACA-CY21C08 to PZ) and China Postdoctoral Science Foundation (Grant no. 2021M702182 to PZ).	Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen LY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01272-9; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Chen T, 2021, ONCOGENE, V40, P2756, DOI 10.1038/s41388-021-01739-z; Chen Y, 2018, J CLIN INVEST, V128, P1937, DOI 10.1172/JCI95089; de Heer EC, 2020, J CLIN INVEST, V130, P5074, DOI 10.1172/JCI137552; Georgilis A, 2018, CANCER CELL, V34, P85, DOI 10.1016/j.ccell.2018.06.007; Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Harrandah AM, 2018, CANCER LETT, V438, P126, DOI 10.1016/j.canlet.2018.09.019; He RF, 2022, CANCERS, V14, DOI 10.3390/cancers14194950; Huan L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1122-z; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jian XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1134-8; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim S, 2021, MODERN PATHOL, V34, P672, DOI 10.1038/s41379-020-00681-x; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Li BT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20527-z; Li J, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01525-z; Loh XY, 2020, CANCER RES, V80, P219, DOI 10.1158/0008-5472.CAN-18-2796; Luo Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01203-8; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Oberstrass FC, 2005, SCIENCE, V309, P2054, DOI 10.1126/science.1114066; Quintero M, 2004, EJSO-EUR J SURG ONC, V30, P465, DOI 10.1016/j.ejso.2004.03.008; Ren SS, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1398-2; Rong ZY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02126-y; Rong ZY, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01400-z; Rong ZY, 2020, CANCER SCI, V111, P1203, DOI 10.1111/cas.14341; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; Sathornsumetee S, 2008, J CLIN ONCOL, V26, P271, DOI 10.1200/JCO.2007.13.3652; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tiwari A, 2020, GASTROENTEROLOGY, V159, P1882, DOI 10.1053/j.gastro.2020.07.046; Wei YP, 2020, HEPATOLOGY, V71, P130, DOI 10.1002/hep.30795; Xia X, 2020, ONCOGENE, V39, P6231, DOI 10.1038/s41388-020-01425-6; Xu S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02824-z; Yang HO, 2020, THERANOSTICS, V10, P8211, DOI 10.7150/thno.44419; Zeng Z, 2021, ONCOGENE, V40, P5505, DOI 10.1038/s41388-021-01960-w; Zhang JY, 2018, HEPATOLOGY, V67, P1872, DOI 10.1002/hep.29681; Zheng J, 2016, NAT GENET, V48, P747, DOI 10.1038/ng.3568; Zhu ZL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1054-7	45	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02548-8	http://dx.doi.org/10.1038/s41388-022-02548-8		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6J4UB	36418471				2022-12-28	WOS:000886818900001
J	Sun, SJ; Ai, YJ; Duan, KL; Zhang, JY; Zhang, C; Sun, YP; Xiong, Y; Guan, KL; Yuan, HX				Sun, Si-Jia; Ai, Ying-Jie; Duan, Kun-Long; Zhang, Jin-Ye; Zhang, Cheng; Sun, Yi-Ping; Xiong, Yue; Guan, Kun-Liang; Yuan, Hai-Xin			TET2 deficiency sensitizes tumor cells to statins by reducing HMGCS1 expression	ONCOGENE			English	Article; Early Access							COA REDUCTASE INHIBITORS; 5-HYDROXYMETHYLCYTOSINE; CANCER; MECHANISM; MUTATION; PATHWAY; SAFETY; GENES	TET2 (ten-eleven-translocation) protein is a Fe(II)- and alpha-ketoglutarate-dependent dioxygenase that catalyzes DNA demethylation to regulate gene expression. While TET2 gene is frequently mutated in hematological cancer, its enzymatic activity is also compromised in various solid tumors. Whether TET2 deficiency creates vulnerability for cancer cells has not been studied. Here we reported that TET2 deficiency is associated with the change of lipid metabolism processes in acute myeloid leukemia (AML) patient. We demonstrate that statins, the inhibitors of beta-Hydroxy beta-methylglutaryl-CoA (HMG-CoA) reductase and commonly used cholesterol-lowering medicines, significantly sensitize TET2 deficient tumor cells to apoptosis. TET2 directly regulates the expression of HMG-CoA synthase (HMGCS1) by catalyzing demethylation on its promoter region, and conversely TET2 deficiency leads to significant down-regulation of HMGCS1 expression and the mevalonate pathway. Consistently, overexpression of HMGCS1 in TET2-deficient cells rescues statin-induced apoptosis. We further reveal that decrease of geranylgeranyl diphosphate (GGPP), an intermediate metabolite in the mevalonate pathway, is responsible for statin-induced apoptosis. GGPP shortage abolishes normal membrane localization and function of multiple small GTPases, leading to cell dysfunction. Collectively, our study reveals a vulnerability in TET2 deficient tumor and a potential therapeutic strategy using an already approved safe medicine.	[Sun, Si-Jia; Duan, Kun-Long; Zhang, Jin-Ye; Zhang, Cheng; Sun, Yi-Ping; Yuan, Hai-Xin] Fudan Univ, Shanghai Coll Med, Peoples Hosp Shanghai 5, Inst Biomed Sci,Mol & Cell Biol Res Lab, Shanghai, Peoples R China; [Ai, Ying-Jie] Fudan Univ, Zhongshan Hosp, Shanghai Coll Med, Dept Gastroenterol & Hepatol, Shanghai, Peoples R China; [Xiong, Yue] Cullgen Inc, 12730 High Bluff Dr, San Diego, CA 92130 USA; [Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92093 USA; [Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA; [Yuan, Hai-Xin] Chongqing Med Univ, Inst Life Sci, Ctr Novel Target & Therapeut Intervent, Chongqing 400016, Peoples R China	Fudan University; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; Chongqing Medical University	Yuan, HX (corresponding author), Fudan Univ, Shanghai Coll Med, Peoples Hosp Shanghai 5, Inst Biomed Sci,Mol & Cell Biol Res Lab, Shanghai, Peoples R China.; Yuan, HX (corresponding author), Chongqing Med Univ, Inst Life Sci, Ctr Novel Target & Therapeut Intervent, Chongqing 400016, Peoples R China.	yuanhaixin@fudan.edu.cn		Yuan, Hai-Xin/0000-0002-1624-3934	National Key Research and Development Project of China [2018YFA0800304]; NSFC [82172595]; Development Fund for Shanghai Talents [2019109]; Supporting Fund for Innovation and Entrepreneurship by Chongqing Returned Oversea Scholars	National Key Research and Development Project of China; NSFC(National Natural Science Foundation of China (NSFC)); Development Fund for Shanghai Talents; Supporting Fund for Innovation and Entrepreneurship by Chongqing Returned Oversea Scholars	This work was supported by the National Key Research and Development Project of China (No. 2018YFA0800304 to H.-X.Y.), the NSFC grants (No. 82172595 to H.-X.Y.), and the Development Fund for Shanghai Talents (No. 2019109 to H.-X.Y.). H.-X.Y. is also supported by the Supporting Fund for Innovation and Entrepreneurship by Chongqing Returned Oversea Scholars.	Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bottorff M, 2000, ARCH INTERN MED, V160, P2273, DOI 10.1001/archinte.160.15.2273; Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016; Bullinger L, 2017, J CLIN ONCOL, V35, P934, DOI 10.1200/JCO.2016.71.2208; Chen L, 2019, J LIPID RES, V60, P1765, DOI 10.1194/jlr.RA119000201; Chen MQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025564; Cheng ML, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00266; Davidson MH, 2001, DRUGS, V61, P197, DOI 10.2165/00003495-200161020-00005; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Farmer JA, 2000, DRUG SAFETY, V23, P197, DOI 10.2165/00002018-200023030-00003; Garcia-Bermudez J, 2019, NATURE, V567, P118, DOI 10.1038/s41586-019-0945-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Illingworth DR, 2001, ADV PROTEIN CHEM, V56, P77; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jawert F, 2013, ANTICANCER RES, V33, P4325; Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023; Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001; Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092; Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x; Laukka T, 2016, J BIOL CHEM, V291, P4256, DOI 10.1074/jbc.M115.688762; Lee JV, 2014, CELL METAB, V20, P306, DOI 10.1016/j.cmet.2014.06.004; Nguyen UTT, 2009, NAT CHEM BIOL, V5, P227, DOI 10.1038/nchembio.149; Nibourel O, 2010, BLOOD, V116, P1132, DOI 10.1182/blood-2009-07-234484; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tefferi A, 2009, LEUKEMIA, V23, P1343, DOI 10.1038/leu.2009.59; Tefferi A, 2009, LEUKEMIA, V23, P905, DOI 10.1038/leu.2009.47; Waller DD, 2019, CRIT REV BIOCHEM MOL, V54, P41, DOI 10.1080/10409238.2019.1568964; Wang YP, 2015, MOL CELL, V57, P662, DOI 10.1016/j.molcel.2014.12.023; Wolf A, 2011, NEUROBIOL DIS, V44, P84, DOI 10.1016/j.nbd.2011.06.007; Wong WWL, 2002, LEUKEMIA, V16, P508, DOI 10.1038/sj.leu.2402476; Wu D, 2018, NATURE, V559, P637, DOI 10.1038/s41586-018-0350-5; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Xu YP, 2019, J CLIN INVEST, V129, P4316, DOI 10.1172/JCI129317; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Zhang XX, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01456-9	40	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02531-3	http://dx.doi.org/10.1038/s41388-022-02531-3		NOV 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D2TY	36348011				2022-12-28	WOS:000882550800001
J	PYERITZ, RE				PYERITZ, RE			A REVOLUTION IN MEDICINE LIKE NO OTHER	FASEB JOURNAL			English	Review							CLINICAL GENETICS; MUTATIONS; DISEASE		JOHNS HOPKINS UNIV, SCH MED, CTR MED GENET, BALTIMORE, MD 21287 USA	Johns Hopkins University			Pyeritz, Reed/A-1364-2010					ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; [Anonymous], 1989, METABOLIC BASIS INHE, V34, P253; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BALL DM, 1992, FASEB J, V6, P2818, DOI 10.1096/fasebj.6.10.1386046; BERNHARDT BA, 1987, AM J HUM GENET, V41, P559; BERNHARDT BA, 1992, AM J HUM GENET, V50, P84; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BROWN MD, 1992, FASEB J, V6, P2791, DOI 10.1096/fasebj.6.10.1634041; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARSON DA, 1992, FASEB J, V6, P2800, DOI 10.1096/fasebj.6.10.1634042; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CHILDS B, 1992, MEDICINE, V71, P102, DOI 10.1097/00005792-199203000-00005; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; COOPER DN, 1990, HUM GENET, V85, P55; Courteau J, 1991, Science, V254, P201, DOI 10.1126/science.1925577; CROW J, 1992, FASEB J, V6; DALTON TA, 1992, AM J MED, V92, P183, DOI 10.1016/0002-9343(92)90110-W; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DIETZ HC, 1992, IN PRESS P NATL ACAD; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; ENGEL E, 1991, AM J MED GENET, V40, P432, DOI 10.1002/ajmg.1320400411; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FLUGELMAN MY, 1992, CIRCULATION, V85, P1110, DOI 10.1161/01.CIR.85.3.1110; FOST N, 1992, FASEB J, V6, P2813, DOI 10.1096/fasebj.6.10.1634044; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GERSHON ES, 1990, TRENDS GENET, V6, P282, DOI 10.1016/0168-9525(90)90233-V; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; GUTIERREZ AA, 1992, LANCET, V339, P715, DOI 10.1016/0140-6736(92)90606-4; HALL JG, 1988, AM J HUM GENET, V43, P355; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hall JG, 1991, CURR OPIN GENET DEV, V1, P34, DOI 10.1016/0959-437X(91)80038-N; HANDYSIDE AH, 1989, LANCET, V1, P347; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HAYDEN MR, 1991, AM J MED GENET, V40, P515, DOI 10.1002/ajmg.1320400430; HEALY B, 1991, HUM GENE THER, V3, P51; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; HOLTZMAN NA, 1992, FASEB J, V6, P2806, DOI 10.1096/fasebj.6.10.1634043; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KAN YW, 1992, JAMA-J AM MED ASSOC, V267, P1532, DOI 10.1001/jama.267.11.1532; KNIGHT SJL, 1992, AM J MED GENET, V43, P217, DOI 10.1002/ajmg.1320430135; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KUO WL, 1991, AM J HUM GENET, V49, P112; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LUNGU O, 1992, JAMA-J AM MED ASSOC, V267, P2493, DOI 10.1001/jama.267.18.2493; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MCINTOSH I, 1992, FASEB J, V6, P2775, DOI 10.1096/fasebj.6.10.1378801; MCKUSICK VA, 1992, AM J HUM GENET, V50, P663; MCKUSICK VA, 1992, ON LINE MENDELIAN IN; MERLINO GT, 1991, FASEB J, V5, P2996, DOI 10.1096/fasebj.5.14.1752364; MILUNSKY A, 1992, AM J HUM GENET, V50, P643; NATOWICZ MR, 1992, AM J HUM GENET, V50, P465; NEEL JV, 1947, MEDICINE, V26, P115, DOI 10.1097/00005792-194705000-00001; OBERLE I, 1992, AM J MED GENET, V43, P224, DOI 10.1002/ajmg.1320430136; OLEE T, 1991, J CLIN INVEST, V88, P193, DOI 10.1172/JCI115277; PEARSON PL, 1991, SCIENCE, V254, P214, DOI 10.1126/science.1925578; PLAUTZ G, 1991, CIRCULATION, V83, P578, DOI 10.1161/01.CIR.83.2.578; PYERITZ RE, 1989, J AM COLL CARDIOL, V13, P1458, DOI 10.1016/0735-1097(89)90333-1; PYERITZ RE, 1989, AM J MED GENET, V34, P124, DOI 10.1002/ajmg.1320340120; ROSSITER BJF, 1991, FASEB J, V5, P21, DOI 10.1096/fasebj.5.1.1846832; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SMEETS DFCM, 1992, NEW ENGL J MED, V326, P807, DOI 10.1056/NEJM199203193261206; SOBELL JL, 1992, GENOMICS, V12, P1, DOI 10.1016/0888-7543(92)90398-C; SOMMER SS, 1992, FASEB J, V6, P2767, DOI 10.1096/fasebj.6.10.1634040; TAYLOR CR, 1992, NEW ENGL J MED, V326, P1436, DOI 10.1056/NEJM199205213262118; VIRCHOW R, 1877, GENERAL PATHOLOGY BA, P69; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047; WILSON GN, 1992, AM J MED GENET, V42, P187, DOI 10.1002/ajmg.1320420211; WRIGHT AF, 1992, TRENDS GENET, V8, P85, DOI 10.1016/0168-9525(92)90195-A; 1992, JAMA-J AM MED ASSOC, V267, P2609	79	5	5	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2761	2766		10.1096/fasebj.6.10.1634038	http://dx.doi.org/10.1096/fasebj.6.10.1634038			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634038				2022-12-28	WOS:A1992JD95400001
J	BLANK, M				BLANK, M			NA,K-ATPASE FUNCTION IN ALTERNATING ELECTRIC-FIELDS	FASEB JOURNAL			English	Article						NA,K-ATPASE; ALTERNATING CURRENT; ENZYME FUNCTION; ION PUMP; ELECTRIC FIELD EFFECTS	SIGNAL TRANSDUCTIONS; CHILDHOOD-CANCER; ENERGY; CELLS; ACTIVATION; (NA,K)-ATPASE; BIOSYNTHESIS; STIMULATION; MODULATION; TRANSPORT	Alternating currents affect ion transport processes and ATP splitting through changes in the activation of the membrane Na,K-ATPase. Both processes vary with the frequency, and the effective range includes the environmental 60 Hz. ATP splitting by Na,K-ATPase suspensions decreases for the enzyme under normal conditions, with the maximum effect at 100 Hz. ATP splitting increases when the enzyme activity is lowered to less than half its optimal value by changes in temperature, ouabain concentration, etc. These observations can be explained by the effects of the ionic currents on ion binding at the enzyme activation sites. Such a mechanism could account for the effects of electromagnetic fields on cells, as the transmembrane enzyme can convey the effect of an extracellular signal into the cell via ionic fluxes, and the measured threshold field is within the range of reported biological effects.			BLANK, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032, USA.							BASSETT CAL, 1985, CLIN PLAST SURG, V12, P259; BLANK M, 1989, BIOELECTROCH BIOENER, V21, P307, DOI 10.1016/0302-4598(89)85009-3; BLANK M, 1989, BIOELECTROCH BIOENER, V22, P313, DOI 10.1016/0302-4598(89)87048-5; BLANK M, 1990, BIOELECTROCH BIOENER, V24, P51, DOI 10.1016/0302-4598(80)85006-9; BLANK M, 1988, BIOELECTROCH BIOENER, V19, P569, DOI 10.1016/0302-4598(88)80035-7; BLANK M, 1987, J ELECTROCHEM SOC, V134, P1112, DOI 10.1149/1.2100626; BLANK M, 1987, BIOCHIM BIOPHYS ACTA, V906, P277, DOI 10.1016/0304-4157(87)90014-1; BLANK M, 1991, IN PRESS BIOELECTROM; BLANK M, 1990, BIOELECTROCHEMISTRY, V3, P311; BUHLER R, 1991, J MEMBRANE BIOL, V121, P141, DOI 10.1007/BF01870529; BYUS CV, 1988, CANCER RES, V48, P4222; Findl, 1987, MECHANISTIC APPROACH; GOODMAN R, 1988, P NATL ACAD SCI USA, V85, P3928, DOI 10.1073/pnas.85.11.3928; LIU DS, 1990, J BIOL CHEM, V265, P7260; LUBEN RA, 1982, P NATL ACAD SCI-BIOL, V79, P4180, DOI 10.1073/pnas.79.13.4180; MCLEOD KJ, 1987, SCIENCE, V236, P1465, DOI 10.1126/science.3589667; ROBERTSON B, 1991, J CHEM PHYS, V94, P7414, DOI 10.1063/1.460173; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SERPERSU EH, 1984, J BIOL CHEM, V259, P7155; TSONG TY, 1986, BIOELECTROCH BIOENER, V15, P457, DOI 10.1016/0302-4598(86)85034-6; TSONG TY, 1989, BIOELECTROCH BIOENER, V21, P319, DOI 10.1016/0302-4598(89)85010-X; TSONG TY, 1990, ANNU REV BIOPHYS BIO, V19, P83, DOI 10.1146/annurev.bb.19.060190.000503; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; MICROWAVE NEWS, V11	25	66	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1992	6	7					2434	2438		10.1096/fasebj.6.7.1314204	http://dx.doi.org/10.1096/fasebj.6.7.1314204			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HP030	1314204				2022-12-28	WOS:A1992HP03000009
J	HUNT, JS; ORR, HT				HUNT, JS; ORR, HT			HLA AND MATERNAL-FETAL RECOGNITION	FASEB JOURNAL			English	Review						ANTIGENS; GENES; HLA; PLACENTA; TROPHOBLAST	CLASS-I GENE; MAJOR HISTOCOMPATIBILITY COMPLEX; CHORIOCARCINOMA CELL-LINE; EMBRYONAL CARCINOMA-CELLS; ENHANCER-LIKE SEQUENCES; NEGATIVE REGULATION; ANTIGEN EXPRESSION; MESSENGER-RNA; LYMPHOBLASTOID-CELLS; INSITU HYBRIDIZATION	Despite genetic differences, mothers do not reject their semiallogeneic embryos. Regulated expression of the major histocompatibility antigens (HLA) by placental trophoblast cells, which intervene between the embryo and maternal blood and tissues, is now believed to play an important role in this surprising feature of pregnancy. Transcription and translation of the highly polymorphic class I HLA-A, -B, -C genes whose products stimulate graft rejection are blocked in trophoblast cells. Instead, these cells express HLA-G, a nonpolymorphic gene. Moreover, the cells do not express class II HLA-D antigens, and factors such as interferons that usually enhance HLA expression have no effect on trophoblast cells in situ. Thus, multiple regulatory mechanisms prevent the cells that sequester the embryo from the mother from expressing the potentially deleterious paternal HLA antigens, immunological rejection is avoided and successful pregnancy ensues.	UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	HUNT, JS (corresponding author), UNIV KANSAS,MED CTR,DEPT PATHOL & ONCOL,39TH ST & RAINBOW BLVD,KANSAS CITY,KS 66103, USA.			Orr, Harry/0000-0001-6118-741X				ALBERTI S, 1986, REPRODUCTIVE IMMUNOL, P60; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEER AE, 1982, BIOL REPROD, V26, P15, DOI 10.1095/biolreprod26.1.15; BEER AE, 1974, J REPROD FERTIL    S, V21, P59; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOUCRAUT J, 1991, TISSUE ANTIGENS, V37, P84, DOI 10.1111/j.1399-0039.1991.tb01850.x; BULMER JN, 1990, AM J REPROD IMMUNOL, V22, P109, DOI 10.1111/j.1600-0897.1990.tb00652.x; CHEN HL, 1991, AM J PATHOL, V139, P327; DESOYE G, 1988, J IMMUNOL, V140, P4157; ELLIS SA, 1986, IMMUNOLOGY, V59, P595; ELLIS SA, 1989, J IMMUNOL, V142, P3281; ELLIS SA, 1990, J IMMUNOL, V144, P731; FAULK WP, 1976, NATURE, V262, P799, DOI 10.1038/262799a0; FEHLMANN M, 1985, P NATL ACAD SCI USA, V82, P8634, DOI 10.1073/pnas.82.24.8634; FEINMAN MA, 1987, AM J OBSTET GYNECOL, V157, P1429, DOI 10.1016/S0002-9378(87)80238-7; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; GANGULY S, 1989, P NATL ACAD SCI USA, V86, P5247, DOI 10.1073/pnas.86.14.5247; GERAGHTY DE, 1987, P NATL ACAD SCI USA, V84, P9145, DOI 10.1073/pnas.84.24.9145; GERAGHTY DE, 1990, J EXP MED, V171, P1, DOI 10.1084/jem.171.1.1; GOODFELLOW PN, 1976, TRANSPLANTATION, V22, P595, DOI 10.1097/00007890-197612000-00009; HSI BL, 1984, IMMUNOLOGY, V52, P621; HUNT JS, 1987, J IMMUNOL, V138, P2481; HUNT JS, 1990, J IMMUNOL, V144, P4420; HUNT JS, 1988, J IMMUNOL, V140, P1293; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JAFFE L, 1990, J IMMUNOL, V145, P3474; JAFFE L, 1991, J IMMUNOL, V147, P2740; KANBOURSHAKIR A, 1990, P NATL ACAD SCI USA, V87, P444, DOI 10.1073/pnas.87.1.444; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KOLLER BH, 1988, J IMMUNOL, V141, P897; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOLLER BH, 1989, J EXP MED, V169, P469, DOI 10.1084/jem.169.2.469; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; LESSIN DL, 1988, AM J REPROD IMMUNOL, V16, P1; MATTSSON R, 1991, J REPROD IMMUNOL, V19, P115, DOI 10.1016/0165-0378(91)90012-F; MEDAWAR PB, 1953, SYM SOC EXP BIOL, V7, P320; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MIZUNO S, 1988, J IMMUNOL, V140, P4024; MOMBERG F, 1988, J IMMUNOL, V142, P352; ORR HT, 1983, NATURE, V302, P534, DOI 10.1038/302534a0; OUDEJANS CBM, 1989, J EXP MED, V169, P447, DOI 10.1084/jem.169.2.447; PARHAM P, 1979, J IMMUNOL, V123, P342; PURCELL DFJ, 1990, IMMUNOLOGY, V70, P155; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; SCHREIBER AB, 1984, J CELL BIOL, V98, P725, DOI 10.1083/jcb.98.2.725; SHIMIZU Y, 1988, P NATL ACAD SCI USA, V85, P227, DOI 10.1073/pnas.85.1.227; SHUKLA H, 1990, NUCLEIC ACIDS RES, V18, P2189, DOI 10.1093/nar/18.8.2189; SUNDERLAND CA, 1981, J IMMUNOL, V127, P2614; SURANI MAH, 1986, EXPT APPROACHES MAMM, P401; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VANROOD JJ, 1958, NATURE, V181, P1735, DOI 10.1038/1811735a0; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2; YELAVARTHI KK, 1991, J IMMUNOL, V146, P2847	53	154	161	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2344	2348		10.1096/fasebj.6.6.1544544	http://dx.doi.org/10.1096/fasebj.6.6.1544544			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544544	Bronze			2022-12-28	WOS:A1992HJ25200012
J	MOORE, FD				MOORE, FD			RADIATION BURDENS FOR HUMANS ON PROLONGED EXOMAGNETOSPHERIC VOYAGES	FASEB JOURNAL			English	Review						MANNED SPACEFLIGHT; EXOMAGNETOSPHERIC VOYAGES; RADIOBIOLOGICAL RISKS; GALACTIC COSMIC RAYS; SOLAR PARTICLE EVENTS	HEAVY-IONS; MISSIONS	The severity of radiation exposure for astronauts outside the magnetosphere poses a critical unanswered question bearing on the use of manned vehicles in extended exploration of the solar system (moon, Mars). Such prolonged exomagnetospheric voyages (1-3 years) enter a radiologic environment more severe than that of low earth orbit, an annual dose equivalent in the range of 0.3-0.5 Sv (30-50 rem), and a lifetime excess cancer fatality risk of 3-5% due to low linear-energy-transfer components of galactic cosmic radiation alone. To this calculus must be added estimates for high-atomic-number, high-energy particles, the probability of solar particle events, and the limited effectiveness of shielding. For a 3-year Mars voyage these could elevate the dose equivalent to 1.5-2.25 Sv (150-225 rem) total (0.5-0.75 Sv [50-75 rem] annual) and risks to 5-9% excess cancer fatality. Both the mission (civilian scientific research) and the alternatives (unmanned robotic devices) enter the policy decision here. This paper presents a brief review of pertinent physical and biological data and of research urgently needed before reaching a decision on this question.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Harvard Medical School								[Anonymous], 1990, HLTH EFFECTS EXPOSUR; Benton E V, 1986, Adv Space Res, V6, P315, DOI 10.1016/0273-1177(86)90307-8; CLOSE F, 1987, PARTICLE EXPLOSION; DAMON TD, 1989, INTRO SPACE SCI SPAC; FRIEDLANDER MW, 1989, COSMIC RAYS; FRY RJM, 1988, HEALTH PHYS, V55, P159, DOI 10.1097/00004032-198808000-00006; FRY RJM, 1985, RADIAT RES, V104, pS188, DOI 10.2307/3576646; FRY RJM, 1988, NATURE, V335, P305, DOI 10.1038/335305c0; GOFMAN JW, 1990, RAD INDUCED CANCER L; Letaw J R, 1989, Adv Space Res, V9, P285, DOI 10.1016/0273-1177(89)90451-1; LETAW JR, 1987, NATURE, V330, P709, DOI 10.1038/330709a0; LETAW JR, 1988, P NATO ADV STUDY I, V154, P663; NACHTWEY DS, 1989, 8TH IAA MAN SPAC S T; Nicogossian AE., 1989, SPACE PHYSL MED, V2nd/4th Edition; SCHIMMERLING W, 1989, RADIAT RES, V119, P193, DOI 10.2307/3577613; SCHIMMERLING W, 1986, MED PHYS, V13, P217, DOI 10.1118/1.595900; SHAPIRO MM, 1970, ANN REV NUCL SCI, V20, P324; SILBERBERG R, 1989, AIP C P, V186, P146; TOWNSEND LW, 1989, J SPACECRAFT ROCKETS, V26, P126, DOI 10.2514/3.26043; TOWNSEND LW, 1983, J SPACECRAFT ROCKETS, V20, P629, DOI 10.2514/3.8597; TOWNSEND LW, 1990, 20TH P INT C ENV SYS; TOWNSEND LW, 1988, NASA100620 TECHN MEM; TOWNSEND LW, 1990, NASA4167 TECHN MEM; TOWNSEND LW, 1989, 19TH INT C ENV SYST; VANALLEN JA, 1961, IGY SATELLITE REPORT, V13, P1; VANALLEN JA, 1983, ORIGINS MAGNETOSPHER; 1989, NCRP98 NAT COUNC RAD	27	23	24	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2338	2343		10.1096/fasebj.6.6.1544543	http://dx.doi.org/10.1096/fasebj.6.6.1544543			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1544543				2022-12-28	WOS:A1992HJ25200011
J	STEVENS, RG; DAVIS, S; THOMAS, DB; ANDERSON, LE; WILSON, BW				STEVENS, RG; DAVIS, S; THOMAS, DB; ANDERSON, LE; WILSON, BW			ELECTRIC-POWER, PINEAL FUNCTION, AND THE RISK OF BREAST-CANCER	FASEB JOURNAL			English	Article						BREAST CANCER; ELECTRIC POWER; PINEAL GLAND; MELATONIN	NUTRITION EXAMINATION SURVEY; MELATONIN SECRETION; FIELD EXPOSURE; DIETARY-FAT; VARYING PHOTOPERIODS; ALCOHOL-CONSUMPTION; RISING INCIDENCE; TEMPORAL TRENDS; NATIONAL-HEALTH; MAGNETIC-FIELD	Breast cancer is the leading cause of cancer death in women in the industrialized world, and the rates of breast cancer incidence are rising. Although risk is high in industrialized societies, it is low in nonindustrialized areas. The search for the causes of breast cancer has not yet yielded a convincing explanation for the geographic and temporal patterns in the occurrence of breast cancer. Generation of electric power is a hallmark of industrialization, and two products of electric power, light-at-night (LAN) and electromagnetic fields (EMF), may affect breast cancer risk. Exposure to either LAN or EMF can decrease production of melatonin by the pineal gland. Melatonin, in turn, has been shown to suppress mammary tumorigenesis in experimental animals. Moreover, recent epidemiological findings indicate an increased risk of breast cancer in workers occupationally exposed to EMF. On the basis of these considerations, it is proposed that the use of electrical power accounts, in part, for the higher risks of breast cancer in industrialized societies.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center	STEVENS, RG (corresponding author), PACIFIC NW LAB, RICHLAND, WA 99352 USA.							AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; Angeli A., 1988, PINEAL GLAND CANC, P145; ARMSTRONG B, 1976, INT J CANCER, V17, P204, DOI 10.1002/ijc.2910170209; BARTSCH C, 1985, J PINEAL RES, V2, P121, DOI 10.1111/j.1600-079X.1985.tb00633.x; BARTSCH C, 1989, CANCER, V64, P426, DOI 10.1002/1097-0142(19890715)64:2<426::AID-CNCR2820640215>3.0.CO;2-O; BECKFRIIS J, 1984, PSYCHONEUROENDOCRINO, V9, P261, DOI 10.1016/0306-4530(84)90005-2; BJARNASON O, 1974, INT J CANCER, V13, P689, DOI 10.1002/ijc.2910130513; BJOKOWSKI CJ, 1988, ACTA ENDOCRINOL-COP, V117, P470; BLASK DE, 1990, EXTREMELY LOW FREQUE, P319; BLOT WJ, 1977, J NATL CANCER I, V59, P1407, DOI 10.1093/jnci/59.5.1407; BLOT WJ, 1980, AM J PUBLIC HEALTH, V70, P833; BORG S, 1983, NEUROENDOCRINOL LETT, V5, P411; Bowman JD, 1988, APPL IND HYG, V3, P189; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; COHEN M, 1978, LANCET, V2, P814; COHEN P, 1983, CANCER RES, V43, P892; COTMAN CW, 1987, NEUROIMMUNEENDOCRINE; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; DEADMAN JE, 1988, AM IND HYG ASSOC J, V49, P409, DOI 10.1080/15298668891379981; DEMERS PA, 1991, AM J EPIDEMIOL, V134, P340, DOI 10.1093/oxfordjournals.aje.a116095; DEWAARD F, 1978, PREV MED, V7, P160, DOI 10.1016/0091-7435(78)90242-6; FLORIG HK, 1987, IEEE T POWER DELIVER, V2, P527, DOI 10.1109/TPWRD.1987.4308137; GLASS AG, 1990, J NATL CANCER I, V82, P693, DOI 10.1093/jnci/82.8.693; GREGORIO DI, 1985, JNCI-J NATL CANCER I, V75, P37; GROSSMAN CJ, 1985, SCIENCE, V227, P257, DOI 10.1126/science.3871252; GUPTA D, 1988, PINEAL GLAND CANCER; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; HAHN RA, 1991, EPIDEMIOLOGY, V2, P459, DOI 10.1097/00001648-199111000-00015; HAHN RA, 1989, AM J PUBLIC HEALTH, V79, P1503, DOI 10.2105/AJPH.79.11.1503; HEMS G, 1978, BRIT J CANCER, V37, P974, DOI 10.1038/bjc.1978.142; HIATT RA, 1984, AM J EPIDEMIOL, V120, P676, DOI 10.1093/oxfordjournals.aje.a113934; HILL SM, 1988, CANCER RES, V48, P6121; HIRAYAMA T, 1978, PREV MED, V7, P173, DOI 10.1016/0091-7435(78)90244-X; HOEL DG, 1983, AM J EPIDEMIOL, V118, P78, DOI 10.1093/oxfordjournals.aje.a113619; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KAUNE W T, 1980, Bioelectromagnetics, V1, P117, DOI 10.1002/bem.2250010203; KAUNE WT, 1987, BIOELECTROMAGNETICS, V8, P315, DOI 10.1002/bem.2250080402; Kelsey J L, 1979, Epidemiol Rev, V1, P74; Lee J A, 1967, Prog Clin Cancer, V3, P96; LEONE AM, 1988, PINEAL GLAND CANCER, P273; LERCHL A, 1990, BIOCHEM BIOPH RES CO, V169, P102, DOI 10.1016/0006-291X(90)91439-Y; LERCHL A, 1991, J PINEAL RES, V10, P109, DOI 10.1111/j.1600-079X.1991.tb00826.x; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; LEWY AJ, 1986, J NEURAL TRANSM, P311; LISSONI P, 1990, ONCOLOGY, V47, P275; LYNCH HJ, 1984, LIFE SCI, V35, P841, DOI 10.1016/0024-3205(84)90409-0; MACMAHON B, 1982, AM J EPIDEMIOL, V116, P867, DOI 10.1093/oxfordjournals.aje.a113477; MACMAHON B, 1973, JNCI-J NATL CANCER I, V50, P21, DOI 10.1093/jnci/50.1.21; MACMAHON B, 1958, CANCER, V11, P250, DOI 10.1002/1097-0142(195803/04)11:2<250::AID-CNCR2820110204>3.0.CO;2-Z; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; MASON BH, 1990, BRIT J CANCER, V61, P137, DOI 10.1038/bjc.1990.28; MATANOSKI GM, 1991, LANCET, V337, P737, DOI 10.1016/0140-6736(91)90325-J; MCDOWALL ME, 1986, BRIT J CANCER, V53, P271, DOI 10.1038/bjc.1986.45; MCGIVERN RF, 1990, TERATOLOGY, V41, P1, DOI 10.1002/tera.1420410102; MCINTYRE IM, 1990, LANCET, V335, P488, DOI 10.1016/0140-6736(90)90732-K; MCINTYRE IM, 1989, J PINEAL RES, V6, P149; MHATRE MC, 1984, JNCI-J NATL CANCER I, V72, P1411; MICOZZI MS, 1987, AM J PHYS ANTHROPOL, V73, P525, DOI 10.1002/ajpa.1330730415; MICOZZI MS, 1985, YEARB PHYS ANTHROPOL, V28, P175; MOOLGAVKAR SH, 1980, J NATL CANCER I, V65, P559; MOOLGAVKAR SH, 1978, J NATL CANCER I, V60, P1223, DOI 10.1093/jnci/60.6.1223; MOOLGAVKAR SH, 1979, J NATL CANCER I, V62, P493, DOI 10.1093/jnci/62.3.493; MORTON WE, 1982, WOMEN HEALTH, V7, P43, DOI 10.1300/J013v07n02_05; MOSS HB, 1986, LIFE SCI, V39, P2209, DOI 10.1016/0024-3205(86)90398-X; NARITA T, 1988, PINEAL GLAND CANCER, P345; PHILO R, 1988, J UROLOGY, V139, P1099, DOI 10.1016/S0022-5347(17)42795-9; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; RANSTAM J, 1990, BRIT J CANCER, V61, P120, DOI 10.1038/bjc.1990.24; REITER RJ, 1985, ANN NY ACAD SCI, V453, P215, DOI 10.1111/j.1749-6632.1985.tb11812.x; REITER RJ, 1988, LIFE SCI, V42, P2203, DOI 10.1016/0024-3205(88)90371-2; REITER RJ, 1990, EXTREMELY LOW FREQUE, P87; REITER RJ, 1981, PINEAL GLAND, V1; SANDYK R, 1989, INT J NEUROSCI, V48, P317, DOI 10.3109/00207458909002177; SANDYK R, 1989, INT J NEUROSCI, V48, P297, DOI 10.3109/00207458909002173; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SCHIPPER L, 1987, ENERGY, V12, P1197, DOI 10.1016/0360-5442(87)90026-0; SHAH PN, 1984, CANCER RES, V44, P3403; SHELLARD SA, 1989, BRIT J CANCER, V60, P288, DOI 10.1038/bjc.1989.272; STEVENS RG, 1987, NEW ENGL J MED, V317, P1287; STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569; STEVENS RG, 1982, AM J EPIDEMIOL, V115, P759, DOI 10.1093/oxfordjournals.aje.a113358; STEVENS RG, 1988, PINEAL GLAND CANCER, P233; TAMARKIN L, 1985, SCIENCE, V227, P714, DOI 10.1126/science.3881822; TAMARKIN L, 1982, SCIENCE, V216, P1003, DOI 10.1126/science.7079745; TAMARKIN L, 1981, CANCER RES, V41, P4432; Tannenbaum A, 1942, CANCER RES, V12, P468; THOMAS DB, 1990, MENOPAUSE BIOL CLIN, P101; TULINIUS H, 1978, INT J CANCER, V21, P724, DOI 10.1002/ijc.2910210609; TYNES T, 1990, LANCET, V336, P1596, DOI 10.1016/0140-6736(90)93387-5; VENA JE, 1991, AM J EPIDEMIOL, V134, P180, DOI 10.1093/oxfordjournals.aje.a116070; WATERHOUSE J, 1982, CANCER INCIDENCE 5 C, V4; WELKER HA, 1983, EXP BRAIN RES, V50, P426; WERTHEIMER N, 1987, ANN NY ACAD SCI, V502, P43, DOI 10.1111/j.1749-6632.1987.tb37645.x; WETTERBERG L, 1978, J NEURAL T         S, V13, P289; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILSON BW, 1989, LIFE SCI, V45, P1319, DOI 10.1016/0024-3205(89)90018-0; WILSON BW, 1990, J PINEAL RES, V9, P259, DOI 10.1111/j.1600-079X.1990.tb00901.x; WILSON BW, 1983, BIOELECTROMAGNETICS, V4, P293; WILSON BW, 1981, BIOELECTROMAGNETICS, V2, P371, DOI 10.1002/bem.2250020408; WILSON BW, 1990, EXTREMELY LOW FREQUE; WURTMAN RJ, 1965, SCI AM, V213, P50, DOI 10.1038/scientificamerican0765-50; 1985, EA3993 EN CONS EL PO; [No title captured]	106	153	157	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB 1	1992	6	3					853	860		10.1096/fasebj.6.3.1740235	http://dx.doi.org/10.1096/fasebj.6.3.1740235			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740235				2022-12-28	WOS:A1992HE39000008
J	LINDEN, J				LINDEN, J			STRUCTURE AND FUNCTION OF ADENOSINE-A1-RECEPTORS	FASEB JOURNAL			English	Article						XANTHINES; GTP-BINDING PROTEIN; RECEPTOR-EFFECTOR COUPLING; PURINERGIC RECEPTOR	NUCLEOTIDE-BINDING PROTEINS; HAMSTER BROWN ADIPOCYTES; ADENOSINE A1 RECEPTORS; RAT-BRAIN MEMBRANES; GUANINE-NUCLEOTIDE; CYCLIC-AMP; INDUCED ACCUMULATION; INOSITOL PHOSPHATES; BOVINE BRAIN; K+ CHANNELS	The A1 adenosine receptor is the best characterized of the widely distributed purinergic receptor family. The purified brain A1 receptor is a monomeric 35- to 36-kDa glycoprotein. A1 receptors can be clearly distinguished from A2 adenosine receptors on the basis of structure activity relationships with selective ligands. Recent structure activity data suggest that subtypes of A1 (A1a, A1b, and A3) and A2 (A2a and A2b) receptors may exist. A1 receptor-mediated responses are coupled via multiple pertussis toxin-sensitive GTP binding proteins (G proteins) to many different effectors in various tissues: adenylate cyclase, phospholipase C, Na+-Ca2+ exchange, Ca2+ channels, Cl- channels, and K+ channels. The formation of calcium-mobilizing inositol phosphates can either be enhanced or inhibited. In general, adenosine has been found to act in concert with other hormones or neurotransmitters in either an inhibitory or a stimulatory way. The myriad modulatory actions of adenosine suggest that: 1) adenosine may simultaneously produce multiple effects within the same cell; and 2) activation of A1 receptors may lead to either a decrease or an increase in the coupling of other receptors to their G proteins.			LINDEN, J (corresponding author), UNIV VIRGINIA,DEPT INTERNAL MED CARDIOL & PHYSIOL,CHARLOTTESVILLE,VA 22908, USA.							ALEXANDER SPH, 1990, J NEUROCHEM, V55, P1138, DOI 10.1111/j.1471-4159.1990.tb03116.x; BARRINGTON WW, 1989, P NATL ACAD SCI USA, V86, P6572, DOI 10.1073/pnas.86.17.6572; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BERTRAND G, 1989, BIOCHEM J, V259, P223, DOI 10.1042/bj2590223; BRECHLER V, 1990, J BIOL CHEM, V265, P16851; BRUNS RF, 1990, PURINES IN CELLULAR SIGNALLING, P126; BRUNS RF, 1987, N-S ARCH PHARMACOL, V335, P59, DOI 10.1007/BF00165037; BRUNS RF, 1987, TOPICS PERSPECTIVES, P59; CHRISTOFI FL, 1990, J PHARMACOL EXP THER, V253, P290; CLEMO HF, 1987, J PHARMACOL EXP THER, V242, P478; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; DALY JW, 1986, J MED CHEM, V29, P1520, DOI 10.1021/jm00158a034; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; DERAY G, 1990, J PHARMACOL EXP THER, V252, P631; DOLPHIN AC, 1985, NATURE, V316, P148, DOI 10.1038/316148a0; DOLPHIN AC, 1986, J PHYSIOL-LONDON, V373, P47, DOI 10.1113/jphysiol.1986.sp016034; DORFLINGER LJ, 1985, ENDOCRINOLOGY, V117, P2330, DOI 10.1210/endo-117-6-2330; ELKS ML, 1987, AM J PHYSIOL, V252, pC342, DOI 10.1152/ajpcell.1987.252.3.C342; ENJALBERT A, 1990, J BIOL CHEM, V265, P18816; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; GERBER JG, 1988, J PHARMACOL EXP THER, V244, P190; GUSTAFSSON LE, 1990, PURINES IN CELLULAR SIGNALLING, P200; HAGGBLAD J, 1987, NEUROSCI LETT, V82, P211, DOI 10.1016/0304-3940(87)90132-7; HUTCHISON AJ, 1990, J MED CHEM, V33, P1919, DOI 10.1021/jm00169a015; IJZERMAN AD, 1990, TRENDS PHARMACOL SCI, V11, P342, DOI 10.1016/0165-6147(90)90157-4; KELLEY GG, 1990, J CLIN INVEST, V85, P1629, DOI 10.1172/JCI114614; KIRSCH GE, 1990, AM J PHYSIOL, V259, pH820, DOI 10.1152/ajpheart.1990.259.3.H820; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; LEID M, 1989, MOL PHARMACOL, V35, P450; LEVY MN, 1971, CIRC RES, V29, P437, DOI 10.1161/01.RES.29.5.437; LINDEN J, 1989, TRENDS PHARMACOL SCI, V10, P114, DOI 10.1016/0165-6147(89)90209-5; LINDEN J, 1985, CIRC RES, V56, P279, DOI 10.1161/01.RES.56.2.279; LINDEN J, 1987, TOPICS PERSPECTIVES, P3; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LONDOS C, 1981, PURINERGIC RECEPTORS, P287; MACDONALD RL, 1986, J PHYSIOL-LONDON, V370, P75, DOI 10.1113/jphysiol.1986.sp015923; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MUNSHI R, 1990, MOL PHARMACOL, V38, P170; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; NAKATA H, 1989, J BIOL CHEM, V264, P16545; OKAJIMA F, 1989, FEBS LETT, V248, P145, DOI 10.1016/0014-5793(89)80450-8; OLIANAS MC, 1990, LIFE SCI, V46, P591, DOI 10.1016/0024-3205(90)90127-D; PATEL A, 1988, MOL PHARMACOL, V33, P585; PEET NP, 1990, J MED CHEM, V33, P3127, DOI 10.1021/jm00174a004; REDDINGTON M, 1989, FEBS LETT, V252, P125, DOI 10.1016/0014-5793(89)80903-2; RIBEIRO JA, 1986, PROG NEUROBIOL, V26, P179, DOI 10.1016/0301-0082(86)90015-8; RUBIO R, 1989, J NEUROCHEM, V52, P797, DOI 10.1111/j.1471-4159.1989.tb02524.x; SARGES R, 1990, J MED CHEM, V33, P2240, DOI 10.1021/jm00170a031; SAWYNOK J, 1990, BRAIN RES, V524, P187, DOI 10.1016/0006-8993(90)90689-9; SCHIMMEL RJ, 1988, BIOCHEM BIOPH RES CO, V152, P886, DOI 10.1016/S0006-291X(88)80122-0; SCHIMMEL RJ, 1987, MOL PHARMACOL, V32, P26; SCHOLFIELD CN, 1988, NEUROSCIENCE, V24, P81, DOI 10.1016/0306-4522(88)90313-2; SCHUBERT P, 1989, ADENOSINE RECEPTORS, P159; SEBASTIAO AM, 1990, BRIT J PHARMACOL, V100, P55, DOI 10.1111/j.1476-5381.1990.tb12051.x; SILINSKY EM, 1989, ADENOSINE RECEPTORS, P141; SIMPKINS I, 1986, BIOL GUIDE PRINCIPLE, P1; SPEILMAN WS, 1990, PURINES CELLULAR SIG, P220; TRIVEDI BK, 1989, J MED CHEM, V32, P8, DOI 10.1021/jm00121a002; TRUSSELL LO, 1985, P NATL ACAD SCI USA, V82, P4857, DOI 10.1073/pnas.82.14.4857; WAN W, 1990, J NEUROCHEM, V55, P1763, DOI 10.1111/j.1471-4159.1990.tb04967.x; WILLIAMS M, 1987, J PHARMACOL EXP THER, V241, P415	62	250	257	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2668	2676		10.1096/fasebj.5.12.1916091	http://dx.doi.org/10.1096/fasebj.5.12.1916091			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916091				2022-12-28	WOS:A1991GE81100007
J	RUBANYI, GM; BOTELHO, LHP				RUBANYI, GM; BOTELHO, LHP			ENDOTHELINS	FASEB JOURNAL			English	Article						ALDOSTERONE; ATRIAL NATRIURETIC PEPTIDE; BIG ENDOTHELIN; CARDIOVASCULAR DISEASES; EDRF; ENDOTHELIUM; ENDOTHELINCONVERTING-ENZYME; ENDOTHELIUM-DERIVED VASOACTIVE FACTORS; ENDOTHELIN RECEPTORS; GENE EXPRESSION; HEART; KIDNEY; NERVOUS SYSTEM; PLATELETS; PROSTACYCLIN; RENIN-ANGIOTENSIN SYSTEM; VASCULAR SMOOTH MUSCLE	VASOCONSTRICTOR PEPTIDE; BIG ENDOTHELIN-1; IMMUNOREACTIVE ENDOTHELIN; VASCULAR-RESPONSES; HYPERTENSIVE RATS; DNA-SYNTHESIS; HUMAN-PLASMA; CELLS; RELEASE; CONVERSION	The discovery of endothelium-derived relaxing (prostacyclin, EDRF) and contracting factors (EDCF) in the past decade opened up new vistas not only for basic and clinical research, but revolutionized our thinking about regulation and control of the cardiovascular system in health and disease. One of the most exciting developments in recent years was the discovery of a peptidergic EDCF and its isolation and identification as a unique 21-amino-acid peptide, endothelin (ET). This review summarizes the state-of-the-art in some areas of this fast-moving field, including the biosynthesis, tissue-specific expression, and binding of ET isoforms. Recent information about the nature of endothelin-converting enzyme (ECE) and the cloning, sequencing, and expression of ET receptor subtypes will be discussed. Based on current knowledge of the wide variety of biological actions of ETs, working hypotheses are presented about the possible autocrine, paracrine, and humoral actions of ETs and their potential role in modulating cardiovascular functions. In addition, the proposed significance of ETs in human cardiovascular diseases is summarized. In spite of the abundance of studies generated over the past 3 years and the postulated working hypotheses based on these findings, the true significance of ETs in short- and long-term regulation/modulation of tissue function remains to be determined. This will be the task of future investigations, using more sensitive detection methods and selective inhibitors of the biosynthesis and actions of ETs.	BERLEX LABS INC,CEDAR KNOLLS,NJ 07927				Moore, Nicholas/B-2368-2013; Richard, Vincent/B-1059-2014	Moore, Nicholas/0000-0003-1212-2817; Richard, Vincent/0000-0003-0590-0158				ANGGARD E, 1989, CARDIOVASC PHARM S5, V13, pS46; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; BERBINSCHI A, 1989, LANCET, V2, P46; BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CADE C, 1990, J VASC MED BIOL, V2, P174; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; CHAPLEAU MW, 1989, HYPERTENSION, V14, P336; CHAPLEAU MW, 1988, AM J MED SCI, V295, P327, DOI 10.1097/00000441-198804000-00019; COZZA EN, 1989, J CLIN INVEST, V84, P1032, DOI 10.1172/JCI114226; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; EMORI T, 1989, BIOCHEM BIOPH RES CO, V162, P217, DOI 10.1016/0006-291X(89)91984-0; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; HAEGERSTRAND A, 1989, ACTA PHYSIOL SCAND, V137, P541, DOI 10.1111/j.1748-1716.1989.tb08791.x; HICKEY KA, 1985, AM J PHYSIOL, V248, pC550, DOI 10.1152/ajpcell.1985.248.5.C550; HINOJOSALABORDE C, 1989, AM J PHYSIOL, V256, pH1742, DOI 10.1152/ajpheart.1989.256.6.H1742; HIRATA Y, 1990, BIOCHEM BIOPH RES CO, V166, P1274, DOI 10.1016/0006-291X(90)91003-B; HOM GJ, 1990, ENDOTHELIUM-DERIVED CONTRACTING FACTORS, P98; HOM GJ, 1990, ENDOTHELIUM-DERIVED CONTRACTING FACTORS, P110; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V171, P669, DOI 10.1016/0006-291X(90)91198-2; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V167, P860, DOI 10.1016/0006-291X(90)92104-8; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA T, 1988, PFLUG ARCH EUR J PHY, V413, P108, DOI 10.1007/BF00581239; KAUSER K, 1990, J PHARMACOL EXP THER, V252, P93; KAWAGUCHI H, 1990, J MOL CELL CARDIOL, V22, P839, DOI 10.1016/0022-2828(90)90115-I; KIMRA S, 1989, J CARDIOVASC PHARM, V13, pS5; KITAMURA K, 1989, BIOCHEM BIOPH RES CO, V162, P38, DOI 10.1016/0006-291X(89)91958-X; KLOOG Y, 1989, TRENDS PHARMACOL SCI, V10, P212, DOI 10.1016/0165-6147(89)90261-7; KNUEPFER MM, 1989, AM J PHYSIOL, V257, pH918, DOI 10.1152/ajpheart.1989.257.3.H918; KON V, 1989, J CLIN INVEST, V83, P1762, DOI 10.1172/JCI114079; KON V, 1990, KIDNEY INT, V37, P1487, DOI 10.1038/ki.1990.139; KOSAKA T, 1989, FEBS LETT, V249, P42, DOI 10.1016/0014-5793(89)80011-0; KOYAMA H, 1989, LANCET, V1, P991; LIDBURY PS, 1990, J VASC MED BIOL, V2, P178; MACCUMBER MW, 1989, P NATL ACAD SCI USA, V86, P7285, DOI 10.1073/pnas.86.18.7285; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; MCMAHON EG, 1990, J VASC MED BIOL, V2, P174; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; Nayler W G, 1990, Trends Pharmacol Sci, V11, P96, DOI 10.1016/0165-6147(90)90188-E; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; OTANI S, 1990, J VASC MED BIOL, V2, P204; PARKERBOTELHO LH, 1991, ENDOTHELIN; PHILLIPS P, 1991, ENDOTHELIN; RAKUGI H, 1988, BIOCHEM BIOPH RES CO, V155, P1244, DOI 10.1016/S0006-291X(88)81273-7; RUBANYI GM, 1990, BLOOD VESSELS, V27, P246; RUBANYI GM, 1991, ENDOTHELIN; RUBANYI GM, 1989, J VASC MED BIOL, V1, P315; SAIDA K, 1989, J BIOL CHEM, V264, P14613; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V161, P320, DOI 10.1016/0006-291X(89)91599-4; SAITO Y, 1990, NEW ENGL J MED, V322, P205; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAWAMURA T, 1989, BIOCHEM BIOPH RES CO, V162, P1287, DOI 10.1016/0006-291X(89)90813-9; SHICHIRI M, 1990, JAMA-J AM MED ASSOC, V263, P661, DOI 10.1001/jama.1990.03440050055027; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; TAKASHI H, 1990, 13TH SCI M INT SOC H; TOYOOKA T, 1989, CIRCULATION S, V80, P126; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; WARNER TD, 1989, J CARDIOVASC PHAR S5, V13, P85; WATANABE T, 1990, NATURE, V344, P114, DOI 10.1038/344114a0; WINQUIST RJ, 1990, ENDOTHELIUM-DERIVED CONTRACTING FACTORS, P104; WINQUIST RJ, 1989, HYPERTENSION, V14, P111, DOI 10.1161/01.HYP.14.1.111; YANAGISAWA M, 1989, BIOCHEM PHARMACOL, V38, P1877; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213; YOSHIZAWA T, 1990, SCIENCE, V247, P462, DOI 10.1126/science.2405487; YOSHIZUMI M, 1989, BIOCHEM BIOPH RES CO, V161, P859, DOI 10.1016/0006-291X(89)92679-X; YOSHIZUMI M, J VASC MED BIOL, V2, P177; 1990, RECOMMENDATIONS IUPH	77	282	284	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2713	2720		10.1096/fasebj.5.12.1916094	http://dx.doi.org/10.1096/fasebj.5.12.1916094			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916094				2022-12-28	WOS:A1991GE81100013
J	MYERS, CD				MYERS, CD			ROLE OF B-CELL ANTIGEN PROCESSING AND PRESENTATION IN THE HUMORAL IMMUNE-RESPONSE	FASEB JOURNAL			English	Article						LYMPHOCYTES-B; ANTIGEN PROCESSING; MHC CLASS-II; T-DEPENDENT ANTIGENS; HUMORAL IMMUNITY	II MHC MOLECULES; T-CELLS; LYMPHOCYTES-B; PROTEIN-SYNTHESIS; INVARIANT CHAIN; PEPTIDE COMPLEXES; PRESENTING CELLS; PRIMING INVIVO; IA; ENDOCYTOSIS	In the 25 years since it was first indicated that lymphocyte subpopulations must interact during the generation of a humoral immune response, there has been an explosion of data on the molecular mechanism of this interaction. It has been demonstrated that T cells recognize a processed antigen fragment presented by a major histocompatibility complex molecule on the surface of an antigen-presenting cell. The minimal peptides required for T cell recognition of several proteins have been determined, the molecular genetics of many of the cell surface molecules involved have been defined, and the three-dimensional structure of the T cell receptor and the major histocompatibility antigens have been deduced. Several cell types have been found to act as antigen-presenting cells, although the roles of these populations in vivo remain unclear. However, it is clear that there must be a physical interaction between a B cell and a T cell before the B cell can respond to a T-dependent antigen. This interaction requires processing and presentation of the antigen by the B cell. Therefore this review focuses on antigen processing and presentation by resting B cells, one of the key steps in initiation of a humoral immune response.			MYERS, CD (corresponding author), UNIV TENNESSEE, CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA.							ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ALLEN PM, 1987, IMMUNOL TODAY, V8, P270, DOI 10.1016/0167-5699(87)90187-3; ASHWELL JD, 1988, J IMMUNOL, V141, P2536; ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BERZOFSKY JA, 1987, IMMUNOL REV, V98, P9, DOI 10.1111/j.1600-065X.1987.tb00518.x; BHAYANI H, 1988, J IMMUNOL, V141, P377; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CHESNUT RW, 1986, ADV IMMUNOL, V39, P51; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; DRAKE JR, 1989, J IMMUNOL, V143, P1768; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HAMMERLING GJ, 1990, IMMUNOL TODAY, V11, P337; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1989, J IMMUNOL, V142, P12; JENSEN PE, 1988, J IMMUNOL, V141, P2545; JENSEN PE, 1989, J IMMUNOL, V143, P3423; KAKIUCHI T, 1990, J IMMUNOL, V145, P1653; KURTJONES EA, 1988, J IMMUNOL, V140, P3773; LENERT P, 1990, SCIENCE, V248, P1639, DOI 10.1126/science.2363051; Max E. E., 1989, Fundamental immunology., P235; METEZEAU P, 1984, EMBO J, V3, P2235, DOI 10.1002/j.1460-2075.1984.tb02121.x; METLAY JP, 1989, ADV IMMUNOL, V47, P45, DOI 10.1016/S0065-2776(08)60662-8; MYERS CD, 1987, J IMMUNOL, V138, P1705; MYERS CD, 1989, CELL IMMUNOL, V121, P174, DOI 10.1016/0008-8749(89)90015-4; MYERS CD, 1989, J MOL CELL IMMUNOL, V4, P179; NOELLE RJ, 1983, P NATL ACAD SCI-BIOL, V80, P6628, DOI 10.1073/pnas.80.21.6628; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; NOSSAL GJV, 1989, FUNDAMENTAL IMMUNOLO, P571; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; RON Y, 1987, J IMMUNOL, V138, P2848; RUUD E, 1988, J IMMUNOL, V141, P2951; SANDERS VM, 1986, J IMMUNOL, V137, P2395; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TONY HP, 1985, J EXP MED, V162, P1695, DOI 10.1084/jem.162.5.1695; Trnka Z, 1980, Monogr Allergy, V16, P245; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; VACCHIO MS, 1989, J IMMUNOL, V143, P2814; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; VITETTA ES, 1989, ADV IMMUNOL, V45, P1, DOI 10.1016/S0065-2776(08)60692-6; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x	54	43	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1991	5	11					2547	2553		10.1096/fasebj.5.11.1907935	http://dx.doi.org/10.1096/fasebj.5.11.1907935			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1907935				2022-12-28	WOS:A1991GB09400007
J	CURRAN, RD; FERRARI, FK; KISPERT, PH; STADLER, J; STUEHR, DJ; SIMMONS, RL; BILLIAR, TR				CURRAN, RD; FERRARI, FK; KISPERT, PH; STADLER, J; STUEHR, DJ; SIMMONS, RL; BILLIAR, TR			NITRIC-OXIDE AND NITRIC OXIDE-GENERATING COMPOUNDS INHIBIT HEPATOCYTE PROTEIN-SYNTHESIS	FASEB JOURNAL			English	Note						NITRIC OXIDE; HEPATOCYTES; ALBUMIN; PROTEIN SYNTHESIS; CGMP	MESSENGER-RNA LEVELS; L-ARGININE; RELAXING FACTOR; GUANYLATE-CYCLASE; ORGANIC NITRATES; MURINE MACROPHAGES; SYNTHESIS INVITRO; RAT HEPATOCYTES; CYTO-TOXICITY; KUPFFER CELLS	Hepatocytes are stimulated to produce nitric oxide (NO.) from L-arginine in response to conditioned Kupffer cell medium or a combination of cytokines. Associated with the production of NO. in hepatocytes, there is a profound decrease in total protein synthesis ([H-3]leucine incorporation). This report demonstrates that authentic NO. and the NO.-generating compound S-nitroso-N-acetylpenicillamine inhibit hepatocyte total protein synthesis in a reversible and concentration-dependent fashion. In parallel with the suppression of hepatocyte total protein synthesis, authentic NO. inhibits the production of two specific hepatocyte proteins, albumin and fibrinogen, without influencing the quantity of albumin mRNA. Although authentic NO. induces a rapid increase in cGMP levels in hepatocytes, the addition of the cGMP analog 8-bromoguanosine 3':5' cyclic monophosphate to unstimulated HC cultures does not reproduce the inhibition of total protein synthesis. These data show that NO. is the hepatocyte L-arginine metabolite that inhibits protein synthesis. Furthermore, these findings indicate that NO. does not inhibit hepatocyte protein synthesis solely through the activation of soluble guanylate cyclase but appears to affect a translational or posttranslational process.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021	Cornell University	CURRAN, RD (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT SURG,497 SCAIFE HALL,PITTSBURGH,PA 15261, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037753, R29GM044100, R01GM044100, R37GM044100] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33144] Funding Source: Medline; NIGMS NIH HHS [GM-37753, GM-44100] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; BILLIAR TR, 1989, ARCH SURG-CHICAGO, V124, P1416; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BROWN PC, 1979, J BIOL CHEM, V254, P9379; BRUNE B, 1989, J BIOL CHEM, V264, P8455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; CURRAN RD, 1990, ANN SURG, V212, P462, DOI 10.1097/00000658-199010000-00009; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DICH J, 1988, HEPATOLOGY, V8, P39, DOI 10.1002/hep.1840080109; DOHI T, 1981, BIOCHIM BIOPHYS ACTA, V673, P14, DOI 10.1016/0304-4165(81)90400-1; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GRANGER DL, 1988, J CLIN INVEST, V81, P1129, DOI 10.1172/JCI113427; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JAHN R, 1984, P NATL ACAD SCI-BIOL, V81, P1684, DOI 10.1073/pnas.81.6.1684; KAPLAN SS, 1989, BLOOD, V74, P1885; LADUCA FM, 1986, ANAL BIOCHEM, V158, P262, DOI 10.1016/0003-2697(86)90547-6; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293; MELLION BT, 1981, BLOOD, V57, P946; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; NAWA K, 1986, J BIOL CHEM, V261, P6883; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; SARGENT TD, 1981, P NATL ACAD SCI-BIOL, V78, P243, DOI 10.1073/pnas.78.1.243; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; SCHRODER H, 1985, J MOL CELL CARDIOL, V17, P931, DOI 10.1016/S0022-2828(85)80106-1; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; WEST MA, 1989, GASTROENTEROLOGY, V96, P1572, DOI 10.1016/0016-5085(89)90529-5	47	222	229	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2085	2092		10.1096/fasebj.5.7.1707021	http://dx.doi.org/10.1096/fasebj.5.7.1707021			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	1707021				2022-12-28	WOS:A1991FF44200011
J	PRZYWARA, DA; BHAVE, SV; BHAVE, A; WAKADE, TD; WAKADE, AR				PRZYWARA, DA; BHAVE, SV; BHAVE, A; WAKADE, TD; WAKADE, AR			STIMULATED RISE IN NEURONAL CALCIUM IS FASTER AND GREATER IN THE NUCLEUS THAN THE CYTOSOL	FASEB JOURNAL			English	Article						CALCIUM; GENE REGULATION; INDO-1; NUCLEUS; SYMPATHETIC NEURONS	SYMPATHETIC NEURONS; TYROSINE-HYDROXYLASE; CA-2+; CHANNELS; EXPRESSION; RELEASE; GROWTH	Calcium is an important regulator of a variety of neuronal activities including gene expression. However, it is not clear how Ca2+ influx affects intracellular Ca2+ concentration ([Ca2+]i) in the nucleus. We have taken advantage of laser photometry, the Ca2+-sensitive dye Indo-1 that allows ratio imaging, and confocal microscopy to eliminate the influences of unequal cell geometry and dye distribution. We show that Ca2+ influx into sympathetic neurons causes a significantly greater and faster increase in [Ca2+]i in the nucleus than in the cytosol. The differential increase in nuclear [Ca2+]i was apparent when Ca2+ entered from the extracellular medium during K+ deplarization, ionomycin or acetylcholine treatment, and brief periods of electrical stimulation. When intracellular Ca2+ was mobilized by caffeine the rise in nuclear [Ca2+]i was again greater than in any other region of the neuron. The increased nuclear Ca2+ levels were uniform throughout the nucleus and not associated with the nuclear envelope. The differential rise in nuclear Ca2+ was eliminated by acridine orange binding to nucleic acids. Nonexcitable cells (astrocytes, oligodendrocytes, and fibroblasts) did not show differential distribution of Ca2+ after ionomycin treatment. These results support the idea that activity-dependent gene regulation in sympathetic neurons may be mediated by changes in Ca2+ concentration at the level of the chromatin material.	WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,540 E CANFIELD,DETROIT,MI 48201	Wayne State University			Bhave, Sanjiv/K-2398-2012					AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEROD A, 1987, P NATL ACAD SCI USA, V84, P1699, DOI 10.1073/pnas.84.6.1699; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACK IB, 1985, BRAIN RES, V339, P151, DOI 10.1016/0006-8993(85)90635-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MELDOLESI J, 1988, TRENDS NEUROSCI, V11, P449, DOI 10.1016/0166-2236(88)90197-X; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; PRZYWARA DA, 1991, IN PRESS J PHYSL LON; WAKADE AR, 1982, EXP CELL RES, V140, P71, DOI 10.1016/0014-4827(82)90157-4; WAKADE AR, 1990, J NEUROCHEM, V54, P1281, DOI 10.1111/j.1471-4159.1990.tb01960.x; WAKADE TD, 1990, J NEUROCHEM, V55, P1806, DOI 10.1111/j.1471-4159.1990.tb04972.x; WALICKE PA, 1981, J NEUROSCI, V1, P343	21	90	90	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					217	222		10.1096/fasebj.5.2.2004666	http://dx.doi.org/10.1096/fasebj.5.2.2004666			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	2004666				2022-12-28	WOS:A1991EZ00200012
J	CARMINES, PK; FLEMING, JT				CARMINES, PK; FLEMING, JT			CONTROL OF THE RENAL MICROVASCULATURE BY VASOACTIVE PEPTIDES	FASEB JOURNAL			English	Article						ANGIOTENSIN-II; ARGININE VASOPRESSIN; ATRIAL NATRIURETIC PEPTIDE; BRADYKININ; CALCIUM; ENDOTHELIN; RENAL MICROCIRCULATION	ATRIAL-NATRIURETIC-PEPTIDE; ANGIOTENSIN-II RECEPTORS; GLOMERULAR MESANGIAL CELLS; MEDULLARY BLOOD-FLOW; ISOLATED RAT-KIDNEY; PROSTAGLANDIN SYNTHESIS; BINDING-SITES; AUTORADIOGRAPHIC LOCALIZATION; ANATOMICAL RELATIONSHIP; CALCIUM-ANTAGONISTS	In recent years, numerous techniques have been developed to study renal microcirculation. These technical advances have provided new insight regarding the specificity of action of vasoconstrictor peptides (angiotensin II, arginine vasopressin, endothelin) and vasodilator peptides (bradykinin, atrial natriuretic peptide) at discrete sites within the renal vascular bed. Differential signal transduction mechanisms, particularly those related to calcium regulation, appear to mediate the renal vascular actions of these compounds, both in a segment-specific and agonist-specific manner. These observations substantiate the concept that regulation of intrarenal and intraglomerular dynamics is accomplished by selective changes in pre- and postglomerular resistance induced by different endogenous peptides. This microvascular selectivity allows precise regulation of glomerular and peritubular capillary function, and ultimately exerts great influence on the volume and composition of the final urine.	UNIV LOUISVILLE, HLTH SCI CTR,SCH MED,DEPT PHYSIOL & BIOPHYS, LOUISVILLE, KY 40202 USA; CTR APPL MICROCIRCULATORY RES, LOUISVILLE, KY 40292 USA	University of Louisville	CARMINES, PK (corresponding author), TULANE UNIV, SCH MED, DEPT PHYSIOL, 1430 TULANE AVE, NEW ORLEANS, LA 70112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018426, R37HL018426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039202, R01DK039202] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06790, HL18426] Funding Source: Medline; NIDDK NIH HHS [DK39202] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALKJAER C, 1985, BRIT J PHARMACOL, V86, P447, DOI 10.1111/j.1476-5381.1985.tb08914.x; ANANDSRIVASTAVA MB, 1983, BIOCHEM BIOPH RES CO, V117, P420, DOI 10.1016/0006-291X(83)91217-2; BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; BADR KF, 1989, BIOCHEM BIOPH RES CO, V161, P776, DOI 10.1016/0006-291X(89)92667-3; BAYLIS C, 1978, CIRC RES, V43, P889, DOI 10.1161/01.RES.43.6.889; BEIERWALTES WH, 1987, AM J PHYSIOL, V252, pF794, DOI 10.1152/ajprenal.1987.252.5.F794; BEIERWALTES WH, 1988, AM J PHYSIOL, V255, pF408, DOI 10.1152/ajprenal.1988.255.3.F408; BROWN GP, 1988, AM J PHYSIOL, V255, pE16, DOI 10.1152/ajpendo.1988.255.1.E16; BUHRLE CP, 1985, AM J PHYSIOL, V249, pF272, DOI 10.1152/ajprenal.1985.249.2.F272; CAO LQ, 1990, AM J PHYSIOL, V258, pF254, DOI 10.1152/ajprenal.1990.258.2.F254; CARMINES PK, 1986, AM J PHYSIOL, V251, pF610, DOI 10.1152/ajprenal.1986.251.4.F610; CARMINES PK, 1989, AM J PHYSIOL, V256, pF1015, DOI 10.1152/ajprenal.1989.256.6.F1015; CHAI SY, 1986, AM J PHYSIOL, V250, pF753, DOI 10.1152/ajprenal.1986.250.4.F753; CHAUDHARI A, 1988, AM J PHYSIOL, V254, pF291, DOI 10.1152/ajprenal.1988.254.2.F291; COGAN MG, 1990, KIDNEY INT, V37, P1148, DOI 10.1038/ki.1990.98; COOPER CL, 1984, J PHARMACOL EXP THER, V229, P139; COOPER CL, 1985, CIRC RES, V56, P97, DOI 10.1161/01.RES.56.1.97; EDWARDS RM, 1987, AM J PHYSIOL, V252, pF317, DOI 10.1152/ajprenal.1987.252.2.F317; EDWARDS RM, 1985, AM J PHYSIOL, V248, pF183, DOI 10.1152/ajprenal.1985.248.2.F183; EDWARDS RM, 1989, AM J PHYSIOL, V256, pF274, DOI 10.1152/ajprenal.1989.256.2.F274; EDWARDS RM, 1983, AM J PHYSIOL, V244, pF526, DOI 10.1152/ajprenal.1983.244.5.F526; FLAMENBAUM W, 1979, AM J PHYSIOL, V237, pF433, DOI 10.1152/ajprenal.1979.237.6.F433; FLEMING JT, 1987, AM J PHYSIOL, V253, pF1157, DOI 10.1152/ajprenal.1987.253.6.F1157; FLEMING JT, 1989, FASEB J, V3, pA1386; FRIED TA, 1986, AM J PHYSIOL, V250, P1119; GRIENDLING KK, 1989, J CARDIOVASC PHARM, V14, pS27, DOI 10.1097/00005344-198906146-00008; HALL JE, 1986, AM J PHYSIOL, V250, pR960, DOI 10.1152/ajpregu.1986.250.6.R960; HEALY DP, 1986, AM J PHYSIOL, V250, pF573, DOI 10.1152/ajprenal.1986.250.3.F573; HELLER J, 1986, RENAL PHYSIOL BIOCH, V9, P357; HURA CE, 1988, AM J PHYSIOL, V254, pF734, DOI 10.1152/ajprenal.1988.254.5.F734; INSCHO EW, 1990, AM J PHYSIOL, V259, pF157, DOI 10.1152/ajprenal.1990.259.1.F157; JARD S, 1987, AM J PHYSIOL, V253, pF41, DOI 10.1152/ajprenal.1987.253.1.F41; JONES CR, 1989, EUR J PHARMACOL, V163, P379, DOI 10.1016/0014-2999(89)90211-2; KATOH T, 1990, AM J PHYSIOL, V258, pF397, DOI 10.1152/ajprenal.1990.258.2.F397; KIBERD B, 1987, AM J PHYSIOL, V253, pF576, DOI 10.1152/ajprenal.1987.253.3.F576; KIBERD BA, 1987, AM J PHYSIOL, V252, pF1112, DOI 10.1152/ajprenal.1987.252.6.F1112; KING AJ, 1989, AM J PHYSIOL, V256, pF1051, DOI 10.1152/ajprenal.1989.256.6.F1051; KOHZUKI M, 1989, EUR J PHARMACOL, V160, P193, DOI 10.1016/0014-2999(89)90673-0; KON V, 1989, J CLIN INVEST, V83, P1762, DOI 10.1172/JCI114079; KREMER SG, 1989, J CELL PHYSIOL, V138, P97, DOI 10.1002/jcp.1041380114; LAFFERTY HM, 1990, AM J PHYSIOL, V258, pF998, DOI 10.1152/ajprenal.1990.258.4.F998; LOUTZENHISER R, 1989, AM J PHYSIOL, V257, pF561, DOI 10.1152/ajprenal.1989.257.4.F561; LOUTZENHISER R, 1990, AM J PHYSIOL, V258, pF61, DOI 10.1152/ajprenal.1990.258.1.F61; Loutzenhiser R, 1988, J CARDIOVASC PHAR S6, V12, pS149; MARINGREZ M, 1986, NATURE, V324, P473, DOI 10.1038/324473a0; MARTIN ER, 1989, AM J PHYSIOL, V257, pF649, DOI 10.1152/ajprenal.1989.257.4.F649; MCCARTHY RT, 1990, AM J PHYSIOL, V258, pF473; MENDELSOHN FAO, 1986, FASEB J, V45, P1420; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; NASJLETTI A, 1981, KIDNEY INT, V19, P860, DOI 10.1038/ki.1981.90; NAVAR LG, 1984, KIDNEY INT, V25, P857, DOI 10.1038/ki.1984.102; NAVAR LG, 1986, FED PROC, V45, P2851; OHISHI K, 1988, AM J PHYSIOL, V255, pF415, DOI 10.1152/ajprenal.1988.255.3.F415; ORSTAVVIK TB, 1982, J HISTOCHEM CYTOCHEM, V30, P385, DOI 10.1177/30.4.7037945; PROUD D, 1981, J BIOL CHEM, V256, P634; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; REGOLI D, 1980, PHARMACOL REV, V32, P1; ROMAN RJ, 1988, AM J PHYSIOL, V255, pF690, DOI 10.1152/ajprenal.1988.255.4.F690; RUEGG UT, 1989, J CARDIOVASC PHARM, V14, pS49; SANCHEZFERRER CF, 1989, CIRC RES, V64, P790, DOI 10.1161/01.RES.64.4.790; SATO M, 1986, HYPERTENSION, V8, P762, DOI 10.1161/01.HYP.8.9.762; SCHARSCHMIDT LA, 1983, J CLIN INVEST, V71, P1756, DOI 10.1172/JCI110931; SCHOR N, 1981, KIDNEY INT, V20, P442, DOI 10.1038/ki.1981.160; SEKAR MC, 1990, BIOCHEM BIOPH RES CO, V166, P373, DOI 10.1016/0006-291X(90)91955-R; SHAYMAN JA, 1986, BIOCHEM BIOPH RES CO, V134, P299, DOI 10.1016/0006-291X(86)90562-0; SIMONSON MS, 1990, HYPERTENSION, V15, pI5, DOI 10.1161/01.HYP.15.2_Suppl.I5; STEINHAUSEN M, 1987, KIDNEY INT, V31, pS64; STEINHAUSEN M, 1989, PROG APPL MICROCIRC, V14, P25; STRANDHOY JW, 1972, P SOC EXP BIOL MED, V141, P336; TAKEZAWA K, 1987, AM J PHYSIOL, V252, pF992, DOI 10.1152/ajprenal.1987.252.6.F992; THIND GS, 1989, FASEB J, V3, pA1016; TRIBOLLET E, 1988, KIDNEY INT, V33, P959, DOI 10.1038/ki.1988.94; VELDKAMP PJ, 1988, AM J PHYSIOL, V254, pF440, DOI 10.1152/ajprenal.1988.254.3.F440; VIO CP, 1988, AM J HYPERTENS, V1, P269, DOI 10.1093/ajh/1.3.269; WIEGMANN TB, 1990, AM J PHYSIOL, V258, pF717, DOI 10.1152/ajprenal.1990.258.3.F717; YARED A, 1985, J CLIN INVEST, V75, P1477, DOI 10.1172/JCI111851; YUAN BH, 1990, AM J PHYSIOL, V258, pF741, DOI 10.1152/ajprenal.1990.258.3.F741; YUAN BH, 1990, IN PRESS AM J PHYSL; ZENSER TV, 1982, J PHARMACOL EXP THER, V221, P532; ZIMMERHACKL B, 1985, J CLIN INVEST, V76, P770, DOI 10.1172/JCI112034; ZIMMERHACKL B, 1985, KIDNEY INT, V27, P17, DOI 10.1038/ki.1985.4	81	45	45	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1990	4	15					3300	3309		10.1096/fasebj.4.15.2147667	http://dx.doi.org/10.1096/fasebj.4.15.2147667			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EN696	2147667				2022-12-28	WOS:A1990EN69600005
J	SNYDER, SH; NARAHASHI, T				SNYDER, SH; NARAHASHI, T			RECEPTOR-CHANNEL ALTERATIONS IN DISEASE - MANY CLUES, FEW CAUSES	FASEB JOURNAL			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Northwestern University; Johns Hopkins University	SNYDER, SH (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; BECKER CM, 1990, FASEB J, V4, P2767, DOI 10.1096/fasebj.4.10.2165011; GUNDLACH AL, 1990, FASEB J, V4, P2761, DOI 10.1096/fasebj.4.10.2165010; INSEL PA, 1990, FASEB J, V4, P2732, DOI 10.1096/fasebj.4.10.2197153; LUETJE CW, 1990, FASEB J, V4, P2753, DOI 10.1096/fasebj.4.10.2197155; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; PALMER AM, 1990, FASEB J, V4, P2745, DOI 10.1096/fasebj.4.10.2165009; POWELL JA, 1990, FASEB J, V4, P2798, DOI 10.1096/fasebj.4.10.2197156; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; SEEMAN P, 1990, FASEB J, V4, P2737, DOI 10.1096/fasebj.4.10.2197154; SNODGRASS S R, 1990, FASEB Journal, V4, P2775; STEINMAN L, 1990, FASEB J, V4, P2726, DOI 10.1096/fasebj.4.10.2197152; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	13	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1990	4	10					2707	2708		10.1096/fasebj.4.10.1695592	http://dx.doi.org/10.1096/fasebj.4.10.1695592			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DP783	1695592				2022-12-28	WOS:A1990DP78300004
J	Yang, YQ; Chen, L; Zheng, BH; Zhou, ST				Yang, Yuqing; Chen, Lin; Zheng, Bohao; Zhou, Shengtao			Metabolic hallmarks of natural killer cells in the tumor microenvironment and implications in cancer immunotherapy	ONCOGENE			English	Review; Early Access							NK CELLS; TGF-BETA; PHASE-I; METASTATIC MELANOMA; GLUCOSE-METABOLISM; T-CELLS; ACTIVATION; CHECKPOINT; INHIBITION; INTERLEUKIN-21	Natural killer (NK) cells belong to the early responder group against cancerous cells and viral infection. Emerging evidence reveals that distinct metabolic reprogramming occurs concurrently with activation and memory formation of NK cells. However, metabolism of NK cells is disturbed in the tumor immune microenvironment, which may promote tumor progression while limiting immunotherapy responses. In this review, we highlight how cell metabolism influences NK cell activity, the key molecular regulators of NK cell metabolism, and emerging strategies to alter metabolism to improve cytotoxicity of NK cells to kill tumor cells for cancer patients.	[Yang, Yuqing; Chen, Lin; Zhou, Shengtao] Sichuan Univ, West China Hosp 2, Dept Obstet & Gynecol, Key Lab Birth Defects & Related Dis Women & Childr, Chengdu, Peoples R China; [Yang, Yuqing; Chen, Lin; Zhou, Shengtao] Sichuan Univ, West China Hosp 2, State Key Lab Biotherapy, Chengdu, Peoples R China; [Yang, Yuqing; Chen, Lin; Zhou, Shengtao] Collaborat Innovat Ctr, Chengdu, Peoples R China; [Zheng, Bohao] Jiangnan Univ, Wuxi Sch Med, Wuxi, Peoples R China	Sichuan University; Sichuan University; Jiangnan University	Zhou, ST (corresponding author), Sichuan Univ, West China Hosp 2, Dept Obstet & Gynecol, Key Lab Birth Defects & Related Dis Women & Childr, Chengdu, Peoples R China.; Zhou, ST (corresponding author), Sichuan Univ, West China Hosp 2, State Key Lab Biotherapy, Chengdu, Peoples R China.; Zhou, ST (corresponding author), Collaborat Innovat Ctr, Chengdu, Peoples R China.	shengtaozhou@scu.edu.cn			National Natural Science Foundation of China [82273255, 81822034, 81821002, 81773119]; National Key Research and Development Program of China [2022YFA1106600, 2017YFA0106800, 2018YFA0109200]; Sichuan Science-Technology Project [22ZYZYTS0070, 2019YFH0144]; West China Second Hospital, Sichuan University [KS021, K1907]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Sichuan Science-Technology Project; West China Second Hospital, Sichuan University	This work was supported by grants from National Natural Science Foundation of China (grant #82273255, #81822034, #81821002, and #81773119 to SZ), National Key Research and Development Program of China (grant #2022YFA1106600, #2017YFA0106800 and #2018YFA0109200 to SZ), Sichuan Science-Technology Project (grant #22ZYZYTS0070 and #2019YFH0144 to SZ), Direct Scientific Research Grants from West China Second Hospital, Sichuan University (grant #KS021 and #K1907 to SZ).	Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Assmann N, 2017, NAT IMMUNOL, V18, P1197, DOI 10.1038/ni.3838; Becker-Hapak MK, 2021, CANCER IMMUNOL RES, V9, P1071, DOI 10.1158/2326-6066.CIR-20-1002; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Chatterjee S, 2018, CELL METAB, V27, P85, DOI 10.1016/j.cmet.2017.10.006; Chiappori A, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9089; Chiappori AA, 2022, CLIN CANCER RES, V28, P2313, DOI 10.1158/1078-0432.CCR-21-2742; Chini CCS, 2020, NAT METAB, V2, DOI 10.1038/s42255-020-00298-z; Cho H, 2021, CLIN CANCER RES, V27, P2947, DOI 10.1158/1078-0432.CCR-20-3418; Choi C, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02377-8; Chou CK, 2019, BONE MARROW TRANSPL, V54, P780, DOI 10.1038/s41409-019-0602-5; Christodoulou I, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003894; Cichocki F, 2018, J EXP MED, V215, P2379, DOI 10.1084/jem.20172168; Cichocki F, 2017, CANCER RES, V77, P5664, DOI 10.1158/0008-5472.CAN-17-0799; Cong JJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01989; Cong JJ, 2018, CELL METAB, V28, P243, DOI 10.1016/j.cmet.2018.06.021; Cozar B, 2021, CANCER DISCOV, V11, P34, DOI 10.1158/2159-8290.CD-20-0655; Daher M, 2021, BLOOD, V137, P624, DOI 10.1182/blood.2020007748; Davis MR, 2015, CANCER LETT, V358, P107, DOI 10.1016/j.canlet.2014.12.047; Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dong H, 2019, NAT IMMUNOL, V20, P865, DOI 10.1038/s41590-019-0388-z; Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558; Felices M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96219; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Ghaben AL, 2019, NAT REV MOL CELL BIO, V20, P242, DOI 10.1038/s41580-018-0093-z; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940; Harmon C, 2019, CANCER IMMUNOL RES, V7, P335, DOI 10.1158/2326-6066.CIR-18-0481; He XD, 2021, EUR J CANCER, V157, P114, DOI 10.1016/j.ejca.2021.08.006; Huang SJ, 2019, J BIOL CHEM, V294, P18726, DOI 10.1074/jbc.REV119.007036; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; Keating SE, 2016, J IMMUNOL, V196, P2552, DOI 10.4049/jimmunol.1501783; Keppel MP, 2015, J IMMUNOL, V194, P1954, DOI 10.4049/jimmunol.1402099; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; Kim J, 2008, MOL BIOL CELL, V19, P433, DOI 10.1091/mbc.E07-02-0182; Lee DA, 2019, IMMUNOL REV, V290, P85, DOI 10.1111/imr.12793; Lee JH, 2018, P NATL ACAD SCI USA, V115, pE12228, DOI 10.1073/pnas.1813458115; Leone RD, 2019, SCIENCE, V366, P1013, DOI 10.1126/science.aav2588; Li FM, 2020, NAT CELL BIOL, V22, P728, DOI 10.1038/s41556-020-0511-2; Lian X, 2022, MOL CANCER, V21, DOI 10.1186/s12943-021-01486-5; Lind H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000433; Littwitz-Salomon E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25715-z; Liu E, 2018, LEUKEMIA, V32, P520, DOI 10.1038/leu.2017.226; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Loftus RM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04719-2; Lokshin A, 2006, CANCER RES, V66, P7758, DOI 10.1158/0008-5472.CAN-06-0478; Lyssiotis CA, 2017, TRENDS CELL BIOL, V27, P873, DOI 10.1016/j.tcb.2017.06.003; Ma XZ, 2021, CELL METAB, V33, P1001, DOI 10.1016/j.cmet.2021.02.015; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Michelet X, 2018, NAT IMMUNOL, V19, P1330, DOI 10.1038/s41590-018-0251-7; Montaigne D, 2021, NAT REV CARDIOL, V18, P809, DOI 10.1038/s41569-021-00569-6; Morello S, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1348-8; Mossmann D, 2018, NAT REV CANCER, V18, P744, DOI 10.1038/s41568-018-0074-8; Muthalagu N, 2020, CANCER DISCOV, V10, P872, DOI 10.1158/2159-8290.CD-19-0620; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Nandagopal N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00187; Ni J, 2020, IMMUNITY, V52, P1075, DOI 10.1016/j.immuni.2020.05.001; O'Connor RS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24676-6; O'Sullivan TE, 2015, IMMUNITY, V43, P331, DOI 10.1016/j.immuni.2015.07.012; Ohta A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00109; Pan RQ, 2022, CELL, V185, P1521, DOI 10.1016/j.cell.2022.03.030; Parameswaran R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11154; Paz-Ares L, 2020, J THORAC ONCOL, V15, P1210, DOI 10.1016/j.jtho.2020.03.003; Petrella TM, 2012, J CLIN ONCOL, V30, P3396, DOI 10.1200/JCO.2011.40.0655; Poznanski SM, 2021, CELL METAB, V33, P1205, DOI 10.1016/j.cmet.2021.03.023; Putz EM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1267892; Raud B, 2018, CELL METAB, V28, P504, DOI 10.1016/j.cmet.2018.06.002; Romee R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2341; Romee R, 2012, BLOOD, V120, P4751, DOI 10.1182/blood-2012-04-419283; Rossi J, 2018, BLOOD, V132, P804, DOI 10.1182/blood-2018-01-828343; Saetersmoen ML, 2019, SEMIN IMMUNOPATHOL, V41, P59, DOI 10.1007/s00281-018-0721-x; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Schafer JR, 2019, J ALLERGY CLIN IMMUN, V143, P346, DOI 10.1016/j.jaci.2018.06.047; Scharping NE, 2021, NAT IMMUNOL, V22, P205, DOI 10.1038/s41590-020-00834-9; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Shaim H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI142116; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152; Slattery K, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002044; Slattery K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02915; Strauss J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001395; Strauss J, 2018, CLIN CANCER RES, V24, P1287, DOI 10.1158/1078-0432.CCR-17-2653; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Tang YA, 2018, P NATL ACAD SCI USA, V115, pE5990, DOI 10.1073/pnas.1801348115; Tarannum M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02655-5; Terren I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02278; Thompson JA, 2008, J CLIN ONCOL, V26, P2034, DOI 10.1200/JCO.2007.14.5193; Turiello R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001689; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Wang HP, 2020, NAT IMMUNOL, V21, P298, DOI 10.1038/s41590-019-0589-5; Wang JC, 2019, THERANOSTICS, V9, P4893, DOI 10.7150/thno.36037; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Willingham SB, 2018, CANCER IMMUNOL RES, V6, P1136, DOI 10.1158/2326-6066.CIR-18-0056; Woan KV, 2021, CELL STEM CELL, V28, P2062, DOI 10.1016/j.stem.2021.08.013; Yao Cong-Hui, 2018, PLoS Biol, V16, pe2003782, DOI 10.1371/journal.pbio.2003782; Yin ZP, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1409-3; Yoshimura A, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028571; Young A, 2018, CANCER RES, V78, P1003, DOI 10.1158/0008-5472.CAN-17-2826; Zaiatz-Bittencourt V, 2018, J IMMUNOL, V200, P3934, DOI 10.4049/jimmunol.1701461; Zhao Y, 2015, ONCOTARGETS THER, V8, P1553, DOI 10.2147/OTT.S82616; Zheng L, 2020, CLIN CANCER RES, V26, P3694, DOI 10.1158/1078-0432.CCR-19-3417; Zheng XH, 2019, NAT IMMUNOL, V20, P1656, DOI 10.1038/s41590-019-0511-1; Zhu H, 2020, CELL STEM CELL, V27, P224, DOI 10.1016/j.stem.2020.05.008	105	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02562-w	http://dx.doi.org/10.1038/s41388-022-02562-w		DEC 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6V0MV	36473909				2022-12-28	WOS:000894753200002
J	Li, DB; Wang, YH; Dong, C; Chen, T; Dong, AQ; Ren, JY; Li, WK; Shu, GG; Yang, JY; Shen, WH; Qin, L; Hu, L; Zhou, J				Li, Dongbao; Wang, Yuhong; Dong, Chao; Chen, Tao; Dong, Anqi; Ren, Jiayu; Li, Weikang; Shu, Gege; Yang, Jiaoyang; Shen, Wenhao; Qin, Lei; Hu, Lin; Zhou, Jin			CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1	ONCOGENE			English	Article; Early Access							CYSTATIN SN; CELL-PROLIFERATION; DEUBIQUITINASE; MIGRATION; INVASION	Metastasis is an important factor contributing to poor prognosis in patients with gastric cancer; yet, the molecular mechanism leading to this cell behavior is still not well understood. In this study, we explored the role of cysteine protease inhibitor SN (Cystatin SN, CST1) in promoting gastric cancer metastasis. We hypothesized that CST1 could regulate gastric cancer progression by regulating GPX4 and ferroptosis. Whole transcriptome sequencing suggested that the expression of CST1 was significantly increased in metastatic cancer, and high CST1 expression was correlated with a worse prognosis. Our data further confirmed that the overexpression of CST1 may significantly promote the migration and invasion of gastric cancer cells in vitro and enhance liver, lung, and peritoneal metastasis of gastric cancer in nude mice. Meanwhile, high expression of CST1 promoted the epithelial-mesenchymal transition (EMT) of gastric cancer cells. Mechanistically, a co-immunoprecipitation experiment combined with mass spectrometry analysis confirmed that CST1 could interact with GPX4, a key protein regulating ferroptosis. CST1 relieves GPX4 ubiquitination modification by recruiting OTUB1, improving GPX4 protein stability and reducing intracellular reactive oxygen species (ROS), thereby inhibiting ferroptosis and, in turn, promoting gastric cancer metastasis. Moreover, clinical data suggested that CST1 is significantly increased in peripheral blood and ascites of gastric cancer patients with metastasis; multivariate Cox regression model analysis showed that CST1 was an independent risk factor for the prognosis of gastric cancer patients. Overall, our results elucidated a critical pathway through which high CST1 expression protects gastric cancer cells from undergoing ferroptosis, thus promoting its progression and metastasis. CST1 may be used as a new oncological marker and potential therapeutic target for gastric cancer metastasis.	[Li, Dongbao; Dong, Chao; Chen, Tao; Dong, Anqi; Ren, Jiayu; Li, Weikang; Shu, Gege; Yang, Jiaoyang; Qin, Lei; Zhou, Jin] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China; [Wang, Yuhong] Soochow Univ, Dept Pathol, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China; [Shen, Wenhao; Hu, Lin] Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, State Key Lab Radiat Med & Protect, Sch Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China; [Shen, Wenhao; Hu, Lin] Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Sch Radiol & Interdisciplinary Sci RADX, Suzhou 215123, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Qin, L; Zhou, J (corresponding author), Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.; Hu, L (corresponding author), Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, State Key Lab Radiat Med & Protect, Sch Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China.; Hu, L (corresponding author), Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Sch Radiol & Interdisciplinary Sci RADX, Suzhou 215123, Jiangsu, Peoples R China.	qinlei@suda.edu.cn; hulin@suda.edu.cn; zhoujinsuda@suda.edu.cn		Wang, Yuhong/0000-0001-7864-0428; Li, Dongbao/0000-0002-2905-9079; Dong, Anqi/0000-0001-8503-4071	National Natural Science Foundation of China (NSFC) [81902969, 81902977, 81871952]; Jiangsu Provincial Key Research and Development Program, China [BE2020657]; Gusu Health Talents Cultivation Program, China [GSWS2019008]; Gusu Leading Talent Program for Innovation and Entrepreneurship [ZXL2021441]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX22_3218]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Key Research and Development Program, China; Gusu Health Talents Cultivation Program, China; Gusu Leading Talent Program for Innovation and Entrepreneurship; Postgraduate Research & Practice Innovation Program of Jiangsu Province	This study was supported by grants from the National Natural Science Foundation of China (NSFC, nos. 81902969, 81902977, 81871952). Jiangsu Provincial Key Research and Development Program, China (no. BE2020657). Gusu Health Talents Cultivation Program, China (no. GSWS2019008). Gusu Leading Talent Program for Innovation and Entrepreneurship (no. ZXL2021441). Postgraduate Research & Practice Innovation Program of Jiangsu Province (no. KYCX22_3218). We thank MedSci Corporation (Shanghai, China) for language editing of this article. In addition, We thank Prof. Changshun Shao and Prof. Yufang Shi, Soochow University Institutes for Translational Medicine, for their helpful discussion of our work and manuscript preparation.	Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chatterjee R, 2020, EUR J CELL BIOL, V99, DOI 10.1016/j.ejcb.2020.151073; Chen S, 2021, CANCER MANAG RES, V13, P1901, DOI 10.2147/CMAR.S277770; Chen X, 2021, NAT REV CLIN ONCOL, V18, P280, DOI 10.1038/s41571-020-00462-0; Chen X, 2021, CELL DEATH DIFFER, V28, P1135, DOI 10.1038/s41418-020-00728-1; Choi EH, 2009, CLIN CHIM ACTA, V406, P45, DOI 10.1016/j.cca.2009.05.008; Cui YF, 2019, J CELL PHYSIOL, V234, P22623, DOI 10.1002/jcp.28828; D'Arcy P, 2015, PHARMACOL THERAPEUT, V147, P32, DOI 10.1016/j.pharmthera.2014.11.002; Dai DN, 2017, J MOL MED, V95, P873, DOI 10.1007/s00109-017-1537-1; de Sousa-Pereira P, 2013, ARCH ORAL BIOL, V58, P451, DOI 10.1016/j.archoralbio.2012.12.011; Ding JJ, 2021, FEBS OPEN BIO, V11, P2186, DOI 10.1002/2211-5463.13221; Ding YH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01016-8; Ernst A, 2013, SCIENCE, V339, P590, DOI 10.1126/science.1230161; Forcina GC, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800311; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hiltke TR, 1999, J DENT RES, V78, P1401, DOI 10.1177/00220345990780080501; Jiang J, 2018, INT J ONCOL, V53, P781, DOI 10.3892/ijo.2018.4419; Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580-020-00324-8; Kim JT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.485; Kim J, 2019, ONCOL REP, V42, P202, DOI 10.3892/or.2019.7164; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Liu YF, 2019, ONCOTARGETS THER, V12, P11359, DOI 10.2147/OTT.S234328; Liu YF, 2019, ONCOTARGETS THER, V12, P3411, DOI 10.2147/OTT.S194332; Lu YQ, 2021, CANCER LETT, V522, P1, DOI 10.1016/j.canlet.2021.09.014; Nagpal A, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1177-1; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Oh BM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.100; Park J, 2020, ARCH PHARM RES, V43, P1144, DOI 10.1007/s12272-020-01281-8; Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769; Pohl SOG, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.018; Saldana M, 2019, ENDOCR-RELAT CANCER, V26, pR1, DOI 10.1530/ERC-18-0264; Smyth EC, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919867522; Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422-020-00441-1; Tseng CC, 2000, ARCH BIOCHEM BIOPHYS, V380, P133, DOI 10.1006/abbi.2000.1909; Ubellacker JM, 2020, NATURE, V585, P113, DOI 10.1038/s41586-020-2623-z; Wang Y, 2020, BIOCHEM BIOPH RES CO, V531, P581, DOI 10.1016/j.bbrc.2020.07.032; Wu J, 2019, NATURE, V572, P402, DOI 10.1038/s41586-019-1426-6; Yang L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00949; Zhou HH, 2018, ONCOGENE, V37, P3356, DOI 10.1038/s41388-018-0224-1; Zhou Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-258; Zhu D, 2021, CELL DEATH DIFFER, V28, P1773, DOI 10.1038/s41418-020-00700-z	43	0	0	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02537-x	http://dx.doi.org/10.1038/s41388-022-02537-x		NOV 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D4SV	36369321	hybrid			2022-12-28	WOS:000882683400001
J	BARNARD, RJ; YOUNGREN, JF				BARNARD, RJ; YOUNGREN, JF			REGULATION OF GLUCOSE-TRANSPORT IN SKELETAL-MUSCLE	FASEB JOURNAL			English	Article						INSULIN STIMULATION; EXERCISE; DIET; DIABETES	INSULIN-RECEPTOR KINASE; DEPENDENT DIABETES-MELLITUS; RAT ADIPOSE CELL; PLASMA-MEMBRANE; TYROSINE KINASE; SARCOLEMMAL VESICLES; EXERCISE; PROTEIN; EXPRESSION; BINDING	The entry of glucose into muscle cells is achieved primarily via a carrier-mediated system consisting of protein transport molecules. GLUT-1 transporter isoform is normally found in the sarcolemmal (SL) membrane and is thought to be involved in glucose transport under basal conditions. With insulin stimulation, glucose transport is accelerated by translocating GLUT-4 transporters from an intracellular pool out to the T-tubule and SL membranes. Activation of transporters to increase the turnover number may also be involved, but the evidence is far from conclusive. When insulin binds to its receptor, it autophosphorylates tyrosine and serine residues on the beta-subunit of the receptor. The tyrosine residues are thought to activate tyrosine kinases, which in turn phosphorylate/activate as yet unknown second messengers. Insulin receptor antibodies, however, have been reported to increase glucose transport without increasing kinase activity. Insulin resistance in skeletal muscle is a major characteristic of obesity and diabetes mellitus, especially NIDDM. A decrease in the number of insulin receptors and the ability of insulin to activate receptor tyrosine kinase has been documented in muscle from NIDDM patients. Most studies report no change in the intracellular pool of GLUT-4 transporters available for translocation to the SL. Both the quality and quantity of food consumed can regulate insulin sensitivity. A high-fat, refined sugar diet, similar to the typical U.S. diet, causes insulin resistance when compared with a low-fat, complex-carbohydrate diet. On the other hand, exercise increases insulin sensitivity. After an acute bout of exercise, glucose transport in muscle increases to the same level as with maximum insulin stimulation. Although the number of GLUT-4 transporters in the sarcolemma increases with exercise, neither insulin or its receptor is involved. After an initial acute phase, which may involve calcium as the activator, a secondary phase of increased insulin sensitivity can last for up to a day after exercise. The mechanism responsible for the increased insulin sensitivity with exercise is unknown. Regular exercise training also increases insulin sensitivity, which can be documented several days after the final bout of exercise, and again the mechanism is unknown. An increase in the muscle content of GLUT-4 transporters with training has recently been reported. Even though significant progress has been made in the past few years in understanding glucose transport in skeletal muscle, the mechanisms involved in regulating transport are far from being understood.			BARNARD, RJ (corresponding author), UNIV CALIF LOS ANGELES, DEPT PHYSIOL SCI, 1804 LIFE SCI, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA.				NIA NIH HHS [AG07592] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007592] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANNUZZI G, 1991, EUR J CLIN INVEST, V21, P6, DOI 10.1111/j.1365-2362.1991.tb01351.x; AZHAR S, 1991, AM J PHYSIOL, V260, pE1, DOI 10.1152/ajpendo.1991.260.1.E1; BAK JF, 1989, J CLIN ENDOCR METAB, V69, P158, DOI 10.1210/jcem-69-1-158; BARNARD RJ, 1990, ENDOCRINOLOGY, V126, P1921, DOI 10.1210/endo-126-4-1921; BARNARD RJ, 1983, DIABETES CARE, V6, P268, DOI 10.2337/diacare.6.3.268; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; BOYD JJ, 1990, AM J PHYSIOL, V259, pE111, DOI 10.1152/ajpendo.1990.259.1.E111; BURANT CF, 1986, J CLIN INVEST, V77, P260, DOI 10.1172/JCI112285; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CONSTABLE SH, 1988, J APPL PHYSIOL, V64, P2329, DOI 10.1152/jappl.1988.64.6.2329; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DOHM GL, 1987, AM J PHYSIOL, V252, pE170, DOI 10.1152/ajpendo.1987.252.2.E170; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; DOUEN AG, 1989, ENDOCRINOLOGY, V124, P449, DOI 10.1210/endo-124-1-449; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; DOUEN AG, 1991, ENDOCRINOLOGY, V128, P611, DOI 10.1210/endo-128-1-611; EXTON JH, 1991, DIABETES, V40, P521, DOI 10.2337/diabetes.40.5.521; FORSAYETH JR, 1987, P NATL ACAD SCI USA, V84, P3448, DOI 10.1073/pnas.84.10.3448; FREIDENBERG GR, 1988, J CLIN INVEST, V82, P1398, DOI 10.1172/JCI113744; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; FRIEDMAN JE, 1990, FEBS LETT, V268, P13, DOI 10.1016/0014-5793(90)80960-Q; FUSHIKI T, 1989, AM J PHYSIOL, V256, pE580, DOI 10.1152/ajpendo.1989.256.5.E580; FUSHIKI T, 1991, AM J PHYSIOL, V260, pE403, DOI 10.1152/ajpendo.1991.260.3.E403; GARETTO LP, 1984, AM J PHYSIOL, V246, pE471, DOI 10.1152/ajpendo.1984.246.6.E471; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; GOODYEAR LJ, 1992, IN PRESS DIABETES; GRIMDITCH GK, 1987, AM J PHYSIOL, V252, pE420, DOI 10.1152/ajpendo.1987.252.3.E420; GRIMDITCH GK, 1986, AM J PHYSIOL, V250, pE570, DOI 10.1152/ajpendo.1986.250.5.E570; GRIMDITCH GK, 1988, AM J CLIN NUTR, V48, P38, DOI 10.1093/ajcn/48.1.38; HARING H, 1989, DIABETES METAB REV, V5, P431; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; HORTON ED, 1991, DIABETES S1, V40, P791; HOUMARD JA, 1991, AM J PHYSIOL, V261, pE437, DOI 10.1152/ajpendo.1991.261.4.E437; IVY JL, 1987, EXERCISE SPORT SCI R, V15, P29; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KING PA, 1989, AM J PHYSIOL, V257, pC1128, DOI 10.1152/ajpcell.1989.257.6.C1128; KING PA, 1992, IN PRESS J CLIN INVE; KLIP A, 1989, J MEMBRANE BIOL, V111, P1, DOI 10.1007/BF01869205; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KLIP A, 1987, SARCOLEMMAL BIOCH, V2, P129; KURODA M, 1987, J BIOL CHEM, V262, P245; LEMONNIER D, 1989, DIABETES METAB, V15, P394; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; NYOMBA BL, 1990, AM J PHYSIOL, V258, pE964, DOI 10.1152/ajpendo.1990.258.6.E964; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; RODNICK KJ, 1990, DIABETES, V39, P1425, DOI 10.2337/diabetes.39.11.1425; ROSEN OM, 1989, DIABETES, V38, P1508, DOI 10.2337/diabetes.38.12.1508; SANTOS RF, 1989, METABOLISM, V38, P376, DOI 10.1016/0026-0495(89)90128-5; SCHECK SH, 1991, DIABETES RES CLIN EX, V16, P111; SLIEKER LJ, 1990, DIABETES, V39, P619, DOI 10.2337/diabetes.39.5.619; SMITH U, 1984, J BIOL CHEM, V259, P8758; STERNLICHT E, 1989, AM J PHYSIOL, V256, pE227, DOI 10.1152/ajpendo.1989.256.2.E227; STERNLICHT E, 1988, AM J PHYSIOL, V254, pE633, DOI 10.1152/ajpendo.1988.254.5.E633; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TREADWAY JL, 1989, AM J PHYSIOL, V256, pE138, DOI 10.1152/ajpendo.1989.256.1.E138; WAKE SA, 1991, DIABETES, V40, P275, DOI 10.2337/diabetes.40.2.275; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555; YOUNG JC, 1983, AM J PHYSIOL, V245, pR684, DOI 10.1152/ajpregu.1983.245.5.R684	77	87	87	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1992	6	14					3238	3244		10.1096/fasebj.6.14.1426762	http://dx.doi.org/10.1096/fasebj.6.14.1426762			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426762				2022-12-28	WOS:A1992JZ73400004
J	BOSMA, PJ; CHOWDHURY, JR; HUANG, TJ; LAHIRI, P; ELFERINK, RPJO; VANES, HHG; LEDERSTEIN, M; WHITINGTON, PF; JANSEN, PLM; CHOWDHURY, NR				BOSMA, PJ; CHOWDHURY, JR; HUANG, TJ; LAHIRI, P; ELFERINK, RPJO; VANES, HHG; LEDERSTEIN, M; WHITINGTON, PF; JANSEN, PLM; CHOWDHURY, NR			MECHANISMS OF INHERITED DEFICIENCIES OF MULTIPLE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS IN 2 PATIENTS WITH CRIGLER-NAJJAR SYNDROME, TYPE-I	FASEB JOURNAL			English	Article						UDP-GLUCURONOSYLTRANSFERASE; CRIGLER-NAJJAR SYNDROME; TYPE-I; EXON SKIPPING; BILIRUBIN; 4-NITROPHENOL; SEQUENCE ABNORMALITY; MULTIPLE ISOFORM DEFICIENCY	URIDINE-DIPHOSPHATE GLUCURONOSYLTRANSFERASE; IMPROVED ASSAY; RNA; ENZYME; RATS; DNA	Crigler-Najjar syndrome, type I (CN-I) is a potentially lethal disorder characterized by severe unconjugated hyperbilirubinemia resulting from a recessively inherited deficiency of hepatic UDP-glucuronosyl-transferase (UGT) activity toward bilirubin (B-UGT). Two forms of B-UGT exist in human liver. mRNAs for these two forms and that for another isoform with activity toward simple phenols (P-UGT) have unique 5' regions, but their 3' regions are identical. The three mRNA species are derived from a single locus; the unique 5' regions are encoded by single unique exons and the identical 3' regions consist of four consecutive exons that are shared by all three isoforms. In this paper, we determined genetic lesions in two CN-I patients with deficiency of hepatic B-UGT and P-UGT activities. In one patient, there was a C-->T substitution in exon 4 (common region) predicting the substitution of a serine residue with a phenylalanine residue; this mutation was present in the identical region of B-UGT and P-UGT mRNAs. In the other patient, a C-->T substitution in exon 2 (common region) of the B-UGT/P-UGT locus resulted in a premature stop codon. This exon (132 nt) was absent in heptic B-UGT and P-UGT mRNAs of this patient due to exon skipping during pre-mRNA processing. Sequence abnormality of three distinct mRNA species explains the abnormality of multiple UGT isoforms in these patients. Presence of identical abnormalities in the common regions of the three mRNAs is consistent with the finding that the common 3' regions of the two B-UGT mRNAs and the P-UGT mRNA are encoded by four shared exons.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MARION BESSIN LIVER RES CTR,ULLMAN 625,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL & LIVER DIS,1105 AZ AMSTERDAM,NETHERLANDS; UNIV CHICAGO,SCH MED,DEPT PEDIAT,CHICAGO,IL 60637	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Amsterdam; Academic Medical Center Amsterdam; University of Chicago			Jansen, Peter LM/I-4509-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035652, R01DK039137, R01DK034357, R37DK035652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35652, R01-DK 39137, R01-DK 34357] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; Burchell B, 1981, Methods Enzymol, V77, P188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chowdhury J. R., 1986, BILE PIGMENTS JAUNDI, P317; CHOWDHURY JR, 1982, J CLIN INVEST, V69, P595, DOI 10.1172/JCI110486; CHOWDHURY JR, 1990, PRINCIPLES PRACTICE, P1135; CHOWDHURY JR, 1991, J BIOL CHEM, V266, P18294; CRIGLER JF, 1952, PEDIATRICS, V10, P169; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; Dutton G., 1980, GLUCURONIDATION DRUG, P3; DUTTON GJ, 1981, METHOD ENZYMOL, V97, P383; ELAWADY M, 1990, J BIOL CHEM, V265, P10752; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; IRSHAID YM, 1987, MOL PHARMACOL, V31, P27; JANSEN PLM, 1992, IN PRESS HEPATOLOGY; KAUFMAN SS, 1986, HEPATOLOGY, V6, P1259, DOI 10.1002/hep.1840060606; LEAKEY JEA, 1978, BIOCHEM J, V175, P1119, DOI 10.1042/bj1751119; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P280; RAO GS, 1976, ANAL BIOCHEM, V74, P35, DOI 10.1016/0003-2697(76)90307-9; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHALABY F, 1990, P NATL ACAD SCI USA, V87, P2652, DOI 10.1073/pnas.87.7.2652; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VANES HHG, 1990, J CLIN INVEST, V85, P1199, DOI 10.1172/JCI114553; VANES HHG, 1988, CELLULAR MOL ASPECTS, P193; [No title captured]	30	102	105	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1992	6	10					2859	2863		10.1096/fasebj.6.10.1634050	http://dx.doi.org/10.1096/fasebj.6.10.1634050			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634050				2022-12-28	WOS:A1992JD95400016
J	SANAL, O; LANGE, E; TELATAR, M; SOBEL, E; SALAZARNOVAK, J; ERSOY, F; MORRISON, A; CONCANNON, P; TOLUN, A; GATTI, RA				SANAL, O; LANGE, E; TELATAR, M; SOBEL, E; SALAZARNOVAK, J; ERSOY, F; MORRISON, A; CONCANNON, P; TOLUN, A; GATTI, RA			ATAXIA-TELANGIECTASIA - LINKAGE ANALYSIS OF CHROMOSOME-11Q22-23 MARKERS IN TURKISH FAMILIES	FASEB JOURNAL			English	Article						AT GENES; GENETIC HETEROGENEITY; COMPLEMENTATION GROUPS; MONTE-CARLO ANALYSIS	REGION; MAP	To further pinpoint the location of the genes for ataxia-telangiectasia on the long arm of chromosome 11, we performed linkage analysis and analysis of recombinants of genetic haplotypes on 14 Turkish families with ataxia-telangiectasia, 12 of which were consanguineous. These studies used more than 25 polymorphic genetic markers spanning a region of the long arm of chromosome 11 that is larger than 50 cm. Seven markers gave significant LOD scores to AT: CJ5, DRD2, CJ208, S144, CD3E, PBGD, and S147, as did haplotypes created with pairs of markers DRD2/CJ5 and S144/CJ208, giving recombination fractions (0) of 0.00, 0.00, 0.05, 0.08, 0.03, 0.09, 0.07, 0.00, and 0.06, respectively. Monte Carlo analysis of these 14 Turkish families indicated the best location for a single AT gene to be within a 6 cm sex-averaged (3 cm male-specific) interval defined by STMY and CJ77; this was three times more likely than the next most likely location (peak III) at the DRD2 locus. The analysis also revealed a peak (peak II) between S147 and S133, which may represent the complementation group D gene. Recombinant analysis of haplotypes also localized an AT locus to the STMY-CJ77 interval. Taken together, these results suggest that at least two distinct AT loci exist (ATA and ATD) at 11q22-23, with perhaps a third locus, ATC, located very near to the ATA gene. This genetic heterogeneity further complicates plans to isolate the major ATA and ATC genes and to begin identifying AT carriers in the general population.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOMATH, LOS ANGELES, CA 90024 USA; HACETTEPE UNIV, DEPT PEDIAT, ANKARA, TURKEY; BOGAZICI UNIV, DEPT BIOL, ISTANBUL, TURKEY; VIRGINIA MASON RES CTR, SEATTLE, WA 98101 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Hacettepe University; Bogazici University; Virginia Mason Medical Center			Tolun, Aslihan/AAS-2250-2020	Tolun, Aslihan/0000-0002-0328-6046; Concannon, Patrick/0000-0002-5801-1859; Sobel, Eric/0000-0002-1718-0031				CHARMLEY P, 1990, GENOMICS, V6, P316, DOI 10.1016/0888-7543(90)90572-C; FOROUD T, 1991, AM J HUM GENET, V49, P1263; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; KAPP LN, 1992, IN PRESS AM J HUM GE, V50; KOMATSU K, 1990, MUTAT RES, V235, P59, DOI 10.1016/0921-8777(90)90058-D; LANGE K, 1991, AM J HUM GENET, V49, P1320; MCCONVILLE CM, 1990, NUCLEIC ACIDS RES, V18, P4335, DOI 10.1093/nar/18.15.4335; SANAL O, 1990, AM J HUM GENET, V47, P860; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SOBEL E, 1992, IN PRESS AM J HUM GE; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; ZIV Y, 1991, GENOMICS, V9, P373, DOI 10.1016/0888-7543(91)90268-J	15	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2848	2852		10.1096/fasebj.6.10.1634048	http://dx.doi.org/10.1096/fasebj.6.10.1634048			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634048				2022-12-28	WOS:A1992JD95400014
J	BRINKHOUS, KM				BRINKHOUS, KM			ADVANCES AND CONTROVERSIES IN BLOOD-COAGULATION - A 50-YEAR RETROSPECTIVE	FASEB JOURNAL			English	Editorial Material											BRINKHOUS, KM (corresponding author), UNIV N CAROLINA,DEPT PATHOL,CB 7525,BRINKHOUS BULLITT BLDG,CHAPEL HILL,NC 27599, USA.							BAUMANN C. A., 1942, Federation Proceedings. Federation of American Societies for Experimental Biology, V1, P100; Brinkhous KM, 1939, AM J MED SCI, V198, P509, DOI 10.1097/00000441-193910000-00008; Brinkhous KM, 1940, MEDICINE, V19, P329, DOI 10.1097/00005792-194009000-00001; COOPER HA, 1973, P NATL ACAD SCI USA, V70, P2326, DOI 10.1073/pnas.70.8.2326; GRAHAM JB, 1957, J EXP MED, V106, P273, DOI 10.1084/jem.106.2.273; GRAHAM JB, 1955, FED PROC, V14, P404; GRIGGS TR, 1973, P NATL ACAD SCI USA, V70, P2814, DOI 10.1073/pnas.70.10.2814; MERTZ ET, 1942, FED PROC, V1, P125; MILLS CA, 1924, ARCH INT PHYSL, V24, P73; OWEN WG, 1972, THROMB DIATH HAEMO, V27, P5502; QUICK AJ, 1942, FED PROC, V1, P130; SEEGERS WH, 1942, FED PROC, V1, P184; SMITH HP, 1933, AM J PHYSIOL, V107, P63; TOCANTINS LM, 1942, FED PROC, V1, P85	14	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					925	926		10.1096/fasebj.6.3.1740242	http://dx.doi.org/10.1096/fasebj.6.3.1740242			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740242				2022-12-28	WOS:A1992HE39000018
J	JIMENEZ, JJ; SAWAYA, ME; YUNIS, AA				JIMENEZ, JJ; SAWAYA, ME; YUNIS, AA			INTERLEUKIN-1 PROTECTS HAIR-FOLLICLES FROM CYTARABINE (ARA-C)-INDUCED TOXICITY INVIVO AND INVITRO	FASEB JOURNAL			English	Note						ALOPECIA; IL-1; IMUVERT; CHEMOTHERAPY; HAIR FOLLICLES; DNA SYNTHESIS		ImuVert, a biologic response modifier, and interleukin 1 (IL 1) have been shown to protect the young rat from alopecia induced by cytarabine (ARA-C). In the present study the inhibition by ARA-C of DNA synthesis in hair follicles (HFs) and the protective effect of ImuVert and IL 1 were investigated in vivo and in vitro. Both ImuVert and IL 1 were equally effective in protecting rats from ARA-C-induced alopecia. DNA synthesis in HFs isolated from ARA-C-treated animals was 10-20% of untreated controls. Follicles isolated from animals given either ImuVert or IL 1 before ARA-C exhibited normal DNA synthesis. In vitro, the incubation of normal rat HF with ARA-C resulted in 80% inhibition of [H-3]-thymidine uptake. Preincubation of the follicles for 1 hr with IL 1 before the addition of ARA-C completely blocked the inhibition. Preincubation with imuVert, however, was less effective in blocking the inhibition from ARA-C.	UNIV MIAMI,SCH MED,DEPT DERMATOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT ONCOL,MIAMI,FL 33101	University of Miami; University of Miami; University of Miami; University of Miami								BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; HASHIMOTO K, 1970, BRIT J DERMATOL, V83, P167, DOI 10.1111/j.1365-2133.1970.tb15041.x; HUSSEIN AM, 1990, SCIENCE, V249, P1564, DOI 10.1126/science.2218498; JAECKLE KA, 1990, J CLIN ONCOL, V8, P1408, DOI 10.1200/JCO.1990.8.8.1408; JIMENEZ JJ, 1991, FASEB J, V5, P2456, DOI 10.1096/fasebj.5.10.2065892; MCCALL CA, 1989, CYTOKINE, V1, P113; SANQUER S, 1990, J INVEST DERMATOL, V95, P700, DOI 10.1111/1523-1747.ep12514500; SAWAYA ME, 1988, J INVEST DERMATOL, V91, P101, DOI 10.1111/1523-1747.ep12463393; URBAN RW, 1836, Patent No. 57344; Warren R P, 1989, Mol Biother, V1, P145	11	13	13	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					911	913		10.1096/fasebj.6.3.1740239	http://dx.doi.org/10.1096/fasebj.6.3.1740239			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740239				2022-12-28	WOS:A1992HE39000015
J	BLACK, SD				BLACK, SD			MEMBRANE TOPOLOGY OF THE MAMMALIAN P450-CYTOCHROMES	FASEB JOURNAL			English	Article						CYTOCHROME-P450; MEMBRANE TOPOLOGY; TOPOGRAPHY; STRUCTURE-FUNCTION	SECONDARY STRUCTURE PREDICTION; RAT-LIVER CYTOCHROME-P-450; MICROSOMAL CYTOCHROME-P-450; ENDOPLASMIC-RETICULUM; SUBSTRATE-BINDING; PROTEIN; ANTIBODIES; IDENTIFICATION; INSERTION; SIGNAL	The membrane topology of the mammalian P450 cytochromes has been studied intensively by computational approaches, proteolysis, chemical modification, genetic engineering, and immunochemistry. Initial results for the cytochromes of the endoplasmic reticulum appeared to indicate a polytopic, four to eight transmembrane anchor model with an active site buried in the membrane. However, recent findings show that the microsomal P450s are bound to the endoplasmic reticulum by only one or two transmembrane peptides located at the NH2-terminal end, and that the active site is part of a large cytoplasmic domain that may have one or two additional peripheral membrane contacts. The membrane-bound state is viewed as rather rigid, and the plane of the heme lies between perpendicular and parallel to the plane of the endoplasmic reticulum. The mitochondrial P450 cytochromes lack a hydrophobic NH2 terminus in the mature form, and thus differ from the microsomal isozymes in this significant way. However, although the exact topology of cytochrome P450 in the inner mitochondrial membrane remains to be elucidated, certain features are clearly comparable to those of microsomal P450. Therefore, the membrane topology of the P450 gene superfamily may follow a similar pattern.	OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210; OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	BLACK, SD (corresponding author), OHIO STATE UNIV,COLL PHARM,DIV MED CHEM & PHARMACOGNOSY,COLUMBUS,OH 43210, USA.				NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038261] Funding Source: NIH RePORTER; NCI NIH HHS [2 P30 CA-16058-16A1] Funding Source: Medline; NIGMS NIH HHS [GM-38261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BERNHARDT R, 1988, BIOCHEM INT, V17, P1143; BERNHARDT R, 1988, BIOMED BIOCHIM ACTA, V47, P581; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; BLACK SD, 1986, CYTOCHROME P450 STRU, P161; BROWN CA, 1989, J BIOL CHEM, V264, P4442; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; DEPIERRE JW, 1977, ANNU REV BIOCHEM, V46, P201, DOI 10.1146/annurev.bi.46.070177.001221; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; ESTABROOK RW, 1981, MITOCHONDRIA MICROSO, P683; FREY AB, 1986, BIOCHEMISTRY-US, V25, P4797, DOI 10.1021/bi00365a012; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HUDECEK J, 1988, BIOCHIM BIOPHYS ACTA, V955, P361, DOI 10.1016/0167-4838(88)90216-6; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KRAINEV AG, 1988, BIOCHEM BIOPH RES CO, V150, P426, DOI 10.1016/0006-291X(88)90538-4; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LOMBARDO A, 1986, BIOCHIM BIOPHYS ACTA, V863, P71, DOI 10.1016/0005-2736(86)90388-3; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MULLER R, 1985, FEBS LETT, V187, P21, DOI 10.1016/0014-5793(85)81205-9; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SCHWARZ D, 1990, BIOCHEM BIOPH RES CO, V171, P175, DOI 10.1016/0006-291X(90)91373-Z; SHAW AW, 1988, P NATL ACAD SCI USA, V856, P7592; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TARR GE, 1983, P NATL ACAD SCI-BIOL, V80, P6552, DOI 10.1073/pnas.80.21.6552; THOMAS PE, 1977, MOL PHARMACOL, V13, P819; TRETIAKOV VE, 1989, ARCH BIOCHEM BIOPHYS, V275, P429, DOI 10.1016/0003-9861(89)90389-5; USANOV SA, 1989, FEBS LETT, V255, P125, DOI 10.1016/0014-5793(89)81074-9; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VERGERES G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P235, DOI 10.1016/0005-2736(91)90376-J; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; VERGERES G, 1989, MUTAT RES, V213, P83, DOI 10.1016/0027-5107(89)90034-1; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VLASUK GP, 1982, BIOCHEMISTRY-US, V21, P789, DOI 10.1021/bi00533a033; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701	43	133	136	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					680	685		10.1096/fasebj.6.2.1537456	http://dx.doi.org/10.1096/fasebj.6.2.1537456			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537456				2022-12-28	WOS:A1992GZ44000006
J	IRWIN, M; BROWN, M; PATTERSON, T; HAUGER, R; MASCOVICH, A; GRANT, I				IRWIN, M; BROWN, M; PATTERSON, T; HAUGER, R; MASCOVICH, A; GRANT, I			NEUROPEPTIDE-Y AND NATURAL-KILLER-CELL ACTIVITY - FINDINGS IN DEPRESSION AND ALZHEIMER CAREGIVER STRESS	FASEB JOURNAL			English	Note						DEPRESSION; LIFE STRESS; SYMPATHETIC NERVOUS SYSTEM ACTIVATION; NEURAL MODULATION OF IMMUNITY	BETA-ADRENERGIC RECEPTORS; AUTONOMIC NERVOUS-SYSTEM; CYTO-TOXICITY; ENDOGENOUS-DEPRESSION; AFFECTIVE-DISORDERS; IMMUNE FUNCTION; NK-CELL; CATECHOLAMINES; NOREPINEPHRINE; SCHIZOPHRENIA	A reduction in immune function has been found in patients with a major depressive disorder and in persons undergoing severe life stress. This study investigated the association between increased sympathetic nervous system activity and reduced natural killer (NK) cytotoxicity in depression and Alzheimer caregiver stress. NK activity and plasma concentrations of epinephrine, norepinephrine, and neuropeptide Y were measured in depressed patients (n = 19) and age- and gender-matched controls (n = 19), and in Alzheimer spousal caregivers (n = 48) and matched noncaregiver controls (n = 17). Plasma levels of neuropeptide Y, but not circulating basal levels of catecholamines, were significantly (P < 0.01) elevated in the depressed patients and in the caregivers compared with respective controls. NK activity was significantly (P < 0.001) lower in the depressed patients than in their controls, but not different between the caregivers and the noncaregiver controls. Circulating concentrations of neuropeptide Y, but not catecholamines, were inversely correlated (r = -0.31, P < 0.001) with NK activity. In addition, multiple regression analyses demonstrated that the significant (P < 0.01) association between neuropeptide Y and natural cytotoxicity was independent of the relative contribution of age and basal and dynamic levels of epinephrine and norepinephrine. These findings suggest that increased sympathetic nervous system activity and the release of neuropeptide Y may be associated with the modulation of NK cytotoxicity.	SAN DIEGO VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	IRWIN, M (corresponding author), UNIV CALIF SAN DIEGO, DEPT PSYCHIAT, LA JOLLA, CA 92093 USA.		Irwin, Michael R./H-4870-2013	Irwin, Michael R./0000-0002-1502-8431	NCRR NIH HHS [MO1RR00827] Funding Source: Medline; NIMH NIH HHS [MH30914] Funding Source: Medline; PHS HHS [M 44275-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH030914, P30MH030914] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADER R, 1990, ANNU REV PHARMACOL, V30, P561, DOI 10.1146/annurev.pa.30.040190.003021; ANDERSON JL, 1982, LANCET, V2, P1124; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Brown G., 1978, SOCIAL ORIGINS DEPRE; BROWN MR, 1989, METHOD ENZYMOL, V168, P431; BUKOWSKI JF, 1985, J EXP MED, V161, P40, DOI 10.1084/jem.161.1.40; CASTAGNE V, 1987, REGUL PEPTIDES, V19, P55, DOI 10.1016/0167-0115(87)90074-7; COFFEY RG, 1985, FED PROC, V44, P112; CUNNICK JE, 1990, PHARMACOL BIOCHEM BE, V36, P645, DOI 10.1016/0091-3057(90)90270-R; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; Dohrenwend B. S., 1981, STRESSFUL LIFE EVENT; ECKSTEIN R, 1982, CIRCULATION, V65, P1224, DOI 10.1161/01.CIR.65.6.1224; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; ENDICOTT J, 1981, ARCH GEN PSYCHIAT, V38, P98; EVANS DL, 1990, IN PRESS ARCH GEN PS; FACCHINI A, 1987, CLIN EXP IMMUNOL, V68, P340; FELTEN DL, 1987, J NEUROSCI RES, V18, P28, DOI 10.1002/jnr.490180107; FELTEN SY, 1988, PROG ALLERGY, V43, P14; FERNANDES G, 1981, J CLIN IMMUNOL, V1, P141, DOI 10.1007/BF00922755; HABU S, 1984, J IMMUNOL, V133, P2743; HAGBARTH KE, 1972, ACTA PHYSIOL SCAND, V84, P164, DOI 10.1111/j.1748-1716.1972.tb05167.x; HALPER JP, 1988, ARCH GEN PSYCHIAT, V45, P241; Hays WL, 1988, STATISTICS; HELLSTRAND K, 1985, J IMMUNOL, V134, P4095; HIRSCHFLED RMA, 1977, MODIFIED LIFE EVENTS; IRWIN M, 1987, LIFE SCI, V41, P2127, DOI 10.1016/0024-3205(87)90531-5; IRWIN M, 1988, AM J PHYSIOL, V255, pR744, DOI 10.1152/ajpregu.1988.255.5.R744; IRWIN M, 1990, ARCH GEN PSYCHIAT, V47, P713; IRWIN M, 1990, ENDOCRINOLOGY, V126, P2837, DOI 10.1210/endo-126-6-2837; IRWIN M, 1987, Brain Behavior and Immunity, V1, P98, DOI 10.1016/0889-1591(87)90011-0; IRWIN M, 1990, J PHARMACOL EXP THER, V255, P101; IRWIN M, 1990, BIOL PSYCHIAT, V27, P22, DOI 10.1016/0006-3223(90)90016-U; IRWIN M, 1987, AM J PSYCHIAT, V144, P437; IRWIN M, 1988, BIOL PSYCHIAT, V24, P173, DOI 10.1016/0006-3223(88)90272-7; KIECOLTGLASER JK, 1984, PSYCHOSOM MED, V46, P7, DOI 10.1097/00006842-198401000-00003; KRISHNARAJ R, 1987, CLIN IMMUNOL IMMUNOP, V45, P268, DOI 10.1016/0090-1229(87)90042-0; KRONFOL Z, 1986, BRIT J PSYCHIAT, V148, P70, DOI 10.1192/bjp.148.1.70; LUNDBERG JM, 1982, ACTA PHYSIOL SCAND, V116, P477, DOI 10.1111/j.1748-1716.1982.tb07171.x; LUNDBERG JM, 1985, BIOCHEM BIOPH RES CO, V133, P30, DOI 10.1016/0006-291X(85)91837-6; LUNDBERG JM, 1987, ACTA PHYSIOL SCAND, V131, P1, DOI 10.1111/j.1748-1716.1987.tb08198.x; LUNDBERG JM, 1986, NEUROSCI LETT, V63, P96, DOI 10.1016/0304-3940(86)90020-0; MAISEL AS, 1989, CLIN PHARMACOL THER, V46, P429, DOI 10.1038/clpt.1989.161; MAISEL AS, 1989, AM J MED, V86, P43, DOI 10.1016/0002-9343(89)90228-3; MANN JJ, 1985, NEW ENGL J MED, V313, P715, DOI 10.1056/NEJM198509193131202; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; PENSCHOW J, 1980, ANN RHEUM DIS, V39, P82, DOI 10.1136/ard.39.1.82; PERNOW J, 1986, CLIN PHYSIOL, V6, P561; PERNOW J, 1989, AM J PHYSIOL, V257, pH866, DOI 10.1152/ajpheart.1989.257.3.H866; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; REDER A, 1989, Brain Behavior and Immunity, V3, P110, DOI 10.1016/0889-1591(89)90011-1; ROMANO TA, 1991, BRAIN BEHAV IMMUN, V5, P116, DOI 10.1016/0889-1591(91)90011-X; SHAVIT Y, 1984, SCIENCE, V223, P188, DOI 10.1126/science.6691146; SOLT VB, 1990, AM J HYPERTENS, V3, P823, DOI 10.1093/ajh/3.11.823; STEIN M, 1991, ARCH GEN PSYCHIAT, V48, P171; URCH A, 1988, J NEUROIMMUNOL, V18, P291, DOI 10.1016/0165-5728(88)90050-1; WAEBER B, 1990, HOSP PRACT, V25, P101; WALLIN BG, 1981, NEUROLOGY, V1, P145; 1980, DIAGNOSTIC STATISTIC	58	197	198	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1991	5	15					3100	3107		10.1096/fasebj.5.15.1743441	http://dx.doi.org/10.1096/fasebj.5.15.1743441			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1743441				2022-12-28	WOS:A1991GU84200014
J	STAHL, N; PRUSINER, SB				STAHL, N; PRUSINER, SB			PRIONS AND PRION PROTEINS	FASEB JOURNAL			English	Article						SCRAPIE; AMYLOID; GLYCOSYLINOSITOL PHOSPHOLIPID	CREUTZFELDT-JAKOB DISEASE; GERSTMANN-STRAUSSLER SYNDROME; SCRAPIE-ASSOCIATED FIBRILS; AMYLOID-ENHANCING FACTOR; ASPARAGINE-LINKED GLYCOSYLATION; NEURO-BLASTOMA CELLS; ALZHEIMERS-DISEASE; TRANSGENIC MICE; CULTURED-CELLS; AGENT PROTEIN	Neurodegenerative diseases of animals and humans including scrapie, bovine spongiform encephalopathy, and Creutzfeldt-Jakob disease are caused by unusual infectious pathogens called prions. There is no evidence for a nucleic acid in the prion, but diverse experimental results indicate that a host-derived protein called PrP(Sc) is a component of the infectious particle. Experiments with scrapie-infected cultured cells show that PrP(Sc) is derived from a normal cellular protein called PrP(C) through an unknown posttranslational process. We have analyzed the amino acid sequence and posttranslational modifications of PrP(Sc) and its proteolytically truncated core PrP 27-30 to identify potential candidate modifications that could distinguish PrP(Sc) from PrP(C). The amino acid sequence of PrP 27-30 corresponds to that predicted from the gene and cDNA. Mass spectrometry of peptides derived from PrP(Sc) has revealed numerous modifications including two N-linked carbohydrate moieties, removal of an amino-terminal signal sequence, and alternative COOH termini. Most molecules contain a glycosylinositol phospholipid (GPI) attached at Ser-231 that results in removal of 23 amino acids from the COOH terminus, whereas 15% of the protein molecules are truncated to end at Gly-228. The structure of the GPI from PrP(Sc) has been analyzed and found to be novel, including the presence of sialic acid. Other experiments suggest that the N-linked oligosaccharides are not necessary for PrP(Sc) formation. Although detailed comparison of PrP(Sc) with PrP(C) is required, there is no obvious way in which any of the modifications might confer upon PrP(Sc) its unusual physical properties and allow it to act as a component of the prion. If no chemical difference is found between PrP(C) and PrP(Sc), then the two isoforms of the prion protein may differ only in their conformations or by the presence of bound cellular components.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,HSE-781,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132, R35AG008967] Funding Source: NIH RePORTER; NIA NIH HHS [AG08967, AG02132] Funding Source: Medline; NINDS NIH HHS [NS14069] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABANKWA GV, 1988, BRIT J EXP PATHOL, V69, P133; AIKEN JM, 1990, MICROBIOL REV, V54, P242, DOI 10.1128/MMBR.54.3.242-246.1990; ALIKHAN Z, 1988, ACTA NEUROPATHOL, V77, P82, DOI 10.1007/BF00688246; ALIZADEHKHIAVI K, 1988, BRIT J EXP PATHOL, V69, P605; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; AXELRAD MA, 1982, LAB INVEST, V47, P139; BALDWIN MA, 1990, ANAL BIOCHEM, V191, P174, DOI 10.1016/0003-2697(90)90405-X; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BELLINGERKAWAHARA C, 1987, VIROLOGY, V160, P271, DOI 10.1016/0042-6822(87)90072-9; BELLINGERKAWAHARA CG, 1988, VIROLOGY, V164, P537, DOI 10.1016/0042-6822(88)90569-7; BENDHEIM PE, 1988, J INFECT DIS, V158, P1198, DOI 10.1093/infdis/158.6.1198; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1990, P NATL ACAD SCI USA, V87, P7240, DOI 10.1073/pnas.87.18.7240; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARP R I, 1989, Alzheimer Disease and Associated Disorders, V3, P79, DOI 10.1097/00002093-198903010-00008; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DIENER TO, 1987, CELL, V49, P719, DOI 10.1016/0092-8674(87)90607-6; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GABIZON R, 1990, BIOCHEM J, V266, P1; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GABIZON R, 1991, Neurology, V41, P160; Gajdusek D C, 1989, Haematol Blood Transfus, V32, P481; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1971, SCIENCE, V174, P712, DOI 10.1126/science.174.4010.712; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; GORMAN JJ, 1990, VIROLOGY, V177, P339, DOI 10.1016/0042-6822(90)90489-E; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1989, SOC NEUROSCI, V15, P70; HAYNES LW, 1988, MOL NEUROBIOL, V2, P263, DOI 10.1007/BF02935635; HECKER R, 1990, 8TH INT C VIR BERL, P284; HIND CRK, 1986, AMYLOIDOSIS AMYLOID; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Kimberlin R.H., 1990, SE VIROL, V1, P153; KITAMOTO T, 1987, LAB INVEST, V57, P230; KRAG SS, 1985, CURR TOP MEMBR TRANS, V24, P181; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LEVIN M, 1973, J EXP MED, V138, P373, DOI 10.1084/jem.138.2.373; LIAO YC, 1987, LAB INVEST, V57, P370; LOWENSTEIN DH, 1990, MOL CELL BIOL, V10, P1153, DOI 10.1128/MCB.10.3.1153; MALONE TG, 1979, NATURE, V278, P575, DOI 10.1038/278575a0; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MCKINLEY M P, 1990, Journal of Cell Biology, V111, p316A; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MCKINLEY MP, 1991, J VIROL, V65, P1440; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MERZ PA, 1987, J VIROL, V61, P42, DOI 10.1128/JVI.61.1.42-49.1987; MERZ PA, 1983, ACTA NEUROPATHOL, V60, P113, DOI 10.1007/BF00685355; MERZ PA, 1984, SCIENCE, V225, P437, DOI 10.1126/science.6377496; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; NIEWOLD TA, 1987, LAB INVEST, V56, P544; NOCHLIN D, 1989, NEUROLOGY, V39, P910, DOI 10.1212/WNL.39.7.910; OESCH B, 1990, BIOCHEMISTRY-US, V29, P5848, DOI 10.1021/bi00476a029; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1988, NOVEL INFECTIOUS AGE, P209; OWEN F, 1989, LANCET, V1, P51; OWEN F, 1990, AM J HUM GENET, V46, P1215; Pattison I. H., 1965, NINDB MONOGRAPH, V2, P249; PRELLI F, 1987, BIOCHEMISTRY-US, V26, P8251, DOI 10.1021/bi00399a035; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1987, NEW ENGL J MED, V317, P1571, DOI 10.1056/NEJM198712173172505; PRUSINER SB, 1980, P NATL ACAD SCI-BIOL, V77, P2984, DOI 10.1073/pnas.77.5.2984; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1990, PRINCIPLES PRACTICE, P604; PRUSINER SB, 1990, INT ACA PAT, V32, P86; PRUSINER SB, 1984, METHOD VIROL, V8, P293; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SAFAR J, 1990, P NATL ACAD SCI USA, V87, P6373, DOI 10.1073/pnas.87.16.6373; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SHIRAHAMA T, 1990, LAB INVEST, V62, P61; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; SOMERVILLE RA, 1989, J GEN VIROL, V70, P25, DOI 10.1099/0022-1317-70-1-25; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; STAHL N, 1990, 8TH INT C VIR BERL, P60; STAHL N, 1990, MOL CELL BIOL MEMBRA, P189; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; WESTAWAY D, 1989, TRENDS NEUROSCI, V12, P221, DOI 10.1016/0166-2236(89)90126-4; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WILESMITH JW, 1988, VET REC, V123, P638	114	119	129	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2799	2807		10.1096/fasebj.5.13.1916104	http://dx.doi.org/10.1096/fasebj.5.13.1916104			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916104	Bronze			2022-12-28	WOS:A1991GJ47100008
J	RICQUIER, D; CASTEILLA, L; BOUILLAUD, F				RICQUIER, D; CASTEILLA, L; BOUILLAUD, F			MOLECULAR STUDIES OF THE UNCOUPLING PROTEIN	FASEB JOURNAL			English	Review						MITOCHONDRIA; TRANSPORT; ADIPOCYTE; THERMOGENESIS	BROWN-ADIPOSE-TISSUE; AMINO-ACID-SEQUENCE; ADP ATP TRANSLOCASE; MESSENGER-RNA; FAT MITOCHONDRIA; LIPOPROTEIN-LIPASE; CARRIER PROTEINS; EXPRESSION; NUCLEOTIDE; BOVINE	The uncoupling protein (UCP) is a proton/anion transporter found in the inner mitochondrial membrane of brown adipocyte. Although UCP has not been detected in mitochondria from any other tissue, it shares structural and catalytic properties with several other mitochondrial carrier proteins. Although UCP was discovered only recently it is one of the most extensively studied mitochondrial carrier proteins. Many tools useful in research on UCP have been developed such as antibodies and cDNAs corresponding to UCP of several animal species. More recently, the mouse, rat, and human genes encoding for UCP have been isolated and sequenced. The availability of these various tools has led to several significant observations. UCP gene expression is strongly controlled at the level of transcription by signals that are activated after the stimulation of brown adipocytes by norepinephrine. The comparison of UCP gene with the genes encoding the adenine nucleotide translocator revealed the existence of structural and evolutionary homologies. Moreover, in humans the UCP gene and one form of adenine nucleotide translocator gene are located on the same chromosome. Recently, the expression of functional UCP in various heterologous systems was achieved (Xenopus oocytes, CHO cells, yeasts). These data will facilitate studies of the structure/function relationship in UCP (identification of residues involved in H+ transport, Cl- transport, nucleotide binding, mitochondrial targeting...). Another aspect of the present research on UCP is the understanding of mechanisms that control the UCP gene and the differentiated commitment of adipose precursor cells to thermogenic brown adipocytes. The multifaceted aspects of research on UCP make this protein interesting in areas of research as different as studies of ion translocating mechanisms, cellular specificity of gene transcription, control of gene expression by neuromediators, adipocyte differentiation, and the pharmacological treatment of obesity.			RICQUIER, D (corresponding author), CNRS,UPR 1511,CTR RECH ENDOCRINOL MOLEC & DEV,9 RUE JULES HETZEL,F-92190 MEUDON,FRANCE.		Bouillaud, Frédéric R/L-3238-2017	Bouillaud, Frédéric R/0000-0002-7518-9237; Casteilla, Louis/0000-0001-9647-3248				AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; ARCH JRS, 1989, P NUTR SOC, V48, P215, DOI 10.1079/PNS19890032; ASHWELL M, 1987, INT J OBESITY, V11, P357; BALOGH AG, 1989, BIOCHEM BIOPH RES CO, V161, P156, DOI 10.1016/0006-291X(89)91574-X; BIANCO AC, 1987, J CLIN INVEST, V79, P295, DOI 10.1172/JCI112798; BIANCO AC, 1988, J BIOL CHEM, V263, P18168; BOUILLAUD F, 1988, CLIN SCI, V75, P21, DOI 10.1042/cs0750021; BOUILLAUD F, 1988, BIOCHEM BIOPH RES CO, V157, P783, DOI 10.1016/S0006-291X(88)80318-8; BOUILLAUD F, 1985, P NATL ACAD SCI USA, V82, P445, DOI 10.1073/pnas.82.2.445; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BOUILLAUD F, 1983, BIOSCIENCE REP, V3, P775, DOI 10.1007/BF01120989; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CASTEILLA L, 1989, BIOCHEM J, V257, P665, DOI 10.1042/bj2570665; CASTEILLA L, 1987, AM J PHYSIOL, V252, pE627, DOI 10.1152/ajpendo.1987.252.5.E627; CASTEILLA L, 1990, P NATL ACAD SCI USA, V87, P5124, DOI 10.1073/pnas.87.13.5124; CASTEILLA L, 1989, NUCLEIC ACIDS RES, V17, P2131, DOI 10.1093/nar/17.5.2131; CHAMPIGNY O, 1990, J NUTR, V120, P1730, DOI 10.1093/jn/120.12.1730; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DALBON P, 1988, BIOCHEMISTRY-US, V27, P5141, DOI 10.1021/bi00414a029; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P151, DOI 10.1016/0005-2728(90)90237-X; HEATON GM, 1978, EUR J BIOCHEM, V82, P515, DOI 10.1111/j.1432-1033.1978.tb12045.x; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HOLLOWAY BR, 1989, P NUTR SOC, V48, P225, DOI 10.1079/PNS19890033; HOUSTEK J, 1990, BIOCHIM BIOPHYS ACTA, V1018, P243, DOI 10.1016/0005-2728(90)90258-6; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KLAUS S, 1990, BIOCHEM BIOPH RES CO, V167, P784, DOI 10.1016/0006-291X(90)92094-G; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KOZAK CP, 1988, J BIOL CHEM, V263, P1274; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; LI K, 1989, J BIOL CHEM, V264, P13998; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; LIU XQ, 1990, J BIOL CHEM, V265, P9; LIU XQ, 1988, J CELL BIOL, V107, P503, DOI 10.1083/jcb.107.2.503; MUZZIN P, 1989, BIOCHEM J, V261, P721, DOI 10.1042/bj2610721; Nedergaard J., 1986, BROWN ADIPOSE TISSUE, P152; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OBREGON MJ, 1989, BIOCHEM J, V259, P341, DOI 10.1042/bj2590341; PRIETO S, 1990, EBEC REP, V6, P32; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; REITER RJ, 1990, ENDOCRINOLOGY, V126, P2550, DOI 10.1210/endo-126-5-2550; RIAL E, 1987, CELL BIOL REV, V11, P75; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; RICQUIER D, 1984, CLIN ENDOCRINOL META, V13, P502; RIDLEY RG, 1986, NUCLEIC ACIDS RES, V14, P4025, DOI 10.1093/nar/14.10.4025; ROTHWELL NJ, 1986, BROWN ADIPOSE TISSUE, P269; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; Trayhurn P., 1986, BROWN ADIPOSE TISSUE, P299; ZARRILLI R, 1989, MOL ENDOCRINOL, V3, P1498, DOI 10.1210/mend-3-9-1498	49	179	183	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2237	2242		10.1096/fasebj.5.9.1860614	http://dx.doi.org/10.1096/fasebj.5.9.1860614			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1860614				2022-12-28	WOS:A1991FP87200003
J	BROWN, AM				BROWN, AM			A CELLULAR LOGIC FOR G-PROTEIN-COUPLED ION CHANNEL PATHWAYS	FASEB JOURNAL			English	Article						HETEROTRIMERIC; SIGNAL TRANSDUCING; GUANINE NUCLEOTIDE-BINDING PROTEIN; PACEMAKER CURRENTS; CA-2+ CURRENTS; SMALL GUANINE NUCLEOTIDE BINDING PROTEIN; NA+ CURRENTS; K+ CURRENTS	MUSCARINIC K+-CHANNEL; GTP-BINDING PROTEINS; POTASSIUM CHANNELS; ADENYLYL CYCLASE; CALCIUM CHANNELS; ALPHA-SUBUNIT; ACTIVATION; RECEPTOR; MODULATION; CELLS	A vast array of cellular signal transduction processes arise from combinations of many different types of agonists, receptors, effectors, and coupling molecules such as heterotrimeric G proteins or protein kinases that connect receptors to effectors. Receptors, effectors, G proteins, and kinases are being newly identified at bewildering speeds and in the process it seems that our understanding of how cells respond to specific stimuli may have diminished just as we lose sight of the forest when we are buried in the trees. Evolution would suggest that there may be a logic to the response provoked by a given stimulus and, using our recently acquired knowledge of G protein pathways between receptors and ion channel effectors, I will attempt to decipher what the underlying logic might be.			BROWN, AM (corresponding author), BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36930, HL37044] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P493, DOI 10.1113/jphysiol.1988.sp017344; DUNLAP K, 1987, TRENDS NEUROSCI, V10, P241, DOI 10.1016/0166-2236(87)90166-4; EDMONDS B, 1990, SCIENCE, V250, P1142, DOI 10.1126/science.2174573; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; OKABE K, 1990, J BIOL CHEM, V265, P12854; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; POWELL T, 1976, BIOCHEM BIOPH RES CO, V72, P1218, DOI 10.1016/S0006-291X(76)80260-4; REUTER H, 1987, NEWS PHYSIOL SCI, V2, P168; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; SCHUBERT B, 1990, AM J PHYSIOL, V258, pH977, DOI 10.1152/ajpheart.1990.258.4.H977; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; YATANI A, 1990, AM J PHYSIOL, V258, pH1947, DOI 10.1152/ajpheart.1990.258.6.H1947; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660; YATANI A, 1990, IN PRESS SCIENCE; 1990, CIRCULATION, V81, P1123	33	55	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1991	5	8					2175	2179		10.1096/fasebj.5.8.1708737	http://dx.doi.org/10.1096/fasebj.5.8.1708737			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1708737				2022-12-28	WOS:A1991FK11100009
J	LEFER, AM; TSAO, PS; LEFER, DJ; MA, XL				LEFER, AM; TSAO, PS; LEFER, DJ; MA, XL			ROLE OF ENDOTHELIAL DYSFUNCTION IN THE PATHOGENESIS OF REPERFUSION INJURY AFTER MYOCARDIAL-ISCHEMIA	FASEB JOURNAL			English	Article						ENDOTHELIUM-DERIVED RELAXING FACTOR; NITRIC OXIDE; ACETYLCHOLINE; SUPEROXIDE RADICALS; NEUTROPHILS	CORONARY VASODILATOR RESPONSE; FREE-RADICAL GENERATION; RELAXING FACTOR; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; OCCLUSION-REPERFUSION; CANINE PREPARATION; SMOOTH-MUSCLE; ACETYLCHOLINE; RELAXATION	Endothelial dysfunction occurs after myocardial ischemia and reperfusion characterized by a marked reduction in endothelium-dependent relaxation (EDR) due to reduced release or action of endothelium-derived relaxing factor (EDRF). This reduced EDR occurs in coronary rings isolated from cats 2.5 min after reperfusion and in isolated perfused cat hearts 2.5 min after reperfusion. No decrease in EDR occurs before reperfusion in either preparations, suggesting that this impairment in EDR occurs during reperfusion. The decrease in EDR occurs soon after the generation of superoxide radicals by the reperfused coronary endothelium. Accumulation of neutrophils and myocardial cell injury does not occur until 3-4.5 h after reperfusion. Thus, endothelial generation of superoxide radicals acts as a trigger mechanism for endothelial dysfunction which is then amplified by neutrophil adherence and diapedesis into the ischemic region enhancing post-reperfusion ischemic injury. Agents that preserve endothelial function or inhibit neutrophil activation (e.g., superoxide dismutase, prostacyclin analogs, TGF-beta, antibodies to adhesive proteins) can protect against endothelial dysfunction and myocardial injury, if administered before reperfusion.			LEFER, AM (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHYSIOL,PHILADELPHIA,PA 19107, USA.		Lefer, David/A-6372-2012	Lefer, David/0000-0003-2293-7278	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007599] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32 HL-07599] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI N, 1988, BRIT J PHARMACOL, V95, P735, DOI 10.1111/j.1476-5381.1988.tb11699.x; BOLLI R, 1989, CIRC RES, V65, P607, DOI 10.1161/01.RES.65.3.607; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; BULKLEY GB, 1989, SPLANCHNIC ISCHEMIA, P191; BUSSE R, 1987, N-S ARCH PHARMACOL, V336, P566; DAUBER IM, 1990, CIRC RES, V66, P986, DOI 10.1161/01.RES.66.4.986; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; FORMAN MB, 1987, CIRCULATION, V76, P469, DOI 10.1161/01.CIR.76.2.469; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; FURLONG B, 1987, BRIT J PHARMACOL, V90, P687, DOI 10.1111/j.1476-5381.1987.tb11221.x; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; JOHNSON G, 1990, CIRC RES, V66, P1362, DOI 10.1161/01.RES.66.5.1362; JOHNSON G, 1990, J PHARMACOL EXP THER, V252, P35; JOHNSON G, 1989, CIRCULATION, V80, P294; KU DD, 1982, SCIENCE, V218, P576, DOI 10.1126/science.7123259; LEFER AM, 1990, SCIENCE, V249, P61, DOI 10.1126/science.2164258; LEFER AM, 1990, IN PRESS 1990 P END; LEFER AM, 1991, IN PRESS J CARDIO S3, V17, pS186; MA XL, 1990, CIRCULATION, V82, P701; MCCALL T, 1988, BRIT J PHARMACOL, V95, pP517; MEHTA JL, 1989, CIRC RES, V64, P43, DOI 10.1161/01.RES.64.1.43; MEHTA JL, 1989, AM J PHYSIOL, V257, pH1240, DOI 10.1152/ajpheart.1989.257.4.H1240; MEHTA JL, 1989, CIRC RES, V65, P1283, DOI 10.1161/01.RES.65.5.1283; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; MYERS PR, 1989, AM J PHYSIOL, V256, pH1030, DOI 10.1152/ajpheart.1989.256.4.H1030; NICHOLS WW, 1988, J MOL CELL CARDIOL, V20, P943, DOI 10.1016/S0022-2828(88)80148-2; OHLSTEIN EH, 1989, CIRC RES, V65, P917, DOI 10.1161/01.RES.65.4.917; OLAFSSON B, 1987, CIRCULATION, V76, P1135, DOI 10.1161/01.CIR.76.5.1135; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POHL U, 1986, J APPL CARDIOL, V1, P215; QUILLEN JE, 1990, CIRCULATION, V82, P586, DOI 10.1161/01.CIR.82.2.586; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; TSAO PS, 1990, CIRCULATION, V82, P1402, DOI 10.1161/01.CIR.82.4.1402; TSAO PS, 1990, AM J PHYSIOL, V259, pH1660, DOI 10.1152/ajpheart.1990.259.6.H1660; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	39	372	387	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2029	2034		10.1096/fasebj.5.7.2010056	http://dx.doi.org/10.1096/fasebj.5.7.2010056			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010056				2022-12-28	WOS:A1991FF44200004
J	STIMPFEL, TM; GERSHEY, EL				STIMPFEL, TM; GERSHEY, EL			SELECTING ANESTHETIC AGENTS FOR HUMAN SAFETY AND ANIMAL RECOVERY SURGERY	FASEB JOURNAL			English	Article						SAFETY; ANESTHESIA; ANIMAL; EXPOSURE	KETAMINE; XYLAZINE	This review provides information to scientists performing animal surgery with recommendations for choosing an appropriate anesthetic agent. The human health risks from exposure to various anesthetic agents as well as methods to minimize exposure are discussed. In brief, methoxyflurane, used with precautions, is recommended for rodent bench-top surgery. When a precision vaporizer is available, isoflurane is usually the agent of choice. Other agents, including injectables, are considered.	ROCKEFELLER UNIV,SAFETY LAB,1230 YORK AVE,NEW YORK,NY 10021; MILES INC,W HAVEN,CT 06516	Rockefeller University								GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107; MULDER JK, 1979, VET MED SMALL ANIM C, V74, P569; VANPELT LF, 1977, J AM VET MED ASSOC, V171, P842; WATERMAN AE, 1978, BRIT J ANAESTH, V50, P885, DOI 10.1093/bja/50.9.885	4	27	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1991	5	7					2099	2104		10.1096/fasebj.5.7.2010062	http://dx.doi.org/10.1096/fasebj.5.7.2010062			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FF442	2010062				2022-12-28	WOS:A1991FF44200013
J	SHOENFELD, Y; MOZES, E				SHOENFELD, Y; MOZES, E			PATHOGENIC IDIOTYPES OF AUTOANTIBODIES IN AUTOIMMUNITY - LESSONS FROM NEW EXPERIMENTAL-MODELS OF SLE	FASEB JOURNAL			English	Review									WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science	SHOENFELD, Y (corresponding author), CHAIM SHEBA MED CTR, MED DEPT B, AUTOIMMUNE DIS RES UNIT, IL-52621 TEL HASHOMER, ISRAEL.							ALCOCERVARELA J, 1982, J CLIN INVEST, V69, P1388, DOI 10.1172/JCI110579; Amital-Teplizki H, 1989, Autoimmunity, V4, P277, DOI 10.3109/08916938909014704; ANDRESCHWARTZ J, 1984, CLIN IMMUNOL IMMUNOP, V31, P261, DOI 10.1016/0090-1229(84)90246-0; BACH JF, 1989, 2ND P INT C SLE SING, P177; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BLANK M, 1990, CLIN EXP IMMUNOL, V79, P443; BLANK M, 1990, SCAND J IMMUNOL, V31, P45, DOI 10.1111/j.1365-3083.1990.tb02741.x; BLANK M, 1988, J AUTOIMMUN, V1, P683, DOI 10.1016/0896-8411(88)90059-5; BLANK M, 1989, 6TH INT C IMM BERL; BLANK M, 1990, J RHEUMATOL, V69, P228; BOCCHIERI MH, 1984, CELL IMMUNOL, V88, P453, DOI 10.1016/0008-8749(84)90177-1; CATHELY G, 1986, CLIN RHEUMATOL, V5, P482; Ebling F M, 1989, Int Rev Immunol, V5, P79, DOI 10.3109/08830188909086990; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; FRICKE H, 1990, IN PRESS INT IMMUNOL; HAHN BH, 1983, J CLIN INVEST, V71, P1728, DOI 10.1172/JCI110927; HUANG YP, 1988, J IMMUNOL, V141, P827; ISENBERG D, 1985, J IMMUNOL, V135, P261; Isenberg D A, 1988, Autoimmunity, V1, P67, DOI 10.3109/08916938808997178; ISENBERG DA, 1984, LANCET, V2, P417; ISENBERG DA, 1985, J CLIN INVEST, V76, P287, DOI 10.1172/JCI111959; ISENBERG DA, 1984, ARTHRITIS RHEUM, V27, P132, DOI 10.1002/art.1780270203; LUCAS JA, 1985, J EXP MED, V147, P1568; MENDLOVIC S, 1989, EUR J IMMUNOL, V19, P729, DOI 10.1002/eji.1830190424; MENDLOVIC S, 1988, P NATL ACAD SCI USA, V85, P2260, DOI 10.1073/pnas.85.7.2260; MENDLOVIC S, 1990, IN PRESS IMMUNOLOGY; MOZES E, 1988, ISRAEL J MED SCI, V24, P741; PACHNER AR, 1984, CLIN EXP IMMUNOL, V56, P659; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P321, DOI 10.1172/JCI111704; SHALEV Y, 1985, CLIN EXP IMMUNOL, V60, P355; SHOENFELD Y, 1983, NEW ENGL J MED, V308, P414, DOI 10.1056/NEJM198302243080802; SHOENFELD Y, 1988, IMMUNOL LETT, V19, P77, DOI 10.1016/0165-2478(88)90123-X; SHOENFELD Y, 1985, EUR J IMMUNOL, V15, P1024, DOI 10.1002/eji.1830151012; SHOENFELD Y, 1982, J CLIN INVEST, V70, P205, DOI 10.1172/JCI110595; SHOENFELD Y, 1989, CLIN IMMUNOL IMMUNOP, V51, P313, DOI 10.1016/0090-1229(89)90030-5; SHOENFELD Y, 1983, J EXP MED, V158, P718, DOI 10.1084/jem.158.3.718; SHOENFELD Y, 1986, CLIN EXP IMMUNOL, V66, P255; SHOENFELD Y, 1989, RHEUMATOLOGY, V1, P360; SHOENFELD Y, 1989, MOSAIC AUTOIMMUNITY, P1; SMITH E, 1987, CLIN EXP IMMUNOL, V67, P319; SOLOMON G, 1983, P NATL ACAD SCI-BIOL, V80, P850, DOI 10.1073/pnas.80.3.850; STEINBERG AD, 1980, J IMMUNOL, V125, P871; SUENAGA R, 1988, J IMMUNOL, V140, P3508; TOMER Y, 1990, IN PRESS J AUTOIMMUN; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117	46	84	87	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1990	4	9					2646	2651		10.1096/fasebj.4.9.2140806	http://dx.doi.org/10.1096/fasebj.4.9.2140806			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DJ088	2140806				2022-12-28	WOS:A1990DJ08800008
J	Fattore, L; Cafaro, G; Di Martile, M; Campani, V; Sacconi, A; Liguoro, D; Marra, E; Bruschini, S; Stoppoloni, D; Cirombella, R; De Nicola, F; Pallocca, M; Ruggiero, CF; Castaldo, V; Catizone, A; Del Bufalo, D; Viglietto, G; Vecchione, A; Blandino, G; Aurisicchio, L; Fanciulli, M; Ascierto, PA; De Rosa, G; Mancini, R; Ciliberto, G				Fattore, Luigi; Cafaro, Giordana; Di Martile, Marta; Campani, Virginia; Sacconi, Andrea; Liguoro, Domenico; Marra, Emanuele; Bruschini, Sara; Stoppoloni, Daniela; Cirombella, Roberto; De Nicola, Francesca; Pallocca, Matteo; Ruggiero, Ciro F.; Castaldo, Vittorio; Catizone, Angiolina; Del Bufalo, Donatella; Viglietto, Giuseppe; Vecchione, Andrea; Blandino, Giovanni; Aurisicchio, Luigi; Fanciulli, Maurizio; Ascierto, Paolo A.; De Rosa, Giuseppe; Mancini, Rita; Ciliberto, Gennaro			Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance	ONCOGENE			English	Article; Early Access							TUMOR-ASSOCIATED MACROPHAGES; ACQUIRED-RESISTANCE; METASTATIC MELANOMA; CANCER; EXPRESSION; COMBINATION; MECHANISMS; MIR-204-5P; EVOLUTION; ANTI-PD-1	BRAF-mutated melanoma relapsing after targeted therapies is an aggressive disease with unmet clinical need. Hence the need to identify novel combination therapies able to overcome drug resistance. miRNAs have emerged as orchestrators of non-genetic mechanisms adopted by melanoma cells to challenge therapies. In this context we previously identified a subset of oncosuppressor miRNAs downregulated in drug-resistant melanomas. Here we demonstrate that lipid nanoparticles co-encapsulating two of them, miR-199-5p and miR-204-5p, inhibit tumor growth both in vitro and in vivo in combination with target therapy and block the development of drug resistance. Mechanistically they act by directly reducing melanoma cell growth and also indirectly by hampering the recruitment and reprogramming of pro-tumoral macrophages. Molecularly, we demonstrate that the effects on macrophages are mediated by the dysregulation of a newly identified miR-204-5p-miR-199b-5p/CCL5 axis. Finally, we unveiled that M2 macrophages programs are molecular signatures of resistance and predict response to therapy in patients. Overall, these findings have strong translational implications to propose new combination therapies making use of RNA therapeutics for metastatic melanoma patients.	[Fattore, Luigi; De Nicola, Francesca; Fanciulli, Maurizio] IRCCS Regina Elena Natl Canc Inst, Dept Res, SAFU Lab, Adv Diagnost & Technol Innovat,Translat Res Area, I-00144 Rome, Italy; [Cafaro, Giordana; Di Martile, Marta; Del Bufalo, Donatella] IRCCS Regina Elena Natl Canc Inst, Preclin Models & New Therapeut Agents Unit, Via Elio Chianesi 53, I-00144 Rome, Italy; [Campani, Virginia; De Rosa, Giuseppe] Univ Napoli Federico II, Dipartimento Farm, Via D Montesano 49, I-80131 Naples, Italy; [Sacconi, Andrea; Pallocca, Matteo] IRCCS Regina Elena Natl Canc Inst, Clin Trial Ctr, Biostat & Bioinformat Unit, I-00144 Rome, Italy; [Liguoro, Domenico; Mancini, Rita] Sapienza Univ Rome, Dept Clin & Mol Med, I-00161 Rome, Italy; [Liguoro, Domenico; Bruschini, Sara; Cirombella, Roberto; Vecchione, Andrea; Mancini, Rita] Sapienza Univ Rome, Fac Med & Psychol, Dept Clin & Mol Med, St Andrea Hosp, I-00118 Rome, Italy; [Marra, Emanuele; Stoppoloni, Daniela; Aurisicchio, Luigi] Takis Srl, I-00128 Rome, Italy; [Ruggiero, Ciro F.; Ascierto, Paolo A.] Ist Nazl Tumori IRCCS Fdn Pascale, Unit Melanoma Canc Immunotherapy & Dev Therapeut, I-80131 Naples, Italy; [Castaldo, Vittorio; Catizone, Angiolina] Sapienza Univ Rome, Dept Anat Histol Forens Med & Orthoped, I-00161 Rome, Italy; [Viglietto, Giuseppe] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy; [Blandino, Giovanni] IRCCS Regina Elena Natl Canc Inst, Oncogen & Epigenet Unit, I-00144 Rome, Italy; [Ciliberto, Gennaro] IRCSS Regina Elena Natl Canc Inst, Sci Directorate, I-00144 Rome, Italy	University of Naples Federico II; Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Fondazione Pascale; Sapienza University Rome; Magna Graecia University of Catanzaro	Ciliberto, G (corresponding author), IRCSS Regina Elena Natl Canc Inst, Sci Directorate, I-00144 Rome, Italy.	gennaro.ciliberto@ifo.it	Fattore, Luigi/K-7791-2016	Fattore, Luigi/0000-0002-9245-0126	Italian Association for Cancer Research (AIRC) [IG19865, IG24451]; Lazio Innova [85-2017-13750, A0375-2020-36657]; Italian Minister of Health grant PRIN [2017HWTP2K]; Lega Italiana per la Lotta ai Tumori (LILT) [2021U0001637]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Lazio Innova; Italian Minister of Health grant PRIN(Ministry of Education, Universities and Research (MIUR)); Lega Italiana per la Lotta ai Tumori (LILT)	This study was supported by Italian Association for Cancer Research (AIRC) grants IG19865 to G. Ciliberto and IG24451 to R. Mancini and by the Lazio Innova grants 2018 n. 85-2017-13750 and 2020 n. A0375-2020-36657 to R. Mancini and by Italian Minister of Health grant PRIN 2017 (Prot. 2017HWTP2K) to G. Ciliberto and R. Mancini. The study was also supported by Lega Italiana per la Lotta ai Tumori (LILT) grant n. 2021U0001637 to L. Fattore.	Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808; Bragelmann J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25728-8; Bruschini S, 2020, J CELL PHYSIOL, V235, P1877, DOI 10.1002/jcp.29121; Cerezo-Wallis D, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1073-3; De Luca T, 2016, MOL CARCINOGEN, V55, P2304, DOI 10.1002/mc.22437; Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1; Di Martile M, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000489; Di Mitri D, 2019, CELL REP, V28, P2156, DOI 10.1016/j.celrep.2019.07.068; Diaz-Martinez M, 2018, CANCER RES, V78, P1017, DOI 10.1158/0008-5472.CAN-17-1318; Duan ZJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00506-6; Dummer R, 2022, J CLIN ONCOL, V40, P1428, DOI 10.1200/JCO.21.01601; Erkes DA, 2020, CANCER DISCOV, V10, P254, DOI 10.1158/2159-8290.CD-19-0672; Fattore L, 2020, CANCERS, V12, DOI 10.3390/cancers12113368; Fattore L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061930; Fattore L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2048-5; Fattore L, 2019, CELL DEATH DIFFER, V26, P1267, DOI 10.1038/s41418-018-0205-5; Fattore L, 2017, CYTOKINE GROWTH F R, V36, P39, DOI 10.1016/j.cytogfr.2017.05.003; Fattore L, 2017, ONCOTARGET, V8, P22262, DOI 10.18632/oncotarget.14763; Fattore L, 2016, P NATL ACAD SCI USA, V113, pE5005, DOI 10.1073/pnas.1607753113; Fattore L, 2015, ONCOTARGET, V6, P24823, DOI 10.18632/oncotarget.4485; Fekete JT, 2019, INT J CANCER, V145, P3140, DOI 10.1002/ijc.32369; Ferrucci PF, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001806; Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29; Galasso M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0819-8; Gilot D, 2017, NAT CELL BIOL, V19, P1348, DOI 10.1038/ncb3623; Gogas H, 2020, J CLIN ONCOL, V38; Gutzmer R, 2020, LANCET, V395, P1835, DOI 10.1016/S0140-6736(20)30934-X; Haas L, 2021, NAT CANCER, V2, P693, DOI 10.1038/s43018-021-00221-9; Hong BS, 2019, CANCER RES, V79, P1520, DOI 10.1158/0008-5472.CAN-18-0891; Hong DVS, 2020, BRIT J CANCER, V122, P1630, DOI 10.1038/s41416-020-0802-1; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Johnson DB, 2017, J IMMUNOTHER, V40, P31, DOI 10.1097/CJI.0000000000000148; Kakavand H, 2017, CLIN CANCER RES, V23, P6054, DOI 10.1158/1078-0432.CCR-16-1688; Kohli K, 2022, CANCER GENE THER, V29, P10, DOI 10.1038/s41417-021-00303-x; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lau PKH, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002995; Lee JS, 2021, CELL, V184, P2487, DOI 10.1016/j.cell.2021.03.030; Li H, 2019, BIOCHEM CELL BIOL, V97, P109, DOI 10.1139/bcb-2018-0141; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Liguoro D, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188440; Lin X, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01397; Liu GT, 2015, CANCER LETT, V357, P476, DOI 10.1016/j.canlet.2014.11.015; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Marin-Bejar O, 2021, CANCER CELL, V39, P1135, DOI 10.1016/j.ccell.2021.05.015; Mason R, 2020, PIGM CELL MELANOMA R, V33, P358, DOI 10.1111/pcmr.12831; Molgora M, 2021, MED-CAMBRIDGE, V2, P666, DOI 10.1016/j.medj.2021.05.001; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; Morris JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090353; Ozga AJ, 2021, IMMUNITY, V54, P859, DOI 10.1016/j.immuni.2021.01.012; Pisanu ME, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0989-7; Propper DJ, 2022, NAT REV CLIN ONCOL, V19, P237, DOI 10.1038/s41571-021-00588-9; Rambow F, 2018, CELL, V174, P843, DOI 10.1016/j.cell.2018.06.025; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Robert C, 2019, NEW ENGL J MED, V381, P626, DOI 10.1056/NEJMoa1904059; Ruggiero CF, 2019, CANCERS, V11, DOI 10.3390/cancers11101425; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Song CY, 2017, CANCER DISCOV, V7, P1248, DOI 10.1158/2159-8290.CD-17-0401; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tremble LF, 2020, BRIT J CANCER, V123, P1553, DOI 10.1038/s41416-020-01037-7; Tupone MG, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0203-6; van Zandwijk N, 2015, ANN ONCOL, V26, P16, DOI 10.1093/annonc/mdv090.2; Vitiello M, 2017, ONCOTARGET, V8, P25395, DOI 10.18632/oncotarget.15915; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wang T, 2015, CLIN CANCER RES, V21, P1652, DOI 10.1158/1078-0432.CCR-14-1554; Wang YJ, 2021, CANCER CELL, V39, P1375, DOI 10.1016/j.ccell.2021.07.023; Winkle M, 2021, NAT REV DRUG DISCOV, V20, P629, DOI 10.1038/s41573-021-00219-z; Yang ZC, 2020, INT ARCH ALLERGY IMM, V181, P239, DOI 10.1159/000505064	71	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02547-9	http://dx.doi.org/10.1038/s41388-022-02547-9		NOV 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6J4TZ	36418472	hybrid, Green Published			2022-12-28	WOS:000886818700001
J	Yan, C; Yang, HJ; Su, P; Li, X; Li, ZB; Wang, DH; Zang, YF; Wang, TS; Liu, ZP; Bao, ZC; Dong, SX; Zhuang, T; Zhu, J; Ding, YL				Yan, Cheng; Yang, Huijie; Su, Peng; Li, Xin; Li, Zhongbo; Wang, Dehai; Zang, Yifeng; Wang, Tianshi; Liu, Ziping; Bao, Zhuocong; Dong, Shuxiao; Zhuang, Ting; Zhu, Jian; Ding, Yinlu			OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer	ONCOGENE			English	Article							ORGAN SIZE CONTROL; CELL-PROLIFERATION; PATHWAY; INVASION	Gastric cancer is one of the most lethal human malignancies in the world. Although great efforts are put in developing novel therapeutic targets, the effective targeting drugs are still limited. Recent studies reveal the abnormality of Hippo/YAP axis play critical role in the oncogenic process of gastric cancer. It is of great importance to demonstrate the regulation of Hippo signaling activity and YAP protein turnover in gastric cancer. Besides, the phosphorylation cascade on YAP function, which has been thoroughly investigated, the ubiquitination of YAP is also important in Hippo signaling status. Here, We utilized the DUB (Deubiquitinase) siRNA library to identify critical DUB for Hippo signaling. We discovered OTUB1 as a critical factor to facilitate gastric cancer cell stemness and progression, which deubiquitinated and stabilized YAP protein. The clinical data analysis implicated OTUB1 was higher expressed in gastric cancer, which correlated with YAP activity and poor survival. OUTB1 interacted with YAP protein via its OTU domain (Ovarian tumor domain) and deubiquitinated YAP at several lysine sites (K90, K280, K343, K494 and K497), which subsequently inhibited YAP degradation. Our study revealed a novel deubiquitinase of Hippo/YAP axis and one possible therapeutic target for YAP-driven gastric cancer.	[Yan, Cheng] Xinxiang Univ, Sch Med, Key Lab Nanocarbon Modified Film Technol Henan Pr, Diagnost Lab Anim Dis, Xinxiang 453003, Henan, Peoples R China; [Yang, Huijie; Li, Xin; Li, Zhongbo; Zhuang, Ting] Xinxiang Med Univ, Sch Lab Med, Xinxiang Key Lab Tumor Migrat & Invas Precis Med, Xinxiang 453003, Henan, Peoples R China; [Su, Peng] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pathol, Jinan 250033, Peoples R China; [Wang, Dehai; Zang, Yifeng; Wang, Tianshi; Liu, Ziping; Bao, Zhuocong; Zhu, Jian; Ding, Yinlu] Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gen Surg, Jinan, Shandong, Peoples R China; [Dong, Shuxiao] Shandong Prov Third Hosp, Dept Gastroenterol Surg, Jinan 250000, Peoples R China; [Zhu, Jian] Shandong First Med Univ, Cent Hosp, Jinan 250013, Peoples R China; [Zhu, Jian] Shandong Acad Med Sci, Jinan 250013, Peoples R China	Xinxiang University; Xinxiang Medical University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan	Zhuang, T (corresponding author), Xinxiang Med Univ, Sch Lab Med, Xinxiang Key Lab Tumor Migrat & Invas Precis Med, Xinxiang 453003, Henan, Peoples R China.; Zhu, J; Ding, YL (corresponding author), Shandong Univ, Hosp 2, Cheeloo Coll Med, Dept Gen Surg, Jinan, Shandong, Peoples R China.; Dong, SX (corresponding author), Shandong Prov Third Hosp, Dept Gastroenterol Surg, Jinan 250000, Peoples R China.; Zhu, J (corresponding author), Shandong First Med Univ, Cent Hosp, Jinan 250013, Peoples R China.; Zhu, J (corresponding author), Shandong Acad Med Sci, Jinan 250013, Peoples R China.	dongsx01@163.com; 77090993@qq.com; jian.zhu@email.sdu.edu.cn; dingyinlu@126.com			National Science Foundation of China [82172999, 82273013]; Program for Science & Technology Innovation Talents in Universities of Henan Province [21HASTIT049]; Henan Provincial National Natural Science Foundation of Excellent Young Scientist [222300420065]; Taishan Scholar Program of Shandong Province [tsqn202103175]; Shandong Provincial National Natural Science Foundation [ZR2016HQ44, ZR2021MH017]; Key Research Program of Education Department of Henan Province [22A310005]; National Science Foundation for Young Scholars of China [32200632]; Program for Science & Technology Innovation in Shandong Society of Geriatrics [LKJGG2021z002]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Science & Technology Innovation Talents in Universities of Henan Province; Henan Provincial National Natural Science Foundation of Excellent Young Scientist; Taishan Scholar Program of Shandong Province; Shandong Provincial National Natural Science Foundation; Key Research Program of Education Department of Henan Province; National Science Foundation for Young Scholars of China(National Natural Science Foundation of China (NSFC)); Program for Science & Technology Innovation in Shandong Society of Geriatrics	The project was supported by the National Science Foundation of China (No. 82172999, TZ; 82273013, YD), the Program for Science & Technology Innovation Talents in Universities of Henan Province (Grant No. 21HASTIT049 to TZ), the Henan Provincial National Natural Science Foundation of Excellent Young Scientist (222300420065 to TZ), the Taishan Scholar Program of Shandong Province (tsqn202103175 to JZ), Shandong Provincial National Natural Science Foundation (ZR2016HQ44 to YD; ZR2021MH017 for JZ), the Key Research Program of Education Department of Henan Province (22A310005 to JZ), the National Science Foundation for Young Scholars of China (32200632 to Cheng Yan) and the Program for Science & Technology Innovation in Shandong Society of Geriatrics (LKJGG2021z002 to YD).	Baietti MF, 2016, EMBO MOL MED, V8, P288, DOI 10.15252/emmm.201505972; Boopathy GTK, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00049; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cenitagoya GF, 1998, DIGEST SURG, V15, P317, DOI 10.1159/000018645; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Garattini SK, 2017, WORLD J GASTRO ONCOL, V9, P194, DOI 10.4251/wjgo.v9.i5.194; Gerson JN, 2017, EXPERT OPIN INV DRUG, V26, P531, DOI 10.1080/13543784.2017.1315406; He MJ, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0013-6; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Jin D, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01161-1; Juris SJ, 2006, FEBS LETT, V580, P179, DOI 10.1016/j.febslet.2005.11.071; Kim J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00314; Kulathu Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2567; Liu T, 2019, CANCER RES, V79, P1913, DOI 10.1158/0008-5472.CAN-18-3037; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Padmanabhan R, 2020, CANCERS, V12, DOI 10.3390/cancers12030636; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Rodriquenz MG, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051427; Sun D, 2016, ONCOTARGET, V7, P81062, DOI 10.18632/oncotarget.13188; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Weng WW, 2016, AM J TRANSL RES, V8, P2234; Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3; Yu FX, 2013, GENE DEV, V27, P1223, DOI 10.1101/gad.219402.113; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00312-6; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhou XF, 2019, NAT IMMUNOL, V20, P879, DOI 10.1038/s41590-019-0405-2; Zhu D, 2021, CELL DEATH DIFFER, V28, P1773, DOI 10.1038/s41418-020-00700-z; Zhu H, 2020, CANCER RES, V80, P2204, DOI 10.1158/0008-5472.CAN-19-2388	34	0	0	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2022	41	48					5186	5198		10.1038/s41388-022-02507-3	http://dx.doi.org/10.1038/s41388-022-02507-3		OCT 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M3CM	36271031	Green Published, hybrid			2022-12-28	WOS:000870984500002
J	SUZUKI, T; FUJITA, S; NARIMATSU, S; MASUBUCHI, Y; TACHIBANA, M; OHTA, S; HIROBE, M				SUZUKI, T; FUJITA, S; NARIMATSU, S; MASUBUCHI, Y; TACHIBANA, M; OHTA, S; HIROBE, M			CYTOCHROME-P450 ISOZYMES CATALYZING 4-HYDROXYLATION OF PARKINSONISM-RELATED COMPOUND 1,2,3,4-TETRAHYDROISOQUINOLINE IN RAT-LIVER MICROSOMES	FASEB JOURNAL			English	Note						GENOTYPIC POOR METABOLIZER; PHENOTYPIC POOR METABOLIZER; METABOLIC POLYMORPHISM; P450-BTL; DEBRISOQUINE; RAT LIVER MICROSOMES; DARK AGOUTI RAT; P450-M1	ENDOGENOUS SUBSTANCE; DRUG-METABOLISM; DEBRISOQUINE; TETRAHYDROISOQUINOLINE; DISEASE; BRAIN; 1-METHYL-TETRAHYDROISOQUINOLINE; MPTP	Microsomal 4-hydroxylase of 1,2,3,4-tetrahydroisoquinoline (TIQ), a possible candidate for causing Parkinson disease, was characterized by using rat hepatic microsomes and purified P450 isozymes. Kinetic analysis revealed that K(m) and V(max) values (mean +/- SE) for hepatic microsomal TIQ 4-hydroxylase of male Wistar rats were 319.6 +/- 26.8-mu-M and 12.13 +/- 1.43 pmol.min-1.mg-1 protein, respectively. When TIQ 4-hydroxylase activity was compared in Wistar (an animal model of extensive debrisoquine metabolizers) and Dark Agouti (an animal model of poor debrisoquine metabolizers) rats, significant strain (Wistar > Dark Agouti) and sex (male > female) differences were observed. The microsomal activity toward TIQ 4-hydroxylation was increased by pretreatment of male Wistar rats with P448 inducers (beta-naphthoflavone and sudan I), but not with phenobarbital. Pretreatment with propranolol, an inhibitor of P450 isozymes belonging to the P450 IID gene subfamily, decreased TIQ 4-hydroxylase activity. P450 BTL, a P450 isozyme belonging to the IID subfamily, showed TIQ 4-hydroxylase activity of 64.1 pmol.min-1.nmol P450-1, which was 3.2-fold that of microsomes (20.9 pmol.min-1.nmol P450-1). Antibody (IgG) against this isozyme suppressed microsomal TIQ 4-hydroxylase activity concentration-dependently. A male-specific P450 ml (P450IIC11) catalyzed this reaction to a much lesser extent (10.0 pmol . min-1 . nmol P450-1), and its antibody did not affect the microsomal activity. These results suggest that TIQ 4-hydroxylation in hepatic microsomes are catalyzed predominantly by a P450 isozyme (or isozymes) belonging to the IID gene subfamily in non-treated rats and its immunochemically related P450 isozyme (or isozymes), and that a P450 isozyme (or isozymes) belonging to the IA subfamily also participates in TIQ 4-hydroxylation in rats pretreated with P448-inducers.	UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN	University of Tokyo	SUZUKI, T (corresponding author), CHIBA UNIV,FAC PHARMACEUT SCI,DEPT BIOPHARMACEUT,1-33 YAYOI CHO,CHIBA 260,JAPAN.							ALDABBAGH SG, 1981, J PHARM PHARMACOL, V33, P161, DOI 10.1111/j.2042-7158.1981.tb13740.x; BALLARD PA, 1985, NEUROLOGY, V35, P949, DOI 10.1212/WNL.35.7.949; BARBEAU A, 1985, LANCET, V2, P1213; BARON JA, 1986, NEUROLOGY, V36, P1490, DOI 10.1212/WNL.36.11.1490; BROSEN K, 1987, PHARMACOL TOXICOL, V60, P312, DOI 10.1111/j.1600-0773.1987.tb01758.x; FUJITA S, 1984, CHEM-BIOL INTERACT, V52, P15, DOI 10.1016/0009-2797(84)90080-2; FUJITA S, 1989, BIOCHEM PHARMACOL, V38, P3925, DOI 10.1016/0006-2952(89)90669-2; GUDJONSSON O, 1990, BRIT J CLIN PHARMACO, V30, P301, DOI 10.1111/j.1365-2125.1990.tb03780.x; KAHN GC, 1985, DRUG METAB DISPOS, V13, P510; KIKUCHI K, 1991, DRUG METAB DISPOS, V19, P257; KOHNO M, 1986, BIOCHEM BIOPH RES CO, V140, P448, DOI 10.1016/0006-291X(86)91111-3; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARET G, 1990, DRUG METAB REV, V22, P291, DOI 10.3109/03602539009041087; MASUBUCHI Y, 1991, BIOCHEM PHARMACOL, V41, P861; NAGATSU T, 1988, NEUROSCI LETT, V87, P178, DOI 10.1016/0304-3940(88)90166-8; NAGATSU T, 1990, PROTEIN NUCLEIC ACID, V35, P1341; NIWA T, 1987, BIOCHEM BIOPH RES CO, V144, P1084, DOI 10.1016/S0006-291X(87)80075-X; OHTA S, 1987, BIOMED RES-TOKYO, V8, P453; OHTA S, 1990, LIFE SCI, V46, P599, DOI 10.1016/0024-3205(90)90128-E; OMURA T, 1964, J BIOL CHEM, V239, P2370; SHAHI GS, 1990, MED HYPOTHESES, V32, P277, DOI 10.1016/0306-9877(90)90106-O; SUZUKI T, 1991, BIOCHEM PHARMACOL, V42, P2241, DOI 10.1016/0006-2952(91)90362-9; WOLFF T, 1985, BIOCHEM PHARMACOL, V34, P2593, DOI 10.1016/0006-2952(85)90553-2; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA M, 1990, NEUROSCI LETT, V119, P109, DOI 10.1016/0304-3940(90)90768-5	26	38	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					771	776		10.1096/fasebj.6.2.1537468	http://dx.doi.org/10.1096/fasebj.6.2.1537468			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537468				2022-12-28	WOS:A1992GZ44000021
J	IYENGAR, V; ALBAUGH, GP; LOHANI, A; NAIR, PP				IYENGAR, V; ALBAUGH, GP; LOHANI, A; NAIR, PP			HUMAN STOOLS AS A SOURCE OF VIABLE COLONIC EPITHELIAL-CELLS	FASEB JOURNAL			English	Article						EPITHELIAL CELLS; HUMAN STOOLS; COUNTERCURRENT CENTRIFUGAL ELUTRIATION	RENEWAL; LOCALIZATION; CULTURE	Human stools consist of a mixture of undigested food residues, colonic microflora, and cellular components shed from the walls of the gastrointestinal tract. The cellular components are made up mostly of terminally differentiated colonic epithelial cells. Using a combination of Percoll density gradient centrifugation and countercurrent centrifugal elutriation, it is now possible to recover these cells as an enriched fraction from fresh human stools. Cells can be visualized on heat-fixed smears of the enriched fractions stained with modified Wright's stain. The enrichment process is optimized by following the segregation of eukaryotic cells as determined by an ELISA technique using monoclonal antibodies against human double-stranded DNA. This work, demonstrating the feasibility of isolating intact colonic cells from stools, has important applications as a noninvasive approach to the biology of exfoliated cells from the gastrointestinal tract.	USDA,BELTSVILLE HUMAN NUTR RES CTR,LIPID NUTR LAB,BLDG 308,BELTSVILLE,MD 20705; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	United States Department of Agriculture (USDA); Johns Hopkins University				Nair, Padmanabhan/0000-0002-8925-1193				ALBAUGH GP, 1989, J CELL BIOL, V107, pA575; CHANG WWL, 1971, AM J ANAT, V131, P73, DOI 10.1002/aja.1001310105; COLE JW, 1961, GASTROENTEROLOGY, V41, P122; EASTWOOD GL, 1977, GASTROENTEROLOGY, V72, P962; FARAJISHADAN F, 1989, ANAL BIOCHEM, V177, P259, DOI 10.1016/0003-2697(89)90049-3; GRIMES A, 1988, ANAL BIOCHEM, V172, P436, DOI 10.1016/0003-2697(88)90466-6; HAGEMANN RF, 1977, CELL TISSUE KINET, V10, P3, DOI 10.1111/j.1365-2184.1977.tb00278.x; HENRY JB, 1979, CLIN DIAGNOSIS MANAG, P788; HOLGERSSON J, 1988, BIOCHIMIE, V70, P1565, DOI 10.1016/0300-9084(88)90292-1; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IYENGAR V, 1990, FASEB J, V4, pA1165; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIPKIN M, 1963, J CLIN INVEST, V42, P767, DOI 10.1172/JCI104769; MACDONALD WC, 1964, GASTROENTEROLOGY, V46, P405; MAZUMDER A, 1978, J NATL CANCER I, V60, P915, DOI 10.1093/jnci/60.4.915; MESSIER B, 1960, AM J ANAT, V106, P247, DOI 10.1002/aja.1001060305; MOYER MP, 1984, SCIENCE, V224, P1445, DOI 10.1126/science.6328655; MOYER MP, 1983, P SOC EXP BIOL MED, V174, P12; MUKHERJEE A, 1981, CELL BIOL INT REP, V5, P409, DOI 10.1016/0309-1651(81)90011-4; PANT KD, 1987, NUCL MED BIOL, V14, P81, DOI 10.1016/0883-2897(87)90136-X; PATNAIK R, 1981, CELL DIFFER DEV, V10, P147, DOI 10.1016/0045-6039(81)90035-X; RADIO SJ, 1989, ARCH PATHOL LAB MED, V133, P333; SHORTER RG, 1964, AM J DIG DIS, V9, P760, DOI 10.1007/BF02231983; STEPHEN AM, 1980, NATURE, V284, P283, DOI 10.1038/284283a0; STRAGAND JJ, 1977, AM J CLIN NUTR, V30, P918, DOI 10.1093/ajcn/30.6.918; WILEY EL, AM J CLIN PATHOL, V76, P806	26	62	79	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2856	2859		10.1096/fasebj.5.13.1655550	http://dx.doi.org/10.1096/fasebj.5.13.1655550			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1655550				2022-12-28	WOS:A1991GJ47100015
J	FARVER, O; PECHT, I				FARVER, O; PECHT, I			ELECTRON-TRANSFER IN PROTEINS - IN SEARCH OF PREFERENTIAL PATHWAYS	FASEB JOURNAL			English	Article						CYTOCHROME-C PEROXIDASE; COPPER PROTEIN; ASCORBATE OXIDASE; AFFINITY LABELING; THROUGH-SPACE DISTANCE; ELECTRON MIGRATION	BLUE COPPER PROTEINS; PSEUDOMONAS-AERUGINOSA; ASCORBATE OXIDASE; CYTOCHROME-C; AZURIN GENE; STELLACYANIN; PLASTOCYANIN; RESOLUTION; MODEL; SITES	Electron migration between and within proteins is one of the most prevalent forms of biological energy conversion processes. Electron transfer reactions take place between active centers such as transition metal ions or organic cofactors over considerable distances at fast rates and with remarkable specificity. The electron transfer is attained through weak electronic interaction between the active sites, so that considerable research efforts are centered on resolving the factors that control the rates of long-distance electron transfer reactions in proteins. These factors include (in addition to the distance and nature of the microenvironment separating the reactants) thermodynamic driving force and the configurational changes required upon reaction. Several of these aspects are addressed in this review, which is based primarily on recent work performed by the authors on model systems of blue copper-containing proteins. These proteins serve almost exclusively in electron transfer reactions, and as it turns out, their metal coordination sites are endowed with properties uniquely optimized for their function.	ROYAL DANISH SCH PHARM, DEPT GEN CHEM, COPENHAGEN, DENMARK	Royal Danish School of Pharmacy	FARVER, O (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.			Pecht, Israel/0000-0002-1883-9547				ARVIDSSON RHA, 1989, EUR J BIOCHEM, V179, P195, DOI 10.1111/j.1432-1033.1989.tb14540.x; BECHTOLD R, 1986, NATURE, V322, P286, DOI 10.1038/322286a0; CANTERS GW, 1987, FEBS LETT, V212, P168, DOI 10.1016/0014-5793(87)81579-X; COWAN JA, 1988, CHEM SCRIPTA, V28A, P21; DEFELIPPIS MR, 1990, J AM CHEM SOC, V112, P5640, DOI 10.1021/ja00170a039; FARAGGI M, 1973, J BIOL CHEM, V248, P3146; FARVER O, 1987, BIOCHEMISTRY-US, V26, P7317, DOI 10.1021/bi00397a018; FARVER O, 1989, FEBS LETT, V244, P379, DOI 10.1016/0014-5793(89)80567-8; FARVER O, 1981, P NATL ACAD SCI-BIOL, V78, P4190, DOI 10.1073/pnas.78.7.4190; FARVER O, 1989, COORDIN CHEM REV, V94, P17, DOI 10.1016/0010-8545(89)80043-8; FARVER O, 1991, MOL CRYST LIQ CRYST, V194, P215, DOI 10.1080/00268949108041167; FARVER O, 1990, INORG CHEM, V29, P4855, DOI 10.1021/ic00349a008; FARVER O, 1989, FEBS LETT, V244, P376, DOI 10.1016/0014-5793(89)80566-6; FARVER O, 1982, BIOCHEMISTRY-US, V21, P1885, DOI 10.1021/bi00537a028; FARVER O, 1989, P NATL ACAD SCI USA, V86, P6968, DOI 10.1073/pnas.86.18.6968; FARVER O, 1981, ISRAEL J CHEM, V21, P13, DOI 10.1002/ijch.198100004; FARVER O, 1982, BIOCHEMISTRY-US, V21, P3556, DOI 10.1021/bi00258a005; GRAY HB, 1986, CHEM SOC REV, V15, P17, DOI 10.1039/cs9861500017; GUSS JM, 1983, J MOL BIOL, V169, P521; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JACKMAN MP, 1988, J AM CHEM SOC, V110, P5880, DOI 10.1021/ja00225a046; JOHNSON MK, 1990, ADV CHEMSERIES, V226; LARSSON S, 1988, INT J QUANTUM CHEM, P1; LIANG N, 1988, SCIENCE, V240, P311, DOI 10.1126/science.2832950; MALMSTROM BG, 1989, BIOCHEMISTRY-US, V28, P7499; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARGALIT R, 1984, P NATL ACAD SCI USA, V81, P6554, DOI 10.1073/pnas.81.20.6554; MCGOURTY JL, 1983, J AM CHEM SOC, V105, P4470, DOI 10.1021/ja00351a056; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; MORPURGO G, 1982, BIOCHEM BIOPH RES CO, V104, P1592, DOI 10.1016/0006-291X(82)91434-6; NORRIS GE, 1983, J MOL BIOL, V165, P501, DOI 10.1016/S0022-2836(83)80216-2; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; Pecht I., 1984, COPPER PROTEINS COPP, V1, P183; RYDEN L, 1976, NATURE, V261, P344, DOI 10.1038/261344a0; TAUBE H, 1984, SCIENCE, V226, P1028, DOI 10.1126/science.6494920; WHERLAND S, 1988, J MOL BIOL, V204, P407, DOI 10.1016/0022-2836(88)90585-2; WOFSY L, 1962, BIOCHEMISTRY-US, V1, P1031, DOI 10.1021/bi00912a013	40	25	25	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1991	5	11					2554	2559		10.1096/fasebj.5.11.1868979	http://dx.doi.org/10.1096/fasebj.5.11.1868979			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868979	Bronze			2022-12-28	WOS:A1991GB09400008
J	JIMENEZ, JJ; WONG, GHW; YUNIS, AA				JIMENEZ, JJ; WONG, GHW; YUNIS, AA			INTERLEUKIN-1 PROTECTS FROM CYTOSINE ARABINOSIDE-INDUCED ALOPECIA IN THE RAT MODEL	FASEB JOURNAL			English	Note						CHEMOTHERAPY; CYTOSINE ARABINOSIDE; ALOPECIA; CYTOKINES; INTERLEUKIN-1	TUMOR-NECROSIS FACTOR; COLONY-STIMULATING FACTOR; HUMAN-ENDOTHELIAL CELLS; HUMAN KERATINOCYTES; RECEPTORS; MURINE	Protection from cytosine arabinoside-induced alopecia by ImuVert has recently been reported in a rat model. ImuVert, a biologic response modifier, is capable of activating mononuclear cells causing release of various cytokines. In the present study, using the young rat model, recombinant human IL l-beta produced excellent protection from cytosine arabinoside-induced alopecia. Mouse recombinant tumor necrosis factor gave definite but modest protection whereas human tumor necrosis factor gave none. It is concluded that the protection from alopecia by ImuVert is mediated by cytokines, primarily IL 1.	UNIV MIAMI,SCH MED,DEPT MED R38,POB 016960,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT ONCOL,MIAMI,FL 33101; GENENTECH INC,SAN FRANCISCO,CA 94080	University of Miami; University of Miami; University of Miami; Roche Holding; Genentech								ANSEL J, 1990, J INVEST DERMATOL, V94, P101; BLANTON RA, 1989, P NATL ACAD SCI USA, V86, P1273, DOI 10.1073/pnas.86.4.1273; BROUDY VC, 1987, J IMMUNOL, V139, P464; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; FIBBE WE, 1989, EXP HEMATOL, V17, P229; HUSSEIN AM, 1990, SCIENCE, V249, P1564, DOI 10.1126/science.2218498; JIMENEZ JJ, 1991, CLIN RES; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; MCCALL CA, 1989, CYTOKINE, V1, P113; SLORDAL L, 1989, EUR J HAEMATOL, V43, P428; SMITH RA, 1986, J BIOL CHEM, V261, P4871	11	38	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2456	2458		10.1096/fasebj.5.10.2065892	http://dx.doi.org/10.1096/fasebj.5.10.2065892			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065892				2022-12-28	WOS:A1991FW08700016
J	JOLICOEUR, P				JOLICOEUR, P			MURINE ACQUIRED-IMMUNODEFICIENCY-SYNDROME (MAIDS) - AN ANIMAL-MODEL TO STUDY THE AIDS PATHOGENESIS	FASEB JOURNAL			English	Review						AIDS; IMMUNODEFICIENCY; RETROVIRUS; MURINE LEUKEMIA VIRUS; MAIDS	VIRUS RADLV-RS; CD4+ T-CELLS; LEUKEMIA-VIRUS; PERIPHERAL-BLOOD; B-CELL; DEFECTIVE VIRUSES; TRANSGENIC MICE; HIV-INFECTION; C57BL/6 MICE; HELPER VIRUS	Murine AIDS (MAIDS) is a disease that shows many similarities with human AIDS. Several immunological parameters of the disease have been analyzed and genetic studies have mapped a gene (or genes) of resistance in the H-2 complex and shown that the genetic background of the mouse can significantly modify some features of the disease. The etiologic agent of MAIDS is a defective murine leukemia virus that seems able to induce disease in the absence of virus replication. This defective virus induces proliferation of its target cells and the cell expansion was found to be oligoclonal, thus suggesting that the immunodeficiency observed in these mice is a paraneoplastic syndrome. The excellent response of MAIDS mice to antineoplastic agents is consistent with this notion. This animal model has already been useful in stimulating the emergence of novel questions and the formulation of new hypotheses about human AIDS, namely about the role of defective HIV, the role of HIV replication in the progression of the disease, and the importance to identify the target cells of HIV in vivo. Although MAIDS and AIDS are not identical and are induced by retroviruses of different classes, the availability of such a model in an easily accessible small animal species, whose genetics is very sophisticated, may be instrumental in understanding the pathogenesis of AIDS if some of the cellular and molecular affected pathways are common in both diseases.	UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, QUEBEC, CANADA	Universite de Montreal	JOLICOEUR, P (corresponding author), CLIN RES INST MONTREAL, MOLEC BIOL LAB, MONTREAL H2W 1R7, QUEBEC, CANADA.							ASTIER T, 1982, J GEN VIROL, V61, P55, DOI 10.1099/0022-1317-61-1-55; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BULLER RML, 1987, J VIROL, V61, P383, DOI 10.1128/JVI.61.2.383-387.1987; CERNY A, 1990, J EXP MED, V171, P315, DOI 10.1084/jem.171.1.315; CERNY A, 1990, EUR J IMMUNOL, V20, P1577, DOI 10.1002/eji.1830200725; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHEUNG SC, 1991, J VIROL, V65, P823, DOI 10.1128/JVI.65.2.823-828.1991; CHEUNG SC, 1991, IN PRESS J IMMUNOL; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; CULLITON BJ, 1989, SCIENCE, V246, P21, DOI 10.1126/science.2781298; DESROSIERS RC, 1987, REV INFECT DIS, V9, P438; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; DEWHURST S, 1990, NATURE, V345, P636, DOI 10.1038/345636a0; DUESBERG P, 1989, NATURE, V340, P515, DOI 10.1038/340515a0; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; EVANS LA, 1989, BIOCHIM BIOPHYS ACTA, V989, P237; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FILICE G, 1988, NATURE, V335, P366, DOI 10.1038/335366a0; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; GANGEMI JD, 1989, ANTIMICROB AGENTS CH, V33, P1864, DOI 10.1128/AAC.33.11.1864; GARDNER MB, 1989, ADV EXP MED BIOL, V251, P279; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; GENGELMAN HE, 1989, AIDS, V3, P475; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; GUILLEMAIN B, 1980, INTERVIROLOGY, V13, P65, DOI 10.1159/000149109; HAAS M, 1980, EUR J CANCER, V16, P909, DOI 10.1016/0014-2964(80)90329-1; HAMELINBOURASSA D, 1989, IMMUNOGENETICS, V30, P266, DOI 10.1007/BF02421330; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLMES KL, 1990, EUR J IMMUNOL, V20, P2783, DOI 10.1002/eji.1830201237; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; HUANG M, 1990, J VIROL, V64, P5764, DOI 10.1128/JVI.64.12.5764-5772.1990; HUANG M, 1990, RNA TUMOR M COLD SPR, P249; JOLICOEUR P, 1991, VIRUSES AFFECT IMMUN; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KULAGA H, 1989, J EXP MED, V169, P321, DOI 10.1084/jem.169.1.321; LEGRAND E, 1982, INT J CANCER, V30, P241, DOI 10.1002/ijc.2910300219; LEGRAND E, 1981, LEUKEMIA RES, V5, P223, DOI 10.1016/0145-2126(81)90107-7; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; Levy J A, 1978, Curr Top Microbiol Immunol, V79, P111; MAMOUN R, 1978, INT J CANCER, V22, P98, DOI 10.1002/ijc.2910220117; MARX PA, 1984, SCIENCE, V223, P1083, DOI 10.1126/science.6695196; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MISTRY PB, 1973, B CANCER, V60, P287; MIZUOCHI T, 1990, J IMMUNOL, V144, P313; MORSE HC, 1989, J IMMUNOL, V143, P844; MOSIER DE, 1987, J EXP MED, V165, P1737, DOI 10.1084/jem.165.6.1737; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; MOSIER DE, 1986, IMMUNOL INVEST, V15, P233, DOI 10.3109/08820138609026687; MULLINS JI, 1986, NATURE, V319, P333, DOI 10.1038/319333a0; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NARAYAN O, 1988, MICROB PATHOGENESIS, V5, P149, DOI 10.1016/0882-4010(88)90017-4; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PITHA PM, 1988, J IMMUNOL, V141, P3611; POIRIER Y, 1989, J VIROL, V63, P2088, DOI 10.1128/JVI.63.5.2088-2098.1989; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; RINFRET A, 1991, AM J PATHOL, V138, P421; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIMARD C, 1991, SCIENCE, V251, P305, DOI 10.1126/science.1987646; SPARGER EE, 1989, AIDS, V3, pS43, DOI 10.1097/00002030-198901001-00006; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEISS RA, 1989, NATURE, V338, P458, DOI 10.1038/338458a0; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YETTER RA, 1988, J EXP MED, V168, P623, DOI 10.1084/jem.168.2.623	73	202	206	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2398	2405		10.1096/fasebj.5.10.2065888	http://dx.doi.org/10.1096/fasebj.5.10.2065888			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065888				2022-12-28	WOS:A1991FW08700010
J	WATT, FM				WATT, FM			CELL-CULTURE MODELS OF DIFFERENTIATION	FASEB JOURNAL			English	Review						DIFFERENTIATION; STEM CELLS; CELL CULTURE; TRANSDIFFERENTIATION; EXTRACELLULAR MATRIX; GROWTH FACTORS	RAT OPTIC-NERVE; STEM-CELLS; TERATOCARCINOMA CELLS; EXTRACELLULAR-MATRIX; ONCOGENE EXPRESSION; MOLECULAR CONTROL; GENE-EXPRESSION; CYTODIFFERENTIATION; COMMITMENT; ENHANCER	It is now possible to culture cells from most organs of the body under conditions in which they continue to express at least some of their differentiated traits, and to model some of the differentiation processes that occur during embryonic and adult life. How much can these cultures tell us about the acquisition and maintenance of the differentiated state? To answer this question I shall outline the features of several cell culture models, dividing them into categories according to whether they mimic differentiation during development, differentiation of adult stem cell progeny, or the transition from one differentiated phenotype to another. In spite of the diversity of cell types under consideration, it is possible to detect some common themes: the stability of the differentiated state; the relationship between proliferation and differentiation; the relative importance of intrinsic cellular programming and environmental regulation; and possible mechanisms for transcriptional control of the genes that are activated during differentiation. In recent years cell culture models have yielded a great deal of information about differentiation and the way is now clear for even more exciting discoveries.			WATT, FM (corresponding author), IMPERIAL CANC RES FUND,KERATINOCYTE LAB,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BISSELL MJ, 1989, ENVIRON HEALTH PERSP, V80, P61, DOI 10.2307/3430732; BLAU HM, 1989, TRENDS GENET, V5, P268, DOI 10.1016/0168-9525(89)90100-5; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; CHEN S, 1989, SCIENCE, V244, P582, DOI 10.1126/science.2470149; COLLINS SJ, 1987, BLOOD, V70, P1233; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEXTER TM, 1982, J CELL PHYSIOL, P87; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EISENSTEIN RS, 1988, MOL CELL BIOL, V8, P3183, DOI 10.1128/MCB.8.8.3183; FFRENCHCONSTANT C, 1986, NATURE, V319, P499, DOI 10.1038/319499a0; GORDON MY, 1988, BRIT J HAEMATOL, V70, P1, DOI 10.1111/j.1365-2141.1988.tb02425.x; GREENBURG G, 1986, DEV BIOL, V115, P363, DOI 10.1016/0012-1606(86)90256-3; HALL PA, 1989, DEVELOPMENT, V106, P619; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HOLZER H, 1978, STEM CELLS TISSUE HO, P1; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; LILLIEN LE, 1990, J CELL BIOL, V111, P635, DOI 10.1083/jcb.111.2.635; MARKS PA, 1989, ENVIRON HEALTH PERSP, V80, P181; MCMAHON J, 1988, ONCOGENE, V3, P717; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NOBLE M, 1990, PHILOS T R SOC B, V327, P127, DOI 10.1098/rstb.1990.0049; PEEK R, 1990, NUCLEIC ACIDS RES, V18, P1189, DOI 10.1093/nar/18.5.1189; PERA MF, 1989, DIFFERENTIATION, V42, P10, DOI 10.1111/j.1432-0436.1989.tb00602.x; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; PINNEY DF, 1989, ENVIRON HEALTH PERSP, V80, P221, DOI 10.2307/3430747; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPIEGELMAN BM, 1988, TRENDS GENET, V4, P203, DOI 10.1016/0168-9525(88)90077-7; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; Sul HS, 1989, CURR OPIN CELL BIOL, V1, P1116, DOI 10.1016/S0955-0674(89)80059-6; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0	46	61	61	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					287	294		10.1096/fasebj.5.3.2001788	http://dx.doi.org/10.1096/fasebj.5.3.2001788			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001788				2022-12-28	WOS:A1991FC55600005
J	WOOD, HG				WOOD, HG			LIFE WITH CO OR CO2 AND H2 AS A SOURCE OF CARBON AND ENERGY	FASEB JOURNAL			English	Article						AUTOTROPHISM; ACETATE SYNTHESIS FROM CO OR CO2 AND H2; ACETYL COA PATHWAY; CORRINOID ENZYME; CO DEHYDROGENASE; CLOSTRIDIUM THERMOACETICUM	ACETYL COENZYME-A; CLOSTRIDIUM-THERMOACETICUM; MONOXIDE DEHYDROGENASE; ACETOGENIC BACTERIA; ACETATE SYNTHESIS; PURIFICATION; PROTEIN; ENZYME; METHYLTETRAHYDROFOLATE; PATHWAY	An account is presented of the recent discovery of a pathway of growth by bacteria in which CO or CO2 and H2 are sources of carbon and energy. The Calvin cycle and subsequently other cycles were discovered in the 1950s, and in each the initial reaction of CO2 involved adding CO2 to an organic compound formed during the cyclic pathway (for example, CO2 and ribulose diphosphate). Studies were initiated in the 1950s with the thermophylic anaerobic organism Clostridium thermoaceticum, which Barker and Kamen had found fixed CO2 in both carbons of acetate during fermentation of glucose. The pathway of acetyl-CoA biosynthesis differs from all others in that two CO2 are combined with coenzyme A (CoASH) forming acetyl CoA, which then serves as the source of carbon for growth. This mechanism is designated the acetyl CoA pathway and some have called it the Wood pathway. A unique feature is the role of the enzyme carbon monoxide dehydrogenase (CODH), which catalyzes the conversion of CoASH, CO, and a methyl group to acetyl CoA, the final step of the pathway. The pathway involves the reduction of CO2 to formate, which then combines with tetrahydrofolate (THF) to form formyl THF. It in turn is reduced to CH3-THF. The methyl is then transferred to the cobalt on a corrinoid-containing enzyme. From there the methyl is transferred to CODH, and CO and CoASH bind with the enzyme at separate sites. Acetyl CoA is then synthesized. CODH would more properly be called carbon monoxide dehydrogenase-acetyl CoA synthase as it catalyzes oxidation of CO to CO2 and the synthesis of acetyl CoA. The solution of the mechanism of this pathway required more than 30 years, in part because the intermediate compounds are bound to enzymes, the enzymes are extremely sensitive to O2 and must be isolated under strictly anerobic conditions, and the role of a corrinoid and CODH was unprecedented. It is now apparent that this pathway occurs (perhaps with some modification) in many bacteria including the methane and sulfur bacteria. In some humans this pathway is catalyzed by the bacteria of the gut and acetate is produced rather than methane; it is calculated that 2.3 x 10(6) metric tons of acetate are formed daily from CO2. A similar synthesis occurs in the hind gut of termites. It is becoming apparent that the acetyl CoA pathway plays a significant role in the carbon cycle. The direct combination of two CO2 to form acetate may have been used by the earliest forms of life rather than the more complicated cyclic mechanisms of autotrophism.			WOOD, HG (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106, USA.							BARKER HA, 1945, P NATL ACAD SCI USA, V31, P219, DOI 10.1073/pnas.31.8.219; Barton, 1991, VARIATIONS AUTOTROPH, P201; BASSHAM JA, 1953, J AM CHEM SOC, V76, P1760; BREZNAK JA, 1991, IN PRESS FEMS MICROB; DIEKERT GB, 1978, J BACTERIOL, V136, P597, DOI 10.1128/JB.136.2.597-606.1978; DRAKE HL, 1980, J BIOL CHEM, V255, P7174; DRAKE HL, 1981, J BIOL CHEM, V256, P1137; Fontaine FE, 1942, J BACTERIOL, V43, P701, DOI 10.1128/JB.43.6.701-715.1942; FUCHS G, 1986, FEMS MICROBIOL LETT, V39, P181, DOI 10.1111/j.1574-6968.1986.tb01859.x; Fuchs G, 1989, AUTOTROPHIC BACTERIA, P365; GRAHAME DA, 1987, J BIOL CHEM, V262, P3706; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HU SI, 1984, J BIOL CHEM, V259, P8892; HU SI, 1982, J BACTERIOL, V149, P440, DOI 10.1128/JB.149.2.440-448.1982; HUGENHOLTZ J, 1989, J BACTERIOL, V171, P2873, DOI 10.1128/jb.171.5.2873-2875.1989; IVEY DM, 1986, J BACTERIOL, V165, P252, DOI 10.1128/jb.165.1.252-257.1986; KNAPPE J, 1963, BIOCHEM Z, V337, P232; LAJOIE SF, 1988, APPL ENVIRON MICROB, V54, P2723, DOI 10.1128/AEM.54.11.2723-2727.1988; LANE MD, 1963, P NATL ACAD SCI USA, V49, P379, DOI 10.1073/pnas.49.3.379; LENTZ K, 1955, J BIOL CHEM, V215, P645; LINDAHL PA, 1990, J BIOL CHEM, V265, P3880; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; Lipmann F., 1965, The origins of pre-biological systems and of their molecular matrices., P259; LJUNGDAH.L, 1965, BIOCHEMISTRY-US, V4, P2771, DOI 10.1021/bi00888a030; LJUNGDAHL L, 1966, FED PROC, V25, P1642; LJUNGDAHL LG, 1986, ANNU REV MICROBIOL, V40, P415, DOI 10.1146/annurev.mi.40.100186.002215; Lohmann K, 1937, BIOCHEM Z, V294, P188; LU WP, 1990, J BIOL CHEM, V265, P3124; LYNEN F, 1961, BIOCHEM Z, V335, P123; MORTON TA, 6TH INT S MICR GROWT, P341; PEZACKA E, 1986, J BIOL CHEM, V261, P1609; PEZACKA E, 1988, J BIOL CHEM, V263, P16000; POSTON JM, 1964, ANN NY ACAD SCI, V112, P804, DOI 10.1111/j.1749-6632.1964.tb45057.x; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RAGSDALE SW, 1983, BIOCHEM BIOPH RES CO, V115, P658, DOI 10.1016/S0006-291X(83)80195-8; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; ROBERTS DL, 1989, P NATL ACAD SCI USA, V86, P32, DOI 10.1073/pnas.86.1.32; ROSE WC, 1949, FED PROC, V8, P546; SHANMUGASUNDARA.T, 1988, J CELL BIOL, V107, P855; SHANMUGASUNDARAM T, 1989, BIOCHEMISTRY-US, V28, P7112, DOI 10.1021/bi00443a049; SHANMUGASUNDARAM T, 1988, BIOCHEMISTRY-US, V27, P6499, DOI 10.1021/bi00417a045; STRAVROPOULOS P, 1990, J AM CHEM SOC, V112, P5385; THAUER RK, 1989, ANNU REV MICROBIOL, V43, P43, DOI 10.1146/annurev.mi.43.100189.000355; WARBURG O., 1935, BIOCHEM ZEITSCHR, V282, P157; WEISSBACH H, 1966, FED PROC, V25, P1649; Winogradsky S., 1891, ANN IMT PASTEUR, V5, P577; WOOD HG, 1988, ROOTS OF MODERN BIOCHEMISTRY, P581; WOOD HG, 1963, BIOCHEM Z, V337, P247; WOOD HG, 1989, AUTOTROPHIC BACTERIA, P33; WOOD HG, J BIOL CHEM, V194, P905	51	124	150	5	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					156	163		10.1096/fasebj.5.2.1900793	http://dx.doi.org/10.1096/fasebj.5.2.1900793			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	1900793				2022-12-28	WOS:A1991EZ00200003
J	KAY, MMB				KAY, MMB			MOLECULAR MAPPING OF HUMAN BAND-3 ANION TRANSPORT REGIONS USING SYNTHETIC PEPTIDES	FASEB JOURNAL			English	Note						AGING; BAND-3; LYSINE; ANTIIDIOTYPIC ANTIBODIES; ARGININE	SITE-DIRECTED MUTAGENESIS; SENESCENT SOMATIC-CELLS; IGG-BINDING ANTIGEN; ERYTHROCYTE-MEMBRANE; XENOPUS-LAEVIS; PROTEIN; LOCALIZATION; MECHANISM; RESIDUES; REMOVAL	Band 3 is a ubiquitous membrane transport protein found in Golgi, mitochondrial, nuclear, and cell membranes. It is the most heavily used anion transport system in the body because it is responsible for CO2 exchange in all tissues and organs and for acid-base balance. The anion transport regions are mapped along the band 3 molecule using synthetic peptides (pep) from extracellular regions of band 3 and/or suspected anion transport regions. Assays include anion transport/inhibition and immunoblotting with anti-idiotypic antibodies to a transport inhibitor. Results indicate that anion binding/transport regions of band 3 reside within residues 549-594, (588-594 being the most active) and 804-839 (822-839 being the most active), and 869-883. Pep-COOH (residues 812-827), which is part of senescent cell antigen, is an anion binding site with most of the activity localized to residues 813-818 (the six amino acids on the amino side of pep-COOH). The stilbene disulfonate inhibitors of transport bind to peptide 812-830, and possibly peptides 788-805 and 800-818, as determined with anti-idiotypic antibodies. Residues 538-554, which have been reported to be a transport segment of band 3, do not bind sulfate. Band 3 external loops containing residues 539-553 and 812-830, and internal segments containing residues 588-594 and 869-883, are in close spacial proximity in the membrane. The contribution of lysine and/or arginine to anion transport is examined by synthesizing peptides in which glycines or arginines are substituted for lysines or arginines. Lysines can contribute to anion binding but are not required.			KAY, MMB (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,TUCSON,AZ 85724, USA.							BARTEL D, 1989, EMBO J, V8, P3601, DOI 10.1002/j.1460-2075.1989.tb08533.x; BARTEL D, 1989, BIOCHIM BIOPHYS ACTA, V985, P355, DOI 10.1016/0005-2736(89)90427-6; BJERRUM PJ, 1983, J GEN PHYSIOL, V81, P453, DOI 10.1085/jgp.81.4.453; BOSMAN G, 1990, IN PRESS GERONTOLOGY; BOSMAN GJCGM, 1988, BLOOD CELLS, V14, P19; ELGAVISH A, 1985, J CELL PHYSIOL, V125, P243, DOI 10.1002/jcp.1041250211; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1987, J BIOL CHEM, V262, P1691; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JENNINGS ML, 1989, ANION TRANSPORT PROT, V3, P59; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KAY MMB, 1985, P NATL ACAD SCI USA, V82, P1731, DOI 10.1073/pnas.82.6.1731; KAY MMB, 1984, P NATL ACAD SCI-BIOL, V81, P5753, DOI 10.1073/pnas.81.18.5753; KAY MMB, 1978, J SUPRAMOL STR CELL, V9, P555, DOI 10.1002/jss.400090409; KAY MMB, 1981, NATURE, V289, P491, DOI 10.1038/289491a0; KAY MMB, 1975, P NATL ACAD SCI USA, V72, P3521, DOI 10.1073/pnas.72.9.3521; KAY MMB, 1990, BRAIN RES BULL, V24, P105, DOI 10.1016/0361-9230(90)90293-9; KAY MMB, 1989, P NATL ACAD SCI USA, V86, P5834, DOI 10.1073/pnas.86.15.5834; KAY MMB, 1988, P NATL ACAD SCI USA, V85, P492, DOI 10.1073/pnas.85.2.492; KAY MMB, 1986, P NATL ACAD SCI USA, V83, P2463, DOI 10.1073/pnas.83.8.2463; KAY MMB, 1988, METHODS HEMATOLOGY R, P135; Kay MMB., 1986, RED CELL ANTIGENS AN, P35; KAY MMB, 1990, IN PRESS P NATL ACAD; KAY MMB, 1990, IN PRESS GERONTOLOGY; KAY MMB, 1990, IN PRESS P NATL ACAD, V3; KAY MMB, 1988, ANTIIDIOTYPES RECEPT, P231; MORGAN M, 1985, EMBO J, V4, P1927, DOI 10.1002/j.1460-2075.1985.tb03872.x; PIMPLIKAR SW, 1986, J BIOL CHEM, V261, P9770; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; ZAKI L, 1983, BIOCHEM BIOPH RES CO, V110, P616, DOI 10.1016/0006-291X(83)91194-4	31	28	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1991	5	1					109	115		10.1096/fasebj.5.1.1991578	http://dx.doi.org/10.1096/fasebj.5.1.1991578			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ET609	1991578				2022-12-28	WOS:A1991ET60900023
J	CAMBIER, JC; CAMPBELL, KS				CAMBIER, JC; CAMPBELL, KS			MEMBRANE IMMUNOGLOBULIN AND ITS ACCOMPLICES - NEW LESSONS FROM AN OLD RECEPTOR	FASEB JOURNAL			English	Review						LYMPHOCYTES-B; SIGNAL TRANSDUCTION; MB-1; B29; ANTIGEN RECEPTORS	B-CELL ANTIGEN; PROTEIN-TYROSINE KINASE; MURINE LYMPHOCYTES-B; CROSS-LINKING; MB-1 GENE; C-FOS; SURFACE IMMUNOGLOBULINS; MOLECULAR-COMPONENTS; SIGNAL TRANSDUCTION; LINEAGE CELLS	B lymphocytes express multisubunit receptors for antigen that play multiple roles in generation of the immune response. These receptors act as transmembrane signal transducers but also act to capture, concentrate, and internalize antigen for subsequent proteolytic processing and presentation to T cells. During the past decade great progress has been made in our understanding of the extended structure of the receptor and the molecular basis by which it transduces signals. It is now clear that the B cell antigen receptor is a complex structure composed of antigen binding and transducer/transporter substructures. The antigen binding substructure is composed of disulfide-linked immunoglobulin H and L chains, and is noncovalently associated with transducer/transporter substructures composed of disulfide-linked heterodimers of alpha, beta, and gamma chain products of the mb-1 (alpha) and B29 (beta and gamma) genes. The cytoplasmic tails of these chains associate with src-family tyrosine kinases including fyn, lyn, blk, and lck and other SH2-containing molecules such as phosphatidylinositol 3-kinase. Available evidence indicates that these interactions are mediated via an amino acid sequence motif of approximately 22 amino acids that is found in both alpha and beta chains. Receptor ligation triggers the activation of multiple receptor-associated src-family kinases leading to phosphorylation and activation of PLCgamma1 and PLCgamma2. Subsequent phosphoinositide hydrolysis and calcium mobilization, presumably acting in concert with other tyrosine kinase-activated mechanisms, leads to transcriptional activation of a number of immediate early genes and, ultimately, to B cell proliferation.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CAMBIER, JC (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.		Campbell, Kerry S./T-1381-2019	Cambier, John/0000-0002-7803-242X				ALESMARTINEZ JE, 1988, P NATL ACAD SCI USA, V85, P6919, DOI 10.1073/pnas.85.18.6919; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; Cambier J C, 1990, Semin Immunol, V2, P139; CAMBIER JC, 1982, J EXP MED, V156, P1635, DOI 10.1084/jem.156.6.1635; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, J IMMUNOL, V147, P1575; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL KS, 1990, LIGANDS RECEPTORS SI, P1; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CAMPBELL MA, 1992, IN PRESS MOL CELL BI; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P27454; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; COGGESHALL KM, IN PRESS P NATL ACAD; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FINKELMAN FD, 1986, B LYMPHOCYTE DIFFERE, P41; FISHER CL, 1991, J IMMUNOL, V146, P1743; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; HA H, 1992, J IMMUNOL, V1445, P1526; HAVRAN WL, 1984, J IMMUNOL, V132, P1712; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLEMSZ MJ, 1989, J IMMUNOL, V143, P1032; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LAZARUS AH, 1990, J IMMUNOL, V144, P4147; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MATSUO T, 1991, J IMMUNOL, V146, P1584; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MONROE JG, 1988, J IMMUNOL, V140, P1454; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PARKHOUSE RME, 1990, IMMUNOLOGY, V69, P298; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PURE E, 1992, P NATL ACAD SCI USA, V89, P114, DOI 10.1073/pnas.89.1.114; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROIFMAN CM, 1988, P NATL ACAD SCI USA, V85, P6914; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; TAKAGI S, 1991, J EXP MED, V174, P381, DOI 10.1084/jem.174.2.381; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TOWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VANNOESEL CJM, 1991, J IMMUNOL, V146, P3881; VANNOESEL CJM, 1990, EUR J IMMUNOL, V20, P2789, DOI 10.1002/eji.1830201238; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; WIENANDS J, 1992, NATURE, V356, P246, DOI 10.1038/356246a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAMANASHI Y, 1991, CELL REGUL, V2, P279; YU LM, 1992, J IMMUNOL, V148, P633	82	88	90	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1992	6	13					3207	3217		10.1096/fasebj.6.13.1397843	http://dx.doi.org/10.1096/fasebj.6.13.1397843			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397843				2022-12-28	WOS:A1992JU51200014
J	CLARKE, SD; ABRAHAM, S				CLARKE, SD; ABRAHAM, S			GENE-EXPRESSION - NUTRIENT CONTROL OF PRETRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL EVENTS	FASEB JOURNAL			English	Review						GENE EXPRESSION; FATTY ACID SYNTHESIS; NUTRIENTS; TRANSCRIPTION	FATTY-ACID SYNTHASE; HIGH-CARBOHYDRATE DIET; ACETYL-COA CARBOXYLASE; PYRUVATE-KINASE GENE; MESSENGER-RNA LEVELS; RAT-LIVER; THYROID-HORMONE; UNSATURATED FAT; MALIC ENZYME; MOUSE-LIVER	Regulation of gene expression by specific nutrients has become a major frontier for the next generation of nutrition scientists. The techniques of molecular biology allow us to define nutrient needs, as well as the outcomes of nutrient excesses, in terms of events that govern gene transcription, mRNA processing, mRNA stability, and mRNA translation. Evidence is presented showing that dietary constituents specifically modulate the nuclear events governing gene transcription and transcript processing. For example, fatty acid synthase gene transcription is inhibited by specific polyunsaturated fatty acids; S14 and pyruvate kinase genes contain a specific carbohydrate response element; and editing of apo B-100 to apo B-48 is enhanced by dietary carbohydrate. Nutrients such as iron and glucose are shown to control mRNA stability and translational rates of certain transcripts by regulating the interaction of cytosolic proteins with specific nucleotide sequences. The data of this review clearly demonstrate that nutrients play an active and specific role in governing the expression of select genes.	CHILDRENS HOSP NO CALIF,BRUCE LYON MEM RES LAB,OAKLAND,CA 94609	Children's Hospital Oakland Research Institute	CLARKE, SD (corresponding author), COLORADO STATE UNIV,DEPT FOOD SCI & HUMAN NUTR,230 GIFFORD HALL,FT COLLINS,CO 80523, USA.							ARMSTRONG MK, 1991, BIOCHEM BIOPH RES CO, V177, P1056, DOI 10.1016/0006-291X(91)90645-N; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BAUM CL, 1990, J BIOL CHEM, V265, P19263; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BREMNER I, 1990, ANNU REV NUTR, V10, P63, DOI 10.1146/annurev.nu.10.070190.000431; BURMEISTER LA, 1991, J BIOL CHEM, V266, P22905; CLANDININ MT, 1991, FASEB J, V5, P2761, DOI 10.1096/fasebj.5.13.1916101; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1990, J NUTR, V120, P218, DOI 10.1093/jn/120.2.218; CLARKE SD, 1992, CRC PRESS REV; COUPE C, 1990, AM J PHYSIOL, V258, pE126, DOI 10.1152/ajpendo.1990.258.1.E126; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; DE LUCA LM, 1991, FASEB J, V5, P2924; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOX JC, 1987, J BIOL CHEM, V262, P7014; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; HAILE DJ, 1990, J BIOL CHEM, V265, P12786; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1990, MOL ENDOCRINOL, V4, P1655, DOI 10.1210/mend-4-11-1655; JUMP DB, 1992, CRC PRESS REV; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MACDOUGALD OA, 1992, BIOCHEM BIOPH RES CO, V182, P631, DOI 10.1016/0006-291X(92)91779-P; MARIASH CN, 1980, J CLIN INVEST, V65, P1126, DOI 10.1172/JCI109766; MARIASH CN, 1989, ENDOCRINOLOGY, V124, P212, DOI 10.1210/endo-124-1-212; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MUNNICH A, 1987, J BIOL CHEM, V262, P17065; NESS GC, 1991, J BIOL CHEM, V266, P14854; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; PROSTKO CR, 1989, BIOCHEM J, V258, P295, DOI 10.1042/bj2580295; RENNERT H, 1990, ENDOCRINOLOGY, V127, P738, DOI 10.1210/endo-127-2-738; RONGNOPARUT P, 1991, J BIOL CHEM, V266, P8086; SCHWARTZ RS, 1983, ARCH BIOCHEM BIOPHYS, V221, P206, DOI 10.1016/0003-9861(83)90137-6; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/pnas.82.13.4526; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; STROBL W, 1989, J BIOL CHEM, V264, P1190; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; WILSON MD, 1986, J NUTR, V116, P1511, DOI 10.1093/jn/116.8.1511; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	48	125	134	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1992	6	13					3146	3152		10.1096/fasebj.6.13.1397836	http://dx.doi.org/10.1096/fasebj.6.13.1397836			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JU512	1397836				2022-12-28	WOS:A1992JU51200006
J	POLLARD, HB; DHARIWAL, K; ADEYEMO, OM; MARKEY, CJ; CAOHUY, H; LEVINE, M; MARKEY, S; YOUDIM, MBH				POLLARD, HB; DHARIWAL, K; ADEYEMO, OM; MARKEY, CJ; CAOHUY, H; LEVINE, M; MARKEY, S; YOUDIM, MBH			A PARKINSONIAN SYNDROME INDUCED IN THE GOLDFISH BY THE NEUROTOXIN MPTP	FASEB JOURNAL			English	Article						CATECHOLAMINES; MPP+; BRAIN; NEURONS; REGENERATION	1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; MONOAMINE-OXIDASE; DOPAMINERGIC NEUROTOXICITY; TYROSINE-HYDROXYLASE; PRIMATE MODEL; OPTIC-NERVE; BRAIN; NEURONS; DISEASE; N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	Parkinson's disease has been modeled in humans, lower primates, and to a lesser extent in some other vertebrates by administration of the potent neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6 tetra-hydropyridine). The MPTP model has thus drawn considerable attention as a system to search for anti-Parkinson's disease drugs, although the cost and scarcity of primates has limited extensive applications. We now report that a parkinsonian syndrome can be elicited in the common goldfish (Carassius auratus) by a single dose of MPTP. The syndrome is characterized by profound bradykinesia (slow movement), the full extent of which is reached 3 days after MPTP administration. The reduction in movement is paralleled by loss of dopamine and norepinephrine from the forebrain and mid-brain and in other brain regions as well. The toxic oxidative product of MPTP, MPP+, is also accumulated predominantly in forebrain and midbrain, and pretreatment with the monoamine oxidase blocker tranylcypromine substantially reduces accumulation of the toxic metabolite. A barely perceptible coarseness in balance adjustment also occurs in treated animals. The MPTP-treated goldfish recover normal movement and normal brain monoamine levels within 10-13 days after administration of the drug. We interpret these and other data to indicate that MPTP can induce a Parkinson's disease-like syndrome in the goldfish that is similar in many aspects to the syndrome induced by MPTP in humans and other primates. This remarkable parallel may permit the goldfish to supplement expensive and scarce primates for the purpose of searching and screening neuroprotective drugs with specific relevance to Parkinson's disease.	UNIFORMED SERV UNIV HLTH SCI, DEPT PHARMACOL, BETHESDA, MD 20892 USA; NIMH, CLIN SCI LAB, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT NEUROL, BETHESDA, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Uniformed Services University of the Health Sciences - USA	POLLARD, HB (corresponding author), NIDDKD, CELL BIOL & GENET LAB, BETHESDA, MD 20892 USA.							ADEYEMO OM, 1991, TOXICOL APPL PHARM, V108, P489, DOI 10.1016/0041-008X(91)90095-V; AMBRE JJ, 1988, CLIN PHARMACOL THER, V44, P1, DOI 10.1038/clpt.1988.104; ATTARDI DG, 1963, EXP NEUROL, V7, P46, DOI 10.1016/0014-4886(63)90093-1; BARBEAU A, 1986, MPTP NEUROTOXIN PROD; BENOWITZ LI, 1981, J NEUROSCI, V1, P300; BERNHEIM.H, 1965, KLIN WOCHENSCHR, V43, P711, DOI 10.1007/BF01707066; BIRKMAYER W, 1985, J NEURAL TRANSM, V64, P113, DOI 10.1007/BF01245973; Birkmayer W, 1983, Mod Probl Pharmacopsychiatry, V19, P170; BOYCE S, 1984, BIOCHEM PHARMACOL, V33, P1747, DOI 10.1016/0006-2952(84)90344-7; BRADBURY M, 1979, CONCEPT BLOOD BRAIN, P301; Bullock Theodore H., 1977, INTRO NERVOUS SYSTEM; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIUEH CC, 1984, PSYCHOPHARMACOL BULL, V20, P548; COHEN G, 1984, EUR J PHARMACOL, V106, P209, DOI 10.1016/0014-2999(84)90700-3; DOLI A, 1990, BRAIN RES, V534, P45; FRITZ RR, 1985, FEBS LETT, V186, P224, DOI 10.1016/0014-5793(85)80713-4; HALLMAN H, 1985, J NEUROCHEM, V44, P117, DOI 10.1111/j.1471-4159.1985.tb07120.x; HEIKKILA RE, 1985, J NEUROCHEM, V44, P310, DOI 10.1111/j.1471-4159.1985.tb07146.x; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; HEIKKILA RE, 1987, HDB PARKINSONS DISEA, P267; HESS A, 1984, ABSTR SOC NEUROSCI, V10, P705; HORNBY PJ, 1987, J COMP NEUROL, V261, P1, DOI 10.1002/cne.902610102; HORNYKIEWICZ O., 1963, WIENER KLIN WOCHENSCHR, V75, P309; IKEDA H, 1992, IN PRESS BRAIN RES; JARVIS MF, 1990, SYNAPSE, V5, P104, DOI 10.1002/syn.890050204; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JENNER P, 1984, NEUROSCI LETT, V50, P85, DOI 10.1016/0304-3940(84)90467-1; JENNER P, 1990, SEMIN NEUROSCI, V2, P117; JOHANNESSEN J N, 1985, Society for Neuroscience Abstracts, V11, P631; KAPPERS CUA, 1936, COMP ANATOMY NERVOUS, V2; KINEMUCHI H, 1987, NEUROCHEM INT, V11, P359, DOI 10.1016/0197-0186(87)90024-6; KOPP N, 1982, ACTA NEUROPATHOL, V56, P17, DOI 10.1007/BF00691177; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, BRAIN RES, V292, P390; LENT CM, 1986, MPTP NEUROTOXIN PROD; LEVINE M, 1988, J BIOL CHEM, V263, P19353; LEVINE RL, 1983, DEV BRAIN RES, V9, P416, DOI 10.1016/0165-3806(83)90043-3; LLOYD KG, 1975, J PHARMACOL EXP THER, V195, P453; MARKEY SP, 1986, MED RES REV, V6, P389, DOI 10.1002/med.2610060402; MEFFORD IN, 1980, ANAL BIOCHEM, V104, P469, DOI 10.1016/0003-2697(80)90101-3; MITCHELL IJ, 1985, NEUROSCI LETT, V61, P195, DOI 10.1016/0304-3940(85)90424-0; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; MURRAY M, 1969, EXP NEUROL, V23, P544, DOI 10.1016/0014-4886(69)90124-1; NAGATSU I, 1984, ACTA HISTOCHEM CYTOC, V17, P151, DOI 10.1267/ahc.17.151; PARISI JE, 1986, MPTP NEUROTOXIN PROD, P141; PIFL C, 1991, NEUROSCIENCE, V44, P591, DOI 10.1016/0306-4522(91)90080-8; PILEBLAD E, 1988, PHARMACOL TOXICOL, V62, P213, DOI 10.1111/j.1600-0773.1988.tb01875.x; Price K S, 1978, Adv Biochem Psychopharmacol, V19, P293; SCATTON B, 1983, BRAIN RES, V275, P321, DOI 10.1016/0006-8993(83)90993-9; SCHERER SS, 1984, J NEUROCYTOL, V13, P519, DOI 10.1007/BF01148079; SCHNEIDER JS, 1986, BRAIN RES, V373, P258, DOI 10.1016/0006-8993(86)90340-9; SPERRY RW, 1974, Q REV BIOL S, V2, P311; SPRINGER AD, 1977, BRAIN RES, V128, P405, DOI 10.1016/0006-8993(77)90167-6; SUN CJ, 1988, J NEURAL TRANSM, V74, P75, DOI 10.1007/BF01245141; TETRUD JW, 1989, ACTA NEUROL SCAND, V80, P35, DOI 10.1111/j.1600-0404.1989.tb01780.x; WOOTEN GF, 1987, HDB PARKINSONS DISEA, P237; YOON MG, 1976, J PHYSIOL-LONDON, V257, P621, DOI 10.1113/jphysiol.1976.sp011388; YOUDIM MBH, 1992, NEUROCHEM INT, V20, pS275; YOUDIM MBH, 1988, CATECHOLAMINE 2, V90; ZAMIR N, 1984, BRAIN RES, V322, P356, DOI 10.1016/0006-8993(84)90133-1; 1990, OTABA436 OFF TECHN A, P361	63	51	54	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1992	6	12					3108	3116		10.1096/fasebj.6.12.1521741	http://dx.doi.org/10.1096/fasebj.6.12.1521741			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JN505	1521741				2022-12-28	WOS:A1992JN50500013
J	SEI, Y; ARORA, PK; SKOLNICK, P; PAUL, IA				SEI, Y; ARORA, PK; SKOLNICK, P; PAUL, IA			SPATIAL-LEARNING IMPAIRMENT IN A MURINE MODEL OF AIDS	FASEB JOURNAL			English	Article						SPATIAL LEARNING AND MEMORY; HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; AIDS; AIDS DEMENTIA COMPLEX; MICE	INDUCED IMMUNODEFICIENCY SYNDROME; MICE; RETROVIRUS; INFECTION; VIRUS; ANTIDEPRESSANTS; LOCALIZATION; BRAINS; MAIDS	Mice infected with an immunosuppressive murine leukemia virus (MuLV) mixture, LP-BM5, displayed profound and selective deficits in spatial learning in a modified Morris water maze. These deficits appeared before the appearance of gross neurological impairment or histopathological changes in the central nervous system. Thus, LP-BM5-infected mice displayed deficits in several aspects of trained performance compared to controls. Furthermore, a failure to exhibit any evidence of task acquisition in this maze was observed almost twice as frequently (P < 0.0005) in infected mice as in uninfected controls. Moreover, in the absence of gross visual, motoric, or motivational impairment, LP-BM5 MuLV-infected animals exhibited neither the target directed search pattern nor the spatial preference characteristic of controls. The spatial learning and memory deficit described here is the first report of cognitive impairment accompanying viral-induced immunosuppression in a nonprimate species.	NIDDK,NEUROSCI LAB,BLDG 8,ROOM 111,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ANDERS KH, 1986, AM J PATHOL, V124, P537; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BRIONI JD, 1990, BRAIN RES, V522, P227, DOI 10.1016/0006-8993(90)91465-S; BULLER RML, 1987, J VIROL, V61, P383, DOI 10.1128/JVI.61.2.383-387.1987; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHATTOPADHYAY SK, 1991, J VIROL, V65, P4232, DOI 10.1128/JVI.65.8.4232-4241.1991; DUNHAM NW, 1956, J AM PHARM ASSOC, V3, P112; EPSTEIN LG, 1985, AIDS RES, V1, P447; GLOWA JR, 1992, BRAIN RES, V570, P49, DOI 10.1016/0006-8993(92)90562-N; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HO DD, 1989, ANN INTERN MED, V107, P828; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; JOHNSON RT, 1988, FASEB J, V2, P2970, DOI 10.1096/fasebj.2.14.2846395; JOLICOEUR P, 1991, FASEB J, V5, P2398, DOI 10.1096/fasebj.5.10.2065888; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SEI Y, 1992, J NEUROIMMUNOL, V37, P131, DOI 10.1016/0165-5728(92)90164-G; SELIGMAN MEP, 1975, J COMP PHYSIOL PSYCH, V88, P542, DOI 10.1037/h0076431; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; UPCHURCH M, 1988, HARM BIOCH BEHAV, V29, P325; WEHNER JM, 1989, PHARMACOL BIOCHEM BE, V32, P543, DOI 10.1016/0091-3057(89)90194-9; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	28	51	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1992	6	11					3008	3013		10.1096/fasebj.6.11.1644264	http://dx.doi.org/10.1096/fasebj.6.11.1644264			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644264				2022-12-28	WOS:A1992JJ66500016
J	HASLER, P; MOORE, JJ; KAMMER, GM				HASLER, P; MOORE, JJ; KAMMER, GM			HUMAN LYMPHOCYTE-T CAMP-DEPENDENT PROTEIN-KINASE - SUBCELLULAR DISTRIBUTIONS AND ACTIVITY RANGES OF TYPE-I AND TYPE-II ISOZYMES	FASEB JOURNAL			English	Note						SIGNAL TRANSDUCTION; IMMUNOREGULATION	SYSTEMIC LUPUS-ERYTHEMATOSUS; CYCLIC-AMP; CATALYTIC SUBUNIT; GOLGI-COMPLEX; PATHWAY; BINDING; ACCUMULATION; MODULATION; MUSCLE; ASSAY	The role of the type I and type II protein kinase A isozymes in the regulation of human T lymphocyte immune effector functions has not been ascertained. To approach this question, we first characterized the distribution and enzyme activities of the type I and type II protein kinase A (PKA) isozymes in normal, human T lymphocytes. T cells possess both type I and type II isozymes with an activity ratio of 5.0:1 +/- 0.71 (mean +/- SD). The type I isozyme associates predominately with the plasma membrane whereas the type II isozyme localizes primarily to the cytosol. Analyses of isozyme activities demonstrated that T cells from approximately one-third of 16 healthy donors exhibited significantly higher type II isozyme activities (higher type II, type II(H)) than the remaining donors (lower type II, type II(L)) (mean = 605 +/- 75 pmol.min-1.mg protein-1, P < 0.001). Scatchard analyses of [H-3]cAMP binding in the cytosolic fraction demonstrated similar K(d) values (type II(H), 1.1 x 10(-7)M; type II(L), 9.0 x 10(-8) M); however, the B(max) (maximal binding) of the type II(H) was 400 fmol/mg protein compared to the B(max) of the type II(L) of 126 fmol/mg protein. Scatchard analysis of [H-3]cAMP binding to the type I isozyme associated with membrane fragments bad a K(d) of 5.6 x 10(-8) M and a B(max) of 283 fmol/mg protein. Eadie-Hofstee plots of type II(H) and type II(L) gave a K(m) and V(max) of 2.3 mg/ml and 1.5 nmol.mg.1.min-1, and 2.1 mg/ml and 1.6 nmol.mg-1.min-1, respectively. The 3.2-fold higher maximal binding of the type II isozyme in one-third of healthy donors may reflect a greater amount of isozyme protein. The compartmentalization of type I PKA isozyme to the plasma membrane and type II PKA isozyme to the cytosol may serve to localize the isozymes to their respective substrates in T lymphocytes.	CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,SCH MED,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,SCH MED,DEPT PEDIAT,CLEVELAND,OH 44106; METROHLTH MED SYSTEM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; MetroHealth System					NCRR NIH HHS [M01-RR 00080] Funding Source: Medline; NIAMS NIH HHS [AR-39501] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039501] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AVERILL LE, 1988, CELL IMMUNOL, V115, P88, DOI 10.1016/0008-8749(88)90164-5; BIRCH RE, 1982, CLIN EXP IMMUNOL, V48, P231; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYUS CV, 1977, NATURE, V268, P63, DOI 10.1038/268063a0; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHAPLIN DD, 1979, BIOCHEM J, V182, P525, DOI 10.1042/bj1820525; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; Cornish-Bowden A., 1979, FUNDAMENTALS ENZYME, DOI 10.1016/C2013-0-04130-8; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; EVANS WH, 1978, LABORATORY TECHNIQUE, P202; FARRAR WL, 1987, J IMMUNOL, V139, P2075; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; Gill G N, 1979, Adv Cyclic Nucleotide Res, V10, P93; GOLDFARB RH, 1981, J IMMUNOL, V126, P2129; GOLDSCHMIDT LP, 1986, ARTHRITIS RHEUM, V29, P646, DOI 10.1002/art.1780290509; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; JOHNSON KW, 1988, P NATL ACAD SCI USA, V85, P6072, DOI 10.1073/pnas.85.16.6072; KAMMER GM, 1988, P NATL ACAD SCI USA, V85, P792, DOI 10.1073/pnas.85.3.792; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KEELY SL, 1975, P NATL ACAD SCI USA, V72, P1501, DOI 10.1073/pnas.72.4.1501; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAXMINARYANA D, 1991, FASEB J, V5, pA992; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MANDLER R, 1982, P NATL ACAD SCI-BIOL, V79, P7542, DOI 10.1073/pnas.79.23.7542; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MOORE JJ, 1983, J CLIN ENDOCR METAB, V56, P1035, DOI 10.1210/jcem-56-5-1035; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RUBIN CS, 1979, J BIOL CHEM, V254, P2439; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TRINCZEK B, 1990, FEBS LETT, V277, P167, DOI 10.1016/0014-5793(90)80835-7; UNO I, 1977, J BIOL CHEM, V252, P5164; WATSON PA, 1989, J BIOL CHEM, V264, P14735; ZICK Y, 1979, J BIOL CHEM, V254, P879	43	27	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2735	2741		10.1096/fasebj.6.9.1319361	http://dx.doi.org/10.1096/fasebj.6.9.1319361			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1319361				2022-12-28	WOS:A1992HZ48100016
J	ECKHARDT, LA				ECKHARDT, LA			IMMUNOGLOBULIN GENE-EXPRESSION ONLY IN THE RIGHT CELLS AT THE RIGHT TIME	FASEB JOURNAL			English	Review						ENHANCER; OCTAMER; TRANSCRIPTION FACTOR; NEGATIVE REGULATION	HEAVY-CHAIN ENHANCER; TRANSGENIC MICE; OCTAMER MOTIF; MU GENE; LOCUS; TRANSCRIPTION; EXTINCTION; PROTEINS; BINDING; REGION	Study of immunoglobulin gene transcriptional control has disclosed a complexity that rivals that of the antibody repertoire itself. Although some DNA sequences that regulate transcription of these genes were identified almost a decade ago, additional regulatory sequences continue to be discovered, some in regions far removed (as much as 200 kb) from the actual site of transcription. This has invoked models of regulation in which the higher-order structure of chromatin must be taken into account. Within the regulatory DNA sequences themselves, there is a bewildering array of sites that bind proteins and a growing catalog of proteins that can bind each of those sites. The proteins are believed to be the physical link between the regulatory DNA sequences and the protein machinery actually carrying out transcription. Specific interactions among proteins that can bind the same site and among proteins that bind different sites have been described. A challenge remaining is to identify those interactions that occur in vivo and that lead to progressively more efficient Ig production in the developing B cell, but which disallow Ig production in non-B cells.			ECKHARDT, LA (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.							ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; ECCLES S, 1990, New Biologist, V2, P801; GERLINGER P, 1986, B LYMPHOCYTE TARGETI; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GREGOR PD, 1986, MOL CELL BIOL, V6, P1903, DOI 10.1128/MCB.6.6.1903; GROSSCHEDL R, 1988, CELL, V55, P645, DOI 10.1016/0092-8674(88)90223-1; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; Honjo T., 1989, Immunoglobulin genes., P123; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; KEMP DJ, 1980, P NATL ACAD SCI-BIOL, V77, P2876, DOI 10.1073/pnas.77.5.2876; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PORTON B, 1990, MOL CELL BIOL, V10, P1076, DOI 10.1128/MCB.10.3.1076; Rathbun G., 1989, Immunoglobulin genes., P63; REIK W, 1987, EUR J IMMUNOL, V17, P465, DOI 10.1002/eji.1830170405; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SEN R, 1989, IMMUNOGLOBULIN GENES, P327; STORB U, 1986, J EXP MED, V164, P627, DOI 10.1084/jem.164.2.627; STORB U, 1989, IMMUNOGLOBULIN GENES, P303; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZALLER DM, 1988, MOL CELL BIOL, V8, P1932, DOI 10.1128/MCB.8.5.1932	45	13	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2553	2560		10.1096/fasebj.6.8.1592208	http://dx.doi.org/10.1096/fasebj.6.8.1592208			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592208				2022-12-28	WOS:A1992HU42300008
J	TEICHBERG, VI				TEICHBERG, VI			GLIAL GLUTAMATE RECEPTORS - LIKELY ACTORS IN BRAIN SIGNALING	FASEB JOURNAL			English	Article						GLIAL GLUTAMATE RECEPTORS; GLIAL MEMBRANE; INTRAGLIAL CALCIUM; KAINATE-BINDING PROTEIN	EXCITATORY AMINO-ACIDS; ION CHANNEL EXPRESSION; WHITE MATTER GLIA; CULTURED ASTROCYTES; KAINATE RECEPTOR; PROGENITOR-CELL; CHICK; DEPOLARIZATION; LOCALIZATION; POTASSIUM	It has become clear that the neurotransmitter glutamate does not confine its excitatory effects to central nervous system neurons but interacts also with glial cells. Neurons and glia share the same types of ionotropic and metabotropic glutamate receptors except for the N-methyl-D-aspartate receptor, which is not found on glia. Applied on cultured glial cells, glutamate regulates the opening of receptor channels, activates second messengers, and causes the release of neuroactive compounds. Although glutamate and glutamate receptors confer on cultured glia the ability to receive and emit signals, it remains to be established whether glial signaling takes place in vivo. The chick Bergmann glial cells provide a unique experimental system with which to test the contribution of glial glutamate receptors to neuronal electrical activity. These cells are the exclusive carriers in the cerebellum of functional kainate receptors. The synaptic location of these receptors, their ion channel properties, and their regulation by phosphorylation reactions suggest that glial kainate receptors play a role in regulating synaptic efficacy and plasticity. If proved, this concept may require a modification of the anatomical and functional definition of a synapse to include a glial component as well.			TEICHBERG, VI (corresponding author), WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL.							BACKUS KH, 1989, J NEUROSCI RES, V22, P274, DOI 10.1002/jnr.490220307; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARRES BA, 1989, NATURE, V339, P343, DOI 10.1038/339343a0; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; BOWMAN CL, 1984, NATURE, V311, P656, DOI 10.1038/311656a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHAN PH, 1990, J NEUROSCI RES, V25, P87, DOI 10.1002/jnr.490250111; CHOI DW, 1987, J NEUROSCI, V7, P357; CONDORELLI DF, 1989, GLIA, V2, P67, DOI 10.1002/glia.440020108; CONSTANTI A, 1978, BRAIN RES, V153, P183, DOI 10.1016/0006-8993(78)91142-3; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORNELLBELL AH, 1990, GLIA, V3, P322, DOI 10.1002/glia.440030503; CULLCANDY SG, 1988, J PHYSIOL-LONDON, V400, P189, DOI 10.1113/jphysiol.1988.sp017117; DAVID P, 1988, EXP EYE RES, V46, P657, DOI 10.1016/S0014-4835(88)80054-X; ENKVIST MOK, 1989, GLIA, V2, P397, DOI 10.1002/glia.440020602; GALLO V, 1989, J NEUROCHEM, V52, P1, DOI 10.1111/j.1471-4159.1989.tb10890.x; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GASSER UE, 1990, J NEUROSCI, V10, P1276; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GREGOR P, 1988, EMBO J, V7, P2673, DOI 10.1002/j.1460-2075.1988.tb03120.x; HAAS J, 1991, GLIA, V4, P111, DOI 10.1002/glia.440040113; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KETTENMANN H, 1984, NEUROSCI LETT, V47, P271, DOI 10.1016/0304-3940(84)90525-1; KETTENMANN H, 1984, NEUROSCI LETT, V52, P25, DOI 10.1016/0304-3940(84)90345-8; KRNJEVIC K, 1967, EXP BRAIN RES, V3, P306, DOI 10.1007/BF00237557; LEHMANN A, 1988, NEUROCHEM INT, V13, P557, DOI 10.1016/0197-0186(88)90088-5; LIEBERMAN EM, 1989, GLIA, V2, P94, DOI 10.1002/glia.440020205; MACVICAR BA, 1988, NEUROSCIENCE, V25, P721, DOI 10.1016/0306-4522(88)90272-2; MARRERO H, 1989, NATURE, V339, P378, DOI 10.1038/339378a0; MURPHY S, 1988, GLIA, V1, P241, DOI 10.1002/glia.440010402; ORTEGA A, 1991, NEUROSCIENCE, V41, P335, DOI 10.1016/0306-4522(91)90331-H; ORTEGA A, 1990, J BIOL CHEM, V265, P21404; PEARCE B, 1986, NEUROSCI LETT, V72, P335, DOI 10.1016/0304-3940(86)90537-9; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1983, J NEUROSCI, V3, P1289; SOMOGYI P, 1990, NEUROSCIENCE, V35, P9, DOI 10.1016/0306-4522(90)90116-L; SONTHEIMER H, 1988, GLIA, V1, P328, DOI 10.1002/glia.440010505; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WEINREICH D, 1975, BRAIN RES, V84, P137, DOI 10.1016/0006-8993(75)90807-0	41	131	132	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1991	5	15					3086	3091		10.1096/fasebj.5.15.1660422	http://dx.doi.org/10.1096/fasebj.5.15.1660422			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1660422	Bronze			2022-12-28	WOS:A1991GU84200012
J	BERGEN, WG; MERKEL, RA				BERGEN, WG; MERKEL, RA			BODY-COMPOSITION OF ANIMALS TREATED WITH PARTITIONING AGENTS - IMPLICATIONS FOR HUMAN HEALTH	FASEB JOURNAL			English	Review						FOOD ANIMAL PRODUCTS; FAT CONTENT; DAILY INGESTION; PARTITIONING AGENTS; LIPID METABOLISM; PROTEIN METABOLISM	SKELETAL-MUSCLE; PROTEIN-SYNTHESIS; GROWTH-HORMONE; CLENBUTEROL; METABOLISM; RACTOPAMINE; DEPOSITION; CIMATEROL; AGONIST; TISSUE	Excess fat in meat products has been identified as a dietary problem by public health officials. The meat animal industry has responded during the last 25 years to concerns about excess fat intake from animal products by implementing strategies to depress fat deposition and increase lean (protein) tissue gain in meat animals. The most successful strategy to date is the use of large, late-maturing animals for meat production. At desired market weights, these animals are much leaner than smaller, early-maturing animals. In addition, exogenous agents such as anabolic steroids (FDA approved for cattle) have been used to increase lean gain and depress fat deposition in cattle. Growth hormone (GH) and beta-adrenergic agonists (beta-AA) are not yet approved by the FDA, but if/when approved would also markedly increase lean gain and depress fat deposition. Both GH and beta-AA are called partitioning agents because they partition nutrients and energy toward lean (protein) accretion and dramatically lower fat deposition. Contingent on approval by the FDA and subsequent adoption of partitioning agents by the animal industry would result in meat products containing less and 30% of total calories from fat.			BERGEN, WG (corresponding author), MICHIGAN STATE UNIV,GROWTH BIOL PROGRAM,205 ANTHONY HALL,E LANSING,MI 48824, USA.							ANDERSON PT, 1990, J NUTR, V120, P1677, DOI 10.1093/jn/120.12.1677; BABIJ P, 1988, AM J PHYSIOL, V254, pC657, DOI 10.1152/ajpcell.1988.254.5.C657; BAUMAN DE, 1982, FED PROC, V41, P2538; BERGEN WG, 1989, J ANIM SCI, V67, P2255, DOI 10.2527/jas1989.6792255x; BERGEN WG, 1974, J ANIM SCI, V38, P1079, DOI 10.2527/jas1974.3851079x; Bergen WG, 1987, J ANIM SCI, V65, P88; BLAXTER K, 1989, ENERGY METABOLISM AN, P254; BOOTH AN, 1960, SCIENCE, V131, P1807, DOI 10.1126/science.131.3416.1807; Boyd R D, 1989, ANIMAL GROWTH REGULA, P257, DOI [10.1007/978-1-4684-8872-2_12, DOI 10.1007/978-1-4684-8872-2_12]; BUTTERY PJ, 1990, P NUTR SOC, V49, P459, DOI 10.1079/PNS19900054; BUTTERY PJ, 1983, P NUTR SOC, V42, P137, DOI 10.1079/PNS19830020; CLAEYS MC, 1989, J ANIM SCI, V67, P2245, DOI 10.2527/jas1989.6792245x; CORNETT S, 1990, DROVERS J, V118, P14; CUNNINGHAM HM, 1963, J ANIM SCI, V22, P632, DOI 10.2527/jas1963.223632x; DAVIDSON TD, 1989, ENDOCR REV, V8, P115; DICKERSON PS, 1990, THESIS MICHIGAN STAT; EADARA JK, 1989, METABOLISM, V38, P883, DOI 10.1016/0026-0495(89)90236-9; EARLY RJ, 1990, J ANIM SCI, V68, P4153; ETHERTON TD, 1989, BIOTECHNOLOGY IN GROWTH REGULATION, P97; FENNESSY PF, 1990, NEW ZEAL J AGR RES, V33, P413, DOI 10.1080/00288233.1990.10428438; GAILBRAITH H, 1981, NUTR ABSTR REV B, V51, P521; Goll DE, 1989, ANIMAL GROWTH REGULA, P141; GRIGSBY JS, 1976, GROWTH, V40, P303; GRIGSBY ME, 1986, DOMEST ANIM ENDOCRIN, V3, P261, DOI 10.1016/0739-7240(86)90024-X; HELFERICH WG, 1990, ENDOCRINOLOGY, V126, P3096, DOI 10.1210/endo-126-6-3096; HOFFMAN B, 1986, VET SCI COMP MED A, P111; JASKEVICH TC, 1990, SCIENCE, V249, P5875; JOHNSON RJ, 1989, WORLDS POULTRY SCI J, V46, P228; MACLENNAN PA, 1989, BIOCHEM J, V264, P573, DOI 10.1042/bj2640573; MCGINNIS JM, 1989, AM J CLIN NUTR, V49, P23, DOI 10.1093/ajcn/49.1.23; MERKEL RA, 1987, FED P 1177A, V46; PELL JM, 1989, BIOTECHNOLOGY IN GROWTH REGULATION, P85; PRESTON RL, 1975, J ANIM SCI, V41, P1414, DOI 10.2527/jas1975.4151414x; RICKS CA, 1984, J ANIM SCI, V59, P1247, DOI 10.2527/jas1984.5951247x; RIKHARDSSON G, 1991, J ANIM SCI, V69, P396; ROUPAS P, 1991, P NATL ACAD SCI USA, V88, P1691, DOI 10.1073/pnas.88.5.1691; SAINZ RD, 1990, ANIM PROD, V51, P551, DOI 10.1017/S0003356100012587; VERDEAL K, 1979, J FOOD PROTECT, V42, P577, DOI 10.4315/0362-028X-42.7.577; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; YANG YT, 1989, BIOCHEM J, V261, P1; 1983, USDA AGR HDB, V813; 1986, USDA AGR HDB, V815; 1988, NUTRIENT VALUES MUSC, P1; 1979, USDA AGR HDB, V87; 1980, USDA AGR HDB, V810; [No title captured]; 1990, MEAT FACTS	47	33	33	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2951	2957		10.1096/fasebj.5.14.1684326	http://dx.doi.org/10.1096/fasebj.5.14.1684326			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1684326	Bronze			2022-12-28	WOS:A1991GP26900010
J	ROSSI, P; MOSCHESE, V				ROSSI, P; MOSCHESE, V			MOTHER-TO-CHILD TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS	FASEB JOURNAL			English	Review						HIV DETECTION; HIV-INFECTED INFANTS; HIV-INFECTED MOTHERS	POLYMERASE CHAIN-REACTION; PRINCIPAL NEUTRALIZING DOMAIN; ENVELOPE GLYCOPROTEIN; CELLULAR CYTOTOXICITY; SEROPOSITIVE MOTHERS; MATERNAL ANTIBODIES; INFANT TRANSMISSION; INCUBATION PERIODS; INFECTED MOTHERS; TYPE-1 ENVELOPE	Transmission of HIV virus from an infected mother to her offspring is becoming the leading cause of spreading in the pediatric population. This is particularly burdensome in the pattern II countries where HIV infection has reached epidemic proportions and infection rates affect more women of childbearing age than men. During the last few years considerable effort has been directed at defining the optimal methods for identifying infants of HIV-infected mothers who will themselves prove to be infected because conventional serological assessment is impaired due to placental transfer of maternal IgG. At present, detection of specific IgA to HIV proteins, evaluation of autochthonous antibody production in vitro from infants' lymphocytes, and gene amplification of HIV DNA/RNA by polymerase chain reaction are the most promising procedures for early diagnosis within the first 6 months of life. Nevertheless all these techniques are cumbersome when evaluating specimens from the newborn child. Many studies have been performed to identify those maternal factors affecting the risk of vertical transmission. So far, none of them has shown real prognostic value. However, evaluation of maternal antibody response to functional epitopes of HIV envelope proteins such as the principal neutralizing domain, in some epidemiological settings, seems to correlate to a reduced rate of mother-to-child transmission.	UNIV ROME TOR VERGATA,SCH MED,DEPT PEDIAT,ROME,ITALY	University of Rome Tor Vergata	ROSSI, P (corresponding author), KAROLINSKA INST,DEPT IMMUNOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		rossi, paolo/D-6504-2012; Rossi, Paolo/K-5746-2016; MOSCHESE, VIVIANA/AHE-8931-2022	Rossi, Paolo/0000-0003-2620-7918; MOSCHESE, VIVIANA/0000-0001-7650-0632				AMADORI A, 1988, LANCET, V1, P852; ANDIMAN WA, 1990, AM J DIS CHILD, V144, P758, DOI 10.1001/archpedi.1990.02150310026020; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BROLIDEN PA, 1989, AIDS, V3, P577, DOI 10.1097/00002030-198909000-00004; BURGER H, 1990, LANCET, V336, P134, DOI 10.1016/0140-6736(90)91657-V; CALDWELL MB, 1991, PEDIATR CLIN N AM, V38, P1; CHANH TC, 1986, EMBO J, V5, P3065, DOI 10.1002/j.1460-2075.1986.tb04607.x; CHIN J, 1989, MATERNAL CHILD CARE, P299; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EVANS LA, 1989, AIDS, V3, P273, DOI 10.1097/00002030-198905000-00004; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FALLOON J, 1989, J PEDIATR-US, V114, P1, DOI 10.1016/S0022-3476(89)80596-7; GNANN JW, 1987, J INFECT DIS, V156, P261, DOI 10.1093/infdis/156.2.261; GOEDERT JJ, 1989, LANCET, V2, P1351; GUPTA P, 1989, J VIROL, V63, P2361, DOI 10.1128/JVI.63.5.2361-2365.1989; HAIGWOOD NL, 1990, AIDS RES HUM RETROV, V6, P855, DOI 10.1089/aid.1990.6.855; HEWLETT IK, 1990, J ACQ IMMUN DEF SYND, V3, P714; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; HOLMBERG JD, 1987, J INFECT DIS, V155, P626; HUSSON RN, 1990, PEDIATRICS, V86, P1; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P458; IPPOLITO G, 1991, J ACQ IMMUN DEF SYND, V4, P402; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KARPAS A, 1990, P NATL ACAD SCI USA, V87, P7613, DOI 10.1073/pnas.87.19.7613; KRASINSKI K, 1991, PEDIATR CLIN N AM, V38, P17; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LAURE F, 1988, LANCET, V2, P538; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LIZHEN P, 1987, J INFECTION, V155, P626; LJUNGGREN K, 1990, J INFECT DIS, V161, P198, DOI 10.1093/infdis/161.2.198; LOCHE M, 1988, LANCET, V2, P418; LOMBARDI V, 1991, IN PRESS ARCH AIDS R; MASUDA T, 1990, J IMMUNOL, V145, P3240; MATHEZ D, 1990, P NATL ACAD SCI USA, V87, P7438, DOI 10.1073/pnas.87.19.7438; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MUNOZ A, 1988, J ACQ IMMUN DEF SYND, V1, P396; OLDSTONE MBA, 1989, CELL, V56, P517, DOI 10.1016/0092-8674(89)90573-4; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PAHWA S, 1989, P NATL ACAD SCI USA, V86, P7532, DOI 10.1073/pnas.86.19.7532; PERRYMAN LE, 1988, J VIROL, V62, P3073, DOI 10.1128/JVI.62.8.3073-3076.1988; PEZZELLA M, 1989, BRIT MED J, V298, P713, DOI 10.1136/bmj.298.6675.713; PIZZO PA, 1990, J INFECT DIS, V161, P316, DOI 10.1093/infdis/161.2.316; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482; ROBERTGUROFF M, 1985, NATURE, V316, P73; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROSSI P, 1990, LANCET, V335, P359, DOI 10.1016/0140-6736(90)90651-K; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; RYDER W, 1989, NEW ENGL J MED, V320, P1367; SCARLATTI G, 1991, IN PRESS AIDS; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P277; SKINNER KS, 1988, VACCINES 1988 NEW CH; TANNEAU F, 1990, J INFECT DIS, V162, P837, DOI 10.1093/infdis/162.4.837; TSCHACHLER E, 1990, J VIROL, V64, P2250, DOI 10.1128/JVI.64.5.2250-2259.1990; VUJCIC L, 1990, AIDS RES HUM RETROV, V6, P847, DOI 10.1089/aid.1990.6.847; WAHREN B, 1989, J ACQ IMMUN DEF SYND, V4, P448; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WEISS RA, 1985, NATURE, V316, P69, DOI 10.1038/316069a0; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003; 1988, LANCET, V2, P1043; 1988, LANCET, V2, P1039; 1991, LANCET, P253	66	23	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1991	5	10					2419	2426		10.1096/fasebj.5.10.2065890	http://dx.doi.org/10.1096/fasebj.5.10.2065890			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065890				2022-12-28	WOS:A1991FW08700013
J	FUNK, CD; FUNK, LB; KENNEDY, ME; PONG, AS; FITZGERALD, GA				FUNK, CD; FUNK, LB; KENNEDY, ME; PONG, AS; FITZGERALD, GA			HUMAN PLATELET ERYTHROLEUKEMIA CELL PROSTAGLANDIN G/H SYNTHASE - CDNA CLONING, EXPRESSION, AND GENE CHROMOSOMAL ASSIGNMENT	FASEB JOURNAL			English	Note						CYCLOOXYGENASE; ASPIRIN; PHORBOL ESTER; QUANTITATIVE PCR; CHRONIC MYELOGENOUS LEUKEMIA	HUMAN ENDOTHELIAL-CELLS; MESSENGER-RNA; ENDOPEROXIDE SYNTHASE; COMPLEMENTARY-DNA; MOLECULAR-CLONING; GROWTH-FACTOR; H SYNTHASE; CYCLOOXYGENASE; ASPIRIN; SHEEP	Platelets metabolize arachidonic acid to thromboxane A2, a potent platelet aggregator and vasoconstrictor compound. The first step of this transformation is catalyzed by prostaglandin (PG) G/H synthase, a target site for nonsteroidal antiinflammatory drugs. We have isolated the cDNA for both human platelet and human erythroleukemia cell PGG/H synthase using the polymerase chain reaction and conventional screening procedures. The cDNA encoding the full-length protein was expressed in COS-M6 cells. Microsomal fractions from transfected cells produced prostaglandin endoperoxide-derived products which were inhibited by indomethacin and aspirin. Mutagenesis of the serine residue at position 529, the putative aspirin acetylation site, to an asparagine reduced cyclooxygenase activity to barely detectable levels, an effect observed previously with the expressed sheep vesicular gland enzyme. Platelet-derived growth factor and phorbol ester differentially regulated the expression of PGG/H synthase mRNA levels in the megakaryocytic/platelet-like HEL cell line. The PGG/H synthase gene was assigned to chromosome 9 by analysis of a human-hamster somatic hybrid DNA panel. The availability of platelet PGG/H synthase cDNA should enhance our understanding of the important structure/function domains of this protein and its gene regulation.			FUNK, CD (corresponding author), VANDERBILT UNIV,DIV CLIN PHARMACOL,NASHVILLE,TN 37232, USA.		FitzGerald, Garret A/A-4222-2010; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NHLBI NIH HHS [HL30400] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030400] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JM, 1990, PROSTAGLANDINS, V40, P585, DOI 10.1016/0090-6980(90)90003-E; BAILEY JM, 1989, TRENDS LIPID MED RES, V3, P8; BRASS LF, 1991, J BIOL CHEM, V266, P958; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEWITT D L, 1989, P109; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EGGLESTON DL, 1990, PROSTAGLANDINS, V39, P675, DOI 10.1016/0090-6980(90)90027-S; FITZGERALD GA, 1987, FASEB J, V46, P154; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1991, IN PRESS J BIOL CHEM; GOERIG M, 1987, J CLIN INVEST, V79, P903, DOI 10.1172/JCI112900; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; PATRONO C, 1986, EUR HEART J, V7, P454, DOI 10.1093/oxfordjournals.eurheartj.a062091; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; ROTH GJ, 1975, J CLIN INVEST, V56, P624, DOI 10.1172/JCI108132; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YOKOYAMA C, 1991, ADV PROSTAG THROMB L, V21, P61; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; 1988, NEW ENGL J MED, V321, P129	36	519	550	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2304	2312		10.1096/fasebj.5.9.1907252	http://dx.doi.org/10.1096/fasebj.5.9.1907252			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1907252				2022-12-28	WOS:A1991FP87200013
J	KATZMAN, R; SAITOH, T				KATZMAN, R; SAITOH, T			ADVANCES IN ALZHEIMERS-DISEASE	FASEB JOURNAL			English	Review						ALZHEIMERS DISEASE; EPIDEMIOLOGY; POSITRON EMISSION TOMOGRAPHY; GENETICS; NEURITIC PLAQUE; NEUROFIBRILLARY TANGLE; PAIRED HELICAL FILAMENT; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; PROTEIN KINASES	BETA-PROTEIN-PRECURSOR; AMYLOID DEPOSITS; SENILE PLAQUES; SECRETED FORM; NEXIN-II; BRAIN; DEMENTIA; IDENTIFICATION; INTERLEUKIN-1; TWINS	The problem of the etiology of Alzheimer's disease has not been solved. But in the past several years there have been significant extensions of our knowledge of the disease and advances in determining the molecular changes underlying the disorder. There is now convincing evidence that the dementia per se is caused by loss of neurons and synapses, particularly in neocortex and hippocampus. The molecular aspects of amyloid and its precursor protein have been defined. The nature of intracellular changes leading to accumulation of the paired helical filament is beginning to be understood. For the first time, putative risk factors can be described in terms of pathogenetic mechanisms. Thus, it may become possible in the not-too-distant future to discover interventions that will slow the progress of this devastating disease.			KATZMAN, R (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, DEPT NEUROSCI, LA JOLLA, CA 92093 USA.				NATIONAL INSTITUTE ON AGING [P50AG005131] Funding Source: NIH RePORTER; NIA NIH HHS [AG05131] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BLASS JP, 1989, BIOL MARKERS ALZHEIM, P153; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; COLE GM, 1990, INT CONGR SER, V884, P113; COOK RH, 1981, ARCH NEUROL-CHICAGO, V38, P300, DOI 10.1001/archneur.1981.00510050066011; CROSS PS, 1986, EPIDEMIOLOGY DEMENTI; DEKOSKY ST, 1990, ANN NEUROL, V27, P457, DOI 10.1002/ana.410270502; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FRACKOWIAK RSJ, 1981, BRAIN, V104, P753, DOI 10.1093/brain/104.4.753; FRIEDLAND RP, 1985, J CEREB BLOOD FLO S1, V5, pS609; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAMOS JE, 1989, NEUROLOGY, V39, P355, DOI 10.1212/WNL.39.3.355; HASEGAWA M, 1990, NEURON, V4, P909, DOI 10.1016/0896-6273(90)90144-5; HAYNES AR, 1989, BIOL AMRKERS ALZHEIM, P138; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1085; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HIGGINS GA, 1990, P NATL ACAD SCI USA, V87, P3032, DOI 10.1073/pnas.87.8.3032; HYMAN BT, 1988, ANN NEUROL, V23, P371, DOI 10.1002/ana.410230410; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JARVIK LF, 1980, ARCH GEN PSYCHIAT, V37, P280; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KOSIK KS, 1989, J GERONTOL, V44, pB55, DOI 10.1093/geronj/44.3.B55; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MASLIAH E, 1990, J NEUROSCI, V10, P2113; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MCKEE AD, 1990, J NEUROAPTHOL EXP NE, V1, P49; Mortimer J A, 1990, Adv Neurol, V51, P27; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; OHTSUBO K, 1990, ACTA NEUROPATHOL, V79, P480, DOI 10.1007/BF00296106; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PEARSON RCA, 1985, P NATL ACAD SCI USA, V82, P4531, DOI 10.1073/pnas.82.13.4531; PETTEGREW JW, 1989, ANN NY ACAD SCI, V568, P5; ROGERS J, 1985, J NEUROSCI, V5, P2801; ROSENBLATT DE, 1989, ANN NEUROL, V26, P628, DOI 10.1002/ana.410260507; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Saitoh T, 1989, Prog Clin Biol Res, V317, P769; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SCHELLENBERG GD, 1987, J NEUROGENET, V4, P97, DOI 10.3109/01677068709102337; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SNOW AD, 1988, AM J PATHOL, V133, P456; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; TERRY RD, 1981, ANN NEUROL, V10, P184, DOI 10.1002/ana.410100209; TERRY RD, 1990, J NEUROPATHOL EXP NE, V49, P335; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEITKAMP LR, 1983, AM J HUM GENET, V35, P443; WHITSON JS, 1990, NEUROSCI LETT, V110, P319, DOI 10.1016/0304-3940(90)90867-9; WOLOZIN B, 1987, ANN NEUROL, V22, P521, DOI 10.1002/ana.410220412; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412	66	310	323	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR 1	1991	5	3					278	286		10.1096/fasebj.5.3.2001787	http://dx.doi.org/10.1096/fasebj.5.3.2001787			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001787				2022-12-28	WOS:A1991FC55600004
J	EDSTROM, RD; YANG, XR; LEE, G; EVANS, DF				EDSTROM, RD; YANG, XR; LEE, G; EVANS, DF			VIEWING MOLECULES WITH SCANNING TUNNELING MICROSCOPY AND ATOMIC FORCE MICROSCOPY	FASEB JOURNAL			English	Article									UNIV MINNESOTA,CTR INTERFACIAL ENGN,INST TECHNOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	EDSTROM, RD (corresponding author), UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,4225 MILLARD HALL,MINNEAPOLIS,MN 55455, USA.		Lee, Gil U/P-8696-2016	Lee, Gil U/0000-0002-7949-5848				AMREIN M, 1989, SCIENCE, V243, P1708, DOI 10.1126/science.2928803; ARSCOTT PG, 1989, NATURE, V339, P484, DOI 10.1038/339484a0; ARSCOTT PG, 1990, IN PRESS TRENDS BIOT; BARO AM, 1985, NATURE, V315, P253, DOI 10.1038/315253a0; BEEBE TP, 1989, SCIENCE, V243, P370, DOI 10.1126/science.2911747; BINNIG G, 1983, PHYS REV LETT, V50, P120, DOI 10.1103/PhysRevLett.50.120; Binnig G., 1984, TRENDS PHYSICS, P38; BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57; CRICENTI A, 1989, SCIENCE, V245, P1226, DOI 10.1126/science.2781279; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; DUNLAP DD, 1989, NATURE, V342, P204, DOI 10.1038/342204a0; EDSTROM RD, 1989, BIOCHEMISTRY-US, V28, P4939, DOI 10.1021/bi00438a004; ELINGS VB, 1990, J VAC SCI TECHNOL A, V8, P652, DOI 10.1116/1.576365; FENG L, 1988, J MICROSC-OXFORD, V152, P811, DOI 10.1111/j.1365-2818.1988.tb01453.x; FENG L, 1988, J COLLOID INTERF SCI, V126, P650, DOI 10.1016/0021-9797(88)90169-5; FENG L, 1990, SCANNING MICROSCOPY, V3, P399; FISHER KA, 1989, J ELECTRON MICR TECH, V13, P355, DOI 10.1002/jemt.1060130408; GOLDSMITH E, 1982, J MOL BIOL, V156, P411, DOI 10.1016/0022-2836(82)90336-9; GOULD S, 1988, NATURE, V332, P332, DOI 10.1038/332332a0; GOULD SAC, 1990, J VAC SCI TECHNOL A, V8, P369, DOI 10.1116/1.576398; GUCKENBERGER R, 1989, ULTRAMICROSCOPY, V31, P327, DOI 10.1016/0304-3991(89)90055-7; HANSMA PK, 1988, SCIENCE, V242, P209, DOI 10.1126/science.3051380; HANSMA PK, 1987, J APPL PHYS, V61, pR1, DOI 10.1063/1.338189; HERRON JN, 1985, BIOCHEMISTRY-US, V24, P3453, DOI 10.1021/bi00335a010; Hiemenz PC, 1986, PRINCIPLES COLLOID S, DOI 10.1201/9781315274287; JERICHO MH, 1990, J VAC SCI TECHNOL A, V8, P661, DOI 10.1116/1.576368; KELLER D, 1989, P NATL ACAD SCI USA, V86, P5356, DOI 10.1073/pnas.86.14.5356; LEE G, 1989, SCIENCE, V244, P475, DOI 10.1126/science.2470146; LINDSAY SM, 1989, SCIENCE, V244, P1063, DOI 10.1126/science.2727694; LINDSAY SM, 1989, J BIOMOL STRUCT DYN, V7, P289, DOI 10.1080/07391102.1989.10507772; LINDSAY SM, 1989, J BIOMOL STRUCT DYN, V7, P279, DOI 10.1080/07391102.1989.10507771; MARTI O, 1988, SCIENCE, V239, P50, DOI 10.1126/science.3336773; MARTI O, 1988, J MICROSC-OXFORD, V152, P803, DOI 10.1111/j.1365-2818.1988.tb01452.x; MASAI J, 1990, J VAC SCI TECHNOL A, V8, P713, DOI 10.1116/1.576989; MILES MJ, 1990, J VAC SCI TECHNOL A, V8, P698, DOI 10.1116/1.576986; Pauling L., 1960, NATURE CHEM BOND; RABE JP, 1990, J VAC SCI TECHNOL A, V8, P679, DOI 10.1116/1.576980; RUPPERSBERG JP, 1989, FEBS LETT, V257, P460, DOI 10.1016/0014-5793(89)81596-0; SALMERON M, 1990, J VAC SCI TECHNOL A, V8, P635, DOI 10.1116/1.576361; SIMICKRSTIC Y, 1989, FASEB J, V3, P2184, DOI 10.1096/fasebj.3.10.2753269; SMITH DPE, 1989, SCIENCE, V245, P43, DOI 10.1126/science.245.4913.43; SMITH DPE, 1987, P NATL ACAD SCI USA, V84, P969, DOI 10.1073/pnas.84.4.969; SPONG JK, 1989, NATURE, V338, P137, DOI 10.1038/338137a0; Thompson D'A. W., 1941, GROWTH FORM; WELLAND ME, 1989, INT J BIOL MACROMOL, V11, P29, DOI 10.1016/0141-8130(89)90036-6; YANG XR, 1990, FASEB J, V4, P3140, DOI 10.1096/fasebj.4.13.2210158; YOUNG R, 1972, REV SCI INSTRUM B, V43, P9990; ZASADZINSKI JAN, 1988, SCIENCE, V239, P1013, DOI 10.1126/science.3344420; ZASADZINSKI JAN, 1989, BIOTECHNIQUES, V7, P174	49	31	32	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1990	4	13					3144	3151		10.1096/fasebj.4.13.2120098	http://dx.doi.org/10.1096/fasebj.4.13.2120098			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EC625	2120098				2022-12-28	WOS:A1990EC62500012
J	WALKER, G; BOURGUIGNON, LYW				WALKER, G; BOURGUIGNON, LYW			MEMBRANE-ASSOCIATED 41-KDA GTP-BINDING PROTEIN IN COLLAGEN-INDUCED PLATELET ACTIVATION	FASEB JOURNAL			English	Note									UNIV MIAMI, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA	University of Miami					NIGMS NIH HHS [GM 36353] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ADUNYAH SE, 1985, BIOCHEM BIOPH RES CO, V128, P1274, DOI 10.1016/0006-291X(85)91078-2; BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOURGUIGNON LYW, 1985, J BIOL CHEM, V260, P1775; BOURGUIGNON LYW, 1984, CELL BIOL INT REP, V8, P19, DOI 10.1016/0309-1651(84)90177-2; BOURGUIGNON LYW, 1986, J CELL BIOL, V103, P2529, DOI 10.1083/jcb.103.6.2529; BOURGUIGNON LYW, 1990, J IMMUNOL, V144, P2242; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1985, J CELL BIOL, V101, P477, DOI 10.1083/jcb.101.2.477; BOURNE HR, 1986, NATURE, V321, P814, DOI 10.1038/321814a0; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BRASS LF, 1985, J BIOL CHEM, V260, P5172; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CULLEN PJ, 1989, BIOCHEM J, V259, P931, DOI 10.1042/bj2590931; DANIEL JL, 1987, BIOCHEM J, V246, P109, DOI 10.1042/bj2460109; EVANS SW, 1987, NATURE, V325, P166, DOI 10.1038/325166a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GONZALEZ.F, 1968, J LIPID RES, V9, P532; GORDON JH, 1988, FEBS LETT, V235, P201, DOI 10.1016/0014-5793(88)81262-6; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; IYENGAR R, 1987, J BIOL CHEM, V262, P9239; JENKINS CSP, 1974, BRIT J HAEMATOL, V28, P561, DOI 10.1111/j.1365-2141.1974.tb06675.x; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1986, J BIOL CHEM, V261, P8182; LAD PM, 1986, FEBS LETT, V200, P91, DOI 10.1016/0014-5793(86)80517-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LAPETINA EG, 1986, P NATL ACAD SCI USA, V83, P5880, DOI 10.1073/pnas.83.16.5880; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; LLOYD JV, 1972, BRIT J HAEMATOL, V23, P571, DOI 10.1111/j.1365-2141.1972.tb07092.x; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; MATHEWS WR, 1988, ANAL BIOCHEM, V168, P63, DOI 10.1016/0003-2697(88)90010-3; MILLIGAN G, 1988, BIOCHEM J, V254, P391, DOI 10.1042/bj2540391; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; SUCHARD SJ, 1988, J CELL PHYSIOL, V134, P67, DOI 10.1002/jcp.1041340108; TAKAMURA H, 1987, J BIOL CHEM, V262, P2262; TARVER AP, 1987, J BIOL CHEM, V262, P17268; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WHEELER GL, 1977, P NATL ACAD SCI USA, V74, P4238, DOI 10.1073/pnas.74.10.4238	58	19	19	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1990	4	11					2924	2933		10.1096/fasebj.4.11.2116341	http://dx.doi.org/10.1096/fasebj.4.11.2116341			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	DT445	2116341				2022-12-28	WOS:A1990DT44500012
J	Cui, KS; Gong, L; Zhang, H; Chen, Y; Liu, BX; Gong, ZC; Li, JM; Wang, YB; Sun, SB; Li, YJ; Zhang, Q; Cao, YL; Li, QL; Fei, BJ; Huang, ZH				Cui, Kaisa; Gong, Liang; Zhang, Han; Chen, Ying; Liu, Bingxin; Gong, Zhicheng; Li, Jiuming; Wang, Yuanben; Sun, Shengbai; Li, Yajun; Zhang, Qiang; Cao, Yulin; Li, Qilin; Fei, Bojian; Huang, Zhaohui			EXOSC8 promotes colorectal cancer tumorigenesis via regulating ribosome biogenesis-related processes	ONCOGENE			English	Article; Early Access							RNA EXOSOME; P53; DELIVERY; SUBUNIT; NUCLEAR	Extensive protein synthesis is necessary for uncontrolled cancer cell proliferation, requiring hyperactive ribosome biogenesis. Our previous Pan-cancer study has identified EXOSC8 as a potential copy number variation (CNV)-driven rRNA metabolism-related oncogene in colorectal cancer (CRC). Herein, we further investigated proliferation-prompting functions and mechanisms of EXOSC8 in CRC by performing in silico analyses and wet-lab experiments. We uncovered that increased EXOSC8 expression and CNV levels are strongly associated with ribosome biogenesis-related factor levels in CRC, including ribosome proteins (RPs), eukaryotic translation initiation factors and RNA polymerase I/III. EXOSC8 silence decreases nucleolar protein and proliferation marker levels, as well as rRNA/DNA and global protein syntheses. Clinically, EXOSC8 is upregulated across human cancers, particularly CNV-driven upregulation in CRC was markedly associated with poor clinical outcomes. Mechanistically, EXOSC8 knockdown increased p53 levels in CRC, and the oncogenic proliferation phenotypes of EXOSC8 depended on p53 in vitro and in vivo. We discovered that EXOSC8 knockdown in CRC cells triggers ribosomal stress, nucleolar RPL5/11 being released into the nucleoplasm and "hijacking" Mdm2 to block its E3 ubiquitin ligase function, thus releasing and activating p53. Furthermore, our therapeutic experiments provided initial evidence that EXOSC8 might serve as a potential therapeutic target in CRC. Our findings revealed, for the first time, that the RNA exosome gene (EXOSC8) promotes CRC tumorigenesis by regulating cancer-related ribosome biogenesis in CRC. This study further extends our previous Pan-cancer study of the rRNA metabolism-related genes. The inhibition of EXOSC8 is a novel therapeutic strategy for the RPs-Mdm2-p53 ribosome biogenesis surveillance pathway in CRC.	[Cui, Kaisa; Zhang, Han; Chen, Ying; Gong, Zhicheng; Wang, Yuanben; Sun, Shengbai; Cao, Yulin; Huang, Zhaohui] Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, Wuxi 214062, Jiangsu, Peoples R China; [Gong, Liang] Jiangnan Univ, Sch Biotechnol, Minist Educ, Key Lab Carbohydrate Chem & Biotechnol, Wuxi 214122, Jiangsu, Peoples R China; [Liu, Bingxin] Nanjing Med Univ, Sch Publ Hlth, Ctr Global Hlth, Key Lab Modern Toxicol,Minist Educ, Nanjing 211166, Jiangsu, Peoples R China; [Li, Jiuming] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Minist Educ,Key Lab Environm Med & Engn, Nanjing 210009, Jiangsu, Peoples R China; [Li, Yajun] Henan Normal Univ, Outstanding Overseas Scientists Ctr Pulm Fibrosis, Coll Life Sci,Henan Int Joint Lab Pulm Fibrosis, Inst Biomed Sci,State Key Lab Cell Differentiat &, Xinxiang 453000, Henan, Peoples R China; [Zhang, Qiang] Sun Yat Sen Univ, Mol Canc Res Ctr, Sch Med, Dept Biochem, Shenzhen Campus, Shenzhen 518107, Guangdong, Peoples R China; [Li, Qilin] CALTECH, Dept Elect Engn, Comp Vis Lab, Pasadena, CA 91125 USA; [Fei, Bojian] Jiangnan Univ, Affiliated Hosp, Dept Surg Oncol, Wuxi 214122, Jiangsu, Peoples R China	Jiangnan University; Jiangnan University; Nanjing Medical University; Southeast University - China; Henan Normal University; Sun Yat Sen University; California Institute of Technology; Jiangnan University	Cui, KS; Huang, ZH (corresponding author), Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, Wuxi 214062, Jiangsu, Peoples R China.	ksxg@foxmail.com; zhaohuihuang@jiangnan.edu.cn		Cui, Kaisa/0000-0001-7255-2689	National Natural Science Foundation of China [82002550, 82173063]; Wuxi Medical Key Discipline [ZDXK2021002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wuxi Medical Key Discipline	We acknowledge the TCGA, GEO, CCLE and CPTAC projects. We would like to thank developers of each dataset, method and package used in this study. We thank the Affiliated Hospital of Jiangnan University for providing the CRC samples. We also thank the platforms of Medical Research Center (Wuxi School of Medicine, Jiangnan University). This work was supported by grants from the National Natural Science Foundation of China (82002550 and 82173063) and Wuxi Medical Key Discipline (ZDXK2021002).	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Andreatta M, 2021, COMPUT STRUCT BIOTEC, V19, P3796, DOI 10.1016/j.csbj.2021.06.043; Bian ZH, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02162-8; Boczonadi V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5287; Boutelle AM, 2021, TRENDS CELL BIOL, V31, P298, DOI 10.1016/j.tcb.2020.12.011; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao PB, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf4304; Chen XL, 2022, J CANCER, V13, P1456, DOI 10.7150/jca.69166; Cui KS, 2021, ONCOGENE, V40, P2130, DOI 10.1038/s41388-021-01677-w; Cui KS, 2020, ONCOGENE, V39, P786, DOI 10.1038/s41388-019-1026-9; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Ferdows BE, 2022, NANOSCALE, V14, P4448, DOI 10.1039/d1nr06991h; Gao RL, 2021, NAT BIOTECHNOL, V39, P599, DOI 10.1038/s41587-020-00795-2; GARDEN GA, 1995, MOL CELL NEUROSCI, V6, P293, DOI 10.1006/mcne.1995.1023; Gong L, 2021, SMALL, V17, DOI 10.1002/smll.202103463; Gong ZC, 2021, ADV SCI, V8, DOI 10.1002/advs.202004504; Hacot S, 2010, CURR PROTOC CELL BIO; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Hong F, 2021, CANCER IMMUNOL RES, V9, P939, DOI 10.1158/2326-6066.CIR-20-1026; Jhan YY, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118802; Jiang TJ, 2002, P NATL ACAD SCI USA, V99, P5295, DOI 10.1073/pnas.072083699; Kang J, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00728-8; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Li D, 2020, CARBOHYD RES, V493, DOI 10.1016/j.carres.2020.108032; Li WJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0523-z; Li YJ, 2021, CELL DEATH DIFFER, V28, P2112, DOI 10.1038/s41418-021-00739-6; Liu QL, 2021, ELIFE, V10, DOI 10.7554/eLife.69454; Morral C, 2020, CELL STEM CELL, V26, P845, DOI 10.1016/j.stem.2020.04.012; Morton DJ, 2018, RNA, V24, P127, DOI 10.1261/rna.064626.117; Muller JS, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000678; Pan HD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00643; Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104; Prakash V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10100-8; Rongshou Z., 2022, J NATL CANC CTR, V2, P1, DOI [DOI 10.1016/J.JNCC.2022.02.002, 10.1016/j.jncc.2022.02.002]; Shen AL, 2019, CANCER RES, V79, P2257, DOI 10.1158/0008-5472.CAN-18-3238; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taniue K, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010496; van Eijndhoven MAJ, 2020, NAT BIOMED ENG, V4, P6, DOI 10.1038/s41551-019-0514-0; Yang BW, 2019, ADV MATER, V31, DOI 10.1002/adma.201802896; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980; Zanchin NIT, 1999, NUCLEIC ACIDS RES, V27, P1283, DOI 10.1093/nar/27.5.1283; Zhang J, 2022, J BIOMED SCI, V29, DOI 10.1186/s12929-022-00789-z; Zhang Y, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951-022-01472-z; Zhu YH, 2022, HEPATOLOGY, DOI 10.1002/hep.32518; Zhu YH, 2020, MOL CELL, V77, P138, DOI 10.1016/j.molcel.2019.10.015	48	0	0	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02530-4	http://dx.doi.org/10.1038/s41388-022-02530-4		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6D2TY	36348012	Bronze			2022-12-28	WOS:000882550800002
J	ZAKIN, MM				ZAKIN, MM			REGULATION OF TRANSFERRIN GENE-EXPRESSION	FASEB JOURNAL			English	Review						TRANSFERRIN EXPRESSION; SERTOLI CELLS; HEPATOCYTES; DNA REGULATORY ELEMENTS	ENRICHED TRANSCRIPTION FACTOR; DNA-BINDING PROTEIN; TRANSGENIC MICE; TESTICULAR TRANSFERRIN; IRON-DEFICIENCY; MESSENGER-RNA; CHICK LIVER; RAT-BRAIN; YOLK-SAC; CELLS	Transferrin (Tf) is the iron-transport protein of vertebrate serum. It is essentially synthesized in the liver, but lower amounts are also produced in other organs, such as testis and brain. A number of studies have been done to characterize the transcriptional elements implicated in the regulation of Tf gene expression in different organs. The results of these studies support the hypothesis that the Tf gene makes use of different combinations of nuclear proteins in different subsets of cells to achieve tissue-specific expression. It is interesting to point out that this occurs in tissues arising from different embryological origin.			ZAKIN, MM (corresponding author), INST PASTEUR,UNITE EXPRESS GENES EUCARYOTES,F-75724 PARIS 15,FRANCE.							ADRIAN GS, 1990, J BIOL CHEM, V265, P13344; AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ALDRED AR, 1987, J BIOL CHEM, V262, P5293; ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; BLOCH B, 1985, P NATL ACAD SCI USA, V82, P6706, DOI 10.1073/pnas.82.19.6706; BOHN M C, 1988, Society for Neuroscience Abstracts, V14, P1057; BOISSIER F, 1991, J BIOL CHEM, V266, P9822; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CONNOR JR, 1990, J NEUROSCI RES, V27, P595, DOI 10.1002/jnr.490270421; DEJONG G, 1990, CLIN CHIM ACTA, V190, P1, DOI 10.1016/0009-8981(90)90278-Z; DELOSMONTEROS AE, 1990, J NEUROSCI RES, V25, P576, DOI 10.1002/jnr.490250416; DELOSMONTEROS AE, 1989, J NEUROSCI RES, V24, P125, DOI 10.1002/jnr.490240202; DZIEGIELEWSKA KM, 1986, DEV BIOL, V115, P93, DOI 10.1016/0012-1606(86)90231-9; EKBLOM P, 1985, DEV BIOL, V110, P29, DOI 10.1016/0012-1606(85)90060-0; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GORINSKY B, 1979, NATURE, V281, P157, DOI 10.1038/281157a0; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; HAMMER RE, 1986, MOL CELL BIOL, V6, P1010, DOI 10.1128/MCB.6.4.1010; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P2723; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAHN A, 1987, ONCOGENES GENES GROW, P277; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEE DC, 1978, J BIOL CHEM, V253, P3494; LEVIN MJ, 1984, BIOCHEM BIOPH RES CO, V122, P212, DOI 10.1016/0006-291X(84)90461-3; MACGILLIVRAY RTA, 1983, J BIOL CHEM, V258, P3545; MCKNIGHT GS, 1980, J BIOL CHEM, V255, P148; MCKNIGHT GS, 1980, J BIOL CHEM, V255, P144; MEEHAN RR, 1984, EMBO J, V3, P1881, DOI 10.1002/j.1460-2075.1984.tb02062.x; MENDELZON D, 1990, NUCLEIC ACIDS RES, V18, P5717, DOI 10.1093/nar/18.19.5717; PARK I, 1985, P NATL ACAD SCI USA, V82, P3149, DOI 10.1073/pnas.82.10.3149; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; PLOWMAN GD, 1986, THESIS U WASHINGTON, P97; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; SKINNER MK, 1989, ENDOCRINOLOGY, V124, P3015, DOI 10.1210/endo-124-6-3015; SKINNER MK, 1982, BIOL REPROD, V27, P211, DOI 10.1095/biolreprod27.1.211; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TSUTSUMI M, 1989, J BIOL CHEM, V264, P9626; TU GF, 1991, J BIOL CHEM, V266, P6201; TUIL D, 1985, FEBS LETT, V189, P310, DOI 10.1016/0014-5793(85)81046-2	44	54	56	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1992	6	14					3253	3258		10.1096/fasebj.6.14.1426763	http://dx.doi.org/10.1096/fasebj.6.14.1426763			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426763				2022-12-28	WOS:A1992JZ73400006
J	MATTINGLY, M; CHAKRABARTI, D; GHOSH, SK				MATTINGLY, M; CHAKRABARTI, D; GHOSH, SK			PROMOTION OF MURINE B-CELL DIFFERENTIATION BY 2-MERCAPTOETHANOL IN CONTRAST TO GLUTATHIONE	FASEB JOURNAL			English	Article						GLUTATHIONE; 2-MERCAPTOETHANOL; DIFFERENTIATION; DICHOTOMY; B-CELL	ANTIBODY-RESPONSE; LYMPHOCYTES; IDIOTYPE; EXPRESSION; ACTIVATION; PROLIFERATION; GENERATION; DISULFIDE; SECRETION; MEMBRANE	The role of thiol compounds in B cell proliferation and differentiation was investigated with a stable, homogeneous population of an antigen-specific plasmablastoma, 2C3. This cell line expresses both membrane and secreted forms of immunoglobulin and is arrested at an intermediate stage of B cell development. Attempts to induce its differentiation into plasma cells using antigen, anti-idiotypic antibodies, or mitogens were unsuccessful. However, cultivation of 2C3 in the presence of 2-mercaptoethanol (5 x 10(-5) M) changed its doubling time from 19.8 to 34.9 h. There was also a significant rise in intracellular glutathione and in immunoglobulin production, but little change in non-Ig protein secretion. In contrast, exposure of 2C3 to exogenous glutathione (5 x 10(-3) M) reduced the doubling time to 11.0 h, with marked increases in proliferation. Moreover, there was no significant rise in either intracellular glutathione or immunoglobulin secretion. Distinct morphological differences were also apparent at the ultrastructural level. Thus, there is a dichotomy in the action of the two thiols. Although the effects of 2-mercaptoethanol could not be reversed, the two thiols together abrogated each other's effects, implying that their actions may be mediated through a common regulatory pathway.	INDIANA STATE UNIV, DEPT LIFE SCI, TERRE HAUTE, IN 47809 USA	Indiana State University								AIDOO A, 1991, CELL BIOL TOXICOL, V7, P215; ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BURCHILL BR, 1978, J CELL BIOL, V76, P439, DOI 10.1083/jcb.76.2.439; DRAKE JR, 1989, J IMMUNOL, V143, P1768; GHOSH SK, 1987, MOL IMMUNOL, V24, P1335, DOI 10.1016/0161-5890(87)90129-5; GHOSH SK, 1989, J IMMUNOL, V142, P409; GHOSH SK, 1990, J IMMUNOL, V145, P365; GHOSH SK, 1984, J IMMUNOL, V133, P1677; GOODMAN MG, 1979, J IMMUNOL, V122, P1433; HAMILOS DL, 1989, IMMUNOPHARMACOLOGY, V18, P223, DOI 10.1016/0162-3109(89)90020-9; HOFFELD JT, 1980, EUR J IMMUNOL, V10, P391, DOI 10.1002/eji.1830100514; JOHO R, 1983, CURR TOP DEV BIOL, V18, P15; LIANG SM, 1991, J IMMUNOL, V146, P1909; MAZZAFERRO PK, 1987, J MOL CELL IMMUNOL, V3, P293; MESSINA JP, 1989, J IMMUNOL, V143, P1974; OHMORI H, 1983, CELL IMMUNOL, V79, P173, DOI 10.1016/0008-8749(83)90060-6; ROEDERER M, 1991, INT IMMUNOL, V3, P933, DOI 10.1093/intimm/3.9.933; SMYTH MJ, 1991, J IMMUNOL, V146, P1921; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; ZMUDA J, 1983, J IMMUNOL, V130, P362	21	5	5	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1992	6	11					3002	3007		10.1096/fasebj.6.11.1644263	http://dx.doi.org/10.1096/fasebj.6.11.1644263			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JJ665	1644263				2022-12-28	WOS:A1992JJ66500015
J	TORCHILIN, VP; KLIBANOV, AL; HUANG, L; ODONNELL, S; NOSSIFF, ND; KHAW, BA				TORCHILIN, VP; KLIBANOV, AL; HUANG, L; ODONNELL, S; NOSSIFF, ND; KHAW, BA			TARGETED ACCUMULATION OF POLYETHYLENE GLYCOL-COATED IMMUNOLIPOSOMES IN INFARCTED RABBIT MYOCARDIUM	FASEB JOURNAL			English	Note						IMMUNOLIPOSOME; POLYETHYLENEGLYCOL; TARGETED DRUG DELIVERY; INFARCTED MYOCARDIUM	LIPOSOMES; ANTIBODY	The less than optimal accumulation of immunoliposome-associated reagents at target sites has often been attributed to the rapid in vivo clearance of immunoliposomes from the blood. In an attempt to overcome the drawback of rapid clearance and use the targeting potential of immunoliposomes, we have prepared long-circulating, In-111-labeled immunoliposomes. Targeting properties and enhanced circulation times were demonstrated in a rabbit model of acute experimental myocardial infarct. The specificity of liposomes for newly exposed intracellular cardiac myosin at the necrotic sites was achieved by incorporating monoclonal antimyosin antibody. Extended circulation times were achieved by cocoating the antimyosin-liposomes with polyethylene glycol (PEG). The half-life of the immunoliposomes was 40 min, which increased to 200 min with 4% mol PEG and to approximately 1000 min with 10% mol PEG. The degree of binding of modified immunoliposomes at the target sites was also dependent on the concentration of PEG incorporated at the liposome surface. This study demonstrates the accumulation of long-circulating targeted liposomes at the area of acute rabbit experimental myocardial infarction.	MASSACHUSETTS GEN HOSP,DEPT NUCL MED,BOSTON,MA 02129; UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996	Harvard University; Massachusetts General Hospital; University of Tennessee System; University of Tennessee Knoxville	TORCHILIN, VP (corresponding author), MASSACHUSETTS GEN HOSP E,CTR IMAGING & PHARMACEUT RES,DEPT RADIOL,BLDG 149,13TH ST,BOSTON,MA 02129, USA.							CARIDE VJ, 1977, SCIENCE, V198, P735, DOI 10.1126/science.910155; KABALKA G, 1987, RADIOLOGY, V163, P255, DOI 10.1148/radiology.163.1.3454163; KHAW BA, 1984, HYBRIDOMA, V3, P11, DOI 10.1089/hyb.1984.3.11; KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; KLIBANOV AL, 1991, AM J PHYSL S, V2611, P60; Leserman LD, 1984, LIPOSOME TECHNOLOGY, V3, P29; MORI A, 1991, FEBS LETT, V284, P263, DOI 10.1016/0014-5793(91)80699-4; TORCHILIN VP, 1979, BIOCHEM BIOPH RES CO, V89, P1114, DOI 10.1016/0006-291X(79)92123-5; WEISSIG V, 1986, FEBS LETT, V202, P86, DOI 10.1016/0014-5793(86)80654-8	10	173	189	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1992	6	9					2716	2719		10.1096/fasebj.6.9.1612296	http://dx.doi.org/10.1096/fasebj.6.9.1612296			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HZ481	1612296				2022-12-28	WOS:A1992HZ48100013
J	MANTOVANI, A; BUSSOLINO, F; DEJANA, E				MANTOVANI, A; BUSSOLINO, F; DEJANA, E			CYTOKINE REGULATION OF ENDOTHELIAL-CELL FUNCTION	FASEB JOURNAL			English	Review						INTERLEUKIN; TUMOR NECROSIS FACTOR; INTERFERON; CHEMOTAXIS; METASTASIS; KAPOSIS SARCOMA	TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; NEUTROPHIL CHEMOTACTIC FACTOR; COLONY-STIMULATING FACTORS; SMOOTH-MUSCLE CELLS; KAPOSIS-SARCOMA; VONWILLEBRAND-FACTOR; INTERLEUKIN-1 IL-1; GRANULOCYTE-COLONY; GENE-EXPRESSION	Endothelial cells have long been viewed as a passive lining of blood vessels endowed essentially with negative properties such as that of being nonreactive to blood components. It is now evident that upon exposure to environmental signals, cytokines in particular, vascular cells undergo profound changes in gene expression and function that allow these cells to participate actively in inflammatory reactions, immunity, and thrombosis. Different mediators (e.g., interleukin-1 [IL-1] and interferon-gamma) activate relatively distinct sets of functions. These functional programs expressed in activated endothelial cells include the production by the same cells of cytokines (e.g., IL-1, IL-6, chemotactic cytokines, and colony-stimulating factors), which regulate hematopoiesis, the differentiation and proliferation of T and B lymphocytes, and the extravasation of leukocytes. The identification of cytokine circuits through which vascular cells participate to thrombotic, inflammatory, and immune reactions provides novel targets for therapeutic intervention.	UNIV TURIN, DIPARTIMENTO GENET BIOL & CHIM MED, I-10124 TURIN, ITALY	University of Turin	MANTOVANI, A (corresponding author), MARIO NEGRI INST PHARMACOL RES, VIA ERITREA 62, I-20157 MILAN, ITALY.		Mantovani, Alberto/HCI-7449-2022; Bussolino, Federico/AES-3951-2022; Introna, Martino/AAA-5823-2019; Luchetti, Michele Maria/J-6955-2019; Bussolino, Federico/K-2500-2016	Mantovani, Alberto/0000-0001-5578-236X; Introna, Martino/0000-0001-6216-0892; Luchetti, Michele Maria/0000-0001-9132-7401; Bussolino, Federico/0000-0002-5348-1341; DEJANA, ELISABETTA/0000-0002-0007-0426				ABE Y, 1990, J IMMUNOL, V145, P2902; ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439; ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; BEITZ JG, 1991, P NATL ACAD SCI USA, V88, P2021, DOI 10.1073/pnas.88.5.2021; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BERTINI R, 1992, CYTOKINE, V4, P44, DOI 10.1016/1043-4666(92)90035-P; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BORASCHI D, 1991, BLOOD, V78, P1262; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BRETT J, 1989, J EXP MED, V169, P1977, DOI 10.1084/jem.169.6.1977; BREVIARIO F, 1990, ARTERIOSCLEROSIS, V10, P129, DOI 10.1161/01.ATV.10.1.129; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; BUSSOLINO F, 1991, J CLIN INVEST, V87, P986, DOI 10.1172/JCI115107; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CARVETH HJ, 1989, BIOCHEM BIOPH RES CO, V162, P387, DOI 10.1016/0006-291X(89)92009-3; CHIN YH, 1990, J IMMUNOL, V145, P3669; CLINTON SK, 1991, AM J PATHOL, V138, P1005; COLOTTA F, 1992, CYTOKINE, V4, P24, DOI 10.1016/1043-4666(92)90032-M; CORBEIL J, 1991, J IMMUNOL, V146, P2972; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEJANA E, IN PRESS LAB INVEST; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DOUKAS J, 1990, J IMMUNOL, V145, P1088; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; ELLIOTT MJ, 1991, BLOOD, V77, P2739; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; ENTMAN ML, 1991, FASEB J, V5, P2529, DOI 10.1096/fasebj.5.11.1868978; FEI RG, 1990, EXP HEMATOL, V18, P953; FU XY, IN PRESS INT J CANCE; GAMBLE JR, 1991, J IMMUNOL, V146, P1149; GIAVAZZI R, 1990, CANCER RES, V50, P4771; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GUSTAFSON KS, 1991, J CLIN INVEST, V87, P1896, DOI 10.1172/JCI115214; HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HECHTMAN DH, 1991, J IMMUNOL, V147, P883; HENNING B, 1987, J LEUKOCYTE BIOL, V42, P551; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HOWELLS G, 1991, EUR J IMMUNOL, V21, P97, DOI 10.1002/eji.1830210115; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; JONIJC N, 1992, IN PRESS J IMMUNOL; JONIJC N, 1992, IN PRESS AM J PATHOL; KAPIOTIS S, 1991, BLOOD, V78, P410; KOCH AE, 1991, LAB INVEST, V64, P313; KOJIMA S, 1989, J CELL PHYSIOL, V138, P192, DOI 10.1002/jcp.1041380125; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; KUIJPERS TW, 1991, J IMMUNOL, V147, P1369; LACASSE C, 1991, J LEUKOCYTE BIOL, V49, P245, DOI 10.1002/jlb.49.3.245; LAURI D, 1991, JNCI-J NATL CANCER I, V83, P1321, DOI 10.1093/jnci/83.18.1321; LAURI D, IN PRESS LAB INVEST; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LESZCZYNSKI D, 1990, HUM IMMUNOL, V28, P175, DOI 10.1016/0198-8859(90)90016-I; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; LIBBY P, 1991, LAB INVEST, V64, P5; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3; MCEVER RP, 1991, THROMB HAEMOSTASIS, V65, P223; MCKENNA TM, 1990, J CLIN INVEST, V86, P160, DOI 10.1172/JCI114679; MEYRICK B, 1991, AM J PATHOL, V138, P93; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MOYER CF, 1991, AM J PATHOL, V138, P951; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PALEOLOG EM, 1990, BLOOD, V75, P688; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RENKONEN R, 1990, EUR J IMMUNOL, V20, P1563, DOI 10.1002/eji.1830200723; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; ROLLINS BJ, 1991, AM J PATHOL, V138, P1315; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; RUBBIABRANDT L, 1991, VIRCHOWS ARCH B, V60, P73, DOI 10.1007/BF02899530; RUCO LP, 1990, AM J PATHOL, V137, P1163; SCHLEEF RR, 1991, J CELL BIOL, V113, P1413, DOI 10.1083/jcb.113.6.1413; SCHRODER JM, 1989, J IMMUNOL, V142, P244; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SICA A, 1990, IMMUNOLOGY, V69, P548; SICA A, 1990, J IMMUNOL, V144, P3034; SIRONI M, 1989, J IMMUNOL, V142, P549; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TANNENBAUM SH, 1990, BLOOD, V75, P2177; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; THORNHILL MH, 1991, J IMMUNOL, V146, P592; TOI M, 1991, BIOCHEM BIOPH RES CO, V174, P1287, DOI 10.1016/0006-291X(91)91561-P; VANHINSBERGH VWM, 1990, BLOOD, V75, P1991; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; WANG JM, 1991, ARTERIOSCLER THROMB, V11, P1166, DOI 10.1161/01.ATV.11.5.1166; WARNER SJC, 1989, J IMMUNOL, V142, P100; WEISS RA, 1990, EUR J CANCER, V26, P657, DOI 10.1016/0277-5379(90)90109-7; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; YONG K, 1991, BLOOD, V77, P1675; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R; ZAVOICO GB, 1989, J IMMUNOL, V142, P3993	119	664	673	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2591	2599		10.1096/fasebj.6.8.1592209	http://dx.doi.org/10.1096/fasebj.6.8.1592209			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592209				2022-12-28	WOS:A1992HU42300012
J	HUANG, TT; CARLSON, EJ; LEADON, SA; EPSTEIN, CJ				HUANG, TT; CARLSON, EJ; LEADON, SA; EPSTEIN, CJ			RELATIONSHIP OF RESISTANCE TO OXYGEN FREE-RADICALS TO CUZN-SUPEROXIDE DISMUTASE ACTIVITY IN TRANSGENIC, TRANSFECTED, AND TRISOMIC CELLS	FASEB JOURNAL			English	Note						MOUSE TRISOMY-16; DOWN SYNDROME; HUMAN TRISOMY-21; PARAQUAT; CUZN-SUPEROXIDE DISMUTASE	GLUTATHIONE-PEROXIDASE-ACTIVITY; PARAQUAT RESISTANCE; ESCHERICHIA-COLI; DOWNS-SYNDROME; TOXICITY; INHIBITION; MICE; DNA; OVEREXPRESSION; ENHANCEMENT	Although CuZn-superoxide dismutase (CuZnSOD) has been shown to reduce oxidative damage in several systems, the quantitative relationship between the degree of protection and CuZnSOD activity has not been well investigated. Therefore, the ability of cells to tolerate superoxide toxicity was assessed as a function of endogenous CuZnSOD activity in several mouse and human cell lines with progressively higher levels of CuZnSOD activity. In five lines of fetal fibroblasts derived from SOD1-transgenic mice, with CuZnSOD activities of 1.7- to 7.1-fold the nontransgenic level and no changes in the cellular glutathione peroxidase (GSHPx) activity, a direct relationship (r = 0.97) between the LD50 to paraquat and enzyme activity was observed, suggesting that CuZnSOD activity is the single most important factor in determining the paraquat LD50. Mouse trisomy 16 fetal fibroblasts and human trisomy 21 lung fibroblasts, both expressing a 1.5-fold increase in CuZnSOD activity, were 1.5-fold more tolerant to paraquat than were their diploid counterparts. Furthermore, the protective effect of CuZnSOD at the DNA level, as shown by reduced thymine glycol generation, was demonstrated in paraquat-treated transgenic fibroblasts. A direct relationship (r = 0.78) of paraquat LD50 and CuZnSOD activity was also observed with a panel of six lines of SOD1-transfected HeLa cells with 1.6- to 7.3-fold the basal CuZnSOD activity. Moreover, there was no correlation between resistance to paraquat toxicity and the cellular GSHPx and/or catalase activity. Taken together, these results demonstrate a consistently protective effect of endogenous CuZnSOD against superoxide toxicity in both primary and transformed cell lines.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,BOX 0748,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT RADIAT ONCOL,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA040453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008938] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40453] Funding Source: Medline; NIA NIH HHS [AG-08938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVRAHAM KB, 1991, J NEUROCYTOL, V20, P208, DOI 10.1007/BF01186993; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; BOREK C, 1983, P NATL ACAD SCI-BIOL, V80, P1304, DOI 10.1073/pnas.80.5.1304; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chow C.K., 1988, CELLULAR ANTIOXIDANT, P217; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; Epstein C.J, 1986, CONSEQUENCES CHROMOS; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; EPSTEIN CJ, 1985, ISSUES REV TERATOLOG, V3, P171; EPSTEIN CJ, 1983, LYMPHOKINES, V8, P277; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fridovich I., 1982, SUPEROXIDE DISMUTASE, V1, P69; FRISCHER H, 1981, RED CELL, P269; GRONER Y, 1990, MOL GENETICS CHROMOS; GRUBER MY, 1990, P NATL ACAD SCI USA, V87, P2608, DOI 10.1073/pnas.87.7.2608; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; INOUE M, 1990, FEBS LETT, V269, P89, DOI 10.1016/0014-5793(90)81126-9; KELNER MJ, 1990, FREE RADICAL BIO MED, V9, P149, DOI 10.1016/0891-5849(90)90118-3; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KRALL J, 1988, J BIOL CHEM, V263, P1910; KUJIRAI K, 1991, Society for Neuroscience Abstracts, V17, P812; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LEADON SA, 1983, MUTAT RES, V112, P191, DOI 10.1016/0167-8817(83)90006-8; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; Luck H., 1974, ESTIMATION CATALASE, V885; MARKEY BA, 1990, FREE RADICAL BIO MED, V9, P307, DOI 10.1016/0891-5849(90)90005-4; MINAKAMI H, 1990, FASEB J, V4, P3239, DOI 10.1096/fasebj.4.14.2172063; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; PRZEDBORSKI S, 1992, IN PRESS J NEUROSCI; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; SAWADA M, 1988, MUTAT RES, V197, P133, DOI 10.1016/0027-5107(88)90149-2; SCHICKLER M, 1989, EMBO J, V8, P1385, DOI 10.1002/j.1460-2075.1989.tb03519.x; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SETO NOL, 1990, P NATL ACAD SCI USA, V87, P4270, DOI 10.1073/pnas.87.11.4270; SINET PM, 1979, LIFE SCI, V24, P29, DOI 10.1016/0024-3205(79)90276-5; STARR J, 1986, SOMAT CELL MOLEC GEN, V12, P141, DOI 10.1007/BF01560661; STAVELEY BE, 1990, GENOME, V33, P867, DOI 10.1139/g90-130; Steinman H., 1982, SUPEROXIDE DISMUTASE, P11	44	51	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					903	910		10.1096/fasebj.6.3.1740238	http://dx.doi.org/10.1096/fasebj.6.3.1740238			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740238				2022-12-28	WOS:A1992HE39000014
J	FULLER, PJ				FULLER, PJ			THE STEROID-RECEPTOR SUPERFAMILY - MECHANISMS OF DIVERSITY	FASEB JOURNAL			English	Article						STEROID; RECEPTOR; TRANSACTIVATION DNA BINDING	THYROID-HORMONE RECEPTOR; DNA-BINDING DOMAIN; GLUCOCORTICOID-RESPONSIVE ELEMENTS; HUMAN ANDROGEN RECEPTOR; RETINOIC-ACID; ESTROGEN-RECEPTOR; GENE-EXPRESSION; C-ERBA; TRANSCRIPTIONAL REGULATION; NEGATIVE REGULATION	The steroid receptor superfamily of ligand-dependent transcription factors is characterized by marked conservation of both structure and function between the various receptors. Despite their well-documented extensive similarities, these receptors respond to a diverse range of ligands, which results in an even more impressive diversity of function. A variety of strategies is used at each point in the pathway from ligand binding to gene expression to achieve this diversity. The nature of the ligand is important as are the tissue-specific patterns of receptor gene expression, the presence of binding proteins, and the effects of cell- or tissue-specific ligand-modifying enzymes. Once bound to the receptor, the nature of which may vary as a result of either differential splicing or gene duplication yielding multiple isoforms, the activated receptor may form hetero- or homodimers. A complex interplay then occurs between the receptor dimer, other nuclear proteins, the response element, and the promoter complex to regulate gene expression. These elements may vary as a function of the cell type, other stimuli, and the context and sequence of the response element (or elements) in a given gene. By these mechanisms diversity may even be achieved for a given ligand, receptor subtype, gene, or cell. The observations may help to explain certain phenomena in hormone biology that are difficult to reconcile with the previous, simple, univariant model of steroid hormone action.			FULLER, PJ (corresponding author), PRINCE HENRY HOSP,PRINCE HENRYS INST MED RES,MELBOURNE,VIC 3004,AUSTRALIA.			Fuller, Peter/0000-0002-0948-2072				ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; ANKENBAUER W, 1988, P NATL ACAD SCI USA, V85, P7526, DOI 10.1073/pnas.85.20.7526; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BRENT GA, 1989, J BIOL CHEM, V264, P178; BURCH JBE, 1990, NUCLEIC ACIDS RES, V18, P4157, DOI 10.1093/nar/18.14.4157; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHANG C, 1989, BIOCHEM BIOPH RES CO, V155, P971; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIEKEN ES, 1990, MOL CELL BIOL, V10, P4574, DOI 10.1128/MCB.10.9.4574; DROUIN J, 1987, J CELL BIOCHEM, V35, P293, DOI 10.1002/jcb.240350404; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GOWLAND PL, 1989, MOL CELL BIOL, V9, P3999, DOI 10.1128/MCB.9.9.3999; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HECHT A, 1988, EMBO J, V7, P2063, DOI 10.1002/j.1460-2075.1988.tb03046.x; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HURLEY DM, 1991, J CLIN INVEST, V86, P680; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEAVENEY M, 1991, J MOL ENDOCRINOL, V6, P111, DOI 10.1677/jme.0.0060111; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RITCHIE HH, 1989, P NATL ACAD SCI USA, V86, P9783, DOI 10.1073/pnas.86.24.9783; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WRANGE O, 1989, J BIOL CHEM, V264, P5253; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	84	184	195	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1991	5	15					3092	3099		10.1096/fasebj.5.15.1743440	http://dx.doi.org/10.1096/fasebj.5.15.1743440			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GU842	1743440	Bronze			2022-12-28	WOS:A1991GU84200013
J	MCPHAUL, MJ; MARCELLI, M; TILLEY, WD; GRIFFIN, JE; WILSON, JD				MCPHAUL, MJ; MARCELLI, M; TILLEY, WD; GRIFFIN, JE; WILSON, JD			ANDROGEN RESISTANCE CAUSED BY MUTATIONS IN THE ANDROGEN RECEPTOR GENE	FASEB JOURNAL			English	Review						ANDROGEN RESISTANCE; POINT MUTATION	GLUCOCORTICOID RECEPTOR; QUALITATIVE ABNORMALITY; PREMATURE TERMINATION; ESTROGEN-RECEPTOR; STEROID-BINDING; POINT MUTATION; MESSENGER-RNA; INSENSITIVITY; FAMILY; EXPRESSION	Defects in the human androgen receptor cause a spectrum of defects in male phenotypic sexual development associated with abnormalities in the receptor protein assayed in cultured fibroblasts and in broken cell assays. In some patients these abnormalities are associated with absent ligand binding, in other qualitative or quantitative abnormalities of ligand binding are present, and in some no abnormality of ligand binding is detected. Analysis of the androgen gene structure in such patients has permitted identification of the causative mutation in many families. Although results of these studies often reinforce concepts established by in vitro mutagenesis studies of other steroid receptors, some mutations have provided unusual insight into the structural organization of the androgen receptor molecule.			MCPHAUL, MJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		marcelli, marco/AGR-6853-2022; McPhaul, Michael/AAC-7124-2020	Tilley, Wayne/0000-0003-1893-2626	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003892] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK03892] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], METABOLIC BASIS INHE; BROWN TR, 1990, MOL ENDOCRINOL, V4, P1759, DOI 10.1210/mend-4-12-1759; BROWN TR, 1988, P NATL ACAD SCI USA, V85, P8151, DOI 10.1073/pnas.85.21.8151; BROWN TR, 1982, J CLIN ENDOCR METAB, V55, P61, DOI 10.1210/jcem-55-1-61; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CHAREST NJ, 1991, MOL ENDOCRINOL, V5, P573, DOI 10.1210/mend-5-4-573; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GASPAR ML, 1990, MOL ENDOCRINOL, V4, P1600, DOI 10.1210/mend-4-10-1600; GOLDSTEIN JL, 1972, J CLIN INVEST, V51, P1647, DOI 10.1172/JCI106966; GRIFFIN JE, 1982, J CLIN ENDOCR METAB, V55, P465, DOI 10.1210/jcem-55-3-465; GRINO PB, 1989, J CLIN ENDOCR METAB, V68, P578, DOI 10.1210/jcem-68-3-578; HE WW, 1991, NUCLEIC ACIDS RES, V19, P2373, DOI 10.1093/nar/19.9.2373; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HUSMANN DA, 1990, ENDOCRINOLOGY, V126, P2359, DOI 10.1210/endo-126-5-2359; KAUFMAN M, 1981, NATURE, V293, P735, DOI 10.1038/293735a0; KRONGRAD A, 1991, MOL CELL ENDOCRINOL, V76, P79, DOI 10.1016/0303-7207(91)90262-Q; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MALLOY PJ, 1990, 12TH AM SOC BON MIN, P5208; MARCELLI M, 1990, J CLIN INVEST, V85, P1522, DOI 10.1172/JCI114599; MARCELLI M, 1991, J CLIN ENDOCR METAB, V73, P318, DOI 10.1210/jcem-73-2-318; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; MARCELLI M, 1991, J CLIN INVEST, V87, P1123, DOI 10.1172/JCI115076; MCCLEAN HE, 1990, ENDOCRINE SOC AUSTR, V33; MCPHAUL MJ, 1991, J CLIN INVEST, V87, P1413, DOI 10.1172/JCI115147; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PINSKY L, 1989, American Journal of Human Genetics, V45, pA212; QUIGLEY CA, 1990, 72ND ANN M END SOC A; RISSTALPERS C, 1990, P NATL ACAD SCI USA, V87, P7866, DOI 10.1073/pnas.87.20.7866; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SAI T, 1990, AM J HUM GENET, V46, P1095; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; WILSON JD, 1974, NEW ENGL J MED, V290, P1097, DOI 10.1056/NEJM197405162902001; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893	39	79	79	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2910	2915		10.1096/fasebj.5.14.1752359	http://dx.doi.org/10.1096/fasebj.5.14.1752359			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752359	Bronze			2022-12-28	WOS:A1991GP26900005
J	COUSINS, RJ; BEERS, WH; FITCH, FW; LORDAN, JJ; SMITH, MM; HODSOLL, F; HEALY, B				COUSINS, RJ; BEERS, WH; FITCH, FW; LORDAN, JJ; SMITH, MM; HODSOLL, F; HEALY, B			CONSENSUS CONFERENCE ON INDIRECT COSTS	FASEB JOURNAL			English	Discussion									SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037; UNIV CHICAGO,PATHOL,CHICAGO,IL 60637; JOHNS HOPKINS UNIV,BUSINESS AFFAIRS,BALTIMORE,MD 21218; DAVID M GRIFFITH ASSOCIATES,DIV HIGHER EDUC,CHICAGO,IL; NCI,BETHESDA,MD 20892; US OFF MANAGEMENT & BUDGET,WASHINGTON,DC	Scripps Research Institute; University of Chicago; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	COUSINS, RJ (corresponding author), UNIV FLORIDA,CTR NUTR & SCI,GAINESVILLE,FL 32611, USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2624	2637						14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916086				2022-12-28	WOS:A1991GE81100002
J	NEURATH, H				NEURATH, H			PROTEIN DENATURATION 50 YEARS AGO	FASEB JOURNAL			English	Editorial Material											NEURATH, H (corresponding author), UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA.							[Anonymous], 1943, SCIENCE, V98, P284, DOI 10.1126/science.98.2543.284; Anson ML, 1934, J GEN PHYSIOL, V17, P399, DOI 10.1085/jgp.17.3.399; Neurath H, 1942, J BIOL CHEM, V142, P249; Neurath H, 1944, CHEM REV, V34, P157, DOI 10.1021/cr60108a003; NEURATH H, 1950, CHEM REV, V46, P69, DOI 10.1021/cr60143a002; Northrop J.H., 1948, CRYSTALLINE ENZYMES; Pauling L, 1940, J AM CHEM SOC, V62, P2643, DOI 10.1021/ja01867a018	7	0	0	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1991	5	10					2489	2489		10.1096/fasebj.5.10.2065899	http://dx.doi.org/10.1096/fasebj.5.10.2065899			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FW087	2065899				2022-12-28	WOS:A1991FW08700027
J	STANLEY, WC; CONNETT, RJ				STANLEY, WC; CONNETT, RJ			REGULATION OF MUSCLE CARBOHYDRATE-METABOLISM DURING EXERCISE	FASEB JOURNAL			English	Article						EXERCISE; GLUCOSE; GLYCOLYSIS; INTERMEDIARY METABOLISM; LACTATE	HUMAN SKELETAL-MUSCLE; FRUCTOSE 2,6-BISPHOSPHATE; GLUCOSE-TRANSPORT; FRUCTOSE-2,6-BISPHOSPHATE CONTENT; PHOSPHOFRUCTOKINASE ACTIVITY; ACID CYCLE; RAT-HEART; INSULIN; CITRATE; GLYCOLYSIS	This review examines the mechanisms that regulate muscle carbohydrate metabolism during exercise. Muscle carbohydrate utilization is regulated primarily by two factors, namely, delivery of substrate to the glycolytic pathway either from glycogenolysis or from transport of extracellular glucose into the fibers,and formation of triosephosphate by phosphofructokinase. The regulation involves the integration of the glycolytic controls with other metabolic controls and the needs of the whole muscle in meeting the physiological demand. The controls operating in the glycolytic sequence in vivo appear to couple glycolytic recruitment to signals from the rate of energy demand, the TCA cycle state, and the mitochondrial redox state so as to satisfy the major regulatory goal of maintaining the supply of ATP for tension development.	UNIV ROCHESTER,DEPT PHYSIOL,ROCHESTER,NY 14642	University of Rochester	STANLEY, WC (corresponding author), UNIV WISCONSIN,BIODYNAM LAB,2000 OBSERV DR,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036154] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-36154] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAGON JJ, 1980, EUR J BIOCHEM, V110, P371, DOI 10.1111/j.1432-1033.1980.tb04877.x; BAUER BA, 1984, CLIN PHYSIOL BIOCH, V2, P137; BEITNER R, 1979, BIOCHIM BIOPHYS ACTA, V586, P266, DOI 10.1016/0304-4165(79)90099-0; BERGSTROM J, 1969, J APPL PHYSIOL, V26, P170, DOI 10.1152/jappl.1969.26.2.170; BRISTOW J, 1987, J BIOL CHEM, V262, P2171; BROSTROM CO, 1971, J BIOL CHEM, V246, P1961; CONLEE RK, 1979, AM J PHYSIOL, V237, pR291, DOI 10.1152/ajpregu.1979.237.5.R291; Connett R J, 1988, Adv Exp Med Biol, V222, P133; CONNETT RJ, 1986, J APPL PHYSIOL, V61, P402, DOI 10.1152/jappl.1986.61.2.402; CONNETT RJ, 1990, J APPL PHYSIOL, V68, P833, DOI 10.1152/jappl.1990.68.3.833; COYLE EF, 1986, J APPL PHYSIOL, V61, P165, DOI 10.1152/jappl.1986.61.1.165; DOUEN AG, 1989, ENDOCRINOLOGY, V124, P449, DOI 10.1210/endo-124-1-449; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; DRUMMOND GI, 1969, J BIOL CHEM, V244, P4235; FAVIER RJ, 1986, J APPL PHYSIOL, V61, P885, DOI 10.1152/jappl.1986.61.3.885; FROM AHL, 1986, FEBS LETT, V206, P257, DOI 10.1016/0014-5793(86)80992-9; GARLAND PB, 1964, BIOCHEM J, V93, P665, DOI 10.1042/bj0930665; GARLAND PB, 1964, BIOCHEM J, V93, P678, DOI 10.1042/bj0930678; GERTZ EW, 1988, J CLIN INVEST, V82, P2017, DOI 10.1172/JCI113822; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; HOLLOSZY J O, 1986, Diabetes Metabolism Reviews, V1, P409; HUE L, 1982, J BIOL CHEM, V257, P4308; HULTMAN E, 1988, EXERCISE NUTRITION E; ISSEKUTZ B, 1984, J APPL PHYSIOL, V57, P1754, DOI 10.1152/jappl.1984.57.6.1754; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JANSSON E, 1984, ACTA PHYSIOL SCAND, V122, P145, DOI 10.1111/j.1748-1716.1984.tb07492.x; JONG YSA, 1983, ARCH BIOCHEM BIOPHYS, V222, P179, DOI 10.1016/0003-9861(83)90515-5; KATZ A, 1988, J APPL PHYSIOL, V65, P487, DOI 10.1152/jappl.1988.65.1.487; KATZ A, 1987, ACTA PHYSIOL SCAND, V131, P119, DOI 10.1111/j.1748-1716.1987.tb08213.x; KEMP RG, 1983, MOL CELL BIOCHEM, V57, P147, DOI 10.1007/BF00849191; KJAER M, 1990, Medicine and Science in Sports and Exercise, V22, pS81; KOBAYASHI K, 1979, CIRC RES, V44, P166, DOI 10.1161/01.RES.44.2.166; LAWSON JWR, 1987, J BIOL CHEM, V262, P3165; LEWIS SF, 1986, J APPL PHYSIOL, V61, P391, DOI 10.1152/jappl.1986.61.2.391; Mansour T E, 1972, Curr Top Cell Regul, V5, P1; MATSUDA M, 1986, ENDOCRINOL JAPON, V33, P913; NARABAYASHI H, 1985, J BIOL CHEM, V260, P9750; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; REN JM, 1989, J APPL PHYSIOL, V67, P2243, DOI 10.1152/jappl.1989.67.6.2243; SAHLIN K, 1990, IN PRESS AM J PHYSL; STANLEY WC, 1988, METABOLISM, V37, P850, DOI 10.1016/0026-0495(88)90119-9; TORNHEIM K, 1988, J BIOL CHEM, V263, P2619; Wahren J, 1977, Ann N Y Acad Sci, V301, P45, DOI 10.1111/j.1749-6632.1977.tb38184.x; WASSERMAN DH, 1989, AM J PHYSIOL, V257, pE108, DOI 10.1152/ajpendo.1989.257.1.E108; WASSERMAN DH, 1990, AM J PHYSIOL, V259, pE195, DOI 10.1152/ajpendo.1990.259.2.E195; WISNESKI JA, 1990, J CLIN INVEST, V85, P1648, DOI 10.1172/JCI114616; WOLFE RR, 1986, J CLIN INVEST, V77, P900, DOI 10.1172/JCI112388; WOODS SC, 1974, PHYSIOL REV, V54, P596, DOI 10.1152/physrev.1974.54.3.596; ZANINETTI D, 1988, DIABETOLOGIA, V31, P108, DOI 10.1007/BF00395557; ZORZANO A, 1985, BIOCHEM J, V232, P585, DOI 10.1042/bj2320585	51	31	31	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1991	5	8					2155	2159		10.1096/fasebj.5.8.1827082	http://dx.doi.org/10.1096/fasebj.5.8.1827082			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FK111	1827082				2022-12-28	WOS:A1991FK11100006
J	VANSCHAFTINGEN, E; DAVIES, DR				VANSCHAFTINGEN, E; DAVIES, DR			FRUCTOSE ADMINISTRATION STIMULATES GLUCOSE PHOSPHORYLATION IN THE LIVERS OF ANESTHETIZED RATS	FASEB JOURNAL			English	Note						GLUCOKINASE; FRUCTOSE; FRUCTOSE 1-PHOSPHATE; GLUCOSE PHOSPHORYLATION	CARBOHYDRATE-METABOLISM; HEPATOCYTES; GLYCOGEN; GLUCOKINASE	A method allowing one to measure the rate of glucose phosphorylation in the livers of anesthetized rats is described. Upon injection of [2-H-3]glucose into the portal vein, about 90% of the radioactivity remained in the liver for approximately 30 s. The proportion of radioactivity accounted for by tritiated water increased linearly at a rate of about 5%/min in control animals. Fructose injected into the penile vein stimulated this rate of up to 2.2- and 2.7-fold in fed and overnight starved rats respectively, a maximal effect being observed at a dose of 50 mg/kg under both conditions. Fructose was also active when administered by intragastric infusion. The ketose caused increases in the concentration of fructose 1-phosphate, which reached values known to relieve the inhibition exerted on glucokinase by its regulatory protein.	CATHOLIC UNIV LOUVAIN,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,PHYSIOL CHEM LAB,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain			Van+Schaftingen, Emile/AAF-5532-2020	Van Schaftingen, Emile/0000-0002-6199-7647	NIDDK NIH HHS [DK 9235] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUR H, 1977, EUR J BIOCHEM, V74, P397, DOI 10.1111/j.1432-1033.1977.tb11404.x; Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1196; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; CLARK DG, 1979, BIOCHEM J, V184, P501, DOI 10.1042/bj1840501; DAVIES DR, 1990, IN PRESS EUR J BIOCH; GORESKY CA, 1974, J CLIN INVEST, V53, P634, DOI 10.1172/JCI107598; HUE L, 1972, EUR J BIOCHEM, V29, P268, DOI 10.1111/j.1432-1033.1972.tb01984.x; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; Hue L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P247; KATZ J, 1978, J BIOL CHEM, V253, P4530; KATZ J, 1975, EUR J BIOCHEM, V60, P91, DOI 10.1111/j.1432-1033.1975.tb20979.x; Katz J, 1976, Curr Top Cell Regul, V10, P237; MALAISSE WJ, 1990, EUR J BIOCHEM, V190, P539, DOI 10.1111/j.1432-1033.1990.tb15607.x; MURATOGLU M, 1986, BIOCHEM J, V233, P245, DOI 10.1042/bj2330245; PARDRIDGE WM, 1975, AM J PHYSIOL, V228, P1155; SATO T, 1987, CIRC SHOCK, V21, P31; SHALLENBERGER R S, 1974, P67; TOPPING DL, 1971, NUTR METAB, V13, P331; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANHOOF F, 1972, BIOCHIMIE, V54, P745, DOI 10.1016/S0300-9084(72)80177-9; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P173; VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P263, DOI 10.1042/bj1920263; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; WILLIAMS TF, 1968, AM J PHYSIOL, V215, P1200, DOI 10.1152/ajplegacy.1968.215.5.1200; WOLLENBERGER A, 1960, PFLUG ARCH GES PHYS, V270, P399, DOI 10.1007/BF00362995; ZALITIS J, 1967, BIOCHEM J, V102, P753, DOI 10.1042/bj1020753	27	34	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					326	330		10.1096/fasebj.5.3.2001793	http://dx.doi.org/10.1096/fasebj.5.3.2001793			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001793				2022-12-28	WOS:A1991FC55600011
J	WAKABAYASHI, GO; GELFAND, JA; BURKE, JF; THOMPSON, RC; DINARELLO, CA				WAKABAYASHI, GO; GELFAND, JA; BURKE, JF; THOMPSON, RC; DINARELLO, CA			A SPECIFIC RECEPTOR ANTAGONIST FOR INTERLEUKIN-1 PREVENTS ESCHERICHIA-COLI-INDUCED SHOCK IN RABBITS	FASEB JOURNAL			English	Note						INTERLEUKIN-1; TUMOR NECROSIS FACTOR; SEPTIC SHOCK; NEUTROPHILS; INTERLEUKIN-1 RECEPTOR ANTAGONIST	TUMOR NECROSIS FACTOR; LETHAL BACTEREMIA; CACHECTIN; HYPOTENSION; ENDOTOXEMIA; ANTIBODIES; APPEARANCE; INHIBITOR; INJURY	Despite antibiotic therapy, the septic shock syndrome continues to have a high mortality. Tumor necrosis factor (TNF) and interleukin 1 (IL 1), two polypeptide cytokines produced during sepsis, are thought to mediate the hypotension and tissue damage of shock. In the present studies, rabbits were infused with Escherichia coli organisms to produce shock. The IL 1 receptor antagonist (IL 1ra), which competes with IL 1 for occupancy of the IL 1 cell-surface receptors without agonist properties, was given 15 min before the bacterial infusion and during the subsequent 4 h. In saline-treated controls, hypotension was sustained for 4 h and death occurred for two of five rabbits; in rabbits treated with the IL 1ra, however, blood pressure was only transiently decreased, returned to pre-E. coli levels, and no deaths occurred. The associated leukopenia was also reduced by treatment with the antagonist (P < 0.05). Histological examination of lung tissues showed reduced infiltrating neutrophils in the IL 1ra treatment group. Despite the attenuated responses in animals treated with the IL 1ra, circulating TNF and IL 1 levels were nearly identical in both groups. We conclude that specific blockade of IL 1 at the receptor level demonstrates an essential role for this cytokine in the pathogenesis of septic shock.	NEW ENGLAND MED CTR HOSP, 750 WASHINGTON ST, BOSTON, MA 02111 USA; TUFTS UNIV, DEPT MED, DIV GEOG MED & INFECT DIS, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; SYNERGEN INC, BOULDER, CO 80301 USA	Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Gelfand, Jeffrey A/G-1885-2018	Gelfand, Jeffrey A/0000-0002-4118-5676	NIAID NIH HHS [AI15614] Funding Source: Medline; NIGMS NIH HHS [GM21700] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614, R56AI015614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; AREND WP, 1985, J IMMUNOL, V134, P3868; BEASLEY D, 1989, J CLIN INVEST, V83, P331, DOI 10.1172/JCI113879; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; CANNON JG, 1989, J IMMUNOL, V142, P2299; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CLARK BD, 1991, J APPL PHYSL; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DOEBBER TW, 1985, BIOCHEM BIOPH RES CO, V127, P799, DOI 10.1016/S0006-291X(85)80014-0; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; EISENBERG SP, 1989, CYTOKINE, V1, P90; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; LEFER AM, 1985, FED PROC, V44, P275; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; SECKINGER P, 1987, J IMMUNOL, V139, P1541; SMEDEGARD G, 1989, AM J PATHOL, V135, P489; SMITH J, 1990, LYMPHOKINE RES, V9, P568; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, SURG GYNECOL OBSTET, V164, P415; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WAKABAYASHI G, 1991, IN PRESS CLIN RES; WAKABAYASHI G, 1991, IN PRESS J CLIN INVE; WEINBERG JR, 1988, CLIN SCI, V75, P251, DOI 10.1042/cs0750251	34	415	433	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR 1	1991	5	3					338	343		10.1096/fasebj.5.3.1825816	http://dx.doi.org/10.1096/fasebj.5.3.1825816			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	1825816				2022-12-28	WOS:A1991FC55600013
J	Zheng, MZ; Ai, ZW; Guo, YY; Chen, YJ; Xie, P; An, W				Zheng, Mingzhe; Ai, Ziwei; Guo, Yuanyuan; Chen, Yujiao; Xie, Ping; An, Wei			Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma	ONCOGENE			English	Article; Early Access							FATTY LIVER-DISEASE; MITOCHONDRIAL FISSION; REGENERATION ALR; AUGMENTOR; ASSOCIATION; EXPRESSION; PROTEIN; CANCER; DRP1; HCC	Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Accumulating evidence indicates that nonalcoholic steatohepatitis (NASH) is a key predisposing factor for HCC occurrence. However, the precise mechanisms driving NASH transition to HCC remain largely obscure. Augmenter of liver regeneration (ALR) is a sulfhydryl oxidase and cytochrome c reductase that functions as an important regulator of mitochondrial dynamics. In this study, we focused on ALR ubiquitination-mediated degradation and its potential contribution to NASH-driven HCC progression at the mitochondria) level. Hepatic ALR expression in HCC patients was determined using immunohistochemical analysis. Mice with liver-specific deletion of ALR (ALR(CKO)) and ALR(WT) mice were fed a western diet (WD) and high-sugar solution for induction of NASH. HCC in animals was induced via peritoneal administration of CCl4. ALR expression was markedly decreased in liver tissues of patients with NASH and HCC compared with nonNASH and non-tumor tissues. Similarly, in ALR(WT) mice, the ALR level in tumor tissue was reduced relative to that in para-tumor tissue. In the ALR(CKO) group, mice fed WD plus CCl4 developed HCC starting at week 12 while ALR(WT) mice fed WD plus ca, developed HCC at week 24. Analysis of protein posttranslational modifications revealed ubiquitylation (Ub) and deubiquitination (DUb) of ALR by murine double minute 2 (MDM2) and ubiquitin-specific protease 36 (USP36), respectively. Imbalance between Ub and DUb of ALR resulted in profound ALR degradation, which appeared to be reversibly associated with Edmondson-Steiner tumor grade. Rescue of ALR levels via gene transfection abolished tumor malignant features to a certain extent in vitro. Notably, ALR deletion substantially enhanced mitochondrial fission by activating Drp1 phosphorylation at Ser616, thus disrupting the balance of mitochondria) dynamics between fission and fusion and severely impairing oxidative phosphorylation (OXPHOS) and ATP synthesis, instead enhancing anaerobic metabolism, which might be attributed to steatotic hepatocyte transition into the malignant HCC phenotype. Hepatic ALR depletion via dysregulation of ubiquitination is a critical aggravator of NASH-HCC progression and represents a promising therapeutic target for related liver diseases.	[Zheng, Mingzhe; Ai, Ziwei; Guo, Yuanyuan; Chen, Yujiao; Xie, Ping; An, Wei] Capital Med Univ, Dept Cell Biol, Municipal Key Lab Liver Protect & Regulat Regener, Beijing, Peoples R China; [Guo, Yuanyuan] China Japan Friendship Hosp Dept Pathol, Beijing, Peoples R China	Capital Medical University	Xie, P; An, W (corresponding author), Capital Med Univ, Dept Cell Biol, Municipal Key Lab Liver Protect & Regulat Regener, Beijing, Peoples R China.	xiep@ccmu.edu.cn; anwei@ccmu.edu.cn			National Natural Science Foundation of China (NSFC) [32071128]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (NSFC) (No. 32071128).	Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Baffy G, 2012, J HEPATOL, V56, P1384, DOI 10.1016/j.jhep.2011.10.027; Begriche K, 2013, HEPATOLOGY, V58, P1497, DOI 10.1002/hep.26226; Cao Y, 2009, FREE RADICAL BIO MED, V47, P1057, DOI 10.1016/j.freeradbiomed.2009.07.017; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Dayoub R, 2011, MOL MED, V17, P221, DOI 10.2119/molmed.2010.00117; Du JH, 2017, THERANOSTICS, V7, P4192, DOI 10.7150/thno.21400; Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fujiwara N, 2018, GUT, V67, P1493, DOI 10.1136/gutjnl-2017-315193; Galloway CA, 2014, AM J PHYSIOL-GASTR L, V307, pG632, DOI 10.1152/ajpgi.00182.2014; Gandhi CR, 2015, GASTROENTEROLOGY, V148, P379, DOI 10.1053/j.gastro.2014.10.008; Hashimoto E, 2012, HEPATOL RES, V42, P1, DOI 10.1111/j.1872-034X.2011.00872.x; Ho DWY, 2002, GUT, V50, P869, DOI 10.1136/gut.50.6.869; Huang DIQ, 2021, NAT REV GASTRO HEPAT, V18, P223, DOI 10.1038/s41575-020-00381-6; Hernandez-Alvarez MI, 2019, CELL, V177, P881, DOI 10.1016/j.cell.2019.04.010; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia XW, 2018, LAB INVEST, V98, P871, DOI 10.1038/s41374-018-0039-2; Kim MS, 2011, J CELL BIOCHEM, V112, P498, DOI 10.1002/jcb.22940; LABRECQUE DR, 1975, J PHYSIOL-LONDON, V248, P273, DOI 10.1113/jphysiol.1975.sp010973; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Mansouri A, 2018, GASTROENTEROLOGY, V155, P629, DOI 10.1053/j.gastro.2018.06.083; MEI MH, 1993, HEPATOLOGY, V17, P638; Nakagawa H, 2015, WORLD J HEPATOL, V7, P2110, DOI 10.4254/wjh.v7.i17.2110; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Nalesnik MA, 2017, HEPATOLOGY, V66, P266, DOI 10.1002/hep.29047; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Shi HB, 2017, ONCOTARGET, V8, P12637, DOI 10.18632/oncotarget.14478; Sung H, 2019, CA-CANCER J CLIN, V69, P88, DOI 10.3322/caac.21499; Thasler WE, 2005, HISTOPATHOLOGY, V47, P57, DOI 10.1111/j.1365-2559.2005.02172.x; Tilg H, 2006, GASTROENTEROLOGY, V131, P934, DOI 10.1053/j.gastro.2006.05.054; Tsuchida T, 2018, J HEPATOL, V69, P385, DOI 10.1016/j.jhep.2018.03.011; Wang N, 2014, EXP THER MED, V7, P93, DOI 10.3892/etm.2013.1140; Wang X, 2022, NUCLEIC ACIDS RES, V50, pD719, DOI 10.1093/nar/gkab962; Wu Y, 2007, ARCH BIOCHEM BIOPHYS, V464, P48, DOI 10.1016/j.abb.2007.03.025; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Younossi ZM, 2015, HEPATOLOGY, V62, P1723, DOI 10.1002/hep.28123; Yu HY, 2014, ONCOTARGETS THER, V7, P887, DOI 10.2147/OTT.S61531; Zhang C, 2017, HEPATOLOGY, V66, P1989, DOI 10.1002/hep.29326	41	0	0	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02549-7	http://dx.doi.org/10.1038/s41388-022-02549-7		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6M2DF	36434180	Green Submitted			2022-12-28	WOS:000888684000002
J	Zeng, WF; Xiong, LX; Wu, W; Li, SR; Liu, J; Yang, LB; Lao, LY; Huang, PH; Zhang, MM; Chen, HP; Miao, NY; Lin, ZR; Liu, ZF; Yang, XY; Wang, JY; Wang, P; Song, EW; Yao, YD; Nie, Y; Chen, JN; Huang, D				Zeng, Wenfeng; Xiong, Lixiong; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Zhang, Mengmeng; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di			CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype	ONCOGENE			English	Article; Early Access							CANCER-ASSOCIATED FIBROBLASTS; MESENCHYMAL TRANSITION; GROWTH-FACTOR; TGF-BETA; KAPPA-B; CARCINOMA; CELLS; METASTASIS; ANGIOGENESIS; IMMUNOSUPPRESSION	The heterogeneity of cancer-associated fibroblasts (CAFs) might be ascribed to differences in origin. CD10 and GPR77 have been reported to identify a chemoresistance-inducing CAF subset in breast cancer. However, the precise mechanism for the formation of the CD10(+)GPR77(+) CAFs remains unknown. In this study, we found that CCL18 expression was positively correlated with the density of CD10(+)GPR77(+) CAFs in breast cancer and associated with a poor response to chemotherapy. Moreover, CCL18 secreted by tumor-associated macrophages (TAMs) activated a CD10(+)GPR77(+) CAF phenotype in normal breast-resident fibroblasts (NBFs), which could then enrich cancer stem cells (CSCs) and induce chemoresistance in breast cancer cells. Mechanistically, CCL18 activated NF-kappa B signaling via PITPNM3 and thus enhanced the production of IL-6 and IL-8. Furthermore, intratumoral CCL18 injection significantly induced the activation of NBFs and the chemoresistance of xenografts in vivo. In addition, targeting CCL18 by anti-CCL18 antibody could inhibit the formation of CD10(+)GPR77(+) CAFs and recover the chemosensitivity in vivo, leading to effective tumor control. Collectively, these findings reveal that inflammatory signaling crosstalk between TAMs and fibroblasts is responsible for the formation of the CD10(+)GPR77(+) CAFs, suggesting CCL18-PITPNM3 signaling is a potential therapeutic target to block the activation of this specific CAF subtype and tumor chemoresistance.	[Zeng, Wenfeng; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China; [Zeng, Wenfeng; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Peoples R China; [Zeng, Wenfeng; Wu, Wei; Li, Shunrong; Liu, Jiang; Yang, Linbing; Lao, Liyan; Huang, Penghan; Chen, Huiping; Miao, Nanyan; Lin, Zhirong; Liu, Zifei; Yang, Xinyu; Wang, Jiayi; Wang, Pei; Song, Erwei; Yao, Yandan; Nie, Yan; Chen, Jianing; Huang, Di] Bioland Lab, Guangzhou 510005, Peoples R China; [Xiong, Lixiong] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pharm, Guangzhou 510655, Peoples R China; [Zhang, Mengmeng] Peking Univ, Peking Univ Peoples Hosp, Dept Breast Surg, Beijing 100044, Peoples R China; [Yao, Yandan] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Shenshan Med Ctr, Shanwei 516621, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory); Sun Yat Sen University; Peking University; Sun Yat Sen University	Yao, YD; Nie, Y; Chen, JN; Huang, D (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China.; Yao, YD; Nie, Y; Chen, JN; Huang, D (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Peoples R China.; Yao, YD; Nie, Y; Chen, JN; Huang, D (corresponding author), Bioland Lab, Guangzhou 510005, Peoples R China.; Yao, YD (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Shenshan Med Ctr, Shanwei 516621, Peoples R China.	yaoyand@mail.sysu.edu.cn; nieyan7@mail.sysu.edu.cn; chenjn335@mail.sysu.edu.cn; huangd63@mail.sysu.edu.cn			Natural Science Foundation of China [92159303, 81930081, 81621004, 81720108029, 91940305, 82173054, 81872158, 82222029, 82002786, 81902699, 81972465, 82071859, 82071860]; Guangdong Science and Technology Department [2020B1212060018, 2020B1212030004, 2020B1515120007]; Guangdong Basic and Applied Basic Research Foundation [2019A1515011485, 2019A1515011467, 2020A1515011458, 2022B1515020101, 2022B1515020048, 2019A050510016, 2021B1515230001, 2021A005]; Department of Natural Resources of Guangdong Province [GDNRC [2021]51]; Bureau of Science and Technology of Guangzhou [20212200003]; Program for Guangdong Introducing Innovative and Enterpreneurial Teams [2019BT02Y198]; Guangzhou Science Technology and Innovation Commission [202102010148]; Fundamental Research Funds for the Central Universities [20ykjc03]; Fountain-Valley Life Sciences Fund of University of Chinese Academy of Sciences Education Foundation; Clinical Innovation Research Program of Bioland Laboratory [2018GZR0201004]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Department; Guangdong Basic and Applied Basic Research Foundation; Department of Natural Resources of Guangdong Province; Bureau of Science and Technology of Guangzhou; Program for Guangdong Introducing Innovative and Enterpreneurial Teams; Guangzhou Science Technology and Innovation Commission; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Fountain-Valley Life Sciences Fund of University of Chinese Academy of Sciences Education Foundation; Clinical Innovation Research Program of Bioland Laboratory	This work was supported by grants from the Natural Science Foundation of China (92159303 (ES), 81930081 (ES), 81621004 (ES), 81720108029 (ES), 81930081 (ES), 91940305 (ES), 82173054 (YN), 81872158 (YN), 82222029 (DH), 82002786 (LY), 81902699 (JL), 81972465 (WW) 82071859 (YY), 82071860 (YY)), Guangdong Science and Technology Department (2020B1212060018 (ES), 2020B1212030004 (ES), 2020B1515120007 (YY)), Guangdong Basic and Applied Basic Research Foundation (2019A1515011485 (JL), 2019A1515011467 (SL), 2020A1515011458 (DH), 2022B1515020101 (DH), 2022B1515020048 (YN), 2019A050510016 (YY), 2021B1515230001 (YY), 2021A005 (YY)), Clinical Innovation Research Program of Bioland Laboratory (2018GZR0201004 (ES)), Department of Natural Resources of Guangdong Province (GDNRC [2021]51), Bureau of Science and Technology of Guangzhou (20212200003 (ES)), the Program for Guangdong Introducing Innovative and Enterpreneurial Teams (2019BT02Y198 (ES, YY)), Guangzhou Science Technology and Innovation Commission (202102010148 (YN)) and the Fundamental Research Funds for the Central Universities (20ykjc03 (YY)). The research is partly supported by Fountain-Valley Life Sciences Fund of University of Chinese Academy of Sciences Education Foundation.	Affo S, 2021, CANCER CELL, V39, P866, DOI 10.1016/j.ccell.2021.03.012; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Aravind A, 2022, J CELL COMMUN SIGNAL, V16, P293, DOI 10.1007/s12079-021-00633-3; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Comito G, 2014, ONCOGENE, V33, P2423, DOI 10.1038/onc.2013.191; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Dulauroy S, 2012, NAT MED, V18, P1262, DOI 10.1038/nm.2848; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Froese AR, 2016, AM J RESP CRIT CARE, V194, P84, DOI 10.1164/rccm.201508-1638OC; Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Huang D, 2017, CANCER RES, V77, P3591, DOI [10.1158/0008-5472.can-16-2706, 10.1158/0008-5472.CAN-16-2706]; Huo XF, 2014, GUT, V63, P1042, DOI 10.1136/gutjnl-2013-305533; Islam SA, 2013, J EXP MED, V210, P1889, DOI 10.1084/jem.20130240; Jotzu C, 2011, CELL ONCOL, V34, P55, DOI 10.1007/s13402-011-0012-1; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kieffer Y, 2020, CANCER DISCOV, V10, P1330, DOI 10.1158/2159-8290.CD-19-1384; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kuppe C, 2021, NATURE, V589, P281, DOI 10.1038/s41586-020-2941-1; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; Leek RD, 1996, CANCER RES, V56, P4625; Lewis CE, 2011, CANCER CELL, V19, P431, DOI 10.1016/j.ccr.2011.03.016; Li HY, 2014, J CELL BIOCHEM, V115, P596, DOI 10.1002/jcb.24697; Li HY, 2018, J CELL PHYSIOL, V233, P3207, DOI 10.1002/jcp.26164; Lin L, 2015, ONCOTARGET, V6, P34758, DOI 10.18632/oncotarget.5325; Liu RP, 2019, HEPATOLOGY, V70, P1317, DOI 10.1002/hep.30662; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Marigo I, 2020, CANCER DISCOV, V10, P1758, DOI 10.1158/2159-8290.CD-20-0036; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Nie Y, 2017, CANCER RES, V77, P3605, DOI 10.1158/0008-5472.CAN-16-2709; Niu N, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00349-4; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Palumbo-Zerr K, 2015, NAT MED, V21, P150, DOI 10.1038/nm.3777; Primac I, 2019, J CLIN INVEST, V129, P4509, DOI 10.1172/JCI125890; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Shalek AK, 2014, NATURE, V510, P363, DOI 10.1038/nature13437; She L, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0620-1; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Su SC, 2017, CELL RES, V27, P461, DOI 10.1038/cr.2017.34; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Sun XT, 2022, GUT, V71, P129, DOI 10.1136/gutjnl-2020-322744; Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073; Vickman RE, 2020, PROSTATE, V80, P173, DOI 10.1002/pros.23929; von Ahrens D, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0448-5; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Yin MZ, 2016, J CLIN INVEST, V126, P4157, DOI 10.1172/JCI87252; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127	62	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02540-2	http://dx.doi.org/10.1038/s41388-022-02540-2		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6J4UB	36418470	hybrid			2022-12-28	WOS:000886818900002
J	Zhang, HW; Liao, ZB; Wang, WJ; Liu, YC; Zhu, H; Liang, HF; Zhang, BX; Chen, XP				Zhang, Hongwei; Liao, Zhibin; Wang, Weijian; Liu, Yachong; Zhu, He; Liang, Huifang; Zhang, Bixiang; Chen, Xiaoping			A micropeptide JunBP regulated by TGF-beta promotes hepatocellular carcinoma metastasis	ONCOGENE			English	Article; Early Access							TRANSCRIPTION; LNCRNA; EXPRESSION; PATHWAY	Transforming growth factor beta (TGF-beta) signaling pathway plays important roles in hepatocellular carcinoma (HCC) progression. Long intergenic non-protein coding RNAs (lincRNAs) are important components of TGF-beta signaling pathway and perform their functions through different mechanisms. Here, we found that LINC02551 was activated by TGF-beta transcriptionally and identified a 174-amino-acid peptide, Jun binding micropeptide (JunBP), encoded by LINC02551 in HCC tissues and HCC cell lines. Functional study showed that JunBP promotes HCC metastasis through binding to c-Jun and subsequent promotion of its phosphorylated activation. Activated c-Jun has higher binding affinity to SMAD3, which in turn leads to more SMAD3 recruited to the promoter region of LINC02551. We find a positive feedback among them, and this mechanism provides a novel potential prognostic biomarker and therapeutic target in HCC.	[Zhang, Hongwei; Liao, Zhibin; Wang, Weijian; Liu, Yachong; Zhu, He; Liang, Huifang; Zhang, Bixiang; Chen, Xiaoping] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Hubei, Peoples R China; [Zhang, Hongwei; Liao, Zhibin; Wang, Weijian; Liu, Yachong; Zhu, He; Liang, Huifang; Zhang, Bixiang; Chen, Xiaoping] Hubei Key Lab HepatoPancreato Biliary Dis, Wuhan, Hubei, Peoples R China; [Zhang, Bixiang; Chen, Xiaoping] Minist Educ, Key Lab Organ Transplantat, Wuhan, Hubei, Peoples R China; [Zhang, Bixiang; Chen, Xiaoping] Minist Hlth, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology	Liang, HF; Zhang, BX; Chen, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Hubei, Peoples R China.; Liang, HF; Zhang, BX; Chen, XP (corresponding author), Hubei Key Lab HepatoPancreato Biliary Dis, Wuhan, Hubei, Peoples R China.; Zhang, BX; Chen, XP (corresponding author), Minist Educ, Key Lab Organ Transplantat, Wuhan, Hubei, Peoples R China.; Zhang, BX; Chen, XP (corresponding author), Minist Hlth, Wuhan, Hubei, Peoples R China.	lianghuifang1997@126.com; bixiangzhang@163.com; chenxpchenxp@163.com		Liao, Zhibin/0000-0003-0305-2079	National Natural Science Foundation of China [81572855, 81572427, 81874189, 82103597]; Graduates' Innovation Fund, Huazhong University of Science and Technology [5003540055]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Graduates' Innovation Fund, Huazhong University of Science and Technology	This work was supported by The National Natural Science Foundation of China (No. 81572855 to XC, No. 81572427 and No. 81874189 to BZ, and No. 82103597 to ZL) and Graduates' Innovation Fund, Huazhong University of Science and Technology (No. 5003540055 to ZL).	Arrese M, 2018, CURR PROTEIN PEPT SC, V19, P1172, DOI 10.2174/1389203718666171117112619; Bridges MC, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202009045; Carrat F, 2019, LANCET, V393, P1453, DOI 10.1016/S0140-6736(18)32111-1; Cheetham SW, 2018, NAT STRUCT MOL BIOL, V25, P809, DOI 10.1038/s41594-017-0006-4; Chen J, 2019, TRENDS MOL MED, V25, P1010, DOI 10.1016/j.molmed.2019.06.007; Choi SW, 2019, BRIEF BIOINFORM, V20, P1853, DOI 10.1093/bib/bby055; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ding ZY, 2014, HEPATOLOGY, V60, P1620, DOI 10.1002/hep.27273; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Finnson KW, 2020, SEMIN CELL DEV BIOL, V101, P115, DOI 10.1016/j.semcdb.2019.11.013; Giannelli G, 2016, J HEPATOL, V65, P798, DOI 10.1016/j.jhep.2016.05.007; Goodall GJ, 2021, NAT REV CANCER, V21, P22, DOI 10.1038/s41568-020-00306-0; Gough NR, 2021, GASTROENTEROLOGY, V161, P434, DOI 10.1053/j.gastro.2021.04.064; Hata A, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022061; Iaccarino I, 2021, METHODS MOL BIOL, V2348, P27, DOI 10.1007/978-1-0716-1581-2_2; Johnson GL, 2007, BBA-MOL CELL RES, V1773, P1341, DOI 10.1016/j.bbamcr.2006.12.009; Kaplan DE, 2019, GASTROENTEROLOGY, V156, P1693, DOI 10.1053/j.gastro.2019.01.026; Kim MS, 2020, CANCERS, V12, DOI 10.3390/cancers12041048; Liao ZB, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01838-5; Liao ZB, 2020, HEPATOLOGY, V72, P997, DOI 10.1002/hep.31104; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Mancarella S, 2019, CANCERS, V11, DOI 10.3390/cancers11101510; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Nahkuri S, 2012, WIRES DEV BIOL, V1, P743, DOI 10.1002/wdev.41; Pang YN, 2020, J HEPATOL, V73, P1155, DOI 10.1016/j.jhep.2020.05.028; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Rapisarda V, 2016, WORLD J HEPATOL, V8, P573, DOI 10.4254/wjh.v8.i13.573; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Rossi M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09754-1; Senmatsu S, 2020, GENES GENET SYST, V95, P213, DOI 10.1266/ggs.20-00024; Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152; Song MJ, 2021, HEPATOLOGY, V73, P1717, DOI 10.1002/hep.31792; Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496; Tan YT, 2021, CANCER COMMUN, V41, P109, DOI 10.1002/cac2.12108; Tang WW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0187-x; Wu P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1147-3; Wu SQ, 2022, ONCOGENE, V41, P2163, DOI 10.1038/s41388-022-02229-6; Zeke A, 2016, MICROBIOL MOL BIOL R, V80, P793, DOI 10.1128/MMBR.00043-14; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhu H, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01861-6; Zi ZK, 2019, J MOL BIOL, V431, P2644, DOI 10.1016/j.jmb.2019.05.022	41	0	0	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02518-0	http://dx.doi.org/10.1038/s41388-022-02518-0		NOV 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6G6YZ	36380240	hybrid			2022-12-28	WOS:000884899800001
J	Yang, H; Zhao, XP; Liu, JJ; Jin, MM; Liu, XY; Yan, J; Yao, XF; Mao, XY; Li, N; Liang, BB; Xie, W; Zhang, KC; Zhao, J; Liu, L; Huang, G				Yang, Hao; Zhao, Xiaoping; Liu, Jianjun; Jin, Mingming; Liu, Xiyu; Yan, Jun; Yao, Xufeng; Mao, Xinyi; Li, Nan; Liang, Beibei; Xie, Wei; Zhang, Kunchi; Zhao, Jian; Liu, Liu; Huang, Gang			TNF alpha-induced IDH1 hyperacetylation reprograms redox homeostasis and promotes the chemotherapeutic sensitivity	ONCOGENE			English	Article; Early Access							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; CANCER-CELLS; ACETYLATION; INHIBITION; RESISTANCE; PHOSPHORYLATION; CHEMORESISTANCE; GROWTH; SIRT3	The heterogeneity and drug resistance of colorectal cancer (CRC) often lead to treatment failure. Isocitrate dehydrogenase 1 (IDH1), a rate-limiting enzyme in the tricarboxylic acid cycle, regulates the intracellular redox environment and mediates tumor cell resistance to chemotherapeutic drugs. The aim of this study was to elucidate the mechanism underlying the involvement of IDH1 acetylation in the development of CRC drug resistance under induction of TNF alpha. We found TNF alpha disrupted the interaction between SIRT1 and IDH1 and increased the level of acetylation at K115 of IDH1. Hyperacetylation of K115 was accompanied by protein ubiquitination, which increased its susceptibility to degradation compared to IDH1 K115R. TNF alpha-mediated hyperacetylation of K115 sensitized the CRC cells to 5FU and reduced the NADPH/NADP ratio to that of intracellular ROS. Furthermore, TNF alpha and 5FU inhibited CRC tumor growth in vivo, while the K115R-expressing tumor tissues developed 5FU resistance. In human CRC tissues, K115 acetylation was positively correlated with TNF alpha infiltration, and K115 hyperacetylation was associated with favorable prognosis compared to chemotherapy-induced deacetylation. Therefore, TNF alpha-induced hyperacetylation at the K115 site of IDH1 promotes antitumor redox homeostasis in CRC cells, and can be used as a marker to predict the response of CRC patients to chemotherapy.	[Yang, Hao; Jin, Mingming; Liu, Xiyu; Yao, Xufeng; Mao, Xinyi; Li, Nan; Liang, Beibei; Xie, Wei; Zhang, Kunchi; Zhao, Jian; Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Jiading Dist Cent Hosp, Shanghai 201318, Peoples R China; [Zhao, Xiaoping; Liu, Jianjun; Huang, Gang] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Nucl Med, Shanghai 200127, Peoples R China; [Yan, Jun] Shanghai Univ Med & Hlth Sci, Dept Oncol, Jiading Dist Cent Hosp, Shanghai 201800, Peoples R China; [Liu, Liu] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China	Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University; Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University	Zhao, J; Huang, G (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Jiading Dist Cent Hosp, Shanghai 201318, Peoples R China.; Huang, G (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Nucl Med, Shanghai 200127, Peoples R China.; Liu, L (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China.	j-zhao@vip.126.com; chestnuclear@126.com; huanggang@sumhs.edu.cn		Yang, Hao/0000-0002-3781-7271	National Natural Science Foundation of China [81903065, 81830052, 82127807, 82003142]; Construction project of Shanghai Key Laboratory of Molecular Imaging [18DZ2260400]; "Chen Guang" project - Shanghai Municipal Education Commission [19CG75]; Shanghai Education Development Foundation; Natural Science Foundation of Shanghai [21ZR1458900]; Nurture projects for the Youth Medical Talents-Medical Imaging Practitioners Program [SHWRS(2020)_087]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Construction project of Shanghai Key Laboratory of Molecular Imaging; "Chen Guang" project - Shanghai Municipal Education Commission; Shanghai Education Development Foundation; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Nurture projects for the Youth Medical Talents-Medical Imaging Practitioners Program	This study was supported by grants from the National Natural Science Foundation of China (Grant No.81903065, 81830052, 82127807, 82003142), Construction project of Shanghai Key Laboratory of Molecular Imaging (18DZ2260400), "Chen Guang" project (No. 19CG75) supported by Shanghai Municipal Education Commission and Shanghai Education Development Foundation, the Natural Science Foundation of Shanghai (Grant No.21ZR1458900), and the Nurture projects for the Youth Medical Talents-Medical Imaging Practitioners Program (Grant No. SHWRS(2020)_087).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Biedermann J, 2019, CANCERS, V11, DOI 10.3390/cancers11122028; Brenner D, 2015, NAT REV IMMUNOL, V15, P362, DOI 10.1038/nri3834; Calvert AE, 2017, CELL REP, V19, P1858, DOI 10.1016/j.celrep.2017.05.014; Carafa V, 2018, CLIN CANCER RES, V24, P2886, DOI 10.1158/1078-0432.CCR-17-3081; Chen L, 2019, NAT METAB, V1, P404, DOI 10.1038/s42255-019-0043-x; Cruceriu D, 2020, CELL ONCOL, V43, P1, DOI 10.1007/s13402-019-00489-1; De Rosa V, 2015, CLIN CANCER RES, V21, P5110, DOI 10.1158/1078-0432.CCR-15-0375; De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286; denDekker AD, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132306; Fluckiger A, 2016, ONCOGENE, V35, P4611, DOI 10.1038/onc.2015.523; Han CJ, 2019, ACTA PHARMACOL SIN, V40, P1292, DOI 10.1038/s41401-019-0225-9; Hou JJ, 2016, CANCER LETT, V376, P22, DOI 10.1016/j.canlet.2016.02.015; Hu HG, 2017, HEPATOLOGY, V65, P515, DOI 10.1002/hep.28887; Huang JL, 2021, AM J CLIN PATHOL, V156, P777, DOI 10.1093/ajcp/aqab023; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jung G, 2020, NAT REV GASTRO HEPAT, V17, P111, DOI 10.1038/s41575-019-0230-y; Kobelt D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00980; Kong MJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0537-6; Kryeziu K, 2019, BBA-REV CANCER, V1871, P240, DOI 10.1016/j.bbcan.2019.01.002; Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384; Lee JH, 2011, CLIN CANCER RES, V17, P7551, DOI 10.1158/1078-0432.CCR-11-1026; Liu B, 2018, MOL MED REP, V18, P1987, DOI 10.3892/mmr.2018.9195; Lizardo DY, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188447; Lu L, 2015, J CONTROL RELEASE, V210, P134, DOI 10.1016/j.jconrel.2015.05.282; Meng FY, 2021, CANCER IMMUNOL IMMUN, V70, P2247, DOI 10.1007/s00262-021-02862-2; Metzig MO, 2016, ONCOGENE, V35, P3399, DOI 10.1038/onc.2015.398; Miller JJ, 2021, NEURO-ONCOLOGY, V23, P53, DOI 10.1093/neuonc/noaa180; Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z; Moon DO, 2009, CANCER LETT, V274, P132, DOI 10.1016/j.canlet.2008.09.013; Narayanan S, 2020, DRUG RESIST UPDATE, V48, DOI 10.1016/j.drup.2019.100663; Nie H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13601-8; Pramono AA, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030358; Rardin MJ, 2013, P NATL ACAD SCI USA, V110, P6601, DOI 10.1073/pnas.1302961110; Shanmugasundaram K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01106-1; Shen J, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12441; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sizemore ST, 2018, CELL RES, V28, P1090, DOI 10.1038/s41422-018-0086-7; Sociali G, 2015, EUR J MED CHEM, V102, P530, DOI 10.1016/j.ejmech.2015.08.024; Tian M, 2021, ACTA PHARMACOL SIN, V42, P1180, DOI 10.1038/s41401-020-00546-8; Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447; Walther W, 2015, INT J ONCOL, V47, P2276, DOI 10.3892/ijo.2015.3189; Wang B, 2020, EMBO REP, V21, DOI 10.15252/embr.201948183; Wang SW, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002243; Weeks J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050740; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Xu F, 2021, CANCER SCI, V112, P4501, DOI 10.1111/cas.15116; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yang H, 2021, J CANCER, V12, P4862, DOI 10.7150/jca.58846; Yu W, 2012, J BIOL CHEM, V287, P14078, DOI 10.1074/jbc.M112.355206; Zhang TP, 2019, J HEPATOL, V70, P87, DOI 10.1016/j.jhep.2018.08.026; Zhang YJ, 2018, MOL CELL, V71, P201, DOI 10.1016/j.molcel.2018.06.023; Zhang ZY, 2018, ONCOGENE, V37, P3456, DOI 10.1038/s41388-018-0221-4; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	55	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/s41388-022-02528-y	http://dx.doi.org/10.1038/s41388-022-02528-y		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6A2MU	36352097				2022-12-28	WOS:000880493900001
J	Watanabe, K; Kimura, S; Seki, M; Isobe, T; Kubota, Y; Sekiguchi, M; Sato-Otsubo, A; Hiwatari, M; Kato, M; Oka, A; Koh, K; Sato, Y; Tanaka, H; Miyano, S; Kawai, T; Hata, K; Ueno, H; Nannya, Y; Suzuki, H; Yoshida, K; Fujii, Y; Nagae, G; Aburatani, H; Ogawa, S; Takita, J				Watanabe, Kentaro; Kimura, Shunsuke; Seki, Masafumi; Isobe, Tomoya; Kubota, Yasuo; Sekiguchi, Masahiro; Sato-Otsubo, Aiko; Hiwatari, Mitsuteru; Kato, Motohiro; Oka, Akira; Koh, Katsuyoshi; Sato, Yusuke; Tanaka, Hiroko; Miyano, Satoru; Kawai, Tomoko; Hata, Kenichiro; Ueno, Hiroo; Nannya, Yasuhito; Suzuki, Hiromichi; Yoshida, Kenichi; Fujii, Yoichi; Nagae, Genta; Aburatani, Hiroyuki; Ogawa, Seishi; Takita, Junko			Identification of the ultrahigh-risk subgroup in neuroblastoma cases through DNA methylation analysis and its treatment exploiting cancer metabolism	ONCOGENE			English	Article							ARGININE DEPRIVATION; SERINE BIOSYNTHESIS; GENE-EXPRESSION; SULFASALAZINE; CLASSIFICATION; PROLIFERATION; INHIBITOR; LYMPHOMA; SUPPORTS; GLYCINE	Neuroblastomas require novel therapies that are based on the exploitation of their biological mechanism. To address this need, we analyzed the DNA methylation and expression datasets of neuroblastomas, extracted a candidate gene characterizing the aggressive features, and conducted functional studies. Based on the DNA methylation data, we identified a subgroup of neuroblastoma cases with 11q loss of heterozygosity with extremely poor prognosis. PHGDH, a serine metabolism-related gene, was extracted as a candidate with strong expression and characteristic methylation in this subgroup as well as in cases with MYCN amplification. PHGDH inhibition suppressed neuroblastoma cell proliferation in vitro and in vivo, indicating that the inhibition of serine metabolism by PHGDH inhibitors is a therapeutic alternative for neuroblastoma. Inhibiting the arginine metabolism, which is closely related to serine metabolism using arginine deiminase, had a combination effect both in vitro and in vivo, especially on extracellular arginine-dependent neuroblastoma cells with ASS1 deficiency. Expression and metabolome analyses of post-dose cells confirmed the synergistic effects of treatments targeting serine and arginine indicated that xCT inhibitors that inhibit cystine uptake could be candidates for further combinatorial treatment. Our results highlight the rational therapeutic strategy of targeting serine/arginine metabolism for intractable neuroblastoma.	[Watanabe, Kentaro; Kimura, Shunsuke; Seki, Masafumi; Isobe, Tomoya; Kubota, Yasuo; Sekiguchi, Masahiro; Sato-Otsubo, Aiko; Hiwatari, Mitsuteru; Kato, Motohiro; Oka, Akira; Takita, Junko] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan; [Kimura, Shunsuke] Hiroshima Univ, Dept Pediat, Grad Sch Biomed Sci, Hiroshima, Japan; [Hiwatari, Mitsuteru] Teikyo Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Koh, Katsuyoshi] Saitama Childrens Med Ctr, Dept Hematol Oncol, Saitama, Japan; [Sato, Yusuke] Univ Tokyo, Dept Urol, Tokyo, Japan; [Tanaka, Hiroko; Miyano, Satoru] Tokyo Med & Dent Univ, M&D Data Sci Ctr, Dept Integrated Analyt, Tokyo, Japan; [Kawai, Tomoko; Hata, Kenichiro] Natl Res Inst Child Hlth & Dev, Dept Maternal Fetal Biol, Tokyo, Japan; [Hata, Kenichiro] Gunma Univ, Dept Mol & Med Genet, Grad Sch Med, Maebashi, Gumma, Japan; [Ueno, Hiroo; Takita, Junko] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Ueno, Hiroo; Nannya, Yasuhito; Suzuki, Hiromichi; Yoshida, Kenichi; Fujii, Yoichi; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan; [Suzuki, Hiromichi] Natl Canc Ctr, Div Brain Tumor Translat Res, Tokyo, Japan; [Nagae, Genta; Aburatani, Hiroyuki] Univ Tokyo, Res Ctr Adv Sci & Technol, Genome Sci Div, Tokyo, Japan; [Ogawa, Seishi] Kyoto Univ, Inst Adv Study Human Biol WPI ASHBi, Dept Pathol & Tumor Biol, Kyoto, Japan	University of Tokyo; Hiroshima University; Teikyo University; Saitama Children's Medical Center; University of Tokyo; Tokyo Medical & Dental University (TMDU); National Center for Child Health & Development - Japan; Gunma University; Kyoto University; Kyoto University; National Cancer Center - Japan; University of Tokyo; Kyoto University	Takita, J (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan.; Takita, J (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan.	jtakita@kuhp.kyoto-u.ac.jp		Seki, Masafumi/0000-0003-4671-7026; Isobe, Tomoya/0000-0002-3487-3307; Kubota, Yasuo/0000-0002-7909-5422; Sekiguchi, Masahiro/0000-0002-7941-9319	JSPS KAKENHI [JP19J11112, JP21K20795, JP22K15521, JP17H04224, JP18K19467, JP20H00528, JP21K19405, 15H05909, 19H05656, JP19cm0106509h9904]; Japan Agency for Medical Research and Development (AMED) [JP19cm0106509h9904, JP22ama221505h0001, JP19ck0106468h0001]; Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics	This work was supported by JSPS KAKENHI Grant Numbers JP19J11112, JP21K20795, and JP22K15521 to KW; JP17H04224, JP18K19467, JP20H00528, and JP21K19405 to JT; 15H05909 and 19H05656 to SO and YN; Project for Cancer Research and Therapeutic Evolution (P-CREATE; grant no. JP19cm0106509h9904), Project for Promotion of Cancer Research and Therapeutic Evolution (P-PROMOTE; grant no. JP22ama221505h0001), Practical Research for Innovative Cancer Control (grant no. JP19ck0106468h0001) from Japan Agency for Medical Research and Development (AMED), and Princess Takamatsu Cancer Research Fund to JT; and Gold Ribbon Network, Children's Cancer Association of Japan, and Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics to KW.	Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Arlt B, 2021, INT J CANCER, V148, P1219, DOI 10.1002/ijc.33423; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dillon BJ, 2004, CANCER-AM CANCER SOC, V100, P826, DOI 10.1002/cncr.20057; Ensor CM, 2002, CANCER RES, V62, P5443; Feun L, 2008, CURR PHARM DESIGN, V14, P1049, DOI 10.2174/138161208784246199; Fultang L, 2019, CANCER RES, V79, P611, DOI 10.1158/0008-5472.CAN-18-2139; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Haryu S, 2018, J NEURO-ONCOL, V136, P23, DOI 10.1007/s11060-017-2621-7; Henrich KO, 2016, CANCER RES, V76, P5523, DOI 10.1158/0008-5472.CAN-15-2507; Hishiki T, 2018, INT J CLIN ONCOL, V23, P965, DOI 10.1007/s10147-018-1281-8; Irwin MS, 2021, J CLIN ONCOL, V39, P3229, DOI 10.1200/JCO.21.00278; Ji JX, 2020, CLIN CANCER RES, V26, P4402, DOI 10.1158/1078-0432.CCR-19-1905; Ji XM, 2018, ONCOGENE, V37, P5007, DOI 10.1038/s41388-018-0307-z; Kremer JC, 2017, CELL REP, V18, P991, DOI 10.1016/j.celrep.2016.12.077; Krueger F, 2012, NAT METHODS, V9, P145, DOI [10.1038/NMETH.1828, 10.1038/nmeth.1828]; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014; Maris John M, 2010, N Engl J Med, V362, P2202, DOI 10.1056/NEJMra0804577; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Mullarky E, 2016, P NATL ACAD SCI USA, V113, P1778, DOI 10.1073/pnas.1521548113; Nakagawara A, 2018, JPN J CLIN ONCOL, V48, P214, DOI 10.1093/jjco/hyx176; Newman AC, 2017, TRENDS CELL BIOL, V27, P645, DOI 10.1016/j.tcb.2017.05.001; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pizzo PA, 2015, PRINCIPLES PRACTICE; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sekiguchi M, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-0125-y; Shitara K, 2017, GASTRIC CANCER, V20, P1004, DOI 10.1007/s10120-017-0720-y; Toya Y, 2007, J CHROMATOGR A, V1159, P134, DOI 10.1016/j.chroma.2007.04.011; Vandekeere S, 2018, CELL METAB, V28, P573, DOI 10.1016/j.cmet.2018.06.009; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Xia YF, 2019, CANCER RES, V79, P3837, DOI 10.1158/0008-5472.CAN-18-3541; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028	48	0	0	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2022	41	46					4994	5007		10.1038/s41388-022-02489-2	http://dx.doi.org/10.1038/s41388-022-02489-2		NOV 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6C4SF	36319669	Green Published, hybrid			2022-12-28	WOS:000877420400001
J	GIVOL, D; YAYON, A				GIVOL, D; YAYON, A			COMPLEXITY OF FGF RECEPTORS - GENETIC-BASIS FOR STRUCTURAL DIVERSITY AND FUNCTIONAL SPECIFICITY	FASEB JOURNAL			English	Article						FIBROBLAST GROWTH FACTORS; GENE STRUCTURE	FIBROBLAST GROWTH-FACTOR; EXPRESSION; CLONING; FAMILY; DIFFERENTIATION; MEMBER; PHOSPHOTYROSINE; PURIFICATION; PROTEINS; AFFINITY	Since 1989, the receptors for fibroblast growth factors (FGFs) were cloned and characterized as a subgroup of the family of receptor tyrosine kinases. Four FGF receptor genes were identified. all of which encode membrane-bound glycoproteins containing three immunoglobulin (Ig) -like domains at the extracellular region, where only two of these domains are involved in ligand binding. Three unique features characterize the FGF receptors: 1) overlapping recognition and redundant specificity, where one receptor may bind with a similar affinity several of the seven known FGFs and one FGF may bind similarly to several distinct receptors. 2) The binding of FGFs to their receptors is dependent on the interaction of FGF with cell surface heparan sulfate proteoglycans. 3) A multitude of isoforms of cell-bound or secreted receptors are produced by the same gene. The gene structure of these receptors revealed two major mechanisms that are responsible for the formation of the diverse forms: alternative mRNA splicing, resulting in deletions or alternate exons usage, and internal polyadenylation, resulting in truncated products. These are reminiscent of mechanisms that also operate in the immunoglobulin family to generate diversity and to produce either secreted or cell-bound molecules. Tissue-specific alternative splicing in FGF receptors allows for the generation of two distinct receptors from a single gene because alternative exons determine the sequence of the COOH-terminal half of the third Ig-like domain involved in ligand binding. This represents a novel genetic mechanism to generate receptor diversity and specificity and to increase receptor repertoire.			GIVOL, D (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.							AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVIVI A, 1992, ONCOGENE, V7, P1957; AVIVI A, 1991, ONCOGENE, V6, P1089; BASILICO C, 1992, IN PRESS ADV CANCER; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; EISEMANN A, 1991, ONCOGENE, V6, P1195; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; McLachlan A.D., 1980, PROTEINS RELATED SUB, V28, P29; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; ORRURTREGER A, 1992, IN PRESS DEVELOPMENT; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PETERS KG, 1992, DEVELOPMENT, V114, P233; PRESTRELSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P314, DOI 10.1016/0003-9861(92)90401-H; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROGERS J, 1984, ADV IMMUNOL, V35, P39, DOI 10.1016/S0065-2776(08)60573-8; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAN GC, 1992, BIOCHEM BIOPH RES CO, V183, P423, DOI 10.1016/0006-291X(92)90498-A; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	48	415	433	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1992	6	15					3362	3369		10.1096/fasebj.6.15.1464370	http://dx.doi.org/10.1096/fasebj.6.15.1464370			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	KD395	1464370				2022-12-28	WOS:A1992KD39500007
J	CARPENTER, G				CARPENTER, G			RECEPTOR TYROSINE KINASE SUBSTRATES - SRC HOMOLOGY DOMAINS AND SIGNAL TRANSDUCTION	FASEB JOURNAL			English	Review						GROWTH FACTOR; PHOSPHORYLATION; CELL PROLIFERATION	EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; PDGF BETA-RECEPTOR; PHOSPHATIDYLINOSITOL-3 KINASE; EGF RECEPTOR; SH2 DOMAINS; INSULIN-RECEPTOR; PERTUSSIS TOXIN	Among the intracellular milieu of proteins are molecules with defined biochemical functions that serve as substrates for ligand-activated tyrosine kinase receptors. It seems likely that some of these substrate molecules are elements of a critical signaling pathway used by growth factors to control cell proliferation and subverted by oncogenes to deregulate this process. Although the process of cell growth and division is relatively slow compared with other hormonally regulated responses, homeostasis in a human being requires approximately 20 x 10(6) cell divisions per second for the renewal of various cell populations. This review summarizes the present understanding of tyrosine kinase substrates that seem likely to have key roles in the signal transduction pathway that regulates cell proliferation. This includes structural features of these molecules, the influence of tyrosine phosphorylation on their functions, the biological roles of these proteins, and the capacity of these substrates to associate with activated receptor tyrosine kinases.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM & MED DERMATOL,NASHVILLE,TN 37232	Vanderbilt University								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P8232; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; KIM UH, 1991, J BIOL CHEM, V266, P1359; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3979; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, ONCOGENES MOL ORIGIN, P125; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RHEE SG, 1992, FASEB J A, V276; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMICKA AV, 1991, SCIENCE, V251, P804; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TRAVALI S, 1990, FASEB J, V4, P3209, DOI 10.1096/fasebj.4.14.2227212; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	78	143	149	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1992	6	14					3283	3289		10.1096/fasebj.6.14.1385243	http://dx.doi.org/10.1096/fasebj.6.14.1385243			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1385243				2022-12-28	WOS:A1992JZ73400010
J	LEVITZKI, A				LEVITZKI, A			TYRPHOSTINS - TYROSINE KINASE BLOCKERS AS NOVEL ANTIPROLIFERATIVE AGENTS AND DISSECTORS OF SIGNAL TRANSDUCTION	FASEB JOURNAL			English	Review						PROTEIN TYROSINE KINASE; PTK BLOCKERS	MOUSE ERYTHROLEUKEMIA-CELLS; INDUCED DNA-SYNTHESIS; GROWTH-FACTOR; PROTEIN-KINASE; HERBIMYCIN-A; PHOSPHOLIPASE-C; INVITRO DIFFERENTIATION; BIOLOGICAL-ACTIVITY; ANTITUMOR-ACTIVITY; LAVENDUSTIN-A	Protein tyrosine kinases (PTKs) are members of a growing family of oncoproteins and protooncoproteins that play a pivotal role in normal and abnormal proliferative processes. This hallmark identifies these unique proteins as potential targets for antiproliferative therapy. This review discusses the current status of PTK inhibitors, with special emphasis on tyrphostins as antiproliferative agents and as potential drugs for cancers, leukemias, psoriasis, and restenosis as well as other proliferative conditions. The development of tyrphostins as selective signal blockers can be viewed as a first step toward the development of "smart" cocktails as antiproliferative agents. Each of these custom-made cocktails will be aimed at proliferative conditions whose transduction pathways can be characterized by molecular tools. The review also discusses the use of PTK blockers as tools to study signal transduction processes in which protein tyrosine kinases are implicated.			LEVITZKI, A (corresponding author), HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANAFI M, 1992, J BIOL CHEM, V267, P4518; ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; ATLURU S, 1991, TRANSPLANTATION, V51, P448, DOI 10.1097/00007890-199102000-00035; BILDER GE, 1991, AM J PHYSIOL, V260, pC721, DOI 10.1152/ajpcell.1991.260.4.C721; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP WR, 1990, BIOCHEM PHARMACOL, V40, P2129, DOI 10.1016/0006-2952(90)90245-G; BROOM AD, 1989, J MED CHEM, V32, P2, DOI 10.1021/jm00121a001; BRYCKAERT MC, 1992, EXP CELL RES, V199, P255, DOI 10.1016/0014-4827(92)90432-8; CLEGG KB, 1989, J HYPERTENS, V7, pS144, DOI 10.1097/00004872-198900076-00068; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; CUSHMAN M, 1991, J MED CHEM, V34, P798, DOI 10.1021/jm00106a047; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DAYAMAKIN M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P87, DOI 10.1016/0167-4889(91)90142-K; DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FAALAND CA, 1991, MOL CELL BIOL, V11, P2697, DOI 10.1128/MCB.11.5.2697; GAUDETTE DC, 1990, BIOCHEM BIOPH RES CO, V170, P238, DOI 10.1016/0006-291X(90)91265-T; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GLOSSMANN H, 1981, N-S ARCH PHARMACOL, V317, P100, DOI 10.1007/BF00506266; GRAZIANI Y, 1982, BIOCHIM BIOPHYS ACTA, V714, P415, DOI 10.1016/0304-4165(82)90148-9; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; HONMA Y, 1989, CANCER RES, V49, P331; HSU CYJ, 1991, J BIOL CHEM, V266, P21105; IMOTO M, 1987, JPN J CANCER RES, V78, P329; IMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P208, DOI 10.1016/S0006-291X(05)81042-3; IMOTO M, 1987, J ANTIBIOT, V40, P1471, DOI 10.7164/antibiotics.40.1471; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KATOH O, 1990, AM J HEMATOL, V35, P145, DOI 10.1002/ajh.2830350302; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; KREUTER MH, 1990, COMP BIOCHEM PHYS B, V97, P151, DOI 10.1016/0305-0491(90)90194-X; LINASSIER C, 1990, BIOCHEM PHARMACOL, V39, P187, DOI 10.1016/0006-2952(90)90664-7; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARKOVITS J, 1989, CANCER RES, V49, P5111; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; POSNER I, 1989, FEBS LETT, V257, P287, DOI 10.1016/0014-5793(89)81554-6; POSNER I, 1992, IN PRESS J BIOL CHEM; RENDU F, 1992, BIOCHEM PHARMACOL, V44, P881, DOI 10.1016/0006-2952(92)90119-4; Rendu F, 1990, Blood Coagul Fibrinolysis, V1, P713; RICOUART A, 1991, J MED CHEM, V34, P73, DOI 10.1021/jm00105a012; ROIFMAN CM, 1991, J IMMUNOL, V146, P2965; ROSS R, 1989, LANCET, V1, P1179; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SCHWARTZ B, 1990, ANTICANCER RES, V10, P1747; SHIRAISHI T, 1990, JPN J CANCER RES, V81, P645, DOI 10.1111/j.1349-7006.1990.tb02622.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STANLEY JB, 1990, J IMMUNOL, V145, P2189; TOI M, 1990, EUR J CANCER, V26, P722, DOI 10.1016/0277-5379(90)90126-E; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UEHARA Y, 1988, J ANTIBIOT, V41, P831, DOI 10.7164/antibiotics.41.831; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; UMEZAWA K, 1991, FEBS LETT, V279, P132, DOI 10.1016/0014-5793(91)80267-7; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WATANABE T, 1991, CANCER RES, V51, P764; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YONEDA T, 1991, CANCER RES, V51, P4430	68	333	362	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1992	6	14					3275	3282		10.1096/fasebj.6.14.1426765	http://dx.doi.org/10.1096/fasebj.6.14.1426765			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JZ734	1426765				2022-12-28	WOS:A1992JZ73400009
J	FOST, N				FOST, N			ETHICAL IMPLICATIONS OF SCREENING ASYMPTOMATIC INDIVIDUALS	FASEB JOURNAL			English	Review						DISCRIMINATION; INSURANCE; GENETIC COUNSELING; STIGMATIZATION; PRENATAL DIAGNOSIS	CYSTIC-FIBROSIS GENE; HETEROZYGOTE DETECTION; PRENATAL-DIAGNOSIS; THALASSEMIA	There has been a long-standing consensus on the principles that should guide screening asymptomatic individuals whether for treatment, counseling, or research. Advances in molecular biology will increase the rate of new opportunities for such screening. The benefits and risks, for individuals as well as the public health, will vary with each new test. As with all new technologies, these benefits and risks will have to be assessed in well-designed and well-reviewed studies if individuals are to be allowed to make informed decisions regarding whether or not to be tested.			FOST, N (corresponding author), UNIV WISCONSIN, SCH MED, DEPT PEDIAT, MADISON, WI 53792 USA.							[Anonymous], 1972, NEW ENGL J MED, V286, P1129; [Anonymous], 1983, PEDIATRICS; BEAUDET AL, 1990, AM J HUM GENET, V47, P603; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; CAO A, 1981, AM J HUM GENET, V33, P592; CASKEY CT, 1990, AM J HUM GENET, V46, P393; CHILDS B, 1976, AM J HUM GENET, V28, P537; FOST N, 1989, CLIN RES, V37, P495; FOST N, 1973, PEDIATRICS, V51, P742; HAMMOND KB, 1991, NEW ENGL J MED, V325, P769, DOI 10.1056/NEJM199109123251104; HOLTZMAN NA, 1991, NEW ENGL J MED, V325, P802, DOI 10.1056/NEJM199109123251109; HOLTZMANN NA, 1992, FASEB J, V6; Katz J., 1972, EXPT HUMAN BEINGS; KOLATA G, 1990, NY TIMES, pB7; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; LEONARD CO, 1972, NEW ENGL J MED, V287, P433, DOI 10.1056/NEJM197208312870904; MODELL B, 1980, BMJ-BRIT MED J, V280, P1347, DOI 10.1136/bmj.280.6228.1347; PEARSON HA, 1972, J PEDIATR-US, V81, P1201, DOI 10.1016/S0022-3476(72)80263-4; Reilly P., 1977, GENETICS LAW SOCIAL; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SEVERO R, 1980, NY TIMES        0204; SHULMAN JD, 1990, AM J HUM GENET, V47, P470; Stamatoyannoulos G., 1974, BIRTH DEFECTS, P268; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; WILFOND BS, 1992, IN PRESS MILBANK Q; 1990, NEW ENGL J MED, V323, P70; 1987, JAMA-J AM MED ASSOC, V258, P1205; 1975, GENETIC SCREENING PR; 1983, SCREENING COUNSELING	29	18	19	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1992	6	10					2813	2817		10.1096/fasebj.6.10.1634044	http://dx.doi.org/10.1096/fasebj.6.10.1634044			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	JD954	1634044				2022-12-28	WOS:A1992JD95400008
J	TEPPERMAN, J; BROBECK, JR				TEPPERMAN, J; BROBECK, JR			A FRAGMENT OF METABOLIC PREHISTORY	FASEB JOURNAL			English	Article																		VENNESLAND B, 1991, FASEB J, V5, P2868, DOI 10.1096/fasebj.5.13.1916109	1	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1992	6	8					2614	2615		10.1096/fasebj.6.8.1592212	http://dx.doi.org/10.1096/fasebj.6.8.1592212			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HU423	1592212				2022-12-28	WOS:A1992HU42300015
J	HANOVER, JA				HANOVER, JA			THE NUCLEAR-PORE - AT THE CROSSROADS	FASEB JOURNAL			English	Review						NUCLEAR TRANSPORT; ONCOGENE; RNA TRANSPORT; TRANSCRIPTION	LINKED N-ACETYLGLUCOSAMINE; SV40 T-ANTIGEN; PROTEIN MIGRATION; XENOPUS OOCYTES; INTRACELLULAR MIGRATION; COMPLEX GLYCOPROTEINS; LOCALIZATION SIGNALS; SLOWER TRANSLOCATION; BINDING-PROTEIN; RAPID BINDING	The nuclear pore complex is at the crossroads of macromolecular traffic across the nuclear envelope. Our knowledge of the mechanism whereby nuclear transport is mediated by the nuclear pore complex is also at a crossroads; a molecular understanding of this process has major implications for applied medical sciences. This becomes obvious with the realization that nuclear proteins are synthesized in the cytoplasm and yet function in the nucleus, and that RNA is transcribed in the nucleus but translated in the cytoplasm. Thus, control of macromolecular traffic across the nuclear membrane is an important means for altering the levels and activities of such molecules as steroid hormone receptors, transcription factors, and enzymes involved in DNA replication. Nuclear proteins have been found to contain nuclear localization sequences (NLS) rich in basic amino acids, which target them for transport through the nuclear pore to the nucleus. It is also clear that a group of novel glycoproteins having a unique carbohydrate modification are required for transport across the nuclear pore complex. However, the mechanism by which the NLS is recognized to mediate transport across the nuclear envelope is poorly understood. It is the aim of this brief review to attempt a synthesis of what is known of this mechanism and what may be newly inferred on the basis of current experimental data.			HANOVER, JA (corresponding author), NIADDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892, USA.							ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; BERRIOS M, 1983, J BIOL CHEM, V258, P3384; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; BERRIOS M, 1991, P NATL ACAD SCI USA, V88, P219, DOI 10.1073/pnas.88.1.219; BONNER WM, 1975, J CELL BIOL, V64, P421, DOI 10.1083/jcb.64.2.421; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CATELLI MG, 1985, EMBO J, V4, P3135; CORDES V, 1991, IN PRESS EUR J CELL; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DEROBERTIS EM, 1978, NATURE, V272, P254, DOI 10.1038/272254a0; DINGWALL C, 1990, NATURE, V346, P512, DOI 10.1038/346512a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FRANKE WW, 1974, CELL NUCLEUS, V1, P219; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOROWITZ SB, 1972, J CELL BIOL, V54, P609, DOI 10.1083/jcb.54.3.609; HOROWITZ SB, 1976, NATURE, V260, P151, DOI 10.1038/260151a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1990, EXP CELL RES, V186, P32, DOI 10.1016/0014-4827(90)90206-P; LEE BA, 1987, MOL CELL BIOL, V7, P3527, DOI 10.1128/MCB.7.10.3527; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PAINE PL, 1975, J CELL BIOL, V66, P652, DOI 10.1083/jcb.66.3.652; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; PICARD D, 1987, EMBO J, V6, P333; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RINGERTZ NR, 1976, CELL HYBRIDS, P1; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHEETZ MP, 1989, TRENDS NEUROSCI, V12, P474, DOI 10.1016/0166-2236(89)90099-4; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STARR CM, 1990, BIOESSAYS, V12, P323, DOI 10.1002/bies.950120704; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; UNDERWOOD MR, 1990, EMBO J, V9, P91, DOI 10.1002/j.1460-2075.1990.tb08084.x; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; WOLFF B, 1991, ARCH BIOCHEM BIOPHYS, V288, P131, DOI 10.1016/0003-9861(91)90174-H; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	87	77	77	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR	1992	6	6					2288	2295		10.1096/fasebj.6.6.1312045	http://dx.doi.org/10.1096/fasebj.6.6.1312045			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ252	1312045				2022-12-28	WOS:A1992HJ25200005
J	ALVAREZ, J; MONTERO, M; GARCIASANCHO, J				ALVAREZ, J; MONTERO, M; GARCIASANCHO, J			CYTOCHROME-P450 MAY REGULATE PLASMA-MEMBRANE CA2+ PERMEABILITY ACCORDING TO THE FILLING STATE OF THE INTRACELLULAR CA2+ STORES	FASEB JOURNAL			English	Note						CA2+ CHANNELS (RECEPTOR-OPERATED); CYTOCHROME-P450; INTRACELLULAR CA2+ STORES; IMIDAZOLE ANTIMYCOTICS; ECONAZOLE; MICONAZOLE; CALMODULIN	OPERATED CALCIUM CHANNELS; OXIDATIVE DRUG-METABOLISM; HUMAN-PLATELETS; MICROSOMAL CYTOCHROME-P-450; ANTIFUNGAL AGENTS; HUMAN-LYMPHOCYTES; LIVER MICROSOMES; SKELETAL-MUSCLE; ACINAR-CELLS; CA-2+ INFLUX	The filling state of the intracellular Ca2+ stores of rat thymocytes regulates plasma membrane permeability to Mn2+, used here as a Ca2+ surrogate for plasma membrane Ca2+ channels. Emptying of the Ca2+ stores accelerated Mn2+ entry about 10-fold, and refilling with Ca2+ restored low Mn2+ permeability. The acceleration of Mn2+ entry observed in cells with empty intracellular Ca2+ stores was prevented by cytochrome P450 inhibitors. Imidazole antimycotics, especially econazole and miconazole, were the most potent inhibitors (IC50 is-approximately-equal-to 10(-6) M). The inhibitor sensitivity profile was similar to IA-type cytochrome P450. Calmodulin antagonists increased the plasma membrane permeability to Mn2+ in cells with filled Ca2+ stores, and this effect was also blocked by imidazole antimycotics. On this basis, we propose a model in which activation of a cytochrome P450, situated at the Ca2+ stores, opens a plasma membrane Ca2+ pathway. This activity would be inhibited by Ca2+ inside the stores by a calmodulin-dependent mechanism.	UNIV VALLADOLID, FAC MED, DEPT BIOQUIM & BIOL MOLEC & FISIOL, E-47005 VALLADOLID, SPAIN	Universidad de Valladolid			Alvarez, Javier/K-8210-2014; Montero, Mayte/K-8212-2014; Garcia-Sancho, Javier/K-2975-2014	Alvarez, Javier/0000-0003-0636-5521; Montero, Mayte/0000-0001-7702-6653; Garcia-Sancho, Javier/0000-0003-4573-7930				AHOKAS JT, 1987, PHARMACOL TOXICOL, V61, P184, DOI 10.1111/j.1600-0773.1987.tb01800.x; ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ALONSO MT, 1989, BIOCHEM BIOPH RES CO, V162, P24, DOI 10.1016/0006-291X(89)91956-6; ALONSO MT, 1990, BIOCHEM J, V272, P435, DOI 10.1042/bj2720435; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ARTALEJO AR, 1988, BIOCHIM BIOPHYS ACTA, V941, P48, DOI 10.1016/0005-2736(88)90212-X; AYUB M, 1988, J STEROID BIOCHEM, V31, P65, DOI 10.1016/0022-4731(88)90207-5; BACK DJ, 1985, BRIT J PHARMACOL, V85, P121, DOI 10.1111/j.1476-5381.1985.tb08838.x; BALLARD SA, 1988, BIOCHEM PHARMACOL, V37, P4643, DOI 10.1016/0006-2952(88)90333-4; BARAN DT, 1973, BIOCHIM BIOPHYS ACTA, V307, P627, DOI 10.1016/0005-2736(73)90307-6; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOCKER RH, 1986, J MED CHEM, V29, P1596; BRADY JF, 1988, CANCER RES, V48, P5937; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FONNEPFISTER R, 1988, BIOCHEM PHARMACOL, V37, P3829, DOI 10.1016/0006-2952(88)90063-9; FORSTERMANN U, 1988, BRIT J PHARMACOL, V93, P569; GARCIASANCHO J, 1989, BIOCHEM SOC T, V17, P980, DOI 10.1042/bst0170980; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIETZEN K, 1983, BIOCHIM BIOPHYS ACTA, V736, P109, DOI 10.1016/0005-2736(83)90175-X; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; HALPERT J, 1985, MOL PHARMACOL, V28, P290; HALPERT JR, 1985, J BIOL CHEM, V260, P8397; HALPERT JR, 1986, MOL PHARMACOL, V30, P19; HURST JS, 1987, PROSTAGLANDINS RELAT; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; KRAUSE KH, 1990, CLIN BIOCHEM, V23, P159, DOI 10.1016/0009-9120(90)80030-M; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MCMANUS ME, 1987, RES COMMUN CHEM PATH, V55, P409; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MURRAY M, 1990, PHARMACOL REV, V42, P85; MURRAY M, 1988, BIOCHEM PHARMACOL, V37, P415, DOI 10.1016/0006-2952(88)90208-0; MURRAY M, 1986, ARCH BIOCHEM BIOPHYS, V251, P471, DOI 10.1016/0003-9861(86)90354-1; OHNISHI T, 1986, J BIOCHEM-TOKYO, V100, P1065, DOI 10.1093/oxfordjournals.jbchem.a121786; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PARKINSON A, 1986, J BIOL CHEM, V261, P1478; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; REIDY GF, 1989, MOL PHARMACOL, V35, P736; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; RYAN DE, 1980, J BIOL CHEM, V255, P7941; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SALHANICK HA, 1982, CANCER RES, V42, P3315; SHEETS JJ, 1986, BIOCHEM PHARMACOL, V35, P487, DOI 10.1016/0006-2952(86)90224-8; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Weiss B, 1978, Adv Cyclic Nucleotide Res, V9, P285; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0	57	123	124	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN 6	1992	6	2					786	792		10.1096/fasebj.6.2.1537469	http://dx.doi.org/10.1096/fasebj.6.2.1537469			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537469				2022-12-28	WOS:A1992GZ44000023
J	CAPDEVILA, JH; FALCK, JR; ESTABROOK, RW				CAPDEVILA, JH; FALCK, JR; ESTABROOK, RW			CYTOCHROME-P450 AND THE ARACHIDONATE CASCADE	FASEB JOURNAL			English	Article						P450; ARACHIDONATE; EICOSANOIDS; EPOXYGENASE; PROSTANOIDS; HYDROXYEICOSATETRAENOIC ACIDS; OMEGA OXIDATION	ENDOGENOUS EPOXYEICOSATRIENOIC ACIDS; LIVER MICROSOMAL CYTOCHROME-P-450; OXIDATIVE-METABOLISM; RAT-LIVER; KIDNEY CORTEX; EPOXYGENASE; HYDROXYLATION; BIOSYNTHESIS; OXYGENATION; ENZYMES	Arachidonic acid and many products of the arachidonate cascade serve as substrates for cytochrome P450-mediated metabolism via allylic oxidation, omega hydroxylation, and epoxygenation as well as peroxide rearrangement. Defining the physiological importance of these metabolites is an area of intense research interest. Cytochrome P450-catalyzed reactions play prominent roles in multiplying the structural and functional diversity of the arachidonate metabolic cascade.	VANDERBILT UNIV, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, CECIL H & IDA GREEN CTR REPROD BIOL SCI, DALLAS, TX 75235 USA	Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	CAPDEVILA, JH (corresponding author), VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA.			Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NIGMS NIH HHS [NIGMS 16488, NIGMS 31278, NIGMS 37922] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; CAPDEVILA J, 1985, ARCH BIOCHEM BIOPHYS, V243, P8, DOI 10.1016/0003-9861(85)90768-4; CAPDEVILA J, 1983, ENDOCRINOLOGY, V113, P421; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA J, 1984, XENOBIOTICA, V14, P105, DOI 10.3109/00498258409151401; CAPDEVILA J, 1981, BIOCHEM BIOPH RES CO, V101, P1357, DOI 10.1016/0006-291X(81)91597-7; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CINTI DL, 1976, BIOCHEM BIOPH RES CO, V73, P171, DOI 10.1016/0006-291X(76)90512-X; COOPER DY, 1965, SCIENCE, V147, P400, DOI 10.1126/science.147.3656.400; DIAUGUSTINE RP, 1969, BIOCHEM J, V115, P547, DOI 10.1042/bj1150547; ELLIN A, 1972, ARCH BIOCHEM BIOPHYS, V150, P64, DOI 10.1016/0003-9861(72)90010-0; ESTABROOK RW, 1963, BIOCHEM Z, V338, P741; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FREI B, 1985, EUR J BIOCHEM, V149, P633, DOI 10.1111/j.1432-1033.1985.tb08971.x; GAST K, 1982, BIOCHIM BIOPHYS ACTA, V686, P99, DOI 10.1016/0005-2736(82)90155-9; GRANSTROM E, 1972, EUR J BIOCHEM, V25, P581, DOI 10.1111/j.1432-1033.1972.tb01731.x; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; IWAI N, 1991, HYPERTENSION, V17, P161, DOI 10.1161/01.HYP.17.2.161; KAPPAS A, 1976, SCIENCE, V192, P60, DOI 10.1126/science.1257757; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KARARA A, 1991, J BIOL CHEM, V266, P7561; KUPFER D, 1988, ARCH BIOCHEM BIOPHYS, V261, P186, DOI 10.1016/0003-9861(88)90117-8; LU AYH, 1969, J BIOL CHEM, V244, P3714; MASTERS BSS, 1989, ADV PROSTAG THROMB L, V19, P335; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; MURPHY RC, 1990, METHOD ENZYMOL, V187, P1; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OLIW EH, 1981, BIOCHIM BIOPHYS ACTA, V666, P327, DOI 10.1016/0005-2760(81)90291-5; PESSAYRE D, 1979, XENOBIOTICA, V9, P301, DOI 10.3109/00498257909038733; SEVANIAN A, 1985, ANNU REV NUTR, V5, P365, DOI 10.1146/annurev.nu.05.070185.002053; SHARMA RK, 1989, EUR J BIOCHEM, V184, P69, DOI 10.1111/j.1432-1033.1989.tb14991.x; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; Verkade PE, 1934, BIOCHEM J, V28, P31, DOI 10.1042/bj0280031; WAKABAYASHI K, 1963, BIOCHIM BIOPHYS ACTA, V70, P132, DOI 10.1016/0006-3002(63)90733-9; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0	40	282	287	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN 6	1992	6	2					731	736		10.1096/fasebj.6.2.1537463	http://dx.doi.org/10.1096/fasebj.6.2.1537463			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537463				2022-12-28	WOS:A1992GZ44000014
J	JOHNSON, EF; KRONBACH, T; HSU, MH				JOHNSON, EF; KRONBACH, T; HSU, MH			ANALYSIS OF THE CATALYTIC SPECIFICITY OF CYTOCHROME-P450 ENZYMES THROUGH SITE-DIRECTED MUTAGENESIS	FASEB JOURNAL			English	Article						ENZYME ENGINEERING; SITE-DIRECTED MUTAGENESIS; CYTOCHROME-P450; PROGESTERONE 21-HYDROXYLATION	RABBIT LIVER-MICROSOMES; PURIFIED CYTOCHROME-P-450; SUBSTRATE-SPECIFICITY; SEQUENCE REQUIREMENTS; CONSTITUTIVE FORM; IDENTIFICATION; HYDROXYLATION; METABOLISM; CYTOCHROMES-P450; PROGESTERONE	The way in which structural diversity encodes the capacity of individual P450 enzymes to metabolize multiple, structurally distinct substrates remains largely unknown. The tools of molecular biology provide a means of identifying amino acid residues among closely related P450s that are determinants of their distinct catalytic properties. Work in our laboratory has identified two substrate specificity-determining segments of the amino acid sequences of subfamily 2C P450s. A pattern has emerged from this work, and that of others, which suggests a model for the structural basis of P450 catalytic diversity.	GODECKE AG, DEPT DRUG METAB, W-7800 FREIBURG, GERMANY		JOHNSON, EF (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM BCR-7, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM31001] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA T, 1989, J BIOL CHEM, V264, P21327; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETER HH, 1982, BIOCHEM BIOPH RES CO, V105, P515, DOI 10.1016/0006-291X(82)91465-6; DIETER HH, 1982, J BIOL CHEM, V257, P9315; DOECKE CJ, 1990, BIOCHEM BIOPH RES CO, V166, P860, DOI 10.1016/0006-291X(90)90889-U; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Guengerich F. P., 1987, MAMMALIAN CYTOCHROME; HASSETT C, 1990, NUCLEIC ACIDS RES, V18, P1429, DOI 10.1093/nar/18.6.1429; HOWARD PC, 1988, CANCER RES, V48, P4261; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; IMAI Y, 1987, J BIOCHEM-TOKYO, V101, P1129, DOI 10.1093/oxfordjournals.jbchem.a121977; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; JOHNSON EF, 1987, J BIOL CHEM, V262, P5918; JOHNSON EF, 1980, J BIOL CHEM, V255, P304; JOHNSON EF, 1989, ARCH BIOCHEM BIOPHYS, V273, P273, DOI 10.1016/0003-9861(89)90484-0; KOOP DR, 1979, BIOCHEM BIOPH RES CO, V91, P1075, DOI 10.1016/0006-291X(79)91990-9; KRONBACH T, 1989, P NATL ACAD SCI USA, V86, P8262, DOI 10.1073/pnas.86.21.8262; KRONBACH T, 1991, BIOCHEMISTRY-US, V30, P6097, DOI 10.1021/bi00239a003; KRONBACH T, 1991, J BIOL CHEM, V266, P6215; KRONBACH T, 1990, CURRENT RES PROTEIN, P481; LANGE R, 1985, BIOCHEM BIOPH RES CO, V126, P833, DOI 10.1016/0006-291X(85)90260-8; LEIGHTON JK, 1984, BIOCHEMISTRY-US, V23, P204, DOI 10.1021/bi00297a005; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LU AYH, 1969, J BIOL CHEM, V244, P3714; LU AYH, 1968, J BIOL CHEM, V243, P1331; MATSUNAGA E, 1990, J BIOL CHEM, V265, P17197; MCMANUS ME, 1984, CARCINOGENESIS, V5, P1717, DOI 10.1093/carcin/5.12.1717; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEGISHI M, 1990, DRUG METABOLIZING EN, P15; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; POULOS TL, 1988, PHARMACEUT RES, V5, P67, DOI 10.1023/A:1015920931701; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAUCY JL, 1985, MOL PHARMACOL, V27, P296; REUBI I, 1984, BIOCHEMISTRY-US, V23, P4598, DOI 10.1021/bi00315a013; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; TUKEY RH, 1985, J BIOL CHEM, V260, P3347; VANDERHO.TA, 1974, J BIOL CHEM, V249, P6302; VANDERHO.TA, 1974, BIOCHEM BIOPH RES CO, V60, P569, DOI 10.1016/0006-291X(74)90278-2; WAXMAN DJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P424, DOI 10.1016/0003-9861(88)90655-8; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	43	38	38	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN 6	1992	6	2					700	705		10.1096/fasebj.6.2.1537459	http://dx.doi.org/10.1096/fasebj.6.2.1537459			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GZ440	1537459				2022-12-28	WOS:A1992GZ44000009
J	NICOLL, CS; RUSSELL, SM				NICOLL, CS; RUSSELL, SM			MOZART, ALEXANDER-THE-GREAT, AND THE ANIMAL RIGHTS LIBERATION PHILOSOPHY	FASEB JOURNAL			English	Article							BIOMEDICAL-RESEARCH		UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley	NICOLL, CS (corresponding author), UNIV CALIF BERKELEY,DEPT INTEGRAT BIOL,LSA 281,BERKELEY,CA 94720, USA.							Bosworth A. B., 1988, CONQUEST EMPIRE REIG; COHEN C, 1986, NEW ENGL J MED, V315, P865, DOI 10.1056/NEJM198610023151405; Conniff Richard, 1990, AUDUBON          NOV, P120; FOX MA, 1985, CASE ANIMAL EXPT; Frey R.G., 1980, INTERESTS RIGHTS CAS; GOODALL J, 1985, CHIMPANZEES GOMBE PA; Hellemans A., 1988, TIMETABLES SCI; HORTON L, 1989, J NATL CANCER I, V81, P736, DOI 10.1093/jnci/81.10.736; Horton L., 1988, Physiologist, V31, P41; HOWARD WE, 1990, ANIMAL RIGHTS NATURE; LANSDELL H, 1988, INT J NEUROSCI, V42, P169, DOI 10.3109/00207458808991594; LEADER RW, 1987, PERSPECT BIOL MED, V30, P470; MCCABE K, 1990, WASHINGTONIAN, V25, P72; MCCABE K, 1990, WASHINGTONIAN, V25, P185; NICOLL CS, 1990, ENDOCRINOLOGY, V127, P985; Regan Tom, 1983, CASE ANIMAL RIGHTS; ROWAN AN, 1983, PERSPECT BIOL MED, V27, P1; SHORT RV, 1986, PRIMATES ROAD SELF S; SINGER P, 1990, BEHAV BRAIN SCI, V13, P45, DOI 10.1017/S0140525X00077529; Singer P., 1975, NEW YORK REV; Singer P., 1990, ANIMAL LIBERATION; SLOANE SA, 1991, NAT HIST, V6, P32; Sperling S., 1988, ANIMAL LIBERATORS; TANNENBAUM J, 1989, VET ETHICS; TIMBERLAKE W, 1990, BEHAV BRAIN SCI, V13, P38, DOI 10.1017/S0140525X0007744X; WHEATER M, 1990, J ROY SOC MED, V83, P586, DOI 10.1177/014107689008300917; 1988, USE ANIMALS BIOMEDIC	27	18	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2888	2892		10.1096/fasebj.5.14.1752356	http://dx.doi.org/10.1096/fasebj.5.14.1752356			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1752356				2022-12-28	WOS:A1991GP26900002
J	TOMEO, AC; EGAN, RW; DURAN, WN				TOMEO, AC; EGAN, RW; DURAN, WN			PRIMING INTERACTIONS BETWEEN PLATELET-ACTIVATING-FACTOR AND HISTAMINE IN THE INVIVO MICROCIRCULATION	FASEB JOURNAL			English	Note						MICROCIRCULATION; PRIMING; PAF; HISTAMINE; LEUKOCYTE	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-ENDOTHELIAL CELLS; RESPONSES; RECEPTOR; LEUKOTRIENE-B4; PERMEABILITY; BINDING; POTENT	To elucidate whether priming exists between platelet-activating factor (PAF) and histamine in the microcirculation, we measured the clearance of FITC-dextran 150 in response to the topical applications of substimulatory concentrations of PAF and histamine. Maximal priming by PAF was observed when a 5-min interval separated the applications of 10(-9)M PAF and 10(-6)M histamine. The mean (+/- SEM) clearance resulting from this sequence of agonist administration was 7529 +/- 659 nl.2 h-1.g-1, representing a 4.5-fold enhancement in FITC-dextran 150 clearance compared with that evoked by 10(-6)M histamine alone (1664 +/- 397 nl.2 h-1.g-1). Lowering the PAF priming dose to 10(-11)M, or reversing the order of agonist addition to the microcirculation, resulted in diminished but significant responses of 3545 +/- 1143 and 4467 +/- 1170 nl.2 hr-1.g-1, respectively. Coapplication of PAF and histamine or increasing the time interval between the agonists to 15 min greatly reduced the responses to 1906 +/- 678 and 2770 +/- 837, respectively. The PAF receptor antagonist WEB 2086 (2 mg/kg i.v.), the H-1 blocker pyrilamine (10 mg/kg i.v.), and leukocyte depletion with cyclophosphamide (150 mg/kg i.p.) completely abolished the PAF priming effect. In addition, the 5-lipoxygenase inhibitor RG 5901 (1 or 10 mg/kg i.v.) produced a two-thirds attenuation in PAF priming. We conclude that 1) PAF has the ability to prime the in vivo microvascular actions of histamine in both a concentration and time-dependent fashion; 2) this primed response is receptor mediated; and 3) histamine can prime the microcirculation for enhanced responses to PAF. Our data also demonstrate that leukocytes and the release of leukotrienes participate in PAF priming.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT SURG,NEWARK,NJ 07103; SCHERING PLOUGH CORP,BLOOMFIELD,NJ 07003	Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company; Schering Plough Corporation	TOMEO, AC (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PHYSIOL,DIV MICROCIRCULATORY RES,NEWARK,NJ 07103, USA.				NHLBI NIH HHS [HL 43146] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043146] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAVEN MA, 1976, NEW ENGL J MED, V294, P30, DOI 10.1056/NEJM197601012940108; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DELMAESTRO RF, 1981, MICROVASC RES, V22, P255, DOI 10.1016/0026-2862(81)90096-0; DILLON PK, 1988, CIRC RES, V62, P732, DOI 10.1161/01.RES.62.4.732; DILLON PK, 1988, INFLAMMATION, V12, P563, DOI 10.1007/BF00914318; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GARCIA JGN, 1988, THROMB RES, V51, P83, DOI 10.1016/0049-3848(88)90285-X; GAY JC, 1986, BLOOD, V67, P931; HONDA C, 1991, NATURE, V349, P342; HUMPHREY DM, 1982, LAB INVEST, V47, P227; HWANG SB, 1988, J BIOL CHEM, V263, P3225; HWANG SB, 1986, J BIOL CHEM, V261, P532; INGRAHAM LM, 1982, BLOOD, V59, P1259; KORTH R, 1987, FASEB J, V46, P444; KUBES P, 1990, AM J PHYSIOL, V258, pG158, DOI 10.1152/ajpgi.1990.258.1.G158; LAMBRECHT G, 1986, BRIT J PHARMACOL, V87, P287, DOI 10.1111/j.1476-5381.1986.tb10816.x; LEWIS RE, 1988, MICROVASC RES, V35, P27, DOI 10.1016/0026-2862(88)90048-9; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; MALMSTEN CL, 1980, ACTA PHYSIOL SCAND, V110, P449, DOI 10.1111/j.1748-1716.1980.tb06696.x; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; NORTHOVER AM, 1989, AGENTS ACTIONS, V26, P367, DOI 10.1007/BF01967303; PALMBLAD J, 1984, J IMMUNOL, V132, P3041; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; PIPER PJ, 1987, BRIT J PHARMACOL, V90, P771, DOI 10.1111/j.1476-5381.1987.tb11231.x; VERCELLOTTI GM, 1988, BLOOD, V71, P1100; WARREN JS, 1989, J CLIN INVEST, V83, P669, DOI 10.1172/JCI113931; YOUNG JM, 1985, PROSTAGLANDINS, V30, P545, DOI 10.1016/0090-6980(85)90018-8	29	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2850	2855		10.1096/fasebj.5.13.1655549	http://dx.doi.org/10.1096/fasebj.5.13.1655549			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1655549				2022-12-28	WOS:A1991GJ47100014
J	GILBERT, EK; WEAVER, BA; REMBOLD, CM				GILBERT, EK; WEAVER, BA; REMBOLD, CM			DEPOLARIZATION DECREASES THE [CA-2+]I SENSITIVITY OF MYOSIN LIGHT-CHAIN KINASE IN ARTERIAL SMOOTH-MUSCLE - COMPARISON OF AEQUORIN AND FURA-2 [CA-2+]I ESTIMATES	FASEB JOURNAL			English	Note						AEQUORIN; [CA-2+]I; CA-2+-CALMODULIN-DEPENDENT PROTEIN KINASE-II; CAMP-DEPENDENT PROTEIN KINASE; FURA-2; HISTAMINE; MYOSIN PHOSPHORYLATION; MYOSIN LIGHT-CHAIN KINASE; SMOOTH MUSCLE	PROTEIN-KINASE; FREE-CALCIUM; CA-2+ SENSITIVITY; MYOPLASMIC CA-2+; PORTAL-VEIN; PHOSPHORYLATION; CONTRACTION; FORCE; CELLS; ACTIVATION	Histamine stimulation of swine arterial smooth muscle is associated with a high [Ca2+]i sensitivity for increases in myosin light-chain phosphorylation. In contrast, KCl depolarization produces a relatively lower [Ca2+]i sensitivity (i.e., similar increases in [Ca2+]i induce less myosin phosphorylation). We evaluated whether 1) artifacts in the methodology for measuring [Ca2+]i or 2) true alterations in the [Ca2+]i sensitivity of myosin light-chain kinase were responsible for these apparent changes in the [Ca2+]i sensitivity of phosphorylation. The [Ca2+]i sensitivity of phosphorylation was higher with histamine stimulation regardless of whether the [Ca2+]i indicator was aequorin (which was loaded intracellularly by reversible hyperpermeabilization) or Fura 2 (which was loaded intracellularly by incubation of the tissues in Fura 2 AM). Aequorin and Fura 2 appeared to detect qualitatively similar stimulus-induced changes in [Ca2+]i with the exception that the initial response to histamine stimulation was different (histamine initially induced a large aequorin light transient and a relatively smaller increase in Fura 2 fluorescence). The [Ca2+]i sensitivity of myosin light-chain kinase extracted from KCl depolarized tissues was lower than the [Ca2+]i sensitivity of myosin light-chain kinase extracted from unstimulated or histamine stimulated tissues. These results suggest that depolarization specifically modifies myosin light-chain kinase to decrease its [Ca2+]i sensitivity. Changes in the [Ca2+]i sensitivity of myosin light-chain phosphorylation are not an artifact of the [Ca2+]i measurement technique.	UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,DIV CARDIOL,BOX 146,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHYSIOL,DIV CARDIOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia			Rembold, Christopher/K-8359-2013	Rembold, Christopher/0000-0003-0819-7488	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038918] Funding Source: NIH RePORTER; NHLBI NIH HHS [1RO1 HL38918] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1978, J BIOL CHEM, V253, P8347; AKSOY MO, 1983, AM J PHYSIOL, V245, pC255, DOI 10.1152/ajpcell.1983.245.3.C255; BECKER PL, 1989, SCIENCE, V244, P211, DOI 10.1126/science.2704996; BOND M, 1984, J PHYSIOL-LONDON, V357, P185, DOI 10.1113/jphysiol.1984.sp015496; BORLE A B, 1987, P159; BRUSCHI G, 1988, AM J PHYSIOL, V254, pH840, DOI 10.1152/ajpheart.1988.254.5.H840; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; DRISKA SP, 1981, AM J PHYSIOL, V240, pC222, DOI 10.1152/ajpcell.1981.240.5.C222; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; HIMPENS B, 1988, J GEN PHYSIOL, V92, P713, DOI 10.1085/jgp.92.6.713; HISAYAMA T, 1990, BRIT J PHARMACOL, V100, P677, DOI 10.1111/j.1476-5381.1990.tb14075.x; IKEBE M, 1990, J BIOL CHEM, V265, P8975; IKEBE M, 1990, J BIOL CHEM, V265, P17607; KARAKI H, 1989, TRENDS PHARMACOL SCI, V10, P320; KITAZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P1291, DOI 10.1016/0006-291X(90)91589-K; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LOUTZENHISER R, 1983, BLOOD VESSELS, V20, P295; MCDANIEL NL, 1990, J PHYSIOL-LONDON, V439, P147; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; OWEN CS, 1991, ANAL BIOCHEM, V192, P142, DOI 10.1016/0003-2697(91)90199-4; RATZ PH, 1989, AM J PHYSIOL, V256, pC96, DOI 10.1152/ajpcell.1989.256.1.C96; REMBOLD CM, 1990, J PHYSIOL-LONDON, V429, P77, DOI 10.1113/jphysiol.1990.sp018245; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; REMBOLD CM, 1989, AM J PHYSIOL, V257, pC122, DOI 10.1152/ajpcell.1989.257.1.C122; REMBOLD CM, 1990, CIRC RES, V66, P1354, DOI 10.1161/01.RES.66.5.1354; REMBOLD CM, 1988, AM J PHYSIOL, V255, pC719, DOI 10.1152/ajpcell.1988.255.6.C719; REMBOLD CM, 1989, J PHYSIOL-LONDON, V416, P273, DOI 10.1113/jphysiol.1989.sp017760; REMBOLD CM, 1986, CIRC RES, V58, P803, DOI 10.1161/01.RES.58.6.803; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SATO K, 1988, J PHARMACOL EXP THER, V246, P294; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; STULL JT, 1990, J BIOL CHEM, V265, P16683; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; VANBREEMEN C, 1986, J CARDIOVASC PHARM, V8, pS111, DOI 10.1097/00005344-198600088-00023; VANBREEMEN C, 1977, J PHYSIOL-LONDON, V272, P317, DOI 10.1113/jphysiol.1977.sp012046	42	43	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2593	2599		10.1096/fasebj.5.11.1868983	http://dx.doi.org/10.1096/fasebj.5.11.1868983			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1868983				2022-12-28	WOS:A1991GB09400014
J	HAYAISHI, O				HAYAISHI, O			MOLECULAR MECHANISMS OF SLEEP-WAKE REGULATION - ROLES OF PROSTAGLANDIN-D2 AND PROSTAGLANDIN-E2	FASEB JOURNAL			English	Article						SLOW WAVE SLEEP; REM SLEEP; WAKEFULNESS; PREOPTIC AREA; POSTERIOR HYPOTHALAMUS	RAT-BRAIN; REGIONAL DISTRIBUTION; BASAL LEVEL; ADULT FOWLS; LOCALIZATION; PURIFICATION; SUBSTANCE	Although sleep-wake cycles are repeated every day and night and almost one-third of our lifetime is spent sleeping, the molecular mechanisms of sleep-wake regulation have remained little understood. Recent experimental evidence indicates that prostaglandins (PG) D2 and E2 are probably two of the major endogenous sleep-regulating substances, one promoting sleep and the other wakefulness, in rats, dogs, rabbits, monkeys, and probably in humans as well. Preliminary evidence indicates that the sites of action of PGD2 and E2 are located in the sleep and wake centers in or near the preoptic area and posterior hypothalamus, respectively.			HAYAISHI, O (corresponding author), OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN.							Baker TL, 1985, BRAIN MECH SLEEP, P199; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; BORBELY AA, 1980, TRENDS PHARMACOL SCI, V1, P356, DOI 10.1016/0165-6147(80)90048-6; DZOLJIC MR, 1978, PROSTAGLANDINS, V15, P317, DOI 10.1016/0090-6980(78)90171-5; HARMS PG, 1973, SCIENCE, V181, P760, DOI 10.1126/science.181.4101.760; HAYAISHI O, 1988, J BIOL CHEM, V263, P14593; HAYAISHI O, 1990, SLEEP 90, P405; HIROSHIMA O, 1986, PROSTAGLANDINS, V32, P63, DOI 10.1016/0090-6980(86)90144-9; HONDA K, 1978, REPORTS I MED DENT E, V12, P81; INOUE S, 1989, BIOL SLEEP SUBSTANCE, P1; ISLAM F, 1991, IN PRESS ARCH BIOCH; JOUVET M, 1984, EXP BRAIN RES S, V8, P81; KASHIMURA M, 1988, PROSTAGLANDINS, V35, P583, DOI 10.1016/0090-6980(88)90033-0; KINOSHITA F, 1982, ENDOCRINOLOGY, V110, P2207, DOI 10.1210/endo-110-6-2207; KRUEGER JM, 1985, ENDOGENOUS SLEEP SUB, P181; KRUEGER JM, 1990, SLEEP BIOL RHYTHMS B, P163; LAYCHOCK SG, 1979, PHRM BIOCH BEHAV, V12, P747; MASEK K, 1976, NEUROPHARMACOLOGY, V15, P491, DOI 10.1016/0028-3908(76)90060-5; MATSUMURA H, 1989, P NATL ACAD SCI USA, V86, P5666, DOI 10.1073/pnas.86.14.5666; MATSUMURA H, 1989, BRAIN RES, V481, P242, DOI 10.1016/0006-8993(89)90800-7; MATSUMURA H, 1988, BRAIN RES, V444, P254; MATSUMURA H, 1991, IN PRESS P NATL ACAD; MILTON AS, 1970, J PHYSIOL-LONDON, V207, P76; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; NAITO K, 1988, BRAIN RES, V453, P329, DOI 10.1016/0006-8993(88)90173-4; NARUMIYA S, 1982, LIFE SCI, V31, P2093, DOI 10.1016/0024-3205(82)90101-1; NAUTA WJH, 1946, J NEUROPHYSIOL, V9, P285, DOI 10.1152/jn.1946.9.4.285; NISHINO S, 1989, P NATL ACAD SCI USA, V86, P2483, DOI 10.1073/pnas.86.7.2483; NISTICO G, 1976, NEUROPHARMACOLOGY, V15, P737, DOI 10.1016/0028-3908(76)90002-2; NISTICO G, 1973, NEUROPHARMACOLOGY, V12, P1009, DOI 10.1016/0028-3908(73)90045-2; OGOROCHI T, 1987, J NEUROCHEM, V48, P900, DOI 10.1111/j.1471-4159.1987.tb05602.x; OGOROCHI T, 1984, J NEUROCHEM, V43, P71, DOI 10.1111/j.1471-4159.1984.tb06680.x; ONOE H, 1990, ENDOGENOUS SLEEP FACTORS, P69; ONOE H, 1968, P NATL ACAD SCI USA, V85, P4082; PENTREATH VW, 1990, T ROY SOC TROP MED H, V84, P795, DOI 10.1016/0035-9203(90)90085-S; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; STERMAN MB, 1962, EXP NEUROL, V6, P103, DOI 10.1016/0014-4886(62)90081-X; SUZUKI F, 1986, BRAIN RES, V385, P321, DOI 10.1016/0006-8993(86)91079-6; TOKUMOTO H, J BIOL CHEM, V257, P13576; UENO R, 1983, P NATL ACAD SCI-BIOL, V80, P1735, DOI 10.1073/pnas.80.6.1735; UENO R, 1982, P NATL ACAD SCI-BIOL, V79, P6093, DOI 10.1073/pnas.79.19.6093; UENO R, 1982, BIOCHEM BIOPH RES CO, V109, P576, DOI 10.1016/0006-291X(82)91760-0; UENO R, 1985, ENDOGENOUS SLEEP SUB, P193; URADE Y, 1987, J BIOL CHEM, V262, P15132; URADE Y, 1985, J BIOL CHEM, V260, P2410; von Economo C, 1926, HDB NORMALEN PATHOLO, P591; WATANABE K, 1981, BIOCHEM INT, V2, P603; WATANABE K, 1980, J BIOL CHEM, V225, P1779; WATANABE Y, 1989, BRAIN RES, V478, P143, DOI 10.1016/0006-8993(89)91486-8; WATANABE Y, 1983, P NATL ACAD SCI-BIOL, V80, P4542, DOI 10.1073/pnas.80.14.4542; WERMUTH B, 1981, J BIOL CHEM, V256, P1206; YAMAMOTO K, 1988, BIOCHEM BIOPH RES CO, V156, P882, DOI 10.1016/S0006-291X(88)80926-4; YAMASHITA A, 1983, P NATL ACAD SCI-BIOL, V80, P6114, DOI 10.1073/pnas.80.19.6114	53	237	241	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	AUG	1991	5	11					2575	2581		10.1096/fasebj.5.11.1907936	http://dx.doi.org/10.1096/fasebj.5.11.1907936			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB094	1907936	Bronze			2022-12-28	WOS:A1991GB09400011
J	QIAN, Z; DREWES, LR				QIAN, Z; DREWES, LR			CROSS-TALK BETWEEN RECEPTOR-REGULATED PHOSPHOLIPASE-D AND PHOSPHOLIPASE-C IN BRAIN	FASEB JOURNAL			English	Note						RECEPTOR; PHOSPHOLIPASE-D; PHOSPHOLIPASE-C; SYNAPTOSOME; PHOSPHATIDYLCHOLINE	LIVER PLASMA-MEMBRANES; PHOSPHATIDIC-ACID; RAT-BRAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; DIACYLGLYCEROL FORMATION; INOSITOL TRISPHOSPHATE; GUANINE-NUCLEOTIDE; GROWTH-FACTOR; STIMULATION; HEPATOCYTES	Because receptors, G proteins, and phospholipases all exist within a membrane lipid environment, it is not unreasonable to assume that an enzyme capable of changing the lipid environment can affect the coupling relationship among these signal transducing components. Our previous study showed that a muscarinic acetylcholine receptor regulates phosphatidylcholine phospholipase D via a G protein in brain. We demonstrate here that phosphatidylinositol phospholipase C and phosphatidylcholine phospholipase D are simultaneously activated within 15 s by muscarine in the presence of 1-mu-M GTP-gamma-S. More important, inhibition of phospholipase D by zinc attenuated carbamylcholine-induced activation of phospholipase C by 30%. Our additional evidence strongly indicates that the receptor-regulated phospholipase D plays an important modulatory role in agonist-stimulated phosphatidylinositol breakdown. This modulatory effect may be achieved by changing the membrane microenvironment in which phospholipase C and phosphoinositol lipids reside, consequently amplifying the inositol phospholipid signaling process. Our results lead us to postulate that the potential interaction between two different signaling pathways may provide a cell with intracellular coordination and enable the cell to achieve functional responses.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,DULUTH,MN 55812	University of Minnesota System; University of Minnesota Duluth			Drewes, Lester R/X-9794-2018	Drewes, Lester R/0000-0002-7440-0387				AGWU DE, 1989, J BIOL CHEM, V264, P1405; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; CABOT MC, 1988, BIOCHIM BIOPHYS ACTA, V959, P46, DOI 10.1016/0005-2760(88)90148-8; CLARO E, 1989, J BIOL CHEM, V264, P18288; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DOWNES CP, 1982, CELL CALCIUM, V3, P413, DOI 10.1016/0143-4160(82)90027-6; EXTON JH, 1990, J BIOL CHEM, V265, P1; IRVINE RF, 1979, EUR J BIOCHEM, V99, P525, DOI 10.1111/j.1432-1033.1979.tb13284.x; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JACOBSON MD, 1985, J NEUROCHEM, V44, P465, DOI 10.1111/j.1471-4159.1985.tb05437.x; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; QIAN Z, 1990, J NEUROCHEM, V54, P1632, DOI 10.1111/j.1471-4159.1990.tb01215.x; QIAN Z, 1990, J BIOL CHEM, V265, P3607; QIAN Z, 1989, J BIOL CHEM, V264, P21720; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; TAKI T, 1979, J BIOL CHEM, V254, P9761; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; UHING RJ, 1986, J BIOL CHEM, V261, P2140; WALLACE MA, 1985, J BIOL CHEM, V260, P9527; WILSON DB, 1984, J BIOL CHEM, V259, P1718; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	28	40	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAR 1	1991	5	3					315	319		10.1096/fasebj.5.3.2001791	http://dx.doi.org/10.1096/fasebj.5.3.2001791			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FC556	2001791				2022-12-28	WOS:A1991FC55600009
J	JAVITT, NB				JAVITT, NB			HEP-G2 CELLS AS A RESOURCE FOR METABOLIC STUDIES - LIPOPROTEIN, CHOLESTEROL, AND BILE-ACIDS	FASEB JOURNAL			English	Review											JAVITT, NB (corresponding author), NYU MED CTR,DIV HEPAT DIS,NEW YORK,NY 10016, USA.			Javitt, Norman B/0000-0001-9265-3508				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOUMA ME, 1988, SCAND J GASTROENTERO, V23, P477, DOI 10.3109/00365528809093897; BOUMA ME, 1989, IN VITRO CELL DEV B, V25, P267; BUSCH SJ, 1989, LIFE SCI, V45, P615, DOI 10.1016/0024-3205(89)90047-7; CHAO C-F, 1988, Proceedings of the National Science Council Republic of China Part B Life Sciences, V12, P222; CHAO YS, 1988, NUCLEIC ACIDS RES, V16, P7061, DOI 10.1093/nar/16.14.7061; CRAIG WY, 1988, J LIPID RES, V29, P299; DASHTI N, 1985, BIOCHIM BIOPHYS ACTA, V833, P100, DOI 10.1016/0005-2760(85)90257-7; DASHTI N, 1987, BIOCHEMISTRY-US, V26, P4837, DOI 10.1021/bi00389a035; DASHTI N, 1986, BIOCHIM BIOPHYS ACTA, V875, P473, DOI 10.1016/0005-2760(86)90067-6; DASHTI N, 1984, BIOCHIM BIOPHYS ACTA, V794, P373, DOI 10.1016/0005-2760(84)90003-1; DAVIS RA, 1983, J BIOL CHEM, V258, P4079; EDELSTEIN C, 1988, ARCH BIOCHEM BIOPHYS, V267, P23, DOI 10.1016/0003-9861(88)90003-3; ESTERMAN AL, 1985, J LIPID RES, V26, P950; EVERSON GT, 1986, J BIOL CHEM, V261, P2197; FENNEWALD SM, 1988, J BIOL CHEM, V263, P15568; FORTE TM, 1987, BIOCHIM BIOPHYS ACTA, V920, P185, DOI 10.1016/0005-2760(87)90094-4; HAVEKES L, 1983, BIOCHEM J, V214, P951, DOI 10.1042/bj2140951; HAVEKES LM, 1986, BIOCHIM BIOPHYS ACTA, V875, P236, DOI 10.1016/0005-2760(86)90173-6; HAVINGA JR, 1987, FEBS LETT, V216, P275, DOI 10.1016/0014-5793(87)80705-6; HOEG JM, 1988, J LIPID RES, V29, P1215; HOSPATTANKAR AV, 1987, BIOCHEM BIOPH RES CO, V149, P289, DOI 10.1016/0006-291X(87)91637-8; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; ISHAK KG, 1967, CANCER-AM CANCER SOC, V20, P396, DOI 10.1002/1097-0142(1967)20:3<396::AID-CNCR2820200308>3.0.CO;2-O; JAVITT NB, 1989, J BIOL CHEM, V264, P10384; JAVITT NB, 1989, BIOCHEM J, V262, P989, DOI 10.1042/bj2620989; JAVITT NB, 1989, BIOMED ENVIRON MASS, V18, P640; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOREN E, 1985, CANCER BIOCHEM BIOPH, V7, P301; LAKSHMANAN MR, 1977, J BIOL CHEM, V252, P4667; LENICH CM, 1987, J LIPID RES, V28, P183; MCCALL MR, 1988, J LIPID RES, V29, P1127; MONGE JC, 1989, FEBS LETT, V243, P213, DOI 10.1016/0014-5793(89)80132-2; PEROVA NV, 1988, BIOCHEM INT, V17, P1029; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RANGANATHAN S, 1989, HEPATOLOGY, V9, P547, DOI 10.1002/hep.1840090407; RASH JM, 1981, BIOCHIM BIOPHYS ACTA, V666, P294, DOI 10.1016/0005-2760(81)90120-X; REUE K, 1988, J BIOL CHEM, V263, P6857; ROINGEARD P, 1988, VIRAL HEPATITIS LIVE, P775; SIMON D, 1982, INT J CANCER, V30, P27, DOI 10.1002/ijc.2910300106; SMITH JD, 1988, J BIOL CHEM, V263, P8300; TAM SP, 1986, P NATL ACAD SCI USA, V83, P3111, DOI 10.1073/pnas.83.10.3111; THRIFT RN, 1986, J LIPID RES, V27, P236; WEN YM, 1983, INFECT IMMUN, V3, P1361	46	330	335	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1990	4	2					161	168		10.1096/fasebj.4.2.2153592	http://dx.doi.org/10.1096/fasebj.4.2.2153592			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CM418	2153592				2022-12-28	WOS:A1990CM41800004
J	SIMMONS, DJ; GRYNPAS, MD; ROSENBERG, GD				SIMMONS, DJ; GRYNPAS, MD; ROSENBERG, GD			MATURATION OF BONE AND DENTIN MATRICES IN RATS FLOWN ON THE SOVIET BIOSATELLITE COSMOS-1887	FASEB JOURNAL			English	Article									UNIV TORONTO,MT SINAI HOSP,SCH MED,DEPT PATHOL,TORONTO M5G 1X5,ONTARIO,CANADA; INDIANA UNIV PURDUE UNIV,DEPT GEOL,INDIANAPOLIS,IN 46202	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Indiana University System; Indiana University-Purdue University Indianapolis	SIMMONS, DJ (corresponding author), UNIV TEXAS,MED BRANCH,DEPT SURG,DIV ORTHOPED SURG,GALVESTON,TX 77550, USA.		Grynpas, Marc/E-4576-2013; Grynpas, Marc/ABG-7096-2020					ALLRED JB, 1964, BRIT J NUTR, V18, P575, DOI 10.1079/BJN19640050; CHANG IH, 1969, METABOLISM, V28, P625; COSSACK ZT, 1984, EXPERIENTIA, V40, P498, DOI 10.1007/BF01952405; GRINDELAND RE, 1990, FASEB J, V4, P105, DOI 10.1096/fasebj.4.1.2295371; GRYNPAS MD, 1986, CALCIFIED TISSUE INT, V39, P57, DOI 10.1007/BF02553291; JEE WSS, 1983, AM J PHYSIOL, V244, pR310, DOI 10.1152/ajpregu.1983.244.3.R310; KAZARIAN LE, 1981, ADV PHYSL SCI GRAVIT, V19, P129; PACE N, 1981, UCLA EPL811 BERK ENV; PECOUD A, 1975, CLIN PHARMACOL THER, V17, P469; Roberts WE., 1981, PHYSIOLOGIST, V24, pS75; Rosenberg G D, 1985, Physiologist, V28, pS189; ROSENBERG GD, 1984, P SOC EXP BIOL MED, V175, P429; SCHWARTZ R, 1989, IN PRESS NUTRITION S; SIMMONS DJ, 1983, AVIAT SPACE ENVIR MD, V54, P1080; SIMMONS DJ, 1986, BONE MINER, V1, P485; SIMMONS DJ, 1983, AM J PHYSIOL, V244, pR319, DOI 10.1152/ajpregu.1983.244.3.R319; SIMMONS DJ, 1984, CLIN ORTHOD REL RES, V182, P220; STARCHER BC, 1980, J NUTR, V110, P2095, DOI 10.1093/jn/110.10.2095; YAMAGUCHI M, 1987, BIOCHEM PHARMACOL, V36, P4007, DOI 10.1016/0006-2952(87)90471-0	19	34	36	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1990	4	1					29	33		10.1096/fasebj.4.1.2153084	http://dx.doi.org/10.1096/fasebj.4.1.2153084			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH311	2153084				2022-12-28	WOS:A1990CH31100007
